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Message from Alex M. Azar II
Secretary, U.S. Department of Health and Human Services
Throughout its history, the U.S. Department of Health and Human Services (USDHHS) has led 
efforts to prevent and reduce the devastating effects of tobacco use, especially the use of combus-
tible tobacco products, as part of its mission to enhance and protect the health and well-being of all 
Americans. USDHHS has provided critical support in the fields of research and evaluation, program and 
policy development, public information and education, regulatory activities, systems-level change and 
management, and clinical practices that has contributed to a dramatic 67% decline in cigarette smoking 
among U.S. adults since 1965. Support from USDHHS has helped medical and healthcare organiza-
tions, government agencies at all levels, and nongovernmental partners create and sustain programs 
that prevent initiation; help tobacco product users quit; and foster healthy, smokefree environments.
This report is the latest of a longstanding tradition of tobacco prevention and control efforts 
by USDHHS. Our work includes a comprehensive tobacco control strategic action plan, Ending the 
Tobacco Epidemic, and coordination of tobacco control efforts with related efforts by other federal agen-
cies through the Interagency Committee on Smoking and Health. Reports such as this one from the 
U.S. Surgeon General give the latest data on tobacco and health to scientists, healthcare professionals, 
and the public. Research leadership and grant funding through USDHHS’s National Institutes of Health 
contribute to growing knowledge of effective tobacco control strategies and smoking cessation tools. 
The National Tobacco Control Program, led by the Centers for Disease Control and Prevention (CDC), 
ensures that these strategies and tools are readily available to state, local, tribal, and territorial public 
health programs, as well as to partners serving a variety of populations that are disproportionately 
affected by tobacco use. The U.S. Food and Drug Administration (FDA) regulates the manufacturing, 
marketing, and sale of tobacco products. Medicare and Medicaid provide smoking cessation tools and 
support to millions of Americans. Multiple public information campaigns, such as CDC’s Tips From 
Former Smokers and FDA’s Every Try Counts, educate Americans about the significant health risks 
from smoking and the importance of quitting. Additionally, many agencies in USDHHS provide direct 
assistance to smokers, including the National Cancer Institute through its Smokefree.gov initiative 
(https://smokefree.gov), and national quitline portal, 1-800-QUIT-NOW.
These and other important efforts are critical to improving the nation’s public health. Smoking 
kills nearly half a million Americans every year, and millions more live with serious chronic diseases 
caused by smoking. We know that comprehensive interventions at all levels of government and by 
partners throughout the public health community are extremely effective at preventing and reducing 
tobacco use. We remain committed to ending the tobacco use epidemic in the United States.

vForeword
Tobacco use remains the number one cause of preventable disease, disability, and death in the 
United States. Approximately 34 million American adults currently smoke cigarettes, with most of 
them smoking daily. Nearly all adult smokers have been smoking since adolescence. More than two-
thirds of smokers say they want to quit, and every day thousands try to quit. But because the nicotine 
in cigarettes is highly addictive, it takes most smokers multiple attempts to quit for good.
Today, we know much more about the science of quitting than ever before. Research shows that 
smokers who use evidence-based tools to help them quit are more likely to succeed than those who do not 
use such tools, and that using a combination of these tools—for example, calling 1-800-QUIT-NOW and 
using nicotine replacement therapy, such as the nicotine patch or gum or a prescription medication—
raises success rates even higher. Studies also show that policies that prohibit smoking in indoor public 
places and work spaces and that increase the price of tobacco products promote smoking cessation.
This Surgeon General’s report
• Examines the effectiveness of various smoking cessation tools and resources;
• Reviews the health effects of smoking and catalogues the improvements to health that can occur 
when smokers quit;
• Highlights important new data on populations in which the prevalence of smoking is high and quit 
rates are low; and
• Identifies gaps in the availability and utilization of programs, policies, and resources that can 
improve cessation rates and help smokers quit.
Although the benefits of quitting are greater the earlier in life that an individual quits, this report 
confirms that it is never too late to quit smoking. Even persons who have smoked for many years or who 
have smoked heavily can realize health and financial benefits from quitting smoking.
The financial toll of smoking is substantial. Each year in the United States, annual healthcare 
spending attributed to smoking exceeds $170 billion. Measured against these numbers, comprehensive 
tobacco prevention and control strategies are extremely cost-effective investments that yield significant 
returns. For example, the first year of CDC’s Tips From Former Smokers national campaign prevented 
thousands of premature deaths in the United States, costing less than $500 for every smoker who quit.
We know what works to prevent and reduce tobacco use, including how to best help smokers quit 
for good. Putting this knowledge into action prevents disease, saves lives, and improves the quality of 
life for all Americans. At CDC, we remain committed to supporting the longstanding national effort to 
end the tobacco use epidemic and provide all Americans with the opportunity to live tobacco-free.
Robert R. Redfield, M.D.
Director
Centers for Disease Control and Prevention
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Preface
from the Surgeon General
One of the most significant public health successes in modern U.S. history has been the reduction 
in smoking that has occurred during the past half century. Today, the prevalence of cigarette smoking 
among American adults is at an all-time low, 14%. Although this overall achievement is a source of 
pride, there is still more work to be done. Today, 16 million Americans are living with a smoking-related 
disease. In addition to the human costs, smoking places a significant financial burden on Americans, 
as smoking-attributable healthcare spending exceeds $170 billion per year.
Research, medical advances, and years of documented experience have given us many tools to 
tackle the tobacco use epidemic in this country. Although quitting smoking can be a difficult pro-
cess for many smokers, most say they want to quit, and every year more than half make a serious quit 
attempt. But only a small portion of smokers who try to quit succeed, and only a small portion use any 
of the tested and proven aids that will significantly increase their chances of success. This Surgeon 
General’s report on smoking cessation, the 34th report on smoking and health since 1964, examines 
the most current research on this important issue, identifies barriers to continued success in reducing 
the prevalence of smoking across all populations, and summarizes evidence-based solutions that can 
help to eliminate those barriers.
Clinical interventions for smoking cessation are critical if we are to achieve our goal of elimi-
nating the devastating effects of smoking on public health. Primary care physicians, nurses, pharma-
cists, and other providers in all medical disciplines and in all healthcare environments should take 
advantage of these opportunities to inform and encourage smokers to quit. Doing so could enable half 
a million smokers to quit each year.
As a physician, I am acutely aware of the many pressing demands that healthcare providers must 
address to deliver the highest quality care possible to their patients. At the same time, the evidence in 
this report clearly points to the tremendous positive impact that healthcare professionals can have on 
the health and quality of life of their patients and on the public health of our nation—just by helping 
smokers to quit.
But healthcare professionals alone cannot solve this public health challenge. Everyone has a role 
in helping to continue to reduce the burden of tobacco use on our society. It is critical that clinical 
interventions be adopted alongside broader efforts at the health system and population levels to pro-
mote and cultivate successful cessation and tobacco-free norms. Even today, with all the gains that have 
been made over the past few decades, smoking remains the single largest cause of preventable disease 
and death in the United States. As a nation, we can and must spare no effort to reduce the completely 
preventable health and financial costs that tobacco smoking has on society.
Jerome M. Adams, M.D., M.P.H.
Vice Admiral, U.S. Public Health Service
Surgeon General of the United States
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Introduction
Tobacco smoking is the leading cause of preventable 
disease, disability, and death in the United States (U.S. 
Department of Health and Human Services [USDHHS] 
2014). Smoking harms nearly every organ in the body and 
costs the United States billions of dollars in direct medical 
costs each year (USDHHS 2014). Although considerable 
progress has been made in reducing cigarette smoking 
since the first U.S. Surgeon General’s report was released 
in 1964 (USDHHS 2014), in 2018, 13.7% of U.S. adults 
(34.2 million people) were still current cigarette smokers 
(Creamer et al. 2019). One of the main reasons smokers 
keep smoking is nicotine (USDHHS 1988). Nicotine, 
a  drug found naturally in the tobacco plant, is highly 
addictive, as with such drugs as cocaine and heroin; acti-
vates the brain’s reward circuits; and reinforces repeated 
nicotine exposure (USDHHS 1988, 2010, 2014; National 
Institute on Drug Abuse [NIDA] 2018).
The majority of cigarette smokers (68%) want to quit 
smoking completely (Babb et al. 2017). The 1990 Surgeon 
General’s report, The Health Benefits of Smoking Cessation, 
was the last Surgeon General’s report to focus on cur-
rent research on smoking cessation and to predominantly 
review the health benefits of quitting smoking (USDHHS 
1990). Because of limited data at that time, the 1990 report 
did not review the determinants, processes, or outcomes 
of attempts at smoking cessation. Pharmacotherapy for 
smoking cessation was not introduced until the 1980s. 
Additionally, behavioral and other counseling approaches 
were slow to develop and not widely available at the time 
of the 1990 report because few were covered under health 
insurance, and programs such as group counseling ses-
sions were hard for smokers to access, even by those who 
were motivated to quit (Fiore et al. 1990).
The purpose of this report is to update and expand 
the 1990 Surgeon General’s report based on new scien-
tific evidence about smoking cessation. Since 1990, the 
scientific literature has expanded greatly on the deter-
minants and processes of smoking cessation, informing 
the development of interventions that promote cessa-
tion and help smokers quit (Fiore et al. 2008; Schlam and 
Baker 2013). This knowledge and other major develop-
ments have transformed the landscape of smoking ces-
sation in the United States. This report summarizes this 
enhanced knowledge and specifically reviews patterns 
and trends of smoking cessation; biologic mechanisms; 
various health benefits; overall morbidity, mortality, and 
economic benefits; interventions; and strategies that pro-
mote smoking cessation.
From 1965 to 2017, the prevalence of current 
smoking declined from 52.0% to 15.8% (relative percent 
change: 69.6%) among men and from 34.1% to 12.2% (rel-
ative percent change: 64.2%) among women (Figure 1.1). 
These declines have been attributed, in part, to prog-
ress made in smoking cessation since the 1960s, which 
has continued since the 1990 Surgeon General’s report. 
Specifically, clinical, scientific, and public health commu-
nities have increasingly embraced and acted upon the con-
cept of tobacco use and dependence as a health condition 
that can benefit from treatment in various forms and levels 
of intensity. Accordingly, a considerable range of effective 
pharmacologic and behavioral smoking cessation treat-
ment options are now available. As of October 16, 2019, the 
U.S. Food and Drug Administration (FDA) has approved 
five nicotine replacement therapies (NRTs) and two non-
nicotine oral medications to help smokers quit, and the 
use of these treatments has expanded, including stronger 
integration with counseling support (Fiore et al. 2008).
In addition, the reach of smoking cessation inter-
ventions has increased substantially since 1990 with 
the emergence of innovative, population-level inter-
ventions and policies that motivate smokers to quit and 
raise awareness of the health benefits of smoking cessa-
tion (McAfee et al. 2013). This includes policies, such as 
comprehensive smokefree laws, that have been shown 
to promote cessation at the population level in addition 
to reducing exposure to secondhand smoke (USDHHS 
2014). The development and subsequent expansion of 
telephone call centers (“quitlines”), mobile phone tech-
nologies, Internet-based applications, and other innova-
tions have created novel platforms to provide behavioral 
and pharmacologic smoking cessation treatments (Ghorai 
et al. 2014). However, the continued diversification of the 
tobacco product landscape could have several different 
potential impacts, ranging from accelerating the rates 
of complete cessation among adult smokers to erasing 
progress in reducing all forms of use of tobacco products, 
especially among youth and young adults. For example, 
the increasing availability and rapidly increasing use of 
novel tobacco products, most notably electronic cigarettes 
(e-cigarettes), raise questions about the potential impact 
that such products could have on efforts to eliminate dis-
ease and death caused by tobacco use at the individual and 
population levels. Therefore, when considering the impact 
of e-cigarettes on public health, it is critical to evaluate 
their effects on both adults and youth.
Collectively, the changes cited in this report pro-
vide new opportunities and challenges for understanding 
and promoting smoking cessation in the United States. 
However, the evidence-based clinical-, health system-, 
and population-based tobacco prevention, control, and 
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cessation strategies that are outlined in this report are a 
necessary but insufficient means to end the tobacco epi-
demic. Reaching the finish line will require coordination 
across federal government agencies and other government 
and non-government stakeholders at the national, state, 
and local levels. To achieve success, we must work together 
to maximize resources and coordinate efforts across a wide 
range of stakeholders.
Figure 1.1 Trends in prevalence (%) of current and former cigarette smoking among adults 18 years of age and 
older, by sex; National Health Interview Survey (NHIS) 1965–2017; United States
Source: NHIS, National Center for Health Statistics, public use data, 1965–2017.
Note: From 1965 to 2017, data were reported for the following years: 1965, 1966, 1970, 1974, 1976–1980, 1983, 1985, 1987, 1988, 
1990–1995, and 1997–2017.
Organization of the Report
This chapter summarizes the report, identifies its 
major conclusions, and presents the conclusions from each 
chapter. It also offers an overview of the evolving landscape 
of smoking cessation and key developments since the 1990 
Surgeon General’s report. Chapter 2 (“Patterns of Smoking 
Cessation Among U.S. Adults, Young Adults, and Youth”) 
documents key patterns and trends in cigarette smoking 
cessation in the United States among adults overall (per-
sons 18 years of age and older), young adults (18–24 years 
of age), and youth (12–17 years of age). The chapter also 
reviews the changing demographic- and smoking-related 
characteristics of cigarette smokers with a focus on how 
these changes may influence future trends in cessa-
tion. Chapter  3 (“New Biological Insights into Smoking 
Cessation”) reviews several areas of intensive research 
since the 2010 Surgeon General’s report on how tobacco 
smoke causes disease: cellular and molecular biology of 
nicotine addiction; vaccines and other immunotherapies as 
treatments for tobacco addiction; neurobiological insights 
into smoking cessation obtained from noninvasive neuro-
imaging; and genetics of smoking behaviors and cessation. 
Chapter  4 (“The Health Benefits of Smoking Cessation”) 
reviews the more recent findings on disease risks from 
smoking and benefits after smoking cessation for major 
types of chronic diseases, including cardiovascular and 
respiratory systems, cancer, and a wide range of repro-
ductive outcomes. Chapter  5 (“The Benefits of Smoking 
Cessation on Overall Morbidity, Mortality, and Economic 
Costs”) discusses general indicators of health that change 
after smoking cessation, the health benefits of smoking ces-
sation on all-cause mortality, and the economic benefits of 
smoking cessation. Chapter 6 (“Interventions for Smoking 
Cessation and Treatments for Nicotine Dependence”) 
reviews the evidence on current and emerging treatments 
for smoking cessation, including research that has been 
conducted since the 2008 U.S. Public Health Service’s 
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Clinical Practice Guideline, Treating Tobacco Use and 
Dependence: 2008 Update (Fiore et al. 2008). Chapter  7 
(“Clinical-, System-, and Population-Level Strategies 
that Promote Smoking Cessation”) focuses on clinical-, 
system-, and population-level strategies that combine indi-
vidual components of treatment for smoking cessation with 
routine clinical care, making cessation interventions avail-
able and accessible to individual smokers and creating con-
ditions whereby smokers are informed of these interven-
tions and are motivated to use them. Chapter 8 (“A Vision 
for the Future”) outlines broad strategies to accelerate the 
progress that has been made in helping smokers quit.
Preparation of the Report
This Surgeon General’s report was prepared by the 
Office on Smoking and Health, National Center for Chronic 
Disease Prevention and Health Promotion, Centers for 
Disease Control and Prevention (CDC), which is part of 
USDHHS. This report was compiled using a longstanding, 
peer-reviewed, balanced, and comprehensive process 
designed to safeguard the scientific rigor and practical rel-
evance from influences that could adversely affect impar-
tiality (King et al. 2018). This process helps to ensure that 
the report’s conclusions are defined by the evidence, rather 
than the opinions of the authors and editors. In brief, under 
the leadership of a senior scientific editorial team, 32 experts 
wrote the initial drafts of the chapters. The experts were 
selected for their knowledge of the topics addressed. These 
contributions, which are summarized in Chapters  1–7, 
were evaluated by 46 peer reviewers. After this initial stage 
of peer review, more than 20  senior scientists and other 
experts examined the scientific integrity of the entire man-
uscript as part of a second stage of peer review. After each 
round of peer review, the report’s scientific editors revised 
each draft based on reviewers’ comments. Chapter 8, which 
summarizes and is founded upon the preceding content 
in the report, was written by the senior scientific edito-
rial team once the content in Chapters 1–7 completed peer 
review. Subsequently, the report was reviewed by various 
institutes and agencies in the U.S. government, including 
USDHHS. Throughout the review process, the content of 
each chapter was revised to include studies and information 
that were not available when the chapters were first drafted; 
updates were made until shortly before the report was sub-
mitted for publication. These updates reflect the full scope 
of identified evidence, including new findings that confirm, 
refute, or refine the initial content. Conclusions are based 
on the preponderance and quality of scientific evidence.
Scientific Basis of the Report
The statements and conclusions throughout this 
report are based on an extensive review of the existing sci-
entific literature. Thus, the report focuses primarily on 
cessation in the context of adults because this is the popu-
lation for which the preponderance of scientific literature 
exists on this topic; however, data on youth and young 
adults are also presented, when available. The report pri-
marily cites peer-reviewed journal articles, including 
reviews that integrate findings from numerous studies 
and books that were published between 2000 and 2018, 
which reflects a period after the last Surgeon General’s 
report on the topic of cessation. This report also refers, on 
occasion, to unpublished research, such as presentations 
at professional meetings, personal communications from 
researchers, and information available in various media. 
These references are used when acknowledged by the edi-
tors and reviewers as being scientifically valid and reli-
able, and a critical addition to the emerging literature on a 
topic. Throughout the writing and review process, highest 
priority was given to peer-reviewed, scientific research 
that is free from tobacco industry interests. As noted in 
the 2014 Surgeon General’s report, the tobacco industry 
has a well-documented record of manipulating scientific 
information about the extent of the harms from cigarette 
smoking (USDHHS 2014).
Following the model of the 1964 report, this 
Surgeon General’s report includes comprehensive compi-
lations of the evidence on smoking cessation. The evidence 
was analyzed to identify causal associations according 
to enunciated principles, sometimes referred to as the 
“Surgeon General’s criteria” or the “Hill” criteria (after Sir 
Austin Bradford Hill) for causality. The criteria, offered in 
Chapter 3 of the 1964 report, included
• Consistency of the association,
• Strength of the association,
• Specificity of the association, 
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• Temporal relationship of the association, and 
• Coherence of the association (U.S. Department of 
Health, Education, and Welfare [USDHEW] 1964, 
p. 20).
In the 2004 Surgeon General’s report (USDHHS 
2004), the framework for interpreting evidence on smoking 
and health was revisited in depth for the first time since 
the 1964 report. The 2004 report provided a four-level 
hierarchy of categories for interpreting evidence, and this 
current report follows the same model:
a. “Evidence is sufficient to infer a causal relationship.
b. Evidence is suggestive but not sufficient to infer a 
causal relationship.
c. Evidence is inadequate to infer the presence or 
absence of a causal relationship (which encompasses 
evidence that is sparse, of poor quality, or conflicting).
d. Evidence is suggestive of no causal relationship” 
(USDHHS 2004, p. 18).
Answers to several questions helped to guide judg-
ment toward these categories:
• Do multiple high-quality studies show a consistent 
association between smoking and disease?
• Are the measured effects large enough and statisti-
cally strong?
• Does the evidence show that smoking occurs before 
the disease occurs (a temporal association)?
• Is the relationship between smoking and disease 
coherent or plausible in terms of known scientific 
principles, biologic mechanisms, and observed pat-
terns of disease?
• Is there a dose-response relationship between 
smoking and disease?
• Is the risk of disease reduced after quitting smoking?
The categories acknowledge that evidence can be 
“suggestive but not sufficient” to infer a causal relation-
ship, and the categories allow for evidence that is “sug-
gestive of no causal relationship.” This framework also 
separates conclusions about causality from the impli-
cations of such conclusions. Inference is sharply and 
completely separated from policy or research implica-
tions of the conclusions, thus adhering to the approach 
established in the 1964 report. However, consistent with 
past Surgeon General’s reports on tobacco, conclusions 
are not limited to just causal determinations and fre-
quently include recommendations for research, policies, 
or other actions.
Major Conclusions
1. Smoking cessation is beneficial at any age. Smoking 
cessation improves health status and enhances 
quality of life.
2. Smoking cessation reduces the risk of prema-
ture death and can add as much as a decade to life 
expectancy.
3. Smoking places a substantial financial burden on 
smokers, healthcare systems, and society. Smoking 
cessation reduces this burden, including smoking-
attributable healthcare expenditures.
4. Smoking cessation reduces risk for many adverse 
health effects, including reproductive health out-
comes, cardiovascular diseases, chronic obstructive 
pulmonary disease, and cancer. Quitting smoking 
is also beneficial to those who have been diagnosed 
with heart disease and chronic obstructive pulmo-
nary disease.
5. More than three out of five U.S. adults who have ever 
smoked cigarettes have quit. Although a majority of 
cigarette smokers make a quit attempt each year, less 
than one-third use cessation medications approved 
by the U.S. Food and Drug Administration or behav-
ioral counseling to support quit attempts.
6. Considerable disparities exist in the prevalence of 
smoking across the U.S. population, with higher 
prevalence in some subgroups. Similarly, the preva-
lence of key indicators of smoking cessation—quit 
attempts, receiving advice to quit from a health pro-
fessional, and using cessation therapies—also varies 
across the population, with lower prevalence in 
some subgroups.
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7. Smoking cessation medications approved by the 
U.S. Food and Drug Administration and behavioral 
counseling are cost-effective cessation strategies. 
Cessation medications approved by the U.S. Food 
and Drug Administration and behavioral counseling 
increase the likelihood of successfully quitting 
smoking, particularly when used in combination. 
Using combinations of nicotine replacement thera-
pies can further increase the likelihood of quitting.
8. Insurance coverage for smoking cessation treat-
ment that is comprehensive, barrier-free, and widely 
promoted increases the use of these treatment ser-
vices, leads to higher rates of successful quitting, 
and is cost-effective.
9. E-cigarettes, a continually changing and hetero-
geneous group of products, are used in a variety of 
ways. Consequently, it is difficult to make general-
izations about efficacy for cessation based on clinical 
trials involving a particular e-cigarette, and there 
is presently inadequate evidence to conclude that 
e-cigarettes, in general, increase smoking cessation.
10. Smoking cessation can be increased by raising the 
price of cigarettes, adopting comprehensive smoke-
free policies, implementing mass media campaigns, 
requiring pictorial health warnings, and main-
taining comprehensive statewide tobacco control 
programs.
Chapter Conclusions
Chapter 2: Patterns of Smoking 
Cessation Among U.S. Adults, 
Young Adults, and Youth
1. In the United States, more than three out of every 
five adults who were ever cigarette smokers have 
quit smoking.
2. Past-year quit attempts and recent and longer term 
cessation have increased over the past 2  decades 
among adult cigarette smokers.
3. Marked disparities in cessation behaviors, such 
as making a past-year quit attempt and achieving 
recent successful cessation, persist across certain 
population subgroups defined by educational attain-
ment, poverty status, age, health insurance status, 
race/ethnicity, and geography.
4. Advice from health professionals to quit smoking has 
increased since 2000; however, four out of every nine 
adult cigarette smokers who saw a health professional 
during the past year did not receive advice to quit.
5. Use of evidence-based cessation counseling and/or 
medications has increased among adult cigarette 
smokers since 2000; however, more than two-thirds 
of adult cigarette smokers who tried to quit during 
the past year did not use evidence-based treatment.
6. A large proportion of adult smokers report using 
non-evidence-based approaches when trying to quit 
smoking, such as switching to other tobacco products.
Chapter 3: New Biological Insights 
into Smoking Cessation
1. The evidence is suggestive but not sufficient to infer 
that increasing glutamate transport can alleviate 
nicotine withdrawal symptoms and prevent relapse.
2. The evidence is suggestive but not sufficient to infer 
that neuropeptide systems play a role in multiple 
stages of the nicotine addiction process, and that 
modulating the function of certain neuropeptides 
can reduce smoking behavior in humans.
3. The evidence is suggestive but not sufficient to 
infer that targeting the habenulo-interpeduncular 
pathway with agents that increase the aversive prop-
erties of nicotine are a useful therapeutic target for 
smoking cessation.
4. The evidence is suggestive but not sufficient to infer 
that vaccines generating adequate levels of nicotine-
specific antibodies can block the addictive effects of 
nicotine and aid smoking cessation.
5. The evidence is suggestive but not sufficient to infer 
that dysregulated brain circuits, including prefrontal 
and cingulate cortical regions and their connections 
with various striatal and insula loci, can serve as 
novel therapeutic targets for smoking cessation.
6. The evidence is suggestive but not sufficient to infer 
that the effectiveness of nicotine replacement therapy 
may vary across specific genotype groups.
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Chapter 4: The Health Benefits of 
Smoking Cessation
Cancer
1. The evidence is sufficient to infer that smoking 
cessation reduces the risk of lung cancer.
2. The evidence is sufficient to infer that smoking 
cessation reduces the risk of laryngeal cancer.
3. The evidence is sufficient to infer that smoking 
cessation reduces the risk of cancers of the oral 
cavity and pharynx
4. The evidence is sufficient to infer that smoking 
cessation reduces the risk of esophageal cancer.
5. The evidence is sufficient to infer that smoking 
cessation reduces the risk of pancreatic cancer.
6. The evidence is sufficient to infer that smoking 
cessation reduces the risk of bladder cancer.
7. The evidence is sufficient to infer that smoking 
cessation reduces the risk of stomach cancer.
8. The evidence is sufficient to infer that smoking 
cessation reduces the risk of colorectal cancer.
9. The evidence is sufficient to infer that smoking 
cessation reduces the risk of liver cancer.
10. The evidence is sufficient to infer that smoking 
cessation reduces the risk of cervical cancer.
11. The evidence is sufficient to infer that smoking 
cessation reduces the risk of kidney cancer.
12. The evidence is sufficient to infer that smoking 
cessation reduces the risk of acute myeloid leukemia.
13. The evidence is sufficient to infer that the relative 
risk of lung cancer decreases steadily after smoking 
cessation compared with the risk for persons con-
tinuing to smoke, with risk decreasing to half that 
of continuing smokers approximately 10–15 years 
after smoking cessation and decreasing further with 
continued cessation.
Smoking Cessation After a Cancer Diagnosis
1. The evidence is suggestive but not sufficient to infer 
a causal relationship between smoking cessation 
and improved all-cause mortality in cancer patients 
who are current smokers at the time of a cancer 
diagnosis.
Cardiovascular Disease
1. The evidence is sufficient to infer that smoking 
cessation reduces levels of markers of inflamma-
tion and hypercoagulability and leads to rapid 
improvement in the level of high-density lipopro-
tein cholesterol.
2. The evidence is sufficient to infer that smoking ces-
sation leads to a reduction in the development of 
subclinical atherosclerosis, and that progression 
slows as time since cessation lengthens.
3. The evidence is sufficient to infer that smoking ces-
sation reduces the risk of cardiovascular morbidity 
and mortality and the burden of disease from cardio-
vascular disease.
4. The evidence is sufficient to infer that the rela-
tive risk of coronary heart disease among former 
smokers compared with never smokers falls rapidly 
after cessation and then declines more slowly.
5. The evidence is sufficient to infer that smoking cessa-
tion reduces the risk of stroke morbidity and mortality.
6. The evidence is sufficient to infer that, after smoking 
cessation, the risk of stroke approaches that of never 
smokers.
7. The evidence is suggestive but not sufficient to infer 
that smoking cessation reduces the risk of atrial 
fibrillation.
8. The evidence is suggestive but not sufficient to infer 
that smoking cessation reduces the risk of sudden 
cardiac death among persons without coronary 
heart disease.
9. The evidence is suggestive but not sufficient to infer 
that smoking cessation reduces the risk of heart 
failure among former smokers compared with per-
sons who continue to smoke.
10. Among patients with left-ventricular dysfunction, 
the evidence is suggestive but not sufficient to infer 
that smoking cessation leads to increased survival 
and reduced risk of hospitalization for heart failure.
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11. The evidence is suggestive but not sufficient to infer 
that smoking cessation reduces the risk of venous 
thromboembolism.
12. The evidence is suggestive but not sufficient to 
infer that smoking cessation substantially reduces 
the risk of peripheral arterial disease among former 
smokers compared with persons who continue to 
smoke, and that this reduction appears to increase 
with time since cessation.
13. The evidence is suggestive but not sufficient to infer 
that, among patients with peripheral arterial dis-
ease, smoking cessation improves exercise toler-
ance, reduces the risk of amputation after peripheral 
artery surgery, and increases overall survival.
14. The evidence is sufficient to infer that smoking ces-
sation substantially reduces the risk of abdominal 
aortic aneurysm in former smokers compared with 
persons who continue to smoke, and that this reduc-
tion increases with time since cessation.
15. The evidence is suggestive but not sufficient to infer 
that smoking cessation slows the expansion rate of 
abdominal aortic aneurysm.
Smoking Cessation After a Diagnosis of Coronary 
Heart Disease
1. In patients who are current smokers when diag-
nosed with coronary heart disease, the evidence 
is sufficient to infer a causal relationship between 
smoking cessation and a reduction in all-cause 
mortality.
2. In patients who are current smokers when diag-
nosed with coronary heart disease, the evidence 
is sufficient to infer a causal relationship between 
smoking cessation and reductions in deaths due to 
cardiac causes and sudden death.
3. In patients who are current smokers when diag-
nosed with coronary heart disease, the evidence 
is sufficient to infer a causal relationship between 
smoking cessation and reduced risk of new and 
recurrent cardiac events.
Chronic Respiratory Disease
Chronic Obstructive Pulmonary Disease
1. Smoking cessation remains the only established 
intervention to reduce loss of lung function over time 
among persons with chronic obstructive pulmonary 
disease and to reduce the risk of developing chronic 
obstructive pulmonary disease in cigarette smokers.
2. The evidence is suggestive but not sufficient to infer 
that airway inflammation in cigarette smokers per-
sists months to years after smoking cessation.
3. The evidence is suggestive but not sufficient to infer 
that changes in gene methylation and profiles of 
proteins occur after smoking cessation.
4. The evidence is inadequate to infer the presence or 
absence of a relationship between smoking cessa-
tion and changes in the lung microbiome.
Asthma
1. The evidence is suggestive but not sufficient to infer 
that smoking cessation reduces asthma symptoms 
and improves treatment outcomes and asthma-
specific quality-of-life scores among persons with 
asthma who smoke.
2. The evidence is suggestive but not sufficient to infer 
that smoking cessation improves lung function 
among persons with asthma who smoke.
Reproductive Health
1. The evidence is sufficient to infer that smoking ces-
sation by pregnant women benefits their health and 
that of their fetuses and newborns.
2. The evidence is inadequate to infer that smoking 
cessation before or during early pregnancy reduces 
the risk of placental abruption compared with con-
tinued smoking.
3. The evidence is inadequate to infer that smoking 
cessation before or during pregnancy reduces the 
risk of placenta previa compared with continued 
smoking.
4. The evidence is inadequate to infer that smoking 
cessation before or during pregnancy reduces the 
risk of premature rupture of the membranes com-
pared with continued smoking.
5. The evidence is inadequate to infer that smoking 
during early or mid-pregnancy alone, and not during 
late pregnancy, is associated with a reduced risk of 
preeclampsia.
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6. The evidence is sufficient to infer that women who 
quit smoking before or during pregnancy gain more 
weight during gestation than those who continue to 
smoke.
7. The evidence is suggestive but not sufficient to infer 
that women who quit smoking before or during 
pregnancy gain more weight during gestation than 
nonsmokers.
8. The evidence is inadequate to infer that smoking 
cessation during pregnancy increases the risk of 
gestational diabetes.
9. The evidence is sufficient to infer that smoking 
cessation during pregnancy reduces the effects of 
smoking on fetal growth and that quitting smoking 
early in pregnancy eliminates the adverse effects of 
smoking on fetal growth.
10. The evidence is inadequate to determine the gesta-
tional age before which smoking cessation should 
occur to eliminate the effects of smoking on fetal 
growth.
11. The evidence is sufficient to infer that smoking ces-
sation before or during early pregnancy reduces the 
risk for a small-for-gestational-age birth compared 
with continued smoking.
12. The evidence is suggestive but not sufficient to infer 
that women who quit smoking before conception or 
during early pregnancy have a reduced risk of pre-
term delivery compared with women who continue 
to smoke.
13. The evidence is suggestive but not sufficient to infer 
that the risk of preterm delivery in women who quit 
smoking before or during early pregnancy does not 
differ from that of nonsmokers.
14. The evidence is inadequate to infer that smoking ces-
sation during pregnancy reduces the risk of stillbirth.
15. The evidence is inadequate to infer that smoking 
cessation during pregnancy reduces the risk of peri-
natal mortality among smokers.
16. The evidence is inadequate to infer that women who 
quit smoking before or during early pregnancy have 
a reduced risk for infant mortality compared with 
continued smokers.
17. The evidence is inadequate to infer an association 
between smoking cessation, the timing of cessation, 
and female fertility or fecundity.
18. The evidence is suggestive but not sufficient to infer 
that smoking cessation reduces the risk of earlier age 
at menopause compared with continued smoking.
19. The evidence is inadequate to infer that smoking 
cessation reduces the effects of smoking on male 
fertility and sperm quality.
20. The evidence is suggestive but not sufficient to infer 
that former smokers are at increased risk of erectile 
dysfunction compared with never smokers.
21. The evidence is inadequate to infer that smoking 
cessation reduces the risk of erectile dysfunction 
compared with continued smoking.
Chapter 5: The Benefits of Smoking 
Cessation on Overall Morbidity, 
Mortality, and Economic Costs
1. The evidence is sufficient to infer that smoking ces-
sation improves well-being, including higher quality 
of life and improved health status.
2. The evidence is sufficient to infer that smoking ces-
sation reduces mortality and increases the lifespan.
3. The evidence is sufficient to infer that smoking 
exacts a high cost for smokers, healthcare systems, 
and society.
4. The evidence is sufficient to infer that smoking ces-
sation interventions are cost-effective.
Chapter 6: Interventions for 
Smoking Cessation and Treatments 
for Nicotine Dependence
1. The evidence is sufficient to infer that behavioral 
counseling and cessation medication interventions 
increase smoking cessation compared with self-help 
materials or no treatment.
2. The evidence is sufficient to infer that behavioral coun-
seling and cessation medications are independently 
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effective in increasing smoking cessation, and even 
more effective when used in combination.
3. The evidence is sufficient to infer that proactive quit-
line counseling, when provided alone or in combina-
tion with cessation medications, increases smoking 
cessation.
4. The evidence is sufficient to infer that short text 
message services about cessation are independently 
effective in increasing smoking cessation, particu-
larly if they are interactive or tailored to individual 
text responses.
5. The evidence is sufficient to infer that web or Internet-
based interventions increase smoking cessation and 
can be more effective when they contain behavior 
change techniques and interactive components.
6. The evidence is inadequate to infer that smartphone 
apps for smoking cessation are independently effec-
tive in increasing smoking cessation.
7. The evidence is sufficient to infer that combining 
short- and long-acting forms of nicotine replacement 
therapy increases smoking cessation compared with 
using single forms of nicotine replacement therapy.
8. The evidence is suggestive but not sufficient to infer 
that pre-loading (e.g., initiating cessation medica-
tion in advance of a quit attempt), especially with 
the nicotine patch, can increase smoking cessation.
9. The evidence is suggestive but not sufficient to infer 
that very-low-nicotine-content cigarettes can reduce 
smoking and nicotine dependence and increase 
smoking cessation when full-nicotine cigarettes are 
readily available; the effects on cessation may be fur-
ther strengthened in an environment in which con-
ventional cigarettes and other combustible tobacco 
products are not readily available.
10. The evidence is inadequate to infer that e-cigarettes, 
in general, increase smoking cessation. However, 
the evidence is suggestive but not sufficient to infer 
that the use of e-cigarettes containing nicotine is 
associated with increased smoking cessation com-
pared with the use of e-cigarettes not containing 
nicotine, and the evidence is suggestive but not suf-
ficient to infer that more frequent use of e-cigarettes 
is associated with increased smoking cessation com-
pared with less frequent use of e-cigarettes.
11. The evidence is sufficient to infer that certain life 
events—including hospitalization, surgery, and 
lung cancer screening—can trigger attempts to quit 
smoking, uptake of smoking cessation treatment, 
and smoking cessation.
12. The evidence is suggestive but not sufficient to infer 
that fully and consistently integrating standardized, 
evidence-based smoking cessation interventions 
into lung cancer screening increases smoking ces-
sation while avoiding potential adverse effects of this 
screening on cessation outcomes.
13. The evidence is suggestive but not sufficient to infer 
that cytisine increases smoking cessation.
Chapter 7: Clinical-, System-, and 
Population-Level Strategies that 
Promote Smoking Cessation
1. The evidence is sufficient to infer that the develop-
ment and dissemination of evidence-based clinical 
practice guidelines increase the delivery of clinical 
interventions for smoking cessation.
2. The evidence is sufficient to infer that with adequate 
promotion, comprehensive, barrier-free, evidence-
based cessation insurance coverage increases the 
availability and utilization of treatment services for 
smoking cessation.
3. The evidence is sufficient to infer that strategies that 
link smoking cessation-related quality measures 
with payments to clinicians, clinics, or health sys-
tems increase the rate of delivery of clinical treat-
ments for smoking cessation.
4. The evidence is sufficient to infer that tobacco quit-
lines are an effective population-based approach 
to motivate quit attempts and increase smoking 
cessation.
5. The evidence is suggestive but not sufficient to infer 
that electronic health record technology increases 
the rate of delivery of smoking cessation treatments.
6. The evidence is sufficient to infer that increasing 
the price of cigarettes reduces smoking preva-
lence, reduces cigarette consumption, and increases 
smoking cessation.
7. The evidence is sufficient to infer that smokefree 
policies reduce smoking prevalence, reduce cigarette 
consumption, and increase smoking cessation.
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8. The evidence is sufficient to infer that mass media 
campaigns increase the number of calls to quitlines 
and increase smoking cessation.
9. The evidence is sufficient to infer that comprehen-
sive state tobacco control programs reduce smoking 
prevalence, increase quit attempts, and increase 
smoking cessation.
10. The evidence is sufficient to infer that large, pictorial 
health warnings increase smokers’ knowledge about 
the health harms of smoking, interest in quitting, 
and quit attempts and decrease smoking prevalence.
11. The evidence is suggestive but not sufficient to infer 
that plain packaging increases smoking cessation.
12. The evidence is suggestive but not sufficient to infer 
that decreasing the retail availability of tobacco 
products and exposure to point-of-sale tobacco mar-
keting and advertising increases smoking cessation.
13. The evidence is suggestive but not sufficient to infer 
that restricting the sale of certain types of tobacco 
products, such as menthol and other flavored prod-
ucts, increases smoking cessation, especially among 
certain populations.
The Evolving Landscape of Smoking Cessation
This section of the chapter reviews the history of 
smoking cessation, from its early origins to the modern 
era, including the changes that have occurred since pub-
lication of the 1990 Surgeon General’s report. It also high-
lights developments that have shaped current initiatives in 
smoking cessation and will set the stage for the chapters 
that follow. Finally, this section highlights a broad set of 
interventions that have been implemented over the past 
three decades and are proven to be effective at helping 
people quit successfully. These interventions, which are 
now being integrated into clinical care and societal policies, 
include (a) low-intensity interventions, such as telephone 
quitlines; (b) brief but systematically repeated interven-
tions in primary care settings; (c) over-the-counter medi-
cations; and (d) public policy approaches, such as increases 
in tobacco prices (e.g., through taxation), comprehensive 
policies to make indoor environments smokefree, and mass 
media campaigns that increase motivation to quit and may 
help sustain quit attempts (CDC 2014a; USDHHS 2014).
Historical Context of Smoking 
Cessation
Addiction Versus Habit
In 2017, a federal court ordered the major U.S. tobacco 
companies to run television and newspaper ads that tell the 
American public the truth about the dangers of smoking 
and secondhand smoke (U.S. Department of Justice 2017b). 
The ads included several statements related to the addic-
tiveness of nicotine:
• “Smoking is highly addictive. Nicotine is the addic-
tive drug in tobacco”;
• “Cigarette companies intentionally designed cigarettes 
with enough nicotine to create and sustain addiction”;
• “It’s not easy to quit”; and 
• “When you smoke, the nicotine actually changes the 
brain—that’s why quitting is so hard” (U.S. Department 
of Justice 2017a; Farber et al. 2018, p. 128).
However, previously secret documents from the 
tobacco industry reveal that the tobacco industry was 
aware of the addictive nature of nicotine for decades, 
long before they publicly acknowledged it or were even-
tually ordered by the court to publicly acknowledge it 
(Elias et al. 2018). In fact, the tobacco industry had been 
engineering cigarettes for decades to improve the rapid 
delivery of nicotine (Proctor 2011). For years, the tobacco 
industry coordinated well-financed, systematic efforts to 
deny the addictiveness of nicotine and the need for users 
to quit smoking, thereby trivializing the harms of tobacco 
use while promoting the benefits of nicotine (Hirschhorn 
2009; USDHHS 2014). The industry did this using well-
documented tactics, including aggressive funding and 
support for academic, medical, and community orga-
nizations that were sympathetic to this perspective 
(Proctor 2011).
Addiction to any substance often brings on a variety 
of efforts to overcome or treat it. However, until the late 
twentieth century, clinical and public health approaches 
to smoking cessation often treated smoking as a habit 
rather than as an addiction (USDHEW 1964). The tobacco 
industry has asserted for many years in public messaging 
and litigation that smoking is a personal choice (Friedman 
et  al. 2015). Indeed, both smoking and smoking cessa-
tion were considered personal choices; the idea was that 
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if persons started smoking cigarettes, they could quit if 
they truly wanted to, putting the onus on the individual 
smoker to quit using his or her own motivation and desire 
to do so. The Surgeon General first concluded in 1988 that 
”cigarettes and other forms of tobacco are addicting,” and 
“nicotine is the drug in tobacco that causes addiction” 
(USDHHS 1988, p. 9). Eventually, intensive medical treat-
ments and protocols—such as the use of multiple medi-
cations for long periods of time, long-term psychological 
counseling, and inpatient hospitalization—were devel-
oped to address the highly addictive nature of nicotine 
(Fiore et al. 2008). However, between 2000 and 2015, less 
than one-third of U.S. adult cigarette smokers reported 
using evidence-based cessation treatments, such as behav-
ioral counseling and/or medication, when trying to quit 
smoking (Babb et al. 2017).
The first comprehensive clinical practice guide-
line for smoking cessation was produced by the federal 
government in 1996 and emphasized the role of health-
care providers in providing assessment and treatment 
interventions for smoking with patients who smoke 
(Fiore et al. 1996). In 2008, an updated federal guide-
line, Treating Tobacco Use and Dependence: 2008 Update 
(hereafter referred to as the Clinical Practice Guideline), 
was published (Fiore et al. 2008). This guideline uses lan-
guage similar to that used in helping persons quit other 
addictive substances and is discussed in more detail in 
Chapter 7.
With the shift toward an improved understanding 
of the nature of nicotine addiction, terminology used 
to describe tobacco use has also shifted. The Diagnostic 
and Statistical Manual of Mental Disorders (5th edition) 
is the primary clinical source of diagnostic criteria for 
mental health disorders. It provides diagnostic criteria for 
“tobacco use disorder,” which includes physiologic depen-
dence, impaired control, and social impairment, among 
others (American Psychiatric Association 2013). These 
diagnostic criteria align with those for other substance use 
disorders and acknowledge the physical, psychological, 
and environmental components of addiction. However, as 
noted in the Clinical Practice Guideline, although not all 
tobacco use results in tobacco use disorder, any tobacco 
use has risks and, therefore, warrants intervention (Fiore 
et al. 2008). Accordingly, throughout this report, the term 
“tobacco use and dependence” is used to be inclusive of 
all patterns of use and to acknowledge the multifactorial 
and chronic relapsing nature of nicotine addiction. The 
term “nicotine dependence” is used specifically to refer 
to physiologic dependence on nicotine. This terminology 
aligns with that used in the Clinical Practice Guideline, 
which further details why the term “tobacco use and 
dependence” is most appropriate when discussing cessa-
tion interventions (Fiore et al. 2008).
Coverage of Smoking Cessation, 
Nicotine, and Addiction in Surgeon 
General’s Reports
Coverage of cessation, nicotine, and addiction in 
Surgeon General’s reports has evolved greatly since 1964, 
reflecting the evolution of scientific understanding of 
addiction to nicotine and its treatment.
Coverage of Smoking Cessation
Of the 34 Surgeon General’s reports on smoking 
and health published to date, this is the second to address 
smoking cessation as the main topic. Even so, beginning 
with the first report in 1964, evidence reviewed in various 
reports has supported some conclusions related to the 
health benefits of smoking cessation. Over time, as the 
epidemiologic findings from prospective cohort studies 
became more abundant and covered longer periods of 
time since quitting smoking, conclusions began to mount 
on the decline in risks for major smoking-caused diseases 
after cessation. In fact, declines in risk after cessation fig-
ured into the causal inference process presented in the 
reports, which documented a decrease in health risks after 
withdrawal of smoking—the presumptive causal agent.
The 1964 Surgeon General’s report reviewed find-
ings from seven prospective cohort studies that had 
included sufficient numbers of former smokers to provide 
estimates about cause-specific relative risk for mortality 
from selected diseases (USDHEW 1964). The data from the 
cohort studies were complemented by case-control studies 
for some cancer sites that had also addressed a change in 
risk after smoking cessation. For all-cause mortality, the 
1964 report stated that compared with never smokers, rel-
ative mortality was 40% higher among former smokers 
and 70% higher among current smokers. For lung cancer, 
quantitative relationships with smoking patterns were 
described as follows: “The risk of developing lung cancer 
increases with duration of smoking and the number of 
cigarettes smoked per day, and is diminished by discon-
tinuing smoking” (p. 37). In considering the causal nature 
of the association between smoking and lung cancer, the 
report stated, “Where discontinuance, time since discon-
tinuance, and amount smoked prior to discontinuance 
were considered in either retrospective studies or, with 
more detail, in prospective studies, these all showed lower 
risks for ex-smokers, still lower risks as the length of time 
since discontinuance increased, and lower risks among 
ex-smokers if they had been light smokers” (p. 188). The 
report did not conclude that smoking caused cardiovas-
cular disease, but it noted a lower risk of death from car-
diovascular disease among former smokers compared with 
continuing smokers and stated, “Although the causative 
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role of cigarette smoking in deaths from coronary disease 
is not proven, the Committee considers it more prudent 
from the public health viewpoint to assume that the estab-
lished association has causative meaning than to suspend 
judgment until no uncertainty remains” (p. 32).
In ensuing Surgeon General’s reports through the 
1970s, the health benefits of smoking cessation did not 
receive systematic attention, but the results identified 
a declining risk for some diseases after cessation. The 
1979 report offered detailed reviews for major diseases, 
and it concluded that compared with smokers, risks were 
lower among former smokers for all-cause mortality, 
atherosclerosis and coronary heart disease, lung cancer, 
larynx cancer, lung function, and respiratory symp-
toms (USDHEW 1979). Three Surgeon General’s reports 
released in the early 1980s focused on the health conse-
quences of smoking on specific major disease categories: 
cancer (USDHHS 1982), cardiovascular disease (USDHHS 
1983), and chronic lung disease (USDHHS 1984). Each 
report also examined the impact of smoking cessation 
on each of those disease categories. In 1988, the report 
reviewed the evidence to date on nicotine and drew major 
conclusions that nicotine was addictive (USDHHS 1988).
By 1990, the scope and depth of evidence on smoking 
cessation was sufficiently abundant to justify a full report, 
The Health Benefits of Smoking Cessation. The report’s 
conclusions expanded on those of earlier reports, sum-
marizing descriptions of the temporal course of declining 
risk for many of the diseases caused by smoking (USDHHS 
1990). For example, the report concluded, “The excess risk 
of [coronary heart disease] caused by smoking is reduced 
by about half after 1 year of smoking abstinence and then 
declines gradually. After 15 years of abstinence, the risk of 
[coronary heart disease] is similar to that of persons who 
have never smoked” (p. 11).
Importantly, the 1990 report was the first to address 
smoking cessation and reproduction. That report offered 
strong conclusions with clinical implications related to 
reproduction and offered conclusions about the timing 
of cessation across gestation and implications for birth-
weight (USDHHS 1990).
The 2004 Surgeon General’s report, The Health 
Consequences of Smoking, covered active smoking and 
disease; and the 2014 Surgeon General’s report, The Health 
Consequences of Smoking—Fifty Years of Progress, again 
covered the full range of health consequences of smoking, 
providing conclusions that drew on data from long-running 
cohort studies that described how risks change in former 
smokers up to several decades after quitting. For example, 
the 2004 report concluded, “Even after many years of not 
smoking, the risk of lung cancer in former smokers remains 
higher than in persons who have never smoked” (USDHHS 
2004, p. 25). In contrast, regarding the effect of smoking in 
accelerating the decline of lung function, the report deter-
mined “[t]he evidence is sufficient to infer a causal rela-
tionship between sustained cessation from smoking and a 
return of the rate of decline in pulmonary function to that 
of persons who had never smoked” (p. 27). The 2014 report 
updated estimates of relative risks in former smokers, 
drawing on more contemporary cohorts, and used the esti-
mates to calculate attributable mortality (USDHHS 2014). 
The extended follow-up of the cohort studies documented 
the benefits of cessation by early middle age for reducing 
the risk of death from any cause.
Coverage of Nicotine and Addiction
The 1964 Surgeon General’s report suggested that 
smoking was a form of habituation, stating that “[e]ven 
the most energetic and emotional campaigner against 
smoking and nicotine could find little support for the view 
that all those who use tobacco, coffee, tea, and cocoa are 
in need of mental care even though it may at some time in 
the future be shown that smokers and nonsmokers have 
different psychologic characteristics” (USDHEW 1964, 
pp. 351–352). The report used such words as “compulsion” 
and “habit” but did not consider nicotine to be addicting: 
“Proof of physical dependence requires demonstration of a 
characteristic and reproducible abstinence syndrome upon 
withdrawal of a drug or chemical which occurs spontane-
ously, inevitably, and is not under control of the subject. 
Neither nicotine nor tobacco comply with any of these 
requirements” (USDHEW 1964, p. 352). Correspondingly, 
the report emphasized habituation and not addiction: “The 
habitual use of tobacco is related primarily to psycholog-
ical and social drives, reinforced and perpetuated by the 
pharmacologic actions of nicotine on the central nervous 
system” (USDHEW 1964, p. 354). In 1977, the National 
Institute on Drug Abuse began to support studies of cig-
arette smoking as a “dependence process,” comparing it 
to other drug addictions (Parascandola 2011). The mono-
graph, The Behavioral Aspects of Smoking (Krasnegor 
1979), reflected an advancing understanding of the power 
of nicotine as a pharmacologic agent: “Nicotine has been 
proposed as the primary incentive in smoking [Jarvik 1973, 
as cited in Krasnegor 1979] and may be instrumental in 
the establishment of the smoking habit. Whether or not 
it is the only reinforcing agent, it is still the most pow-
erful pharmacological agent in cigarette smoke” (p. 12). 
The 1979 Surgeon General’s report, Smoking and Health, 
devoted considerable attention to the behavioral aspects 
of smoking, but it still did not use the term “addiction” 
(USDHEW 1979). That report also concluded that there was 
general acceptance of the existence of a tobacco withdrawal 
syndrome, which was more prominent in heavy smokers.
The 1988 Surgeon General’s report explored the 
clinical and public health implications of smoking, with 
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several major conclusions serving as an indictment of the 
addictiveness of nicotine in cigarettes. In fact, this report 
stated for the first time that cigarettes are addictive and 
function in a similar fashion to cocaine and heroin use. 
The three major conclusions of that report were:
• “Cigarettes and other forms of tobacco are addicting”;
• “Nicotine is the drug in tobacco that causes addic-
tion”; and 
• “The pharmacologic and behavioral processes that 
determine tobacco addiction are similar to those 
that determine addiction to drugs such as heroin 
and cocaine” (USDHHS 1988, p. 9).
Later Surgeon General’s reports on tobacco have 
addressed the subsequent scientific advances in the 
area of smoking and addiction, particularly the 2010 
report on mechanisms by which smoking causes disease 
(USDHHS 2010).
Perspectives on Smoking Cessation
In 2015, most smokers stated that they wanted to 
quit smoking (68%), and about 56% of smokers made 
a serious attempt to quit; however, only about 7% of 
smokers reported that they had recently quit (Babb 
et  al. 2017). Despite evidence demonstrating that using 
smoking cessation pharmacotherapy with behavioral sup-
port is more effective than quitting without these treat-
ments, most smokers who had recently quit reported 
that they did not quit with medication or counseling 
assistance (see Chapter 6). Proponents of encouraging 
smokers to quit without treatment, often called quitting 
“cold turkey,” point to data indicating that most smokers 
who quit successfully do so without medications or any 
type of formal assistance, as well as to population surveys 
suggesting that cold-turkey quitters do as well or better 
than those who use over-the-counter NRTs. Proponents of 
this approach also suggest that medicalization may dis-
empower smokers and create artificial barriers to quitting 
(Alpert et al. 2013; Polito 2013). In contrast, others note 
that because of a lack of insurance coverage and other bar-
riers, many smokers have little choice but to quit without 
formal treatment. Selection bias may also play a factor, as 
the most heavily addicted smokers are those most likely to 
use NRT, but these smokers also have a lower likelihood of 
success. In addition, most of those who use NRT do so for 
short periods of time or at lower-than-recommended doses 
and do not have adjunctive support available from tobacco 
cessation quitlines or other interventions (Amodei and 
Lamb 2008). There are also issues of recall and attribution 
bias, which may make smokers more likely to report their 
most proximal experiences with use or nonuse of pharma-
cologic smoking cessation aids and/or behavioral supports 
and not to report previous quit attempts during which 
they used pharmacologic aids and/or behavioral support.
During most of the twentieth century, smokers 
who wanted to quit had limited resources to do so, espe-
cially smokers with mental health or substance use dis-
orders. For example, the investment in research required 
for behavioral, pharmacologic, and systems-level inter-
ventions that increase successful cessation had been rel-
atively limited given the magnitude of tobacco-related 
disease burden and the size of the population affected 
(Dennis 2004; Carter et al. 2015; Hall et al. 2016). Even 
when interventions developed in the 1980s and 1990s 
were clearly shown to be effective, most health insurers 
and health systems showed little interest in providing 
coverage for or integrating into regular practice any new 
pharmacologic, behavioral, or systems approaches to ces-
sation (see Chapter 6). Additionally, many medical schools 
provide only a small amount of time, if any, in their aca-
demic curriculum or programs for developing clinical 
skills to train future physicians in addressing tobacco use 
and dependence in patients (Ferry et al. 1999; Montalto 
et al. 2004; Powers et al. 2004; Association of American 
Medical Colleges 2007; Geller et al. 2008; Richmond et al. 
2009; Torabi et al. 2011; Griffith et al. 2013).
Development and Evolution of 
a Paradigm for Treating Nicotine 
Addiction
Clinicians’ views on smoking cessation shifted toward 
the end of the twentieth century. Given the increasing 
amount of evidence and awareness of the robust and wide-
spanning beneficial effects of smoking cessation on var-
ious chronic diseases (USDHHS 1990), clinicians began to 
understand that promoting smoking cessation was among 
the most powerful interventions for increasing health, 
while merely advising patients to quit was insufficient in 
promoting smokers to initiate quitting and sustain absti-
nence without relapsing. Concurrently, researchers began 
to better understand the powerfully addictive properties 
of nicotine and the complexities of the nicotine addiction 
process (USDHHS 1988). This knowledge was dissemi-
nated widely to health professionals and the community 
(Fiore et al. 1996).
Nicotine addiction is now increasingly empha-
sized as a main driver of both the initiation and contin-
uation of smoking. Thus, the medical community sees 
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the morbidity and mortality associated with smoking as 
clinical endpoints and nicotine addiction as the cause. 
Correspondingly, a growing number of intensive behav-
ioral and pharmacologic treatments have become avail-
able to promote sustained abstinence.
Epidemiologic Shifts in Smoking 
Cessation
Chapter 2 provides a detailed discussion of key pat-
terns and trends in cigarette smoking cessation in the 
United States. It also reviews the changing demographic 
and smoking-related characteristics of cigarette smokers, 
with a focus on how these changes may influence future 
trends in cessation.
Changes in the Patterns of Smoking and 
Population Characteristics of Smokers
The typical profile of the smoker has evolved over 
the years. The “hardening hypothesis” suggests that adults 
who continue to smoke cigarettes in the face of strength-
ening tobacco control policies and the increasing avail-
ability of efficacious cessation interventions will tend to be 
heavier smokers who are more highly addicted, less inter-
ested in quitting, and likely to have more difficulty in quit-
ting (National Cancer Institute [NCI] 2003). Only a lim-
ited amount of evidence supports this hypothesis (Hughes 
2011). Instead of increases over time in the proportion of 
smokers with frequent or heavy patterns of smoking, as 
would be predicted by hardening, the proportion has actu-
ally decreased (Jamal et al. 2016). Furthermore, from 2005 
to 2015, the percentage of current smokers who were daily 
smokers declined from 80.8% to 75.7%, and the propor-
tion of current smokers who smoked on only some days 
(i.e., nondaily smokers) increased from 19.2% to 24.3% 
(Jamal et al. 2016). Similarly, among daily smokers, the 
average number of cigarettes smoked per day declined 
from 16.7 in 2005 to 13.8 in 2014. However, when con-
sidering other measures of dependence, some modest and 
preliminary support exists for hardening among treat-
ment-seeking smokers. For example, in a summary review 
by Hughes and colleagues (2011), two of four studies 
showed increases in dependence and decreases in quit 
rates, but similar trends were not found among the gen-
eral population of smokers who had quit.
Reductions in the frequency and heaviness of 
smoking do not necessarily suggest that a simple continu-
ation of current approaches to increase smoking cessation 
will increase or even maintain progress in successful quit-
ting. Nondaily or light smokers would be expected to be 
less addicted to nicotine and, therefore, when motivated 
to make a cessation attempt, would find it easier to 
quit than heavier smokers. Still, helping light and non-
daily smokers to quit presents challenges. For example, 
some light and nondaily smokers do not self-identify as 
smokers, do not believe that they are addicted to nicotine, 
do not feel that they are at risk of smoking-related health 
effects, and do not expect quitting to be difficult (Berg 
et al. 2013; Scott et al. 2015; Chaiton et al. 2016). The 2008 
Clinical Practice Guideline does not recommend cessa-
tion medications for use by light smokers, based on insuf-
ficient evidence of effectiveness in this population (Fiore 
et al. 2008). Ten years later, this gap in knowledge about 
treating light smokers is largely unchanged (Ebbert et al. 
2016) (see Chapter 6) and presents a barrier for addressing 
this growing subpopulation of smokers.
The prevalence of smoking is increasingly concen-
trated in the United States in populations that may face 
barriers to quitting. These include persons with behav-
ioral health conditions (including mental health condi-
tions or substance use disorders); persons of low socio-
economic status; persons who are lesbian, gay, bisexual, 
or transgender; American Indians/Alaska Natives; recent 
immigrants from countries with a high prevalence of 
smoking; residents of the South and Midwest; and per-
sons with a disability. Such populations have a markedly 
higher prevalence of cigarette smoking than their respec-
tive counterparts, and the decline in the prevalence of 
smoking in the United States as a whole has been slower 
among these groups, particularly those with behavioral 
health conditions and those of lower socioeconomic 
status (Grant et al. 2004; Schroeder and Morris 2010; CDC 
2013b, 2016; Cook et  al. 2014; Szatkowski and McNeill 
2015) (see Chapter 2).
Changes in the Products Used by Smokers
The emergence of a wide array of new tobacco prod-
ucts and the increasing use of those products, combined 
with continued use of other conventional tobacco prod-
ucts, such as menthol cigarettes and smokeless tobacco, 
could complicate cessation efforts aimed at cigarette 
smoking (Trinidad et  al. 2010; USDHHS 2014; Villanti 
et al. 2016; Wang et al. 2016). These products include hoo-
kahs (water pipes), little cigars and cigarillos, e-cigarettes, 
and heated tobacco products. Cigarette smokers who also 
use one or more other tobacco products, generally known 
as “dual” or “poly” use, have higher dependence on nic-
otine and greater difficulty quitting (Wetter et  al. 2002; 
Bombard et al. 2007; Soule et al. 2015).
As of July  26, 2019, 11  states and the District of 
Columbia have passed laws legalizing nonmedical mari-
juana use (National Conference of State Legislatures 
[NCSL] 2019). Although not a tobacco product, mari-
juana is frequently used in combination with conventional 
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cigarettes or other tobacco products (e.g., cigars, 
e-cigarettes). For example, approximately 70% of adults 
who are current users of marijuana are also current users 
of tobacco (Schauer et al. 2016). Results from population-
based surveys and some clinical studies indicate an asso-
ciation between the use of menthol-flavored cigarettes or 
marijuana and a lower probability of successful quitting 
(Ford et al. 2002; Patton et al. 2005; Gandhi et al. 2009; 
Schauer et al. 2017). The available longitudinal evidence 
from rigorously conducted studies is limited, so it is too 
soon to determine whether this association is correla-
tional or causal.
Developments in Approaches 
to Smoking Cessation at the 
Individual Level
This section summarizes the landmark developments 
since the 1990 Surgeon General’s report that have shaped 
treatment for tobacco dependence and corresponding 
breakthroughs in smoking cessation interventions at the 
individual level. Chapter 6 provides detailed evidence for 
current and emerging smoking cessation treatments, 
adding to the evidence presented in the Clinical Practice 
Guideline (Fiore et al. 2008). It also explores approaches 
to increasing the impact of tobacco cessation treatment 
through improved efficacy and increased reach.
Pharmacotherapy
The scientific understanding of the neurobiologic 
impact of chronic exposure to nicotine (USDHHS 2010) 
has stimulated research and development that focuses 
on identifying novel medications and improving existing 
medications. The only FDA-approved smoking cessation 
medication at the time of the 1990 Surgeon General’s 
report was the gum form of NRT (USDHHS 1990). Since 
then, several additional NRT formulations (transdermal 
patch, lozenge, inhaler, and nasal spray) have been devel-
oped, with all but the inhaler and spray now approved for 
over-the-counter sale. Additionally, FDA has approved 
two non-NRT medications for smoking cessation: bupro-
pion and varenicline (GlaxoSmithKline 2017; FDA 2017; 
Pfizer 2019).
Adding to the progress seen for individual agents, 
favorable developments in pharmacologic treatment have 
been seen in a variety of other areas over the past two 
decades. For example, because of the modest efficacy of 
monotherapy and the recognition that persons with nico-
tine addiction benefit from intensive treatments, a variety 
of combination pharmacotherapies have been studied (see 
Chapter 6).
Behavioral Interventions
Discoveries in the behavioral and social sciences 
have deepened our understanding of psychosocial influ-
ences on the nature and treatment of tobacco dependence, 
which has propelled new approaches to behavioral treat-
ment. The evidence has clarified that during and long after 
the dissipation of acute pharmacologic withdrawal from 
nicotine during cessation, several factors—including 
vacillation of negative emotional states, repeated urges 
to smoke, diminished motivation, and having less con-
fidence in the ability to successfully quit—can persist 
throughout the cessation process and undermine quitting 
(Liu et al. 2013; Ussher et al. 2013). Furthermore, encoun-
tering environments and situations previously associated 
with smoking, such as establishments that serve alcohol 
or interacting with friends who smoke, has been demon-
strated to increase risk of relapse (Conklin et al. 2013). 
Fortunately, behavioral treatment models for mental 
health conditions and other substance use disorders have 
been translated and adapted for nicotine addiction to 
address these factors and have been shown to improve quit 
rates (Hall and Prochaska 2009).
In addition to quitlines, which have been a long-
standing intervention to deliver population-based behav-
ioral smoking cessation support, technological innovations 
have opened new service delivery platforms for sophisti-
cated behavioral cessation interventions in other modali-
ties. In the 1990s, computer-tailored, in-depth, personal-
ized mailings based on answers to a lengthy questionnaire 
were developed and tested on smokers; the tailored or per-
sonalized mailings were more effective than mailings with 
standard text (Prochaska et al. 1993; Strecher et al. 1994). 
Receipt of personalized written feedback and self-help 
materials was also found to increase cessation rates (Curry 
et al. 1991). A systematic review by the U.S. Preventive 
Services Task Force (USPSTF) (2015) found self-help mate-
rials that were tailored to the individual patient to be effec-
tive cessation interventions. Interactive program modal-
ities have been developed and tested (USPSTF 2015) for 
desktop and laptop computers, first via programs operated 
from a CD-ROM or hard drive, later via Internet down-
loads, and more recently from “the cloud” (Strecher et 
al. 2005; Haskins et al. 2017). The current state of science 
and technology also allows the leveraging of mobile phone 
technology and applications to deliver cessation interven-
tions (Whittaker et al. 2016). These include applications 
involving standardized motivation-enhancing texts or 
quit-promoting strategies—some of which offer real-time, 
live-peer, or professional advising or counseling within the 
application (Smokefree.gov n.d.). Preliminary evaluations 
have suggested that these applications may be beneficial 
to users (Cole-Lewis et al. 2016; Squiers et al. 2016, 2017; 
Taber et al. 2016) and that the cost of delivery is low.
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Treating Tobacco Use and Dependence
The 2000 and 2008 Clinical Practice Guidelines had 
marked impacts on increasing understanding of and oper-
ationalizing the current paradigm of treating tobacco use 
and dependence (Fiore et al. 2000, 2008). Until the 1990s, 
synopses of the state of the evidence on smoking cessa-
tion usually relied on a somewhat informal aggregation 
of clinical and population-based studies, an approach that 
is prone to author bias in the choice of studies included 
and in their interpretations. Markedly more formal review 
processes, such as systematic literature reviews, were 
applied to smoking cessation and treatment in the 1990s 
and 2000s, as thousands of cessation-related studies accu-
mulated. These more formal reviews systematized the lit-
erature review process by using strict criteria for grading 
studies and employing meta-analyses where appropriate; 
they also included a more transparent and elaborate pro-
cess for synthesizing evidentiary findings into conclusions 
and recommendations.
In addition, the standards and framing of cessation 
research have evolved over the past several decades, which 
is consistent with the increased sophistication of phar-
maceutical and population-based trials in general. For 
example, clinical trials have evolved from examining the 
success rates of persons completing the trial, often exam-
ining only the point prevalence of abstinence, into using 
intent-to-treat, where all persons starting treatment are 
considered in the denominator and those lost to follow-up 
are counted as smokers or subject to data imputation tech-
niques (Hall et al. 2001; Mermelstein et al. 2002; SRNT 
Subcommittee on Biochemical Verification 2002; Hughes 
et al. 2003; Shiffman et al. 2004). Definitions of successful 
abstinence often examine smoking status at 1  month, 
6 months, and 1 year of abstinence after treatment.
Notably, some definitions of successful abstinence 
allow for brief lapses in smoking cessation to more accu-
rately reflect the natural course of achieving long-term 
abstinence (Zhu et al. 1996). Similarly, population-level 
surveillance and research have evolved to include increas-
ingly more complex questions and techniques to more 
accurately capture the nature of respondents’ use of 
tobacco products and cessation behavior. For example, 
sets of questions have been developed to better categorize 
respondents’ use of healthcare services and the nature of 
cessation support they received. In addition, new technol-
ogies have been deployed to better understand the patterns 
of behavior among smokers, such as ecological momen-
tary assessment, which cues smokers to provide data on 
their smoking urges and other thoughts, emotions, and 
behaviors in real time (Shiffman 2009). Large clinical 
trials have also examined the interplay between multiple 
factors that affect quit success, such as different medica-
tions, dual-medication therapy, and different approaches 
and intensities of behavioral interventions (Redmond 
et al. 2010).
The Clinical Practice Guidelines used formal sci-
entific review processes to analyze thousands of studies 
produced in the 1990s and 2000s—analyses that included 
detailed evidence reviews that resulted in practical rec-
ommendations for clinicians (Fiore et al. 2000, 2008). 
Unlike most clinical guidelines, they also included rec-
ommendations at the health systems and policy levels 
based on evidence and tools designed specifically for cli-
nicians to use in office practices. In addition, multiple 
Cochrane reviews have been performed on medications 
and counseling approaches (Hajek et al. 2013; Stead et 
al. 2013; Lindson-Hawley et al. 2015), and USPSTF has 
updated its literature on clinical preventive services (Siu 
and USPSTF 2015; USPSTF 2015). Based on the findings 
presented, the current paradigm for smoking cessation 
conceptualizes nicotine addiction as a chronic, relapsing 
disorder that benefits from long-term management and 
intensive treatment approaches, as do other chronic dis-
eases. The major findings have shaped the way cessation 
is currently viewed:
• Any level of treatment is beneficial, and more inten-
sive and longer behavioral and pharmacologic treat-
ment is generally better.
• Physicians, psychologists, pharmacists, dentists, 
nurses, and numerous other healthcare professionals 
can treat nicotine addiction in smokers. Thus, by 
extension, the various settings in which such profes-
sionals work represent appropriate venues for pro-
viding these services.
• Behavioral interventions and FDA-approved phar-
macotherapies are effective for treating nicotine 
dependence. A combination of behavioral interven-
tions and pharmacotherapy is the optimal treatment 
based on overwhelming scientific evidence, with 
superiority in efficacy over either intervention alone.
Advances in research and technology have shaped 
how the clinical and scientific communities view and 
approach treatment for nicotine addiction in smokers, 
but this progress continues to lag the advances made in 
treating other chronic diseases. For instance, in cancer, 
cardiovascular disease, and other illnesses with multifac-
torial etiologies, major strides have been made toward pre-
cision treatment methods, which are based on the premise 
that clinical outcomes can be enhanced by selecting, 
adapting, and tailoring treatment on the basis of a patient’s 
specific clinical profile and disease pathogenesis (Collins 
and Varmus 2015). Such approaches have been endorsed 
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and promoted as part of the Precision Medicine Initiative 
(Genetics Home Reference 2018), which reinforces that the 
future of clinical care lies in basic and clinical research and 
their translation to optimize health outcomes. Although 
precision treatment has not advanced for smoking cessa-
tion at the same rate as it has for treating certain other ill-
nesses, emerging findings suggest that a personalized, pre-
cision approach has the potential to meaningfully improve 
smoking cessation outcomes (Allenby et al. 2016).
Evolution of Approaches to 
Smoking Cessation at the 
Population Level
More Intensity Versus Higher Reach of Support 
Services
Through the first decades in which cessation inter-
ventions were developed, most of the emphasis was on 
improved efficacy—specifically, increasing the probability 
that if smokers engaged and fully used an intervention ser-
vice, their chances of success would be increased. As inter-
ventions, both behavioral or pharmacologic therapies and 
combination therapies have become increasingly effec-
tive, but despite the effectiveness of such therapies, they 
are not being used as designed by substantial numbers of 
smokers (Zhu et al. 2012). Several theoretical models sug-
gested that efforts to develop interventions need to con-
sider their population impact, not just their individual 
efficacy for those taking part in the intervention.
In the 1990s, the potential for smoking cessation 
interventions to make an impact on the tobacco epidemic 
was overshadowed by the low rate at which smokers actu-
ally used interventions. Several factors contributed to this 
phenomenon, and several other factors initially assumed 
to be the main drivers were eliminated. One assumption 
was that smokers were just not very interested in quit-
ting or in accessing help to quit. However, population-
level surveys over time and among diverse populations 
showed that not only were smokers interested in quitting, 
but more than half planned to quit in the next 6 months 
and had attempted to quit in the past year (Babb et al. 
2017). In addition, when physicians or other healthcare 
providers systematically offered support for quitting, such 
as medications or follow-up, a much larger than expected 
fraction of smokers agreed to accept support. Even so, fur-
ther examination revealed that helping smokers quit pre-
sented unique obstacles. Up to the 1990s,
• Almost no health insurers provided any coverage 
of smoking treatments—either medications, coun-
seling, or physician intervention.
• Most physicians did not systematically address 
smoking in the course of clinical practice for mul-
tiple reasons, including lack of time, perception that 
patients are unready to quit, limited resources, and 
inadequate clinical skills related to cessation.
• Although smokers generally understood that 
smoking had unfavorable health effects, many did 
not fully understand or accept the magnitude or 
personal relevance of smoking’s effects on various 
aspects of health and its dramatic overall effect on 
longevity (USDHHS 1989; Chapman et al. 1993). 
Even if smokers accept the theoretical possibility 
of risk, they often do not believe that the hypothet-
ical future risk from smoking applies to them per-
sonally—for example, they believe they have “good 
genes” or other healthy habits, or they smoke in a 
less dangerous manner (Oakes et al. 2004).
• Smokers and physicians did not realize that effective 
treatments were available.
• Even when smokers wanted to quit and were poten-
tially interested in getting help, evidence-based treat-
ments were not readily available to them because of 
financial and practical barriers.
Thus, during the 1980s and 1990s, a series of system 
and policy innovations were developed and tested to 
address these barriers. These innovations included the use 
of organizational system change and quality improvement 
theory to systematically address opportunities to influ-
ence smokers during routine interactions with healthcare 
systems (Solberg et al. 1990; Manley et al. 1992); experi-
ments providing different types of insurance coverage for 
cessation treatments (Curry et al. 1998); the development 
of more easily accessible treatments, such as phone-based 
quitlines (Orleans et al. 1991; Zhu et al. 2012); integrated 
promotion of cessation via mass media campaigns that 
encouraged the use of cessation services (McAfee et  al. 
2013); and easily accessible, in-person cessation clinics 
(Lee et al. 2016).
The lack of accessibility to cessation support was 
addressed in several ways. One approach attempted to 
bypass the lack of availability of support within healthcare 
services by creating easily accessible, low-intensity ces-
sation supports, such as telephone quitlines or in-person 
clinics, that were generally operated and funded out-
side the healthcare system. Another approach attempted 
to integrate very brief but systematic, repeated support 
for cessation into primary care clinical practices while 
working to obtain insurance coverage and accessibility to 
more intense services for those interested in quitting. In 
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some instances, these approaches were combined syner-
gistically (McAfee et al. 1998). A few U.S. states and some 
other countries, such as the United Kingdom, success-
fully developed—through funding from tobacco tax dol-
lars or government healthcare—networks of freestanding, 
in-person cessation clinics that provided basic cessation 
counseling and medications (Gibson et al. 2010; West et al. 
2013). However, this model has not been sustained in any 
geographic region of the United States, primarily because 
of limited resources to maintain it over time. Still, a higher 
intensity model, which includes more intensive and com-
prehensive cessation components, has continued to focus 
on markedly improving the chances of success by treating 
nicotine addiction via a tertiary treatment delivery model, 
akin to how a cancer center approaches patients who are 
referred for its services. For example, the Mayo Clinic and a 
handful of similar referral clinics use such strategies as in-
depth evaluation by multidisciplinary staff; personalized 
treatment plans; recurrent follow-up; and, in some cases, 
admission to a residential facility or hospital (Hays et al. 
2011). Although such programs often achieve high rates 
of smoking cessation, their utility is greatly limited by the 
high cost of implementation, unclear cost-effectiveness, 
and limited reach. For example, during a 7-year period, in 
a study of a large outpatient clinic, 2–3% of smokers used 
the available nicotine dependence services, even when the 
services were optimally promoted and delivered (Burke 
et al. 2015).
Population-Based Interventions
Historically, tobacco control efforts have focused 
on either helping smokers quit at the individual level, 
such as through clinical interventions, or on providing 
population-level interventions to decrease the preva-
lence of smoking. Potential synergies between these two 
approaches have become increasingly apparent over the 
past several decades. This section discusses four exam-
ples of attempts to combine individually delivered cessa-
tion support and population-based strategies to smoking 
cessation: quitlines, health systems transformation, mass 
media campaigns, and health insurance coverage of 
smoking cessation treatment. Chapter 7 provides a more 
in-depth review of the current literature on each of these 
topics and on other population-based interventions that 
have been shown to promote cessation, such as increasing 
the prices of tobacco products and the implementation of 
smokefree policies.
Quitlines
In the late 1980s and throughout the 1990s, re-
searchers interested in helping large numbers of smokers 
quit smoking began to experiment with the provision of 
behavioral counseling support via telephone, in the hope 
of overcoming such barriers to utilization as cost and the 
reluctance of many smokers to attend face-to-face group 
or individual sessions. Providing counseling centrally was 
thought to provide more opportunities for systematically 
improving the quality of the counseling and the research 
infrastructures used to answer questions about the ces-
sation process. Protocols were developed and tested in 
a variety of environments, ranging from academic cen-
ters (Ossip-Klein et al. 1991) to health systems (Orleans 
et al. 1991) to state health departments (Zhu et al. 1996). 
Multiple large, randomized trials have since established 
the effectiveness of the telephone modality (Stead et al. 
2013). The availability of quitlines grew rapidly during the 
1990s and the early 2000s.
The adoption of quitlines by state health departments 
was initially facilitated by the increased revenue provided 
to states from the Master Settlement Agreement in 1998 
and higher taxes on tobacco products. In 2003, CDC pro-
vided supplemental funding to state health departments to 
establish quitlines in those that did not have them and to 
enhance quitline services and access in those with existing 
quitlines (Zhang et al. 2016). In 2004, a national network 
of state quitlines was created with a single national portal 
number (1-800-QUIT-NOW), which is serviced by NCI 
(Cummins et al. 2007; CDC 2014b). By 2006, residents in 
all 50 states, the District of Columbia, and U.S. territories 
had access to quitlines, and the North American Quitline 
Consortium had been developed to help set evaluation stan-
dards and enhance the collection of information, including 
an agreed-upon minimum dataset to be collected from 
all callers, with a data warehouse funded by CDC (North 
American Quitline Consortium 2007; Keller et al. 2010). 
Providers of quitline services grew from modest operations 
with a few dozen employees to multiple large providers 
based in a range of organizations, including for-profit and 
nonprofit national healthcare organizations and academic 
centers, some employing hundreds of “quit coaches.” 
Mass Media Campaigns
Mass media educational campaigns on the hazards 
of smoking have been used for decades, in part to moti-
vate quit attempts in the general population of current 
smokers, and a considerable evidence base shows their 
effectiveness in promoting successful cessation at the pop-
ulation level (NCI 2008; USDHHS 2014). These campaigns 
are generally thought of as being unrelated to efforts 
to provide direct assistance and support to individual 
smokers in healthcare settings or through community 
initiatives. However, since 1990, numerous efforts have 
been made to create synergies and efficiencies between 
mass media campaigns and the provision of individual 
support for quit attempts. For example, CDC’s Tips From 
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Former Smokers (Tips) media campaign features ads with 
real people (former smokers) who have suffered the health 
consequences of smoking to increase awareness of suf-
fering caused by smoking. The ads are also tagged with a 
quitline number (CDC 2012, 2013a). Tagging the ads with 
an offer of assistance may help smokers absorb the mes-
sage of the ad by making it actionable rather than simply 
negative. Chapter 7 discusses the effectiveness of mass 
media campaigns, including Tips.
Healthcare Systems
Clinic-Based Integration of Health Systems
In the 1980s, NCI funded primary care-based 
research showing that a systematic approach to addressing 
tobacco use could help individual smokers in a clinical 
practice to quit and could lower the prevalence of tobacco 
use in the population served by a clinic (Solberg et al. 
1990; Manley et al. 1992). Out of this research grew the 
“4 A’s model,” a carefully crafted intervention for trans-
forming the approach of primary care clinics to tobacco 
cessation that was developed and packaged for widespread 
dissemination. This model differed from previous efforts 
in that it emphasized a systems approach to effectively 
address tobacco use in the context of primary care clin-
ical practice, rather than simply developing an interven-
tion that required for delivery its own separate health-
care or community infrastructure. The model had four 
components:
• Ask: Systematically identify the smoking status of 
all patients flowing through a practice, usually by 
an assistant interviewing the patient rather than 
relying on physician recall of patients’ smoking 
status at every visit;
• Advise: Provide at every encounter very brief, non-
threatening recommendations to quit;
• Assist: Offer practical help for quitting, including 
tips to make it through the first few weeks and brief 
supportive counseling; and
• Arrange: Ensure that any smoker planning a quit 
attempt will receive follow-up (e.g., during future 
office visits and/or through off-site resources).
Despite being shown to have significant benefits to 
smokers in clinical practices in the 1980s and 1990s, 
the adoption, implementation, and subsequent mainte-
nance of this systematic approach was slow and uneven 
(Ferketich et al. 2006).
Based on an additional review of the evidence (Fiore 
et al. 2008), a fifth step, “Assess,” was added between the 
“Advise” and “Assist” components, thereby emphasizing 
the importance of determining a patient’s level of interest 
in quitting so that assistance and follow-up could be tai-
lored to that person’s specific circumstances. For example, 
a brief interaction with a patient not interested in quitting 
would focus on enhancing motivation rather than pro-
viding quit advice.
The 5 A’s model is an example of an intervention 
designed to maximize the probability of a smoker making 
a quit attempt and the probability that he or she will be 
successful during such an attempt. The model seeks to 
accomplish these two tasks for a population of smokers. 
Building on the effectiveness of the 5 A’s model, the Ask, 
Advise, Refer (AAR) model was developed as a shorter 
alternative to the 5 A’s model in clinical settings where 
there is less time afforded for the patient encounter 
(Schroeder 2005). In addition, a different model, termed 
Ask, Advise, Connect (AAC) (Vidrine et al. 2013) was 
developed to ameliorate the low rate of participation 
among persons passively referred to a smoking cessation 
treatment, usually a quitline, through the AAR model. 
In the AAC model, smokers who accept the referral are 
subsequently contacted by the provider of smoking ces-
sation treatment, typically a quitline counselor. The 
referral or connection services, such as to quitlines, have 
very strong evidence for effectiveness (Vidrine et al. 2013; 
Adsit et al. 2014) (also see Chapter 7). However, fewer 
studies have assessed the overall population impact of 
the AAR and AAC models compared with the 4 A’s and 
5 A’s models.
Although the identification of smoking status is now 
routine in most healthcare systems, providing assistance 
and follow-up to smokers occurs in only less than half of 
primary care visits (King et al. 2013; Bartsch et al. 2016). 
Health professionals have reported barriers to adopting 
and implementing these healthcare-based treatment pro-
tocols, including
• Lack of time;
• Lack of reliable reimbursement for provision of 
services;
• Lack of acceptance that addressing tobacco depen-
dence is part of a physician’s job;
• Lack of training and/or comfort addressing prob-
lems with substance abuse;
• Lack of reliable, accessible referral resources;
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• High prevalence of smoking, meaning that even 
brief interventions significantly affect clinic flow, 
as the interventions may need to be implemented 
with a large number of patients (Vogt et al. 2005; 
Association of American Medical Colleges 2007; 
Blumenthal 2007); and 
• Privacy concerns, fear of losing patients, the dis-
couraging belief that most patients will not be able 
to stop, and concern about stigmatizing the smoker 
(Schroeder 2005).
Responding to these issues, several professional orga-
nizations, including the American Academy of Family 
Physicians, have recommended using the AAR model at 
the clinical level to address smoking behaviors.
In recent years, increased attention has also been 
paid to the importance of building linkages between public 
health and the healthcare system and between community 
and clinical healthcare resources. This draws on the recog-
nition that public health and healthcare stakeholders have 
complementary strengths and perspectives; that ultimately 
achieving lasting improvements in population health will 
take the combined efforts of both; and that improved coor-
dination efforts will hasten this outcome. As part of this 
broader trend, national public health organizations and 
state tobacco control programs have begun to engage with 
healthcare systems to encourage and help them integrate 
treatment for tobacco dependence into their workflows 
(CDC 2006). Some healthcare systems have broadened the 
scope of their interventions to address upstream factors 
that shape health outcomes. For example, some health-
care systems have championed evidence-based interven-
tions that go beyond the clinical sphere, such as smokefree 
and tobacco-free policies, increases in the price of tobacco 
products, and policies raising the age of sale for tobacco 
products to 21 years (Campaign for Tobacco-Free Kids 
2016). Predicting the evolution of cessation treatment in 
the United States and the various roles of different seg-
ments of the healthcare system is challenging because of 
the volatility and uncertain future structure of healthcare, 
especially the nature of healthcare insurance. Regardless 
of what type of delivery system emerges, efforts should 
continue to integrate evidence-based tobacco treatment 
and cessation supports into healthcare settings and expand 
those supports. This would require further embedding of 
smoking processes and outcomes in quality measures, 
adequate funding, and routinization of training. Such ser-
vices could be provided in the general healthcare system, 
as well as through specialized cessation clinics. The ability 
to deliver services effectively would be aided by having suf-
ficient geographic locations for delivering care, promoting 
services, and removing barriers to services.
Health Insurance Coverage
Comprehensive insurance coverage for evidence-
based cessation treatments plays a key role in helping 
smokers quit by increasing their access to proven treat-
ments that raise their chances of quitting successfully 
(Fiore et  al. 2008; CDC 2014a). Research in multiple 
healthcare settings in the 1990s (Curry et  al. 1998) and 
2000s (Joyce et al. 2008; Hamlett-Berry et al. 2009; Smith 
et al. 2010; Fu et al. 2014; Fu et al. 2016) has demonstrated 
that comprehensive cessation coverage increases quit 
attempts, the use of cessation treatments, and successful 
quitting (Fiore et al. 2008). Accordingly, implementation 
of comprehensive cessation coverage is important in both 
private and public health insurance.
Significant milestones in the recognition that com-
prehensive insurance coverage for smoking cessation 
plays a key role in helping smokers quit include (a) the 
Community Preventive Services Task Force’s finding that 
reducing tobacco users’ out-of-pocket costs for proven ces-
sation treatments increases the number of tobacco users 
who quit (Hopkins et al. 2001), and (b) the recommenda-
tion in each of the Clinical Practice Guidelines that health 
insurers cover the FDA-approved cessation treatments and 
the behavioral treatments that the Guidelines found to be 
effective (Fiore et al. 2000, 2008). These recommendations 
draw on a body of research that has documented the out-
comes of insurance coverage for cessation, including its 
cost-effectiveness. This research has also helped to iden-
tify the levels of coverage that influence tobacco cessation. 
More recently, several studies have examined the utiliza-
tion of cessation treatments covered by health insurance, 
especially cessation medications, and how this has changed 
over time. Initial findings from these analyses suggest that 
cessation treatments continue to be underused, especially 
among Medicaid populations, and utilization varies con-
siderably across states (Babb et al. 2017).
Healthcare Insurance Policies
After 2010, several national levers were added to 
make tobacco use and dependence treatment a part of 
healthcare. Both Medicare and Medicaid required cov-
erage of certain smoking cessation treatments, and the 
Affordable Care Act included several provisions that 
required non-grandfathered commercial health plans to 
provide in-network smoking cessation medications and 
counseling without financial barriers because those two 
treatments had “A” ratings from USPSTF (McAfee et al. 
2015). Even with these new regulatory levers, many 
national plans are not yet providing the required coverage 
(Kofman et al. 2012). Chapter 7 provides an in-depth dis-
cussion of private and public health insurance coverage 
for the treatment of tobacco use and dependence.
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E-Cigarettes: Potential Impact on 
Smoking Cessation
E-cigarettes (also called electronic nicotine delivery 
systems [ENDS], vapes, vape pens, tanks, mods, and pod-
mods) are battery-powered devices designed to convert a 
liquid (often called e-liquid)—which contains a humectant 
(propylene glycol and vegetable glycerin) and also typically 
contains nicotine, flavorings, and other compounds—
into aerosol for inhalation by the user. First introduced 
in the United States in 2007 (USDHHS 2016), the advent 
of e-cigarettes into the tobacco product marketplace was 
seen by some as a potential harm-reduction tool for cur-
rent adult smokers if the products were used to transition 
completely from conventional cigarettes (Fagerstrom et al. 
2015; Warner and Mendez 2019). E-cigarette aerosol has 
been shown to contain markedly lower levels of harmful 
constituents than conventional cigarette smoke (National 
Academies of Sciences, Engineering, and Medicine 2018). 
Accordingly, interest remains in policies and approaches 
that could maximize potential benefits of these devices 
while minimizing potential pitfalls posed by the devices at 
the individual and population levels, including concerns 
about initiation among young people. The 2016 Surgeon 
General’s report, E-Cigarette Use Among Youth and Young 
Adults, examined many aspects of e-cigarettes related to 
young people; however, it did not address the potential 
impact of e-cigarettes on smoking cessation among adult 
smokers (USDHHS 2016). It is also important to note that 
the landscape of available e-cigarette products has rapidly 
diversified since their introduction in the United States in 
2007, including the introduction of “pod mod” e-cigarettes 
that have dominated the e-cigarette marketplace in recent 
years (Barrington-Trimis and Leventhal 2018; Office of the 
U.S. Surgeon General n.d.). This section highlights salient 
issues about how e-cigarettes may influence cessation, 
which is reviewed in more depth in Chapter 6.
Implications of E-Cigarette Characteristics for 
Smoking Cessation
Nicotine delivery through inhalation, as is the case 
with cigarette smoking, results in rapid nicotine absorp-
tion and delivery to the brain. The pharmacokinetics of 
nicotine delivery varies across products and is influenced 
by user topography, with some, but not all, e-cigarette 
products providing nicotine delivery comparable to con-
ventional cigarettes (National Academies of Sciences, 
Engineering, and Medicine 2018). By contrast, the nicotine 
inhaler, one of several FDA-approved NRTs, delivers nico-
tine primarily through the buccal mucosa; it is designed 
to reduce nicotine withdrawal and cravings while mini-
mizing abuse liability (Schneider et al. 2001). For smokers 
of conventional cigarettes who seek a product with a rapid 
delivery of nicotine similar to cigarettes, e-cigarettes that 
deliver nicotine in a similar way to cigarettes may have 
greater appeal than NRTs. Although rapid boluses of nico-
tine could increase the appeal, as well as addiction and 
potential greater abuse liability, of e-cigarettes relative 
to NRTs, whether this pharmacokinetic profile produces 
an effective method of cessation is presently inconclusive 
from the emerging base of empirical evidence (Shihadeh 
and Eissenberg 2015).
Other features of e-cigarettes that may enhance their 
appeal to smokers of conventional cigarettes include the 
ways in which they mirror some of the sensorimotor fea-
tures of conventional cigarette smoking, including stimu-
lation of the airways, the sensations and taste of e-cigarette 
aerosol in the mouth and lungs, the hand-to-mouth move-
ments and puffing in which e-cigarette users engage, and 
the exhalation of aerosol that may visually resemble cig-
arette smoking. Given the potentially important role of 
such sensorimotor factors in the reinforcing and addictive 
qualities of conventional cigarettes (Chaudhri et al. 2006), 
the presence of these attributes could make e-cigarettes 
more appealing to smokers as a substitute for cigarettes 
than NRTs because the NRTs either lack such sensorim-
otor features (e.g., the transdermal patch, nicotine gum) 
or offer only partial approximations (e.g., the inhaler).
However, when considering e-cigarettes as a poten-
tial cessation aid for adult smokers, it is also important to 
take into account factors related to both safety and efficacy. 
NRT has been proven safe and effective, but there is no 
safe tobacco product. Although e-cigarette aerosol gener-
ally contains fewer toxic chemicals than conventional cig-
arette smoke, all tobacco products, including e-cigarettes, 
carry risks.
As noted in the 2016 Surgeon General’s report, many 
of the characteristics that distinguish e-cigarettes from con-
ventional cigarettes increase the appeal of these new prod-
ucts to youth and young adults, particularly nonsmokers 
(USDHHS 2016). These factors include appealing flavors, 
high concentrations of nicotine, concealability of use, 
and widespread marketing through social media promo-
tion and other channels (Barrington-Trimis and Leventhal 
2018). Many e-cigarettes differ markedly in shape and feel 
compared with conventional cigarettes; e-cigarettes come 
in a variety of shapes, including rectangular tank-style 
and USB-shaped devices (as discussed in Chapter  6 and 
shown in Figure 6.1). For example, JUUL, the top-selling 
e-cigarette brand in the United States in 2018 (Wells Fargo 
Securities 2018), is shaped like a USB flash drive and offers 
high concentrations of nicotine in the cartridges, which 
are also known as “pods” (Huang et  al. 2018). Notably, 
the novelty, diversity, and customizability of e-cigarettes 
appeal to youth (Chu et al. 2017; Office of the U.S. Surgeon 
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General n.d.). For example, there are numerous scien-
tific reports documenting the appeal of, and dramatic rise 
in, JUUL use among youth and young adults (Chen 2017; 
Teitell 2017; Beal 2018; Bertholdo 2018; Coughlin 2018; 
Grigorian 2018; Saggio 2018; Suiters 2018; FDA 2018; 
Willett et al. 2018; Radding n.d.).
Of note, a growing number of e-cigarettes, including 
JUUL, also use nicotine salts, which have a lower pH than 
the freebase nicotine used in most other e-cigarettes and 
traditional tobacco products, and allow particularly high 
levels of nicotine to be inhaled more easily and with less 
irritation. Although this type of product may be appealing 
to adult smokers seeking e-cigarettes with potentially 
greater nicotine delivery, the potency and appeal of such 
products can also make it easier for young people to ini-
tiate the use of nicotine and become addicted (Office of the 
U.S. Surgeon General n.d.).
The final chapter of the 2014 Surgeon General’s 
report concluded that the use of e-cigarettes could have 
both positive and negative impacts at the individual and 
population levels (USDHHS 2014). One of its conclusions 
was that “the promotion of noncombustible products is 
much more likely to provide public health benefits only in 
an environment where the appeal, accessibility, promotion, 
and use of cigarettes and other combusted tobacco prod-
ucts are being rapidly reduced” (USDHHS 2014, p. 874). 
Therefore, it is important to continue (a)  monitoring 
the findings of research on the potential of e-cigarettes 
as a smoking cessation aid and (b) evaluating the positive 
and negative impacts that these products could have at 
the individual and population levels, so as to ensure that 
any potential benefits among adult smokers are not offset 
at the population level by the already marked increases 
in the use of these products by youth. It is particularly 
important to evaluate scientific evidence on the impact 
of e-cigarettes on adult smoking cessation in the cur-
rent context of the high level of e-cigarette use by youth, 
which increased at unprecedented levels in recent years 
following the introduction of JUUL and other e-cigarettes 
shaped like USB flash drives (Cullen et al. 2019).
Summary
Once erroneously considered a habit that could be 
broken by simply deciding to stop, nicotine addiction is 
now recognized as a chronic, relapsing condition. The 
prevalence of cigarette smoking in the United States has 
declined steadily since the 1960s; however, as of 2017, 
there were still more than 34 million adult current ciga-
rette smokers in the United States (Wang et al. 2018).
Proven smoking cessation treatments are widely 
available today. However, the reach and use of existing 
smoking cessation interventions remain low, with less than 
one-third of smokers using any proven cessation treat-
ments (behavioral counseling and/or medication) (Babb 
et al. 2017). A majority of smokers still attempt to quit 
without using such treatments, contributing to a failure 
rate in excess of 90% (Hughes et al. 2004; Fiore et al. 2008).
Medications and behavioral interventions with 
increasing levels of efficacy and sophistication are becoming 
more widely available, but there is considerable room for 
improvement. Further, the challenge of getting behavioral 
and pharmacologic interventions to be used concurrently 
and disseminated more broadly to the public has only been 
partially solved.
Full integration of treatment for nicotine depen-
dence into all clinical settings—including primary and 
specialty clinics, hospitals, and cancer treatment set-
tings—can benefit from increases in barrier-free health 
insurance coverage. Combining health service systems 
and electronic media platforms for the delivery of smoking 
cessation interventions has emerged as one promising 
method to increase reach of smoking cessation treatment 
to smokers (e.g.,  evidence-based cessation interventions 
using phone lines and mobile phone applications, and 
use of electronic health records to promote more timely 
referral to cessation support services). Barrier-free health 
insurance coverage (e.g.,  copays, coverage limits, prior 
authorization) and access to services, coupled with the 
use of quality improvement metrics and methodologies, 
have been shown to increase smokers’ use of evidence-
based services.
Clinical-, system-, and population-level strategies are 
increasingly taking a more holistic approach to decreasing 
the prevalence of smoking, with interventions designed to 
increase quit attempts and enhance the chances of success. 
Examples include the national Tips From Former Smokers 
media campaign, which used ads featuring smokers who 
had suffered tobacco-related morbidity to increase aware-
ness of individual suffering caused by smoking while simul-
taneously enhancing the capacity of the national quitline 
network to respond to upsurges in calls that were gener-
ated by tagging the ads with the phone number for the quit-
line. Millions of smokers made quit attempts as a result of 
exposure to the ads, and hundreds of thousands have suc-
cessfully quit smoking. In addition, the development and 
dissemination of the carefully crafted and research-tested 
5 A’s model in healthcare settings, combined with public 
and private policy changes that encourage coverage of ces-
sation, have systematically encouraged more smokers to 
try to quit and provided them with evidence-based sup-
port. Still, the potential of mass media campaigns, quit-
lines, and clinical support has been tapped only partially, 
leaving many opportunities for further adoption, dissemi-
nation, and extensions of these approaches.
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Use of e-cigarettes could have varied impacts on dif-
ferent segments of the population, including potential 
benefits to current adult cigarette smokers who transition 
completely; however, potential efficacy may depend on 
many factors, such as type of devices and e-liquids used, 
reason for use, and duration of use. Well-controlled, ran-
domized clinical trials and rigorous, large-scale observa-
tional studies with long-term follow-ups will be critical to 
better understand the impact of e-cigarettes on cessation 
under various conditions and settings. Nevertheless, the 
potential benefit of e-cigarettes for cessation among adult 
smokers cannot come at the expense of escalating rates of 
use of these products by youth. Accordingly, the current 
science base supports a number of actions to minimize 
population risks while continuing to explore the poten-
tial utility of e-cigarettes for cessation, including efforts 
to prevent e-cigarette use among young people, regulate 
e-cigarette products and marketing, and discourage long-
term use of e-cigarettes as a partial substitute for conven-
tional cigarettes rather than completely quitting.
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Smoking Cessation
Introduction
This chapter documents key patterns and trends in 
cigarette smoking cessation in the United States among 
adults overall (persons 18 years of age and older), young 
adults (18–24 years of age), and youth (12–17 years of age). 
The chapter also reviews the changing demographic and 
smoking-related characteristics of cigarette smokers, with 
a focus on how these changes may influence future trends 
in cessation.
This chapter also describes persistent disparities 
in cessation by age, race/ethnicity, level of education, 
status of health insurance, and other demographic char-
acteristics. In addition, this chapter highlights trends and 
recent findings for several different measures, including 
the quit ratio (the proportion of ever smokers who are 
former smokers); recent successful cessation; past-year 
quit attempts; interest in quitting; receipt of cessation 
advice from healthcare professionals; and use of effective 
cessation strategies, such as counseling and medication. 
As with previous Surgeon General’s reports, this chapter 
focuses primarily on cigarette smoking (U.S. Department 
of Health and Human Services [USDHHS] 1990, 2014); 
however, given the shifting patterns of tobacco product 
use in the United States, it also touches on cessation as 
it relates to all tobacco products. Monitoring key trends 
and current patterns in tobacco use and cessation is crit-
ical for informing the development and implementa-
tion of policies and programs to increase cessation and, 
as a result, reduce the morbidity, mortality, and associ-
ated financial costs caused by tobacco product use in the 
United States.
Data Sources
A variety of national surveillance systems in the 
United States collect data on smoking cessation among 
adults and youth. These systems typically collect an array 
of information on cigarette smoking history; use of other 
tobacco products; and various aspects of cessation, such 
as quit intentions, quit attempts, and successful cessation. 
These surveys use different data collection methods and 
may define specific cessation behaviors using comparable, 
but not identical, approaches. Accordingly, it is important 
to monitor the results from national surveys that include 
cessation-related data involving adults, young adults, and 
youth to create a comprehensive picture of cessation prev-
alence and patterns.
Appendix 2.1 describes the surveys referenced in 
this chapter, all of which are cross-sectional except for 
the Population Assessment of Tobacco and Health (PATH) 
Study. The primary source for data on adults was the 
National Health Interview Survey (NHIS), and the pri-
mary sources for data on youth were the national Youth 
Risk Behavior Survey (YRBS), conducted as part of the 
Youth Risk Behavior Surveillance System (YRBSS), and 
the National Youth Tobacco Survey (NYTS) (Table  2.1). 
These surveys were chosen because of their scientific and 
methodologic reliability and validity and because they 
are conducted as part of long-standing surveillance sys-
tems (Thacker et al. 1988; Centers for Disease Control and 
Prevention [CDC] 2001). Additionally, most of these sur-
veys have historically been used to track progress toward 
national cessation goals, including the U.S. Department 
of Health and Human Services’ Healthy People initiative 
(Office of Disease Prevention and Health Promotion n.d.b).
These data systems have additional strengths, 
including the timeliness of data releases and proven data 
collection methodologies, which use anonymous or con-
fidential self-reported surveys that yield relatively high 
response rates. Self-reported data have been found to 
adequately reflect patterns of cigarette smoking among 
adults, including whether a respondent who has smoked 
in the past is currently not smoking, using scientifically 
validated biomarkers and other approaches (Connor 
Gorber et al. 2009; Wong et al. 2012); however, few studies 
have examined the validity of other cessation-related mea-
sures (Brigham et al. 2010; Persoskie and Nelson 2013).
NHIS, which has been a major source of health data 
among the U.S. adult population since the 1950s, is an 
annual household interview survey of the civilian, non-
institutionalized population. At the time this report was 
compiled, NHIS data on cigarette smoking among adults 
18 years of age and older were available from 1965 to 2017, 
and data on cigarette smoking cessation for daily smokers 
and nondaily smokers were available from 1997 to 2017. In 
addition, since 2000, NHIS has fielded a CCS every 5 years, 
which includes detailed questions on cigarette smoking 
cessation; NHIS also fielded the CCS in 1987 and 1992, but 
the cessation questions were not consistent between these 
surveys. Therefore, for analyses of adult cessation trends, 
the present report uses the longest series of years available 
for each cessation measure. Data on the characteristics of 
A Report of the Surgeon General
38  Chapter 2
Table 2.1 Sources of national survey data on smoking cessation used for this report, 1965–2017; United States
  BRFSS HINTS MTF NAMCS NATS NHIS NYTS PATH TUS-CPS YRBS
Sponsoring 
agency or 
organization
Centers for 
Disease Control 
and Prevention; 
Health Resources 
and Services 
Administration; 
Administration 
on Aging; U.S. 
Department of 
Veterans Affairs; 
and Substance 
Abuse and Mental 
Health Services 
Administration
Health 
Communication 
and Informatics 
Research Branch, 
Division of 
Cancer Control 
and Population 
Sciences, 
National Cancer 
Institute
National Institute 
on Drug Abuse, 
administered by 
the University 
of Michigan’s 
Institute for 
Social Research
Centers for 
Disease Control 
and Prevention
Centers for 
Disease Control 
and Prevention 
and U.S. Food 
and Drug 
Administration
National Center 
for Health 
Statistics
Centers for 
Disease Control 
and Prevention 
(with support 
from U.S. Food 
and Drug 
Administration 
since 2011)
U.S. Food 
and Drug 
Administration; 
National Institute 
on Drug Abuse 
National Cancer 
Institute 
(2014–2015 wave 
cosponsored by 
the U.S. Food 
and Drug 
Administration)
Centers for 
Disease Control 
and Prevention
Type Cross-sectional Cross-sectional Cross-sectional 
and longitudinal
Cross-sectional Cross-sectional Cross-sectional Cross-sectional Longitudinal Cross-sectional 
and longitudinal
Cross-sectional
Years 2017 2017 2011–2017 2004–2011 2013–2014 1965–2017; 
Cancer Control 
Supplements 
2000, 2005, 2010, 
and 2015
1999, 2000, 2002, 
2004, 2006, 2009, 
2015, and 2017
2013–2014, 
2014–2015
2001–2002, 
2003, 2006–2007, 
2010–2011, and 
2014–2015
1991, 1993, 1995, 
1997, 1999, 2001, 
2003, 2005, 2007, 
2009, 2011, 2013, 
2015, and 2017
Mode Telephone-based 
questionnaire 
that state health 
departments 
conduct monthly 
over landline 
and cellular 
telephones using 
a standardized 
questionnaire 
and technical and 
methodologic 
assistance 
provided by CDC
Household-
based, mailed 
questionnaire
School-based, 
self-administered 
questionnaire
• Review medical 
records for 
information 
about patient 
visits
• Interview 
physicians and 
community 
health center 
providers
Telephone-based 
questionnaire
Computer-
assisted personal 
interview
School-based, 
self-administered 
questionnaire 
(paper-based)
Computer-
assisted personal 
interview
Questionnaire 
via telephone 
and in-person 
interviews 
School-based, 
self-administered 
questionnaire 
(paper-based)
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Table 2.1 Continued
  BRFSS HINTS MTF NAMCS NATS NHIS NYTS PATH TUS-CPS YRBS
Response rate 2017: 45.9% • 2017: 25.0%
• HINTS-FDA: 
34.1% (NCI 
2017a)
• HINTS 5 
Cycle 1 (2017): 
32.4% (NCI 
2017b)
• 2015: 
 – 12th-grade 
RR: 83%
 – Schools: 382
• 2016: 
 – 12th-grade 
RR: 80%
 – Schools: 372
• 2017: 
 – 12th-grade 
RR: 79%
• 2009: 62.4%
• 2010: 57.3%
• 2011: 54.1%
• 2012: 39.4%
• 2013: 40.4%
• 2014: 39.0%
• 2015: 29.6%
• 2016: 32.7%
2013–2014: 
36.1% overall 
(47.6% landline 
and 17.1%, 
cellular)
• 2015a: 
 – Household: 
70.1%
 – Family: 
69.3%
 – Sample 
adult: 63.4%
• 2016a: 
 – Household: 
67.9%
 – Family: 
67.1%
 – Sample 
adult: 61.9%
• 2017a: 
 – Household: 
66.5%
 – Family: 
65.7%
 – Sample 
adult: 53.0%
• For years 
1997–2017, the 
question about 
a past-year 
quit attempt 
was asked of 
all current 
cigarette 
smokers
• 2015: 
 – School: 
72.6%
 – Student: 
87.4%
 – Overall: 
63.4% 
• 2016: 
 – School: 
81.5%
 – Student: 
87.9%
 – Overall: 
71.6%
• 2017: 
 – School: 
76.8%
 – Student: 
88.7%
 – Overall: 
68.1% 
• 2013–2014:
 – 74.0% 
(adult)
 – 78.4% 
(youth)
• 2014–2015:
 – 83.1% 
(adult)
 – 88.4% 
(youth)
2014–2015: 
Average self-
response rate 
(for all waves 
combined) 54.2%
• 2015:
 – School:  
69%
 – Student: 
86%
 – Overall: 
60%
• 2017:
 – School:  
75%
 – Student: 
81%
 – Overall: 
60%
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Table 2.1 Continued
  BRFSS HINTS MTF NAMCS NATS NHIS NYTS PATH TUS-CPS YRBS
Sample size 2017: 450,016 • 2017: 3,335
• HINTS-FDA: 
1,736
• HINTS 5 
Cycle 1 (2017): 
3,285
• 2015: 
 – 12th-grade 
students: 
13,730
 – Schools: 382
• 2016: 
 – 12th-grade 
students: 
12,600
 – Schools: 372
• 2017: 
 – 12th-grade 
students 
13,522
 – Schools: 360
• Patient records 
extracted:
 – 2009: 
32,281 from 
a sample 
of 3,319 
physicians
 – 2010: 
31,229 from 
a sample 
of 3,525 
physicians
 – 2011: 
30,872 from 
a sample 
of 3,819 
physicians
 – 2012: 
76,330 from 
a sample 
of 15,740 
physicians
 – 2013: 
54,873 from 
a sample 
of 11,212 
physicians
 – 2014: 
45,710 from 
a sample 
of 9,989 
physicians
 – 2015: 
28,332 from 
a sample 
of 8,091 
physicians
 – 2016: 
13,165 from 
a sample 
of 3,699 
physicians
2013–2014: 
75,233 
respondents 
(70% landline 
and 30% cellular)
• Adults >18 
years of age:
 – 2015: 33,672
 – 2016: 33,028
 – 2017: 26,742
• Overall 
households:
 – 2015: 41,493
 – 2016: 30,220
 – 2017: 32,617
• Students in 
grades 6–12:
 – 2015: 17,711
 – 2016: 20,675
 – 2017: 17,872
• 2013–2014: 
45,971 (32,320 
adults/16,651 
youth)
• 2014–2015: 
40,534 (28,362 
adults/12,172 
youth) 
2014–2015:
163,920
• Students in 
grades 9–12:
 – 2015: 15,624
 – 2017: 14,765
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Table 2.1 Continued
  BRFSS HINTS MTF NAMCS NATS NHIS NYTS PATH TUS-CPS YRBS
Cessation 
measure(s)
Quit ratio Use of Internet-
based programs 
or tools in quit 
attempts
Interest in 
quitting
• Screening for 
tobacco use
• Counseling 
for use of or 
exposure to 
tobacco
Advice to quit Quit ratio, 
recent successful 
cessation, past-
year quit attempt, 
Cancer Control 
Supplements, 
interest in 
cessation, 
provider advice 
to quit, and 
use of effective 
treatments
Advice to quit and 
use of counseling 
and medications 
to quitb
Quit attempts, 
quit ratio, recent 
successful 
cessation; use of 
NRT, medications, 
or counseling 
to quit
Past-year quit 
attempts, interest 
in quitting, 
recent smoking 
cessation, or 
receipt of medical 
doctor’s advice 
to quit
Past-year quit 
attempt 
Notes: BRFSS = Behavioral Risk Factor Surveillance System; CDC = Centers for Disease Control and Prevention; HINTS = Health Information National Trends Survey; MTF = Monitoring the Future; 
NATS = National Adult Tobacco Survey; NAMCS = National Ambulatory Medical Care Survey; NHIS = National Health Interview Survey; NYTS = National Youth Tobacco Survey; PATH = Population 
Assessment of Tobacco and Health; RR = relative risk; TUS-CPS = Tobacco Use Supplement to the Current Population Survey; YRBS = National Youth Risk Behavior Survey.
aRR for household component, and unconditional RR for family and sample adult components.
bThe measure of advice to quit has changed over time: 2009 (“During the past 12 months, did a medical doctor, dentist, or nurse tell you to stop smoking?”) and 2015 (“During the past 12 months, 
did any doctor, dentist, or nurse give you advice not to use tobacco that is smoked or put in your mouth?”). In 2017, NYTS did not contain either of these measures (advice to quit; use of counseling/
cessation medications). There are other cessation measures that are not listed here (e.g., thinking about quitting during the past 12 months, and stopped using because trying to quit).
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cigarette smokers are reviewed beginning with the year 
2000 to correspond with the available cessation data.
YRBSS monitors six categories of health-related 
behaviors that contribute to the leading causes of death 
and disability among youth and adults. In operation since 
1991, the national YRBS is a biennial survey that utilizes 
probability samples of students in public and private high 
schools; students anonymously complete questionnaires 
administered in schools. The survey is nationally repre-
sentative of the U.S. high school population. This Surgeon 
General’s report uses biennial data from the national YRBS 
to examine trends in youth cigarette smoking and past-
year quit attempts among current cigarette smokers. For 
trends in cigarette smoking cessation among youth, this 
report uses biennial data from 1991 to 2015 from the 
national YRBS. However, this report does not include state 
and local data from YRBS surveys because (a) only one state 
and two districts produced weighted data for all years of 
the YRBS and (b) some of these surveys had small sample 
sizes for the measures examined in this report (CDC 2013).
NYTS is a cross-sectional, voluntary, school-based, 
self-administered, pencil-and-paper survey of U.S. middle 
and high school students. A three-stage cluster sampling 
procedure is used to generate a nationally representative 
sample of U.S. students who attend public and private 
schools in grades 6–12. Because the NYTS is a tobacco-
focused survey as opposed to a general health survey, it 
collects more comprehensive data than YRBS on a variety 
of tobacco-related measures from middle school and high 
school students, including tobacco product use, smoking 
cessation, exposure to secondhand smoke, tobacco-related 
knowledge and attitudes, access to tobacco products, and 
other tobacco-related indicators. The NYTS has been con-
ducted most years since 1999. This chapter examined data 
from 2000, 2004, 2009, and 2015, corresponding roughly 
with the years of adult data from the NHIS Cancer Control 
Supplement (CCS). In 2017, the most recent wave of data 
available at the time this report was compiled, cessation 
of all tobacco products was assessed, and separate ques-
tions were not asked about cigarette smoking cessation 
specifically.
As reviewed in more detail in Appendix  2.1, this 
chapter also considers other sources of data, including 
the Tobacco Use Supplement to the Current Population 
Survey (TUS-CPS), the Behavioral Risk Factor Surveillance 
System (BRFSS), the National Adult Tobacco Survey 
(NATS), the National Ambulatory Medical Care Survey 
(NAMCS), the Health Information National Trends Survey 
(HINTS), and the Monitoring the Future (MTF) Study. Data 
from Nielsen Retail Management Services were also used 
to assess sales of over-the-counter nicotine replacement 
therapy (NRT). The data contain projected NRT sales from 
two major retail channels: expanded all outlets combined 
and convenience stores. The former category includes 
aggregated sales from food stores, drug stores, mass mer-
chandizers, club stores, dollar stores, and military com-
missaries. In addition, published baseline and longitudinal 
analyses from the PATH Study are summarized.
Key Epidemiologic Measures
Appendix 2.2 defines the survey measures used in 
this chapter. In brief, this chapter examines a variety of 
epidemiologic areas related to cigarette smoking and ces-
sation, including trends in current and former cigarette 
smoking and the smoking characteristics of adult and 
youth current cigarette smokers; disparities in current 
smoking, trends in the quit ratio, recent successful ces-
sation, past-year quit attempts, current interest in quit-
ting, and ever trying to quit smoking cigarettes among 
adult and youth smokers; tobacco screening and advice 
to quit delivered by health professionals; counseling and 
use of Food and Drug Administration (FDA)-approved 
medications for smoking cessation; use of other strat-
egies for smoking cessation; and disparities in smoking 
cessation. This chapter also briefly addresses cessation of 
other tobacco products to the extent possible, given that 
national surveys include few measures of cessation for 
noncigarette tobacco products. Patterns of use of nonciga-
rette tobacco products were included in the 2014 Surgeon 
General’s report (USDHHS 2014). However, because lim-
ited cessation information is available for noncigarette 
tobacco products, this report does not review trends in the 
use of these products and changes in the characteristics of 
the populations that use these products.
Data are presented in an order that first highlights 
the primary public health goal of tobacco use cessation 
(i.e.,  successful cessation), including the following three 
measures: prevalence of former smoking (persons who 
ever smoked >100 cigarettes who do not currently smoke), 
quit ratio (the proportion of ever smokers who are former 
smokers), and prevalence of recent smoking cessation (per-
sons who quit smoking for >6 months in the past year). 
These measures are then followed by intermediary mea-
sures that reflect a smoker’s journey to cessation (i.e., the 
cessation continuum), starting with the most proximate 
measure (prevalence of past-year quit attempts) and moving 
backward on the continuum from assessing a smoker’s cur-
rent interest in quitting completely to whether he or she 
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has ever made a quit attempt (Institute of Medicine 2007). 
The chapter concludes by examining tobacco screening and 
cessation interventions provided by health professionals 
and the utilization of other selected cessation strategies.
For adults overall, the most recent year of data from 
NHIS is presented for each indicator by key demographic 
characteristics (e.g., sex, age [18–24, 25–44, and 45–64 years 
of age and 65 years of age and older], race/ethnicity, level 
of education, geographic region, and status of health 
insurance), followed by trends over time among adults 
for men and women overall and for non-Hispanic Whites 
(hereafter referred to as Whites), non-Hispanic Blacks 
(hereafter referred to as Blacks), and Hispanics. These data 
on adults are then followed by corresponding sections for 
analyses on young adults (18–24 years of age) and youth 
from various data sources. Some measures for young 
adults are missing, and statistically stable estimates could 
not be produced because of small sample sizes.
Trends in Current and Former Cigarette Smoking
Tests for linear and quadratic (nonlinear) trends were 
performed and controlled for variations in sex and race/
ethnicity over time. Models for adults overall controlled for 
age over time, and models for youth controlled for grade 
level. A test for linear trend is statistically significant if a 
straight line (indicating a consistent increase or decrease) 
fits the adjusted data significantly better than no linear 
trend (i.e., the null hypothesis of no linear trend over time 
is rejected). Similarly, a test for quadratic trend is statisti-
cally significant if a curved line with one bend (indicating 
an accelerated or decelerated rate of change during the 
assessed period) fits the adjusted data better than no qua-
dratic trend. Quadratic trends were initially assessed. If the 
quadratic trend was not statistically significant, then tests 
for linear trends were performed. Tests for other time func-
tions (i.e., trend shapes) were not assessed; it is possible 
that other time functions could also fit the data.
Adults
The NHIS definition of current cigarette smoking 
has changed over time. For the purposes of this report, 
the definition of current smoking has been standard-
ized. Specifically, current cigarette smokers are defined as 
those who smoked at least 100 cigarettes in their lifetime 
and who smoked every day or on some days at the time of 
the survey. Former cigarette smokers are defined as those 
who smoked at least 100 cigarettes during their lifetime 
but were not smoking at the time of the survey.
Among adults in 2018, the prevalence of current 
cigarette smoking was 13.8%, the lowest measured prev-
alence among U.S. adults since NHIS data collection for 
this measure began in 1965; the prevalence of former 
cigarette smoking was 20.9% (NHIS, public use data, 
2018) (Blackwell and Villarroel 2018; Wang et al. 2018a). 
From 1965 to 2017, the prevalence of current smoking 
declined by 36.2  percentage points (relative percentage 
change: 69.6%) among men (from 52.0% to 15.8%) 
and 21.9  percentage points (relative percentage change: 
64.2%) among women (from 34.1% to 12.2%) (p <0.001 
for quadratic trend for both groups) (Figure  2.1). The 
prevalence of former smoking among all men peaked in 
1985 (at 30.9%), and the prevalence of former smoking 
among women peaked in 1994 (at 20.0%) (p <0.001 for 
quadratic trend for both groups). Among men, 1991 was 
the first year in which the prevalence of former smoking 
was higher than the prevalence of current smoking; how-
ever, not until 2010–2017 was the prevalence of former 
smoking consistently greater each year than the preva-
lence of current smoking. Among women, the prevalence 
of former smoking first surpassed the prevalence of cur-
rent smoking in 2011 and remained higher through 2017.
Declines in the prevalence of current smoking 
were also observed across racial and ethnic subgroups 
(Figure  2.2) (p  <0.001 for linear trend for Whites from 
42.2% in 1965 to 15.2% in 2017, Blacks [p <0.001 for linear 
trend] from 46.0% in 1965 to 14.9% in 2017, and Hispanics 
[p <0.0001 for linear trend] from 31.6% in 1978 to 9.9% 
in 2017). Although the prevalence of former smoking 
exceeded the prevalence of current smoking among 
Whites during 2002–2017 and among Hispanics during 
2014–2017, the prevalence of former smoking among 
Blacks never exceeded the prevalence of current cigarette 
smoking during 1965–2017 (p <0.001 for quadratic trends 
for former smoking among Whites and Blacks and a linear 
trend [p <0.001] for Hispanics). The pattern of lower prev-
alence of former smoking than current smoking among 
Blacks may be the result of both their lower prevalence of 
initiation and their lower quit ratios compared with other 
racial/ethnic groups (USDHHS 2014).
It is important to note that the definition of a 
former smoker is broad and contains both persons who 
quit many years ago and persons who are actively trying 
to quit (i.e.,  they were not smoking at the time of the 
survey but could have quit for only 1 day). Decreases in 
the prevalence of former cigarette smoking among adults 
during the past 20–30 years primarily reflect decreases in 
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Figure 2.1 Trends in prevalence (%) of current and former cigarette smoking among adults 18 years of age and 
older, by sex; National Health Interview Survey (NHIS) 1965–2017; United States
Source: NHIS, National Center for Health Statistics, public use data, 1965–2017.
Note: From 1965 to 2017, data were reported for the following years: 1965, 1966, 1970, 1974, 1976–1980, 1983, 1985, 1987, 1988, 
1990–1995, and 1997–2017.
Figure 2.2 Trends in prevalence (%) of current and former cigarette smoking among adults 18 years of age and 
older, by race/ethnicity; National Health Interview Survey (NHIS) 1965–2017; United States
Source: NHIS, National Center for Health Statistics, public use data, 1965–2017.
Note: From 1965 to 2015, data were reported for the following years: 1965, 1966, 1970, 1974, 1976–1980, 1983, 1985, 1987, 1988, 
1990–1995, and 1997–2017.
aData were not collected for 1965, 1966, 1970, 1974, 1976, and 1977.
bData were statistically unreliable (relative standard error >30% or denominator <50 sample cases) for the following years: 1980, 
1987, 1992–1995, 2002, 2003, 2005, 2007–2013, and 2015–2017.
cData were statistically unreliable (relative standard error >30% or denominator <50 sample cases) for 1992 and 2016.
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cigarette smoking initiation, as illustrated by data from 
birth cohorts (USDHHS 2014). Specifically, this means 
that the prevalence of former smoking has primarily 
decreased because youth and young adults, in particular, 
are less likely to initiate cigarette smoking than they might 
have been in the past. Therefore, the pool of persons who 
are eligible to quit has decreased over time. Nevertheless, 
during the past decade, adult former cigarette smokers 
have become more common than current smokers, with 
the exception of Black adults.
Young Adults
Current cigarette smokers are defined as those 
who smoked at least 100 cigarettes in their lifetime and 
who smoked every day or on some days at the time of the 
survey. Among U.S. young adults (18–24 years of age) in 
2017, the prevalence of current cigarette smoking was 
10.4%, and the prevalence of former cigarette smoking was 
5.1% (NHIS, public use data, 2017) (Wang et al. 2018a). 
Similar to data for adults overall, the prevalence of current 
smoking during 1965–2017 declined by 42.3  percentage 
points (relative percentage change: 77.9%) among young 
adult men (from 54.3% in 1965 to 12.0% in 2015; p <0.001 
for linear trend) and 29.6 percentage points (relative per-
centage change: 77.1%) among young adult women (from 
38.4% in 1965 to 8.8% in 2017; p  <0.001 for quadratic 
trend) (Figure 2.3). In contrast to the findings for adults 
overall, the prevalence of former smoking among young 
adult men peaked in 1977 (at 13.6%), and the prevalence 
of former smoking among young adult women peaked 
in 1978 (at 10.4%). Among young adult men and young 
adult women, the prevalence of former smoking has never 
exceeded the prevalence of current smoking (Figure 2.3).
Declines in the prevalence of current smoking 
among young adults across racial and ethnic subgroups 
were also similar to those for adults overall (Figure 2.4), 
declining for young adult Whites from 45.4% in 1965 to 
13.5% in 2017 (p <0.001 for quadratic trend), for young 
adult Blacks from 49.2% in 1965 to 8.6% in 2017 (p <0.001 
for quadratic trend), and for young adult Hispanics from 
36.1% in 1978 to 5.6% in 2017 (p <0.001 for linear trend) 
(Figure 2.4). In contrast to the findings for adults overall, 
the prevalence of former smoking among young adults in 
any of the three racial/ethnic groups never exceeded the 
prevalence of current smoking (Figure 2.4).
Youth
Current cigarette smoking in YRBS is defined as 
having smoked cigarettes on at least 1  day during the 
30 days before the survey. In 2017, the prevalence of current 
Figure 2.3 Trends in prevalence (%) of current and former cigarette smoking among young adults 18–24 years of 
age, by sex; National Health Interview Survey (NHIS) 1965–2017; United States
Source: NHIS, National Center for Health Statistics, public use data, 1965–2017.
Note: From 1965 to 2017, data were reported for the following years: 1965, 1966, 1970, 1974, 1976–1980, 1983, 1985, 1987, 1988, 
1990–1995, and 1997–2017.
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smoking among U.S. students in grades  9–12 was 8.8% 
(Kann et al. 2018). Many youth experiment with cigarette 
smoking, and some progress to a more established pattern 
of smoking. Those with a more established pattern may be 
particularly important to study for future cessation trends, 
as they are most likely to become adult smokers (USDHHS 
2012). Among students in grades 9–12, the prevalence of 
current frequent cigarette smoking (ever smokers who 
had smoked 20  or more days during the past 30 days) 
was 2.7% (Kann et  al. 2018). The prevalence of current 
smoking increased during 1991–1997 (27.5–36.4%) and 
then decreased during 1997–2017 (36.4–8.8%), and a sig-
nificant quadratic trend was observed (Kann et al. 2018). 
Similarly, the prevalence of current frequent smoking 
increased during 1991–1999 (12.8–17.0%) and then 
decreased during 2001–2017 (13.9–2.7%), and a  signifi-
cant quadratic trend was also observed (Figure 2.5).
Similar nonlinear trends in these measures over time 
were observed by sex (YRBS, public use data, 1991–2017) 
and race/ethnicity (Figures 2.6a and 2.6b). The prevalence 
of current frequent smoking was consistently and statisti-
cally higher in Whites than in Blacks and Hispanics.
The YRBS does not contain a measure of former 
smoking that is similar to the NHIS measure of former 
Figure 2.4 Trends in prevalence (%) of current and former cigarette smoking among young adults 18–24 years of 
age, by race/ethnicity; National Health Interview Survey (NHIS) 1965–2017; United States
Source: NHIS, National Center for Health Statistics, public use data, 1965–2017.
Note: From 1965 to 2017, data were reported for the following years: 1965, 1966, 1970, 1974, 1976–1980, 1983, 1985, 1987, 1988, 
1990–1995, and 1997–2017.
aData were not collected for 1965, 1966, 1970, 1974, 1976, and 1977.
bData were statistically unreliable (relative standard error >30% or denominator <50 sample cases) for the following years: 1980, 
1987, 1992–1995, 2002, 2003, 2005, 2007–2013, and 2015–2017.
cData were statistically unreliable (relative standard error >30% or denominator <50 sample cases) for 1992 and 2016.
smoking for adults (i.e.,  ever smoked at least 100  ciga-
rettes but was not a current smoker at the time of the 
survey). However, during 2001–2013, the YRBS asked 
students whether they had ever smoked daily. Students 
who were former daily smokers (i.e.,  ever smokers who 
were not smoking currently but reported smoking daily 
in the past) presumably include the majority of youth who 
had smoked at least 100 cigarettes and had since stopped 
smoking. In 2013, the prevalence of former daily smoking 
(i.e., ever daily smokers who reported no current smoking) 
among students in grades 9–12 was 1.3%, and the preva-
lence of former nondaily smoking was 22.2% (Figure 2.5). 
From 2001 to 2013, a nonlinear decrease was observed 
in the prevalence of former daily smoking, and the prev-
alence of former nondaily smoking decreased linearly. 
Similar patterns were observed among females (YRBS, 
public use data, 2001–2013) and Whites (Figure 2.6b). In 
contrast, males (YRBS, public use data, 2001–2013) and 
Blacks (Figure 2.6b) had linear decreases for former daily 
smoking, but changes in this measure were not observed 
among Hispanics. In addition, nonlinear decreases in 
former nondaily smoking occurred among Blacks.
For all years, the prevalence of former nondaily 
smoking was higher than the prevalence of current 
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Figure 2.5 Trends in prevalence (%) of current frequenta, former dailyb, and former nondailyc cigarette smoking 
among high school students; National Youth Risk Behavior Survey (YRBS) 1991–2017; United States
Source: YRBS, Centers for Disease Control and Prevention, public use data, 1991–2017.
Note: The question about daily smoking was not asked in 2015 and 2017.
aStudents who answered “yes” to “have you ever smoked” and “yes” to “do you currently smoke?”; and reported smoking on >19 days 
during the past 30 days.
bStudents who answered “yes” to “have you ever smoked” and “no” to “do you currently smoke?” and answered “yes” to “ever daily.”
cStudents who answered “yes” to “have you ever smoked” and “no” to “do you currently smoke?” and answered “no” to “ever daily.”
frequent and former daily smoking (Figure  2.5), indi-
cating high percentages of youth tried (i.e., experimented 
with), but did not maintain, cigarette smoking. In con-
trast, the low prevalence of former daily smokers most 
likely reflects the low prevalence of daily smoking among 
students in grades 9–12 and the low prevalence of cessa-
tion among those who only recently became daily smokers 
(Fiore et al. 2008; USDHHS 2014).
Changing Characteristics of Current Cigarette Smokers
Adults
Demographic characteristics of current adult cig-
arette smokers have changed in recent years, reflecting 
changes in demographics of the U.S. population and 
advancements in national and state tobacco prevention 
and control policies (Howden and Meyer 2011; Humes 
et al. 2011; Ryan and Bauman 2016; National Center for 
Health Statistics 2018). These changes may have affected 
levels of interest in quitting cigarettes, the prevalence 
of quit attempts, and the prevalence of successful cessa-
tion. For example, during 2000–2017, notable changes 
occurred across several demographic variables (Table 2.2): 
• During 2000–2017, the proportion of current 
smokers who were 45–64  years of age increased 
from 30.9% to 39.9%, and the proportion of cur-
rent smokers who were 65  years of age and older 
rose from 6.8% to 11.8%. Conversely, during this 
period, the proportions of current smokers who were 
18–24 or 25–44 years of age decreased, reflecting the 
decreased initiation of smoking among youth since 
1997 (USDHHS 2014).
• The proportion of current smokers who were Hispanic 
increased from 8.4% in 2000 to 11.3% in 2017, and 
the proportion of current smokers who were White 
decreased from 76.4% in 2000 to 69.5% in 2017.
• The proportion of current smokers 25 years of age 
and older whose highest level of education was 
a high school diploma decreased from 33.4% in 
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Figure 2.6a Trends in prevalence (%) of current frequenta cigarette smoking among high school students, 
by race/ethnicity; National Youth Risk Behavior Survey (YRBS) 1991–2017; United States
Source: YRBS, Centers for Disease Control and Prevention, public use data, 1991–2017.
Note: The question about daily smoking was not asked in 2015 and 2017.
aStudents who answered “yes” to “have you ever smoked” and “yes” to “do you currently smoke?”; and reported smoking on >19 days 
during the past 30 days.
Figure 2.6b Trends in prevalence (%) of former dailya and former nondailyb cigarette smoking among high school 
students, by race/ethnicity; National Youth Risk Behavior Survey (YRBS) 1991–2017; United States
Source: YRBS, Centers for Disease Control and Prevention, public use data, 1991–2017.
Note: The question about daily smoking was not asked in 2015 and 2017.
aStudents who answered “yes” to “have you ever smoked” and “no” to “do you currently smoke?”; and answered “yes” to “daily.”
bStudents who answered “yes” to “have you ever smoked” and “no” to “do you currently smoke?”; and answered “no” to “daily.”
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Table 2.2 Distribution of selected demographic characteristics of adult current cigarette smokersa 18 years of age and older; National Health Interview 
Survey (NHIS) 2000, 2005, 2010, 2015, and 2017; United States
Characteristic 2000: % (95% CI) 2005: % (95% CI) 2010: % (95% CI) 2015: % (95% CI) 2017: % (95% CI)
Sex (% male) 52.9 (51.6–54.3) 54.9 (53.5–56.4) 53.8 (52.2–55.4) 53.4 (51.5–55.3) 54.7 (52.6–56.8)
Age group (in years)          
18–24 15.2 (14.0–16.3) 15.2 (14.0–16.4) 13.4 (12.1–14.7) 10.6 (9.3–12.0) 8.9 (7.6–10.2)
25–44 47.2 (45.9–48.5) 43.4 (41.9–44.9) 40.3 (38.8–41.9) 40.1 (38.2–42.1) 39.4 (37.5–41.3)
45–64 30.9 (29.7–32.0) 34.8 (33.4–36.2) 38.1 (36.4–39.7) 38.6 (36.7–40.5) 39.9 (38.0–41.8)
≥65 6.8 (6.2–7.3) 6.6 (6.0–7.2) 8.2 (7.4–9.1) 10.6 (9.6–11.7) 11.8 (10.7–12.9)
Race/ethnicity          
White, non-Hispanic 76.4 (75.2–77.7) 74.4 (72.9–76.0) 74.1 (72.6–75.6) 71.3 (69.5–73.1) 69.5 (67.1–71.8)
Black, non-Hispanic 11.1 (10.3–11.9) 11.4 (10.4–12.4) 12.4 (11.2–13.5) 12.9 (11.7–14.2) 12.6 (11.0–14.2)
Hispanic 8.4 (7.7–9.2) 10.0 (9.0–10.9) 9.0 (8.2–9.8) 10.4 (9.3–11.5) 11.3 (9.5–13.1)
American Indian/Alaska Native, 
non-Hispanic
0.8 (0.5–1.1) 0.8 (0.4–1.1) 0.8 (0.5–1.1) 0.9 (0.6–1.2) 1.2 (0.7–1.8)
Asian, non-Hispanic 2.0 (1.5–2.5) 2.3 (1.8–2.9) 2.2 (1.8–2.6) 2.6 (2.1–3.2) 3.0 (2.3–3.8)
Multiple races, non-Hispanic 1.2 (0.9–1.5) 1.1 (0.8–1.5) 1.5 (1.2–1.9) 1.9 (1.4–2.3) 2.3 (1.8–2.9)
Level of educationb          
≤12 years (no diploma) 21.5 (20.4–22.6) 19.8 (18.5–21.1) 18.4 (17.1–19.8) 19.8 (18.3–21.3) 18.0 (16.4–19.7)
GED certificate 5.5 (4.8–6.1) 5.6 (4.9–6.4) 6.7 (5.8–7.6) 6.1 (5.2–7.0) 7.0 (6.0–8.0)
High school diploma 33.4 (32.0–34.9) 32.0 (30.5–33.5) 29.4 (27.8–31.0) 27.4 (25.7–29.2) 27.2 (25.5–28.9)
Some college (no degree) 18.0 (17.0–19.1) 19.0 (17.8–20.2) 21.2 (19.8–22.5) 20.5 (18.9–22.1) 20.0 (18.4–21.6)
Associate degree 8.7 (7.9–9.5) 10.5 (9.5–11.4) 10.7 (9.6–11.8) 13.0 (11.7–14.2) 12.6 (11.3–13.9)
Undergraduate degree 9.5 (8.6–10.3) 9.6 (8.7–10.5) 10.0 (8.9–11.0) 10.0 (8.8–11.2) 11.1 (9.7–12.4)
Graduate degree 3.4 (2.8–3.9) 3.5 (3.0–4.1) 3.7 (3.0–4.4) 3.2 (2.5–3.8) 4.0 (3.2–4.8)
Poverty status (% below poverty level) 14.8 (13.7–15.8) 16.3 (15.2–17.4) 19.5 (18.2–20.9) 21.0 (19.6–22.5) 19.2 (17.5–20.9)
Geographic region          
Northeast 18.0 (16.7–19.3) 16.8 (15.5–18.2) 15.9 (14.6–17.2) 15.6 (13.9–17.2) 14.7 (12.8–16.6)
Midwest 27.8 (26.4–29.1) 28.7 (27.1–30.2) 26.2 (24.6–27.8) 27.8 (25.6–29.9) 26.4 (24.3–28.6)
South 37.9 (36.2–39.5) 37.7 (35.8–39.5) 38.7 (36.8–40.6) 37.7 (35.7–39.7) 40.3 (37.9–42.6)
West 16.4 (15.2–17.5) 16.8 (15.6–18.1) 19.2 (17.7–20.8) 19.0 (17.3–20.7) 18.6 (16.7–20.5)
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Table 2.2 Continued
Characteristic 2000: % (95% CI) 2005: % (95% CI) 2010: % (95% CI) 2015: % (95% CI) 2017: % (95% CI)
Health insurance coverage          
Private 61.9 (60.5–63.3) 56.4 (54.7–58.1) 48.3 (46.6–50.0) 48.1 (46.1–50.1) 48.7 (46.6–50.8)
Medicaid (includes persons with 
Medicaid and Medicare)
7.7 (7.0–8.5) 11.0 (10.1–11.9) 13.4 (12.4–14.4) 21.6 (19.9–23.3) 20.9 (19.1–22.7)
Medicare only 1.9 (1.6–2.3) 1.8 (1.5–2.1) 2.8 (2.3–3.2) 4.0 (3.3–4.7) 4.6 (3.9–5.4)
Other coverage 3.7 (3.3–4.2) 4.3 (3.7–4.8) 5.7 (5.0–6.4) 6.7 (5.8–7.6) 7.6 (6.6–8.6)
Uninsured 24.0 (22.9–25.2) 26.3 (24.9–27.7) 29.5 (28.1–30.9) 18.8 (17.2–20.3) 17.7 (16.1–19.2)
Source: NHIS, National Center for Health Statistics, public use data, 2000, 2005, 2010, 2015, and 2017.
Notes: CI = confidence interval; GED = General Educational Development.
aPersons who reported smoking ≥100 cigarettes during their lifetime and who, at the time of the interview, reported smoking every day or some days.
bAmong only adults 25 years of age and older.
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2000 to 27.2% in 2017; the proportion of current 
smokers with 12 or fewer years of education (with 
no diploma) decreased from 21.5% in 2000 to 18.0% 
in 2017; and the proportion of current smokers with 
an associate degree increased from 8.7% to 12.6% 
during the time period.
• The proportion of current smokers living below the 
poverty level increased from 2000 (14.8%) to 2017 
(19.2%).
• The proportion of current smokers covered by 
Medicaid rose from 7.7% in 2000 to 20.9% in 2017, 
and the proportion of current smokers with private 
health insurance decreased from 61.9% in 2000 to 
48.7% in 2017.
• The proportion of current smokers covered only by 
Medicare increased from 1.9% in 2000 to 4.6% in 
2017, and the proportion of current smokers who 
were uninsured increased from 24.0% in 2000 to 
29.5% in 2010 but then decreased to 17.7% in 2017.
Tobacco-use characteristics among current adult 
cigarette smokers also changed during 2000–2017. The 
proportion of current smokers who did not smoke every 
day increased from 17.9% in 2000 to 25.1% in 2017 
(Table  2.3), and the proportion of current smokers who 
smoked fewer than 14 cigarettes per day also increased: 
the proportion of smokers who smoked 1–4 cigarettes per 
day rose from 4.0% in 2000 to 7.0% in 2017; and the pro-
portion of smokers who smoked 5–14 cigarettes per day 
rose from 25.4% to 34.9%. The proportion of smokers 
who usually smoked menthol cigarettes increased from 
26.4% in 2005 to 31.6% in 2010 but did not change sig-
nificantly (31.5%) in 2015 (data on menthol cigarettes 
were not available in 2017). Use of other tobacco products 
(cigars, smokeless tobacco, and/or pipes) by current ciga-
rette smokers increased from 10.2% in 2000 to 14.5% in 
2017. Current adult cigarette smokers who were also cur-
rent users of electronic cigarettes (e-cigarettes) decreased 
from 13.6% in 2015 to 10.0% in 2017 (NHIS, public use 
data, 2015, 2017). Current e-cigarette users who were also 
current cigarette smokers decreased from 58.8% in 2015 
to 49.6% in 2017 (NHIS, public use data, 2015, 2017).
Young Adults
Trends in demographic characteristics among 
young adult current smokers (18–24  years of age) were 
similar to trends among all adults, except that the propor-
tion of young adult smokers living below the poverty level 
was the highest in 2010 (29.9%) (Table 2.4), and the pro-
portion of adult current smokers living below the poverty 
level was highest in 2015 (21.0%) (Table  2.2). The pro-
portion of young adult current smokers who had private 
insurance was lowest (38.2%) in 2010. Among adult cur-
rent smokers, the lowest proportion with private insur-
ance (48.1%) was in 2015 (Table 2.2).
Changes in the distribution of tobacco product use 
over time among young adults are similar to those for all 
adults (Table  2.5). In 2017, the proportion of cigarette 
smokers who were some-day smokers was higher among 
young adults (34.7%) than among adults overall (25.1%) 
(Table 2.3), and the proportion who smoked 15–24 ciga-
rettes per day was lower among young adults (15.8%) than 
among adults overall (27.8%). In addition, in 2017, the 
prevalence of cigar smoking, smokeless tobacco use, and 
pipe use among current smokers was higher among young 
adults (19.2%, 9.3%, and 7.7%, respectively) (Table  2.5) 
than it was among adults overall (10.6%, 3.5%, and 2.7%, 
respectively) (Table  2.3); the same was also true for the 
combined category of any cigar, smokeless tobacco, and/or 
pipe use (28.4% vs. 14.5%).
Youth
Findings from the national YRBS indicate that, 
among high school students (grades 9−12) who were cur-
rent frequent cigarette smokers (ever smokers who had 
smoked >19  days during the past 30  days), the propor-
tion who were White decreased from 84.5% in 2001 to 
75.6% in 2005 and remained lower through 2017 (73.7%, 
p  <0.001 for quadratic trend)), and the proportion who 
were Hispanic increased from 6.2% in 2001 to 13.6% in 
2015 to 14.5% in 2017 (Table 2.6; p <0.001 for quadratic 
trend). The proportion who were Black remained statis-
tically unchanged during this period (3.9% in 2001 and 
5.3% in 2017).
Use of smokeless tobacco increased during 2001–
2015 among frequent youth smokers (from 19.9% to 
35.2%) (Table  2.7); comparable data were not available 
from the 2017 YRBS because the smokeless tobacco ques-
tion changed. In 2017, the majority of frequent youth 
smokers (68.0%) also used e-cigarettes. According to 
NYTS, use of menthol cigarettes among high school stu-
dents increased among frequent smokers, from 33.7% in 
2000 to 52.9% in 2017 (Table 2.8) to 53.0% in 2018 (NYTS, 
public use data, 2018). Similar findings were observed 
among current youth cigarette smokers, in a comparison 
of NYTS data between 1999–2009 and 2010–2013 using a 
slightly different definition of use of menthol cigarettes 
(Courtemanche et  al. 2017). Of note, caution should be 
taken when assessing trends among youth or comparing 
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Table 2.3 Distribution of tobacco use characteristics among adult current cigarette smokersa 18 years of age and older; National Health Interview Survey 
(NHIS) 2000, 2005, 2010, 2015, and 2017; United States
Characteristic 2000: % (95% CI) 2005: % (95% CI) 2010: % (95% CI) 2015: % (95% CI) 2017: % (95% CI)
Cigarette smoking frequency, amount          
Some-day smokers 17.9 (16.8–19.0) 19.4 (18.2–20.6) 21.9 (20.5–23.2) 24.4 (22.8–26.0) 25.1 (23.4–26.9)
Daily smokers, 1–4 cpd 4.0 (3.4–4.4) 4.4 (3.7–5.0) 5.9 (5.2–6.6) 6.6 (5.8–7.5) 7.0 (5.9–8.1)
Daily smokers, 5–14 cpd 25.4 (24.2–26.6) 29.4 (27.9–30.8) 32.5 (31.0–33.9) 34.4 (32.6–36.2) 34.9 (33.1–36.8)
Daily smokers, 15–24 cpd 37.7 (36.4–39.0) 35.4 (33.9–36.9) 32.5 (30.9–34.0) 28.5 (26.7–30.2) 27.8 (26.0–29.6)
Daily smokers, ≥25 cpd 15.1 (14.1–16.1) 11.4 (10.4–12.5) 7.3 (6.4–8.2) 6.1 (5.1–7.0) 5.1 (4.3–5.9)
Usually smokes menthol          
Yes NA 26.4 (24.9–27.9) 31.6 (30.0–33.3) 31.5 (29.7–33.4) NA
No NA 71.3 (69.9–72.7) 66.3 (64.7–67.9) 66.0 (64.1–67.9) NA
No usual type NA 2.3 (1.8–2.8) 2.0 (1.6–2.5) 2.4 (1.9–3.0) NA
Current use of other tobacco products          
Cigars 7.4 (6.7–8.1) 8.0 (7.1–8.9) 10.3 (9.2–11.3) 8.7 (7.6–9.8) 10.6 (9.1–12.0)
Smokeless tobacco 2.7 (2.2–3.2) 3.5 (2.7–4.3) 3.6 (3.0–4.3) 4.0 (3.1–4.9) 3.5 (2.8–4.2)
Pipes 1.4 (1.1–1.7) 1.4 (1.0–1.8) NA 2.6 (2.0–3.3) 2.7 (2.0–3.3)
Any use of cigars, smokeless 
tobacco, pipes
10.2 (9.4–11.1) 11.3 (10.3–12.4) NA 13.3 (11.9–14.6) 14.5 (12.9–16.1)
E-cigarettes NA NA NA 13.6 (12.2–14.9) 10.0 (8.8–11.1)
Source: NHIS, National Center for Health Statistics, public use data, 2000, 2005, 2010, 2015, and 2017.
Notes: CI = confidence interval; cpd = cigarettes smoked per day; NA = not available.
aPersons who reported smoking ≥100 cigarettes during their lifetime and who, at the time of the interview, reported smoking every day or some days.
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Table 2.4 Distribution of selected demographic characteristics of young adult current cigarette smokersa 18–24 years of age; National Health Interview 
Survey (NHIS) 2000, 2005, 2010, 2015, and 2017; United States
Characteristic 2000: % (95% CI) 2005: % (95% CI) 2010: % (95% CI) 2015: % (95% CI) 2017: % (95% CI)
Sex (% male) 53.0 (49.5–56.6) 57.5 (53.0–61.9) 57.2 (51.9–62.5) 58.2 (51.5–64.8) 57.6 (49.9–65.4)
Race/ethnicity          
White, non-Hispanic 77.7 (74.6–80.6) 73.0 (68.9–77.0) 72.7 (68.3–77.1) 64.3 (58.1–70.6) 71.2 (64.2–78.2)
Black, non-Hispanic 8.8 (6.7–10.8) 9.5 (6.9–12.1) 12.0 (8.7–15.4) 12.9 (8.5–17.4) 11.4 (6.6–16.3)
Hispanic 9.5 (7.5–11.5) 12.8 (10.3–15.2) 10.3 (7.5–13.1) 14.5 (10.2–18.9) 12.1 (7.0–17.2)
American Indian/Alaska Native, 
non-Hispanic
—b —b —b —b —b
Asian, non-Hispanic 1.9 (0.9–3.0) —b 2.3 (1.3–3.4) 3.1 (1.3–4.9) —b
Multiple races, non-Hispanic 1.7 (0.8–2.6) —b —b —b —b
Poverty status (% below poverty level) 21.0 (17.7–24.2) 24.2 (19.5–28.9) 29.9 (25.1–34.7) 24.5 (19.3–29.6) 24.5 (17.7–31.3)
Geographic region          
Northeast 17.5 (14.1–20.9) 13.0 (9.8–16.3) 16.7 (12.2–21.2) 16.2 (10.2–22.3) 13.4 (6.5–20.3)
Midwest 32.4 (28.3–36.5) 31.6 (27.5–35.8) 28.1 (23.8–32.5) 30.0 (23.5–36.4) 27.3 (21.2–33.4)
South 35.8 (31.6–39.9) 40.8 (35.8–45.8) 36.8 (31.8–41.7) 33.3 (27.1–39.6) 42.0 (34.3–49.7)
West 14.4 (11.9–16.9) 14.5 (11.9–17.2) 18.4 (14.6–22.2) 20.5 (15.2–25.7) 17.3 (11.7–22.8)
Health insurance coverage          
Private 52.9 (49.0–56.9) 43.5 (39.0–48.0) 38.2 (33.1–43.3) 47.4 (40.3–54.5) 46.5 (39.4–53.6)
Medicaid and persons with Medicaid 
and Medicare
9.0 (7.0–10.8) 13.7 (10.8–16.5) 16.9 (13.2–20.6) 26.2 (20.3–32.0) 21.5 (15.2–27.8)
Other coverage —b 1.8 (0.8–2.8) 3.0 (1.4–4.7) —b —b
Uninsured 35.6 (31.7–39.5) 40.4 (36.0–44.8) 41.0 (35.9–46.2) 22.0 (17.0–27.0) 28.1 (21.4–34.7)
Source: NHIS, National Center for Health Statistics, public use data, 2000, 2005, 2010, 2015, and 2017.
Notes: CI = confidence interval.
aPersons who reported smoking ≥100 cigarettes during their lifetime and who, at the time of the interview, reported smoking every day or some days.
bPrevalence estimates with a relative standard error ≥30% are not presented due to low precision.
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Table 2.5 Distribution of tobacco use characteristics of young adult current cigarette smokersa 18–24 years of age; National Health Interview Survey 
(NHIS) 2000, 2005, 2010, 2015, and 2017; United States
Characteristic 2000: % (95% CI) 2005: % (95% CI) 2010: % (95% CI) 2015: % (95% CI) 2017: % (95% CI)
Cigarette smoking frequency, amount          
Some-day smoker 21.8 (18.5–25.1) 24.4 (20.6–28.3) 30.0 (25.4–34.5) 40.8 (34.1–47.6) 34.7 (28.1–41.2)
Daily smoker, 1–4 cpd 5.4 (3.7–7.0) 7.6 (5.0–10.2) 8.8 (6.0–11.6) 9.5 (5.5–13.6) 8.6 (4.5–12.7)
Daily smoker, 5–14 cpd 36.2 (32.4–40.0) 38.7 (34.6–42.7) 36.6 (31.7–41.6) 36.2 (29.3–43.1) 40.6 (33.0–48.1)
Daily smoker, 15–24 cpd 30.9 (27.5–34.3) 24.0 (20.1–27.9) 21.9 (17.7–26.0) 12.1 (7.8–16.4) 15.8 (10.1–21.5)
Daily smoker, ≥25 cpd 5.8 (3.9–7.6) —b —b —b —b
Usually smokes menthol          
Yes NA 30.7 (26.1–35.2) 43.8 (38.5–49.0) 35.4 (28.5–42.4) NA
No NA 66.3 (61.6–71.1) 52.7 (47.4–58.0) 58.7 (51.4–66.0) NA
No usual type NA 3.0 (1.7–4.3) 3.5 (1.6–5.4) 5.9 (2.5–9.2) NA
Current use of other tobacco products          
Cigars 10.0 (7.6–12.4) 10.8 (7.7–13.9) 15.6 (11.8–19.4) 10.0 (6.0–14.0) 19.2 (13.3–25.1)
Smokeless tobacco 4.6 (2.6–6.5) 8.1 (4.0–12.2) 6.7 (4.1–9.3) 10.6 (5.4–15.7) 9.3 (5.2–13.3)
Pipes 2.5 (1.3–3.6) 2.4 (1.1–3.7) NA 6.1 (2.8–9.3) 7.7 (4.0–11.5)
Any use of cigars, smokeless 
tobacco, and pipes
15.0 (12.0–18.1) 17.3 (12.8–21.9) NA 21.5 (15.3–27.8) 28.4 (21.7–35.0)
E-cigarettes NA NA NA 18.6 (13.1–21.7) 16.1 (11.0–21.1)
Source: NHIS, National Center for Health Statistics, public use data, 2000, 2005, 2010, 2015, and 2017.
Notes: CI = confidence interval; cpd = cigarettes smoked per day; NA = not available.
aPersons who reported smoking ≥100 cigarettes during their lifetime and who, at the time of the interview, reported smoking every day or some days.
bPrevalence estimates with a relative standard error ≥30% are not presented due to low precision.
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Table 2.6 Distribution of demographic characteristics of high school students who are frequent cigarette smokersa; National Youth Risk Behavior Survey 
(YRBS) 2001, 2005, 2009, 2015, and 2017; United States
Characteristic 2001: % (95% CI) 2005: % (95% CI) 2009: % (95% CI) 2015: % (95% CI) 2017: % (95% CI)
Sex (% male) 52.0 (48.1–55.9) 50.3 (46.4–54.3) 57.2 (53.2–61.0) 52.0 (47.0–56.9) 49.1 (42.0–56.3)
Grade          
9 19.2 (15.4–23.7) 21.8 (18.5–25.5) 18.1 (15.1–21.6) 17.4 (11.0–26.6) 14.4 (9.9–20.5)
10 23.3 (20.0–26.8) 21.0 (17.3–25.2) 20.6 (17.9–23.6) 22.9 (17.4–29.5) 17.1 (12.1–23.6)
11 25.3 (21.0–30.3) 26.3 (23.0–30.0) 26.9 (23.1–31.0) 23.4 (17.3–30.8) 26.5 (20.0–34.2)
12 32.2 (28.5–36.1) 30.9 (26.8–35.4) 34.4 (31.0–38.1) 36.3 (30.6–42.4) 42.0 (35.2–49.2)
Race/ethnicityb          
White, non-Hispanic 84.5 (81.1–87.4) 75.6 (69.5–80.8) 78.9 (73.8–83.3) 66.0 (57.6–73.5) 73.7 (67.6–78.9)
Black, non-Hispanic 3.9 (2.7–5.7) 5.4 (3.3–8.6) 4.2 (2.6–7.0) 7.1 (4.1–12.1) 5.3 (2.3–11.9)
Hispanic 6.2 (4.4–8.6) 10.5 (7.6–14.2) 10.2 (7.8–13.1) 13.6 (9.7–18.7) 14.5 (10.8–19.3)
Source: YRBS, Centers for Disease Control and Prevention, public use data, 2001, 2005, 2009, 2015, and 2017.
Notes: CI = confidence interval.
aStudents who answered “yes” to “have you ever smoked?”; and “yes” to “do you currently smoke?”; and reported smoking on >19 days during the past 30 days.
bEstimates will not add up to 100% because data were not reported for students of other/multiple races/ethnicities.
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Table 2.8 Prevalence of use of menthol cigarettes among high school students who currently smoke cigarettes, by frequency of smokinga; National 
Youth Tobacco Survey (NYTS) 2000, 2004, 2009, 2015, and 2017; United States
Usually smokes menthol cigarettes 2000: % (95% CI) 2004: % (95% CI) 2009: % (95% CI) 2015: % (95% CI) 2017: % (95% CI)
Yes 33.7 (28.7–38.7) 47.2 (40.3–54.1) 50.5 (44.1–56.9) 48.8 (39.8–57.8) 52.9 (41.0–64.7)
No 63.7 (58.7–68.6) 52.8 (45.9–59.7) 49.5 (43.1–55.9) 45.2 (36.6–53.8) 42.2 (30.0–54.3)
No usual brand 2.7 (1.9–3.4) NA NA NA NA
Not sure NA NA NA 6.0 (1.9–10.0) —b
Source: NYTS, Centers for Disease Control and Prevention, public use data, 2000, 2004, 2009, 2015, and 2017.
Notes: CI = confidence interval; NA = not available; 
aStudents who answered “yes” to “have you ever tried cigarette smoking?” were categorized as (a) current infrequent smokers for smoking 1–19 days during the past 30 days 
or (b) current frequent smokers for smoking ≥20 days during the past 30 days.
bPrevalence estimates with a relative standard error ≥30% are not presented due to low precision.
Table 2.7 Prevalence of use of other tobacco products among high school students who are frequent cigarette smokersa; National Youth Risk Behavior 
Survey (YRBS) 2001, 2005, 2009, 2015, and 2017; United States
Other tobacco products 2001: % (95% CI) 2005: % (95% CI) 2009: % (95% CI) 2015: % (95% CI) 2017: % (95% CI)
Cigarsb 44.3 (40.0–48.8) 47.6 (42.7–52.7) 52.7 (45.6–59.7) 54.1 (47.1–61.0) 54.8 (46.7–62.7)
Smokeless tobaccoc 19.9 (15.9–24.5) 23.5 (19.9–27.6) 35.5 (31.1–40.2) 35.2 (29.2–41.7) NA
Electronic vapor productsd NA NA NA 76.4 (70.8–81.2) 68.0 (58.2–76.4)
Source: YRBS, Centers for Disease Control and Prevention, public use data, 2001, 2005, 2009, 2015, and 2017.
Notes: CI = confidence interval; NA = not available.
aStudents who answered “yes” to “have you ever smoked?”; “yes” to “do you currently smoke?”; and reported smoking ≥20 days during the past 30 days.
bSmoked cigars, cigarillos, or little cigars on at least 1 day during the 30 days before the survey.
cUsed chewing tobacco, snuff, or dip on at least 1 day during the 30 days before the survey.
dUsed e-cigarettes, e-cigars, e-pipes, vape pipes, vaping pens, e-hookahs, or hookah pens during the 30 days before the survey.
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Smoking Cessation
Key Disparities in Current Cigarette Smoking Among Adults 
and Youth
Numerous Surgeon General’s reports have reviewed 
disparities in the prevalence of current smoking (USDHHS 
1998, 2001, 2012, 2014). In 2017, the prevalence of cur-
rent cigarette smoking was 20.0% or higher in a variety of 
vulnerable or high-risk groups:
• 36.8% among those who had obtained a General 
Educational Development (GED) certificate but 
went no further in their education;
• 35.2% among persons with serious psychological 
distress, a proxy variable for mental illness;
• 24.7% among persons with no health insurance;
• 24.5% among Medicaid enrollees;
• 24.0% among American Indians/Alaska Natives; and
• 20.3% among lesbian, gay, and bisexual adults 
(Wang et al. 2018a).
Disparities by Behavioral Health 
Condition
Data from the U.S. National Survey on Drug Use and 
Health (NSDUH) from 2005 to 2013 indicate that current 
smoking among adults reporting anxiety, depression, or 
substance abuse disorders ranged from 39.6% to 56.3% 
(Stanton et  al. 2016). In the 2014 NSDUH, the preva-
lence of current smoking among persons who abused 
or were dependent on illicit drugs other than marijuana 
was 63.3%, and among those who abused or were depen-
dent on marijuana, it was 51.3% (Weinberger et al. 2018). 
Data from the 2012 NHIS indicate that the age-adjusted 
prevalence of current smoking was 53.0% among those 
with a lifetime history of bipolar disorder, 31.5% among 
those with a lifetime history of depression, 30.6% among 
those with a lifetime history of attention deficit disorder or 
attention deficit hyperactivity disorder, and 28.3% among 
those with a lifetime history of phobias or fears (NHIS, 
public use data, 2012).
Disparities by Chronic Disease 
Status
Using 2017 NHIS data, the prevalence of cur-
rent smoking was high among persons with emphy-
sema (35.2%) and those with chronic bronchitis (29.7%). 
Among those with other smoking-related diseases (lung 
cancer, other cancers, coronary heart disease, and stroke) 
(see Chapter 4), the prevalence of current smoking ranged 
from 13.5% to 35.2% and was 14.8% among those with 
other chronic diseases1 and 12.2% among those with no 
chronic diseases (NHIS, public use data, 2017).
Disparities by Geographic Location
The prevalence of current smoking varies widely 
by geographic location. Data from the 2017 NHIS indi-
cate that by region, cigarette smoking was higher in 
the Midwest (16.9%) and South (15.5%) than in the 
Northeast (11.2%) and West (11.0%) (Wang et al. 2018a). 
Data from the 2017 BRFSS indicate that by state, West 
Virginia, Kentucky, and Louisiana had the highest prev-
alence of current cigarette smoking (26.0%, 24.6%, and 
23.1%, respectively), and the states of Utah, California, 
and Connecticut had the lowest prevalence (8.9%, 11.3%, 
and 12.7%, respectively) (CDC 2017). Data from the 2013 
1Other chronic diseases are defined as those that are not related to smoking, including hypertension; other heart condition or heart dis-
ease; ulcer; and cancers, including blood, bone, brain, breast, gallbladder, lymphoma, melanoma, ovarian, prostate, skin (non-melanoma 
and other), soft tissue, testicular, thyroid, and other types of cancer.
the timing of the increases among youth with the increases 
among adults (Table 2.3) because wording of the question 
in NYTS changed over time, which may have influenced 
the likelihood of an affirmative response. For example, 
in 2000, the question was, “Is the brand of cigarettes you 
usually smoked during the past 30 days mentholated?” but 
in questionnaires in 2015 and 2017, the question changed 
to, “Menthol cigarettes are cigarettes that taste like mint. 
During the past 30 days, were the cigarettes that you usu-
ally smoked menthol?” (CDC 2018).
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BRFSS indicate that persons who live in rural counties 
have a higher prevalence of smoking than persons who 
live in metropolitan areas, with estimates ranging from 
a high of 25.1% in rural counties to a low of 16.1% in 
large metropolitan centers (Matthews et  al. 2017). In a 
multivariate logistic regression model controlling for age, 
sex, poverty, and geographic region, the 2013–2014 PATH 
Study observed that, compared with urban residents, 
rural residents had 25% greater odds of being current 
cigarette smokers (smoked in the past 30 days) (Roberts 
et al. 2017).
Disparities by Sexual Orientation 
and Gender Identity
The prevalence of cigarette smoking among les-
bian, gay, bisexual, and transgender (LGBT) individuals 
is higher than the prevalence of smoking among het-
erosexual or straight persons. According to NHIS data, 
in 2017, current cigarette smoking was 20.3% among 
lesbian, gay, and bisexual adults compared with 13.7% 
among heterosexual or straight adults (Wang et  al. 
2018a). Variations in the prevalence of cigarette smoking 
also exist across sexual orientation and gender minority 
subgroups. Data from the 2012–2013 NATS indicated that 
cigarette smoking was particularly high among bisexual 
women, and that sexual minority women started smoking 
and transitioned to daily smoking earlier than their het-
erosexual or straight counterparts (Johnson et al. 2016). 
Data from the 2009–2010 NATS indicated that menthol 
cigarette smoking was significantly higher among LGBT 
adult smokers, particularly among LGBT women, than 
among their heterosexual counterparts (Fallin et  al. 
2015). Limited information exists on the prevalence of 
cigarette smoking by gender identity. A 2013 cross-sec-
tional online survey of U.S. adults found that the prev-
alence of cigarette smoking was higher among trans-
gender adults than among cisgender adults (Buchting 
et al. 2017).
Similar disparities in the prevalence of smoking 
by sexual orientation and gender identity exist among 
youth. Data from the 2017 YRBS indicated that current 
cigarette smoking by high school students in grades 
9–12  was higher among gay, lesbian, and bisexual stu-
dents (16.2%) than among heterosexual students (8.1%) 
and those unsure of their sexual orientation (10.1%) 
(Kann et  al. 2018). Moreover, 2017 YRBS data from 
19 states and large urban school districts found that ever 
use of cigarettes was significantly higher among trans-
gender high school students (32.9%) than among cis-
gender male (23.2%) and cisgender female (22.0%) stu-
dents (Johns et al. 2019).
Sexual orientation and gender identity are two sepa-
rate and distinct measures, and existing surveillance data 
suggest disparities in smoking prevalence by both sexual 
orientation and gender identity. Taken together, these 
findings reinforce the heterogeneity of tobacco product 
use by sexual orientation and the critical importance 
of (a)  tobacco control efforts designed to reach sexual 
and gender minorities and (b)  tobacco survey measures 
designed specifically to ask adults and youth about gender 
identity separately from sexual orientation.
Disparities in Smoking in Pregnant 
Women
Smoking during pregnancy can have devastating 
health consequences for the mother, such as the outcome 
of the pregnancy, and for the future health of the child, 
making quitting smoking an important part of prenatal 
care (USDHHS 2014) (also see in this report related sec-
tions on smoking cessation and reproductive health in 
Chapter  4). According to data from birth certificates of 
children of women who gave birth in 2016, 7.2% of women 
in the United States reported smoking during pregnancy 
(Drake et al. 2018).
In a study using the first wave of data from the 2013–
2014 PATH Study, the prevalence of current cigarette 
smoking among women of reproductive age was 20.1%, 
and current cigarette smoking was highly correlated with 
the use of other tobacco products (Lopez et al. 2018). Data 
from the 2013 Pregnancy Risk Assessment Monitoring 
System (PRAMS) indicated that 21.1% of women had 
smoked during the 3 months before pregnancy, and 14.0% 
had smoked postpartum. Estimates of the prevalence of 
smoking in working women of reproductive age and in 
working pregnant women from the 2009–2013 NHIS are 
generally lower than estimates in PRAMS, with 17.3% and 
6.8% of these women, respectively, being current smokers 
(Mazurek and England 2016).
In 2016, disparities in cigarette smoking during 
pregnancy occurred by age, race/ethnicity, educational 
level, and geographic location (Drake et  al. 2018). For 
smoking during pregnancy, women 20–24 years of age had 
the highest prevalence (10.7%) by age group; American 
Indian/Alaska Native women had the highest prevalence 
(16.7%) by race/ethnicity; and women with a high school 
diploma or GED had the highest prevalence by level of 
education (12.2%). Prevalence of current smoking among 
pregnant women was highest in West Virginia (25.1%), 
Kentucky (18.4%), and Montana (16.5%) and lowest in 
Arizona, California, Connecticut, Hawaii, New Jersey, New 
York, Nevada, Texas, Utah, and Washington, D.C. (each 
<5.0%) (Drake et al. 2018).
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Disparities in Smoking Among 
Active Duty Service Members
Tobacco use can negatively impact the readi-
ness and resilience of active duty service members and 
is a major concern to the Military Health System of the 
U.S. Department of Defense (Bondurant and Wedge 2009). 
In June 2019, the Surgeons General of the Air Force, 
Army, Navy, and United States released an open letter 
stating tobacco use is a threat to the health and fitness of 
U.S. military forces and compromises readiness, which is 
the foundation of a strong national defense (Adams et al. 
2019). An estimated 38% of current cigarette smokers 
in the military initiated smoking after enlisting (Carter 
2016), and tobacco use has been associated with higher 
dropout rates during basic training, poorer visual acuity, 
higher rates of leaving military service during the first 
year, and higher rates of absenteeism (Bondurant and 
Wedge 2009). Factors that may promote tobacco use in 
the military include stress, peer influence, and easy access 
to less expensive tobacco products (Haddock et al. 2014). 
Additionally, the tobacco industry has previously been 
shown to target marketing toward active duty service 
members (Smith and Malone 2009).
In addition to the health-related burden, tobacco 
use also exacts significant financial costs to the mili-
tary. In 2009, it was estimated that tobacco use costs the 
U.S. Department of Defense $1.6 billion a year for med-
ical care, increased hospitalizations, and absenteeism 
(Bondurant and Wedge 2009). Additionally, in 2010, 
Veterans Health Administration (VHA) spent $2.7 billion 
on smoking-related ambulatory care, prescription drugs, 
hospitalizations, and home healthcare (Barnett et al. 2015).
According to data from the 2015 Health Related 
Behaviors Survey (HRBS) from the U.S. Department of 
Defense, 13.9% of service members currently smoked ciga-
rettes, a prevalence that is two-fold higher among military 
personnel who have been deployed (28.0%) (Meadows 
et al. 2018). Additionally, among active duty service mem-
bers, disparities exist by branch of service, sex, age group, 
race/ethnicity, education, and pay grade. For example, 
cigarette smoking is highest among those in the Marine 
Corps (20.7%); men (14.4%); persons 17–24 years of age 
(19.5%); those who reported being Other race/ethnicity 
(16.1%), White (14.6%), or Hispanic (14.6%); those with a 
high school education or less (25.1%); and those with low 
salaries (E1–E4 pay grade) (17.9%).
Correlation of Smoking-Related 
Risk Factors
As with many health behaviors and chronic dis-
eases, several risk factors for cigarette smoking are highly 
correlated (Remington et al. 2016). For example, in 2017, 
the prevalence of serious psychological distress was 9.6% 
among those who completed grades  9–12 (with neither 
a high school diploma nor a GED certificate) compared 
with 2.8% among those with at least a high school edu-
cation (NHIS, public use data, 2017). Similarly, those 
who completed grades 9–12 (with neither a diploma or a 
GED certificate) were more likely than those with more 
than a high school education to live below the poverty 
level (27.9%  vs. 7.2%, respectively) or to be uninsured 
(20.3%  vs. 7.3%, respectively) (NHIS, public use data, 
2017). Persons with multiple risk factors for current 
smoking had a higher prevalence of smoking than those 
with a single risk factor. For example, the prevalence of 
smoking was 58.5% among those with serious psycholog-
ical distress who completed 9–12 years of education with 
neither a diploma or a GED certificate, but it was 32.7% 
among those with serious psychological distress with 
at least a high school education (Figures  2.7a and 2.7b 
[NHIS, public use data, 2017]).
Cigarette Smoking Cessation Among Adults and Youth
Recent Successful Cessation
Recent successful cessation is defined as having 
smoked during the past year but having quit for at least 
6 months at the time of the survey interview. The denom-
inator in the prevalence calculation includes all persons 
who smoked during the past year (i.e., both current ciga-
rette smokers and former smokers who reported quitting 
during the past year). Furthermore, to be included in the 
denominator, current smokers had to have smoked for at 
least 2 years—corresponding to the Healthy People 2020 
definition for recent smoking cessation success (mea-
sure TU-5.1) (Office of Disease Prevention and Health 
Promotion n.d.a). Recent smoking cessation gives a more 
proximate measure of current patterns in smoking cessa-
tion than prevalence of former smoking; however, recent 
smoking cessation may overestimate sustained quitting 
because some former smokers will relapse to smoking after 
6 months (Hughes et al. 2008). Estimates of long-term sus-
tained quit rates using smoking prevalence and initiation 
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Figure 2.7a Prevalence of current cigarette smoking by level of education and presence or absence of serious 
psychological distress and poverty status among adults 25 years of age and older: National Health 
Interview Survey (NHIS) 2017; United States
Source: NHIS, National Center for Health Statistics, public use data, 2017.
Note: GED = General Educational Development.
Figure 2.7b Prevalence of current cigarette smoking by level of education and status of health insurance among 
adults 25 years of age and older: National Health Interview Survey (NHIS) 2017; United States
Source: NHIS, National Center for Health Statistics, public use data, 2017.
Note: GED = General Educational Development.
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data from NHIS and NSDUH, as well as death rates of 
smokers from the Cancer Intervention and Surveillance 
Modeling Network, indicate that permanent annual quit 
rates during 2008–2014 were 4.5% using NHIS data and 
4.2% using NSDUH data (Mendez et al. 2017).
Adults
Data from the 2017 NHIS indicate that 7.6% of adults 
who were ever cigarette smokers reported recent suc-
cessful cessation (Table 2.9). Recent successful cessation 
generally decreased with age (14.0% among young adults 
[18–24  years of age] and 6.3% among adults [65  years 
of age and older]) (Table  2.9). Among the 50  states, the 
District of Columbia, Guam, and Puerto Rico, the highest 
prevalence of recent successful cessation was observed in 
South Dakota, Connecticut, Minnesota, and the District 
of Columbia. (7.5–7.9%), and the lowest prevalence was 
observed in Mississippi, Indiana, Nevada, Pennsylvania, 
and Tennessee (3.3–3.9%) (Table 2.10). It is important to 
note that, because the BRFSS does not ask current smokers 
about the number of years smoked, the BRFSS measure is 
not restricted to current smokers who smoked for at least 
2 years; therefore, this measure is not directly comparable 
to that used in NHIS (see Appendix 2.2 for more informa-
tion). The PATH Study observed that (a) 15.5% of current 
cigarette smokers at Wave 1 (September 2013–December 
2014) who reported at Wave 2 (October 2014–October 2015) 
that they had attempted to quit in the past 12 months were 
abstinent for 30 or more days at Wave 2 and (b) cigarette 
smokers with a college degree had a higher prevalence of 
cessation (i.e., abstinence of >30 days) (20.0%) than those 
with lower levels of education (14.9%) (Benmarhnia et al. 
2018). In a second analysis of the PATH Study, Berry and 
colleagues (2019) did not limit the analysis to current 
cigarette smokers who were trying to quit, but instead 
examined quitting among all current cigarette smokers at 
Wave 1. Through multivariate logistic regression models, 
the study observed that (a) daily smokers were less likely 
(odds ratio [OR] = 0.27; 95% confidence interval [CI], 0.19–
0.38) to quit than some-day smokers and (b) daily smokers 
who had tried to quit during the year before Wave 1 were 
more likely to quit (OR  =  1.25; 95% CI, 1.00–1.57) for 
30 or more days at Wave 2 than those who did not attempt 
to quit during the previous year. In a third analysis of the 
PATH Study, Rodu and Plurphanswat (2017) examined cor-
relates at Wave 1 of having quit smoking during the past 
year. The study found that, among cigarette smokers who 
tried to quit during the past year, the odds of having quit in 
the past year decreased with increased age, with increased 
number of quit attempts, and with increased level of edu-
cation; and odds of having quit in the past year were lower 
among Blacks than they were among Whites (OR = 0.70; 
95% CI, 0.50–0.97).
During 2000−2015, a linear increase in recent suc-
cessful cessation was observed (from 5.7% to 7.4%), as 
noted previously (Babb et al. 2017). Using data from NHIS, 
Mendez and colleagues (2017) also observed an increase 
in permanent annual quit rates from 2.4% (1990–1995) 
to 4.5% (2008–2014). No significant trends for this mea-
sure were observed among young adults (NHIS, public use 
data, 2000, 2005, 2010, and 2015).
Quit Ratio
The quit ratio represents the percentage of ever 
smokers who have quit smoking and is defined as the 
number of former smokers divided by the number of ever 
smokers. Similar to the prevalence of former smoking, 
quit ratio is a broad cessation measure encompassing cig-
arette smokers who quit many decades ago through those 
who have quit for 1 day at the time of their survey inter-
view. However, although the denominator for the preva-
lence of former smoking includes all adults in the United 
States, the denominator for quit ratio includes only per-
sons who have ever smoked 100 or more cigarettes in their 
lifetime. Data from the 2017 NHIS show that the quit ratio 
for U.S. adults was 61.7% (Table 2.9), indicating that there 
are more former cigarette smokers in the United States 
than current cigarette smokers (by a ratio of almost 3:2). 
The quit ratio in 2017 represents a 6-percentage-point 
increase over the quit ratio in 2012 (55.1%) and reflects 
a continued increasing trend in the population-based quit 
ratio since 1965 (USDHHS 2014).
Adults
 Data from the 2017 NHIS indicate that the quit ratio 
increased linearly with age, ranging from 32.7% among 
18- to 24-year-olds to 82.9% among those 65 years of age 
and older (Table 2.9). The quit ratio has been consistently 
highest among adults 65 years of age and older and consis-
tently lowest among young adults (Figure 2.8a). The quit 
ratio has increased in all adult age groups since 1965, with 
some variability from year to year.
Data from the 2017 NHIS indicate that quit ratios 
were lower among Blacks (46.1%) than Asians (64.3%), 
Whites (63.9%), and Hispanics (61.5%) (Table 2.9). Persons 
of multiple races (50.0%) had lower quit ratios than Whites 
(63.9%). The quit ratio increased among White and Black 
adults from 1965 to 2017, and it increased between 1980 
and 2017 among Hispanics (data on Hispanics were not 
available before 1980), with variability from year to year 
(Figure 2.8b).
Data from the 2017 NHIS also indicate that the 
quit ratio generally increased with level of education. 
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Table 2.9  Percentage of ever cigarette smokers 18 years of age and older who have recently successfully quit and 
quit smoking (quit ratio), by selected characteristics; National Health Interview Survey (NHIS) 2017; 
United States
Characteristic
Recent successful cessation:a 
% (95% CI) Quit ratio: % (95% CI)
Total 7.6 (6.6–8.6) 61.7 (60.4–63.0)
Sex      
Men 7.2 (5.9–8.5) 61.9 (60.2–63.6)
Women 8.1 (6.5–9.6) 61.5 (59.6–63.3)
Age group (years)      
18–24 14.0 (9.4–18.7) 32.7 (26.6–38.8)
25–44 7.9 (6.5–9.4) 50.7 (48.4–53.0)
45–64 6.1 (4.5–7.6) 59.7 (57.7–61.7)
≥65 6.3 (3.9–8.6) 82.9 (81.3–84.5)
Race/ethnicity      
White, non-Hispanic 7.4 (6.3–8.5) 63.9 (62.5–65.3)
Black, non-Hispanic 7.0 (4.0–10.1) 46.1 (42.3–50.0)
Hispanic 9.1 (5.7–12.5) 61.5 (57.3–65.7)
American Indian/Alaska Native, non-Hispanic —b —b
Asian, non-Hispanic —b 64.3 (57.3–71.2)
Multiple races, non-Hispanic —b 50.0 (41.2–58.8)
Level of educationc      
≤12 years (no diploma) 5.8 (3.7–7.9) 50.6 (47.2–53.9)
GED certificate 6.1 (3.1–9.0) 42.4 (37.1–47.7)
High school diploma 6.1 (4.1–8.0) 58.4 (56.0–60.9)
Some college (no degree) 8.2 (5.6–10.8) 62.4 (59.9–65.0)
Associate degree 5.7 (3.5–8.0) 63.3 (60.2–66.5)
Undergraduate degree 8.7 (5.7–11.7) 76.1 (73.3–78.9)
Graduate degree 11.0 (6.0–16.0) 82.8 (79.8–85.8)
Poverty status      
At or above poverty level 8.0 (6.9–9.2) 64.5 (63.2–65.8)
Below poverty level 5.8 (3.9–7.6) 42.2 (38.7–45.7)
U.S. Census region      
Northeast 8.6 (5.8–11.4) 68.0 (65.0–70.9)
Midwest 6.8 (4.8–8.7) 59.3 (56.7–61.9)
South 7.7 (6.0–9.3) 56.6 (54.5–58.7)
West 7.8 (5.8–9.7) 67.6 (65.1–70.1)
Health insurance coverage      
Private 8.5 (6.9–10.1) 67.9 (66.4–69.4)
Medicaid (includes persons with Medicaid and Medicare) 6.6 (4.6–8.7) 41.1 (37.5–44.6)
Medicare only —b 81.5 (78.6–84.4)
Other coverage 6.6 (3.7–9.5) 60.4 (56.4–64.4)
Uninsured 7.5 (5.0–10.0) 38.7 (35.0–42.5)
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Table 2.10  Percentage of current and ever smokers 18 years of age and older who quit smoking (quit ratio)a and 
prevalence of recent successful cessationb and a past-year quit attempt,c by state; Behavioral Risk Factor 
Surveillance System (BRFSS) 2017; United States
State/territory Quit ratio: % (95% CI)
Recent successful cessation: 
% (95% CI)
Past-year quit attempt: 
% (95% CI)
Overall 59.2 (57.0–61.4) — —
Alabama 52.8 (50.3–55.3) 4.7 (3.2–6.2) 67.5 (64.1–70.9)
Alaska 54.9 (50.6–59.3) 5.1 (2.8–7.4) 63.6 (57.2–70.0)
Arizona 61.3 (59.7–63.0) 6.3 (5.0–7.6) 66.6 (64.2–69.0)
Arkansas 53.4 (49.7–57.1) 5.2 (2.9–7.5) 66.7 (61.7–71.8)
California 66.3 (63.9–68.7) 7.0 (5.2–8.8) 68.0 (64.2–71.7)
Colorado 63.6 (61.6–65.6) 6.2 (4.5–7.8) 68.2 (65.2–71.1)
Connecticut 67.1 (65.0–69.2) 7.7 (5.6–9.9) 71.6 (68.3–74.9)
Delaware 59.5 (56.2–62.9) 6.3 (3.4–9.2) 71.0 (66.5–75.4)
District of Columbia 56.3 (53.0–59.6) 7.0 (4.7–9.3) 69.3 (64.9–73.8)
Florida 60.8 (58.5–63.1) 5.2 (3.8–6.7) 67.6 (64.4–70.8)
Georgia 53.8 (51.1–56.5) 4.4 (2.9–6.0) 64.3 (60.5–68.1)
Hawaii 67.6 (65.2–70.0) 6.6 (4.2–8.9) 67.0 (63.2–70.8)
Idaho 62.4 (59.3–65.6) 6.0 (3.1–8.9) 62.2 (57.2–67.1)
Illinois 59.8 (57.1–62.6) 5.4 (3.5–7.2) 64.8 (60.7–68.9)
Indiana 52.9 (51.2–54.6) 3.9 (3.0–4.9) 62.0 (59.6–64.3)
Iowa 59.0 (57.0–61.1) 4.7 (3.5–6.0) 59.9 (56.9–63.0)
Kansas 58.3 (57.0–59.7) 5.0 (4.1–6.0) 64.3 (62.4–66.2)
Kentucky 51.0 (48.4–53.5) 4.3 (2.8–5.7) 62.1 (58.7–65.5)
Louisiana 49.9 (47.1–52.7) 5.3 (3.7–7.0) 69.7 (66.3–73.2)
Maine 64.7 (62.5–66.9) 6.1 (4.3–7.9) 62.2 (58.5–66.0)
Maryland 61.4 (59.2–63.6) 5.3 (3.5–7.1) 65.9 (62.4–69.3)
Massachusetts 64.7 (61.7–67.7) 5.0 (3.2–6.9) 64.6 (59.8–69.3)
Michigan 58.1 (56.2–59.9) 4.5 (3.4–5.6) 66.2 (63.6–68.8)
Minnesota 64.5 (63.0–66.0) 7.5 (6.2–8.7) 63.8 (61.5–66.1)
Mississippi 49.3 (46.2–52.4) 3.3 (1.9–4.6) 61.1 (56.8–65.5)
Missouri 55.4 (53.0–57.8) 5.5 (3.9–7.0) 59.7 (56.2–63.1)
Montana 61.4 (58.7–64.0) 4.8 (3.1–6.4) 60.6 (56.6–64.7)
Nebraska 61.5 (59.6–63.5) 5.7 (4.2–7.1) 63.9 (61.0–66.8)
Nevada 57.7 (53.9–61.5) 3.9 (2.2–5.7) 62.7 (57.2–68.2)
New Hampshire 65.9 (63.0–68.8) 5.6 (3.5–7.7) 63.7 (58.8–68.6)
Table 2.9 Continued
Source: NHIS, National Center for Health Statistics, public use data, 2017; Babb and colleagues (2017).
Notes: CI = confidence interval; GED = General Educational Development.
aThe numerator includes former smokers who quit smoking for ≥6 months during the past year. The denominator for this measure 
includes both current smokers who smoked for ≥2 years and former smokers who quit during the past year. 
bPrevalence estimates with a relative standard error ≥30% are not presented due to low precision.
cAmong only adults 25 years of age and older.
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For example, in 2017, the quit ratio among those with 
a graduate degree (82.8%) was far higher than the quit 
ratio among those who had 12 or fewer years of education 
(with no diploma) (50.6%) or a GED certificate (42.4%) 
(Table  2.9). Those living below the federal poverty level 
had a much lower quit ratio (42.2%) than persons at or 
above the poverty level (64.5%). By geographic region, the 
Northeast (68.0%) and West (67.6%) had higher quit ratios 
than the Midwest (59.3%) and the South (56.6%). By status 
of health insurance, those who were uninsured (38.7%) or 
enrolled in Medicaid (41.1%) had the lowest quit ratios.
Data from the 2017 BRFSS indicate that quit ratios 
were greater than 50% in every state except Mississippi 
(49.3%) and Louisiana (49.9%) (Guam also had a preva-
lence  <50%) (Table  2.10). Thus, in the vast majority of 
states, more than half of the persons who had ever smoked 
cigarettes had quit smoking. In three states (Hawaii 
[67.7%], Connecticut [67.1%], and Washington [66.8%]), 
more than two-thirds of ever smokers had quit smoking, 
and the quit ratio in 20 other states and Puerto Rico was 
between 60.1% and 66.3%. These are marked improve-
ments from 2004, when only 34  states had quit ratios 
Table 2.10 Continued
State/territory Quit ratio: % (95% CI)
Recent successful cessation: 
% (95% CI)
Past-year quit attempt: 
% (95% CI)
New Jersey 64.8 (62.4–67.2) 5.5 (3.8–7.2) 71.3 (67.7–74.9)
New Mexico 57.7 (55.0–60.5) 5.3 (3.5–7.1) 65.5 (61.7–69.3)
New York 62.1 (60.1–64.1) 6.2 (4.6–7.9) 66.4 (63.4–69.5)
North Carolina 60.1 (57.3–62.9) 4.8 (3.1–6.4) 65.4 (61.3–69.6)
North Dakota 57.7 (55.3–60.2) 4.2 (2.8–5.6) 62.2 (58.7–65.7)
Ohio 53.6 (51.6–55.6) 4.4 (3.1–5.7) 61.7 (58.9–64.6)
Oklahoma 54.9 (52.5–57.3) 5.9 (4.4–7.4) 65.9 (62.5–69.2)
Oregon 61.5 (59.1–64.0) 4.6 (3.1–6.0) 62.5 (58.8–66.2)
Pennsylvania 59.0 (56.6–61.3) 3.9 (2.7–5.1) 64.3 (60.9–67.6)
Rhode Island 65.6 (62.7–68.5) 6.3 (4.0–8.7) 69.6 (64.9–74.3)
South Carolina 58.5 (56.5–60.5) 4.7 (3.2–6.2) 65.8 (62.9–68.7)
South Dakota 57.1 (53.6–60.6) 7.9 (5.0–10.8) 64.5 (59.4–69.6)
Tennessee 51.2 (48.5–54.0) 3.9 (2.4–5.4) 60.3 (56.6–64.0)
Texas 55.8 (52.6–59.1) 5.4 (3.4–7.3) 70.7 (66.6–74.7)
Utah 62.8 (60.3–65.3) 6.1 (4.3–7.9) 66.4 (62.8–70.1)
Vermont 65.1 (62.6–67.6) 6.3 (4.1–8.5) 66.0 (62.0–70.0)
Virginia 59.2 (57.0–61.4) 5.6 (3.9–7.4) 66.4 (63.2–69.6)
Washington 66.8 (65.1–68.6) 6.3 (4.9–7.7) 68.1 (65.4–70.7)
West Virginia 50.2 (47.9–52.5) 5.8 (4.3–7.3) 61.6 (58.5–64.8)
Wisconsin 61.5 (58.8–64.2) 5.1 (3.2–6.9) 58.6 (54.3–62.8)
Wyoming 58.1 (55.2–61.0) 6.7 (4.4–9.1) 65.0 (61.0–69.0)
Guam 43.6 (38.5–48.7) 6.7 (3.8–9.7) 72.3 (66.7–77.9)
Puerto Rico 62.3 (58.5–66.1) 6.3 (2.9–9.6) 67.1 (61.5–72.7)
Source: BRFSS, Centers for Disease Control and Prevention, public use data, 2017.
Notes: CI = confidence interval.
aQuit ratio is calculated as the proportion of current smokers who reported having stopped smoking for >1 day during the past year 
because they were trying to quit smoking, and former smokers who quit smoking during the past year (numerator), among all current 
and former smokers who only quit in the past year (denominator).
bThe percentage of former smokers who quit smoking for >6 months during the past year among current smokers and former smokers 
who quit during the past year.
cCurrent smokers who reported that they stopped smoking for >1 day during the past 12 months because they were trying to quit 
smoking and former smokers who quit during the past year.
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Figure 2.8b Percentage of ever smokers 18 years of age and older who quit smoking (quit ratio), by race/ethnicity; 
National Health Interview Survey (NHIS), 1965–2017; United States
Source: NHIS, National Center for Health Statistics, public use data, 1965–2017.
Note: From 1965 to 1996, data were reported for the following years (as indicated by the dotted line): 1965, 1970, 1974, 1978, 1980, 
1983, 1985, 1987, 1990, 1993, and 1995. Data were reported annually for years 1997–2017 (as indicated by the solid line).
Figure 2.8a Percentage of ever smokers 18 years of age and older who quit smoking (quit ratio), by age group; 
National Health Interview Survey (NHIS), 1965–2017; United States
Source: NHIS, National Center for Health Statistics, public use data, 1965–2017.
Note: From 1965 to 1996, data were reported for the following years (as indicated by the dotted line): 1965, 1970, 1974, 1978, 1980, 
1983, 1985, 1987, 1990, 1993, and 1995. Data were reported annually for years 1997–2017 (as indicated by the solid line).
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greater than 50% and just 4 states had quit ratios greater 
than 60% (CDC 2005). In 2004, the median quit ratio 
across 49 states and the District of Columbia was 52.4%, 
and in 2017, the median quit ratio for all 50 states and the 
District of Columbia was 59.2%.
Young Adults
The quit ratio among young adults has consis-
tently been the lowest of all adult age groups since 1965 
(Figure  2.8a). The quit ratio among young adult ever 
smokers has increased since 1965 (from 13.1% in 1965 
to 32.7% in 2017); however, little change has occurred 
since the 1980s. The positive relationship between quit 
ratio and age is due in part to the accumulation of quitters 
with age; specifically, the numerator among older ever 
smokers includes persons who quit many decades ago, 
but among young adult ever smokers, a decade ago would 
be when they were 8–14 years of age—a time when many 
were smoking their first cigarette, not quitting (USDHHS 
2012). This positive relationship is also due, in part, to 
the increased mortality among older current smokers 
compared with long-term former smokers, which would 
decrease the denominator among older versus younger 
ever smokers (USDHHS 2014).
Youth
Compared with adults, smoking behaviors among 
youth are less established and the prevalence of quitting 
is much lower (USDHHS 2012). Therefore, quit ratios 
among youth are not included in this report because they 
would most likely reflect cessation attributable to both 
quitting and experimentation, or discontinuation of non-
established smoking patterns (USDHHS 2012).
Trends in the Cessation Continuum 
for Current Smokers
Data from TUS-CPS from 2006–2007, 2010–2011, 
and 2014–2015 were used to develop a cigarette smoking 
cessation continuum for adults 18 years of age and older 
who were current smokers. A cessation continuum was con-
structed to describe more completely the dynamic process 
of smoking cessation, including interest in quitting, quit-
ting history, and past-year quit attempts. The continuum 
included six subgroups of current cigarette smokers: 
• Persons who had never tried to quit and who were 
currently not interested in quitting,
• Persons who had never tried to quit but were cur-
rently interested in quitting,
• Persons who had ever tried to quit but did not try in 
the past year and who were currently not interested 
in quitting,
• Persons who had ever tried to quit but did not try to 
quit in the past year and who were currently inter-
ested in quitting,
• Persons who tried to quit in the past year but were 
currently not interested in quitting, and
• Persons who tried to quit in the past year and were 
currently interested in quitting.
It is important to note that, although the definition 
of those who ever tried to quit includes cigarette smokers 
whose quit attempt lasted less than 1 day, the definition of 
trying to quit in the past year includes only quit attempts 
that lasted for 1 day or longer (i.e., not attempts that lasted 
for less than 1  day) among current daily smokers and 
some-day smokers who smoked 12 or more days in the past 
30 days—thereby underestimating the prevalence of past-
year quit attempts (Hughes et  al. 2013). The more con-
servative definition of past-year quit attempt was selected 
to match more closely the past-year quit attempt question 
on NHIS, which has the greatest number of years of data 
on the prevalence of past-year quit attempts. Appendix 2.2 
presents more information about the potential effect of 
excluding past-year quit attempts of less than 1  day on 
prevalence estimates.
The proportion of current adult smokers who had 
never tried to quit but were interested in quitting increased 
from 16.8% (95% CI, 16.2–17.3) in 2006–2007 to 23.7% 
(95%  CI, 22.9–24.4) in 2010–2011, and then decreased 
to 20.3% (95% CI, 19.6–21.0) in 2014–2015 (Figure 2.9). 
From 2006–2007 to 2010–2011, the proportions of three 
groups changed: (a)  the proportion of current adult 
smokers who had never tried to quit and were not inter-
ested in quitting increased from 11.3% (95% CI, 10.8–11.8) 
to 15.9% (95% CI, 15.3–16.6), (b)  the proportion of cur-
rent adult smokers who had ever tried to quit but did not 
try during the past year and at the time of the survey were 
not interested in quitting decreased from 6.1% (95% CI, 
5.7–6.4) to 3.9% (95% CI, 3.6–4.2), and (c) the proportion 
of current adult smokers who had ever tried to quit but did 
not try during the past year and were interested in quit-
ting decreased from 23.2% (95% CI, 22.6–23.7) to 14.0% 
(95% CI, 13.5–14.6). The proportion of those who had tried 
to quit during the past year and were interested in quitting 
increased from 39.1% (95% CI, 38.3–40.0) in 2010–2011 
to 43.5% (95% CI, 42.7–44.3) in 2014–2015.
For all years, the proportion of those who were 
interested in quitting was greater than the proportion of 
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those who were not interested in quitting, regardless of 
quit attempt status. In addition, the ratio between those 
interested and those not interested in quitting increased 
across the quit attempt continuum from those who had 
never tried to quit to those who had tried to quit during 
the past year. The following sections examine trends and 
demographic differences in the cessation components of 
this continuum.
Attempts to Quit Smoking During the Past Year
Adults
According to NHIS, in 2015, 55.4% of adult cigarette 
smokers had made a past-year quit attempt (Table 2.11). 
This included current smokers (those who had smoked 
100 cigarettes in their lifetime and now smoked some days 
or every day) who had made a quit attempt lasting at least 
1 day during the past year and former smokers who had 
quit during the past year. Persons younger than 45 years 
of age had a higher prevalence of quit attempts than 
those 45 years of age and older. Asians (69.4%) and Blacks 
(63.4%) had a higher prevalence of quit attempts during 
the past year compared with Whites (53.3%). Those with 
Medicare had a lower prevalence of making a quit attempt 
during the past year compared with those who had private 
insurance. The prevalence of quit attempts did not change 
during 2015–2017 (both 55.4%) (NHIS, public use data, 
2017). Also, the prevalence of quit attempts did not change 
within each of the demographic groups, and the quit 
attempt patterns by demographic subgroups were similar 
except for level of education and insurance status. In 2017, 
the prevalence of past-year quit attempts was higher among 
persons with graduate degrees (64.9%) than among those 
with 12 or fewer years of education and no diploma (50.4%) 
and those with a high school diploma (47.6%); prevalence 
of past-year quit attempts was higher among those with 
an associate degree (59.8%) than among those with a high 
school diploma (47.6%) (NHIS, public use data, 2017). In 
2017, the prevalence of past-year quit attempts was lower 
among both those with Medicare (40.5%) and the unin-
sured (50.9%) than among those with private insurance 
(58.6%) (NHIS 2017, public use data, 2017).
In 2015, quit attempts varied by smoking fre-
quency but not by status of smoking menthol cigarettes 
(Table  2.12). Among adults 18  years of age or older in 
2015, nondaily smokers had a higher prevalence of past-
year quit attempts (63.6%) compared with daily smokers 
(44.6%). These findings are similar to those obtained in 
previous analyses of nationally representative data (Tindle 
and Shiffman 2011; Schauer et al. 2014b; Keeler et  al. 
2017) and to data in the 2017 NHIS (NHIS, public use 
data, 2017). Although quit attempts during the past year 
did not differ significantly across age groups of nondaily 
Figure 2.9 Cessation continuum for current cigarette smokers 18 years of age and older; Tobacco Use Supplement 
to the Current Population Survey (TUS-CPS) 2006–2007, 2010–2011, 2014–2015; United States
Source: TUS-CPS, public use data, 2006–2007, 2010–2011, and 2014–2015.
aEver tried to quit but did not try to quit during the past year.
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Table 2.11 Prevalence of a past-year quit attempta and interest in quitting smokingb among adult cigarette smokers 
18 years of age and older, by selected characteristics; National Health Interview Survey (NHIS) 2015; 
United States
Characteristic
Past-year quit attempt: 
% (95% CI)
Interest in quitting: 
% (95% CI)
Total 55.4 (53.5–57.3) 68.0 (65.9–70.0)
Sex    
Men 55.3 (52.7–57.9) 66.7 (63.8–69.6)
Women 55.6 (53.0–58.1) 69.4 (66.7–72.1)
Age group (years)    
18–24 66.7 (61.0–72.4) 62.3 (55.7–69.0)
25–44 59.8 (57.3–62.3) 72.7 (69.7–75.7)
45–64 49.6 (46.8–52.5) 68.7 (65.8–71.6)
≥65 47.2 (42.2–52.3) 53.7 (48.4–58.9)
Race/ethnicity    
White, non-Hispanic 53.3 (50.8–55.7) 67.5 (65.0–70.0)
Black, non-Hispanic 63.4 (59.0–67.9) 72.8 (68.2–77.4)
Hispanic 56.2 (51.6–60.9) 67.4 (61.9–72.8)
American Indian/Alaska Native, non-Hispanic 52.1 (32.1–72.2) 55.6 (35.8–75.4)
Asian, non-Hispanicc 69.4 (62.1–76.7) 69.6 (59.5–79.8)
Multiple races, non-Hispanic 57.8 (47.2–68.4) 59.8 (45.7–73.9)
Level of educationd    
≤12 years (no diploma) 50.4 (46.2–54.5) 68.0 (63.7–72.2)
GED certificate 48.1 (40.1–56.0) 65.7 (58.0–73.4)
High school diploma 52.2 (48.3–56.2) 65.5 (61.9–69.1)
Some college (no degree) 57.8 (53.6–61.9) 70.2 (66.1–74.4)
Associate degree 57.4 (52.2–62.7) 70.6 (65.3–76.0)
Undergraduate degree 57.6 (51.5–63.8) 73.3 (67.7–78.8)
Graduate degree 55.8 (46.0–65.6) 74.0 (65.1–82.9)
Poverty status    
At or above poverty level 55.5 (53.3–57.7) 68.2 (65.9–70.4)
Below poverty level 55.2 (51.6–58.8) 67.3 (63.4–71.1)
U.S. Census region    
Northeast 58.8 (54.6–63.0) 74.5 (69.0–80.1)
Midwest 54.0 (49.7–58.4) 67.1 (63.1–71.1)
South 54.3 (51.6–57.0) 67.2 (64.0–70.4)
West 56.9 (52.5–61.3) 65.5 (60.7–70.2)
Health insurance coverage    
Private 57.2 (54.6–59.9) 69.0 (66.1–71.8)
Medicaid (includes persons with Medicaid and Medicare) 56.3 (52.5–60.1) 69.2 (65.3–73.2)
Medicare only 42.3 (35.5–49.4) 47.7 (40.3–55.2)
Other coverage 50.7 (43.9–57.4) 63.6 (57.2–69.9)
Uninsured 53.5 (49.7–57.2) 69.5 (65.2–73.9)
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Table 2.11 Continued
Source: Babb and colleagues (2017).
Notes: CI = confidence interval; GED = General Educational Development.
aCurrent smokers who reported that they stopped smoking for >1 day during the past 12 months because they were trying to quit 
smoking and former smokers who quit during the past year.
bCurrent smokers who reported that they wanted to stop smoking completely.
cDoes not include Native Hawaiians or Other Pacific Islanders.
dAmong only adults 25 years of age and older.
Table 2.12 Prevalence of a past-year quit attempta among adult current cigarette smokers 18 years of age and older, 
by selected smoking-related and demographic characteristics; National Health Interview Survey (NHIS) 
2015; United States
Characteristic
Nondaily: 
% (95% CI)
Daily:  
% (95% CI)
Menthol:  
% (95% CI)
Nonmenthol: 
% (95% CI)
Total 63.6 (60.2–67.1) 44.6 (42.3–46.9) 51.5 (47.9–55.1) 48.3 (45.6–51.1)
Sex        
Male 60.9 (56.3–65.4) 45.0 (41.7–48.3) 52.7 (47.5–57.9) 49.0 (45.4–52.7)
Female 67.8 (62.6–72.9) 44.2 (41.2–47.1) 50.5 (45.8–55.2) 47.4 (43.8–51.1)
Age group (years)        
18–24 63.5 (53.8–73.3) 58.8 (50.3–67.3) 60.5 (50.2–70.7) 64.8 (54.4–75.1)
25–44 64.1 (59.0–69.2) 49.4 (45.9–52.9) 54.8 (49.7–60.0) 51.9 (48.0–55.8)
45–64 64.5 (59.1–69.9) 39.1 (36.0–42.2) 46.2 (40.7–51.7) 43.1 (39.4–46.8)
≥65 57.4 (46.4–68.4) 37.4 (31.8–43.0) 42.7 (31.8–53.6) 42.1 (35.9–48.3)
Race/ethnicity        
White, non-Hispanic 66.4 (61.6–71.1) 41.9 (39.2–44.7) 47.1 (42.2–52.0) 46.8 (43.7–50.0)
Black, non-Hispanic 70.1 (62.0–78.1) 56.6 (51.0–62.3) 60.0 (54.2–65.8) 62.4 (52.9–72.0)
Hispanic 50.3 (42.3–58.3) 48.0 (41.7–54.3) 48.2 (39.6–56.8) 53.5 (46.6–60.3)
American Indian/Alaska Native, 
non-Hispanic
—b —b —b —b
Asian, non-Hispanic 67.2 (53.0–81.4) 55.9 (43.3–68.5) —b 56.5 (42.7–70.2)
Multiple races, non-Hispanic —b 40.0 (26.6–53.4) —b 42.6 (25.1–60.2)
Level of educationc        
≤12 years (no diploma) 67.4 (57.4–77.3) 40.7 (35.7–45.7) 50.7 (43.1–58.2) 43.4 (38.3–48.5)
GED certificate —b 40.2 (31.8–48.7) 55.3 (42.4–68.2) 39.1 (28.4–49.8)
High school diploma 67.0 (59.0–75.0) 41.5 (37.0–45.9) 49.1 (41.9–56.2) 45.9 (40.8–51.0)
Some college (no degree) 66.4 (59.2–73.7) 47.2 (42.2–52.2) 50.2 (42.5–58.0) 52.3 (46.9–57.7)
Associate degree 56.7 (47.1–66.3) 48.0 (41.6–54.5) 52.5 (41.5–63.5) 48.5 (40.8–56.1)
Undergraduate degree  61.1 (50.9–71.3) 43.2 (35.4–51.0) 53.9 (42.7–65.1) 46.3 (38.2–54.4)
Graduate degree 46.3 (30.4–62.2) 45.6 (31.5–59.7) —b 49.8 (37.2–62.3)
Poverty status        
At or above poverty level 63.7 (59.8–67.6) 43.8 (41.1–46.5) 51.0 (46.7–55.2) 48.1 (44.9–51.3)
Below poverty level 63.5 (55.5–71.4) 47.5 (43.1–51.9) 53.2 (46.9–59.6) 49.5 (44.6–54.4)
U.S. Census region        
Northeast 72.4 (64.1–80.7) 47.2 (41.6–52.8) 58.2 (49.7–66.7) 51.8 (43.7–60.0)
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smokers, the prevalence of quit attempts among daily 
smokers (Table 2.12) was higher among persons younger 
than 45 years of age than among those 45 years of age and 
older; in 2017, the prevalence of quit attempts was higher 
among those younger than 45  years of age than among 
only those 65 years of age and older. Among daily smokers, 
Blacks had a higher prevalence of quit attempts compared 
with Whites (NHIS, public use data, 2017). Among non-
daily smokers in 2015, Whites and Blacks were more likely 
than Hispanics to make a quit attempt (Table 2.12); these 
racial/ethnic differences were not observed in 2017: Whites 
(55.9%), Blacks (67.8%), and Hispanics (57.8%) (NHIS, 
public use data, 2017). Also, among nondaily smokers, for 
all education levels below a graduate degree, the prevalence 
of making a past-year quit attempt was greater than 50%, 
although prevalence across educational groups was not 
statistically significant. In contrast, among daily smokers, 
the prevalence of making a past-year quit attempt was 
greater than 50% in only three groups: those 18–24 years 
of age, Blacks, and Asians (NHIS, public use data, 2017).
According to findings from the 2017 BRFSS, the 
prevalence of having a past-year quit attempt among ciga-
rette smokers was greater than 60% in every state except 
Wisconsin (58.6%), Missouri (59.7%), and Iowa (59.9%) 
(Table 2.10). The prevalence of having a past-year quit 
attempt exceeded 70% in four states and one U.S. terri-
tory: Connecticut (71.6%), New Jersey (71.3%), Delaware 
(71.0%), Texas (70.7%), and Guam (72.3%).
Young Adults
Quit attempts among young adults varied signifi-
cantly across demographic subgroups (NHIS, public use 
data, 2017). During 1997–2017, significant nonlinear 
increases in quit attempts among young adults were 
found among males, females, and Whites (p  <.05 for 
quadratic trends), and significant linear increases were 
found among Hispanics (p  <.05 for linear trends), but 
there were no significant changes in quit attempts among 
Blacks (NHIS, public use data, 1997–2017). Since 2009, 
across males and females and across Whites, Blacks, and 
Hispanics, the majority of cigarette smokers had tried 
to quit smoking during the past year. The prevalence of 
quit attempts among young adults differed across states; 
the prevalence of a quit attempt was highest in Vermont 
(86.5%), Mississippi (85.7%), and Florida (85.5%) and 
lowest in Oregon (58.9%), District of Columbia (59.6%), 
and Illinois (60.5%) (BRFSS, public use data, 2017).
Youth
Using data from the 2015 national YRBS, among the 
10.8% of students in grades 9–12 who currently smoked 
cigarettes, 45.4% had tried to quit smoking cigarettes 
during the 12 months preceding the survey (Kann et al. 
2016). The prevalence of having tried to quit smoking 
cigarettes was higher among female (52.8%) than male 
(39.7%) students. The prevalence of having tried to quit 
Table 2.12 Continued
Characteristic
Nondaily: 
% (95% CI)
Daily:  
% (95% CI)
Menthol:  
% (95% CI)
Nonmenthol: 
% (95% CI)
U.S. Census region (continued)        
Midwest 71.2 (63.2–79.3) 41.5 (36.5–46.5) 48.8 (41.0–56.7) 46.5 (40.7–52.4)
South 59.3 (54.2–64.3) 45.0 (41.7–48.2) 50.5 (45.2–55.7) 47.5 (43.9–51.1)
West 56.8 (49.8–63.8) 46.7 (41.1–52.2) 51.8 (43.5–60.0) 49.8 (43.7–55.8)
Health insurance coverage        
Private 63.8 (59.1–68.4) 43.6 (40.4–46.9) 53.3 (48.5–58.1) 47.0 (43.0–51.0)
Medicaid (includes persons 
with Medicaid and Medicare)
65.2 (57.2–73.2) 48.0 (43.2–52.8) 55.0 (48.2–61.8) 49.9 (44.6–55.2)
Medicare only —b 36.2 (28.0–44.3) 41.2 (24.2–58.1) 38.0 (28.8–47.3)
Other coverage 69.6 (56.1–83.1) 39.9 (32.7–47.0) 37.7 (25.7–49.7) 48.5 (40.5–56.5)
Uninsured 60.9 (52.9–69.0) 45.7 (40.9–50.4) 49.5 (42.2–56.8) 49.9 (44.6–55.2)
Source: NHIS, National Center for Health Statistics, public use data, 2015.
Notes: CI = confidence interval; GED = General Educational Development.
aCurrent smokers who reported that they stopped smoking for >1 day during the past 12 months because they were trying to quit 
smoking and former smokers who quit during the past year.
bPrevalence estimates with a relative standard error ≥30% are not presented due to low precision.
cAmong only adults 25 years of age and older. 
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smoking cigarettes was higher among 9th-grade (47.8%), 
10th-grade (51.6%), and 12th-grade (47.7%) students 
than among 11th-grade students (37.9%). In contrast to 
the report from the national YRBS, the analysis of data 
from NYTS found that, in 2015, the prevalence of having a 
past-year quit attempt among students in grades 9–12 was 
57.8% (NYTS, public use data, 2015), or 12.4 percentage 
points higher than the YRBS finding (Table  2.13a). 
Appendix 2.2 discusses factors contributing to this differ-
ence and other differences between the two surveys. The 
analysis of data from the 2017 NYTS also found that the 
prevalence of a past-year quit attempt was 61.1% among 
students in grades  9–12 and 67.2% among students in 
grades 6–8 (Tables 2.13a and 2.13b) (the YRBS did not ask 
this question in 2017).
Trends in Attempts to Quit Smoking During the 
Past Year
Adults
According to data from NHIS, from 1997 to 2017, 
the prevalence of a past-year quit attempt increased sig-
nificantly among men and women (p <0.05 for quadratic 
trends) (Figure 2.10). The percentage of female cigarette 
smokers who made a past-year quit attempt increased 
from 1997 (49.5%) to 2008 (54.1%); this percentage was 
50% or greater from 2005 to 2017 and peaked at 57.7% 
in 2014; however, percentages from 2008 to 2017 were 
not statistically significantly different. The prevalence of 
past-year quit attempts among men also increased from 
1997 (48.9%) to 2009 (52.2%) (Figure 2.10); it was 50% or 
higher every year from 2009 to 2017 and peaked at 55.3% 
in 2015; however, percentages from 2009 to 2017 were not 
significantly different.
During 1997–2017, there were significant increasing 
trends in quit attempts among Whites, Blacks, and 
Hispanics (p  <0.05 for quadratic trends among Whites 
and Blacks and p <0.05 for linear trend among Hispanics). 
Among Whites, the prevalence of past-year quit attempts 
rose from 48.5% in 1997 to 54.4% in 2014; larger increases 
were observed among Blacks from 1997 (49.0%) to 2016 
(63.8%) and among Hispanics from 1997 (53.3%) to 
2012 (61.1%) (Figure  2.11); prevalence was not statisti-
cally different from 2014 to 2017 for Whites, 2016 to 2017 
for Blacks, and 2012 to 2017 for Hispanics. The preva-
lence of past-year quit attempts peaked in 2016 among 
Blacks (63.8%), in 2014 among Whites (54.4%), and in 
2012 among Hispanics (61.6%). From 2013 (Lavinghouze 
et al. 2015) to 2017 (Table 2.10), the prevalence of a quit 
attempt increased in Delaware, decreased in Missouri and 
Wisconsin, and remained stable in all other states and the 
District of Columbia.
Young Adults
Among young adults, significant nonlinear increases 
in quit attempts were found among males, females, and 
Whites (p  <0.05 for quadratic trends), and significant 
linear increases were observed for Hispanics (p <0.05 for 
linear trends) (NHIS, public use data, 1997–2017). Peak 
prevalence of past-year quit attempts occurred in 2013 
among young adult males (60.6%), in 2014 among young 
adult females (65.6%), and in 2015 among young adult 
Whites (66.6%).
Youth
Data from the national YRBS showed, among high 
school students who were current cigarette smokers, a sig-
nificant linear decrease in the prevalence of past-year quit 
attempts from 2001 to 2015 among males (from 53.4% to 
39.7%) and females (from 61.4% to 52.8%) (Figure 2.12). 
A similar linear decrease occurred in the prevalence of 
past-year quit attempts among Whites (from 57.2% in 
2001 to 44.1% in 2015), but no change occurred among 
Hispanics (50.3% in 2001 and 49.6% in 2015) (YRBS, 
public use data, 2001–2015). The sample size for Blacks 
was insufficient to yield statistically stable estimates.
In contrast, data from the NYTS (Tables  2.13a and 
2.13b) suggest a more stable trend in the prevalence of past-
year quit attempts among high school students between 
2000 (59.3%) and 2017 (61.1%). These differences could 
be the result of multiple factors, including variations in the 
length of the questionnaire and its content, time of admin-
istration (i.e.,  spring  vs. fall semester), periodicity of the 
survey (i.e., biennial vs. annual), and sample demographics. 
Analysis of data from NYTS indicates that the prevalence of 
a past-year quit attempt among middle school students in 
grades 6–8 increased from 59.9% in 2000 to 77.0% in 2015 
and then remained unchanged in 2017 (67.2%).
Number and Duration of Quit Attempts During 
the Past Year
Adults
Successfully quitting cigarette smoking usually 
involves multiple quit attempts. For example, estimates 
from a longitudinal study of adult smokers in Ontario, 
Canada, indicated that among those currently trying to 
quit, the highest probability of successful cessation on a 
given quit attempt, accounting for self-reported lifetime 
quit attempts, occurred on quit attempts  4–6 (Chaiton 
et al. 2016). However, further life table analyses of these 
smokers estimated that the average number of quit 
attempts before successfully quitting for at least 1 year was 
29.6 (95% CI, 27.6–31.7) (Chaiton et al. 2016). Analysis of 
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Table 2.13a Quitting behaviors among current cigarette smokersa in high school (grades 9–12); National Youth Tobacco Survey (NYTS) 2000, 2004, 
2009, 2015, and 2017; United States
Quitting behaviors 2000: % (95% CI) 2004: % (95% CI) 2009: % (95% CI) 2015: % (95% CI) 2017: % (95% CI)
Tried to quit cigarettes ≥1 days during 
the past year
59.3 (57.4–61.2) 57.6 (54.9–60.3) 53.7 (49.8–57.7) 57.8 (53.0–62.6) 61.1 (54.8–67.4)
Number of times tried to quit cigarettes 
during the past yearb
         
1 35.0 (33.3–36.8) 23.7 (20.7–26.8) 22.2 (18.7–25.6) 24.6 (17.8–31.3) 24.8 (19.1–30.5)
2 29.8 (27.8–31.7) 22.0 (19.3–24.6) 22.0 (18.6–25.4) 20.0 (15.0–25.0) 19.5 (14.4–24.7)
3–5 23.7 (22.1–25.4) 26.5 (23.5–29.5) 25.1 (21.5–28.8) 25.2 (20.6–29.8) 18.2 (13.8–22.6)
6–9 4.4 (3.6–5.2) 8.8 (7.2–10.5) 8.8 (6.9–10.8) 7.7 (5.2–10.3) 10.5 (7.1–13.8)
≥10 7.1 (5.9–8.3) 19.0 (15.9–22.1) 21.9 (18.1–25.7) 22.5 (17.7–27.3) 27.0 (22.6–31.5)
Considered quitting cigarettes within          
30 days NA 41.6 (36.5–46.6) 44.3 (39.8–48.9) 30.1 (25.0–35.1) 33.6 (29.4–37.8)
6 months NA 30.1 (26.1–34.1) 32.5 (28.6–36.5) 21.5 (15.4–27.5) 18.3 (13.6–23.1)
Not within 6 months NA 28.3 (24.5–32.2) 23.1 (19.0–27.3) 48.5 (42.3–54.6) 48.1 (42.7–53.5)
Source: NYTS, Centers for Disease Control and Prevention, public use data, 2000, 2004, 2009, 2015, and 2017.
Notes: CI = confidence interval; NA = not applicable, question not asked in this year.
aSmoked cigarettes during the past 30 days.
bAmong those who tried to quit smoking cigarettes during the past year.
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Table 2.13b Quitting behaviors among current cigarette smokersa in middle school (grades 6–8); National Youth Tobacco Survey (NYTS) 2000, 2004, 
2009, 2015, and 2017; United States
Quitting behaviors 2000: % (95% CI) 2004: % (95% CI) 2009: % (95% CI) 2015: % (95% CI) 2017: % (95% CI)
Tried to quit cigarettes ≥1 day during 
the past year
59.9 (56.8–63.0) 64.7 (60.2–69.2) 63.2 (53.6–72.7) 77.0 (71.0–83.0) 67.2 (58.3–76.1)
Number of times tried to quit cigarettes 
during the past yearb
         
1 35.2 (31.6–38.8) 20.4 (16.4–24.4) 22.8 (17.7–27.8) 21.7 (12.2–31.2) 15.3 (8.6–22.0)
2 27.6 (24.1–31.1) 16.9 (14.1–19.7) 20.0 (14.8–25.2) —c 19.1 (9.3–28.9)
3–5 18.6 (15.8–21.3) 23.3 (19.5–27.1) 21.9 (16.1–27.7) 21.8 (13.3–30.4) 24.0 (12.7–35.3)
6–9 6.3 (3.9–8.8) 10.1 (7.4–12.7) 7.0 (3.8–10.1) —c —c
≥10 12.3 (9.9–14.7) 29.3 (26.0–32.5) 28.4 (22.9–33.8) 23.9 (12.1–35.7) 33.3 (22.7–43.9)
Considered quitting cigarettes within          
30 days NA 57.8 (51.0–64.6) 56.7 (44.1–69.2) 51.7 (39.0–64.4) 45.5 (31.8–59.1)
6 months NA 17.6 (13.2–22.1) 25.6 (14.6–36.6) —c 18.4 (9.0–27.8)
Not within 6 months NA 24.5 (19.5–29.5) 17.8 (10.2–25.3) 38.8 (24.6–53.1) 36.2 (24.6–47.7)
Source: NYTS, Centers for Disease Control and Prevention, public use data, 2000, 2004, 2009, 2015, and 2017.
Notes: CI = confidence interval; NA = not applicable, question not asked in this year.
aSmoked cigarettes during the past 30 days.
bAmong those who tried to quit smoking cigarettes during the past year. 
cPrevalence estimates with a relative standard error ≥30% are not presented due to low precision.
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Figure 2.11 Prevalence of past-year quit attemptsa among adult cigarette smokers 18 years of age and older, 
by race/ethnicity; National Health Interview Survey (NHIS) 1997–2017; United States
Source: NHIS, National Center for Health Statistics, public use data, 1997–2017.
aCurrent smokers who reported that they stopped smoking for >1 day during the past 12 months because they were trying to quit 
smoking and former smokers who quit during the past year.
Figure 2.10 Prevalence of past-year quit attemptsa among adult cigarette smokers 18 years of age and older, by sex; 
National Health Interview Survey (NHIS) 1997–2017; United States
Source: NHIS, National Center for Health Statistics, public use data, 1997–2017.
aCurrent smokers who reported that they stopped smoking for >1 day during the past 12 months because they were trying to quit 
smoking and former smokers who quit during the past year.
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the 2014–2015 TUS-CPS data found that, among current 
daily smokers or some-day smokers who had smoked on 
12 or more days during the past 30 days and had tried to 
quit during the past year, the most common range of past-
year quit attempts was two or three (40.4%). The percent-
ages were 30.7% for one attempt and 28.9% for at least 
four attempts (Table 2.14).
According to findings using the 2014–2015 TUS-CPS 
data, for more than one-third of current smokers (daily 
smokers plus some-day smokers who had smoked for 
12  or more days during the past month) who had tried 
to quit during the past year, their longest quit attempt 
lasted between 1 and 6 days (35.7%), and 10.7% had a quit 
attempt of 6 months or longer (Table 2.14). The percentage 
with a past-year quit attempt lasting 6 months or longer 
increased from 7.5% in 2001–2002 to 11.1% in 2006–2007 
and 14.6% in 2010–2011 but declined to 10.7% in 2014–
2015. The percentage with a past-year quit attempt lasting 
30 days to less than 6 months also declined from 32.8% 
in 2010–2011 to 24.4% in 2015, and the percentage with 
a quit attempt of 1–6 days increased from 21.5% in 2010–
2011 to 35.7% in 2014–2015.
Young Adults
Among young adult current cigarette smokers (daily 
smokers plus some-day smokers who had smoked on 12 or 
more days during the past 30 days) who had made a quit 
attempt during the past year, the distribution of quit 
attempts was similar to that for all adults (Table  2.15). 
For all years except 2006–2007, a smaller proportion of 
young adult smokers (compared with adult smokers 
overall) reported a longest quit attempt during the past 
year of 1–6 days. In contrast to adults overall, the preva-
lence of a long quit attempt—that is, 30 days to less than 
6 months or 6 months or longer—did not change signifi-
cantly over time.
Youth
Findings from the 2017 NYTS indicate that among 
high school current cigarette smokers who had tried to 
quit during the past year, more than one-fourth (27.0%) 
reported trying 10  or more times in the past year and 
slightly less than one-fourth reported trying to quit one 
time (24.8%) (Table  2.13a). In addition, approximately 
one-fifth reported trying to quit two times (19.5%) or 
three to five times (18.2%), and 10.5% reported trying to 
quit six to nine times. Among current cigarette smokers 
in middle school who tried to quit during the past year, 
one-third (33.3%) reported trying to quit 10  or more 
times, and a smaller percentage (15.3%) reported trying 
to quit one time. Although the prevalence of one or two 
quit attempts decreased from 2000 to 2004 among middle 
Figure 2.12 Prevalence of past-year quit attempts among students in grades 9–12 who currently smoke cigarettesa, 
by sex; National Youth Risk Behavior Survey (YRBS) 2001–2015; United States
Source: YRBS, Centers for Disease Control and Prevention, public use data, 2001–2015.
aRespondents who reported that they had smoked cigarettes on at least 1 day during the 30 days before the survey and also reported 
that they had tried to quit smoking during the past 12 months.
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Table 2.14 Quitting behaviors among current cigarette smokersa 18 years of age and older, by year; Tobacco Use 
Supplement to the Current Population Survey (TUS-CPS) 2001–2002, 2006–2007, 2010–2011, and 
2014–2015; United States
Quitting behaviors
2001–2002: 
% (95% CI)
2006–2007: 
% (95% CI)
2010–2011: 
% (95% CI)
2014–2015: 
% (95% CI)
Ever tried to quitb 71.2 (70.5–71.8) 72.2 (71.6–72.9) 60.4 (59.6–61.2) 64.4 (63.6–65.2)
Tried to quit during the past year NA 42.5 (41.8–43.3) 42.6 (41.8–43.3) 46.7 (45.9–47.5)
Tried to quit >1 days during the 
past year
50.0 (49.2–50.7) 35.5 (34.7–36.2) 37.2 (36.4–37.9) 41.3 (40.4–42.2)
Number of times tried to quit 
during the past yearc
       
1 31.9 (30.9–33.0) 36.1 (35.0–37.3) 32.3 (31.2–33.4) 30.7 (29.5–31.9) 
2–3 40.7 (39.5–41.8) 37.9 (36.7–39.0) 41.2 (40.0–42.4) 40.4 (39.1–41.7) 
≥4 27.4 (26.4–28.4) 26.0 (25.0–27.0) 26.5 (25.4– 27.6) 28.9 (27.7–30.1)
Duration of longest quit attempt 
during the past 12 monthsc
       
1–6 days 35.1 (33.9–36.2) 33.4 (32.3–34.6) 21.5 (18.7–24.3) 35.7 (34.5–37.0)
7–29 days 32.7 (31.7–33.8) 30.0 (28.9–31.0) 31.1 (27.8–34.4) 29.1 (28.0–30.3) 
30 days to <6 months 24.7 (23.8–25.6) 25.5 (24.6–26.5) 32.8 (29.4–36.2) 24.4 (23.3–25.6) 
>6 months 7.5 (6.9–8.1) 11.1 (10.3–11.8) 14.6 (12.0–17.2) 10.7 (9.8–11.6)
Considered quitting within:c        
30 days 18.2 (17.6–18.7) 17.9 (17.3–18.5) 16.4 (15.9–16.9) 19.7 (18.9–20.4) 
6 months 26.5 (26.0–27.1) 26.5 (25.9–27.1) 24.2 (23.6–24.9) 25.8 (25.1–26.5) 
Not within 6 months 55.3 (54.6–56.0) 55.6 (54.9–56.3) 59.4 (58.6–60.2) 54.5 (53.7–55.3)
Level of interest in quittingc        
1 (not at all interested) NA 20.2 (19.6–20.8) 23.2 (22.4–24.0) 22.5 (21.7–23.2)
2–5 NA 31.9 (31.3–32.6) 32.2 (31.5–33.0) 30.3 (29.6–31.1) 
6–8 NA 23.3 (22.7–23.9) 21.3 (20.7–21.9) 22.5 (21.9–23.2) 
9 or 10 (extremely interested) NA 24.6 (24.0–25.2) 23.3 (22.6–23.9) 24.7 (24.0–25.4)
Think they would be likely to 
succeed in quitting if tried 
during the next 6 monthsd
       
Not likely NA 11.8 (11.3–12.3) 11.0 (10.4–11.6) 10.8 (10.1–11.4) 
A little likely NA 22.3 (21.6–23.0) 21.8 (21.0–22.5) 21.6 (20.9–22.3) 
Somewhat likely NA 37.1 (36.4–37.9) 37.9 (37.1–38.7) 38.4 (37.5–39.3) 
Very likely NA 28.8 (28.1–29.5) 29.3 (28.5–30.1) 29.3 (28.3–30.2)
Source: TUS-CPS, National Cancer Institute, public use data, 2001–2002, 2006–2007, 2010–2011, and 2014–2015.
Notes: CI = confidence interval; NA = not applicable.
aSmoked 12 or more days during the past 30 days and had tried to quit during the past year.
bFor 2001–2002, estimates are from the question, “Have you ever stopped smoking for one day or longer because you were trying to 
quit smoking?” In other years, the question for current some-day smokers who smoked less than 12 days during past 30 days included, 
“Have you ever tried to quit smoking completely?” and for current daily smokers and some-day smokers who smoked 12 or more days 
during the past 30 days included, “Have you ever made a serious attempt to stop smoking because you were trying to quit—even if you 
stopped for less than a day?” Also, in 2006–2007, current daily smokers and some-day smokers who smoked less than 12 days/month 
were asked, “Have you ever stopped smoking one day or longer because you were trying to quit smoking?”
cAmong current daily smokers and some-day smokers who smoked 12 or more days during the past 30 days who tried to quit during the 
past year.
dAmong those who were interested in quitting. 
Patterns of Smoking Cessation Among U.S. Adults, Young Adults, and Youth  77
Smoking Cessation
Table 2.15 Quitting behaviors among current cigarette smokersa 18–24 years of age, by year; Tobacco Use Supplement 
to the Current Population Survey (TUS-CPS) 2001–2002, 2006–2007, 2010–2011, 2014–2015; 
United States
Quitting behaviors
2001–2002: 
% (95% CI)
2006–2007: 
% (95% CI)
2010–2011: 
% (95% CI)
2014–2015: 
% (95% CI)
Ever tried to quitb 67.7 (65.9–69.5) 65.7 (63.7–67.7) 56.7 (54.4–58.9) 61.6 (58.7–64.5)
Tried to quit during the past year NA 50.1 (47.8–52.4) 47.9 (45.5–50.2) 52.6 (49.6–55.7)
Tried to quit ≥1 day during the 
past year
69.1 (67.0–71.3) 43.8 (41.5–46.1) 42.9 (40.5–45.4) 50.0 (46.7–53.2)
Number of times tried to quit 
during the past yearc
       
1 30.4 (28.2–32.6) 34.0 (30.8–37.3) 29.4 (25.9–32.9) 30.4 (26.2–34.5)
2–3 41.7 (39.2–44.2) 38.3 (35.2–41.5) 46.4 (42.5–50.2) 42.1 (37.6–46.7)
≥4 27.9 (25.6–30.1) 27.6 (24.8–30.5) 24.2 (20.9–27.6) 27.5 (23.5–31.4)
Duration of longest quit attempt 
during the past 12 monthsc
       
1–6 days 30.7 (28.3–33.0) 26.0 (23.1–28.9) 20.1 (12.2–28.0) 25.5 (22.0–29.0)
7–29 days 34.5 (32.0–36.9) 32.9 (29.9–35.8) 32.0 (22.5–41.5) 34.0 (29.8–38.2)
30 days to <6 months 26.9 (24.5–29.3) 28.0 (25.2–30.9) 33.2 (24.2–42.2) 28.3 (24.7–31.8)
≥6 months 7.9 (6.5–9.4) 13.1 (10.8–15.3) 14.7 (8.4–21.1) 12.3 (9.2–15.3)
Considered quitting within:c        
30 days 20.3 (18.6–22.0) 17.5 (15.8–19.2) 16.6 (14.9–18.3) 19.1 (16.6–21.6)
6 months 27.8 (26.1–29.4) 25.4 (23.7–27.1) 23.8 (21.6–26.0) 24.6 (22.0–27.3)
Not within 6 months 52.0 (50.1–53.8) 57.1 (54.8–59.4) 59.6 (57.0–62.2) 56.3 (53.1–59.5)
Level of interest in quittingc        
1 (not at all interested) NA 17.5 (15.9–19.1) 20.5 (18.3–22.7) 19.5(16.9–22.1)
2–5 NA 37.1 (35.0–39.1) 36.9 (34.5–39.3) 36.9 (33.8–40.0)
6–8 NA 27.6 (25.5–29.7) 24.8 (22.8–26.7) 23.8 (20.9–26.6)
9 or 10 (extremely interested) NA 17.8 (16.1–19.4) 17.9 (16.0–19.8) 19.8 (17.2–22.4)
Think they would be likely to 
succeed in quitting if tried 
during the next 6 monthsd
       
Not likely NA 10.8 (9.2–12.5) 11.0 (10.4–11.6) 8.8 (6.7–10.9)
A little likely NA 22.8 (20.9–24.6) 21.8 (21.0–22.5) 18.4 (16.0–20.9)
Somewhat likely NA 38.1 (35.9–40.4) 37.9 (37.1–38.7) 39.3 (35.9–42.6)
Very likely NA 28.3 (26.2–30.3) 29.3 (28.5–30.1) 33.5 (30.3–36.7)
Source: TUS-CPS, National Cancer Institute, public use data, 2001–2002, 2006–2007, 2010–2011, and 2014–2015.
Notes: CI = confidence interval; NA = not applicable.
aSmoked 100 cigarettes in their lifetime and currently smoked some days or every day.
bFor 2001–2002, estimates are from the question, “Have you ever stopped smoking for one day or longer because you were trying to 
quit smoking?” In other years, questions for current some-day smokers who smoked less than 12 days during the past 30 days included, 
“Have you ever tried to quit smoking completely?” and for current daily smokers and some-day smokers who smoked 12 or more days 
during the past 30 days included, “Have you ever made a serious attempt to stop smoking because you were trying to quit—even if you 
stopped for less than a day?” Also, in 2006–2007, current daily smokers and some-day smokers who smoked less than 12 days/month 
were asked, “Have you ever stopped smoking one day or longer because you were trying to quit smoking?”
cAmong current daily smokers and some-day smokers who smoked 12 or more days during the past 30 days who tried to quit during 
the past year.
dAmong those who were interested in quitting.
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and high school smokers who tried to quit during the past 
year, the prevalence of one or two quit attempts remained 
relatively stable from 2004 to 2017. In contrast, the preva-
lence of 10 or more quit attempts increased during 2000–
2004 among current cigarette smokers in both middle 
school and high school who tried to quit in the past year 
and increased further among high school students from 
19.0% in 2004 to 27.0% in 2017.
Interest in Quitting Smoking
Adults
NHIS data for 2015 indicated that 68.0% of current 
cigarette smokers were interested in quitting smoking 
completely (Table 2.11). However, when a 10-point scale 
was used for the 2014−2015 TUS-CPS (Table  2.14) to 
determine any interest, the estimate was somewhat higher 
(77.5%). In contrast to the prevalence of quit attempts, 
the prevalence of interest in quitting was highest among 
those 25–44 years of age (72.7%) and lowest among those 
65 years of age and older (53.7%) and those 18–24 years of 
age (62.3%) (Table 2.11). This age difference was reflected 
in the results for health insurance: those with Medicare 
only were less interested in quitting (47.7) than those with 
other types of insurance. However, for 29 of the 30 demo-
graphic groups that were examined, only the group with 
Medicare only did not have a majority of current cigarette 
smokers who wanted to quit smoking completely. A more 
proximate measure of interest in quitting smoking may be 
whether the current cigarette smoker is interested in quit-
ting in the next 30 days or 6 months. According to data from 
the 2014–2015 TUS-CPS, the majority of smokers were 
not considering quitting within 6 months (54.5%), 25.8% 
were considering quitting within 6  months, and 19.7% 
were considering quitting within 30 days (Table 2.14).
Young Adults
In 2015, an estimated 62.3% of young adult 
(18−24 years of age) current cigarette smokers wanted to 
stop smoking completely (Table  2.11); this measure did 
not vary across demographic subgroups (NHIS, public 
use data, 2015). According to data from the 2014–2015 
TUS-CPS, young adult current cigarette smokers (daily 
smokers plus some-day smokers who had smoked on 12 or 
more days during the past 30 days) had a lower prevalence 
(19.8%) of having an extreme interest (determined by a 
report of “9” or “10” on a 10-point scale) in quitting smoking 
(Table 2.15) than adults overall (24.7%) (Table 2.14). The 
distribution of the periods in which young adult current 
smokers were considering quitting (i.e.,  within 30  days, 
within 6 months, or not within 6 months) (Table 2.15) was 
similar to that for adults overall (Table 2.14).
Youth
In the MTF Study, combined data from 2011 to 
2017 (Table  2.16) indicated that 21.8% of high school 
seniors (12th graders) who were current smokers wanted 
to stop smoking “now.” Seniors whose parents had the 
highest level of education were less likely to want to stop 
smoking immediately (15.0%) than were those whose 
parental education fell into the second-to-lowest category 
(26.4%) and the middle category (22.1%). Another mea-
sure related to interest in quitting in the MTF Study is 
whether the smoker thinks that he or she will be smoking 
in 5 years. The majority of high school seniors who were 
current smokers thought that they would probably or def-
initely not be smoking in 5 years (60.3%). The percentage 
who thought that they would not be smoking in 5 years 
increased with level of parental education, from 50.7% 
among those with the lowest level to 68.8% among those 
with the highest level.
According to NYTS, in 2017, 33.6% of students in 
grades  9–12 and 45.5% of students in grades  6–8 who 
were current cigarette smokers were considering quit-
ting smoking in the next 30 days, and 18.3% of students 
in grades 9–12 and 18.4% of students in grades 6–8 were 
considering quitting in the next 6 months (Tables 2.13a 
and 2.13b).
Trends in Interest in Quitting Smoking
Adults
NHIS data showed no significant change from 2000 
(70.0%) to 2015 (68.0%) in the prevalence of being inter-
ested in completely stopping cigarette smoking among 
adults 18 years of age and older (Babb et al. 2017). Similarly, 
during 2000–2015, no significant change was observed in 
the prevalence of being interested in quitting among men, 
women, Whites, and Hispanics (NHIS, public use data, 
2000–2015). In contrast, interest in quitting increased 
among Blacks from 2000 (68.4%) to 2010 (75.6%), then 
remained stable in 2015 (72.8%) (p  <0.05 based on 
linear trend analysis; NHIS, public use data, 2000–2015). 
However, data from the TUS-CPS indicate that the propor-
tion of current smokers who were considering quitting 
within the next 30 days may have slightly increased from 
2001–2002 (18.2%) to 2014–2015 (19.7%) (Table 2.14).
Young Adults
Similar to changes observed for adults overall, no 
significant changes were observed from 2000 to 2015 in 
interest in quitting among young adults overall. Unlike 
changes observed for adults overall, no significant changes 
were observed among any demographic subgroups (NHIS, 
public use data, 2000–2015). As for considering quitting 
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Table 2.16  Prevalence of cessation behaviors and attitudes among high school seniors who are current cigarette 
smokersa; Monitoring the Future (MTF) Study 2011–2017 combined data; United States
Characteristic
Ever tried to 
quit smoking:  
% (95% CI)
Tried to stop 
but could not: 
% (95% CI)
Wants to stop 
smoking now: 
% (95% CI)
Will probably or 
definitely not smoke in 
5 years: % (95% CI)
Total 44.8 (42.8–46.7) 22.1 (20.5–23.7) 21.8 (20.3–23.3) 60.3 (58.5–62.1)
Sex        
Male 43.9 (40.9–46.8) 21.3 (19.0–23.6)b 21.4 (19.3–23.5) 60.7 (58.3–63.2)
Female 44.2 (41.2–47.2) 21.3 (19.0–23.7)b 22.7 (20.3–25.1) 61.3 (58.6–64.0)
Race/ethnicity        
White, non-Hispanic 43.6 (41.1–46.1) 21.9 (19.9–23.9) 22.8 (20.9–24.8) 61.6 (59.4–63.7)
Black, non-Hispanic 47.7 (40.7–54.6) 24.9 (18.7–31.2) 20.4 (14.5–26.2) 60.7 (52.6–68.7)
Hispanic 42.8 (37.9–47.6) 17.8 (13.5–22.0) 18.0 (13.8–22.2) 59.1 (53.5–64.8)
Parental educationc        
1–2 (low) 44.7 (39.0–50.5) 21.9 (17.0–26.8) 20.7 (16.1–25.4) 50.7 (44.8–56.6)
2.5–3 48.9 (45.2–52.5) 24.9 (21.7–28.2) 26.4 (22.9–30.0) 57.8 (54.0–61.6)
3.5–4 45.1 (41.7–48.4) 21.8 (19.1–24.4) 22.1 (19.2–25.0) 61.1 (58.1–64.1)
4.5–5 39.8 (36.0–43.6) 18.9 (16.0–21.9) 19.8 (16.6–23.0) 65.9 (62.3–69.5)
5–6 (high) 38.8 (32.4–45.2) 15.5 (11.2–19.9) 15.0 (11.1–18.9) 68.8 (62.9–74.8)
U.S. Census region        
Northeast 47.7 (43.9–51.6) 23.2 (20.1–26.3) 24.0 (20.7–27.3) 60.3 (56.2–64.4)
Midwest 43.6 (39.0–48.2) 22.0 (18.5–25.4) 21.7 (18.6–24.8) 61.3 (57.8–64.8)
South 45.2 (42.4–48.1) 23.0 (20.5–25.5) 22.6 (20.1–25.1) 58.5 (55.4–61.6)
West 42.6 (37.9–47.3) 19.2 (14.9–23.6) 18.4 (15.1–21.7) 62.7 (58.4–66.9)
Source: MTF Study, University of Michigan, Institute for Social Research, 2011–2017 (unpublished data).
Notes: CI = confidence interval. Data come from a randomly selected 33% of the entire sample (questions on cessation and attitudes were 
asked on two survey forms out of a total of six). The total weighted N for 30-day smoking is 4,320; variable-specific missing data reduce 
the sample size slightly overall and in results for each sociodemographic subgroup presented here.
aBased on responses to the question, “How frequently have you smoked cigarettes during the past 30 days?” Respondents who reported 
that they had smoked less than 1 cigarette per day or more were classified as current smokers.
bThe overall percentage does not fall between the sex-specific percentages because of missing values for sex.
cParental education is the average of a mother’s education and a father’s education based on answers from respondents about the 
highest level of education achieved by each parent, using the following scale: completed (1) grade school or less, (2) some high school, 
(3) high school, (4) some college, (5) college, and (6) graduate or professional school after college. Missing data were allowed for one 
of the two parents.
in the next 30 days, unlike adults overall, data from the 
TUS-CPS indicated that no significant change occurred 
over time in the prevalence of young adults who were con-
sidering quitting in the next 30 days (Table 2.15).
Youth
According to the MTF Study, the prevalence of high 
school seniors who were current smokers and wanted to 
stop smoking “now” decreased from 31.0% in 2000–2004 
to 16.5% in 2015–2017 (Table 2.17). The proportion who 
believed they would probably or definitely not be smoking 
in 5  years was similar between 2000–2004 (63.2%) and 
2015–2017 (65.4%). Using data from the NYTS, among 
current smokers in grades  9–12, the prevalence of con-
sidering quitting within 30 days decreased from 44.3% in 
2009 to 33.6% in 2017 (Table 2.13a). Similarly, the preva-
lence in this group of wanting to quit in the next 6 months 
decreased from 32.5% in 2009 to 18.3% in 2017.
History of a Quit Attempt
Adults
According to the TUS-CPS, in 2001–2002, 71.2% 
of current adult cigarette smokers had ever tried to quit 
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Table 2.17 Prevalence of cessation behaviors and attitudes among high school seniors who are current cigarette 
smokersa, by year; Monitoring the Future (MTF) Study 2000–2004, 2005–2009, 2010–2014, and 
2015–2017 combined data; United States
Characteristic
2000–2004: 
% (95% CI)
2005–2009: 
% (95% CI)
2010–2014: 
% (95% CI)
2015–2017: 
% (95% CI)
Ever tried to quit smoking 49.6 (47.2–52.0) 44.2 (42.1–46.3) 45.0 (41.9–48.1) 40.2 (35.6–44.8)
Tried to stop but could not 28.8 (26.6–30.9) 22.3 (20.7–24.0) 22.9 (20.4–25.4) 17.6 (14.2–21.0)
Wants to stop smoking now 31.0 (28.9–33.2) 21.8 (20.2–23.4) 22.9 (20.5–25.2) 16.5 (13.3–19.7)
Will probably or definitely 
not smoke in 5 years
63.2 (61.0–65.4) 62.5 (60.7–64.4) 58.7 (56.1–61.3) 65.4 (61.0–69.8)
Source: MTF, University of Michigan, Institute for Social Research, 2001–2017 (unpublished data).
Notes: CI = confidence interval.
aRespondents who reported that they had smoked one cigarette per day or more.
Other Tobacco Products: Use and Cessation
Adults
Data from the 2017 NHIS indicate that 3.8% of 
adults currently smoked cigars, cigarillos, or filtered little 
cigars; 2.8% of U.S. adults currently used e-cigarettes; 
2.1% used smokeless tobacco; 1.0% smoked regular pipes, 
water pipes, or hookahs; and 3.7% used 2 or more types 
of tobacco products (Wang et al. 2018a). The PATH Study 
found that in 2013–2014, 17.7% of U.S. adult respondents 
reported having ever tried e-cigarettes; among those, 3.8% 
of 18- to 24-year-old respondents reported becoming reg-
ular users of e-cigarettes (Kasza et al. 2017). In addition, 
5.5% of adults in Wave 1 (2013–2014) of PATH reported 
currently using e-cigarettes (now uses e-cigarettes every 
day or some days); among those who used e-cigarettes, 
42.2% reported infrequent use (current some-day use 
and used 0–2  days in the past 30 days), 36.5% reported 
moderate use (some-day use and used more than 2 days of 
the past 30 days), and 21.3% reported daily use (Coleman 
et al. 2017; Kasza et al. 2017). The 2013–2014 PATH Study 
also observed that the prevalence of current established 
use of cigarillos (1.7%; 95% CI, 1.5–1.8) was higher than 
the prevalence of use of filtered cigars (0.9%; 95%  CI, 
0.8–1.0), nonpremium cigars (other larger mass-market 
cigars) (0.8%; 95%  CI, 0.7–0.8), and premium cigars 
(0.7%; 95  CI, 0.6–0.7) (the term “current established 
users” was defined as persons who had ever heard of the 
cigar type, ever smoked the cigar type “fairly regularly,” 
smoking, even just once. This percentage remained rel-
atively stable in 2006–2007 (72.2%), but by 2010–2011 
it had decreased by more than 10  percentage points, to 
60.4%. Although the percentage increased to 64.4% in 
2014–2015, it was lower than in 2001–2002 or 2006–2007 
(Table 2.14).
Young Adults
Through 2010–2011, young adult current smokers 
had a lower prevalence of ever having tried to quit smoking 
(Table 2.15) than adults overall (Table 2.14). But in 2014–
2015, the prevalence among young adults of ever having 
tried to quit smoking (61.6%) (Table 2.15) was similar to 
that of adults overall (64.4%, Table 2.14). The patterns of 
change over time in ever trying to quit smoking were sim-
ilar between young adult smokers (Table 2.15) and adults 
overall (Table 2.14).
Youth
The MTF Study found that in 2011–2017, 44.8% of 
high school seniors who were current smokers had ever 
tried to quit smoking (Table 2.16). A significant decrease in 
this percentage was seen from 2000–2004 (49.6%) to 2015–
2017 (40.2%) (Table 2.17). Similarly, in 2015–2017, 17.6% 
of youth had tried to quit smoking but could not, which 
was lower than in 2000–2004 (28.8%) (Table 2.17). In 2011–
2017, high school seniors with parents with the second-
lowest level of parental education were more likely than stu-
dents with parents in the two highest categories of parental 
education to have ever tried to quit (48.9% vs. 39.8% and 
38.8%, respectively) (Table 2.16). In addition, high school 
seniors with parents with the second-lowest level of parental 
education were more likely to report that they had tried to 
quit but could not (24.9%) than those with parents in the 
highest category of parental education (15.5%).
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and now smoked every day or some days) (Corey et  al. 
2017). In addition, in the 2013–2014 PATH Study, 31.9% 
of adults reported smoking hookahs during the past year, 
and among these, 10.7% were daily or weekly users, 13.7% 
were monthly users, 42.1% used every couple of months, 
and 33.5% used about once a year (Robinson et al. 2018).
For all four types of tobacco products (i.e., e-cigarettes, 
cigars, smokeless tobacco, pipes), NHIS 2017 prevalence 
was higher among men than women, decreased with 
age and, correspondingly, was lower among those with 
Medicare only than among those with other types of insur-
ance (Wang et al. 2018a). However, when each type of cigar 
product was examined separately for the 2013–2014 PATH 
Study, only use of cigarillos decreased with age; use of fil-
tered cigars increased with age; and prevalence of premium 
cigars and nonpremium cigars was the highest among 
persons 35–54 years of age (Corey et al. 2017). Prevalence 
of cigar smoking was higher among Blacks than among 
Whites and Hispanics (Wang et al. 2018a); however, for the 
2013–2014 PATH Study, prevalence of premium and non-
premium cigar use was higher among Whites than Blacks 
(Corey et al. 2017).
Data from the 2017 NHIS indicate that smokeless 
tobacco use was higher among Whites than among Blacks 
and Hispanics (Wang et al. 2018a). E-cigarette use was also 
higher among Whites and persons of multiple races than 
Hispanics and Asians. Prevalence of pipe and/or hookah 
use was higher among Whites than Hispanics. Cigar use 
and smokeless tobacco use were higher in the Midwest 
than in the Northeast and the West, and the Midwest had 
a higher prevalence of pipe and/or hookah use than the 
Northeast. Data from the PATH Study suggest that there 
are urban–rural differences in the use of noncigarette 
tobacco products—for example, smokeless tobacco use 
was more prevalent in rural than urban counties; and the 
use of hookahs, cigarillos among women, and e-cigarettes 
among men was more prevalent in urban areas than in 
rural areas (Roberts et al. 2017).
Data from the 2017 NHIS indicate that the prevalence 
of e-cigarette and smokeless tobacco use was lower among 
those with a graduate degree than among those with an 
associate degree or lower level of education. E-cigarette 
use was higher among those with a GED than among 
those with any other level of education, and e-cigarette 
use was lower among those with an undergraduate degree 
than among those with a GED, a high school diploma, or 
those with some college and no degree. Smokeless tobacco 
use was also lower among those with an undergraduate 
degree than those with a high school diploma (Wang et al. 
2018a). For the 2013–2014 PATH Study, use of premium 
cigars increased as level of education increased, and use 
of nonpremium cigars, cigarillos, and filtered cigars was 
greatest among those with some college or an associate 
degree (Corey et al. 2017). Among pregnant women in the 
2013–2014 PATH Study, 4.9% used e-cigarettes, 2.5% used 
hookahs, and 2.3% used cigars (Kurti et al. 2017).
Cross-sectional evidence suggests that the majority 
of adult e-cigarette users in the United States are either 
current or former cigarette smokers. Among current adult 
e-cigarette users in the 2017 NHIS, 49.6% were current 
smokers of conventional cigarettes, 33.5% were former 
cigarette smokers, and 17.0% had never been cigarette 
smokers (NHIS, public use data, 2017).
Although significant declines in cigarette smoking 
have occurred among U.S. adults during the past 5 decades, 
the use of noncigarette tobacco products has increased 
in recent years (USDHHS 2014; Hu et al. 2016), making 
cessation of all tobacco products an important measure. 
In addition, health risk behaviors, similar to cigarette 
smokers, also tend to cluster among persons who use other 
tobacco products. For example, an analysis of patterns of 
alcohol, marijuana, and tobacco use in the PATH Study 
revealed that co-use of alcohol, cigarettes, and e-cigarettes 
was one of the top five use patterns among adults 25 years 
of age and older (Cohn et  al. 2018). In addition, among 
young adults (18–24 years of age), mental health and sub-
stance use problems were associated with higher odds of 
alcohol and hookah co-use (OR = 1.48; 95% CI, 1.03–2.13; 
OR = 1.97; 95% CI, 1.04–3.74, respectively) than alcohol-
only use. Among adults (25  years of age and older) and 
compared with alcohol-only users, mental health and sub-
stance use problems were associated with higher odds 
of alcohol, cigarette, and e-cigarette co-use (OR  =  1.55; 
95% CI, 1.24–1.93; OR = 2.22; 95% CI, 1.43–3.44, respec-
tively) and with higher odds of alcohol and cigar co-use 
(OR = 1.60; 95% CI, 1.20–2.14; OR = 4.64; 95% CI, 3.10–
6.94, respectively) (Cohn et al. 2018).
Data from the 2017 NHIS indicated that 8.0% of 
adults were former users of smokeless tobacco; 11.6% 
were former users of e-cigarette; 12.2% were former users 
of pipes, water pipes, or hookahs; and 23.7% were former 
users of cigars, cigarillos, or little cigars (NHIS, public use 
data, 2017). In contrast to the measure of former cigarette 
smoking, former users of noncigarette tobacco products 
was defined as persons who ever used the product but were 
not currently using. The quit ratio (defined as the ratio 
of former smokers to ever smokers) was 92.1% for pipes, 
water pipes, and hookahs; 86.2% for cigars, cigarillos, and 
little cigars; 79.4% for smokeless tobacco; and 80.6% for 
e-cigarettes (NHIS, public use data, 2017). The 2014–2015 
TUS-CPS also examined the use of pipes: the prevalence of 
former use was 5.4% for a regular pipe and 4.1% for water 
or hookah pipes, and quit ratios were 93.9% for those who 
had used a regular pipe and 87.8% for those who had used 
a water or hookah pipe (TUS-CPS, public use data, 2014–
2015). In the 2013–2014 PATH Study, among women 
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15–44 years of age, prevalence of former use was 3.8% for 
e-cigarettes, 3.2% for cigars, 6.9% for hookah, 1.2% for 
pipes, and 0.4% for smokeless tobacco and snus (Lopez 
et al. 2018). Initial prospective longitudinal evidence from 
Wave 1 (2013–2014) and Wave 2 (2014–2015) of the PATH 
Study indicated that 48.8% of U.S. adult e-cigarette users 
overall at Wave 1 had discontinued their use of e-cigarettes 
at Wave 2 (Coleman et al. 2018). Cessation of e-cigarettes at 
Wave 2 decreased with increasing frequency of e-cigarette 
use at Wave 1. In addition, adjusted prevalence ratios indi-
cated that e-cigarette users who also used combustible 
tobacco products at Wave 1 and e-cigarette users who used 
customizable e-cigarette devices were less likely to quit 
e-cigarette use at Wave 2. Among dual users of e-cigarettes 
and conventional cigarettes at Wave 1, 44.3% had main-
tained dual use at Wave 2; 43.5% had discontinued the use 
of e-cigarettes but maintained smoking conventional cig-
arettes; 7.0% had discontinued both products; and 5.1% 
had discontinued conventional cigarettes but continued 
smoking e-cigarettes (Coleman et al. 2018).
Additional longitudinal data from Kurti and col-
leagues (2018) from the PATH Study indicated that 1-year 
quit rates among nonpregnant women 18–44 years of age 
who were established tobacco users (i.e.,  used product 
fairly regularly in the past and currently used) were 
highest for users of cigars (60.6%), followed by hookah 
users (45.4%) and e-cigarette users (32.8%). Quit rates 
for users of these products were higher than the 1-year 
quit rate (11.5%) among women who had smoked 100 or 
more cigarettes in their lifetime. In separate multivar-
iate logistic regression models containing data on both 
established and experimental users (used product in the 
past but not fairly regularly and used some days or every 
day at the time of the survey), experimental use was asso-
ciated with increased odds of quitting e-cigarette use, 
hookah use, cigar use, and all tobacco use at Wave 2 com-
pared with established use. In addition, respondents who 
used illicit drugs were more likely to quit e-cigarettes at 
Wave 2 than those who did not use these drugs, and those 
who belonged to a racial/ethnic group other than White, 
Black, or Hispanic were less likely to quit hookah use at 
Wave 2. Women with lower levels of education were less 
likely than those with higher levels of education to quit 
hookah use and all tobacco use. Hispanic women were 
more likely to quit all tobacco use than White women 
(Kurti et al. 2018).
Additional key cessation measures for individual 
tobacco products other than cigarettes generally have not 
been included in national surveillance systems. The 2014–
2015 TUS-CPS assessed past-year quit attempts for other 
tobacco products, but the population for these questions 
was limited to persons who used only one product. The 
2012–2014 NHIS included a question about trying to quit 
all tobacco use during the past year, and the 2013–2014 
NATS included a question about interest in quitting all 
tobacco products. In contrast, the PATH Study has data on 
interest and intentions to quit all tobacco products and on 
quit attempts, as well as longitudinal data on quitting, as 
described previously (Hyland et al. 2017).
In 2012–2014, 39.8% of persons who used two 
or more tobacco products (cigarettes, cigars, smoke-
less tobacco, or pipes) had tried to quit all tobacco use 
during the past year (NHIS, public use data, 2012–2014) 
(Table  2.18). Among cigarette smokers who also used 
another tobacco product, the prevalence of attempting to 
quit all tobacco products during the past year (40.1%) was 
lower than the prevalence of making an attempt to quit 
cigarette smoking (48.9%). This lower prevalence of trying 
to quit all tobacco use versus cigarette smoking was also 
observed among men; persons 25–64 years of age, Whites, 
Blacks, those with 12 or fewer years of education or a high 
school diploma, those living at or above the poverty level, 
those living in the South, and those without insurance. 
Similarly, the PATH Study found that adult users of more 
than one type of combustible tobacco product were less 
likely to try to quit tobacco use completely during the 
past year than cigarette-only users (OR = 0.82, p <0.05) 
(Kypriotakis et al. 2018).
Among those who used two or more tobacco prod-
ucts, the associations between having tried to quit all 
tobacco product use during the past year and demographic 
characteristics (Table  2.18) were similar to those for a 
past-year attempt to quit cigarette smoking (Table 2.11), 
except for race/ethnicity; specifically, no differences were 
observed among Whites, Blacks, and Asians (38.8%, 
39.5%, and 43.2%, respectively) (Table 2.18). Overall, the 
prevalence of trying to quit cigarette smoking during the 
past year did not differ significantly between those who 
smoked cigarettes only (47.1%) and cigarette smokers 
who used other tobacco products (48.9%) (Table  2.18). 
Thus, although cigarette smokers who use other tobacco 
products (i.e., cigars, smokeless tobacco, and pipes) have 
a similar prevalence of making a past-year cigarette quit 
attempt to that of cigarette-only smokers, they have a 
lower prevalence of trying to quit all tobacco use than 
trying to quit cigarette smoking during the past year.
The PATH Study, using Wave 1 data, also compared 
past-year tobacco quit attempts among adult users of var-
ious combinations of tobacco products and observed that 
cigarette-only (OR  =  0.59, p  <0.01), smokeless tobacco-
only (OR = 0.39, p <0.001), and polycombustible tobacco 
users (OR = 0.48, p <0.001) were less likely to attempt to 
quit than those who used both e-cigarettes and hookah 
(Kypriotakis et al. 2018). In addition, smokeless tobacco-
only users were less likely to attempt to quit than cigarette-
only users (OR = 0.66, p <0.001).
Patterns of Smoking Cessation Among U.S. Adults, Young Adults, and Youth  83
Smoking Cessation
Table 2.18 Prevalence of a past-year quit attempt for cigarette smokinga and all tobacco useb by type of tobacco used 
among adult current tobacco users 18 years of age and older, by selected demographic characteristics; 
National Health Interview Survey (NHIS) 2012–2014; United States
  Attempted to quit cigarette smoking Attempted to quit all tobacco use
Characteristic
Cigarette-only 
smokers: % (95% CI)
Cigarette smokers 
who used other 
tobacco products: 
% (95% CI)
Cigarette smokers 
who used other 
tobacco products: 
% (95% CI)
Used ≥2 tobacco 
products: % (95% CI)
Total 47.1 (46.0–48.3) 48.9 (46.3–51.6) 40.1 (37.7–42.6) 39.8 (37.5–42.1)
Sex        
Male 46.0 (44.4–47.7) 47.2 (44.3–50.2) 38.7 (36.0–41.5) 38.5 (36.0–41.1)
Female 48.2 (46.6–49.7) 55.3 (48.9–61.6) 45.2 (38.4–52.1) 45.0 (38.3–51.8)
Age group (years)        
18–24 54.3 (49.5–59.2) 57.6 (51.5–63.7) 50.6 (44.2–56.9) 50.3 (44.4–56.2)
25–44 50.3 (48.6–52.0) 49.7 (46.3–53.1) 40.3 (37.1–43.4) 39.5 (36.6–42.5)
45–64 44.3 (42.7–46.0) 43.0 (38.2–47.8) 33.4 (29.0–37.7) 33.8 (29.6–38.1)
≥65 38.3 (35.3–41.3) 31.4 (23.6–39.2) 23.7 (16.8–30.7) 23.0 (16.3–29.7)
Race/ethnicity        
White, non-Hispanic 45.0 (43.6–46.4) 47.8 (44.7–50.9) 39.3 (36.4–42.3) 38.8 (36.1–41.6)
Black, non-Hispanic 52.9 (50.4–55.5) 50.3 (44.8–55.7) 38.0 (32.6–43.3) 39.5 (34.2–44.8)
Hispanic 52.5 (49.5–55.5) 60.4 (52.6–68.2) 50.1 (42.0–58.1) 49.2 (41.5–56.8)
American Indian/Alaska Native, 
non-Hispanic
39.7 (28.3–51.2) —c —c —c
Asian, non-Hispanic 51.6 (45.0–58.2) 48.8 (33.1–64.5) 43.4 (28.8–57.9) 43.2 (29.2–57.3)
Multiple races, non-Hispanic 51.1 (43.5–58.7) 39.8 (26.9–52.8) 35.8 (23.0–48.6) 35.3 (22.9–47.8)
Level of educationd        
≤12 years (no diploma) 43.6 (41.3–45.8) 45.8 (39.5–52.0) 33.1 (27.8–38.4) 33.6 (28.3–38.8)
GED certificate 47.3 (42.9–51.4) 48.9 (39.6–58.1) 43.4 (34.3–52.5) 43.4 (34.4–52.4)
High school diploma 43.8 (41.6–46.0) 40.3 (35.9–44.7) 30.2 (26.0–34.4) 31.1 (26.9–35.3)
Some college (no degree) 47.7 (45.2–50.1) 49.6 (44.3–55.0) 39.4 (34.1–44.6) 39.0 (34.0–44.0)
Associate degree 50.6 (47.4–53.9) 51.5 (39.7–63.2) 42.9 (32.9–52.9) 42.4 (33.2–51.5)
Undergraduate degree 50.8 (47.5–54.1) 45.7 (38.6–52.8) 39.6 (32.8–46.3) 35.8 (29.4–42.3)
Graduate degree 47.4 (42.3–52.4) 40.7 (28.9–52.6) 36.3 (24.9–47.7) 35.0 (24.1–45.9)
Poverty status        
At or above poverty level 46.6 (45.2–48.0) 50.4 (47.1–53.8) 41.4 (38.2–44.7) 40.7 (37.7–43.7)
Below poverty level 49.0 (46.9–51.0) 43.9 (39.3–48.5) 35.7 (31.3–40.1) 36.6 (32.3–40.8)
U.S. Census region        
Northeast 48.0 (45.2–50.8) 50.2 (44.2–56.1) 39.9 (33.7–46.0) 37.6 (32.0–43.1)
Midwest 46.8 (44.4–49.3) 49.2 (43.5–55.0) 40.7 (35.5–45.9) 40.8 (35.8–45.9)
South 47.1 (45.3–48.8) 48.7 (44.5–52.9) 39.1 (35.1–43.1) 38.6 (34.8–42.5)
West 46.7 (44.0–49.3) 48.3 (43.5–53.0) 41.2 (37.1–45.3) 41.6 (37.8–45.4)
Health insurance coverage        
Private 47.1 (45.4–48.8) 51.0 (46.5–55.4) 43.1 (38.8–47.4) 41.9 (38.1–45.8)
Medicaid and those with 
Medicaid and Medicare
50.8 (48.4–53.2) 48.2 (42.5–54.0) 39.2 (33.5–44.8) 38.7 (33.2–44.3)
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Findings using data from the 2013–2014 NATS indi-
cated that the majority (87.2%) of U.S. adults who used 
cigarettes and at least one other tobacco product were 
thinking about quitting all tobacco products for good 
(NATS, public use data, 2013–2014). This percentage was 
significantly higher than the comparable estimate for 
those who used at least two noncigarette tobacco products 
but no conventional cigarettes, which was 52.8%.
The PATH Study also examined adult tobacco users’ 
intentions to quit at Wave 1 and observed that both poly-
combustible tobacco users and smokeless tobacco users 
were somewhat less likely to be interested in quitting 
(OR = 0.92, p <001; and OR = 0.94, p <0.01, respectively) 
than cigarette-only smokers (Kypriotakis et al. 2018). In 
addition, polycombustible tobacco users were also less 
likely than cigarette-only smokers and smokeless tobacco-
only users to respond that they planned to quit for good 
(OR = 0.41, p <0.001; and OR = 0.48, p <0.01, respectively).
Young Adults
Findings using data from the 2017 NHIS indicated 
that quit ratios for young adults (18–24  years of age) 
who used other tobacco products ranged from 82.7% for 
pipes, 79.6% for e-cigarettes, 80.6% for cigars, and 63.4% 
for smokeless tobacco (NHIS, public use data, 2017). 
According to the 2014–2015 TUS-CPS, the prevalence of 
former use of a regular pipe among young adults was 3.6% 
(significantly lower than the prevalence among all adults 
of 5.4%), and the prevalence of former use of a water or 
hookah pipe was 9.5% (significantly higher than the prev-
alence among all adults of 4.1%) (TUS-CPS, public use 
data, 2014–2015). Data from the PATH Study indicated 
that among women who used tobacco at Wave  1, those 
18–24 years of age were more likely to quit all tobacco use 
at Wave 2 than those 25–44 years of age (Kurti et al. 2018).
Similar to data on adults overall, data from the 2012–
2014 NHIS indicated no differences in past-year quit attempts 
for cigarette smoking among young adult cigarette-only 
smokers and cigarette smokers who used another tobacco 
product (i.e., cigars, smokeless tobacco, and pipes) (NHIS, 
public use data, 2012–2014). In contrast to data on adults 
overall, no significant differences were observed between 
the prevalence of trying to quit all tobacco products (50.6%) 
and trying to quit cigarettes (57.6%) among young adult 
cigarette smokers who also used another tobacco product 
(NHIS, public use data, 2012–2014).
Youth
Data from the 2017 YRBS indicate that 13.2% of stu-
dents in grades 9–12 were current users (used on at least 
1 day during the 30 days before the survey) of e-cigarettes; 
8.0% currently smoked cigars, cigarillos, or little cigars; 
Table 2.18 Continued
  Attempted to quit cigarette smoking Attempted to quit all tobacco use
Characteristic
Cigarette-only 
smokers: % (95% CI)
Cigarette smokers 
who used other 
tobacco products: 
% (95% CI)
Cigarette smokers 
who used other 
tobacco products: 
% (95% CI)
Used ≥2 tobacco 
products: % (95% CI)
Health insurance coverage 
(continued)
       
Medicare only 36.5 (31.8–41.3) 31.2 (17.4–45.1) 24.9 (12.2–37.6) 25.7 (13.7–37.8)
Other coverage 47.3 (43.3–51.4) 47.8 (38.9–56.6) 40.0 (31.0–49.0) 39.5 (30.8–48.3)
Uninsured 46.7 (44.5–49.0) 47.4 (43.2–51.6) 36.5 (32.5–40.5) 37.2 (33.2–41.1)
Source: NHIS, National Center for Health Statistics, public use data, 2015.
Notes: CI = confidence interval; GED = General Educational Development.
aCurrent cigarette smokers who reported that they stopped smoking for >1 day during the past 12 months because they were trying 
to quit smoking.
bCurrent users of at least two tobacco products—cigarettes, other smoked tobacco products (including cigars, pipes, water pipes or 
hookahs, very small cigars, bidis, cigarillos), and smokeless tobacco (including chewing tobacco, snuff, dip, snus, dissolvable tobacco)—
who reported that they stopped using all kinds of tobacco products for >1 day during the past 12 months because they were trying to 
quit using tobacco. 
cPrevalence estimates with a relative standard error ≥30% are not presented due to low precision.
dAmong only adults 25 years of age and older.
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and 5.5% currently used chewing tobacco, snuff, dip, snus, 
or dissolvable tobacco products (Kann et al. 2018). For all 
three types of assessed tobacco products (e-cigarettes, 
cigars, and smokeless tobacco products), prevalence of 
current use was higher among male than among female 
students and increased as grade level increased. The 
prevalence of current e-cigarette and smokeless tobacco 
use was higher among Whites than among Blacks and 
Hispanics, and higher among Hispanics than among 
Blacks. Whites also had a higher prevalence of current 
cigar use than Hispanics (Kann et al. 2018). Among stu-
dents in grades 9–12 who used at least two tobacco prod-
ucts (cigarettes, e-cigarettes, cigar products, or smokeless 
tobacco) (10.5% of students), 52.7% (95% CI, 47.9–57.5) 
had tried to quit all tobacco product use in the past year 
(YRBS, public use data, 2017). The prevalence of having 
tried to quit using all tobacco products in the past year was 
higher among 12th-grade students (61.9%) than among 
9th-grade students (42.0%) (YRBS, public use data, 2017).
According to 2017 data from the NYTS, 9.2% of 
high school students and 2.4% of middle school stu-
dents reported using two or more tobacco products, and 
e-cigarettes were the most commonly used tobacco product 
among high school (11.7%) and middle school (3.3%) stu-
dents (Wang et al. 2018b). However, trends in the use of dif-
ferent tobacco products have varied. For example, decreases 
in cigarette and cigar smoking during 2011–2016 were 
offset by increases in hookah and e-cigarette use, resulting 
in no significant change in any tobacco use (Jamal et al. 
2017). E-cigarette use has continued to increase among 
U.S. youth more recently. During 2017–2018, current use 
of e-cigarettes among high school students rose 77.8% 
(from 11.7% to 20.8%) and among middle school students 
rose 48.5% (from 3.3% to 4.9%) (Gentzke et al. 2019). This 
increase resulted in a corresponding increase in overall 
tobacco product use among middle and high school stu-
dents during 2017–2018: Current use of any tobacco 
product increased 38.3% (from 19.6% to 27.1%) among 
high school students and 28.6% (from 5.6% to 7.2%) 
among middle school students (Gentzke et al. 2019).
The majority of high school and middle school stu-
dents who used at least two tobacco products had tried 
to quit all tobacco use for at least 1 day during the past 
year (55.9% and 62.0%, respectively) (Table 2.19). Among 
users who had tried to quit all tobacco products during 
the past year, the distribution of their number of attempts 
(Table  2.19) was similar to the distribution for quitting 
cigarettes (Tables  2.13a and  2.13b). Similarly, among 
those who used at least two tobacco products, the distri-
bution of the timeframes of when they considered quitting 
all tobacco products (Table 2.19) was similar to the dis-
tribution for quitting cigarettes (Tables 2.13a and 2.13b).
Table 2.19 Quitting behaviors among current users of two or more tobacco products,a by grade in school; National 
Youth Tobacco Survey (NYTS) 2017; United States
Quitting behaviors
High school (grades 9–12): 
% (95% CI)
Middle school (grades 6–8): 
% (95% CI)
Tried to quit all tobacco ≥1 days during the past year 55.9 (51.5–60.4) 62.0 (51.2–72.7)
Number of times tried to quit all tobacco during the past yearb    
1 22.7 (16.8–28.6) 15.6 (7.5–23.7)
2 16.0 (10.2–21.9) 21.9 (9.5–34.4)
3–5 24.1 (17.4–30.9) 22.8 (13.6–32.0)
6–9 12.5 (8.1–16.9) RSE >30%
>10 24.7 (20.1–29.3) 29.0 (16.2–41.7)
Considered quitting all tobacco within    
30 days 25.3 (19.7–30.9) 43.4 (27.9–58.9)
6 months 17.9 (12.4–23.3) RSE >30%
Not within 6 months 56.8 (49.8–63.9) 39.4 (26.5–52.3)
Tried to quit cigarettes ≥1 day during the past year 63.1 (57.2–69.0) 68.2 (58.5–78.0)
Source: NYTS, Centers for Disease Control and Prevention, public use data, 2017.
Notes: CI = confidence interval; RSE = relative standard error.
aAmong those who used at least two of the following tobacco products: cigarettes, e-cigarettes, cigars, cigarillos, little cigars, chewing 
tobacco, snuff, dip, bidis, hookahs, waterpipe with tobacco, pipe filled with tobacco, snus, dissolvable tobacco products.
bAmong those who tried to quit all tobacco products at least once during the past year.
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The Clinical Practice Guideline for Treating Tobacco 
Use and Dependence (Clinical Practice Guideline) rec-
ommends that healthcare providers screen all patients 
for tobacco use and deliver brief advice to quit to all 
tobacco users at every visit (Fiore et al. 2008). The Clinical 
Practice Guideline specifically recommends following 
the “5 A’s” model to deliver a brief cessation intervention 
in the primary care setting (i.e.,  Ask about tobacco use, 
Advise to quit, Assess willingness to quit, Assist by offering 
counseling and medication, and Arrange for follow-up). 
Chapter  6 of this report provides detailed information 
about these clinical interventions.
Two types of national data are available to track 
screening for tobacco use and counseling on tobacco ces-
sation by healthcare professionals. The first type depends 
on abstracting medical records from a sample of visits 
to office-based physicians (e.g.,  NAMCS), which is used 
to assess screening for tobacco use and the provision of 
information on tobacco and/or prescriptions or orders 
for cessation medication to identified users. The second 
type of national surveillance data involves self-reports and 
includes assessment by patients of the receipt of advice to 
quit and the other 5 A’s, use of effective counseling and 
medications for cessation, and the use of unproven cessa-
tion strategies (datasets include NHIS, TUS-CPS, NATS, 
and NYTS).
Screening for Tobacco Use and 
Receipt of Advice to Quit from 
Health Professionals
Adults
Clinical Data from Abstractions of Medical 
Records
Reports from NAMCS that were based on the 
abstraction of medical records for outpatient visits to 
office-based physicians showed that, in 2009–2011, adults 
18 years of age and older made an estimated 2.5 billion 
outpatient visits. NAMCS started including a panel of 
community health centers in 2006, which included visits 
to physicians and to non-physician clinicians. Data for 
office-based and community health center-based physi-
cians were included in analyses for 2009–2011. According 
to the review, screening for tobacco use was documented 
in 66.6% of the outpatient visits (average annual estimate) 
(Table  2.20), an increase from 62.7% during 2005–2008 
(CDC 2012). Of the total documented visits in 2009−2011, 
16.4% were made by current tobacco users, a decrease 
from 17.6% in 2005–2008. Among outpatient visits made 
by patients who were identified as current tobacco users in 
2009–2011, 20.1% reported counseling or education was 
ordered or provided during their visits, a percentage that 
reflects no change from 2005–2008 (CDC 2012), and 3.8% 
received a prescription or an order for cessation medica-
tion (Table 2.20).
These estimates were similar to estimates made by 
screening records for visits to outpatient departments of 
nonfederal general and short-stay hospitals. From 2005 
to 2010, screening for tobacco use occurred in 63.0% of 
these visits; 24.5% of visits from patients who were iden-
tified as current tobacco users included counseling on 
tobacco, prescriptions or orders for cessation medication, 
or both (Jamal et al. 2015). No significant changes in these 
measures occurred in hospital outpatient visits during 
2005–2010 (Jamal et al. 2015).
During 2009–2011 (Table  2.20), visits to psychia-
trists had a lower proportion that included screening for 
tobacco use (56.3%) compared with visits to general and 
family practitioners (69.7%) or to obstetricians and gyne-
cologists” (69.8%). Patients who were identified as cur-
rent tobacco users varied by status of health insurance, 
as those with Medicaid/State Children’s Health Insurance 
Program (SCHIP)/Children’s Health Insurance Program 
(33.9%), those who were self-payers (23.6%), and those 
covered by other insurance (25.3%) were more likely to be 
current tobacco users than those with private insurance 
(15.3%) or Medicare (11.8%).
For office-based outpatient visits among current 
tobacco users (i.e.,  the patient was identified as a cur-
rent tobacco user during screening), the prevalence of 
visits that included tobacco counseling was lower among 
patients 18–24 years of age (14.5%) than among patients 
45–64 years of age (22.1%) (Table 2.20).
Visits by tobacco users with other types of insurance 
(9.4%) were less likely to include counseling than were 
visits among persons in any of the other insurance sub-
groups (e.g., worker’s compensation, no charge/charity). 
Tobacco-using patients who visited their primary care 
physicians were more likely to receive counseling 
(25.0%  of their visits) than were tobacco-using patients 
who visited doctors who were not their primary care phy-
sicians (16.2%  of visits). A similar finding was made in 
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Table 2.20 Receipt of screening for tobacco use, counseling, and a prescription for a cessation medication during 
outpatient visits to office-based physicians among adults 18 years of age and older, by patient and 
physician characteristics; National Ambulatory Medical Care Survey (NAMCS) 2009–2011 combined 
data; United States
Characteristic
Visits with screening 
for tobacco usea: 
% (95% CI)
Visits with current 
tobacco useb: 
% (95% CI)
Visits with current 
tobacco use and 
tobacco counselingc: 
% (95% CI)
Visits with current 
tobacco use and 
prescription 
of cessation 
medicationd: 
% (95% CI)
Total 66.6 (64.7–68.5) 16.4 (15.4–17.5) 20.1 (17.9–22.5) 3.8 (3.1–4.7)
Sex        
Male 65.7 (63.2–68.2) 19.8 (18.4–21.2) 19.8 (17.2–22.7) 3.7 (2.9–4.7)
Female 67.2 (64.7–69.6) 14.3 (13.3–15.3) 20.4 (17.9–23.1) 4.0 (3.1–5.1)
Age (in years)        
18–24 67.2 (63.9–70.3) 17.8 (16.0–19.9) 14.5 (10.9–18.9) —e
25–44 68.2 (65.7–70.7) 19.8 (18.1–21.6) 18.7 (15.9–21.8) 4.4 (3.1–6.1)
45–64 66.6 (64.0–69.1) 20.1 (18.7–21.6) 22.1 (19.2–25.2) 4.5 (3.7–5.6)
≥65 65.3 (62.7–67.9) 9.1 (8.3–9.9) 19.9 (16.5–23.8) 1.3 (0.8–2.1)
Race/ethnicity        
White, non-Hispanic 67.8 (65.4–70.1) 17.1 (16.0–18.2) 20.0 (17.4–22.9) 4.1 (3.3–5.1)
Black, non-Hispanic 61.7 (56.2–66.9) 18.2 (16.1–20.5) 23.4 (18.8–28.7) 2.8 (1.5–4.9)
Hispanic 64.3 (60.5–68.0) 11.3 (9.9–12.8) 18.5 (13.8–24.4) —e
Other race/multiple race, 
non-Hispanic
63.8 (55.8–71.1) 11.2 (8.6–14.5) 14.1 (8.6–22.2) —e
Health insurance coverage        
Private insurance 68.3 (65.8–70.7) 15.3 (14.3–16.3) 20.4 (18.0–23.0) 4.2 (3.3–5.2)
Medicare 66.3 (63.5–69.0) 11.8 (10.8–12.9) 21.3 (18.0–24.9) 3.2 (2.2–4.7)
Medicaid/SCHIP/CHIP 66.1 (61.2–70.8) 33.9 (30.3–37.6) 23.0 (17.6–29.5) 4.5 (3.0–6.7)
Self-pay 61.5 (55.9–66.9) 23.6 (20.6–27.0) 19.3 (14.8–24.8) 4.7 (3.1–7.0)
Other f 66.1 (60.4–71.4) 25.3 (21.4–29.5) 9.4 (6.2–14.2) —e
Patient’s primary care physician        
Yes 69.9 (66.8–72.8) 18.3 (16.6–20.1) 24.7 (21.4–28.9) 5.1 (3.8–6.7)
No 66.6 (64.2–68.8) 14.8 (14.0–15.8) 16.2 (14.0–18.7) 2.8 (2.2–3.5)
Physician specialty        
General or family practice 69.7 (65.9–73.2) 21.6 (19.9–23.5) 22.1 (18.9–25.7) 4.8 (3.8–6.1)
Internal medicine 67.1 (60.7–72.9) 16.2 (13.9–18.9) 27.8 (22.3–34.1) 4.1 (2.5–6.9)
Obstetrics and gynecology 69.8 (64.4–74.7) 10.6 (9.0–12.5) 16.7 (11.1–24.3) —e
Cardiovascular disease 67.8 (61.7–73.4) 12.3 (10.6–14.2) 38.6 (31.7–46.1) —e
Psychiatry 56.3 (49.4–63.1) 23.9 (19.6–28.8) 28.8 (19.0–41.1) 13.3 (9.9–17.7)
All other specialties 64.8 (61.7–67.8) 14.6 (13.6–15.7) 12.9 (10.5–15.8) 2.1 (1.5–3.1)
Time spent with physician        
<20 minutes 64.8 (61.9–67.7) 15.8 (14.8–16.9) 17.6 (15.3–20.1) 3.3 (2.6–4.2)
≥20 minutes 68.8 (66.4–71.1) 17.0 (15.7–18.5) 22.8 (19.9–26.0) 4.4 (3.4–5.6)
Source: NAMCS, National Center for Health Statistics, public use data, 2009–2011.
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the examination of the 2005–2010 data on visits to hos-
pital outpatient departments (Jamal et al. 2015). Among 
patients who used tobacco, those who visited cardiovas-
cular disease specialists were more likely to receive coun-
seling on tobacco use (38.6%) than were patients who 
visited general and family practitioners (22.0%), obstetri-
cians and gynecologists (16.7%), or all other specialists 
(12.9%). Similar differences by type of healthcare insur-
ance, primary care physician, and physician specialty were 
observed in the 2005–2008 NAMCS (CDC 2012).
Among current smokers who visited office-based 
physicians, the percentage of visits at which tobacco ces-
sation medications were prescribed varied by age group. 
The percentage was lower for visits by those 65 years of 
age and older compared with those 25–44 or 45–64 years 
of age (Table  2.20). Outpatient visits by current ciga-
rette smokers that included a prescription of cessation 
medication also varied by whether the physician was the 
patient’s primary care physician (5.1% of visits) or was 
not (2.8% of visits). Visits to psychiatrists had a higher 
proportion with prescribed medication (13.3%) than 
visits to all other specialists. These differences by age and 
physician specialty were also observed in the 2005–2008 
NAMCS (CDC 2012).
Self-Reported Data from Cigarette Smokers
According to NHIS data, in 2015, 83.9% of adult 
cigarette smokers saw a physician or other health profes-
sional during the past year, and among this group, 57.2% 
reported receiving advice to quit smoking (Table  2.21). 
The prevalence of smokers who received advice to quit 
was higher among older age groups (45–64 years of age 
[65.7%] and those aged 65 years of age and older [65.7%]) 
than among younger age groups (18–24  years of age 
[44.4%] and 25–44  years of age [49.8%]). Whites were 
more likely to receive advice to quit (60.2%) than were 
Asians (34.2%), American Indians/Alaska Natives (38.1%), 
or Hispanics (42.2%) (Table 2.21). Smokers living in the 
Northeast were more likely to report being advised to quit 
smoking (65.1%) than smokers living in the West (50.6%) 
or the South (55.2%). In addition, the prevalence of 
smokers who received advice to quit was lower in the West 
(50.6%) than it was in the Midwest (60.0%). Uninsured 
smokers were less likely to report receiving advice to quit 
(44.1%) than smokers with any type of insurance (range: 
56.8–69.2%). There were no significant differences in 
receipt of advice to quit between persons identifying as 
lesbian, gay, or bisexual (57.7%) (Table  2.22) and those 
identifying as heterosexual (57.1%). These demographic 
differences were similar to those seen in the 2010 NHIS, 
although sexual orientation was not assessed prior to the 
2013 NHIS (CDC 2011).
According to the 2009–2010 NATS, the prevalence 
of self-reported receipt of advice from a health profes-
sional to quit smoking was 65.8% among current ciga-
rette smokers who had seen a health professional during 
the past year (King et al. 2013). This figure is higher than 
the estimate using the 2010 NHIS, in which 48.3% of 
current cigarette smokers and former smokers who quit 
during the past year reported receiving cessation advice 
(CDC 2011). Appendix 2.1 discusses NATS and NHIS, and 
Appendix  2.2 discusses methodologic features that may 
have contributed to this difference, including that NATS 
was a tobacco-focused survey that may have contributed 
to a social desirability bias among cigarette smokers to 
answer that they received cessation advice. Using data 
from the 2010–2011 TUS-CPS, 64.8% of current ciga-
rette smokers reported receiving advice to quit (TUS-CPS, 
public use data, 2010–2011), which was similar to the esti-
mate from the 2009–2010 NATS. Although the TUS-CPS 
was another tobacco-focused survey and may have been 
subject to social desirability bias, it is also possible that 
data from NHIS may underestimate the prevalence of cig-
arette smokers receiving advice to quit.
Also using the 2009–2010 NATS, 87.9% of current 
smokers who visited a health professional recalled being 
asked if they smoked cigarettes, and 42.6% recalled being 
asked if they wanted to quit (King et  al. 2013). Among 
Table 2.20 Continued
Note: CHIP = Children’s Health Insurance Program; CI = confidence interval; SCHIP = State Children’s Health Insurance Program.
aVisits during which the status (yes, no) of current tobacco use (cigarettes, cigars, or snuff or chewing tobacco) was recorded. 
Denominator includes current tobacco use, no current use, unknown, and blanks.
bDocumented visits during which current tobacco use (smoking cigarettes or cigars or using snuff or chewing tobacco) was recorded.
cTobacco counseling refers to the provision of any information related to tobacco use in any form, including cigarettes, cigars, snuff, 
and chewing tobacco, and also includes information about exposure to tobacco in the form of secondhand smoke, smoking cessation, 
and the prevention of tobacco use; referrals to other healthcare providers for smoking cessation programs are also included.
dCessation medications include nicotine replacement therapy (nicotine patch, gum, lozenge, nasal spray, and inhaler), bupropion, 
and varenicline.
ePrevalence estimates with a relative standard error ≥30% are not presented due to low precision.
fIncludes response options “Worker’s compensation, No charge/Charity, Other.”
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Table 2.21 Prevalence of receiving a health professional’s advice to quit smokinga and use of counselingb 
and medicationsc for cessation among cigarette smokers 18 years of age and older, by selected 
characteristics; National Health Interview Survey (NHIS) 2015; United States
Characteristic
Received health 
professional's advice 
to quit: % (95% CI)
Used counseling: 
% (95% CI)
Used medication: 
% (95% CI)
Used counseling 
and/or medication: 
% (95% CI)
Overall 57.2 (55.3–59.1) 6.8 (5.7–7.9) 29.0 (26.8–31.2) 31.2 (28.9–33.5)
Sex        
Men 55.2 (52.5–57.9) 5.8 (4.3–7.4) 27.0 (24.0–30.0) 29.1 (26.0–32.2)
Women 59.3 (56.6–61.9) 7.9 (6.4–9.5) 31.3 (28.2–34.3) 33.6 (30.5–36.6)
Age group (in years)        
18–24 44.4 (37.1–51.6) —c 15.6 (9.5–21.7) 16.8 (10.6–23.0)
25–44 49.8 (46.6–53.0) 6.1 (4.5–7.8) 25.5 (22.2–28.7) 27.4 (24.1–30.8)
45–64 65.7 (62.9–68.4) 8.8 (6.9–11.1) 37.7 (34.0–41.4) 40.2 (36.4–43.9)
≥65 65.7 (61.4–70.0) 9.2 (5.3–13.1) 33.7 (27.7–39.7) 37.0 (31.0–43.1)
Race/ethnicity        
White, non-Hispanic 60.2 (58.0–62.4) 6.9 (5.5–8.3) 32.6 (29.8–35.4) 34.3 (31.4–37.2)
Black, non-Hispanic 55.7 (50.2–61.1) 7.6 (4.5–10.8) 25.2 (20.1–30.3) 28.9 (23.5–34.4)
Hispanic 42.2 (37.0–47.5) 5.1 (2.4–7.7) 16.6 (12.4–20.9) 19.2 (14.4–24.0)
American Indian/Alaska Native, 
non-Hispanic
38.1 (21.4–54.8) —c —c —c
Asian, non-Hispanicd 34.2 (24.2–44.3) —c 17.4 (9.4–25.4) 20.5 (12.2–28.8)
Multiple races, non-Hispanic 69.6 (59.2–80.1) —c 22.1 (10.5–33.6) 24.6 (12.7–36.4)
Level of educatione        
≤12 years (no diploma) 60.8 (56.6–65.1) 5.4 (3.1–7.6) 26.5 (21.8–31.2) 28.7 (23.8–33.6)
GED certificate 61.6 (52.4–70.7) —c 30.8 (21.5–40.1) 31.4 (22.0–40.7)
High school diploma 58.1 (53.9–62.3) 7.0 (4.7–9.4) 30.3 (25.5–35.1) 33.1 (28.1–38.1)
Some college (no degree) 59.1 (55.3–63.0) 8.6 (6.0–11.1) 32.5 (28.1–36.9) 34.6 (30.1–39.2)
Associate degree 61.6 (56.4–66.8) 8.6 (5.1–12.2) 33.2 (27.4–39.0) 36.0 (29.8–42.3)
Undergraduate degree 52.6 (46.6–58.5) 7.4 (3.7–11.1) 33.2 (26.5–39.8) 35.1 (28.4–41.7)
Graduate degree 57.7 (48.5–66.8) —c 32.8 (22.9–42.6) 35.9 (25.7–46.0)
Poverty status        
At or above poverty level 57.8 (55.6–60.1) 6.8 (5.6–8.1) 29.5 (27.1–31.8) 31.7 (29.2–34.2)
Below poverty level 54.7 (50.7–58.7) 6.7 (4.6–8.9) 27.0 (21.6–31.6) 29.0 (24.2–33.7)
U.S. Census region        
Northeast 65.1 (60.2–70.1) 8.2 (4.9–11.5) 34.7 (27.9–41.5) 37.6 (30.9–44.2)
Midwest 60.0 (56.1–63.9) 4.9 (3.0–6.8) 28.9 (24.9–32.8) 30.2 (26.1–34.4)
South 55.2 (52.2–58.2) 7.2 (5.3–9.0) 27.2 (23.8–30.6) 29.3 (25.7–33.0)
West 50.6 (46.9–54.4) 7.5 (5.1–9.9) 28.0 (23.1–32.8) 30.7 (25.5–35.9)
Health insurance coverage        
Private 56.8 (54.0–59.5) 6.8 (5.3–8.3) 29.9 (27.0–32.7) 32.1 (29.1–35.1)
Medicaid and dual eligibles 59.9 (55.7–64.1) 8.0 (5.3–10.7) 32.2 (27.3–37.2) 34.5 (29.3–39.6)
Medicare Advantage 66.6 (56.5–76.6) —c 26.5 (15.5–37.4) 31.6 (19.7–43.4)
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those wanting to quit, 78.2% were offered assistance, and 
17.5% were scheduled for follow-up. Among persons who 
received assistance, 50.6% were provided with access to 
booklets, videos, websites, or other information; 37.5% 
were referred to a quitline, class, program, or counseling; 
and 57.8% received recommendations or prescriptions for 
cessation medication. Thus, in the 5 A’s model of clinician 
cessation intervention, the prevalence of provider inter-
vention was higher for asking, assessing, and assisting 
than for more time-comprehensive and time-intensive 
components, such as scheduling for follow-up.
Trends
For 2000–2015, NHIS data indicate a nonlinear 
(quadratic) trend in the prevalence of receiving advice 
to quit smoking. Among adult current cigarette smokers 
who had visited a healthcare professional during the 
past year, prevalence of receiving advice to quit smoking 
increased from 52.4% in 2000 to 57.0% in 2005, decreased 
to 48.2% in 2010, but then increased again to 57.2% in 
2015 (Babb et al. 2017). These trends did not differ by sex 
(NHIS, public use data, 2000–2015). Similar trends were 
observed among Whites, Blacks, and Hispanics. However, 
among Asians, advice from healthcare professionals to 
quit decreased linearly over time, from 54.7% in 2000 to 
34.2% in 2015 (NHIS, public use data, 2000–2015).
Young Adults
Clinical Data Obtained by Abstracting 
Medical Records
According to combined data for 2004–2010 from 
NAMCS, an average of 65.7% of physician visits among 
patients 18–21 years of age included screening for tobacco 
use; among these, an average of 16.1% visits were made 
by current tobacco users (Jamal et al. 2014). Among visits 
made by persons identified as current tobacco users, 
19.1% received any assistance with cessation, including 
counseling on tobacco in the form of health education 
ordered or provided at the visit, a prescription or order for 
a cessation medication, or both.
Using 2004–2010 data from NAMCS, Jamal and col-
leagues (2014) examined physician visits among 11-  to 
21-year-old patients and found that a higher proportion of 
visits included screening for tobacco use among patients 
with private insurance (71.0%) and Medicaid or SCHIP 
(69.6%) than among patients with other types of insur-
ance (59.9%). In addition, a higher proportion of visits to 
a patient’s primary care physician included screening for 
tobacco use (72.7%) compared with visits with nonpri-
mary care physicians (67.9%), and a higher proportion of 
visits to a pediatrician (74.7%) included tobacco screening 
compared with visits to general or family practitioners 
Table 2.21 Continued
Characteristic
Received health 
professional's advice 
to quit: % (95% CI)
Used counseling: 
% (95% CI)
Used medication: 
% (95% CI)
Used counseling 
and/or medication: 
% (95% CI)
Health insurance coverage 
(continued)
       
Medicare only 
(excluding Advantage)
62.0 (51.7–72.3) —c 28.5 (15.5–41.5) 35.9 (22.6–49.1)
Other coverage 69.2 (62.8–75.7) 5.2 (2.7–7.7) 34.9 (26.2–43.6) 36.0 (27.3–44.7)
Uninsured 44.1 (38.8–49.3) 4.3 (2.2–6.4) 20.0 (15.6–24.6) 21.4 (17.0–25.8)
Source: Babb and colleagues (2017).
Notes: CI = confidence interval; GED = General Educational Development.
aReported receiving advice from a medical doctor, dentist, or other health professional to quit smoking or quit using other kinds of 
tobacco among current smokers and those who quit during the past year who saw a doctor or other health professional during the 
past year.
bUsed one-on-one counseling; attended a stop-smoking clinic, class, or support group; and/or sought a telephone helpline or quitline 
during the past year among current smokers who tried to quit during the past year or used when stopped smoking among former 
smokers who quit during the past 2 years.
cUsed nicotine patch, nicotine gum or lozenge, nicotine-containing nasal spray or inhaler, varenicline (U.S. trade name Chantix), and/or 
bupropion (including trade names Zyban and Wellbutrin) during the past year among current smokers who tried to quit during the past 
year or used when they stopped smoking among former smokers who quit during the past 2 years.
dDoes not include Native Hawaiians or Other Pacific Islanders.
eAmong only adults 25 years of age and older.
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Table 2.22 Prevalence of interest in quittinga, past-year quit attemptb, receipt of a health professional’s advice to quitc, use of counselingd and/or 
medicatione, quit ratiof, and recent successful cessationg among smokers 18 years of age and older, by selected subpopulations; National 
Health Interview Survey (NHIS) 2015, 2017; United States
Subpopulation
Interested 
in quitting: 
% (95% CI) 
(2015)
Past-year 
quit attempt: 
% (95% CI) 
(2017)
Received health 
professional’s 
advice to quit: 
% (95% CI)  
(2015)
Used counseling 
and/or medication: 
% (95% CI)  
(2015)
Quit ratio: 
% (95% CI) 
(2017)
Recent successful 
cessation: 
% (95% CI) 
(2017)
Cigarette smoking frequencyh            
Some-day smokers 71.0 (67.4–74.7) 58.5 (54.5–62.5) 44.6 (40.2–49.0) 24.2 (19.7–28.7) NA NA
Daily smokers, 1–4 cpd 71.8 (65.0–78.7) 59.8 (52.0–67.6) 51.3 (43.7–59.0) 33.6 (24.4–42.7) NA NA
Daily smokers, 5–14 cpd 68.8 (65.6–72.0) 49.8 (46.5–53.2) 64.5 (61.1–67.8) 36.2 (31.5–41.0) NA NA
Daily smokers, 15–24 cpd 66.3 (62.6–70.0) 40.2 (36.7–43.7) 68.4 (64.4–72.3) 42.5 (36.5–48.4) NA NA
Daily smokers, ≥25 cpd 55.6 (48.1–63.2) 29.5 (22.6–36.4) 79.3 (73.1–85.6) 46.7 (32.5–60.9) NA NA
Usually smokes mentholh            
Yes 71.3 (68.1–74.5) NA 58.6 (54.8–62.4) 32.8 (28.4–37.1) NA NA
No 67.3 (64.7–69.9) NA 62.8 (60.4–65.3) 35.9 (31.6–38.7) NA NA
No usual type 40.0 (28.2–51.9) NA 34.1 (21.8–46.4) —i NA NA
Serious psychological distress            
Yes (Kessler scorej ≥13) 67.4 (61.3–73.5) 58.2 (51.8–64.6) 70.1 (64.5–75.8) 41.6 (33.7–49.5) 40.7 (35.4–46.1) 7.2 (3.9–10.5)
No (Kessler score <13) 68.2 (66.0–70.3) 55.0 (53.1–56.9) 55.7 (53.7–57.7) 30.1 (27.8–32.5) 63.0 (61.6–64.3) 7.7 (6.7–8.8)
Chronic illness diagnosis            
Any smoking-related 
chronic diseasek
67.9 (65.1–70.8) 56.5 (54.0–58.9) 67.3 (64.7–69.8) 35.4 (32.0–38.8) 65.2 (63.6–66.8) 6.8 (5.6–8.0)
Other chronic diseasel 69.4 (66.6–72.2) 55.8 (53.3–58.3) 66.5 (64.0–69.1) 37.2 (33.6–40.7) 67.6 (66.1–69.1) 6.5 (5.0–7.9)
No chronic disease 69.3 (66.8–71.8) 56.1 (54.0–58.3) 64.8 (62.6–67.1) 36.1 (33.0–39.2) 64.8 (63.4–66.2) 6.7 (5.5–7.8)
Disability/limitationm            
Yes 66.4 (61.4–71.3) 54.0 (50.0–58.0) 71.8 (67.4–76.2) 39.0 (32.1–45.9) 59.4 (56.7–62.1) 5.4 (3.5–7.4)
No 66.8 (63.5–70.2) 54.6 (51.9–57.2) 53.6 (50.5–56.8) 28.5 (25.1–31.9) 62.6 (60.7–64.4) 8.4 (6.8–9.9)
Sexual orientation            
Heterosexual 68.1 (65.9–70.2) 55.4 (53.4–57.3) 57.1 (55.1–59.1) 31.7 (29.3–34.1) 62.1 (60.8–63.4) 7.5 (6.4–8.5)
Lesbian/gay/bisexual 66.7 (56.9–76.6) 54.6 (46.4–62.9) 57.7 (48.5–66.9) 14.5 (7.9–21.1) 50.6 (44.1–57.0) —i
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Table 2.22 Continued
Subpopulation
Interested 
in quitting: 
% (95% CI) 
(2015)
Past-year 
quit attempt: 
% (95% CI) 
(2017)
Received health 
professional’s 
advice to quit: 
% (95% CI)  
(2015)
Used counseling 
and/or medication: 
% (95% CI)  
(2015)
Quit ratio: 
% (95% CI) 
(2017)
Recent successful 
cessation: 
% (95% CI) 
(2017)
Binge drinking (past month)            
Yes 70.1 (66.0–74.2) 54.8 (51.2–58.4) 53.5 (49.3–57.7) 29.9 (25.2–34.5) 51.5 (48.7–54.4) 6.4 (4.8–8.1)
No 67.2 (64.8–69.6) 55.8 (53.6–58.0) 58.8 (56.6–61.0) 32.1 (29.5–34.7) 64.8 (63.4–66.1) 8.0 (6.7–9.2)
Source: NHIS, National Center for Health Statistics, public use data, 2015, 2017; Babb and colleagues (2017).
Notes: CI = confidence interval; cpd = cigarettes smoked per day; NA = not available.
aCurrent smokers who reported that they stopped smoking for >1 day during the past 12 months because they were trying to quit smoking and former smokers who quit 
during the past year.
bCurrent smokers who reported that they wanted to stop smoking completely.
cReceived advice from a medical doctor, dentist, or other health professional to quit smoking or quit using other kinds of tobacco among current smokers and those who 
quit during the past year who saw a doctor or other health professional during the past year.
dUsed one-on-one counseling; attended a stop-smoking clinic, class, or support group; and/or sought a telephone helpline or quitline during the past year among current 
smokers who tried to quit during the past year or among former smokers who quit during the past 2 years.
eUsed nicotine patch, nicotine gum or lozenge, nicotine-containing nasal spray or inhaler, varenicline (U.S. trade name Chantix), and/or bupropion (including trade names 
Zyban and Wellbutrin) during the past year among current smokers who tried to quit during the past year or among former smokers who quit during the past 2 years.
fThe percentage of ever smokers who have quit smoking. Defined as the number of former smokers divided by the number of ever smokers.
gHaving smoked during the past year but having been quit for at least 6 months at the time of the survey interview. The denominator in the prevalence calculation includes 
all persons who smoked during the past year (i.e., both current cigarette smokers and former smokers who reported quitting during the past year).
hAnalysis limited to current smokers.
iPrevalence estimates with a relative standard error ≥30% are not presented due to low precision.
jThe Kessler Psychological Distress Scale was developed for mental health screening in population surveys. The 10-item questionnaire is intended to yield a global measure 
of distress based on questions about anxiety and depressive symptoms that a person has experienced in the most recent 4-week period.
kIncludes lung cancer, other tobacco-related cancers (bladder, cervical, colon, esophageal, kidney, larynx-windpipe, leukemia, liver, mouth/tongue/lip, pancreas, rectum, 
stomach, throat-pharynx, and uterine), coronary heart disease, stroke, emphysema, chronic bronchitis, asthma, diabetes, and arthritis.
lIncludes hypertension, other heart condition or heart disease, ulcer, and cancers including blood, bone, brain, breast, gallbladder, lymphoma, melanoma, ovarian, prostate, 
skin (non-melanoma and other), soft tissue, testicular, thyroid, and other.
mDefined on the basis of self-reported presence of selected limitations, including vision, hearing, cognition, and movement. Limitations in performing activities of daily living 
were defined on the basis of responses to the following question: “Does [person] have difficulty dressing or bathing?” Limitations in performing instrumental activities of daily 
living were defined on the basis of responses to the following question: “Because of a physical, mental, or emotional condition, does [person] have difficulty doing errands 
alone such as visiting a doctor’s office or shopping?” Any disability was defined as a “yes” response pertaining to at least one of the limitations (vision, hearing, cognition, 
movement, activities of daily living, or instrumental activities of daily living). Results include responses from a random sample of half of the respondents from the 2017 
Person File who were asked about limitations and weights from the Family Disability Questions File.
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or internal medicine physicians (68.3%), psychiatrists 
(62.4%), or physicians in all other specialties, except 
obstetrics and gynecology (65.0%). A higher proportion 
of visits in which preventive care was the major reason for 
the visit (28.9%) included cessation assistance (including 
counseling, medication, or both) compared with visits for 
other reasons (16.7%) (Jamal et al. 2014).
Data from Self-Reports of Cigarette Smokers 
Among young adult current cigarette smokers 
(18–24  years of age), differences in the prevalence of 
receiving a health professional’s advice to quit were similar 
to differences in the advice received by all adults in 2015. 
However, regional differences were more pronounced, as 
28.6% of smokers in the South were advised to quit com-
pared with 66.7% of smokers in the Northeast and 57.3% 
of smokers in the Midwest (NHIS, public use data, 2015).
Trends
Among adults 18–24  years of age, NHIS data for 
2000–2015 indicated that trends in receiving advice from a 
provider to quit among men were similar to the quadratic 
trends among all adults (Babb et al. 2017), but there was 
no significant increase among women from 2010 (42.4%) 
to 2015 (42.0%) (NHIS, public use data, 2000–2015).
Youth
Clinical Data Obtained by Abstracting 
Medical Records
According to combined data for 2004–2010 from 
NAMCS, an average of 71.5% of outpatient visits by patients 
11–17  years of age included screening for tobacco use; 
among these, an average of 3.0% outpatient visits were 
made by current tobacco users (Jamal et al. 2014). Among 
visits made by persons identified as current tobacco users, 
21.8% included the receipt of any cessation assistance, 
including tobacco counseling in the form of health edu-
cation ordered or provided at the visit, a prescription or 
order for a cessation medication, or both. Using 2004–
2010 data from NAMCS, Jamal and colleagues (2014) 
examined demographic differences in the screening and 
provision of education and/or medication among visits by 
patients 11–21  years of age; these were discussed previ-
ously in the section on young adults.
Self-Reported Data
In 2015, according to data from the NYTS, 46.2% of 
high school students and 23.9% of middle school students 
who had visited a healthcare provider during the past 
year, were asked at any visit during that year if they had 
used tobacco (Tables 2.23a and 2.23b). Twelfth-grade stu-
dents (54.3%) were more likely than 9th-grade students 
(40.6%) and 10th-grade students (41.6%) to report being 
asked about tobacco use. This question was not asked in 
the 2016 or 2017 NYTS.
According to 2017 data from the NYTS, 31.4% of 
high school students and 28.1% of middle school stu-
dents who had smoked cigarettes during the past 30 days 
had been advised by a doctor, dentist, or nurse not to use 
tobacco. The prevalence of receiving advice to quit was 
similar between these students and students who used 
any type of tobacco (29.5% of high school students and 
24.6% of middle school students) (NYTS, public use data, 
2017). According to data from the 2011 NYTS, high school 
students who smoked on more than 19 days during the 
past 30 days were more likely to receive a health profes-
sional’s advice to not use tobacco (54.0%) than those who 
smoked on 1–19 of the past 30 days (33.0%) (Schauer et al. 
2014a). According to the 2013 NSDUH, 26.3% of past-
30-day tobacco users 12–17  years of age were screened 
for tobacco use and advised to quit (Collins et al. 2017). 
Furthermore, males were more likely to be advised to quit 
than females, and Hispanics were less likely to be advised 
to quit than Whites.
Use of Counseling and Medications 
to Quit Smoking
Adults
In 2015, according to data from the NHIS, the use 
of cessation counseling and/or medication among cur-
rent smokers who had tried to quit during the past year 
and former smokers who had successfully quit during the 
past 2 years was 31.2% (Table 2.21). In all, 6.8% had used 
counseling, 29.0% had used medications, and 4.7% had 
used both (Babb et al. 2017). Counseling services (alone 
or in combination) included a telephone quitline (4.1%); 
one-on-one counseling (2.8%); and a stop-smoking clinic, 
class, or support group (2.4%). Medications included the 
seven FDA-approved medications for smoking cessation 
(alone or in combination); the prevalence of medication 
use was 16.6% for the nicotine patch, 12.5% for nicotine 
gum or lozenges, 2.4% for nicotine nasal spray or inhaler, 
7.9% for varenicline, and 2.7% for bupropion.
According to NHIS, in 2015, the use of effective treat-
ment (counseling and/or medications) was lower among 
persons 18–24  years of age (16.8%) than in any of the 
other age groups (Table 2.21). In addition, prevalence of 
the use of counseling and/or medication was lower among 
smokers 25–44 years of age (27.4%) than among smokers 
45–64 years of age (40.2%) or those 65 years of age and 
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Table 2.23a Prevalence of being asked about tobacco usea and being advised not to use tobaccob among high school 
students (grades 9–12) who saw a healthcare provider during the past year, by grade in school; National 
Youth Tobacco Survey (NYTS) 2015; United States
Characteristic Asked about tobacco use: % (95% CI)
Current cigarette smokers advised not 
to use tobacco: % (95% CI)
Total 46.2 (43.6–48.8) 30.2 (28.0–32.4)
Sex    
Male 45.2 (42.2–48.2) 34.1 (27.3–41.0)
Female 47.4 (44.4–50.4) 32.9 (26.4–39.4)
Grade    
9 40.6 (36.8–44.4) 27.2 (18.9–35.5)
10 41.6 (38.2–45.0) 28.6 (19.7–37.5)
11 49.7 (46.1–53.4) 38.1 (29.8–46.3)
12 54.3 (51.5–57.2) 36.6 (28.8–44.3)
Race/ethnicity    
White, non-Hispanic 47.5 (44.2–50.8) 33.1 (27.8–38.4)
Black, non-Hispanic 45.9 (42.0–49.9) 33.5 (16.8–50.2)
Other, non-Hispanic 44.8 (40.2–49.4) 33.5 (14.9–52.1)
Hispanic 44.3 (40.5–48.1) 35.4 (24.6–46.1)
Source: NYTS, public use data, 2015.
Notes: This question was not asked in the 2016 or 2017 NYTS. CI = confidence interval.
aBeing asked about tobacco use was defined as being asked at any visit to a doctor, dentist, or nurse during the past year if the student 
used tobacco that is smoked or put in the mouth.
bBeing advised not to use tobacco was defined as being advised by a doctor, dentist, or nurse during the past 12 months not to use tobacco 
that is smoked or put in the mouth among current cigarette smokers (smoked cigarettes during the 30 days preceding the survey).
Table 2.23b Prevalence of being asked about tobacco usea and being advised not to use tobaccob among middle school 
students (grades 6–8) who saw a healthcare provider during the past year, by grade in school; National 
Youth Tobacco Survey (NYTS) 2015; United States
Characteristic Asked about tobacco use: % (95% CI)
Current cigarette smokers advised not 
to use tobacco: % (95% CI)
Total 23.9 (21.9–26.0) 22.9 (21.0–24.8)
Sex    
Male 23.4 (21.2–25.5) 31.5 (17.0–46.0)
Female 24.7 (22.1–27.2) 25.6 (14.7–36.5)
Race/ethnicity    
White, non-Hispanic 24.0 (20.9–27.0) 26.5 (17.5–35.4)
Black, non-Hispanic 28.6 (24.0–33.2) —c
Other, non-Hispanic 21.2 (17.4–25.0) —c
Hispanic 23.5 (21.3–25.8) —c
Source: NYTS, public use data, 2015.
Notes: This question was not asked in the 2016 or 2017 NYTS. CI = confidence interval; RSE = relative standard error.
aBeing asked about tobacco use was defined as being asked at any visit to a doctor, dentist, or nurse during the past year if the student 
used tobacco that is smoked or put in the mouth.
bBeing advised not to use tobacco was defined as being advised by a doctor, dentist, or nurse during the past 12 months not to use tobacco 
that is smoked or put in the mouth among current cigarette smokers (smoked cigarettes during the 30 days preceding the survey).
cData are not shown because sample size was <50 and the relative standard error of the estimate was >30%.
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older (37.0%). Hispanics used effective treatments less 
often than Whites (19.2% vs. 34.3%). Uninsured smokers 
were less likely to use effective treatments (21.4%) than 
were smokers who were privately insured (32.1%), had 
Medicaid (34.5%), or had other coverage (36.0%). Use of 
counseling and/or medication was also lower among les-
bian, gay, and bisexual smokers than among heterosexuals 
(14.5% vs. 31.7%) (Table 2.22).
According to data from the 2014–2015 TUS-CPS, 
the prevalence of using a telephone quitline for cessa-
tion was 3.5% among current cigarette smokers who had 
tried to quit during the past year (Table  2.24), a figure 
that was quite similar to the prevalence using the 2015 
NHIS for using such a quitline among current smokers 
who had tried to quit during the past year combined with 
former smokers who had quit during the past 2  years 
(4.1%) (Babb et al. 2017). Use of a telephone quitline by 
current cigarette smokers during the last time they tried 
to quit within the past year was higher among women 
(4.2%) than men (2.8%), among those 45–64 years of age 
(4.4%) than those aged 65  years and older (2.1%), and 
among those living below the poverty level (5.2%) than 
among those living at or above the poverty level (3.0%) 
(Table 2.24).
Young Adults
In 2015, according to data from the NHIS, 16.8% of 
young adult current smokers 18–24 years of age who had 
tried to quit during the past year and former smokers who 
successfully quit during the past 2  years used cessation 
counseling and/or medications (Table  2.21) (Babb et  al. 
2017). This included 15.6% who used only medications, 
but because of small numbers and low precision (relative 
standard error ≥30%), the percentages who used either 
counseling only or both counseling and medication could 
not be estimated (Babb et al. 2017). Regardless, both per-
centages were lower than those for smokers 25 years of 
age and older (Babb et al. 2017). The association between 
demographic characteristics and treatment use among 
young adults could not be examined using 2015 NHIS 
data because of small sample sizes and the low precision 
of estimates (relative standard error ≥30%).
Youth
In 2015, according to data from the NYTS, 17.8% 
of high school current cigarette smokers who had tried 
to quit during the past year used a program, counseling, 
and/or medication to quit during the past 12 months, and 
69.9% reported that they had “tried to quit on my own 
or quit cold turkey” (Table  2.25). Among middle school 
students, 30.4% of current cigarette smokers used a pro-
gram, counseling, and/or medication to quit, and 81.9% 
tried to quit cold turkey. However, caution is warranted 
in interpreting these results because a large proportion 
of middle school students reported using both a strategy 
to quit and quitting cold turkey, suggesting that they had 
different interpretations of what was meant by “quitting 
on their own” or quitting cold turkey.
Among high school students who were current ciga-
rette smokers and had attempted to quit during the past 
year, the use of a program, counseling, and/or medication 
was higher among males (22.8%; 95% CI, 15.6–30.1) than 
females (8.9%; 95% CI, 4.2–13.6) (NYTS, public use data, 
2015; not shown in Table 2.25). Estimates for other demo-
graphic characteristics were of low precision and there-
fore were not examined (relative standard error ≥30%).
Trends Among Adults
The prevalence among current cigarette smokers of 
using effective cessation treatments increased nonlinearly 
during 2000–2015. A significant increase was observed 
from 2000 (21.9%) to 2010 (31.7%), but there was no 
change during 2010–2015 (31.2%) (Babb et  al. 2017). 
A similar trend was observed among women (2000, 22.4%; 
2005, 32.7%; 2010, 35.1%; and 2015, 33.6%). Among men, 
a linear increase in the use of effective treatments was seen 
from 2000 (21.4%) to 2015 (29.1%) (NHIS, public use data, 
2000–2015). Trends in the use of cessation aids also differed 
by race/ethnicity: Trends among Whites and Hispanics were 
similar to those for adults overall, but a linear increase was 
observed for Blacks (Figure 2.13). Data from Nielsen Retail 
Management Services showed sales of NRT gum, lozenge, 
and patch totaled $1.0 billion in 2018 (adjusted for infla-
tion to 2018 dollars) (Figure 2.14). From Quarter 2 of 2014 
to Quarter 4 of 2018, NRT gum had the highest sales fol-
lowed by NRT lozenge and NRT patch. During this time 
period, sales of NRT gum increased steadily from Quarter 2 
of 2014 to Quarter 4 of 2015, peaked in Quarter 2 of 2016 
at $145.6 million, and then decreased through Quarter 4 
of 2018 ($132.0  million). In contrast, sales of NRT loz-
enge increased fairly steadily from Quarter  2 of 2014 to 
Quarter  4 of 2018, when sales peaked at $78.2  million. 
Sales of NRT patch appeared to have a seasonal pattern 
from 2014 to 2018, as sales peaked in the first quarter of 
each year and then generally declined throughout the year. 
Sales of NRT patch peaked in Quarter 1 of 2016 ($48.3 mil-
lion) but then decreased generally through 2018 despite its 
annual first-quarter peaks.
Trends Among Young Adults
Among young adults 18–24 years of age, trends in 
the use of effective cessation treatments among female 
smokers and White smokers were similar to trends among 
adults overall; but among men, use of effective cessation 
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Table 2.24 Prevalence of using strategies to quit cigarette smokinga among current cigarette smokersb 18 years of 
age and older who tried to quit during the past year, by selected characteristics; Tobacco Use Supplement 
to the Current Population Survey (TUS-CPS) 2014–2015; United States
Characteristic
Used telephone 
quitline: 
% (95% CI)
Used Internet 
or web-based 
program or tool: 
% (95% CI)
Used switching 
to smokeless 
tobacco: 
% (95% CI)
Used switching 
to cigar or pipe: 
% (95% CI)
Used switching 
to e-cigarettes: 
% (95% CI)
Overall 3.5 (3.1–3.9) 2.1 (1.8–2.4) 5.4 (4.8–6.0) 2.7 (2.4–3.1) 34.7 (33.6–35.7)
Sex
Men 2.8 (2.3–3.4) 1.7 (1.3–2.1) 7.7 (6.7–8.7) 4.0 (3.3–4.6) 32.7 (31.2–34.3)
Women 4.2 (3.6–4.7) 2.5 (2.0–3.0) 3.0 (2.4–3.5) 1.5 (1.0–1.9) 36.8 (35.3–38.3)
Age group (in years)          
18–24 2.7 (1.4–4.0) 2.4 (1.1–3.6) 7.8 (5.6–10.0) 3.7 (2.2–5.1) 39.2 (35.2–43.2)
25–44 3.2 (2.6–3.8) 2.3 (1.7–2.8) 5.8 (4.8–6.7) 2.3 (1.7–2.8) 38.0 (36.3–39.8)
45–64 4.4 (3.7–5.1) 1.9 (1.4–2.4) 4.5 (3.8–5.3) 3.0 (2.4–3.6) 32.2 (30.6–33.7)
≥65 2.1 (1.2–3.0) 1.8 (1.0–2.6) 3.8 (2.5–5.1) 2.5 (1.6–3.5) 23.7 (20.7–26.7)
Race/ethnicity          
White, non-Hispanic 3.2 (2.8–3.7) 2.1 (1.7–2.5) 5.5 (4.8–6.1) 2.5 (2.0–2.9) 38.8 (37.6–40.0)
Black, non-Hispanic 4.0 (2.8–5.2) 2.3 (1.3–3.2) 4.6 (3.3–6.0) 4.0 (2.7–5.3) 23.1 (20.3–25.9)
Hispanic 4.3 (2.6–6.1) 2.2 (1.0–3.3) 4.7 (3.0–6.5) 3.0 (1.5–4.4) 22.8 (19.6–26.0)
American Indian/Alaska 
Native, non-Hispanic
—c —c —c —c 24.5 (16.7–32.2)
Asian, non-Hispanic —c —c —c —c 25.4 (18.1–32.7)
Multiple races, non-Hispanic —c —c —c —c 50.6 (42.4–58.9)
Level of educationd          
≤12 years (no diploma) 4.3 (3.2–5.3) 1.0 (0.6–1.5) 4.5 (3.4–5.7) 3.5 (2.4–4.5) 28.4 (25.9–31.0)
High school diploma 3.0 (2.4–3.7) 1.7 (1.2–2.2) 5.5 (4.6–6.5) 2.6 (2.0–3.2) 34.6 (32.7–36.4)
Some college (no degree) 3.2 (2.5–4.0) 2.5 (1.8–3.2) 5.9 (4.8–7.1) 2.9 (2.1–3.8) 37.8 (35.4–40.2)
Associate degree 4.6 (3.1–6.1) 2.2 (0.9–3.6) 5.2 (3.8–6.7) 2.0 (0.9–3.0) 37.7 (34.8–40.6)
Undergraduate degree 3.5 (2.2–4.8) 4.1 (2.7–5.5) 5.0 (3.4–6.6) 2.0 (0.9–3.1) 35.7 (32.3–39.1)
Graduate degree 3.1 (0.5–5.8) 3.4 (1.2–5.7) 6.2 (2.8–9.6) 3.5 (1.3–5.7) 32.4 (26.3–38.6)
Poverty status          
At or above poverty level 3.0 (2.6–3.4) 2.1 (1.7–2.5) 5.5 (4.9–6.1) 2.4 (2.0–2.8) 35.1 (34.0–36.3)
Below poverty level 5.2 (4.2–6.2) 2.1 (1.5–2.6) 5.1 (4.1–6.1) 3.9 (2.9–4.8) 33.2 (30.7–35.7)
U.S. Census region          
Northeast 3.9 (2.7–5.0) 2.3 (1.4–3.1) 4.7 (3.4–6.1) 3.0 (1.9–4.1) 32.2 (29.2–35.1)
Midwest 3.1 (2.3–3.9) 1.7 (1.2–2.3) 5.6 (4.4–6.8) 2.2 (1.5–2.8) 35.6 (33.5–37.7)
South 3.2 (2.7–3.8) 2.2 (1.6–2.7) 5.3 (4.5–6.2) 3.1 (2.4–3.7) 35.3 (33.5–37.1)
West 4.2 (3.2–5.1) 2.4 (1.6–3.2) 5.9 (4.7–7.2) 2.6 (1.7–3.5) 34.5 (31.7–37.2)
Source: TUS-CPS, National Cancer Institute, public use data, 2014–2015.
Notes: CI = confidence interval. 
aUsed during their last quit attempt among those who tried to quit for at least 1 day during the past 12 months.
bPersons who reported smoking more than 100 cigarettes during their lifetime and who, at the time of the interview, reported smoking 
every day or some days.
cPrevalence estimates with a relative standard error ≥30% are not presented due to low precision.
dAmong only adults 25 years of age and older.
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treatments increased from 2000 (5.7%) to 2005 (15.9%) 
and then remained unchanged through 2015 (17.2%) 
(NHIS, public use data, 2000–2015). Estimates for other 
racial/ethnic groups are not presented because of low pre-
cision (relative standard error ≥30%).
Trends Among Youth
Use of cessation treatments (e.g., school or commu-
nity programs, telephone quitlines, nicotine patches, nic-
otine gum, or any other medications) among high school 
and middle school students decreased during 2000–2004, 
and the use of cessation treatments in 2015 was similar to 
that seen in 2000 (Table 2.25).
Use of Other Cessation Strategies
Adults
According to the 2014–2015 TUS-CPS, among adult 
cigarette smokers who tried to quit smoking during the 
past year, switching to e-cigarettes was the most prevalent 
strategy (34.7%) used the last time they tried to quit 
(Table 2.24), despite inconclusive data on the efficacy of 
these products for promoting long-term cessation (see 
Chapter 7) (Hartmann-Boyce et al. 2016; Kalkhoran and 
Glantz 2016; Coleman et al. 2017; Verplaetse et al. 2018; 
Young-Wolff et al. 2018; Berry et al. 2019). The percentage 
of adult smokers switching to e-cigarettes was similar to 
the percentage of adult cigarette smokers (as estimated 
in the 2015 NHIS) who used any evidence-based cessa-
tion treatment (31.2%) (Table  2.21). According to the 
TUS-CPS data, switching to e-cigarettes in an attempt to 
quit smoking conventional cigarettes was more common 
among women (36.8%) than men (32.7%). Cigarette 
smokers younger than 45  years of age were more likely 
to try to quit by switching to e-cigarettes than were 
older smokers, and their use of e-cigarettes to try to 
quit was greater than their use of proven cessation treat-
ments (Table 2.21). Whites (38.8%) and persons of mul-
tiple races (50.6%) were more likely than smokers of all 
other racial/ethnic groups to switch to e-cigarettes in an 
attempt to quit (Table 2.24), and the percentage of those 
who switched to e-cigarettes in an attempt to quit was 
Table 2.25 Strategies used to quit smoking among high school and middle school current cigarette smokersa who 
tried to quit during the past year; National Youth Tobacco Survey (NYTS) 2000, 2004, 2009, and 2015; 
United States
Quitting behaviors 2000: % (95% CI) 2004: % (95% CI) 2009: % (95% CI) 2015: % (95% CI)
High school (grades 9–12)        
Used a program, counseling, 
and/or medicationb 
16.5 (15.0–18.0) 11.8 (9.3–14.3) 10.2 (6.7– 13.7) 17.8 (12.9–22.7)
Attended a program in my school 4.7 (3.8–5.6) 2.6 (1.2–4.0) —c —c
Used nicotine gum, nicotine 
patch, or any medicine to quit
12.2 (10.9–13.5) 8.9 (6.9–10.9) 7.8 (5.0–10.7) 10.8 (7.1–14.5)
Tried to quit on my own or quit 
“cold turkey”
NA NA NA 69.9 (58.3–81.5)
Middle school (grades 6–8)        
Used a program, counseling, 
and/or medicationb
31.8 (27.8–35.9) 17.4 (13.8–20.9) 26.1 (19.4–32.7) 30.4 (18.4–42.3)
Attended a program in my school 9.9 (7.4–12.5) 3.0 (1.6–4.3) —c —c
Used nicotine gum, nicotine 
patch, or any medicine to quit
19.7 (16.4–23.0) 13.4 (10.5–16.2) 19.7 (13.1–26.2) 23.7 (13.4–33.9)
Tried to quit on my own or quit 
“cold turkey”
NA NA NA 81.9 (77.4–86.4)
Source: NYTS, Centers for Disease Control and Prevention, public use data, 2000, 2004, 2009, and 2015.
Notes: CI = confidence interval; NA = not available.
aSmoked cigarettes during the past 30 days.
bAttended a program in school or a program in the community; called a telephone helpline or telephone quitline; and/or used nicotine 
gum, nicotine patch, and/or any medication to quit.
cPrevalence estimates with a relative standard error ≥30% are not presented due to low precision.
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higher than the percentage of smokers who used effective 
cessation treatments (Table 2.21) for both groups. Persons 
with 12 or fewer years of education (with no high school 
diploma) were less likely to switch to e-cigarettes in an 
attempt to quit smoking than those with higher levels of 
education, with the exception of those with a graduate 
degree (Table 2.24). The use of e-cigarettes for cessation 
was also a commonly reported strategy among cigarette 
smokers in Wave  1 of the PATH Study: 25.2% reported 
using e-cigarettes to quit, and 23.5% reported using an 
FDA-approved cessation medication—NRT (18.7%), var-
enicline (5.7%), or bupropion (3.1%) (Benmarhnia et al. 
2018). Similar to the TUS-CPS, younger (18–34 years of 
age) cigarette smokers in the PATH Study who were trying 
to quit had a higher prevalence of using e-cigarettes as 
a cessation aid than those 35  years of age and older 
(Benmarhnia et al. 2018). In their analysis of data from the 
PATH Study, Harlow and colleagues (2018) observed that, 
among cigarette-only smokers at Wave 1, Whites, persons 
with greater than a high school education, and persons 
living at or above 200% of the poverty level were more 
likely to become exclusive e-cigarette users at Wave  2 
than Blacks and Hispanics, persons with a high school 
education or GED, and persons living below the poverty 
level, respectively. Whites were also more likely than 
Blacks and Hispanics to become dual users of e-cigarettes 
and cigarettes at Wave  2, and Whites were more likely 
to have quit conventional cigarettes (with no uptake of 
e-cigarettes) than Blacks at Wave 2. Persons with greater 
than high school education and those living at or above 
200% of the poverty level were also more likely to quit 
conventional cigarettes (with no uptake of e-cigarettes) 
than those with lower levels of education and persons with 
less income, respectively.
According to 2013–2014 data from the NATS, 
among former smokers who quit during the past year 
and had ever used e-cigarettes, 45.9% had completely 
switched to e-cigarettes from conventional cigarettes at 
some time during the past 12 months (NATS, public use 
data, 2013–2014). Among the recent former smokers who 
reported having switched to e-cigarettes during the past 
year, 66.0% were current e-cigarette users (NATS, public 
use data, 2013–2014). In contrast, among recent former 
smokers who had ever used e-cigarettes but did not 
report switching to e-cigarettes during the past year, just 
13.4% were current e-cigarette users (NATS, public use 
Figure 2.13 Prevalence of use of counseling or medications for cessationa among adult smokers 18 years of age and 
older, by race/ethnicity; National Health Interview Survey (NHIS) 2000–2015; United States
Source: NHIS, National Center for Health Statistics, public use data, 2000, 2005, 2010, and 2015.
aFor 2010 and 2015, used one-on-one counseling; a stop-smoking clinic, class, or support group; telephone helpline or quitline; 
nicotine patch, nicotine gum, or lozenge; nicotine-containing nasal spray or inhaler; or varenicline (U.S. trade name Chantix) and/or 
bupropion (including trade names Zyban and Wellbutrin) during the past year among current smokers who tried to quit during the 
past year or among former smokers who quit during the past 2 years. For 2005, the list included a nicotine tablet and excluded var-
enicline, as that drug was not approved by the Food and Drug Administration until 2006. For 2000, the list included a stop-smoking 
program and excluded a stop-smoking class or support group, nicotine lozenge (not approved by the Food and Drug Administration 
until 2002), and varenicline.
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data, 2013–2014). In their analysis of data from the PATH 
Study, Harlow and colleagues (2018) found that cigarette 
smokers at Wave 1 who reported new use of e-cigarettes at 
Wave 2 had almost the same prevalence of quitting ciga-
rettes from Wave 1 to Wave 2 (8.06%) as those who did 
not begin using e-cigarettes at Wave 2 (8.42%). However, 
using multivariate logistic regression models, Berry and 
colleagues (2019) found that adult cigarette smokers who 
initiated daily e-cigarette use at Wave 1 had 7.88 times the 
odds of having quit cigarette smoking at Wave 2 than those 
who did not use e-cigarettes. In contrast, adult cigarette 
smokers who initiated experimental e-cigarette use (cur-
rent e-cigarette use but no regular use) were less likely 
to quit cigarette smoking than those who were not using 
e-cigarettes (OR  =  0.51; 95%  CI, 0.26–1.00). Similarly, 
findings from Wave 1 to Wave 2 of the PATH Study indi-
cated that cigarette smokers who were daily e-cigarette 
users at Wave  1 had higher odds of quitting cigarette 
smoking at Wave 2 (OR = 1.56; 95% CI, 1.12–2.18) than 
never e-cigarette users. But among men, former ciga-
rette smokers who were daily or nondaily e-cigarette users 
at Wave  1 were more likely than men who were never 
e-cigarette users to relapse to cigarette smoking at Wave 2 
(OR = 2.96; 95% CI, 1.49–5.86 and OR = 3.05; 95% CI, 
1.29–7.17, respectively) (Verplaetse et al. 2018).
According to the 2014–2015 TUS-CPS data, more 
cigarette smokers reported switching to e-cigarettes 
(31.2%) in an attempt to quit than switching to smoke-
less tobacco (5.4%), switching to cigars or pipes (2.7%), or 
using the Internet or a web-based program or tool (2.1%) 
(Table  2.24). The estimate for switching to smokeless 
tobacco in an attempt to quit cigarette smoking is similar 
to that from the 2013–2014 NATS, where 4.9% of former 
cigarette smokers who had quit during the past year had 
switched to smokeless tobacco to quit smoking (NATS, 
public use data, 2013–2014). According to data from the 
2014–2015 TUS-CPS, higher percentages of men than 
women switched to cigars or pipes in an attempt to quit 
(4.0% vs. 1.5%) or switched to smokeless tobacco in an 
attempt to quit (7.7% vs. 3.0%) (Table 2.24). Also, 18- to 
24-year-old smokers were more likely to switch to smoke-
less tobacco in an attempt to quit than smokers who were 
45 years of age and older. In addition, persons living below 
the poverty level were more likely to switch to cigars or 
Figure 2.14 Quarterly, inflation-adjusteda dollar sales of over-the-counter nicotine replacement therapy, by type; 
Quarter 2, 2014–Quarter 4, 2018; United States
Source: FDA CTP’s licensed Nielsen Retail Measurement Services data.
Note: Nielsen Retail Measurement Services data, including projected sales from expanded all outlet combined and convenience stores. 
Types of outlets include food and grocery stores, drug stores, mass merchandizers, club stores, dollar stores, military commissaries, 
and convenience stores. Data do not include food stores with annual sales volume <$2 million, certain specialty food stores, drug 
stores with annual volume <$1 million, certain club stores, certain dollar stores, and Internet sales (including those from point-
of-sale retailers). Data do not include the category of “other” NRT, which represented 0.07% of sales during this period. Nielsen did 
not participate in the data analysis, summary, or interpretation. CTP = Center for Tobacco Products; FDA = U.S. Food and Drug 
Administration; NRT = nicotine replacement therapy.
aAdjusted to 2018 dollars using data from the Bureau of Labor Statistics on the Consumer Price Index for all items.
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pipes (3.9%) in an attempt to quit than those living at or 
above the poverty level (2.4%). Finally, smokers with an 
undergraduate degree (4.1%) were more likely to use the 
Internet for help with cessation than those with a high 
school education or less.
Although the estimate for use of specific Internet or 
web-based programs or tools for quitting smoking was low 
(2.1%) in the 2014–2015 TUS-CPS (Table 2.24), according 
to the 2017 HINTS, 43.7% of current cigarette smokers 
who were 18  years of age and older and were Internet 
users had used the Internet during the past 12  months 
to look for information about quitting smoking. Of note, 
the HINTS did not ask whether they used specific Internet 
programs or tools in their quit attempt (Graham and 
Amato 2018).
Data from the 2010–2011 TUS-CPS assessed different 
cessation strategies from those described above for the 
2014−2015 version. According to the 2010–2011 TUS-CPS, 
the most common cessation strategy among smokers who 
had tried to quit during the past year was trying to quit 
abruptly (78.0%), followed by gradually reducing consump-
tion (43.0%) and receiving help from friends and family 
(32.4%) (Schauer et  al. 2015). In the 2013–2014 PATH 
Study, the three most prevalent cessation methods among 
current smokers who tried to quit in the past 12 months 
and former smokers who quit during the past 12 months 
were unaided quit attempts (i.e., no reported use of sup-
port or cessation strategy) (47.1% and 47.7%, respectively), 
support from friends and family (18.7% and 16.5%, respec-
tively), and use of other tobacco products (18.3% and 
24.8%, respectively) (Rodu and Plurphanswat 2017).
Young Adults
According to the 2014–2015 TUS-CPS, the preva-
lence of young adults’ (18–24 years of age) use of other ces-
sation strategies, including switching to another tobacco 
product and using the Internet, was similar to the esti-
mates for adults overall (Table  2.24). Similar to the case 
with adults overall, no differences in use were observed by 
race/ethnicity and geographic region among young adults; 
however, estimates were of low statistical precision for other 
cessation strategies among young adults, and e-cigarette 
use could not be examined by poverty status because esti-
mates were of low precision (relative standard error ≥30%) 
and statistically unstable (TUS-CPS, public use data, 2014–
2015). In contrast to findings for all adults (Table 2.24), the 
prevalence of switching to e-cigarettes in an attempt to quit 
cigarette smoking among young adults did not differ by sex 
(men: 38.7%; 95% CI, 33.1–44.3; women: 39.8%; 95% CI, 
33.8–45.8) (TUS-CPS, public use data, 2014–2015).
Youth
Unlike surveillance systems for adults, surveillance 
systems that focus on youth do not assess whether ciga-
rette smokers in that age group who were trying to quit 
during the past year had switched to another tobacco 
product. However, in the 2017 NYTS, among youth who 
had ever used e-cigarettes, an estimated 5.3% of middle 
school students (grades 6–8) and 5.6% of high school stu-
dents (grades 9–12) reported one of the reasons they had 
used e-cigarettes was to try to quit using other tobacco 
products (NYTS, public use data, 2017).
Key Disparities in Cessation Among Adults
In addition to the disparities in key measures of ces-
sation by age, race/ethnicity, geographic region, status 
of health insurance, and sexual orientation that were 
described previously, important disparities exist by the 
amount and frequency of cigarette smoking and other 
health-related and demographic factors (Babb et al. 2017).
With regard to the frequency of cigarette smoking, 
in 2015, current daily smokers who smoked >25 cigarettes 
per day had a lower prevalence of being interested in quit-
ting (55.6%) than current some-day smokers (71.0%) and 
daily smokers of 1–14  cigarettes per day (daily, 1–4  cig-
arettes per day: 71.8%; daily, 5–14  cigarettes per day: 
68.8%) (Table  2.22). In addition, in 2017, current daily 
smokers who smoked >25 cigarettes per day had a lower 
prevalence of a past-year quit attempt (29.5%) than some-
day smokers (58.5%) and daily smokers of lesser amounts 
(daily, 1–4 cigarettes per day: 59.8%; daily, 5–14 cigarettes 
per day: 49.8%; daily, 15–24 cigarettes per day: 30.2%). In 
contrast, in 2017, both the prevalence of having received 
advice to quit and use of counseling and/or medication 
for cessation increased with the frequency and amount of 
smoking. Current some-day smokers had the lowest prev-
alence of using counseling and/or medications (24.2% vs. 
46.7% for daily smokers who smoked 25  or more ciga-
rettes per day), a finding likely related to (a)  their lower 
prevalence of receiving advice from a health professional 
and (b) the lack of evidence for medication utilization by 
some-day smokers (Fiore et al. 2008).
Persons who had serious psychological distress, a 
smoking-related chronic disease, or a disability/limitation 
were more likely to receive a health professional’s advice 
to quit than those without these conditions (70.1%  vs. 
55.7%, 67.3% vs. 64.8%, and 71.8% vs. 53.6%, respectively) 
(Table 2.22). This may be because such persons have more 
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contact with the healthcare system and because quitting 
could improve, or avoid exacerbating, conditions that are 
related to smoking. Those who had serious psychological 
distress or a disability/limitation were more likely to use 
cessation treatments than those without such conditions 
(41.6% vs. 30.1% and 39.0% vs. 28.5%, respectively).
Disparities also exist in rates of quitting smoking 
while pregnant. In a study based on birth certificates, 
which included 46  states and the District of Columbia, 
10.9% of women who gave birth in 2014 smoked during the 
3 months before pregnancy (Curtin and Mathews 2016). 
Of these women, 24.2% reported smoking no cigarettes 
during each trimester of pregnancy and thus presum-
ably quit before becoming pregnant, and 20.6% of women 
who smoked in the first or second trimesters quit by the 
third trimester. By level of education, cessation during the 
3 months before pregnancy was lowest among those with 
less than a high school education (14.1%) and highest 
among those with a bachelor’s degree or more education 
(53.7%). By insurance status, cessation was lowest among 
those with Medicaid insurance or who self-paid (18.9% 
and 17.3%, respectively) and highest among those with 
private insurance (38.3%). In addition, Asian women ciga-
rette smokers were more than twice as likely to quit during 
the 3 months before their pregnancy (45.0%) as American 
Indian or Alaska Native women (21.8%). In an analysis of 
data from the PATH Study, Kurti and colleagues (2018) 
observed that, among nonpregnant women, 18–44 years 
of age who used tobacco at Wave 1 and became pregnant 
at Wave  2, 98.3% had quit hookah use, 88.0% had quit 
cigar use, 81.3% had quit e-cigarette use, and 58.7% had 
quit any tobacco use. The prevalence of quitting hookah, 
cigars, and e-cigarettes was higher than the prevalence of 
quitting cigarettes (53.4%).
Residing in a rural or nonmetropolitan area as 
opposed to an urban area or a metropolitan area is also 
associated with cessation-related disparities. According 
to the 2017 BRFSS, the quit ratio (see the “Quit Ratio” 
section earlier in this chapter) and the prevalence of a 
past-year quit attempt were significantly lower among 
cigarette smokers who lived in micropolitan (54.8% and 
61.1%, respectively) and rural (54.8% and 62.2%, respec-
tively) counties than among those who lived in large fringe 
(62.8% and 66.2%, respectively) or large central metro-
politan areas (59.9% and 68.2%, respectively) (Table 2.26). 
Quit ratios were also lower among persons in micropol-
itan and rural counties than among those in small and 
medium metropolitan counties, and prevalence of a past-
year quit attempt was also lower among persons in micro-
politan counties than among those in medium metropol-
itan counties. In addition, recent successful cessation was 
significantly higher among persons living in large metro-
politan fringe areas (5.9%) compared with those living in 
micropolitan (4.3%) counties.
Table 2.26  Percentage of ever cigarette smokers 18 years of age and older who quit smoking (quit ratio)a and 
prevalence of recent successful cessationb and a past-year quit attempt,c by urban or rural status; 
Behavioral Risk Factor Surveillance System (BRFSS) 2017; United States
  Quit ratio: % (95% CI)
Recent successful cessation: 
% (95% CI)
Past-year quit attempt: 
% (95% CI)
Overall 59.3 (58.8–59.8) 5.3 (5.0–5.7) 65.5 (64.7–66.2)
Large metropolitan center 59.9 (58.6–61.1) 5.8 (5.0–6.7) 68.2 (66.5–69.9)
Large fringe metropolitan 62.8 (61.8–63.8) 5.9 (5.2–6.7) 66.2 (64.7–67.6)
Medium metropolitan 59.4 (58.5–60.3) 5.1 (4.6–5.8) 65.3 (63.9–66.6)
Small metropolitan 57.5 (56.3–58.7) 5.1 (4.5–5.9) 63.8 (62.0–65.6)
Micropolitan 54.8 (53.6–56.1) 4.3 (3.6–5.1) 61.1 (59.4–62.9)
Noncore 54.8 (53.4–56.2) 4.5 (3.8–5.3) 62.6 (60.7–64.5)
Source: BRFSS, Centers for Disease Control and Prevention, public use data, 2017.
Notes: CI = confidence interval. A metropolitan statistical area is defined as a group of counties that contain at least one urbanized area 
of 50,000 or more inhabitants. A micropolitan statistical area is defined as a group of counties that contain at least one urban cluster of 
at least 10,000 but less than 50,000 inhabitants.
aQuit ratio is calculated as the proportion of current smokers who reported having stopped smoking for >1 day during the past year 
because they were trying to quit smoking, and former smokers who quit smoking during the past year (numerator), among all current 
and former smokers who only quit in the past year (denominator).
bThe percentage of former smokers who quit smoking for >6 months during the past year among current smokers and former smokers 
who quit during the past year.
cCurrent smokers who reported that they stopped smoking for >1 day during the past 12 months because they were trying to quit 
smoking and former smokers who quit during the past year.
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In the United States, 61.7% of adults who have 
ever been a cigarette smoker have now quit, highlighting 
the marked progress in smoking cessation observed 
in this chapter. Among adults, past-year quit attempts 
and recent (i.e.,  recent successful cessation) and longer 
term (i.e., quit ratio) cessation measures have increased 
over the past 2 decades. Nevertheless, survey data indi-
cate that several subpopulations—including those with 
less education, racial/ethnic minorities, and those who 
are older in age—are less likely to try to quit each year 
than those in the general population. These disparities, in 
turn, may be affected by other variables, such as receiving 
advice from a health professional to quit smoking, using 
evidence-based resources, and patterns and frequency of 
cigarette smoking.
Disparities across cessation-related variables existed 
by level of educational attainment, which is closely cor-
related with income, poverty, overall socioeconomic 
status, status of health insurance, and geographic loca-
tion. Notably, smokers with the lowest levels of education 
(<12 years or GED certificate) had significantly lower quit 
ratios compared with smokers with the highest levels of 
education (undergraduate or graduate degree).
These socioeconomic disparities also may be partly 
explained by emerging geographic disparities, given that 
rural populations, who tend to have lower socioeconomic 
status (U.S. Department of the Census 2016), have lower 
quit ratios and a lower prevalence of recent successful ces-
sation than metropolitan populations, despite having a 
similar prevalence of past-year quit attempts. In addition, 
quit ratios and the prevalence of recent successful cessa-
tion and past-year quit attempts vary widely across U.S. 
states and territories. These variations might be linked 
to differences in state and local tobacco control policies, 
healthcare coverage and policies, and historical relation-
ships of resident populations with tobacco (e.g., growers 
of tobacco). Tobacco growing, pervasive tobacco adver-
tising and marketing (e.g.,  sponsorships of rodeos and 
auto races), and more prevalent exposure to secondhand 
smoke in public and private settings may also be influen-
tial environmental factors that make quitting more diffi-
cult among rural residents compared with urban residents 
(Chaloupka et al. 2002; Roeseler et al. 2010; USDHHS 2011; 
Vander Weg et al. 2011). Rural areas may also have fewer 
resources, including a more limited capacity to implement 
comprehensive tobacco control programs (American Lung 
Association 2012).
Persons of lower socioeconomic status, including 
lower levels of education, have a higher incidence of 
lung cancer and other tobacco-related diseases than 
persons in higher socioeconomic groups (Clegg et  al. 
2009; Singh et al. 2011), making persons of lower socio-
economic status a critical population for treating nico-
tine dependence. Challenges to quitting smoking among 
this subpopulation may include heavier patterns of ciga-
rette smoking and earlier initiation (Siahpush et al. 2010; 
Ham et al. 2011). In addition, predatory marketing by the 
tobacco industry, reflected in part by an increased density 
of retail outlets and more retail and point-of-sale promo-
tions in low-income areas, may contribute to an environ-
ment that is challenging for successful cessation (Brown-
Johnson et  al. 2014; Center for Public Health Systems 
Science 2014, 2016).
Disparities also exist by race/ethnicity. For example, 
Black adult smokers have a higher prevalence of past-
year quit attempts than White adult smokers. However, 
prevalence of recent successful cessation does not vary 
by race/ethnicity, suggesting that a higher percentage of 
Black adults are trying to quit cigarette smoking than 
White adults but are less successful. This may also be 
reflected in the lower quit ratio among Blacks compared 
with Whites. The use of menthol cigarettes may play a 
role in this disparity, as Black smokers are more likely to 
use menthol cigarettes than other racial/ethnic groups 
(Giovino et  al. 2015); however, research findings on the 
relation between menthol use and successful cessation are 
mixed (Delnevo et al. 2011; Levy et al. 2011; Keeler et al. 
2017). Although data presented in this chapter show that 
Blacks who smoke menthol cigarettes are just as likely 
to try to quit smoking as those who do not smoke men-
thol cigarettes (Table 2.12), menthol use might increase 
dependence on nicotine and make quitting more difficult 
(Hoffman and Simmons 2011). In addition, similar to tar-
geting populations with low socioeconomic status, pred-
atory marketing by the tobacco industry is common in 
geographic areas with large numbers of Black residents, 
which may negatively influence cessation (Yu et al. 2010; 
Richardson et al. 2015; Alexander et al. 2016).
Age is another demographic factor with pronounced 
cessation disparities. To date, both past-year quit attempts 
and recent successful cessation decrease as adult cigarette 
smokers’ ages increase. Although quitting smoking at any 
age is beneficial, smokers who quit by the time they are 
35–44 years of age avoid most of the risk of dying from a 
smoking-related disease (Doll et al. 2004; Jha et al. 2013). 
Continued public health strategies that specifically target 
adults 45 years of age and older are needed to increase quit 
attempts, given the inverse relationships between age and 
both quit attempts and the prevalence of recent successful 
cessation. In addition, among youth, trends in past-year 
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quit attempts have remained stable or slightly declined, 
depending on the data source. More research is needed to 
better understand how the growing use of other tobacco 
products will affect cigarette smoking cessation and to 
assess cessation from other tobacco products that youth 
and young adults are using regularly.
Factors contributing to the previously noted dis-
parities could also be affected by a health professional’s 
advice to quit tobacco and by the use of evidence-based 
cessation approaches, such as counseling and medica-
tion. For example, receiving advice from a health profes-
sional to quit smoking and using evidence-based cessation 
resources increased from 2000 to 2015; however, 42.8% 
of cigarette smokers who saw a healthcare professional 
during the past year did not receive advice to quit, and 
less than one-third (31.2%) of cigarette smokers who tried 
to quit during the past year used evidence-based cessa-
tion resources. Cigarette smokers younger than 45 years 
of age were less likely than older cigarette smokers to be 
advised to quit or to use an evidence-based cessation treat-
ment. One potential explanation for these findings is that 
young adult cigarette smokers are more likely than older 
smokers to be some-day smokers (also called intermittent 
or nondaily smokers) and light daily smokers (smoking 
<5 cigarettes per day) (Babb et al. 2017).
Data presented previously in this chapter suggest 
that light daily and some-day smokers are among the most 
interested in quitting, and they have the highest preva-
lence of past-year quit attempts. Nevertheless, many do 
not consider themselves to be smokers (Levinson et  al. 
2007; Smith et  al. 2012) and, thus, may not be identi-
fied as a smoker by clinical screening. Furthermore, light 
daily and nondaily smokers may be able to abstain from 
cigarettes on some days but continue smoking on other 
days. As discussed in Chapter  6, existing clinical guid-
ance concludes that there is insufficient evidence for the 
use of pharmacotherapy to assist with cessation in light 
smokers (Fiore et  al. 2008). Given these challenges and 
the increasing prevalence of some-day and light daily 
smokers, new approaches may be needed to help persons 
in these subgroups quit successfully.
Clinical interventions may also play an important 
role in helping youth quit smoking cigarettes. Although 
screening for tobacco use among 11-  to 17-year-olds is 
fairly high in ambulatory care settings (71.5%), only 
approximately 20% of tobacco users were provided assis-
tance for tobacco cessation (Jamal et al. 2014). The 2008 
update of the Clinical Practice Guideline on Treating 
Tobacco Dependence recommends that clinicians provide 
counseling interventions to aid youth smokers in quitting 
(Fiore et al. 2008). Far less is known about how to help 
youth quit compared with how to help adults, and use of 
effective cessation strategies is lower among youth than 
adults (Fiore et  al. 2008). Because many youth, like the 
young adults discussed previously, are some-day smokers, 
more research is needed on how to address these occa-
sional users and on effective and appropriate clinical 
interventions for youth overall.
Data presented in this chapter suggest that fewer 
than 2 of every 3 of adult smokers who saw a healthcare 
provider in the past year were advised to quit smoking, 
fewer than 1  of every 3  reported using cessation medi-
cations to help them quit, and fewer than 1  of every 
10 reported using counseling. Taken together, these find-
ings reinforce the need for the implementation of addi-
tional public health interventions that aim to increase ces-
sation counseling in clinical settings and the number of 
quit attempts among adults and youth (Fiore et al. 2008; 
The Community Guide 2014).
Encouraging and helping tobacco users to quit 
remains the quickest approach to reducing tobacco-related 
disease, death, and healthcare costs (Institute of Medicine 
2007), including through both individual (see Chapter 6) 
and population-based (see Chapter  7) interventions. 
However, as is noted in this chapter, use of tobacco ces-
sation resources among persons who use tobacco remains 
low: among adults, 18 years of age and older, only 29.0% 
used cessation medication, just 6.8% used any counseling, 
and only 4.1% used a telephone-based quitline, which is a 
freely available resource in all states (see Chapter 6). Use 
of counseling and/or medication was lower among young 
adults (16.6%) than among all adults (31.2%) (Babb et al. 
2017). To further increase cessation among adults and 
youth, public health efforts can continue the aforemen-
tioned strategies and encourage healthcare providers 
to consistently identify smokers, advise them to quit, 
and offer them cessation treatments (Fiore et  al. 2008; 
U.S. Preventive Services Task Force 2015). Nevertheless, 
it  is also important to recognize that a majority of cig-
arette smokers who quit do so without using evidence-
based treatments. As is described in Chapter  6, identi-
fying ways to continue to promote quit attempts to help 
cigarette smokers in quitting, even among those who do 
not intend to use treatment or are not interested in using 
treatment, is still needed. Furthermore, continuing to 
include questions in population-based surveys to assess 
(a)  the prevalence of tobacco screening and interven-
tions and (b) the proportion of smokers who use cessation 
counseling and medication is needed for ongoing tracking 
of smokers’ engagement with evidence-based treatments 
that can improve the odds of quitting and staying quit.
Importantly, this chapter’s review of epidemiologic 
data focused on cigarette smoking because measures 
of other tobacco product use and cessation are limited. 
Therefore, many of the analyses centered on cigarettes may 
underestimate the impact that the use of other tobacco 
A Report of the Surgeon General
104  Chapter 2
products, such as little cigars and e-cigarettes, has on 
tobacco cessation. Although limited national surveillance 
data are available on cessation of noncigarette tobacco 
products, survey data indicate that adult cigarette smokers 
who use cigars, smokeless tobacco, and/or pipes are less 
likely to try to quit all tobacco products than to try to quit 
cigarette smoking; however, this is not the case among 
young adult cigarette smokers, who are as likely to try to 
quit all tobacco products as they are to try to quit cigarette 
smoking (NYTS, public use data, 2017). Polytobacco use, 
which is the use of two or more tobacco products, is now 
common (3.7% in 2017) (Wang et  al. 2018a), especially 
among youth and young adults (USDHHS 2014), and 
e-cigarettes have been the most prevalent tobacco product 
used among middle and high school students since 2014 
(Wang et al. 2018b). Therefore, enhanced national surveil-
lance of both use and cessation of these tobacco products 
is warranted (USDHHS 2014), Since the PATH Study is 
a nationally representative, longitudinal cohort study of 
adults and youth 12 years of age and older, it will continue 
to contribute key information on patterns of use of these 
tobacco products, including initiation, cessation, relapse, 
and transitions between tobacco products (Hyland et  al. 
2017; Coleman et al. 2018; Kurti et al. 2018; Kypriotakis 
et  al. 2018; Lopez et  al. 2018). However, comprehensive 
surveillance of all of the diverse tobacco products being 
used by the American public is essential to effectively 
inform tobacco control policies, planning, and practices.
In addition, continued surveillance of the use of 
switching to other tobacco products by smokers who are 
trying to quit cigarettes is needed. Switching to smokeless 
tobacco and cigars as a quit strategy is relatively uncommon 
(see “Other Tobacco Products: Use and Cessation” in this 
chapter). However, switching to e-cigarettes in an attempt 
to quit cigarette smoking (34.7% in 2014−2015) was as 
popular a cessation strategy among those who tried to 
quit during the past year as was the use of counseling 
and/or the seven FDA-approved smoking cessation med-
ications (31.2% in 2015) (Fiore et  al. 2008; Babb et  al. 
2017), even though the efficacy of using e-cigarettes for 
smoking cessation is inconclusive. For example, switching 
to e-cigarettes in an attempt to quit cigarette smoking is 
the most prevalent cessation strategy among all demo-
graphic groups, despite the lack of clear evidence for the 
long-term effectiveness and safety of e-cigarettes as a ces-
sation approach (Hartmann-Boyce et al. 2016; Kalkhoran 
and Glantz 2016). More research is needed to better 
understand the patterns of usage of noncigarette prod-
ucts and their relationship with quitting cigarettes and 
all tobacco use. In addition, research is needed to under-
stand long-term outcomes among cigarette smokers who 
report switching to noncigarette products to quit ciga-
rette smoking, including dual usage, the substitution 
of noncigarette products use for cigarette smoking, and 
the potential use of noncigarette products as temporary 
cessation aids with eventual cessation of all tobacco use. 
The findings on the use of switching to another tobacco 
product to quit conventional cigarettes underscore the 
pressing need to (a) consider more effective and efficient 
ways to reach smokers with evidence-based cessation sup-
port and (b) continue to research the efficacy of emerging 
strategies to reduce combustible tobacco use.
Conclusions
1. In the United States, more than three out of every 
five adults who were ever cigarette smokers have 
quit smoking.
2. Past-year quit attempts and recent and longer term 
cessation have increased over the past 2  decades 
among adult cigarette smokers.
3. Marked disparities in cessation behaviors, such 
as making a past-year quit attempt and achieving 
recent successful cessation, persist across certain 
population subgroups defined by educational attain-
ment, poverty status, age, health insurance status, 
race/ethnicity, and geography.
4. Advice from health professionals to quit smoking has 
increased since 2000; however, four out of every nine 
adult cigarette smokers who saw a health professional 
during the past year did not receive advice to quit.
5. Use of evidence-based cessation counseling and/or 
medications has increased among adult cigarette 
smokers since 2000; however, more than two-thirds 
of adult cigarette smokers who tried to quit during 
the past year did not use evidence-based treatment.
6. A large proportion of adult smokers report using 
non-evidence-based approaches when trying to quit 
smoking, such as switching to other tobacco products.
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Appendix 2.1: Sources of Data
Data summarized in this chapter come from two 
national surveys, the National Health Interview Survey 
(NHIS) and the National Youth Risk Behavior Survey 
(YRBS) (Table 2.1), which are described below. After 
descriptions of NHIS and YRBS, brief summaries of other 
national surveys that provided limited information for this 
chapter are provided.
National Health Interview Survey
NHIS, a multipurpose survey conducted by the 
National Center for Health Statistics of the Centers for 
Disease Control and Prevention (CDC), is the principal 
source of information on the health of the civilian, non-
institutionalized population of the United States. NHIS 
has been conducted continuously since 1957. Questions 
on smoking have been included in selected survey years 
since 1965, and detailed items allowing classification by 
race/ethnicity have been included since 1978. Information 
on quit attempts among all cigarette smokers has been 
assessed since 1991. Detailed questions on tobacco use 
cessation are included in a CCS to NHIS, which was initi-
ated in 1987 and subsequently conducted in 1992, 2000, 
2005, 2010, and 2015, with relatively consistent ques-
tions on cessation included from 2000 to 2015. Face-to-
face interviews are used to collect confidential data from a 
representative sample of the population using the place of 
residence of individual respondents.
The sampling plan follows a multistage area prob-
ability design that permits the representative sampling 
of households and noninstitutional group living quarters 
(e.g., college dormitories) in all 50 states and the District 
of Columbia. Non-Hispanic African American or Black, 
Hispanic or Latino, and Asian persons were oversampled 
during 2006–2015. For each family included in NHIS, 
one sample child (younger than 18 years of age) and one 
sample adult are randomly selected, and information on 
each is collected. For children and those adults not capable 
of doing so, information is provided by a knowledgeable 
adult family member. Since 1974, only self-reports of cig-
arette smoking and use of other tobacco products have 
been used, and thus no proxy data have been used since 
that year on questions of importance to this report. Since 
1997, NHIS has been conducted using computer-assisted 
personal interviewing by interviewers from the U.S. 
Census Bureau; sampling and interviewing are continuous 
throughout each year. CDC (2017c) has detailed informa-
tion on NHIS questionnaires and sampling on its website.
Youth Risk Behavior Surveillance 
System
Developed in 1990 by CDC, the Youth Risk Behavior 
Surveillance System (YRBSS) monitors priority health 
risk behaviors, including past-year quit attempts among 
current cigarette smokers, among high school students 
in the United States. In addition to the surveys that are 
conducted by state, local, territorial, and tribal health 
and education agencies, there is the national YRBS con-
ducted by CDC. The current report includes data from 
the national YRBS only, which has a sampling frame of 
all public and private school students in grades 9–12 in 
the 50 states and the District of Columbia. A three-stage 
cluster sample design is used to sample (1)  large-sized 
counties or groups of smaller adjacent counties, (2) public 
and private schools with a probability proportional to the 
schools’ enrollment, and (3) one or two randomly selected 
classes in each grade. Examples of classes include home-
rooms, classes of a required discipline (e.g.,  English or 
social studies), and all classes meeting during a required 
period (e.g., second period). All students in a sampled class 
are eligible to participate. Oversampling is used to achieve 
sufficiently large subsamples of Black or African American 
and Hispanic or Latino students to enable separate anal-
yses of these subgroups. Schools that decline to participate 
in the original sample are not replaced. Students complete 
self-administered, paper-and-pencil questionnaires and 
record their answers directly in the questionnaire booklet 
(CDC 2013). Local procedures to obtain the permission 
of parents are followed. Trained personnel administer the 
questionnaires to students in their classrooms for the 
national survey. The participation of students is both vol-
untary and anonymous (CDC 2013).
Tobacco Use Supplement to the 
Current Population Survey
The Tobacco Use Supplement to the Current 
Population Survey (TUS-CPS) is a National Cancer 
Institute-sponsored survey of tobacco use that has been 
administered as part of the U.S. Census Bureau’s Current 
Population Survey approximately every 3–4 years since 
1992–1993 (since 2000, surveys were conducted for 2001–
2002, 2003, 2006–2007, 2010–2011, and 2014–2015). In 
each cycle, the TUS-CPS collects nationally representative 
data from about 240,000 adults (data collected between 
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1992 and 2006 also included youth 15–17 years of age). 
About two-thirds of respondents complete the question-
naire by telephone, and responses for the remaining one-
third are obtained through in-person interviews. More 
detailed information about the TUS-CPS is available from 
the National Cancer Institute (NCI) (n.d.b).
Behavioral Risk Factor Surveillance 
System
In 1984, CDC initiated the state-based Behavioral 
Risk Factor Surveillance System (BRFSS), a cross-sectional 
telephone survey that state health departments conduct 
monthly over landline and cellular telephones (included 
since 2011), using a standardized questionnaire and tech-
nical and methodologic assistance provided by CDC. The 
BRFSS is used to collect data among U.S. adults 18 years 
of age and older regarding their risk behaviors and preven-
tive health practices that can affect their health status. Data 
from respondents are forwarded to CDC to be aggregated 
for each state, returned with standard tabulations, and pub-
lished at year’s end by each state. In 2011, BRFSS adopted 
new methods, including the addition of cellular tele-
phone households to its sample, and used new methods of 
weighting to adjust survey data for differences between the 
demographic characteristics of respondents and the survey 
population (CDC 2012). As a result of these methodologic 
changes, data from 2011 to 2017 cannot be compared with 
years before 2011. In 2017, more than 450,000 interviews 
were conducted with respondents from all 50  states, the 
District of Columbia, and participating U.S. territories 
and other geographic areas. The number of completed 
interviews at each site ranged from 1,508  to 22,059,  and 
the median response rate was 45.9%. For this Surgeon 
General’s report, data have been weighted to reflect the 
age, race/ethnicity, and sex distribution of each partici-
pating state. CDC (2017a) offers detailed information about 
the BRFSS.
National Adult Tobacco Survey
The 2013–2014 National Adult Tobacco Survey 
(NATS)—a stratified, random-digit-dialed (RDD), tele-
phone survey of noninstitutionalized adults 18 years of age 
and older—was conducted from October 2013 to October 
2014. The survey was part of a collaborative effort between 
CDC and the U.S. Food and Drug Administration (FDA). 
The survey sought to determine the prevalence and cor-
relates of tobacco use behaviors among a nationally rep-
resentative sample of U.S. adults. The 2013–2014 NATS 
included 75,233 respondents (70% landline, 30% cellular), 
and the overall response rate was 36.1% (47.6%, landline; 
17.1%, cellular). Data were weighted to provide nationally 
representative estimates of prevalence. Detailed informa-
tion on NATS is available at CDC (2016).
National Ambulatory Medical Care 
Survey
The National Ambulatory Medical Care Survey 
(NAMCS), conducted by CDC’s National Center for Health 
Statistics, is a survey designed to meet the need for objec-
tive, reliable information about the provision and use of 
ambulatory medical care services in the United States. 
Findings are based on a sample of visits to nonfederal, 
office-based physicians who are primarily engaged in 
direct patient care. Abstraction of medical records includes 
documentation of screening for tobacco use, counseling 
on tobacco cessation in the form of health education 
ordered or provided during the visit, and tobacco cessa-
tion medications ordered or continued during the visit. 
In 2009, 32,281 records were abstracted from a sample of 
3,319 physicians, with a response rate of 62.4% (in 2010, 
31,229 records were abstracted from a sample of 3,525 phy-
sicians, with a response rate of 57.3%, and in 2011, 
30,872 records were abstracted from a sample of 3,819 phy-
sicians, with a response rate of 54.1%). CDC (2017b) offers 
on its website more detailed information about NAMCS.
Population Assessment of Tobacco 
and Health Study
The Population Assessment of Tobacco and Health 
(PATH) Study was launched in October 2011 through 
a collaboration between the FDA Center for Tobacco 
Products and the National Institutes of Health, National 
Institute for Drug Abuse. PATH is a nationally represen-
tative, longitudinal cohort study that uses computer-
assisted interviews to collect information from approxi-
mately 49,000 current, never, and former tobacco users, 
including noninstitutionalized youth (12–17 years of age) 
and adults (18 years of age and older). The study also col-
lects biospecimens (i.e., buccal cell, urine, blood) from 
consenting adults. Wave  1 of data collection was com-
pleted in 2014 (September 2013–December 2014), and 
four subsequent waves have been completed: Wave  2 
(October 2014–October 2015), Wave  3 (October 2015–
October 2016), Wave 4 (December 2016–November 2017), 
and an additional wave among only 12-  to 17-year-old 
youth (December 2017 to November 2018).
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The goal of the Path Study is to monitor and assess 
behavioral and biological between-person differences and 
within-person changes over time in tobacco product use 
patterns and behaviors, attitudes and risk perceptions, 
tobacco-related biomarkers of exposure and harm, and 
health conditions. The findings may inform FDA regula-
tory activities related to product standards (e.g., toxicity, 
appeal, abuse liability/addictiveness), health warnings, 
and the authorization of new and modified risk tobacco 
products, as well as FDA’s public education efforts.
Health Information National Trends 
Survey
The Health Information National Trends Survey 
(HINTS) was developed by the Health Communication 
and Informatics Research Branch of the Division of Cancer 
Control and Population Sciences of NCI. The HINTS is a 
biennial, cross-sectional survey that routinely collects data 
about the use of cancer-related information, including 
information on quitting smoking, from a nationally rep-
resentative sample of adults 18 years of age and older in 
the civilian noninstitutionalized population of the United 
States. Data from the survey are used to assess the impact 
of the health information environment. There have been 
nine iterations of the HINTS: in 2003, 2005, 2007, 2011, 
2012, 2013, 2014, 2015, and 2017. The 2017 survey, which 
was used for this report, was conducted primarily by tele-
phone (95%) with incentives promised of either $0, $5, or 
$15 upon survey completion (there were 3,335 completed 
surveys, a 25.0% response rate). More detailed informa-
tion about the HINTS is available from NCI (n.d.a).
Monitoring the Future Study
The Monitoring the Future (MTF) Study, conducted 
annually since its inception in 1975, is conducted by the 
University of Michigan’s Institute for Social Research and 
supported through grants from the National Institute on 
Drug Abuse. The MTF—a study of American youth, col-
lege students, and adults through 45 years of age—moni-
tors changes in the beliefs, attitudes, and behaviors rele-
vant to drug use and other health and social issues among 
young persons in the United States. This report presents 
data on high school seniors from confidential, self-admin-
istered paper-and-pencil questionnaires used to survey 
nationally representative samples of 12th-grade students 
in public and private schools in 48 of the 50 states (all but 
Alaska and Hawaii). From 2011 to 2015, the years used in 
this report, sample sizes for the 12th-grade students (from 
121 to 129 schools) who participated in the MTF Study 
ranged from 13,015 to 14,855, and response rates ranged 
from 82% to 83% (Miech et al. 2016).
National Youth Tobacco Survey
The National Youth Tobacco Survey (NYTS) was devel-
oped by CDC to assist with the evaluation of the National 
Tobacco Control Program (NTCP) and state tobacco con-
trol programs. CDC and FDA have co-administered the 
survey since 2011. The NYTS, which provides nationally 
representative data on tobacco-related behaviors among 
middle school (grades 6–8) and high school (grades 9–12) 
students, was first conducted in fall 1999 and was subse-
quently conducted in 2000, 2002, 2004, 2006, 2009, and 
2011–2017. The NYTS sampling frame consists of all stu-
dents enrolled in public, Catholic, and other private middle 
schools and high schools (grades 6–12) in the 50  states 
and Washington, D.C. Participation is voluntary and anon-
ymous. Participants complete a self-administered paper-
and-pencil questionnaire and record their responses on 
a computer-scannable questionnaire booklet. For the 
NYTS years used in this report (2000, 2004, 2009, 2015, 
and 2017), sample sizes were as low as 17,711 and as high 
as  35,828; the number of participating schools ranged 
from 185 to 324; and response rates ranged from 63.4% 
to 84.8% (Office on Smoking and Health et al. 2001; CDC 
2010; Singh et al. 2016).
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Appendix 2.2: Measures of Cessation
Validity of Measures of Cessation 
Among Youth
All of the data on cessation among youth that are pre-
sented in this report are based on self-reported responses 
to questionnaires. Because tobacco use is viewed by many 
as a socially undesirable behavior, there is a risk of inaccu-
rate or dishonest responses. Because it was not feasible to 
verify the self-reported data included here, it is important for 
researchers to interpret these data with some caution and an 
understanding of possible sources of inaccuracy. Many fac-
tors can affect the validity of self-reported data—factors that 
can be categorized as cognitive or situational. Cognitive pro-
cesses that affect responses include comprehension of the 
question, retrieval of relevant information from memory, 
decision making about the adequacy of the information 
retrieved, and the generation of a response (Brener et al. 
2003). Each of these processes can contribute to errors in 
responses and, subsequently, to problems with validity.
Situational factors that affect the validity of self-
reported data refer to characteristics of the external envi-
ronment in which the survey is being conducted. These 
include the setting (i.e.,  school or home based), the 
method (i.e., self-administered questionnaire or in-person 
interview), the social desirability of the behavior being 
reported, and the perception of privacy and/or confidenti-
ality of responses (U.S. Department of Health and Human 
Services [USDHHS] 1994; Brener et al. 2003).
Many studies have found that youth are more likely 
to report engaging in sensitive behaviors when a survey is 
completed in a school setting rather than in their homes 
(Gfroerer et al. 1997; Hedges and Jarvis 1998; Kann et al. 
2002). A study that compared the school-based National 
Youth Risk Behavior Survey (YRBS) with the household-
based YRBS supplement to the National Health Interview 
Survey (NHIS) found that the school-based survey pro-
duced a significantly higher reporting of many sensi-
tive behaviors, such as driving after drinking alcohol, 
binge drinking, and current use of marijuana and cocaine 
(Brener et al. 2006). Four measures of various stages of the 
smoking uptake process were higher in the school-based 
survey, but estimates for current cigarette use and frequent 
cigarette use, although elevated in the school-based survey, 
did not differ significantly from estimates generated in the 
household-based survey. Few differences in nonsensitive 
behaviors were observed. Two other studies (Gfroerer et al. 
1997; Brener et al. 2003) indicated that, although estimates 
based on self-reports of current use of alcohol and illicit 
drugs were higher in school-based than in household-based 
surveys, estimates of current cigarette smoking were quite 
similar across settings. It is noteworthy that all three of 
these studies use self-administered rather than interviewer-
administered interviews/questionnaires. Nevertheless, the 
privacy that school surveys provide is important, espe-
cially if smoking becomes more socially unacceptable over 
time. Household-based surveys, however, are more likely 
to include youth who drop out of school or are frequently 
absent from school, and youth in these groups are more 
likely to smoke. In addition, the Population Assessment of 
Tobacco and Health (PATH) Study (which uses audio, com-
puter-administered self-interviews in a respondent’s house-
hold) recently conducted a reliability and validity study of 
current use of a variety of tobacco products among youth 
12–17 years of age, finding high levels of agreement across 
interviews conducted 6–24  days apart (Tourangeau et  al. 
2018). There was also a high level of agreement between 
self-reported current tobacco use and salivary cotinine 
tests among a combined sample of adults and youth (87.5% 
of the reports and tests agreed).
Overall, the factors described above may affect point 
estimates of cessation. If these factors remain stable over 
the years, however, they should not affect the trends seen 
over time.
Validity of Measures of Tobacco 
Use Among Adults
All of the data on tobacco use among adults pre-
sented in this report were based on self-reported responses 
to questionnaires. Biochemical validation studies suggest 
that data on self-reported cigarette smoking are generally 
valid, except in certain situations, such as when data are col-
lected in conjunction with intense smoking cessation pro-
grams or with certain populations, such as pregnant women 
(Velicer et al. 1992; Kendrick et al. 1995). Misclassification 
may also be more common among intermittent smokers, 
who may not classify themselves as smokers because they 
do not perceive themselves as being addicted or because of 
social desirability bias. Additionally, smokers may misreport 
the number of cigarettes they smoke per day because of 
“digit preference” (a preference for multiples of 10) (Klesges 
et  al. 1995). Although self-reported data have been found 
to adequately reflect cigarette smoking patterns (including 
whether a respondent who has smoked in the past is cur-
rently not smoking) (Connor Gorber et al. 2009; Wong et al. 
2012; Tourangeau et al. 2018), few studies have examined the 
validity of other cessation measures (Brigham et al. 2010; 
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Persoskie and Nelson 2013). It should be noted, however, 
that much of the research literature on the validity of self-
reported data is restricted to cigarette smoking—and not 
measures of cessation or other tobacco products. However, 
among adult tobacco users, a recent PATH Study found 
high levels of agreement at initial interview and subsequent 
re-interview 6–24 days later between self-reported current 
use of cigarettes, electronic nicotine products, traditional 
cigars, cigarillos, filtered cigars, pipes, snus, hookahs, and 
smokeless tobacco (Tourangeau et  al. 2018). High agree-
ment was also found for self-reported information on cur-
rent tobacco use and salivary cotinine among a combined 
sample of youth and adults (Tourangeau et al. 2018). Thus, a 
discussion of the factors that may affect validity is important 
so that the data presented in this report are interpreted with 
some caution and an understanding of possible sources of 
inaccuracy. Clearly, many factors can affect the validity of 
self-reported data, such as response biases and the particular 
methodologic features of the surveys. For example, method-
ologic differences in survey administration include but are 
not limited to timing, order of survey questions, sampling, 
mode of data collection (e.g.,  computer-assisted personal 
interviewing vs. computer-assisted telephone interviewing), 
participation rates, and operational definitions (Ryan et al. 
2012). In addition, responses to questions may be subject to 
more social desirability biases in surveys that are focused 
solely on tobacco use versus those where tobacco use is just 
one of several health behaviors being assessed, as research 
has found that the context in which sensitive questions are 
asked can effect responses to survey questions (Tourangeau 
and Yan 2007; Krumpal 2013).
Definitions
Measures of cessation differ between surveys of 
youth and those focused on adults. Three surveys (NHIS, 
Behavioral Risk Factor Surveillance System [BRFSS], 
and Tobacco Use Supplement to the Current Population 
Survey [TUS-CPS]) included in this chapter provide infor-
mation about cessation among adults and young adults, 
while three other surveys (YRBS, Monitoring the Future 
[MTF] Study, and National Youth Tobacco Survey [NYTS]) 
provide information about smoking among youth. For 
each smoking measure, the definitions used in the various 
surveys are summarized below.
Current and Former Cigarette Smoking
Adults and Young Adults
In NHIS from 1965 to 1991, current cigarette 
smokers were defined as respondents who had smoked at 
least 100 cigarettes and who answered “yes” to the question, 
“Do you smoke cigarettes now?” Beginning in 1992, NHIS 
assessed whether respondents smoked cigarettes every day, 
some days, or not at all. Persons who smoked every day 
or some days were classified as current cigarette smokers. 
Also in NHIS, former cigarette smokers were those 
who reported smoking at least 100 cigarettes during their 
lifetime but currently did not smoke.
Youth
The YRBS defines current cigarette smoking among 
students as having smoked cigarettes on at least 1 day 
during the 30 days before the survey. To be classified as a 
current smoker, students had to answer “yes” to questions 
about ever smoking and current smoking. In addition, stu-
dents who were current smokers and reported smoking on 
20 or more of the past 30 days were categorized as current 
frequent cigarette smokers. This measure was examined 
for youth because current frequent cigarette smokers most 
likely have a more established pattern of use and are more 
likely to smoke as adults, thereby potentially representing 
the future group of adult smokers who are trying to quit. 
Former smoking among youth in the YRBS was cat-
egorized as either (a) former daily smokers, representing 
those who had an established pattern of smoking daily 
but were not currently smoking and perhaps reflecting 
youth who had quit smoking; and (b)  former nondaily 
smokers, who may contain a higher proportion of youth 
who experimented with smoking, in addition to those 
who quit smoking. Students who answered “yes” to ever 
smoke and “no” to currently smoke were categorized as 
(a)  former daily smokers, if they answered “yes” to ever 
daily; or (b)  former nondaily smokers, if they answered 
“no” to ever daily.
Quit Ratio
Adults
In NHIS, the quit ratio is defined as the ratio of 
former smokers to ever smokers; ever smokers were those 
who had smoked at least 100 cigarettes in their lifetimes. 
Former smokers were defined as ever smokers who did not 
currently smoke at the time of the survey. Because smoking 
behaviors are less established among youth and young 
adults, this measure was not examined for those groups.
Recent Successful Cessation
Adults and Young Adults
In NHIS, the recent smoking cessation percentage 
includes in the numerator only former smokers who quit 
smoking 6–12 months ago (i.e., persons who reported 
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having smoked 100  cigarettes in their life but were not 
smoking at time of interview and had quit smoking 
6–12  months prior). The denominator for this measure 
includes both current smokers who smoked for at least 
2  years and former smokers who quit during the past 
year. This measure was not examined for youth. Because 
the BRFSS did not include a question about the length 
of time that current cigarette smokers had smoked, the 
estimate from BRFSS does not include this restriction 
in its denominator and, therefore, is not comparable to 
the estimate from NHIS. Nevertheless, when the restric-
tion of having smoked for at least 2 years is removed from 
the denominator in NHIS, the resulting estimate of the 
prevalence of recent successful cessation is 7.4% (95% CI, 
6.4–8.4%) (NHIS, NCHS, public use data, 2017), which is 
similar to the estimate with this restriction (7.6%, 95% 
CI, 6.6–8.6%) (Table 2.13).
Cessation Continuum
Using TUS-CPS data, a cessation continuum was 
constructed to more completely describe the dynamic 
process of smoking cessation. This measure was examined 
only for adult current smokers. The continuum included 
the proportion of current smokers who had ever tried to 
quit smoking, whether they had attempted to quit during 
the past year, and their current interest in quitting.
Past-Year Quit Attempts
Adults and Young Adults
NHIS defines past-year quit attempts among cur-
rent smokers as those who answer “yes” to, “During the 
past 12  months, have you quit smoking for one day or 
longer?” In the 1998 NHIS, the question was revised to, 
“During the past 12 months, have you stopped smoking 
for more than one day because you were trying to quit 
smoking?” This measure also includes former smokers 
who quit during the past year. It is important to note that 
in addition to excluding those who may have quit for 1 day 
during the past year, this measure does not include past-
year quit attempts of less than 1 day. Therefore, the mea-
sure may underestimate quit-attempt prevalence. Data 
from the 2014–2015 TUS-CPS indicated that among cur-
rent cigarette smokers, the prevalence of past-year quit 
attempts increased by 5.4 percentage points from 41.3% to 
46.7% when self-reported quit attempts of less than 1 day 
were included (Table 2.14). Questions defining past-year 
quit attempts in the 2014–2015 TUS-CPS included asking 
some-day smokers who smoked fewer than 12 days in the 
past 30 days, “During the past 12 months, have you tried 
to quit smoking completely?” and asking daily smokers 
and some-day smokers who smoked on 12 or more days 
during the past 30 days, “During the past 12 months, have 
you stopped smoking for one day or longer because you 
were trying to quit smoking?” Those who answered “no” 
to this question were asked, “During the past 12 months, 
have you made a serious attempt to stop smoking because 
you were trying to quit—even if you stopped for less than a 
day?” Quit attempts of less than 1 day comprised 12.9% of 
past-year quit attempts among current daily smokers and 
some-day smokers who smoked on 12 or more days during 
the past 30 days (TUS-CPS, public use data, 2014–2015).
It is also important to note that Table 2.14 estimates 
past-year quit attempt prevalence in 2014–2015 TUS-CPS 
only among current smokers and does not include former 
smokers who quit in the past year; therefore, the quit 
attempt prevalence in Table 2.14 (41.3%) is much lower 
than the quit attempt prevalence in Table  2.11, which 
is estimated from the 2015 NHIS and includes former 
smokers who quit during the past year (55.4%). However, 
the absence of former smokers who quit during the past 
year from the 2014–2015 TUS-CPS estimate does not 
entirely explain the difference in prevalence. In the com-
bined 2014–2015 NHIS among current smokers only, the 
quit attempt prevalence was 48.9% (NHIS, public use 
data, 2014–2015), which was still above the quit attempt 
prevalence of 41.3% among the same group in the 2014–
2015 TUS-CPS.
Youth
In the YRBS, students were asked the question, 
“During the past 12  months, did you ever try to quit 
smoking cigarettes?”
The NYTS defines past-year quit attempts as those 
made by current smokers who reported having tried to 
quit smoking for a day or longer during the past year.
Number and Duration of Quit Attempts
Adults and Young Adults
In the 2014–2015 TUS-CPS, among current daily 
smokers and some-day smokers who smoked at least 12 or 
more days during the past 30  days, the question, “How 
many TIMES during the past 12 months have you stopped 
smoking for one day or longer because you were trying to 
quit smoking?” was asked of those who responded “yes” 
to the question, “During the past 12  months, have you 
stopped smoking for one day or longer because you were 
trying to quit smoking?”
Duration of quit attempts was examined with the 
questions, “During the past 12 months, what is the length 
of time of this single quit attempt where you stopped 
smoking because you were trying to quit smoking” and 
“Thinking of those attempts during the past 12 months, 
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what was the length of time of the one attempt that lasted 
the longest?”
Youth
In the 2017 NYTS, middle and high school stu-
dents who were current smokers and had tried to quit 
smoking during the past year were asked, “During the 
past 12 months, how many times have you stopped using 
all tobacco products for one day or longer because you 
were trying to quit all tobacco products for good?” The 
response options were “I did not smoke cigarettes during 
the past 12  months,” “I did not try to quit during the 
past 12 months,” “1 time,” “2 times,” “3 to 5 times,” “6 to 
9 times,” and “10 or more times.”
Interest in Quitting
Adults and Young Adults
In the 2014–2015 TUS-CPS, among current daily 
and some-day smokers, interest in quitting was assessed 
using a 10-point scale. Participants were asked, “Overall, 
on a scale from 1 to 10, where 1 is not at all interested and 
10 is extremely interested, how interested are you in quit-
ting smoking?”
NHIS defines interest in quitting as current smokers 
who reported that they wanted to stop smoking completely. 
Youth
In the 2011–2015 MTF Study, interest in quitting 
was assessed by asking high school seniors who were 
current smokers whether they wanted to stop smoking 
“now.” Another measure included in this survey con-
cerned whether the smoker thought that he or she would 
be smoking in 5 years.
In the 2015 NYTS, interest in quitting was assessed 
by asking current smokers, “Are you seriously thinking 
about quitting cigarettes?”
Ever Tried to Quit Smoking
Adults and Young Adults
In the 2001–2002 TUS-CPS, estimates for ever 
trying to quit smoking relied on one question, “Have you 
ever stopped smoking for one day or longer because you 
were trying to quit smoking?” In other years, questions for 
current some-day smokers who had smoked fewer than 
12  days during the past 30  days were asked, “Have you 
ever tried to quit smoking completely?” and current daily 
smokers and some-day smokers who had smoked 12  or 
more days during the past 30 were asked, “Have you ever 
made a serious attempt to stop smoking because you were 
trying to quit—even if you stopped for less than a day?” 
For the 2006–2007 TUS-CPS, current daily smokers and 
some-day smokers who smoked 12 or more days during 
the past 30 days were also asked, “Have you ever stopped 
smoking one day or longer because you were trying to quit 
smoking?”
Youth
In the MTF Study, high school seniors who were 
current smokers were asked if they had ever tried to quit 
smoking.
Cessation of Other Tobacco Products
Adults and Young Adults
In NHIS, cessation of other tobacco products was 
examined using past-year quit attempts (“During the past 
12 months, have you stopped using all kinds of tobacco 
products for more than one day because you were trying 
to quit using tobacco?” “All kinds” meant trying to quit 
using tobacco completely, including smoking cigarettes, 
smoking products other than cigarettes, and using smoke-
less tobacco products.). This question was asked of cur-
rent cigarette smokers who used another tobacco product 
or who used two or more tobacco products.
Screening for Tobacco Use
Adults and Young Adults
Screening for tobacco use was examined using 
2009–2011 NAMCS data, based on abstraction of medical 
records for visits to office-based physicians during which 
current tobacco use (smoked cigarettes or cigars or used 
snuff or chewing tobacco) or no current use was recorded. 
The same measure was used for youth. Because of meth-
odologic changes, this chapter does not report the most 
recent NAMCS data (2012–2013).
Advice to Quit—Clinical Data from Abstractions 
of Medical Records
Adults and Young Adults
Using 2009–2011 NAMCS data, receipt of advice to 
quit was based on abstraction of medical records for visits 
to office-based physicians by identified current tobacco 
users (i.e., the patient was identified as a current tobacco 
user during screening). Receipt of advice is defined as 
visits where tobacco counseling was recorded. Tobacco 
counseling refers to any information provided that related 
to tobacco use in any form, including cigarettes, cigars, 
snuff, and chewing tobacco, and on exposure to tobacco 
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in the form of secondhand smoke, smoking cessation, and 
prevention of tobacco use, as well as referrals to other 
healthcare providers for smoking cessation programs. 
The same measure was used for youth. Because of meth-
odologic changes, this chapter does not report the most 
recent NAMCS data (2012–2013).
Advice to Quit—Self-Reported Data
Adults and Young Adults
In the 2015 NHIS, receipt of advice to quit was 
assessed among current smokers and former smokers who 
quit during the past year and also saw a doctor or other 
health professional during the past year. Receipt of advice 
to quit was defined as having been given advice from a 
medical doctor, dentist, or other health professional to quit 
smoking or to quit using other kinds of tobacco among 
current cigarette smokers and former smokers who quit 
during the past year.
Youth
In the 2013 NYTS, high school and middle school 
students were asked whether at any visit to a doctor, den-
tist, or nurse during the time covered by the survey, they 
had been asked by the provider whether they used tobacco 
that is smoked or put in the mouth. A separate measure, 
being advised not to use tobacco, was defined using cur-
rent cigarette smokers (smoked cigarettes during the 
30 days preceding the survey) as being advised by a doctor, 
dentist, or nurse during the past 12  months not to use 
tobacco that is smoked or put in the mouth.
Use of Counseling and Medications to Quit 
Smoking
Adults and Young Adults
To define the use of counseling, NHIS considers 
two groups, current smokers who tried to quit during the 
past year and former smokers who quit during the past 
2 years. Counseling is defined as having used one-on-one 
counseling; a stop-smoking clinic, class, or support group; 
and/or a telephone helpline or quitline during the past year, 
among current smokers who tried to quit in the past year 
and among former smokers who quit in the past 2 years. 
The 2014–2015 TUS-CPS asked current smokers who tried 
to quit during the past year about their use of a telephone 
helpline or quitline the last time they tried to quit.
NHIS defines use of medications as having used 
during the past year the nicotine patch, nicotine gum 
or lozenge, a nicotine-containing nasal spray or inhaler, 
varenicline (U.S. trade name Chantix), and/or bupropion 
(including trade names Zyban and Wellbutrin).
Youth
The 2000, 2004, and 2009 NYTS asked high school 
and middle school students if they did any of the fol-
lowing during the past 12 months to help themselves stop 
smoking: attend a program in their school, attend a pro-
gram in their community, call a helpline or quitline, use 
nicotine gum or lozenge, use a nicotine patch, and/or use 
any medication. (In 2000, the strategies of using nicotine 
gum and using a nicotine patch were asked together as 
one strategy.) The same cessation strategies were assessed 
in the 2015 NYTS but the question changed to, “In the 
past 12 months, did you do any of the following to help 
you quit using tobacco of any kind for good?” and the word 
“telephone” was added before “helpline” and “quitline.”
Use of Other Cessation Strategies
Adults and Young Adults
The 2014–2015 TUS-CPS asked current smokers 
who tried to quit during the past year about their use 
of the Internet or a web-based program or tool the last 
time they tried to quit. Current smokers were also asked 
if they did any of the following the last time they tried to 
quit: tried to quit by switching to (a) smokeless tobacco, 
such as chewing tobacco, snuff, or snus; (b) regular cigars, 
cigarillos, little filtered cigars, or any pipes filled with 
tobacco, and (c) electronic or e-cigarettes. The survey did 
not operationalize what switching meant (i.e., completely 
switching vs. dual use while reducing cigarette smoking).
Youth
The 2015 NYTS asked high school and middle school 
students if they had tried to quit “on my own” or cold turkey 
during the past 12 months to help themselves quit using 
tobacco of any kind for good. The 2015 NYTS also asked if 
one of the reasons why they had used e-cigarettes was to 
try to quit using tobacco products, such as cigarettes.
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Introduction
The 1988 Surgeon General’s report on nicotine 
addiction was the first in this series to conclude that 
“[n]icotine is the drug in tobacco that causes addic-
tion” (U.S. Department of Health and Human Services 
[USDHHS] 1988, p. 9). The biologic mechanisms under-
lying nicotine addiction continue to be a subject of great 
research interest, and several promising pharmacothera-
peutic targets have emerged. For example, acquisition of 
basic knowledge about the function of nicotinic acetyl-
choline receptors (nAChRs) led to the development of tar-
geted smoking cessation medications currently in use, and 
research would benefit from an additional understanding 
of molecular mechanisms (USDHHS 2010). The 2010 
Surgeon General’s report on how tobacco causes disease 
described the pharmacokinetics of nicotine, the behav-
ioral pharmacology of nicotine addiction, and the known 
genotypes and receptor subtypes that contribute to nico-
tine addiction (USDHHS 2010). This chapter focuses on 
how biology can influence smoking cessation and reviews 
four areas of intensive research since the publication of 
the 2010 Surgeon General’s report.
1. Cell and molecular biology of nicotine addiction 
focuses on the nAChRs as the primary target of cur-
rently available medications and on the following 
potential targets for medication development: gluta-
matergic signaling, neuropeptide systems, habenulo-
interpeduncular pathway, and noradrenergic system. 
This section describes the preclinical basis for 
understanding nicotine addiction and the ways that 
this knowledge could be used to enhance smoking 
cessation.
2. Vaccines and other immunotherapies as treat-
ments for tobacco addiction focuses on the concep-
tual basis of vaccine treatment, vaccine mechanistic 
design, and vaccine animal studies; progress made 
and barriers encountered with the early generation 
vaccines; and approaches to next-generation treat-
ments and passive immunization.
3. Insights into smoking cessation from the field of 
neurobiology describes the brain circuitry involved 
in nicotine dependence, as understood primarily 
through advances in brain imaging techniques; the 
role of stress, craving, and reward; and changes in 
cognitive control. Findings provide insight into the 
effects of smoking on the brain and the potential to 
identify new types of targets for smoking cessation.
4. Genetic studies of smoking phenotypes focuses on 
the further mechanistic understanding gained from 
the interindividual differences that genetics creates 
and from some of the methodologic approaches that 
can be used to examine genetics in humans. Findings 
provide insight into distinct classes of genes that rep-
resent potential targets for novel smoking cessation 
therapeutics and optimizing choice of treatment.
Cell and Molecular Biology of Nicotine Addiction
Literature Review Methods
For this section of the chapter, PubMed was searched 
in January 2017 for studies published between 2010 and 
2017 that focused on the neurobiologic mechanisms 
underlying nicotine addiction in model organisms and in 
human subjects. Such search teams included “nACh” and 
“nicotinic receptor,” and these terms were combined with 
such terms as “addiction” and “behavior.” Studies about 
nicotinic acetylcholine receptor mechanisms that were 
cited in these articles were also reviewed to identify pri-
mary research articles. These studies and a current search 
of clinical trials websites were used to identify molecular 
targets for the development of novel smoking cessation 
aids and ongoing clinical trials of relevant therapeutic 
agents. One reviewer conducted a full review and identi-
fied 76 articles for this section. The cited references for 
preclinical work represent a compilation of the current 
knowledge base obtained from rodent studies, but the base 
cannot be considered completely comprehensive because 
of the large volume of studies in this area.
Neurobiology of Nicotine Addiction
Nicotine, the main addictive constituent of ciga-
rette smoke, binds to nAChRs, a class of ligand-gated ion 
channels that, following the binding of acetylcholine or 
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nicotine, open and allow the trafficking of cations (positive 
ions [e.g., Ca++, Na+, K+]) (USDHHS 2010). nAChRs play 
an important role in transmitter release, cell excitability, 
and neuronal integration. Through these processes, nico-
tine stimulates the release of many different neurotrans-
mitters throughout the brain. In particular, nicotine acti-
vates the mesocorticolimbic dopamine system, which can 
induce both reward or aversion (USDHHS 2010).
The mesocorticolimbic system, which is char-
acterized by the ventral tegmental area (VTA) located 
in the midbrain, transmits dopamine to two main tar-
gets: one cortical, the prefrontal cortex (PFC); and one 
limbic, the nucleus accumbens (NAc) in the ventral stri-
atum (Figure 3.1). Nicotine increases extracellular dopa-
mine in all of these structures but mainly in the NAc. 
The reward associated with the release of dopamine is 
one of the underlying mechanisms of the development of 
nicotine dependence. In fact, the dopaminergic pathway 
is targeted by existing pharmacotherapies for smoking 
cessation. At present, the approved pharmacologic treat-
ments in the United States or Europe are nicotine replace-
ment therapy (NRT), varenicline, and bupropion  (U.S. 
Food and Drug Administration [FDA] 2016). Varenicline 
(trade names: Chantix, Champix) partially blocks the 
α4β2 nAChRs, and bupropion (trade names: Wellbutrin, 
Zyban) is a norepinephrine/dopamine reuptake inhibitor 
that also can decrease the function of nAChRs by acting 
as an antagonist of the receptors (Mansvelder et al. 2007). 
These two medications act indirectly and directly on the 
dopamine pathway.
Nicotinic Acetylcholine Receptors
nAChRs are ion channels that normally are activated 
by the neurotransmitter acetylcholine, but the nicotine 
in tobacco products “hijacks” nAChRs. In humans, these 
receptors are assembled from combinations of 17 known 
subunits, 12 of which are expressed in the brain (α2–α10 
and β2–β4) (Picciotto et al. 2008; Picciotto and Kenny 
2013). Importantly, co-assembly of specific combinations 
of subunits results in a set of nAChR subtypes that vary in 
their properties, location in the brain, and sensitivity to nic-
otine (Figure 3.2). For example, α7 can form a functional 
nAChR on its own [(α7)5,], while all other nAChRs contain 
at least one α subunit and one β subunit [e.g., (α4)2(β2)3]. 
The α4 and β2 subunits, which are expressed throughout 
the brain and body in many types of cells, nearly always 
assemble together, sometimes with additional subunits, 
and their interface forms a high-affinity nicotine binding 
site (Kutlu and Gould 2016). Activation of these α4- and 
β2-containing receptors is required for many of the neu-
robiologic and behavioral effects associated with nicotine 
reward. The α6 subunit also can associate selectively with 
these receptors in dopamine and norepinephrine neurons 
(Kutlu and Gould 2016).
Nicotine and the endogenous ligand acetylcholine 
bind to the extracellular interface between two nAChR 
subunits. Upon binding of either nicotine or acetylcholine, 
the receptors undergo a structural change that causes the 
ion channel to open, permitting the influx of cations and 
membrane depolarization. Cellular responses to nico-
tine depend on the composition of nAChR subunits and 
their subcellular localization. For example, activation of 
nAChRs located on nerve terminals stimulates the release 
of neurotransmitters, and activation of cell body recep-
tors increases neuronal excitability and can induce action 
potentials. Nicotine also binds to intracellular receptors in 
the endoplasmic reticulum and promotes their assembly 
and trafficking. Long-term exposure to nicotine increases 
the surface expression of nAChRs, particularly the high-
affinity α4- and β2-containing receptors. Cells in the 
brains of smokers, therefore, have an increased capacity 
for nicotine binding, which may result in altered neuronal 
signaling once nicotine is cleared from the brain and these 
nAChRs become available for acetylcholine signaling. In 
fact, heightened expression of nAChRs is observed in 
the brains of smokers for weeks following cessation; this 
might contribute to craving and withdrawal symptoms 
(Cosgrove et al. 2012). Although low levels of nicotine 
activate nAChRs, leading to nicotine reinforcement, con-
tinued exposure to nicotine desensitizes the receptors, 
which contributes to tolerance. The extent of desensiti-
zation varies with the composition of receptors and con-
centration of nicotine. β2 subunit-containing nAChRs, 
which are required for the rewarding effects of nicotine, 
desensitize rapidly in response to very low concentrations 
of nicotine (Picciotto et al. 2008). α7 receptors, however, 
will continue to respond in the presence of sustained low 
concentrations of nicotine.
 The physiologic consequences of nAChR desensitiza-
tion are complex and not entirely understood, but chronic 
exposure to nicotine in the brains of users of tobacco 
products likely results in phases of activation and desensi-
tization of nAChRs that contribute to nicotine reinforce-
ment and tolerance, respectively. The variability in this 
balance also may contribute to individual differences in 
susceptibility to nicotine addiction. In addition, receptors 
are reactivated once nicotine is removed from the system. 
Thus, increases in the number of nAChRs and receptor 
reactivation when nicotine is cleared from the system that 
last at least 4 weeks after cessation (Cosgrove et al. 2012) 
result in robust potentiation of nAChR signaling following 
abstinence, which then contributes to withdrawal symp-
toms (Millar and Harkness 2008; Picciotto et al. 2008; 
Changeux 2010).
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Figure 3.1 Stages of the addiction cycle
Source: From Volkow and colleagues (2016, p. 365). Copyright © 2016 Massachusetts Medical Society. Reprinted with permission 
from Massachusetts Medical Society. 
Notes: “Binge and intoxication” and “feeling euphoric” are not relevant to nicotine. “During intoxication, drug-induced activation of 
the brain’s reward regions (in blue) is enhanced by conditioned cues in areas of increased sensitization (in green). During withdrawal, 
the activation of brain regions involved in emotions (in pink) results in negative mood and enhanced sensitivity to stress. During pre-
occupation, the decreased function of the prefrontal cortex leads to an inability to balance the strong desire for the drug with the will 
to abstain, which triggers relapse and reinitiates the cycle of addiction. The compromised neurocircuitry reflects the disruption of the 
dopamine and glutamate systems and the stress-control systems of the brain, which are affected by corticotropin-releasing factor and 
dynorphin. The behaviors during the three stages of addiction change as a person transitions from drug experimentation to addiction 
as a function of the progressive neuroadaptations that occur in the brain” (Volkow et al. 2016, p. 365).
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Nicotine Reward
As for all drugs of abuse, the primary reinforcing 
(i.e., initial rewarding or addictive) effects of nicotine 
are driven by its activation of the mesolimbic dopamine 
system, commonly known as the brain’s reward circuit. 
Nicotine promotes phasic firing of dopamine neurons in 
the VTA through several nAChR-mediated mechanisms 
(USDHHS 2010). Activation of α4- and β2-containing 
nAChRs on dopamine cell bodies increases their excit-
ability and is required for the reinforcing properties of nic-
otine. Nicotine also acts through α7 nAChRs located on 
glutamatergic terminals in the VTA to promote glutamate 
release onto dopamine neurons, further enhancing their 
excitation (USDHHS 2010). Similarly, nicotine stimula-
tion of nAChRs made of the α4, β2, and α6 subunits that 
are found on dopamine terminals promotes the release of 
dopamine in NAc and other regions (Picciotto and Kenny 
2013; Wickham et al. 2013; Picciotto and Mineur 2014).
Nicotine Withdrawal and Relapse
Chronic nicotine use can induce a physical depen-
dence severe enough that cessation induces a series of 
negative withdrawal symptoms in humans and in labora-
tory animals (Picciotto et al. 2008; USDHHS 2010). Thus, 
Figure 3.2 Structure and properties of nAChRs
Source: Created by Marina Picciotto and Megan Miller, Yale University School of Medicine, for this Surgeon General’s report.
Notes: α = alpha; β = beta; nAChR = nicotinic acetylcholine receptor. nAChRs in the brain assemble as pentameric (5-member) 
structures from 12 subunits: α2–α10 and β2–β4. The most common combinations are formed as homomers (all subunits the same) 
of the α7 subunit, or heteromers of the α4 and β2, or α3 and β4 subunits. Many subunit combinations with different properties are 
possible, with variability particularly at the fifth position in the receptor (indicated in grey as a choice of α or β subunit in this figure). 
Assembled receptors form a channel through the membrane, with a pore that is closed under resting conditions. The neurotransmitter 
acetylcholine normally binds to interfaces between subunits in the assembled nAChRs, activating the receptors and allowing ions to 
flow through the opened pore into cells expressing them. Nicotine binds to the same site in the nAChR as acetylcholine and can open 
the channel, although with different open times and likelihood of desensitization.
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in addition to being drawn to the primary reinforcing 
properties of nicotine, many persons return to smoking 
to avoid negative effects of abstinence, such as irritability, 
anxiety, depression, insomnia, and difficulty concen-
trating. Additionally, environmental cues (sights, sounds, 
or other sensations) associated with nicotine often elicit 
drug cravings that can be sufficient to induce relapse to 
regular smoking after a quit attempt (USDHHS 2010). 
For example, former smokers who used to have a ciga-
rette with their morning coffee may experience intense 
nicotine cravings at the smell of coffee, which could 
trigger relapse to smoking (Bevins and Palmatier 2004). 
Importantly, drug-paired cues (things in the environ-
ment that are associated with nicotine being on board) 
can become themselves reinforcing after repeated pair-
ings, and this conditioned reinforcement may be at least 
partially responsible for continuing drug use and relapse. 
Mechanistically, perseverative drug use and high relapse 
rates happen because of persistent neurobiologic adap-
tations (tolerance), particularly within the mesocorti-
colimbic dopamine system. Thus, although developing 
therapies aimed at reducing the reinforcing properties 
of nicotine itself is reasonable, this strategy is unlikely to 
be completely effective in combating relapse to smoking 
(USDHHS 2010). For this reason, several research efforts 
have focused on elucidating the neurobiologic underpin-
nings of relapse.
Animal Models of Nicotine Addiction
Studies of animal models of disease have contrib-
uted to much of our understanding of the neurobio-
logic basis of nicotine addiction. Although animal models 
cannot capture the full range of human addiction, mice 
and rats do develop addiction-like behaviors, and several 
reliable paradigms have been established to measure spe-
cific aspects of the disease in animals. The drugs that ani-
mals self-administer correspond well with drugs that have 
high abuse liability in humans (Carter and Griffiths 2009). 
As described in detail below, nicotine-dependent animals 
will work to obtain nicotine and to relieve nicotine with-
drawal symptoms (Koob and Simon 2009). Therefore, 
animal models are useful for measuring the abuse liability 
of addictive drugs, such as nicotine, and identifying phar-
macotherapies that make addictive drugs less reinforcing 
or that mitigate withdrawal symptoms.
Modeling Nicotine Reward
The conditioned place preference (CPP) and self-
administration paradigms are two common models used 
to evaluate nicotine reinforcement and drug-seeking 
behavior. CPP is established by repeatedly pairing nicotine 
administration with exposure to a particular environmental 
context. Over time, the animal learns to associate the con-
text with nicotine and develops a preference for that envi-
ronment over an adjacent, similar environment that is not 
paired with nicotine. The development of such a prefer-
ence is considered to be an indication of the rewarding 
effects of the drug.
In the self-administration model, animals are trained 
to complete an operant task, such as pressing a lever to 
receive an infusion of nicotine. Once the task is learned, 
changes in operant behavior are thought to indicate 
changes in drug reinforcement or craving. Variations of 
this task also can be used to measure motivation (i.e., how 
hard an animal is willing to work for nicotine), extinction, 
and relapse. Interestingly, self-administration of nicotine 
is more robust if infusion is paired with a cue versus with 
the drug alone (Caggiula et al. 2001).
Modeling Nicotine Withdrawal and Relapse
Human smokers often relapse in response to one of 
three stimuli: exposure to environmental cues associated 
with nicotine, aversive or stressful life events, or a small 
amount of the drug (i.e., a “lapse”) (USDHHS 2010). Each of 
these types of stimuli is also sufficient to induce reinstate-
ment of nicotine-seeking behavior in rodents after forced 
extinction of the behavior. In the cue-induced reinstate-
ment model, animals are trained to self-administer nico-
tine that is paired with an innocuous cue, such as a light 
or a tone. After self-administration of nicotine is acquired, 
the operant behavior can be extinguished by placing the 
animals in the same context but in the absence of the drug 
and the associated cue. Following extinction, animals will 
resume responding to the cue alone, even in the absence of 
nicotine. Similar paradigms have been developed to model 
stress-induced reinstatement and drug-induced rein-
statement in animals, all of which may be valid for nico-
tine relapse in humans (Mantsch et al. 2016). Preclinical 
studies using these paradigms have been useful in identi-
fying cellular and molecular processes that contribute to 
drug reinstatement, as discussed in this section.
Molecular Targets of Current 
Pharmacotherapies
As a consequence of our understanding of the neuro-
biology of nicotine addiction, several successful pharmaco-
therapies have been developed to aid in smoking cessation 
(Table 3.1) (Cochrane Tobacco Addiction Group n.d.), most 
of which alter nAChR signaling (Cahill et al. 2013, 2016). 
These include varenicline (a partial agonist of nAChRs) 
and bupropion (an atypical antidepressant with the ability 
to block nAChRs). Various forms of NRT—including 
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the patch, gums, lozenges, and nasal sprays—also act 
on nAChRs. Varenicline activates nAChRs, although to 
a lesser extent than nicotine, and blocks the binding of 
nicotine from tobacco to the nAChR, thereby resulting 
in reduced withdrawal symptoms and less reward from 
a lapse to smoking. Although not currently approved for 
use in the United States, cytisine is another nAChR partial 
agonist and has been used as an herbal smoking cessa-
tion aid for decades in Eastern European countries and 
Canada (Gómez-Coronado et al. 2018). Repeated efficacy 
studies, including a Phase 3 clinical trial in New Zealand, 
have found cytisine to be effective for smoking cessation 
at levels similar to varenicline (Etter 2006). Because cyti-
sine is a naturally occurring compound, it is less expen-
sive than currently available cessation aids, making it a 
potentially promising tool for reducing smoking rates in 
certain populations, including low-income individuals. 
With withdrawal-induced negative affect a major problem 
for smokers trying to quit, antidepressants are often pre-
scribed, and several of these drugs have shown efficacy 
Table 3.1 Current pharmacotherapies for smoking cessation
Line Trade name(s) Target Action
FDA approved 
for smoking 
cessation: Yes/no Other information
First-line          
Bupropion • Wellbutrin
• Elontril
• Zyban
Catecholemine 
system/nAChRs 
(multiple subtypes)
Norepinephrine or 
dopamine reuptake 
inhibitor/nAChR 
antagonist
Yes Atypical antidepressant; 
also approved for 
ADHD and obesity
NRT • Nicoderm
• Commit
• Nicorette
• Others
nAChRs (multiple 
subtypes)
Agonist Yes —
Varenicline • Chantix
• Champix
nAChRs (multiple 
subtypes)
Partial agonist Yes —
Second-line          
Nortriptyline • Sensoval
• Aventyl
• Pamelor
• Norpress
• Allegron
• Noritren
• Nortrilen
Serotonin and 
norepinephrine 
systems
Serotonin or 
norepinephrine 
reuptake inhibitor
No Tricyclic antidepressant
Clonidine • Catapres
• Kapvay
• Duraclon
• Nexiclon
Adrenergic 
receptors
Agonist No Also indicated for high 
blood pressure, ADHD, 
anxiety, migraine, 
withdrawal (opiates, 
alcohol, and nicotine), 
and other
Others          
Cytisine • Tabex nAChR Partial agonist No Popular in Eastern 
Europe but not 
available in the United 
States; relatively 
inexpensive
Naltrexone • Revia
• Vivitrol
Opioid receptors 
(μ, κ)
Antagonist No Commonly used to 
treat alcoholism and 
opioid dependence
Notes: κ = kappa; μ = mu; ADHD = attention-deficit/hyperactivity disorder; FDA = U.S. Food and Drug Administration; 
nAChR = nicotinic acetylcholine receptor; NRT = nicotine replacement therapy.
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in reducing smoking (Hughes et al. 2014). Bupropion 
can alleviate withdrawal symptoms and reduce the 
severity of nicotine cravings. Overall, its efficacy for ces-
sation is about double that of placebo (Wu et  al. 2006). 
Notably, bupropion is also an nAChR antagonist that alters 
nicotine-mediated dopamine responses, which likely con-
tributes to its efficacy in reducing smoking (Mansvelder 
et al. 2007). Although it has not been approved by FDA for 
smoking cessation, nortriptyline (trade names: Sensoval, 
Pamelor, Aventyl, and others), a tricyclic antidepressant 
and serotonin/norepinephrine reuptake inhibitor, also has 
shown off-label efficacy in improving rates of smoking 
cessation (Hughes et al. 2005).
Novel Targets for Smoking Cessation
Glutamatergic Signaling
Although enhanced dopamine signaling is critical 
for the initial reinforcing properties of nicotine, both 
the maintenance and reinstatement of nicotine-seeking 
behavior require long-lasting alterations in the actions of 
glutamate, the major excitatory neurotransmitter in the 
brain (Knackstedt and Kalivas 2009; Li et al. 2014; Marchi 
et al. 2015). Glutamate levels are elevated in both the NAc 
and the VTA after exposure to nicotine, and glutamate 
inputs to the VTA mediate the increases in the activity 
of dopamine neurons in response to nicotine. Repeated 
exposure to nicotine results in a long-term potentiation 
(or long-lasting increase in activation) of these synapses, 
which contributes to elevated excitability of dopamine 
neurons. Furthermore, sustained low levels of nicotine, 
as would be observed in the brains of smokers, can desen-
sitize nAChRs located on inhibitory nerve terminals in 
the VTA. This may reduce the inhibition of dopamine 
neurons, further shifting the excitatory–inhibitory bal-
ance in the VTA. Nicotine dependence also is associated 
with long-term potentiation of glutamate synapses in the 
NAc, and disruption of glutamate signaling in this region 
alters nicotine-mediated physiology and behavior. Thus, 
chronic use of nicotine causes long-lasting changes to the 
mesolimbic dopamine system, many of which are driven 
by alterations in glutamate transmission. Behaviorally, 
these adaptations sustain drug cravings and contribute 
to a vulnerability to relapse. Glutamate binds to and acti-
vates two types of receptors: ionotropic, which are ion 
channels that allow current to pass through and activate 
cell membranes; and metabotropic, which are G-protein-
coupled receptors that activate downstream cell signaling 
cascades. Neuroadaptive mechanisms in the glutamate 
system, perhaps on both types of glutamate receptors, 
may be targets for pharmacologic intervention.
Ionotropic Glutamate Receptors
Glutamate signaling through the ionotropic gluta-
mate receptors N-methyl-D-aspartate (NMDA) and α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) is 
implicated in the neurobiologic mechanisms of nicotine 
dependence (Li et al. 2014; D’Souza 2015). Pharmacologic 
blockade of both NMDA and AMPA receptors in the VTA 
attenuates nicotine-induced dopamine release in the NAc, 
and inhibition of NMDA receptors impairs nicotine-seeking 
behaviors (Kenny et al. 2009; Mao et al. 2011). Conversely, 
blockade of NMDA receptors in the shell region of the NAc 
increases the self-administration of nicotine, suggesting 
that glutamatergic transmission in this region may offset 
the rewarding effects of nicotine (D’Souza and Markou 
2014). The mechanisms underlying this effect are not fully 
understood, but one hypothesis is that medium spiny neu-
rons in the shell region of the NAc are activated by glu-
tamate, and these medium spiny neurons project to and 
inhibit dopamine neurons in the VTA (Yang et al. 2018). 
Regardless, glutamatergic signaling in mesocorticolimbic 
regions clearly contributes to nicotine reinforcement.
Gipson and colleagues (2013) demonstrated that 
long-lasting changes in glutamate signaling are central 
to post-withdrawal reinstatement of nicotine-seeking 
behavior in rats. Long-term potentiation of glutamatergic 
synapses in the NAc was apparent after 2 weeks of nico-
tine withdrawal, with further strengthening observed fol-
lowing cue-induced reinstatement of nicotine seeking. 
Furthermore, blocking the function of NMDA receptors 
in the core region of the NAc prevented cue-induced rein-
statement of nicotine-seeking behavior. Similar observa-
tions have been made with other drugs of abuse, such as 
cocaine and alcohol. These data suggest that dampening 
mesolimbic glutamate signaling, potentially by inhib-
iting the function of NMDA receptors in the core of the 
NAc, may be a useful strategy for reducing vulnerability to 
smoking relapse in humans.
Although blockade of ionotropic glutamate recep-
tors is effective in reducing addiction-like behaviors in 
animal models, systemic use of these drugs in humans is 
likely not feasible using current pharmacologic agents, 
given the crucial role of glutamate in the function of the 
nervous system. Also, because glutamate plays different 
roles in different regions of the brain, a more targeted, 
region-specific approach is warranted.
Metabotropic Glutamate Receptors
Metabotropic glutamate receptors (mGluRs) are 
widely expressed, G-protein-coupled receptors that use 
second-messenger systems (key distributors of an external 
signal) to modulate neuronal excitability. Two of these 
receptors, mGluR5 and mGluR2, have been implicated in 
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the neurobiology of nicotine addiction. Because pharma-
cologic manipulation of metabotropic glutamate signaling 
may have a more subtle effect on the function of the nervous 
system than do ionotropic drugs, targeting these receptors 
may be a more feasible clinical approach for smoking ces-
sation (D’Souza 2015; Mihov and Hasler 2016; Acri et al. 
2017; Chiamulera et al. 2017). Table 3.2 summarizes novel 
pharmacologic targets for smoking cessation.
mGluR5. mGluR5 is localized postsynaptically 
where it signals through the excitatory G-protein Gαs, 
to enhance neuronal excitability. Reducing the function 
of mGluR5 with MPEP (2-methyl-6-(phenylethynyl pyri-
dine), a negative allosteric modulator (NAM) in the NAc 
shell, attenuates nicotine self-administration and dopa-
mine release (Paterson et al. 2003; Tronci et al. 2010), sug-
gesting a role for this receptor in the primary reinforcing 
properties of nicotine. Additionally, both drug- and cue-
induced reinstatement of nicotine-seeking behavior 
are reduced in animals that have been pretreated with 
mGluR5 antagonists (Bespalov et al. 2005). In humans, 
studies using selective mGluR5 radiotracers have revealed 
a significant reduction of binding sites in the brains of per-
sons addicted to nicotine, which is normalized after cessa-
tion (Akkus et al. 2013; Hulka et al. 2014). The mechanism 
for this reduction is not entirely understood, but it may be 
a compensatory action meant to limit aberrant glutamate 
signaling in the brains of smokers.
The preclinical efficacy of mGluR5 NAMs in reducing 
drug-seeking behavior is well documented, but higher 
doses of the same drugs also have been reported to impair 
food-seeking behaviors in animals (Mihov and Hasler 2016). 
Although the curbing of appetite during smoking cessation 
may seem like an appealing side effect, such overly gener-
alized effects may be dangerous or undesirable. mGluR5 
NAMs also have been shown to increase the severity of 
nicotine withdrawal symptoms (Chiamulera et  al. 2017), 
which could limit their feasibility for clinical use.
mGluR2. In contrast to mGluR5, mGluR2 is 
expressed on presynaptic glutamate terminals, acting as an 
autoreceptor that inhibits the release of this neurotrans-
mitter. Therefore, dopamine neurons can be inhibited 
by the activation of mGluR2 receptors on glutamatergic 
inputs to the VTA.
Stimulation with the nonselective mGluR2/3 ago-
nist LY379268 can reduce drug- and cue-induced rein-
statement of nicotine responding, and these effects can be 
blocked by an mGluR2 antagonist (Justinova et al. 2016). 
mGluR2/3 stimulation also can reduce the primary rein-
forcing properties of nicotine, but these effects are smaller 
and less consistent than the effects on reinstatement. In 
nicotine-experienced rats, LY379268 reduced nicotine-
induced increases in dopamine levels in the NAc only in 
the presence of drug-predicting cues (D’Souza et al. 2011), 
supporting the hypothesis that mGluR2/3 stimulation is 
more effective at reducing the conditioned effects of nico-
tine than its primary reinforcing effects.
Although a selective mGluR2 positive allosteric 
modulator (PAM) was not shown to improve schizo-
phrenia symptoms in a Phase 2 clinical trial, it has been 
repurposed as a possible therapy for nicotine addiction 
because of its good safety profile and preclinical efficacy in 
reducing nicotine reinstatement (Justinova et al. 2015). 
A  Phase  2 clinical trial of this drug for smoking cessa-
tion was completed in January 2017, but results are not 
yet available. This study enrolled 210 female cigarette 
smokers and evaluated abstinence from nicotine as a pri-
mary endpoint. Although GluR5 and GluR2 have been 
linked to addiction-like behaviors in animals, Acri and 
colleagues (2017) argued that mGluR2 may be a more fea-
sible drug target because of its relatively mild side-effect 
profile compared with mGluR5 antagonists.
Glutamate Transporters
Alterations in the function of glutamate trans-
porters also contribute to nicotine-mediated disruptions 
in the excitatory–inhibitory balance. Mesocorticolimbic 
expression of glutamate transporter 1 (GLT-1), the cystine/
glutamate exchanger, and excitatory amino acid trans-
porter  3 are all decreased after chronic administration 
of nicotine in rodents (Knackstedt and Kalivas 2009; 
Knackstedt et al. 2009; Yoon et al. 2014). In addition, rein-
statement of nicotine-seeking behavior is associated with 
decreased expression of GLT-1 and elevated concentration 
of extracellular glutamate (Gipson et  al. 2013). In mice, 
upregulation of GLT-1 with ceftriaxone had no effect on 
CPP acquisition but reduced withdrawal symptoms and 
significantly attenuated nicotine-primed reinstatement 
of nicotine CPP (Alajaji et al. 2013). Stimulating cystine/
glutamate exchanger activity with N-acetylcysteine also 
may be effective in reducing nicotine consumption. An 
open-label pilot study of a combination therapy of var-
enicline and N-acetylcysteine showed a favorable safety 
profile. Although the study was not designed to evaluate 
differences in cessation efficacy, patients receiving both 
therapies smoked fewer cigarettes than those receiving 
only varenicline (McClure et  al. 2015). In addition, a 
double-blind, randomized controlled trial (RCT) found 
that, in combination with group behavioral therapy, 
N-acetylcysteine was effective in reducing the number of 
cigarettes smoked and in increasing quit rates versus a 
placebo control group (Prado et al. 2015).
Neuropeptide Systems
Neuropeptides are a class of short-chain polypep-
tides that serve as neurotransmitters (Table 3.2). Acting 
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Table 3.2 Novel pharmacologic targets for smoking cessation
Target Pharmacology
Expected 
neurobiologic 
effect
Expected 
behavioral 
outcome
Stage of drug 
development Other information
Glutamate system          
mGluR5 NAM • Decreased Glu 
transmission
• Decreased 
nicotine intake
• Decreased relapse 
vulnerability
Preclinical —
mGluR2 PAM • Decreased Glu 
transmission
• Decreased relapse 
vulnerability
• Decreased 
nicotine intake
Phase 2 —
GLT-1 Agonist • Decreased Glu 
transmission
• Decreased relapse 
vulnerability
Preclinical —
xCT Agonist 
(N-acetylcysteine)
• Decreased Glu 
transmission
• Decreased 
nicotine intake
Phase 2 —
Neuropeptides          
CRF-1 Antagonist 
(Paxacerfont)
• Decreased 
reactivity to 
withdrawal
• Decreased 
dopamine 
response
• Decreased relapse 
vulnerability
• Decreased 
nicotine intake
Preclinical Failed Phase 2 anxiety 
trial
DOR Antagonist • Decreased 
dopamine 
response
• Decreased 
nicotine intake
Preclinical Naltrexone is a non-
selective opioid receptor 
antagonist used to treat 
alcoholism and opioid 
dependence
KOR Antagonist • Decreased 
reactivity to 
withdrawal
• Decreased relapse 
vulnerability
Preclinical Naltrexone is a non-
selective opioid receptor 
antagonist used to treat 
alcoholism and opioid 
dependence
MHb-IPN pathway          
α5 PAM • Increased 
nicotine-
mediated MHb-
IPN activation
• Decreased 
nicotine intake
Preclinical —
Noradrenergic system          
α1 Antagonist • Decreased 
norepinephrine 
signaling
• Decreased 
nicotine intake
• Decreased relapse 
vulnerability
— —
α2 Agonist (clonidine) • Decreased 
norepinephrine 
signaling
• Decreased relapse 
vulnerability
Off-label use Potent side effects 
include sedation and 
low blood pressure
Notes: α = alpha; CRF = corticotropin-releasing factor; DOR = delta (δ) opioid receptor; GLT = glutamate transporter; KOR = kappa 
(κ) opioid receptor; mGluR = metabotropic glutamate receptor; MHb-IPN = medial habenulo-interpeduncular nucleus; NAM = nega-
tive allosteric modulator; PAM = positive allosteric modulator; xCT = cystine/glutamate exchanger.
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on designated G-protein-coupled receptors, these mole-
cules can modulate neuronal activities. As outlined in the 
upcoming sections of this chapter, a substantial amount of 
preclinical evidence suggests that multiple neuropeptide 
systems can contribute to the development of nicotine 
dependence. Additionally, because several neuropeptides 
can modulate mood, manipulating these systems may be 
an effective strategy for improving success rates for cessa-
tion by reducing the severity of negative withdrawal symp-
toms. Although at least a dozen neuropeptides have been 
linked to nicotine dependence, this section focuses on two 
primary promising targets: corticotropin-releasing factor 
(CRF) and the opioid system.
Corticotropin-Releasing Factor
CRF is a peptide hormone known best for its role 
in the stress response. Chronic nicotine administra-
tion increases CRF levels in the VTA of rats, and genetic 
knockdown of this peptide attenuates self-administration 
of nicotine (Grieder et al. 2014). In addition, blockade of 
the peptide’s receptor, CRF1, in rats prevented the nor-
mally observed increase in nicotine self-administration 
following a period of forced abstinence and prevented 
the aversive effects of withdrawal (Cohen et al. 2015). In 
an intracranial self-stimulation paradigm, the sensitivity 
of the brain reward pathway can be assessed by mea-
suring the intensity of a stimulus required to elicit self-
stimulation behavior, such that higher stimulation thresh-
olds indicate a less sensitive reward system. Exposure to 
nicotine (or other drugs of abuse) causes animals to per-
form for much less intense stimulation (i.e., they have 
lower thresholds), indicating a drug-induced potentiation 
of the reward system. Conversely, a period of abstinence 
from a drug elicits a large increase in the intracranial self-
stimulation threshold, indicating reduced excitability of 
the reward system and signifying a depression-like brain 
state (reflected in elevations of brain reward thresholds) 
(Stoker et al. 2012).
In nicotine-dependent animals, withdrawal-induced 
increases in the intracranial self-stimulation threshold 
are absent in animals treated systemically with CRF1 
receptor antagonists, or only in the central amygdala, 
a brain region known to regulate mood (Marcinkiewcz 
et al. 2009; Bruijnzeel et al. 2012). Similarly, withdrawal-
induced, anxiety-like behavior is exacerbated by infusion of 
CRF into the interpeduncular nucleus (IPN), and blockade 
of CRF1 alleviates this behavior (Zhao-Shea et al. 2015). 
Thus, CRF signaling, particularly in the amygdala and IPN, 
contributes to the negative affect associated with nicotine 
withdrawal. Lastly, inhibition of the CRF1 receptor can 
block both stress-induced potentiation of nicotine CPP and 
stress-induced reinstatement of self-administration (Zislis 
et  al. 2007). Together, these studies suggest that CRF 
signaling is central to changes in nicotine-seeking behavior 
in response to stress. Although clinical data regarding the 
role of CRF in smoking behavior are not available, many 
studies in animal models of nicotine dependence suggest 
that CRF antagonists may be useful for reducing smoking 
in humans (Bruijnzeel 2017).
Notably, several small-molecule CRF ligands can 
cross the blood–brain barrier. Although most are being 
used only for preclinical research, several have been evalu-
ated clinically to treat anxiety and depression. In a clinical 
trial of 260 patients, Paxacerfont (a CRF1 receptor ago-
nist) was no more effective than placebo for treating gen-
eralized anxiety disorder (Coric et al. 2010); however, this 
drug has not been evaluated for smoking cessation.
The Opioid System
Mounting evidence has implicated the endoge-
nous opioid system in both neurobiologic and behavioral 
responses to nicotine. The opioid system consists of three 
G-protein-coupled opioid receptors that are activated by 
endogenous peptide ligands. Delta (δ) opioid receptors 
(DORs) are activated primarily by enkephalins; kappa 
(κ) opioid receptors (KORs) are activated by dynorphins; 
and mu (µ) opioid receptors (MORs) are activated by 
β-endorphins. Each of these receptor–ligand pairs appears 
to play a role in nicotine addiction. Nicotine-induced 
dopamine release is attenuated in mice lacking DORs, 
and these animals do not acquire a CPP for nicotine 
(Berrendero et al. 2012). Genetic ablation or pharmaco-
logic blockade of DORs with naltrindole also substantially 
reduces self-administration of nicotine (Berrendero et al. 
2012). Although DORs do not appear to play an impor-
tant role in the somatic responses to nicotine (Berrendero 
et  al. 2012), animals treated with the KOR antagonist 
JDTic have diminished physical and affective nicotine 
withdrawal symptoms (Jackson et al. 2010a).
Interestingly, KOR activity does not appear to be 
necessary for the initial reinforcing properties of nico-
tine (Jackson et  al. 2010a), but pharmacologic blockade 
of the receptor reduces the anxiogenic effects of nicotine 
withdrawal and prevents stress-induced reinstatement of 
nicotine-seeking behavior (Jackson et  al. 2010a; Nygard 
et al. 2016). In addition, withdrawal-mediated activation 
of the amygdala was reduced in mice pretreated with 
the KOR antagonist norbinaltorphimine (Nygard et  al. 
2016). Together, these data suggest that DORs and KORs 
play discrete roles in the physiological and behavioral 
responses to nicotine. Although DOR contributes to dopa-
mine release and nicotine reinforcement, KOR appears 
to be more involved in the physiologic effects of nicotine 
withdrawal.
In humans, MORs have been linked to craving 
and addiction severity among smokers. Compared with 
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nonsmoking controls, smokers had fewer available 
MOR-binding sites in the basal ganglia and thalamus, and 
the number of binding sites in the basal ganglia was nega-
tively associated with baseline craving levels (Nuechterlein 
et al. 2016). Additionally, the availability of MOR-binding 
sites in both the basal ganglia and temporal cortex was 
inversely correlated with the severity of physical depen-
dence on nicotine, as assessed by the Fagerström Test 
for Nicotine Dependence (FTND) (Kuwabara et al. 2014; 
Nuechterlein et al. 2016). Interestingly, a MOR gene variant 
(OPRM1 A118G) was found to be potentially associated 
with reduced availability of MOR binding (Nuechterlein 
et al. 2016).
Naltrexone (trade names: Revia, Vivitrol), a nonse-
lective opioid receptor antagonist, is commonly used to 
treat alcoholism and opioid dependence. A clinical trial 
of 121  smokers found that combining naltrexone with 
bupropion was associated with higher rates of abstinence 
from smoking after 7 weeks of treatment compared with 
bupropion alone, but these rates did not differ signifi-
cantly between the bupropion-plus-placebo group and the 
bupropion-plus-naltrexone group at 6  months (Mooney 
et  al. 2016). Similarly, a Cochrane review of eight trials 
showed no effect of naltrexone alone or as an adjunct to 
NRT (David et al. 2013a).
Finally, preclinical studies have implicated orexin/
hypocretin peptides, originally thought to be involved 
mainly in feeding and arousal but now shown to modu-
late the rewarding effects of nicotine, as potential ther-
apies for smoking cessation (Plaza-Zabala et  al. 2010; 
Hollander et  al. 2012). An orexin/hypocretin receptor  2 
polymorphism has been associated with nicotine depen-
dence in human smokers (Nishizawa et al. 2015), and in 
rats the selective receptor 2 antagonist (2-SORA 18) can 
block both cue-induced reinstatement of nicotine self-
administration and motivation to respond to nicotine cues, 
as determined by a progressive ratio experiment in which 
animals had to press a lever exponentially more times to 
receive each successive nicotine-paired cue (Uslaner et al. 
2014). Similarly, the orexin/hypocretin receptor 1 antag-
onist SB-334867 decreased the reward-enhancing effects 
of nicotine in rats, as well as their cue-induced reinstate-
ment of nicotine-seeking behaviors (Hollander et  al. 
2008; Plaza-Zabala et al. 2013). Interestingly, stimulation 
of nAChRs increased the activity of orexin/hypocretin 
neurons (Zhou et al. 2015), suggesting that stimulation 
of this system may contribute to the physiologic effects 
of nicotine.
Summary
Neuropeptide systems play a role in multiple stages 
of the addiction process. Experiments in animals have 
shown that CRF and the opioid system, neuropeptide Y, 
hypocretin, galanin, ghrelin, and vasopressin and addi-
tional peptides not discussed here are associated with nic-
otine dependence (Bruijnzeel 2017). Thus, modulating the 
function of neuropeptides may effectively reduce smoking 
behavior in humans. Even so, the role that neuropeptide 
systems play in human addiction should be investigated 
further. Several drugs targeting neuropeptide receptors 
are already in use for treatment of other disorders, but 
none are approved by FDA for use in smoking cessation.
The Habenulo-Interpeduncular Pathway
Aversive Effects of Nicotine
As discussed previously, nicotine stimulates dopa-
mine pathways to generate the rewarding effects that 
contribute to addiction. At the same time, activation of 
nAChRs in the brain and elsewhere results in highly aver-
sive effects, such as nausea, dizziness, and irregular heart-
beat. In fact, most first-time smokers report a largely 
unpleasant experience with nicotine, and sensitivity to 
the aversive effects of cigarette smoke is inversely corre-
lated with the likelihood of developing habitual smoking 
(Sartor et al. 2010).
Animal studies of nicotine withdrawal and aver-
sion have identified a crucial role for the habenulo-
interpeduncular pathway in mediating these responses. 
The medial habenula (MHb) is composed mostly of cholin-
ergic neurons that also express Substance P and co-release 
glutamate. MHb neurons project to the IPN, and activation 
of this circuit is required for many of the negative effects 
associated with exposure to nicotine, including the seda-
tive effects induced by high concentrations of this chem-
ical and negative symptoms of withdrawal. Furthermore, 
stimulation of the MHb or IPN reduces the reinforcing 
properties of nicotine, but disrupting neuronal signaling 
in these connected brain regions has the opposite effect—
resulting in increased self-administration of nicotine in 
rodents (Fowler and Kenny 2014).
Potential Molecular Targets
Nicotinic receptors are highly expressed on MHb 
and IPN neurons, and these regions have the highest 
expressions of α3, β4, and α5 nAChR subunits in the brain. 
Several human genomewide association studies (GWAS) 
have linked variants in the CHRNA3-CHRNA5-CHRNB4 
gene cluster (genes that encode the α3, α5, and β4 
nAChR subunits, respectively) to susceptibility to tobacco 
use, and preclinical studies in rodents have revealed an 
important role for these subunits in moderating nicotine 
intake. α5 knockout mice lacking the α5 nAChR subunit 
acquired a CPP for high doses of nicotine, but such doses 
were aversive to their wild-type littermates (Jackson et al. 
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2010b). Similarly, α5 knockout animals failed to titrate 
their responses in a self-administration paradigm when 
increasing doses of nicotine were offered, and this effect 
was rescued by expression of α5 in MHb (Fowler et  al. 
2011). Interestingly, α5 knockout mice were indistin-
guishable from controls at low doses of nicotine in both 
CPP and self-administration paradigms (Jackson et  al. 
2010b; Fowler et al. 2011), indicating that the α5 nAChR 
subunit is not required for the rewarding properties of 
nicotine. Furthermore, overexpression of the β4 nAChR 
subunit in MHb resulted in increased aversion to nicotine 
(Frahm et  al. 2011). Mice overexpressing β4 nAChRs—
with or without a β4 mutation, which is associated with 
decreased risk of smoking in humans—displayed larger 
nicotine-evoked current amplitudes and enhanced aver-
sive behavior (Slimak et al. 2014). Together, these studies 
suggest that α5- and β4-containing nAChRs in the MHb 
are essential for encoding the aversive properties of nico-
tine, and they likely serve to limit nicotine intake.
Characterization of the MHb to IPN aversive circuit 
offers a novel and intriguing approach to addiction phar-
macotherapy, in which the goal is to enhance the aversive 
effects of nicotine rather than to reduce its reinforcing 
effects. α5- and β4-containing nAChRs are obvious tar-
gets. Unfortunately, continuous stimulation of this aver-
sive pathway likely will warrant the use of full agonists 
of these receptors and is, therefore, clinically unreal-
istic, because the β4-containing nAChRs are also highly 
expressed in the autonomic ganglia and a full agonist 
would likely be poorly tolerated. Instead, the use of PAMs 
that would enhance signaling only in the presence of an 
agonist may be more feasible (Fowler and Kenny 2014). 
Recent findings show that galantamine, which acts as a 
positive allosteric modulator of α5 subunit-containing 
nAChRs at low doses, can reduce nicotine intake in rats 
and smoking in humans (Ashare et al. 2016), supporting 
the rationale for developing α5 PAMs as novel smoking 
cessation agents. Notably, other brain regions and neu-
ronal systems, including the mesocorticolimbic dopamine 
pathway and autonomic nervous system, also contribute 
to the aversive effects of nicotine. However, the specific 
mechanisms by which aversive pathways communicate 
with reward pathways are uncertain.
The Noradrenergic System
Norepinephrine (also known as noradrenaline) is a 
monoamine neurotransmitter that signals through α1, 
α2, and β G-protein-coupled adrenoceptors. Like other 
neuromodulators, norepinephrine receptors are found 
throughout the brain, and norepinephrine is well known 
for its role in arousal and the stress response. The norad-
renergic system has also been implicated in neurobiologic 
responses to nicotine, contributing to both nicotine 
reward and reinstatement (Fitzgerald 2013). Nicotine 
increases activity of adrenergic neurons in the locus coe-
ruleus, resulting in increased levels of norepinephrine in 
the brain. In animal models of nicotine addiction, blocking 
the transmission of norepinephrine with prazosin, the α1 
receptor antagonist, reduced nicotine-induced dopamine 
signaling and attenuated nicotine self-administration 
and reinstatement (Forget et al. 2010). In other studies, 
reducing the tone of norepinephrine by stimulating α2, an 
inhibitory autoreceptor, with clonidine or dexmedetomi-
dine diminished stress-induced reinstatement of nicotine-
seeking behavior in rats (Zislis et  al. 2007; Yamada and 
Bruijnzeel 2011).
In humans, long-term smoking is associated with 
reduced expression of α2- and β-adrenergic receptors, 
which normalize after a period of abstinence (Klimek et al. 
2001). In addition, guanfacine, the α2 agonist, reduced 
stress-induced nicotine craving and smoking in a study 
of 33 smokers (McKee et al. 2015). Thus, both clinical and 
preclinical evidence suggest that nicotine increases nor-
adrenergic activity and that correction of this increase 
may be an effective strategy for reducing smoking.
Clonidine (trade names: Catapres, Kapvay, Nexiclon), 
the α2a receptor agonist, has consistently shown some 
efficacy in improving cessation rates by alleviating nega-
tive withdrawal symptoms (Gourlay et al. 2004), but cloni-
dine is not an FDA-approved cessation aid, and prominent 
adverse side effects, mainly sedation and low blood pres-
sure, limit its practicality. Notably, bupropion and nor-
triptyline, the antidepressant smoking cessation aids, are 
norepinephrine reuptake inhibitors.
Summary
Although current pharmacotherapies are effective 
in reducing smoking in some persons, many are unable to 
maintain abstinence. With continued interest in the neu-
robiologic mechanisms of addiction, preclinical advances 
have improved considerably our understanding of the 
pathophysiology of nicotine dependence, withdrawal, and 
relapse. Correspondingly, dozens of novel targets for phar-
macologic intervention have emerged, and further inves-
tigation into the role of these targets in human smoking 
is warranted.
Moving forward, the need to develop individual-
ized, multifaceted approaches to smoking cessation is 
becoming apparent. For instance, drugs that reduce the 
initial rewarding properties of nicotine are unlikely to 
normalize the long-lasting neuroadaptations associated 
with persistent drug use, which underlie craving, with-
drawal, and vulnerability to relapse. Another approach 
may be combination therapy that targets multiple aspects 
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of addiction behavior, such as a combination of bupro-
pion with NRT or varenicline, which has been successful 
in human clinical trials. Current evidence is conclusive 
that current pharmacotherapies for smoking cessation, 
including such combination therapies as bupropion with 
NRT or varenicline, improve quit rates (see Chapter 6) but 
many persons still relapse to smoking (see Chapter 2).
Finally, the pathophysiology underlying addiction to 
other drugs of abuse, particularly stimulants like cocaine, 
is similar to that of nicotine. Thus, research that leads to 
improved smoking cessation therapies also may benefit 
the treatment of other addictions. The literature should 
be mined to identify novel targets for interventions that 
promote smoking cessation.
Vaccines and Other Immunotherapies as Treatments for 
Nicotine Addiction
Nicotine vaccines are a new class of medication 
being developed for smoking cessation; interest in these 
vaccines stems from their novel mechanism of action. 
Unlike existing cessation medications that act on neu-
rotransmitter receptors in the brain to reduce the rein-
forcement or withdrawal associated with the use of 
tobacco products, vaccines act directly on nicotine, the 
principal addictive constituent of tobacco (Pentel and 
LeSage 2014). Vaccines stimulate the immune system 
to produce antibodies that can bind and retain nicotine 
in the blood, thereby reducing or slowing its delivery 
to the brain (LeSage et  al. 2006b; Esterlis et  al. 2013). 
Interrupting nicotine delivery to its site of action blocks 
or reduces its behavioral effects (Jefferson et  al. 2004; 
Goniewicz and Delijewski 2013; Maglione et al. 2014). If it 
proves feasible for nicotine vaccines to produce very high 
levels of antibodies in blood, efficacy for this approach to 
smoking cessation should be possible. Because vaccines 
act in a different manner than existing medications for 
smoking cessation, such as varenicline or bupropion, 
combining a nicotine vaccine with those medications to 
enhance overall efficacy may be possible. An additional 
potential benefit of nicotine vaccines is that their effects 
last for many months (Cornuz et  al. 2008; Hatsukami 
et al. 2011), avoiding the need to take a medication each 
day or, for some products, even more often (Prochaska 
and Benowitz 2016).
Literature Review Methods
For this section of the chapter, PubMed was searched 
in January 2017 for studies published between January 
1966 and January 2017 about active or passive immuniza-
tion against nicotine in vitro in animals or humans. The 
following terms were searched alone or in combination: 
nicotine, tobacco, smoking, cigarette, vaccine, vaccina-
tion, immunogen, immunization, antibody, linker, hapten, 
conjugate, adjuvant, addiction, dependence, cessation, 
and monoclonal. Articles identified in this manner were 
also reviewed to find additional primary references. One 
reviewer conducted a full review and identified 35 articles 
for this section.
Design and Mechanism of Action
The human immune system can recognize foreign 
(nonhuman) proteins present on infectious agents, such as 
bacteria or viruses, and can form antibodies to help defend 
against them. Nicotine is a much smaller molecule than 
a protein and lacks the structure needed to be recognized 
as foreign. Even so, nicotine can be chemically linked to a 
foreign carrier protein to stimulate the production of anti-
bodies against it (Pentel et al. 2000; Isomura et al. 2001; 
Maurer et al. 2005). This nicotine–protein immunogen is 
typically administered with an adjuvant, a chemical or mix 
of chemicals that generally enhances immune responsive-
ness. Administration of such a vaccine results in the pro-
duction of antibodies that circulate in the blood and bind 
nicotine tightly and with high specificity. Because these 
antibodies do not bind appreciably to anything other than 
nicotine, they might not disrupt the actions of other drugs 
or medications, and they might not interfere with normal 
physiologic functions.
Nicotine vaccines have not shown any serious side 
effects in animals and humans (Hatsukami et  al. 2005; 
Fahim et al. 2013). Autoimmune reactions from vaccine-
generated antibodies have not been observed (Hatsukami 
et al. 2005). Nicotine-specific antibodies do not bind ace-
tylcholine (the endogenous ligand that nicotine mimics), 
and nicotine itself is a small molecule that should not be 
able to cross-link antibodies and form immune complexes 
(Pentel et al. 2000).
Nicotine-specific antibodies in blood cannot enter 
the brain because of their large size (Satoskar et al. 2003). 
In addition, nicotine that binds to an antibody cannot enter 
the brain to interact with the receptors that mediate its 
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actions. As a consequence, vaccination can attenuate many 
of the effects of nicotine, provided a sufficient amount of 
antibody is present (Lindblom et  al. 2002; LeSage et  al. 
2006a). After vaccination, levels of nicotine-specific anti-
bodies in blood decline slowly, over months, and periodic 
booster doses of vaccine are needed to maintain high levels 
of antibody (Cornuz et  al. 2008; Hatsukami et  al. 2011). 
Because smoking cessation medications generally are 
required for only 3–6 months, vaccine efficacy should be 
obtainable after an initial three or four monthly doses of 
vaccine to achieve high serum antibody concentrations and 
perhaps a booster dose 3–6 months after that (Hatsukami 
et al. 2011).
After vaccination, nicotine in blood exists as an equi-
librium between a large amount of nicotine bound to anti-
body and a much smaller amount that remains unbound. 
Nicotine that is bound to antibody cannot be metabolized, 
but the unbound nicotine is metabolized normally. As the 
concentration of unbound nicotine in blood is reduced by 
metabolism, bound nicotine dissociates from the antibody 
to re-establish equilibrium and is, in turn, metabolized. In 
this manner, nicotine can be eliminated even in the pres-
ence of antibody, albeit more slowly than otherwise. For 
example, in rats, immunization doubled the elimination 
half-life of nicotine from 1 hour in controls to 2 hours in 
rats vaccinated against nicotine (Keyler et al. 2005). This 
process frees the antibody of its bound nicotine so that it 
is once again available to bind newly delivered nicotine 
(e.g., from the next cigarette).
Examining Data from Animals to 
Confirm Vaccine Activity
In rats and mice, nicotine vaccination reduces by 
up to 80% the delivery of single doses of clinically rele-
vant nicotine (equivalent to one or two cigarettes) to the 
brain (Cerny et  al. 2002; Maurer et al. 2005; Pravetoni 
et al. 2011). Vaccine efficacy is lower with chronic doses 
of nicotine that approximate regular smoking, but the 
entry of nicotine into the brain is still slowed (Hieda 
et al. 2000). In rats, which are thought to provide the best 
animal models for smoking behavior in humans, vaccina-
tion markedly reduces addiction-relevant behaviors, such 
as nicotine self-administration (Lindblom et  al. 2002; 
LeSage et  al. 2006a). Animal studies consistently show 
that vaccine efficacy is greatest when the level of nicotine-
specific antibodies in the blood is high, maximizing the 
nicotine-binding capacity provided in relation to the 
amount of nicotine present (Maurer et al. 2005; Pravetoni 
et  al. 2011). For the same reason, vaccination is more 
effective in blocking the effects of fewer or lower doses of 
nicotine than against regular or higher doses (Keyler et al. 
1999). Extrapolating these findings to humans, it appears 
that nicotine vaccines will be most useful for preventing 
relapse, which is often triggered by taking just a few puffs 
or smoking just a few cigarettes, and may be less effec-
tive for encouraging smoking cessation among regular 
smokers who are not motivated to quit.
Clinical Trials of Nicotine Vaccines
Several nicotine vaccines have progressed through 
Phase  2 or  3 clinical trials (i.e.,  have been tested for 
safety, efficacy, and effectiveness relative to other treat-
ments), in  combination with standard behavioral coun-
seling (Cornuz et al. 2008; Hatsukami et al. 2011; Fahim 
et al. 2013; Tonstad et al. 2013). All of these studies pro-
vide preliminary evidence of safety, but levels of antibody 
in the blood have been substantially lower than those 
achieved in rats or mice. Mean levels of antibody in par-
ticipants in human studies have reached approximately 
40 micrograms per milliliter (µg/mL), but levels of 200–
500 µg/mL can be produced in mice or rats (Maurer et al. 
2005; Keyler et  al. 2008). Part of this difference comes 
from the ability to administer higher doses of immuno-
gens and stronger adjuvants in animals than would be 
tolerated in humans without producing side effects. Not 
surprising, therefore, is that the overall efficacy of vac-
cines for enhancing smoking cessation has not been dem-
onstrated. In several studies, however, participants with 
the highest levels of serum antibody also had higher rates 
of smoking cessation compared with those who received 
a placebo vaccine (Cornuz et  al. 2008; Hatsukami et  al. 
2011). This key observation suggests that the vaccine 
strategy has merit and has the potential to be effective. 
At this time, FDA has not approved any nicotine vaccines.
Next-Generation Vaccines
Next-generation vaccines hold promise for pro-
ducing higher levels of antibody than those studied to 
date; several approaches are being evaluated:
• Improving the way in which nicotine is attached 
to its carrier protein to provide tighter binding to 
the immune cells that initiate antibody production 
(Moreno et al. 2012);
• Using more immunogenic carrier proteins or 
designing and synthesizing carrier proteins that are 
optimized to enhance the interaction of nicotine 
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with immune cells (McCluskie et al. 2013; Rosenberg 
et al. 2013; Miller et al. 2014; Jacob et al. 2016);
• Mixing or combining the nicotine–protein immu-
nogen with newer adjuvants (e.g., CpG oligonucle-
otides, water/lipid emulsions) that enhance the pro-
duction of antibodies by activating novel molecular 
pathways, or using combinations of adjuvants that 
provide additive efficacy (McCluskie et  al. 2013; 
Jacob et al. 2016); and
• Attaching nicotine to synthetic nanoparticle scaf-
folds that are designed to more precisely control 
and optimize interactions between nicotine and 
the immune system (Lockner et al. 2013; Desai and 
Bergman 2015; Liu et al. 2016).
Combining Vaccines with 
Medications
Nicotine vaccines can be designed to display dif-
ferent surfaces of the nicotine molecule to the immune 
system. Because the immune system sees each surface as 
a distinct stimulus, two or three suitably designed nico-
tine vaccines can be co-administered to get an additive 
antibody response (Keyler et  al. 2008; de Villiers et  al. 
2013). Nicotine vaccines also can be combined with small-
molecule medications because those drugs act by separate 
mechanisms. For example, nicotine-specific antibodies 
can be combined with mecamylamine, a nicotine antago-
nist that blocks the action of nicotine on its receptors in 
the brain and has been used experimentally to promote 
smoking cessation. This combination is more effective 
in rats than either of these treatments alone for blocking 
nicotine discrimination, a measure of whether the animal 
recognizes that it has received nicotine (LeSage et  al. 
2012). However, a clinical trial of a nicotine vaccine com-
bined with another drug for smoking cessation, vareni-
cline, found no additional effect from vaccination com-
pared with the drug alone (Hoogsteder et al. 2014).
Passive Immunization with 
Monoclonal Antibodies or 
Gene Transfer
The amount of antibody produced by vaccination is 
limited by the capacity of the immune system. Thus, it 
could be possible to produce nicotine-specific monoclonal 
antibodies in bacterial cultures or other in vitro systems 
and bypass the need for vaccination by administering the 
preformed antibodies directly (passive immunization). In 
animals, this approach mimics vaccination, but greater 
efficacy is possible because very large doses of antibody 
can be safely administered (Carrera et  al. 2004; Keyler 
et  al. 2005). The main limitations to this approach in 
humans are its high cost and the likely need to administer 
the antibodies intravenously (Skolnick 2015). An alterna-
tive approach to passive immunization is to administer a 
harmless virus (not capable of replication) that contains 
DNA coding for the production of the desired antibody. 
This virus can take up temporary residence in tissues and 
produce nicotine-specific antibodies that are independent 
of the host’s immune system. In rodents, extremely high 
levels of antibody have been achieved using this strategy 
for periods of up to several months (Hicks et  al. 2012). 
This approach holds promise for human therapies if mea-
sures to ensure its safety can be established.
Summary
Animal studies and early clinical trials have pro-
vided proof-of-principle that drug-specific antibodies 
can block the addictive effects of nicotine and serve as an 
adjunct to smoking cessation. The main benefit of this 
approach may be preventing relapse. Anticipated prog-
ress in vaccine design and enhancement of the immune 
response should (a) provide substantially more effective 
vaccines and other approaches to providing nicotine-
specific antibodies and (b) create opportunities to better 
explore their therapeutic potential.
Insights into Smoking Cessation from the Field of Neurobiology
Smokers trying to quit often can maintain absti-
nence for short periods, ranging from days to weeks. 
However, quitting smoking usually requires several 
attempts (USDHHS 2000, 2010; García-Rodríguez et  al. 
2013). Evidence shows that smokers often require mul-
tiple quit attempts (even more than 20, depending on the 
metrics used) and many years to obtain long-term (greater 
than 1  year) smoking abstinence (Chaiton et  al. 2016). 
This clinical observation highlights the often-mistaken 
assumption made by both practitioners and smokers 
trying to quit that the absence of the behavior (smoking) 
reflects the absence of the disease (dependence). Thus, to 
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enhance treatment outcomes, a better understanding of 
the neurobiologic basis of the disease is required. Until 
the development of noninvasive brain imaging (initially 
positron emission tomography [PET] and more recently 
and prominently, functional magnetic resonance imaging 
[fMRI]), such an understanding of affected humans has 
been difficult to obtain. In contrast, considerable preclin-
ical data (Leslie et al. 2013) have convincingly supported 
the proposition that chronic self-administration of nico-
tine—like that of other dependence-producing drugs, 
including stimulants and opiates—alters specific long-
term regional neurobiologic processes that have been 
hypothesized to explain the high rates of recidivism in 
persons who are trying to quit smoking (Sutherland and 
Stein 2018).
During the past two decades, noninvasive brain 
imaging has repeatedly demonstrated differences in 
brain structure and function in smokers compared with 
matched, never-smoking, healthy persons. Thus, it is 
plausible that such differences might be applied usefully 
and clinically to develop better behavioral interventions 
and pharmacologic treatment strategies to improve the 
current rates of cessation. There are, however, no cur-
rently available brain-based neuroimaging biomarkers of 
treatment outcome, and much of the historic behavioral 
and personality characterizations that have been shown 
to differ between smokers and nonsmokers have failed to 
serve as accurate predictors of treatment success.
Why, after consistent demonstrations of differences 
in brain and behavior between groups, have these data 
not been effective in predicting treatment outcomes? One 
working hypothesis is that the differences are not a result 
of the addiction process, but rather that they reflect a pre-
dispositional trait that preceded drug use and dependence 
and are more likely to reflect risk factors for addiction than 
consequences of drug use. If so, it would seem unlikely 
that differences identified from cross-sectional popula-
tion studies would or should signal outcome changes in 
brain circuits.
The alternative hypothesis is that the aforemen-
tioned brain differences are indeed caused by chronic 
drug use and reflect dependence-induced, neuroplastic 
brain changes. If so, this would suggest that longitudinal, 
within-participant neuroimaging data collected along the 
trajectory from the onset of treatment through short- and 
long-term recovery might serve as a biomarker of current 
disease severity and, importantly, be predictive of disease 
remission. Such a biomarker also could determine the 
possible liability risk for addiction of potential novel phar-
macologic agents and help match treatment options with 
the highest probability of aiding the individual smoker. 
A review of the neuroimaging literature reveals a min-
iscule number of studies performed on former smokers 
(Neuhaus et al. 2006; Nestor et al. 2011, 2018a,b; Krönke 
et al. 2015; Zanchi et al. 2015, 2016; Weywadt et al. 2017; 
Ono et al. 2018), leaving mostly unknown the answer to 
the question of what a former smoker’s brain actually 
looks like.
Once the data become available in greater numbers, 
noninvasive brain imaging could:
• Identify differences in brain structure and function 
between smokers and nonsmokers;
• Follow persons along the course of treatment to 
identify brain circuits and networks that uniquely 
change in those whose treatments induce prolonged 
abstinence versus those who relapse (i.e.,  whether 
the above-group differences return to a [presumed] 
pre-addicted state vs. whether other neurobiological 
systems strengthen to compensate for the dysregu-
lated brain system and networks);
• Make post hoc predictions of treatment outcomes 
by using pretreatment data and posttreatment 
outcomes;
• Develop brain-based biomarkers in clinical trials 
that predict treatment outcomes;
• Identify intermediate phenotypes of brain circuits 
and networks that can be used to fractionate the 
phenotype of the individual smoker to allow for per-
sonalized medicine and identify treatments with the 
highest probability of successful outcomes.
The ultimate goal of this strategy is to develop a 
system to individualize predictions of health outcomes 
on the basis of a model developed from group studies 
(Gabrieli et al. 2015).
Literature Review Methods
For this section of the chapter, PubMed was searched 
in January 2017 for articles that were published between 
2014 and 2017 about studies that focused on the inter-
section of human neuroimaging and nicotine addiction. 
The following terms were searched: fMRI, PET, MRI, nico-
tine, and nicotine addiction. The references cited repre-
sent publications in this domain since the 2014 Surgeon 
General’s report. From these articles, some studies con-
ducted between the publication of the 2010 and 2014 
Surgeon General’s reports were also included. One 
reviewer conducted a full review and identified 77 articles 
for this section. Articles were omitted if the studies were 
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considered to be underpowered or if quality could not be 
assessed because of incomplete descriptions.
Methodology of Neuroimaging 
Studies
In contrast to PET technology, which is best suited 
to identify molecular changes in neurotransmitter sys-
tems (for a review, see Lameka et al. 2016), MRI can be 
used to study brain structure, including gray matter den-
sity and cortical thickness, and the microstructure and 
integrity of white matter tracts (diffusion tensor imaging). 
MRI also can measure certain biochemical constituents of 
the brain using magnetic resonance spectroscopy. Finally, 
fMRI measures changes in brain activity (as inferred from 
changes in blood flow, blood volume, and oxygenation). 
The strength of fMRI is that it can measure brain activity 
while persons perform various cognitive and emotionally 
laden tasks, linking the behavioral performance of such 
nicotine addiction-related processes as working memory, 
attention, cue reactivity, and inhibitory (cognitive) con-
trol to the localization and magnitude of brain activity 
(for a review, see Huettel et al. 2014).
Data from fMRI also can be acquired in the absence 
of a directed task (i.e.,  the participant is at rest) (Biswal 
et al. 1995). Studies using resting-state fMRI have dem-
onstrated that specific brain connections (i.e., circuits and 
networks) are apparent in the absence of a directed task, 
with the strength of connections at rest sufficient to pre-
dict the strength of subsequent task activation and behav-
ioral performance (Kelly et  al. 2008; Baldassarre et  al. 
2012). Differences in resting-brain circuits may reflect 
neuropsychiatric disease, including nicotine dependence 
(Fedota and Stein 2015).
Despite their increasing applicability, neuroimaging 
studies are inherently correlative. Nevertheless, designs 
that include a pharmacologic intervention and incorpo-
rate a parametric manipulation of the task or drug (dose-
response) enable more precise interpretations. Finally, 
the advent of noninvasive brain stimulation (NIBS) 
(e.g.,  transcranial magnetic stimulation and transcranial 
direct [or alternating] current stimulation) may enable 
more direct probes of and interventions directed at puta-
tive neural circuit plasticity. The rationale for applying 
NIBS in addiction is that it could enhance circuits related 
to cognitive control or weaken circuits that are sensitive 
to provocations from cues. Although these circuits are 
also targets for many of the behavioral therapies applied in 
addiction (e.g., cognitive behavioral therapy), brain elec-
trical stimulation has the potential to improve the efficacy 
of the treatment intervention by directly engaging the 
affected circuits. Having achieved some modest success, 
transcranial magnetic stimulation, an FDA-approved treat-
ment for depression, has been proposed as a treatment for 
addiction in general (Barr et al. 2008; Gorelick et al. 2014; 
Dunlop et al. 2017) and for smoking in particular (Fraser 
and Rosen 2012; Li et al. 2013b; Dinur-Klein et al. 2014; 
Pripfl et al. 2014). However, the data for NIBS are too pre-
liminary to evaluate its efficacy in smoking cessation.
Differences in Brain Circuitry and 
Cognitive Constructs in Nicotine 
Dependence
The neuroimaging studies reviewed in this section 
have examined the effects of chronic cigarette smoking, 
acute versus extended abstinence, treatment interventions, 
and smoking cessation on the major cognitive and affective 
constructs hypothesized to be involved in nicotine addic-
tion (for a general review of addiction neurobiology, see 
earlier discussion, Koob and Volkow 2016, and USDHHS 
2010). Although different drugs of abuse initially bind to 
receptors specific to that drug’s pharmacology (e.g., opiate 
receptors [opioids]; psychostimulants [monoamine trans-
porters]; tobacco [various nicotinic receptor subtypes]), 
the “downstream” neurobiologic circuits and mechanisms 
generally are believed to share a common substrate across 
all (or most) addictions. The cyclic nature of addiction and 
the underlying circuitry and neuroplastic consequences of 
chronic drug administration provide a theoretical frame-
work to discuss the circuitry of nicotine addiction (Koob and 
Volkow 2016; Volkow et al. 2016). A better understanding of 
these neurobiologic mechanisms may yield more effective 
tools to aid in smoking cessation and also may be achiev-
able using many fewer participants than are necessary in 
a behavior-only-based clinical trial, because the effect size 
of a brain response, which is more proximal to the caus-
ative mechanism, is significantly greater than the more 
distal behavioral response (Rasetti and Weinberger 2011). 
A review of the literature by Menossi and colleagues (2013) 
summarized the role of neuroimaging in pharmacologic 
treatment for smoking and nicotine dependence. They iden-
tified multiple brain regions—including the anterior and 
posterior cingulate cortex, orbitofrontal cortex, ventral stri-
atum, amygdala, thalamus, and insula—that are involved 
in both the maintenance of smoking and processes related 
to nicotine withdrawal, such that two reasonably efficacious 
drugs used to treat nicotine dependence, varenicline and 
bupropion, modulated activity in these areas. In contrast, 
although NRT improves cognitive symptoms related to 
withdrawal, it does not generally alter the activity of neural 
circuits that are associated with nicotine addiction.
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Smoking Cues and Craving 
Provocation
Exposure to cues related to smoking is thought to 
activate brain circuits related to the salience (i.e., of imme-
diate relevance) of the stimuli and to engage memory, affec-
tive, and cognitive processes that promote drug seeking 
and, in most cases, drug taking. Moreover, smoking cues 
can directly interfere with the abstinent person’s ability to 
concentrate and to focus attention on performing a task 
or on a therapeutic intervention that involves behavioral 
change (Luijten et al. 2011). Accordingly, a better under-
standing of the brain circuits and neurobiologic mech-
anisms engaged by cues might lead to novel targets for 
treatment interventions and potentially the development 
of a biomarker of outcome efficacy. For example, treatment 
with bupropion is associated with improved ability to resist 
cue-induced cravings and a reduction in cue-induced acti-
vation of limbic and prefrontal brain regions, including the 
ventral striatum, medial orbitofrontal cortex (OFC), and 
anterior cingulate cortex (ACC) (Culbertson et al. 2011). 
Similarly, responses to varenicline in the medial OFC (as a 
function of reward) and in the lateral OFC (during reward 
evaluation) may play a role in a diminished response to 
smoking cues, which may contribute to the drug’s clinical 
efficacy (Franklin et al. 2011). Consistent with these find-
ings, Hartwell and colleagues (2013) found that successful 
smoking cessation with varenicline was associated with 
increased activation, before a quit attempt, in brain areas 
related to attentiveness and memory while the person 
resisted the urge to smoke, suggesting the drug may exert 
its effects by reducing craving and enhancing resistance to 
urges to smoke during cue-elicited craving.
More mechanistically, activation in the amygdala—
a structure long associated with stress processing, rein-
forcement learning, and risk of relapse—is dampened by 
both varenicline and nicotine, but a report by Sutherland 
and colleagues (2013b) found that this was only in a subset 
of smokers who appeared most susceptible to the negative 
consequences of nicotine abstinence for behavioral per-
formance (in this case, forced choice reaction time). This 
finding on individual difference may provide a useful step 
toward fractionating the smoker phenotype by discrete 
neurobiologic characteristics, which in turn could lead 
to differential treatment algorithms. Furthermore, the 
functional connectivity between the amygdala and insula 
and, in turn, of the insula to components of the default 
mode network (DMN) (which is composed of the ventro-
medial PFC, parahippocampal gyrus, and posterior cingu-
late cortex [PCC] and is thought to process interoceptive 
states, ruminations, reflective thoughts, and similar phe-
nomena) is downregulated by both varenicline and nico-
tine in abstinent (but not sated) smokers, and the circuit 
reduction is linked to reduced symptoms of nicotine with-
drawal, which may help to promote cessation (Sutherland 
et al. 2013a).
Consistent with a role for the amygdala and insula in 
cessation, 3 months of mindfulness treatment was found 
to reduce both behavioral reactivity and responsivity in 
both brain regions and to predict successful cessation 
(Kober et al. 2017). In another study, 2 weeks of meditation 
training (vs.  a relaxation control) resulted in an average 
60% reduction in smoking that correlated with increased 
activity in the ACC and PFC, which are brain areas related 
to self-control (Tang et  al. 2013). Taken together, these 
studies suggest that reducing DMN-insula-amygdala circuit 
activity (via pharmacologic or behavioral interventions) 
may promote abstinence by modulating the interoceptive, 
negative affective, and ruminatory consequences (i.e., crav-
ings) of cessation and point toward reduced strength of dis-
crete circuit connectivity, contributing in turn to the ame-
lioration of subjective withdrawal symptoms.
Sutherland and colleagues (2012) hypothesized that 
the balance between various large-scale brain networks 
modulates both normal and addiction-related behaviors. 
The three major large-scale brain networks in this model 
were (1) the DMN; (2) the executive control network, pri-
marily composed of the dorsolateral prefrontal cortex 
(dlPFC) and posterior parietal cortex and thought to be 
engaged during the cognitive processing of exteroceptive 
signals; and (3) the salience network, which is anchored by 
the dorsal anterior cingulate cortex (dACC) and anterior 
insula and is thought to attribute salience to stimuli and 
the selection of action during times of conflict. In a test 
of this hypothesis, Lerman and colleagues (2014) demon-
strated that the dynamic interrelationship among these 
three major large-scale networks is altered during acute 
24-hour abstinence (vs. satiety) and predicts the (a) differ-
ence in abstinence-induced changes in craving to smoke 
and (b) reduced cognitive performance and brain activa-
tion seen during a working memory task. Independently, 
a study by Zhang and colleagues (2011) positively corre-
lated cue-elicited activity in the dlPFC with the strength 
of functional connectivity between the dlPFC and rostral 
anterior cingulate cortex.
If acute abstinence in fact modulates the circuits 
and networks described above, intervention strategies 
aimed at changing their activities might prove efficacious. 
One such potential cessation treatment uses real-time 
feedback of the fMRI signal to facilitate volitional control 
over regions of the brain that regulate craving. In a proof-
of-concept study, modulating the strength of functional 
connectivity between the ACC and medial PFC via feed-
back was associated with a reduction in craving among 
heavy smokers (Kim et al. 2015). Furthermore, feedback 
from the ACC but not the dorsomedial PFC (dmPFC), 
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which is thought to be more involved in resisting craving, 
reduced activation to smoking cues, especially in persons 
with less severe nicotine dependence (Canterberry et  al. 
2013; Hanlon et al. 2013; Hartwell et al. 2016).
The amount of nicotine presented to the brain via 
smoking is directly related to the severity of nicotine 
dependence, which in turn is linked to the severity of crav-
ings during abstinence. Emergent data suggest a genetic 
link between the rate of nicotine metabolism, success 
in smoking cessation, pharmacologic efficacy, and brain 
activity (see “Genetic Studies of Smoking Phenotypes” 
later in this chapter for a discussion about the influence of 
nicotine metabolism on dependence). For example, com-
pared with slow metabolizers, persons who are fast nicotine 
metabolizers demonstrate significantly greater responses 
to cigarette cues in the amygdala, hippocampus, striatum, 
insula, and cingulate cortex—supporting the impor-
tance of cue-induced craving in recidivism and helping to 
explain why fast metabolizers have lower cessation rates 
(Tang et al. 2012). In one study, greater activation in the 
caudate and frontal pole in fast versus normal metabo-
lizers predicted abstinence-induced subjective cravings 
in response to smoking cues, suggesting that adjunctive 
behavioral cessation treatment, such as desensitization to 
repeated exposures to cues, may be useful in faster metab-
olizing persons (Falcone et al. 2016).
Reward
Like other abused drugs, nicotine, by virtue of its 
ability to interact with components of the mesocortico-
limbic system and to enhance levels of dopamine (Volkow 
et  al. 2015), modulates reward processes in ways that 
may help perpetuate smoking and limit successful ces-
sation. For example, 24-hour abstinence is associated 
with increased striatal activation during anticipation of a 
smoking reward and decreased activation in anticipation 
of a monetary reward, and greater abstinence-induced dec-
rements in striatal activation during monetary reward are 
associated with a greater likelihood of relapse (Sweitzer 
et  al. 2016b). Consistently, administration of nicotine 
during abstinence reduces activity in the ventral striatum 
when the person is anticipating a win or loss (i.e., reward 
valence) and increases activity in the dorsal striatum when 
the person is anticipating the magnitude of a rewarded out-
come (Rose et al. 2013; Fedota et al. 2015), suggesting a 
mechanism influencing the observed continued motiva-
tion to smoke and difficulty with cessation when trying 
to quit. Importantly, chronic dependence on nicotine, but 
not acute nicotine administration (i.e., NRT), reduced the 
ventral striatal temporal difference error signal (a learning 
mechanism construct related to dopamine release) in a 
classical conditioning reward paradigm, which is consistent 
with the inability of NRT to alter reward-related functional 
properties and perhaps explains its only modest ability to 
aid in smoking cessation (Rose et  al. 2012). In contrast, 
varenicline blunts the magnitude of mesocorticolimbic 
dopamine activity when a smoker is processing a reward, 
likely contributing to the drug’s greater efficacy as pharma-
cotherapy for smoking cessation (Fedota et al. 2015).
Practically speaking, smokers who show lower pre-
quit brain reactivity to pleasant stimuli than to cigarette-
related cues are less likely to be abstinent 6 months after 
their quit attempt. Therefore, an important factor under-
lying relapse may be the lack of alternative forms of rein-
forcement when someone is deprived of nicotine (Versace 
et  al. 2014). Indeed, ambivalence about treatment neg-
atively correlates with cue-related activation in brain 
areas linked to reward processing, motivation, and atten-
tion—including the rostral ACC, medial PFC, and cau-
date nucleus—thus, supporting the importance of both 
motivation to quit and expectancy to smoke (Wilson et al. 
2012, 2013).
Cognition and Cognitive Control
Cognitive performance and control processes have 
long been known to regulate so-called top-down con-
trol over behaviors, such as the ability to resist the drug-
seeking drive following cue presentation, subsequent drug 
craving, and ultimately drug taking. Such processes may 
serve as potential markers of sustained abstinence and 
treatment efficacy. For example, in a study by Krönke and 
colleagues (2015), former smokers exhibited less Stroop 
interference, indicating superior cognitive control, com-
pared with current smokers. (Stroop interference is a 
behavioral task designed to induce a conflict in cognitive 
processing that leads to a reduction in reaction time to 
perform the task. One example of this effect requires indi-
viduals to identify the color of a word that is incongruent 
with the word itself [e.g.,  the word green written in red 
ink] [Stroop 1935].) Furthermore, when more demanding 
incongruent trials were contrasted with easier congruent 
trials in this study, former smokers showed stronger 
activity in the superior frontal gyrus and ACC than cur-
rent smokers, suggesting successful smoking cessation 
may be mediated by enhanced cognitive control (Krönke 
et al. 2015). Elsewhere, in a study by Froeliger and col-
leagues (2017), differences in baseline corticothalamic 
function were predictive of inhibitory control processing 
and vulnerability to smoking relapse. In another study, 
greater activation in the inferior frontal gyrus, presupple-
mentary motor area, and basal ganglia during a response 
inhibition task at pretreatment baseline was associated 
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with an attenuated association between cravings and sub-
sequent smoking (Berkman et al. 2011).
Externalizing tendencies and/or compromised error 
processing among subsets of smokers may be relevant 
factors for the success of smoking cessation. Specifically, 
higher externalizing tendencies correlated with more per-
formance errors and predicted less recruitment of the 
insula and dACC following the commission of errors in 
smokers, and smaller error-related insula activity and less 
dACC activity correlated with higher craving during absti-
nence (Carroll et  al. 2015). In support of these regional 
alterations, reduced density of gray matter in the dlPFC of 
smokers, a structure long implicated in working memory, 
was associated with cue-elicited activity in the same brain 
area, suggesting a neurobiologic mechanism for the 
impaired cognitive control associated with chronic drug 
use (Zhang et al. 2011). Finally, smoking is associated with 
a diffuse cortical thinning that accelerates normal age-
induced thinning and cognitive decline, which requires 
approximately 25  years post-cessation for complete cor-
tical recovery (Karama et al. 2015). Although the amount 
of cortical thinning was related to the amount of nicotine 
used, as an association, the causation of the thinning is not 
known. Similarly, Power and colleagues (2015) observed a 
dose-dependent relationship between smoking and white 
matter hyperintensities.
Working memory is a sensitive biomarker of nico-
tine dependence and acute withdrawal (Loughead et  al. 
2010). Relapse to smoking was highly predictive by 
decreased dlPFC and increased PCC activation during 
acute abstinence versus smoking satiety (Loughead et al. 
2015). Moreover, acute smoking abstinence was sufficient 
to reduce dmPFC activity and performance on a working 
memory task, and because smoking a low-nicotine ciga-
rette did not ameliorate the deficit, NRT may be sufficient 
to resolve cognitive function during smoking abstinence. 
In contrast, an attempt to improve withdrawal-induced 
cognitive deficits by using tolcapone (to inhibit dopamine 
metabolism) only modestly improved the performance of 
working memory (Ashare et al. 2013). Similarly, a nicotine 
vaccine that blocks binding to nicotinic receptors in the 
brain did not block effectively either cue responsivity or 
brain activity during a working memory task (Havermans 
et al. 2014). Thus, like most vaccines, a nicotine vaccine 
may prove more effective in preventing a disease (i.e., nic-
otine addiction) because brain circuits that have been 
modified or dysregulated as a result of nicotine depen-
dence are not likely to return to their pre-addiction state 
simply by blocking new nicotine from reaching the brain. 
Indeed, that smoking relapses occur months or even years 
after smoking cessation suggests that the absence of nico-
tine alone is insufficient to reverse dependence-induced 
circuit neuroadaptations.
Insights from Neuroimaging for 
Antismoking Messages
In addition to providing a salient stimulus to seek 
out or enhance drug use (Wang et  al. 2013), smoking 
cues could serve, together with appropriate messaging, 
as a negative reinforcement. For example, analyses using 
neuroimaging of responses to antismoking ads that were 
intended to change attitudes toward smoking appeared to 
predict the severity of subsequent smoking and treatment 
outcomes (Camenga and Klein 2016). Most persons begin 
using nicotine and often become nicotine dependent 
during adolescence (USDHHS 2012; Camenga and Klein 
2016). Compared with adult smokers, adolescent smokers 
exhibited greater craving reduction and greater blunted 
recruitment of insula and dlPFC in response to package 
warning labels (Do and Galván 2015). Furthermore, 
greater dlPFC regulation of limbic regions predicted 
cigarette craving. These data underscore the prominent 
role of frontoinsular circuitry in predicting the efficacy 
of graphic warning labels for reducing craving in adult 
and adolescent smokers. In adult smokers, activation in 
the dmPFC in response to persuasive advertisements pre-
dicted urine cotinine levels 1  month later (Wang et  al. 
2013). In smokers trying to quit, the amygdala’s response 
to smoking cessation messages was modulated by genetic 
variation in the serotonin transporter and was predictive 
of quitting outcome (Jasinska et al. 2012). Genetic altera-
tions in the dopamine D4 receptor also modulated respon-
siveness of the amygdala to cues (Xu et al. 2014). A study 
by Chua and colleagues (2011) supports the hypothesis 
that tailored health interventions are more effective at 
eliciting positive behavior change than generic interven-
tions. For example, messages tailored to the individual 
increased activation of the dmPFC, a region known to be 
involved in self-related processing, and predicted quitting 
during a 4-month follow-up. Taken together, these data 
suggest that fMRI may aid the prerelease evaluation of 
televised public health ads.
Neuronal Circuits and Networks
Studies of resting-state functional connectivity have 
revealed that the ACC, PCC, medial and lateral OFC, ventral 
striatum, amygdala, thalamus, and insula are all heavily 
involved in the maintenance of smoking and nicotine with-
drawal (Figure 3.3). Varenicline and bupropion modulate 
activities in these brain areas, providing mechanistic sup-
port for their abilities to alleviate withdrawal symptoms 
and help with smoking cessation. For example, among non-
lapsed smokers who were making a 3-week quit attempt, 
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Sweitzer and colleagues (2016a) observed abstinence-
induced increases in connectivity strength between the 
ventral striatum and a network of regions implicated in 
addictive disorders, including the insula, superior tem-
poral gyrus, and ACC; the opposite pattern was observed 
for those who later lapsed. Also in this study, following 
24-hour abstinence, decreased connectivity between the 
dorsal striatum and the medial PFC, PCC, hippocampus, 
and supplemental motor area was observed across both 
successful and unsuccessful cessation groups. These find-
ings suggest that modulation of striatal connectivity with 
the cingulo-insular network during early withdrawal may 
be associated with outcomes for smoking cessation.
This potential association is particularly impor-
tant because a high density of nAChRs has been found in 
the cingulo-insula network (Picard et al. 2013), and this 
salience network has been implicated in the switching of 
cognitive resources during abstinence (vs. satiety) toward 
more internal bodily processing and nicotine craving 
(Sutherland et  al. 2012; Lerman et  al. 2014). Moran-
Santa Maria and colleagues (2015) found a psychophysi-
ological interaction between the anterior insula and the 
Figure 3.3 Neuronal mechanisms involved in nicotine addiction: A model
Source: Changeux (2010, p. 391), with permission.
Notes: α = alpha; β = beta; HB–IPN = habenula–interpeduncular; LDTg = laterodorsal tegmental nucleus; NAc = nucleus accumbens; 
nAChR = nicotinic acetylcholine receptor; PPTg = pedunculopontine tegmental nucleus; SNpc = substantia nigra pars compacta; 
VTA = ventral tegmental area. “Many brain areas contain nAChR subunits and are involved in nicotine addiction. First, the somata of 
the dopaminergic neurons that contribute to nicotine intake and reinforcement are in the VTA of the midbrain: they project to the 
prefrontal cortex and to limbic areas, in particular the hippocampus and NAc in the striatum [Balfour et al. 2000; Di Chiara 2000; 
Maskos et al. 2005; Balfour 2009]. These VTA neurons receive cholinergic innervation from the PPTg and the adjacent LDTg [Picciotto 
and Corrigall 2002; Maskos 2008]. Second, the emergence of a negative emotional state and withdrawal syndrome following smoking 
cessation—or nicotine deprivation—mobilizes distinct neural circuits that can include the extended amygdala and brain stress systems 
[Koob 2008], the hypothalamus, hippocampus [Davis and Gould 2009], SNpc, and/or the HB–IPN system [Salas et al. 2009]. Third, 
the ‘switch’ from voluntary nicotine use to compulsive drug use may represent a global top-down ‘gating’ transition from control 
by a prefrontal (cortical and insular) global neuronal workspace (BOX 1) to subcortical (striatal) control [Grace 2000; Changeux and 
Dehaene 2008; Naqvi and Bechara 2009]” (Changeux 2010, p. 391).
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precuneus (a part of the DMN)—which  are regions known 
to be involved in self-awareness and interoception, or the 
sense of internal bodily states—during the presentation of 
smoking cues. According to Zelle and colleagues (2017), 
connectivity strength between the anterior insula and 
dlPFC following provocation from smoking cues predicts 
the ability to resist smoking after acute abstinence.
Vulnerability to relapse after a quit attempt was 
associated with weaker connectivity between the posterior 
insula and primary sensorimotor cortex, suggesting that 
greater connectivity in this network improves the ability 
to inhibit a motor response to cigarette cravings when 
those cravings conflict with the goal to remain abstinent 
(Addicott et  al. 2015). Elsewhere, research has consis-
tently shown that the insula and basal ganglia play a role 
in addiction to smoking, as revealed by localized stroke 
lesions in these regions (Naqvi and Bechara 2010; Gaznick 
et al. 2014), and that local connectivity coherence within 
the PCC, a key DMN region, can predict the success of ces-
sation (Wang et al. 2017).
In contrast to the insula-based circuits related to the 
state of nicotine withdrawal and the positive effects of NRT 
on cognitive processing, NRT does not alter the activity 
in an ACC-ventral striatal neural circuit that is associated 
with the severity of trait nicotine addiction (Hong et al. 
2009). Further speaking to the role of the ACC and striatum 
in trait addiction, slow nicotine metabolizers, which pre-
sumably have relatively higher nicotine levels in the brain, 
showed greater functional connectivity in the dACC and 
ventral striatum, which is negatively associated with the 
severity of nicotine dependence (Li et al. 2017). Critically, 
the dACC and ventral striatum are biased by inputs from 
the insula. Moreover, a similar gene–environment reduc-
tion was seen in the dACC and ventral striatum during 
smoking abstinence when study participants performed a 
cognitive control response inhibition task and a reward 
task to probe their function, which were both normalized 
following NRT. These data suggest that the inherited rate 
of nicotine metabolism fundamentally changes brain cir-
cuits and function, which may, in turn, influence the out-
comes of smoking cessation (Li et al. 2017).
The findings that both nicotine trait addiction (long 
standing) and current state (transient) engage distinct 
neural mechanisms (dACC and ventral striatum) and cir-
cuits (amygdala, insula, and DMN) and that NRT appears 
to improve cognitive symptoms related to withdrawal but 
does not alter a measure of disease severity (the FTND), 
suggest that both nicotinic and non-nicotinic pharmaco-
therapy may reduce smoking via distinct neural mecha-
nisms of action and thereby endorse the potential value of 
neuroimaging in the development of new medications and 
discovery of brain-based biomarkers of early therapeutic 
response in cigarette smokers (Menossi et al. 2013).
Molecular Imaging
PET imaging has contributed to a better understanding 
of the biochemical and molecular alterations in nicotine 
addiction and smoking cessation. Clearly, understanding 
the mechanisms of action of effective pharmacotherapies 
for nicotine dependence is critical to the development of 
better treatments. A PET study using [(11)C]-(+)-PHNO 
demonstrated that varenicline, the most effective pharmaco-
therapy currently available, increases levels of striatal dopa-
mine, much as smoking does (Cosgrove et al. 2014), which 
may contribute to the drug’s efficacy (Di Ciano et al. 2016).
An important public health question is whether doc-
umented changes in brain structure and function in per-
sons who are dependent on nicotine can be reversed or nor-
malized following extended abstinence. Notably, smoking 
cessation is accompanied by a decrease in the density of 
α4β2* nAChRs across the brain, suggesting a normaliza-
tion of the receptors that primarily bind nicotine following 
intake (Brody et al. 2013). Additionally, smokers with less 
upregulation of α4β2* were found to have a greater prob-
ability of quitting smoking than those with greater upreg-
ulation, providing a potential biomarker of cessation suc-
cess (Brody et al. 2014). In a different study (Akkus et al. 
2016), compared with recent former smokers, long-term 
former smokers showed higher mGluR5 binding, most 
prominently in the frontal cortex and thalamus, sug-
gesting that downregulation of these receptors may be a 
mechanism underlying nicotine dependence and the high 
rate of relapse seen in those previously exposed to nico-
tine. Accordingly, mGluR5 receptor binding may serve 
as an effective smoking biomarker and a potential target 
for future medications (Akkus et  al. 2016). In contrast, 
binding at the GABA(A) receptor, a component of the prin-
cipal brain inhibitory system, does not seem to normalize 
with sustained abstinence (Stokes et al. 2013).
Sex differences in smoking behavior and brain molec-
ular mechanisms have been reported (Sieminska and Jassem 
2014). Consistent with the notions that men smoke ciga-
rettes for their reinforcing properties and women smoke for 
such reasons as mood regulation and cue reactivity (Perkins 
et al. 2001; Xu et al. 2008), Cosgrove and colleagues (2014) 
found, in an analysis of smoking in a PET scanner, that 
smoking resulted in rapid increases in dopamine in the ven-
tral striatum of men, while dopamine release in women was 
faster than in men in a subregion of the dorsal putamen. 
Moreover, smoking-induced alterations in nAChR binding 
appeared to differ by sex, with receptor upregulation seen in 
male but not female smokers (vs. nonsmokers, respectively). 
In contrast, nAChRs are negatively correlated with levels 
of progesterone, which in turn are positively correlated 
with symptoms of depression and intensities of cigarette 
craving and withdrawal (Cosgrove et al. 2012). These data 
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suggest that female smokers may be best treated by medi-
cations that do not interact directly with nicotinic mech-
anisms. Additionally, a study using fMRI indicated higher 
reactivity to smoking cues (vs. neutral cues) in males com-
pared with females in specific reward-related regions of the 
brain (the ventral striatum/ventral pallidum and the ven-
tral medial prefrontal cortex) (Dumais et al. 2017). Brain 
activation during smoking cues correlated positively with 
cue-induced subjective craving in males but not in females. 
These data suggest that, compared with women, men have 
greater reward-related brain activation to drug cues.
Although these small studies may have been under-
powered to definitively distinguish smoking-related, sex-
specific differences in the neurochemistry and circuitry in 
the brain, they add to a growing and important base of 
literature on sex differences in nicotine addiction. They 
also underscore the need for more research on sex-specific 
neurobiology of the etiology and treatment of nicotine 
dependence.
Summary
The data presented in this section highlight new 
biologic insights into smoking cessation gained from mul-
tiple neuroimaging modalities, including PET and fMRI. 
These studies highlight the neurobiologic complexities of 
nicotine dependence and, in their totality, are sufficient 
to support the multiple cognitive and affective systems 
that are dysregulated in persons with this disease, sug-
gesting why persons who are addicted to nicotine are so 
resistant to treatment even with multiple FDA-approved 
medications. On a more positive note, these neuroim-
aging findings have begun to reveal neurobiologic mecha-
nisms and cognitive constructs that may serve as novel 
targets for future therapeutic developments, including 
reward processing, cognitive control, and executive func-
tions (such as working memory and inhibitory control 
processes and affective responses to internal and external 
cues and stressors). These studies are suggestive of dys-
regulated brain regions, including various prefrontal and 
cingulate cortical regions, and their corresponding cir-
cuits and interactions with various striatal and insula 
loci. Almost all studies were cross-sectional—not longitu-
dinal. Therefore, specific causal relationships are difficult 
to infer in the absence of repeated measurements within 
subjects. Nevertheless, outcomes for smoking cessation 
may be improved by using pre- and posttreatment, mul-
timodal neuroimaging measures that are coupled with 
recent computational advances (e.g., machine learning) to 
create objective, quantifiable biomarkers that can be used 
to assess disease severity and treatment efficacy.
Genetic Studies of Smoking Phenotypes
Studies of twins suggest that smoking behaviors are 
moderately to highly heritable. For example, according 
to earlier studies, genetic factors explain an estimated 
46–84% of the variability in smoking initiation and 
smoking persistence, up to 75% of the variability in nico-
tine dependence (Kendler et  al. 1999; Vink et  al. 2005), 
and 50–58% of the variability in smoking cessation (Xian 
et al. 2003; Broms et al. 2006). Two broad approaches to 
molecular genetics exist: Candidate gene studies identify a 
specific gene to investigate, on the basis of biologic plausi-
bility, and test the association between the selected genetic 
variants and the phenotype of interest. In contrast, GWAS 
are not restricted to individual genes. Instead, they assess 
the association between hundreds of thousands of variants 
(and, more recently, several million variants) across the 
genome with the phenotype of interest.
The 2010 Surgeon General’s report summarized 
studies of candidate genes involved in the dopamine 
pathway, which at the time was considered a promising 
target for genetic dissection, with the DRD2 Taq1A poly-
morphism being one focus of interest (USDHHS 2010). 
Early studies suggested that the A1 allele at this locus was 
associated with increased short-term effectiveness of NRT 
and bupropion. Subsequent studies, however, have not 
confirmed an association with smoking status (Tobacco 
and Genetics Consortium 2010) or with response to phar-
macotherapy for smoking cessation (Choi and Shin 2015). 
The 2010 Surgeon General’s report also reviewed studies 
of candidate genes (e.g., CYP2A6 and CYP2E1) involved in 
nicotine metabolism in relation to smoking phenotypes, 
but it concluded that findings were not consistent, possibly 
because of differences in samples across studies (USDHHS 
2010). Two later studies used the nicotine metabolite ratio 
(NMR), which is the ratio of 3’-hydroxycotinine (the product 
of CYP2A6 activity) to cotinine, as a phenotypic biomarker 
for CYP2A6 activity and concluded that NMR predicts the 
outcomes of treatment for smoking (Kaufmann et al. 2015; 
Lerman et al. 2015). This conclusion likely results from 
better measurement of nicotine metabolism activity gained 
using a phenotype instead of a genotype, as this gene locus is 
very complicated and results can be inconsistent because of 
the different variants being tested. Since the 2010 Surgeon 
General’s report, considerable progress has been made in 
understanding the genetic basis of smoking phenotypes, 
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particularly through GWAS. Candidate gene studies and 
GWAS have identified variants in the CHRNA5-CHRNA3-
CHRNB4 region as promising targets for the study of nico-
tine dependence and smoking intensity.
Literature Review Methods
For this section of the chapter, MEDLINE was 
searched for articles that were published between 2000 
and 2018 about studies that focused on genetic associa-
tions with smoking behavior (including cessation). A com-
bination of controlled vocabulary and keyword terms was 
used for each of the concepts: smoking cessation, smoking 
behavior, smoking phenotype, genetics, and precision 
medicine. Studies were excluded if they did not focus 
on the underlying biology of smoking behavior and/or 
smoking cessation. Conclusions were formulated from 
evidence cited in the 2014 Surgeon General’s report on 
smoking and any newly available evidence. Search results 
were limited to studies published in English and to orig-
inal research. Duplicates were deleted, and unique hits 
were screened. Two independent reviewers conducted a 
full review and identified 47 articles for this section. From 
these articles, seven more articles about studies conducted 
in the 1990s were also included.
Candidate Gene Studies
Candidate gene approaches require some theoretical 
knowledge of the biologic mechanism underlying the phe-
notype of interest that points to specific genes. Typically, 
these approaches focus on genetic variants that result in 
functional changes (Kwon and Goate 2000). The selected 
variant is tested for its occurrence in cases and controls 
(e.g.,  assigned by smoking status) or for its association 
with a continuously distributed trait (e.g., nicotine depen-
dence) (Patnala et al. 2013).
Findings from candidate gene studies are difficult 
to reproduce. This is likely because of the typically small 
samples used in these studies, the small effect sizes asso-
ciated with common genetic variants and complex behav-
ioral traits, and the relatively liberal alpha threshold used 
(Chang et al. 2014). Despite these limitations, candidate 
gene studies have produced some robust associations, 
as discussed later in this section.
Genomewide Association Studies
GWAS adopt the same approach as candidate gene 
studies, but rather than testing the association of one or 
a small number of genetic variants with a phenotype of 
interest, GWAS simultaneously test hundreds of thousands 
of genetic variants (typically single nucleotide polymor-
phisms [SNPs]) across the genome. The multiple testing 
burden implicit in GWAS has led to a consensus that sig-
nals have to achieve a very stringent threshold for statis-
tical significance (typically p  <5  ×  10−8). This, in turn, 
requires very large samples or the pooling of data across 
multiple studies to achieve the necessary sample size to 
robustly identify the small effects associated with the 
common genetic variants. Most GWAS also report results 
from discovery and replication datasets. This combination 
of large sample sizes, statistical stringency, and replica-
tion means that GWAS have been extremely successful 
in identifying genetic variants associated with a range of 
complex phenotypes, including variants that would not 
have been considered previously on the basis of biological 
function. GWAS have identified novel genetic associations 
with smoking behaviors, such as BDNF for smoking ini-
tiation, the CHRNA5-A3-B4 gene cluster for intensity of 
smoking, and DBH for smoking cessation (Berrettini et al. 
2008; Bierut et al. 2008; Thorgeirsson et al. 2008; Tobacco 
and Genetics Consortium 2010).
As would be expected, one of the limitations of 
GWAS is their limited ability to detect low-frequency vari-
ants. For example, Lindquist and colleagues (2013) esti-
mated the first GWAS to have detected less than 20% of 
all independent GWAS-detectable SNPs in chronic dis-
eases. More recent GWAS have employed imputation to 
expand genomic coverage to better capture low-frequency 
variants. To impute genotypes, data for the microarray are 
matched to a genome reference panel, which consists of 
densely sequenced genomic data from multiple persons 
(e.g., 1,000 Genomes Project Consortium et al. 2010).
Microarrays designed in this manner cover a large 
portion of all SNPs in the human genome by directly 
measuring high- and low-frequency variants and by mea-
suring SNPs in linkage disequilibrium (Lindquist et  al. 
2013). Even so, another limitation of GWAS is that the 
phenotypes are relatively crude because they are tested in 
large samples and in the case of smoking behavior, often 
rely on retrospective self-reports. Carefully defined and 
well-characterized phenotypes offer greater precision of 
measurement, increase the genetic signal, and improve 
the likelihood of replication (Munafò et al. 2012).
Examples of Biologically Promising Candidate 
Genes (DRD2 and DAT1)
The mesolimbic dopamine system is particularly 
important in addictive behaviors and is activated by nico-
tine. As a consequence, genes encoding proteins involved 
in the neurotransmission of dopamine have been consid-
ered plausible candidate genes for nicotine dependence 
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and smoking cessation, and they have been widely inves-
tigated in candidate gene studies. Variations of the dopa-
mine receptor D2 (DRD2) and the dopamine transporter 
SLC6A3 (also known as DAT1) genes have received par-
ticular attention (Sullivan and Kendler 1999; Dani 2003; 
Duan et al. 2003; Li et al. 2003; Dahl et al. 2006; Lerman 
et al. 2006a; Schnoll et al. 2007).
Associations Between the DRD2 and DAT1 Genes 
and Smoking Behavior
In the DRD2 gene, rs1800497 (Taq1A) is one poly-
morphism that is located downstream and in the neigh-
boring ankyrin repeat and kinase domain containing 
1 (ANKK1) gene (Neville et al. 2004). This polymorphism, 
which is involved in inhibiting the synthesis and release 
of dopamine, leads to decreased density of the dopamine 
receptor (Noble et al. 1991, 1997; Pohjalainen et al. 1998; 
Jonsson et  al. 1999) and, therefore, reduced dopamine 
binding in the brain (Thompson et  al. 1997). Various 
studies have reported that the A1 allele of the DRD2 Taq1A 
polymorphism is associated with being a former or current 
smoker (Noble et al. 1994; Morton et al. 2006); with age of 
smoking initiation and duration of abstinence (Comings 
et  al. 1996); and with smoking intensity (Connor et  al. 
2007). In addition, meta-analyses have reported suggestive 
evidence of an association of the A1 allele with increased 
likelihood of smoking persistence (Munafò 2004; Munafò 
et  al. 2004, 2009). Other studies, however, did not yield 
similar findings (Batra et al. 2000; Bierut et al. 2000).
Other studies have investigated whether DAT1 vari-
ants are associated with smoking behavior. DAT1 has a 
polymorphic variable number of tandem repeats sequence 
that varies from 3 to 11 copies, of which only the 9- and 
10-repeat alleles are common (Chen and Reith 2000). DAT1 
plays a key role in regulating the transport of dopamine by 
regulating its reuptake (Choi and Shin 2015). Timberlake 
and colleagues (2006) reported that the absence of the 
9-repeat allele in DAT1 (DAT-9) was associated with being 
less likely to be a smoker; other studies have suggested 
that this association is stronger if the person was also car-
rying the DRD2 A2 allele (Lerman et al. 1999), had a later 
onset of smoking (Lerman et al. 1999; Schmid et al. 2009), 
had longer quitting attempts (Lerman et  al. 1999), or 
had formally tried smoking cessation (Sabol et al. 1999). 
However, these associations have not been found in other 
studies (Bierut et al. 2000; Jorm et al. 2000; Vandenbergh 
et al. 2002).
Meta-analyses of GWAS conducted by the Tobacco 
and Genetic Consortium (2010), using data from three 
GWAS of smoking consortia to evaluate a number of phe-
notypes, did not find evidence of an association between 
loci in either DRD2 or DAT1 and smoking behavior. Despite 
these equivocal results, several pharmacogenetic studies 
have suggested an association between genes involved 
in the dopaminergic pathway and response to pharma-
cotherapy that is aimed at smoking cessation (David and 
Munafò 2008).
The Moderating Effect of DRD2 and DAT1 on the 
Efficacy of Treatment for Smoking Cessation
Some studies have found that the A1 allele of the 
DRD2 gene is associated with better response to NRT 
(Johnstone et al. 2004; Yudkin et al. 2004; Lerman et al. 
2006b), and others have found an association between 
A2 and better response to bupropion for specific nico-
tine withdrawal symptoms (David et al. 2003; Swan et al. 
2005; David et al. 2007). In contrast, Berlin and colleagues 
(2005) did not find an association between the DRD2 
genotype and smoking cessation. Additionally, Choi and 
Shin (2015) did not find an association between DRD2 
polymorphisms and response to therapy for smoking 
cessation. Finally, in a randomized, placebo-controlled, 
smoking cessation study of bupropion, Lerman and col-
leagues (2003) did not find an association between the 
DRD2 and DAT1 genotypes and either the abstinence rate 
or response to treatment.
These findings suggest that many genes likely play 
a role in the efficacy of treatment for smoking cessa-
tion (David et  al. 2013b). Each genetic variant probably 
explains only a small fraction of the variation in response 
to medication and success in quitting, and most studies 
have investigated only a single variant or just a small 
number of them. A combination of genetic variants in 
a single genetic risk score may reveal stronger associa-
tions with the outcomes of therapies for smoking cessa-
tion and support personalized therapy on the basis of a 
person’s score.
Genetic Risk Scores
Additive genetic scores (AGS) are an alterna-
tive approach to evaluate the effects of multiple suscep-
tible SNPs for a single phenotype. These scores take into 
account the collective impact of several variants, on the 
basis of theoretical knowledge of those included, and pro-
vide greater statistical power than single-variant studies 
(David et al. 2013b). Early approaches developed AGS on 
the basis of candidate genes of theoretical interest, and 
recent approaches have generated scores from variants 
identified via GWAS.
In two randomized clinical trials of bupropion for 
smoking cessation, David and colleagues (2013b) used an 
AGS from genes in the dopaminergic system, including 
COMT, DRD2, DRD4, and DAT1. The score was calculated 
on the basis of the number of alleles considered to promote 
smoking cessation through bupropion and was estimated 
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for each participant. The score was not associated with 
the number of days to first lapse, but evidence from this 
study indicated that bupropion (vs. placebo) counteracts 
the propensity to lapse in persons with a higher additive 
genetic efficacy score.
Uhl and colleagues (2014) studied smokers by using 
the “v1.0 score,” which is based on 12,058 SNPs (Uhl et al. 
2010). Using a randomized controlled clinical trial in 
which dose of NRT was matched to the smoking intensity 
of each participant, the study found that the v1.0 score can 
predict success of quitting.
More recently, Chenoweth and Tyndale (2017) sug-
gested that including environmental effects (e.g.,  use 
of estrogen-containing hormonal therapy) into AGS 
approaches would improve the ability to predict the out-
comes of treatment for smoking cessation. At the same 
time, evaluative tools, such as biomarkers, could lead to 
tailored or personalized treatment (Bough et  al. 2013). 
Regardless, early approaches to AGS, which used candi-
date genes, need to be treated with caution in light of the 
poor reproducibility of many findings for candidate genes.
Examples of Biologically Promising Genes That 
May Help Optimize Treatment
Both genetic and metabolic biomarkers have the 
potential to predict outcomes for different treatments 
for smoking cessation and individual responses to medi-
cation. Particularly promising genetic variants include 
those in the CHRNA5-A3-B4 gene cluster on chromo-
some  15 (at  15q25) that encodes 3  (α3, α5, β4) of the 
11  (α2–α7, α9, α10, β2–β4) neuronal nAChR subunits 
(Gold and Lerman 2012). Multiple candidate gene studies 
and GWAS have verified the small but robust association 
of this cluster of genes with smoking intensity and nico-
tine dependence (Saccone et al. 2007; Bierut et al. 2008; 
Thorgeirsson et al. 2010). Importantly, smoking intensity 
and nicotine dependence predict the success of cessation 
(Piper et al. 2006; Transdisciplinary Tobacco Use Research 
Center on Tobacco and Dependence et al. 2007), and thus 
the relationship between the CHRNA5-A3-B4 gene cluster 
and cessation phenotypes has been investigated (Munafò 
et al. 2011; Bergen et al. 2013; Tyndale et al. 2015).
NMR is a metabolic predictive biomarker that cap-
tures activity of the CYP2A6 gene. CYP2A6 plays an impor-
tant role in nicotine metabolism; up to 80% of nicotine is 
inactivated to cotinine by the hepatic enzyme cytochrome 
P450 (CYP) 2A6, with a small contribution (10%) from 
CYP2B6. Most of the cotinine is further metabolized to 
3’-hydroxycotinine. NMR is used as a proxy of CYP2A6 
activity and is preferred over assessing the gene itself 
because CYP2A6 is characterized by dozens of polymor-
phisms. A faster NMR reflects higher CYP2A6 activity and 
is associated with several smoking phenotypes.
The CHRNA5-A3-B4 Gene Cluster
Associations with Nicotine Dependence and 
Smoking Intensity
Saccone and colleagues (2007) authored the first 
candidate gene study to report an association between 
the SNP rs16969968 in CHRNA5 and nicotine depen-
dence. The following year, GWAS conducted separately by 
Berrettini and colleagues (2008) and Thorgeirsson and col-
leagues (2008) reported that rs1051730 at the same locus 
but in CHRNA3 (and strongly correlated with rs16969968 
in samples of European ancestry) was associated with the 
number of cigarettes smoked per day. CHRNA5 was not 
considered a strong candidate gene at the time, given 
what was then known about the neurobiology of nicotine 
dependence. Animal experiments had implicated the α4 
and β2 nicotinic receptor subunits as critical to nicotine’s 
reinforcing effects (Picciotto et  al. 1998; Tapper et  al. 
2004), and α4β2* partial agonists are now known to be 
one of the most effective treatments available for smoking 
cessation (Fowler and Kenny 2014). Findings from GWAS 
have made variants in the CHRNA5-A3-B4 region prom-
ising targets for the study of nicotine dependence and 
smoking intensity, given their association with response 
to nicotine and its consequent consumption.
In particular, the rs1051730 SNP in CHRNA3 is 
a coding-synonymous variant that does not result in an 
altered protein, and thus it likely does not have any func-
tional significance. However, the highly correlated variant 
rs16969968 in CHRNA5 is functional and presents with a 
missense mutation that results in an amino acid substi-
tution of aspartate to asparagine in the α5 subunit pro-
tein. Both in vitro and in vivo studies have further char-
acterized the role of the rs16969968 variant. In in vitro 
studies, α5 receptor complexes featuring the aspartic acid 
variant, when exposed to a nicotine agonist, have exhib-
ited a substantially greater maximal response than the 
α5 receptor complexes containing the asparagine variant 
(i.e., the risk variant associated with the number of ciga-
rettes smoked per day and nicotine dependence) (Bierut 
et al. 2008). A series of animal studies has established the 
role of the α5 nAChR subunit by investigating the pheno-
type via an α5 knockout mouse model, which is analogous 
to a reduced α5 receptor function in humans (i.e., carriers 
of the rs16969968 risk allele) (Salas et  al. 2009; Fowler 
et al. 2011; Frahm et al. 2011). Salas and colleagues (2009) 
showed that α5 knockout mice, when exposed to chronic 
infusions of nicotine, exhibited withdrawal symptoms com-
parable to those of saline-infused mice (i.e., a lack of with-
drawal symptoms relative to wild-type mice). In the exper-
iment conducted by Fowler and colleagues (2011), both 
wild-type and mutant mice were trained to press a lever 
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to obtain nicotine intravenously. All the mice showed the 
expected inverted U-shaped dose-response curve, with the 
difference that knockout mice responded more vigorously 
at high doses. Knockout mice consumed a greater amount 
of nicotine, and the wild-type mice appeared to titrate the 
delivery of nicotine to achieve a desired level. Although 
knockout mice appeared to experience rewarding effects 
of nicotine similar to those experienced by wild-type mice, 
the inhibitory effects of the high doses of nicotine on the 
activity of the rewarding circuitry seemed to be largely 
altered. The injection of a lentivirus vector into the MHb 
in α5 knockout mice rescued the expression of α5 subunits 
in this region and the phenotype.
Similarly, a study by Jackson and colleagues (2010b) 
showed differential effects of nicotine dose on reward 
between α5 knockout and wild-type mice using a CPP task. 
Later, in a study of humans, Jensen and colleagues (2015) 
found an attenuated aversive response to nicotine admin-
istered intravenously in overnight-abstinent smokers who 
were carriers of the CHRNA5 rs16969968 risk allele geno-
type. In summary, high doses of nicotine seem to stimu-
late the MHb–IPN tract through nAChRs containing α5 
subunits and elicit aversion, limiting further intake. This 
does not happen when the α5 signaling is deficient and, 
consequently, the negative effects of nicotine are atten-
uated. Similarly, smokers carrying the rs16969968 risk 
allele are more likely to smoke more heavily than their 
counterparts without the risk allele.
Evidence from in vitro and in vivo studies further 
indicates that the MHb acts as a gatekeeper for nicotine 
intake. Frahm and colleagues (2011) manipulated the 
concentration of α5 and β4 subunits in vitro, while α3 was 
kept constant. Nicotine-evoked currents in MHb neurons 
of wild-type and transgenic Tabac mice (characterized by 
an overexpression of β4) led to a dramatically higher firing 
rate in the neurons of the Tabac mice. Those mice exhib-
ited a reduced nicotine intake and a strong preference for 
water rather than low-nicotine-concentration solutions in 
a two-bottle choice test that compared them with wild-
type mice presented with the same volumes of water and 
the low-nicotine solution. When the expression of the α5 
risk variant was elicited by injecting a lentivirus vector 
into MHb neurons in the Tabac mice, the latter restored 
their nicotine consumption and their two-bottle choice 
behavior to a level comparable to that of the wild-type 
mice. These animal studies show that α5 and β4 play an 
important role and compete in regulating nicotine intake.
In humans, Hong and colleagues (2010) used 
resting-state functional connectivity to understand the 
mechanistic link between variation at the CHRNA5-A3-B4 
locus and nicotine addiction. Their study identified a cir-
cuit between the dorsal anterior cingulate and the ventral 
striatum/extended amygdala that distinguished smokers 
from nonsmokers and predicted nicotine dependence. Both 
smokers and nonsmokers with the risk allele had a weaker 
circuit than those with the more common allele (although 
the circuit strength was even weaker in smokers), sug-
gesting a trait-like circuit biomarker. A nearly identical 
circuit was described previously in smokers (Hong et al. 
2009) as a function of nicotine dependence. Critically, in 
that study, circuit strength did not change following NRT, 
suggesting that it reflected chronic dependence.
CHRNA5-A3-B4 Variants and Smoking Cessation 
in Absence of Treatment
The genetic risk variants associated with nicotine 
dependence and smoking intensity also were associated 
with smoking cessation. Interestingly, persons who smoke 
a greater number of cigarettes per day seem to quit at a 
later age (Chen et  al. 2015). Some studies have shown 
that CHRNA5, in particular the rs16969968 risk variant, 
has potential clinical significance in predicting delayed 
smoking cessation. Chen and colleagues (2015) conducted 
a large meta-analysis to investigate whether rs16969968 
plays a role in the age of smoking cessation among smokers 
without smoking-related disease and patients with lung 
cancer, chronic obstructive pulmonary disease, or coro-
nary heart disease. Results from 24 datasets in their study 
showed evidence for an association only for the smokers 
without a smoking-related disease and the rs16969968 risk 
allele, with a median delay of 4 years. The heterogeneity of 
the studies in this meta-analysis shows that a number of 
factors may moderate genetic risk, such as the presence of 
disease, use of medication, and environmental risk factors 
(e.g., having a partner or friend who smokes).
Freathy and colleagues (2009) assessed smoking ces-
sation in a large cohort of women of European ancestry, 
over the course of their pregnancies. Carriers of the risk 
variant rs1051730 showed a reduced likelihood of stop-
ping smoking. The effect did not appear to be solely medi-
ated by intensity of smoking, as adjusting the analysis for 
that variable did not affect the results, although this may 
have been because the number of cigarettes smoked per 
day does not fully capture intensity of smoking (e.g., given 
interindividual differences in depth of smoke inhalation 
and other measures of smoking topography). Thorgeirsson 
and Stefansson (2010) replicated this finding in a retro-
spective study of pregnant women, which found an associ-
ation between the risk variant rs1051730 and continuing 
smoking during pregnancy.
CHRNA5-A3-B4 Variants and Smoking Cessation 
with Pharmacotherapy
Several studies have examined whether personal-
ized smoking cessation treatments based on genotype 
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can improve cessation success. Such treatments require 
knowledge of whether genetic variants moderate the effects 
of the available pharmacotherapies for smoking cessation.
Baker and colleagues (2009) studied the effect of 
haplotypes on the basis of five tagging SNPs (rs680244, 
rs569207, rs16969968, rs578776, and rs1051730) in 
the CHRNA5-CHRNA3-CHRNB4 locus. For participants 
receiving either bupropion or placebo, the haplotypes were 
associated with tolerance, craving, and loss of control, but 
only among persons who had started smoking early in life. 
Elsewhere, Munafò and colleagues (2011) found 
evidence for a weak association between the same locus, 
looking at the risk variant rs1051730 in CHRNA3 and at 
the short-term ability to quit smoking in heavy smokers 
receiving either the placebo or NRT. Interestingly, the 
effect size reported in this study was comparable to the 
effects found in the studies of pregnant women (Freathy 
et  al. 2009; Thorgeirsson and Stefansson 2010) and the 
study by Baker and colleagues (2009).
Chen and colleagues (2012) conducted a large 
study to examine genetic associations with age of cessa-
tion. CHRNA5-A3-B4 risk haplotypes (rs16969968 and 
rs680299, both in CHRNA5) were associated with the 
number of cigarettes smoked per day and a later quitting 
age; the latter was no longer associated with the haplotypes 
when the analysis was adjusted for the number of ciga-
rettes smoked per day. This study suggested that intensity 
of smoking, measured as the number of cigarettes smoked 
per day, impedes cessation. Furthermore, carriers of the 
medium- to high-risk haplotypes found abstinence more 
difficult, but if carriers received pharmacologic treatment 
(e.g.,  nicotine patch, nicotine lozenge, bupropion), they 
showed an increased rate of quitting success.
A meta-analysis by Bergen and colleagues (2013), 
which included eight RCTs, found that 6 months after a 
quit attempt, the risk allele rs1051730 was associated with 
higher rates of abstinence in the NRT group compared 
with the placebo group. The authors of this study assessed 
the association of four SNPs with smoking cessation and 
response to medication at the end of the treatment (8- to 
12-weeks post-quit) and after 6 months. The genetic vari-
ants were rs1051730, rs578776, and rs588765 in CHRNA5 
and CHRNA3, and rs2072661 in CHRNB2. CHRNB2 has 
been associated with a number of smoking cessation phe-
notypes, such as abstinence, FTND, and nausea among 
treatment-seeking smokers randomized to behavioral 
therapies and prescribed varenicline (Ehringer et al. 2007; 
Conti et  al. 2008; Wessel et  al. 2010; Swan et  al. 2012). 
The eight RCTs considered in the meta-analysis employed 
placebo, NRT, bupropion, varenicline, or a combination of 
NRT and bupropion (along with a variety of counseling 
options). Although rs2072661 and rs578776 were not 
associated with smoking cessation, rs1051730 and, to a 
lesser degree, rs588765 were associated with quitting 
success in persons randomized to NRT and in those who 
received the placebo. Participants in the placebo condi-
tions were less likely to be abstinent after 6 months, but 
those who received NRT were more likely to achieve absti-
nence after that time. Mediation analysis indicated that 
rs1051730 increased nicotine dependence—a variable 
that decreases the success of abstinence—and that a fur-
ther mechanism (speculated to be abstinence-induced 
impairment in cognitive function) increased abstinence 
in the NRT group at the 6-month follow-up from the end 
of drug administration.
Two subsequent studies—a meta-analysis of four 
studies and a clinical trial—did not confirm these find-
ings. The meta-analysis revealed no evidence at the end of 
NRT that rs16969968 or rs1051730 were associated with 
cessation (Leung et al. 2015). The clinical trial, conducted 
by Tyndale and colleagues (2015), examined the associa-
tion between CHRNA5-A3-B4 haplotypes and smoking 
abstinence, finding no associations between rs16996968, 
rs578776, and rs588765 and abstinence at 6- or 12-month 
follow-up in participants who received placebo, NRT, 
or varenicline.
An important factor in smoking cessation is adher-
ence to treatment. Ware and colleagues (2015), who 
studied this phenotype in a secondary analysis of data 
from an RCT of smoking cessation, found an association 
between rs1051730 and adherence to NRT after 7 days of 
the quit attempt but not after 28 days. Each copy of the 
minor allele corresponded to a 2.9% decrease in adher-
ence to the prescribed dose of NRT over 7  days. This 
association was robust to adjustments made for age, sex, 
socioeconomic status, trial condition, body mass index at 
baseline, and daily cigarette consumption at baseline.
Most studies to date have used samples of European 
ancestry, but a few have examined samples from other 
populations, including African Americans. For example, 
in a small deep-sequencing discovery study of African 
Americans, Hamidovic and colleagues (2011) reported 
an association between rs12915366 in CHRNA5 and 
rs12914385 in CHRNA3 and smoking persistence. David 
and colleagues (2012), who performed a genomewide 
meta-analysis of 13  studies of African Americans, found 
that rs2036527, which is in linkage disequilibrium with 
rs1051730, was significantly associated genomewide with 
the number of cigarettes smoked per day. In another study 
of African Americans, Zhu and colleagues (2014) failed 
to find an association between rs16969968 and smoking 
abstinence in either the placebo or NRT group. In con-
trast, the minor allele of rs588765 was associated with 
lower abstinence in the placebo group and greater absti-
nence in the group receiving NRT during treatment but 
not after 6 months.
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The study by Zhu and colleagues (2014) also reported 
an association, both during and at the end of treatment, 
between the risk allele of rs2036527 in CHRNA5 and lower 
smoking abstinence in those who received NRT but not in 
the placebo group. Interestingly, adjusting the analyses for 
the number of cigarettes smoked per day had a negligible 
effect. The rs2036527 SNP was in high linkage disequilib-
rium with rs1051730, and these findings are consistent 
with the association reported by Munafò and colleagues 
(2011) for rs1051730 and short-term smoking cessation in 
their study of a European population. These findings sug-
gest that linkage disequilibrium structures differ between 
European and African American populations.
Overall, although the association between the 
CHRNA5-A3-B4 gene cluster and smoking intensity is 
robust, its role in smoking cessation needs further inves-
tigation, and currently no clear evidence exists that it 
influences responses to specific pharmacotherapies. Some 
of the inconsistent results may be due to differences in 
methods and sampling or to environmental factors that 
influence each study. AGS could be employed to explore 
the collective genetic influence of several variants that 
may exert a role in complex phenotypes, such as smoking 
behaviors, but more work is required to understand the 
role of these genes in ethnic groups other than those of 
European ancestry.
The CYP2A6 Gene and the Nicotine 
Metabolite Ratio
Nicotine from cigarette smoke is distributed in the 
body via the bloodstream (Benowitz et al. 2009). Its elimi-
nation half-life is around 2 hours, and up to 90% of nicotine 
is converted to cotinine, mainly by the metabolic enzyme 
CYP2A6, which, in turn, is solely responsible for the 
metabolism of cotinine to 3’-hydroxycotinine (Benowitz 
and Jacob 3rd 1994; Tanner and Tyndale 2017). Nicotine is 
also metabolized to more minor metabolites by additional 
enzymes, including FMO3 and UGT2B10 (Benowitz et al. 
2009). NMR is the ratio of 3’-hydroxycotinine to cotinine; 
studies of twins have estimated that about 60% of the vari-
ation in NMR is due to genetic factors (Swan et al. 2004). 
Importantly, CYP2A6 enzyme activity is reflected by NMR 
(Dempsey et  al. 2004; Johnstone et  al. 2006; Malaiyandi 
et al. 2006a). CYP2A6 is a highly polymorphic gene (with 
>30  genetic variants), and its numerous variants have 
an impact on NMR. Grouping variants, however, is pos-
sible according to the impact of CYP2A6 on the rate of 
NMR (i.e.,  faster or slower). Importantly, NMR also cap-
tures environmental influences (e.g.,  hormonal thera-
pies and body mass index). Furthermore, NMR values are 
stable across time and exhibit high test-retest reliability 
when measured 2 to 3 weeks apart (Hamilton et al. 2015). 
Despite no consensus on the cut-off point between faster 
and slower metabolizers, several studies have used the 
lowest 25–50% of the NMR distribution to classify slower 
metabolizers (Lerman et al. 2006b; Ray et al. 2009; Schnoll 
et al. 2009; Dubroff et al. 2015).
Nicotine Metabolite Ratio and Smoking Behavior
The GWAS by Thorgeirsson and colleagues (2010) 
found an association between reduced smoking quan-
tity, measured as the number of cigarettes smoked per 
day, and variants in or near CYP2A6 that reduce the enzy-
matic activity of CYP2A6 (in particular, rs4105144). Later, 
Loukola and colleagues (2015) conducted a GWAS meta-
analysis of current smokers using data from three Finnish 
cohorts and identified novel genetic variants associated 
with NMR. Their study detected three strong indepen-
dent signals in the immediate vicinity of CYP2A6: SNPs 
rs56113850, rs113288603, and rs2663194. Although 
the functional consequences of the first two SNPs are 
unknown, the third one is associated with a decreased 
clearance rate, and the three SNPs captured up to 31% of 
the total variance in NMR.
NMR has been assessed in several studies to fur-
ther characterize smoking behavior. In one study, slower 
metabolizers smoked an average of 6  to 7  fewer ciga-
rettes per day and had an earlier smoking onset by about 
1 year (Schoedel et al. 2004). Other studies found slower 
metabolizers to be less dependent on nicotine, as mea-
sured by the FTND (Malaiyandi et  al. 2006b; Wassenaar 
et al. 2011; Sofuoglu et al. 2012), and slower metabolizers 
took longer to become dependent on nicotine (Audrain-
McGovern et al. 2007; Al Koudsi et al. 2010). Fast metab-
olizers exhibited a higher total cigarette puff volume 
(Strasser et al. 2011). This finding is consistent with the 
observation that fast metabolizers require higher levels of 
nicotine intake than those with a slower nicotine clear-
ance, which is consistent with self-titration by smokers to 
achieve the desired circulating level of nicotine (Strasser 
et  al. 2007). Adolescents who were slow metabolizers, 
however, had a higher risk of becoming nicotine depen-
dent compared with fast metabolizers (Chenoweth et al. 
2013, 2016). It  is not clear if adolescent smokers titrate 
their level of nicotine intake according to their NMR to 
maintain desired levels, but Chenoweth and colleagues 
(2013) found that once adolescents who were slow metab-
olizers became dependent on nicotine, they smoked fewer 
cigarettes and were more likely to become adult smokers 
(Chenoweth et al. 2013). In fact, slow metabolizers who 
were adults were more likely than fast metabolizers to 
successfully quit smoking in the absence of pharmaco-
therapy (Gu et al. 2000; Patterson et al. 2008; Chenoweth 
et al. 2013).
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In a study of mice, Bagdas and colleagues (2014) 
used an inhibitor of CYP2A5, the mouse ortholog of human 
CYP2A6, to mimic the slower nicotine metabolism of 
humans. The effects of this manipulation were illustrated 
using a CPP task. A low dose of nicotine administrated on 
one side of a box, versus saline administrated on the other 
side, did not induce a CPP in mice in the control group. In 
contrast, mice treated with the CYP2A5/6 inhibitor before 
being exposed to nicotine developed a CPP for the nicotine 
side and showed increased levels of plasma nicotine. Thus, 
it appears that the treated mice had become more sensi-
tive to the effects of nicotine. Li and colleagues (2013a) 
reported similar results from a study that measured CPP 
in CYP2A4/5 knockout mice that were exposed to nico-
tine. In addition, Bagdas and colleagues (2014) adminis-
tered nicotine to naïve mice across 5 days and pretreated 
half of the mice with the CYP2A5/6 inhibitor; they then 
tested the somatic signs of withdrawal after nicotine absti-
nence. The pretreated mice showed a potentiation of the 
intensity of somatic signs of withdrawal and higher levels 
of plasma nicotine. In summary, the mice tested in these 
studies experienced a decrease of nicotine clearance, sim-
ilar to human slow metabolizers, and a greater exposure 
to nicotine in these mice enhanced nicotine dependence 
and affected nicotine withdrawal behaviors.
Nicotine Metabolite Ratio and Smoking 
Cessation in Absence of Treatment
Gu and colleagues (2000), who compared the likeli-
hood of quitting smoking between slow and fast metab-
olizers, found that slow metabolizers were almost twice 
as successful in quitting smoking. Later, in a prospective 
cohort of adolescents, Chenoweth and colleagues (2016) 
also assessed the hypothesis that slow metabolizers are 
more likely to quit smoking than fast metabolizers and 
found a linear relationship between CYP2A6 activity and 
quit rate: slow metabolizers were more than twice as likely 
as fast metabolizers to quit smoking.
Smoking Cessation in Treatment Seekers
Compared with slow metabolizers, fast metabo-
lizers have a higher NMR and inactivate nicotine quickly. 
A higher NMR results in lower levels of nicotine in the 
blood. Lerman and colleagues (2006b) found that a lower 
NMR was associated with increased odds of abstinence, 
both at the end of treatment and after 6 months, in per-
sons who received a nicotine patch but not in those who 
received nicotine in the form of nasal spray, suggesting 
that, in contrast with transdermal nicotine (for which the 
dose is fixed), users of nicotine nasal spray may titrate 
their intake of nicotine. Furthermore, cravings for ciga-
rettes after 1 week of abstinence were more severe in fast 
metabolizers who received the transdermal patch. A sub-
sequent study by Lerman and colleagues (2010) found 
that slow metabolizers benefitted from using the trans-
dermal nicotine patch for an extended period of time 
(i.e., 6 months vs. the standard 8 weeks).
Some evidence suggests that bupropion enhances 
the quit success of fast metabolizers and that the nico-
tine patch enhances the quit success of slow metabo-
lizers. Patterson and colleagues (2008) assessed the base-
line NMR in smokers who subsequently participated in 
a 10-week randomized trial of bupropion versus placebo 
with counseling support. With placebo, quit rates were 
lower among fast metabolizers than slow metabolizers, 
but with bupropion, quit rates were similar between fast 
and slow metabolizers.
Because slow metabolizers showed no difference in 
the likelihood of relapse in either the placebo or bupro-
pion conditions, Lerman and colleagues (2015) conducted 
an NMR-stratified, placebo-controlled, randomized trial of 
nicotine patch versus varenicline to test whether vareni-
cline had a superior effect compared with placebo. On the 
basis of evidence for an interaction of NMR by treatment, 
fast metabolizers receiving varenicline had higher odds of 
being abstinent. These studies suggest that NMR may be a 
predictive biomarker that can be used to personalize treat-
ments for smoking cessation.
Summary
This section examined the role in smoking cessa-
tion played by candidate genes in the dopamine system 
(dopamine receptor D2, DRD2, and the dopamine trans-
porter, DAT1) and variants in the CHRNA5-A3-B4 gene 
cluster and the CYP2A6 gene. Despite early evidence for 
associations between genetic variation in DRD2 or DAT1 
and smoking cessation and response to smoking cessa-
tion therapy, subsequent studies have failed to replicate 
these findings. In contrast, the small but robust asso-
ciation between the CHRNA5-A3-B4 gene cluster and 
smoking intensity and nicotine dependence has been rep-
licated in several candidate gene studies and GWAS, and 
smoking intensity and nicotine dependence predict the 
success of cessation. Whether variants in this gene cluster 
influence responses to specific pharmacotherapies is still 
not clear. Investigating polygenic risk scores may better 
capture the quitting success and variations in responses 
to medication.
More consistent results have been provided by 
studies assessing CYP2A6 or related biomarkers, such 
as NMR, and smoking cessation (both with and without 
pharmacologic treatment). A linear relationship exists 
between CYP2A6 activity and quit rate: slow nicotine 
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metabolizers are more likely than fast metabolizers to 
quit smoking. In addition, studies suggest that bupropion 
and varenicline enhance the quit success of fast metabo-
lizers, and the nicotine patch enhances the quit success of 
slow metabolizers.
Schuit and colleagues (2017) published the first 
Cochrane systematic review and meta-analyses of phar-
macogenetic biomarkers for smoking cessation, which 
included clinical trials with available genetic or NMR data 
for all approved smoking cessation pharmacotherapies, 
all genomewide significant SNPs for number of cigarettes 
smoked per day or smoking cessation, non-SNP polymor-
phisms with replication, and NMR. Data were available 
for 18 clinical trials and the following gene variants: nine 
SNPs (rs1051730 [CHRNA3]; rs16969968, rs588765, and 
rs2036527 [CHRNA5]; rs3733829 and rs7937 [in EGLN2, 
near CYP2A6]; rs1329650 and rs1028936 [LOC100188947]; 
and rs215605 [PDE1C]), two variable number tandem 
repeats (DRD4 and SLC6A4), and the NMR biomarker.
The meta-analyses indicated that genotype groups 
within certain ethnic groups may benefit more from NRT 
than from placebo (non-Hispanic Black individuals at 
6-months with rs169969968 GG genotype, slow metabo-
lizers, non-Hispanic White and non-Hispanic Black indi-
viduals at the end of treatment with rs1051730 GA or AA 
genotype, and rs169969968 GG genotype) and from NRT 
(non-Hispanic Black individuals with rs2036527 GG geno-
type), or may benefit less from a combination of bupropion 
with NRT (non-Hispanic White individuals with rs1329650 
TT genotype and non-Hispanic Black individuals with 
rs3733829 AG or GG genotype). These results should be 
interpreted with caution because none of the statistically 
significant meta-analyses from placebo-controlled trials 
included more than two trials per genotype comparison, 
many confidence intervals were wide, and the quality of 
this evidence was generally moderate. Although evidence 
existed of superior NRT efficacy for NMR of normal versus 
slow metabolizers, the authors could not conclude that 
NRT is more effective in slow metabolizers. Given the 
number of trials and investigators who did not provide or 
publish meta-analyzable data, access to additional data is 
needed, particularly for comparisons of different pharma-
cotherapies to improve the reliability of meta-analysis and 
the potential clinical utility of genomic testing to guide 
treatment choice for smoking cessation.
Benefits may be derived from personalized precision 
tailoring of interventions based on genetic approaches. 
The efficacy of treatment could be improved by assigning 
patients to a specific treatment based on the results of 
genetic or biomarker testing. However, for a pharmacoge-
netic approach to be cost-effective, the effect size must be 
substantially larger in one stratum compared with another 
stratum. Other considerations, such as the proportion of 
the population that falls into each stratum, are also rel-
evant. In particular, before pharmacogenetic or biomarker 
stratification becomes routine in clinical practice, an RCT 
should be conducted to determine whether this approach 
improves overall cessation outcomes. Ideally, the RCT 
would also include a health economic analysis to help 
determine the cost-effectiveness of this approach.
Summary of the Evidence
Although current pharmacotherapies are effec-
tive in increasing quitting, many current smokers want 
to quit but have been unable to sustain abstinence, so 
smoking remains one of the leading causes of prevent-
able disease and death globally. Decades of preclinical 
advances have improved our understanding of the neu-
robiologic mechanisms underlying nicotine addiction. 
Although more remains to be understood, this informa-
tion has identified dozens of novel and promising targets 
for pharmacologic intervention that remain to be evalu-
ated in humans. Preclinical studies suggest that targeting 
multiple stages of addiction may be the most effective way 
to reduce smoking.
Immunotherapies for nicotine dependence offer an 
alternative therapeutic mechanism, producing antibodies 
that bind nicotine in blood and reduce nicotine delivery 
to the brain (see “Vaccines and Other Immunotherapies 
as Treatments for Tobacco Addiction”). This approach 
involves targeting the drug rather than the brain, poten-
tially reducing the side effects of existing medications to 
treat nicotine dependence and perhaps treating a lim-
ited repertoire of smoking behaviors (see “Insights into 
Smoking Cessation from the Field of Neurobiology”). 
Immunotherapies are highly effective in animal models 
for blocking nicotine reinforcement, but they have not yet 
been effective in Phase 3 clinical trials for smoking cessa-
tion, at least in part because of insufficient and variable 
antibody concentrations in humans.
Multiple cognitive systems (e.g., attention, reward, 
inhibitory control) and affective processes (negative and 
positive emotion) are dysregulated in nicotine depen-
dence, which might help to explain poor treatment out-
comes. Regions of the brain involved in the maintenance 
of smoking and nicotine withdrawal include the anterior 
and posterior cingulate, amygdala, insula, striatum, and 
orbitofrontal cortex. Large-scale brain networks altered as 
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a result of nicotine dependence include the default mode, 
salience, and executive control networks. Circuit and net-
work connections may serve as predictive biomarkers to 
personalize treatment choices and as predictors of the 
outcomes of cessation treatment. More longitudinal neu-
roimaging studies are needed to understand brain altera-
tions as a function of sustained abstinence. Neuroimaging 
and genetic analyses to fractionate the nicotine addiction 
phenotype would help to identify novel therapeutic tar-
gets. Transcranial magnetic stimulation, an FDA-approved 
treatment for depression, has been proposed as a treat-
ment for addiction in general, but further evaluation is 
needed to determine its efficacy for smoking cessation.
Large GWAS are identifying molecular genetic influ-
ences on smoking phenotypes. The greater sensitivity of 
these large studies allows signals to be identified that may 
inform the search for potential therapeutic targets, but the 
studies require somewhat blunt phenotypes. The strongest 
evidence on potential therapeutic targets to date points to 
variants related to nAChRs (CHRNA5-A3-B4 gene cluster) 
and nicotine metabolism (CYP2A6  gene). Variation in 
these genes influences intensity of smoking and nicotine 
dependence, and an increasing amount of evidence sug-
gests that such variation may influence smoking cessation 
and be useful for personalized optimization of therapeutic 
choice. Genetic variants associated with smoking behav-
iors also provide tools that can be used to support stronger 
causal inference in observational studies—for example, 
by treating these genetic variants as instrumental variables 
(a method known as Mendelian randomization, which is 
predicated on the assumption that because genotype is 
assigned randomly at meiosis it should not be associated 
with potential confounders at a population level) (Gage 
et al. 2016). Emerging evidence suggests that genetic vari-
ants may influence responses to smoking cessation treat-
ments, offering the potential for personalized or strati-
fied approaches to treatment. However, this approach 
requires a randomized clinical trial to determine its effi-
cacy and cost-effectiveness. Future research should focus 
on assessing smoking cessation outcomes prospectively 
(e.g.,  by routinely collecting genetic data at baseline in 
RCTs of smoking cessation interventions) and using inter-
mediate phenotypes (e.g., brain circuits that are relevant to 
nicotine dependence) through modern genetic approaches. 
Research should also investigate genetic predictors of 
responses to behavioral and pharmacologic interventions.
From a public health perspective, interventions to 
achieve smoking cessation must be developed that are 
more effective than the current options. The development 
of biologically based biomarkers for diseases involving 
organ systems has led to the development of successful 
therapies for a variety of these diseases. However, such 
biomarker research lags behind in the fields of addiction 
(in  general) and of nicotine dependence (in particular). 
It will be important to invest in continued efforts to trans-
late findings and observations from animal models of nic-
otine addiction and apply them to clinical settings to pro-
vide novel, mechanistically sound therapies for humans.
Limited ecologic validity and questions about 
subsequent predictability are limitations to almost all 
studies summarized in this chapter. Smoking is fre-
quently comorbid with other neuropsychiatric diseases, 
including schizophrenia, depression, and anxiety disor-
ders. Moreover, persons who abuse nicotine also use other 
drugs, including alcohol and marijuana. And yet, most 
research cohorts involving drugs are only on the basis of 
smoking. Therefore, a better understanding of the con-
nections between nicotine dependence and neuropsychi-
atric comorbidity dual-drug dependence is warranted. 
Similarly, responses to smoking pharmacotherapies 
clearly differ by sex, but to date, little work has focused on 
these differences, whether in basic neurobiology or in the 
interactions with pharmacogenetics. For example, some 
studies suggest that female smokers may be best treated 
by medications that do not interact directly with nico-
tinic mechanisms; this should be explored further. Sex 
differences also should be evaluated further in the patho-
physiology of nicotine addiction and be considered when 
treating patients. A shift toward developing individualized, 
multifaceted approaches to smoking cessation is critical.
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Conclusions
1. The evidence is suggestive but not sufficient to infer 
that increasing glutamate transport can alleviate 
nicotine withdrawal symptoms and prevent relapse. 
2. The evidence is suggestive but not sufficient to infer 
that neuropeptide systems play a role in multiple 
stages of the nicotine addiction process, and that 
modulating the function of certain neuropeptides 
can reduce smoking behavior in humans.
3. The evidence is suggestive but not sufficient to 
infer that targeting the habenulo-interpeduncular 
pathway with agents that increase the aversive prop-
erties of nicotine are a useful therapeutic target for 
smoking cessation.
4. The evidence is suggestive but not sufficient to infer 
that vaccines generating adequate levels of nicotine-
specific antibodies can block the addictive effects of 
nicotine and aid smoking cessation.
5. The evidence is suggestive but not sufficient to infer 
that dysregulated brain circuits, including prefrontal 
and cingulate cortical regions and their connections 
with various striatal and insula loci, can serve as 
novel therapeutic targets for smoking cessation.
6. The evidence is suggestive but not sufficient to infer 
that the effectiveness of nicotine replacement therapy 
may vary across specific genotype groups.
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Introduction
Evidence on the health benefits of smoking cessa-
tion continues to expand and evolve since the topic was 
last covered comprehensively in the 1990 report of the 
Surgeon General. This chapter primarily reviews the find-
ings published between 2000 and 2017 on disease risks 
from smoking and how these risks change after smoking 
cessation for major types of chronic diseases, including 
cancer, the cardiovascular and respiratory systems, and 
a wide range of reproductive outcomes. The more recent 
studies expand the observational evidence documenting 
the benefits of smoking cessation and provide insights 
into the mechanisms underlying these benefits. The 
review of the effects of smoking cessation on reproductive 
outcomes documents health benefits of maternal smoking 
cessation across all phases of reproduction, from precon-
ception to birth, and also for male reproductive health. 
Chapter 5 summarizes the health benefits of smoking ces-
sation for all-cause mortality in the general population; 
thus, that topic is not discussed here.
This chapter also addresses the clinically relevant ben-
efits of cessation for mitigating the effects of diseases, par-
ticularly in persons with cancer and coronary heart disease. 
This general topic received mention in previous Surgeon 
General’s reports (U.S. Department of Health and Human 
Services [USDHHS] 1982, 1983, 1990, 2004), and the conse-
quences of smoking following a diagnosis of cancer received 
specific attention in the 2014 Surgeon General’s report, 
leading to a conclusion that cigarette smoking has adverse 
causal effects on persons already diagnosed with cancer 
(USDHHS 2014). This chapter also reviews cessation and 
cardiovascular disease and the implications of cessation for 
the natural history of chronic obstructive pulmonary disease.
Observational studies should consider factors that 
might differ between those who quit smoking and those 
who continue to smoke. Some persons may quit smoking 
because they are sick, and health-conscious persons may 
be more motivated to quit. In an effort to address bias 
attributable to “sick quitters,” those with preexisting dis-
eases can be excluded from analyses. This strategy also 
addresses “reverse causation,” or quitting because of the 
development of symptoms or a disease. Whenever pos-
sible, observational analyses should also adjust for other 
risk factors that may confound the relationship between 
smoking habits and disease risk.
There are methodologic challenges related to 
assessing smoking cessation and its links to health out-
comes in both observational and intervention studies. 
Risks in former smokers should be compared with those 
of current or never smokers, thus necessitating a pre-
cise definition of former smoking (Lindstrom 2010); the 
same is true for time since cessation, cumulative smoking 
(e.g., pack-years [which is defined as the number of packs 
of cigarettes smoked per day multiplied by the number of 
years smoked], which incorporates both smoking inten-
sity and duration), and changes in smoking status during 
follow-up.
Methodologic Challenges
Conclusions from Previous 
Surgeon General’s Reports
At the time of release of the 1990 Surgeon General’s 
report, the U.S. Surgeon General and/or the International 
Agency for Research on Cancer (IARC) classified six can-
cers as causally associated with cigarette smoking: cancer 
of the lung, larynx, oral cavity and pharynx, esophagus, 
pancreas, and bladder (USDHHS 1990). The 1990 Surgeon 
This section reviews evidence from epidemiologic 
studies about the impact of smoking cessation on the risk 
of 12 cancers caused by smoking, as concluded in previous 
Surgeon General’s reports (U.S. Department of Health and 
Human Services [USDHHS] 2004, 2014). The types of can-
cers reviewed for this section include cancers of the lung, 
larynx, oral cavity and pharynx, esophagus, pancreas, 
bladder, stomach, liver, colon and rectum, kidney, and 
cervix and acute myeloid leukemia (AML).
Cancer
A Report of the Surgeon General
178  Chapter 4
General’s report concluded that smoking cessation 
reduced the risk of these six cancers. That report set forth 
nine conclusions about smoking cessation and cancer 
(Table 4.1). The 2004 and 2014 Surgeon General’s reports 
concluded that smoking causes at least six additional can-
cers beyond those for which the associations were consid-
ered causal in 1990: cancer of the stomach, liver, colon 
and rectum, kidney, cervix, and AML (USDHHS 2004, 
2014). However, the 2004 and 2014 Surgeon General’s 
reports did not explicitly conclude that smoking cessation 
reduces the risk of these six additional cancers. 
Biological Mechanisms
Smoking contributes to carcinogenesis through 
multiple biological mechanisms, including direct geno-
toxicity, hypermethylation of gene promoters, receptor-
mediated pathways, and inflammation (USDHHS 2010, 
2014; Hecht 2012). In addition, smoking has been shown 
to increase the somatic mutation load (Alexandrov et al. 
2016). Collectively, these mechanisms can act at the early 
and late stages of carcinogenesis, implying that smoking 
cessation could have short- and long-term effects on the 
risk of cancer. Regardless of the specific mechanisms, 
smoking cessation ends further increments to cumulative 
exposure to tobacco smoke and, therefore, is expected to 
reduce the risk of cancers caused by smoking, since cumu-
lative exposure does not increase further, allowing repair 
processes to come into play (USDHHS 2010). The particular 
mechanisms that are most important in smoking-induced 
carcinogenesis likely vary by site, as described below. 
Literature Review Methods
For this report, systematic literature reviews were 
not conducted for the six cancers (lung, larynx, oral cavity 
and pharynx, esophagus, pancreas, and bladder) for which 
the 1990 Surgeon General’s report (USDHHS 1990) con-
cluded that smoking cessation reduces risk. Instead, for 
these sites, this report summarizes new evidence from 
large pooled analyses or meta-analyses that were deter-
mined to clarify the consequences of smoking cessation. 
For the six smoking-attributable cancer sites for 
which smoking cessation has not previously been con-
cluded to lower risk (stomach, liver, colon and rectum, 
kidney, cervix, and AML), epidemiologic evidence was 
reviewed in great detail (USDHHS 1990, 2004, 2014). The 
evidence review focused on whether relative risks (RRs) 
(a) are lower for former smokers than for current smokers 
and (b)  decrease in former smokers with increasing 
number of years since cessation. Summary RRs for former 
and current smokers of cigarettes, compared with never 
smokers, were identified from the most recent sufficiently 
comprehensive meta-analyses, as found through litera-
ture searches conducted in January 2017 of the National 
Library of Medicine’s PubMed service. For some papers, 
current cigarette smokers were the comparison group for 
former smokers.
Table 4.1 Conclusions from the 1990 Surgeon General’s report on the health benefits of smoking cessation and cancer
Conclusions
1. Smoking cessation reduces the risk of lung cancer compared with continued smoking. For example, after 10 years of abstinence, 
the risk of lung cancer is about 30 to 50 percent of the risk for continuing smokers: with further abstinence, the risk continues 
to decline.
2. The reduced risk of lung cancer among former smokers is observed in males and females, in smokers of filter and nonfilter 
cigarettes, and for all histologic types of lung cancer.
3. Smoking cessation lowers the risk of laryngeal cancer compared with continued smoking.
4. Smoking cessation reduces the severity and extent of premalignant histologic changes in the epithelium of the larynx and lung.
5. Smoking cessation halves the risks for cancers of the oral cavity and esophagus, compared with continued smoking, as soon as 
5 years after cessation, with further reduction over a longer period of abstinence.
6. Smoking cessation reduces the risk of pancreatic cancer, compared with continued smoking, although this reduction in risk 
may only be measurable after 10 years of abstinence.
7. Smoking is a cause of bladder cancer; cessation reduces risk by about 50 percent after only a few years, in comparison with 
continued smoking.
8. The risk of cervical cancer is substantially lower among former smokers in comparison with continuing smokers, even in the first 
few years after cessation. This finding supports the hypothesis that cigarette smoking is a contributing cause of cervical cancer.
9. Neither smoking nor smoking cessation are associated with the risk of cancer of the breast.
Source: U.S. Department of Health and Human Services (1990, p. 10).
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The literature searches for the six sites for which 
smoking cessation has not been previously tied to risk 
at the casual level used the term “smoking or tobacco,” 
a term for the specific cancer of interest (e.g., “colorectal 
neoplasms” or “liver neoplasms”), and limited the pub-
lication types to “meta-analysis.” The same terms were 
used in literature searches of PubMed to identify, for each 
cancer, individual studies published after the time period 
covered by the most recent comprehensive meta-analysis. 
All studies identified through meta-analyses or litera-
ture searches were examined to determine whether they 
included results by the number of years since cessation. 
Results by years since cessation were tabulated in sum-
mary tables. Because there were many studies of cessation 
in relation to stomach and colorectal cancer, summary 
tables for these cancers include only results from cohort 
studies, which generally have less potential for bias than 
case-control studies. 
Epidemiologic Evidence
Cancers for Which Previous Surgeon General’s 
Reports Have Concluded That Smoking Cessation 
Reduces Risk
Lung
The 2004 Surgeon General’s report added to the con-
clusions of the 1990 Surgeon General’s report by noting 
that, while the risk of lung cancer declines with increasing 
numbers of years since cessation, the risk remains higher 
in former smokers than in never smokers, even after many 
years of not smoking (USDHHS 2004). The 2014 Surgeon 
General’s report covered findings from more recent 
reports documenting a rise of RR in smokers (USDHHS 
2014). For this report, epidemiologic studies of smoking 
cessation and risk of lung cancer were reviewed in detail 
in publications by IARC, including two monographs 
(International Agency for Research on Cancer 2004, 2012) 
and a cancer prevention handbook that focused specifi-
cally on the effects of smoking cessation (IARC 2007). In 
the handbook, IARC (2007) included meta-analyses with 
separate estimates of summary RRs for smoking cessa-
tion grouped by gender and global region. In most groups, 
estimates of summary RRs for former smokers were about 
0.7–0.8 compared with continuing current smokers up 
to 10 years after cessation, about 0.3 from 10 to 19 years 
after cessation, and even lower with longer periods of suc-
cessful quitting. 
There is an ongoing need to examine the relation-
ship between smoking cessation and lung cancer for the 
following reasons: (a) In the United States, lung cancer due 
to smoking still accounts for the majority of lung cancer 
deaths (U.S. Cancer Statistics Working Group 2019), and 
(b) changes have occurred over time in the epidemiologic 
relationship between smoking and lung cancer (USDHHS 
2014). This report includes data from three large U.S. 
cohorts: the Cancer Prevention Study-II (CPS-II) (lung 
cancer mortality follow-up, 1982–1988) and two cohorts 
with follow-up for the incidence of lung cancer from the 
1990s and 2000s—the CPS-II Nutrition Cohort (Calle 
et  al. 2002) and the Prostate, Lung, Colorectal, and 
Ovarian cancer screening cohort (PLCO) (Pinsky et  al. 
2015) (Figure  4.1). The American Cancer Society pro-
vided, specifically for this report, analyses of the CPS-II 
cohort and CPS-II Nutrition Cohort. RRs by the number 
of years since cessation, analyzed as a time-varying vari-
able in 5-year categories, were similar in the three cohorts 
(Figure 4.1, Table 4.2). As shown, a former cigarette smok-
er’s risk of lung cancer decreases to half that of a simi-
larly aged continuing smoker about 10–15 years after ces-
sation. RRs continue to decline as time since cessation 
increases, but RRs remain higher in former smokers than 
in persons who have never smoked (Table 4.2). Results by 
histologic subtype from the PLCO cohort suggest that RRs 
may decline somewhat more slowly for adenocarcinoma 
than for squamous cell carcinoma (Pinsky et  al. 2015). 
Table 4.3 provides results using never cigarette smokers 
as the reference group rather than current smokers.
A few studies that examined age at smoking cessa-
tion, rather than number of years since cessation, consis-
tently showed that compared with continued smoking, the 
earlier the age at quitting, the lower the risk of lung cancer 
(International Agency for Research on Cancer 2004) (Peto 
et al. 2000; Jha et al. 2013; Pirie et al. 2013; Thun et al. 
2013a). Notably, results of these studies indicate that quit-
ting smoking by age 40, rather than continuing to smoke, 
will eliminate most of the excess risk of developing lung 
cancer faced by long-term smokers later in life. 
Since the 1990 Surgeon General’s report, substantial 
research has addressed the genetic determinants of risk for 
lung cancer among cigarette smokers (Chen et al. 2016; 
Liu et al. 2017). Genetic variation in the α5 nicotinic cho-
linergic receptor subunit (CHRNA5) has been linked to risk 
for lung cancer, as low- and high-risk genotypes have been 
identified. Chen and colleagues (2016), who carried out a 
meta-analysis involving cohort and case-control studies 
from two collaborative groups, found that the number of 
years by which a diagnosis of lung cancer was delayed fol-
lowing cessation was the same for the two genotypes.
Larynx, Oral Cavity, and Pharynx
Previous Surgeon General’s reports have con-
cluded that smoking is a cause of laryngeal cancer (U.S. 
Department of Health, Education, and Welfare [USDHEW] 
A Report of the Surgeon General
180  Chapter 4
1964), cancer of the oral cavity (USDHEW 1979b), and 
cancers of the oral cavity and pharynx (USDHHS 2004). 
The 1990 Surgeon General’s report concluded that 
“smoking cessation lowers the risk of laryngeal cancer 
compared with continued smoking [and]  .  .  . halves the 
risk for cancer of the oral cavity and esophagus . . . as soon 
as 5 years after cessation” (USDHHS 1990, p. 10). 
Results of studies published since the 1990 Surgeon 
General’s report (IARC 2004, 2012; Marron et al. 2010) 
have strengthened the evidence that risks of both laryn-
geal cancer and cancer of the oral cavity and pharynx are 
approximately halved within 10 years of cessation. Further, 
the International Head and Neck Cancer Epidemiology 
Consortium, which conducted a very large pooled analysis 
of data on smoking cessation from 17 case-control studies 
(Marron et al. 2010) that included a total of 12,040 cases 
and 16,884 controls, found gradients of declining RR with 
increasing numbers of years since cessation. The find-
ings were similar for cancers of the larynx, oral cavity, and 
pharynx. Compared with continued cigarette smokers, 
reductions in RR in former smokers were approximately 
30% within 5 years of cessation, 50% from 5 to 9 years 
after cessation, and 80% 20 or more years after cessation. 
These estimates for RR may actually underestimate the 
decline in this measure resulting from smoking cessa-
tion because they were adjusted for pack-years of smoking 
(USDHHS 1990). 
Esophagus
The 1979 Surgeon General’s report concluded 
that smoking is a cause of esophageal cancer (USDHEW 
1979b), and the 1990 Surgeon General’s report con-
cluded that smoking cessation halves the risk of esopha-
geal cancer as soon as 5 years after cessation (USDHHS 
1990). In addition, the 2004 Surgeon General’s report 
concluded that smoking causes squamous cell carcinoma 
of the esophagus, historically the predominant histo-
logic type of cancer at this site, as well as adenocarcinoma 
(USDHHS 2004), which is currently the most common 
type of esophageal cancer in the United States (Hur et al. 
2013; Xie et al. 2017). Studies of esophageal squamous cell 
carcinoma have revealed declining risks with increasing 
number of years since cessation among former smokers 
(IARC 2004, 2007, 2012), and most studies of esophageal 
adenocarcinoma have also found lower risk in former 
cigarette smokers than in current smokers (IARC 2012). 
Notably, a large pooled analysis of esophageal adeno-
carcinoma and esophageal gastric junction adenocarci-
noma from 11 studies, including 10 case-control studies 
and 1  cohort study, found an approximate 30% reduc-
tion in relative risk among former cigarette smokers who 
had quit for at least 10 years compared with continuing 
smokers, even after adjusting for pack-years of smoking 
(Cook et al. 2010).
Figure 4.1 Relative risk of lung cancer incidence or mortality by number of years since smoking cessation, 
compared with continued smoking, in three large U.S. cohorts
Source: American Cancer Society, unpublished data.
Note: CPS = Cancer Prevention Study; PLCO = Prostate, Lung, Colorectal, and Ovarian cancer screening cohort.
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Table 4.2 Relative risk of lung cancer incidence or mortality by number of years since smoking cessation, compared 
with continued smoking, in three large U.S. cohorts
  CPS-II 1982–1988 (mortality)a
CPS-II Nutrition Cohort 
1992–2011 (incidence)b PLCO 1993–2009 (incidence)c
  Deaths RR (95% CI) Cases RR (95% CI) Cases RR (95% CI)
Current smokers 2,571 1.00 (referent) 880 1.00 (referent) 271 1.00 (referent)
Never smokers 332 0.05 (0.046–0.059) 358 0.04 (0.035–0.045) 253 0.03 (0.02–0.03)
Former smokers, by 
number of years since 
smoking cessation
— — — — — —
≤5 193 0.91 (0.78–1.06) 293 0.85 (0.74–0.97) 83 0.86 (0.67–1.10)
>5–10 360 0.64 (0.57–0.72) 411 0.68 (0.60–0.74) 90 0.62 (0.48–0.78)
>10–15 220 0.37 (0.32–0.42) 400 0.52 (0.46–0.58) 151 0.41 (0.33–0.51)
>15–20 179 0.26 (0.22–0.30) 361 0.40 (0.35–0.45) 236 0.38 (0.30–0.47)
>20–25 137 0.21 (0.18–0.25) 277 0.27 (0.24–0.31) 173 0.28 (0.22–0.35)
>25–30 82 0.16 (0.13–0.20) 241 0.21 (0.18–0.24) 101 0.23 (0.17–0.30)
>30 97 0.09 (0.07–0.11) 648 0.12 (0.11–0.13) 111 0.18 (0.14–0.23)
Source: American Cancer Society, unpublished data.
Notes: CI = confidence interval; CPS = Cancer Prevention Study; PLCO = Prostate, Lung, Colorectal, and Ovarian cancer screening 
cohort; RR = relative risk.
aAnalyses of the CPS-II mortality cohort were restricted to those 55 years of age and older and excluded ever pipe/cigar smokers, those 
with prevalent cancer, and those with unknown smoking status. Data were adjusted for race, sex, and level of education.
bAnalyses of the CPS-II Nutrition Cohort were restricted to those 55 years of age and older and excluded those with prevalent cancer. 
Data were adjusted for race, sex, and level of education. 
cAnalyses of participants in the PLCO were restricted to those 55 years of age and older and excluded ever smokers with more than 
30 pack-years of cigarette smoking. RRs provided in the published analysis (Pinsky et al. 2015) used never smokers as the referent 
group. Using current smokers as the referent group, Paul Pinsky, Ph.D., of the National Cancer Institute provided equivalent results 
for this report.
Pancreas
The 1990 Surgeon General’s report concluded that 
smoking cessation reduces the risk of pancreatic cancer, 
but noted that “this reduction in risk may only be measur-
able after 10 years of abstinence” (USDHHS 1990, p. 10). 
In  a meta-analysis performed by Iodice and colleagues 
(2008) of 14  studies with analyses by number of years 
since cessation, the summary RRs, compared with never 
smokers, were 1.74 (95% confidence interval [CI], 1.61–
1.87) for current cigarette smokers, 1.48 (95% CI, 1.25–
1.76) for persons with less than 10 years since smoking 
cessation, 1.15  for persons with 10  or more years since 
cessation, and 0.95 for persons with 20 or more years since 
cessation. In other large pooled analyses of cohort studies 
(Lynch et al. 2009) and case-control studies (Bosetti et al. 
2012), RRs declined with increased time since cessation, 
and no excess risk (compared with never smokers) was 
observed among former smokers with 20 or more years 
since quitting (Bosetti et  al. 2012). Thus, collectively, 
the available scientific evidence indicates that the RR for 
pancreatic cancer declines steadily with increased time 
since cessation and approaches that of never smokers 
approximately 20 years after quitting smoking.
Bladder
The 1990 Surgeon General’s report concluded that 
“[smoking] cessation reduces risk [of bladder cancer] by 
about 50  percent after only a few years in comparison 
with continued smoking” (USDHHS 1990, p.  10). Since 
that report, many studies have provided more evidence 
that RRs for bladder cancer are lower in former cigarette 
smokers than in current smokers and that they decline 
steadily as the number of years since cessation increases 
(IARC 2004, 2012; Freedman et  al. 2011; Jiang et  al. 
2012). In comparisons with continued smoking, most 
studies have observed measurable reductions in risk for 
bladder cancer within 10 years of smoking cessation. In 
the three largest studies (Hartge et  al. 1987; Brennan 
et al. 2000; Freedman et al. 2011), however, each of which 
included more than 2,500 cases of bladder cancer in their 
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analyses, more than 10 years since cessation was required 
before risk fell in former cigarette smokers to half that of 
continuing smokers.
Cancers for Which Previous Reports Have Not 
Concluded That Smoking Cessation Reduces Risk 
Stomach
The 2004 Surgeon General’s report concluded that 
there was sufficient evidence to infer a causal relationship 
between smoking and stomach cancer (USDHHS 2004). 
The association between smoking and this type of cancer 
is independent of Helicobacter pylori infection, an estab-
lished risk factor for stomach cancer (Moy et al. 2010; IARC 
2012). Potential biological mechanisms include chronic 
inflammation in the stomach and exposure to carcinogens 
in tobacco smoke, including tobacco-specific nitrosamines 
(Li et al. 2014).
A meta-analysis of more than 30 studies of cigarette 
smoking and risk for stomach cancer published through 
2003 (Gandini et al. 2008) found that risk was lower for 
former cigarette smokers (RR = 1.31; 95% CI, 1.17–1.46) 
than for current smokers (RR = 1.64; 95% CI, 1.37–1.95) 
when compared with never smokers. Similar results were 
reported in studies published in 2003 or later (Gonzalez 
et al. 2003; Jee et al. 2004; Koizumi et al. 2004; Wen et al. 
2004; Doll et al. 2005; Fujino et al. 2005; Lindblad et al. 
2005; Sauvaget et al. 2005; Tran et al. 2005; Kurosawa et al. 
2006; Freedman et al. 2007; Kim et al. 2007; Ozasa 2007; 
Sjodahl et  al. 2007; Sung et  al. 2007; Batty et  al. 2008; 
Shikata et al. 2008; Zendehdel et al. 2008; Moy et al. 2010; 
Steevens et  al. 2010; Nomura et  al. 2012; Blakely et  al. 
2013; Tabuchi et al. 2013; Buckland et al. 2015; Chen et al. 
2015; Eom et  al. 2015; Jayalekshmi et  al. 2015; Charvat 
et al. 2016).
Risk for stomach cancer by time elapsed since quit-
ting among former cigarette smokers has been examined 
in nine cohort studies (Chao et  al. 2002; Koizumi et  al. 
2004; Sauvaget et al. 2005; Freedman et al. 2007; Ozasa 
2007; Zendehdel et al. 2008; Moy et al. 2010; Steevens et al. 
2010; Ordonez-Mena et al. 2016). These studies are sum-
marized in Table 4.4, but the table does not include studies 
that may underestimate the effect of smoking cessation 
(USDHHS 1990). For example, Table 4.4 does not include 
a small study from India that included many dual users 
Table 4.3 Relative risk of lung cancer incidence or mortality by number of years since smoking cessation, compared 
with never smokers, in three large U.S. cohorts
  CPS-II 1982–1988 (mortality)a
CPS-II Nutrition Cohort 
1992–2011 (incidence)b PLCO 1993–2009 (incidence)c
  Deaths RR (95% CI) Cases RR (95% CI) Cases RR (95% CI)
Never smokers 332 1.00 (referent) 358 1.00 (referent) 253 1.00 (referent)
Current smokers 2,571 19.21 (17.09–21.59) 880 24.96 (22.02–28.28) 271 35.9 (29.0–44.5)
Former smokers, by 
number of years since 
smoking cessation
— — — — — —
≤5 193 17.48 (14.58–20.96) 293 21.08 (18.03–24.64) 83 30.8 (23.4–40.5)
>5–10 360 12.30 (10.57–14.32) 411 16.96 (14.69–19.56) 90 22.1 (16.9–28.9)
>10–15 220 7.08 (5.96–8.41) 400 12.94 (11.20–14.94) 151 14.8 (11.9–18.2)
>15–20 179 4.93 (4.10–5.92) 361 9.90 (8.54–11.47) 236 13.5 (11.3–16.2)
>20–25 137 4.02 (3.29–4.92) 277 6.73 (5.75–7.88) 173 9.9 (8.1–12.0)
>25–30 82 3.13 (2.46–3.99) 241 5.21 (4.42–6.14) 101 8.1 (6.4–10.2)
>30 97 1.65 (1.32–2.07) 648 2.90 (2.55–3.31) 111 6.4 (5.1–8.0)
Source: American Cancer Society, unpublished data.
Notes: CI = confidence interval; CPS = Cancer Prevention Study; PLCO = Prostate, Lung, Colorectal, and Ovarian cancer screening 
cohort; RR = relative risk.
aAnalyses of the CPS-II mortality cohort were restricted to those 55 years of age and older and excluded ever pipe/cigar smokers, those 
with prevalent cancer, and those with unknown smoking status. Data were adjusted for race, sex, and level of education.
bAnalyses of the CPS-II Nutrition Cohort were restricted to those 55 years of age and older and excluded those with prevalent cancer. 
Data were adjusted for race, sex, and level of education. 
cAnalyses of participants in the PLCO were restricted to those 55 years of age and older and excluded ever smokers with more than 
30 pack-years of cigarette smoking. Results are from Pinsky and colleagues (2015).
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Table 4.4 Cohort studies of stomach cancer incidence or mortality, by number of years since smoking cessation
Study Design/populationa Exposure estimates: RR (95% CI)b Comments
Chao et al. 
(2002)
• Cohort study (Cancer Prevention Study II)
• Men and women ≥30 years of age
• 1,055,841 participants and 1,505 deaths 
from stomach cancer
• United States
• Follow-up period: 1982–1996
• Men:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 2.16 (1.75–2.67)
	| Former smoker: 1.55 (1.28–1.88)
 – Number of years since smoking cessation:
	| Never smoker: 1.00 (referent)
	| ≤10: 1.92 (1.50–2.47)
	| 11–19: 1.64 (1.26–2.14)
	| ≥20: 1.23 (0.95–1.59)
 – P for trend among former smokers: 0.0015
• Women
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.49 (1.18–1.88)
	| Former smoker: 1.36 (1.08–1.71)
 – Number of years since smoking cessation:
	| Never smoker: 1.00 (referent)
	| ≤10: 1.31 (0.91–1.87)
	| 11–19: 1.46 (1.00–2.13)
	| ≥20: 1.34 (0.95–1.89)
 – p trend among former smokers: 0.68
Adjusted for age; race; level of education; 
family history of stomach cancer; consumption 
of high-fiber grain foods, vegetables, and 
citrus fruits or juices; and use of vitamin C, 
multivitamins, and aspirin
Koizumi et al. 
(2004)
• Two population-based cohort studies 
• Men ≥40 years of age
• Cohort 1: 9,980 men and 228 cases 
of stomach cancer
• Cohort 2: 19,412 men and 223 cases 
of stomach cancer
• Northern Japan
• Follow-up period:
 – Cohort 1: 1984–1992
 – Cohort 2: 1990–1997
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Current smoker: 1.84 (1.39–2.43)
 – Former smoker: 1.77 (1.29–2.43)
• Number of years since smoking cessation:
 – Never smoker: 1.00 (referent)
 – <5: 1.72 (1.12–2.64)
 – 5–14: 2.08 (1.41–3.07)
 – ≥15: 1.31 (0.77–2.21)
Results from the two cohorts were pooled
Adjusted for age, BMI, history of peptic ulcer, 
parental history of stomach cancer, type of health 
insurance, alcohol use, daily intake of pickled 
vegetables, and intake of bean-paste soup
Cohort 1 also adjusted for intake of green or 
yellow vegetables and other vegetables and fruits
Cohort 2 also adjusted for intake of spinach, 
carrots, pumpkin, cabbage, lettuce, Chinese 
cabbage, and oranges and other fruits
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Study Design/populationa Exposure estimates: RR (95% CI)b Comments
Sauvaget et al. 
(2005)
• Cohort study (Life Span Study) 
• 38,576 men and women who were in 
Hiroshima or Nagasaki (Japan) at the time 
of the atomic bombings in August 1945
• 1,280 cases of stomach cancer 
• Japan
• Follow-up period: 1980–1999
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Current smoker: 1.50 (1.28–1.76)
 – Former smoker: 1.37 (1.13–1.66)
• Number of years since smoking cessation:
 – Never smoker: 1.00 (referent)
 – 1–5: 1.29 (0.90–1.85)
 – 6–10: 1.32 (0.88–1.96)
 – 11–15: 1.06 (0.67–1.67)
 – ≥16: 0.74 (0.54–1.00)
Adjusted for city, sex, sex-specific age, calendar 
period, level of education, and radiation dose
Freedman et al. 
(2007)
• Cohort study (NIH-AARP Diet and Health 
Study)
• 474,606 men and women ≥50 years of age 
who were members of AARP
• 188 cases of stomach cardia and 187 cases 
of stomach non-cardia
• Six states (California, Florida, Louisiana, 
New Jersey, North Carolina, and Pennsylvania) 
and two U.S. metropolitan areas (Atlanta, 
Georgia; and Detroit, Michigan)
• Follow-up period: 1995–2000
• Number of years since smoking cessation:
 – Cardia:
	| Never smoker: 1.00 (referent)
	| Current smoker: 2.87 (1.75–4.73)
	| 1–4: 2.39 (1.16–4.92)
	| 5–9: 2.73 (1.55–4.82)
	| ≥10: 2.01 (1.32–3.07)
 – Non-cardia:
	| Never smoker: 1.00 (referent)
	| Current smoker: 2.05 (1.33–3.18)
	| 1–4: 1.18 (0.54–2.62)
	| 5–9: 1.79 (1.05–3.05)
	| ≥10: 1.12 (0.78–1.63)
Adjusted for age, fruit intake, vegetable intake, 
total energy intake, sex, BMI, education level, 
alcohol intake, and physical activity
Analyses of non-cardia cancer additionally 
adjusted for race/ethnicity
Table 4.4 Continued
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Study Design/populationa Exposure estimates: RR (95% CI)b Comments
Ozasa (2007) • Cohort study (Japan Collaborative Cohort 
Study for Evaluation of Cancer)
• 1,048 deaths from stomach cancer
• Japan
• Follow-up period: starting in 1988
• Men:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.47 (1.19–1.80)
	| Former smoker: 1.22 (0.97–1.53)
 – Number of years since smoking cessation:
	| Never smoker: 1.00 (referent)
	| <5: 1.19 (0.84–1.67)
	| 5–14: 1.25 (0.94–1.67)
	| ≥15: 1.14 (0.84–1.55)
• Women:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 0.86 (0.50–1.48)
	| Former smoker: 1.07 (0.50–2.28)
 – Number of years since smoking cessation:
	| Never smoker: 1.00 (referent)
	| <5: 0.61 (0.08–4.37)
	| 5–14: 1.35 (0.43–4.23)
	| ≥15: 0.56 (0.07–4.02)
Adjusted for age and area of study
Table 4.4 Continued
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Table 4.4 Continued
Study Design/populationa Exposure estimates: RR (95% CI)b Comments
Zendehdel et al. 
(2008)
• Cohort study
• 336,381 men in the Swedish building industry 
who had records of at least one preventive 
health checkup between 1971 and 1993
• 276 cases of stomach cardia and 1,109 cases 
of stomach non-cardia
• Nord-Trondelag County, Norway
• Follow-up period: from date of initial checkup 
to 2004
• Cardia:
 – Smoking status:
	| Never smoker: 1.0 (referent)
	| Current smoker: 2.3 (1.6–3.3)
	| Former smoker: 1.8 (1.2–2.7)
 – Number of years since smoking cessation:
	| Never smoker: 1.0 (referent)
	| <5: 1.9 (1.1–3.4)
	| ≥5: 1.7 (1.1–2.6)
 – p trend among former smokers: 0.7
• Non-cardia:
 – Smoking status:
	| Never smoker: 1.0 (referent)
	| Current smoker: 1.4 (1.2–1.6)
	| Former smoker: 1.3 (1.1–1.5)
 – Number of years since smoking cessation:
	| Never smoker: 1.0 (referent)
	| <5: 1.2 (0.9–1.6)
	| ≥5: 1.3 (1.1–1.6)
 – p trend among former smokers: 0.6
Adjusted for age and BMI
Definition of smoking included pipe/cigar 
smoking, but study population predominantly 
smoked cigarettes
Moy et al. (2010) • Cohort study (Shanghai Cohort Study)
• 18,244 men 45–64 years of age
• 391 cases of stomach cancer
• Shanghai, China
• Follow-up period: 1986–2005
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Current smoker: 1.55 (1.23–1.96)
 – Former smoker: 1.79 (1.25–2.57)
• Number of years since smoking cessation:
 – Never smoker: 1.00 (referent)
 – Current smoker: 1.30 (0.82–2.05)
 – <5: 1.24 (0.66–2.34)
 – 5–9: 0.91 (0.49–1.66)
 – ≥10: 0.64 (0.51–0.81)
Adjusted for age, year, and neighborhood
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Study Design/populationa Exposure estimates: RR (95% CI)b Comments
Steevens et al. 
(2010)
• Cohort study (Netherlands Cohort Study)
• 120,852 men and women (3,962 in the 
subcohort for the case-cohort design) 
55–70 years of age
• 164 cases of cardia and 491 cases of 
non-cardia
• The Netherlands
• Follow-up period: 1986–2002
• Number of years since smoking cessation:
 – Cardia:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.61 (0.97–2.66)
	| <10: 1.72 (0.97–3.05)
	| 10–19: 1.43 (0.81–2.52)
	| ≥20: 1.00 (0.53–1.91)
 – Non-cardia:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.86 (1.39–2.47)
	| <10: 1.81 (1.30–2.52)
	| 10–19: 1.41 (0.98–2.02)
	| ≥20: 1.13 (0.77–1.67)
Cases in the case-cohort approach derived from 
entire cohort and number of person-years at risk 
for entire cohort estimated from a subcohort 
of 5,000 men and women who were randomly 
sampled from the total cohort at baseline
Adjusted for age; sex; alcohol use; BMI; level of 
education; energy intake; and intake of fruits, 
vegetables, and fish
Ordonez-Mena 
et al. (2016)
• Collaboration of 19 prospective cohort studies
• 897,021 men and women
• 1,866 cases of stomach cancer and 1,396 deaths 
from stomach cancer
• Europe and United States
• Incidence of stomach cancer:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.74 (1.50–2.02)
	| Former smoker: 1.18 (0.95–1.46)
 – Number of years since smoking cessation:
	| Current smoker: 1.00 (referent)
	| ≤9: 0.85 (0.60–1.20)
	| 10–19: 0.68 (0.41–1.12)
	| ≥20: 0.69 (0.51–0.93)
 – p trend among former smokers: 0.0461
• Death from stomach cancer:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.73 (1.36–2.19)
	| Former smoker: 1.31 (1.02–1.68)
 – Number of years since smoking cessation:
	| Current smoker: 1.00 (referent)
	| ≤9: 1.13 (0.80–1.58)
	| 10–19: 0.72 (0.46–1.14)
	| ≥20: 0.87 (0.64–1.19)
 – p trend among former smokers: 0.2355
Analyses of number of years since smoking 
cessation included only cohorts with these 
data and therefore included substantially 
fewer participants
Adjusted for sex, age, BMI, level of education, 
vigorous physical activity, history of diabetes, 
and alcohol consumption
Notes: AARP = formerly American Association of Retired Persons; BMI = body mass index; CI = confidence interval; NIH = National Institutes of Health; RR = relative risk.
aStudies are of cancer incidence unless number of cancer deaths is identified.
bp trend values are shown only if described as being among former smokers.
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of cigarettes and bidis (Jayalekshmi et al. 2015), a study 
in which the highest category of number of years since 
quitting was only ≥3  years (Guo et  al. 1994), or studies 
where the number of years since quitting was adjusted for 
duration or pack-years of smoking (Gonzalez et al. 2003; 
Sjodahl et al. 2007; Nomura et al. 2012). In general, risk 
estimates for the highest category of number of years 
since cessation (ranging from >10  years to >20  years) 
were lower than those for categories with fewer numbers 
of years since cessation (Table 4.4). 
Colon and Rectum
The 2014 Surgeon General’s report concluded that 
the evidence was sufficient to infer a causal relation-
ship between cigarette smoking and colorectal cancer 
(USDHHS 2014). For example, Botteri and colleagues 
(2008), in a meta-analysis of 26 studies of the incidence of 
colorectal cancer published through 2008, reported RRs 
of 1.17 (95% CI, 1.11–1.22) for former cigarette smokers 
and 1.07 (95% CI, 0.99–1.16) for current smokers, both 
compared with never smokers. Although the excess risk 
of colorectal cancer associated with current smoking 
overall was relatively small in this meta-analysis, there 
were statistically significant trends for increasing risk 
with increasing years of smoking duration, number of 
cigarettes smoked per day, and number of pack-years. In 
studies of colorectal cancer mortality that were included 
in the meta-analysis, summary RRs were 1.28 (95% CI, 
1.15–1.42) for current smokers based on 14 studies, and 
1.23 (95% CI, 1.14–1.32) for former smokers based on 
12 studies (Botteri et al. 2008). Since 2008, four cohort 
studies that each included more than 1,000 incident cases 
of colorectal cancer (Hannan et al. 2009; Limsui et al. 
2010; Leufkens et al. 2011) or deaths (Parajuli et al. 2014) 
have been published that provide RRs for both current and 
former cigarette smokers. In general, the RRs for current 
smokers were above those for former smokers: 
• 1.27 (95% CI, 1.06–1.52) for current smokers and 
1.23 (95% CI, 1.23 1.11–1.36) for former smokers 
(Hannan et al. 2009);
• 1.22 (95% CI, 1.04–1.41) for current smokers and 
1.18 (95% CI, 1.02–1.36) for former smokers (Limsui 
et al. 2010);
• 1.31 (95% CI, 1.06–1.64) and 1.25 (1.04–1.50) for cur-
rent and former smokers, respectively, with proximal 
colon cancer; and 0.91 (95% CI, 0.73–1.14) and 1.13 
(95% CI 0.95-1.36) for current and former smokers, 
respectively, with distal colon cancer (Leufkens et al. 
2011); and 
• 1.27 (95% CI, 1.10–1.46) and 1.20 (95% CI, 1.03–
1.38) for current and former smokers, respectively, 
who were men; and 1.30 (95% CI, 1.12–1.52) and 1.08 
(95% CI, 0.90–1.30) for current and former smokers, 
respectively, who were women (Parajuli et al. 2014). 
Taken together, these four studies provide evi-
dence that former smokers have somewhat lower risk for 
colorectal cancer than do current smokers. Twelve cohort 
studies have examined risk of colorectal cancer by time 
since cessation, as summarized in Table 4.5 (Chao et al. 
2000; Rohan et al. 2000; Limburg et al. 2003; Ozasa 2007; 
Kenfield et al. 2008; Weijenberg et al. 2008; Gram et al. 
2009; Hannan et al. 2009; Leufkens et al. 2011; Gong et al. 
2012; Nishihara et al. 2013; Ordonez-Mena et al. 2016). In 
most of these studies (Chao et al. 2000; Rohan et al. 2000; 
Limburg et al. 2003; Kenfield et al. 2008; Weijenberg et al. 
2008; Hannan et al. 2009; Leufkens et al. 2011; Gong et al. 
2012; Ordonez-Mena et al. 2016), the RR point estimates 
for the categories with the greatest number of years since 
smoking cessation (ranging from ≥10 years to ≥40 years) 
were lower than those for categories with fewer number of 
years since cessation.
The influence of smoking cessation on the risk of 
colorectal cancer may be most clearly observable in anal-
yses that focus on smoking-related molecular subtypes, 
including colorectal tumors with microsatellite instability 
(MSI-high) and the cytosine-phosphate-guanine (CpG) 
island methylator phenotype (CIMP-high). Several studies 
have associated smoking with about a two-fold increase in 
risk of MSI-high and CIMP-high colorectal cancer, but not 
with risk of other subtypes of colorectal cancer (Campbell 
et al. 2017). To date, only Nishihara and colleagues (2013) 
have examined time since smoking cessation by molec-
ular subtype. In their study, smoking cessation, compared 
with continued smoking, was associated with considerably 
lower risk of MSI-high and CIMP-high colorectal cancer 
starting 10–20 years after cessation, but risk of other 
subtypes of colorectal cancer was similar in current and 
former smokers and did not change with number of years 
since smoking cessation.
Liver
The 2014 Surgeon General’s report concluded that the 
evidence was sufficient to infer a causal relationship between 
cigarette smoking and liver cancer (USDHHS 2014). 
Potential biological mechanisms include long-term direct 
exposure of the liver to carcinogens in tobacco smoke and 
smoking-induced fibrosis and cirrhosis (USDHHS 2014).
A meta-analysis of 23 studies was carried out for 
the 2014 Surgeon General’s report. The meta-analysis 
provided estimates of the RR for liver cancer for cur-
rent and former cigarette smokers compared with never 
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Table 4.5 Cohort studies of colorectal cancer incidence or mortality, by number of years since smoking cessation
Study Design/populationa Exposure estimates: RR (95% CI)b Comments
Chao et al. 
(2000)
• Cohort study (Cancer Prevention Study II)
• 781,351 men and women ≥30 years of age
• 4,432 deaths from colorectal cancer
• United States
• Follow-up period: 1982–1996
• Current smoker:
 – Men: 1.32 (1.16–1.49)
 – Women: 1.41 (1.26–1.58)
• Number of years since smoking cessation 
(men and women):
 – Never smoker: 1.00 (referent)
 – ≤10: 1.32 (1.19–1.47)
 – 11–19: 1.20 (1.08–1.35)
 – ≥20: 1.04 (0.94–1.16)
 – p trend among former smokers: 0.0001
Adjusted for age; race; level of education; family 
history of colorectal cancer; exercise; aspirin 
and multivitamin use; alcohol use; and intake of 
vegetables, high-fiber grain foods, and fatty meats
Models among women also included hormone 
replacement therapy
Presented only sex-specific RRs for current 
smokers compared with never smokers
Rohan et al. 
(2000)
• Cohort study (Canadian National Breast 
Screening Study)
• 56,837 women 40–59 years of age
• 90 deaths from colorectal cancer
• Canada
• Follow-up period: 1982–1993
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Current smoker: 1.15 (0.61–2.16)
 – Former smoker: 1.52 (0.91–2.56)
• Number of years since smoking cessation:
 – Never smoker: 1.00 (referent)
 – 1–10: 1.74 (0.91–3.33)
 – ≥11: 1.33 (0.70–2.57)
Adjusted for age; BMI; hours per week of 
vigorous activity; and intake of dietary fiber, 
calcium, and alcohol; and energy level
Limburg et al. 
(2003)
• Cohort study (Iowa Women’s Health Study)
• 34,467 women 55–69 years of age
• 869 cases of colorectal cancer
• Iowa
• Follow-up period: 1986–1999
• Smoking status: 
 – Never smoker: 1.00 (referent)
 – Current smoker: 1.10 (0.89–1.37)
 – Former smoker: 1.21 (1.01–1.45)
• Number of years since smoking cessation:
 – Never smoker: 1.00 (referent)
 – <10: 1.21 (0.93–1.56)
 – 10–19: 1.08 (0.77–1.51)
 – 20–29: 1.51 (1.09–2.09)
 – >30: 1.07 (0.71–1.62)
 – p trend among former smokers: 0.14
Adjusted for age; BMI; waist-to-hip ratio; 
physical activity; alcohol consumption; hormone 
replacement therapy; and intake of methionine, 
total calories, total fat, sucrose, red meat, 
calcium, folate, and vitamin E
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Study Design/populationa Exposure estimates: RR (95% CI)b Comments
Ozasa (2007) • Cohort study (Japan Collaborative Cohort 
Study for Evaluation of Cancer)
• 381 deaths from colon cancer and 226 deaths 
from rectal cancer
• Japan
• Follow-up period: starting in 1988
• Men, colon:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.18 (0.80–1.72)
	| Former smoker: 1.27 (0.85–1.91)
 – Number of years since smoking cessation:
	| Never smoker: 1.00 (referent)
	| <5: 2.05 (1.23–3.42)
	| 5–14: 0.96 (0.55–1.68)
	| ≥15: 1.27 (0.74–2.17)
• Men, rectum:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.31 (0.85–2.01)
	| Former smoker: 0.95 (0.58–1.53)
 – Number of years since smoking cessation:
	| Never smoker: 1.00 (referent)
	| <5: 0.50 (0.19–1.31)
	| 5–14: 1.16 (0.64–2.10)
	| ≥15: 1.00 (0.51–1.96)
• Women, colon:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 0.67 (0.29–1.53)
	| Former smoker: 2.05 (0.95–4.41)
 – Number of years since smoking cessation:
	| Never smoker:1.00 (referent)
	| <5: 3.74 (1.19–11.8)
	| 5–14: 0.77 (0.10–5.56)
	| ≥15: 2.14 (0.52–8.68)
• Women, rectum:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.31 (0.52–3.29)
	| Former smoker: 0.68 (0.09–4.95)
 – Number of years since smoking cessation:
	| Never smoker: 1.00 (referent)
	| <5: 2.93 (0.40–21.3)
	| 5–14: Not reported
	| ≥15: Not reported
Adjusted for age and area of study
Table 4.5 Continued
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Study Design/populationa Exposure estimates: RR (95% CI)b Comments
Kenfield et al. 
(2008)
• Cohort study (Nurses’ Health Study)
• 104,519 women 30–55 years of age
• 578 deaths from colorectal cancer
• United States (11 states)
• Follow-up period: 1980–2004
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Current smoker: 1.63 (1.29–2.05)
 – Former smoker: 1.23 (1.02–1.49)
• Number of years since smoking cessation:
 – Never smoker: 1.00 (referent)
 – Current smoker: 0.76 (0.55–1.05)
 – <10: 0.95 (0.70–1.29)
 – 10–19: 0.70 (0.53–0.93)
 – ≥20: 0.62 (0.49–0.77)
 – p trend among former smokers: 0.40
Adjusted for age; follow-up period; history of 
hypertension, diabetes, and high cholesterol; 
BMI; change in weight from 18 years of age to 
baseline; alcohol intake; physical activity; use 
of oral contraception; hormone replacement 
therapy and menopausal status; parental history 
of myocardial infarction before 60 years of 
age; number of cigarettes smoked per day; age 
started smoking; servings of beef, pork, lamb, 
or processed meat; total calcium and folate 
intake; and duration of aspirin use
All covariates updated until diagnosis
Weijenberg et al. 
(2008)
• Case-cohort study (subset of the Netherlands 
Cohort Study)
• Men and women 55–69 years of age
• 4,083 persons in subcohort and 648 cases 
of colorectal cancer
• The Netherlands
• Follow-up period: 1989–1994
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Current smoker: 0.81 (0.62–1.05)
 – Former smoker: 1.22 (0.97–1.53)
• Number of years since smoking cessation:
 – Never smoker: 1.00 (referent)
 – <10: 0.96 (0.76–1.22)
 – 10–30: 1.24 (0.96–1.61)
 – >30: 0.78 (0.45–1.33) 
 – p = 0.33
Adjusted for age, sex, family history of colorectal 
cancer, BMI, and alcohol and coffee consumption
Gram et al. 
(2009)
• Cohort study (The Norwegian Women and 
Cancer study) 
• 68,160 women 30–69 years of age
• 425 cases of colorectal cancer
• Norway
• Follow-up period: 1996–2005
• Smoking status:
 – Never smoker: 1.0 (referent)
 – Current smoker: 1.2 (0.9–1.5)
 – Former smoker: 1.3 (1.0–1.6)
• Number of years since smoking cessation:
 – Never smoker: 1.0 (referent)
 – Current smoker: 1.2 (1.0–1.5)
 – 1–9: 1.1 (0.8–1.7)
 – 10–19: 1.5 (1.1–2.1)
 – ≥20: 1.1 (0.8–1.5)
Adjusted for age, menopausal status, use of 
hormonal contraceptives and postmenopausal 
hormonal therapy, BMI, and alcohol consumption
Table 4.5 Continued
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Study Design/populationa Exposure estimates: RR (95% CI)b Comments
Hannan et al. 
(2009)
• Cohort study (CPS-II Nutrition Cohort)
• 124,751 men and women, most 50–74 years 
of age
• 1,962 cases of colorectal cancer
• United States (21 states) 
• Follow-up period: 1992–2005
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Current smoker: 1.27 (1.06–1.52)
 – Former smoker: 1.23 (1.11–1.36)
• Number of years since smoking cessation:
 – Never smoker: 1.00 (referent)
 – 1–10: 1.48 (1.27–1.73)
 – 11–20: 1.33 (1.14–1.55)
 – 21–30: 1.28 (1.10–1.49)
 – ≥31: 1.03 (0.89–1.19)
 – p trend among former smokers: 0.0003
Adjusted for age, BMI, level of education, family 
history of colorectal cancer, physical activity, race, 
aspirin use, alcohol use, vegetable consumption, 
fiber and whole grain consumption, red and 
processed meat consumption, and history 
of endoscopy
Leufkens et al. 
(2011)
• Cohort study (European Prospective 
Investigation into Cancer and Nutrition)
• 465,879 men and women, most 35–70 years 
of age
• 2,741 cases of colorectal cancer
• 23 centers in 10 European countries 
(Denmark, France, Germany, Greece, Italy, 
the Netherlands, Norway, Spain, Sweden, 
and United Kingdom)
• Follow-up period: 1991–2000
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Current smoker: 1.08 (0.96–1.21)
 – Former smoker: 1.17 (1.07–1.29)
• Number of years since smoking cessation:
 – Never smoker: 1.00 (referent)
 – ≤4: 1.15 (0.95–1.40)
 – 5–9: 1.16 (0.95–1.40)
 – 10–14: 1.24 (1.03–1.49)
 – 15–19: 1.34 (1.12–1.60)
 – 20–24: 1.11 (0.91–1.35)
 – ≥25: 1.08 (0.92–1.26)
 – p trend among former smokers: 0.52
Adjusted for center, age, sex, weight, height, 
physical activity, level of education, intake 
of energy from fat and nonfat, fiber, fruit, 
vegetables, red meat, processed meat, alcohol, 
and fish
Gong et al. 
(2012)
• Pooled analysis of eight studies from the 
Genetics and Epidemiology of Colorectal 
Cancer Consortium (Health Professionals 
Follow-up Study; Nurses’ Health Study; 
Prostate, Lung, Colorectal, and Ovarian 
Cancer Screening Trial; VITamins and 
Lifestyle Study; Women’s Health Initiative; 
Colon Cancer Family Registry; Diet, Activity, 
and Lifestyle Survey; and Ontario Familial 
Colorectal Cancer Registry)
• Men and women
• 6,796 cases of colorectal cancer and 
7,770 controls
• Number of years since smoking cessation:
 – Never smoker: 1.00 (referent)
 – Current smoker: 1.36 (1.12–1.64)
 – <15: 1.47 (1.21–1.78)
 – 15–24: 1.31 (1.07–1.60)
 – 25–34: 1.15 (0.85–1.55)
 – ≥35: 0.74 (0.47–1.18)
Adjusted for age, sex, BMI, level of education, 
alcohol intake, and study site
Number of years since smoking cessation 
additionally adjusted for pack-years of smoking
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Nishihara et al. 
(2013)
• Two cohort studies:
 – Men from the Health Professionals 
Follow-up Study
 – Women from the Nurses’ Health Study
• 134,204 men and women
• 1,260 cases of colorectal cancer with 
available tumors
• United States
• Follow-up period: 
 – Nurses’ Health Study: 1980–2008
 – Health Professionals Follow-up Study: 
1986–2008
• Colorectal cancer (all):
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.17 (0.96–1.43)
	| Former smoker: 1.18 (1.05–1.34)
 – Number of years since smoking cessation:
	| Current smoker: 1.00 (referent)
	| 1–4: 0.99 (0.73–1.34)
	| 5–9: 1.30 (0.99–1.71)
	| 10–19: 0.96 (0.75–1.23)
	| 20–39: 0.92 (0.74–1.14)
	| ≥40: 1.05 (0.80–1.37)
• CIMP-high:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 2.08 (1.35–3.20)
	| Former smoker: 1.30 (0.95–1.76)
 – Number of years since smoking cessation:
	| Current smoker: 1.00 (referent)
	| 1–4: 1.09 (0.58–2.02)
	| 5–9: 0.89 (0.48–1.66)
	| 10–19: 0.52 (0.29–0.93)
	| 20–39: 0.52 (0.32–0.84)
	| ≥40: 0.48 (0.26–0.90)
Adjusted for calendar year, age, sex, BMI, 
family history of colorectal cancer, regular 
use of aspirin, physical activity level, alcohol 
consumption, total caloric intake, and intake 
of red meat
Focused on molecular subtypes of colorectal 
cancer previously established to be smoking 
related, including CIMP-high
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Ordonez-Mena 
et al. (2016)
• Collaboration of 19 prospective cohort studies
• 897,021 men and women
• 12,696 cases of colorectal cancer and 
4,878 deaths from colorectal cancer
• Europe and United States
• Incidence of colorectal cancer:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.20 (1.07–1.34)
	| Former smoker: 1.20 (1.15–1.25)
 – Number of years since smoking cessation:
	| Current smoker: 1.00 (referent)
	| ≤9: 1.00 (0.87–1.16)
	| 10–19: 1.11 (0.97–1.27)
	| ≥20: 0.88 (0.78–1.00)
• Mortality from colorectal cancer:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.35 (1.16–1.58)
	| Former smoker: 1.22 (1.13–1.31)
 – Number of years since smoking cessation:
	| Current smoker: 1.00 (referent)
	| ≤9: 1.07 (0.86–1.32)
	| 10–19: 1.07 (0.87–1.31)
	| ≥20: 0.76 (0.63–0.93)
Analyses of number of years since smoking 
cessation included only cohorts with these 
data and therefore included substantially 
fewer participants
Adjusted for sex, age, BMI, level of education, 
vigorous physical activity, history of diabetes, 
and alcohol consumption
Notes: BMI = body mass index; CI = confidence interval; CIMP-high = cytosine-phosphate-guanine island methylator phenotype; CpG = cytosine-phosphate-guanine; 
CPS = Cancer Prevention Study; RR = relative risk.
aStudies are of cancer incidence unless number of cancer deaths is identified.
bp trend values are shown only if described as being among former smokers.
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smokers. This meta-analysis reported a lower summary RR 
for former smokers (1.4; 95% CI, 1.1–1.7) than for current 
smokers (1.7; 95% CI, 1.5–1.9). Seven other studies pub-
lished in 2014 or later found similar results (Everatt et al. 
2014; Moura et al. 2014; Chen et al. 2015; Meyer et al. 2015; 
Pang et al. 2015; Chiang et al. 2016; Niu et al. 2016). Of the 
30 studies overall, only 4 (all case-control studies) reported 
information on risk by number of years since smoking ces-
sation (Table 4.6) (Choi and Kahyo 1991; Goodman et al. 
1995; Ozasa 2007; Hassan et al. 2008). Results from these 
studies are inconsistent and are limited by small samples, 
as the largest (Hassan et al. 2008) included only 154 cases 
of liver cancer among former smokers. 
Cervix
The 1990 Surgeon General’s report concluded that 
“risk of cervical cancer is substantially lower among former 
smokers in comparison with continuing smokers, even in 
the first few years after cessation” (USDHHS 1990, p. 10). 
However, it did not explicitly conclude that smoking ces-
sation reduced risk of cervical cancer. The 2004 Surgeon 
General’s report concluded that there was sufficient evidence 
to infer a causal relationship between cigarette smoking and 
cervical cancer (USDHHS 2004). The association between 
smoking and higher risk of cervical cancer persists when 
adjusted for measures of infection with the human papil-
lomavirus (HPV) (IARC 2012; Roura et al. 2014). Potential 
biological mechanisms include direct genotoxic effects of 
nitrosamines and polyaromatic hydrocarbons from tobacco 
smoke and suppression of the immune system, including 
reduced ability to clear infection caused by HPV (Fonseca-
Moutinho 2011; Gadducci et al. 2011).
In a meta-analysis of more than 20  studies pub-
lished through 2003 that used never smokers as the ref-
erence group, Gandini and colleagues (2008) found that 
RRs for cervical cancer were lower for former smokers 
(1.26; 95%  CI, 1.11–1.42) than for current smokers 
(1.83; 95% CI, 1.51–2.21) (Roura et al. 2014). Earlier, the 
International Collaboration of Epidemiological Studies of 
Cervical Cancer (ICESCC) (2006) conducted a large pooled 
analysis of 23  studies (8  cohort, 15  case control) that 
included data from most of the studies published up to 
that time. In that analysis, summary RRs for squamous cell 
carcinoma, by far the most common histologic type of cer-
vical cancer (American Cancer Society 2016), were lower 
for former smokers (1.12; 95%  CI, 1.01–1.25) than for 
current smokers (1.60; 95% CI, 1.48–1.73). Smoking was 
not associated with adenocarcinoma of the cervix (0.89; 
95% CI, 0.74–1.06), which accounts for a small proportion 
of cervical cancers (American Cancer Society 2016). RRs 
have also been greater for current smokers than for former 
smokers in studies published after 2006 (Odongua et  al. 
2007; Madsen et al. 2008; Roura et al. 2014).
Using data from a subset of studies in its pooled anal-
ysis, ICESCC (2006) reported on the risk of cervical cancer 
by number of years since smoking cessation. Table  4.7 
summarizes these results and results from two other 
studies published since 2004, including a case-control 
study (Shields et al. 2004) and a cohort study (Roura et al. 
2014). In the pooled analysis, estimates of RR were slightly 
lower for having quit 10 or more years ago versus having 
done so more recently, although trends by number of years 
since smoking cessation were not statistically significant. 
The cohort study (Roura et al. 2014), which was conducted 
in Europe among 308,036 women, included 261 cases of 
invasive cervical cancer and 804 cases of carcinoma in situ 
(CIS) or cervical intraepithelial cancer grade 3 (CIN3). For 
both invasive cancer and CIS/CIN3, Roura and colleagues 
(2014) found statistically significant decreases in risk as 
the number of years since quitting increased, with risk 
reaching less than or about half that in current smokers 
among women who had quit smoking 20 or more years 
earlier. Finally, Shields and colleagues (2004), in a case-
control study conducted in five U.S. cities, did not find any 
trends related to number of years since quitting; however, 
their study included relatively few former smokers.
Kidney
The 2004 Surgeon General’s report concluded that 
the evidence was sufficient to infer a causal relationship 
between cigarette smoking and kidney cancer (USDHHS 
2004). Biological mechanisms for such a relationship may 
include oxidative stress (Patel et al. 2015) and exposure 
to nitrosamines and other carcinogens in tobacco smoke 
(USDHHS 2004; Clague et al. 2009). 
In a meta-analysis of more than 20 studies of 
smoking and incident kidney cancer, Cumberbatch and 
colleagues (2016) found that the RR for kidney cancer, in 
comparisons with never smokers, was lower for former 
smokers (RR = 1.16; 95% CI, 1.08–1.25) than for cur-
rent smokers (RR = 1.36; 95% CI, 1.19–1.56). Finally, 10 
studies, all case-control, examined risk for kidney cancer 
by time since quitting among former smokers (Table 4.8) 
(McLaughlin et al. 1984, 1995; La Vecchia et al. 1990; 
McCredie and Stewart 1992; Kreiger et al. 1993; Muscat 
et al. 1995; Yuan et al. 1998; Parker et al. 2003; Hu et al. 
2005; Cote et al. 2012). In most of these studies, the odds 
ratio (OR) for the highest category of number of years 
since quitting (ranging from >10 to >30 years) was lower 
than the OR for categories with fewer years since quitting. 
Acute Myeloid Leukemia
The 2004 Surgeon General’s report concluded that 
the evidence was sufficient to infer a causal relationship 
between smoking and AML (USDHHS 2004). Potential 
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Table 4.6 Studies of liver cancer incidence or mortality, by number of years since smoking cessation
Study Design/populationa Exposure estimates: RR (95% CI) Comments
Choi et al. 
(1991)
• Case-control, hospital-based study 
• 216 cases of liver cancer in males and 
648 male controls
• Korea
• Time period in which cases were diagnosed: 
1986–1990
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Current smoker: 1.01 (0.65–1.57)
 – Former smoker: 0.65 (0.35–1.19)
• Number of years since smoking cessation:
 – Current smoker: 1.00 (referent)
 – 1–4: 0.76 (0.31–1.89)
 – 5–9: 0.43 (0.15–1.26)
 – ≥10: 0.44 (0.11–1.82)
Adjusted for age, marital status, level of 
education, serum hepatitis B virus surface 
antigen, and alcohol consumption
Goodman et al. 
(1995)
• Cohort study (Life Span Study)
• 36,133 men and women who were in 
Hiroshima or Nagasaki at the time of 
the atomic bombings in August 1945
• 242 cases of liver cancer
• Japan
• Follow-up period: 1980–1989
• Men:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 4.26 (1.87–9.72)
	| Former smoker: 4.56 (1.95–10.7)
 – Number of years since smoking cessation:
	| Never smoker: 1.00 (referent)
	| <14: 5.60 (2.15–14.6)
	| 14–23: 4.11 (1.58–10.7)
	| ≥24: 4.04 (1.54–10.6)
• Women:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.58 (0.86–2.88)
	| Former smoker: 1.66 (0.76–3.63)
 – Number of years since smoking cessation:
	| Never smoker: 1.00 (referent)
	| <10: 10.4 (2.51–43.5)
	| 10–24: 1.03 (0.25–4.24)
	| ≥25: 2.31 (0.72–7.43)
Adjusted for city, age at time of the atomic 
bombings, attained age, and radiation dose 
to the liver
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Ozasa (2007) • Cohort study (Japan Collaborative Cohort 
Study for Evaluation of Cancer)
• 620 deaths from liver cancer
• Japan
• Follow-up period: starting in 1988
• Men:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.59 (1.20–2.12)
	| Former smoker: 1.48 (1.09–2.00)
 – Number of years since smoking cessation:
	| Current smoker: 1.00 (referent)
	| <5: 1.27 (0.81–1.98)
	| 5–14: 1.54 (1.06–2.23)
	| ≥15: 1.54 (1.05–2.27)
• Women:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.95 (1.19–3.19)
	| Former smoker: 0.76 (0.24–2.39)
 – Number of years since smoking cessation:
	| Current smoker: 1.00 (referent)
	| <5: 1.05 (0.14–7.51)
	| 5–14: 1.40 (0.34–5.69)
	| ≥15: Not reported
Adjusted for age and area of study
Hassan et al. 
(2008)
• Case-control, hospital-based study
• 319 cases of liver cancer among men and 
women treated at MD Anderson Cancer 
Center, and 1,061 controls who were 
relatives of the patients 
• Houston, Texas
• Time period in which cases were diagnosed: 
2000–2006
• Number of years since smoking cessation:
 – Never smoker: 1.0 (referent)
 – ≤10: 1.7 (1.0–3.1)
 – >10: 1.3 (0.8–1.9)
Adjusted for age, race, level of education, 
marital status, state of residency, hepatitis B 
virus, hepatitis C virus, diabetes, heavy alcohol 
consumption, and family history of cancer
Did not present results by smoking status
Notes: CI = confidence interval; RR = relative risk.
aStudies are of cancer incidence unless the number of cancer deaths is identified.
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Table 4.7 Studies of cervical cancer incidence by years since smoking cessation
Study Design/populationa Exposure estimates: RR (95% CI) Comments
International 
Collaboration of 
Epidemiological 
Studies of 
Cervical Cancer 
(2006)
• Collaborative analysis of 23 cohort and 
case-control studies (The International 
Collaboration of Epidemiological Studies 
of Cervical Cancer)
• 9,052 cases of invasive cancer (7,498 with 
data on number of years since smoking 
cessation), 4,489 cases of carcinoma in situ 
or cervical intraepithelial neoplasia III, and 
23,017 controls
• Studies from Algeria, Brazil, Chile, Colombia, 
Costa Rica, Denmark, India, Italy, Mali, Mexico, 
Morocco, Norway, Panama, Paraguay, Peru, 
Philippines, South Africa, Spain, Sweden, 
Thailand, United Kingdom, and United States
• Number of years since smoking cessation:
 – Invasive cancer:
	| Never smoker: 1.00 (0.94–1.06)
	| Current smoker: 1.46 (1.35–1.58)
	| 1–4: 1.05 (0.87–1.28)
	| 5–9: 1.08 (0.85–1.38)
	| ≥10: 0.99 (0.83–1.18)
 – Carcinoma in situ or cervical intraepithelial 
neoplasia III:
	| Never smoker: 1.00 (0.91–1.10)
	| Current smoker: 1.83 (1.68–1.99)
	| 1–4: 1.35 (1.05–1.74)
	| 5–9: 1.35 (0.99–1.83)
	| ≥10: 1.19 (0.85–1.66)
Cohort studies analyzed as nested case-control 
studies, with up to four controls selected 
randomly per case according to age
Adjusted for study, study center, age, age at 
first intercourse, duration and use of oral 
contraception, number of full-term pregnancies, 
and lifetime number of sexual partners
Shields et al. 
(2004)
• Case-control, population-based study
• Women 20–74 years of age
• 235 cases of squamous cell carcinoma 
and 209 controls with seropositive human 
papillomavirus
• Controls obtained from random-digit dialing
• Time period in which cases were diagnosed: 
1982–1984
• Five U.S. cities (Birmingham, Chicago, 
Denver, Miami, and Philadelphia)
• Smoking status: 
 – Never smoker: 1.0 (referent)
 – Current smoker: 1.9 (1.2–2.8)
 – Former smoker: 1.4 (0.8–2.4)
• Number of years since smoking cessation:
 – 1–5: 1.0 (referent)
 – 6–14: 0.6 (0.2–2.0)
 – ≥15: 0.8 (0.3–2.5)
Cases restricted to squamous cell carcinoma
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Roura et al. 
(2014)
• Cohort study (European Prospective 
Investigation into Cancer and Nutrition)
• 308,036 women, most 35–70 years of age
• 261 cases of ICC and 804 cases of CIS or CIN3
• 10 European countries (Denmark, France, 
Germany, Greece, Italy, Norway, Spain, Sweden, 
the Netherlands, and United Kingdom)
• Follow-up period: 1992–2006
• Smoking status:
 – ICC:
	| Never smoker: 1.0 (referent)
	| Current smoker: 1.9 (1.4–2.5)
	| Former smoker: 1.5 (1.1–2.1)
 – CIS or CIN3:
	| Never smoker: 1.0 (referent)
	| Current smoker: 2.1 (1.8–2.5)
	| Former smoker: 1.5 (1.2–1.8)
 – p trend among former smokers: 0.02
• Number of years since smoking cessation:
 – ICC:
	| Current smoker: 1.0 (referent)
	| ≤4: 1.2 (0.7–2.0)
	| 5–9: 0.9 (0.5–1.7)
	| 10–19: 0.8 (0.5–1.3)
	| ≥20: 0.4 (0.2–0.8)
 – CIS or CIN3:
	| Current smoker: 1.0 (referent)
	| ≤4: 0.8 (0.6–1.1)
	| 5–9: 1.0 (0.7–1.3)
	| 10–19: 0.5 (0.4–0.8)
	| ≥20: 0.5 (0.3–0.7)
• Statistically significant p trends for the 
association between smoking-related variables 
and the risk of CIN3/CIS and ICC by risk factor:
 – Smoking duration (years); p trends among 
ever smokers: <0.0001 (CIN3/CIS), 0.08 (ICC)
 – Lifetime smoking intensity (cig/day); 
p trend among ever smokers: 0.07 (ICC)
 – Smoking pack years; p trends among ever 
smokers: 0.001 (CIN3/CIS); 0.07 (ICC)
 – Time since quitting; p trends among past 
smokers: 0.02 (CIN3/CIS); 0.02 (ICC)
Adjusted for BMI, marital status, level of 
education, physical activity, number of full-
term pregnancies, and use and duration of 
oral contraception
Notes: BMI = body mass index; CI = confidence interval; CIN3 = cervical intraepithelial neoplasia III; CIS = carcinoma in situ; ICC = invasive cervical cancer; RR = relative risk.
aStudies are of cancer incidence unless the number of cancer deaths is identified.
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Table 4.8 Studies of kidney cancer incidence by number of years since smoking cessation
Study Design/populationa Exposure estimates: OR (95% CI) Comments
McLaughlin 
et al. (1984)
• Case-control, population-based study
• White men and women 30–85 years of age
• 495 cases of kidney cancer and 697 controls
• Time period in which cases were diagnosed: 
1974–1979
• Minneapolis-St. Paul, Minnesota, 
metropolitan area
• Number of years since smoking cessation:
 – Men:
	| Never smoker: 1.0 (referent):
	|  ≤10 prior to 1974: 1.7
	| >10 prior to 1974: 1.1
	| Current smoker: 1.8
 – Women:
	| Never smoker: 1.0 (referent)
	| ≤10 prior to 1974: 1.7
	| >10 prior to 1974: 1.6
	| Current smoker: 2.0
Adjusted for age
Confidence intervals not provided
LaVecchia et al. 
(1990)
• Case-control, hospital-based study
• Cases: Men and women <75 years of age
• Controls: Admitted for acute conditions 
• 131 cases of kidney cancer and 394 controls
• Time period in which cases were diagnosed: 
1985–1989
• Northern Italy
• Number of years since smoking cessation:
 – Never smoker: 1.0 (referent)
 – <10: 2.2 (1.1–4.4)
 – ≥10: 1.3 (0.6–2.7)
Adjusted for age, sex, area of residence, level of 
education, and BMI
Did not present results for current smoking status
McCredie et al. 
(1992)
• Case-control, population-based study 
• Men and women 20–79 years of age
• 489 cases of kidney cancer and 523 controls
• Time period in which cases were diagnosed: 
1989–1990
• New South Wales, Australia
• Smoking status: 
 – Never smoker: 1.00 (referent)
 – Current smoker: 2.17 (1.55–3.02)
 – Former smoker: 1.41 (1.03–1.95)
• Number of years since smoking cessation:
 – Current smoker: 1.00 (referent)
 – 1–12: 0.85 (0.53–1.38)
 – 13–24: 0.89 (0.52–1.53)
 – ≥25: 0.47 (0.22–1.00)
Adjusted for age, sex, method of interview, 
and BMI
Number of years since smoking cessation 
additionally adjusted for duration of cigarette 
smoking and number of cigarettes smoked 
per day
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Kreiger et al. 
(1993)
• Case-control, population-based study 
• Men and women 25–69 years of age 
• 518 cases of kidney cancer and 1,381 controls
• Time period in which cases were diagnosed: 
1994–1997
• Ontario, Canada
• Number of years since smoking cessation:
 – Men:
	| Never smoker: 1.0 (referent)
	| Current smoker: 2.3 (1.5–3.4) 
	| 1–4: 2.1 (1.2–3.8)
	| 5–9: 1.8 (1.0–3.3)
	| 10–19: 2.1 (1.3–3.4)
	| ≥20: 1.3 (0.8–2.1)
 – Women:
	| Never smoker: 1.0 (referent)
	| Current smoker: 2.2 (1.5–3.2)
	| 1–4: 1.4 (0.6–2.9)
	| 5–9: 1.6 (0.7–3.7)
	| 10–19: 1.9 (0.8–4.2)
	| ≥20: 1.5 (0.7–3.1)
Adjusted for age and BMI
McLaughlin 
et al. (1995) 
• Case-control, population-based study
• Men and women 20–79 years of age
• 1,732 cases of kidney cancer and 2,309 controls
• Time period in which cases were diagnosed: 
1989–1991
• Six study centers in five countries: Australia 
(Sydney), Denmark, Germany (Berlin and 
Heidelberg), Sweden (Uppsala), and United 
States (Minnesota)
• Smoking status:
 – Never smoker: 1.0 (referent)
 – Current smoker: 1.4 (1.2–1.7)
 – Former smoker: 1.2 (1.0–1.4)
• Number of years since smoking cessation:
 – Current smoker: 1.0 (referent)
 – ≤5: 0.90 (0.7–1.2)
 – 6–15: 0.84 (0.7–1.1)
 – 16–25: 0.75 (0.6–1.0)
 – >25: 0.85 (0.6–1.1)
Adjusted for age, sex, study center, and BMI
Number of years since smoking cessation 
additionally adjusted for number of cigarettes 
smoked per day
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Study Design/populationa Exposure estimates: OR (95% CI) Comments
Muscat et al. 
(1995)
• Case-control, hospital-based study
• Cases: Men and women diagnosed at hospitals 
in the study areas
• Controls: Hospitalized for conditions unrelated 
to tobacco use 
• 788 cases of kidney cancer and 779 controls
• Time period in which cases were diagnosed: 
1977–1993
• Multicenter hospitals in New York (New York 
City and New Hyde Park), Illinois (Chicago 
and Hines), Michigan (Detroit), and 
Pennsylvania (Philadelphia)
• Men:
 – Smoking status:
	| Never smoker: 1.0 (referent)
	| Current smoker: 1.4 (1.02–2.0)
	| Former smoker: 0.9 (0.7–1.5)
 – Number of years since smoking cessation:
	| Never smoker: 1.0 (referent)
	| 1–5: 1.6 (0.9–2.6)
	| 6–10: 2.2 (1.2–4.4)
	| >10: 0.7 (0.5–0.9)
• Women
 – Smoking status:
	| Never smoker: 1.0 (referent)
	| Current smoker: 1.0 (0.7–1.6)
	| Former smoker: 1.1 (0.7–1.7)
 – Number of years since smoking cessation:
	| Never smoker: 1.0 (referent)
	| 1–5: 1.0 (0.4–2.2)
	| 6–10: 1.3 (0.3–6.0)
	| >10: 1.1 (0.6–1.8)
Adjusted for age and level of education
Yuan et al. 
(1998)
• Case-control, population-based study
• Non-Asian men and women 25–74 years of age
• 1,204 cases of kidney cancer and 1,204 controls
• Time period in which cases were diagnosed: 
1986–1994
• Los Angeles, California
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Current smoker: 1.53 (1.23–1.90)
 – Former smoker: 1.24 (1.02–1.50)
• Number of years since smoking cessation:
 – Never smoker: 1.00 (referent)
 – 1–9: 1.33 (1.02–1.74)
 – 10–19: 1.25 (0.94–1.64)
 – ≥20: 1.15 (0.89–1.50)
Adjusted for level of education
Parker et al. 
(2003)
• Case-control, population-based study
• Men and women 40–85 years of age
• 387 cases of kidney cancer and 2,333 controls
• Time period in which cases were diagnosed: 
1985–1987
• Iowa
• Number of years of smoking cessation:
 – Current smoker: 1.00 (referent)
 – Never smoker: 0.6 (0.4–0.9)
 – <10: 0.7 (0.4–1.1)
 – 10–19: 0.8 (0.5–1.2)
 – 20–29: 0.7 (0.4–1.1)
 – ≥30: 0.5 (0.3–1.0)
Adjusted for age, sex, BMI, history of 
hypertension, and pack-years of smoking
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Hu et al. (2005) • Case-control, population-based study 
• Men and women 20 years of age and older
• 1,279 cases of kidney cancer and 5,370 controls
• Time period in which cases were diagnosed: 
1994–1997
• Eight Canadian provinces: Alberta, British 
Columbia, Manitoba, Newfoundland, Nova 
Scotia, Ontario, Prince Edward Island, 
and Saskatchewan
• Men:
 – Smoking status:
	| Never smoker: 1.0 (referent)
	| Current smoker: 0.9 (0.7–1.2)
	| Former smoker: 1.2 (1.0–1.5)
 – Number of years since smoking cessation:
	| Never smoker: 1.0 (referent)
	| ≤10: 1.5 (1.0–2.3)
	| 11–20: 1.1 (0.8–1.5)
	| 21–30: 1.2 (0.8–1.6)
	| ≥31: 1.0 (0.7–1.4)
• Women:
 – Smoking status:
	| Never smoker: 1.0 (referent)
	| Current smoker: 0.9 (0.7–1.2)
	| Former smoker: 1.3 (1.0–1.6)
 – Number of years since smoking cessation:
	| Never smoker: 1.0 (referent)
	| ≤10: 1.5 (0.8–2.6)
	| 11–20: 0.6 (0.4–1.1)
	| ≥20: 1.1 (0.7–1.6)
Adjusted for age; Canadian province; level of 
education; BMI; alcohol use; and consumption 
of meats, vegetables, and fruits
Number of years since smoking cessation 
additionally adjusted for pack-years of smoking
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Cote et al. 
(2012)
• Case-control, population-based study
• Men and women 20–79 years of age
• 1,217 cases of kidney cancer and 1,235 controls
• Time period in which cases were diagnosed: 
2002–2007
• Detroit (Michigan) and Chicago (Illinois)
• White:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.46 (1.05–2.04)
	| Former smoker: 0.99 (0.78–1.25)
 – Number of years since smoking cessation:
	| Current smoker: 1.00 (referent)
	| ≤5: 1.34 (0.83–2.17)
	| 6–15: 0.82 (0.53–1.25)
	| 16–25: 0.61 (0.39–0.94)
	| ≥25: 0.62 (0.39–1.01)
• Black:
 – Smoking status:
	| Never smoker: 1.00 (referent)
	| Current smoker: 1.16 (0.81–1.65)
	| Former smoker: 0.81 (0.56–1.18)
 – Number of years since smoking cessation:
	| Current smoker: 1.00 (referent)
	| ≤5: 0.97 (0.51–1.85)
	| 6–15: 0.73 (0.42–1.26)
	| 16–25: 0.72 (0.38–1.37)
	| ≥25: 0.47 (0.25–0.88)
Adjusted for age, study site, sex, BMI, education 
level, family history of kidney cancer, and 
hypertension
Number of years since smoking cessation 
additionally adjusted for pack-years of smoking
Notes: BMI = body mass index; CI = confidence interval; OR = odds ratio.
aStudies are of cancer incidence unless number of cancer deaths is identified.
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mechanisms include inhalation of benzene, a known 
cause of leukemia, and radioactive substances in tobacco 
smoke (Thomas and Chelghoum 2004; USDHHS 2004; 
Lichtman 2007).
In a meta-analysis of 5 cohort and 12 case-control 
studies of smoking and AML, Colamesta and colleagues 
(2016) reported separate summary RRs for cohort and case-
control studies. For the cohort studies, summary RR esti-
mates were 1.45 (95% CI, 1.08–1.94) for former smokers 
and 1.52 (95% CI, 1.10–2.14) for current smokers. For the 
case-control studies, summary RRs were 1.21 (95%  CI, 
1.03–1.41) for former smokers and 1.36 (95%  CI, 1.11–
1.66) for current smokers. This meta-analysis also pooled 
data that included information on number of years since 
cessation from three case-control studies (Severson et al. 
1990; Kane et  al. 1999; Musselman et  al. 2013). In the 
pooled analysis, risk declined with increasing time since 
smoking cessation, with no statistically significant reduc-
tion in risk among former smokers who had quit within 
10 years compared with continuing smokers (OR = 1.01; 
95% CI, 0.60–1.72). The risk was lower for those who had 
quit for 10–20 years (OR = 0.74; 95% CI, 0.53–1.03) and 
even lower for those who had quit for more than 20 years 
(OR = 0.59; 95% CI, 0.45–0.78).
Synthesis of the Evidence
The 1990 Surgeon General’s report concluded that 
smoking cessation reduces the risk of six cancers: lung, 
larynx, oral cavity and pharynx, esophagus, pancreas, 
and bladder (USDHHS 1990). Results of studies pub-
lished since 1990 expand the role of smoking as a cause of 
cancer and support the reduction of cancer risk following 
smoking cessation.
The 2004 and 2014 Surgeon General’s reports con-
cluded that smoking causes at least six additional cancers 
beyond those for which the associations were considered 
causal in 1990: stomach, liver, colon and rectum, kidney, 
cervix, and AML (USDHHS 2004, 2014). The 12  types of 
cancer reviewed in this section have all been judged to be 
caused by cigarette smoking in reports of the U.S. Surgeon 
General (USDHHS 2014) and IARC (IARC 2012)—based on 
evaluating the evidence against criteria for causality utilized 
in Surgeon Generals’ reports, including consistency across 
studies, temporal relationship of association, strength of 
association, and biological plausibility (USDHHS 2004).
These same criteria have been used to evaluate the 
evidence on smoking cessation. Because smoking cessa-
tion reduces cumulative exposure to tobacco smoke across 
the life course, biological plausibility alone, coupled with 
appropriate temporality, supports the conclusion that 
smoking cessation reduces the risk of all 12  cancers 
that have been causally linked to cigarette smoking. 
Additionally, epidemiological evidence documents that 
the risk for most of these cancers drops progressively as 
the time since successful quitting lengthens, and findings 
are generally consistent across studies.
The effect of smoking cessation on risk for lung 
cancer is particularly important because lung cancer is 
the largest contributor to smoking-attributable cancer 
mortality in the United States and the number of new 
cases continues to increase (U.S. Cancer Statistics 
Working Group 2019). Since 1990, many studies have 
been published characterizing how risk for lung cancer 
changes with time since smoking cessation. As noted 
previously, results from many studies (Calle et al. 2002; 
IARC 2007; Pinsky et al. 2015) indicate that, in compar-
ison with smokers who do not quit, RRs for lung cancer 
decline steadily after smoking cessation, with RRs for 
former smokers falling to half those of RRs for continuing 
smokers after approximately 10–15 years of cessation. 
While the 2004 and 2014 Surgeon General’s reports 
concluded that smoking causes cancers of the stomach, 
colon and rectum, kidney, and cervix and AML (USDHHS 
2004, 2014), the two reports did not explicitly conclude 
that smoking cessation reduces the risk for these can-
cers. For four of these malignancies (stomach, kidney, 
cervix, and AML), RRs are consistently lower among 
former cigarette smokers than among current smokers, 
supporting a causal association between smoking cessa-
tion and lower risk for these cancers. Similarly, the 2004 
and 2014 Surgeon General’s reports also concluded that 
smoking causes cancer of the liver (USDHHS 2004, 2014). 
This report considered four specific studies showing that 
RRs decline in former smokers with time since smoking 
cessation. These findings were consistent with the meta-
analysis of 29 studies conducted for the 2014 Surgeon 
General’s report that documented a much lower RR in 
former smokers than in current smokers, compared with 
never smokers (USDHHS 2014). Taken together, these 
epidemiological findings support a causal association 
between smoking cessation and lower risk for liver cancer. 
In studies of colorectal cancer, RRs for former 
smokers have not been consistently lower than those for 
current smokers. However, in many of the studies where 
lower RRs have not been observed for former smokers, cur-
rent smokers likely did not have sufficiently long induction 
periods to fully reflect the long-term effects of smoking. 
In addition to the studies where lower RRs were observed, 
other evidence supports the hypothesis that smoking ces-
sation reduces risk of colorectal cancer. This evidence 
includes studies that document substantially lower RRs 
for colorectal adenoma, an established precursor lesion for 
colorectal cancer, among former smokers than among cur-
rent smokers. These studies have also found declining RRs 
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for colorectal cancer among former smokers with increased 
time since smoking cessation, particularly for specific 
molecular subtypes that are associated with smoking. Taken 
together, these epidemiological findings, including those of 
incident colorectal cancer and established precursor lesions 
for colorectal cancer, support a causal association between 
smoking cessation and lower risk for colorectal cancer.
Conclusions
1. The evidence is sufficient to infer that smoking 
cessation reduces the risk of lung cancer. 
2. The evidence is sufficient to infer that smoking 
cessation reduces the risk of laryngeal cancer. 
3. The evidence is sufficient to infer that smoking 
cessation reduces the risk of cancers of the oral 
cavity and pharynx
4. The evidence is sufficient to infer that smoking 
cessation reduces the risk of esophageal cancer. 
5. The evidence is sufficient to infer that smoking 
cessation reduces the risk of pancreatic cancer.
6. The evidence is sufficient to infer that smoking 
cessation reduces the risk of bladder cancer. 
7. The evidence is sufficient to infer that smoking 
cessation reduces the risk of stomach cancer.
8. The evidence is sufficient to infer that smoking 
cessation reduces the risk of colorectal cancer.
9. The evidence is sufficient to infer that smoking 
cessation reduces the risk of liver cancer.
10. The evidence is sufficient to infer that smoking 
cessation reduces the risk of cervical cancer.
11. The evidence is sufficient to infer that smoking 
cessation reduces the risk of kidney cancer.
12. The evidence is sufficient to infer that smoking 
cessation reduces the risk of acute myeloid leukemia.
13. The evidence is sufficient to infer that the relative 
risk of lung cancer decreases steadily after smoking 
cessation compared with the risk for persons con-
tinuing to smoke, with risk decreasing to half that 
of continuing smokers approximately 10–15  years 
after smoking cessation and decreasing further with 
continued cessation.
Implications
The evidence that smoking cessation reduces cancer 
risk has long been an important part of the rationale for 
efforts—including educational, clinical, health systems, 
community, and population-based interventions and ini-
tiatives to make evidence-based, barrier-free cessation 
services widely available—to motivate and help smokers 
to quit. This report’s conclusion that smoking cessation 
reduces the risk of several additional types of cancer fur-
ther strengthens that rationale and provides an opportu-
nity for broadening and intensifying messages about the 
important role that smoking cessation plays in cancer 
prevention.
Smoking Cessation After a Cancer Diagnosis
This section reviews evidence of the health benefits 
of smoking cessation at the time of a cancer diagnosis or 
after that diagnosis compared with continuing to smoke. 
At the time of cancer diagnosis, approximately 20–30% of 
all cancer patients self-reported current cigarette smoking 
(Warren and Simmons 2018); however, self-reported rates 
of smoking were typically lower than biochemically con-
firmed smoking, as smokers with cancer may misrepre-
sent their smoking. Among long-term cancer survivors, 
the smoking prevalence is approximately 9% (Warren 
and Simmons 2018). This review is limited to all-cause 
mortality, an integrative indicator, and does not explore 
disease progression or recurrence, cancer-specific mor-
tality, second primary cancer, quality of life, or treatment 
toxicity as outcomes of interest.
Conclusions from Previous 
Surgeon General’s Reports
Previous reports of the Surgeon General have not 
evaluated the health benefits of smoking cessation after 
a cancer diagnosis, but smoking is causally associated 
with diseases of every major organ system and is therefore 
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strongly linked with all-cause mortality (USDHHS 2014).
The 2014 Surgeon General’s report concluded that 
smoking increases all-cause mortality. The 2014 report 
was also the first to conclude that continued smoking 
after a cancer diagnosis causes adverse health outcomes 
among cancer patients or survivors (i.e., persons who have 
been diagnosed with cancer) (U.S. Department of Health 
and Human Services [USDHHS] 2014). Smoking cessa-
tion has been shown to reduce all-cause mortality in the 
general population (USDHHS 2014), providing strong jus-
tification for the hypothesis that cessation after a cancer 
diagnosis will result in improved survival compared with 
continued smoking. Given the conclusions in the 2014 
Surgeon General’s report about the adverse health effects 
that cancer patients who smoke can experience, a review 
of the evidence on smoking cessation after a cancer diag-
nosis is important.
Literature Review Methods
The literature search for this section followed 
the strategy used in the 2014 Surgeon General’s report 
(USDHHS 2014), which queried the National Library 
of Medicine’s MEDLINE database for “smoking” and 
“cancer.” Studies were considered for inclusion if they met 
three criteria:
• They were original reports that compared all-cause 
mortality between (a)  current smokers who were 
diagnosed with cancer but continued smoking and 
(b) patients who had quit smoking within 1 year of a 
cancer diagnosis or patients who had quit smoking 
after a cancer diagnosis;
• They had a baseline and final cohort size of at least 
100 cancer patients, including cigarette smokers 
and quitters; and 
• They were published from 2000 to 2016. 
Studies were excluded if they reported findings on only 
continued smoking after a cancer diagnosis versus quit-
ting smoking substantially before a cancer diagnosis. 
Smoking Cessation and All-Cause 
Mortality in Cancer Patients
Ten studies (seven prospective cohort studies 
and three retrospective cohort studies) reporting on 
10,975 patients met the inclusion criteria (Table 4.9). The 
studies are grouped in the table by their reference group: 
never smokers, current smokers who did not stop smoking 
with diagnosis (referred to as persistent smokers), and 
quitters. The cohorts were composed of patients with 
lung cancer (four studies), with head/neck cancer (three 
studies), with breast cancer (one study), and with multiple 
types of cancer (two studies). Eight studies did not specify 
the treatment modality (surgery, radiotherapy, chemo-
therapy), and two patient cohorts were composed exclu-
sively of patients treated with radiotherapy (Al-Mamgani 
et al. 2014; Roach et al. 2016).
Three prospective cohort studies (Al-Mamgani et al. 
2014; Choi et  al. 2016; Passarelli et  al. 2016) compared 
continued smoking and quitting smoking with never 
smoking. In all three studies, continued smoking after a 
cancer diagnosis significantly increased risk of mortality 
compared with never smoking, and the risk of mortality 
for quitters was greater than that for never smokers but 
not as great as that for continuing smokers.
Three studies (Sardari Nia et  al. 2005; Sandoval 
et al. 2009; Chen et al. 2010) compared quitting smoking 
with persistent smoking using persistent smokers as 
the referent. Quitting was significantly associated with 
reduced all-cause mortality in two studies, with associa-
tions that were significant in patients with non-small cell 
lung cancer (relative risk [RR] = 0.34; 95% CI, 0.16–0.71) 
(Sardari Nia et  al. 2005) and in patients with small cell 
lung cancer (hazard ratio [HR] = 0.55; 95% CI, 0.38–0.79) 
(Chen et al. 2010), but not in a study of patients with oral 
cavity cancer (RR  =  0.92; 95%  CI, 0.46–1.84) (Sandoval 
et al. 2009).
Four studies compared continued cigarette smoking 
with quitting, using quitters as the referent (Tao et  al. 
2013; Al-Mamgani et al. 2014; Dobson Amato et al. 2015; 
Roach et al. 2016). In all four studies, continued smoking 
was associated with increased all-cause mortality rela-
tive to quitting. For a group of 1,632 male cancer patients 
from the Shanghai Cancer Cohort (Tao et al. 2013), results 
by disease site showed (a) a significantly increased risk of 
all-cause mortality in persistent (continued) smokers for 
lung cancer (HR  =  1.89; 95%  CI, 1.18–3.02), colorectal 
cancer (HR = 3.46; 95% CI, 1.69–7.10), and bladder cancer 
(HR = 17.29; 95% CI, 2.25–132.64) and (b) indication of 
increased mortality in other cancers (HR = 1.49; 95% CI, 
0.92–2.40).
Evaluation of the Evidence
This is the first review in a report of the Surgeon 
General on the potential health benefits of smoking ces-
sation after a cancer diagnosis. This section considers sci-
entific evidence with reference to five key guidelines for 
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Table 4.9 Cohort studies that compared all-cause mortality in persons who were smokers at the time of a cancer diagnosis but had quit smoking after 
the diagnosis with those who continued smoking after the diagnosis
Study Design/population Follow-up period
Comparison 
group(s) Definitions of groups Findings
Reference group: 
Never smokers
         
Yang et al. (2015a) • Prospective cohort
• 2,548 patients with 
colorectal cancer from 
CPS II
• 153 current smokers 
at baseline
• Every 2 years 
from 1997 to 
December 31, 
2010
• Quitters
• Persistent 
smokers
• Never smokers: Those who never 
smoked
• Quitters: Those who had quit 
smoking after a cancer diagnosis
• Persistent smokers: Those 
who continued to smoke after a 
cancer diagnosis
• Adjusted RR:
 – Never smokers: 1.0 (referent)
 – Quitters: 1.94 (95% CI, 
1.29–2.91)
 – Persistent smokers: 2.33 
(95% CI, 1.62–3.34)
• RR for quitters vs. persistent 
smokers: 0.833 (p = 0.37, 
1.94 vs. 2.33)
Choi et al. (2016) • Prospective cohort
• 590 patients with head 
or neck cancer
• 146 persistent smokers 
at any time after a 
cancer diagnosis
• 99 quitters
• University of Michigan
• Every 3 months 
for 2 years
• Annually after 
the first 2 years 
until 8 years 
of follow-up or 
September 11, 
2011, whichever 
came first
• Quitters 
• Persistent 
smokers
• Never smokers: Those who never 
smoked
• Quitters: Those who had quit 
within the first 3 months of 
diagnosis of squamous cell 
carcinoma (head or neck) and 
remained a quitter through the 
first 2 years after the diagnosis
• Persistent smokers: Those who 
smoked at any time after a cancer 
diagnosis (defined as continuing 
smokers in the study)
• Adjusted HR:
 – Never smokers: 1.0 (referent)
 – Quitters: 2.38 (95% CI, 
1.29–4.36)
 – Persistent smokers: 2.71 
(95% CI, 1.48–4.98)
• RR for quitters vs. persistent 
smokers: 0.877 (2.38 vs. 2.71, 
calculated)
Passarelli et al. 
(2016)
• Prospective cohort
• 4,562 patients with breast 
cancer, as a part of the 
Collaborative Breast Cancer 
Study and Collaborative 
Women’s Longevity Study
• 424 persistent smokers 
• 352 quitters
• Median follow-up 
of 6 years after 
diagnosis
• Quitters
• Persistent 
smokers
• Never smokers: Those who never 
smoked
• Quitters: Those who had quit 
smoking during the year before the 
cancer diagnosis and remained a 
quitter after the diagnosis 
• Persistent smokers: Those 
who reported actively smoking 
during the year before the cancer 
diagnosis and after the diagnosis 
• Adjusted HR:
 – Never smokers: 1.0 (referent)
 – Quitters: 2.34 (95% CI, 
1.85–2.96)
 – Persistent smokers: 2.57 
(95% CI, 2.06–3.21)
• RR for quitters vs. persistent 
smokers: 0.911 (2.34 vs. 2.57, 
calculated)
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Study Design/population Follow-up period
Comparison 
group(s) Definitions of groups Findings
Reference group: 
Persistent smokers
         
Sardari Nia et al. 
(2005)
• Prospective cohort
• 321 patients with non-small 
cell lung cancer
• 169 persistent smokers
• 35 quitters
• Belgium
• Every 4 months 
in Years 1 and 2
• Every 6 months 
in Year 3
• Annually from 
Years 4 to 6 
through January 
2003
• Quitters • Persistent smokers: Patients who 
continued smoking (defined as 
current smokers in the study)
• Quitters: Patients who had stopped 
smoking between the cancer 
diagnosis and the surgery. (1 week 
to more than 19 years)
• Persistent smokers: 1.0 (referent)
• Quitters: unadjusted RR = 0.34 
(95% CI, 0.16–0.71)
Chen et al. (2010) • Retrospective cohort
• 284 patients with limited-
stage, small cell lung cancer
• 76 persistent smokers
• 87 quitters
• Mayo Clinic
• At 6 months after 
diagnosis, then 
annually until 
December 2003
• Quitters • Persistent smokers: Those who 
never quit smoking
• Quitters: Those who had quit 
smoking at the time of or after 
the cancer diagnosis
• Persistent smokers: 1.0 (referent)
• Quitters: adjusted HR = 0.55 
(95% CI, 0.38–0.79)
Sandoval et al. 
(2009)
• Prospective cohort
• 146 patients with oral 
cavity cancer
• 101 patients who were 
current smokers at baseline
• 30 persistent smokers at 
1-year follow-up 
• 55 quitters
• Spain
• At 1 year and 
2 years after 
diagnosis
• Quitters • Persistent smokers: Those 
who were classified as current 
smokers at diagnosis of oral cancer 
and continued to smoke after 
the diagnosis
• Quitters: Those who had quit 
smoking after the diagnosis, 
defined as quitting smoking at 
1-year follow-up
• Persistent smokers: 1.0 (referent)
• Quitters: unadjusted RR = 0.92 
(95% CI, 0.46–1.84)
Table 4.9 Continued
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Study Design/population Follow-up period
Comparison 
group(s) Definitions of groups Findings
Reference group: 
Quitters
         
Tao et al. (2013) • Prospective cohort
• Shanghai Cohort Study
• 1,632 male patients 
with cancer
 – 288 with lung cancer
 – 362 with stomach cancer
 – 248 with colorectal cancer
 – 107 with bladder cancer
 – 132 with prostate cancer
 – 492 with other cancer
• 197 persistent smokers
• 214 quitters
• Annually for 
25 years through 
2010
• Persistent 
smokers
• Quitters: Those who had quit 
smoking after a cancer diagnosis 
and remained quit throughout 
follow-up
• Persistent smokers: Those who 
continued to smoke after a cancer 
diagnosis throughout follow-up
• Adjusted HR:
 – Quitters: 1.0 (referent)
 – Persistent smokers: 1.76 
(95% CI, 1.37–2.27)
• RR for quitters vs. persistent 
smokers: 0.568 (95% CI, 
0.441–0.730)
Al-Mamgani et al. 
(2014)
• Retrospective cohort
• 549 patients with T1a 
glottic cancer
• 52 persistent smokers 
after radiotherapy
• 215 quitters
• At the end of 
radiotherapy:
 – Weeks 4 and 6
 – Months 3, 6, 12, 
18, and 24
• Year 1: Every 
2 months
• Years 2 and 3: 
Every 3 months
• Year 4 and beyond: 
Every 6 months
• Persistent 
smokers
• Quitters: Those who had stopped 
smoking after radiotherapy for 
T1a glottic cancer
• Persistent smokers: Those 
who continued to smoke after 
radiotherapy for T1a glottic cancer
• Surviving percentage (not defined, 
but implied as 10-year survival):
 – Persistent smokers: 36%
 – Quitters: 70% (p <0.001) 
• RR for quitters vs. persistent 
smokers: 0.190 (95% CI, 
0.126–0.288, calculated)
Dobson Amato 
et al. (2015)
• Prospective cohort 
• 224 patients with lung 
cancer, all of whom were 
enrolled in a telephone-based 
tobacco treatment program
• 129 persistent smokers at 
last follow-up
• 95 quitters at last follow-up
• Roswell Park Cancer 
Institute
• Survival duration 
was assessed in 
May 2014
• Persistent 
smokers
• Quitters: Those who reported 
having at least 24 hours’ abstinence 
since the previous contact or 
follow-up assessment, or who had 
quit before the initial contact
• Persistent smokers: Current 
smokers found at every contact 
not to have quit
• Adjusted HR:
 – Quitters: 1.0 (referent)
 – Persistent smokers: 1.79 
(95% CI, 1.14–2.82)
• RR for quitters vs. persistent 
smokers: 0.558 (95% CI, 
0.355–0.877)
Table 4.9 Continued
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Study Design/population Follow-up period
Comparison 
group(s) Definitions of groups Findings
Reference group: 
Quitters (continued)
         
Roach et al. (2016) • Retrospective cohort
• 119 patients with lung 
cancer who were current 
smokers and treated 
with SBRT
• 87 persistent smokers
• 32 quitters
• Physical exam 
every 3 months 
for Years 1 and 2
• Chest CT scan 
every 3 months for 
Years 1 and 2, then 
every 6 months 
thereafter
• Follow-up from 
2004 to 2013
• Persistent 
smokers
• Quitters: Those who had quit 
smoking after SBRT
• Persistent smokers: Those who 
smoked during and after SBRT
• Adjusted HR:
 – Quitters: 1.0 (referent)
 – Persistent smokers: 2.07 
(95% CI, 1.02–4.2)
• RR for quitters vs. persistent 
smokers: 0.483 (95% CI, 
0.238–0.980)
Notes: CI = confidence interval; CPS = Cancer Prevention Study; CT = computed tomography; HR = hazard ratio; RR = risk ratio; SBRT = stereotactic body radiation therapy.
Table 4.9 Continued
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causal inference set out in the 1964 and 2004 Surgeon 
General’s reports (U.S. Department of Health, Education, 
and Welfare 1964; USDHHS 2004).
Temporality
All studies evaluated the effects of smoking cessa-
tion after a cancer diagnosis. In all the studies, the tem-
poral relationship was appropriate for causation because 
evaluation of smoking status, including smoking cessa-
tion, preceded the outcome of all-cause mortality.
Consistency
Six of the seven studies that directly compared 
smoking cessation with continued smoking observed sig-
nificant improvements in all-cause mortality (Sardari Nia 
et  al. 2005; Sandoval et  al. 2009; Chen et  al. 2010; Tao 
et al. 2013; Al-Mamgani et al. 2014; Dobson Amato et al. 
2015). In the three studies that compared the risks of con-
tinued smoking or smoking cessation after a cancer diag-
nosis with never smoking, quitting smoking reduced risk 
compared with continued smoking (Yang et  al. 2015a; 
Choi et al. 2016; Passarelli et al. 2016). The consistency 
of the observations extended across multiple types of 
cancer: head/neck, lung, breast, colorectal, bladder, and 
prostate. Observations spanned treatments with surgery, 
chemotherapy, or radiotherapy. Studies varied in geo-
graphic location and time span and in methodologic defi-
nitions for smoking status. Thus, in the broad range of 
the studies across cancer sites, treatments, and defini-
tions of changes in smoking status, evidence consistently 
showed an improvement in all-cause mortality as a result 
of smoking cessation.
Strength of Association
The 2014 Surgeon General’s report observed a 51% 
median increase in risk of all-cause mortality among 
cancer patients who were smokers compared with those 
who were never smokers (USDHHS 2014). For compar-
ison, a review of 22  population-based cohorts from the 
Consortium on Health and Ageing: Network of Cohorts in 
Europe and the United States (CHANCES) found a doubled 
risk of all-cause mortality in current smokers and a 30% 
increased risk in former smokers compared with never 
smokers, reflecting an approximately 50% higher risk 
for current smokers compared with those who had quit 
smoking (Müezzinler et  al. 2015). In the seven cohorts 
reviewed for this report that compared the effects of con-
tinued smoking and smoking cessation on all-cause mor-
tality, the median relative risk of all-cause mortality was 
1.82. Thus, with regard to all-cause mortality, the strength 
of the association between smoking and the reduction in 
risk for quitters is similar among cancer survivors and the 
general population.
Existing scientific evidence indicates that cancer 
patients substantially underreport their smoking: approx-
imately 30% of patients who were smokers based on coti-
nine level reported themselves as nonsmokers (Khuri 
et al. 2001; Warren et al. 2012; Morales et al. 2013; Alberg 
et al. 2015). Thus, the associations between self-reported 
smoking and all-cause mortality, as reported in the 2014 
Surgeon General’s report, may be conservative.
Coherence
Smoking cessation at any age reduces all-cause 
mortality (USDHHS 2010, 2014; Thun et al. 2013b; 
Müezzinler et  al. 2015). The adverse effects of smoking 
and the benefits of smoking cessation are well established 
for many diseases in the general population, including 
coronary heart disease, pulmonary disease, stroke, and 
other chronic health conditions. Smoking cessation 
reduces the risk of developing multiple types of cancer. 
Cigarette smoking by cancer patients increases all-
cause mortality and cancer-specific mortality (USDHHS 
2014). Much is known about the mechanisms by which 
smoking causes cancer (USDHHS 2010). Among these 
mechanisms, smoking appears to increase tumor pro-
gression. In experimental systems, constituents of cig-
arette smoke promote more aggressive phenotypes in 
cancer cells (Sobus and Warren 2014; Warren et al. 2014). 
A body of experimental evidence suggests that nicotine 
may promote all proliferation and tumor progression 
and increase risk for metastasis (Schaal and Chellappan 
2014). Thus, smoking cessation among cancer patients 
would be anticipated to reduce all-cause mortality by 
reducing both noncancer-related mortality and cancer-
related mortality. The 2014 Surgeon General’s report 
identified a 51% median increased risk of all-cause mor-
tality among cancer patients who smoked compared with 
cancer patients who quit smoking.
Synthesis of the Evidence
Ten studies in this section met the inclusion cri-
teria, all including participants who were current smokers 
at the time of cancer diagnosis and who were evaluated for 
smoking cessation after diagnosis. The findings showed a 
benefit of cessation across a variety of cancer diagnoses 
and treatments. The magnitude of the observed associa-
tions is consistent with established reductions in all-cause 
mortality for smoking cessation in the general population. 
Given the relatively small body of evidence, limitations 
in the quality of the evidence, and the breadth of cancer 
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diagnoses and treatments, current evidence is suggestive 
but not sufficient to conclude that the observed reduc-
tions in all-cause mortality following smoking cessation 
generalize to all types of malignancies and modalities of 
treatment. The 2014 Surgeon General’s report concluded 
that “quitting smoking improves the prognosis of cancer 
patients” (USDHHS 2014, p. 9). This cancer-specific con-
clusion contrasts with nonspecific, all-cause mortality, 
as considered above.
Conclusion
1. The evidence is suggestive but not sufficient to infer 
a causal relationship between smoking cessation 
and improved all-cause mortality in cancer patients 
who are current smokers at the time of a cancer 
diagnosis.
Implications
The evidence suggests that smoking cessation after 
a cancer diagnosis can significantly reduce all-cause mor-
tality relative to continued smoking. This evidence is con-
sistent with the known reduction in all-cause mortality 
due to smoking cessation in the general population. Thus, 
smoking cessation likely reduces all-cause mortality in 
cancer patients.
These conclusions strengthen the scientific basis 
for existing recommendations that emphasize the impor-
tance of quitting smoking after a cancer diagnosis. Many 
large national and international cancer organizations rec-
ommend addressing tobacco use among cancer patients. 
The American Society of Clinical Oncology (ASCO) and 
the American Association for Cancer Research (AACR)—
two of the largest clinical oncology and research orga-
nizations—maintain updated recommendations for 
addressing tobacco use in cancer patients. These orga-
nizations advocate for tobacco control, development of 
methods to facilitate smoking cessation, and practical 
approaches to enhance clinical care and research (AACR 
n.d.; ASCO n.d.). The International Association for the 
Study of Lung Cancer (IASLC) offers advanced recom-
mendations for addressing tobacco use, particularly in 
the context of cancer care and lung cancer screening 
(IASLC n.d.). Recognizing the importance of addressing 
tobacco use and the lack of standardized approaches to 
screening, the National Cancer Institute (NCI) and the 
AACR developed standardized approaches for assessing 
tobacco use in clinical cancer research trials (Land et al. 
2016). Similar standardized approaches to screening 
recommended by the NCI and AACR can also be applied 
to clinical care. Using these approaches, the National 
Comprehensive Cancer Network (NCCN) initiated the 
first series of recommendations to address tobacco use 
in all cancer patients who report having smoked during 
the past 30 days (NCCN n.d.). These guidelines follow the 
same format and approach as other clinical cancer guide-
lines, offering a resource to facilitate support for smoking 
cessation in a format that oncologists are familiar with. 
Although guidelines are available, they are not always 
implemented completely (Goldstein et al. 2013; Toll et al. 
2013; Gritz et al. 2014; Gallaway et al. 2019), and tobacco 
treatment/cessation programs are not always offered in all 
cancer centers (Gallaway et al. 2019), suggesting a need 
to identify and address barriers to adoption of guidelines.
At present there is no standard format to promote 
smoking cessation in cancer patients. The context of 
addressing tobacco use in cancer patients is different from 
the context of addressing tobacco use in the general popu-
lation of persons who do not have cancer because cancer 
patients are commonly presented with life-changing diag-
noses and will regularly return for treatment for sev-
eral months or years (Warren et al. 2014). The change in 
clinical care patterns associated with a new cancer diag-
nosis can affect frequency of follow-up with clinical pro-
viders and the perceived urgency of addressing tobacco 
use. Recognizing the clinical importance of tobacco use 
and tobacco cessation with the importance of developing 
approaches across a wide spectrum of clinical settings, 
NCI initiated in 2017 a Cancer Center Cessation Initiative 
(C3I) to fund the development of dedicated tobacco ces-
sation approaches in 22 NCI Designated Cancer Centers 
(NCI 2018). In 2018, an additional 20  centers received 
funding at the same level (Croyle et  al. 2019). Results 
from these centers are expected to help refine standard-
ized approaches to screening for tobacco use and pro-
viding evidence-based support for smoking cessation. 
Furthermore, Warren and colleagues (2019) modeled 
the incremental costs due to failure of first-line cancer 
treatments because of continued smoking. Compared 
with nonsmokers, the attributable costs were estimated 
as $2.1 million per 1,000 patients or $10,700 per patient. 
These estimates strengthen the rationale for encouraging 
cessation among persons being treated for cancer.
The evidence reviewed in the 2014 Surgeon 
General’s report documented the harm of smoking by 
persons with a cancer diagnosis, and this report builds 
on that finding by showing that such harm is reduced 
to some extent by smoking cessation. The conclusions 
of this report strengthen the rationale for aggressively 
promoting and supporting smoking cessation in cancer 
patients and survivors.
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Conclusions from Previous 
Surgeon General’s Reports
The 1990 Surgeon General’s report on the health 
benefits of smoking cessation (U.S. Department of Health 
and Human Services [USDHHS] 1990) provided several 
conclusions on smoking cessation and CVD (Table 4.10) 
that were updated in subsequent reports. Table 4.10 sum-
marizes the major conclusions related to smoking ces-
sation and CVD from the 1990, 2001, 2004, and 2010 
Surgeon General’s reports.
Literature Review Methods
For this Surgeon General’s report, a literature 
review was conducted to update the cessation-specific 
findings from the 1990, 2001, 2004, 2006, 2010, and 2014 
Surgeon General’s reports. The search was restricted 
to English-language papers available on PubMed and 
published between January 2000 and August  31, 2017. 
Medical Subject Headings (MeSH) in PubMed were used 
to capture relevant articles. Retrieved articles included at 
least one term related to smoking cessation (e.g., “former 
smokers”) and at least one term related to CVD (e.g., “cor-
onary heart disease” [CHD]) or a term to describe the 
mechanism of disease (e.g., “thrombosis”). Citations from 
relevant retrieved articles and previous Surgeon General’s 
reports and targeted searches were used to identify arti-
cles not captured by the search.
Relevant Mechanistic Data
Previous Surgeon General’s reports have provided 
detailed reviews of potential mechanisms underlying how 
smoking and smoking cessation could affect the devel-
opment of CVD (USDHHS 1983, 1990, 2004, 2006, 2010, 
2014). This section reviews the links between smoking ces-
sation and the following CVDs: CHD, cerebrovascular dis-
eases, atrial fibrillation (AF), sudden cardiac death (SCD), 
heart failure, venous thromboembolism (VTE), lower- 
extremity peripheral artery disease (PAD), and abdominal 
aortic aneurysm (AAA). These diseases share some under-
lying mechanisms, and multiple risk factors contribute to 
each disease; for example, atherosclerosis and thrombosis 
are important for most of these diseases (International 
Agency for Research on Cancer [IARC] 2007). 
Approximately 92.1 million American adults 20 
years of age or older (more than 1 in 3 adults) have one 
or more types of cardiovascular disease (CVD), and by 
2030 almost 44% of the population will have some form 
of CVD (Benjamin et al. 2017). In 2014, coronary heart 
disease (CHD) was listed on the death certificate for 
approximately 1 of every 7 deaths (Benjamin et al. 2017; 
National Center for Health Statistics 2017). The CVDs 
comprise some of the most common causes of death: 
CHD, congestive heart failure (CHF), cerebrovascular 
disease (including stroke), atherosclerosis (including 
aortic aneurysm), and hypertension. In the United States, 
CVD has accounted for more deaths since 1919 than any 
other major cause of death (Benjamin et al. 2019). CHD 
(43.2%) is the leading cause of death attributable to CVD, 
followed by stroke (16.9%), heart failure (9.3%), high 
blood pressure (9.8%), diseases of the arteries (3.0%), 
and other CVDs (Benjamin et al. 2019). In 2015, CVD 
was the leading cause (41.2%) of smoking-attributable 
age-standardized disability-adjusted life-years (DALYs), 
a combined indicator of smoking-attributable mortality 
and disease burden (GBD 2015 Tobacco Collaborators 
2017). Since the first Surgeon General’s report in 1964, 
the rates of age-adjusted CVD mortality have declined 
greatly; a reduction in smoking has been a major contrib-
uting factor to the decline in CHD mortality in particular 
(USDHHS 2014).
From 2014 to 2015, the average annual direct (med-
ical) plus indirect costs of heart disease were estimated to 
total $218.7  billion (Benjamin et  al. 2019). Heidenreich 
and colleagues (2011) projected that the direct (medical) 
cost of CHD in the United States would increase by approx-
imately 200%, from $272.2 billion in 2010 to $818.1 bil-
lion in 2030.
Surgeon General’s reports published since 1990 have 
not systematically covered the benefits of smoking cessa-
tion with regard to risk and outcomes for men and women 
with CVD. This section expands on previous reports by 
summarizing current knowledge of the effects of smoking 
cessation on risk of CVD and the natural history of this 
disease. This is not a systematic update, given the scope 
of the literature, and it does not cover all topics. Instead, 
this section provides examples of new findings that expand 
our understanding of conclusions from previous reports. 
Because of the wide range of research on this topic, this 
review focuses, where relevant, on summarizing results 
from meta-analyses or pooled analyses of findings from 
multiple cohorts and clinical trials. 
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Atherosclerosis is the key underlying pathophysi-
ologic process leading to most clinical manifestations of 
CVD, including CHD, cerebrovascular disease, and PAD. 
Atherosclerosis involves the hardening and narrowing 
of arteries because of deposition of lipids in the inner 
layers of arteries, fibrosis, and thickening of the arte-
rial wall. This complex process involves the deposition of 
lipids, inflammatory and immune responses to oxidized 
lipids, and endothelial dysfunction. When the processes 
involved in atherosclerosis culminate in thrombosis, this 
can lead to myocardial infarction (MI) or ischemic stroke 
(Nagareddy and Smyth 2013). 
Key mechanisms through which smoking and 
smoking cessation affect atherogenesis and throm-
bosis include endothelial function and injury, oxidative 
stress, hemostatic factors (platelet function, fibrinogen, 
and d-dimer), fibrinolysis, inflammation, lipid modifica-
tion, and vasomotor function (IARC 2007). Smoking and 
smoking cessation may also influence CVD risk through the 
effect of oxygen demand and supply on cardiovascular func-
tion (USDHHS 2004) and through effects on occurrence of 
arrhythmias and coronary artery spasm (USDHHS 1990).
The 1990 Surgeon General’s report focused primarily 
on how smoking affects or may affect mechanisms leading 
to CVD and described mechanisms that could come into 
play when smokers quit (USDHHS 1990). The report con-
cluded that some CVD effects of smoking appeared to be 
reversed within days or weeks of quitting (e.g.,  increased 
platelet activation, changes in clotting factors, level of car-
boxyhemoglobin, occurrence of coronary artery spasm 
and ventricular arrhythmias), but that other effects 
(e.g.,  advance of atherosclerosis, proliferation of smooth 
Table 4.10 Conclusions from previous Surgeon General’s reports on smoking cessation and cardiovascular disease
Year of report (page numbers) Conclusions
USDHHS (1990, pp. 10–11) 1. Compared with continued smoking, smoking cessation substantially reduces risk of CHD 
among men and women of all ages.
2. The excess risk of CHD caused by smoking is reduced by about half after 1 year of smoking 
abstinence and then declines gradually. After 15 years of abstinence, the risk of CHD is similar 
to that of persons who have never smoked.
3. Among persons with diagnosed CHD, smoking cessation markedly reduces the risk of 
recurrent infarction and cardiovascular death. In many studies, this reduction in risk of 
recurrence or premature death has been 50% or more.
4. Smoking cessation substantially reduces the risk of peripheral artery occlusive disease compared 
with continued smoking.
5. Among patients with peripheral artery disease, smoking cessation improves exercise tolerance, 
reduces the risk of amputation after peripheral artery surgery, and increases overall survival.
6. Smoking cessation reduces the risk of both ischemic stroke and subarachnoid hemorrhage 
compared with continued smoking. After smoking cessation, the risk of stroke returns to the 
level of never smokers; in some studies this has occurred within 5 years, but in others as long 
as 15 years of abstinence were required.
USDHHS (2001, pp. 13–14) 1. The risk for coronary heart disease among women is substantially reduced within 1 or 2 years 
of smoking cessation. This immediate benefit is followed by a continuing but more gradual 
reduction in risk to that among nonsmokers by 10 to 15 or more years after cessation.
2. In most studies that include women, the increased risk for stroke associated with smoking is 
reversible after smoking cessation; after 5 to 15 years of abstinence, the risk approaches that 
of women who have never smoked.
3. Smoking is a strong predictor of the progression and severity of carotid atherosclerosis among 
women. Smoking cessation appears to slow the rate of progression of carotid atherosclerosis.
4. Women who are current smokers have an increased risk for peripheral vascular atherosclerosis. 
Smoking cessation is associated with improvements in symptoms, prognosis, and survival.
USDHHS (2004, p. 25) 1. Quitting smoking has immediate as well as long-term benefits, reducing risks for diseases 
caused by smoking and improving health in general.
USDHHS (2010, p. 11) 1. Smoking cessation reduces the risk of cardiovascular morbidity and mortality for smokers 
with or without coronary heart disease.
2. The use of nicotine or other medications to facilitate smoking cessation in people with known 
cardiovascular disease produces far less risk than the risk of continued smoking.
Notes: CHD = coronary heart disease.
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muscle cells, lipid deposition) may be irreversible or only 
slowly reversible.
The 2004 Surgeon General’s report provided a 
detailed overview of mechanisms linking smoking with CVD 
development. That report concluded that smoking (1) pro-
motes endothelial injury and cell dysfunction; (2) produces 
a substantial shift in hemostatic balance at the endothe-
lium, leading to atherosclerosis and thrombotic compli-
cations; (3)  diminishes the ability of the blood to carry 
oxygen; and (4) increases physiologic demands of the myo-
cardium (USDHHS 2004). Through these mechanisms, 
smoking results in substantial adverse alterations in the 
cardiovascular system’s hemostatic balance, explaining the 
relationship between smoking and the subclinical and clin-
ical manifestations of atherosclerosis. The 2010 Surgeon 
General’s report reviewed in detail the mechanisms 
through which cigarette smoking causes CHD (USDHHS 
2010), concluding that smoking produces insulin resis-
tance that could, in tandem with chronic inflammation, 
accelerate the development of macrovascular and micro-
vascular complications, such as nephropathy.
The 2014 Surgeon General’s report expanded on the 
research related to the mechanisms through which ciga-
rette smoking affects cardiovascular function, focusing on 
how smoking affects atherogenesis, endothelial function, 
thrombosis, and inflammation (USDHHS 2014). The year 
before, Csordas and Bernard (2013) reviewed the biology 
of the atherothrombotic effects of smoking. Elsewhere, 
Messner and Bernhard (2014) reviewed how smoking 
causes endothelial dysfunction and initiates atherogen-
esis. The next sections highlight some of the findings 
related to mechanisms through which smoking cessation 
could alter the development and progression of CVD.
Mechanisms Through Which Smoking Cessation 
Could Affect Cardiovascular Disease
As described in the 2010 Surgeon General’s report, 
there are multiple mechanisms by which cigarette 
smoking contributes to acute cardiovascular events and 
increases the risk for developing CVDs over the long term 
(USDHHS 2010). Smoking cessation terminates exposure 
to the constituents and metabolites in tobacco smoke that 
drive some of these mechanisms, leading to both rapid 
and more delayed reduction of risk.
Carbon Monoxide and Nicotine
Several specific components of cigarette smoke are 
directly relevant to the benefits of smoking cessation: 
carbon monoxide (CO), nicotine, and oxidant gases, which 
contribute to inflammation. Tobacco smoke contains high 
concentrations of CO, which is a gas (USDHHS 2010). 
The mechanisms by which CO may contribute to acute 
cardiovascular events are well characterized. CO binds 
to hemoglobin, reducing oxygen-carrying capacity, and 
also shifts the oxyhemoglobin desaturation curve so that 
less oxygen is released to tissues from hemoglobin. The 
half-life of CO is brief: smoking-related CO in the body is 
cleared within several days of cessation (USDHHS 2010).
Nicotine is pharmacologically active and sympatho-
mimetic in its action, causing release of catecholamines 
from the neurons and from the adrenal gland. This release 
of catecholamines transiently increases heart rate and 
blood pressure and results in vasoconstriction, which can 
contribute to myocardial hypoxia and, hence, increase risk 
for acute cardiovascular events. Successful smoking cessa-
tion ends exposure to nicotine and provides an immediate 
benefit in terms of reducing risk for acute cardiac events. 
Hemodynamic Effects
Smoking impairs vascular endothelial function 
and activates the sympathetic nervous system. In com-
bination with underlying atherosclerosis, these hemo-
dynamic consequences of smoking increase the risk for 
CVD events. Alterations in vasomotor function because of 
smoking appear to be substantially reversible, suggesting 
the important role that smoking cessation and smokefree 
environments can play in reducing the burden of CVDs 
(USDHHS 2010).
Endothelial Effects
The endothelium plays a role in vascular tone, 
growth, thrombogenicity, and inflammation (Lerman 
and Zeiher 2005). Dysfunction and injury of the endo-
thelium affects atherogenesis initiation and the develop-
ment of acute CVD events, and endothelial dysfunction is 
an independent risk factor for CVD morbidity and mor-
tality (USDHHS 2010). Smoking may impair regeneration 
of the endothelium; however, 2–4 weeks of cessation has 
been associated with increases in the number of progen-
itor cells, which is indicative of repair of the endothelium 
(Kondo et al. 2004).
Both active smoking and exposure to secondhand 
smoke can alter coronary and peripheral arterial vaso-
motion among persons with or without CHD (Czernin 
and Waldherr 2003). Correspondingly, evidence suggests 
that  smoking cessation can improve endothelial func-
tioning. Smoking cessation leads to improved endothelial-
dependent vasodilation in veins in the human hand within 
24  hours of cessation (Moreno  Jr et  al. 1998). Reduced 
altered brachial artery flow-mediated dilation (FMD) is an 
early marker for endothelial dysfunction and a risk factor 
for CVD. Smoking is associated with reduced FMD. This 
relationship is dose related and may be reversible, as a 
weaker association has been observed in former smokers 
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(Celermajer et al. 1993; Raitakari et al. 1999). Johnson and 
colleagues (2010) reported on a clinical trial that assessed 
smoking cessation pharmacotherapies in 1,504 smokers; 
among the 36% of participants who quit smoking, FMD 
increased by 1% (from 6.2% +/- 4.4% to 7.2% +/- 4.2%) 
after 1 year—a relative gain of approximately 15%. In con-
trast, FMD did not change among those who continued 
to smoke. Results were similar after adjusting for artery 
diameter, reactive hyperemia, low-density lipoprotein cho-
lesterol, and the presence of a smokefree rule in the home.
In another study, smoking “light” cigarettes 
(a  type of cigarette that was claimed by manufacturers 
to produce less tobacco tar than a regular cigarette when 
smoked) was not associated with improved FMD relative 
to smoking regular cigarettes, providing evidence that 
“light” cigarettes are not a less harmful alternative to 
higher yield cigarettes for reducing CVD risk (Amato et al. 
2013). In cross-sectional adjusted analyses of data from 
the Bogalusa Heart Study, former cigarette smokers, com-
pared with current smokers, had higher small-artery com-
pliance, as estimated by radial artery pressure pulse con-
tour analysis, and decreased systemic vascular resistance, 
with a trend of improvement with increased time since 
cessation (Li et al. 2006). In the U.S.-based Multi-Ethnic 
Study of Atherosclerosis (MESA), McEvoy and colleagues 
(2015b) did not find consistent associations between 
smoking status (current, former, or never) and measures 
of vascular dynamics and function (carotid distensibility, 
aortic distensibility, or FMD). In addition, time since ces-
sation was not associated with these outcomes, possibly 
because of the older ages of the participants.
Studies have also found that smoking cessation 
is associated with changes in biomarkers of endothe-
lial function, dysfunction, or activation. In an interven-
tion study focused on lifestyle changes in young adults 
with family histories of premature CHD, those who quit 
smoking had significantly lower concentrations of inter-
cellular adhesion molecule-1 (ICAM-1), a biomarker of 
endothelial activation, compared with those continuing to 
smoke (Tonstad et al. 2005). Elsewhere, in a small study of 
a smoking cessation intervention among persons at high 
risk of CVD, ICAM-1 decreased among quitters after 1 year 
of cessation but increased among persons who continued 
to smoke (Halvorsen et al. 2007). Other markers related 
to endothelial function, thrombotic state, or inflam-
mation (E-selectin, interleukin  6, sCD40 ligand, tumor 
necrosis factor  a, von  Willebrand factor, and C-reactive 
protein [CRP]) did not change during the study period. 
In a small study of young, healthy smokers, coronary vaso-
motor abnormality appeared to improve after 1 month of 
smoking cessation (Morita et al. 2006). Later, Huang and 
colleagues (2016) examined two Swedish cohorts to assess 
the relationships of smoking with 80  protein markers 
known to be related to CVD risk. In replication analyses, 
current cigarette smoking was associated with 10  pro-
teins representing endothelial dysfunction, inflammation, 
neointimal formation, foam cell formation, and plaque 
instability (Huang et  al. 2016). Among former smokers, 
no consistent associations were observed.
A systematic review of the literature concluded that 
the evidence was uncertain as to whether smoking ces-
sation leads to a reversal in arterial stiffness (Doonan 
et al. 2010). In the Atherosclerosis Risk in Communities 
(ARIC) study of older adults, among women, femoral-
ankle pulse wave velocity, a measure of arterial stiffness, 
was lower in current smokers and former smokers than 
in never smokers, and lower in former smokers than in 
current smokers (Camplain et al. 2016). Among women, 
both smoking status and cumulative smoking exposure 
were associated with lower peripheral arterial stiffness. 
Among men, this study did not find a relationship between 
smoking cessation and a reversal in arterial stiffness, and 
it did not reveal an association with time since smoking 
cessation or with carotid-femoral pulse wave velocity.
Thrombogenic Effects
The 2010 Surgeon General’s report noted that 
smoking-mediated thrombosis appears to be a major 
factor in the pathogenesis of acute cardiovascular events 
and described how smoking leads to alterations in the 
blood and in the blood vessels that promote thrombosis, 
a pathologic reaction that can result in smoking-related 
MI or stroke (USDHHS 2010). The report summarized 
how the hypercoagulable state associated with both active 
smoking and exposure to secondhand smoke is evident in 
the epidemiology of related cardiovascular events and in 
the rapid decline in risk of such events after smoking ces-
sation (USDHHS 2010).
In cross-sectional analyses of 19,600  participants 
from the Third National Health and Nutrition Examination 
Survey (NHANES III, conducted from 1988 to 1994), ciga-
rette smoking was strongly and positively associated with 
elevated levels of fibrinogen and homocysteine, which are 
markers of a hypercoagulable state (fibrinogen is also a 
marker of inflammation) (Bazzano et  al. 2003). In addi-
tion, there was a dose-response relationship with these 
markers. Compared with never smokers, former smokers 
(median of 10 years since cessation) had higher odds of 
elevated fibrinogen but not of elevated homocysteine. 
Additionally, current smokers had higher odds of elevated 
fibrinogen compared with former smokers. Further anal-
yses of data from the NHANES III showed a trend of lower 
levels of fibrinogen with increasing time since smoking 
cessation: After approximately 5 years of cessation, levels 
were similar to those of never smokers (Bakhru and 
Erlinger 2005).
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Among 174  smokers who underwent an inten-
sive 12-month smoking cessation program, levels of 
von Willebrand factor (a marker of circulating endothelial-
coagulative activation) decreased significantly 2, 6, and 
12 months after smoking cessation compared with base-
line among those who maintained cessation at each 
follow-up (Caponnetto et  al. 2011). In those who quit 
smoking, concentrations of d-dimer, prothrombin frag-
ment 1 + 2, platelet factor-4, and β-thromboglobulin (all 
markers of circulating endothelial-coagulative activa-
tion) were significantly lower 6 and 12 months after ces-
sation compared with baseline. In a nicotine replacement 
therapy trial among 197  men, those who quit smoking 
had improved plasma fibrinogen, reactive capillary flow, 
and transcutaneous partial oxygen tension (three param-
eters of blood flow) after 6 months of cessation compared 
with levels measured at baseline (Haustein et  al. 2002). 
Hematocrit levels and white blood cell counts were lower 
in quitters compared with those who relapsed; this sug-
gests decreased inflammation in these individuals, as 
white blood cells play an important role in the inflamma-
tory process. Changes in plasma viscosity and erythrocyte 
deformability were inconclusive.
Other studies have also found that circulating levels 
of fibrinogen are higher in smokers and decrease with ces-
sation, with one study finding a decreased rate of fibrinogen 
synthesis and lower plasma fibrinogen concentrations 
just 2  weeks after cessation (Hunter et  al. 2001). Blann 
and colleagues (1997) found decreases in many hemato-
logic and coagulation indices in former smokers who used 
nicotine gum or patches to quit smoking; there were few 
additional changes after the participants no longer used 
any nicotine replacement products. Lúdvíksdóttir and col-
leagues (1999) observed similar results for atherogenic 
and thrombogenic factors in a smoking cessation trial 
involving a nicotine nasal spray versus placebo.
Inflammation
Research suggests that smoking leads to a chronic 
inflammatory state, activates monocytes, and enhances 
the recruitment and adhesion of leukocytes to blood 
vessel walls, an important step in vascular inflammation 
(USDHHS 2010). Evidence indicates that vascular inflam-
mation, in turn, appears to play a role in atherogenesis; 
and markers of inflammation, such as CRP, predict the 
risk of future CVD events (Libby et al. 2002).
Several studies have explored the relationships 
between smoking and markers of inflammation, such as 
CRP (Bermudez et al. 2002; Bazzano et al. 2003; Bakhru 
and Erlinger 2005; Helmersson et al. 2005; Ohsawa et al. 
2005; Madsen et al. 2007; Hastie et al. 2008; Levitzky et al. 
2008; Lao et al. 2009; Reichert et al. 2009; Asthana et al. 
2010; Zatu et al. 2011; Golzarand et al. 2012; Marano et al. 
2015; McEvoy et  al. 2015b; Kianoush et  al. 2017; King 
et al. 2017). In most of these studies, current and former 
smokers had higher levels of inflammatory markers than 
nonsmokers (Bermudez et al. 2002; Bazzano et al. 2003; 
Helmersson et al. 2005; Madsen et al. 2007; Hastie et al. 
2008; Levitzky et al. 2008; Lao et al. 2009; Golzarand et al. 
2012; Marano et al. 2015; McEvoy et al. 2015b; Kianoush 
et al. 2017), and in five of the studies inflammatory levels 
decreased in former smokers with increasing time since 
smoking cessation (Bakhru and Erlinger 2005; Ohsawa 
et  al. 2005; Reichert et  al. 2009; McEvoy et  al. 2015b; 
Kianoush et al. 2017).
In the cross-sectional analyses of data from NHANES 
III (described previously), cigarette smoking was indepen-
dently and positively associated with elevated levels of CRP, 
and there was a dose-response relationship (Bazzano et al. 
2003). In analyses of the odds of having either a detectable 
CRP or a clinically elevated CRP level, former smokers 
had higher odds compared with never smokers but lower 
odds compared with current smokers. Additional anal-
yses showed a trend of decreasing white blood cell counts 
and clinically detectable CRP with increased time since 
smoking cessation: Approximately 5 years after cessation, 
white blood cell counts and the odds of detectable CRP 
did not differ significantly from those of never smokers 
(Bakhru and Erlinger 2005).
In the Brazilian Longitudinal Study of Adult Health 
(ELSA-Brasil), among 4,121  former smokers, time since 
cessation was inversely related to levels of high-sensitivity 
CRP (Kianoush et al. 2017). Similarly, in the U.S.-based 
MESA cohort, levels of high-sensitivity CRP were higher 
in current smokers than in former smokers, and levels of 
high-sensitivity CRP decreased with increased time since 
cessation (McEvoy et al. 2015b). Notably, this study used 
cotinine to classify smoking status. In a cross-sectional 
study by Hastie and colleagues (2008), levels of CRP 
were similar in never and former smokers approximately 
5  years after cessation. In that study, extent of lifetime 
smoking (assessed by number of pack-years) was a pre-
dictor of levels of CRP after smoking cessation, indepen-
dent of time since cessation, suggesting that levels of CRP 
may be higher in smokers because of a secondary effect, 
such as tissue damage caused by inflammation.
In observational analyses of 1,504 smokers enrolled 
in a smoking cessation trial in which 36% of participants 
had abstained for 1 year, smoking cessation was not asso-
ciated with level of CRP (Asthana et al. 2010). There was 
also no relationship of smoking intensity to CRP, although 
smoking intensity was associated with increased white 
blood cell counts. The authors suggested that the effects 
of adiposity on levels of CRP may have masked the rela-
tionship between smoking and CRP. A study by King and 
colleagues (2017) of 1,652  smokers attempting to quit 
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examined six inflammatory markers of CVD risk: CRP, 
D-dimer, fibrinogen, urinary F2 isoprostane:creatinine 
(F2:Cr) ratio, white blood cell count, and myeloperoxi-
dase. After 1  year, 21% of participants had successfully 
quit. Cessation was associated with an improved F2:Cr 
ratio and decreased white blood cell counts indepen-
dent of weight change but not with other inflammatory 
markers. Smoking intensity was associated with the F2:Cr 
ratio, myeloperoxidase, and white blood cell counts. The 
authors concluded that smoking cessation may have led to 
reduced inflammation by lowering oxidative stress.
Lipid Abnormalities
Cigarette smoking is associated with lipid profiles 
that are likely to contribute to the development of ath-
erosclerosis and CVD risk, a topic reviewed in depth in the 
2010 Surgeon General’s report (USDHHS 2010). Much 
evidence supports the conclusion that smoking is asso-
ciated with higher levels of triglycerides (which in turn 
are associated with levels of very-low-density lipoproteins, 
total triglycerides, and apolipoprotein  B [APO  B]), with 
modestly higher levels of low-density lipoproteins cho-
lesterol (LDL-C), and with lower levels of plasma high-
density lipoprotein cholesterol (HDL-C) and apolipopro-
tein A-I (APO  A-I) (USDHHS 2010). The 2010 Surgeon 
General’s report also found that plasma lipid and lipopro-
tein levels among former cigarette smokers were typically 
similar to those of nonsmokers.
In a meta-analysis of articles published from 1966 to 
2000, Maeda and colleagues (2003) concluded that, based 
on analyses from 27 prospective studies, smoking cessation 
is associated with beneficial increases in HDL-C. In this 
analysis, changes in the levels of total cholesterol, LDL-C, 
and triglycerides were not significant. Later, Forey and 
colleagues (2013), in a meta-analysis of 45 studies, found 
that levels of HDL-C increased rapidly (within weeks) after 
cessation, but there was no clear pattern after that time. 
In a study conducted by Gepner and colleagues 
(2011), a clinical trial of cessation pharmacotherapies in 
1,504 smokers that was included in the meta-analysis by 
Forey and colleagues (2013), those who successfully quit 
(36% of participants) had, at 1-year follow-up, higher 
levels of HDL-C, total HDL, and large HDL particles com-
pared with baseline. Smoking cessation was not, how-
ever, associated with changes in LDL-C or LDL size. These 
results were similar to those reported in the meta-analysis 
by Maeda and colleagues (2003). Importantly, smokers 
in the study by Gepner and colleagues (2011) generally 
had a higher body mass index (BMI) than those in pre-
vious studies and thus were more representative of the 
contemporary U.S. population. Elsewhere, in two reports 
based on a study in which participants were on the nico-
tine patch for 32 days and then taken off it for 45 days, 
HDL-C levels did not increase significantly among former 
smokers on the patch, but those levels increased quickly 
after they stopped using the patch (Moffatt et  al. 2000; 
Chelland Campbell et al. 2008). Of note, nicotine products 
were used in some arms of the trial by Gepner and col-
leagues (2011), but that trial did observe higher levels of 
total HDL at 1-year follow-up. 
Summary of the Evidence
Substantial evidence shows that smoking cessation 
is associated with an improvement in many pathogenetic 
factors involved in processes through which cigarette 
smoking causes CVD. Some effects appear to be rapidly 
reversible with smoking cessation, but other effects may 
reverse much more slowly or not at all. Evidence indi-
cates that smoking cessation (1) leads to a reduction in 
markers of inflammation and hypercoagulability and to 
rapid changes in levels of HDL-C in a favorable direction 
and (2) may lead to improved endothelial function. 
Smoking Cessation and 
Subclinical Atherosclerosis
According to the 2004 Surgeon General’s report, the 
evidence is sufficient to infer a causal relationship between 
smoking and subclinical atherosclerosis (USDHHS 2004). 
That report addressed the implications of this conclusion, 
finding that cigarette smoking has a causal relationship 
with the full natural history of atherosclerosis—from the 
early stages that are detected by subclinical markers to the 
late, often fatal, stages. Findings presented at that time 
indicated the potential for smoking cessation (including 
quitting and then maintaining cessation) to prevent more 
advanced, clinically symptomatic disease. 
The 2001 Surgeon General’s report concluded that 
smoking is a strong predictor of the progression and 
severity of carotid atherosclerosis among women and that 
smoking cessation appears to slow the rate at which carotid 
atherosclerosis progresses (USDHHS 2001). Since this 
report appeared, additional approaches have been devel-
oped to measure subclinical atherosclerosis, and more 
evidence has been published indicating that smoking ces-
sation can slow the progression of atherosclerosis.
As described in the 2004 Surgeon General’s report, 
examining measures of subclinical atherosclerosis facili-
tates assessment of the relationship between smoking and 
the earlier, preclinical stages of the atherosclerotic disease 
process. In studies of subclinical measures among healthy 
persons, findings may be less susceptible to reverse causa-
tion, as there is no onset of symptoms that could lead to 
cessation and distort the temporal relationship between 
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smoking and CVD. The possibility of reverse causation 
(for  clinical and subclinical outcomes) is of particular 
concern for cross-sectional analyses in which it may not 
be possible to ascertain temporality.
Table  4.11 describes findings from 12  studies that 
have assessed the relationships between smoking cessa-
tion and subclinical atherosclerosis (Kiechl et  al. 2002; 
Baldassarre et  al. 2009; Jöckel et  al. 2009; Liang et  al. 
2009; Jiang et al. 2010; Kweon et al. 2012; Lehmann et al. 
2014; McEvoy et  al. 2015b; Yang et  al. 2015b; Hansen 
et al. 2016; Hisamatsu et al. 2016; Kianoush et al. 2017). 
Studies in many different populations have found, gener-
ally, that smoking is positively associated with the pres-
ence, extent, and progression of atherosclerosis measured 
in different vascular beds. Compared with never cigarette 
smokers, both current and former smokers tend to have 
more extensive atherosclerosis, although former smokers 
generally have less extensive atherosclerosis than current 
smokers. Studies in other populations and studies of other 
markers for atherosclerosis have reported similar findings 
(Fowkes et al. 2013; Yi et al. 2015; Pacheco et al. 2016). 
Time since smoking cessation is also related to the extent 
of atherosclerosis, with less atherosclerotic burden as time 
since cessation increases (Jiang et al. 2010; Kweon et al. 
2012; McEvoy et al. 2015b; Hansen et al. 2016; Hisamatsu 
et al. 2016; Kianoush et al. 2017).
Hansen and colleagues (2016) conducted one of sev-
eral studies assessing the relationship between smoking 
cessation and the progression of atherosclerosis. This 
study examined a subcohort of the prospective Malmö Diet 
and Cancer study in Sweden and found that, compared 
with never smokers, former smokers had an adjusted dif-
ference in the yearly progression rate of 0.0074 millime-
ters (mm) per year (95% confidence interval [CI], 0.0018–
0.0129) in maximal intimal-media thickness (IMT) in the 
carotid bifurcation (Table 4.11). But compared with never 
smokers, moderate smokers had an adjusted difference of 
0.0106 mm (95% CI, 0.0038–0.0175) and heavy smokers 
had an adjusted difference of 0.0146 mm (95% CI, 0.0016–
0.0230). Among former smokers, as time since smoking 
cessation increased, there was a reduction in yearly pro-
gression of IMT in the carotid bifurcation and in the rate 
of lumen reduction, with a distinct lowering in progres-
sion rates more than 5 years after cessation. In a study of 
127 smokers in the Netherlands, successful smoking ces-
sation for 2 years did not result in slowing of the increase in 
carotid IMT or a reduction in the thickening of the carotid 
artery, a finding potentially attributable to the study’s 
small size and relatively short follow-up (data not shown 
in table) (van  den Berkmortel et  al. 2004). Carotid IMT 
is a predictor of future CVD events (Lorenz et al. 2007), 
although its measurement may have no added value for 
predicting cardiovascular risk (Den Ruijter et al. 2012).
Results from cross-sectional analyses in 2000–2003 
of the Heinz Nixdorf Recall Study in Germany were used 
to estimate the slowing by cessation of coronary artery 
calcification (CAC), compared with continued smoking 
(Table 4.11). Compared with continued smoking, smoking 
cessation at 45, 55, and 65 years of age was estimated to 
slow CAC progression at 75 years of age by 9, 6, and 3 years, 
respectively (Jöckel et al. 2009). CAC is a predictor of future 
CVD events (Pletcher et  al. 2004; Chaikriangkrai et  al. 
2017). Although the findings from Jöckel and colleagues 
(2009) were based on modeling assumptions and cross-
sectional data, their results suggest that smoking cessa-
tion may reduce the progression of atherosclerosis, which 
could potentially reduce the risk of future clinical CVD.
Several studies (Table  4.11) have assessed associa-
tions between smoking and the ankle-brachial index (ABI), 
which is also known as the ankle-arm index (McEvoy et al. 
2015b; Hisamatsu et al. 2016; Kianoush et al. 2017). The 
ABI is the ratio of blood pressure in the lower leg to that in 
the upper arm. A low ABI is associated with an increased 
risk of CHD and of CVD (Lin et  al. 2013). The ABI has 
been used as a way to assess the presence of PAD, but it 
does not assess which blood vessels are narrow or blocked. 
In two studies (Table 4.11), former smoking was associ-
ated with higher odds of a low ABI compared with never 
smoking (McEvoy et al. 2015b; Kianoush et al. 2017), and 
in three studies, increased time since quitting was associ-
ated with lower odds of having a low ABI (McEvoy et al. 
2015b; Hisamatsu et al. 2016; Kianoush et al. 2017). For 
example, in the MESA cohort, the odds ratio (OR) for an 
ABI <1.0  was 0.91 (95%  CI, 0.86–0.96) for every 5-year 
increment since smoking cessation (McEvoy et al. 2015b). 
The relationship between smoking cessation and clinical 
manifestations of PAD is discussed in more detail in a 
later section. 
Summary of the Evidence
Evidence indicates that smoking cessation reduces 
the development and progression of markers of subclinical 
atherosclerosis, with the degree of reduction increasing 
as time since cessation increases. This pattern of change 
in markers provides mechanistic background on the evi-
dence of how smoking cessation reduces risk of CVD. 
Smoking Cessation and 
Cardiovascular Disease
The 2010 Surgeon General’s report concluded that 
smoking cessation reduces the risk of cardiovascular mor-
bidity and mortality for cigarette smokers with or without 
CHD (USDHHS 2010). This report also found that there 
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Table 4.11 Studies on the association between smoking cessation and subclinical atherosclerosis
Study Design/population Main results Comments
Kiechl et al. 
(2002)
• Prospective cohort (Bruneck Study)
• 826 healthy or sick participants, 40–79 years 
of age, 50% men, 26% former smokers
• 1990–1995
• Italy
• Follow-up: 5 years
• Outcome: carotid IMT, early atherogenesis 
(nonstenotic plaques), advanced atherogenesis 
(stenosis >40%)
• Current and former smokers had increased 
risk of early atherogenesis only if they had 
chronic infections; risks were similar in 
never, former, and current smokers without 
chronic infection
• Advanced atherogenesis developed 
independently of chronic infection; risk 
returned to normal soon after cessation
Impact of smoking on atherosclerosis appears to 
be partially mediated by chronic infections
Baldassarre et al. 
(2009)
• Cross-sectional study
• 1,804 consecutive patients’ first visit to 
lipid clinic, 21–85 years of age, 48% men, 
21% former smokers
• 2000–2003 
• Italy
• Outcome: carotid IMT (mean, total, 
and maximum)
• Carotid IMT was highest in current smokers, 
then former smokers, then never smokers
• Only after adjusting for risk factors was 
carotid IMT significantly higher among 
current smokers than former smokers
• Carotid IMT was positively associated with 
pack-years of smoking among both former 
and current smokers
Results may not be generalizable to populations 
without dyslipidemia
Liang et al. 
(2009)
• Cross-sectional and prospective analyses 
(Collaborative Study of Cardiovascular and 
Cardiopulmonary Epidemiology)
• 1,132 participants, 35–64 years of age; 
34% men; 3% former smokers at baseline; free 
of myocardial infarction, stroke, and diabetes
• Scanned in 1993–1994 and 2002
• China
• Exposure: smoking status at baseline and 
consistency during follow-up
• Outcome: mean common carotid IMT
• Mean adjusted IMT was 0.72 mm for consistent 
current smokers, 0.71 mm for former and 
inconsistent smokers, and 0.70 mm for 
consistent never smokers (p for trend <0.01)
• Compared with consistent never smokers, 
consistent current smokers had higher 
adjusted odds of carotid plaques; a similar 
pattern was observed among former smokers 
and former/inconsistent smokers, but the 
results were not significant
—
Jöckel et al. 
(2009)
• Cross-sectional study (Heinz Nixdorf Recall 
Study)
• 4,078 participants, 45–75 years of age, 50% men, 
without manifest CHD (myocardial infarction 
or coronary revascularization) or stroke
• Scanned in 2000–2003
• Germany
• Outcome: CAC
• Smoking cessation at 45, 55, or 65 years of 
age was associated with CAC at the age of 
75 years that would have been reached 9, 6, 
or 3 years earlier, respectively, had smoking 
continued
• CAC accumulation slowed after cessation, but 
advanced CAC persisted for a long time
Results are based on predictions from regression 
models run separately by smoking status; models 
were not run separately for men and women
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Table 4.11 Continued
Study Design/population Main results Comments
Jiang et al. 
(2010)
• Cross-sectional study
• 959 men, 50–85 years of age, 26% former 
smokers
• Scanned in 2006–2007
• China
• Outcome: mean common carotid IMT, 
presence of CCA plaques; CCA atherosclerosis 
defined as CCA-IMT ≥1.0 mm or with a 
stenosis diameter ≥20%
• IMT and number of plaques increased from 
never, to former, to current smokers 
• Longer duration since cessation was associated 
with decreased odds of the presence and 
severity of atherosclerosis in CCA (explored 
in categories of 1–9, 10–19, ≥20 years since 
cessation; observed benefit compared with 
current smokers for ≥10 years since quitting)
—
Kweon et al. 
(2012)
• Cross-sectional study (Dong-gu Study)
• 2,503 men, ≥50 years of age, 51% former 
smokers
• Scanned in 2007–2009
• Korea
• Outcome: CCA-IMT, carotid plaque, 
CCA diameter
• Compared with never smokers, current 
smokers had greater CCA IMT, CCA diameter, 
and odds of carotid plaque
• Among former smokers, CCA IMT and CCA 
diameter decreased with years since cessation; 
not observed for carotid plaque
• For current smokers, but not for former 
smokers, a dose-response relationship was 
observed between pack-years of smoking 
and CCA IMT
Only men were included in analysis because of a 
very low prevalence of smoking among women
Lehmann et al. 
(2014)
• Prospective study (Heinz Nixdorf Recall 
Study)
• 1,261 participants, 45–75 years of age, 
27% men, no detectable CAC at first scan, 
no history of CHD or stroke
• Scanned in 2000–2003, rescanned 5 years later
• Germany
• Outcome: onset of detectable CAC
• Compared with never smokers, onset of 
detectable CAC occurred approximately 
10 years earlier among current smokers and 
5 years earlier among former smokers
• Among women, in adjusted analyses, current 
smokers had higher odds of progression 
to detectable CAC than never smokers; 
no association for former smokers
• Among men, smoking was not related to 
CAC onset
Unclear whether there was adjustment for other 
factors in the analysis of time to detectable CAC
Smoking Cessation
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Table 4.11 Continued
Study Design/population Main results Comments
McEvoy et al. 
(2015b)
• Cross-sectional study (Multi-Ethnic Study of 
Atherosclerosis)
• 6,796 multiethnic participants, 45–84 years 
of age, 47% men, 38% former smokers, free 
of CVD
• 2000–2002
• United States (six centers)
• Outcomes: mean internal carotid IMT, CAC, 
and ABI
• Difference in log(IMT)a (95% CI):
 – Never smoker: 0.00 (referent)
 – Former smoker: 0.05 (0.03–0.07)
 – Current smoker: 0.09 (0.06–0.12)
• Odds ratio of CAC >0 (95% CI):
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.28 (1.21–1.57)
 – Current smoker: 1.79 (1.49–2.14)
• Odds ratio of CAC >75th percentile (95% CI):
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.18 (0.99–1.41)
 – Current smoker: 1.38 (1.08–1.77)
• Odds ratio of ABI <1 (95% CI):
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.24 (1.02–1.50)
 – Current smoker: 2.22 (1.74–2.83)
• Time since quitting was independently 
associated with atherosclerosis; for example, 
OR of CAC >0 was 0.94 (95% CI, 0.90–0.97) 
for each 5 years since quitting
—
Yang et al. 
(2015b)
• Cross-sectional study (Northern Manhattan 
Study)
• 1,743 multiethnic participants, ≥39 years of 
age, 40% men, 38% former smokers, free 
of stroke
• Years of data collection: not provided
• New York, New York (northern Manhattan)
• Outcome: carotid plaque echodensity divided 
into quintiles
• Compared with never smokers, current 
smokers were more likely to have soft or 
calcified plaques
• Compared with never smokers, former smokers 
were more likely to have echodense plaques
More research is needed to understand whether 
plaque morphology mediates the relationship 
between smoking and clinical CVD
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Table 4.11 Continued
Study Design/population Main results Comments
Hansen et al. 
(2016)
• Prospective cohort (Malmö Diet and Cancer 
cardiovascular cohort)
• 2,992 middle-aged participants, 41% men, 
35% former smokers, free of CVD
• 1991–1994 baseline and 2007–2012 visit 
(subcohort of those born 1926–1945)
• Sweden
• Outcomes: mean common carotid IMT and 
maximum carotid bifurcation, degree of 
lumen diameter reduction
• Difference in IMT progression (mm/year) 
(95% CI):
 – CCA:
	| Never smoker, unexposed to secondhand 
smoke: 1.00 (referent)
	| Former smoker: 0.0014 (0.0001–0.0028)
	| Moderate smoker (1–15 cigarettes smoked 
per day): 0.0027 (0.0010–0.0044)
	| Heavy smoker (>15 cigarettes smoked 
per day): 0.0041 (0.0020–0.0062)
 – Carotid bifurcation:
	| Never smoker, unexposed to secondhand 
smoke: 1.00 (referent)
	| Former smoker: 0.0074 (0.0018–0.0129)
	| Moderate smoker: 0.0106 (0.0038–0.0175) 
	| Heavy smoker: 0.0146 (0.0061–0.0230)
• Differences in rate of diameter reduction 
(%/year) (95% CI):
 – Never smoker, unexposed to secondhand 
smoke: 1.00 (referent)
 – Former smoker: 0.25 (0.001–0.36)
 – Moderate smoker: 0.25 (0.11–0.38)
 – Heavy smoker: 0.43 (0.26–0.59)
• Stronger associations for current smokers
• With >5 years since cessation, rate of IMT 
bifurcation progression decreased; similar 
pattern for lumen reduction
Similar results when adjusted for inflammatory 
markers
Smoking Cessation
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Study Design/population Main results Comments
Hisamatsu et al. 
(2016)
• Cross-sectional study (Shiga Epidemiological 
Study of Subclinical Atherosclerosis)
• 1,019 Japanese men, 40–79 years of age, 
50% former smokers, free of CVD
• 2006–2008
• Japan
• Outcomes: ABI <1.1; mean carotid IMT; 
AoAC and CAC
• Former smoking was associated with higher 
carotid IMT (IMT >1.0 mm, OR = 1.94 
[95% CI, 1.13–3.34]) and AoAC (AoAC >0, 
OR = 2.55 [95% CI, 1.45–4.49]) compared 
to never smokers
• Current smoking was positively associated 
with all four outcomes:
 – CAC >0, OR = 1.79 (95% CI, 1.16–2.79)
 – Carotid IMT >1.0 mm, OR = 1.88 (95% CI, 
1.02–3.47)
 – AoAC >0, OR = 4.29 (95% CI, 2.30–7.97)
 – ABI <1.1, OR = 1.78 (95% CI, 1.16–2.74)
• For most outcomes, a dose-response 
relationship was observed between pack-years 
of smoking and daily consumption for current 
and former smokers. Time since cessation was 
linearly associated with less atherosclerotic 
burden for all four outcomes
• p for trend <0.05
—
Kianoush et al. 
(2017)
• Cross-sectional study (Brazilian Longitudinal 
Study of Adult Health)
• 14,103 civil servants, 35–74 years of age; 45% 
men; multiethnic (52% White, 28% Brown 
[mixed], 16% Black, and 4% Asian or other); 
30% former smokers, free of prevalent disease 
(including CVD)
• 2008–2010
• Brazil (multicenter cohort, six cities)
• Outcomes: mean carotid IMT, ABI, and CAC
• Compared with never smokers, former 
smokers had higher IMT and odds of ABI ≤1.0 
(p = <.001)
• Compared with never smokers, current 
smokers had higher IMT, odds of ABI ≤1.0, 
and odds of CAC >0 (p = <.001)
• Among former smokers, time since quitting 
was negatively associated with carotid IMT, 
ABI ≤1.0, and CAC >0 (p = <.001)
—
Notes: ABI = ankle-brachial index; AoAC = aortic artery calcium; CAC = coronary artery calcification; CCA = common carotid artery; CHD = coronary heart disease; 
CVD = cardiovascular disease; IMT = intimal-media thickness; mm = millimeters.
aNatural log-transformed IMT.
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was not enough evidence to conclude that reducing 
the number of cigarettes smoked per day reduces the 
risk for CVD. Among current smokers, however, a dose-
response relationship has been observed between the 
number of cigarettes smoked per day and the incidence 
of CVD (USDHHS 2010; Benjamin et al. 2017). The next 
section briefly summarizes the evidence that supports 
these conclusions.
Intervention Studies
Much of the evidence linking smoking cessation to 
reduced risk of CVD morbidity and mortality is based on 
observational studies, but the link has also been observed 
in intervention studies directed at increasing cessation. 
The 1990 Surgeon General’s report, which summarized 
results from several clinical trials, found that, overall, 
such interventions tend to decrease risk of CHD or CVD 
mortality. Among these studies, some had interventions 
directed at only smoking cessation, and others addressed 
risk factors in addition to smoking (USDHHS 1990). For 
some of these studies, findings from long-term follow-up 
have been reported subsequently. 
One example is the Lung Health Study, a clinical 
trial started in 1986 that compared a 10-week smoking 
cessation program with usual care among 5,887 smokers 
with asymptomatic airway obstruction (Anthonisen et al. 
2005). The intervention involved strong messaging by 
a physician and a total of twelve 2-hour group sessions 
using behavior modification and nicotine gum. Those 
who quit smoking entered a maintenance program that 
focused on coping skills; this group was described as the 
special-intervention group.
Part of the intervention group received ipratropium, 
a treatment for chronic obstructive pulmonary disease 
and asthma, and the rest of that group received a placebo 
inhaler. A separate group (controls) received care as usual. 
Over 14  years of follow-up, the all-cause mortality rate 
was higher in the usual-care group than in the special-
intervention group (hazard ratio [HR]  =  1.18; 95%  CI, 
1.02–1.37). The benefit of cessation was most pronounced 
among the 21.7% of the special-intervention group who 
had quit smoking at 5 years (only 5.4% of usual-care par-
ticipants had quit). Although there were no significant dif-
ferences in rates of CHD mortality or CVD mortality, these 
rates were lower in the special-intervention group than 
in the usual-care group. Finally, in observational anal-
yses comparing sustained quitters, intermittent quitters, 
and continuing smokers in this study, smoking status 
was significantly related to unadjusted risk of CHD and 
CVD, with the highest risk among those who continued 
to smoke. 
In the Oslo cardiovascular study, which began in 
1972, 1,232  men free of CVD and diabetes—with total 
serum cholesterol levels of 6.9–8.9  millimoles/liter 
(mmol/L) (80% were smokers)—participated in a 5-year 
intervention study (Hjermann et  al. 1981). At clinical 
visits every 6  months, those in the intervention group 
received dietary advice, and smokers in the intervention 
group were advised to quit. At 40-year follow-up, the inter-
vention group had a reduced risk of death from MI versus 
the control group (HR = 0.71; 95% CI, 0.51–1.00). Most of 
the reduction in MI risk occurred during the first 15 years 
of follow-up; the survival curves for MI were parallel after 
that point (Holme et al. 2016). There was no significant 
difference in all-cause mortality from MI at 40  years, 
although there was a reduction in risk of dying among 
the intervention group across the first 15 years that was 
statistically significant at follow-up. At 5-year follow-up, 
the rate of CHD, MI, and SCD combined was 47% lower 
in the intervention group than in the control group, with 
an estimated 25% of the benefit attributable to smoking 
cessation (Hjermann et al. 1981). Follow-up at 8.5 years 
found a significant reduction in CHD incidence, similar to 
that found at 5 years, among the intervention group com-
pared with the control group; this analysis also observed 
increases in the rate of smoking in the intervention group 
after the end of the trial (Hjermann et al. 1986).
In the Multiple Risk Factor Intervention Trial 
(MRFIT), which was initiated in 1973, 12,866 men at high 
risk of CHD were randomized to usual care or to a mul-
tifactor special intervention aimed at lowering serum 
cholesterol and blood pressure and promoting smoking 
cessation. Over follow-up averaging 7  years (during the 
active-intervention period), the rates of the composite 
outcomes of fatal or nonfatal CHD and of fatal or nonfatal 
CVD were significantly lower in the special-intervention 
group than in the usual-care group, by 14% (95%  CI, 
3–24%) for CHD and by 11% (95% CI, 1–21%) for CVD 
(Stamler et al. 2012). Rates of a priori defined endpoints 
(CHD death, CHD death or nonfatal MI, CVD death, and all-
cause death), however, did not differ significantly between 
the two groups, possibly because of inadequate statistical 
power (Multiple Risk Factor Intervention Trial Research 
Group 1982; Gotto Jr 1997). Importantly, because the 
interventions in the MRFIT and the Oslo cardiovascular 
study did not focus solely on smoking cessation, the effects 
of the smoking cessation intervention cannot be readily 
separated from the effects of the other interventions.
Observational Studies
Much evidence from observational studies supports 
previous conclusions that smoking cessation decreases 
risk of CVD. Based on analyses of mortality in two his-
torical cohorts (Cancer Prevention Study I [CPS I, 1959–
1965] and II [CPS II, 1982–1988]) and five contemporary 
cohorts followed from 2000 to 2010, Thun and colleagues 
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(2013a) concluded that smoking cessation at any age 
reduces the risk of smoking-related death, including 
death from CVD; that much of the excess risk of all-cause 
mortality can be avoided by quitting smoking before 
40 years of age, with additional benefit from quitting ear-
lier (Doll et al. 2004; Jha et al. 2013; Pirie et al. 2013); and 
that quitting smoking completely is much more benefi-
cial than reducing the number of cigarettes smoked per 
day. For example, an analysis of data from the National 
Health Interview Survey found that, on average, smokers 
who quit at 25–34 years of age gained 10 years of life com-
pared with those who continued to smoke; smokers who 
quit at 35–44 years of age gained 9 years; and smokers who 
quit at 45–54 years of age gained 6 years (Jha et al. 2013). 
Similarly, the 50-year analysis of the British Doctors’ 
Study showed that, among men born close to 1920, long-
term cigarette smoking beginning in early adulthood tri-
pled age-specific mortality rates, while quitting at 50 years 
of age halved the hazard and quitting at 30 years of age 
avoided most of the hazard (Doll et al. 2004).
Mons and colleagues (2015), who performed a 
pooled analysis of individual-level data from European and 
U.S. cohorts (Consortium on Health and Ageing: Network 
of Cohorts in Europe and the United States [CHANCES]), 
assessed the relationship between smoking cessation 
and risk of cardiovascular mortality in women and men 
60 years of age and older. Smoking was strongly related 
to increased cardiovascular mortality; compared with cur-
rent smokers, the adjusted HR of cardiovascular mortality 
in former smokers was lower by 0.85 for each 10 years of 
smoking cessation (95%  CI, 0.82–0.89), providing evi-
dence of the benefit of smoking cessation among adults 
60 years of age and older. Former smokers had a higher 
risk of cardiovascular mortality than never smokers 
(Table 4.12 and Figures 4.2a and 4.2b), but the evidence 
suggests a trend of decreasing excess risk as the number 
of years since cessation increases (Table 4.12).
Mons and colleagues (2015) also measured the rela-
tionships between smoking cessation and risk advance-
ment periods, which are the average periods of time by 
which the occurrence of an outcome (such as death) 
attributable to a risk factor is advanced in exposed versus 
nonexposed persons (Brenner et  al. 1993; Mons et  al. 
2015). In general, the risk advancement period decreased 
as time since smoking cessation increased. For instance, 
risk advancement periods ranged from 3.75 years (95% CI, 
2.78–4.71) among those who had quit more than 5 years 
earlier to -0.79 years (95% CI, -0.12–1.69) among those 
who had quit 20 or more years earlier.
Many studies have assessed the relationships between 
time since cessation or cumulative exposure and CVD risk. 
For example, in the Nurses’ Health Study, former ciga-
rette smokers had an increased risk of vascular mortality 
compared with never smokers (adjusted HR  =  1.32; 
95% CI, 1.20–1.44) (Kenfield et al. 2008), and compared 
with current smokers, the risk of vascular mortality 
trended downward with increased time since cessation 
(from <5 years to ≥20 years). In the ARIC study of Whites 
and African Americans, former smokers had a 17% signifi-
cantly greater risk of CVD (defined as MI or stroke) com-
pared with never smokers, with similar elevations observed 
by race and sex (Table 4.13) (Huxley et al. 2012). The ben-
efit of smoking cessation increased as time since cessation 
increased; those who had quit 10  or more years earlier 
had a 33% lower risk of CVD than those who continued to 
smoke (Table 4.13). In the MESA cohort, former smokers 
(median cessation at 22  years of age [+/-  13  years]) did 
not have a significantly higher adjusted HR for all-cause 
CVD compared with never smokers (Table 4.13) (McEvoy 
et al. 2015a). Among current smokers in that same cohort, 
there was a dose-response relationship, as more pack-
years were associated with a higher risk of CVD, but this 
trend was not observed among former smokers. Another 
analysis of data from the MESA cohort found that former 
smokers—regardless of duration, intensity, or recency of 
cessation—were not at increased risk of CVD compared 
with never smokers (Nance et al. 2017).
Similar findings have been observed in many dif-
ferent populations. For example, in a cohort in China, 
deaths attributable to tobacco-related causes trended 
downward with increased time since smoking cessation 
(He et  al. 2014). A similar pattern was observed in that 
study for deaths attributable to vascular causes (CHD or 
stroke), where compared with current smokers, those who 
had quit for 2–7 years had 0.82 times (95% CI, 0.46–1.47) 
the risk and those who had quit for 8 or more years had 
0.71 times (95% CI, 0.42–1.20) the risk. This pattern did 
not hold for all subtypes of vascular disease, but there were 
limited cases within these categories. In Japan, in a cohort 
of healthy, young, and middle-aged persons, adjusted risk 
of CVD events decreased as time since cessation increased, 
with risk being significantly lower 4 or more years after 
cessation (data not shown) (Kondo et al. 2011).
Similar results have been found among persons 
with diabetes. In a meta-analysis of persons with diabetes, 
former smokers had an increased risk of CVD, CVD mor-
tality (Table  4.12), and total mortality compared with 
never smokers (Pan et  al. 2015). In the Framingham 
Offspring Cohort (included in the meta-analysis by Pan 
and colleagues [2015]), among persons without diabetes, 
nonsmokers, those who had quit for 4 or fewer years, and 
those who had quit for more than 4 years, all had lower 
adjusted risks of CVD than current smokers (Table 4.13) 
(Clair et al. 2013). Similar patterns were observed among 
those with diabetes, but results were not statistically 
significant.
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Table 4.12 Meta-analyses of observational studies on smoking cessation and incidence of total cardiovascular disease
Study Design/population Findings: RR (95% CI) Comments
Mons et al. 
(2015)a
• Individual-level meta-analysis
• 434,278 men and women, ≥60 years of age, 
47% former smokers
• 31,802 CVD deaths
• 25 prospective cohorts
• Data collected from different cohorts in 
various years from the 1980s to the 2010s
• Europe and North America
• Mean follow-up: 1.6–14.8 years (approximately 
8–13 years for most studies)
• Outcome: CVD mortality
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.37 (1.25–1.49)
 – Current smoker: 2.07 (1.82–2.36)
• Years since smoking cessation (never vs. 
former smoker):
 – Never smoker: 1.00 (referent)
 – Former smoker:
	| <5: 1.74 (1.51–2.01)
	| 5–9: 1.60 (1.36–1.88)
	| 10–19: 1.43 (1.24–1.64)
	| ≥20: 1.15 (1.02–1.30)
• Years since smoking cessation (current vs. 
former smoker):
 – Current smoker: 1.00 (referent)
 – Former smoker:
	| <5: 0.90 (0.81–1.00)
	| 5–9: 0.84 (0.73–0.95)
	| 10–19: 0.78 (0.71–0.85)
	| ≥20: 0.61 (0.54–0.69)
Figure 1 in Mons and colleagues (2015) provides 
more details on results by smoking status
Pan et al. (2015)a • Meta-analysis
• Men and women, >18 years of age with type 1 
or type 2 diabetes mellitus
• Prospective cohort studies:
 – CVD: 7 studies for former smokers, 
16 studies for current smokers
 – CVD mortality: 8 studies for former 
smokers, 13 studies for current smokers
• Sample: 
 – CVD: n = 1,028,982; cases = 94,929
 – CVD mortality: n = 37,550; cases = 3,163
• United States, Europe, China, New Zealand, 
Australia, and other international collaborations
• Studies included in the meta-analysis were 
published between 1989 and 2015
• Outcomes: CVD and CVD mortality
• CVD:
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.09 (1.05–1.13)
 – Current smoker: 1.44 (1.34–1.54)
• CVD mortality:
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.15 (1.00–1.32)
 – Current smoker: 1.49 (1.29–1.71)
—
Notes: CI = confidence interval; CVD = cardiovascular disease; RR = risk ratio.
aSome overlap exists between the cohorts included in these publications.
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Figure 4.2a Results from the meta-analyses of the association between current and never smoking status and 
cardiovascular mortality
Study
Number of 
events/total
Hazard ratio 
(95% CI)a
ELSA 777/5,128 1.94 (1.55–2.41)
EPIC-Elderly Greece 899/9,325 2.00 (1.61–2.49)
EPIC-Elderly Spain 173/5,023 2.03 (1.29–3.19)
EPIC-Elderly Sweden 148/3,165 2.56 (1.74–3.78)
EPIC-Elderly the Netherlands 277/6,561 2.63 (1.93–3.58)
ESTHER 304/5,062 2.08 (1.51–2.86)
HAPIEE Czech Republic 117/2,742 3.15 (1.90–5.23)
HAPIEE Lithuania 126/4,021 3.49 (2.10–5.81)
HAPIEE Poland 127/3,118 2.52 (1.59–3.98)
HAPIEE Russia 345/3,876 2.25 (1.59–3.17)
MORGAM Brianza 70/672 2.33 (1.19–4.55)
MORGAM Catalonia 25/725 3.20 (0.55–18.54)
MORGAM FINRISK 904/5,326 2.31 (1.88–2.83)
MORGAM Gostrup 427/2,328 1.65 (1.31–2.06)
MORGAM KORA Augsburg 712/3,060 2.50 (2.02–3.10)
MORGAM Northern Sweden 55/859 1.78 (0.83–3.83)
MORGAM SHIP Greifswald 121/1,259 1.24 (0.66–2.33)
MORGAM Warsaw 53/360 0.86 (0.41–1.82)
NHANES 1,762/5,571 1.51 (1.31–1.75)
NIH-AARP 22,683/330,305 2.75 (2.63–2.87)
SENECA 296/1,850 1.48 (1.02–2.14)
SHARE 171/25,835 1.67 (1.03–2.72)
SMC 30/3,519 4.14 (1.62–10.61)
Tromsø 947/3,834 1.68 (1.39–2.02)
Zutphen 253/754 1.83 (1.23–2.71)
Summary estimates    
Fixed effects model   2.45 (2.36–2.54)
Random effects model   2.07 (1.82–2.36)
Source: Mons et al. (2015), with permission.
Note: CI = confidence interval; ELSA = English Longitudinal Study of Aging; EPIC = European Prospective Investigation into Cancer 
and Nutrition; ESTHER = Epidemiological Investigations on Opportunities for Prevention, Early Detection and Optimised Treatment 
of Chronic Diseases in the Elderly Population; FINRISK = a large Finnish population survey on risk factors on chronic, noncommu-
nicable diseases; HAPIEE = Health, Alcohol, and Psychosocial factors In Eastern Europe; KORA = Kooperative Gesundheitsforschung 
in der Region Augsburg (Cooperative Health Research in the Augsburg Region); MORGAM = Monica Risk Genetics Archiving and 
Monograph; NHANES = National Health and Nutrition Examination Survey; NIH-AARP = National Institutes of Health–American 
Association of Retired Persons; SENECA = Survey Europe on Nutrition in the Elderly; SHARE = Survey of Health, Aging, and 
Retirement in Europe; SMC = Swedish Mammography Cohort.
aTest for heterogeneity:  τ2 = 0.023, p <0.001, I2 = 68.7%. 
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Figure 4.2b Results from the meta-analyses of the association between former and never smoking status and 
cardiovascular mortality
Study
Number of 
events/total
Hazard ratio 
(95% CI)a
ELSA 777/5,128 1.44 (1.22–1.69)
EPIC-Elderly Greece 899/9,325 1.50 (1.23–1.83)
EPIC-Elderly Spain 173/5,023 1.81 (1.15–2.85)
EPIC-Elderly Sweden 148/3,165 1.24 (0.83–1.87)
EPIC-Elderly the Netherlands 277/6,561 1.62 (1.22–2.16)
ESTHER 304/5,062 1.09 (0.82–1.44)
HAPIEE Czech Republic 117/2,742 2.09 (1.30–3.36)
HAPIEE Lithuania 126/4,021 2.05 (1.25–3.35)
HAPIEE Poland 127/3,118 1.51 (0.97–2.35)
HAPIEE Russia 345/3,876 1.79 (1.25–2.57)
MORGAM Brianza 70/672 1.47 (0.67–3.19)
MORGAM Catalonia 25/725 3.50 (0.59–20.78)
MORGAM FINRISK 904/5,326 1.41 (1.18–1.68)
MORGAM Gostrup 427/2,328 0.88 (0.68–1.15)
MORGAM KORA Augsburg 712/3,060 1.70 (1.41–2.06)
MORGAM Northern Sweden 55/859 2.07 (1.10–3.90)
MORGAM SHIP Greifswald 121/1,259 0.72 (0.47–1.11)
MORGAM Warsaw 53/360 1.04 (0.47–2.31)
NHANES 1,762/5,571 1.13 (1.01–1.26)
NIH-AARP 22,683/330,305 1.53 (1.48–1.58)
SENECA 296/1,850 1.04 (0.74–1.47)
SHARE 171/25,835 1.34 (0.91–1.97)
SMC 30/3,519 1.12 (0.47–2.71)
Tromsø 947/3,834 1.30 (1.09–1.55)
Zutphen 253/754 1.15 (0.78–1.69)
Summary estimates    
Fixed effects model   1.47 (1.43–1.51)
Random effects model   1.37 (1.25–1.49)
Source: Mons and colleagues (2015).
Notes: CI = confidence interval; ELSA = English Longitudinal Study of Aging; EPIC = European Prospective Investigation into 
Cancer and Nutrition; ESTHER = Epidemiological Investigations on Chances of Preventing, Recognizing Early and Optimally 
Treating Chronic Diseases in an Elderly Population; HAPIEE = Health, Alcohol, and Psychosocial factors In Eastern Europe; 
KORA = Kooperative Gesundheitsforschung in der Region Augsburg (Cooperative Health Research in the Augsburg Region); 
MORGAM = Monica Risk Genetics Archiving and Monograph; NHANES = National Health and Nutrition Examination Survey; 
NIH-AARP = National Institutes of Health-American Association of Retired Persons; SENECA = Survey Europe on Nutrition in 
the Elderly; SHARE = Survey of Health, Aging, and Retirement in Europe; SMC = Swedish Mammography Cohort.
aTest for heterogeneity: τ2 = 0.067, P < 0.001, I2 = 82.3%.
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Table 4.13 Observational studies on smoking cessation and cardiovascular disease
Study Design/population Findings: RR (95% CI) Comments
Kondo et al. 
(2004)
• Case-control study
• 29 men
• Mean age:
 – Nonsmokers: 43.9 years of age
 – Smokers: 38.9 years of age
• Nagoya, Japan (years not reported)
• Smoking cessation led to rapid restoration of 
progenitor cells and endothelial progenitor 
cell levels
• Circulating progenitor cells and endothelial 
progenitor cells increased rapidly after 
cessation (p <0.0001) and decreased after 
resumption of smoking to a level similar to 
that before cessation (p = 0.0031)
—
He et al. (2006) • Cross-sectional study
• 2,334 participants
• 60 years of age or older
• 2001–2002
• Beijing, China
• Smoking cessation was associated with 
decreased risks of PAD. Excess risk of PAD was 
nearly eliminated after stopping smoking for 
10 or more years:
 – Never smoker (referent)
 – Current smoker 1.57 (1.16–2.13), p <0.01
 – Former smoker: 1.42 (1.02–1.98), p <0.05
—
Kenfield et al. 
(2008)
• Prospective cohort (Nurses’ Health Study)
• 104,519 women 
• 1980–2004
• United States
• Compared with never smokers, former 
cigarette smokers had an increased risk 
of vascular mortality (adjusted HR = 1.32; 
95% CI, 1.20–1.44)
Most of the excess risk of vascular mortality 
due to smoking can be eliminated rapidly upon 
cessation and within 20 years for lung diseases
Huxley et al. 
(2012)a,b
• Prospective cohort (Atherosclerosis Risk in 
Communities Study)
• 14,200 participants with 2,777 CVD events, 
45–64 years of age, 43% men, 31% former 
smokers at baseline, 15% quit during follow-
up, African Americans (27%) and Whites, 
free of CHD or stroke
• 1987–2007
• United States (four communities)
• Mean follow-up: 17.1 years
• Outcome: CVD events (myocardial infarction, 
stroke)
• Compared with never smokers, former 
smokers had a 17% higher risk of CVD
• Compared with never smokers, current 
smokers had:
 – Men: 70% higher risk of CVD
 – Women: >200% higher risk of CVD
• Years since smoking cessation (overall):
 – Continuous smokers: 1.00 (referent)
 – 1–3: 0.87 (0.67–1.14)
 – 4–9: 0.90 (0.69–1.16)
 – ≥10: 0.67 (0.45–1.01)
 – p trend: 0.061 (0.69 in African Americans, 
0.044 in Whites)
—
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Study Design/population Findings: RR (95% CI) Comments
Clair et al. 
(2013)a,b
• Prospective cohort (Framingham Offspring)
• 3,251 participants and 631 CVD events
• Baseline: mean age = 47.8 years, 48% men, 
mostly White, 26% quit for >4 years and 
9% quit for ≤4 years, free of CVD
• 1984–2011
• United States
• Mean follow-up: 25 years
• Outcome: CVD (defined as CHD, cerebrovascular 
events, PAD, or congestive heart failure)
• Among participants without diabetes mellitus:
 – Current smokers: 1.00 (referent)
 – Former smokers (quit ≤4 years): 0.47 
(0.23–0.94)
 – Former smokers (quit >4 years): 0.46 
(0.34–0.63)
 – Nonsmokers: 0.30 (0.21–0.44)
• Similar results in those with diabetes, but not 
significant (included in the meta-analysis by 
Pan and colleagues [2015] in Table 4.13)
—
McEvoy et al. 
(2015a)a
• Prospective cohort (Multi-Ethnic Study of 
Atherosclerosis)
• 6,814 multiethnic participants with 638 CVD 
events, 45–84 years of age, 47% men, 
38% former smokers, free of CVD
• 1996–2011
• United States
• Median follow-up 10.2 years
• Outcome: all-cause CVDc
• Risk of CVD by smoking status:
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.07 (0.89–1.29)
 – Current smoker: 1.70 (1.32–2.18)
Median cessation among former smokers was 
22 (+/-13) years; smoking exposure confirmed 
by levels of urinary cotinine
Nance et al. 
(2017)
• Multi-Ethnic Study of Atherosclerosis cohort
• 6,814 participants free of clinical heart disease 
at baseline
• 45–84 years of age
• 47% men, 53% women
• 2000–2002
• United States
• Former smokers—regardless of duration, 
intensity, or recency—were not at increased 
risk for suggesting that risk may drop 
precipitously from the time of quitting
• Current smoker:
 – CVDH: HR = 1.98 (1.51–2.60), p <0.0005
 – CVDA: HR = 1.80 (1.42–2.29), p <0.0005
 – CHDH: HR = 1.94 (1.38–2.74), p <0.0005
 – CHDA: HR = 1.66 (1.23–2.22), p = 0.001
• Former smoker:
 – CVDH: HR = 0.89 (0.72–1.11), p = 0.308
 – CVDA: HR = 1.06 (0.89–1.27), p = 0.496
 – CHDH: HR = 0.91 (0.69–1.20), p = 0.507
 – CHDA: HR = 1.13 (0.92–1.40), p = 0.251
—
Notes: CHD = coronary heart disease; CHDA = CHDH, definite angina, probable angina if followed by revascularization; CHDH = coronary heart disease hard (myocardial 
infarction, resuscitated cardiac arrest, CHD death); CI = confidence interval; CVD = cardiovascular disease; CVDA = CVDH, CHDH, atherosclerotic death, CVD death; 
CVDH = CHDH, stroke death, stroke; HR = hazard ratio; PAD = peripheral artery disease; RR = risk ratio.
Table 4.13 Continued
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aMeasure(s) of association adjusted for covariate(s).
bPooled logistic regression analyses.
cAll-cause CVD events defined as all-cause CHD events plus cerebrovascular accident (CVA), transient ischemic attack, or ischemic or hemorrhagic stroke; CVA death; and 
other CVD death.
Table 4.13 Continued
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Summary of the Evidence
The additional evidence reviewed in this sec-
tion strengthens the basis for previous conclusions that 
smoking cessation reduces the risk of CVD morbidity and 
mortality. For those who quit, there are short-term benefits 
in terms of reduced risk for CVD and a continued decline 
over the long term as time since cessation increases. 
Smoking Cessation and 
Coronary Heart Disease
CHD, the most common form of heart disease in 
the United States, results in part from the buildup of 
plaque (atherosclerosis) on the walls of coronary arteries 
(Centers for Disease Control and Prevention [CDC] 2015). 
MI, or heart attack, occurs when the flow of blood to part 
of the heart muscle is reduced or blocked, damaging that 
part of the heart muscle or causing it to die. The main 
cause of MI is plaque in the coronary arteries; a less 
common cause is severe spasm or contraction of a coro-
nary artery (CDC 2017).
In the United States, someone has an MI once every 
40 seconds (Benjamin et al. 2017). Approximately 7.9 mil-
lion adults (20 years of age or older) have had an MI, and 
8.7 million have angina pectoris (Benjamin et al. 2017).
In the CHANCES study of women and men 60 years 
of age or older, cigarette smoking was strongly associated 
with acute coronary events (confirmed fatal and nonfatal 
coronary events, such as acute MI, unstable angina pec-
toris, or coronary death) (Mons et al. 2015). Overall, risk 
of acute coronary events was higher in former smokers 
than in never smokers, and compared with risk among 
current smokers, risk of acute coronary events in former 
smokers decreased greatly as the number of years since 
cessation increased (Table  4.14). Compared with cur-
rent smokers, the adjusted HR of acute coronary events 
decreased by 0.83 for every 10 years of smoking cessation 
(95% CI, 0.78–0.89).
Similarly, in pooled analyses of two older cohorts 
and five contemporary cohorts that were restricted to men 
and women 55  years of age or older, smoking cessation 
was associated with lower rates of death from CHD com-
pared with the rate of current smokers, but risk of CHD 
death was higher among former smokers compared with 
never smokers (Table  4.14) (Thun et  al. 2013a). Among 
the five contemporary cohorts in that study, benefits gen-
erally increased among those who had quit at younger 
ages or who had quit for longer periods of time, but com-
pared with the risk among never smokers, risks remained 
elevated for many years. Among women who had quit for 
30 or more years and among men who had quit for 40 or 
more years, risk of CHD death was similar to that of never 
smokers. Risks of CHD mortality were not elevated among 
men and women who had quit before they were 40 years 
of age. Similar results, showing that the greatest benefit 
occurred among those who had quit at younger ages, were 
observed in a large cohort study of women in the United 
Kingdom (Table 4.15) (Pirie et al. 2013).
The 2014 Surgeon General’s report (USDHHS 2014) 
noted that the pattern of declining CHD risk with increasing 
time since cessation was not as strong among the contem-
porary cohorts analyzed by Thun and colleagues (2013a) 
as with earlier observational analyses (including the Lung 
Health Study and MRFIT cohorts) that reported a larger 
decline in CVD risk as time since cessation increased. The 
report attributed this difference to the fact that analyses by 
Thun and colleagues (2013a) focused on older adults.
In a meta-analysis of studies comparing smoking as 
a risk factor for CHD in women and men, the adjusted rel-
ative risk (RR) of CHD was higher in women than in men 
for current cigarette smokers compared with nonsmokers, 
but the risk did not differ between women and men who 
were former smokers (Huxley and Woodward 2011).
Pujades-Rodriguez and colleagues (2015) reported 
on the relationship between smoking and initial  presen-
tations of CVD in the CALIBER (ClinicAl research using 
LInked Bespoke studies and Electronic health Records) 
(University College London n.d.), drawing on linked elec-
tronic health records of 1.93 million persons 30 years of 
age or older in England. In age-adjusted analyses (strati-
fied by sex and general practice), the hazards of stable 
angina, unstable angina, MI, and sudden coronary death 
decreased gradually with increasing time since smoking 
cessation (Table 4.15). After 10 years of cessation, former 
smokers tended to have the same hazard of CHD out-
comes as never smokers (not shown in table), although 
the HR for sudden coronary death in women (HR = 2.74; 
95% CI, 1.36–5.51) remained elevated. The main analysis 
imputed smoking status for 523,611 participants. Results 
were similar for complete case analyses (1.41 million per-
sons with smoking status) and when adjusting for other 
variables. It is unclear, however, how many persons in this 
study had missing covariates and whether any analyses 
were run without imputed covariates, which could have 
influenced the validity of the findings.
In the Nurses’ Health Study (included in the pooled 
analysis by Thun and colleagues [2013]), former smokers 
had an increased risk of CHD mortality compared with 
never smokers (adjusted HR = 1.24; 95% CI, 1.09–1.42) 
(Kenfield et  al. 2008). Compared with current smokers, 
former smokers showed a trend of decreased risk of CHD 
mortality with increased time since cessation (from fewer 
than 5 years to 20 or more years). In this study, former 
smoking was also associated with risk of all CHD events 
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Table 4.14 Meta-analyses and a pooled analysis of observational studies on smoking cessation and incidence of coronary heart disease
Study Design/population Findings: RR (95% CI) Comments
Thun et al. 
(2013a)a,b
• Pooled analysis
• Men and women, ≥55 years of age
• Two historical cohorts (CPS I and II) and 
five contemporary cohorts:b
 – CPS I: n = 518,982; cases = 17,809 
 – CPS II: n = 746,485; cases = 16,308 
 – Contemporary cohorts: n = 956,756; 
cases = 22,622
• United States
• Follow-up:
 – CPS I: 1959–1965
 – CPS II: 1982–1988
 – Contemporary cohorts: 2000–2010
• Outcome: CHD deaths
• CPS I:
 – Men:
	| Never smoker: 1.00 (referent)
	| Former smoker: 1.28 (1.21–1.36)
	| Current smoker: 1.69 (1.61–1.77)
 – Women:
	| Never smoker: 1.00 (referent)
	| Former smoker: 1.39 (1.22–1.59)
	| Current smoker: 1.56 (1.46–1.67)
• CPS II:
 – Men:
	| Never smoker: 1.00 (referent)
	| Former smoker: 1.27 (1.21–1.33)
	| Current smoker: 1.78 (1.69–1.88)
 – Women:
	| Never smoker: 1.00 (referent)
	| Former smoker: 1.27 (1.19–1.36)
	| Current smoker: 2.00 (1.88–2.13)
• Contemporary cohorts:
 – Men:
	| Never smoker: 1.00 (referent)
	| Former smoker: 1.43 (1.37–1.48)
	| Current smoker: 2.50 (2.34–2.66)
 – Women:
	| Never smoker: 1.00 (referent)
	| Former smoker: 1.44 (1.38–1.51)
	| Current smoker: 2.86 (2.65–3.08)
—
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Table 4.14 Continued
Study Design/population Findings: RR (95% CI) Comments
Mons et al. 
(2015)a,b
• Individual-level meta-analysis of 19 prospective 
cohorts
• 64,221 men and women, ≥60 years of age, 
47% former smokers, excluded those with a 
history of acute coronary events
• Europe
• Studies included data collected from different 
cohorts from various years from the 1980s to 
the 2010s
• Mean follow-up: 1.6–14.8 years (approximately 
8–13 years for most studies)
• Outcome: acute coronary events
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.18 (1.06–1.32)
 – Current smoker: 1.98 (1.75–2.25)
• Years since smoking cessation:
 – Current smoker: 1.00 (referent)
 – <5: 0.84 (0.72–0.98) 
 – 5–9: 0.86 (0.72–1.02)
 – 10–19: 0.69 (0.58–0.82)
 – ≥20: 0.58 (0.46–0.72)
—
Pan et al. (2015)a • Meta-analysis of prospective cohort studies:
 – 13 studies of former smokers
 – 21 studies of current smokers
• 1,009,457 men and women, >18 years of 
age with diabetes mellitus (type 1 or 2), 
38,752 cases
• Studies in the meta-analysis were published 
between 1989 and 2015
• United States, Europe, China, New Zealand, 
and other international collaborations
• Outcome: CHD
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.14 (1.00−1.30)
 – Current smoker: 1.51 (1.41−1.62)
—
Notes: CHD = coronary heart disease; CI = confidence interval; CPS = Cancer Prevention Study; RR = risk ratio.
aThere was some overlap between cohorts included in two or more of these publications in this table.
bHistorical cohorts: CPS I (1959–1965) and CPS II (1982–1988). Contemporary cohorts (2000–2010): National Institutes of Health–American Association of Retired Persons 
Diet and Health Study, CPS II Nutrition Cohort, Women’s Health Initiative (women only), Nurses’ Health Study (women only), and Health Professionals Follow-Up Study 
(men only).
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Table 4.15 Observational studies on smoking cessation and incident coronary heart disease
Study Design/population Findings: RR (95% CI) Comments
Song and Cho 
(2008)a
• Prospective cohort
• 475,734 men, 30–58 years of age in 1990, 
6% quitters,b 16% ex-smokers,b free of stroke 
or myocardial infarction, 2,164 cases of CHD
• 1992–2001
• Korea
• Mean follow-up: 8.83 years
• Outcome: myocardial infarction
• Nonreducing heavy smoker (>20 cigarettes 
per day), moderate smoker (10–19 cigarettes 
per day), light smoker (<10 cigarettes per day); 
reducer from heavy to moderate smoking; 
reducer from heavy to light smoking; reducer 
from moderate to light smoking; quitter from 
any smoking status; sustained ex-smoker; 
and sustained never smoker.
• Smoking status:b
 – Current smoker (by smoking intensity):
	| Non-reducing heavy smoker 1.00 (referent)
	| Moderate smoker: 0.74 (0.65–0.85)
	| Light smoker: 0.65 (0.57–0.75)
 – Quitter: 0.43 (0.34–0.53)
 – Sustained ex-smoker: 0.37 (0.32–0.44)
 – Never smoker: 0.29 (0.25–0.34)
Women not included because of their low 
percentage of smoking
Pirie et al. 
(2013)a
• Prospective cohort (Million Women Study)
• 1.2 million women; 55 years of age (median) 
at baseline; 28% former smokers; free of 
prior cancer (other than nonmelanoma skin 
cancer), heart disease, stroke, and current 
respiratory disease treatment; 4,458 cases 
of CHD among never or current smokers
• 1996–2011
• United Kingdom
• Mean follow-up: 12 years
• Outcome: CHD mortality
• Age (in years) quit smoking:
 – Never smoker: 1.00 (referent)
 – <25: 0.8
 – 25–34: 1.0
 – 35–44: 1.4c
 – 45–54: 1.9c
Exact CIs not reported for these results; total 
number of CHD cases not provided
McEvoy et al. 
(2015a)a
• Prospective cohort (Multi-Ethnic Study of 
Atherosclerosis)
• 6,814 participants, 45–84 years of age, 
47% men, multiethnic, 38% former smokers, 
free of CVD at baseline; 284 hard CHD events 
and 449 all-cause CHD events
• 1996–2011
• United States
• Median follow-up: 10.2 years
• Outcomes: hard CHD and all-cause CHDd
• Hard CHD events:
 – Never smoker: 1.00 (referent)
 – Former smoker: 0.93 (0.70–1.24)
 – Current smoker: 1.70 (1.18–2.45)
• All-cause CHD events:
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.14 (0.91–1.42)
 – Current smoker: 1.55 (1.14–2.10)
Median length of cessation among former 
smokers was 22 (+/-13) years; smoking exposure 
confirmed by urinary cotinine
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Study Design/population Findings: RR (95% CI) Comments
Pujades-
Rodriguez et al. 
(2015)
• Prospective cohort
• 1.93 million participants, ≥30 years of age, 
49% men, predominantly White (also South 
Asian and Black), 16.2% former smokers 
(among those with smoking data); drawn from 
CALIBER program (linked electronic health 
records); no history of CVD, 4,253 cases of 
myocardial infarction in former smokers
• 1997–2010
• England
• Median follow-up: 6 years
• Myocardial infarction by smoking status 
(age-adjusted):
 – Current smoker: 1.00 (referent)
 – Former smoker (years since quitting):
	| <2: 0.55 (0.34–0.88)
	| 2–9: 0.52 (0.41–0.65)
	| ≥10: 0.45 (0.38–0.55)
• Stronger association with more time since 
cessation for outcomes of unheralded 
coronary death and unstable angina
 – Former smoker (years since quitting):
	| <2: 1.01 (0.60–1.71)
	| 2–9: 0.76 (0.47–1.23)
	| ≥10: 0.61 (0.41–0.89)
 – Former smoker (years since quitting):
	| <2: 1.05 (0.55–1.99)
	| 2–9: 0.86 (0.63–1.18)
	| ≥10: 0.63 (0.52–0.77)
• Weaker trend for outcome of stable angina
 – Former smoker (years since quitting):
	| <2: 1.03 (0.66–1.60)
	| 2–9: 0.88 (0.69–1.12)
	| ≥10: 0.81 (0.81–0.99)
Imputed smoking status in the main 
analyses, as smoking data were missing in 
523,611 participants; results were similar for 
complete case analysis (1.41 million participants 
with smoking status) and when adjusted for 
other potential confounders; unclear how many 
persons had missing covariates and whether 
analyses were run without imputed covariates, 
which might have influenced validity of findings
Notes: CALIBER = Clinical research using LInked Bespoke studies and Electronic health Records; CHD = coronary heart disease; CI = confidence interval; CVD = cardio-
vascular disease; RR = risk ratio.
aMeasure(s) of association adjusted for covariate(s).
bSmoking categories based on smoking status in 1990 baseline exam and change in status from 1990 to 1992 exams: non-reducing heavy smoker (≥20 cigarettes per day), 
moderate smoker (10–19 cigarettes per day), light smoker (<10 cigarettes per day), reducer from heavy to moderate, reducer from heavy to light, reducer from moderate 
to light, quitter from any smoking status, sustained ex-smoker, sustained never smoker. Results for reducers not shown in table.
cLower boundary of 95% CI >1.0.
dHard CHD events defined as myocardial infarction or death from CHD. All-cause CHD events defined as hard CHD events plus definite angina, probable angina resulting 
in revascularization, and resuscitation after cardiac arrest.
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(fatal and nonfatal), but there was a stronger association 
for current smokers than for former smokers (Hu et  al. 
2000; Stampfer et al. 2000). In the MESA cohort, former 
smokers (median cessation: 22  years [+/-  13  years]) did 
not have a higher adjusted hazard for either a more 
strictly defined or a more broadly defined CHD outcome 
(Table 4.15) (McEvoy et al. 2015a). Despite a positive dose-
response relationship between pack-years of smoking and 
CHD among current smokers, the dose-response relation-
ship was null among former smokers (data not shown). 
Both a high-sensitivity CRP ≥3  mg/L and, particularly, 
a CAC >100 identified current smokers with a higher RR 
of CHD. In a large cohort of Korean men, both those who 
quit smoking within 2 years before the start of follow-up 
and those who had quit for a longer period had a lower 
adjusted hazard of MI compared with current heavy 
smokers (Table 4.15) (Song and Cho 2008).
Lee and colleagues (2012) used a negative expo-
nential distribution to quantitatively estimate how rap-
idly the risk of CHD declines following smoking cessa-
tion. Estimates from this approach were used to inform 
a special report from the American Heart Association and 
the American College of Cardiology on the longitudinal 
risks and benefits of therapies to prevent cardiovascular 
problems among Medicare patients (Lloyd-Jones et  al. 
2017). Based on a literature search and on consultation 
within their own team and with biostatistical and content 
experts, Lloyd-Jones and colleagues (2017) concluded that 
the approach set forth by Lee and colleagues (2012) was 
the most rigorous methodology for estimating the lon-
gitudinal reduction in MI risk associated with tobacco 
cessation. The quantitative review by Lee and colleagues 
(2012) had estimated that the excess risk of CHD associ-
ated with smoking decreased by 50% at 4.40 years after 
cessation (95% CI, 3.26–5.95), but there was a substan-
tial range in the estimate of the time required to achieve 
a 50% decrease in CHD risk across the studies, from less 
than 2 years to greater than 10 years. The cohort studies 
considered by Lee and colleagues (2012) had little follow-
up time after 2000, and alternative models to the negative 
exponential model were not considered. It should be noted 
that Philip Morris funded the research for this paper.
In line with IARC (2007), the risk of MI appears to 
decrease asymptotically as time since cessation increases, 
eventually reaching the risk among never smokers. In 
another modeling paper, Hurley (2005) also observed a 
rapid decrease in the risk of acute MI within 1–2 years of 
cessation, followed by a slower decline thereafter.
Summary of the Evidence
Building on evidence reviewed in previous Surgeon 
General’s reports, additional studies have added to the 
evidence base indicating that smoking cessation reduces 
the risk of CHD. The risk declines rapidly in the period 
immediately following cessation and then declines at a 
slower rate in the longer term. In some studies, the risk 
for CHD in former smokers eventually decreases to that of 
never smokers.
Smoking Cessation and 
Cerebrovascular Disease
Cerebrovascular disease results from interruptions 
in the flow of arterial blood to the brain, resulting in a 
syndrome of mild-to-severe neurologic deficits. Deficits 
can be temporary (transient ischemic attack) or perma-
nent (stroke). In the United States, cerebrovascular dis-
ease is the fifth leading cause of death (Kochanek et  al. 
2016), responsible for approximately 140,000 deaths each 
year (Yang et  al. 2017). In 2017 it was estimated that 
7.7 million U.S. adults 18 years of age or older have had 
a stroke (Benjamin et  al. 2017). Ischemic stroke, which 
results from an obstruction in a blood vessel that blocks 
the supply of blood to the brain, accounts for an esti-
mated 87% of strokes in the United States (Benjamin 
et al. 2017). Hemorrhagic stroke occurs when a weakened 
blood vessel ruptures and causes either an intracerebral 
(within the brain) hemorrhage (ICH) or a subarachnoid 
hemorrhage (SAH). From 2014 to 2015, the annual direct 
(medical) plus indirect costs of stroke in the United States 
was estimated to be $45.5 billion (Benjamin et al. 2019). 
Heidenreich and colleagues (2011) projected that the 
direct (medical) cost of stroke will increase by 238% from 
2010 to 2030.
Previous Surgeon General’s reports (USDHHS 
1989, 2004) have concluded that smoking is a cause of 
stroke. The 1990 Surgeon General’s report concluded 
that smoking cessation reduces the risk of both ischemic 
stroke and SAH compared with continued smoking, and 
that the risk of stroke returns to that of never smokers 
5–15 years after quitting (USDHHS 1990) (Table  4.10). 
Similarly, the 2001 Surgeon General’s report concluded 
that in most studies including women, the increased 
risk for stroke associated with smoking is reversible after 
smoking cessation; after 5–15 years of abstinence, the risk 
among former smokers approaches that of women who 
have never smoked (USDHHS 2001) (Table 4.10).
Several pooled studies or meta-analyses have found 
that smoking cessation is associated with a reduced risk of 
stroke or stroke mortality (Table 4.16) (Feigin et al. 2005; 
Peters et  al. 2013; Thun et  al. 2013a; Mons et  al. 2015; 
Pan et al. 2015). Peters and colleagues (2013), in a meta-
analysis of prospective cohort studies from around the 
world that were published between January 1, 1966, and 
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Table 4.16 Observational studies (meta-analyses and pooled analyses) on smoking cessation and cerebrovascular disease 
Study Design/population Findings: RR (95% CI) Comments
Feigin et al. 
(2005)a
• Meta-analysis of five longitudinal studies 
and three case-control studies
• Men and women
• Number of cases for analysis of current 
smoking: 
 – Longitudinal studies: 453
 – Case-control studies: 607
• Follow-up: 5–22 years
• Studies included in the meta-analysis were 
published between 1966 and 2015
• United States, Europe, and Asia-Pacific region
• Outcome: subarachnoid hemorrhage
• Longitudinal studies:
 – Never smoker vs. former smoker:
	| Never smoker: 1.00 (referent)
	| Former smoker: 1.9 (1.5–2.3)
 – Nonsmoker vs. current smoker:
	| Nonsmoker: 1.00 (referent)
	| Current smoker: 2.2 (1.3–3.6)
• Case-control studies:
 – Never smoker vs. former smoker:
	| Never smoker: 1.00 (referent)
	| Former smoker: 2.3 (2.2–2.4)
 – Nonsmoker vs. former smoker:
	| Nonsmoker: 1.00 (referent)
	| Current smoker: 3.1 (2.7–3.5)
—
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Table 4.16 Continued
Study Design/population Findings: RR (95% CI) Comments
Thun et al. 
(2013a)a,b
• Pooled analysis
• Men and women, ≥55 years of age
• Two historical cohorts (CPS I and II) 
and five contemporary cohortsc
• Sample:
 – CPS I: n = 518,982; 5,890 deaths 
from stroke
 – CPS II: n = 746,485; 4,037 deaths 
from stroke 
 – Contemporary cohorts: 956,756; 7,536
• United States
• Follow-up:
 – CPS I: 1959–1965
 – CPS II: 1982–1988
 – Contemporary cohorts: 2000–2010
• Outcome: deaths from stroke
• CPS I:
 – Men:
	| Never smoker: 1.00 (referent)
	| Former smoker: 0.95 (0.83–1.09)
	| Current smoker: 1.38 (1.26–1.52)
 – Women:
	| Never smoker: 1.00 (referent)
	| Former smoker: 1.46 (1.19–1.78)
	| Current smoker: 1.51 (1.35–1.69)
• CPS II:
 – Men:
	| Never smoker: 1.00 (referent)
	| Former smoker: 1.07 (0.95–1.20)
	| Current smoker: 1.97 (1.74–2.23)
 – Women:
	| Never smoker: 1.00 (referent)
	| Former smoker: 1.16 (1.03–1.31)
	| Current smoker: 2.19 (1.96–2.44)
• Contemporary cohorts:
 – Men:
	| Never smoker: 1.00 (referent)
	| Former smoker: 1.16 (1.07–1.25)
	| Current smoker: 1.92 (1.66–2.21)
 – Women:
	| Never smoker: 1.00 (referent)
	| Former smoker: 1.15 (1.07–1.22)
	| Current smoker: 2.10 (1.87–2.36)
—
Peters et al. 
(2013)a
• Meta-analysis of prospective cohorts
 – Current smokers: 76 cohorts
 – Former smokers: 72 cohorts
• Men and women, ≥18 years of age:
 – Current smokers: n = 3,817,289; 
39,042 cases of stroke
 – Former smokers: n = 3,534,330; 
36,449 cases of stroke
• Studies in the meta-analysis were published 
between January 1, 1996, and January 26, 2013
• United States, Europe, and Asia-Pacific region
• Outcome: fatal and nonfatal stroke
• Men:
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.08 (1.03–1.13)
 – Nonsmoker: 1.00 (referent)
 – Current smoker: 1.67 (1.49–1.88)
• Women:
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.17 (1.12–1.22)
 – Nonsmoker: 1.00 (referent)
 – Current smoker: 1.83 (1.58–2.12)
—
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Table 4.16 Continued
Study Design/population Findings: RR (95% CI) Comments
Mons et al. 
(2015)a,b
• Individual-level meta-analysis of 
19 prospective cohorts
• 66,136 men and women, ≥60 years of 
age, approximately 47% former smokers, 
excluded those with a history of stroke, 
4,052 cases of stroke
• Years of data collection: not provided
• Europe
• Mean follow-up: 1.6–14.8 years (8–13 years 
for most studies)
• Outcome: stroke
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.17 (1.07–1.26)
 – Current smoker: 1.58 (1.40–1.78)
• Years since quitting:
 – Current smoker: 1.00 (referent)
 – Former smoker:
	| <5: 0.97 (0.79–1.19)
	| 5–9: 0.98 (0.74–1.31)
	| 10–19: 0.79 (0.69–0.92)
	| ≥20: 0.67 (0.60–0.76)
—
Pan et al. (2015) • Meta-analysis of prospective cohort studies:
 – 9 studies of former smokers
 – 15 studies of current smokers
• 1,013,724 men and women >18 years of 
age with diabetes mellitus (type 1 or 2); 
33,170 cases of stroke
• Studies in the meta-analysis were published 
between 1989 and 2015
• United States, Europe, China, and other 
international collaborations
• Outcome: stroke
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.04 (0.87–1.23)
 – Current smoker: 1.54 (1.41–1.69)
—
Notes: CI = confidence interval; CPS = Cancer Prevention Study; RR = risk ratio.
aThere was some overlap between cohorts that were included in two or more of the publications in this table.
bHistorical cohorts: CPS I (1959–1965) and CPS II (1982–1988). 
cContemporary cohorts (2000–2010): National Institutes of Health–American Association of Retired Persons Diet and Health Study, CPS II Nutrition Cohort, Women’s 
Health Initiative (women only), Nurses’ Health Study (women only), and Health Professionals Follow-Up Study (men only).
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January 26, 2013, found that, compared with nonsmokers 
(who were either never smokers or former smokers), the 
risk of stroke in current smokers was 83% higher (95% CI, 
1.58–2.12) for women and 67% higher for men (95% CI, 
1.49–1.88) (Table  4.16) (Peters et  al. 2013). Compared 
with never smoking, former smoking was associated with 
a 17% higher risk of stroke among women (95% CI, 1.12–
1.22) and an 8% higher risk among men (95% CI, 1.03–
1.13). There was no evidence of a difference in the ben-
efit of smoking cessation between women and men. This 
analysis did not evaluate the relationships between risk of 
stroke and smoking duration or time since quitting.
Mons and colleagues (2015) examined individual data 
from the CHANCES study (European and North American 
cohorts) to assess the relationship between smoking ces-
sation and risk of stroke in women and men 60 years of 
age or older, and found that smoking was strongly associ-
ated with increased risk of stroke. Overall, former smokers 
had a higher risk of stroke than never smokers. Compared 
with current smokers, there was a dose-response relation-
ship, with risk decreasing among former smokers as years 
since cessation increased (Table 4.16). In this comparison, 
the adjusted HR of stroke was 0.87 for every 10 years of 
smoking cessation (95% CI, 0.84–0.91). Similarly, Thun 
and colleagues (2013a) reported that smoking cessa-
tion reduced rates of death from stroke in two older and 
five contemporary cohorts restricted to men and women 
55 years of age or older (Table 4.16), with a greater ben-
efit generally found among those who had quit at younger 
ages. Risk of stroke mortality among former smokers 
tended to decrease as time since cessation increased.
Similarly, in a large cohort study of women in 
the United Kingdom, most of the benefit from cessa-
tion occurred among those who had quit at younger 
ages (Table  4.17) (Pirie et al. 2013). Elsewhere, in the 
Nurses’ Health Study (included in the pooled analysis 
by Thun and colleagues [2013]), former smokers had an 
increased risk of cerebrovascular mortality compared with 
never smokers (adjusted HR = 1.27; 95% CI, 1.06–1.51) 
(Kenfield et al. 2008). Compared with current smokers, 
risk of cerebrovascular-disease mortality decreased among 
former smokers with increased time since cessation (from 
fewer than 5 years to 20 or more years). In contrast to 
the Nurses’ Health Study, the British Regional Heart 
Study found that former light smokers (1–19 cigarettes 
per day) did not have an increased risk of stroke when 
compared with never smokers; current heavy smokers 
(≥21 cigarettes per day), however, had an increased risk 
(Wannamethee et al. 1995). In that study, compared with 
never smokers, former smokers had 1.7 times the adjusted 
hazard of stroke (95% CI, 0.9–4.8); there was not a consis-
tent pattern of decreasing risk with increased time since 
cessation, but this pattern was seen in some categories. 
Similar findings have been reported by many other 
studies (Table  4.17). In a case-control study of young 
women (15–40 years of age) with ischemic stroke, former 
smokers did not have an increased risk of stroke com-
pared with never smokers, but this study had the poten-
tial limitation of recall bias (Bhat et al. 2008). The Strong 
Heart Study, a population-based cohort recruited from 
13 American Indian tribes/communities, found that cur-
rent and former smokers had an increased adjusted hazard 
of stroke compared with never smokers (Zhang et al. 2008). 
For this study, former smoking was defined as having 
smoked 100 or more cigarettes in one’s lifetime, having 
smoked cigarettes regularly in the past, and not smoking 
currently. In a meta-analysis of persons with diabetes mel-
litus, former smokers did not have an increased risk of 
stroke compared with never smokers (Pan et al. 2015).
In an analysis similar to the one of CHD, Lee and 
colleagues (2014) quantitatively estimated reduction in 
stroke risk following smoking cessation. In a fixed-effects 
model, they estimated that the excess risk of stroke asso-
ciated with smoking decreased by 50% after 4.78 years of 
smoking abstinence (95% CI, 2.17–10.50), which is similar 
to the time needed to realize a 50% reduction in risk that 
they had estimated for CHD. There was considerable unex-
plained heterogeneity in the results, however, making a 
definitive conclusion challenging; the random-effects esti-
mate for a 50% reduction was 3.08 years (95% CI, 1.32–
7.16). Hurley (2005), in another modeling paper, observed 
a rapid decrease in risk of stroke shortly after cessation 
(within 1–2 years), followed by a slower decline.
Stroke Subtypes
Several studies have assessed relationships between 
smoking cessation and subtypes of stroke (SAH, ICH, and 
ischemic stroke) (Kawachi et al. 1993; Kurth et al. 2003a,b; 
Feigin et al. 2005; Sturgeon et al. 2007; Song and Cho 2008; 
Pujades-Rodriguez et al. 2015; Lindbohm et al. 2016). 
In a meta-analysis of longitudinal and case-control 
studies by Feigin and colleagues (2005), former smoking 
was associated with twice the risk of SAH compared with 
never smoking (Table  4.16). Some of the studies in this 
meta-analysis assessed amount smoked or time since cessa-
tion or examined subtypes of stroke. Kurth and colleagues 
(2003a,b) assessed associations between smoking and 
hemorrhagic stroke subtypes in men (Physician’s Health 
Study) and women (Women’s Health Study) (Table 4.17). 
In both studies, former smokers and never smokers had 
no significant difference in risk of total hemorrhagic 
stroke, ICH, and SAH (Table  4.17). Earlier, Kawachi and 
colleagues (1993) reported that, in women in the Nurses’ 
Health Study, the excess risk for total strokes decreased 
within approximately 2–4  years after smoking cessation 
compared with the risk among current smokers. Those 
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Table 4.17 Observational studies on smoking cessation and cerebrovascular disease
Study Design/population Findings: RR (95% CI) Comments
Kurth (2003a)a • Prospective cohort (observational analyses 
of Women’s Health Study, a randomized 
controlled trial)
• 39,783 women, 40–84 years of age at entry, 
95% White, apparently healthy and free of 
stroke at baseline, seven hemorrhagic strokes
• 1993–2003
• United States
• Mean follow-up: 9 years
• Outcome: hemorrhagic stroke (and subtypes)
• Total hemorrhagic stroke:
 – Never smoker: 1.00 (referent)
 – Former smoker: 0.97 (0.55–1.72)
 – Current smoker (<20 cigarettes smoked 
per day): 1.93 (0.75–5.02)
 – Current smoker (≥20 cigarettes smoked 
per day): 3.29 (1.72–6.29)
• Similar patterns for subtype analysis of 
intracerebral hemorrhage and subarachnoid 
hemorrhage
—
Kurth (2003b)a • Prospective cohort (observational analyses 
of Physicians’ Health Study, a randomized 
controlled trial)
• 22,022 male physicians, 40–84 years of age at 
entry, 92% White, apparently healthy and free 
of stroke at baseline, 139 cases of stroke
• 1982–2002
• United States
• Mean follow-up: 17.8 years
• Outcome: hemorrhagic stroke (and subtypes)
• Total hemorrhagic stroke:
 – Never smoker: 1.00 (referent)
 – Former smoker: 0.76 (0.53–1.09)
 – Current smoker (<20 cigarettes smoked 
per day): 1.65 (0.61–4.50)
 – Current smoker (≥20 cigarettes smoked 
per day): 2.36 (1.38–4.02)
• Similar patterns for subtype analysis of 
intracerebral hemorrhage and subarachnoid 
hemorrhage
—
Bhat et al. 
(2008)a
• Case-control (Stroke Prevention in Young 
Women Study)
• Females, 15–40 years of age, 466 cases 
of stroke and 604 controls (random-digit 
dialing; matched by age and geographic 
region of residence)
• Recruited in 1992–1996 and 2001–2003
• United States (greater Baltimore–Washington, 
D.C., area)
• Outcome: ischemic stroke
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.0 (0.6–1.4)
 – Current smoker (cigarettes smoked per day):
	| All: 2.6 (1.9–3.6)
	| 1–10: 2.2 (1.5–3.3)
	| 11–20: 2.5 (1.6–3.8)
	| 21–39: 4.3 (1.8–10)
	| ≥40: 9.1 (3.2–26)
Potential for recall bias
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Table 4.17 Continued
Study Design/population Findings: RR (95% CI) Comments
Song and Cho 
(2008)a
• Prospective cohort
• 475,734 men, 30–58 years of age in 1990, 
6% quitters,b 16% ex-smokers,b free of 
stroke or myocardial infarction, 6,092 cases 
of stroke
• 1992–2001
• Korea
• Mean follow-up: 8.83 years
• Outcome: total stroke
• Smoking status:b
 – Current smoker:
	| Non-reducing heavy smoker 
(≥20 cigarettes per day): 1.00 (referent)
	| Moderate smoker: (10–19 cigarettes 
per day): 0.86 (0.78–0.93)
	| Light smoker (<10 cigarettes per day): 
0.84 (0.77–0.93)
 – Quitter: 0.70 (0.62–0.80)
 – Ex-smoker: 0.53 (0.48–0.58)
 – Never smoker: 0.57 (0.52–0.63)
• Similar patterns observed for stroke subtypes 
(ischemic stroke, hemorrhagic stroke, and 
subarachnoid hemorrhage):
 – Hemorrhagic stroke: lighter smokers and 
quitters did not have a significantly different 
risk vs. heavy smokers
 – Subarachnoid hemorrhage: moderate 
smokers (10–19 cigarettes per day) did 
not have a lower risk than heavy smokers 
(≥20 cigarettes per day)
—
Zhang et al. 
(2008)a
• Prospective cohort (Strong Heart Study)
• 4,507 participants from 13 American Indian 
tribes/communities, 45–74 years of age, 
41% men, no history of stroke, 306 events 
of stroke
• 1989–2004
• Arizona, North Dakota, Oklahoma, and 
South Dakota
• Mean follow-up: 13.4 years
• Outcome: stroke
• Smoking status:c
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.6 (1.14–2.25)
 – Current smoker: 2.38 (1.69–3.36)
—
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Table 4.17 Continued
Study Design/population Findings: RR (95% CI) Comments
Kim et al. 
(2012a)a
• Case-control study (multicenter)
• Participants, 30–84 years of age (mean 
age: 50.7 years); 39% men; 426 cases and 
426 age–sex-matched controls (recruited 
from siblings, friends, or neighbors of 
controls); free of stroke, dementia, or other 
neurological diseases
• Recruited in 2002–2004
• Korea
• Outcome: subarachnoid hemorrhage
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Former smoker: 1.79 (0.86–3.75)
 – Current smoker: 2.84 (1.63–4.97)
• Years since quitting (current vs. former smoker):
 – Current smoker: 1.00 (referent)
 – Former smoker
	| <5: 0.94 (0.41–2.16)
	| ≥5: 0.41 (0.17–0.97)
• Years since quitting (never vs. former smoker):
 – Never smoker: 1.00 (referent)
 – Former smoker:
	| <5: 2.71 (1.07–6.81)
	| ≥5: 1.17 (0.46–3.00)
• Smoking intensity (current vs. former smoker):
 – Current smoker: 1.00 (referent)
 – Former smoker: 
	| 1–19 cigarettes per day: 0.36 (0.13–1.01)
	| ≥20 cigarettes per day: 0.84 (0.40–1.78)
• Smoking intensity (never vs. former smoker):
 – Never smoker: 1.00 (referent)
 – Former smoker: 
	| 1–19 cigarettes per day: 0.99 (0.32–3.06)
	| ≥20 cigarettes per day: 2.34 (1.02–5.36)
Potential for bias because of recall and selection 
of controls from siblings, friends, or neighbors 
Smoking Cessation
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Table 4.17 Continued
Study Design/population Findings: RR (95% CI) Comments
Tse et al. (2012)a • Prospective cohort (extension of 7-5 China 
Stroke Prevention Project)
• 26,607 participants ≥35 years of age, 
47% men, free of stroke; former smokers 
included 7.2% of men and 1.5% of women; 
1,108 cases of stroke
• 1986–2000
• China
• Mean follow-up: 9.5 years 
• Outcomes: total stroke, ischemic stroke, 
and hemorrhagic stroke
• Men
 – Total stroke:
	| Never smoker: 1.00 (referent)
	| Former smoker: 1.35 (1.00–1.81)
	| Current smoker: 1.39 (1.15–1.67)
 – Similar patterns for ischemic and 
hemorrhagic stroke
• Women:
 – Total stroke:
	| Never smoker: 1.00 (referent)
	| Former smoker: 0.86 (0.45–1.65)
	| Current smoker: 1.34 (1.06–1.69)
 – Similar patterns for ischemic and 
hemorrhagic stroke
Limited power to detect associations because of 
few former smokers
Pirie et al. 
(2013)a
• Prospective cohort (Million Women’s Study)
• 1.2 million women; stopped smoking before 
55 years of age (at baseline); 28% former 
smokers, and free of prior cancer (other than 
nonmelanoma skin cancer), heart disease, 
stroke, and current respiratory disease 
treatment; 2,986 cases of cerebrovascular 
disease among never or current smokers
• 1996–2011
• United Kingdom
• Mean follow-up: 12 years
• Outcome: cerebrovascular disease mortality
• Age (in years) quit smoking
 – Never smoker: 1.00 (referent)
 – <25: 0.9
 – 25–34: 0.9
 – 35–44: 1.1
 – 45–54: 1.3d
Exact CIs not reported for these results; total 
cases of cerebrovascular disease not provided
Pujades-
Rodriguez et al. 
(2015)
• Prospective cohort
• 1.93 million participants; ≥30 years of age; 
49% men, predominantly White (also South 
Asian and Black), and 16.2% former smokers 
(among those with smoking data); drawn from 
CALIBER program (linked electronic health 
records); no history of CVD; and 1,558 cases 
of ischemic stroke in former smokers
• 1997–2010
• England
• Median follow-up: 6 years
• Ischemic stroke by smoking status (age-
adjusted):
 – Current smoker: 1.00 (referent)
 – Former smoker (<2 years): 0.62 (0.32–1.22)
 – Former smoker (2–9 years): 0.63 (0.45–0.87)
 – Former smoker (≥10 years): 0.51 (0.43–0.61)
• Reduced risk for longer time since cessation 
for outcomes of transient ischemic attack, 
subarachnoid hemorrhage, and intracerebral 
hemorrhage
See Table 4.17 for concerns about validity
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Table 4.17 Continued
Study Design/population Findings: RR (95% CI) Comments
Lindbohm et al. 
(2016)a
• Prospective cohort (FINRISK Survey)
• 65,521 participants, 45 years of age (median), 
48% men, no prior subarachnoid hemorrhage 
at baseline, 492 cases of subarachnoid 
hemorrhage
• 1972–2011
• Finland
• Median follow-up: 21.1 years (full cohort) 
and 14.8 years (cases)
• Outcome: subarachnoid hemorrhage
• Age quit smoking:
 – Never smoker: 1.00 (referent)
 – Recent quitter (<6 months): 1.93 (0.98–3.79)
 – Former smoker (quit for >6 months): 
1.34 (0.98–1.82)
 – Current smoker (cigarettes per day):
	| 1–10: 2.54 (1.90–3.40)
	| 11–20: 2.82 (2.14–3.70)
	| 21–30: 3.79 (2.51–5.71)
	| ≥31: 3.91 (1.97–7.75)
—
Notes: CALIBER = Clinical research using LInked Bespoke studies and Electronic health Records; CI = confidence interval; FINRISK = a large Finnish population survey 
on risk factors on chronic, noncommunicable diseases; RR = risk ratio.
aMeasure(s) of association adjusted for covariate(s).
bSmoking categories based on smoking status in 1990 exam and change from 1990 to 1992: non-reducing heavy smoker (≥20 cigarettes per day), moderate smoker 
(10–19 cigarettes per day), light smoker (<10 cigarettes per day), quitter from any smoking status, sustained ex-smoker, sustained never smoker. Results in reducers not 
shown in table.
cFormer smoking defined as having smoked ≥100 cigarettes, having smoked cigarettes regularly in the past, and not smoking currently.
dLower boundary of 95% CI >1.0 (CIs not provided).
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researchers found a similar pattern of decreasing risk as 
time since cessation increased for ischemic stroke and 
SAH (Kawachi et  al. 1993). Elsewhere, in a case-control 
study, the adjusted odds of SAH due to ruptured intra-
cranial aneurysm were higher among current cigarette 
smokers than former smokers (Kissela et al. 2002).
More recent research has produced similar findings, 
but associations have been less consistent for ICH than for 
SAH (Table  4.17). In the FINRISK study cohort (a large 
Finnish population survey on risk factors for chronic, non-
communicable diseases) (Lindbohm et  al. 2016), former 
smokers had a decreased risk of SAH compared with cur-
rent smokers. In a nationwide, multicenter, case-control 
study in Korea (Kim et  al. 2012a), former smokers who 
had quit for 5 or more years had a lower adjusted risk of 
SAH than current smokers. This study also found a pattern 
of lower risk for former smokers with lower levels of prior 
smoking intensity. The study, however, may have been 
biased because of faulty recall of smoking history and selec-
tion of controls who were siblings, friends, or neighbors. 
Earlier, in a large cohort of Korean men, in a comparison 
with heavy smokers, former smokers who quit smoking 
2  years or less before the start of follow-up had a lower 
adjusted hazard of total stroke, ischemic stroke, and SAH 
(Song and Cho 2008). A similar pattern, although not sta-
tistically significant, was observed for hemorrhagic stroke. 
Compared with heavy smokers, former smokers who had 
stopped smoking for a longer period of time had lower 
adjusted hazards of all types of strokes. Elsewhere, in  a 
pooled analysis of the ARIC study and the Cardiovascular 
Health Study, there was no clear relationship between 
smoking status and ICH (not shown in tables) (Sturgeon 
et al. 2007). 
In a hospital-based case-control study comparing 
patients with ruptured aneurysms against controls with 
unruptured aneurysms, the adjusted odds of ruptured 
cerebral aneurysm were 1.26 (95% CI, 0.98–1.61) in cur-
rent smokers versus former smokers (Can et  al. 2017). 
In that study, former smokers had higher adjusted odds 
of ruptured aneurysm than never smokers (OR  =  1.56; 
95% CI, 1.31–1.86). These findings are in line with those 
in the meta-analysis performed by Feigin and colleagues 
(2005) that compared SAH cases with healthy controls. 
In this analysis, current smokers had a two- to three-fold 
increase in risk of SAH compared with never smokers, 
and the risk was approximately twice as great in former 
smokers as it was in never smokers.
In the electronic health records-based CALIBER pro-
gram (Table 4.17), the age-adjusted hazards of transient 
ischemic attack, ischemic stroke, SAH, and ICH gradually 
decreased with increased time since smoking cessation 
(Pujades-Rodriguez et  al. 2015). After 10  years of cessa-
tion, former smokers tended to have the same hazard of 
these cerebrovascular-disease outcomes as never smokers 
(not shown in table). Note that the section on CHD in this 
chapter discussed concerns about the validity of this study.
In a multicenter, population-based prospective 
cohort study in China (Table 4.17), men who were former 
smokers had a higher risk of stroke than those who were 
never smokers (HR = 1.35; 95% CI, 1.00–1.81) (Tse et al. 
2012). Among women, there was no significant difference 
in this comparison (HR = 0.86; 95% CI, 0.45–1.65), but 
there were only 11  cases of stroke. Further, power was 
limited because of the low prevalence of former smokers.
Prognosis of Cerebrovascular Disease
Among four randomized controlled trials that 
assessed the rate of smoking cessation following cerebro-
vascular disease with follow-ups ranging from 6 months to 
3.5 years, the overall cessation rate was 23.9% (42 of 176) 
among those who received a smoking cessation interven-
tion and 20.8% (37 of 178) for those who did not receive 
one (Edjoc et  al. 2012). Elsewhere, in a single study of 
110 patients with acute stroke, 40% had stopped smoking 
1  year after hospital admission; the best predictors of 
cessation were insular damage and a prestroke inten-
tion to stop (Suner-Soler et al. 2012). Finally, in a study 
of 198 patients, 21.7% gave up smoking within 6 months 
after their first stroke (Bak et al. 2002).
Among persons with cerebrovascular disease, find-
ings from several studies suggest that former cigarette 
smokers have a lower risk of morbidity or mortality com-
pared with those who continue to smoke after devel-
oping cerebrovascular disease. For example, in a litera-
ture review, Straus and colleagues (2002) estimated that 
smoking cessation would reduce the risk of a new stroke 
by 33% (95% CI, 29–38%) in survivors of stroke.
In a British study that followed 308 men and women 
with a history of stroke for an average of 7.5 years, cur-
rent smokers had 2.27 times the adjusted risk of mortality 
(95% CI, 1.12–4.57) of never smokers, and former smokers 
had 1.46 times the risk (95% CI, 0.87–2.43) (Myint et al. 
2006). In an Australian cohort of 1,589 cases of first-ever 
and recurrent stroke, among those who survived 28 days 
after the index event, the adjusted hazard of death or a 
nonfatal vascular event was higher for current smokers 
than former smokers (HR = 1.23; 95% CI, 1.00–1.50) (Kim 
et  al. 2012b). In addition, former smokers had a higher 
adjusted hazard for such an outcome than never smokers 
(HR  =  1.18; 95%  CI, 1.01–1.39). Using data from the 
Registry of the Canadian Stroke Network, Edjoc and col-
leagues (2013) reported that, among patients with stroke, 
former smoking was associated with a reduced risk of the 
presenting stroke’s severity, of mortality at 30 days, and of 
a prolonged stay in the hospital when compared with cur-
rent smoking; the results varied by stroke subtype.
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Summary of the Evidence
Building on evidence reviewed in previous Surgeon 
General’s reports, the additional studies reviewed in this 
report further strengthen the evidence that smoking 
cessation reduces the risk of stroke morbidity and mor-
tality and that the risk of such outcomes decreases with 
increased time since cessation.
Smoking Cessation 
and Atrial Fibrillation
Atrial fibrillation (AF) is a condition in which the atria 
(upper chambers of the heart) beat irregularly. Earlier esti-
mates of the prevalence of AF in the United States ranged 
from approximately 2.7  to 6.1 million persons (Go et al. 
2001; Miyasaka et al. 2006), but it is estimated that preva-
lence will increase to approximately 12.1 million in 2030 
(Colilla et al. 2013). AF is associated with an increased risk 
of mortality, including mortality attributable to CVD and 
non-CVD causes (Benjamin et al. 2017).
Zhu and colleagues (2016) found in a meta-analysis of 
16 prospective studies (286,217 patients and 11,878 cases 
of AF) that cigarette smoking was associated with a higher 
risk of AF (RR  =  1.23; 95%  CI, 1.08–1.39). Findings on 
AF related to current, former, and never smokers were 
available from 8 of the 16  studies. Former smokers had 
1.16  times the risk of AF (95%  CI, 1.00–1.36), and cur-
rent smokers had 1.39 times the risk (95% CI, 1.11–1.36) 
compared with never smokers. Time since cessation was 
not assessed in any of the studies. Among persons with AF, 
smoking has also been associated with an increased risk 
of adverse events (Albertsen et al. 2014; Kwon et al. 2016). 
In the cohorts of the ARIC study and the Cardiovascular 
Health Study, current, but not former, smoking was asso-
ciated with an increased risk of CVD deaths or ischemic 
stroke among persons with AF (Kwon et al. 2016). In the 
Danish Diet and Cancer study, former smoking was asso-
ciated with an increased risk of thromboembolism or 
death among women with AF but not among men with AF 
(Albertsen et al. 2014).
Summary of the Evidence
A meta-analysis found that current and former 
cigarette smoking is associated with a higher risk of AF 
than never smoking, and the pooled estimate for former 
smokers was lower than that for current smokers. Findings 
from other studies regarding AF-related adverse events 
are mixed. No additional evidence is currently available 
on how the risk of AF changes with smoking cessation or 
with time since cessation.
Smoking Cessation and 
Sudden Cardiac Death
Cardiac arrest is the cessation of cardiac mechanical 
activity, as confirmed by the absence of signs of circulation 
(Jacobs et al. 2004). Although it is a leading cause of death, 
the absence of nationwide surveillance standards makes it 
difficult to understand the epidemiology of cardiac arrest 
in the United States (Benjamin et al. 2017). Sudden car-
diac death (SCD) is an unexpected death without an 
obvious noncardiac cause that occurs, if witnessed, within 
1  hour of symptom onset or, if not witnessed, within 
24  hours of the person’s last being observed in normal 
health, although it is challenging to apply these criteria in 
practice (Benjamin et al. 2017). SCD can be attributable to 
cardiac or noncardiac causes; it is usually presumed to be 
attributable to cardiac causes unless another explanation 
can be identified. Based on the Resuscitation Outcomes 
Consortium registry of all emergency management system 
(EMS)-attended calls in 2015 for out-of-hospital cardiac 
arrests in eight U.S. and three Canadian regions, the inci-
dence of out-of-hospital cardiac arrests assessed by EMS 
was estimated to be 110.8 persons per 100,000 (95% CI, 
108.9–112.6) (Benjamin et al. 2019). Based on this registry, 
the rate of survival to hospital discharge for EMS-treated 
out-of-hospital cardiac arrest was 11.4% (95%  CI, 10.4–
12.4%) in adults, and survival after bystander-witnessed 
ventricular fibrillation was 37.4% (95%  CI, 32.7–42.0%) 
for patients of any age (Benjamin et al. 2017).
The 2014 Surgeon General’s report reviewed epi-
demiologic evidence from several studies showing that 
cigarette smoking is associated with SCD of all types. 
During 30 years of follow-up of 101,018 women without 
known CHD, stroke, or cancer at the 1980 baseline in 
the Nurses’ Health Study, there were 351  SCD events, 
of which 148  occurred in former smokers (Sandhu 
et  al. 2012). Overall, compared with never smokers, 
the adjusted hazard of SCD was higher among current 
smokers (HR  =  2.44; 95%  CI, 1.80–3.31) and former 
smokers (HR = 1.40; 95% CI, 1.10–1.79). Compared with 
current cigarette smokers, former smokers had a lower 
risk of SCD (HR = 0.58; 95% CI, 0.43–0.77). The risk of 
SCD decreased linearly over time after quitting smoking 
(p for trend <0.0001). After 15 years of cessation, the risk 
was significantly lower in former smokers than in current 
smokers; after 20 years of cessation, the risk was similar 
in former smokers and never smokers. In analyses strati-
fied by CHD status, women with CHD who quit smoking 
tended to have a higher risk of SCD than never smokers, 
while increased risk of SCD dropped within 5 years and did 
not decline further among those who quit and did not have 
CHD (p-value interaction = 0.15). Among women who quit, 
The Health Benefits of Smoking Cessation  251
Smoking Cessation
those without CHD had a more rapid reduction in SCD 
risk than those with CHD (p-value interaction = 0.03). 
Similar findings have been observed among popula-
tions with known CHD (Vlietstra et al. 1986; Peters et al. 
1995; Goldenberg et al. 2003) or with prior cardiac arrest 
(Hallstrom et al. 1986). For example, among 3,122 patients 
with previous MI or stable angina, smoking was associ-
ated with an increased risk of SCD, and those who quit 
smoking had a decreased risk of SCD (Goldenberg et al. 
2003). Compared with never smokers (43 cases of SCD), 
current smokers had 2.47  times (95%  CI, 1.46–4.49, 
30 cases) the adjusted risk of SCD, while former smokers 
did not have an elevated adjusted risk (HR = 1.06; 95% CI, 
0.70–1.62, 83 cases). 
In a study of data from the CALIBER program in 
England, which uses electronic health records, there was 
no pattern of decreased age-adjusted risk of cardiac arrest 
or SCD with increasing time since smoking cessation 
(not shown) (Pujades-Rodriguez et al. 2015). In this study, 
however, current smoking also was not associated with 
increased hazard of this outcome compared with never 
smoking; the section on CHD discusses concerns about 
the validity of this study. 
Summary of the Evidence
Several studies show that smoking cessation is asso-
ciated with a reduced risk of SCD. The majority of these 
studies were carried out among patients with prior CHD. 
A large study in women found a similar association; how-
ever, among those with and without CHD, results show 
a quicker benefit from smoking cessation among those 
without known CHD. In this study, the risk of SCD 
returned to that of never smokers after approximately 
20 years of cessation.
Smoking Cessation 
and Heart Failure
Heart failure results from the inability of the heart 
to pump sufficient blood and deliver enough oxygen to 
support other organs in the body. An estimated 6.5 mil-
lion U.S. adults have heart failure (Benjamin et al. 2017); 
in 2014, heart failure was mentioned on the death certifi-
cate for one in every eight deaths (Benjamin et al. 2017; 
National Center for Health Statistics 2017). Approximately 
half of those with heart failure die within 5 years of diag-
nosis (Roger et al. 2004; Benjamin et al. 2017). In 2012, 
heart failure cost the United States an estimated $30.7 bil-
lion in direct and indirect costs; this figure is projected to 
increase to $69.8 billion by 2030 (Heidenreich et al. 2013). 
The prevalence of heart failure is projected to increase to 
approximately 46% by 2030; thus, more than 8  million 
persons 18 years of age or older are expected to have heart 
failure in that year (Heidenreich et al. 2013).
The 1990 Surgeon General’s report did not address 
smoking cessation and risk for heart failure. The 2004 
Surgeon General’s report suggested that CHD caused by 
smoking may contribute to heart failure and that this 
contribution is likely mediated by CHD (USDHHS 2004). 
Regardless, the pathophysiologic mechanisms underlying 
the development of heart failure overlap with the effects of 
cigarette smoking on the cardiovascular system (Suskin 
et al. 2001). This section briefly reviews the literature on 
smoking cessation and the development and prognosis of 
heart failure.
Ahmed and colleagues (2015) reported on the rela-
tionships in the Cardiovascular Health Study between 
prolonged smoking cessation (>15 years) and risk of heart 
failure and death among 4,482 adults 65 years of age or 
older who were free of heart failure at baseline. During 
the 13-year follow-up, former smokers had risks for inci-
dent heart failure (adjusted HR = 0.99; 95% CI, 0.85–1.16) 
and all-cause mortality (adjusted HR  =  1.08; 95%  CI, 
0.96–1.20) that were similar to those of never smokers 
(Table 4.18). In another cohort study of older adults, both 
current and former smokers had elevated risk of heart 
failure compared with the risk among never smokers 
(Table 4.18) (Gopal et al. 2012). 
In the Cardiovascular Health Study, compared 
with never smokers, former heavy smokers (≥32  pack-
years) had a higher risk of heart failure (multivariable-
adjusted HR  =  1.31; 95%  CI, 1.03–1.65) and mortality 
(multivariable-adjusted HR = 1.26; 95% CI, 1.06–1.49 [not 
shown in table]) (Ahmed et al. 2015). Compared with cur-
rent smokers, however, former heavy smokers had a lower 
risk of mortality (age-, sex-, and race-adjusted HR = 0.64; 
95% CI, 0.53–0.77) but not of heart failure (age-, sex-, and 
race-adjusted HR = 0.97; 95% CI, 0.74–1.28). Overall, this 
study found that after prolonged smoking cessation the 
risk of heart failure was similar between former smokers 
and never smokers, but not for former heavy smokers with 
cumulative consumption of 32 or more pack-years.
In the CALIBER program in England, the age-
adjusted HR for heart failure decreased with increased 
time since smoking cessation (Table  4.18); 2  years after 
cessation, the age-adjusted hazard of heart failure was 
not elevated compared with never smokers (not shown 
in table) (Pujades-Rodriguez et  al. 2015). In a study of 
267,010 Australian men and women 45 years of age or older 
with self-reported smoking status that had been linked to 
administrative hospital data, former smokers and cur-
rent smokers had a higher adjusted hazard of heart failure 
hospitalization compared with never smokers (Tran et al. 
2015). Risks of hospitalization for heart failure decreased 
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Table 4.18 Observational studies on smoking cessation and heart failure (incident heart failure and heart failure-related complications)
Study Design/population Findings: RR (95% CI) Comments
Suskin et al. 
(2001)a
• Prospective cohorts (observational analyses 
of two multicenter trials included in the Study 
of Left Ventricular Dysfunction Prevention 
and Intervention) 
• 6,704 participants with left ventricular 
ejection fraction <35% but no history of overt 
congestive heart failure, mean 60 years of 
age, 86% men, predominantly White but also 
African American and other races/ethnicities, 
55% former smokers
• Years of data collection: not provided
• Belgium, Canada, and United States
• Mean follow-up: 41 months (treatment trial) 
and 37 months (prevention trial)
• Main outcome: total mortality
• Total mortality:
 – Never smoker: 1.00 (referent)
 – Former smoker (quit ≤2 years): 1.10 
(0.94–1.29)
 – Former smoker (quit >2 years): 0.95 
(0.82–1.09)
 – Current smoker: 1.40 (1.21–1.63)
• Similar results for mortality from congestive 
heart failure, hospitalization for congestive 
heart failure, hospitalization for MI, and 
mortality or hospitalization because of 
congestive heart failure or MI
—
Shah et al. 
(2010)a
• Prospective cohort (observational analyses of 
Survival and Ventricular Enlargement trial)
• 924 patients with left ventricular dysfunction 
3–16 days after MI, restricted to smokers at 
baseline who survived to 6 months without 
interim event, 82% men, 54 years of age 
(mean), 63% quit smoking, 85 deaths
• Years of data collection: not provided
• United States
• Median follow-up: 42 months
• Main outcome: death
• Total mortality:
 – Current smoker: 1.00 (referent)
 – Former smoker (months of consistent 
cessationb):
	| 6: 0.57 (0.36–0.91)
	| 12: 0.58 (0.33–0.99)
	| 16: 0.60 (0.34–1.07)
	| 24: 0.53 (0.25–1.08)
• Similar results for outcomes of death or 
recurrent MI and death or hospitalization 
for heart failure
• Similar trend of decreased risk at 6 months 
of cessation for endpoint of death or recurrent 
MI, hospitalization for heart failure, or stroke
—
Smoking Cessation
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Table 4.18 Continued
Study Design/population Findings: RR (95% CI) Comments
Gopal et al. 
(2012)a
• Prospective cohort (Health, Aging, and Body 
Composition Study)
• 2,125 participants, 70–79 years of age (mean: 
73.6 years), 30% men, Whites and African 
Americans, 35% former smokers, all Medicare 
beneficiaries and without prevalent heart 
failure, 231 cases of heart failure
• Recruited in 1997–1998
• United States
• Median follow-up: 9.4 years
• Outcome: heart failure
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Former smoker (overall): 1.31 (0.98–1.75)
 – Current smoker (overall): 1.73 (1.15–2.59)
• Smoking intensity (number of pack-yearsc):
 – Never smoker: 1.00 (referent)
 – Former smoker:
	| 1–11: 1.05 (0.64–1.72)
	| 12–35: 1.23 (0.82–1.83)
	| >35: 1.64 (1.11–2.42)
 – Current smoker:
	| 1–11: 1.92 (0.76–4.88)
	| 12–35: 1.67 (0.89–3.15)
	| >35: 1.71 (0.97–3.01)
—
Ahmed et al. 
(2015)a
• Prospective cohort (Cardiovascular 
Health Study)
• 4,482 participants, ≥65 years of age, 40% men, 
multiple races/ethnicities (Whites, African 
Americans, others), 29% former smokers who 
quit >15 years earlier without prevalent heart 
failure, 1,204 cases of heart failure
• 1989–1993 (baseline)
• United States (four counties)
• Follow-up: 13 years
• Main outcome: heart failure
• Former smokers restricted to those who had 
quit >15 years
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Former smoker (overall): 1.07 (0.91–1.25)
 – Current smoker (overall): 1.19 (0.99–1.44)
• Smoking intensity (number of pack-yearsc):
 – Never smoker: 1.00 (referent)
 – Former smoker:
	| <8: 1.06 (0.83–1.36)
	| 8–15: 0.86 (0.62–1.20)
	| 16–31: 0.99 (0.77–1.28)
	| ≥32: 1.31 (1.03–1.65)
• Similar results for outcome of mortality, 
but stronger association for current smokers:
 – 2.17 (1.91–2.47)
—
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Table 4.18 Continued
Study Design/population Findings: RR (95% CI) Comments
Pujades-
Rodriguez et al. 
(2015)a
• Prospective cohort
• 1.93 million participants; ≥30 years of age; 
49% men, predominantly White (also South 
Asian and Black), and 16.2% former smokers 
(among those with smoking data); drawn from 
CALIBER program (linked electronic health 
records); no history of CVD; 4,097 cases of 
heart failure in former smokers
• 1997–2010
• England
• Median follow-up: 6 years
• Heart failure by smoking status (age-adjusted):
 – Current smoker: 1.00 (referent)
 – Former smoker (years since quitting):
	| <2: 0.87 (0.60–1.26)
	| 2–9: 0.72 (0.52–0.99)
	| >10: 0.60 (0.44–0.81)
See Table 4.17 for concerns about validity
Notes: CALIBER = Clinical research using LInked Bespoke studies and Electronic health Records; CI = confidence interval; CVD = cardiovascular disease; MI = myocardial 
infarction; RR = risk ratio.
aMeasure(s) of association adjusted for covariate(s).
bDuration of consistent smoking cessation after MI, compared with continuation of smoking, among those who were stable baseline smokers and survived up to that time 
without recurrent MI or hospitalization for heart failure.
cPack-years = number of packs of cigarettes smoked per day multiplied by the number of years smoked cigarettes.
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with increased time since quitting; the decrease was sub-
stantially different between current and former smokers 
after 25 or more years of cessation.
In their analyses of data from 4,850 elderly partici-
pants free of overt CHD, heart failure, and significant val-
vular disease in the ARIC study, Nadruz and colleagues 
(2016) found that, after adjusting for potential con-
founders, current smokers had a greater left-ventricular 
mass index and left-ventricular mass/volume ratio, a 
higher prevalence of left-ventricular hypertrophy, and 
worse diastolic function than never smokers. In contrast, 
former smokers showed echocardiographic features sim-
ilar to those of never smokers.
Other researchers have assessed the relationship 
between smoking cessation and elevated risk of compli-
cations related to heart failure and found associations 
between cessation and decreased risk of hospitalization for 
or mortality from heart failure and other adverse events. 
For example, the prevention and intervention trials of the 
Study of Left Ventricular Dysfunction studied 6,704 per-
sons with a left ventricular ejection fraction <0.35 with or 
without symptoms of congestive heart failure. Compared 
with never smokers (Table 4.18), former smokers had no 
difference in adjusted risk of overall mortality, mortality 
from congestive heart failure, hospitalization for conges-
tive heart failure, hospitalization for MI, or risk of mor-
tality or hospitalization due to congestive heart failure or 
MI (Suskin et al. 2001). Risks were similar in those who 
had stopped smoking for 2 or fewer years and those who 
had quit more than 2 years earlier. In contrast, continued 
smoking was associated with higher risk of overall mor-
tality, hospitalization for congestive heart failure, hos-
pitalization for MI, and mortality or hospitalization due 
to congestive heart failure or MI. Suskin and colleagues 
(2001) concluded that smoking cessation was associated 
with a rapid decrease in risk of morbidity and mortality 
among these participants. The reduction in mortality was 
similar in magnitude to the decrease from (a) the appro-
priate use of an angiotensin-converting enzyme inhibitor 
or beta-adrenergic blocking agents, or (b) all commonly 
used treatments of spironolactone among patients with 
reduced left ventricular systolic function and symptoms 
of congestive heart failure.
In the Survival and Ventricular Enlargement trial 
involving patients with left ventricular dysfunction after 
MI, 924  participants were stable smokers at baseline. 
Among those who survived to 6 months without a recur-
rent event, those who had quit for 6 months had a lower risk 
of death than those who continued to smoke (Table 4.18) 
(Shah et al. 2010). Similar patterns were observed during 
follow-up at 12, 16, and 24 months and for composite end-
points (death or hospitalization for heart failure; death or 
recurrent MI). At 6 months of cessation after an MI, there 
was a similar trend toward lower risk for the combined 
endpoint of death, MI, hospitalization for heart failure, or 
stroke (adjusted HR = 0.72; 95% CI, 0.52–1.01). Earlier, 
in a cohort of 4,024  patients receiving dialysis, the rate 
of new-onset congestive heart failure (based on hospital 
claims data) was similar in former smokers and never 
smokers (Foley et  al. 2003). These findings indicate the 
importance of smoking cessation among persons who are 
at elevated risk for complications related to heart failure 
(Suskin et al. 2001; Shah et al. 2010).
Summary of the Evidence
There is limited evidence that smoking cessation is 
associated with a reduced risk of incident heart failure and 
adverse events related to heart failure. 
Smoking Cessation and 
Venous Thromboembolism
The term “venous thromboembolism” (VTE) refers 
to a blood clot that forms in a vein; an embolism occurs 
when the clot breaks free. The incidence of VTE in the 
United States has been estimated to be approximately 
300,000 to 600,000 per year (Silverstein et al. 1998; White 
et al. 2005; Spencer et al. 2006), but these estimates are 
based on older data (Benjamin et al. 2017). A systematic 
review and meta-analysis (covering 1980–2013) found 
that, compared with never smoking, current smoking 
(RR  =  1.23; 95%  CI, 1.14–1.33; 15  studies) and former 
smoking (RR = 1.10; 95% CI, 1.03–1.17; 14 studies) are 
associated with an increased risk of incident VTE (Cheng 
et  al. 2013). This study did not evaluate the association 
between time since smoking cessation and risk of VTE. 
Summary of the Evidence
A meta-analysis showed that current and former cig-
arette smokers have an increased risk of VTE when com-
pared with never smokers, and the RR for former smokers 
is lower than that for current smokers. There is no evi-
dence available on how the risk of VTE changes with time 
since cessation. 
Smoking Cessation and Lower-
Extremity Peripheral Artery Disease
Peripheral artery disease (PAD) results from the nar-
rowing (usually due to atherosclerosis) of the peripheral 
arteries leading to the legs, abdominal organs, arms, and 
head. This disorder most commonly affects the arteries 
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of the legs. The presence of PAD of the lower limbs can 
be detected by measuring the ABI, which is the ratio of 
blood pressure in the lower leg to that in the upper arm 
(as discussed in the earlier section on smoking cessa-
tion and subclinical atherosclerosis). Importantly, a low 
ABI does not indicate which blood vessels are narrowed 
or blocked. Approximately 8.5 million people in the U.S. 
have PAD (CDC 2016a). One symptom of PAD is inter-
mittent claudication, or leg cramping induced by exer-
cise (also known as classic claudication). An estimated 
10% of persons with PAD have intermittent claudication, 
approximately 40% have no leg pain, and 50% have other 
leg symptoms (Hirsch et al. 2001; Benjamin et al. 2017). 
PAD leads to impaired function and reduces quality of 
life. Further, PAD is a systemic atherosclerotic disease, 
and is therefore a risk factor for poor clinical outcomes, 
including CHD and stroke (Heald et al. 2006; Benjamin 
et al. 2017).
The 1983 Surgeon General’s report concluded that 
cigarette smoking is the most powerful risk factor pre-
disposing men and women to atherosclerotic peripheral 
vascular disease (USDHHS 1983). According to the 2004 
Surgeon General’s report, the evidence is sufficient to infer 
a causal relationship between smoking and atheroscle-
rosis (USDHHS 2004), as discussed earlier in this section. 
The 2004 Surgeon General’s report concluded that “the 
new findings on subclinical disease indicate the potential 
for preventing more advanced and clinically symptomatic 
disease through quitting smoking and maintained cessa-
tion” (USDHHS 2004, p. 379).
The 1990 Surgeon General’s report discussed 
results from two small studies comparing the risk of 
PAD between smokers and former smokers, finding that 
former smokers had a 50–58% lower risk of PAD than cur-
rent smokers (Hughson et al. 1978; Jacobsen et al. 1984). 
Several studies of persons with PAD found that those who 
quit smoking had improved performance and overall sur-
vival. Since 1990, the literature on this topic has grown 
substantially, as reviewed in the next two sections. 
A meta-analysis conducted by Lu and colleagues 
(2014) quantified the association between active smoking 
and PAD. This meta-analysis, which was restricted to 
studies examining the risk of developing PAD, defined PAD 
on the basis of an ABI ≤0.90, a claudication questionnaire, 
or peripheral angiography. Although the risk of PAD was 
lower for former smokers than for current smokers, the 
risk of PAD in both groups was still significantly higher 
than that for never smokers. Compared with nonsmokers, 
current smokers had 2.71 times the pooled odds of PAD 
(95% CI, 2.28–3.21). As shown in Figure 4.3, there were 
40 estimates in this meta-analysis (Lu et al. 2014) of the 
risk of PAD gathered from 29 studies of former smokers 
compared with never smokers. Of the 40  estimates, 
29 (72.5%) were statistically significant, and the pooled OR 
comparing former with never smokers was 1.67 (95% CI, 
1.54–1.81). This estimate included studies of the general 
population, as well as studies of persons with underlying 
diseases, such as diabetes mellitus.
Lu and colleagues (2014) identified two studies 
(Törnwall et al. 2000; Cui et al. 2006) that compared risk 
of PAD between former and current smokers and found a 
reduced risk of PAD among former smokers. In the Finnish 
Alpha-Tocopherol, Beta-Carotene Cancer Prevention 
Study, among a cohort of 26,872 male smokers who were 
50–69 years of age at entry, the HR of PAD during a median 
follow-up of 4 years in former smokers was 0.86 (95% CI, 
0.75–0.99) compared with the HR among current smokers 
(Törnwall et al. 2000). As this study did not include never 
smokers, its results were not included in the pooled esti-
mate reported by Lu and colleagues (2014). In the report 
by Cui and colleagues (2006) on a cross-sectional study 
of 1,215 elderly Japanese men, those authors found that, 
compared with current smokers, there was no significant 
difference in the odds of PAD (ABI <0.90) after less than 
10 years of smoking cessation (OR = 0.8; 95% CI, 0.4–1.8) 
or after 10–19 years of cessation (OR = 1.0; 95% CI, 0.4–
2.2) (Cui et al. 2006). The risk of PAD was reduced, how-
ever, among those who had quit smoking for 20 or more 
years (OR = 0.3; 95% CI, 0.1–0.9).
The meta-analysis by Lu and colleagues (2014) 
focused on publications that reported ORs or RRs, and it 
treated RRs as ORs. Several other key articles on this topic 
that were not included in the meta-analysis—because of a 
restriction or publication after the literature search or for 
another reason—are described below.
Fowkes and colleagues (1992) reported that lifetime 
cumulative cigarette smoking was strongly related to risk 
of PAD, with additional risks among current and former 
smokers abstinent less than 5 years. Elsewhere, in a cohort 
of Icelandic men, when compared with never smoking, 
former smoking was associated with having 3.5 times the 
odds of prevalent intermittent claudication and 2.3 times 
the odds of incident intermittent claudication during 
follow-up from 1968 to 1986; neither of these ORs was 
significant (Ingolfsson et al. 1994). Among smokers, those 
who smoked 15 or more cigarettes per day had a higher 
risk of incident intermittent claudication. In a later study, 
Foley and colleagues (2003) reported that in a cohort of 
4,024 patients receiving dialysis, former smokers had an 
adjusted rate of peripheral vascular disease similar to that 
of lifelong nonsmokers. In a prospective cohort study 
of 39,825  initially healthy women from the Women’s 
Health Study, Conen and colleagues (2011) reported that 
smoking cessation substantially reduced the risk of symp-
tomatic PAD, but former smokers still had an excess risk 
of PAD compared with never smokers. Compared with 
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Figure 4.3  Comparison of risk of peripheral arterial disease between former and never smokers
Study Estimate (95% CI) Weight (%)a
General population    
Skalkidis et al. 1989 (MF) 2.30 (0.40–15.20) 0.19
Bowlin et al. 1994 (M) 1.43 (1.05–1.95) 3.37
Leng et al. 1995 (MF) 2.15 (1.21–3.82) 1.53
Ögren et al. 1996 (M) 3.10 (1.40–6.90) 0.90
Hooi et al. 1998 (asymptomatic) (MF) 1.60 (1.10–2.40) 2.62
Hooi et al. 1998 (symptomatic) (MF) 2.70 (1.40–5.40) 1.19
Meijer et al. 2000 (MF) 1.15 (0.75–1.78) 2.30
Passos et al. 2001 (MF) 3.10 (1.20–8.50) 0.62
Fowler et al. 2002a (M) 2.10 (1.60–2.60) 4.16
Jensen et al. 2005 (F) 1.70 (1.10–2.70) 2.19
Jensen et al. 2005 (M) 1.70 (0.90–3.20) 1.31
Zheng et al. 2005 (African M) 6.60 (2.00–21.50) 0.44
Zheng et al. 2005 (African F) 2.30 (1.50–3.50) 2.36
Zheng et al. 2005 (White M) 10.40 (3.80–28.30) 0.59
Zheng et al. 2005 (White F) 1.90 (1.40–2.60) 3.37
Kennedy et al. 2005 (MF) 1.32 (0.94–1.87) 3.02
He et al. 2006 (stop 2–9 years) (M) 1.74 (1.01–2.98) 1.68
He et al. 2006 (stop ≥10 years) (M) 1.18 (0.68–2.03) 1.65
He et al. 2006 (stop 2–9 years) (F) 1.27 (0.59–2.73) 0.96
He et al. 2006 (stop ≥10 years) (F) 0.93 (0.37–2.31) 0.70
Woo et al. 2006 (MF) 2.00 (1.18–3.38) 1.75
Bendermacher et al. 2007 (MF) 1.40 (1.20–1.60) 5.48
Agarwal et al. 2009 (MF) 1.55 (1.16–2.08) 3.57
Cacoub et al. 2009 (>1 year) (MF) 1.38 (1.15–1.66) 4.95
Cacoub et al. 2009 (≤1 year) (MF) 2.48 (1.79–3.42) 3.22
Kröger et al. 2009 (MF) 1.99 (1.44–2.75) 3.23
Alzamora et al. 2010 (MF) 2.19 (1.34–3.58) 1.93
Lakshmanan et al. 2010 (M) 2.03 (1.39–2.98) 2.69
St-Pierre et al. 2010 (M) 1.14 (0.59–2.21) 1.23
Aboyans et al. 2011 (MF) 1.39 (0.97–1.97) 2.93
Lee et al. 2011 (M) 2.31 (1.20–4.42) 1.26
Subtotal (I-squared = 52.3%, p = 0.000) 1.76 (1.58–1.97) 67.40
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Study Estimate (95% CI) Weight (%)a
Disease study population    
Adler et al. 2002 (DM) (MF) 0.80 (0.37–1.72) 0.95
O'Hare et al. 2002 (hemodialysis) (wave 3, 4) (MF) 1.27 (1.13–1.42) 5.85
O'Hare et al. 2002 (hemodialysis) (wave 1) (MF) 1.55 (1.31–1.83) 5.17
Rajagopalan et al. 2006 (<1 year) (hemodialysis) (MF) 1.68 (1.41–2.01) 5.03
Rajagopalan et al. 2006 (>1 year) (hemodialysis) (MF) 1.51 (1.38–1.65) 6.13
Norman et al. 2006 (DM) (MF) 1.16 (0.62–2.15) 1.36
Li et al. 2007 (DM) (MF) 1.79 (1.30–2.46) 3.27
Luo et al. 2007 (HT) (MF) 1.79 (1.40–2.29) 4.10
Tavintharan et al. 2009 (DM) (MF) 2.55 (1.05–6.20) 0.74
Subtotal (I-squared = 54.0%, p = 0.026) 1.52 (1.36–1.69) 32.60
Overall (I-squared = 54.7%, p = 0.000) 1.67 (1.54–1.81) 100.00
Source: Lu et al. (2014), with permission.
Note: CI = confidence interval; DM = diabetes mellitus; F = females; HT = hypertension; M = males; MF = males and females.
aWeights are from random effects analysis.
Figure 4.3 Continued
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current smokers, the adjusted HR of symptomatic PAD 
among former smokers was 0.39 (95% CI, 0.24–0.66) for 
less than 10 years of cessation, 0.28 (95% CI, 0.17–0.46) 
for 10–20 years of cessation, and 0.16 (0.10–0.26) for more 
than 20 years of cessation. Compared with never smokers, 
the adjusted HR of symptomatic PAD among former 
smokers was 3.16 (95% CI, 2.04–4.89).
In the CALIBER program, the age-adjusted HR of 
PAD decreased substantially with increased time since 
smoking cessation (Pujades-Rodriguez et  al. 2015). 
Compared with current smokers, former smokers who had 
quit for more than 10 years had an age-adjusted HR for 
PAD of 0.27 (95% CI, 0.22–0.33). Compared with women 
who had never smoked, however, the age-adjusted hazard 
of PAD was still elevated significantly in women who had 
quit smoking for 10 or more years (HR = 1.36; 95% CI, 
1.11–1.67). 
Smoking has also been associated with other forms 
of PAD, such as Raynaud’s disease or syndrome, which is 
a form of functional PAD that begins with severe vasocon-
striction followed by dilatation (widening of the blood ves-
sels) not due to blockage. Various studies have associated 
current smoking with Raynaud’s, with a stronger associa-
tion evident in men than in women. In the Framingham 
Offspring cohort, former smokers did not have an ele-
vated risk of Raynaud’s compared with never smokers 
(Brand et al. 1997; Suter et al. 2007). Smoking cessation 
is recommended for persons with Raynaud’s, because the 
vasoconstrictive substances in cigarettes likely make the 
condition worse (Pope 2007). The IARC’s (2007) review 
on smoking cessation found consistent evidence from a 
number of small case series that smoking cessation was 
associated with improved thromboangiitis obliterans 
(Buerger’s disease), which is an inflammatory, obliterative 
disease that affects small- and medium-sized arteries, is 
unrelated to atherosclerosis, and is specific to smokers. 
Later, Klein-Weigel and colleagues (2016) concluded that 
smoking cessation is the most important intervention 
among patients with Buerger’s disease.
Prognosis of PAD
In addition to its association with the onset of PAD, 
smoking or the continuation of smoking after a PAD diag-
nosis is a major risk factor for the progression of PAD and 
PAD-related outcomes (Jonason and Ringqvist 1985; Ameli 
et al. 1989; Wiseman et al. 1989; Selvarajah et al. 2014). 
Correspondingly, current clinical guidelines recommend 
smoking cessation among patients with PAD (Olin et al. 
2010; Rooke et al. 2011; Smith Jr et al. 2011; Tendera et al. 
2011; Gerhard-Herman et al. 2017).
A systematic review that assessed the effects of clin-
ical interventions for persons with chronic PAD (based 
on literature searched through 2005) concluded that 
smoking cessation combined with exercise may increase 
walking distance (Cassar and Bachoo 2006). This con-
clusion was based on a randomized controlled study 
that assessed the impact of a “stop smoking and keep 
walking” intervention compared with usual care among 
882 Australian men 65–79 years of age who had early PAD 
(Fowler et al. 2002b). Specifically, the intervention com-
bined a community-based intervention of smoking cessa-
tion (where applicable) with increased physical activity. 
At 12 months, a higher proportion of men in the interven-
tion group had an improved maximum walking distance 
compared with those in the usual-care group (23%  vs. 
15%, p  =  0.008). In addition, compared with the con-
trol group, more men in the intervention group reported 
walking more than three times per week for recreation 
(34% vs. 25%, p = 0.01). Also, although the finding was 
not statistically significant, more men in the intervention 
group had stopped smoking (12% vs. 8%, p = 0.43).
A systematic review of smoking cessation and prog-
nosis for PAD based on a 1996 search (Girolami et  al. 
1999) summarized some of the findings reported in the 
1990 Surgeon General’s report (USDHHS 1990). Most of 
the findings showed that smoking cessation was associ-
ated with favorable outcomes. A study of 415 smokers with 
intermittent claudication and an ABI <0.9, however, found 
no difference in deterioration of the ABI at 1 year between 
current smokers and former smokers (Smith et al. 1996). 
Of note, this analysis adjusted only for diabetes status; 
former smokers were more likely than current smokers 
to have diabetes.
In a registry of 467 stable outpatients who smoked 
and had symptomatic PAD, those who quit smoking had, 
during a mean follow-up of 14  months, a nonadjusted 
relative risk of death of 1.83 (95%  CI, 0.65–5.15) com-
pared with continuing smokers (Álvarez et al. 2013). This 
study was limited by the small number of events, how-
ever, making it challenging to draw conclusions. In an 
earlier study, among 138  patients with peripheral arte-
rial occlusive disease, a subgroup of 38 patients who had 
smoked an average of 1.5 packs of cigarettes per day for 
more than 42  years had more severe claudication pain, 
lower oxygen uptake at peak exercise, and a higher oxim-
eter electrode power than a subgroup of 100 patients who 
had quit smoking for an average of 7 years (Gardner 1996). 
Results were similar after adjusting for baseline ABI. In 
a later study of 204 patients with claudication or critical 
limb ischemia who had undergone lower-extremity angi-
ography, smoking cessation was associated with a lower 
5-year adjusted HR of mortality (HR = 0.33; 95% CI, 0.13–
0.80) and improved amputation-free survival (HR = 0.40; 
95% CI, 0.19–0.83) compared with those who continued 
to smoke (Armstrong et  al. 2014). Nonsignificant HRs 
were observed in this study for MI, stroke, and major 
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amputation (there were few cases of these outcomes); a 
nonsignificant HR in the opposite direction was observed 
for major adverse limb events.
Summary of the Evidence
There is evidence that former cigarette smokers 
have a lower risk of incident PAD than current smokers 
and that the risk of PAD decreases with increased time 
since smoking cessation. Compared with never smokers, 
former smokers typically have an increased risk of PAD. 
Despite few large prospective cohort studies assessing 
these associations, evidence suggests that smoking cessa-
tion is associated with improved prognosis among persons 
with PAD.
Smoking Cessation and 
Abdominal Aortic Aneurysm
An aortic aneurysm is a ballooning or bulging area 
on the aorta wall, which can lead to rupture or dissec-
tion (a split between the layers of the wall of the aorta, 
thus trapping blood) (American Heart Association 2017). 
The prevalence of abdominal aortic aneurysms (AAAs) 
extending 2.9–4.9 centimeters (cm) among men has been 
estimated to be 1.3% in those 45–54  years of age and 
12.5% in those 75–85 years of age; the prevalence among 
women has been estimated at 0% (45–54  years of age) 
and 5.2% (75–85 years of age) (Hirsch et al. 2006). These 
estimates, however, came predominantly from cohorts of 
White men and women. Ruptures in patients with AAA are 
more common in current smokers (a doubling of risk) 
and among women (almost four times the risk) (Sweeting 
et al. 2012). 
According to the 2004 Surgeon General’s report, 
the evidence is sufficient to infer a causal relationship 
between smoking and AAA (USDHHS 2004). That report 
stated that “smoking is one of the few currently avoidable 
causes of this frequently fatal disease” (p. 397). According 
to the 1990 Surgeon General’s report (USDHHS 1990), 
former smokers have a reduced risk of death from aortic 
aneurysm compared with current smokers, but the report 
noted that more detailed analyses by duration of smoking 
abstinence are needed. The 1990 report did not provide 
any formal conclusions about smoking cessation and AAA.
The 1990 report discussed results from five prospec-
tive cohort studies that compared risk of death from AAA 
between former smokers and current smokers. Overall, 
in men there was a consistent pattern of a reduced risk 
of death from AAA among former smokers compared with 
current smokers. At the time, evidence was more limited 
in women. Since publication of the 1990 report, many 
additional studies have been published on this topic, as 
summarized below and in Table 4.19.
In 1999, a literature review concluded that smoking 
was strongly associated with AAA (Blanchard 1999). Some 
of the studies in this review examined associations with this 
outcome between former smokers and never smokers. For 
example, during 40 years of follow-up of the British Doctors’ 
Study, the rate of death from non-syphilitic AAA (standard-
ized for age and calendar period) was more than four times 
as high among current smokers and more than twice as 
high among former smokers as among never smokers 
(CIs not provided) (Doll et al. 1994). In the Cardiovascular 
Health Study of older Americans, the prevalence of AAA 
was 6.8% for never smokers, 11.5%  for former smokers, 
and 14.4% for current smokers (Alcorn et al. 1996).
Several observational studies published in 1997 or 
later have assessed the relationship between smoking ces-
sation and the incidence or prevalence of AAA. Overall, the 
evidence suggests that smoking cessation is associated 
with a decreased risk of AAA (Lederle et  al. 1997, 2000, 
2003; Wilmink et al. 1999; Singh et al. 2001; Wong et al. 
2007; Forsdahl et al. 2009; Kent et al. 2010; Stackelberg 
et  al. 2014; Tang et  al. 2016). Even so, compared with 
never smokers, former smokers tend to have an increased 
risk of AAA that can persist for decades after quitting 
(Wong et al. 2007).
Findings from observational studies on cessation and 
AAA are summarized in Table  4.19. For example, in two 
cohorts of veterans undergoing screening in the Aneurysm 
Detection and Management study, the OR for AAA (diameter 
≥4.0 cm) among former smokers compared with current 
smokers was 0.73 (95% CI, 0.66–0.82) for every 10 years 
of smoking cessation (Lederle et al. 1997, 2000). In addi-
tion, after accounting for number of years smoked, risk of 
AAA was higher in current smokers than in former smokers 
(Table 4.19). In a later study, in a large cohort of patients who 
underwent ultrasound screening for AAA, former smokers 
had a lower prevalence of AAA than current smokers, and 
risk decreased as duration of cessation increased from 
less than 5 years to more than 10 years (Kent et al. 2010). 
Similar patterns of decreasing risk as duration of cessation 
increased were observed in other studies (Wong et al. 2007; 
Stackelberg et al. 2014; Tang et al. 2016). 
According to data from 2002 from CPS II that was 
reported in the 2004 Surgeon General’s report, mortality 
attributable to AAA was significantly higher among men 
and women who were current smokers compared with 
never smokers (USDHHS 2004). Risk of mortality due to 
AAA was lower in former smokers than in current smokers 
but was higher in former smokers than in never smokers. 
Pujades-Rodriguez and colleagues (2015), in their anal-
ysis of data from the CALIBER program, reported that the 
age-adjusted HR of AAA tended to decrease with increased 
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Table 4.19 Observational studies on smoking cessation and abdominal aortic aneurysm
Study Design/population Findings: RR (95% CI) Comments
Lederle et al. 
(1997, 2000)a
• Cross-sectional analyses (Aneurysm Detection 
and Management)
• Two cohorts of veterans, 50–79 years of age, 
97% men, 87% White (also African American 
and other races/ethnicities), no history of AAA
• Sample sizes and number of AAAs (≥3.0 cm):
 – Cohort 1: n = 73,451; 3,366 AAAs 
 – Cohort 2: n = 52,745; 1,917 AAAs
• Screened in 1992–95 and 1995–97, 
respectively
• United States
• Cohort 1: 
 – AAA 3.0–3.9 cm diameter 
	| Current smoker: 1.00 (referent)
	| Former smoker (per 10 years since 
quitting): 0.81 (0.76−0.86)
 – AAA ≥4.0 cm diameter 
	| Current smoker: 1.00 (referent)
	| Former smoker (per 10 years since 
quitting): 0.72 (0.65−0.79)
• Cohort 2: similar findings
—
Wilmink et al. 
(1999)a
• Nested case-control study
• Men, >50 years of age, 210 cases of AAA 
(>29 cm) from AAA screening study, 237 age-
matched controls, 64% of cases and 63% of 
controls were former smokers
• Years of data collection: not provided
• Huntingdon, United Kingdom
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Former smoker: 4.0 (1.7–9.5)
 – Current smoker: 9.0 (3.4–24.0)
 – Similar results when reclassified based 
on cotinine level
• Years since quitting:
 – Current smoker: 1.00 (referent)
 – Former smoker
	| 1–5: 0.62 (0.2–1.7)
	| 6–10: 0.47 (0.2–1.3)
	| 11–20: 0.61 (0.3–1.3)
	| 21–30: 0.28 (0.1–0.7)
	| ≥30 years: 0.20 (0.1–0.4)
 – When also adjusted for duration of smoking, 
results trended toward weaker associations
Adjusting for duration of smoking in the 
time-since-quitting analysis might lead 
to overadjustment (results not shown)
Lederle et al. 
(2003)
• Prospective cohort (Cancer Prevention Study II)
• 508,351 participants; >30 years of age; 
tended to be White, married, and educated; 
1,296 deaths from AAA
• Participants were screened between October 
1992 and March 1995
• United States (all 50 states)
• Follow-up: 14 years
• Smoking status:
 – Never smoker: 1.00 (referent)
 – Former smoker: 2.4
 – Current smoker: 6.0
Unpublished data presented in systematic 
review; 95% CIs not provided; adjusted for 
age and potentially other factors
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Table 4.19 Continued
Study Design/population Findings: RR (95% CI) Comments
Wong et al. 
(2007)a
• Prospective cohort (Health Professionals 
Follow-Up Study)
• 39,352 men, 40–75 years of age at baseline, 
10% current smokers at baseline, healthy 
(no prior CVD), excluded nondrinkers who 
had quit in prior 10 years, 376 cases of AAA
• 1986–2002
• United States
• Smoking status:
 – Current smoker: 1.00 (referent)
 – Former smoker (years since quitting):
	| <10: 6.5 (4.5–9.3)
	| ≥10: 2.5 (1.8–9.3)
 – Current smoker (number of cigarettes 
smoked per day):
	| 1–4: 1.8 (0.4–7.4)
	| 5–14: 5.9 (3.0–11.4)
	| 15–24: 14.2 (9.4–21.5)
	| ≥25: 15.2 (9.9–23.3)
—
Forsdahl et al. 
(2009)a
• Prospective cohort study (Tromsø)
• 4,345 participants, 25–82 years of age at 
baseline, 59.5 years of age (mean), 37% former 
smokers, no AAA or unknown AAA status, 
119 incident cases of AAA
• 1994–2001
• Norway
• Smoking status: 
 – Never smoker: 1.00 (referent)
 – Former smoker (years since quitting):
	| <10: 2.88 (1.23–6.75)
	| 10–19: 2.90 (1.25–6.72)
	| ≥20: 1.26 (0.54–2.96)
 – Current smoker (number of cigarettes 
smoked per day):
	| <10: 6.19 (2.86–13.38)
	| 10–19: 9.78 (4.89–19.58)
	| ≥20: 13.72 (6.12–30.78)
Logistic regression used; cross-sectional 
analyses (Singh et al. 2001) found smoking 
was a risk factor for prevalence of AAA
Kent et al. 
(2010)a
• Cross-sectional analysis (prevalence in cohort, 
Life Line Screening database)
• 3.1 million participants without prior repair 
of AAA, <85 years of age, 63.1 years of age 
(mean), 35% men, 87% White (also Hispanic, 
African American, Native American, and Asian), 
and 23,446 with AAA (≥3 cm)
• Screened in 2003–2008
• United States
• Smoking status:
 – Current smoker: 1.00 (referent)
 – Former smoker (years since quitting):
	| <5: 0.87 (0.84–0.912)
	| 5–10: 0.68 (0.65–0.71)
	| >10: 0.42 (0.41–0.43)
—
Smoking Cessation
The Health Benefits of Smoking Cessation  263
Table 4.19 Continued
Study Design/population Findings: RR (95% CI) Comments
Pujades-
Rodriguez et al. 
(2015)
• Prospective cohort
• 1.93 million participants, ≥30 years of age, 
49% men, predominantly White (also South 
Asian and Black), 16.2% former smokers 
(among those with smoking data); drawn from 
CALIBER program (linked electronic health 
records), no history of CVD, 1,238 cases of 
AAA in former smokers
• 1997–2010
• England
• Median follow-up: 6 years
• AAA by smoking status (age-adjusted):
 – Current smoker: 1.00 (referent)
 – Former smoker (years since quitting):
	| <2: 0.84 (0.47–1.51)
	| 2–9: 0.78 (0.52–1.17)
	| >10: 0.25 (0.20–0.32)
See Table 4.17 for concerns about validity
Stackelberg 
et al. (2014)a
• Two prospective cohorts (Cohort of Swedish 
Men and Swedish Mammography Cohort)
• Participants 46–84 years of age, 37% of 
men were former smokers, 25% of women 
were former smokers, no known diagnosis 
of AAA or cancer (other than nonmelanoma 
skin cancer)
• Sample sizes and number of AAAs by cohort:
 – Cohort of Swedish Men: 42,596, 958 AAA
 – Swedish Mammography Cohort: 35,550, 
199 AAA
• 1998–2011
• Sweden
• Mean follow-up: 12.7 years
• Men:
 – Never smoker: 1.00 (referent)
 – Former smoker (<20 years since quitting): 
3.77 (3.08–4.63)
 – Former smoker (≥20 years since quitting): 
1.61 (1.27–2.03)
 – Current smoker (<20 pack-years): 3.06 
(2.37–3.95)
 – Current smoker (≥20 pack-years): 6.55 
(5.36–7.99)
• Women:
 – Never smoker: 1.00 (referent)
 – Former smoker (<20 years since quitting): 
4.63 (3.04–7.06)
 – Former smoker (≥20 years since quitting): 
0.82 (0.35–1.92)
 – Current smoker (<20 pack-years): 7.01 
(4.63–10.62)
 – Current smoker (≥20 pack-years): 6.55 
(5.36–7.99)
Less power to detect associations in women 
(199 cases) than in men (958 cases)
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Table 4.19 Continued
Study Design/population Findings: RR (95% CI) Comments
Tang et al. 
(2016)a
• Prospective cohort (Atherosclerosis Risk in 
Communities Study)
• 26% former smokers
• 15,703 participants, 45–64 years of age at 
baseline, 45% men, 26% former smokers 
at baseline, African Americans (27%) and 
Whites, no prior repair of AAA, excluded 
uncertain AAA status during follow-up, 
590 incident clinical AAAs, 5,578 participants 
underwent ultrasound screening from 2011 
to 2013 (identified 75 asymptomatic AAAs)
• 1987–2011
• United States
• Median follow-up: 22.5 years
• Incident clinical AAAs:
 – Baseline smoking status:
	| Never smoker: 1.00 (referent)
	| Former smoker: 2.45 (1.85–3.25)
	| Current smoker: 7.59 (5.78–10.0)
 – Longitudinal smoking status:
	| Never smoker: 1.00 (referent)
	| Quit before first visit: 1.83 (1.19–2.81) 
	| Recent quitterb:3.50 (1.53–8.04)
	| Continuous smoker: 6.41 (3.67–11.2)
• Similar pattern of associations with prevalent 
asymptomatic AAAs detected in 2011–2013 
subgroup
—
Notes: AAA = abdominal aortic aneurysm; CALIBER = Clinical research using LInked Bespoke studies and Electronic health Records; CI = confidence interval; 
cm = centimeter; RR = risk ratio.
aMeasure(s) of association adjusted for covariate(s).
bRecent quitter defined as someone who had quit for at least 3–8 years after the first visit in 1987.
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time since smoking cessation (Table 4.19). Even so, in a 
comparison restricted to men and using never smokers as 
the referent, the age-adjusted hazard of AAA was still ele-
vated in those who had quit smoking for 10 or more years 
(HR = 1.47, 95% CI, 1.10–1.95).
Prognosis of AAA
In the Aneurysm Detection and Management study, 
Bhak and colleagues (2015) assessed 534 veterans for the 
clinical risk factors associated with the expansion rate of 
AAA (i.e., the rate at which the AAA widens). The expansion 
rate of AAA is important to monitor, because (1) the risk of 
an AAA rupture is proportional to the maximum diameter 
of the AAA and (2) the mortality rate for rupture is high 
in those with aneurysms greater than 4–5 cm in diameter 
(Hirsch et al. 2006). Current smokers had an aortic expan-
sion rate 0.05  cm/year greater (95%  CI, 0.2–0.8) than 
former smokers—a 19% increase (Bhak et al. 2015).
Bhak and colleagues (2015) performed a pooled anal-
ysis of individual-level data from 12 studies. In one of the 
12 studies, Sweeting and colleagues (2012) found that, com-
pared with former and never smoking, current smoking 
increased the growth rate of AAA by 0.35 mm/year, and the 
rupture rate was twice as high in men and women who 
were current smokers as it was in nonsmokers. In another 
of the 12 studies (Brady et al. 2004), among 1,743 patients 
in the United Kingdom Small Aneurysm Trial, the growth 
rate of AAA was 0.42 mm/year higher in current smokers 
than in former smokers (95%  CI, 0.17–0.68). There was 
no difference in the growth rate of AAA between former 
and never cigarette smokers. Using this same study popu-
lation, Brown and Powell (1999) found that the adjusted 
hazard of AAA rupture was lower in former smokers 
(HR = 0.59; 95% CI, 0.39–0.89) than in current smokers. 
Other researchers have also found that smoking or a his-
tory of smoking is associated with an increased growth 
rate in AAA (Chang et al. 1997; Lindholt et al. 2001).
Koole and colleagues (2012) assessed the relation-
ships between smoking status and outcomes of endovas-
cular aneurysm repair among 8,638 patients (2,406 former 
smokers) in the European Collaborators on Stent/Graft 
Techniques for Aortic Aneurysm Repair study. Compared 
with never smokers, former and current smokers were 
more likely to need percutaneous transluminal angio-
plasty procedures or stents at the time of surgery (10.5%, 
11.8%, and 13.7%, respectively). Regarding late complica-
tions, however, current smokers and former smokers had 
fewer endoleaks than never smokers. Current cigarette 
smokers (adjusted HR  =  1.45; 95%  CI, 1.03–2.05) and 
former smokers (adjusted HR = 1.23; 95% CI, 0.87–1.72) 
were more likely than never smokers to have migration of 
the stent graft.
Summary of the Evidence
Substantial evidence suggests that former smokers 
have a lower risk of incident AAA than current smokers 
and that risk decreases with increasing time since 
smoking cessation. Compared with never smokers, former 
smokers have an increased risk of AAA that can persist for 
decades. The evidence also suggests that the diameter of 
AAA expands at a lower rate in former smokers compared 
with current smokers.
Summary of the Evidence
This section builds on the 1990 (USDHHS 1990) 
and subsequent Surgeon General’s reports (USDHHS 
2001, 2004, 2006, 2010, 2014), providing an updated and 
overarching summary of what is now known about the 
relationships between smoking cessation and CVD out-
comes. Previous Surgeon General’s reports concluded 
that smoking cessation reduces the risk of CHD, PAD, 
ischemic stroke, SAH, and, more broadly, CVD morbidity 
and mortality (Table  4.10). These past reports also con-
cluded that smoking cessation reduces risk of recurrent 
MI or CVD death among persons with CHD and improves 
exercise tolerance, reduces risk of amputation, and 
improves overall survival among patients with PAD. In 
particular, the 2001 Surgeon General’s report concluded 
that smoking cessation appears to slow the rate of pro-
gression of carotid atherosclerosis in women and is asso-
ciated with improvements in symptoms, prognosis, and 
survival among women with peripheral vascular athero-
sclerosis (USDHHS 2001). The evidence presented in this 
report shows that smoking cessation benefits persons at 
any age, reducing relative risk of CVD for smokers and the 
burden of disease from cardiovascular causes.
This section summarizes the large body of evidence 
related to the benefits of smoking cessation for reducing 
risk of CVD outcomes, considering evidence from mech-
anistic, epidemiologic, and clinical studies and applying 
established guidelines for causal inference (consistency; 
strength of association; temporality; specificity; exper-
iment and biologic gradient; and coherence, plausi-
bility, and analogy). Previous reports (U.S. Department 
of Health, Education, and Welfare [USDHEW] 1964; 
USDHHS 2004) have described this approach to causal 
inference. The approach is used here to systematically 
develop the basis for causal conclusions. As described in 
the 2004 Surgeon General’s report, rather than serving 
as a checklist for assessing causal inference, these causal 
criteria are used to integrate multiple lines of evidence 
(USDHHS 2004). 
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Evaluation of the Evidence
Consistency
The relationships between smoking status and ces-
sation with most of the outcomes described here have 
been extensively studied in well-designed and adequately 
powered studies (using observational and experimental 
designs) across different populations and time periods. 
Multiple studies have found that smoking cessation is 
associated with reduction in inflammatory markers and 
hypercoagulability and with rapid improvement in levels 
of HDL-C. Several, but not all, studies have found an asso-
ciation between smoking cessation and improved endo-
thelial function. Much evidence documents the fact that 
former cigarette smokers tend to have less extensive sub-
clinical atherosclerosis than current smokers and that 
smoking cessation is followed by slower progression of 
atherosclerosis, particularly for the outcomes of carotid 
IMT and ABI.
Many studies have also found that, compared with 
current smokers, former smokers have a lower risk of 
incident CVD, CHD, stroke, and AAA and that the risks 
decrease with increasing time since cessation. Studies 
support similar associations between smoking cessation 
and outcomes related to AF, SCD, heart failure, VTE, and 
PAD, although the evidence is more limited with regard 
to reduced risk with increased time since cessation. 
Additionally, smoking cessation is consistently associated 
with reduced risk of recurrent infarction and CVD death 
among patients with CHD (USDHHS 1990). Similarly, for 
persons who have already had a stroke, cessation reduces 
risk for recurrent events. Studies have also found that 
among patients with PAD, morbidity and mortality are 
lower in former smokers than in current smokers; in addi-
tion, the expansion rate of AAA is lower in former smokers 
than in current smokers. 
Strength of Association
For many CVD outcomes, there is consistent evi-
dence of a substantial reduction in risk among former 
smokers compared with current smokers; after a certain 
amount of time has elapsed since cessation, the risk for 
some outcomes among former smokers even approaches 
that of never smokers. For example, research estimates 
that the excess risk of CHD decreases by half approxi-
mately 4–5  years after cessation, albeit with substantial 
variation in estimates among studies, and then gradually 
approaches the risk of never smokers. For stroke, a similar 
pattern has been observed, although the risk may not reach 
that of never smokers. Smoking is strongly related to the 
risk of AAA; former smokers (particularly those who have 
quit for long periods) tend to have a substantially lower 
risk than those who continue to smoke. For example, in 
adjusted analyses in the ARIC study, compared with never 
smokers, current smokers had 6.41  times the risk of a 
clinical AAA (95% CI, 3.67–11.2); recent quitters (who had 
quit for at least 3–8 years) had 3.50 times the risk (95% CI, 
1.53–8.04); and longer term quitters had 1.83  times the 
risk (95% CI, 1.19–2.81) (Tang et al. 2016).
Temporality
Many of the studies reviewed here are prospective 
in nature, and thus smoking status or smoking cessation 
was measured before the incident outcome. For measure-
ments of biomarkers, several studies assessed changes in 
these biomarkers after cessation; similar analyses have 
been carried out for markers of subclinical atheroscle-
rosis. Although some studies are cross-sectional in nature, 
prospective cohort studies have been carried out for each 
of the main outcomes discussed, thereby ensuring that 
smoking cessation preceded the occurrence of the health 
outcomes. The potential for reverse causality has also 
been accounted for in these studies to diminish the poten-
tial for such bias.
Specificity
In line with observations of reduced risk of overall 
CVD morbidity or mortality among former smokers com-
pared with current smokers, similar reductions were 
observed for major causes of CVD morbidity and mortality, 
such as CHD and stroke and many other subtypes of CVD.
Experiment and Biologic Gradient
Both smoking cessation and time since cessation 
serve as naturally occurring changes in exposure status 
that can be used to infer the effect of the intervention of 
stopping smoking. The temporal pattern of declining risk 
after smoking cessation is strong evidence for a causal 
benefit of quitting and reflects a waning of the processes 
of injury caused by smoking. For most of the CVD out-
comes reviewed in this report, most cited studies found a 
reduction in risk after cessation, followed by a pattern of 
a continued decrease in risk with longer time since cessa-
tion. In parallel, studies using biomarkers found greater 
reductions in inflammatory markers and hypercoagula-
bility with increasing time since cessation. Evidence from 
observational studies and clinical trials supports a rapid 
(within weeks) improvement in levels of HDL-C after ces-
sation, with no clear pattern of change after that time 
(Forey et al. 2013). Complementary evidence comes from 
studies showing greater reduction in risk with longer 
time since cessation for outcomes of incident CVD, con-
gestive heart failure, stroke, and AAA. For the outcomes 
of incident AF, SCD, heart failure, VTE, and PAD, there 
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is less evidence available on how risk of these outcomes 
changes with time since cessation, although the available 
evidence supports a decrease in risk with increased time 
since cessation for SCD (Sandhu et al. 2012), heart failure 
(Pujades-Rodriguez et al. 2015), and PAD (Cui et al. 2006; 
Conen et al. 2011; Pujades-Rodriguez et al. 2015).
The 1990 Surgeon General’s report estimated that 
excess risk of CHD is reduced by about half after 1 year of 
smoking cessation and that risk of CHD is similar among 
former and never smokers after 15 years of smoking ces-
sation (USDHHS 1990). Similarly, the 2001 Surgeon 
General’s report concluded that there is a substantial 
reduction in risk of CHD among women within 1–2 years 
of cessation; such a reduction in risk gradually continued 
to reach that of nonsmokers 10–15  or more years after 
cessation (USDHHS 2001). More recent analyses using an 
exponential distribution to quantitatively estimate how 
rapidly CHD risk decreases after smoking cessation indi-
cate that the excess risk of CHD associated with smoking 
decreases by 50% about 4.4 years after cessation (95% CI, 
3.26–5.95) (Lee et al. 2012). The risk then decreases asymp-
totically toward the risk among never smokers, as was also 
reported by the IARC (2007). Another model suggests a 
rapid decline in risk of acute MI soon after cessation, fol-
lowed by a slower decline to a risk close to that of never 
smokers (Hurley 2005).
Similarly, the 1990 Surgeon General’s report con-
cluded that after smoking cessation, the risk of stroke 
returns to that of never smokers within 5–15  years 
(USDHHS 1990). The 2001 Surgeon General’s report 
modified this conclusion slightly, stating that in most 
studies, including studies of women, the increased risk 
of stroke associated with smoking is reversible after ces-
sation, with this risk approaching that of never smokers 
after 5–15 years of cessation. Another modeling study by 
Lee and colleagues (2014) estimated that the excess risk 
of stroke associated with smoking decreases by 50% after 
4.78 years (95% CI, 2.17–10.50), but there was consider-
able unexplained heterogeneity. The modeling study by 
Hurley (2005) reported a rapid decrease in risk of stroke 
shortly after cessation (within 1–2  years), followed by a 
slower decline; the decline in risk of stroke was not as rapid 
as the decline in risk of acute MI following cessation, and 
the risk of stroke was estimated to remain elevated even 
among long-time former smokers. Evidence also supports 
a reduction in risk of mortality and of subsequent CVD 
events among patients with CHD who quit smoking after 
an index CHD event compared with those who continue to 
smoke (Wilson et al. 2000; Critchley and Capewell 2003; 
Twardella et  al. 2004, 2006; Shah et  al. 2010; Breitling 
et al. 2011a) (Table 4.20). Studies of the impact of coun-
seling on smoking cessation have also found reduced risk 
of all-cause mortality among patients who received or 
were randomized to receive such counseling (Mohiuddin 
et al. 2007; Van Spall et al. 2007; Bucholz et al. 2017).
Coherence, Plausibility, and Analogy
Evidence linking smoking cessation to reduced risk 
of CVD should be considered within the broader context 
of mechanistic research on smoking and CVD. Previous 
reports concluded that smoking initiates several pathoge-
netic mechanisms that underlie the development of CVD 
(USDHHS 2004, 2010, 2014). The 1990 and 2001 Surgeon 
General’s reports and the present updated review have 
provided evidence of how smoking cessation can reverse 
or slow these pathogenetic processes (USDHHS 1990) 
and slow the progression of subclinical atherosclerosis 
(USDHHS 2001).
Previous reports have also concluded that smoking 
causes CVD, including subclinical atherosclerosis, CHD, 
stroke, and AAA (USDHHS 2004). Much evidence sup-
ports a dose-response relationship between pack-years of 
smoking and risk of CVD. Evidence from the present report 
and previous reports supports the benefits of smoking ces-
sation in terms of reducing risk of CVD. Multiple studies 
have found a larger relative benefit of cessation among 
those who quit smoking at younger ages (compared with 
those who quit later in life), which also aligns with research 
on the dose-response relationship between smoking and 
risk of CVD (Doll et al. 2004; Jha et al. 2013; Pirie et al. 
2013; Thun et al. 2013a). However, given the increasing 
rates of the various CVDs with increasing age, substan-
tial absolute reductions in the number of CVD events and 
deaths can still be made by quitting smoking at older ages.
Synthesis of the Evidence
The conclusions presented below are based on inter-
pretations of multiple lines of evidence from a frame-
work built around the guidelines for causal inference. 
Generally, when the evidence (a) is strong and consistent, 
(b) shows that former smokers have a lower risk of a CVD 
outcome (clinical or subclinical) compared with current 
smokers, (c)  shows that the risk of a CVD outcome in 
former smokers decreases with increased time since ces-
sation, and (d) results from well-designed and sufficiently 
powered studies, then such evidence is deemed sufficient 
to support the conclusion that smoking cessation causes a 
reduction in risk of the CVD outcome. When evidence for 
CVD outcomes is not as strong (e.g.,  if evidence on how 
CVD risk changes with time since cessation is not suffi-
cient), then the evidence is deemed to be suggestive but 
not sufficient that smoking cessation decreases the risk of 
these outcomes.
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Table 4.20 Observational studies (meta-analyses and individual cohorts) on smoking cessation and prognosis of coronary heart disease or 
cardiovascular disease
Study Design/population Findings: RR (95% CI) Comments
Critchley and 
Capewell (2003)
• Meta-analysis of 20 prospective cohorts:
 – Total mortality analysis: n = 12,603; 
2,928 cases
 – Nonfatal MI analysis: n = 6,089; 779 cases
• Participants with prior CHD:
 – Mean: 55 years of age
 – 20% of cases were women (6 studies of 
men only)
 – 28–77% cessation rates (mean: 45%)
• Most studies began in the 1960s or 1970s
• Most from United States or Europe; one from 
Japan; and one from India
• Follow-up: 2–26 years; mean: 5 years 
• Outcomes: total mortality and nonfatal MI
• Total mortality:
 – Continued smokers: 1.00 (referent)
 – Cessation group: 0.64 (0.58–0.71)
• Nonfatal MI:
 – Continued smokers: 1.00 (referent)
 – Cessation group: 0.68 (0.57–0.82)
Restriction to high-quality studies yielded 
similar results; results were also similar across 
studies, irrespective of age, sex, index cardiac 
event, country, or year the study began
Dagenais et al. 
(2005)a
• Prospective analyses of clinical trial (Heart 
Outcomes Prevention Evaluation) 
• 8,905 participants with stable CVD or diabetes 
and one additional risk factor (approximately 
50% had prior MI); 58% were former smokers 
• Cases (restricted to those who survived for 
6 months):
 – CVD death: 641
 – MI: 978
 – Stroke: 358
 – Total mortality: 1,021
• Started in 1993
• Median follow-up: 4.5 years
• Cardiovascular death, MI, or stroke:
 – Never smoker: 1.00 (referent)
 – Former smoker: 0.91 (0.80–1.03)
 – Current smoker: 1.37 (1.14–1.64)
 – Similar findings for individual outcomes 
of CVD death, MI, and stroke
• Mortality:
 – Never smoker: 1.00 (referent)
 – Former smoker: 0.93 (0.80–1.08)
 – Current smoker: 1.99 (1.63–2.44)
• No consistent pattern for increased risk of 
heart failure, revascularization, unstable 
angina, or occurrence of microalbuminuria
—
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Table 4.20 Continued
Study Design/population Findings: RR (95% CI) Comments
Breitling et al. 
(2011a)a
• Prospective cohort study (Long-Term Success 
of Cardiologic Rehabilitation Therapy study)
• 1,062 participants:
 – Mean: 59 years of age
 – 85% male with acute MI, coronary 
syndrome, or coronary artery intervention 
seen for rehabilitation
 – 154 cases who had secondary CVD events
• Started in 2000
• Germany
• Median follow-up: 8.1 years
• Outcome: secondary CVD events
• Abstained from smoking according to 
self-report:
 – Continued smoker: 1.00 (referent)
 – Quit after event: 0.38 (0.20–0.73)
 – Quit before event: 0.62 (0.40–0.97)
 – Never smoker: 0.47 (0.28–0.78)
• Restricted to those who did not change 
status for 1–3 years:
 – Continued smoker: 1.00 (referent)
 – Quit after event: 0.17 (0.06–0.44)
 – Quit before event: 0.42 (0.25–0.70)
 – Never smoker: 0.32 (0.18–0.55)
Similar findings for 1-year and 3-year follow-ups 
(Twardella et al. 2004, 2006)
Notes: CHD = coronary heart disease; CI = confidence interval; CVD = cardiovascular disease; MI = myocardial infarction; RR = risk ratio.
aMeasure(s) of association adjusted for covariate(s).
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Conclusions
1. The evidence is sufficient to infer that smoking 
cessation reduces levels of markers of inflamma-
tion and hypercoagulability and leads to rapid 
improvement in the level of high-density lipopro-
tein cholesterol.
2. The evidence is sufficient to infer that smoking ces-
sation leads to a reduction in the development of 
subclinical atherosclerosis, and that progression 
slows as time since cessation lengthens. 
3. The evidence is sufficient to infer that smoking ces-
sation reduces the risk of cardiovascular morbidity 
and mortality and the burden of disease from cardio-
vascular disease.
4. The evidence is sufficient to infer that the rela-
tive risk of coronary heart disease among former 
smokers compared with never smokers falls rapidly 
after cessation and then declines more slowly. 
5. The evidence is sufficient to infer that smoking cessa-
tion reduces the risk of stroke morbidity and mortality.
6. The evidence is sufficient to infer that, after smoking 
cessation, the risk of stroke approaches that of never 
smokers. 
7. The evidence is suggestive but not sufficient to infer 
that smoking cessation reduces the risk of atrial 
fibrillation. 
8. The evidence is suggestive but not sufficient to infer 
that smoking cessation reduces the risk of sudden 
cardiac death among persons without coronary 
heart disease.
9. The evidence is suggestive but not sufficient to infer 
that smoking cessation reduces the risk of heart 
failure among former smokers compared with per-
sons who continue to smoke. 
10. Among patients with left-ventricular dysfunction, 
the evidence is suggestive but not sufficient to infer 
that smoking cessation leads to increased survival 
and reduced risk of hospitalization for heart failure. 
11. The evidence is suggestive but not sufficient to infer 
that smoking cessation reduces the risk of venous 
thromboembolism.
12. The evidence is suggestive but not sufficient to 
infer that smoking cessation substantially reduces 
the risk of peripheral arterial disease among former 
smokers compared with persons who continue to 
smoke, and that this reduction appears to increase 
with time since cessation.
13. The evidence is suggestive but not sufficient to infer 
that, among patients with peripheral arterial dis-
ease, smoking cessation improves exercise toler-
ance, reduces the risk of amputation after peripheral 
artery surgery, and increases overall survival.
14. The evidence is sufficient to infer that smoking ces-
sation substantially reduces the risk of abdominal 
aortic aneurysm in former smokers compared with 
persons who continue to smoke, and that this reduc-
tion increases with time since cessation. 
15. The evidence is suggestive but not sufficient to infer 
that smoking cessation slows the expansion rate of 
abdominal aortic aneurysm.
Implications
The evidence is clear and certain that smoking ces-
sation reduces the risk for major CVD outcomes. The 
decline over time in the prevalence of adult cigarette 
smoking has contributed to the decline of CVD mortality. 
Intensified efforts by clinicians, healthcare systems, com-
munities, and states to encourage and help smokers to 
quit will contribute to reducing the burden of CVD at the 
patient and population levels.
Heart disease is the leading cause of death in the 
United States for both men and women (Xu et al. 2018). 
The term “heart disease” refers to several types of heart 
conditions. In the United States the most common type of 
heart disease is coronary artery disease, which affects the 
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blood flow to the heart. Smoking is a key risk factor for 
developing coronary heart disease (CHD) (U.S. Department 
of Health and Human Services [USDHHS] 2004). 
This section reviews the evidence on the benefits 
of cigarette smoking cessation in people with established 
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CHD. It focuses on the endpoints of all-cause mortality, 
cause-specific mortality, and the incidence of new or 
recurrent cardiac events. As advances in clinical treat-
ment regimens for CHD have improved the prognosis for 
persons with cardiovascular events, the previously estab-
lished evidence that smoking represents a causal factor for 
CHD has led to studies investigating the potential benefit 
of smoking cessation for reducing risk of mortality after a 
diagnosis. The body of evidence on this topic, which began 
to emerge in the 1970s, has grown to the point that sub-
stantial scientific evidence now exists on this topic.
Conclusions from Previous 
Surgeon General’s Reports
Previous Surgeon General’s reports have not specifi-
cally evaluated the evidence concerning the impact of cig-
arette smoking cessation on mortality after a diagnosis of 
CHD; in fact, this is the first Surgeon General’s report to 
address the potential health benefits of smoking cessation 
after such a diagnosis. Previous reports have concluded 
that sufficient evidence exists to infer that smoking causes 
premature death, multiple diseases, and other adverse 
health effects (USDHHS 2014). The 1990 report, which 
focused on the benefits of smoking cessation, reported 
conclusions on the decline in risk for CHD and stroke 
among those who quit smoking compared with those who 
continued to smoke. In addition, the report concluded 
that, “Among persons with diagnosed CHD, smoking ces-
sation markedly reduces the risk of recurrent infarction 
and cardiovascular death. In many studies this reduction 
in risk of recurrence or premature death has been 50 per-
cent or more” (USDHHS 1990, p. 260). The report noted a 
lack of relevant findings for stroke. 
Considering the biological processes by which 
smoking increases risk for multiple diseases and mortality, 
the adverse health effects of smoking would be expected 
to apply to persons diagnosed with CHD in the same way 
as they apply to persons in the general population who 
are at risk for first events. The 2010 Surgeon General’s 
report, How Tobacco Smoke Causes Disease, detailed the 
many mechanisms leading to these adverse health effects 
(USDHHS 2010). 
Biological Basis
This review emphasizes all-cause mortality, cause-
specific mortality, and the incidence of new or recurrent 
cardiac events. Regarding all-cause mortality, the mor-
tality burden from smoking is largely attributable to its 
role in causing multiple types of cancer, various cardiovas-
cular diseases, and chronic obstructive pulmonary disease 
(COPD). Many aspects of the pathogenesis of these dis-
eases in smokers have been characterized, and these same 
mechanisms would apply to persons who have been diag-
nosed with CHD (USDHHS 2010). With regard to the risk 
for cardiovascular disease following cessation, the risk for 
several consequences of smoking—including endothelial 
dysfunction, increased risk for thrombosis, and reduced 
oxygen delivery—would be expected to lessen in the short 
term after cessation (USDHHS 2010). As detailed in the 
2014 Surgeon General’s report, in addition to causally 
increasing risk for specific disease endpoints, smoking 
causes systemic inflammation and oxidative stress and 
has widespread and complex effects on immune function 
(USDHHS 2014). The 2004 Surgeon General’s report con-
cluded that smoking causes overall poorer health that 
leaves smokers with a diminished health status compared 
with nonsmokers (USDHHS 2004).
Literature Review Methods and 
Other Methodologic Considerations
The literature search strategy for this review was 
designed to have high sensitivity by searching broadly 
in the MEDLINE database and then manually identi-
fying articles with evidence on the association between 
smoking cessation in patients with CHD and clinical 
endpoints. For example, key terms in the initial search 
included “smoking cessation” and “coronary heart dis-
ease” OR “cardiovascular disease.” The relevant evidence 
identified was most abundant on the specific topics of the 
associations between persistent smoking versus quitting 
smoking with the outcomes of all-cause mortality, cause-
specific mortality (focused on cardiac causes of death and 
sudden death), and risk of new or recurrent cardiac events. 
Consequently, the evidence review for this section focuses 
on these three endpoints.
Because of the methodologic limitations of other 
designs, the summary tables in this section include data 
only from original research reports on prospective cohort 
studies. Relevant systematic reviews and meta-analyses 
were incorporated into the discussion of the evidence, but 
they were not included in the evidence tables. The refer-
ence lists of all published papers reviewed, including the 
systematic reviews, were searched to check for potentially 
eligible studies.
Several points relevant to considerations of meth-
odology were consistent across the range of outcomes 
addressed. First, because all evidence summarized in the 
evidence tables was generated from prospective cohort 
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studies, it benefited from the methodologic strengths 
of such studies in addressing the question of the effect 
of smoking cessation in patients with CHD. Specifically, 
these were studies of cohorts of patients diagnosed with 
a specific heart disease, most often myocardial infarc-
tion (MI), or who had undergone a specific cardiovas-
cular procedure such as percutaneous coronary interven-
tion (PCI) or coronary bypass surgery. In all the studies, 
smoking status was measured at the time of initial diag-
nosis. To assess the health effects of smoking cessation, 
areas of interest included findings only from those who 
were current smokers at the time of diagnosis; this review 
did not consider results pertaining to those who were 
never smokers or former smokers at diagnosis. Further, 
a follow-up measurement of smoking status after base-
line was required to distinguish those who quit smoking 
(henceforth called “quitters”) from those who remained 
smokers (henceforth called “persistent smokers”). The 
timing of the follow-up assessment of smoking status rep-
resents a key study design feature because only patients 
who survived to the follow-up assessment were eligible 
for inclusion in the cohorts, as explained below. The more 
remote the follow-up assessment from the start of follow-
up, the greater the likelihood for cohort attrition due to 
mortality; to the extent that persistent smokers experi-
ence greater mortality soon after the cardiac diagnosis, 
there would be an increasing bias toward the null with a 
lengthening interval from baseline to follow-up. 
The definitions of “quitters” and “persistent 
smokers” varied across studies, ranging from sustained 
abstinence or continued smoking across several lon-
gitudinal follow-up points to self-reported quitting or 
continued smoking at a single follow-up time point. 
Alternatively, in some studies smoking status was ana-
lyzed as a time-dependent variable to account for the many 
possible transitions in smoking status that can take place 
over time. After the baseline assessment, current smokers 
could be classified as quitters or persistent smokers on 
the basis of a follow-up assessment; at that point, the pro-
spective follow-up for outcomes began. With these shared 
features of study design, this body of evidence is focused 
specifically on those who were current smokers at the 
time of the cardiac diagnosis, with the analysis targeting 
the effect of quitting compared with persistent smoking 
within this population. Of note, several studies were ini-
tially randomized treatment trials in which sufficient data 
had been collected to address smoking cessation within 
the context of a subsequent observational cohort study of 
trial participants.
For the endpoint of all-cause mortality, evi-
dence tables (Tables  4.21 and  4.22) present details of 
34  reports from 32  studies. The index diagnosis used to 
define the patient cohorts was MI (or included MI with 
other conditions such as angina) in the majority (61%) 
of studies on this topic. Other index diseases were coro-
nary artery disease (CAD) (15% of studies); CHD (6% of 
studies); and in one study, cardiac arrest. Among studies 
that defined the cohort on the basis of an index proce-
dure, the most common procedures were PCI (9%  of 
studies) and coronary artery bypass surgery (6%). The 
studies included in the evidence tables for cause-specific 
mortality (Table  4.23) and new/recurrent cardiac events 
(Table 4.24) numbered 13 and 15, respectively.
Epidemiologic and Clinical Evidence
Smoking Cessation and All-Cause Mortality 
in Patients with Coronary Heart Disease
Table 4.21 summarizes studies (N = 24) of cohorts of 
patients who were current smokers at the time of a CHD 
diagnosis that assessed the association between smoking 
cessation and all-cause mortality by comparing quitters 
and persistent smokers (the referent). Although all the 
studies relied on prospective cohorts, they varied widely in 
sample size, population composition, duration of follow-
up, and consideration of potential confounding variables. 
Sample sizes ranged from 87 to 8,489 persons, and follow-
up ranged from 6  months to 30  years. Some estimates 
of relative risk (RR) were unadjusted, and others were 
extensively adjusted for demographic, lifestyle, family his-
tory, or clinical characteristics. Despite this variability in 
design features, the results across studies were consis-
tent, as illustrated by the forest plot in the top portion 
of Figure 4.4. When quitters were compared with persis-
tent smokers, this forest plot, which illustrates results 
for the 24 studies that included an RR estimate and 95% 
confidence interval (CI) for all-cause mortality, shows 
that the RR estimates in every case were less than 1.0. 
The estimates ranged from 0.11  to 0.93, with a median 
RR of 0.55, or a reduction of 45% in the rate of mor-
tality. The study showing the weakest association (Chow 
et al. 2010) (RR = 0.93; 95% CI, 0.59−1.46) also had the 
shortest follow-up (6  months); this may be too brief a 
period to observe the full impact of quitting (versus per-
sistent smoking) on mortality. When the results of this 
study were presented on the basis of a composite outcome 
of MI or stroke or death, the results aligned more closely 
with those of other studies (RR = 0.74; 95% CI, 0.53–1.02) 
(Chow et al. 2010).
One of the 24 studies (Breitling et al. 2011a) in 
Table 4.21 measured self-reported smoking and also incor-
porated a biomarker of smoking (blood concentration of 
cotinine). This study found that smoking classification 
based on self-reports alone underestimated the strength of 
Smoking Cessation
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Table 4.21 Summary of results from prospective cohort studies of patients with coronary heart disease who were cigarette smokers at diagnosis, 
comparing all-cause mortality in those who quit smoking with persistent cigarette smokers
Study Design/population Findings: RRa (95% CI) Comments
Wilhelmsson 
et al. (1975)
• 405 male patients with first MI who were 
current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 3 months after MI
• 231 quitters, 174 persistent smokers
• Study period: 1968–1972
• Sweden
• 2-year follow-up results presented
• 0.51 (0.27–0.96) Quitters vs. persistent smokers (referent)
Unadjusted risk ratios 
Risk ratio calculated on basis of data presented 
in Table 5 in Wilhelmsson and colleagues (1975)
Sparrow and 
Dawber (1978)
• Framingham Study
• 195 patients with MI who were current 
smokers at diagnosis
• All current smokers at baseline
• Categorized as former smokers or persistent 
smokers based on smoking status after 
data collection immediately preceding and 
following MI (indeterminate timing)
• 56 quitters, 139 persistent smokers
• Cohort established 1949, 22 years of follow-up 
through 1978
• United States
• 6-year follow-up results presented
• 0.62 (0.33–1.15) Quitters vs. persistent smokers (referent)
Unadjusted risk ratios 
Risk ratio calculated on basis of data presented 
on page 429 in Sparrow and Dawber (1978)
Baughman et al. 
(1982)
• 87 patients with MI who were current 
smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status after infarct 
(indeterminate timing)
• 45 quitters, 42 persistent smokers
• Enrollment period: 1968–1971, with follow-up 
through 1978
• United States
• 99-month mean follow-up (survivors)
• 0.35 (0.18–0.66) Quitters vs. persistent smokers (referent)
Unadjusted risk ratios
Risk ratio calculated on basis of data presented 
at top of right-hand column on page 877 in 
Baughman and colleagues (1982)
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Table 4.21 Continued
Study Design/population Findings: RRa (95% CI) Comments
Mulcahy et al. 
(1982)
• 517 male patients <60 years of age with first 
diagnosis of unstable angina or MI who were 
current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters if stopped smoking at 
least 3 months before last follow-up or death 
(indeterminate timing)
• 282 quitters, 235 persistent smokers
• Enrollment period: 1961–1975 with follow-up 
through 1979
• Ireland
• 99-month mean follow-up (survivors)
• 0.59 (0.47–0.73) Quitters vs. persistent smokers (referent)
Unadjusted risk ratios
Risk ratio calculated on basis of data presented 
in Table 1 in Mulcahy and colleagues (1982)
Aberg et al. 
(1983)
• 983 male patients with first MI who were 
current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 3-month follow-up
• 542 quitters, 441 persistent smokers
• Enrollment period: 1968–1977 
• Sweden
• 10.5 years maximum follow-up
• All-cause mortality:
 – All ages: 0.63 (0.50–0.79)
 – ≤50 years of age: 0.46 (0.25–0.84)
 – >50 years of age: 0.65 (0.50–0.83)
• 5-year survival:
 – Quitters: 84%
 – Persistent smokers: 78%
 – p <0.0001
Quitters vs. persistent smokers (referent)
Unadjusted risk ratios
Presented survival plots and p values only from 
Cox proportional hazards regression models 
Risk ratio calculated from data presented in 
Table 6 in Aberg and colleagues (1983)
Perkins and Dick 
(1985)
• 119 patients with first-time diagnosis of MI 
who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent 
smokers based on smoking status after MI 
(indeterminate timing)
• 52 quitters, 67 persistent smokers
• Enrollment period: 1974–1977 
• United Kingdom
• 5-year follow-up
•  0.39 (0.20–0.74) Quitters vs. persistent smokers (referent)
Unadjusted risk ratios
Risk ratio calculated from data presented in 
Table II in Perkins and Dick (1985)
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Table 4.21 Continued
Study Design/population Findings: RRa (95% CI) Comments
Rønnevik et al. 
(1985)
• 453 patients with first-time diagnosis of AMI 
who were current smokers at diagnosis within 
a randomized controlled trial
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status after MI on basis of 
continued follow-up (indeterminate timing)
• 276 quitters, 177 persistent smokers
• Enrollment period: 1978–1979
• Norway
• Mean follow-up: 17.3 months
• All-cause mortality (placebo group): 0.74 
(0.42–1.30)
Quitters vs. persistent smokers (referent)
Unadjusted risk ratios
Results presented limited to placebo group 
because of observed interaction of treatment 
(timolol) with smoking
Risk ratio calculated from data presented in 
Table 3 in Rønnevik and colleagues (1985)
Hallstrom et al. 
(1986)
• 310 patients with cardiac arrest who were 
current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status 2 months or less 
after cardiac arrest
• 91 quitters, 219 persistent smokers
• Study period: 1970–1981
• United States
• Mean follow-up: 47.5 months
• 0.79 (0.50–1.06) Quitters vs. persistent smokers (referent)
Unadjusted risk ratios
Risk ratio calculated from data presented in 
bottom right-hand column of page 272 of 
Hallstrom and colleagues (1986)
Burr et al. 
(1992)
• DART
• 1,186 nondiabetic male patients ≤70 years 
of age with MI who were current smokers at 
diagnosis and survived at least 6 months
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 6-month follow-up
• 665 quitters, 521 persistent smokers
• Study period: indeterminate
• United Kingdom
• 18-month follow-up
• 0.52 (0.32–0.83) Quitters vs. persistent smokers (referent)
Unadjusted risk ratios
Mortality ratios based on average annual 
mortality rates 
Unadjusted risk ratio calculated from Table 2 
in Burr and colleagues (1992)
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Table 4.21 Continued
Study Design/population Findings: RRa (95% CI) Comments
Cavender et al. 
(1992)
• CASS
• 284 patients with angiographically confirmed 
CAD who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 6-month follow-up
• 97 quitters, 187 persistent smokers
• Enrollment period: 1974–1979 
• United States and Canada (15 clinical sites)
• 10-year follow-up
• All-cause mortality: 0.63 (0.40–0.97)
• 10-year survival:
 – Quitters: 80%
 – Persistent smokers: 69%
 – p = 0.025
Quitters vs. persistent smokers (referent)
Unadjusted risk ratios
“Persistent smoker” defined as a person 
who smoked during the follow-up interval 
(questionnaires every 6 months)
Risk ratio calculated from data presented in 
the title of Figure 2 in Cavender and colleagues 
(1992); a Cox proportional hazards model was 
fit with smoking as a time-dependent covariate 
to account for quitters who reverted to smoking
Cox proportional hazards model showed that 
smoking during 50% and 100% of the follow-up 
period increased the RR of death by 1.56 and 
1.73, respectively
Survival plots and p values presented only from 
Cox proportional hazards regression models
Gupta et al. 
(1993)
• 225 patients with CHD who were current 
smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status since the time of 
diagnosis of CAD (indeterminate timing)
• 173 quitters, 52 persistent smokers
• Study baseline: 1980
• India
• Approximately 6-year follow-up
• 0.70 (0.49–1.01) Quitters vs. persistent smokers (referent)
Unadjusted risk ratios
Risk ratio calculated from data presented on 
page 127 of Gupta and colleagues (1993)
Adjusted hazards ratio comparing persistent 
smokers to quitters plus nonsmokers presented 
in Table 3 in Gupta and colleagues (1993) 
underestimated association because of inclusion 
of nonsmokers in the reference category; hazard 
ratio was 1.28 (95% CI, 1.01–2.09) after adjusting 
for sex, age, hypertension, cholesterol, diabetes, 
and history of MI or congestive heart failure
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Study Design/population Findings: RRa (95% CI) Comments
Tofler et al. 
(1993)
• MILIS study
• 641 patients with AMI who were current 
smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 6-month follow-up
• 360 quitters, 281 persistent smokers
• Enrollment period: 1974–1979 
• United States
• 4-year follow-up results presented
• All-cause mortality:
 – Total: 0.48 (0.31–0.73)
 – <12 years of education: 0.63 (0.39–1.03)
 – ≥12 years of education: 0.39 (0.18–0.89)
Quitters vs. persistent smokers (referent)
Unadjusted risk ratios
Risk ratio calculated from data presented in 
Table 3 in Tofler and colleagues (1993)
Greenwood et al. 
(1995)
• ASSET
• 532 patients with MI who were current 
smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 1-month follow-up
• 396 quitters, 136 persistent smokers
• Study period: 1986–1988 (enrollment)
• England
• 6.3-year median follow-up
• All-cause mortality: 0.56 (0.33–0.98)
• 10-year survival:
 – Quitters: 80%
 – Persistent smokers: 69%
 – p = 0.025
Quitters vs. persistent smokers (referent) 
Logistic regression models
Adjusted for age, history of diabetes, history 
of angina, and treatment with antiarrhythmic 
drugs at discharge
Herlitz et al. 
(1995)
• 217 patients with AMI who were current 
smokers at diagnosis and survived at least 
1 year
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status after 1 year of 
follow-up
• 115 quitters, 102 persistent smokers
• Enrollment period: 1986–1987
• Sweden
• 4-year follow-up results presented
• 0.55 (0.34–0.91) Quitters vs. persistent smokers (referent) 
Unadjusted risk ratios
Risk ratio calculated on basis of data presented 
in text and mortality rates presented in Figure 2 
in Herlitz and colleagues (1995)
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Table 4.21 Continued
Study Design/population Findings: RRa (95% CI) Comments
Kinjo et al. 
(2005)
• OACIS study
• 1,424 patients with AMI who were current 
smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent 
smokers based on smoking status 3 months 
after discharge
• 1,056 quitters, 368 persistent smokers
• Study period: 1998–2003
• Japan
• 2.5-year mean follow-up
• Adjusted hazard ratio: 0.39 (0.20–0.77) Quitters vs. persistent smokers (referent)
Proportional hazards models
Adjusted for sex, age, BMI, hypertension, 
dyslipidemia, diabetes, obesity, prior MI, prior 
angina pectoris, prior cerebrovascular disease, 
heart rate, Killip class ≥2, anterior wall MI, 
atrial fibrillation, ventricular fibrillation, 
and revascularization
Gerber et al. 
(2009)
• ISFAMI
• 798 patients ≤65 years of age with first-time 
MI who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status during follow-up
• 417 quitters, 381 persistent smokers
• Study period: 1992–2005
• Israel
• 13.2-year median follow-up
• Adjusted odds ratio: 0.63 (0.48–0.82) Quitters vs. persistent smokers (referent)
Proportional hazards models, with smoking 
modeled as time-dependent covariate
Adjusted for sex, age, ethnicity, education, 
income, employment, hypertension, dyslipidemia, 
diabetes, obesity, physical activity, Q-wave AMI, 
CABG, PTCA, unstable angina pectoris, and 
heart failure during follow-up
Chow et al. 
(2010)
• OASIS 5 trial
• 4,324 patients with unstable angina or MI 
who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status after 30 days of 
follow-up
• 2,802 quitters, 1,522 persistent smokers
• Study baseline: 2003–2005
• 41 countries
• 6-month follow-up
• Adjusted odds ratio: 0.93 (0.59–1.46) Quitters vs. persistent smokers (referent)
Logistic regression models 
Paper presented measures of association as odds 
ratios, but because they were from a prospective 
cohort study, these are RR estimates
Adjusted for sex, age, hypertension history, 
diabetes, prior MI, BMI, creatinine, PCI/CABG 
before 30 days, and medications
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Study Design/population Findings: RRa (95% CI) Comments
Shah et al. 
(2010)
• SAVE trial
• 731 patients with AMI with left ventricular 
systolic dysfunction who were current 
smokers at diagnosis
• All current smokers at baseline who survived 
at least 6 months
• Categorized as quitters or persistent smokers 
based on smoking status after 6 months of 
follow-up
• 463 quitters, 268 persistent smokers
• Study baseline: 1987–1990
• United States
• 42-month median follow-up
• Adjusted hazard ratio for all-cause mortality 
by follow-up interval:
 – 6 months: 0.57 (0.36–0.91)
 – 12 months: 0.58 (0.33–0.99)
 – 16 months: 0.60 (0.34–1.07)
 – 24 months: 0.53 (0.25–1.08)
Quitters vs. persistent smokers (referent)
Proportional hazards regression models
Propensity score (on basis of 24 parameters) 
adjusted model
Reduction in risk started early and was 
maintained over time
Results presented combined mortality with 
MI or hospitalization for heart failure
Breitling et al. 
(2011a)
• KAROLA study
• 1,062 total patients with AMI, coronary 
syndrome, coronary artery intervention 
who were current smokers at diagnosis
• All results presented in table limited to 
current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at rehabilitation 
discharge
• Numbers of quitters and persistent smokers 
vary by classification method
• 85% men, mean 59 years of age
• Study baseline: 2000
• Germany
• 8.1-year median follow-up
• Outcome was fatal or nonfatal secondary 
cardiovascular disease events (MI, ischemic 
stroke, deaths with cardiovascular disease 
as the main cause):
 – Self-report plus cotinine (169 quitters, 
154 persistent smokers): adjusted hazard 
ratio 0.38 (0.20–0.73)
 – Self-report plus cotinine, limited to those 
who remained quitters or persistent 
smokers throughout follow-up (101 quitters, 
98 persistent smokers): adjusted hazard 
ratio 0.17 (0.06–0.44)
 – Self-report only (204 quitters, 53 persistent 
smokers): adjusted hazard ratio 0.75 
(0.35–1.60)
Hazard ratio for quitters vs. persistent smokers
Results indicate that using a biomarker of 
smoking results in greater magnitude of risk 
reduction compared with self-report alone
Results indicate that magnitude of risk reduction 
is greater when maintaining abstinence
Taken in combination, these findings indicate 
that the association with quitting smoking is 
likely underestimated in most studies because 
studies of this type typically have not used 
biomarkers and continuous maintenance of 
smoking abstinence
Earlier results from this same study showing 
similar findings were included in Twardella 
and colleagues (2006) 
Adjusted for sex, age, diabetes, triglycerides, 
total and LDL cholesterol, and ACE inhibitor 
at discharge 
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Study Design/population Findings: RRa (95% CI) Comments
Chen et al. 
(2012)
• 8,489 patients undergoing PCI (stent 
implantation) who were current smokers 
at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status during follow-up 
(indeterminate timing)
• 4,440 quitters, 4,049 persistent smokers
• Study period: 2004–2010
• China
• 3.0-year median follow-up
• Adjusted hazard ratio: 0.11 (0.06–0.22) Hazard ratio for quitters vs. persistent smokers
Adjusted for sex, age, diabetes, prior MI, 
hypertension, hyperlipidemia, prior bypass 
surgery, unstable angina, family history of 
CHD, ejection fraction, lesion type, reference 
vessel diameter, lesion length, restenotic 
lesion, calcification, angulated/total occlusion, 
thrombus, predilation, stent length, 
and postdilation
Álvarez et al. 
(2013)
• FRENA registry
• 1,182 patients who were current smokers 
at diagnosis
• 475 with CAD, 240 with CVD, 467 with PAD 
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 4-month follow-up
• 512 quitters, 670 persistent smokers
• Study period: 2003–2010
• Spain
• 14-month mean follow-up
• Adjusted hazard ratio: 0.51 (0.22–1.15) Mortality ratio for quitters vs. persistent smokers
Adjusted for comorbidity, atrial fibrillation, 
medications, and creatinine clearance
de Boer et al. 
(2013)
• 497 patients undergoing PCI who were 
current smokers at diagnosis and survived 
at least 1 year
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 1-year follow-up
• 210 quitters, 287 persistent smokers
• Study baseline: 1980–1985
• Netherlands
• 19.5-year median follow-up, 30 years maximum
• 56 years of age average
• All cause-mortality: adjusted hazard ratio 
0.57 (0.46–0.71)
• 30-year survival: 2.1 times as high in quitters 
as in persistent smokers (29% vs. 14%)
• Life expectancy: 2.1 years longer in quitters 
vs. persistent smokers (18.5 vs. 16.4 years)
Adjusted hazard ratio comparing quitters plus 
nonsmokers vs. persistent smokers
Having the baseline age of the cohort combined 
with a 30-year follow-up period enabled unique 
evaluation of impact on survival; adjustments 
not clearly specified, but there appears to have 
been adjustment for sex, age, indication for PCI, 
diabetes, prior MI, hypertension, hyperlipidemia, 
prior bypass surgery, multivessel disease, clinical 
success of PCI, and family history of CHD
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Table 4.21 Continued
Study Design/population Findings: RRa (95% CI) Comments
Liu et al. (2013) • 430 male CHD patients undergoing PCI who 
were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status immediately after 
the index procedure (indeterminate)
• 283 quitters, 147 persistent smokers
• Study baseline: 2009–2010, follow-up to 2012
• China
• Follow-up 27.2 months (assumed to be average)
• Risk ratio: 0.17 (0.05–0.63) Risk ratio calculated from data presented in 
Table 2 in Liu and colleagues (2013); data 
represent major clinical outcomes for persistent 
smokers, quitters, and nonsmokers 
Adjusted hazard ratio comparing persistent 
smokers to quitters plus nonsmokers presented 
in Table 3 in Liu and colleagues (2013) will 
underestimate association because of inclusion 
of nonsmokers in the reference group; hazard 
ratio was 2.43 (95% CI, 1.17–5.05) after 
adjusting for age, hypertension, dyslipidemia, 
aspirin use, and statin use
Hammal et al. 
(2014)
• APPROACH registry
• 2,583 patients undergoing coronary 
angiography for CAD who were current 
smokers at diagnosis and survived at least 
1 year
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 1-year follow-up
• 1,519 quitters, 1,064 persistent smokers
• Study period: 2003–2010
• Canada
• 42.2-month mean follow-up
• 56 years of age (mean)
• Outcome all-cause mortality plus comparison 
of survival: 
 – Total cohort (unmatched): 0.54 (0.39–0.73)
 – Subgroup receiving medical treatment 
(matched): 0.59 (0.31–1.11)
 – Subgroup receiving revascularization: 
0.46 (0.22–0.96)
 – Survival in total cohort: 95.7% in quitters vs. 
92.0% in persistent smokers
 – Survival in subgroup receiving medical 
treatment: 93.0% in quitters vs. 88.0% 
in persistent smokers
 – Survival in subgroup receiving 
revascularization: 94.9% in quitters vs. 
88.9% in persistent smokers (p <0.05)
Quitters vs. persistent smokers
Risk ratios calculated from data presented in 
Table 7 in Hammal and colleagues (2014)
No explicit adjustments; matching was on 
basis of propensity scores
Notes: ACE = angiotensin-converting enzyme; AMI = acute myocardial infarction; APPROACH = Alberta Provincial Project for Outcomes Assessment in Coronary Heart 
Disease; ASSET = Anglo-Scandinavian Study of Early Thrombolysis; BMI = body mass index; CABG = coronary artery bypass grafting; CAD = coronary artery disease; 
CASS = Coronary Artery Surgery Study; CHD = coronary heart disease; CI = confidence interval; DART = Diet and Reinfarction Trial; FRENA = Factores de Riesgo y 
ENfermedad Arterial [Registry]; ISFAMI = Israel Study of First Acute Myocardial Infarction; KAROLA = Langzeiterfolge der Kardiologischen Anschlussheilbehandlung 
(Long-Term Success of Cardiologic Rehabilitation Therapy); LDL = low-density lipoprotein; MI = myocardial infarction; MILIS = Multicenter Investigation of Limitation of 
Infarct Size; OACIS = Osaka Acute Coronary Insufficiency Study; OASIS = Organization to Assess Strategies in Acute Ischemic Syndromes; PAD = peripheral artery disease; 
PCI = percutaneous coronary intervention; PTCA = percutaneous transluminal coronary angioplasty; RR = relative risk; SAVE = Sleep Apnea Cardiovascular Endpoints.
aRR unless specified otherwise.
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Table 4.22  Summary of results from prospective cohort studies of patients with coronary heart disease who were cigarette smokers at diagnosis, 
comparing all-cause mortality in those who remained persistent smokers with those who quit smoking
Study Design/population Findings: RR (95% CI) Comments
Salonen (1980) • 523 male patients ≤65 years of age with MI 
who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 6-month follow-up
• 221 quitters, 302 persistent smokers
• Enrollment period: 1968–1977 
• Finland
• 3-year follow-up
• 1.7 (1.1–2.6) Persistent smokers vs. quitters (referent) 
Unadjusted rate ratios
Daly et al. (1983) • 374 patients with unstable angina or MI 
who were current smokers at diagnosis and 
survived at least 2 years
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 2-year follow-up
• 217 quitters, 157 persistent smokers
• Enrollment period: 1974–1979 
• Ireland
• 7.4-year mean follow-up, 13-year follow-up 
after smoking status defined
• 2.8 (p <0.01) Persistent smokers vs. quitters (referent) 
Mortality ratios calculated from average annual 
mortality rates
Unadjusted rate ratios
Presented survival plots and p values only from 
Cox proportional hazards regression models
Johansson et al. 
(1985)
• 156 female patients with MI who were current 
smokers at diagnosis and survived at least 
3 months
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 3 months of 
follow-up
• 81 quitters, 75 persistent smokers
• Study period: 1968–1977 
• Ireland
• 7.4-year mean follow-up, 13-year follow-up 
after smoking status defined
• Unadjusted: 2.3 (1.2–4.4)
• Fully adjusted: 2.7 (CI not presented)
Persistent smokers vs. quitters (referent)
Unadjusted rate ratios
Cox proportional hazards models; fully adjusted 
model included mean peak SAST, Q waves, and 
angina pectoris known before the infarction
Presented survival plots
Example of adjustment resulting in stronger 
association
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Table 4.22 Continued
Study Design/population Findings: RR (95% CI) Comments
Vliestra et al. 
(1986)
• CASS
• 4,165 patients with angiographically confirmed 
CAD who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at time of diagnosis
• 1,490 quitters, 2,675 persistent smokers
• Enrollment period: 1975–1977 
• United States (15 clinical sites)
• 5-year follow-up results presented
• 1.55 (1.29–1.85) Persistent smokers vs. quitters (referent)
Quitters had a worse prognostic profile than 
persistent smokers at baseline 
The definition of persistent smoker was self-
reported smoking at every follow-up
The definition of quitter was someone who 
quit 1 year before study entry and reported 
not smoking at every follow-up
Cox proportional hazards models using a 
propensity-score approach to adjust for covariates 
Propensity-score adjustment approach on basis 
of the following variables: age, sex congestive 
heart failure score, left ventricular wall motion 
score, CAGE 50, surgery, left ventricular end-
diastolic blood pressure, hypertension, diabetes, 
Gensini score, prior MI, degree of functional 
impairment because of congestive heart failure, 
left main coronary stenosis of ≥50%
Hermanson 
et al. (1988)
• CASS
• 1,893 patients with CAD who were current 
smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters based on quitting 
smoking within 1 year before the baseline 
angiogram
• 807 quitters, 1,086 persistent smokers
• Enrollment period: 1974–1979 
• United States
• Average follow-up: 5.3 years
• All-cause mortality, total: 1.7 (1.4–2.0)
• All-cause mortality stratified by age 
group (years):
 – 55–64: 1.7 (1.4–2.1)
 – ≥70: 1.6 (1.1–2.3)
 – 55–59: 1.5 (1.1–2.0)
 – 60–64: 2.0 (1.5–2.6)
 – 65–69: 1.4 (0.9–2.0)
 – ≥70: 3.3 (1.5–7.1)
Persistent smokers vs. quitters (referent)
Hazard ratios
Same CASS as in Vliestra and colleagues (1986)
Presented age-specific associations
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Table 4.22 Continued
Study Design/population Findings: RR (95% CI) Comments
Peters et al. 
(1995)
• CAST I and CAST II
• 1,026 patients with left ventricular dysfunction 
after MI who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 4-month follow-up
• 517 quitters, 509 persistent smokers
• Enrollment period: 1987–1991
• United States
• 15.5-month mean follow-up
• 1.64 (0.97–2.79) Persistent smokers vs. quitters (referent)
Cox proportional hazards regression models 
using smoking as a time-dependent covariate
Adjusted for sex, age, angina, heart failure, 
ejection fraction, history of MI, diabetes, 
hypertension, history of coronary artery 
angioplasty or bypass grafts, history of 
diabetes, history of congestive heart failure, 
CAST treatment condition, angina, use of 
thrombolytic agents during qualifying MI, 
and other study-specific treatment variables
Voors et al. 
(1996)
• 167 patients with coronary bypass surgery 
who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 1 year of follow-up
• 72 quitters, 95 persistent smokers
• Enrollment period: 1976–1977
• Netherlands
• 15 years of follow-up
• 0.9 (0.5–1.6) Persistent smokers vs. quitters (referent) 
Cox proportional hazards regression models
This result is for the complete follow-up period 
from 1 year to 15 years after surgery
In Table 6 in Voors and colleagues (1996), the 
result for 5 to 15 years after surgery was an RR of 
1.7 (95% CI, 0.8–3.5) adjusted for sex, age, plus 
the following variables if p <0.10 (unclear from 
text which variables met this criterion): obesity; 
elevated cholesterol and triglyceride levels; 
angina; heart failure; ejection fraction; history 
of MI, diabetes, and/or hypertension; family 
history of CAD, diabetes, and/or congestive 
heart failure; and number of vessels diseased 
and other characteristics of index diagnosis
Hasdai et al. 
(1997)
• 1,169 patients who had undergone successful 
percutaneous coronary revascularization who 
were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status during follow-up
• 435 quitters, 734 persistent smokers
• Study period: 1979–1995
• United States
• 4.5-year mean follow-up, 16-year maximum
• 1.44 (1.02–2.11) Persistent smokers vs. quitters (referent) 
Proportional hazards models 
Adjusted for significant differences in 
baseline variables
Unclear which variables were included in the 
model, but baseline variables included sex, age, 
angina, heart failure, ejection fraction, diabetes, 
hypertension, and family history of CAD
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Table 4.22 Continued
Study Design/population Findings: RR (95% CI) Comments
van Domburg 
et al. (2000)
• 556 patients who had undergone CABG surgery 
who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status >1 year after CABG 
(median 2.8 years)
• 238 quitters, 318 persistent smokers
• Study period: 1971–1980
• Netherlands
• 20-years median follow-up (range 13–26 years)
• 1.68 (1.33–2.13) Persistent smokers vs. quitters (referent)
Proportional hazards models
Adjusted for sex, age, vessel disease, ejection 
fraction, and complete revascularization
Zhang et al. 
(2015)
• SYNTAX
• 1,793 patients with complex CAD who were 
current smokers at diagnosis
• Use of time-dependent covariates may have 
included all participants (never, former, and 
current smokers at baseline)
• Smoking categorized at 6 months, 1 year, 
3 years, and 5 years of follow-up
• Indeterminate study period 
• Multicenter, multinational study
• 5 years of follow-up
• 1.80 (1.27–2.54) Smoking status analyzed as a time-dependent 
covariate
Cox proportional hazards regression models
Composite endpoint of death/MI/stroke
Never precisely specified, but this estimate 
likely included the total study population, 
including never smokers and former smokers 
as well as current smokers at baseline
Assume adjusted for other independent 
predictors listed in Table 3 in Zhang and 
colleagues (2015): PCI vs. CABG, age, COPD, 
PVD, LVEF <30%, amiodarone therapy on 
discharge (never specified in text)
Notes: CABG = coronary artery bypass grafting; CAD = coronary artery disease; CAGE 50 = number of segments with coronary artery stenosis ≥50%; CASS = Coronary 
Artery Surgery Study; CAST = Cardiac Arrhythmia Suppression Trial; CI = confidence interval; COPD = chronic obstructive pulmonary disease; LVEF = left ventricular 
ejection fraction; MI = myocardial infarction; PVD = peripheral vascular disease; PCI = percutaneous coronary intervention; RR = relative risk; SAST = serum aspartate 
amino transferase; SYNTAX = SYNergy between Percutaneous Coronary Intervention with TAXus and Cardiac Surgery Trial.
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Table 4.23  Summary of results from prospective cohort studies of patients with coronary heart disease who were cigarette smokers at diagnosis, 
comparing cause-specific mortality from cardiac endpoints and sudden death in those who remained persistent cigarette smokers with 
those who quit smoking
Study Design/population Findings: RR (95% CI) Comments
Wilhelmsson 
et al. (1975)
• 405 male patients with first MI who were 
current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 3 months 
following MI
• 231 quitters, 174 persistent smokers
• Study period: 1968–1972
• Sweden
• 2-year follow-up results presented
• Cardiovascular death: 2.05 (0.99–4.27) Persistent smokers vs. quitters (referent)
Unadjusted risk ratios
Risk ratio calculated using the data presented in 
Table 5 in Wilhelmsson and colleagues (1975)
Salonen (1980) • 523 male patients ≤65 years of age with MI 
who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 6-month follow-up
• 221 quitters, 302 persistent smokers
• Enrollment period: 1968–1977 
• Finland
• 3-year follow-up
• Ischemic heart disease: 1.6 (1.0–2.7)
• Other cardiovascular disease: 1.5 (0.3–8.0)
Persistent smokers vs. quitters (referent)
Unadjusted risk ratios
Mulcahy et al. 
(1982)
• 517 male patients <60 years of age with first 
diagnosis of unstable angina or MI who were 
current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters based on stopping 
smoking at least 3 months before the last 
follow-up or death (indeterminate timing)
• 282 quitters, 235 persistent smokers
• Enrollment period: 1961–1975, with follow-up 
through 1979
• Ireland
• 99-month mean follow-up (survivors)
• Cardiac failure: 2.70 (0.84–8.66)
• Sudden death: 1.77 (1.23–2.54)
• Fatal MI: 1.68 (1.04–2.72)
Persistent smokers vs. quitters (referent)
Unadjusted risk ratios
Risk ratio calculated using data presented in 
Table 2 in Mulcahy and colleagues (1982)
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Table 4.23 Continued
Study Design/population Findings: RR (95% CI) Comments
Daly et al. (1983) • 374 patients with unstable angina or MI 
who were current smokers at diagnosis and 
survived at least 2 years
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 2-year follow-up
• 217 quitters, 157 persistent smokers
• Enrollment period: 1974–1979 
• Ireland
• 7.4-year mean follow-up, 13-year follow-up 
after smoking status defined
• Vascular causes: 2.4 (p <0.01)
• Fatal reinfarction: 2.6 (p = 0.02)
• Sudden death: 1.6 (p = 0.14)
Persistent smokers vs. quitters (referent)
Unadjusted risk ratios 
Mortality ratios based on average annual 
mortality rates
Presented survival plots and p values only from 
Cox proportional hazards regression models
Rønnevik et al. 
(1985)
• 453 patients with first-time diagnosis of acute 
MI who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status after MI with 
continued follow-up (indeterminate time)
• 276 quitters, 177 persistent smokers
• Enrollment period: 1978–1979
• Norway
• Mean follow-up 17.3 months
• Cardiac causes (placebo group): 1.17 
(0.62–2.22)
Persistent smokers vs. quitters (referent)
Unadjusted risk ratios 
Risk ratio calculated from data presented in 
Table 3 in Rønnevik and colleagues (1985)
Results presented limited to the placebo group 
because of an observed interaction of the 
treatment (timolol) with smoking 
Hallstrom et al. 
(1986)
• 310 patients with cardiac arrest who were 
current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status 2 months or less 
after cardiac arrest
• 91 quitters, 219 persistent smokers
• Study period: 1970–1981
• United States
• Mean follow-up 47.5 months
• Cardiac arrest: 1.55 (0.98–2.45) Persistent smokers vs. quitters (referent)
Unadjusted risk ratios 
Risk ratio calculated from data presented on 
page 272 in Hallstrom and colleagues (1986)
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Table 4.23 Continued
Study Design/population Findings: RR (95% CI) Comments
Vliestra et al. 
(1986)
• CASS Trial
• 4,165 patients with angiographically confirmed 
coronary artery disease who were current 
smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at time of diagnosis
• 1,490 quitters, 2,675 persistent smokers
• Enrollment period: 1975–1977 
• United States (15 clinical sites)
• 5-year follow-up results presented
• Cardiac contributing: 1.60 (0.89–2.86)
• Sudden death: 1.82 (1.14–2.89)
• MI: 1.78 (1.36–2.33)
Persistent smokers vs. quitters (referent)
Cox proportional hazards models using a 
propensity score approach to adjust for covariates
Quitters had a worse prognostic profile than 
persistent smokers at baseline 
The definition of persistent smoker was self-
reported smoking at every follow-up; the 
definition of a quitter was someone who had 
quit 1 year before study entry and reported 
not smoking at every follow-up
Propensity-score adjustment approach based 
on age, sex, congestive heart failure score, 
left ventricular wall motion score, CAGE 50, 
surgery, left ventricular end-diastolic blood 
pressure, hypertension, diabetes, Gensini score, 
prior MI, degree of functional impairment 
because of congestive heart failure, left main 
coronary stenosis of ≥50%
Hermanson 
et al. (1988)
• CASS
• 1,893 patients with CAD who were current 
smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters based on quitting 
smoking within 1 year before the baseline 
angiogram
• 807 quitters, 1,086 persistent smokers
• Study period: 1974–1979 (enrollment)
• United States
• Average follow-up 5.3 years
• Cardiac causes: 1.37 (p = .001) Persistent smokers vs. quitters (referent)
Hazard ratios
Overall and stratified by age group
Same CASS as in Vliestra et al. (1986)
Risk ratio calculated from data presented on 
page 1,367 of Hermanson and colleagues (1988)
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Table 4.23 Continued
Study Design/population Findings: RR (95% CI) Comments
Gupta et al. 
(1993)
• 225 patients with CHD who were current 
smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status since the time of 
diagnosis of CAD (indeterminate)
• 173 quitters, 52 persistent smokers
• Study baseline: 1980
• India
• ~ 6-year average follow-up
• Sudden death: 1.48 (0.81–2.71) Persistent smokers vs. quitters (referent)
Unadjusted risk ratios 
Risk ratio calculated from data presented on 
page 127 of Gupta and colleagues (1993)
Peters et al. 
(1995)
• CAST I and CAST II
• 1,026 patients with left ventricular dysfunction 
after MI who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 4-month follow-up
• 517 quitters, 509 persistent smokers
• Enrollment period: 1987–1991 
• United States
• 15.5-month mean follow-up
• Arrhythmic mortality: 1.80 (0.88–3.67) Persistent smokers vs. quitters (referent)
Cox proportional hazards regression models 
using smoking as a time-dependent covariate
Adjusted for sex, age, angina, heart failure, 
ejection fraction, history of MI, diabetes, 
hypertension, history of coronary artery 
angioplasty or bypass grafts, history of 
diabetes, history of congestive heart failure, 
CAST treatment condition, angina, use of 
thrombolytic agents during qualifying MI, 
and other study-specific treatment variables 
Hasdai et al. 
(1997)
• 1,169 patients who had undergone successful 
percutaneous coronary revascularization who 
were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status during follow-up
• 435 quitters, 734 persistent smokers
• Study period: 1979–1995
• United States
• 4.5-year mean follow-up, 16 years maximum
• Cardiac causes: 1.49 (0.89–2.51) Persistent smokers vs. quitters (referent)
Proportional hazards models 
Adjusted for significant differences in 
baseline variables
Unclear which variables were included in the 
model, but baseline variables included sex, age, 
angina, heart failure, ejection fraction, diabetes, 
hypertension, and family history of CAD
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Table 4.23 Continued
Study Design/population Findings: RR (95% CI) Comments
van Domburg 
et al. (2000)
• 556 patients who had undergone CABG surgery 
who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status >1 year after CABG 
(median 2.8 years)
• 238 quitters, 318 persistent smokers
• Study period: 1971–1980
• Netherlands
• 20-year median follow-up (range 13–26 years)
• Cardiac causes: 1.75 (1.30–2.37) Persistent smokers vs. quitters (referent)
Proportional hazards models 
Adjusted for sex, age, vessel disease, ejection 
fraction, and complete revascularization
Liu et al. (2013) • 430 male CHD patients undergoing 
percutaneous coronary intervention who were 
current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status immediately after the 
index procedure (indeterminate)
• 283 quitters, 147 persistent smokers
• Study baseline: 2009–2010, follow-up to 2012
• China
• Follow-up 27.2 months (assumed to be average)
• Cardiac causes: 7.7 (0.9–68.8) Persistent smokers vs. quitters (referent)
Risk ratio calculated from data presented in 
Table 2 in Liu and colleagues (2013)
Notes: CABG = coronary artery bypass grafting; CAD = coronary artery disease; CAGE 50 = number of segments with coronary artery stenosis ≥50%; CASS = Coronary Artery 
Surgery Study; CAST = Cardiac Arrhythmia Suppression Trial; CHD = coronary heart disease; CI = confidence interval; MI = myocardial infarction; RR = relative risk.
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Table 4.24  Summary of results from prospective cohort studies of patients with coronary heart disease who were cigarette smokers at diagnosis, 
comparing incidence of cardiac endpoints in those who remained persistent cigarette smokers with those who quit smoking or vice versa
Study Design/population Findings: RR (95% CI) Comments
Wilhelmsson 
et al. (1975)
• 405 male patients with first MI who were 
current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 3 months 
following MI
• 231 quitters, 174 persistent smokers
• Study period: 1968–1972
• Sweden
• 2-year follow-up results presented
• Reinfarction: 0.49 (0.29–0.82) Persistent smokers vs. quitters (referent)
Unadjusted risk ratios 
Risk ratio calculated based on the data presented 
in Table 5 in Wilhelmsson and colleagues (1975)
Sparrow and 
Dawber (1978)
• Framingham Study
• 195 patients with MI who were current 
smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status after data collection 
immediately preceding and following MI 
(indeterminate timing)
• 56 quitters, 139 persistent smokers
• Cohort established 1949: 22 years of follow-up 
through 1978
• United States
• 6-year follow-up results presented
• Reinfarction: 0.76 (0.37–1.58) Persistent smokers vs. quitters (referent)
Unadjusted risk ratios 
Risk ratio calculated based on data presented 
on page 430 in Sparrow and Dawber (1978)
Aberg et al. 
(1983)
• 983 male patients with first MI who were 
current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 3-month follow-up
• 542 quitters, 441 persistent smokers
• Enrollment period: 1968–1977 
• Sweden
• 10.5-year maximum follow-up
• Reinfarction: 0.67 (0.53–0.84) Persistent smokers vs. quitters (referent)
Unadjusted risk ratios 
Risk ratio calculated from data presented in 
Table 7 in Aberg and colleagues (1983)
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Table 4.24 Continued
Study Design/population Findings: RR (95% CI) Comments
Perkins and Dick 
(1985)
• 119 patients with first-time diagnosis of MI 
who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent 
smokers based on smoking status after MI 
(indeterminate time)
• 52 quitters, 67 persistent smokers
• Enrollment period: 1974–1977 
• United Kingdom
• 5-year follow-up
• Reinfarction: 3.87 (0.81–18.37) Persistent smokers vs. quitters (referent)
Unadjusted risk ratios 
Risk ratio calculated from data presented in 
Table II in Perkins and Dick (1985)
Rønnevik et al. 
(1985)
• 453 patients with first-time diagnosis of acute 
MI who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status after MI based on 
continued follow-up (indeterminate time)
• 276 quitters, 177 persistent smokers
• Enrollment period: 1978–1979
• Norway
• Mean follow-up 17.3 months
• MI: 0.54 (0.32–0.93) Persistent smokers vs. quitters (referent)
Unadjusted risk ratios
Results presented limited to the placebo group 
because of an observed interaction of treatment 
(timolol) with smoking 
Risk ratio calculated from data presented in 
Table 3 in Rønnevik and colleagues (1985)
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Table 4.24 Continued
Study Design/population Findings: RR (95% CI) Comments
Vliestra et al. 
(1986)
• CASS
• 4,165 patients with angiographically confirmed 
CAD who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at time of diagnosis
• 1,490 quitters, 2,675 persistent smokers
• Enrollment period: 1975–1977 
• United States (15 clinical sites)
• 5-year follow-up results presented
• 5-year MI hospitalization: 0.63 (0.51–0.78) Persistent smokers vs. quitters (referent)
Cox proportional hazards models using a 
propensity score approach to adjust for covariates 
Propensity-score adjustment approach on basis 
of the following variables: age, sex, congestive 
heart failure score, left ventricular wall motion 
score, CAGE 50, surgery, left ventricular end-
diastolic blood pressure, hypertension, diabetes, 
Gensini score, prior MI, degree of functional 
impairment because of congestive heart failure, 
left main coronary stenosis of ≥50%
Quitters had a worse prognostic profile than 
persistent smokers at baseline 
The definition of persistent smoker was self-
reported smoking at every follow-up; the 
definition of a quitter was someone who had 
quit 1 year before study entry and reported 
not smoking at every follow-up
Herlitz et al. 
(1995)
• 217 patients with acute MI who were current 
smokers at diagnosis and survived at least 
1 year
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status after 1 year of 
follow-up
• 115 quitters, 102 persistent smokers
• Enrollment period: 1986–1987
• Sweden
• 4-year follow-up results presented
• Reinfarction: 0.99 (0.42–2.33) Persistent smokers vs. quitters (referent)
Unadjusted risk ratios
Risk ratio calculated from data presented in 
Table 4 in Herlitz and colleagues (1995)
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Table 4.24 Continued
Study Design/population Findings: RR (95% CI) Comments
Voors et al. 
(1996)
• 167 patients with coronary bypass surgery 
who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 1 year of follow-up
• 72 quitters, 95 persistent smokers
• Enrollment period: 1976–1977 
• Netherlands
• 15 years of follow-up
• MI: 2.3 (1.1–5.1)
• Reoperation: 2.5 (1.1–5.9)
• Angina:
 – 1–15 years post-surgery: 1.2 (0.8–1.7)
 – 5–15 years post-surgery: 2.0 (1.1–3.6)
Persistent smokers vs. quitters (referent)
Cox proportional hazards regression models
Adjusted for sex, age, plus the following variables 
if p <0.10 (unclear from text which variables 
met this criterion): obesity, diabetes, elevated 
cholesterol and triglyceride levels, hypertension, 
history of heart failure, preoperative angina 
pectoris, family history of CAD, number of vessels 
diseased, completeness of revascularization, 
number of distal anastomoses, left ventricular 
function, history of MI, indication for operation, 
presence of collateral arteries, left main CAD, and 
proximal left anterior descending artery disease 
Hasdai et al. 
(1997)
• 1,169 patients who had undergone successful 
percutaneous coronary revascularization who 
were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status during follow-up
• 435 quitters, 734 persistent smokers
• Study period: 1979–1995
• United States
• 4.5-year mean follow-up, 16 years maximum
• MI: 0.68 (.54–.86) Quitters vs. persistent smokers (referent)
Proportional hazards model
Never smokers were used as the referent for 
estimating the RRs; 0.68 was the RR of MI for 
quitters vs. never smokers, and 1.44 (1.02–2.11) 
was the RR for death for persistent smokers vs. 
never smokers 
Adjusted for significant differences in 
baseline variables
Unclear which variables were included in the 
model, but baseline variables included sex, age, 
angina, heart failure, ejection fraction, diabetes, 
hypertension, and family history of CAD
Smoking Cessation
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Table 4.24 Continued
Study Design/population Findings: RR (95% CI) Comments
van Domburg 
et al. (2000)
• 556 patients who had undergone CABG surgery 
who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status >1 year after CABG 
(median 2.8 years)
• 238 quitters, 318 persistent smokers
• Study period: 1971–1980
• Netherlands
• 20-year median follow-up (range 13–26 years)
• Repeat CABG/PTCA: 1.41 (1.02–1.94) Persistent smokers vs. quitters (referent) 
Proportional hazards models
Adjusted for sex, age, vessel disease, ejection 
fraction, and complete revascularization
Chow et al. 
(2010)
• OASIS trial
• 4,324 patients with unstable angina or MI 
who were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status after 30 days of 
follow-up
• 2,802 quitters, 1,522 persistent smokers
• Study baseline: 2003–2005
• 41 countries
• 6-month follow-up
• MI: 0.57 (0.36–0.89)
• Stroke: 0.40 (0.14–1.17)
Quitters vs. persistent smokers (referent)
Logistic regression models
Paper presented measures of association as odds 
ratios, but for this prospective cohort study, 
these were converted to RR
Adjusted for sex, age, hypertension history, 
diabetes, prior MI, BMI, creatinine, PCI/CABG 
before 30 days, and medications
Chen et al. 
(2012)
• 8,489 patients undergoing PCI (stent 
implantation) who were current smokers 
at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status during follow-up 
(indeterminate timing)
• 4,440 quitters, 4,049 persistent smokers
• Study period: 2004–2010
• China
• 3.0-year median follow-up
• Repeat revascularization: 1.59 (1.36–1.85) Hazard ratio for quitters vs. persistent smokers
Adjusted for sex, age, diabetes, prior MI, 
hypertension, hyperlipidemia, prior bypass 
surgery, unstable angina, family history of 
CHD, ejection fraction, lesion type, reference 
vessel diameter, lesion length, restenotic 
lesion, calcification, angulated/total occlusion, 
thrombus, predilation, stent length, 
and postdilation 
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Table 4.24 Continued
Study Design/population Findings: RR (95% CI) Comments
Álvarez et al. 
(2013)
• FRENA registry
• 1,182 patients who were current smokers 
at diagnosis
• 475 with CAD, 240 with CVD, 467 with PAD 
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 4-month follow-up
• 512 quitters, 670 persistent smokers
• Study period: 2003–2010
• Spain
• 14-month mean follow-up
• MI: 0.70 (0.26–1.88) Mortality ratio for quitters vs. persistent smokers 
Adjusted for comorbidity, atrial fibrillation, 
medications, and creatinine clearance
Choi et al. 
(2013)
• Prospective cohort 
• 275 patients who were current smokers at 
diagnosis of MI
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status at 4-month follow-up
• 144 quitters, 131 persistent smokers
• Study period: 1999–2008
• South Korea
• Regularly followed for 1 year after MI
• Re-intervention or MI: 2.9 (0.2–33.0) Persistent smokers vs. quitters (referent)
Risk ratio for re-intervention or MI
Not clear that the estimate was adjusted for 
any factors
Liu et al. (2013) • 430 male CHD patients undergoing PCI who 
were current smokers at diagnosis
• All current smokers at baseline
• Categorized as quitters or persistent smokers 
based on smoking status immediately after the 
index procedure (indeterminate)
• 283 quitters, 147 persistent smokers
• Study baseline: 2009–2010, follow-up to 2012
• China
• Follow-up 27.2 months (assumed to be average)
• Revascularization: 2.89 (1.05–8.0)
• MI:
 – 1.4% in persistent smokers
 – 0% in quitters
• RR for quitters vs. persistent = 0.0
Persistent smokers vs. quitters (referent)
Risk ratio calculated from data presented in 
Table 2 in Liu and colleagues (2013)
Adjusted hazard ratio comparing persistent 
smokers to quitters plus nonsmokers presented 
in Table 3 in Liu and colleagues (2013) will 
underestimate association because of inclusion 
of nonsmokers in the referent 
Hazard ratio was 2.43 (95% CI, 1.17–5.05) after 
adjusting for age, hypertension, dyslipidemia, 
aspirin use, and statin use
Notes: BMI = body mass index; CABG = coronary artery bypass grafting; CAD = coronary artery disease; CAGE 50 = number of segments with coronary artery stenosis ≥50%; 
CASS = Coronary Artery Surgery Study; CHD = coronary heart disease; CI = confidence interval; CVD = cardiovascular disease; FRENA = Factores de Riesgo y ENfermedad 
Arterial [Registry]; MI = myocardial infarction; OASIS = Organization to Assess Strategies in Ischemic Syndromes; PAD = peripheral artery disease; PCI = percutaneous 
coronary intervention; PTCA = percutaneous transluminal coronary angioplasty; RR = relative risk.
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Figure 4.4 Relative risk for all-cause mortality after cardiac event among those who were current smokers when diagnosed, by smoking status
Study Relative risk (95% CI)
Quit vs. persistent  
Wilhemsson et al. 1975 0.51 (0.27–0.96)
Sparrow et al. 1978 0.62 (0.33–1.15)
Baughman et al. 1982 0.35 (0.18–0.66)
Mulcahy et al. 1982 0.59 (0.47–0.73)
Aberg et al. 1983 0.63 (0.50–0.79)
Perkins et al. 1985 0.39 (0.20–0.74)
Rønnevik et al. 1985 0.74 (0.42–1.30)
Hallstrom et al. 1986 0.79 (0.50–1.06)
Burr et al. 1992 0.52 (0.32–0.83)
Cavender et al. 1992 0.63 (0.40–0.97)
Gupta et al. 1993 0.70 (0.49–1.01)
Tofler et al. 1993 0.48 (0.31–0.73)
Greenwood et al. 1995 0.56 (0.33–0.98)
Herlitz et al. 1995 0.55 (0.34–0.91)
Kinjo et al. 2005 0.39 (0.20–0.77)
Gerber et al. 2009 0.63 (0.48–0.82)
Chow et al. 2010 0.93 (0.59–1.46)
Shah et al. 2010 0.57 (0.36–0.91)
Breitling et al. 2011 0.38 (0.20–0.73)
Chen et al. 2012 0.11 (0.06–0.22)
Álvarez et al. 2013 0.51 (0.22–1.15)
de Boer et al. 2013 0.57 (0.46–0.71)
Liu et al. 2013 0.17 (0.05–0.63)
Hammal et al. 2014 0.54 (0.39–0.73)
Persistent vs. quit  
Salonen et al. 1980 1.70 (1.10–2.60)
Johansson et al. 1985 2.30 (1.20–4.40)
Vliestra et al. 1986 1.55 (1.29–1.85)
Hermanson et al. 1988 1.70 (1.40–2.00)
Peters et al. 1995 1.64 (0.97–2.79)
Voors et al. 1996 0.90 (0.50–1.60)
Hasdai et al. 1997 1.44 (1.02–2.11)
van Domburg et al. 2000 1.68 (1.33–2.13)
Zhang et al. 2015 1.80 (1.27–2.54) 
Note: CI = confidence interval.
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the association between cessation and mortality compared 
with classification of smoking by both self-reported and 
biomarker data. These results replicated previous findings 
from this research group (Twardella et al. 2006). Because 
most findings are based on self-reported smoking status, 
the pattern of associations in comparisons of self-reported 
with biomarker-based classification suggests that the 
associations observed in studies that rely on self-reported 
smoking may be underestimated because of the misclas-
sification from self-reports. 
Table 4.22 summarizes studies in cohorts of patients 
with CHD that assessed the association between smoking 
cessation and all-cause mortality by comparing persistent 
smokers with quitters as the reference group; the lower 
portion of Figure 4.4 presents a forest plot for the nine 
reports that included an RR and a 95%  CI. Among the 
10 reports from the 9 studies detailed in Table 4.22, all but 
1 report showed an RR estimate of 1.44 or greater for per-
sistent smokers. As can be seen in the forest plot, seven of 
the nine RR estimates it contains were statistically signifi-
cant. The median RR was 1.67, indicative of an increase 
of two-thirds in the all-cause mortality rate in persistent 
smokers compared with quitters.
Taken together, the results of the studies summa-
rized in Tables 4.21 and 4.22 and in Figure 4.4 show very 
clear, consistent, and strong associations. In total, 97% 
(31/32) of the studies reported associations indicating that 
smoking cessation was associated with a reduction in all-
cause mortality when compared with persistent smoking. 
These associations were statistically significant in 78% 
(25/32) of the studies—a high proportion, given that 
25% (8/32) of the studies had total samples of fewer than 
300  patients and the median follow-up period was only 
4.5  years. These results align closely with the results of 
meta-analyses published in 1999 (van Berkel et al. 1999) 
and in 2003 (Critchley and Capewell 2003) that reported 
summary RRs in quitters versus persistent smokers of 
0.62  (95%  CI, 0.57–0.68) (van  Berkel et  al. 1999) and 
0.64 (95% CI, 0.58–0.71) (Critchley and Capewell 2003), 
respectively. When these associations are viewed from 
the reverse perspective of comparing persistent smokers 
with quitters, they are of a magnitude similar to the asso-
ciation of smoking with all-cause mortality in general 
cohorts, as reported in the 2014 Surgeon General’s report 
(USDHHS 2014).
A central issue in assessing this body of evidence 
is that among current cigarette smokers diagnosed with 
CHD, those who quit may differ from persistent smokers 
in ways that could generate an apparent benefit of smoking 
cessation that reflects confounding. Many of the asso-
ciations presented in the evidence tables in the present 
report are not adjusted for any potential confounding vari-
ables. The results in Table 4.21 that begin with the study 
of Kinjo and colleagues (2005) and then go up through a 
2014 report were estimated mainly with Cox proportional 
hazard models that adjusted for a wide range of potential 
confounding variables. These 10 studies had RR estimates 
that ranged from 0.11 to 0.93, with a median of 0.52. Only 
3  of the 17  RR estimates were 0.63  or higher, and the 
3  lowest RRs equaled 0.11  (once) and 0.17  (twice), with 
those results indicating a very strong protective effect for 
quitting. Notably, the studies that compared the charac-
teristics of quitters with persistent smokers found that 
quitters tended to be older and to have a predominance 
of other characteristics associated with a worse prog-
nosis. This pattern could lead to confounding that would 
diminish a true association.
The presence of confounding is supported by the 
increased association observed in some studies that 
adjusted for potential confounding variables. For example, 
in the study by Johansson and colleagues (1985), which 
compared persistent smokers with quitters, the unad-
justed RR of death was 2.3 for the persistent smokers, 
and after adjustment for the key prognostic factors that 
differed between persistent smokers and quitters, the RR 
increased to 2.7 (Table 4.22). Thus, confounding appears 
an unlikely explanation for the finding of reduced all-cause 
mortality in quitters versus persistent smokers among 
those who were current smokers at the time of diagnosis 
with a cardiac condition. In contrast, it could be helpful 
in explaining the results of studies in which quitters, not 
persistent smokers, were the referent. 
Concerns about confounding can be further 
addressed by analyzing evidence from studies of smoking 
cessation interventions that provide evidence to address 
this issue. For example, in an observational cohort study 
of 13,815  patients diagnosed with MI who were current 
smokers discharged alive from the hospital, those who 
received an inpatient smoking cessation intervention were 
compared with those who did not receive this interven-
tion (Bucholz et al. 2017). At 30 days of follow-up, those 
who received the intervention had significantly reduced 
all-cause mortality (hazard ratio [HR]  =  0.77; 95%  CI, 
0.62–0.96), and this benefit persisted even after 17 years 
of follow-up (HR = 0.93; 95% CI, 0.89–0.96) after adjust-
ment for a wide range of potential confounding variables. 
Elsewhere, in a randomized controlled trial of an 
intensive smoking cessation intervention (n = 109) com-
pared with usual care (n = 100) in a population of 30- to 
75-year-olds diagnosed with acute cardiovascular dis-
ease, after 2 years of follow-up the intervention group had 
4.3  times the proportion of continuous abstinence from 
smoking compared with the usual-care group (Mohiuddin 
et al. 2007). During this same 2-year interval, compared 
with the usual-care group, the intervention group expe-
rienced a 44% reduction in hospitalizations (RR = 0.56; 
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95% CI, 0.37–0.85) and a reduction of more than three-
quarters in all-cause mortality (RR = 0.23; 95% CI, 0.07–
0.79) (Mohiuddin et al. 2007). Given the randomized trial 
design, this study provides experimental evidence of the 
association between smoking cessation and reduced fatal 
and nonfatal outcomes. Associations of this magnitude 
from a high-quality experimental study with relatively 
short-term follow-up provide strong evidence supporting 
an immediate and direct benefit of quitting and greatly 
reduce the likelihood that uncontrolled confounding 
explains the results of the observational studies.
Smoking Cessation and Cause-Specific 
Mortality in Cardiac Patients
The indication of a strong inverse association 
between smoking cessation and all-cause mortality after 
patients are diagnosed with CHD raises a question as to 
which causes of death are affected. Table  4.23 presents 
20 specific associations comparing persistent smokers to 
quitters from 13 studies of cohorts of patients with CHD 
that assessed smoking cessation in relation to cause-
specific mortality; these studies focused on either specific 
cardiac endpoints or sudden death. The 16 RR estimates 
with CIs are summarized in forest plots in Figure 4.5. 
The results shown in Figure  4.5 are stratified by 
cause-of-death groups, with “cardiac” and “cardiac con-
tributing” comprising the largest group (n = 9 data points), 
followed by sudden death (n = 3 data points), fatal rein-
farction (n = 2 data points), and 1 each for ischemic heart 
disease and arrhythmic mortality. The visual impression 
of consistently strong associations shown in Figure 4.5 is 
reinforced by the complete evidence in Table 4.23, as all 
20 associations presented in the table indicate increased 
risk associated with persistent smoking, with RRs ranging 
from 1.17  to 7.70, with a median of 1.60. The RRs were 
statistically significant in 45% (9/20), a smaller propor-
tion than observed for all-cause mortality; because the 
magnitudes of the RRs were similar for all-cause and 
cause-specific mortality, the reduced statistical precision 
due to the smaller numbers of deaths for cause-specific 
compared with all-cause mortality likely explains the 
lower proportion of significant estimates. This body of evi-
dence demonstrates that in current smokers diagnosed 
with CHD, the reduction in all-cause mortality associated 
with smoking cessation is attributable, at least in part, to a 
reduction in mortality from cardiac outcomes and sudden 
death. Cigarette smoking is an established cause of MI 
and other cardiovascular endpoints, as reviewed in prior 
Surgeon General’s reports (USDHHS 1983, 2010, 2014); 
thus, the associations reviewed in Table 4.23 and summa-
rized in a forest plot in Figure 4.5 are consistent with prior 
evidence on this topic in the general population.
Smoking Cessation and Risk of Recurrence 
or New Cardiac Events in Cardiac Patients
Studies in cohorts of patients with CHD who were 
current smokers at the time of diagnosis that assessed 
the risk of new or recurrent cardiac events in relation to 
quitting versus persistent smoking are summarized in 
Table 4.24 and, for those studies with RRs and 95% CIs, 
in forest plots in Figure  4.6. Thirteen studies provided 
results for MI, including the outcomes of “reinfarction” 
and “MI hospitalization”; consistent with Figure 4.6, the 
associations tended to be either strongly in the protective 
direction for quitters compared with persistent smokers 
as the reference category (85% [11/13] RRs ≤0.76; overall 
median RR = 0.67) or, alternatively, strongly in the direc-
tion of increased risk for persistent smokers relative to 
quitters as the referent. Of the two studies with results 
not strongly in the protective direction, the associations 
were null in one (RR = 0.99; 95% CI, 0.42–2.33) (Herlitz 
et al. 1995) and positive in the other (RR = 3.87; 95% CI, 
0.81–18.37) (Perkins and Dick 1985). As seen in Figure 4.6, 
these two studies introduce heterogeneity. The overall 
results of these studies comprise a strong body of evidence 
indicating that smoking cessation after a diagnosis of a 
previous MI or other cardiac disease reduces the risk of MI.
The results for the endpoints of stroke, angina, or 
repeat procedures also indicate benefit from smoking ces-
sation—that is, reduced risk in quitters versus persistent 
smokers. One study found that quitters had a lower risk 
of stroke (RR = 0.40; 95% CI, 0.14–1.17) compared with 
persistent smokers, but the results were not statistically 
significant (Chow et  al. 2010). The one study of angina 
(Voors et  al. 1996) found a weak, nonsignificant associ-
ation for the entire follow-up period (RR = 1.2; 95% CI, 
0.8–1.7), but a significant association for the period from 
5  to 15 years after surgery (RR = 2.0; 95% CI, 1.3–3.6). 
Four studies reported results using repeat procedures as 
endpoints; these included repeat coronary artery bypass 
grafting/percutaneous transluminal coronary angioplasty 
(CABG/PTCA), reoperation, and repeat vascularization. 
Three studies observed increased risk for repeat proce-
dures—CABG/PTCA, reoperation, or repeat vasculariza-
tion—in persistent smokers when quitters were the ref-
erent (RR  ≥1.4). In the fourth study, authored by Chen 
and colleagues (2012), the results were strongly in the 
opposite direction, with an RR of 1.59 (95% CI, 1.36–1.85) 
for repeat revascularization in quitters compared with 
persistent smokers as the referent. This discrepant result 
notwithstanding, the overall evidence summarized in 
Table 4.24 and Figure 4.6 indicates reduced risk associated 
with smoking cessation relative to persistent smoking for 
the occurrence of adverse cardiac events among patients 
with CHD who were current smokers at diagnosis.
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Figure 4.5 Cause-specific mortality from cardiovascular endpoints and sudden death in persistent smokers versus quitters
Study Relative risk (95% CI)
Cardiac  
Wilhemsson et al. 1975 2.05 (0.99–4.27)
Salonen et al. 1980 1.50 (0.30–8.00)
Mulcahy et al. 1982 2.70 (0.84–8.66)
Rønnevik et al. 1985 1.17 (0.62–2.22)
Hallstrom et al. 1986 1.55 (0.98–2.45)
Vliestra et al. 1986 1.60 (0.89–2.86)
Hasdai et al. 1997 1.49 (0.89–2.51)
van Domburg et al. 2000 1.75 (1.30–2.37)
Liu et al. 2013 7.70 (0.87–68.27)
Sudden death  
Mulcahy et al. 1982 1.77 (1.23–2.54)
Vliestra et al. 1986 1.82 (1.14–2.89)
Gupta et al. 1993 1.48 (0.81–2.71)
Fatal reinfarction  
Mulcahy et al. 1982 1.68 (1.04–2.72)
Vliestra et al. 1986 1.78 (1.36–2.33)
Ischemic heart disease  
Salonen et al. 1980 1.60 (1.00–2.70)
Arrhythmic mortality  
Peters et al. 1995 1.80 (0.88–3.67)
Note: CI = confidence interval.
Smoking Cessation
The Health Benefits of Smoking Cessation  301
Figure 4.6 Comparison of incidence of new cardiac endpoints among persistent smokers and quitters
Study Relative risk (95% CI)
Myocardial infarction or 
hospitalization or reinfarction
 
Quit vs. persistent  
Wilhemsson et al. 1975 0.49 (0.29–0.82)
Sparrow et al. 1978 0.76 (0.37–1.58)
Aberg et al. 1983 0.67 (0.53–0.84)
Perkins et al. 1985 3.87 (0.81–18.37)
Rønnevik et al. 1985 0.54 (0.32–0.93)
Vliestra et al. 1986 0.63 (0.51–0.78)
Herlitz et al. 1995 0.99 (0.42–2.33)
Chow et al. 2010 0.57 (0.36–0.89)
Álvarez et al. 2013 0.70 (0.26–1.88)
Persistent vs. quit  
Voors et al. 1996 2.30 (1.10–5.10)
Choi et al. 2013 2.86 (0.25–33.04)
Stroke  
Quit vs. persistent  
Chow et al. 2010 0.40 (0.14–1.17)
Angina  
Persistent vs. quit  
Voors et al. 1996 (1- to 15-year 
follow-up)
1.20 (0.80–1.70)
Voors et al. 1996 (5- to 15-year 
follow-up)
2.00 (1.10–3.60)
Repeat procedures (CABG/PTCA/
vascularization) 
 
Quit vs. persistent  
Chen et al. 2012 1.59 (1.36–1.85)
Persistent vs. quit  
Voors et al. 1996 2.50 (1.10–5.90)
van Domburg et al. 2000 1.41 (1.02–1.94)
Liu et al. 2013 2.89 (1.05–8.00)
Note: CABG = coronary artery bypass grafting; CI = confidence  
interval; PTCA = percutaneous transluminal coronary angioplasty.
A Report of the Surgeon General
302  Chapter 4
Summary of the Evidence
This review is the first Surgeon General’s report 
to address the benefits of smoking cessation specifically 
in patients diagnosed with CHD. The importance of this 
topic is amplified by the fact that survival after a diagnosis 
of CHD has improved markedly during the past several 
decades (e.g., Savastano et al. 2014). Within this focus on 
the health benefits of cessation among patients already 
diagnosed with CHD, evidence was summarized on asso-
ciations of cessation (versus persistent smoking) with all-
cause mortality, deaths from cardiac causes and sudden 
death, and risk of recurrent or new cardiac events. 
Methodologic Considerations
This review focused on direct evidence regarding 
the potential health benefits of smoking cessation—that 
is, quitting rather than continuing to smoke—among 
patients with CHD who were current smokers at the time of 
the index event. All the studies used in the review involved 
a prospective cohort, ensuring that the temporal relation-
ship between cessation and outcome was correctly charac-
terized. The evidence was abundant: Among the identified 
studies included in the evidence tables on the associa-
tion between smoking cessation and important outcomes, 
there were 34 reports on all-cause mortality, 13 (yielding 
20 distinct associations) on cause-specific mortality, and 
15 on the risk of new or recurrent cardiac events. Thus, the 
strength with which inferences can be made is enhanced 
by the focus, quality, and scope of the evidence.
However, the potential role of confounding is a 
concern in drawing inferences from this body of evi-
dence because (1)  some associations considered were 
not adjusted for potential confounding variables and 
(2) among current cigarette smokers diagnosed with CHD, 
those who quit may have had a lower risk profile. A com-
parison of results from a study (Johansson et al. 1985) that 
used both unadjusted results and those that were adjusted 
for potential confounders indicated, however, that the 
adjusted results tended to be equal to or stronger than the 
unadjusted results. Thus, despite the potential for con-
founding to threaten the internal validity of the evidence, 
confounding is unlikely to have affected the validity of the 
overall evidence. 
Compared with cohort studies in the general pop-
ulation, another noteworthy feature of follow-up studies 
of smoking cessation in patients with CHD is that the 
duration of follow-up tends to be shorter, sometimes only 
6  months, and the median follow-up in this review was 
just 4.5 years. By contrast, 10 years was the median length 
of follow-up in cohort studies of smoking, in relation to 
all-cause mortality in the general population, that were 
included in the meta-analysis of Gellert and colleagues 
(2012). With a shorter duration of follow-up, fewer end-
points will be observed, and precision is reduced for esti-
mating differences in outcome rates between quitters and 
persistent smokers. 
Another caveat is that most studies included in this 
review relied on self-reports to determine smoking status; 
the results of two studies that compared biochemical 
assessments of smoking status with self-reported smoking 
suggest that relying on self-reported smoking alone can 
underestimate the true association (Twardella et al. 2006; 
Breitling et al. 2011a).
Evaluation of the Evidence
Causal Criteria
This Surgeon General’s report is the first to con-
sider the potential health benefits of smoking cessation 
in patients after a diagnosis of CHD. The report considers 
the totality of the evidence and references key criteria 
for causation established in the 1964 and 2004 Surgeon 
General’s reports (U.S. Department of Health, Education, 
and Welfare [USDHEW] 1964; USDHHS 2004). 
Temporality
The studies included in the evidence tables all had 
similar design features commonly used in prospective 
cohort studies. First, they studied patients who were cur-
rent smokers when diagnosed with CHD. Second, patients 
were followed and reassessed to determine who quit 
smoking and who remained a smoker. Third, after quit-
ters were distinguished from persistent smokers, there 
was subsequent follow-up for mortality and/or new car-
diac events. Therefore, appropriate temporality is evi-
dent because, in all studies reviewed, smoking cessation 
preceded the occurrence of health outcomes in patients 
with CHD.
Consistency
The preponderance of the high-quality, focused 
bodies of evidence reviewed in this section showed that 
among patients who were current smokers when diag-
nosed with CHD, quitting smoking was consistently asso-
ciated with reduced all-cause mortality compared with 
continuing to smoke. The studies focused primarily on 
MI as the index diagnosis, but they also included people 
with established CHD; the results were consistent regard-
less of the index condition. The studies were carried out 
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in a wide range of geographic locations; spanned several 
decades of research; and varied widely in methodology, 
such as sample size, timing of the measurement of change 
in smoking status, definition of quitters and persistent 
smokers, and control for potential confounding variables. 
Despite the potential for this variability to introduce 
inconsistencies across studies, a very clear, consistent set 
of results accrued over time. The evidence about cause-
specific mortality and new or recurrent cardiac events also 
was highly consistent.
Strength of Association
The strength of the association observed for the out-
come of all-cause mortality is best viewed in context of the 
existing evidence from the general population. The associa-
tion between smoking and overall mortality was reviewed 
in the 1979 Surgeon General’s report with a finding that 
the RR for overall mortality in cigarette smokers compared 
with nonsmokers was 1.7 (USDHEW 1979b), which is quite 
similar to an estimate arrived at in 2014 based on data in 
the 1964 Surgeon General’s report (Schumacher et  al. 
2014). Because patients with CHD tend to be older than the 
general population, evidence specific to elderly populations 
is relevant. A systematic review of smoking and all-cause 
mortality in the elderly (defined as ≥60 years old) estimated 
a summary RR across studies of 1.83 (95% CI, 1.65–2.03) 
for current smoking versus never smoking (Gellert et al. 
2012). Against this backdrop, the evidence for the associa-
tion between smoking cessation and all-cause mortality in 
patients with CHD is of similar magnitude to findings from 
studies in the general population. In comparisons with per-
sistent smokers, the median RR for all-cause mortality was 
0.545  for those who quit smoking cigarettes; conversely, 
in reports that compared persistent smokers with quitters, 
the median RR was 1.67. The comparable magnitude of 
these associations is notable, considering that results for 
the general population are based on current versus never 
smokers, whereas the evidence reviewed here contrasts 
quitters with persistent smokers within a population made 
up entirely of current smokers at baseline.
The evidence presented for cause-specific mor-
tality as an endpoint showed that, compared with quitting 
smoking, persistent smoking was strongly associated with 
increased mortality from cardiovascular disease endpoints 
and sudden death, with the median RR of 1.6 being very 
similar to that observed for all-cause mortality. Among 
patients with CHD who were current smokers when diag-
nosed, the risk of new or recurrent cardiac events was 
also observed to be strongly reduced by smoking cessa-
tion compared with persistent smoking; for example, the 
median RR for MI was 0.67.
When this body of evidence is viewed collectively, 
a consistent and coherent pattern of findings emerges 
showing that among patients with CHD who are smokers 
when they are diagnosed, compared with those who 
remain smokers, those who quit smoking have a reduced 
risk of (1)  dying from all causes and, specifically, dying 
from cardiovascular disease or experiencing sudden death 
and (2) experiencing new or recurrent cardiac events. The 
observed associations were strong, and the magnitude of 
these associations is even more impressive when the meth-
odologic issues discussed above that would tend to bias 
these associations toward the null are carefully considered.
Experiment
For drawing causal inferences, studies of smoking 
cessation interventions that include results for clinical 
endpoints provide very strong evidence. In what can be 
viewed as quasi-experimental evidence, a large-scale, 
observational prospective cohort study found a strong all-
cause mortality benefit in patients diagnosed with MI who 
received an inpatient smoking cessation intervention com-
pared with those who did not receive an inpatient smoking 
cessation intervention (Bucholz et al. 2017). Earlier, in a 
randomized controlled trial of an intensive smoking ces-
sation intervention compared with usual care among 
patients diagnosed with acute coronary syndrome or 
decompensated heart failure, the intervention group expe-
rienced marked and statistically significant reductions in 
all-cause mortality and hospitalizations (Mohiuddin et al. 
2007). Strong associations from an experimental study 
favor the likelihood of an actual direct and causal associa-
tion and weigh against uncontrolled confounding as an 
explanation of the results of the observational studies. The 
studies that provide direct evidence on this question con-
sistently indicate that compared with persistent smoking, 
smoking cessation leads to substantial decreases in all-
cause mortality.
Specificity
The relevance of the criterion of specificity to the 
evidence considered in this report lies in the comparison 
of the results for cause-specific mortality with the results 
for all-cause mortality. These results are similar. A sub-
stantial reduction in all-cause mortality associated with 
smoking cessation that was paralleled by a similar reduc-
tion for specific cardiac causes of death provides evidence 
to support the conclusion that at least a portion of the 
health benefits of smoking cessation in patients with CHD 
results from reduced risk of death from cardiac causes. 
The mortality reduction experienced in quitters would 
also be expected to be present for other causes of death 
known to be caused by smoking, but the evidence base 
ascertained for this review provided little evidence on 
this question.
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Coherence
The causal criterion of coherence weighed heavily 
in evaluating the overall body of evidence as to whether 
smoking cessation can be considered a cause of mortality 
reduction in patients with CHD. The evidence on mor-
tality reduction in patients with CHD following cessation 
needs to be interpreted in the context of the larger body 
of evidence on smoking cessation in relation to mortality 
in the general population. Previous Surgeon General’s 
reports have concluded that smoking causes increased all-
cause mortality in the general population. Based on the 
causal criterion of coherence, smoking cessation would 
be expected to decrease all-cause mortality in patients 
with heart disease, as in the general population. Similarly, 
because active smoking is causally associated with many 
adverse cardiac endpoints, it would be expected a priori 
that smoking cessation in patients with CHD would be 
associated with reduced risk of developing recurrent 
CHD. The combination of the substantial body of evidence 
reviewed here, which documents that smoking cessation 
is associated with reduced risk of death and disease, along 
with the fact that this evidence is in accord with a priori 
expectations about the known adverse health effects of 
smoking in the general population, strengthens the argu-
ment inferring a causal association.
Further adding to the coherence of the evidence are 
the established roles of smoking in causing endothelial 
dysfunctions and increasing risk for thrombosis, two etio-
logic pathways that contribute substantially to ischemic 
heart disease (USDHHS 2010; Barua and Ambrose 2013; 
Vanhoutte et al. 2017). Increasing endothelial produc-
tion of adhesion molecules and decreasing production of 
vasodilators are some known mechanisms through which 
smoking causes endothelial dysfunction (USDHHS 2010). 
In addition, through adverse effects on endothelial cells, 
as well as on platelets, fibrinogen, and coagulation factors, 
smoking increases the risk of thrombosis, a key mecha-
nism in the pathogenesis of MI and stroke (USDHHS 
2010; Barua and Ambrose 2013). McEvoy and colleagues 
(2015b) examined three sets of markers in participants in 
the Multi-Ethnic Study of Atherosclerosis (MESA): inflam-
matory biomarkers, vascular dynamics and function, and 
subclinical atherosclerosis. Inflammatory markers were 
lower in former smokers compared with current smokers, 
and a longer time since quitting was associated with lower 
inflammatory markers. Results from a few studies provide 
evidence that in current smokers diagnosed with heart dis-
ease, quitting smoking is associated with biomarker pro-
files of reduced risk compared with persistent smoking. 
For example, smoking cessation in patients with acute MI 
was associated with improved coronary endothelial func-
tion, an improvement not seen in nonsmokers (Hosokawa 
et al. 2008). Further, in patients with CAD, smoking ces-
sation resulted in a reduced risk profile for macrophage 
cholesterol efflux (Song et al. 2015).
Synthesis of the Evidence
An extensive body of relevant evidence from pro-
spective cohort studies was identified and reviewed. All 
studies were based on cohorts of patients who were cur-
rent cigarette smokers when diagnosed with heart disease 
and who were followed up to first determine if they had 
quit smoking or continued to smoke and then to deter-
mine their vital status and to identify new or recurrent 
cardiac events. Most of this overall high-quality evidence 
indicates that in patients who are current smokers when 
diagnosed with heart disease, smoking cessation after 
the diagnosis is strongly and causally associated with 
reduced all-cause mortality. In patients with heart dis-
ease who are current smokers when diagnosed, the evi-
dence indicates that smoking cessation reduces the risk 
of dying by almost one-half, a very strong clinical benefit. 
Not only is this unequivocally demonstrated in the data 
from prospective cohort studies, but the corroborating 
experimental evidence on this topic strongly reinforces 
this conclusion. Additionally, the evidence reviewed here 
demonstrates that the health benefits of smoking cessa-
tion after a heart disease diagnosis extend to mortality 
specifically from cardiac causes and sudden death. Third, 
the evidence indicates that smoking cessation is asso-
ciated with decreased risk of new or recurrent cardiac 
events. Based on the causal criterion of coherence, the 
known causal associations between smoking and these 
outcomes in the general population support the causal 
nature of the associations. 
Because all the currently available evidence is from 
prospective studies, the temporal nature of the associa-
tion is not ambiguous. The evidence for each outcome 
showed a high degree of consistency across diverse study 
populations and measurement approaches. These char-
acteristics of the evidence clearly indicate that in cur-
rent smokers diagnosed with heart disease, smoking 
cessation is associated with reduced risk of all-cause 
mortality, cause-specific mortality, and new or recurrent 
cardiac events.
Conclusions
1. In patients who are current smokers when diag-
nosed with coronary heart disease, the evidence 
is sufficient to infer a causal relationship between 
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smoking cessation and a reduction in all-cause 
mortality.
2. In patients who are current smokers when diag-
nosed with coronary heart disease, the evidence 
is sufficient to infer a causal relationship between 
smoking cessation and reductions in deaths due to 
cardiac causes and sudden death. 
3. In patients who are current smokers when diag-
nosed with coronary heart disease, the evidence 
is sufficient to infer a causal relationship between 
smoking cessation and reduced risk of new and 
recurrent cardiac events.
Implications
The evidence summarized in this section docu-
ments that cigarette smoking cessation has a profoundly 
positive impact on overall survival in patients who are 
current cigarette smokers when diagnosed with CHD. 
The reductions in risk are substantial for total mortality 
and cardiovascular disease-specific outcomes. Estimates 
across studies indicate that smoking cessation reduces 
relative risks for these outcomes by 30–40%. Considered 
in the context of current knowledge of the health ben-
efits of smoking cessation in the general population, 
cessation of smoking would be expected to have major 
health benefits in patients diagnosed with CHD. This evi-
dence has clear clinical implications. Current cigarette 
smokers who are diagnosed with CHD can improve their 
prognosis by quitting smoking. Providing evidence-based 
smoking cessation services to patients with CHD who 
smoke would be expected to have a substantial benefi-
cial impact on their prognosis, with the magnitude of the 
benefits in some instances even equaling or exceeding 
that of other state-of-the-art therapies. A Cochrane 
review found evidence for efficacy of smoking cessation 
interventions in patients hospitalized for cardiovascular 
disease (Rigotti et al. 2012). The critical role of smoking 
cessation in cardiac rehabilitation is already recognized 
in evidence-based medicine guidelines (King et al. 2005; 
Smith et al. 2006); the new conclusions of this report 
can be cited in further emphasizing to the public health, 
clinical, and patient and caregiver communities just how 
critical it is to provide evidence-based smoking cessa-
tion services to cardiac patients. In particular, cardiolo-
gists who provide care to patients who have experienced 
cardiovascular events should (a) clearly communicate to 
these patients that quitting smoking is the most impor-
tant action they can take to improve their prognosis and 
(b)  offer patients evidence-based cessation treatments, 
including counseling, medications, and referral to more 
intensive assistance, including state quitlines (Fiore 
et al. 2008; U.S. Preventive Services Task Force 2015).
Tobacco smoke contains thousands of chemical com-
ponents that are inhaled and then deposited throughout 
the large and small airways and alveoli of the lungs (U.S. 
Department of Health and Human Services [USDHHS] 
2010). The toxic components of cigarette smoke injure 
the lungs through a variety of mechanisms, including 
oxidative injury and inflammation, carcinogenesis, and 
effects on the immune system (USDHHS 2010, 2014). 
For example, acrolein and formaldehyde impair ciliary 
clearance and nitrogen oxides cause inflammation of the 
airways, while cadmium and hydrogen cyanide result in 
direct oxidant injury and impaired oxidative metabolism 
(USDHHS 2010). Cigarette smoke initiates an inflam-
matory process that results in direct destruction of lung 
parenchyma that is mediated through (a)  the release of 
proteinases that damage the extracellular matrix of the 
lung, (b) apoptosis because of oxidative stress, and (c) loss 
of matrix–cell attachment and ineffective repair of elastin 
and other extracellular matrix components that enlarge 
the airspace (USDHHS 2010, 2014). Although successful 
smoking cessation ends daily exposure to innumerable 
injurious compounds, the prolonged deleterious effects 
of tobacco smoke result in irreversible impairment in 
immune responses, changes in the makeup of the lung 
microbiome, and continued lung injury even after cessa-
tion (USDHHS 2014).
This section provides an update on the evidence 
about smoking cessation and respiratory health among 
persons with chronic obstructive pulmonary disease 
(COPD) or asthma.
Conclusions from Previous 
Surgeon General’s Reports
Associations of cigarette smoking with chronic 
respiratory diseases, including COPD, asthma, and inter-
stitial lung diseases, have been addressed in numerous 
Surgeon General’s reports since 1964 (U.S. Department 
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Table 4.25 Conclusions about smoking cessation and chronic respiratory disease from previous 
Surgeon General’s reports
Report Conclusions
USDHHS (2010, p. 10) • Smoking cessation remains the only proven strategy for reducing the pathogenetic processes 
leading to chronic obstructive pulmonary disease.
USDHHS (1990, p. 11) • Smoking cessation reduces rates of respiratory symptoms such as cough, sputum production, 
and wheezing, and respiratory infections such as bronchitis and pneumonia, compared with 
continued smoking.
• For persons without overt chronic obstructive pulmonary disease (COPD), smoking cessation 
improves pulmonary function about 5 percent within a few months after cessation.
• Cigarette smoking accelerates the age-related decline in lung function that occurs among never 
smokers. With sustained abstinence from smoking, the rate of decline in pulmonary function 
among former smokers returns to that of never smokers.
• With sustained abstinence, the COPD mortality rates among former smokers decline in 
comparison with continuing smokers.
USDHHS (1984, p. 10) • Cessation of smoking leads eventually to a decreased risk of mortality from COLD compared 
with that of continuing smokers. The residual excess risk of death for the ex-smoker is directly 
proportional to the overall lifetime exposure to cigarette smoke and to the total number of years 
since one quit smoking. However, the risk of COLD mortality among former smokers does not 
decline to equal that of the never smoker even after 20 years of cessation.
USDHEW (1979a, p. 18) • Cessation of smoking definitely improves pulmonary function and decreases the prevalence 
of respiratory symptoms. Cessation reduces the chance of premature death from chronic 
bronchitis and emphysema.
Notes: COLD = chronic obstructive lung disease; COPD = chronic obstructive pulmonary disease; USDHEW = U.S. Department of 
Health, Education, and Welfare; USDHHS = U.S. Department of Health and Human Services.
of Health, Education, and Welfare [USDHEW] 1964). The 
1964 report concluded that cigarette smoking is the most 
important cause of chronic bronchitis (USDHEW 1964). 
The principal topic of the 1984 report was COPD (USDHHS 
1984), and later reports addressed active smoking, expo-
sure to secondhand smoke, and major respiratory dis-
eases (USDHHS 2004, 2006, 2014). The conclusions from 
these reports addressed the causation and exacerbation of 
chronic respiratory disease by tobacco smoking; the risks 
of respiratory infections, a frequent contributor to exac-
erbation of chronic respiratory diseases; and the benefits 
of cessation (USDHEW 1964; USDHHS 1984). Several 
Surgeon General’s reports have addressed the health ben-
efits of smoking cessation for COPD; these conclusions are 
listed in Table 4.25.
Literature Review Methods
MEDLINE, SCOPUS, and EMBASE were searched for 
studies that focused on smoking cessation and COPD or 
asthma and were published between January 1, 2008, and 
May 26, 2016. A systematic literature search was created 
for PubMed and translated to the EMBASE and SCOPUS 
databases. A combination of controlled vocabulary and 
keyword terms was used for each of the following con-
cepts: (1) smoking cessation, (2) respiratory phenomena, 
(3)  asthma, (4)  chronic obstructive pulmonary disease, 
(5) emphysema, and (6) chronic bronchitis. Studies that 
did not focus on smoking cessation were excluded. To for-
mulate conclusions, evidence cited in the 2014 Surgeon 
General’s report on smoking was considered along with 
any newly available evidence. Search results were limited 
to studies published in English and to original research. 
The primary search identified 1,977 items. Two indepen-
dent reviewers identified 45  articles through consensus 
after reviewing the titles and abstracts. After a full review 
of the 45 articles, 24 articles (17 on COPD and 7 on asthma) 
were selected as relevant for this update.
Chronic Obstructive 
Pulmonary Disease
This section addresses advances in the evidence base 
on COPD and smoking cessation and the implications of 
the new findings. Our current understanding of the patho-
genesis of COPD underscores the importance of smoking 
cessation in slowing and eventually ending lung damage 
associated with tobacco smoke. The occurrence of clinical 
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COPD reflects a long course of progressive deterioration 
of lung function that can begin before conception, as 
maternal smoking during pregnancy affects the develop-
ment of lungs in fetuses (Cook et al. 1998; Checkley et al. 
2010, 2016).
COPD is a common, preventable, and treatable dis-
ease characterized by persistent respiratory symptoms 
and airflow limitation that is due to airway and/or alve-
olar abnormalities usually caused by significant exposure 
to noxious particles or gases (Celli et al. 2004; USDHHS 
2014; Benditt n.d.) (Figure 4.7). The development of air-
flow limitation among those with COPD is usually pro-
gressive and reflects the ongoing processes of lung injury 
that are initiated and sustained by persistent exposure to 
tobacco smoke (Rabe et al. 2007). Thus, smoking cessation 
is critical in preventing COPD, slowing its progression, 
and treating this disorder. Although previous definitions 
have focused on phenotypes of COPD, such as chronic 
bronchitis and emphysema, the diagnosis of COPD has 
now been standardized on the basis of spirometry and 
the presence of airflow obstruction (i.e.,  a reduced ratio 
of forced expiratory volume at 1 second [FEV1] to forced 
vital capacity [FVC]) that does not fully reverse after 
bronchodilation (Tashkin and Murray 2009). Previously, 
COPD was defined by a fixed ratio (post-bronchodilator 
FEV1/FVC <70%) (Rabe et al. 2007). There is debate, how-
ever, on using the lower limit of normal for selected ref-
erence populations as the best approach to standardizing 
the interpretation of spirometry results by accounting for 
age, sex, height, and race (Mannino et al. 2007; Swanney 
et al. 2008; Miller et al. 2011b; Mannino and Diaz-Guzman 
2012; Quaderi and Hurst 2017).
Thus, FEV1/FVC is generally used to define COPD, 
but FEV1 and the rate of decline of FEV1 have been the 
two most widely used outcome measures for clinical trials 
related to COPD. These indicators are also associated 
Figure 4.7 Flow-volume loops for a person with (obstruction) and without (normal) chronic obstructive 
pulmonary disease
Source: Benditt (n.d.). Copyright © University of Washington, 2004.
Note: RV = residual volume; TLC = total lung capacity.
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with measures of health-related quality of life and mor-
tality (Wise 2006). Additionally, however, there is evidence 
to support the presence of considerable smoking-related 
respiratory disease among persons with normal lung func-
tion. For example, in a study by Woodruff and colleagues 
(2016), half of current or former smokers with preserved 
pulmonary function exhibited respiratory symptoms, 
and former smokers with preserved lung function had 
higher rates of exacerbation events than lifelong non-
smokers. Sensitive imaging approaches are now used to 
quantify changes in the lungs, including emphysema, that 
have health implications. Oelsner and colleagues (2014) 
found higher all-cause mortality among former and cur-
rent smokers with emphysematous changes on computed 
tomography (CT) and preserved pulmonary function. 
However, the analysis did not find differences in the risk of 
having such changes by smoking status.
Smoking Cessation and Chronic Obstructive 
Pulmonary Disease
Cigarette smoking is the most common cause of 
COPD in the United States (Xu et  al. 1992; Anthonisen 
et  al. 1994; Perret et  al. 2014) and is a consistent and 
strong risk factor for the development of COPD (USDHHS 
2014). In the United States, the population-attributable 
risk for developing COPD caused by smoking has been 
estimated to be as high as 80–90% (Eisner et  al. 2010; 
USDHHS 2014). Although observational evidence shows 
that air pollution adversely affects persons with COPD, 
not starting to smoke and smoking cessation remain the 
only proven prevention strategies for reducing the risk 
of developing chronic respiratory diseases caused by cig-
arette smoking (Xu et  al. 1992; Anthonisen et  al. 1994; 
Abramson et al. 2015). Smoking cessation can prevent or 
delay the development of airflow limitation and slow the 
progression of chronic respiratory disease; it is the only 
intervention that has been shown to reduce the rate of 
FEV1 decline in both men and women (Thomson et  al. 
2004) and to reduce all-cause mortality among those with 
COPD (Anthonisen et al. 2005).
Epidemiology of Mortality from Chronic 
Obstructive Pulmonary Disease in Relation 
to Tobacco Cessation
The relationship between temporal trends in the 
decline of smoking prevalence and trends in COPD mor-
bidity and mortality is complex, as evidenced by data col-
lected in the United States (Mannino and Buist 2007). 
Prevalence estimates of COPD have limited validity 
because symptoms related to COPD, such as dyspnea on 
exertion and limitation in physical activity, are nonspecific 
(Tashkin and Murray 2009). Nonetheless, some trends 
are quickly apparent from surveillance data. Among all 
U.S. adults, age-adjusted mortality from COPD increased 
from 29.4  per 100,000  population in 1968 to 67.0  per 
100,000  population in 1999 and then declined slightly 
to 63.7  per 100,000  population in 2011 (Ford 2015). 
Mortality from COPD among men has declined since 1999, 
but among women, the age-adjusted mortality continues 
to increase (Ford 2015). Despite this narrowing of the dif-
ference between men and women, mortality rates in men 
continue to exceed those in women (Ford 2015). Notably, 
among certain population subgroups (i.e.,  Black men, 
White men, adults 55–64 years of age, adults 65–74 years 
of age), mortality rates have declined during the past 
decade (Ford 2015).
How Smoking Cessation Affects the Decline 
of Lung Function in Smokers
The 1990 Surgeon General’s report on the health 
benefits of smoking cessation cited only three studies con-
cerning the effect of smoking cessation on the decline 
of lung function (USDHHS 1990). The 1990 report did 
provide a conclusion that “With sustained abstinence 
from smoking, the rate of decline of pulmonary func-
tion in former smokers returns to that of never smokers” 
(USDHHS 1990, p 349). Since the 1990 report, both clin-
ical and population studies have examined the association 
between cessation of tobacco smoking and the decline of 
lung function. 
The Lung Health Study, a randomized clinical trial 
of smoking cessation and respiratory outcomes, evalu-
ated the effect of an intensive smoking cessation interven-
tion (combined randomly with either the inhaled bron-
chodilator ipratropium bromide or placebo) on the rate of 
FEV1 decline among 5,887 cigarette smokers 35–60 years 
of age with mild-to-moderate airflow limitation from 
COPD (Anthonisen et  al. 1994). Participants who con-
tinued to smoke had a greater decline in FEV1 at the 
5-year follow-up (Figure  4.8) compared with those who 
quit. In a separate analysis of data from the Lung Health 
Study, a decrease in the number of cigarettes smoked by 
continued smokers did not reduce the rate of decline of 
lung function compared with complete cessation, unless 
the number of cigarettes smoked was reduced by at least 
85% (Simmons et al. 2005). The benefit of a lower decline 
of FEV1 among participants in the smoking intervention 
program compared with the control group persisted over 
11 years of follow-up (Anthonisen et al. 2002; Murray et al. 
2002). Participants in the smoking intervention group had 
a lower decline of FEV1 than participants receiving usual 
care (the control group) (Anthonisen et al. 2002). Men who 
quit smoking at the beginning of the Lung Health Study 
had a rate of decline in FEV1 of 30.2 milliliters (mL)/year, 
whereas this measure declined at 21.5 mL/year in women 
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who quit. Men who continued to smoke throughout the 
11  years of follow-up experienced an FEV1 decline of 
66.1 mL/year, and women who continued to smoke expe-
rienced a decline of 54.2 mL/year (Anthonisen et al. 1994). 
At the 14.5-year follow-up, all-cause mortality was lower 
in the intervention group than in the usual-care group 
(8.8  per 1,000  person-years  vs. 10.4  per 1,000  person-
years, p = 0.03) (Anthonisen et al. 2005).
Several studies have examined how quickly bene-
fits of smoking cessation are observed. In an analysis of 
a 6-year follow-up of 4,451 Japanese American men par-
ticipating in the Honolulu Heart Program, Burchfiel and 
colleagues (1995) reported that the rate of FEV1 decline 
was reduced in participants who quit smoking compared 
with those who continued smoking. These researchers 
also found that, after 2 years of successful cessation, the 
reduced rate of FEV1 decline among quitters approxi-
mated that of participants who never smoked. In contrast, 
the rate of FEV1 decline in the first 2 years was similar 
between quitters and those who continued to smoke. This 
last finding suggests that the effects of smoking cessation 
on decline in lung function are not immediate and may 
take up to 2 years to be manifested.
Table  4.26 summarizes reports published in 2009 
or later offering further evidence on smoking cessation 
and the natural history of COPD and other respiratory 
outcomes from long-term studies. Studies and trials 
have continued to demonstrate immediate improvement 
in self-reported respiratory symptoms at 1  to 3  months 
after cessation (Louhelainen et al. 2009; Etter 2010) and 
an improvement in FEV1 and in COPD-specific outcomes 
at 1  year after quitting (Tashkin et  al. 2011; Dhariwal 
et  al. 2014). Smoking cessation has a beneficial effect 
at any age, although the benefit was found to be more 
pronounced among persons who quit before 30 years of 
age compared with those who quit after 40 years of age 
(Kohansal et al. 2009).
Although smoking cessation results in less severe 
respiratory symptoms, the inflammatory burden may per-
sist. In a prospective cohort, Louhelainen and colleagues 
(2009) found oxidant and protease burden in airways 
(using sputum as a proxy to measure airway inflamma-
tion) that persisted for months after smoking cessation. 
Versluis and colleagues (2009) found that adenosine 
receptor mechanisms may be implicated in the progres-
sion of the inflammatory response after cessation in ciga-
rette smokers with COPD. Specifically, the expression of 
adenosine receptors increased in some sputum cell types 
and sputum adenosine levels appeared to rise in those with 
COPD 1 year after smoking cessation (Versluis et al. 2009). 
Figure 4.8  Impact of smoking cessation and resumption on FEV1 decline in the Lung Health Study cohort of 
patients with chronic obstructive pulmonary disease
Source: Scanlon and colleagues (2000, p. 384). Reprinted with permission of the American Thoracic Society. Copyright © 2018 
American Thoracic Society. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American 
Thoracic Society.
Note: FEV1 = forced expiratory volume at 1 second.
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Table 4.26 Studies on smoking cessation and chronic obstructive pulmonary disease, 2009–2017
Study Design/population Findings
Lung function    
Kohansal et al. 
(2009)
• Prospective cohort
• 4,391 participants 13–71 years of age with two 
or more valid spirometry measurements during 
follow-up periods (1971–1997) of the Framingham 
Offspring Study
• Participants divided into three groups: 
 – Never smokers (n = 1,578)
 – Continuous smokers (n = 754)
 – Other smokers, which included former smokers 
(n = 2,059)
• Never smokers and continuous smokers were 
further divided into categories of healthy and 
nonhealthy 
Smoking cessation had a beneficial effect at any age, 
but it was more pronounced in earlier quitters 
The rate of FEV1 decline in both male and female 
smokers who quit before age 30 was indistinguishable 
from healthy never smokers
In contrast, smokers who quit after 40 years of age 
showed a significantly enhanced rate of decline of FEV1 
versus healthy never smokers and earlier quitters, but 
their rate was not significantly different from that of 
continuous smokers
The mean FEV1 decline value among continuous 
smokers (with 95% CI) was 38.2 ml (33.9–42.6) for males 
and 23.9 ml (20.9–27.0) for females, with p = 0.001 for 
male vs. female (p ≤0.05 versus healthy never smokers)
Louhelainen 
et al. (2009)
• Prospective cohort
• 61 smokers:
 – 21 with chronic bronchitis or COPD
 – 15 with asthma
 – 25 asymptomatic
• Followed 3 months after smoking cessation
Although symptoms improved after smoking cessation, 
oxidant and protease burden in the airways continued 
for months after cessation
Takabatake 
et al. (2009)
• Prospective cohort
• 82 former smokers with COPD
• Followed for 30 months 
CDC6 may be one of the susceptibility genes that 
contributes to rapid decline in lung function despite 
smoking cessation in patients with COPD
Versluis et al. 
(2009)
• Prospective cohort
• 26 smokers who had successfully quit for at least 
1 year:
 – 11 with COPD
 – 15 asymptomatic
• Followed at 1 year after cessation 
Adenosine-related effector mechanisms are involved in 
the persistence and progression of the inflammatory 
response in COPD after 1 year of smoking cessation
Mazur et al. 
(2011)
• Prospective cohort
• 474 current smokers
• 155 with COPD symptoms
• 319 no symptoms
• Followed for 2 years, with 111 succeeding 
in cessation
After 2 years of follow-up, levels of surfactant protein 
A were higher in those who continued smoking 
compared with those who quit
Tashkin et al. 
(2011)
• Randomized controlled trial 
• 504 participants (smokers with mild-to-
moderate COPD:
 – 250 in the varenicline treatment group
 – 254 in the placebo treatment group
In this 1-year cessation trial of smokers with COPD, 
continuous abstinence compared with continuous 
smoking significantly improved (p = 0.0069) mean 
change from baseline in post-bronchodilator FEV1 
(although the difference subsequently narrowed) and 
total scores on the Clinical COPD Questionnaire at 
12 weeks, with sustained improvement thereafter 
on that instrument
Dhariwal et al. 
(2014)
• Prospective cohort
• 358 heavy smokers screened:
 – 38 with COPD
 – 55 with normal spirometry
• Control group: 19 nonsmokers
• Followed for 1 year
Smoking cessation had differential effects on lung 
function (FEV1 and gas transfer) and features 
revealed on high-resolution CT images (emphysema 
and micronodules)
Smoking cessation in patients with COPD caused 
transient improvement in FEV1 and decreased the 
presence of micronodules
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Table 4.26 Continued
Study Design/population Findings
Lung function 
(continued)
   
Ito et al. (2015) • Cross-sectional
• 93 participants divided into four groups:
 – Former smokers with COPD (n = 23)
 – Smokers with COPD (n = 17)
 – Current smokers (n = 27)
 – Nonsmokers (n = 26)
One year after smoking cessation, participants with 
COPD had improved mucociliary clearance
Respiratory 
symptoms
   
Etter (2010) • Prospective cohort
• Visitors to Stop-tabac.ch website
• 18 years of age or older
• 15,916 participants at baseline
• 1,831 participants at 1-month follow-up
Smoking cessation was followed by a rapid and 
substantial improvement in self-reported respiratory 
symptoms 
In the 252 baseline smokers who had quit smoking at 
30-day follow-up, there was a substantial decrease in 
the proportion of participants who declared that they 
often coughed even without a cold (from 51.6% at 
baseline to 15.5% at follow-up), expectorated when 
they coughed in the morning (from 47.6% to 19.4%), 
were out of breath after climbing stairs or after a quick 
walk (from 75.0% to 48.4%), and who had a wheezing 
respiration (from 33.7% to 10.3%) (p = 0.001 for all 
before/after comparisons)
Josephs et al. 
(2017)
• Retrospective cohort
• 16,479 patients with COPD with outcomes over 
3 years
• 8,941 former smokers 
Former smokers had significantly reduced risk of death, 
hospitalization, and visits to the emergency department
Compared with active smokers, ex-smokers had 
significantly reduced risk of death, with a hazard 
ratio (95% CI) of 0.78 (0.70–0.87); hospitalization, 
0.82 (0.74–0.89); and emergency department 
attendance, 0.78 (0.70–0.88)
Imaging    
Ashraf et al. 
(2011)
• Prospective cohort
• 726 current and former smokers 
• Aged 50–70 years 
• Smoking history of more than 20 pack-years. 
• Former smokers were only included if they had 
quit smoking after the age of 50 years and less 
than 10 years before inclusion. 
• All subjects had to have an FEV1 at least 30% 
of predicted normal.
• Followed for more than 2 years
Current smoking status was associated with lower 
lung density and a difference in lung density between 
current and former smokers who were observed at 
baseline, which corresponded closely to changes in 
lung density after cessation 
After smoking cessation (n = 77) 15th percentile 
density (PD15) decreased by 6.2 g/l (p < 0.001) in 
the first year, and by a further 3.6 g/l (p < 0.001) in 
the second year, after which no further change could 
be detected; moreover, the first year after relapse to 
smoking (n = 18) PD15 increased by 3.7 g/l (p = 0.02)
Miller et al. 
(2011a)
• Prospective cohort
• 10 former smokers with COPD after 4 years 
of not smoking
Cessation of tobacco smoking in heavy smokers 
with moderately severe emphysema was associated 
with evidence of persistent airway inflammation and 
progression of emphysema on CT
Shaker et al. 
(2011)
• Prospective cohort
• 36 former smokers with COPD
• Followed for 2–4 years
Inflammation partly masked the presence of emphysema 
on CT, and smoking cessation resulted in a paradoxical 
fall in lung density, which resembled rapid progression 
of emphysema; this fall in density likely resulted from 
an anti-inflammatory effect of smoking cessation
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Table 4.26 Continued
Study Design/population Findings
Imaging 
(continued)
   
Hoesein et al. 
(2013)
• Prospective cohort
• 3,670 male smokers
• 1- and 3-year follow-up
• Follow-up CT and pulmonary testing
Current smokers had yearly FEV1 decline of 69 mL, 
and participants who had quit smoking more than 
5 years earlier had a yearly decline of 57.5 mL
Compared with current smokers, participants who 
had quit smoking more than 5 years earlier showed 
significantly lower rates of progression of emphysema 
on CT
Hlaing et al. 
(2015)
• Prospective cohort
• 45 persons with COPD who stopped smoking
• Followed for 1 year
On the CT image, significant decreases occurred in 
mean lung density and the attenuation value separating 
the least 15% pixels, but there was a significant increase 
in the percentage of the relative area of the lungs with 
attenuation values <-950 Hounsfield units
Takayanagi 
et al. (2017)
• Prospective cohort
• 58 patients with COPD at the time of their 
enrollment at the hospital and 2 years later
Airway disease and vascular remodeling may be 
reversible to some extent through smoking cessation 
and appropriate treatment
Immunity    
Roos-Engstrand 
et al. (2009)
• Case-control 
• 19 persons with stable COPD:
 – 7 smokers
 – 12 former smokers
• Compared with 12 age-matched never smokers 
and 13 pack-years-matched smokers with normal 
lung function
Five years after smoking cessation, former smokers 
with COPD had significantly higher percentages of 
CD8+ cells compared with never smokers
DNA methylation    
Tsaprouni et al. 
(2014)
• Cross-sectional
• Discovery cohort: 464 participants who were either 
diagnosed with CAD (n = 238) or were considered 
healthy (controls, n = 226):
 – Current smokers (n = 22)
 – Former smokers (n = 263)
 – Never smokers (n = 179)
• Replication cohort: 356 female participants, all twins: 
 – Current smokers (n = 41)
 – Former smokers (n = 104)
 – Never smokers (n = 211)
The effect of smoking on DNA methylation was 
partially reversible following smoking cessation 
for longer than 3 months
Wan et al. 
(2012)
• Cross-sectional
• Discovery cohort: 1,085 participants with 
≥5 pack-years of cigarette smoking and reported 
FEV1 limitation, as well as one eligible sibling 
with ≥5 pack-years of cigarette smoking:
 – Current smokers (n = 396)
 – Former smokers (n = 689)
• Replication cohort: 369 participants with 
FEV1 limitation: 
 – Never smokers (n = 68)
 – Current smokers (n = 103)
 – Former smokers (n = 198)
The existence of dynamic, site-specific methylation 
changes in response to smoking may contribute 
to the risks associated with cigarette smoking that 
persist after cessation
Notes: CI = confidence interval; COPD = chronic obstructive pulmonary disease; CT = computed tomography; FEV1 = forced expiratory 
volume at 1 second; CAD = coronary artery disease; mL = milliliter.
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In a later study, Mazur and colleagues (2011) assessed 
levels of surfactant protein A (SP-A) among smokers, 
nonsmokers, and former smokers over a 2-year period. 
Although plasma SP-A levels tended to decline among 
those who quit smoking, no significant difference from 
baseline was evident at the 2-year follow-up. A difference 
in plasma SP-A levels was evident, however, between those 
who quit and active smokers, whose SP-A levels continued 
to increase (Mazur et al. 2011). 
Novel Diagnostics for Assessing the Impact 
of Smoking Cessation on the Progression of 
Chronic Obstructive Pulmonary Disease
Since the earlier Surgeon General’s reports on this 
topic (USDHHS 1984, 2004), new techniques—such as 
imaging—have been used to investigate the natural his-
tory of COPD. These techniques have provided insights 
into structural changes and genomics, epigenomics, and 
other “-omics” approaches that help to better understand 
the molecular determinants of COPD risk and the persis-
tence of risk after cessation. Furthermore, novel thera-
peutic options—such as epigenetic regulation—can be 
reprogrammed, potentially modifying risk and supporting 
treatment of disease states (Sakao and Tatsumi 2011).
Imaging
Quantitative volumetric CT scanning, a well-
established diagnostic modality, can assess pathology in 
vivo, enabling morphologic phenotyping of three critical 
components of the progression of COPD: emphysema 
(Bankier et al. 2002; Madani et al. 2008), thickening of the 
airway wall (Orlandi et al. 2005; Coxson 2008), and trap-
ping of expiratory air (Mets et al. 2012). These measures 
correlate with pathologic measures of emphysema and 
small airways disease and predict such clinical outcomes 
as FEV1 decline (Mohamed Hoesein et al. 2011) and fre-
quency of exacerbation (Han et al. 2011). Additionally, the 
growing adoption of annual CT scans to screen for lung 
cancer makes possible volumetric analysis at a population 
level over time, providing a powerful tool for assessing 
changes in lung structure after cessation of exposure to 
tobacco smoke, at least in this high-risk group. Low-dose 
CT used in annual screening enables the assessment of air-
ways and lung parenchyma with less radiation compared 
with conventional CT scanning. Examining the effects of 
cessation on volumetric CT imaging is complicated, how-
ever, by the contradiction between the reported short-
term and long-term effects of smoking. Specifically, pre-
vious studies have demonstrated that current cigarette 
smoking increases measurements of lung density and that 
these changes are most likely a result of accumulation of 
particulate matter resulting in inflammation (Grydeland 
et  al. 2009), but over the long term, the emphysema-
tous changes related to inhaling tobacco smoke result 
in low lung density (Ashraf et  al. 2011). It is important 
that changes in lung density over the short term not be 
interpreted as either the progression of emphysema or 
improvement in that condition. Smoking cessation has 
been shown to reduce lung density, and the rate of reduc-
tion increases at 2  years post-cessation (Scanlon et  al. 
2000; Ashraf et al. 2011). At 2 years post-cessation, lung 
density stabilizes, suggesting a reversal of the inflamma-
tory sequelae of exposure to tobacco smoke, which is con-
sistent with findings on lung function in the Lung Health 
Study (Scanlon et al. 2000; Ashraf et al. 2011). A similar 
study by Takayanagi and colleagues (2017) demonstrated 
progression of emphysema, particularly in the subgroup of 
patients with exacerbations, but imaging findings related 
to airway disease and pulmonary vasculature did not 
change in proportion to the progression of emphysema.
Advances in Epigenetics
Epigenetics is defined as the study of mechanisms 
that cause heritable changes in gene expression rather 
than alterations in the underlying sequence of deoxyri-
bonucleic acid (DNA) (Dupont et al. 2009). Epigenetics 
can help measure the extent to which gene expression is 
altered in response to environmental exposure. Because 
epigenetics is a dynamic process, tracking the epigenome 
over time in relation to smoking cessation becomes rel-
evant. Recent studies have demonstrated a role of DNA 
methylation, one of the main forms of epigenetic modifi-
cation, in the pathways of smoking and smoking-induced 
diseases via the regulation of gene expression and genome 
stability (Figure 4.9). Methylation may underlie disease-
specific gene expression changes, and characterization of 
these changes is a critical first step toward the identifi-
cation of epigenetic markers and the possibility of devel-
oping novel epigenetic therapeutic interventions for 
COPD (Vucic et al. 2014). 
Smoking alters the bronchial airway epithelial tran-
scriptome and induces expression of genes involved in the 
regulation of oxidative stress, xenobiotic metabolism, and 
oncogenesis while suppressing those involved in the regu-
lation of inflammation and tumor suppression (Spira et al. 
2004). DNA methylation studies have been performed on 
a range of samples, including whole-blood homogenates 
and cells obtained from bronchial brushing and buccal 
swabbing (Breitling et al. 2011b; Tsaprouni et al. 2014; 
Guida et al. 2015; Wan et al. 2015).
An increasing number of smoking-related CpG sites 
(sites with a cytosine nucleotide next to a guanine nucle-
otide in the linear sequence) in various genes—such as 
aryl-hydrocarbon receptor repressor (AHRR), coagulation 
factor  II receptor-like 3  (F2RL3), and G protein-coupled 
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receptor 15  (GPR15)—have been discovered by 
epigenome-wide association studies based on samples of 
whole blood; these markers have shown utility as quantita-
tive biomarkers of current and past smoking exposure and 
predictors of smoking-related disease risk (Figure  4.10) 
(Breitling et al. 2011b; Tsaprouni et al. 2014; Guida et al. 
2015). Breitling and colleagues (2011b) found that DNA 
methylation was significantly lower in smokers than 
nonsmokers (percent difference in methylation  =  12%; 
p = 2.7 × 10-31) in F2RL3 and correlated negatively with 
the number of smoked cigarettes and positively with the 
duration of smoking abstinence. Similar exposure-related 
differences in the methylation of this gene were seen in 
another study, with the intensity of F2RL3 methylation 
increasing gradually in long-term (>20 years) quitters to 
levels similar to that of never smokers (Zhang et al. 2014).
Guida and colleagues (2015) conducted epigenome-
wide association studies to capture the dynamics of 
smoking-induced epigenetic changes after smoking ces-
sation using genome-wide methylation profiles obtained 
from blood samples in 745  women from two European 
populations. The authors found that LRRN3 also was sig-
nificantly overexpressed in current smokers as compared 
with never smokers (fold change = 2.85; p = 2.1 × 10−24). 
Similar to the findings of Breitling and colleagues (2011b), 
Guida and colleagues (2015) demonstrated a dose-
response relationship between methylation and time since 
cessation. The expression of only one additional gene, 
FOXO3, was found to be upregulated in current smokers 
(fold change = 1.27; p = 4.3 × 10−6) (Guida et al. 2015). 
Wan and colleagues (2012) assessed the impact 
of DNA methylation after smoking cessation over time 
among those in the International COPD Genetics Network 
(n = 1,085), followed by replication in the Boston Severe 
Early Onset COPD study (n  =  369). These investigators 
identified a novel locus (GPR15) associated with cigarette 
smoking and found evidence to suggest that the existence 
of smoking-related, site-specific methylation changes 
may contribute to extended risks associated with ciga-
rette smoking after cessation. Among former smokers, 
participants with the highest cumulative exposure to 
smoke and shortest duration of smoking cessation had the 
lowest mean methylation, but participants with the lowest 
cumulative exposure to smoke and the longest duration of 
cessation had the highest mean methylation, suggesting 
a dose-dependent response. Tsaprouni and colleagues 
Figure 4.9  Cigarette smoking and DNA methylation
Source: Lee and Pausova (2013). Copyright © 2013 Lee and Pausova.
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(2014) showed that the effect of smoking on DNA meth-
ylation was partially reversible following cessation of more 
than 3 months. That study additionally used whole-blood, 
ribonucleic acid (RNA) sequencing to demonstrate evi-
dence of the higher expression of PSEN2, PRSS23, RARA, 
F2RL3, GPR15, CPOX, AHRR, and RPS6KA2 genes among 
former and current smokers. Only GPR15 showed a clear 
trend of higher gene expression in smokers compared 
with nonsmokers, suggesting that a reduction in meth-
ylation levels observed in smokers leads to higher levels of 
RNA transcription (Tsaprouni et al. 2014). 
Advances in Proteomics
Smoking-related inflammation secondary to lung 
disease has been well described in earlier reports (USDHHS 
2014). The 2014 Surgeon General’s report concluded that 
sufficient evidence exists to infer that components of ciga-
rette smoke affect the immune system and that some of 
these effects are immune system activating, while others 
are immunosuppressive (USDHHS 2014). Alterations 
in innate and adaptive immunity result in both emphy-
sema and airway remodeling, and a range of pathways 
for inflammatory biomarkers related to smoking have 
been described (Ito et al. 2006; USDHHS 2014). Profiles 
of inflammatory biomarkers change after smoking cessa-
tion. The Evaluation of COPD Longitudinally to Identify 
Predictive Surrogate Endpoints (ECLIPSE) study (Coxson 
et al. 2013) found that several circulating biomarkers were 
associated with both the severity (SP-D, soluble receptor 
for advanced glycation end products [sRAGE], CCL18) 
and progression (SP-D, sRAGE, fibrinogen, interleukin 
[IL]  6, and CRP) of emphysema assessed by volumetric 
Figure 4.10  Epigenome-wide association study Manhattan plot and Q-Q plot for smoking status in the 
Cardiogenics Cohort
Source: Tsaprouni and colleagues (2014), with permission.
Note: In Panel A, the vertical axis indicates (-log10 transformed) observed p values, and the dotted horizontal line indicates the 
threshold of significance (p = 10−6) to select markers for replication. Previously reported loci are indicated in blue, and new loci and 
new signals in known loci are marked in red. Panel B illustrates the distribution of the p values.
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CT imaging. Circulating biomarkers may provide an 
additional proxy for lung inflammation and emphysema-
tous change. SP-D, one of several surfactant proteins, is 
thought to be related to pulmonary immunity (Kishore 
et al. 2006) and is higher in persons with COPD (Lomas 
et  al. 2009). This relative increase is believed to reflect, 
in part, inflammation in the lung leading to degradation 
and leakage into the circulation. sRAGE is thought to pro-
tect against inflammation, and low levels of sRAGE have 
been associated with several inflammatory diseases, such 
as diabetes and cardiovascular disease (Raposeiras-Roubín 
et  al. 2010). Although the biomarkers discussed in this 
chapter thus far were found to be associated with lower 
baseline lung density and accelerated decline in lung den-
sity among smokers, whether the low levels of sRAGE and 
SP-D are a contributing factor or a consequence of COPD 
is unclear (Coxson et al. 2013). Circulating sRAGE could 
be a useful biomarker in monitoring the consequences 
of novel interventions such as the administration of reti-
noic acid, stem cell technology, and the use of growth fac-
tors targeting the emphysema component of COPD and 
smoking cessation (Coxson et al. 2013).
Biomarkers in sputum also have been found to 
change after smoking cessation. In a cross-sectional study 
of 240 participants, Titz and colleagues (2015) found that 
the sputum proteome and the transcriptome of former 
smokers largely approached those in never smokers. 
Nevertheless, some long-term effects of prior smoking 
remain evident in the sputum of former smokers, as indi-
cated by the increase in IFNG and NFKB signaling, which 
are both associated with an M1 polarization in the sputum 
of former smokers (Titz et al. 2015). Singh and colleagues 
(2011) found that IL-18R protein expression was higher on 
alveolar macrophages in the lung tissue of COPD patients 
(mean:  23.2%) compared with controls (mean:  2% in 
former smokers and 2.5% in nonsmokers). 
Advances in the Microbiome
The role of the microbiome in COPD pathogenesis 
has become an active area of research (Martinez et  al. 
2013; Sze et al. 2014; Mammen and Sethi 2016). Studies 
have shown that tobacco smoking affects both the oral 
and intestinal microbiota (Biedermann et al. 2013; Morris 
et al. 2013), but it is not clear whether the lung micro-
biota is also affected by tobacco cessation (Morris et  al. 
2013; Yu  et  al. 2016). Some researchers postulate that 
alterations of the gut microbiome may help to explain 
mechanisms of inflammation in the lung that lead to 
the development of COPD or its exacerbations (Martinez 
et  al. 2013; Sze et  al. 2014; Malhotra and Olsson 2015). 
Research has revealed that smoking cessation also leads 
to changes in the microbiome, but it is uncertain whether 
smoking cessation leads to higher or lower bacterial diver-
sity and whether specific families of bacteria are consis-
tently affected (Delima et al. 2010; Biedermann et al. 2013; 
Munck et al. 2016; Yu et al. 2016). 
Synthesis of the Evidence
Evidence considered in this report strengthens the 
foundation for inferring that smoking cessation remains 
the only intervention that attenuates loss of lung func-
tion over time among those with COPD and reduces risk 
of developing COPD in cigarette smokers (USDHHS 1984, 
2004, 2014). The beneficial effect of cessation in slowing 
the decline of lung function in persons with COPD is well 
documented and was stated in a conclusion of the 1990 
Surgeon General’s report; the rate of decline decreases 
after cessation and is maintained at the new lower level 
unless smoking is resumed (USDHHS 1990). The available 
evidence shows an immediate benefit over several years 
for the rate of decline, but does not show whether further 
gains occur subsequently. Clinical studies show recovery 
of lung function and improvement in respiratory symp-
toms shortly after cessation, but inflammation continues 
to exist months after cessation. 
Unfortunately, COPD is a progressive disease in the 
face of sustained smoking, and at the time of diagnosis the 
loss of lung function is irreversible. However, further pro-
gression can be prevented by cessation. Support for this 
conclusion, reinforcing that of the 1990 report, comes 
from the understanding that smoking leads to inflamma-
tion and injury of the lungs and from mounting epidemio-
logical evidence that cessation slows the accelerated loss 
of lung function in smokers. Turning to the criteria used 
for causal inference in these reports, temporality is appro-
priate (i.e., cessation is followed by changes in the progres-
sion of COPD), the biological basis for a benefit of cessa-
tion has been well established in prior Surgeon General’s 
reports, and the epidemiological evidence is consistent. 
Further insights on mechanisms are emerging. 
Recent imaging studies suggest that there are longer-
term benefits of cessation (e.g., research has shown mea-
surable reductions in lung density on CT imaging 2 years 
after cessation). Accordingly, the mechanisms by which 
smoking cessation attenuates the decline of lung function 
and reduces the risk of COPD need to be better understood. 
Many studies using new approaches are now 
underway. Studies using biomarkers and  omics can provide 
insights into the potential mechanisms by which smoking 
cessation could attenuate declines in lung function. This 
review did not find any evidence to link genetic makeup 
to how cessation affects this decline. However, studies that 
evaluated the emerging areas of epigenetics, proteomics, 
and the microbiome have yielded promising findings. 
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Conclusions
1. Smoking cessation remains the only established 
intervention to reduce loss of lung function over time 
among persons with chronic obstructive pulmonary 
disease and to reduce the risk of developing chronic 
obstructive pulmonary disease in cigarette smokers.
2. The evidence is suggestive but not sufficient to infer 
that airway inflammation in cigarette smokers per-
sists months to years after smoking cessation.
3. The evidence is suggestive but not sufficient to infer 
that changes in gene methylation and profiles of 
proteins occur after smoking cessation.
4. The evidence is inadequate to infer the presence or 
absence of a relationship between smoking cessa-
tion and changes in the lung microbiome.
Asthma
Asthma is characterized by variable airflow obstruc-
tion, and its symptoms include wheezing and dyspnea 
with exertion (Chung et al. 2014). Chronic changes in the 
airway, referred to as airway remodeling, can lead to irre-
versible loss of lung function (Pascual and Peters 2005). 
The 2004 and 2014 Surgeon General’s reports (USDHHS 
2004, 2014) reviewed the topic of active smoking and 
asthma in children and adults, a topic updated here to 
focus on smoking cessation. Smoking has detrimental 
effects on asthma morbidity. Compared with nonsmokers 
with asthma, smokers with asthma have more severe symp-
toms, higher rates of hospitalization, accelerated decline 
in lung function, a shift from eosinophilia toward neutro-
philia, and impaired therapeutic response to inhaled and 
oral corticosteroids (Thomson et  al. 2004; McLeish and 
Zvolensky 2010). 
Smoking as a Risk Factor for Asthma
The 2014 Surgeon General’s report concluded that 
the evidence is suggestive but not sufficient to infer a 
causal relationship between active smoking and the inci-
dence of asthma in adults. With regard to exacerbation of 
asthma, the report concluded that the evidence is suffi-
cient to infer a causal relationship between active smoking 
and exacerbation of asthma in adults. In the United States, 
cigarette smoking is prevalent among persons with 
asthma. Data from 2010 from the Behavioral Risk Factor 
Surveillance System show that nearly 17% of people 
without asthma smoked, and 21% of people with asthma 
smoked (CDC n.d.). For example, Silverman and colleagues 
(2003) examined nearly 2,000 persons 18–54 years of age 
who presented at an emergency department with acute 
asthma. Asthma symptoms and smoking status were 
assessed via structured interview. Of persons presenting at 
the emergency department with acute asthma, 35% were 
current cigarette smokers, and an additional 23% were 
former smokers. Interestingly, no difference in pulmonary 
function was seen between smokers and nonsmokers upon 
their arrival in the emergency department.
Some observational evidence shows an association 
between incident asthma and smoking, but the evidence 
is mixed (McLeish and Zvolensky 2010). The association 
of smoking with asthma is stronger among certain sub-
groups of the population. Specifically, among women, the 
prevalence of asthma is higher among cigarette smokers 
compared with nonsmokers, but findings have not been 
consistent in showing a similar difference in the preva-
lence of asthma among men (McLeish and Zvolensky 
2010). Additionally, women who quit smoking may have 
a higher asthma remission rate (Holm et al. 2007). Most 
studies concerning adolescents have found higher rates 
of smoking among adolescents with asthma than among 
those without asthma (McLeish and Zvolensky 2010). 
Among adults, this trend is less consistent, possibly 
because of smoking cessation among adults with asthma. 
The U.S. Black Women’s Health Study, a prospective 
cohort study with 46,182 participants, found an exposure-
response relationship between smoking and the incidence 
of adult-onset asthma. Adjusted hazard ratios for former 
active smoking, current active smoking, and exposure to 
secondhand smoke were, respectively, 1.36  (95%  confi-
dence interval [CI], 1.11–1.67), 1.43 (95% CI, 1.15–1.77), 
and 1.21 (95% CI, 1.00–1.45) compared with never active 
or never passive smoking (Coogan et al. 2015). Although 
current evidence suggests a possible causal relationship 
between active smoking and the incidence of asthma in 
adults, the evidence is not sufficient to state conclusively 
whether smoking is a directly causal risk factor, per the 
conclusion of the 2014 Surgeon General’s report (McLeish 
and Zvolensky 2010; USDHHS 2014). 
Smoking Cessation, Asthma 
Symptoms, and Lung Function
Asthma-related morbidity and mortality are higher 
in current cigarette smokers compared with never smokers 
(Thomson et al. 2004). Smokers with asthma have more 
severe symptoms (Althuis et al. 1999; Siroux et al. 2000), 
a greater need for rescue medications (Gallefoss and Bakke 
2003), and poorer health status compared with never 
smokers (Gallefoss and Bakke 2003; Jang et  al. 2010). 
In  an experimental study of smokers with asthma, the 
decrement in FEV1 after smoking cessation was inversely 
associated with baseline FEV1. This finding suggests that 
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smokers with asthma who have worse lung function may 
be particularly susceptible to the acute effects of tobacco 
smoke (Jang et al. 2010). Compared with nonsmokers with 
asthma, smokers with atopic asthma are less responsive to 
inhaled adenosine and corticosteroids, which may point 
toward differences in airway inflammation (Oosterhoff 
et al. 1993; Lazarus et al. 2007). Admission rates to hos-
pital for asthma and hospital-based care are higher in 
smokers than in those who have never smoked (Prescott 
et al. 1997; Sippel et al. 1999), although possibly not in 
younger adult smokers (Rasmussen et  al. 2002). The 
6-year mortality rate following a near-fatal asthma attack 
is higher for smokers than nonsmokers (age-adjusted odds 
ratio [OR] = 3.6; 95% CI, 2.0–6.2) (Marquette et al. 1992).
In combination, cigarette smoking and asthma 
accelerate the decline of lung function to a greater degree 
than either factor alone (Lange et al. 1998; Apostol et al. 
2002). For example, the Copenhagen City Heart Study, 
which included longitudinal measurement of FEV1 over 
a 15-year period, found that the average decline in FEV1 
among persons with asthma was greater in smokers than 
nonsmokers (Lange et al. 1998). The average annual decline 
in FEV1 in men with asthma who were 40–59 years of age 
was 33 mL/year in nonsmokers (n = 36) and 58 mL/year in 
smokers (n = 150; p <0.001) (Lange et al. 1998). The com-
bination of chronic hypersecretion of mucus and smoking 
in adults with asthma was associated with a greater decline 
in FEV1 than in adults without asthma (Lange et al. 1998). 
A study of 4,000  adults who were 18–30  years of age at 
enrollment (Apostol et al. 2002) and who were followed for 
more than 10 years with serial spirometry measurements 
found that the decline in FEV1 was 8.5% in never smokers 
without asthma (n = 2,393), 10.1% in never smokers with 
asthma (n = 437), and 11.1% in smokers without asthma 
(n = 514). The combination of having asthma and smoking 
≥15 cigarettes per day (n = 101) had a synergistic effect on 
the decline in lung function, resulting in a 17.8% decline 
in FEV1 over 10 years (Apostol et al. 2002). 
Cigarette smoking has been found to decrease the 
effectiveness of inhaled corticosteroids (Thomson et  al. 
2004). The mechanisms of corticosteroid resistance in 
smokers with asthma are not well understood, but this 
resistance could result from alterations in the pheno-
types of airway inflammatory cells (e.g., increased neutro-
phils, reduced eosinophils); changes in the glucocorticoid 
receptor α-to-β ratio (e.g.,  overexpression of glucocorti-
coid receptor β); and increased activation of proinflam-
matory transcription factors (e.g.,  nuclear factor-κB) or 
reduced activity of histone deacetylase (Thomson et  al. 
2004). Chalmers and colleagues (2002), who examined the 
effect of treatment with inhaled fluticasone propionate on 
morning and evening peak expiratory flow (PEF) among a 
cohort of steroid-naïve smokers and nonsmokers, found 
that the mean morning PEF increased significantly more 
in nonsmokers than in smokers (27 liters [L]/minute vs. 
-5 L/minute). Inhaled corticosteroids that are often pre-
scribed to treat the exacerbations discussed in this chapter 
thus far appear to be less effective in treating asthma 
among smokers (Chalmers et  al. 2002). Chaudhuri 
and colleagues (2006) examined the effects of smoking 
cessation on lung function and airway inflammation 
among 32 smokers with asthma at 6 weeks and found a 
decreased proportion of sputum neutrophils (mean per-
cent difference,  29  [51  to  -8]; p  =  0.013) among those 
who quit smoking, suggesting a possible mechanism for 
improved response to inhaled corticosteroids after cessa-
tion (Chaudhuri et al. 2006). 
Several studies have examined smoking cessation and 
its association with asthma symptoms and lung function 
(Table 4.27). For example, Tønnesen and colleagues (2005) 
examined the effects of smoking cessation and reduction in 
smoking on asthma symptoms. Participants were divided 
into three groups: smokers who had reduced their ciga-
rette consumption (to fewer than seven cigarettes per day), 
former smokers who had achieved complete cessation, and 
smokers who continued smoking as usual. Participants in 
both the smoking reduction and smoking cessation groups 
also used nicotine replacement therapy as an aid to reduce 
or quit use. Those in the cessation group experienced sig-
nificant decreases in the use of rescue inhalers, frequency 
of daytime asthma symptoms, and bronchial hyperreac-
tivity, and they had a 25% reduction in inhaled steroids 
(Tønnesen et al. 2005). In addition, persons in this group 
reported significant improvements in both their overall 
and asthma-related quality of life. Compared with those 
in the cessation group, improvements were not as great 
among those who reduced their consumption of ciga-
rettes. Chaudhuri and colleagues (2006) found signifi-
cant improvements in spirometry (FEV1 and PEF) among 
former smokers after 1 week of cessation, and the improve-
ments continued through 6 weeks of cessation. Moreover, 
asthma control improved, and after 6 weeks of cessation, 
counts of sputum neutrophils decreased. 
Observational studies suggest that cigarette 
smoking increases the risk for poor asthma control by 
as much as 175% for such outcomes as asthma attacks, 
interference with daily activities, and greater severity of 
wheezing and breathlessness (McLeish and Zvolensky 
2010). The wide range of effect sizes appears to be attrib-
utable in large measure to differences in methodology 
across these investigations. Regardless, cigarette smoking 
among persons with asthma is associated with increased 
risk of mortality, more frequent asthma attacks, exacer-
bations of the disease, and symptoms such as wheezing 
and nighttime awakenings (McLeish and Zvolensky 2010). 
In persons with asthma, smoking cessation is associated 
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with improvements in lung function (specifically PEF), 
the number of asthma symptoms, treatment outcomes, 
and asthma-specific quality-of-life scores. 
Smoking Cessation Biomarkers and the 
Microbiome in Asthma
Counts of sputum neutrophils, an indicator of 
airway inflammation, are reported to be higher in heavy 
smokers with mild asthma compared with nonsmokers 
with asthma (Chalmers et  al. 2001). Sputum concentra-
tions of cytokines such as IL-8 are also higher in smokers 
with asthma (Chalmers et al. 2001), but sputum concen-
trations in other cytokines, such as IL-18, are suppressed 
in smokers with asthma (McKay et al. 2004). The elevated 
sputum neutrophil count found in high-intensity smokers 
with asthma may be partly responsible for their reduced 
responsiveness to corticosteroids (Meagher et  al. 1996). 
Unlike eosinophils, which are exquisitely sensitive to cor-
ticosteroids, neutrophils are poorly responsive to cortico-
steroid therapy (Green et al. 2002), and their survival and 
proliferation are promoted by glucocorticoids. In a study 
of 32  smokers, smoking cessation resulted in reduction 
in induced sputum neutrophils by bronchoalveolar lavage 
among subjects with asthma but no change in mediator 
levels (Chaudhuri et  al. 2006). In contrast, research on 
the effect of smoking cessation on airway inflammation in 
COPD has shown that elevated levels of most inflamma-
tory cells, including neutrophils, persist in former smokers 
Table 4.27 Studies on smoking cessation and asthma, 2009–2017
Study Design/population Findings
Tønnesen et al. 
(2005)
• Prospective cohort
• 220 smokers with asthma:
 – 79 reducers (reduced consumption to 
<7 cigarettes per day)
 – 82 quitters
 – 59 continued smokers
• Reduction and cessation groups used NRT 
as cessation aid
Quitters reported a significant decrease in use 
of rescue inhalers, frequency of daytime asthma 
symptoms and bronchial hyperactivity, and 
reduction in inhaled steroid use
Those in this group also reported significant 
improvement both in overall and asthma-related 
quality of life
Chaudhuri et al. 
(2006)
• Prospective cohort
• 32 smokers with asthma:
 – 21 quitters
 – 11 continued smokers
• Followed up for 6 weeks 
• Recorded PEF morning and night
Lung function in quitters improved significantly within 
a week of stopping smoking and these improvements 
continued through 6 weeks of cessation
Broekema et al. 
(2009)
• Cross-sectional
• 147 patients with asthma:
 – 66 never smokers
 – 46 former smokers
 – 35 current smokers 
Epithelial characteristics in former smokers were 
similar to those in never smokers, suggesting 
that smoke-induced changes can be reversed by 
smoking cessation
Jang et al. (2010) • Prospective cohort 
• 22 patients with asthma who continued to smoke
• 10 patients with asthma who quit smoking at 
3 months
• Measured FEV1
Patients with asthma who quit smoking showed 
less airway obstruction
Cerveri et al. 
(2012)
• Prospective cohort 
• 9,092 with asthma
• 1,045 without asthma at 9-year follow-up
Smoking was significantly less frequent among 
participants with asthma than in the rest of the 
population (26 vs. 31%; p <0.001)
Polosa et al. 
(2014)
• Prospective cohort 
• 18 e-cigarette users with mild-to-moderate asthma
• Followed up for 24 months 
E-cigarette use ameliorated both objective and 
subjective asthma outcomes, and beneficial effects 
may persist in the long term
Munck et al. 
(2016)
• Prospective cohort 
• 44 patients with asthma, of whom 25 quit smoking 
at 12 weeks
Although tobacco smokers with asthma had a greater 
bacterial diversity in the induced sputum compared 
with nonsmoking healthy controls, smoking cessation 
did not change microbial diversity
Notes: FEV1 = forced expiratory volume at 1 second; PEF = peak expiratory flow.
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(Turato et al. 1995; Domagala-Kulawik et al. 2003; Willemse 
et  al. 2004) and that inflammation can even increase 
(Willemse et al. 2005). Only a few studies have specifically 
assessed the lung microbiome among former smokers with 
asthma (Charlson et  al. 2010; Huang et  al. 2011; Morris 
et al. 2013), with Munck and colleagues (2016) finding that 
current smokers had greater bacterial diversity in their 
induced sputum and that smoking cessation did not lead 
to changes in microbial diversity at 12 weeks.
Synthesis of the Evidence
Cigarette smoking has adverse effects on the respi-
ratory health of people with asthma and has been found 
to causally contribute to the worsening of asthma. 
Asthma involves chronic inflammation of the airways, 
and smoking has been shown to increase inflammation, 
with clinical consequences. Smoking cessation has been 
linked to improvement in a variety of clinical indicators, 
including fewer asthma symptoms; less frequent use of 
inhalers, including inhaled corticosteroids; and improved 
outcomes, including an attenuation in the decline of lung 
function, fewer asthma exacerbations, and lower mortality. 
In the 2014 Surgeon General’s report, the evidence 
was considered sufficient to infer a causal relationship 
between active smoking and asthma exacerbations in 
adults. The report did not specifically address smoking 
cessation, while offering the recommendation that people 
with asthma should not smoke, given the causal associa-
tion of smoking with exacerbations.
The evidence reviewed in this report documents that 
smoking cessation improves lung function, reduces symp-
toms, and improves treatment outcomes among persons 
with asthma. Cohort studies have documented that ciga-
rette smoking acts synergistically with asthma to accelerate 
the decline of lung function. With regard to the natural his-
tory of asthma, the findings of cohort studies also suggest 
that smoking cessation can attenuate the decline of lung 
function among persons with asthma (Apostol et al. 2002). 
Because smoking is a powerful cause of inflamma-
tion of the respiratory tract, cessation would be expected 
to reduce inflammation in people with asthma, thereby 
improving clinical status. Thus it is biologically plausible 
that smoking cessation would improve outcomes in people 
with asthma who smoke. The observational evidence 
is consistent with this conclusion but limited in scope, 
and there are few studies that have followed people with 
asthma over longer periods of time to characterize how 
outcomes change with increasing duration of cessation.
Conclusions
1. The evidence is suggestive but not sufficient to infer 
that smoking cessation reduces asthma symptoms 
and improves treatment outcomes and asthma-
specific quality-of-life scores among persons with 
asthma who smoke. 
2. The evidence is suggestive but not sufficient to infer 
that smoking cessation improves lung function 
among persons with asthma who smoke. 
Implications
While the evidence remains “suggestive” concerning 
smoking cessation and clinical outcomes in people with 
asthma who smoke, clinicians should recommend cessa-
tion for their patients with asthma who smoke. Smoking 
worsens the status of those with asthma, and the evidence 
reviewed in this report shows favorable consequences of 
quitting. Even the perception of a causal relationship with 
asthma among smokers may be an impetus for cessation 
(Godtfredsen et al. 2001). 
Further research is needed to address gaps in the 
evidence related to smoking cessation and asthma. One 
area that requires further investigation is the relationship 
between cigarette smoking and the response to cortico-
steroids among persons with asthma. The mechanisms for 
this relationship are not well understood, and smoking 
cessation studies can help to elucidate pathways and 
potential therapies, including the potential role of neutro-
phils in corticosteroid resistance in asthma.
Reproductive Health
The first Surgeon General’s report addressed the 
deleterious effects of maternal smoking on fetal growth 
(U.S. Department of Health, Education, and Welfare 
[USDHEW] 1964). Subsequent Surgeon General’s reports 
identified causal associations between active smoking and 
other adverse reproductive health outcomes for women 
or men, including decreased female fertility, pregnancy 
complications, preterm delivery, and erectile dysfunc-
tion (U.S.  Department of Health and Human Services 
[USDHHS] 2014). Although the effects of smoking on 
reproductive health are well established, the benefits of 
smoking cessation for reproductive health have been 
studied less extensively. This section provides current 
information on the potential benefits of smoking cessation 
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for maternal health during pregnancy, for birth outcomes, 
and for female and male reproductive health.
Conclusions from Previous 
Surgeon General’s Reports
The 1990 Surgeon General’s report on the health 
benefits of smoking cessation included six conclusions on 
smoking cessation and reproductive health (Table  4.28) 
(USDHHS 1990). The report concluded that women who 
stopped smoking before or during the first trimester of 
pregnancy had infants with a birth weight similar to that 
seen among never smoking or nonsmoking women, while 
smoking cessation later in pregnancy increased infants’ 
birth weights relative to those of infants born to women 
who continued to smoke throughout pregnancy. In con-
trast, reductions in smoking intensity during pregnancy 
did little to reverse the smoking-related reduction of 
birth weight. The 1990 report also found that women who 
stopped smoking experienced natural menopause at an 
age similar to that of nonsmoking women, which was 1 to 
2 years later than women who were active smokers. 
Four subsequent Surgeon General’s reports pro-
vided updated conclusions on the reproductive health 
effects of smoking and the biological mechanisms under-
lying these effects. However, these reports did not address 
the effects of smoking cessation (USDHHS 2001, 2004, 
2010, 2014). 
Literature Review Methods
A systematic literature review was conducted to 
update the cessation-specific conclusions of the 1990 
Surgeon General’s report. The search was restricted 
to English-language articles available on PubMed or 
EMBASE  and published between January  2000 and 
February 2017. In the PubMed search strategy (Table 4.29), 
Medical Subject Headings (“MeSH”) terms were used to 
capture relevant articles. Retrieved articles included at 
least one term related to smoking cessation (e.g., “former 
smokers”) and at least one term related to reproductive 
health (e.g.,  “pregnancy”). Citations from retrieved arti-
cles and past Surgeon General’s reports were used to iden-
tify articles not captured by the search, including several 
articles published between 1997 and 1998.
Sources of Bias in Observational Studies 
of Smoking and Reproductive Health
Most studies related to prenatal maternal smoking, 
smoking cessation, and health outcomes rely on self-reports 
to characterize maternal smoking, but findings from sev-
eral studies indicate that the use of self-reports to deter-
mine smoking status in pregnant women substantially 
misclassifies exposure as a result of underreporting. For 
example, various studies that assessed smoking cessation 
using both self-reports and biochemical markers, such 
as salivary or urinary cotinine, have found that pregnant 
women consistently underreport being smokers and gen-
erally overreport cessation (George et  al. 2006; England 
et al. 2007; Andersen et al. 2009; Shipton et al. 2009; Dietz 
et al. 2011; Rode et al. 2013). Notably, in a study of women 
participating in a randomized trial for preeclampsia pre-
vention, an analysis that included cotinine-validation of 
self-reported quit status found that the degree of misclas-
sification was lower among women who reported never 
smoking or who reported quitting before pregnancy than 
among women who reported quitting after becoming 
pregnant (England et al. 2007; Rode et al. 2013). In this 
study, misclassification from over-reporting of cessation 
led to a modest overestimation of the magnitude of asso-
ciations between maternal smoking and such outcomes as 
birth weight and small-for-gestational age (SGA) (England 
et al. 2007). Finally, reports on quitting late in pregnancy 
may be subject to more misclassification than reports on 
quitting early in pregnancy (Tong et al. 2015).
The degree of misclassification of smoking status 
varies across studies. Factors that may have contributed 
to this variation include the type of biomarker and the 
cut point selected for classification of active smoking, the 
country where the study was conducted, whether women 
were aware that biochemical validation would occur, 
when during the pregnancy the women were asked about 
smoking, the woman’s smoking intensity, and the woman’s 
age and other sociodemographic factors. Estimates of the 
percentage of true active smokers misclassified as quitters 
or nonsmokers have ranged from 23% to 25% (England 
et al. 2007; Shipton et al. 2009; Dietz et al. 2011), while 
estimates of the percentage of self-reported quitters who 
had evidence from a biomarker of active smoking have 
ranged from 0% to 25% (George et al. 2006; Andersen et al. 
2009; Rode et al. 2013; Tong et al. 2015). Differential mis-
classification of smoking status by such factors as inten-
sity of smoking can bias the results of studies examining 
the effects of smoking or smoking cessation on birth out-
comes. For example, England and colleagues (2007) found 
that women who misreported cessation were more likely 
to be light smokers (1–9 cigarettes per day) than women 
who accurately reported their smoking status. This mis-
classification may bias estimates of associations between 
smoking status during pregnancy and birth outcomes, 
such as hypertensive disorders of pregnancy and SGA, for 
both quitters (e.g.,  by including continuing smokers in 
the group classified as quitters) and continuing smokers 
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Table 4.28 Conclusions from the 1990 Surgeon General’s report on the health benefits of smoking cessation and 
reproductive health
Conclusions
1. Women who stop smoking before becoming pregnant have infants of the same birth weight as those born to never smokers.
2. Pregnant smokers who stop smoking at any time up to the 30th week of gestation have infants with higher birth weight than 
do women who smoke throughout pregnancy. Quitting in the first 3 to 4 months of pregnancy and abstaining throughout the 
remainder of pregnancy protect the fetus from the adverse effects of smoking on birth weight.
3. Evidence from two intervention trials suggests that reducing daily cigarette consumption without quitting has little or no 
benefit for birth weight.
4. Recent estimates of the prevalence of smoking during pregnancy, combined with an estimate of the relative risk of low birth 
weight outcome in smokers, suggest that 17 to 26 percent of low birth weight births could be prevented by eliminating smoking 
during pregnancy: in groups with a high prevalence of smoking (e.g., women with less than a high school education), 29 to 
49 percent of low birth weight births might be prevented by elimination of cigarette smoking during pregnancy. 
5. Approximately 30 percent of women who are cigarette smokers quit after recognition of pregnancy, with greater proportions 
quitting among married women and especially among women with higher levels of educational attainment.
6. Smoking causes women to have natural menopause 1 to 2 years early. Former smokers have an age at natural menopause 
similar to that of never smokers.
Source: USDHHS (1990, p. 410). 
Table 4.29 PubMed systematic search strategy
Smoking search terms Reproductive health search termsa
smoking cessation OR “former 
smoker” OR “former smokers” 
OR ex-smok* OR exsmok* OR 
quit* smok* OR stop* smok*
reproduction OR reproductive OR Reproductive Health[mh] OR Reproductive Medicine[mh] OR 
birth OR Parturition[mh] OR pregnancy OR pregnan* OR gestation* OR fertility OR infertility OR 
fertile OR infertile OR fecundability OR fecundity OR subfertility OR “sub-fertility” OR Subfertile 
OR “sub-fertile” OR amenorrhea OR conception OR Fertilization[mh] OR “spontaneous abortion” 
OR “Abortion, Spontaneous”[mh] OR stillbirth OR Miscarriage* OR Fetal Death[mh] OR preterm 
OR Premature Birth[mh] OR “Infant, Premature”[mh] OR “Obstetric Labor, Premature”[mh] 
OR placenta OR Placenta Diseases[mh] OR preeclampsia OR “Pre-Eclampsia”[mh] OR “pre-
eclampsia” OR “fetal growth” OR Fetal Development[mh] OR Fetal Growth Retardation[mh] OR 
birthweight OR “birth weight” OR “Infant, Low Birth Weight”[mh] OR Birth Weight[mh] OR 
“fetal mortality” OR Fetal Mortality[mh] OR “neonatal mortality” OR “perinatal mortality” OR 
Perinatal Mortality[mh] OR Perinatal Death[mh] OR “infant mortality” OR Infant Mortality[mh] 
OR congenital OR Congenital Abnormalities[mh] OR SIDS OR Sudden Infant Death[mh] OR 
“Sudden Infant Death” OR menopause OR “sexual performance” OR “sexual dysfunction” OR 
“Sexual Dysfunction, Physiological”[mh] OR erection OR Penile Erection[mh] OR erectile OR 
Erectile Dysfunction[mh] OR impotence OR “Impotence, Vasculogenic”[mh] OR sperm OR 
Spermatozoa[mh] OR Spermatogenesis[mh] OR semen OR Semen Analysis[mh] OR Prenatal 
OR “pre-natal” OR Prenatal Care[mh] OR Prenatal Injuries[mh] OR Prenatal Diagnosis[mh] 
OR “Embryonic and Fetal Development”[mh]
Notes: Mh = to search Medical Subjects Headings (MeSH) in MEDLINE or PubMed.
aUsed in conjunction with all smoking search terms.
(e.g., by omitting light smokers because they incorrectly 
reported cessation) (England et al. 2007). 
Many studies of the association of tobacco use 
with pregnancy outcomes have assessed smoking status 
at a single point during pregnancy, but because women 
may change their patterns of tobacco use during preg-
nancy by quitting, cutting back, and/or relapsing, using a 
single assessment of exposure can result in misclassifica-
tion of exposure across a pregnancy (Pickett et al. 2003, 
2005). For example, in a prospective cohort of Dutch 
women, 34% reported cessation during the first trimester, 
but were later reclassified as continuing smokers after 
responding to questionnaires in the second and third 
trimesters (Bakker et  al. 2011). Thus the assessment of 
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smoking status at a single time point rather than multiple 
time points during pregnancy can result in misclassifica-
tion of exposure (Pickett et al. 2009). 
Overall, women who smoke differ from those who 
do not in several ways with regard to lifestyle and behav-
iors, leading to the potential for confounding (Subar 
et al. 1990; Midgette et al. 1993; Maxson et al. 2012). For 
example, smokers may be more likely than nonsmokers 
to use alcohol and/or illicit substances that can affect 
birth outcomes (Coleman-Cowger et al. 2017). Fully con-
trolling for these differences in estimating the benefits of 
quitting can be difficult, but failure to do so may result 
in unrecognized residual confounding, which was illus-
trated, for example, in a study of Swedish women. There, 
Juárez and Merlo (2013) compared results of a conven-
tional multivariable linear regression analysis with those 
of a multilevel analysis that used siblings to estimate 
woman-specific, smoking-associated changes in birth 
weight (i.e., comparing the birth weights of infants born 
to the same woman whose exposure to smoking changed 
between pregnancies and controlling for birth order). The 
association between maternal smoking behavior and birth 
weight remained significant in the sibling analysis, but it 
was attenuated in comparison with the conventional anal-
ysis. Specifically, the babies of women who smoked heavily 
throughout pregnancy had an adjusted reduction in birth 
weight of 303 grams (g) relative to those of nonsmokers 
in the conventional analysis; in the sibling analysis, the 
reduction was 226 g. Using similar methods in a cohort 
of Danish births, Obel and colleagues (2016) also found 
that the association between smoking during pregnancy 
and low birth weight (<2,500 g) was moderately attenu-
ated in a sibling analysis in comparison with a conven-
tional analysis (adjusted odds ratio [aOR]  =  1.68 and 
2.60, respectively). 
Pregnancy Complications
Ectopic Pregnancy
An ectopic pregnancy, which occurs when implanta-
tion of the fertilized ovum takes place outside the uterus, 
most often in the fallopian tubes, affects an estimated 1% 
to 2% of pregnancies (CDC 1995; Van Den Eeden et  al. 
2005). The 1990 Surgeon General’s report found only 
sparse evidence that current or former smokers were 
at higher risk of ectopic pregnancy (Chow et  al. 1988; 
USDHHS 1990; Kalandidi et  al. 1991; Stergachis et  al. 
1991; Parazzini et  al. 1992; Phillips et  al. 1992; Saraiya 
et  al. 1998; Bouyer et  al. 2003; Karaer et  al. 2006), but 
the 2014 Surgeon General’s report found sufficient evi-
dence to conclude that active smoking causally increases 
the risk of ectopic pregnancy (USDHHS 2014). Potential 
mechanisms underlying this relationship identified from 
animal research include damage to a fallopian tube or dys-
function of that structure, damage to the oviduct epithe-
lium, a decrease in the ratio of ciliated to secretory ovi-
ductal cells, a decrease in smooth muscle contractions of 
the oviduct, and decreased oviductal blood flow (USDHHS 
2014). A review of studies that included former smokers 
with an ectopic pregnancy found that the majority of 
studies reported no significant association between that 
outcome and past smoking (Chow et al. 1988; Kalandidi 
et al. 1991; Stergachis et al. 1991; Parazzini et al. 1992; 
Phillips et al. 1992; Saraiya et al. 1998; Bouyer et al. 2003; 
Karaer et al. 2006).
Summary of the Evidence
The 2014 Surgeon General’s report concluded that 
“the evidence is sufficient to infer a causal relationship 
between maternal active smoking and ectopic pregnancy” 
(USDHHS 2014, p. 487). A systematic review of the litera-
ture did not identify additional studies since that report 
that assessed the risk of ectopic pregnancy among former 
smokers. Therefore, a new conclusion on smoking cessa-
tion and ectopic pregnancy is not provided in this report. 
Spontaneous Abortion
Spontaneous abortion is defined as the involun-
tary termination of an intrauterine pregnancy before 
20 weeks’ gestation, although it is sometimes defined as 
occurring before 28 weeks. Recognized spontaneous abor-
tion occurs in approximately 12% of pregnancies, usually 
before 12 weeks’ gestation (McNair and Altman 2011). Very 
early losses may go unrecognized, and the true incidence 
of pregnancy loss may be as high as 30% to 45% (Wilcox 
et al. 1988; Eskenazi et al. 1995). 
The 1990 Surgeon General’s report did not pro-
vide a conclusion about the association between smoking 
cessation and spontaneous abortion because of a paucity 
of research among former smokers. The 2004 Surgeon 
General’s report, however, reviewed the evidence on an 
association between maternal smoking and spontaneous 
abortion, finding the evidence suggestive but not suffi-
cient to infer a causal relationship (USDHHS 2004), and 
cessation was not examined. The 2010 Surgeon General’s 
report updated the 2004 report, but it did not include con-
clusions on the strength of evidence for causality. Proposed 
mechanisms underlying a potential association that were 
set forth in that report included effects of hypoxia due to 
exposure to CO, vasoconstrictive and antimetabolic effects 
resulting from placental insufficiency, and the direct 
toxic effects of constituents in cigarette smoke (USDHHS 
2010). The 2014 Surgeon General’s report noted that 
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studies have found associations between active smoking 
and spontaneous abortion, but it considered the evidence 
suggestive but not sufficient to reach a causal conclusion, 
in part because of study limitations, including difficulty 
controlling for potential confounders and a lack of data on 
conception karyotype (USDHHS 2014). 
Summary of the Evidence
The 2014 Surgeon General’s report concluded that 
“the evidence is suggestive, but not sufficient, to infer a 
causal relationship between maternal active smoking and 
spontaneous abortion” (USDHHS 2014, p. 489). However, 
a systematic review of the literature identified no known 
studies that have specifically assessed the association 
between smoking cessation and risk of spontaneous abor-
tion; therefore, this report does not make any new conclu-
sions regarding this outcome.
Placental Abruption
Placental abruption, which affects an estimated 
0.3% to 2% of pregnancies (Ananth et  al. 2015; Ruiter 
et al. 2015), is the premature separation of the placenta 
from the uterine wall (Rasmussen et  al. 1996; Ananth 
et  al. 2001, 2005; Kyrklund-Blomberg et  al. 2001; Luke 
et  al. 2017; Räisänen et  al. 2018). Placental abruption 
can lead to perinatal mortality (Raymond and Mills 1993; 
Ananth and Wilcox 2001; Kyrklund-Blomberg et al. 2001; 
Räisänen et  al. 2018), neonatal asphyxia (Heinonen and 
Saarikoski 2001), preterm delivery, significant maternal 
blood loss, and disseminated intravascular coagulation 
(Hladky et al. 2002). 
The only study on the risk of placental abruption 
(Naeye 1980) cited in the 1990 Surgeon General’s report 
(USDHHS 1990) found that smoking for more than 
6 years was associated with an increased risk of placental 
abruption, but that women who quit smoking by their 
first prenatal visit were not at increased risk of placental 
abruption relative to never smokers. The 2004 Surgeon 
General’s report found sufficient evidence to conclude that 
maternal smoking increases the risk of placental abrup-
tion, and it included one study demonstrating increased 
risk of this event in former smokers (Spinillo et al. 1994; 
USDHHS 2004). That study, however, was limited by its 
small sample, and it did not include information about the 
timing of cessation. The 2010 Surgeon General’s report 
reviewed potential mechanisms underlying the associa-
tion between smoking and abruption, including smoking-
related degenerative and/or inflammatory changes in the 
placenta, reduced vitamin C levels and impaired collagen 
synthesis in smokers, microinfarcts, and atheromatous 
changes in placental vessels (USDHHS 2010). That report 
identified one study indicating that, when women stop 
smoking between pregnancies, their risk of abruption is 
similar to that of nonsmokers (Ananth and Cnattingius 
2007). Because abruption is a rare outcome, large, pop-
ulation-based samples are needed to study risk factors for 
its occurrence. One study published since the 2010 report 
(Räisänen et al. 2014) had a sufficient sample to examine 
smoking cessation and placental abruption. In this pop-
ulation-based cohort of more than 1  million births in 
Finland, Räisänen and colleagues (2014) found that pla-
cental abruption occurred in 0.3% of pregnancies among 
both nonsmokers and women who quit smoking during 
the first trimester of pregnancy, but in 0.6% of pregnan-
cies among women who continued to smoke after the first 
trimester. That study, however, did not include adjust-
ments for covariates, and the results of testing for statis-
tical significance were not presented. A smaller study of 
births at an Australian hospital found that women who 
were smokers at the first antenatal visit did not differ sig-
nificantly in risk of placental abruption from nonsmokers 
(aOR  =  0.82; 95% confidence interval [CI], 0.27–2.44) 
or from women who quit smoking within a year before 
their first antenatal visit (aOR = 2.45; 95% CI, 0.20–29.29) 
(Bickerstaff et al. 2012). 
Summary of the Evidence
The 2004 Surgeon General’s report found sufficient 
evidence to conclude that maternal smoking increases the 
risk of placental abruption. Since then, only two studies 
have examined smoking cessation and risk of placental 
abruption, and both had important methodological limi-
tations. Consequently, the evidence is inadequate to infer 
that smoking cessation before or during early pregnancy 
reduces the risk of placental abruption compared with 
continued smoking. 
Placenta Previa
Placenta previa is the complete or partial obstruc-
tion of the cervix by the placenta, a problem that affects 
an estimated 0.4% to 0.7% of births (Comeau et al. 1983; 
Iyasu et  al. 1993; Faiz and Ananth 2003; Luke et  al. 
2017). Placenta previa can lead to important maternal 
and infant complications, including preterm delivery, 
hemorrhage, and even maternal, fetal, or neonatal death 
(Salihu et al. 2003; Creasy et al. 2004). One mechanism 
through which smoking could increase risk for this con-
dition is compensatory placental enlargement in response 
to chronic hypoxia and ischemia resulting from smoking 
(USDHHS 2010).
The 1990 Surgeon General’s report cited only one 
study examining the risk of placenta previa among former 
smokers (Naeye 1980); this study found that women who 
quit smoking before or during early pregnancy were 
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at increased risk relative to never smokers. The 2004 
Surgeon General’s report found sufficient evidence to 
conclude that active smoking increases the risk of pla-
centa previa, but it did not address risk in former smokers 
(USDHHS 2004). Since the 2004 report, two studies have 
examined placenta previa in quitters. In a study of Finnish 
women, Räisänen and colleagues (2014) observed that pla-
centa previa occurred in an estimated 0.2% of pregnan-
cies in each of four exposure groups (nonsmokers, women 
who quit smoking during the first trimester, women who 
continued to smoke after the first trimester, and women 
for whom no information was available on their smoking 
status). As indicated earlier, however, the study did not 
adjust for covariates, and the results of testing for sig-
nificance were not presented. In their study of Australian 
women, Bickerstaff and colleagues (2012) found that 
women who had quit smoking in the 12 months before 
entry into prenatal care had a reduced risk of placenta 
previa compared with those still smoking when they 
entered prenatal care, but the difference was not statisti-
cally significant (aOR = 0.45; 95% CI, 0.16–1.29). 
Summary of the Evidence
Since the 2004 Surgeon General’s report, only two 
studies have examined smoking cessation and risk of pla-
cental abruption, and both had important methodological 
limitations. Consequently, the evidence is inadequate to 
determine whether smoking cessation before or during 
pregnancy reduces the risk of placenta previa compared 
with continued smoking. 
Premature Rupture of Membranes
Premature rupture of the membranes (PROM) 
refers to rupture of the amniotic sac before the onset of 
labor. When this occurs before 37 weeks’ gestation, it is 
referred to as preterm PROM (PPROM). PPROM compli-
cates 1–2% of pregnancies, and it may contribute to up to 
40% of preterm deliveries (Arias and Tomich 1982; Mercer 
et al. 2000; Lee and Silver 2001; Bond et al. 2017; Mercer 
2017). PPROM (Smith et  al. 2005) increases perinatal 
morbidity and mortality through increased rates of pre-
term delivery and by elevating the risk of intra-amniotic 
infection, neonatal sepsis, placental abruption, and pul-
monary hypoplasia (Bond et  al. 2017; Sim et  al. 2017). 
Risk factors for PPROM include nutritional deficiencies 
in vitamin C (Hadley et al. 1990; Casanueva et al. 1993; 
Woods Jr et al. 2001; Siega-Riz et al. 2003), copper (Artal 
et  al. 1979; Kiilholma et  al. 1984), and zinc (Sikorski 
et al. 1988; Harger et al. 1990; Ekwo et al. 1992; Scholl 
et  al. 1993); vaginal bleeding (Harger et  al. 1990; Ekwo 
et al. 1992; Committee on Practice Bulletins—Obstetrics 
2016); bacterial vaginosis (Kurki et al. 1992; Mercer et al. 
2000); and intra-amniotic infections (Naeye and Peters 
1980; Ekwo et  al. 1993; Heffner et  al. 1993; Asrat 2001; 
Committee on Practice Bulletins—Obstetrics 2016). 
PROM may result from structural deficiencies of the cho-
rioamniotic membranes (Lee and Silver 2001; Tchirikov 
et al. 2018), disruptions in collagen metabolism (Draper 
et al. 1995; Tchirikov et al. 2018), and accelerated senes-
cence of membranes because of high levels of oxidative 
stress (Menon et al. 2014). 
The 1990 Surgeon General’s report on smoking 
cessation did not consider associations between cessa-
tion and PROM. The 2004 Surgeon General’s report on 
smoking concluded that active smoking causally increases 
the risk of PROM (USDHHS 2004). Hypothesized mecha-
nisms included effects of smoking on the immune system, 
resulting in increased risk of genital tract infections or 
inflammatory responses or reductions in nutrients, such 
as vitamin C (USDHHS 2010). One study included in the 
2004 report assessed risk in former smokers; the aOR for 
PPROM among quitters compared with never smokers 
was less than that for continuing smokers versus never 
smokers (aOR = 1.58; 95% CI, 0.77–3.27 and aOR = 2.08; 
95% CI, 1.37–3.13, respectively), suggesting that smoking 
cessation may reduce the risk of PPROM compared with 
continued smoking (Harger et al. 1990). 
Four studies published since the 2004 Surgeon 
General’s report have examined the risk of PROM and/or 
of PPROM in smokers and quitters. Bickerstaff and col-
leagues (2012) found that the risk of term PROM in 
women who had quit smoking in the 12 months before 
entry into prenatal care did not differ significantly from 
that of women still smoking when they entered pre-
natal care (aOR = 0.61; 95% CI, 0.33–1.15). Later, Blatt 
and colleagues (2015) analyzed data from certificates of 
live births in Ohio and found that women who quit after 
the second trimester had a higher incidence of PROM 
(5.3%) than nonsmokers and continuing smokers (2.8% 
and 3.2%, respectively), but they did not report results 
of testing for statistical significance or adjustments for 
confounders. In  a subsample of women in this cohort 
with a previous preterm delivery, Wallace and colleagues 
(2017) found that second-trimester quitters also expe-
rienced the highest prevalence of PROM (14.4%), with 
rates of 6.2% and 7.3% for nonsmokers and continuing 
smokers, respectively. Again, potential confounding was 
not addressed, and it is possible that the findings could 
be explained by reverse causation (i.e.,  the occurrence 
of pregnancy complications could have motivated late-
pregnancy cessation). Finally, in a study involving data 
from three randomized trials of metronidazole for bacte-
rial vaginosis that included more than 4,000  deliveries, 
Andres and colleagues (2013) found no differences in risk 
of PPROM between nonsmokers (4.1%), smokers who 
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quit during pregnancy (4.2%), and continuing smokers 
(4.5%); the OR for quitters was 1.04 (95% CI, 0.55–1.95) 
in a comparison with nonsmokers. Adjustment for demo-
graphic and obstetrical factors did not change this finding.
Summary of the Evidence
The 2004 Surgeon General’s report found sufficient 
evidence to conclude that maternal smoking increases 
the risk of PROM (USDHHS 2004). Since then, studies 
examining the effect of smoking cessation compared 
with continuing to smoke on the risk of PROM have not 
shown significant reductions in risk, and in one sample 
from Ohio, PROM risk appears to have increased in quit-
ters. Therefore, the evidence is inadequate to determine 
whether smoking cessation before or during pregnancy 
reduces the risk of PROM compared with continuing 
to smoke.
Preeclampsia
Preeclampsia is a syndrome of reduced organ per-
fusion attributable to vasospasm and endothelial activa-
tion that is marked by proteinuria, hypertension, and dys-
function of the endothelial cells lining the uterus, with 
onset after 20 weeks’ gestation. Eclampsia refers to a con-
dition in which preeclampsia is accompanied by general-
ized seizures not explained by other causes (Cunningham 
et al. 2013). Preeclampsia affects an estimated 1% to 6% 
of pregnancies (Abalos et al. 2013). Advances in research 
during the past 15 years have led to significant progress 
in our understanding of the etiology of preeclampsia. 
A process known as pseudo-vascularization enables 
increased uteroplacental perfusion and adequate oxygen 
and nutrient transport to the fetus by converting low-
capacity uterine spiral arteries into high-capacitance, low-
resistance vessels; this requires the upregulation of pro-
angiogenic molecules in processes completed by around 
20 weeks’ gestation. Evidence indicates that preeclampsia 
is a manifestation of an imbalance between proangio-
genic factors, such as placental growth factor (PlGF), and 
antiangiogenic factors, such as soluble fms-like tyrosine 
kinase  1 (sFlt-1) and soluble endoglin (sEng). Elevated 
levels of sFlt-1 and reduced levels of PlGF have been doc-
umented in women with preeclampsia, and evidence of 
this imbalance can precede the onset of clinical disease 
(Chaiworapongsa et al. 2004; Levine et al. 2004; Robinson 
et al. 2006). Importantly, pseudo-vascularization is incom-
plete in preeclampsia; cytotrophoblasts do not adequately 
invade the spiral arteries, resulting in placental ischemia, 
downregulation of proangiogenic vascular endothelial 
growth factor (VEGF) family molecules, and upregula-
tion of antiangiogenic placental factors, such as sFlt-1 and 
sEng. The etiology of abnormal placentation that precedes 
preeclampsia is uncertain, but it may involve placental 
hypoxia, oxidative stress, and genetic factors (Jim  and 
Karumanchi 2017).
An inverse association between maternal cigarette 
smoking and the risk of preeclampsia has been recognized 
for decades, and now some mechanistic understanding 
exists of this association. Smoking during pregnancy has 
been associated with reduced sFlt-1 levels in uncompli-
cated pregnancies (Levine et  al. 2006; Jeyabalan et  al. 
2008), and a reduction in the ratio of sFlt-1:PlGF has been 
described in smokers with preeclampsia (Jääskeläinen 
et  al. 2017). Notably, reductions in the risk of pre-
eclampsia have not been observed in users of smokeless 
tobacco, suggesting that nicotine is not the agent respon-
sible for reduced risk in cigarette smokers. In an sFlt-1 
preeclampsia-like mouse model, treatment with low-dose 
CO prevented late-gestation hypertension, proteinuria, 
and reduced Bowman’s space in the kidneys (Venditti et al. 
2014), supporting a role for CO rather than nicotine. 
Some investigators have proposed that preeclampsia 
is a two-stage disease, requiring abnormal placentation, 
insufficient invasion of extravillous cytotrophoblasts, 
insufficient remodeling of the maternal spiral arteries, 
and reduced placental perfusion in the first stage, followed 
by the clinical stages of the disease that involve the release 
of damaging endothelial factors into the maternal circula-
tion (Roberts and Hubel 2009; Palei et al. 2013; Gathiram 
and Moodley 2016). It is unclear whether smoking could 
affect the risk of preeclampsia in one or both of these 
stages. Developing a better understanding of the implica-
tions of the timing of exposure to cigarette smoking in the 
risk of preeclampsia could lead to a better understanding 
of the underlying pathophysiological process and point to 
potential treatments. 
The 1990 Surgeon General’s report found that the 
available data supported the idea that former smokers 
were at reduced risk of preeclampsia relative to never 
smokers (although to a lesser extent than active smokers) 
(Marcoux et al. 1989; USDHHS 1990), but there was inad-
equate evidence from which to draw causal conclusions 
(USDHHS 1990). The 2004 Surgeon General’s report 
concluded that maternal active smoking is causally asso-
ciated with reduced risk of preeclampsia, but it did not 
review the outcomes with regard to former smokers 
(USDHHS 2004). The 2010 and 2014 reports reviewed 
potential underlying mechanisms (summarized above), 
but they did not review the outcomes for risk relative to 
smoking cessation. 
A 2007 review of preeclampsia and smoking included 
six studies of the risk of preeclampsia in quitters (England 
and Zhang 2007); of the three studies that evaluated risk 
in women who quit before pregnancy, none found a sig-
nificant protective effect among quitters (Marcoux et al. 
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1989; England et al. 2002; Parazzini et al. 2003). Four of 
the six studies examined cessation during pregnancy: one 
found a significantly reduced risk in quitters (Sibai et al. 
1995), and three reported point estimates less than unity 
but no statistically significant associations (Marcoux et al. 
1989; Martin et al. 2000; England et al. 2002). Finally, one 
study combined women who quit before pregnancy with 
women who quit during early pregnancy and reported 
no significant associations for any intensity of smoking 
(Zhang et al. 1999).
Table 4.30 presents eight studies published in 2007 
or later and not included in the above review that assessed 
the relationship between smoking status (including cessa-
tion) and risk of preeclampsia. One of the eight (England 
et al. 2007) was a reanalysis of an earlier study (England 
et  al. 2002) that was included in the review by England 
and Zhang (2007), but in the reanalysis, the authors used 
urine cotinine to validate cessation. Two of the eight 
studies combined preeclampsia with gestational hyper-
tension and thus did not evaluate preeclampsia separately 
(England et al. 2007; Blatt et al. 2015); two assessed ces-
sation before pregnancy (Blatt et al. 2015; Kharkova et al. 
2017); one combined cessation before pregnancy with 
cessation during early pregnancy (England et  al. 2007); 
and six assessed cessation during pregnancy (Fasting 
et al. 2009; Xiong et al. 2009; Wikstrom et al. 2010; Engel 
et al. 2013; Räisänen et al. 2014; Blatt et al. 2015). Five 
of the eight studies reported results of statistical testing, 
and none found a significant reduction in the risk of pre-
eclampsia among quitters. Two of the three studies not 
reporting results of statistical testing reported prevalence 
estimates in quitters that were lower than those in non-
smokers (Räisänen et  al. 2014; Blatt et  al. 2015), but in 
one study, this was only true for women who quit in the 
second trimester (Blatt et al. 2015), and neither of these 
studies adjusted for potential confounders (preeclampsia 
was not a primary outcome in either study). Of the six 
studies assessing cessation during pregnancy, the timing 
of cessation varied, including at greater than 28  weeks 
gestation (Fasting et al. 2009), in the first 20 weeks gesta-
tion or the second 20 weeks gestation (Xiong et al. 2009), 
between 15 and 30 weeks gestation (Wikstrom et al. 2010), 
in the first trimester or in the second trimester (Engel 
et  al. 2013), and in the first trimester (Räisänen et  al. 
2014; Blatt et al. 2015).
All eight studies found lower point estimates for risk 
of preeclampsia among women who continued to smoke 
during pregnancy compared with women who did not 
smoke (range of aORs  =  0.5–0.8) (England et  al. 2007; 
Fasting et al. 2009; Xiong et al. 2009; Wikstrom et al. 2010; 
Engel et al. 2013; Räisänen et al. 2014; Blatt et al. 2015; 
Kharkova et al. 2017). Findings were statistically signifi-
cant in four studies (England et al. 2007; Wikstrom et al. 
2010; Engel et al. 2013; Kharkova et al. 2017) and not sig-
nificant in one study (Xiong et al. 2009), and the results 
of statistical testing were not presented in three studies 
(Fasting et al. 2009; Räisänen et al. 2014; Blatt et al. 2015). 
Of interest, one of the three studies with a significant 
finding was a large population-based study in Sweden in 
which women who did not smoke at the first antenatal 
visit, but who had resumed by the third trimester, had a 
significantly reduced risk of preeclampsia compared with 
women who did not smoke during pregnancy (aOR = 0.65; 
95% CI, 0.50–0.85) (Wikstrom et al. 2010).
Summary of the Evidence
The 2004 Surgeon General’s report concluded 
that maternal active smoking is causally associated with 
reduced risk of preeclampsia (USDHHS 2004). Results 
of studies published since the 2004 report provide addi-
tional support that continued smoking during preg-
nancy is associated with reduced risk of preeclampsia. 
However, the review did not find substantial evidence to 
support an inverse association between smoking before or 
during early pregnancy and reduced risk of preeclampsia 
among women who quit smoking before late pregnancy. 
Therefore, the evidence is insufficient to conclude that 
smoking during early or mid-pregnancy alone, and not 
during late pregnancy, is associated with a reduced risk 
of preeclampsia. Continued smoking may reduce the risk 
of preeclampsia through its effects on angiogenic factors 
late in pregnancy rather than through upstream effects 
on placentation during early pregnancy, but the evi-
dence is currently insufficient to draw conclusions about 
such mechanisms. 
Gestational Weight Gain
Weight gain associated with smoking cessation has 
been well described in the general population (reviewed 
by Bush et al. 2016), but it has been less well studied in 
pregnant and postpartum women. Fear of weight gain 
and/or weight retention could be a barrier to cessation or 
sustained abstinence from smoking in pregnant and post-
partum women (Lawson 1994; Hotham et al. 2002; Berg 
et al. 2008). Gaining weight above the recommended levels 
(Institute of Medicine [IOM] 2009) can result in infants’ 
being born large for gestational age (Goldstein et al. 2017), 
and weight gain below the recommended levels can result 
in infants’ being born small for gestational age or with low 
birth weight (Siega-Riz et  al. 2009). Smoking cessation 
during pregnancy could have unintended adverse effects 
on pregnancy or other health outcomes by increasing the 
number of pregnancies with excessive weight gain; con-
versely, smoking cessation-related weight gain could also 
reduce the number of pregnancies with inadequate weight 
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Table 4.30 Studies on smoking cessation and preeclampsia
Study Design Tobacco exposure Outcome definition Outcomes/findings Comments
England et al. 
(2002) (original 
analysis); 
England et al. 
(2007)  
(reanalysis)
• Randomized trial for 
preeclampsia prevention 
(2007 study was a 
reanalysis of 2002 study)
• n = 4289
• 1992–1995
• United States (multisite)
• Nonsmokers: Never smoked regularly
• Quit before pregnancy: Quit before 
last menstrual period, validated with 
cotinine mid-pregnancy
• Quit during pregnancy: Quit after last 
menstrual period, validated with cotinine 
mid-pregnancy
• Continued smoking: Smoking at 
study enrollment
• Smoking status based on self-reports 
obtained at study enrollment 
(13–21 weeks’ gestation) in 2007 study
• Quit status validated with urine cotinine 
concentration obtained mid-pregnancy 
(mean: 28 weeks)
• For 2007 analysis, quit groups were 
combined
2002 analysis:
• Preeclampsia: Gestational 
hypertension plus 
proteinuria within 7 days 
or the development of 
HELLP syndrome or 
eclampsia in the presence 
of hypertension 
2007 analysis:
• Hypertensive disorders of 
pregnancy: Pregnancy-
associated hypertension 
without proteinuria, 
preeclampsia, or 
eclampsia
2002 analysis—adjusted RR for 
preeclampsia (95% CI):
• Quit before pregnancy: 1.1 (0.7–1.7) 
• Quit during pregnancy: 0.9 (0.6–1.3) 
• Continued smoking: 0.7 (0.5–1.1)
2007 reanalysis—crude and adjusted OR 
for hypertensive disorders of pregnancy 
(95% CI):
• Quit preconception or by mid-pregnancy: 
 – Unadjusted: 0.9 (0.8–1.2)
 – Adjusted: 1.1 (0.9–1.3)
• Continued smoking: 
 – Unadjusted: 0.6 (0.5–0.7) 
 – Adjusted 0.6 (0.5–0.8)
Reanalysis of data used in 
2002 study after obtaining 
cotinine validation of 
smoking status
Results adjusted for 
maternal BMI, study 
center, and private 
health insurance
Did not account for 
alcohol or substance use
Fasting et al. 
(2009)
• Prospective intervention 
study to prevent allergies 
in children
• n = 711
• 2000–2002
• Norway
• Nonsmoker: Not smoking when 
became pregnant
• Quit smoking: Smoking when became 
pregnant, quit by study enrollment
• Continued smoking: Smoking when 
became pregnant, still smoking 
at enrollment
• Smoking status based on self-reports 
collected at enrollment (median 
gestational age: 11 weeks, all <28 weeks)
Preeclampsia assessed by 
maternal questionnaire
Number (%) of women with preeclampsia:
• Nonsmoker: 21 (4%)
• Quit smoking: 11 (10%)
• Continued smoking: 1 (2%)
Results not adjusted for 
potential confounders
Results of statistical 
testing not presented
Did not account for 
alcohol or substance use
Smoking Cessation
The Health Benefits of Smoking Cessation  329
Table 4.30 Continued
Study Design Tobacco exposure Outcome definition Outcomes/findings Comments
Xiong et al. 
(2009)
• Case-control study
• n = 337
• 2003–2006
• Quebec, Canada
• Nonsmokers: Did not smoke before 
or during pregnancy
• Quit smoking early: Smoked during 
pregnancy but quit in the first 20 weeks
• Quit smoking late: Smoked during 
pregnancy but quit in the second 
20 weeks of pregnancy
• Continued smoking: Smoked before 
and during pregnancy
• Smoking status based on self-reports 
ascertained from interviews conducted 
during postpartum period
Preeclampsia: Blood 
pressure at least 140/90 
on two occasions at 
least 4 hours apart after 
20 weeks’ gestation and 
with proteinuria
Unadjusted and adjusted OR for 
preeclampsia (95% CI):
• Nonsmokers: Reference
• Quit smoking early:
 – Unadjusted: 0.91 (0.42–1.96)
 – Adjusted 1.03 (0.41–2.60)
• Quit smoking late:
 – Unadjusted: 0.79 (0.21–2.96)
 – Adjusted 0.78 (0.12–5.02)
• Continued smoking: 
 – Unadjusted: 0.63 (0.23–1.73)
 – Adjusted 0.62 (0.16–2.37)
Results adjusted for 
maternal age, race, 
education, marital 
status, family income, 
BMI, gravidity, abortion, 
alcohol consumption, 
and cesarean section 
Did not account for 
substance use
Wikström et al. 
(2010)
• Population-based 
cohort study 
• Swedish Medical 
Birth Register
• Singleton, term births
• n = 379,214
• 1999–2006 
• Sweden
• Nonuser: Did not smoke or use tobacco 
at either study visit (early or late)
• Quit by late pregnancy: Smoked at the 
early visit but not the late visit
• Continued smoking: Smoked at the 
time of both visits (early and late)
• Started smoking by late pregnancy: 
Did not smoke at early visit but 
smoked at late visit
• Smoking status obtained by midwives 
from maternal self-reports at entry into 
prenatal care (<15 weeks’ gestation) 
and at 30–32 weeks’ gestation
Preeclampsia identified 
using ICD-10 codes 
Blood pressure ≥140/90 
with proteinuria after 
20 weeks’ gestation
Adjusted OR for preeclampsia: 
• Nonsmoker: Reference
• Quit by late pregnancy: 0.94 (0.83–1.08)
• Continued smoking: 0.50 (0.45–0.56)
• Started smoking by late pregnancy: 
0.65 (0.50–0.85)
Results adjusted for early-
pregnancy BMI, maternal 
age, parity, and years of 
education 
Did not account for 
alcohol or substance use
Engel et al. 
(2013)
• Population-based 
prospective cohort
• n = 70,729
• 1999–2008
• Norway
• Nonsmoker: Never smoked
• Smoked first trimester only
• Smoked first and second trimesters
• Smoked first and third trimesters
• Smoked third trimester only
• Smoked all trimesters
• Smoking status obtained from maternal 
interviews conducted in early pregnancy 
(~18 weeks) and late pregnancy 
(~30 weeks)
Preeclampsia obtained 
from registry, diagnosis 
obtained by midwife from 
antenatal medical record
Adjusted OR for preeclampsia (95% CI):
• Nonsmoker: Reference
• Smoked first trimester only: 0.99 
(0.87–1.11)
• Smoked first and second trimesters: 
0.89 (0.64–1.23)
• Smoked first and third trimesters: 
0.62 (0.31−1.27)
• Smoked third trimester only: 0.78 
(0.20−3.09)
• Smoked all trimesters: 0.57 (0.46–0.70)
Results adjusted for parity, 
maternal education, BMI, 
education level, diabetes, 
and multiple observations 
per woman 
Did not account for 
alcohol or substance use
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Table 4.30 Continued
Study Design Tobacco exposure Outcome definition Outcomes/findings Comments
Räisänen et al. 
(2014)
• Population-based 
retrospective cohort 
• Finnish Medical 
Birth Register
• Singleton deliveries, 
live or stillborn after 
22 weeks’ gestation
• n = 1,164,953
• 1991–2010
• Finland
• Nonsmokers
• Quit smoking: Quit during the first 
trimester
• Continued smoking: Still smoking 
after the first trimester
• Smoking history based on self-reports 
ascertained from the Finnish Medical 
Birth Register
• Details on when and how data were 
collected were not reported
Preeclampsia definition 
and ascertainment not 
described
Percentage preeclampsia: 
• Nonsmokers: 2.0%
• Quit smoking: 1.1%
• Continued smoking: 1.3%
Results not adjusted for 
potential confounders 
Results of statistical 
testing not presented 
Did not account for 
alcohol or substance use
Blatt et al. 
(2015)
• Population-based 
retrospective cohort 
• Ohio certificates of 
live birth
• n = 927,424
• 2006–2012
• Ohio
• Nonsmoker: Did not smoke during 
the 3 months before pregnancy or 
during pregnancy
• Quit preconception: Smoked during 
the 3 months before pregnancy but 
not during pregnancy
• Quit first trimester: Smoked first 
trimester only
• Quit second trimester: Smoked first 
and second trimester, not third
• Continued smoking: Smoked 
throughout pregnancy 
• Smoking history ascertained from vital 
statistics data and certificates of live birth
Gestational hypertension/
preeclampsia combined; 
obtained from certificate 
of live birth
Percentage gestational hypertension/
preeclampsia: 
• Nonsmokers: 4.6%
• Quit preconception: 5.2%
• Quit first trimester: 4.9%
• Quit second trimester: 4.2%
• Continued smoking: 3.3%
Findings not adjusted for 
potential confounders 
Results of statistical 
testing not presented
Did not account for 
alcohol or substance use
Kharkova et al. 
(2017)
• Population-based study 
using registry data
• n =39,566
• 2006–2009
• Russia
• Nonsmokers: Did not smoke before or 
during pregnancy
• Quit smoking: Smoked before but not 
during pregnancy
• Continued smoking: Smoked before 
and during pregnancy
• Smoking status based on self-reports 
obtained at first antenatal visit 
Preeclampsia or eclampsia 
classified according to ICD-
10 definitions: hypertension 
≥140/90 accompanied by 
edema and proteinuria 
with onset after 20 weeks’ 
gestation; eclampsia was 
convulsions or coma in 
pregnant or puerperal 
women with hypertension, 
edema, or proteinuria
OR for eclampsia/preeclampsia:
• Smokers: Reference
• Quit smoking:
 – Unadjusted: 1.09 (0.91–1.30)
 – Adjusted: 1.10 (0.91–1.32)
• Nonsmokers: 
 – Unadjusted: 1.32 (1.19–1.47)
 – Adjusted: 1.37 (1.23–1.54)
Results adjusted for 
maternal age, residence, 
ethnicity, marital status, 
parity, alcohol abuse, 
year of delivery, BMI, and 
excessive weight gain 
Did not account for 
substance use
Notes: BMI = body mass index; CI = confidence interval; kg = kilogram; ICD = International Classification of Diseases; lbs = pounds; HELLP = hemolysis, elevated liver enzymes, and low platelet 
count; OR = odds ratio; RR = risk ratio: SD = standard deviation.
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gain. In 2015, 48% of U.S. women gained weight in excess 
of recommended levels, and 21% gained below recom-
mended levels (CDC 2016b).
The 1990 Surgeon General’s report noted that, com-
pared with continued smoking, cessation during preg-
nancy may be associated with increased gestational weight 
gain (USDHHS 1990). More recent Surgeon General’s 
reports have not addressed gestational weight gain and 
smoking cessation. 
In a 2017 Cochrane Review of psychosocial inter-
ventions for supporting women to stop smoking during 
pregnancy, two of the identified randomized clinical trials 
addressed weight gain and also included biochemical vali-
dation of cessation (Chamberlain et al. 2017). One found a 
significant increase in weight gain by 8 months’ gestation 
of 1.0  kilogram (kg) (2.2  pounds [lbs]) in the interven-
tion versus the control group (Sexton and Hebel 1984); 
the other, which had fewer participants, found a 2.8-kg 
(6.2 lbs) unadjusted increase in weight gain among quitters 
compared with continuing smokers (Washio et al. 2011). 
This difference was no longer significant after adjustment 
for potential confounders (including pre-pregnancy BMI), 
but those possible confounders did not include gestational 
age at delivery. A significant increase in mean gestational 
weight gain per 10% increase in the number of negative 
smoking tests (during the course of the study) was not 
significant after adjustment for birth weight, suggesting 
that at least some of the potential effects of cessation on 
weight gain were from an increase in fetal growth (Washio 
et al. 2011).
Various observational studies have also found 
increased gestational weight gain in quitters compared with 
continuing smokers. Of six observational studies published 
since 2000, one examined gestational weight gain among 
women by smoking status across two consecutive pregnan-
cies (Abrevaya 2008), and five examined this outcome by 
smoking status in individual pregnancies (Favaretto et al. 
2007; Adegboye et al. 2010; Rode et al. 2013; Blatt et al. 
2015; Hulman et al. 2016) (Table 4.31). Each of the latter 
five studies examined cessation at different time points in 
the conception and timing of pregnancy: two examined 
cessation before pregnancy (Favaretto et  al. 2007; Blatt 
et  al. 2015), four examined cessation during pregnancy 
(Favaretto et  al. 2007; Adegboye et  al. 2010; Blatt et  al. 
2015; Hulman et al. 2016), and two examined cessation by 
combining those who quit before and during pregnancy 
(Favaretto et al. 2007; Rode et al. 2013). None of the five 
studies compared gestational weight gain or rate of weight 
gain before and after smoking cessation. Four of the five 
studies (Favaretto et al. 2007; Adegboye et al. 2010; Rode 
et al. 2013; Hulman et al. 2016) adjusted for at least some 
potential confounders (including pre-pregnancy BMI) in 
some of the analyses. Four of the five studies (Favaretto 
et al. 2007; Adegboye et al. 2010; Rode et al. 2013; Hulman 
et  al. 2016 ) assessed gestational weight gain using rec-
ommendations from the IOM, which are specific for pre-
pregnancy BMI (Rasmussen et al. 2009).
In the single study examining weight gain by smoking 
status across pregnancies, Abrevaya and colleagues (2008) 
found a significantly greater gain in gestational weight 
during the second pregnancy among women who quit 
smoking between pregnancies compared with those who 
smoked during both pregnancies, even after adjusting for 
potential confounders. However, a limitation of this study 
was that smoking patterns were reduced to a few simpli-
fied categories. If smoking cessation during pregnancy 
does increase weight gain, then the effect could have been 
missed using this approach. 
All five of the studies of individual pregnancies 
found that gestational weight gain in quitters was higher 
than gestational weight gain in continuing smokers 
(range: 0.5–2.8  kg). The comparisons were statistically 
significant in three of the five studies (Adegboye et  al. 
2010; Rode et al. 2013; Blatt et  al. 2015), and statistical 
comparisons were not presented in the other two studies 
(Favaretto et al. 2007; Hulman et al. 2016). Adegboye and 
colleagues (2010) found that women who quit smoking 
during the first trimester gained 1.5-kg more weight 
than women who continued to smoke during pregnancy 
(unadjusted, p  <0.001). Rode and colleagues (who com-
bined women who quit smoking before and during preg-
nancy) reported weight gains of 15.9  kg in quitters and 
13.3 kg in continuing smokers, and the differences were 
significant after adjustment. Blatt and colleagues found, 
in unadjusted analyses, that women who quit smoking in 
the first or second trimester gained 6.2- and 3.3-pounds 
(2.8 kg and 1.5 kg, respectively) more weight than women 
who continued to smoke during pregnancy (Blatt et  al. 
2015). Hulman and colleagues (2016) examined cessation 
during pregnancy and trajectories of gestational weight 
gain based on weight gain in the first trimester and rate 
of weight gain in the second and third trimesters. The 
authors reported higher projected weight gains of 2.7 kg 
(adjusted for pre-pregnancy BMI) in quitters compared 
with continuing smokers, but did not report whether the 
findings were statistically significant. Favaretto and col-
leagues (2007) found a modest increase in gestational 
weight gain in women who quit smoking before or during 
pregnancy compared with those who continued to smoke 
during pregnancy: unadjusted estimates extrapolated to 
delivery were 13.4 kg and 12.9 kg, respectively. However, 
the authors did not stratify results by the timing of cessa-
tion with conception and did not report results of signifi-
cance testing for this portion of the analysis.
Four of the five studies examining individual 
pregnancies and comparing quitters with nonsmokers 
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Table 4.31 Studies on smoking cessation and gestational weight gain
Study Study design Tobacco exposure Outcome definition Results Comments
Sexton and 
Hebel (1984)
• Randomized controlled 
trial of a behavioral 
intervention to increase 
smoking cessation
• Enrolled pregnant 
women <18 weeks’ 
gestation who smoked at 
least 10 cigarettes/day at 
or just before pregnancy
• n = 935
• Years of data collection 
not reported
• Maryland
• Quit smoking by late pregnancy 
(8th month)
• Continued smoking in late pregnancy 
(8th month)
• Cessation confirmed with salivary 
thiocyanate collected during 8th month 
of pregnancy
Gestational weight gain 
during the 8th month 
of pregnancy
Mean gestational weight gain:
• Control group: 11.9 kg
• Intervention group: 12.9 kg
• Difference: 1.0 kg
• p <0.05
Results not adjusted for 
confounders or gestational 
age at last measurement 
Did not account for 
alcohol or substance use
Smoking Cessation
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Table 4.31 Continued
Study Study design Tobacco exposure Outcome definition Results Comments
Favaretto et al. 
(2007)
• Prospective cohort study
• n = 4,000
• 1991–1995
• Brazil
• Nonsmoker: Never smoked
• Continued smoking: Smoking at least 
1 cigarette/day as of study interview
• Quit smoking:
 – >6 months before pregnancy
 – Between 6 months before pregnancy 
and conception 
 – Between conception and mid-
pregnancy
• Smoking history ascertained from 
maternal interviews conducted during 
the second trimester
Gestational weight 
gain calculated using 
information from chart 
review; used last measured 
weight and extrapolated 
to delivery
Mean gestational weight gain (SD):
• Measured:
 – Never smoked: 11.2 kg (5.8 kg)
 – Quit smoking (groups combined): 
12.1 kg (6.1 kg)
 – Continued smoking: 11.7 (6.5 kg)
• Extrapolated:
 – Never smoker: 12.4 kg (6.1 kg)
 – Quit smoking (groups combined): 
13.4 kg (6.2 kg)
 – Continued smoking: 12.9 kg (6.8 kg)
Difference in gestational weight gain 
by timing of cessation (95% CI):
• Never smoked: Reference
• Before conception: 
 – Unadjusted: 0.14 kg (-0.54–0.81 kg)
 – Adjusted: 0.53 kg (-0.12–1.19 kg)
• Quit <6 months before conception:
 – Unadjusted: 0.90 (0.19–1.62 kg)
 – Adjusted: 1.00 (0.32–1.69 kg)
• Quit after conception through mid-
pregnancy:
 – Unadjusted: 1.78 (0.98–2.57 kg)
 – Adjusted: 1.54 (0.78−2.31 kg)
Adjusted RR for weight gain in excess 
of IOM standards (95% CI):
• Never smoked: Reference
• Quit overall: 1.2 (1.05–1.37)
• Quit <6 months before conception: 
1.14 (0.94–1.38)
• Quit after conception through mid-
pregnancy: 1.34 (1.10–1.63)
Results adjusted for 
maternal age, education, 
race, parity, clinical center, 
and pre-pregnancy BMI 
Did not account for 
alcohol or substance use
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Table 4.31 Continued
Study Study design Tobacco exposure Outcome definition Results Comments
Abrevaya et al. 
(2008)
• Population-based, 
retrospective 
cohort study 
• Linked Michigan 
certificates of live birth
• First and second 
pregnancies in which 
women smoked during 
the first pregnancy
• n = 14,731 (18–24 years 
of age)
• n = 8,044 (25–30 years 
of age)
• 1989–2004
• Michigan
• Smoking status across pregnancies
• Quit smoking: Smoked during the 
first pregnancy, not during the 
second pregnancy
• Continued smoking in both pregnancies
• Smoking status based on smoking 
history collected for certificates of live 
birth, which used one question on 
tobacco use during pregnancy (yes/no)
Gestational weight gain 
obtained from certificates 
of live birth
Difference in mean gestational weight 
gain among women who smoked during 
the first pregnancy (95% CI):
• Quit smoking: Reference
• Continued smoking: 
 – 18–24 years of age: -1.99 lbs 
(-2.50– -1.49 lbs)
 – 25–30 years of age: -2.10 lbs 
(-2.67– -1.54 lbs)
Results adjusted for 
maternal race, education, 
income, population, 
interpregnancy interval, 
year of birth, trimester 
of first prenatal visit, 
presence of father’s name 
on birth certificate, 
number of prenatal visits, 
and first-birth value of 
the outcome
Did not account for 
alcohol or substance use
Adegboye et al. 
(2010)
• Retrospective 
cohort study 
• Risk factors for 
postpartum weight 
retention
• Singleton pregnancies
• n = 1,753
• 1984–1985
• Sweden
• Nonsmokers: Did not smoke 
during pregnancy
• Quit smoking: Quit smoking during 
first trimester and remained abstinent 
throughout pregnancy
• Continued smoking: Continued to 
smoke during pregnancy 
• Smoking status based on self-reports 
but details not reported
Gestational weight gain 
calculated by subtracting 
maternal weight at 
the end of gestation 
from self-reported pre-
pregnancy weight
Compared with IOM 
(2009) recommendations
Unadjusted mean gestational weight 
gain (SD):
• Nonsmoker: 14.1 kg (4.0 kg)
• Quit smoking: 15.3 kg (4.4 kg)
• Continued smoking: 13.8 kg (4.3 kg)
• p <0.001, ANOVA
OR (95% CI) for gestational weight gain 
in excess of IOM recommendations:
• Nonsmoker: Reference
• Quit smoking: 
 – Unadjusted: 1.6 (1.1–2.1)
 – Adjusted: 2.0 (1.4–3.0)
• Continued smoking: 
 – Unadjusted: 1.0 (0.8–1.3)
 – Adjusted: 1.3 (0.9–1.8)
Results adjusted for birth 
weight, gestational age, 
parity, pre-pregnancy BMI, 
alcohol consumption, 
physical activity, and 
breakfast frequency
Did not account for 
substance use
Smoking Cessation
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Table 4.31 Continued
Study Study design Tobacco exposure Outcome definition Results Comments
Washio et al. 
(2011)
• Randomized controlled 
trial of a voucher 
incentive to increase 
smoking cessation
• Pregnant smokers
• n = 154
• 2001–2006
• Vermont 
• Quit smoking: Past 7-day abstinence 
confirmed by urine cotinine at the 
end of pregnancy
• Continued smoking: Not abstinent 
at the end of pregnancy
• Not reported when cessation data 
were collected
Weight at delivery and pre-
pregnancy weight
Mean gestational weight gain (SD):
• Control group: 15.0 +/- 0.8 kg
 – Intervention group: 15.0 +/- 0.9 kg
 – Difference = 0.0 kg
 – p = 0.97
• Quit smoking: 17.2 +/- 1.1 kg
 – Continued smoking: 15.4 +/- 0.6 kg
 – Difference = 2.8 kg
 – p = 0.04
Adjusted mean difference in gestational 
weight gain:
• Quit smoking vs. continued smoking:
 – 2.4 kg
 – p = 0.06
• Mean increase in gestational weight 
gain of 0.34 kg per 10% increase 
in cessation:
 – p = 0.03 (results adjusted for 
pre-pregnancy BMI and parity)
 – p = 0.13 (results adjusted for 
pre-pregnancy BMI, parity, and 
birth weight)
Loss of significance after 
adjustment for birth 
weight suggests that the 
increase in gestational 
weight gain in quitters 
compared with continuing 
smokers was attributable 
in part to increased 
fetal growth
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Table 4.31 Continued
Study Study design Tobacco exposure Outcome definition Results Comments
Rode et al. 
(2013)
• Prospective cohort of 
pregnant women who 
received an intervention 
to be smokefree
• Singleton, term 
pregnancies 
• n = 1,774
• 1996–1999
• Denmark
• Nonsmokers: Not defined
• Quit smoking: Quit immediately before 
or during pregnancy
• Continued smoking: Not further defined 
• Smoking status based on self-reports 
assessed at 12–18 weeks’ and 37 weeks’ 
gestation and 1 year postpartum 
• Salivary cotinine obtained in a subgroup 
at 16 and 37 weeks’ gestation
Gestational weight 
gain at 37 weeks’ 
gestation compared with 
recommendations from 
IOM (2009)
Mean gestational weight gain at 37 weeks 
(SD), difference in gestational weight 
gain (95% CI):
• Nonsmokers: 13.46 kg (4.71 kg) 
(reference)
• Quit smoking: 
 – Unadjusted: 2.44 kg (1.86–3.03 kg)
 – Adjusted: 2.01 kg (1.51–2.64 kg)
• Continued smoking: 
 – Unadjusted: -0.14 kg (-7.4–0.47 kg)
 – Adjusted: -0.10 kg (-0.67–0.48 kg)
Adjusted OR (95% CI) for gestational 
weight gain in excess of IOM 
recommendations:
• Nonsmokers: Reference
• Quit smoking: 1.9 (1.5–2.4)
• Continued smoking: 1.2 (0.9–1.5)
Weight gain adjusted 
for pre-pregnancy BMI, 
gestational age, and parity
Salivary cotinine for 
subgroup reported but 
report did not describe 
whether it was integrated 
into main analysis
Did not account for 
alcohol or substance use
OR for gaining in excess 
of IOM recommendations 
adjusted for gestational 
age and preeclampsia
Blatt et al. 
(2015)
• Population-based 
retrospective 
cohort study
• Ohio certificates of 
live birth
• n = 927,424
• 2006–2012
• Ohio
• Nonsmoker: Did not smoke during 
the 3 months before pregnancy or 
during pregnancy
• Quit smoking before pregnancy: 
Smoked during the 3 months before 
pregnancy but not during pregnancy
• Quit smoking first trimester: Smoked 
first trimester only
• Quit smoking second trimester: Smoked 
first and second trimester, not third
• Continued smoking: Smoked 
throughout pregnancy 
• Smoking history ascertained from vital 
statistics data and certificates of live birth
Gestational weight gain 
calculated from maternal 
weight at delivery vs. 
preconception weight
Mean gestational weight gain (SD):
• Nonsmoker: 31.2 lbs (+/- 16.9 lbs)
• Quit smoking before pregnancy: 
36.4 lbs (+/- 18.8 lbs)
• Quit smoking first trimester: 
36.5 lbs (+/- 19.2 lbs)
• Quit smoking second trimester: 
33.6 lbs (+/- 19.5 lbs)
• Continued smoking: 30.3 lbs 
(+/- 8.9 lbs)
• All comparisons: p <0.001
Findings not adjusted for 
potential confounders 
Did not account for 
alcohol or substance use
Smoking Cessation
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Table 4.31 Continued
Study Study design Tobacco exposure Outcome definition Results Comments
Hulman et al. 
(2016)
• Longitudinal 
cohort study
• Singleton pregnancies
• n = 509
• 2013
• Ontario, Canada
• Nonsmokers: Women who never smoked
• Quit smoking: Smoked previously 
but quit when they found out they 
were pregnant
• Continued smoking: Still smoking at 
study assessment
• Smoking status based on maternal 
self-reports obtained during survey 
conducted at ~32 weeks’ gestation
Gestational weight 
gain calculated from 
pre-pregnancy weight 
(or first available 
antenatal visit) and serial 
weight measurements 
obtained from medical 
record review
Rate of weight gain 
(kg/week) in second and 
third trimesters compared 
with recommendations 
from IOM:
• Underweight: 0.44–0.58
• Normal: 0.35–0.50
• Overweight: 0.23–0.33
• Obese: 0.17–0.27
Mean gestational weight gain (95% CI) 
based on trajectories for the end of the 
39th week:
• Nonsmoker: 14 kg
• Quit smoking: 16.7 kg (15.1–18.4 kg)
• Continued smoking: 14 kg
Total first trimester gestational weight 
gain (95% CI):
• Nonsmoker: 1.7 kg (1.4–2.1 kg)
• Quit smoking: 1.2 kg (0.3–2.1 kg)
• Continued smoking: 3.5 kg (2.4–4.6 kg)
Rate of weight gain in second and third 
trimesters:
• Quit smoking: 0.60 kg/week 
(0.54–0.65 kg/week)
• Vs. nonsmokers: +22% (11–34%)
• Vs. continued smokers: +53% (32–75%)
Rate of weight gain by IOM categories: 
kg/week (95% CI):
• Nonsmoker:
 – Underweight: 0.52 (0.42–0.62)
 – Normal: 0.51 (0.49–0.54)
 – Overweight: 0.52 (0.48–0.55)
 – Obese: 0.38 (0.33–0.42)
• Quit smoking:
 – Underweight: 0.62 (0.50–0.73)
 – Normal: 0.61 (0.56–0.67)
 – Overweight: 0.62 (0.56–0.68)
 – Obese: 0.48 (0.41–0.54)
• Continued smoking:
 – Underweight: 0.44 (0.33–0.56)
 – Normal: 0.44 (0.37–0.50)
 – Overweight: 0.44 (0.37–0.51)
 – Obese: 0.30 (0.23–0.37)
Results adjusted for 
maternal age, race, parity, 
marital status, education, 
income, and BMI
Did not account for 
alcohol or substance use
Notes: ANOVA = analysis of variance; BMI = body mass index; CI = confidence interval; IOM = Institute of Medicine; kg = kilograms; lbs = pounds; OR = odds ratio; RR = relative risk; 
SD = standard deviation.
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(Favaretto et  al. 2007; Adegboye et  al. 2010; Rode et  al. 
2013; Blatt et al. 2015) found a significant increase in ges-
tational weight gain in quitters (range: 0.5–2.4 kg). One 
study did not report statistical comparisons (Hulman 
et al. 2015). The two studies examining cessation before 
pregnancy both found significant increases in gestational 
weight gain among women who quit before but close to 
the time of conception in comparisons with nonsmokers 
(range: 1.0–2.4  kg) (Favaretto et  al. 2007; Blatt et  al. 
2015). The study by Favaretto and colleagues (2007) also 
found that weight gain in women who had quit more than 
6  months before conception did not differ significantly 
from that of nonsmokers, even after adjusting for poten-
tial confounders. Of the four studies examining cessation 
during pregnancy, three (Favaretto et al. 2007; Adegboye 
et al. 2010; Blatt et al. 2015) reported significant increases 
in weight in quitters compared with nonsmokers. 
Adegboye and colleagues (2010) and Blatt and colleagues 
(2015) examined cessation in the first trimester, which 
was associated with increases in weight gain of 1.2  kg 
(Adegboye et  al. 2010) and 1.1  kg (Blatt et  al. 2015), 
respectively. Blatt and colleagues (2015) also described a 
significant increase in weight gain (2.4 kg) among women 
who quit during the second trimester in a comparison 
with nonsmokers. Favaretto and colleagues (2007) exam-
ined cessation between conception and mid-pregnancy 
(20–28 weeks gestation) and found a 1.54-kg increase in 
weight gain in quitters compared with nonsmokers after 
adjusting for pre-pregnancy BMI and other potential con-
founders. Hulman and colleagues (2016) also examined 
cessation during pregnancy and reported that projected 
gestational weight gain, based on weight gain trajecto-
ries and adjusted for confounders, was higher by 2.7 kg 
in quitters than in nonsmokers, but results of testing for 
statistical significance were not presented. Rode and col-
leagues reported a 2.0-kg (95%  CI, 1.5–2.6  kg) increase 
in adjusted gestational weight gain in women who quit 
smoking before or during pregnancy compared with 
women who were nonsmokers (Rode et al. 2013).
Two of the four studies examining cessation during 
pregnancy also compared weight gain early and late in 
pregnancy. Rode and colleagues (2013) found that at 
16 weeks’ gestation no differences existed in weight gain 
when nonsmokers, women who quit before or during 
pregnancy, and continuing smokers were compared after 
adjustment for pre-pregnancy BMI, gestational age, and 
parity. By 37 weeks’ gestation, however, women who had 
quit smoking had a significant, adjusted 4.4-lb [2.0  kg] 
increase in weight gain in comparison with nonsmokers, 
while continuing smokers and nonsmokers did not experi-
ence relative increases in weight gain. In contrast, Hulman 
and colleagues (2016) found that continuing smokers 
gained more than twice as much weight during the first 
trimester as women who quit smoking upon learning of 
their pregnancy (adjusted difference  =  3.0  kg [6.6  lbs] 
after controlling for sociodemographic characteristics 
and pre-pregnancy BMI). The weekly rate of weight gain in 
the second and third trimesters was highest, however, in 
women who quit smoking during pregnancy. Quitters had 
a 22% faster rate of weight gain in the second and third 
trimesters of pregnancy compared with nonsmokers and a 
53% faster rate of weight gain compared with continuing 
smokers (Hulman et al. 2016).
Four studies (Favaretto et al. 2007; Adegboye et al. 
2010; Rode et  al. 2013; Hulman et  al. 2016) examined 
gestational weight gain with respect to IOM recommen-
dations (IOM 1990). Two studies (Favaretto et  al. 2007; 
Adegoye et al. 2010) found that women who quit smoking 
during pregnancy were significantly more likely to gain 
weight in excess of IOM recommendations compared with 
nonsmokers, even after controlling for pre-pregnancy 
BMI and other factors (adjusted RR: 1.34 [95% CI, 1.10–
1.63]; and adjusted OR: 2.0  [95%  CI, 1.4–3.0], respec-
tively). Rode and colleagues (2013) found that the per-
centage of women who gained in excess of IOM guidelines 
differed significantly by smoking status (45.9%, 34.6%, 
and 31.3% for women who quit before or during preg-
nancy, continuing smokers, and nonsmokers, respec-
tively, P  <  0.001), and after adjustment for gestational 
age and preeclampsia, quitters were significantly more 
likely to gain in excess of IOM recommendations than 
nonsmokers (OR  1.9 95%  CI 1.5-2.4). Adjusted models 
comparing quitters with continuing smokers were not 
reported (Rode et al. 2013). Hulman and colleagues (2016) 
examined IOM recommendations for rate of weight gain 
and found that women who quit smoking during preg-
nancy on average gained above the rate recommended by 
the IOM in the second and third trimesters for all pre-
pregnancy BMI categories, and weight gain by women 
who continued to smoke varied by pre-pregnancy BMI 
category (under- and normal-weight women on average 
gained within the recommended rate range while over-
weight and obese women gained faster than the recom-
mended rate). Among nonsmokers, only those who were 
underweight gained at a rate within IOM recommenda-
tions; all other groups gained at a rate exceeding IOM rec-
ommendations (Hulman et al. 2016).
Summary of the Evidence
The evidence describing the associations between 
smoking status, quitting, and gestational weight gain has 
expanded considerably since the 1990 Surgeon General’s 
report, but there has been some variation in the covari-
ates included in the analytic models and in the time points 
used to define smoking cessation (e.g.,  preconception, 
in early gestation, by mid-pregnancy, during gestation). 
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Nonetheless, the evidence is sufficient to infer that women 
who quit smoking shortly before or during pregnancy 
gain more weight during gestation than women who con-
tinue to smoke, and the findings are consistent, including 
data from two randomized clinical trials. The evidence is 
suggestive but not sufficient to infer that women who quit 
smoking before or during pregnancy gain more weight 
during gestation than nonsmokers. The evidence is sug-
gestive but not sufficient to infer that women who quit 
smoking before or during pregnancy are at increased risk 
of excess weight gain, per IOM guidelines, compared with 
nonsmokers. However, very little evidence could be used 
to compare the risk of excess gestational weight gain in 
quitters with that in continuing smokers.
Prenatal smoking cessation has substantial health 
benefits for mothers and offspring, and providing assis-
tance with weight management while promoting smoking 
cessation could help to optimize outcomes.
Gestational Diabetes
Gestational diabetes mellitus (GDM), which is 
defined as carbohydrate intolerance leading to hypergly-
cemia with onset or first recognition during pregnancy, 
affects 4% to 9% of pregnancies in the United States 
(DeSisto et al. 2014). Although this complication usually 
resolves after delivery, up to one-third of affected women 
have diabetes or impaired glucose metabolism at post-
partum screening. Women with GDM are at increased risk 
for cesarean delivery, and their infants are at increased 
risk for macrosomia (i.e.,  being large for gestational 
age), neonatal hypoglycemia, and fetal hyperinsulinemia 
(Hyperglycemia and Adverse Pregnancy Outcome Study 
Cooperative Research Group 2008). Most women who 
develop GDM have preexisting impaired beta cell func-
tion and chronic insulin resistance that is characteristic 
of type 2 diabetes, and women with a history of GDM are 
at substantially increased risk for the future development 
of type 2 diabetes, providing evidence of a common under-
lying mechanism (Mack and Tomich 2017). Furthermore, 
GDM is consistently associated with both higher pre-
pregnancy BMI and excessive gestational weight gain 
(Brunner et al. 2015; Najafi et al. 2019).
The 1990 Surgeon General’s report did not examine 
smoking and GDM, but the 2001 Surgeon General’s report 
on women and smoking described inconsistent evidence 
of an association between smoking and GDM (USDHHS 
2001). The 2014 Surgeon General’s report did not examine 
smoking and GDM, but did conclude that smoking is 
causally associated with type  2 diabetes and did address 
smoking cessation and risk of type 2 diabetes (USDHHS 
2014). In one large study, the risk of incident type 2 dia-
betes for short-term quitters was higher than that of cur-
rent smokers but decreased to the level for never smokers 
by 12 years (Yeh et al. 2010; USDHHS 2014). In another 
large study, the risk of type 2 diabetes decreased to that of 
nonsmokers 5 years after quitting in women and 10 years 
after quitting in men (Will et  al. 2001; Wendland et  al. 
2008; USDHHS 2014). The transient increase in risk for 
quitters may be the result of short-term effects on weight 
gain. The 2014 report did not address GDM specifically.
In light of the potential for increased short-term 
morbidity associated with weight gain following smoking 
cessation, an increase in gestational weight gain associ-
ated with smoking cessation could be associated with 
adverse pregnancy outcomes, such as GDM or macro-
somia, regardless of whether smoking itself is directly 
causally associated with GDM (Rasmussen et  al. 2009). 
Therefore, smoking cessation and GDM were reviewed 
in this section absent an established causal relationship 
between active smoking and GDM in these reports. 
Five studies on smoking and GDM published 
since the 2001 report included prevalence estimates for 
GDM among nonsmokers, former smokers, and con-
tinuing smokers (England et  al. 2004; Fasting et  al. 
2009; Erickson and Arbour 2012; Räisänen et  al. 2014; 
Blatt et al. 2015). Three of these were large, population-
based studies (Erickson and Arbour 2012; Räisänen 
et al. 2014; Blatt et al. 2015), and two were small, clinic-
based studies (England et  al. 2004; Fasting et  al. 2009). 
Räisänen and colleagues (2014) reported a greater prev-
alence of GDM among women who quit smoking in the 
third trimester (9.8%) compared with never smokers 
(7.6%) and with continuing smokers (7.6%); Erickson 
and Arbour (2012) reported the lowest GDM prevalence 
in continuing smokers (3.8%  to 4.9%), with prevalence 
equaling 5.4% in quitters and 6.7% in nonsmokers; and 
Blatt and colleagues (2015) reported the lowest prevalence 
in nonsmokers (5.4%) and a slightly higher prevalence in 
preconception quitters (5.8%) and in first- and second-
trimester quitters (5.6% and 5.5%, respectively). In none 
of these three studies was GDM the primary outcome of 
interest, and none reported results of testing for statis-
tical significance in direct comparisons or the results of 
adjusted analyses. The study populations in these analyses 
were very large, however.
In one of the two smaller studies, England and col-
leagues (2004) reported a significant increase in mean 
adjusted plasma glucose concentration after a 1-hour, 50-g 
glucose challenge in continuing smokers compared with 
never smokers (112.6 milligrams per deciliter [mg/dL] vs. 
108.3 mg/dL, p <0.01), but no differences were seen when 
never smokers were compared with women who had quit 
before pregnancy (108.5  mg/dL) or during pregnancy 
(109.5  mg/dL). Compared with nonsmokers, continued 
smoking was significantly associated with GDM (aOR = 1.9; 
95%  CI, 1.0–3.6), but no significant associations were 
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observed for smoking with cessation before (aOR  =  0.8; 
95% CI, 0.3–2.1) or during pregnancy (aOR = 1.4; 95% CI, 
0.5–2.9) (England et al. 2004). In the other of the smaller 
studies, Fasting and colleagues (2009) reported identical 
estimates of GDM prevalence (3%) for never smokers and 
smokers who quit early in pregnancy and an estimate of 
5% for women who continued to smoke. GDM was not the 
primary outcome of interest, however, and the number of 
GDM cases was small (only three each in the groups of 
quitters and continuing smokers), and an adjusted anal-
ysis was not performed. 
Summary of the Evidence
Only a limited number of studies on the relationship 
between smoking cessation and GDM were identified, and 
in the majority of those studies, GDM was not the main 
outcome of interest, potentially limiting assessment for 
relevant covariates and confounders. Thus, the evidence 
is inadequate to determine whether smoking cessation 
during pregnancy increases the risk of gestational diabetes. 
Birth Outcomes
Birth Defects
The 2014 Surgeon General’s report concluded 
that there was sufficient evidence to infer a causal rela-
tionship between maternal smoking in early pregnancy 
and increased risk for orofacial clefts (USDHHS 2014). 
However, the evidence was suggestive but not sufficient to 
infer an increased risk for other birth defects—including 
clubfoot, gastroschisis, and atrial septal heart defects—for 
women who smoke in early pregnancy (USDHHS 2014). 
Based on the available scientific evidence, the 2014 report 
recommended providing information on the risk of oro-
facial clefts as part of efforts to reduce smoking prior to 
conception and in early pregnancy (USDHHS 2014); how-
ever, few studies have specifically assessed the risk for oro-
facial clefts among women who are former smokers. One 
study has assessed the risk for any major anomaly among 
women who quit smoking during the first trimester com-
pared with women who did not smoke during pregnancy 
(Räisänen et al. 2014). However, due to the limited number 
of studies published to date specifically related to cessa-
tion and risk for specific birth defect categories, including 
orofacial clefts, this report does not reach any new conclu-
sions regarding these outcomes. 
Fetal Growth and Birth Weight
The effects of maternal smoking on birth weight 
have been recognized since the 1964 Surgeon General’s 
report, which found that infants of smokers were more 
likely than those of nonsmokers to weigh less than 
2,500 g at birth (USDHEW 1964). Birth weight is deter-
mined by both gestational age at delivery and the rate of 
fetal growth, and subsequent Surgeon General’s reports 
have addressed these factors separately when examining 
birth weight as an outcome. The 1990 Surgeon General’s 
report noted that the risk of being small for gestational 
age (typically defined as weight ≤10th percentile for gesta-
tional age) was 3.5- to 4-fold higher in infants of smokers 
than in infants of nonsmokers (USDHHS 1990). The 
report concluded that babies of women who quit smoking 
before conception did not experience smoking-related 
reductions in fetal growth, while cessation before the 
third trimester significantly attenuated the deleterious 
effects of maternal smoking on fetal growth (USDHHS 
1990). The 2004 Surgeon General’s report found sufficient 
evidence to infer a causal relationship between smoking 
and both fetal growth restriction and reduced gestational 
age/increased preterm delivery (USDHHS 2004). It con-
firmed the 1990 Surgeon General’s report’s finding that 
cessation eliminates much of the reduction in birth 
weight caused by maternal smoking (USDHHS 2004). The 
2014 Surgeon General’s report explored in depth the rela-
tionships between smoking and fetal growth. The report 
concluded that nicotine is unlikely to be the main con-
tributor in tobacco smoke to fetal growth restriction, with 
products of combustion likely playing a major role in this 
regard (USDHHS 2014). This report did not address the 
benefits of smoking cessation, however.
Several subsequent studies have supported the con-
clusions of the 1990 and 2004 Surgeon General’s reports 
that smoking cessation attenuates the adverse effects of 
smoking on fetal growth and birth weight. There are sev-
eral methodologic challenges, however, in studies of fetal 
growth and birth weight. First, fetal growth is not linear, 
and the most rapid rate of growth occurs in the third tri-
mester (Kiserud et al. 2017). As a consequence, assessing 
the timing of tobacco exposure with respect to posi-
tion on the fetal growth curve is essential to character-
izing the mechanisms through which tobacco use exerts 
adverse effects and cessation benefits fetal growth. Many 
of the studies identified in the literature review, however, 
did not assess tobacco use and cessation across the entire 
pregnancy. Second, as previously described, smokers 
typically differ from nonsmokers in numerous behav-
ioral, obstetrical, and other health-related factors, and a 
failure to control for potential confounders may result in 
residual confounding. High-quality data on many poten-
tially important exposures for fetal growth, such as use of 
alcohol and/or illicit drugs, are often lacking in registries 
and other commonly used sources of data. 
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Smoking Cessation
Birth Weight
Table 4.32 presents 40  studies that examined birth 
weight and smoking cessation during pregnancy. Studies 
varied in the use of biochemical validation of reported ces-
sation, in descriptions about the timing of cessation, and 
in adjustments for potential confounders. Twenty of the 
studies addressed gestational age by restricting the anal-
ysis to term infants and/or adjusting for gestational age 
(Hrubá and Kachlik 2000; Lindley et  al. 2000; England 
et al. 2001a,b, 2007; Mendez et al. 2008; Nijiati et al. 2008; 
Sasaki et al. 2008; Andersen et al. 2009; Kabir et al. 2009; 
Prabhu et al. 2010; Vardavas et al. 2010; Bakker et al. 2011; 
Benjamin-Garner and Stotts 2013; Juarez and Merlo 2013; 
Miyake et  al. 2013; Rode et  al. 2013; Slatter et  al. 2014; 
Suzuki et al. 2014, 2016; Hayes et al. 2016); 25 included 
adjustment for at least some additional confounders 
(Lindley et al. 2000; England et al. 2001a,b, 2007; Dejmek 
et al. 2002; Wen et al. 2005; Abrevaya 2008; Nijiati et al. 
2008; Sasaki et al. 2008; Andersen et al. 2009; McCowan 
et al. 2009; Prabhu et al. 2010; Vardavas et al. 2010; Bakker 
et al. 2011; Benjamin-Garner and Stotts 2013; Himes et al. 
2013; Juarez and Merlo 2013; Miyake et al. 2013; Murphy 
et al. 2013; Rode et al. 2013; Meghea et al. 2014; Suzuki 
et  al. 2014, 2016; Bailey 2015; Yan and Groothuis 2015; 
Hayes et al. 2016); and 9 included biochemical validation of 
smoking cessation (England et al. 2001a,b; Secker-Walker 
and Vacek 2002; Malchodi et al. 2003; England et al. 2007; 
Andersen et  al. 2009; Benjamin-Garner and Stotts 2013; 
Rode et  al. 2013; Bailey 2015; Hayes et  al. 2016). Five 
studies did not differentiate between either quitting before 
pregnancy and quitting during early pregnancy or a com-
bination of both and, thus, could not isolate the effects 
of quitting during pregnancy (Hrubá and Kachlik 2000; 
England et  al. 2007; Vardavas et  al. 2010; Murphy et  al. 
2013; Rode et  al. 2013). Nineteen studies used smoking 
status in late pregnancy to categorize exposure groups, 
thus those studies did not combine late quitters with con-
tinuing smokers, or women who relapsed with women 
who remained abstinent (Lindley et  al. 2000; England 
et  al. 2001a,b, 2007; Dejmek et  al. 2002; Secker-Walker 
and Vacek 2002; Malchodi et al. 2003; Andersen et al. 2009; 
Bakker et  al. 2011; Benjamin-Garner and Stotts 2013; 
Himes et  al. 2013; Juarez and Merlo 2013; Miyake et  al. 
2013; Murphy et al. 2013; Rode et al. 2013; Slatter et al. 
2014; Bailey 2015; Blatt et  al. 2015; Yan and Groothuis 
2015; Wallace et al. 2017). Only two studies adjusted for 
or otherwise addressed alcohol and other substance use 
(Murphy et al. 2013; Bailey 2015), and seven adjusted for 
alcohol use but not other substance use (Dejmek et al. 2002; 
Wen et al. 2005; Sasaki et al. 2008; McCowan et al. 2009; 
Bakker et al. 2011; Miyake et al. 2013; Yan and Groothuis 
2015), and one excluded women who used illicit drugs 
(Himes et al. 2013). Five studies accounted for gestational 
age and also adjusted for confounders, included biochem-
ical validation of quit status, and incorporated well-defined 
exposure groups that included smoking status in late preg-
nancy (England et al. 2001a,b, 2007; Andersen et al. 2009; 
Benjamin-Garner and Stotts 2013; Rode et al. 2013). None 
of these five adjusted for alcohol or illicit drug use. 
Despite these methodologic differences, most of the 
40 studies found that (a) women who continued to smoke 
past early pregnancy delivered infants of lower birth 
weight than those of nonsmokers and (b) cessation before 
or during pregnancy attenuated or eliminated this effect. 
These findings were consistent in studies controlling for 
gestational age at birth and/or excluding preterm deliveries 
(Lindley et al. 2000; England et al. 2001b, 2007; Mendez 
et al. 2008; Nijiati et al. 2008; Sasaki et al. 2008; Andersen 
et al. 2009; Kabir et al. 2009; Prabhu et al. 2010; Vardavas 
et  al. 2010; Bakker et  al. 2011; Juarez and Merlo 2013; 
Miyake et al. 2013; Rode et al. 2013; Slatter et al. 2014; 
Suzuki et  al. 2014, 2016) and in studies that addressed 
illicit drug and/or alcohol use (Dejmek et al. 2002; Wen 
et al. 2005; Sasaki et al. 2008; McCowan et al. 2009; Bakker 
et al. 2011; Himes et al. 2013; Miyake et al. 2013; Murphy 
et al. 2013; Bailey 2015; Yan and Groothuis 2015).
Four of the 40  studies validated smoking status 
while also adjusting for gestational age or restricting 
the study to term births, adjusting for potential con-
founders, and assessing smoking status in late pregnancy. 
Results from the two studies comparing quitters with 
nonsmokers found no difference in mean adjusted birth 
weight (England et al. 2007; Andersen et al. 2009), and the 
other two studies were randomized clinical trials of cessa-
tion interventions and thus compared quitters with con-
tinuing smokers (England et al. 2001b; Benjamin-Garner 
and Stotts 2013). In these two studies, the adjusted mean 
difference in birth weight between infants of quitters and 
those of continuing smokers was an excess of 100  and 
300 g, respectively. However, England and colleagues (2007) 
combined women who quit before pregnancy with women 
who quit during pregnancy and, thus, could not address 
the effect of cessation during pregnancy.
One large study (previously described) used a 
sibling-comparison analysis to address the problem of 
potential uncontrolled confounding in the relation-
ship between smoking during pregnancy and the birth 
weight of offspring (Juarez and Merlo 2013). Compared 
with the conventional analysis performed with all sin-
gleton births in the dataset, the sibling analysis revealed 
a reduced effect of smoking on gestational age–adjusted 
birth weight. In the sibling analysis, continuous smoking 
through pregnancy reduced birth weight by 162 g for light 
smokers (≤10 cigarettes per day) and by 226 g for heavy 
smokers (>10  cigarettes per day), versus reductions of 
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Table 4.32 Studies on smoking cessation and birth weight
Study Design/population Exposure groups/how determined Estimate of effects Comments
Hrubá and 
Kachlik (2000)
• Retrospective, 
clinic-based study
• Term, singleton deliveries 
• n = 1,147
• Years of data collection 
not reported
• Czech Republic
• Nonsmokers: Never smoked
• Quit smoking: Smoked but quit before 
pregnancy or during the first trimester
• Continued smoking: Smoked throughout 
pregnancy, either daily or occasionally
• Smoking status based on self-report 
from interview conducted shortly 
after delivery 
Mean birth weight (SD) and difference 
in mean birth weight (among women 
without exposure to secondhand smoke):
• Nonsmokers: 3,383 g (456) (reference)
• Quit smoking: 3,414 g (459), +31 g
• Continued smoking: 3,298 g (484), -85 g
Analysis restricted to 
term births
Results not adjusted for 
potential confounders
Analysis stratified by exposure 
to secondhand smoke
Did not account for alcohol 
or illicit drug use
Lindley et al. 
(2000)
• Population-based, 
retrospective cohort study
• Analysis of births from the 
Swedish Birth Registry 
• ≥32 weeks’ gestation at 
delivery, excluded pregnan-
cies with complication or 
congenital malformations 
• n = 15,185 
• 1991–1992
• Sweden
• Nonsmoker: Not a smoker or less than 
daily smoker at first prenatal visit
• Quit smoking: Smoked daily at first 
prenatal visit but did not smoke at 
late visit
• Continued smoking: Smoked at first 
and late prenatal visits:
 – Light smoker: 1–9 cigarettes/day
 – Heavy smoker: ≥10 cigarettes/day
• Smoking status based on self-reports at 
first and late (~32 weeks) prenatal visits 
Mean adjusted birth weight and difference 
in mean adjusted birth weight: 
• Nonsmokers: 3,459 g, p <0.001
• Quit smoking: -26 g (not significant)
• Continued smoking
 – Light smokers: -136 g, p <0.001
 – Heavy smokers: -175 g, p <0.001
Results adjusted for sex of 
the infant, gestational age, 
parity, maternal age, height, 
and BMI 
Did not account for alcohol 
or illicit drug use
England et al. 
(2001b)
• Randomized clinical trial 
of a smoking cessation 
intervention
• Singleton, term 
pregnancies
• n = 926 
• 1987–1991
• Multiple centers in the 
United States
• Quit smoking before enrollment: Smoked 
within 1 week of learning they were 
pregnant but quit by enrollment
• Quit smoking after enrollment: Smoked 
within 1 week of learning they were 
pregnant and at enrollment but quit 
after enrollment
• Continued to smoke:
 – Did not change: Cotinine, 
cigarettes/day changed by <50%
 – Reduced: Reduced cotinine, 
cigarettes/day by >50%
 – Increased: Increased cotinine, 
cigarettes/day by >50%
• Smoking status based on self-report 
obtained at enrollment and in the third 
trimester, validated using urine cotinine 
collected concurrently 
Mean adjusted birth weight (95% CI) and 
difference in mean adjusted birth weight 
(95% CI)
• Self-report:
 – Continued to smoke/did not change: 
3,205 g (reference)
 – Quit smoking after enrollment: 
+286 g (196–376 g)
• Cotinine validated:
 – Continued to smoke/did not change: 
3,216 g (reference)
 – Quit smoking after enrollment: 
+197 g (94–301 g)
• Mean adjusted birth weight of those 
who reduced or increased cotinine or 
cigarettes/day did not differ from that 
of women who did not change
Only smokers enrolled; 
no nonsmoker comparison 
group
Analysis restricted to 
term births
Results adjusted for maternal 
age, parity, race, BMI, state 
of clinic’s location, sex of the 
infant, and gestational age
Did not account for alcohol 
or illicit drug use
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Table 4.32 Continued
Study Design/population Exposure groups/how determined Estimate of effects Comments
MacArthur et al. 
(2001)
• Randomized clinical 
trial of a behavioral 
intervention of 
antismoking education 
with long-term follow-up
• n = 1,853
• 1981–1982
• Alabama
• Nonsmokers: Not smoking at enrollment
• Quit smoking by 6 weeks 
• Quit smoking 7–16 weeks
• Quit smoking ≥17 weeks
• Continued smoking
• Smoking status based on self-reports at 
enrollment into prenatal care
Unadjusted mean birth weight and 
difference in mean birth weight:
• Nonsmokers: 3,445 g (reference)
• Quit by 6 weeks: 3,433 g, -12 g
• Quit 7–16 weeks: 3,389 g, -56 g
• Quit ≥17 weeks: 3,327 g, -118 g
• Continued smoking: 3,149 g, -296 g
Results not adjusted for 
potential confounders
Did not account for 
alcohol or substance use
Direct statistical 
comparisons between 
groups not shown
Dejmek et al. 
(2002)
• Population-based 
retrospective cohort
• n = 6,866
• 1994–1999
• Czech Republic
• Nonsmoker: Not smoking when 
pregnancy recognized
• Quit after pregnancy recognized:
 – Moderate smokers: 1–10 cigarettes/day
 – Heavy smokers: >10 cigarettes/day
• Continued smoking:
 – Moderate smokers: 1–10 cigarettes/day
 – Heavy smokers: >10 cigarettes/day
• Smoking status based on self-reports 
obtained at delivery
Difference in mean adjusted birth weight 
(95% CI):
• Nonsmoker (reference)
• Quit after pregnancy recognized:
 – Moderate smoker: -22 g (-64–19 g)
 – Heavy smoker: -66 g (-146–14 g)
• Continued smoking:
 – 1–10 cigarettes/day: -152 g 
(-185– -117 g)
 – >10 cigarettes/day: -259 g 
(-342– -175 g)
Results adjusted for 
maternal age, district, 
ethnicity, education, 
parity, sex, height, pre-
pregnancy weight, alcohol 
consumption, and season
Did not account for illicit 
drug use
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Table 4.32 Continued
Study Design/population Exposure groups/how determined Estimate of effects Comments
Secker-Walker 
and Vacek 
(2002)
• Randomized clinical trial 
of a smoking cessation 
intervention
• Singleton births 
• n = 240
• 1988–1992
• Vermont
• Quit smoking: Smoked at enrollment 
but quit in late pregnancy (~35 weeks’ 
gestation)
• Continued smoking: Smoked at 
enrollment and in late pregnancy:
 – Reduced by <50%
 – Reduced by ≥50%
• Smoking status based on self-
reports and urine cotinine obtained 
at enrollment into prenatal care 
[14.6 (7.0) weeks] and near the end 
of pregnancy [35.0 (1.2) weeks]
Mean infant birth weight (95% CI):
• Self-report (adjusted results were adjusted 
for number of cigarettes smoked/day at 
first visit):
 – Reduced <50%: 
	| Unadjusted: 3,203 g (3,127–3,278 g) 
	| Adjusted: 3,203 g (3,128–3,278 g)
 – Reduced ≥50%: 
	| Unadjusted: 3,239 g (3,096–3,382 g) 
	| Adjusted: 3,267 g (3,124–3,410 g)
 – Quit: 
	| Unadjusted: 3,446 (3,298–3,594 g)
	| Adjusted: 3,413 g (3,270–3,556 g) 
• With biochemical validation (adjusted 
results were adjusted for cotinine 
concentration at first visit):
 – Reduced <50%: 
	| Unadjusted: 3,205 g (3,124–3,286 g)
	| Adjusted: 3,214 g (3,133–3,295 g)
 – Reduced ≥50%: 
	| Unadjusted: 3,184 g (3,069–3,298 g)
	| Adjusted: Reduced 3,226 g (3,114–
3,338 g) 
 – Quit (based on self-reports):
	| Unadjusted: 3,465 g (3,306–3,624 g)
	| Adjusted: 3,447 g (3,291–3,604 g) 
Difference in mean adjusted infant 
birth weight: 
• Quit vs. reduced <50%: 
 – Self-report: 210 g
 – Cotinine validated: 233 g
All study participants were 
smokers at the time of 
recruitment; no nonsmoker 
comparison group
Did not account for alcohol 
or illicit drug use
Smoking Cessation
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Study Design/population Exposure groups/how determined Estimate of effects Comments
Malchodi et al. 
(2003)
• Randomized clinical trial 
of a smoking cessation 
intervention
• n = 142 
• 1998–2000
• Connecticut
• Quit smoking: Smoked daily in the week 
before learning they were pregnant but 
quit by 36 weeks’ gestation
• Continued smoking: Smoked daily in 
the week before learning they were 
pregnant and were still smoking at 
36 weeks’ gestation:
 – 1–6 cigarettes/day
 – >6 cigarettes/day
• Smoking status based on self-reports
• Quit status confirmed with both expired 
CO and urine cotinine collected at 
36 weeks 
Mean birth weight (SD):
• Continued smoking, 1–6 cigarettes/day: 
3,071 g (525)
• Continued smoking, >6 cigarettes/day: 
2,841 g (447)
• Quit smoking: 3,289 g (592) 
Difference in mean birth weight:
• Quit smoking vs. continued smoking 
>6 cigarettes/day: +448 g, p <0.01
All study participants were 
smokers; no nonsmoker 
comparison group
Results not adjusted for 
potential confounders
Authors reported that no 
baseline variables were 
associated with infant 
birth weight 
Did not account for alcohol 
or illicit drug use
Vogazianos et al. 
(2005)
• Population-based 
retrospective cohort
• n = 59,014
• 1990–1996
• Cyprus
• Nonsmoker: Did not smoke before or 
during pregnancy
• Quit smoking: Smoked before but not 
during pregnancy; not clear how many 
women quit smoking during pregnancy 
and how they were categorized
• Continued smoking: Smoked before 
and during pregnancy
• Smoking status based on retrospective 
self-reports; exact timing of data 
collection not reported
Mean birth weight:
• Nonsmoker: 3,254 g
• Quit smoking: 3,258 g
• Continued smoking: 3,162 g
Difference in mean birth weight (95% CI):
• Quit smoking vs. nonsmoker: +4 g 
(-29–37 g)
• Continued smoking vs. nonsmoker: 
-92 g (-125– -59 g)
Results not adjusted for 
potential confounders
Did not account for alcohol 
or illicit drug use
Wen et al. 
(2005)
• Wen et al. (2005)
• Pregnancy Risk Assessment 
Monitoring System 
• Singleton, live births
• n = 9,499
• 1989–1992
• Taipei City, Taiwan
• Nonsmokers: Details not provided
• Quit smoking: Quit by the time of the 
first prenatal visit in the first trimester; 
not clear if this included those who quit 
before pregnancy
• Continued smoking: Smoked after the 
first visit in the first trimester
• Smoking status based on self-reports 
Mean adjusted birth weight (SD) and 
difference in mean adjusted birth weight:
• Continuing smokers: 3,027 g (450) 
(reference)
• Nonsmokers: 3,184 g (430 g), +157 g, 
p <0.05
• Quit smoking: 3,195 g (447 g), +168 g, 
p <0.05
Results adjusted for 
maternal age, parity, alcohol 
use, and sex of the infant
Did not account for illicit 
drug use
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Study Design/population Exposure groups/how determined Estimate of effects Comments
England et al. 
(2007)
• Randomized trial for 
preeclampsia prevention
• Nulliparous women
• n = 4,289
• 1992–1995
• Multiple centers in the 
United States 
• Nonsmokers: Never smoked regularly
• Quit before pregnancy: Quit before last 
menstrual period and validated with 
cotinine mid-pregnancy
• Quit during pregnancy: Quit after last 
menstrual period and validated with 
cotinine mid-pregnancy
• Quit before/during pregnancy: Women 
from two previous categories combined
• Continued smoking: Smoking at 
study enrollment
• Smoking status based on self-reports 
obtained at study enrollment 
(13–21 weeks’ gestation)
• Quit status validated with urine cotinine 
concentration obtained mid-pregnancy 
(mean: 28 weeks’ gestation)
Mean adjusted birth weight (SE) and 
difference in mean adjusted birth weight:
• Nonsmokers: 3,232 g (12.3 g) (reference)
• Quit before or during pregnancy, self-
report: 3,233 g (17.7 g), +1 g
• Quit before or during pregnancy, cotinine 
validated: 3,253 g (19.3 g), +21 g
• Continued smoking: 3,071 g (19.1g), 
-161 g, p <0.05
Results adjusted for 
maternal BMI, race, study 
center, sex of the infant, 
and gestational age
Did not account for alcohol 
or illicit drug use
Abrevaya et al. 
(2008)
• Analysis of linked 
certificates of live births 
• First and second singleton 
pregnancies in which 
women smoked during 
the first pregnancy
• n = 22,775
• 1989–2004
• Michigan
• Quit smoking between pregnancies: 
Smoked during the first pregnancy but 
not during the second pregnancy
• Continued smoking during both 
pregnancies: Smoked during first and 
second pregnancies
• Smoking status based on smoking 
history collected from certificates of 
live births, which used one question on 
tobacco use during pregnancy (yes/no)
Mean adjusted birth weight (SD) and 
difference in mean adjusted birth weight 
(95% CI):
• 18–24 years of age:
 – Quit: 3,258 g (545 g) (reference)
 – Continued smoking: -134 g 
(-152– -115 g)
• 25–30 years of age:
 – Quit: 3,317 g (536 g) (reference)
 – Continued smoking: -115 g 
(-138– -92 g)
Results adjusted for maternal 
race, education, income, 
population, interpregnancy 
interval, year of birth, 
trimester of first prenatal 
visit, presence of father’s 
name on birth certificate, 
number of prenatal visits, 
and first-birth value of 
the outcome
Did not account for alcohol 
or illicit substance use
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Mendez et al. 
(2008)
• Prospective cohort study 
of childhood overweight
• Term births
• n = 482
• 1997–1998
• Spain
• Nonsmokers: Never smoked
• Quit smoking before pregnancy
• Quit smoking during the first trimester
• Continued smoking: Still smoking 
during the second trimester
• Smoking status based on self-reports 
ascertained at recruitment
Mean unadjusted birth weight (SD) and 
difference in mean adjusted birth weight:
• Nonsmokers/quit smoking before 
pregnancy: 3,282 g (442 g)
• Quit smoking during the first trimester: 
3,259 g (417 g), +23 g
• Continued smoking: 3,085 g (430 g), 
-197 g, p <0.05 compared with 
nonsmokers/women who quit smoking 
before pregnancy
Analysis restricted to 
term births
Results not adjusted for 
potential confounders
Did not account for alcohol 
or illicit drug use
Nijiati et al. 
(2008)
• Prospective cohort study
• Singleton births
• n = 939
• 2006
• Hiroshima, Japan 
• Nonsmokers: Did not smoke before or 
during pregnancy
• Quit smoking: Quit during pregnancy
• Continued smoking: Smoked before and 
continued smoking during pregnancy
• Smoking status based on self-reports 
ascertained by questionnaire 
• Did not describe when questionnaire 
was administered, when women quit 
smoking, and procedures for follow-up 
and outcomes ascertainment
Mean birth weight (SD) and difference 
in mean birth weight:
• Nonsmokers: 
 – Unadjusted: 3,075 g (368 g) (reference)
 – Adjusted 3,241 g (377 g) (reference)
• Quit smoking: 
 – Unadjusted: 3,043 g (421 g), -32 g
 – Adjusted: 3,197 g (377 g), -44 g
• Continued smoking: 
 – Unadjusted: 2,897 g (348 g), -178 g
 – Adjusted: 3,099 g (462 g), -142 g, 
p = 0.0004
Results adjusted for sex of 
the infant, parity, maternal 
age, mother’s BMI and 
height, gestational age, and 
exposure to secondhand 
smoke during pregnancy
Did not account for alcohol 
or illicit drug use
Sasaki (2008) • Prospective cohort study 
of gene–environment 
interactions in women
• Singleton pregnancies
• Excluded women with 
pregnancy complications 
(hypertension, diabetes) 
• n = 460
• 2002–2005
• Sapporo, Japan
• Nonsmokers: Did not smoke during 
pregnancy
• Quit smoking: Quit in the first trimester
• Continuing smokers: Smoked after the 
first trimester
• Smoking status based on self-reports 
ascertained from a questionnaire 
administered at study enrollment 
Mean unadjusted birth weight (SD) 
(Kruskal-Wallis test, p = 0.003) and 
difference in mean adjusted birth weight:
• Nonsmokers: 3,078 g (347 g) (reference)
• Quit smoking: 3,138 g (384 g), -60 g
• Continued smoking: 2,961 g (386 g), 
-117 g
Difference in mean adjusted birth weight:
• Nonsmokers (reference)
• Quit smoking: -31 g 
• Continued smoking: -148 g
Results adjusted for 
maternal age, height, weight, 
gestational weight gain, 
alcohol use, parity, sex of 
the infant, gestational age, 
and income
Did not account for illicit 
drug use
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Andersen et al. 
(2009)
• Clinic-based study of 
endothelial function by 
smoking status
• Term pregnancies without 
complications (diabetes, 
hypertension)
• n = 266
• 2003–2004
• Denmark
• Nonsmoker: Did not smoke before 
pregnancy
• Quit smoking: Smoked during pregnancy 
but quit by 18 weeks’ gestation
• Continued smoking: Smoked 
throughout pregnancy
• Smoking status based on self-reports 
ascertained from questionnaire and 
validated with serum cotinine
Mean unadjusted birth weight (95% CI) 
and difference in mean birth weight 
• Nonsmoker: 3.65 kg (3.01–4.50 kg) 
(reference)
• Quit smoking: 3.60 kg (3.06–4.55 kg), 
-0.05 kg
• Continued smoking: 3.30 kg (2.54–4.14):
 – Unadjusted: -364 g
 – Adjusted: -242 g, p = 0.002
Analysis restricted to 
term births
Birth weight difference 
for continued smoking vs. 
nonsmokers adjusted for 
endothelial nitric oxide 
synthase, pre-pregnancy 
BMI, parity, gestational 
age, and sex of the infant
Did not account for alcohol 
or illicit drug use
Fasting et al. 
(2009)
• Prospective intervention 
of allergy prevention 
in children
• n = 711
• 2000–2002
• Norway
• Nonsmoker: Not smoking when 
became pregnant
• Quit smoking: Smoking when became 
pregnant but quit by enrollment
• Continued smoking: Smoking when 
became pregnant and still smoking 
at enrollment
• Smoking status based on self-reports 
collected at study enrollment (median 
gestational age 11 weeks, all <28 weeks)
Mean birth weight (SD) and difference 
in mean birth weight:
• Nonsmoker: 3,646 g (518 g) (reference)
• Quit smoking: 3,628 g (497 g), -14 g
• Continued smoking: 3,449 g (486 g), 
-197 g
Results not adjusted for 
potential confounders
Did not account for alcohol 
or illicit drug use
Did not show direct 
statistical comparisons 
between groups
Johansson et al. 
(2009)
• Births from the Swedish 
Birth Registry
• First and second 
consecutive, singleton 
pregnancies
• n = 555,046
• 1983–2002
• Sweden
• Nonsmoker: Did not smoke during 
either pregnancy
• Quit smoking: Smoked during first but 
not during second pregnancy
• Started smoking: Smoked during second 
but not during first pregnancy
• Continued smoking: Smoked during 
both pregnancies
• Smoking status ascertained from 
Swedish Birth Registry, as derived from 
first antenatal visit, typically <15 weeks’ 
gestation; no information on cessation 
during pregnancy 
Mean birth weight second pregnancy (SD) 
and difference in mean birth weight:
• First pregnancy for each exposure 
group (reference) 
• Nonsmoker: 3,658 g (535 g), +173 g
• Quit smoking: 3,643 g (539 g), +233 g
• Started smoking: 3,520 g (545 g), +80 g
• Continued smoking: 3,430 g (539 g), 
+119 g
Quit status defined across 
pregnancies but not 
within pregnancies
Results not adjusted for 
potential confounders
Did not account for alcohol 
or substance use
Did not show direct 
statistical comparisons 
between groups
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Kabir et al. 
(2009)
• Cross-sectional study 
of changes in smoking 
status after a workplace 
smoking ban
• Singleton, live births
• n = 15,241
• 2003 and 2005
• Ireland
• Nonsmokers: Never smokers
• Quit smoking: Former smokers
• Continued smoking: Current smokers
• Smoking status based on self-reports
• No details of how and when smoking 
status was ascertained
• Authors reported that smoking status 
across different periods of gestation 
was not available 
Mean adjusted birth weight (95% CI) and 
difference in mean adjusted birth weight:
• 2003:
 – Nonsmoker: 3,527 g (3,450–3,604 g) 
(reference)
 – Quit smoking: 3,549 g (3,435–3,663 g), 
+22 g
 – Continued smoking: 3250 g 
(3,157–3,343 g), -370 g
• 2005:
 – Nonsmoker: 3,503 g (3,426–3,580 g) 
(reference)
 – Former smoker: 3,547 g 
(3,433–3,661 g), +44 g
 – Current smoker: 3,220 g 
(3,127–3,313 g), -283 g
Results adjusted for 
gestational age
Results not adjusted for 
other potential confounders
Did not account for alcohol 
or substance use
McCowan et al. 
(2009)
• Prospective cohort study 
designed to develop 
screening tests for 
pregnancy complications
• n = 2,504
• 2004–2007
• New Zealand and Australia
• Nonsmokers: Did not smoke during 
pregnancy
• Quit smoking: Smoked during pregnancy 
but quit before being interviewed at 
15 weeks’ gestation
• Continued smoking: Smoked at 15 weeks’ 
gestation
• Smoking status based on self-reports 
ascertained at 15 weeks’ gestation
Mean adjusted birth weight (SD) and 
difference in mean adjusted birth weight:
• Nonsmoker: 3,409 (592 g) (reference)
• Quit smoking: 3,479 g (560 g) +70 g 
(-6–146 g), p = 0.09
• Continued smoking: 3,139 (751g) -270 g 
(-350– -190 g), p <0.001
Results adjusted for maternal 
age; ethnicity; marital 
status; employment; BMI; 
bleeding during pregnancy; 
folic acid use; multivitamin 
use; alcohol consumption 
at 15 weeks’ gestation; and 
scores for depression, stress, 
or anxiety
Did not account for illicit 
drug use
Adegboye et al. 
(2010)
• Retrospective cohort 
study of risk factors 
for postpartum 
weight retention
• Singleton pregnancies
• n = 1,753
• 1984–1985
• Sweden
• Nonsmokers: Never smoked
• Quit smoking: Quit smoking during 
first trimester and remained abstinent 
throughout pregnancy
• Continued smoking: Continued to 
smoke during pregnancy 
• Smoking status based on self-reports 
collected after delivery; details 
not reported
Mean unadjusted birth weight (SD):
• Nonsmoker: 3.5 kg (0.5 kg)
• Quit smoking: 3.4 kg (0.5 kg)
• Continued smoking 3.3 kg (0.5 kg)
• p <0.001
Results not adjusted for 
potential confounders
Did not account for alcohol 
or substance use
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Prabhu et al. 
(2010)
• Prospective cohort 
study of risk factors 
for childhood asthma 
and allergy
• n = 1,924
• 1997–1999
• Scotland
• Nonsmoker: Never smoked or quit 
smoking before pregnancy (additional 
details related to timing of cessation 
not reported)
• Quit smoking: Quit in first trimester
• Continued smoking in first trimester:
 – No change in number of cigarettes/day
 – Reduced number of cigarettes/day
• Smoking status based on self-reports 
obtained at enrollment in the first 
trimester and at 32 weeks’ gestation
Difference in mean adjusted birth weight 
(95% CI):
• Continued smoking, no change in 
number of cigarettes/day (reference)
• Nonsmoker: +290 g (115–463 g)
• Reduced number of cigarettes/day: 
+104 g (-73–282 g)
• Quit smoking: +246 g (46–445 g)
Results adjusted for sex of 
the infant, maternal height, 
plasma alpha-tocopherol 
and cholesterol, paternal 
smoking, and gestational age
Did not account for alcohol 
or substance use
Vardavas et al. 
(2010)
• Population-based 
cohort study
• n = 1,400
• 2007–2008
• Crete, Greece
• Nonsmoker: Did not smoke from 
3 months before and throughout 
pregnancy
• Quit smoking: Stopped smoking 
between 3 months before pregnancy 
and 12 weeks’ gestation 
• Continued smoking: Smoked at 
12 weeks’ gestation
• Smoking status based on self-reports 
obtained at enrollment, second, and 
third trimesters 
Mean unadjusted birth weight (SD) and 
difference in mean adjusted birth weight 
(95% CI):
• Nonsmoker: 3,171 g (473 g) (reference)
• Quit smoking: 3,207 g (465 g), +39 g 
(-18–96 )
• Continued smoking: 3,059 g (498 g), 
-119 g (-177– -62 g)
Results adjusted for 
gestational age, parity, 
origin (Greek/non-Greek), 
maternal education, age, 
and sex of the infant
Did not account for alcohol 
or illicit drug use
Bakker et al. 
(2011)
• Population-based, 
prospective cohort study
• n = 5,389
• 2001–2005
• Netherlands
• Nonsmokers: Did not smoke during 
pregnancy
• Quit smoking: Smoked during pregnancy 
but only during first trimester
• Continued smoking (categories collapsed 
for analysis):
 – Second trimester: Smoked during 
pregnancy and during second trimester
 – Third trimester: Smoked during 
pregnancy and during third trimester 
• Smoking status based on self-reports 
obtained in each trimester of pregnancy
Mean birth weight (SD) and difference in 
mean birth weight (95% CI):
• Nonsmokers: 3,473 g (547 g) (reference)
• Quit smoking:
 – Unadjusted: 3,418 g (555 g), -55 g, 
p <0.05
 – Adjusted, single assessment: -14 g 
(-49–20 g)
 – Adjusted, repeated assessment of 
smoking status: +38 g (-3–79 g)
• Continued smoking: 
 – Unadjusted: 3,274 g (500 g), -199 g, 
p <0.01
 – Adjusted, single assessment: -157 
(-194– -120 g)
 – Adjusted, repeated assessment of 
smoking status: -143 (-175– -111 g)
Results adjusted for 
maternal age, BMI, height, 
education, ethnicity, parity, 
alcohol consumption, 
caffeine intake, folic acid 
intake, maternal stress, 
gestational age at birth, 
and sex of the fetus
Did not account for illicit 
drug use
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Benjamin-
Garner and 
Stotts (2013)
• Randomized trial of a 
behavioral intervention 
for smoking cessation
• Term, singleton 
pregnancies
• 2001–2004
• n = 260 
• 2001–2004
• Texas
• Quit smoking: Salivary cotinine 
<15 ng/mL in late pregnancy 
(36 weeks’ gestation)
• Light smoker: Salivary cotinine 
<150 ng/mL at enrollment, continued 
smoking (stayed light or increased 
to heavy)
• Heavy smoker: Salivary cotinine 
≥150 ng/mL at enrollment, continued 
smoking (stayed heavy or decreased 
to light)
• Smoking status based on self-report and 
salivary cotinine obtained at enrollment 
(16–26 weeks’ gestation), 36 weeks’ 
gestation, and 6 weeks postpartum
Mean unadjusted birth weight (SD) 
and difference in mean unadjusted 
birth weight:
• Quit smoking: 3,415 g (521g) (reference)
• Light smoker, stayed light: 3,252 g 
(504 g), -163 g
• Light smoker, increased to heavy: 3,212 g 
(447 g), -203 g
• Heavy smoker, decreased to light: 3,315 g 
(368 g), -100 g
• Heavy smoker, stayed heavy: 3,116 g 
(447 g), 299 g
• Pairwise comparison found that the only 
significant difference was between heavy 
smokers who stayed heavy smokers and 
quitters (p = 0.02). Findings did not 
change after adjustment for potential 
confounders (p = 0.05).
Randomized cessation trial, 
and thus no comparison 
group of nonsmokers
Results adjusted for maternal 
age, race/ethnicity, parity, 
education, income, sex of 
the infant, gestational age 
at delivery, pre-pregnancy 
BMI, and gestational weight 
gain (education and parity 
removed from final models)
Restricted to term births
Did not account for alcohol 
or substance use
Himes et al. 
(2013)
• Prospective cohort study
• Date not provided
• n = 119
• Rhode Island
• Nonsmokers: Did not smoke 
during pregnancy
• Quit smoking: Smoked during 
pregnancy but quit before delivery
• Smoked throughout pregnancy
• Smoking status throughout pregnancy 
based on self-reports obtained 
in third trimester of pregnancy, 
>28 weeks’ gestation
Mean unadjusted birth weight (SD) and 
difference in mean birth weight:
• Smokers: 3,162 g (434 g) (reference)
• Nonsmokers: 3,464 g (444 g), +302 g
• Quit smoking: 3,557 g (504 g), +395 g 
Differences between 
continuing smokers and 
nonsmokers and quitters 
were statistically significant, 
even after adjusting for 
socioeconomic status, 
maternal age, income, and 
education (data not shown)
Excluded women who used 
illicit drugs
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Juarez and 
Merlo (2013)
• Births from the Swedish 
Medical Birth Register
• Singleton, term births
• n = 677,922 births for 
conventional analysis
• n = 62,941 siblings for 
sibling analysis
• 2002–2010
• Sweden
• Nonsmokers: Not smoking at either 
early or late antenatal visit
• Continued smoking: Smoking at early 
and late antenatal visits:
 – Light, light smoker
 – Light, heavy smoker
 – Heavy, light smoker
 – Heavy, heavy smoker
• Quit smoking: Smoked at first but not 
second antenatal visit:
 – Light, quit smoking
 – Heavy, quit smoking
• Started smoking: Did not smoke at first 
antenatal visit but smoked at second 
antenatal visit:
 – Nonsmoker, light smoker
 – Nonsmoker, heavy smoker
• Light smokers: 1–9 cigarettes/day
• Heavy smokers: ≥10 cigarettes/day
• Smoking status obtained from the 
Swedish Medical Birth Register which 
relies on self-reported data collected 
during early (10–12 weeks’ gestation) 
and late (30–32 weeks’ gestation) 
antenatal visits 
Difference in mean adjusted birth weight 
(95% CI):
• Conventional analysis:
 – Nonsmokers (reference)
 – Quit smoking:
	| Light, quit: -47 g (-55– -40 g)
	| Heavy, quit: -79 g (-100– -58 g)
 – Continued smoking:
	| Heavy, heavy: -303 g (-313– -292 g)
	| Light, heavy: -265 g (-279– -250 g)
	| Heavy, light: -254 g (-266– -242 g)
	| Light, light: -221 g (-227– -214 g)
 – Started smoking: 
	| Nonsmoker, light: -129 g 
(-142– -117 g)
	| Nonsmoker, heavy: -142 g 
(-177– -108 g)
• Sibling analysis:
 – Nonsmokers (reference)
 – Quit smoking: 
	| Light, quit: -29 g (-42– -16 g)
	| Heavy, quit: -1 g (-46–44 g)
 – Continued smoking:
	| Heavy, heavy: -226 g (-274– -179 g)
	| Light, heavy: -259 g (-309– -209 g)
	| Heavy, light: -194 g (-238– -151 g)
	| Light, light: -162 g (-178– -147 g)
 – Started smoking:
	| Nonsmoker, light: -77 g (-97– -57 g)
	| Nonsmoker, heavy: -83 g 
(-140– -25 g)
 – Effects of smoking on birth weight 
were attenuated by 6–78 g using 
sibling analysis compared with 
traditional analysis
Results adjusted for 
gestational age, marital 
status, maternal age, birth 
order, sex of the newborn, 
pregnancy complications 
(diabetes, hypertension, 
urinary problems). and 
use of snus
Did not account for alcohol 
or substance use
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Miyake et al. 
(2013)
• Prospective cohort study
• n = 1,565
• 2007–2008
• Japan
• Nonsmoker: Did not smoke 
during pregnancy
• Quit smoking:
 – First trimester: Smoked during 
first trimester only
 – Second or third trimester: Smoked 
during second or third trimester 
but not throughout pregnancy
• Continued smoking: Smoked 
throughout pregnancy
• Smoking status for each trimester 
of pregnancy based on self-reports 
obtained after delivery
Mean adjusted birth weight (95% CI) and 
difference in mean adjusted birth weight:
• Nonsmoker: 3,011 g (2,994, 3,027) 
(reference)
• Quit smoking first trimester: 3,028 g 
(2,951–3,104 g), +17 g
• Quit smoking second or third trimester: 
2,958 g (2,838–3,079 g), -53 g
• Continued smoking: 2,841 g 
(2,738–2,944 g), -170 g
• p for trend = 0.005
Results adjusted for 
maternal age, residence, 
education, employment, 
alcohol consumption, and 
BMI; family structure; 
gestational age at birth; 
and sex of the infant
Did not address illicit 
drug use
Murphy et al. 
(2013)
• Prospective cohort study 
• Singleton pregnancies
• n = 1,216
• 2010–2011
• Dublin, Ireland
• Nonsmoker: Not defined
• Quit smoking: Smoked during 6 months 
before pregnancy but quit by first 
prenatal visit
• Continued smoking: Smoked during 
6 months before pregnancy, at first 
prenatal visit, and during third trimester
• Smoking status based on self-reports 
obtained at enrollment and third 
trimester
Mean birth weight (SD) and difference in 
mean adjusted birth weight (95% CI):
• Nonsmoker: 3,496 g (509 g) (reference)
• Quit smoking: 3,503 (491 g), +7 g 
(-81–95 g)
• Continued smoking: 3,305 g (491 g), 
-191 g (-194– -88 g)
Results adjusted for maternal 
age, BMI, nationality, 
unplanned pregnancy, 
private healthcare, alcohol 
use, and illicit drug use
Rode et al. 
(2013)
• Prospective cohort study
• Singleton, term 
pregnancies 
• n = 1,774
• 1996–1999
• Copenhagen, Denmark
• Nonsmokers: Not defined
• Quit smoking: Quit smoking immediately 
before or during pregnancy
• Continued smoking: Not defined
• Smoking status based on self-reports 
and on salivary cotinine obtained in a 
subgroup at 16 and 37 weeks’ gestation 
• Smoking status assessed at 12–18 weeks’ 
gestation, 37 weeks’ gestation, and 
1 year postpartum
Mean birth weight (SD) and difference in 
mean birth weight (95% CI):
• Nonsmokers: 3,675 g (482 g) (reference)
• Quit: 3,670 g (510 g)
 – Unadjusted difference: +4 g (-66–64 g)
 – Adjusted difference: +26 g (-29–81 g)
• Continued smoking: 3,405 g (487 g)
 – Unadjusted difference: -270 g 
(-333– -208 g) 
 – Adjusted difference: -260 g 
(-318– -204 g)
Results adjusted for pre-
pregnancy BMI, gestational 
age, and parity
Restricted to term births
Did not account for alcohol 
or substance use
Salivary cotinine for 
subgroup reported but 
not integrated into main 
analysis
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Meghea et al. 
(2014)
• Prospective cohort study 
• n = 474
• 2008–2009
• Romania
• Nonsmokers: Not smoking when learned 
of pregnancy
• Quit smoking: Quit upon learning 
of pregnancy 
• Continued smoking: Smoking at time 
of study interview (gestational age 
not reported)
• Smoking history based on self-reports 
obtained at study enrollment (gestational 
age not reported)
Mean unadjusted birth weight and 
difference in mean birth weight:
• Nonsmoker: 3382 g (reference) 
• Quit smoking: 3340 g
 – Unadjusted: -42 g
 – Adjusted: -48 g
• Continued smoking: 3176 g
 – Unadjusted: -206 g, p <0.05
 – Adjusted: -165 g
Results adjusted for stress, 
depressive symptoms, 
maternal age >35 years old, 
education, rural residence, 
marital status, and 
nulliparity 
Did not account for alcohol 
or substance use
Räisänen et al. 
(2014)
• Finnish Medical 
Birth Register
• Singleton deliveries, 
live or stillborn
• n = 1,164,953
• 1991–2010
• Finland
• Nonsmokers: Not defined
• Quitters: Quit smoking during 
first trimester
• Continuing smokers: Smoked after 
first trimester
• Smoking history ascertained from 
the Finnish Medical Birth Register
Mean unadjusted birth weight (SD) and 
difference in mean birth weight:
• Nonsmokers: 3,575 g (547 g) (reference)
• Quitters: 3,531 g (546 g), -44 g
• Continuing smokers: 3,383 g (586 g), 
-192 g
Results not adjusted for 
potential confounders
Results of statistical testing 
not provided.
Did not account for alcohol 
or substance use
Slatter et al. 
(2014)
• Study of smoking and 
placental pathology
• Singleton, term births
• Excluded women with 
diabetes or hypertension
• n = 236
• 2009–2011
• New Zealand
• Nonsmokers: Did not smoke 
during pregnancy
• Quit smoking: Stopped smoking at 
least 4 weeks before delivery
• Continued smoking: Smoked during 
pregnancy and up to delivery
• Smoking history based on self-reports 
obtained at the time placentas 
were collected
Mean unadjusted birth weight (SD) and 
difference in mean adjusted birth weight:
• Nonsmokers: 3.56 kg (0.36 kg)
• Quit smoking: 3.64 kg (0.59 kg), +0.08 kg 
• Continuing smokers: 3.29 kg (0.49 kg), 
-0.27 kg
Results not adjusted for 
potential confounders, but 
restricted to term births
Did not account for alcohol 
or substance use
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Suzuki et al. 
(2014)
• Prospective cohort study
• Singleton deliveries
• 1991–2006
• n = 2,663
• Japan
• Nonsmokers: Never smoked
• Quit smoking before pregnancy
• Quit smoking during early pregnancy
• Continued smoking: Smoking at 
study enrollment
• Smoking exposure categories not 
further defined
• Smoking history based on self-reports 
obtained during early pregnancy 
(usually first trimester)
Mean unadjusted birth weight (SD):
• Nonsmokers: 3,069 g (387 g)
• Quit before pregnancy: 3,052 g (393 g)
• Quit during early pregnancy: 3,046 g 
(409 g)
• Continued smoking: 2,902 g (409 g)
Mean adjusted birth weight and difference 
in mean adjusted birth weight, by sex:
• Boys:
 – Nonsmokers: 3,084 g (reference)
 – Quit smoking before pregnancy: 
3,015 g, -69 g, p = 0.2
 – Quit smoking during early pregnancy: 
3,065 g, -19 g, p = 0.9
 – Continued smoking: 2,960 g, -124 g, 
p = 0.002
• Girls:
 – Nonsmokers: 3,039 g (reference)
 – Quit smoking before pregnancy: 
3,029 g, -10 g, p = 0.99
 – Quit smoking during early pregnancy: 
3,063 g, +24 g, p = 0.8
 – Continued smoking: 2,888 g, -151 g, 
p = 0.002
Results adjusted for 
maternal age, parity, BMI, 
and gestational age
Did not account for alcohol 
or substance use
Bailey (2015) • Randomized clinical trial 
of smoking cessation 
intervention
• n = 1,486
• 2008–2012
• Tennessee
• Quit smoking: Smoked at first prenatal 
visit but quit by third trimester
• Continued smoking: Smoked at first 
prenatal visit and still smoking in the 
third trimester
• Smoking history based on self-reports 
obtained at first prenatal visit
• Quit status ascertained in third trimester 
by exhaled CO, urine cotinine, and self-
report at delivery
Mean adjusted birth weight and difference 
in mean adjusted birth weight:
• Quit smoking: 3,216 g, +204 g
• Continued smoking: 3,012 g (reference)
• p <0.001
Randomized cessation trial 
and thus no comparison 
group of nonsmokers
Results adjusted for 
maternal age, education, 
marital status, insurance 
status, and marijuana use
Examined alcohol use, 
but it was not significant 
in the model 
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Blatt et al. 
(2015)
• Population-based 
retrospective cohort 
study using Ohio 
certificates of live birth
• n = 927,424
• 2006–2012
• Ohio
• Nonsmoker: Did not smoke during 
3 months before pregnancy or 
during pregnancy
• Quit smoking before pregnancy: Smoked 
during 3 months before pregnancy but 
not during pregnancy
• Quit smoking, first trimester: Smoked 
during first trimester only
• Quit smoking, second trimester: Smoked 
during first and second trimesters, but 
not third trimester
• Continued smoking: Smoked 
throughout pregnancy
• Smoking history ascertained from vital 
statistics data and certificates of live birth
Mean birth weight (SD) and difference in 
mean birth weight:
• Nonsmokers: 3,340 g (558 g) (reference)
• Quit smoking before pregnancy: 3,339 g 
(557 g), -1 g
• Quit smoking, first trimester: 3,280 g 
(590 g), -60 g
• Quit smoking, second trimester: 3,072 g 
(763 g), -268 g
• Continued smoking: 3,090 g (542), -250 g
Results not adjusted for 
potential confounders 
Statistical testing 
not reported
Did not account for alcohol 
or substance use
Grzeskowiak 
et al. (2015)
• Retrospective cohort study 
• n = 7,658
• 2000–2005
• South Australia
• Nonsmokers
• Quit smoking during pregnancy
• Continued smoking: Smoked 
during pregnancy
• Smoking status not further defined
• Smoking history based on self-reports 
ascertained at first prenatal care visit
Mean birth weight (SD) and difference in 
mean birth weight:
• Nonsmokers: 3,410 g (610 g) (reference)
• Quit smoking: 3,408 g (608 g) (-2 g)
• Continuing smokers 3,155 g (628 g), 
-255 g, p <0.001
Results not adjusted for 
potential confounders
Did not account for alcohol 
or substance use
Yan and 
Groothuis 
(2015)
• Population-based 
cohort study
• Singleton pregnancies
• Excluded women with 
chronic diseases
• n = 11,131
• 2000–2001
• United Kingdom
• Nonsmokers: Not defined
• Quit smoking before pregnancy 
(timing of cessation not specified)
• Quit smoking during pregnancy 
(month of cessation noted)
• Continued smoking: Smoked beyond 
7 months’ gestation
• Smoking history based on self-reports 
ascertained when infants were 
9 months old
Mean unadjusted birth weight (SD) and 
difference in mean birth weight:
• Nonsmokers 3,452 g (551 g) 
• Quit smoking before pregnancy: -8 g
• Quit smoking month 1: -5 g
• Quit smoking month 2: -5 g
• Quit smoking month 3: -9 g
• Quit smoking month 4: -143 g, p <0.05
• Quit smoking month 5: -170 g, p <0.05
• Quit smoking month 6: -184 g
• Quit smoking month 7: -215 g, p <0.05
• Continued smoking: -245 g, p <0.05
• Quit smoking trimester 1: -5 g
• Quit smoking trimester 2: -159 g, p <0.05
• Continued smoking: -245 g, p <0.05
Results adjusted for birth 
year/quarter of infant, 
maternal weight, height, 
income, prenatal care 
initiation, alcohol use, 
maternal employment 
status, home satisfaction, 
religion affiliation, and 
racist or religion-based 
insults in living area
Did not account for 
substance use
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Study Design/population Exposure groups/how determined Estimate of effects Comments
Hayes et al. 
(2016)
• Quasi-experimental, 
historical cohort of 
smoking cessation 
intervention trial 
• Excluded deliveries of 
infants <1,500 g
• n = 652
• 2004–2005
• Ireland
• Quit smoking before enrollment: 
Smoked when became pregnant, quit 
before first study visit, and did not 
resume smoking
• Quit smoking after enrollment: Smoked 
at time of first study visit but quit by third 
study visit (combined with “attempted 
to quit” for adjusted analysis)
• Attempted to quit: Attempted to quit at 
first or second study visit but resumed 
at one or more visits (combined with 
“quit smoking after enrollment” for 
adjusted analysis)
• Continued smoking: Smoked at the time 
of all three study visits
• Smoking status based on self-reports 
and validated with urine cotinine levels 
at second study visit (did not describe 
how cotinine levels were used in the 
analysis), and ascertained at three visits 
(12–18 weeks’ gestation, 28–32 weeks’ 
gestation, and within 1 week of delivery) 
Median birth weight and difference in 
mean birth weight (95% CI):
• Quit smoking before enrollment: 3,600 g, 
3,595 g (reference)
• Quit smoking after enrollment: 3,340 g, 
p = 0.07
• Attempted to quit: 3,450 g, p = 0.13
• Continued smoking: 3,260 g, 3,269 g, 
-326 g (-483– -17), p < 0.01
Difference in mean adjusted birth weight 
(95% CI):
• All:
 – Continued smoking (reference)
 – Quit smoking before enrollment: 
+288 g (153–423 g)
 – Quit smoking after enrollment or 
attempted to quit: +147 g (50–244 g)
• Preterm:
 – Continued smoking (reference)
 – Quit smoking before enrollment: +67 g 
(-272–407 g)
 – Quit smoking after enrollment or 
attempted to quit: +181 g (-236–600 g)
• Term:
 – Continued smoking (reference)
 – Quit smoking before enrollment: 
+327 g (183–472 g)
 – Quit smoking after enrollment or 
attempted to quit: +146 g (46–246 g)
Randomized cessation trial 
and thus no comparison 
group of never smokers
Results adjusted for other 
smokers in the household, 
gestational age at delivery, 
and sex of infant
Did not account for alcohol 
or substance use
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Table 4.32 Continued
Study Design/population Exposure groups/how determined Estimate of effects Comments
Suzuki et al. 
(2016)
(continues on 
next page)
• Population-based 
cohort study
• Singleton pregnancies
• n = 7,734
• 2011–2014
• Japan
• Nonsmokers: Never smoked
• Quit smoking before pregnancy: 
Not further defined
• Quit smoking during early pregnancy: 
Not further defined
• Continued smoking: Currently smoking 
at time in which study questionnaire 
was administered
• Smoking status based on self-reports 
collected in second trimester
Mean birth weights (SD) and difference in 
mean birth weight:
• Nonsmokers: 3,015 g (427 g) (reference)
• Quit smoking before pregnancy: 3,029 g 
(408 g), +14 g
• Quit smoking during early pregnancy: 
3,011 g (444 g), -4 g
• Continued smoking: 2,873 g (423 g), 
-142 g
Mean adjusted birth weights (SE) and 
difference in mean adjusted birth weight 
by sex of newborn:
• Female:
 – Nonsmokers: 3,018 g (16 g) (reference)
 – Quit smoking before pregnancy: 
3,030 g (18 g), +12 g, p = 0.7
 – Quit smoking during early pregnancy: 
2,979 g (21 g), -39 g, p = 0.06
 – Continued smoking: 2,894 (28 g), 
-124 g, p <0.001
• Male:
 – Nonsmokers: 3,096 g (17 g) (reference)
 – Quit before pregnancy: 3,089 g (18 g), 
-7 g, p = 0.9
 – Quit during early pregnancy: 3,068 g 
(20 g), -28 g, p = 0.2
 – Continued smoking: 2,960 g (27 g), 
-136 g, p <0.001
• Term births—Female:
 – Nonsmokers: 3,056 g (16 g) (reference)
 – Quit before pregnancy: 3,069 g (19 g), 
+13, p = 0.6
 – Quit during early pregnancy: 3,021 g 
(21 g), -35 g, p = 0.1
 – Continued smoking: 2,928 g (28 g), 
-128 g, p <0.001
Results adjusted for 
partner’s smoking status, 
income, birth order, 
pregnancy complications 
(hypertension, diabetes), 
pre-pregnancy weight, 
gestational weight 
gain, maternal age, and 
gestational age
Results stratified by term/
preterm delivery
Did not account for alcohol 
or substance use
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(continued from 
previous page)
Suzuki et al. 
(2016)
— — • Term births—Male:
 – Nonsmokers 3,142 g (18 g) (reference)
 – Quit before pregnancy: 3,134 g (19 g), 
+8 g, p = 0.9
 – Quit during early pregnancy: 3,110 g 
(21 g), -32 g, p = 0.2
 – Continued smoking: 3,005 g (28 g), 
-137 g, p <0.001
—
Wallace et al. 
(2017)
(reanalysis 
of Blatt et al. 
[2015])
• Population-based 
retrospective cohort study 
using Ohio certificates of 
live birth
• Singleton pregnancies
• Excluded congenital 
malformations
• All participants had 
at least one previous 
preterm delivery
• n = 36,432
• 2006–2012
• Ohio
• Nonsmoker: Did not smoke during 
3 months before pregnancy or 
during pregnancy
• Quit smoking by first trimester: Smoked 
during 3 months before pregnancy 
but not during pregnancy
• Quit by second trimester: Smoked 
during first trimester but not during 
second and third trimesters
• Quit by third trimester: Smoked 
during second trimester but not during 
third trimester
• Continued smoking: Smoked during 
all three trimesters
• Smoking status obtained from U.S. 
certificates of live birth
Mean birth weight (SD) and difference in 
birth weight:
• Nonsmokers: 2,964 g (764 g) (reference)
• Quit smoking by first trimester: 2,951 g 
(745 g), -13 g
• Quit smoking by second trimester: 
2,841 g (819 g), -123 g
• Quit smoking by third trimester: 
2,343 g (1,061 g), -621 g
• Continued smoking: 2,743 g (667 g), 
-221 g
• All comparisons significant at p <0.01
Results not adjusted for 
confounders
Did not account for alcohol 
or substance use
Notes: BMI = body mass index; CI = confidence interval; CO = carbon monoxide; g = grams; kg = kilograms; ng/mL = nanograms per milliliter; SD = standard deviation; 
SE = standard error.
A Report of the Surgeon General
360  Chapter 4
221 and 303 g in the conventional analysis for light and 
heavy smokers, respectively. Also, in the sibling analysis, 
cessation was associated with a reduction in birth weight 
of 29 g (95% CI, -42 to -16) for light smokers compared 
with nonsmokers, but it was not associated with a signif-
icant reduction in birth weight in heavy smokers (-1  g; 
95% CI, -46–44). By  comparison, using nonsibling con-
trols, babies of light smokers who quit had a reduction 
in birth weight of 47 g (95% CI, -55 to -40), while heavy 
smokers who quit had a reduction of 79 g (95% CI, -100 to 
-58) compared with nonsmokers during pregnancy. 
Several of the studies published since the 1990 and 
2004 Surgeon General’s reports examined the specific 
timing of tobacco smoke exposure and fetal growth. Yan 
and Groothuis (2015), who examined birth outcomes in 
more than 11,000  women and 2,000  smokers by gesta-
tional month of cessation through month 7, found little 
effect of smoking on birth weight in the first 3 months of 
pregnancy but increasing effects for every month women 
smoked after that. Estimates of the effect of smoking on 
birth weight were adjusted for several socioeconomic 
factors and alcohol use but not for gestational age, and 
they were statistically significant for months 4, 5, and 7. 
However, cessation status was not biochemically validated. 
Elsewhere, Blatt and colleagues (2015) examined cessation 
in a cohort of more than 900,000 births by trimester in a 
study using Ohio birth certificate data. Those researchers 
found a greater reduction in birth weight in quitters com-
pared with nonsmokers over time (-60 g for smoking in 
the first trimester only, -268 g for smoking in the second 
trimester) but no further reduction for smoking through 
the third trimester (-250 g). The results were not adjusted 
for potential confounders or for gestational age, however, 
and there was no biochemical validation of cessation. All 
comparisons were statistically significant. 
Two studies examined smoking patterns across preg-
nancies and, thus, focused on cessation between pregnan-
cies rather than on cessation during pregnancies. Abrevaya 
(2008) found that, after stratifying results by age, both 
the younger (18–24 years of age) and older (25–30 years 
of age) groups of continuing smokers had babies with 
lower mean birth weights compared with quitters, even 
after adjusting for multiple potential confounders (-134 g 
and -115  g, respectively) (Abrevaya 2008). In Sweden, 
Johansson and colleagues (2009) assessed smoking status 
during antenatal care for mothers having two live births, 
comparing the outcomes of the second pregnancy within 
exposure groups with those for the first pregnancy, and 
found increases in birth weight of the babies of quitters 
(233 g) and nonsmokers (173 g) that exceeded the increase 
in continuing smokers (119 g). An important limitation 
of study designs that examine outcomes across consecu-
tive pregnancies is that the smoking exposure categories 
are often simplified (e.g., assessing smoking at only one 
time point for each pregnancy). If the timing of cessation 
(such as during pregnancy rather than before pregnancy, 
or during a specific trimester of pregnancy) affects infant 
birth weight, the effect may not be detected in studies with 
limited assessment of smoking exposure. 
Summary of the Evidence. Since the 2004 Surgeon 
General’s report confirmed that smoking cessation elim-
inates much of the reduction in birth weight caused by 
maternal smoking (USDHHS 2004), numerous studies 
have assessed the relationships between smoking and 
smoking cessation and fetal growth. Many studies adjusted 
for multiple confounders, and some included biochem-
ical validation of quit status. The evidence is sufficient to 
infer that smoking cessation during pregnancy reduces 
the effects of smoking on birth weight and gestational-
age adjusted birth weight. Depending on the timing of 
cessation, the birth weight of infants of women who quit 
smoking before or in early pregnancy approached or met 
that of nonsmokers in many studies. The evidence is inad-
equate to infer the exact gestational age before which ces-
sation should occur to eliminate the effects of smoking 
on birth weight or gestational-age adjusted birth weight. 
Small for Gestational Age
In addition to gestational age–adjusted birth weight 
or birth weight in term infants, the designation of SGA 
(a birth weight ≤10th  percentile for gestational age) or 
the infant’s SGA status can be used as an indicator of fetal 
growth. SGA is a less sensitive measure of fetal growth 
than gestational age–adjusted birth weight, but it is 
strongly associated with increased morbidity and mortality 
(Pallotto and Kilbride 2006; Katz et al. 2013). The associa-
tion between smoking-related reduction in birth weight 
and infant mortality has been studied in detail, as reviewed 
in the 2014 Surgeon General’s report (USDHHS 2014).
Table 4.33 presents studies published after the year 
2000 that addressed smoking cessation and SGA infants. 
Twenty-two studies were identified. Definitions for SGA 
included, by percentile of birth weight, less than the 
2.5th, 3rd, 5th, and 10th percentiles; they also included 
greater than 2 standard deviations (SD) below the mean. 
All of the studies but one (Grzeskowiak et  al. 2015) 
included adjustments for potential confounders; three 
also adjusted for alcohol consumption but not substance 
use (McCowan et al. 2009; Bakker et al. 2011; Tong et al. 
2017); and two addressed both alcohol consumption and 
substance use (Erickson and Arbour 2012; Murphy et al. 
2013). Two studies examined smoking status across two 
consecutive pregnancies (Okah et al. 2007; Kvalvik et al. 
2017), and 20 examined cessation with respect to single 
pregnancies. Of those 20  studies, 19  compared infants 
of women who quit smoking with those of nonsmokers 
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Table 4.33 Studies on smoking cessation and small for gestational age infants
Study Design/population Exposure groups/how determined Outcome definition Findings Comments
Mitchell et al. 
(2002)
• Case-control
• Term births without 
congenital anomalies
• n = 1,714 
• 1995–1997
• New Zealand
• Nonsmokers: Never smoked cigarettes 
regularly, or did not smoke during 
12 months before pregnancy or 
during pregnancy
• Quit smoking before pregnancy: Smoked 
during 12 months before pregnancy but 
not during pregnancy
• Quit smoking during pregnancy
• Continued smoking during pregnancy, 
increased amount
• Continued smoking during pregnancy, 
decreased amount
• Continued smoking during pregnancy, 
amount did not change
• Smoking status based on self-reports 
obtained from a postpartum interview
<10th percentile for sex Unadjusted and adjusted ORs for SGA 
(95% CI):
• Nonsmokers (reference)
• Quit smoking before pregnancy: 
 – Unadjusted: 0.83 (0.55–1.27)
 – Adjusted: 1.03 (0.64–1.64)
• Quit smoking during pregnancy:
 – Unadjusted: 1.13 (0.73–1.75) 
 – Adjusted: 1.14 (0.68–1.91)
• Continued smoking during pregnancy, 
increased amount: 
 – Unadjusted: 1.94 (1.02–3.67)
 – Adjusted: 2.07 (0.97–4.42)
• Continued smoking during pregnancy, 
decreased amount: 
 – Unadjusted: 2.56 (1.86–3.52)
 – Adjusted: 3.23 (2.14–4.86)
• Continued smoking during pregnancy, 
amount did not change: 
 – Unadjusted: 3.35 (1.98–5.66)
 – Adjusted: 4.88 (2.66–8.94)
Results adjusted for 
maternal education, 
occupation, marital status, 
ethnicity, parity, age, 
age at first pregnancy, 
height, pre-pregnancy 
weight, hypertension, 
and marijuana use
England et al. 
(2007)
• Randomized trial for 
preeclampsia prevention 
• n = 4,289
• 1992–1995
• United States
• Nonsmokers: Never smoked regularly
• Quit before pregnancy: Quit before last 
menstrual period and validated with 
cotinine mid-pregnancy
• Quit during pregnancy: Quit after last 
menstrual period and validated with 
cotinine mid-pregnancy
• Quit before or during pregnancy: 
Quit groups from two previous 
categories combined
• Continued smoking: Smoking at 
study enrollment
• Smoking status based on self-
reports obtained at study enrollment 
(13–21 weeks’ gestation) in 2007 study
• Quit status validated with urine cotinine 
concentration obtained mid-pregnancy 
(mean: 28 weeks’ gestation)
≤10th percentile for 
race, sex, and parity
Unadjusted and adjusted OR (95% CI):
• Nonsmoker (reference)
• Quit before or during pregnancy: 
 – Unadjusted: 1.0 (0.7–1.4)
 – Adjusted: 1.0 (0.7–1.5)
• Continued smoking: 
 – Unadjusted: 1.9 (1.5–2.4)
 – Adjusted: 2.0 (1.6, 2.7)
Results adjusted for 
maternal BMI and 
study center
Did not account for 
alcohol or substance use
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Table 4.33 Continued
Study Design/population Exposure groups/how determined Outcome definition Findings Comments
Okah et al. 
(2007)
• Population-based 
retrospective cohort 
study using certificates 
of live births in Missouri
• First and second 
singleton live births
• n = 5,107
• 1994–2003
• Missouri
• Nonsmokers: Smoked during neither 
pregnancy
• Smoked during first but not during 
second pregnancy
• Smoked during second but not 
during first pregnancy
• Smoked during both pregnancies
• Smoking history ascertained from vital 
statistics data and certificates of live 
births, which used one question on 
tobacco use during pregnancy (yes/no)
<10th percentile for 
gestational age
Adjusted OR for SGA in second pregnancy 
(95% CI):
• Nonsmoker (reference)
• Smoked during first but not during second 
pregnancy: 1.31 (0.65–2.65)
• Smoked during second but not during 
first pregnancy: 1.83 (1.19–2.82)
• Smoked during both pregnancies: 
2.80 (2.00–3.93)
Results adjusted for 
maternal age, race, and 
medical risk for SGA
Did not account for 
alcohol or substance use
Pipkin (2008) • Prospective cohort 
study of the genetics 
of preeclampsia
• Singleton pregnancies 
with moderate to 
severe preeclampsia
• n = 1,001
• Years: Not reported
• United Kingdom
• Nonsmoker: Never smoked
• Quit smoking: Quit before first antenatal 
visit but quit time not reported
• Continued smoking: Smoking at the 
time of antenatal booking
• Smoking status based on self-reports 
obtained at antenatal booking
<3rd percentile for 
gestational age
Percentage SGA and adjusted OR for SGA 
(95% CI):
• Nonsmoker: 27.9% (reference)
• Quit smoking: 37.5%
• Continued smoking: 46.1%; 2.20 (1.41–3.44)
Results adjusted for 
maternal parity and BMI 
and sex of the infant
McCowan 
et al. (2009)
• Prospective cohort study 
• n = 2,504
• 2004–2007
• New Zealand and 
Australia
• Nonsmoker: Did not smoke during 
pregnancy
• Quit smoking: Smoked during pregnancy 
but quit before being interviewed at 
15  weeks’ gestation
• Continued smoking: Smoking at 
15 weeks’ gestation
• Smoking status based on self-reports 
ascertained at 15 weeks’ gestation
SGA birth weight 
<10th customized 
centile
Adjusted OR (95% CI):
• Nonsmoker (reference)
• Quit smoking: 1.06 (0.67–1.68)
• Continued smoking: 1.76 (1.03–3.02)
Results adjusted for 
maternal age; ethnicity; 
marital status; employment 
status; BMI; bleeding 
during pregnancy; folic 
acid use; multivitamin use; 
alcohol use at 15 weeks’ 
gestation; and scores 
for depression, stress, 
or anxiety
Did not account for 
substance use
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Polakowski 
et al. (2009)
• Population-based 
retrospective cohort 
study using certificates 
of live births
• Singleton pregnancies 
>28 weeks’ gestation
• n = 915,441
• 2005
• Multiple sites in the 
United States
• Nonsmoker: Did not smoke during any 
trimester of pregnancy
• Quit smoking, first trimester: Smoked 
during first trimester but not during 
second and third trimesters
• Quit smoking, second trimester: Smoked 
during second trimester but not during 
third trimester
• Continued smoking: Smoked during all 
three trimesters
• Excluded women who did not fit any of 
the categories above
• Smoking history ascertained from vital 
statistics data and certificates of live births
Birth weight <10th 
percentile weight for 
gestational age
Adjusted OR for SGA (95% CI):
• Term (≥37 completed weeks):
 – Continued smoking (reference)
 – Nonsmokers: 0.41 (0.40–0.42)
 – Quit smoking, first trimester: 
0.45 (0.42–0.48)
 – Quit smoking, second trimester: 
0.59 (0.54–0.64)
• Preterm (28–36 completed weeks):
 – Continued smoking (reference)
 – Nonsmokers: 0.45 (0.42–0.47)
 – Quit smoking, first trimester: 
0.47 (0.40–0.55)
 – Quit smoking, second trimester: 
0.88 (0.72–1.08)
Results adjusted for 
maternal age, race/
ethnicity, marital status, 
education, late entry into 
prenatal care, and history 
of preterm delivery
Did not account for 
alcohol or substance use
Vardavas 
et al. (2010)
• Population-based, 
prospective cohort study
• Singleton pregnancies
• n = 1,400
• 2007–2008
• Crete, Greece
• Nonsmoker: Did not smoke from 3 months 
before pregnancy through pregnancy
• Quit smoking: Stopped smoking 
sometime between 3 months before 
pregnancy and 12 weeks’ gestation.
• Continued smoking: Smoking at 12 weeks’ 
gestation
• Smoking status based on self-reports 
obtained at enrollment and during 
second and third trimesters
Birthweight <10th 
percentile for 
gestational age
Unadjusted OR for SGA (95% CI):
• Nonsmoker (reference)
• Quit smoking: 0.73 (0.34–1.59)
• Continued smoker: 2.36 (1.42–3.93)
Adjusted OR for SGA (95% CI):
• Nonsmoker (reference)
• Quit smoking: 0.74 (0.34–1.62)
• Continued smoker: 2.63 (1.55–4.49)
Results adjusted for 
origin, parity, maternal 
education, and age and 
sex of the infant
Did not account for 
alcohol or substance use
Bakker et al. 
(2011)
• Population-based, 
prospective cohort study
• n = 5389
• 2001–2005
• Netherlands
• Nonsmokers: Did not smoke during 
pregnancy
• Quit smoking, first trimester: Smoked 
only during first trimester
• Quit smoking, second trimester: Smoked 
during second trimester (combined with 
“continued smoking” for this analysis)
• Continued smoking: smoked during third 
trimester (combined with “quit smoking, 
second trimester” for this analysis)
• Smoking status based on self-reports 
obtained in each trimester of pregnancy
Birth weight <5th 
percentile for 
gestational age
Adjusted OR for SGA (95% CI):
• Nonsmokers (reference)
• Quit smoking: 1.17 (0.73–1.88)
• Continued smoking 2.11 (1.55–2.88)
Results adjusted for 
maternal age, BMI, height, 
education, ethnicity, parity, 
alcohol consumption, 
caffeine intake, folic acid 
intake, maternal stress, 
gestational age at birth; 
and sex of the fetus
Did not account for 
substance use
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Study Design/population Exposure groups/how determined Outcome definition Findings Comments
Baba et al. 
(2012)
• Population-based cohort 
study based on Swedish 
Medical Birth Register
• Singleton pregnancies
• n = 846,411
• 1999–2010
• Sweden
• Nonusers: Did not use snuff or smoke 
cigarettes before pregnancy or during 
early pregnancy (≤15 weeks’ gestation)
• Quit smoking, early: Smoked before 
pregnancy but quit during early pregnancy
• Continued smoking, early: Smoked 
before and during early pregnancy 
(based on first assessment of smoking 
status at ≤15 weeks’ gestation)
• Quit smoking, late: Smoked during early 
pregnancy but not during late pregnancy 
(based on assessment of smoking status 
at ≤15 weeks’ gestation and 30–32 weeks’ 
gestation)
• Continued smoking: Smoked during 
early and late pregnancy
• Smoking status based on self-reports 
assessed at first antenatal visit (typically 
≤15 weeks’ gestation) and again in 
late pregnancy (typically 30–32 weeks’ 
gestation)
Birth weight >2 SD 
below the mean for 
gestational age using 
sex-specific growth 
curves
Unadjusted and adjusted OR for SGA 
(95% CI):
• Based on early assessment:
 – Nonuser (reference)
 – Quit smoking, early: 
	| Unadjusted: 1.17 (1.11–1.24)
	| Adjusted: 1.03 (0.98–1.09)
 – Continued smoking, early:
	| Unadjusted: 2.69 (2.58–2.80)
	| Adjusted: 2.55 (2.43–2.67)
• Based on late assessment:
 – Nonuser (reference)
 – Quit smoking, late:
	| Unadjusted: 2.01 (1.83–2.21)
	| Adjusted: 1.82 (1.65–2.01)
 – Continued smoking, late:
	| Unadjusted: 3.18 (3.01–3.36)
	| Adjusted: 3.21 (3.02–3.40)
Adjusted OR for preterm SGA and term SGA 
(95% CI):
• Nonuser (reference)
• Quit smoking, early: 
 – Preterm SGA: 0.86 (0.76–0.98)
 – Term SGA: 1.07 (1.01–1.14)
• Continued smoking, early: 
 – Preterm SGA: 1.85 (1.67–2.06)
 – Term SGA: 2.76 (2.62–2.91)
Results adjusted for 
maternal age, parity, 
education, early pregnancy 
BMI, cohabitation, height, 
pregestational diabetes, 
and essential hypertension
Did not account for 
alcohol or substance use
Bickerstaff 
et al. (2012)
• Retrospective cohort
• n = 30,524
• 1997–2006
• Australia
• Nonsmokers: Never smoked or quit 
>12 months before booking
• Quit smoking: Smoked during 12 months 
before booking but quit before booking
• Continuing smokers: Currently smoking 
at booking
• Smoking status based on routinely 
collected clinical data
<10th and <3rd 
percentiles using 
customized centiles 
for Australian 
ethnicities
Adjusted OR for SGA (95% CI):
• 10th percentile:
 – Continuing smokers vs. nonsmokers: 
2.26 (2.08–2.47)
 – Quit smoking vs. continuing smokers: 
0.43 (0.33–0.57)
• 3rd percentile:
 – Continuing smokers vs. nonsmokers: 
2.41 (2.14–2.73)
 – Quit smoking vs. continuing smokers: 
0.46 (0.31–0.68)
Results adjusted for 
plurality, previous 
pregnancy complications, 
parity, and ethnicity
Did not account for 
alcohol or substance use
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Erickson 
and Arbour 
(2012)
• Population-based, 
retrospective cohort 
study using the 
British Columbia 
Perinatal Registry
• Singleton pregnancies
• n = 233,891
• 2001–2006
• British Columbia, 
Canada
• Nonsmokers: Never smoked
• Quit smoking: Not further defined, 
timing not specified
• Continued smoking: Smoking at 
first prenatal visit, subgrouped by 
smoking intensity:
 – Light: 1–4 cigarettes/day
 – Moderate: 5–9 cigarettes/day
 – Heavy: ≥10 cigarettes/day
• Smoking history based on self-reports 
typically ascertained at the first prenatal 
visit (12–18 weeks’ gestation)
Birth weight <3rd and 
<10th percentiles for 
gestational age
Adjusted OR for SGA (95% CI):
• 3rd percentile:
 – Nonsmokers (reference)
 – Quit smoking: 0.86 (0.72–1.03)
 – Continued smoking:
	| Light: 1.33 (1.11–1.60)
	| Moderate: 1.82 (1.51–2.20)
	| Heavy: 2.37 (2.06–2.72)
• 10th percentile:
 – Nonsmokers (reference)
 – Quit smoking: 0.84 (0.76–0.92)
 – Continued smoking:
	| Light: 1.24 (1.12–2.72)
	| Moderate: 1.74 (1.57–1.93)
	| Heavy: 2.14 (1.98–2.32)
Results adjusted for 
maternal age, parity, 
prenatal care visits, 
diabetes, hypertension, 
pre-pregnancy weight, 
presence of a partner, 
alcohol and drug use, 
and sex of the infant
Miyake et al. 
(2013)
• Retrospective 
cohort study
• n = 1,565
• 2007–2008
• Japan
• Nonsmoker: Did not smoke during 
pregnancy
• Quit smoking, first trimester: Smoked 
only during first trimester
• Quit smoking, second or third trimester: 
Smoked during the second or third 
trimester but not throughout pregnancy
• Continued smoking: Smoked throughout 
pregnancy
• Smoking status for each trimester of 
pregnancy based on self-reports obtained 
after delivery
Birth weight <10th 
percentile for 
gestational age
Adjusted OR for SGA (95% CI): 
• Nonsmoker (reference)
• Quit smoking, first trimester: 
 – Overall: 0.53 (0.13–1.49)
 – Male infants: 1.02 (0.16–3.81)
 – Female infants: 0.24 (0.01–1.22)
• Quit smoking, second or third trimester:
 – Overall: 1.93 (0.55–5.27)
 – Male infants: 1.67 (0.08–11.08)
 – Female infants: 2.14 (0.48–6.92)
• Continued smoking: 
 – Overall: 2.87 (1.11–6.56)
 – Male infants: 4.21 (1.26–12.14)
 – Female infants: 1.51 (0.23–5.96)
Results adjusted for region 
of residence; number of 
children; family structure; 
maternal age, education, 
employment, alcohol 
consumption, and BMI; 
gestational age at birth; 
and sex of the infant
Did not account for 
substance use
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Table 4.33 Continued
Study Design/population Exposure groups/how determined Outcome definition Findings Comments
Murphy et al. 
(2013)
• Prospective cohort study
• Singleton pregnancies
• n = 1,216
• 2010–2011
• Ireland
• Nonsmoker: Not defined
• Quit smoking: Smoked during 6 months 
before pregnancy but quit by first 
prenatal visit
• Continued smoking: Smoked during 
6 months before pregnancy, at first 
prenatal visit, and during third trimester
• Smoking status based on self-reports 
obtained at enrollment and in third 
trimester
Birth weight <10th 
percentile, corrected 
for maternal height 
and weight, parity, 
infant sex, ethnicity, 
and gestation
OR for SGA (95% CI):
• Nonsmoker (reference)
• Quit smoking:
 – Unadjusted: 0.81 (0.46–1.40)
 – Adjusted: 1.05 (0.58–1.89)
• Continued smoking: 
 – Unadjusted: 2.09 (1.27–3.44),
 – Adjusted: 1.39 (1.06–1.84)
Birth weight adjusted for 
maternal age, nationality, 
unplanned pregnancy, 
private healthcare, alcohol 
use, and illicit drug use
Rode et al. 
(2013)
• Prospective cohort study
• Singleton, term 
pregnancies
• n = 1,774
• 1996–1999
• Denmark
• Nonsmokers: Not defined
• Quit smoking: Quit immediately before 
or during pregnancy
• Continued smoking: Not defined.
• Smoking status based on self-reports 
assessed at 12–18 weeks’ and 37 weeks’ 
gestation and 1 year postpartum
• Salivary cotinine obtained in a subgroup 
at 16 and 37 weeks’ gestation 
Birth weight <10th 
percentile for 
gestational age
OR for SGA (95% CI):
• Nonsmokers (reference)
• Quit smoking: 
 – Unadjusted: 1.1 (0.7–1.7)
 – Adjusted: 1.0 (0.6–1.6)
• Continued smoking:
 – Unadjusted: 3.5 (2.4–4.9)
 – Adjusted: 3.6 (2.5–5.2)
Birth weight adjusted 
for pre-pregnancy BMI, 
preeclampsia, and parity
Salivary cotinine for 
subgroup reported but 
not integrated into 
main analysis
Did not account for 
alcohol or substance use
Meghea et al. 
(2014)
• Prospective cohort study
• n = 474
• 2008–2009
• Romania
• Nonsmokers: Not smoking when learned 
they were pregnant
• Quit smoking: Quit upon learning 
of pregnancy 
• Continued smoking: Smoking at time 
of study interview (gestational age 
not reported)
• Smoking history based on self-reports 
obtained at study enrollment (gestational 
age not reported)
Birth weight <10th 
percentile for 
gestational age
Adjusted OR for SGA (95% CI):
• Nonsmokers (reference)
• Quit smoking: 2.16 (1.05–4.43)
• Continued smoking: 1.79 (0.74–4.32)
Results adjusted for 
stress, depressive 
symptoms, maternal age 
>35 years old, education, 
rural residence, marital 
status, and nulliparity 
Did not account for 
alcohol or substance use
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Study Design/population Exposure groups/how determined Outcome definition Findings Comments
Räisänen 
et al. (2014)
• Population-based 
study based on Finnish 
Medical Birth Register
• Singleton pregnancies, 
live or stillborn after 
22 weeks’ gestation
• n = 1,164,953
• 1991–2010
• Finland
• Nonsmokers: Not further defined
• Quit smoking: Quit smoking during 
first trimester
• Continued smoking: Smoked after 
first trimester
• Smoking history ascertained from the 
Finnish Medical Birth Register
Birth weight >2 SD 
below sex- and parity-
specific means for 
gestational age
OR for SGA (95% CI):
• Nonsmokers (reference)
• Quit smoking:
 – Unadjusted 1.33 (1.26–1.41)
 – Adjusted: 1.16 (1.09–1.23)
• Continued smoking: 
 – Unadjusted: 2.38 (2.33–2.44)
 – Adjusted: 2.47 (2.41–2.53)
Results adjusted for 
maternal age, parity, 
socioeconomic status, 
and sex of the infant 
Did not account for 
alcohol or substance use
Suzuki et al. 
(2014)
• Prospective cohort study
• Singleton pregnancies
• n = 2,663
• 1991–2006
• Japan
• Nonsmoker: Never smoked
• Quit smoking before pregnancy: 
Not further defined
• Quit smoking, first trimester
• Continued smoking: Smoked after 
first trimester
• Smoking history based on self-reports 
obtained in early pregnancy (usually 
first trimester)
Birth weight <10th 
percentile using sex-
specific growth curves 
for infants in Japan
Adjusted OR for SGA (95% CI): 
• Boys:
 – Nonsmokers (reference)
 – Quit smoking before pregnancy: 
1.2 (0.5–3.2)
 – Quit smoking, first trimester: 
1.0 (0.5–2.1)
 – Continued smoking: 3.2 (1.7–6.2)
• Girls:
 – Nonsmokers (reference)
 – Quit smoking before pregnancy: 
0.5 (0.1–1.5)
 – Quit smoking, first trimester: 
1.1 (0.6–2.0)
 – Continued smoking: 2.5 (1.3–5.2)
Results adjusted for 
maternal age and BMI
Did not account for 
alcohol or substance use
Blatt et al. 
(2015)
• Population-based 
retrospective cohort 
study using certificates 
of live births in Ohio
• n = 927,424
• 2006–2012
• Ohio
• Nonsmoker: Did not smoke during 
3 months before pregnancy or 
during pregnancy
• Quit before pregnancy: Smoked during 
3 months before pregnancy but not 
during pregnancy
• Quit first trimester: Smoked only during 
first trimester
• Quit second trimester: Smoked during 
first and second trimesters but not 
third trimester
• Continued smoking: Smoked throughout 
pregnancy
• Smoking history ascertained from vital 
statistics data and certificates of live births
Birthweight <10th and 
<5th percentiles for 
gestational age
Adjusted OR for SGA (95% CI):
• <10th percentile:
 – Nonsmoker (reference)
 – Quit first trimester: 1.19 (1.13–1.24)
 – Quit second trimester: 1.67 (1.57–1.78)
 – Continued smoking: 2.26 (2.22–2.31)
• <5th percentile:
 – Nonsmoker (reference)
 – Quit first trimester: 1.25 (1.17–1.33)
 – Quit second trimester: 1.83 (1.68–1.99)
 – Continued smoking: 2.44 (2.37–2.51)
Results adjusted for 
maternal age, race, 
education, marital status, 
hypertension, diabetes, 
and BMI
Did not account for 
alcohol or substance use
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Table 4.33 Continued
Study Design/population Exposure groups/how determined Outcome definition Findings Comments
Grzeskowiak 
et al. (2015)
• Retrospective 
cohort study
• n = 7,658
• 2000–2005
• South Australia
• Nonsmokers
• Quit smoking
• Continued smoking
• Smoking status not further defined
• Smoking history based on self-reports 
ascertained at antenatal booking
Birth weight <10th 
percentile for 
gestational age by 
sex of the infant and 
maternal height 
and parity
Percentage SGA:
• Nonsmokers: 7.1% (reference)
• Quit smoking: 8.1%, p = 0.81
• Continued smoking: 15.3%, p <0.001
Results not adjusted for 
potential confounders
Did not account for 
alcohol or substance use
Kvalvik et al. 
(2017)
• Population-based 
retrospective cohort 
study using the Medical 
Birth Registry of Norway
• First and second births
• n = 118,355
• 1999–2014
• Norway
• Nonsmoker: Did not smoke at the end of 
either pregnancy
• Daily smoker/quit smoking: Smoked daily 
at end of first pregnancy but not smoking 
at end of second pregnancy
• Nonsmoker/daily smoker: Not smoking 
at end of first pregnancy but smoked 
daily at end of second pregnancy
• Daily smoker/daily smoker: Smoked daily 
at end of both pregnancies
• Did not describe how smoking status 
was ascertained
Birth weight <10th and 
<2.5th percentile for 
gestational age by sex
RR for SGA at second pregnancy (95% CI):
• <10th percentile:
 – Nonsmoker (reference)
 – Daily smoker/quit smoking: 
	| Unadjusted: 1.5 (1.3–1.6)
	| Adjusted: 1.5 (1.3–1.7)
 – Nonsmoker/daily smoker:
	| Unadjusted: 2.1 (1.8–2.5)
	| Adjusted: 2.1 (1.8–2.5)
 – Daily smoker/daily smoker:
	| Unadjusted: 2.9 (2.7–3.1)
	| Adjusted: 2.9 (2.7–3.1)
• < 2.5th percentile:
 – Nonsmoker (reference)
 – Daily smoker/quit smoking:
	| Unadjusted: 1.5 (1.1–2.0)
	| Adjusted: 1.5 (1.1–2.0)
 – Nonsmoker/daily smoker:
	| Unadjusted: 3.2 (2.4–4.3)
	| Adjusted: 3.1 (2.3–4.2)
 – Daily smoker/daily smoker:
	| Unadjusted: 4.0 (3.4–4.7)
	| Adjusted: 3.9 (3.3–4.6)
Results adjusted for 
maternal age, marital 
status, and year of 
first birth
Did not account for 
alcohol or substance use
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Study Design/population Exposure groups/how determined Outcome definition Findings Comments
Tong et al. 
(2017)
• Population-based 
retrospective 
cohort study
• n = 88,933
• 2009–2011
• United States
• Nonsmoker: Did not smoke during 
3 months before pregnancy or during 
last 3 months of pregnancy
• Quit smoking: Smoked during 3 months 
before pregnancy but not during last 
3 months of pregnancy
• Continued smoking, nondaily: Smoked 
during 3 months before pregnancy and 
<1 cigarette/day during last 3 months 
of pregnancy
• Continued smoking, daily: Smoked 
during 3 months before pregnancy and 
smoked ≥1 cigarette/day during last 
3 months of pregnancy
• Smoking status based on survey 
administered postpartum
≤10th percentile birth 
weight for gestational 
age by sex and race
Prevalence ratio for SGA (95% CI):
• Nonsmoker (reference)
• Quit smoking:
 – Unadjusted: 1.0 (0.9–1.1)
 – Adjusted: 0.9 (0.9–1.0)
• Continued smoking: 
 – Nondaily:
	| Unadjusted: 1.6 (1.3–1.9)
	| Adjusted: 1.4 (1.1–1.8)
 – Daily:
	| Unadjusted: 2.2 (2.0–2.4)
	| Adjusted: 2.0 (1.9–2.2)
Results adjusted for 
maternal age, parity, 
education, marital 
status, BMI, trimester 
of entry into prenatal 
care, and alcohol use 
during pregnancy
Did not account for 
substance use
Notes: BMI = body mass index; CI = confidence interval; OR = odds ratio; RR = risk ratio; SD = standard deviation; SGA = small for gestational age.
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(Mitchell et  al. 2002; England et  al. 2007; Pipkin 2008; 
Andersen et  al. 2009; McCowan et  al. 2009; Polakowski 
et al. 2009; Vardavas et al. 2010; Bakker et al. 2011; Baba 
et al. 2012; Erickson and Arbour 2012; Miyake et al. 2013; 
Murphy et al. 2013; Rode et al. 2013; Meghea et al. 2014; 
Räisänen et al. 2014; Suzuki et al. 2014; Blatt et al. 2015; 
Grzeskowiak et  al. 2015; Tong et  al. 2017), and 1  study 
compared them with the infants of continuing smokers 
(Bickerstaff et al. 2012). In general, these 20 studies found 
that women who continued to smoke past early pregnancy 
had an elevated risk of SGA delivery and that cessation 
attenuated or eliminated this excess risk. 
Seven of the 20  studies examined a combined-
exposure variable of cessation before pregnancy with ces-
sation during early pregnancy, and thus could not isolate 
the effects of cessation by timeframe (before and after 
conception) (England et  al. 2007; Andersen et  al. 2009; 
Vardavas et al. 2010; Bickerstaff et al. 2012; Murphy et al. 
2013; Rode et al. 2013; Tong et al. 2017). Six of these seven 
studies found no difference in SGA risk in quitters com-
pared with nonsmokers (England et  al. 2007; Andersen 
et al. 2009; Vardavas et al. 2010; Murphy et al. 2013; Rode 
et al. 2013; Tong et al. 2017), while one (Bickerstaff et al. 
2012) found a significant decrease in risk among quitters 
compared with continuing smokers (aOR = 0.43; 95% CI, 
0.33–0.57). In 2 of the 20 studies, the timing of cessation 
with respect to conception was not described (Pipkin 2008; 
Erickson and Arbour 2012). Pipkin and colleagues (2008) 
did not perform any testing for statistical significance; and 
Erickson and Arbour (2012) found no increased risk of SGA 
among infants of quitters. Six of the 20 studies included 
assessment of smoking status in late pregnancy (typically 
in the third trimester) (Mitchell et al. 2002; Bakker et al. 
2011; Baba et al. 2012; Rode et al. 2013; Blatt et al. 2015; 
Tong et  al. 2017), thus reducing any potential contribu-
tion of unidentified relapse. Of these studies, five found no 
significant increase in risk of SGA infants among quitters 
whose status was verified in late pregnancy, and one (Baba 
et al. 2013) found an increased risk for late, but not early, 
quitters. One of the six studies assessed timing by trimester 
(Blatt et al. 2015) and found significant increases in risk 
in both early quitters (smoked in first trimester only) and 
later quitters (smoked in first and second trimesters only) 
(aOR = 1.19; 95% CI, 1.13–1.24, and 1.67; 95% CI, 1.57–
1.78, respectively) when compared with nonsmokers. One 
study included biochemical validation of smoking cessa-
tion (Rode et al. 2013) and combined preconception and 
early-pregnancy quitters. The study found no increase for 
SGA risk in quitters when compared with nonsmokers. 
Of the two studies that examined smoking cessation 
across consecutive pregnancies, one found no increased 
risk of SGA in babies of women who quit by the second 
pregnancy compared with women who did not smoke in 
either pregnancy (Okah et al. 2007), and the other found 
a significant increase for SGA in quitters compared with 
women who did not smoke during either pregnancy 
(Kvalvik et al. 2017). However, the basis for the different 
findings is not clear. Both studies were population based, 
used an SGA definition of less than 10th percentile, and 
relied on self-reported smoking status, and both adjusted 
for several potential confounders (for maternal age, race, 
and medical risk factors for SGA, and for maternal age, 
marital status, and year of first birth, respectively). The 
two studies were conducted in different countries (United 
States and Norway, respectively), however, and although 
Okah and colleagues (2007) categorized smoking status as 
positive or negative for each pregnancy, Kvalvick and col-
leagues (2017) specifically assessed smoking status at the 
end of each pregnancy. 
Summary of the Evidence. Since the 2004 Surgeon 
General’s report confirmed that smoking cessation elim-
inates much of the reduction in birth weight caused by 
maternal smoking (USDHHS 2004), numerous studies 
have assessed the relationships between smoking and 
smoking cessation and SGA, and most have adjusted for 
multiple confounders. The evidence is sufficient to infer 
that smoking cessation before or during early pregnancy 
reduces the risk of SGA birth compared with continued 
smoking. The evidence is suggestive but not sufficient to 
infer that the risk of an SGA birth in women who quit 
smoking before or during early pregnancy does not differ 
from that for nonsmokers. The evidence is inadequate 
to determine the gestational age before which smoking 
cessation should occur to eliminate the effects of smoking 
on risk of SGA. 
Preterm Delivery
Delivery before 37  completed weeks’ gestation 
is a leading cause of neonatal morbidity and mortality 
(March of Dimes et al. 2012; Menon 2012; Blencowe et al. 
2013; Katz et al. 2013), and this problem affects approxi-
mately 15 million births per year globally (World Health 
Organization 2017) and nearly 10% of births in the United 
States (Martin et al. 2017). Preterm delivery can be medi-
cally indicated (about two-thirds of all preterm deliveries) 
or spontaneous (about one-third of preterm deliveries). 
Spontaneous preterm delivery encompasses preterm 
labor, premature rupture of membranes, and spontaneous 
fetal loss. Medically indicated preterm delivery can be 
the outcome of numerous maternal and fetal conditions, 
including maternal chronic diseases, such as hyperten-
sion or diabetes, and pregnancy complications, such as 
preeclampsia, GDM, or abnormal placentation (Purisch 
and Gyamfi-Bannerman 2017). Numerous risk factors 
for spontaneous preterm delivery have been identified, 
including prior spontaneous preterm delivery, intrauterine 
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infections, shortened cervix, multifetal pregnancy, fetal 
abnormalities, uterine anomalies, Black race, interpreg-
nancy interval less than 18  months, low socioeconomic 
status, low gestational weight gain, poor nutrition status, 
and advanced maternal age (Conde-Agudelo et  al. 2006; 
USDHHS 2010; Purisch and Gyamfi-Bannerman 2017). 
The 1990 Surgeon General’s report identified a 
reduced risk of preterm delivery among women who 
quit smoking before or during pregnancy relative to con-
tinuing smokers, but the report found insufficient evi-
dence to draw conclusions about the effects of smoking 
cessation on both preterm delivery and gestational dura-
tion (USDHHS 1990). The 2004 Surgeon General’s report 
found a causal relationship between maternal smoking 
and preterm delivery (gestational age <37  weeks) and 
shorter gestational duration (number of days or weeks of 
pregnancy) (USDHHS 2004). The 2010 Surgeon General’s 
report reviewed mechanisms hypothesized to explain 
the increased risk of preterm delivery among smokers, 
including increased risk of genitourinary tract infections, 
alterations in vaginal flora and localized immunosup-
pression, alterations in cervical cytokine profiles, reduc-
tions in maternal zinc levels, dysregulation of the fetal 
immune system, and alterations in myometrial contrac-
tility (USDHHS 2010). 
Twenty-five studies published in 2000 or later that 
examined smoking cessation and preterm delivery were 
identified (Table  4.34). Two studies (Abrevaya 2008; 
Mohsin and Jalaludin 2008) examined cessation across two 
consecutive pregnancies, and 23  examined cessation in 
single pregnancies (Hrubá and Kachlik 2000; Vogazianos 
et al. 2005; McCowan et al. 2009; Polakowski et al. 2009; 
Anderka et  al. 2010; Vardavas et  al. 2010; Bakker et  al. 
2011; Baba et  al. 2012; Bickerstaff et  al. 2012; Erickson 
and Arbour 2012; Batech et al. 2013; Miyake et al. 2013; 
Murphy et  al. 2013; Meghea et  al. 2014; Räisänen et  al. 
2014; Bailey 2015; Smith et al. 2015; Yan and Groothuis 
2015; Dahlin et al. 2016; Moore et al. 2016; Suzuki et al. 
2016; Tong et al. 2017; Wallace et al. 2017). All but three 
studies (Hrubá and Kachlik 2000; Vogazianos et al. 2005; 
Suzuki et  al. 2016) adjusted for at least some potential 
confounders, and five addressed alcohol consumption 
(McCowan et  al. 2009; Bakker et  al. 2011; Miyake et  al. 
2013; Yan and Groothuis 2015; Tong et  al. 2017), while 
three addressed both alcohol and substance use (Erickson 
and Arbour 2012; Bailey 2015; Smith et al. 2015). 
Of the 23 studies examining individual pregnancies, 
8  classified exposure combining cessation before preg-
nancy with cessation during early pregnancy and, thus, 
could not estimate the effect of cessation after conception 
(Hrubá and Kachlik 2000; Anderka et al. 2010; Vardavas 
et al. 2010; Baba et al. 2012; Bickerstaff et al. 2012; Murphy 
et al. 2013; Dahlin et al. 2016; Tong et al. 2017). Of these 
eight studies, five compared quitters with nonsmokers and 
found no statistically significant difference in risk between 
the two groups (Vardavas et  al. 2010; Baba et  al. 2012; 
Murphy et al. 2013; Dahlin et al. 2016; Tong et al. 2017). 
Bickerstaff and colleagues (2012) compared quitters with 
continuing smokers and found no difference in risk. Six 
of the 23  studies examined cessation before conception; 
4 compared quitters with nonsmokers (Vogazianos et al. 
2005; Smith et al. 2015; Yan and Groothuis 2015; Moore 
et al. 2016). Three of the four found no significant differ-
ences in preterm deliveries (Vogazianos et al. 2005; Smith 
et  al. 2015; Yan and Groothuis 2015), and one found a 
slightly reduced risk in quitters (Moore et al. 2016). One 
study compared women who quit before pregnancy with 
continuing smokers and found a significantly reduced risk 
of preterm delivery (Batech et  al. 2013); and one study 
reported percentages of preterm infants for nonsmokers 
and women who quit before pregnancy (5.0% and 5.8%, 
respectively), as well as for other cessation groups, but 
adjustment for confounding was not performed, and only 
an overall chi-square test result was reported (Suzuki 
et al. 2016).
Twelve of the 23 studies examined cessation during 
pregnancy (McCowan et al. 2009; Polakowski et al. 2009; 
Bakker et al. 2011; Miyake et al. 2013; Meghea et al. 2014; 
Räisänen et al. 2014; Bailey 2015; Smith et al. 2015; Yan 
and Groothuis 2015; Moore et al. 2016; Suzuki et al. 2016; 
Wallace et al. 2017); of those, 7 found no statistically sig-
nificant increase in the risk of preterm delivery in quitters 
compared with nonsmokers (McCowan et al. 2009; Bakker 
et al. 2011; Miyake et al. 2013; Meghea et al. 2014; Räisänen 
et al. 2014; Smith et al. 2015; Yan and Groothuis 2015). 
Moore and colleagues (2016) and Wallace and colleagues 
(2017) used data from state certificates of live birth in 
Ohio, and both found an increased risk of preterm delivery 
in those who quit late in pregnancy, but not in those who 
quit early in the pregnancy compared with nonsmokers. 
Using a large sample of more than 900,000 births, Moore 
and colleagues (2016) found an increase in risk among 
second-trimester quitters (aOR  =  1.70; 95%  CI, 1.60–
1.80) but not in earlier quitters (first trimester) compared 
with those who were nonsmokers. Wallace and colleagues 
(2017) found an increased risk in third-trimester quitters 
(aOR = 1.81; 95% CI, 1.48–2.21) but not in second- or first-
trimester quitters compared with nonsmokers. One study 
found a significant difference across smoking categories 
overall, but women who quit during pregnancy were not 
compared directly with other groups (Suzuki et al. 2016). 
In another study using a large sample of 900,000 births, 
significant reductions in the risk of preterm delivery were 
found among first- and second-trimester quitters com-
pared with continuing smokers (aOR  =  0.69; 95%  CI, 
0.65–0.74 and aOR = 0.87; 95% CI, 0.79–0.96, respectively) 
A Report of the Surgeon General
372  Chapter 4
Table 4.34 Studies on smoking cessation and preterm delivery
Study Design/population Exposure groups/how determined Outcome definition Findings Comments
Hrubá and 
Kachlik 
(2000)
• Retrospective, clinic-
based study
• Term, singleton 
deliveries
• n = 1,147
• Years of data collection 
not reported
• Czech Republic
• Nonsmoker: Never smoked
• Quit smoking: Smoked but quit before 
pregnancy or during first trimester
• Continued smoking: Smoked throughout 
pregnancy either daily or occasionally
• Smoking status based on self-reports 
from interviews conducted shortly 
after delivery
• Findings stratified by exposure to 
environmental tobacco smoke
≤36 weeks’ gestation Percentage preterm delivery:
• Continued smoking: 10.0%
• No exposure to environmental tobacco 
smoke:
 – Nonsmoker: 6.5% 
 – Quit smoking: 6.3%
 – Continued smoking: 10.0%
• Exposure to environmental tobacco smoke:
 – Nonsmoker: 9.4%
 – Quit smoking: 4.8%
Results not adjusted for 
potential confounders
No statistical testing 
reported
Did not account for 
alcohol or substance use
Vogazianos 
et al. (2005)
• Population-based, 
retrospective 
cohort study
• n = 59,014
• 1990–1996
• Cyprus
• Nonsmokers: Did not smoke before or 
during pregnancy
• Quit smoking: Smoked before but not 
during pregnancy
• Continued smoking: Smoked before 
and during pregnancy
• Not clear how many women quit 
smoking during pregnancy and how 
they were categorized
• Smoking status based on maternal 
self-reports obtained during 
physician interviews 
<38 weeks’ gestation OR for preterm delivery (95% CI):
• Nonsmokers (reference)
• Quit smoking: 1.02 (0.73–1.43)
• Continued smoking: 2.58 (2.05–3.25)
Results not adjusted for 
potential confounders
Did not account for 
alcohol or substance use
Abrevaya 
et al. (2008)
• Population-based, 
retrospective cohort 
study using linked 
certificates of live 
births in Michigan
• First and second 
pregnancies in which 
women smoked during 
the first pregnancy
• n = 14,731
• n = 8,044
• 1989–2004
• Michigan
• Quit smoking between pregnancies: 
Smoked during first pregnancy but not 
during second pregnancy
• Continued smoking: Smoked during first 
and second pregnancies
• Smoking status based on smoking history 
collected from certificates of live births, 
which used one question on tobacco use 
during pregnancy (yes/no)
<37 weeks’ gestation Adjusted OR for preterm delivery (95% CI):
• Quit smoking between pregnancies 
(reference)
• Continued smoking:
 – 18–24 years of age: 1.04 (0.89–1.22)
 – 25–30 years of age: 1.12 (0.89–1.40)
Results adjusted for 
maternal race, education, 
income, population, 
interpregnancy interval, 
and year of birth; trimester 
of first prenatal visit; 
number of prenatal visits; 
presence of father’s name 
on birth certificate; 
and first-birth value 
of the outcome
Did not account for 
alcohol or substance use
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Table 4.34 Continued
Study Design/population Exposure groups/how determined Outcome definition Findings Comments
Mohsin and 
Jalaludin 
(2008)
• Population-based 
retrospective 
cohort study
• Consecutive 
singleton births
• n = 244,480
• 1994–2004
• Australia
• Nonsmoker: Did not smoke during 
either pregnancy
• Quit smoking between pregnancies: 
Smoked during first pregnancy but not 
during second pregnancy
• Resumed smoking between pregnancies: 
Smoked during second pregnancy but 
not during first pregnancy
• Continued smoking: Smoked during 
first and second pregnancies
• Smoking status based on self-reports
<37 weeks’ gestation Adjusted OR for preterm delivery at second 
pregnancy (95% CI):
• Nonsmoker (reference)
• Quit smoking between pregnancies: 
1.41 (1.29–1.55)
• Resumed smoking between pregnancies: 
1.43 (1.37–1.60)
• Continued smoking: 1.89 (1.8–1.99)
Results adjusted for 
interpregnancy interval 
and other factors not 
explicitly reported
McCowan 
et al. (2009)
• Prospective cohort 
study designed to 
develop screening 
tests for pregnancy 
complications
• 2004–2007
• n = 2,504
• New Zealand 
and Australia
• Nonsmokers (did not smoke during 
pregnancy)
• Quit smoking: Smoked during pregnancy 
but quit before the study interview 
(~15 weeks’ gestation)
• Continued smoking: Smoking at time of 
study interview (~15 weeks’ gestation)
• Smoking status based on self-reports 
ascertained at 15 weeks’ gestation
Spontaneous preterm 
labor or preterm, 
premature rupture of 
membranes resulting 
in a preterm delivery at 
<37 weeks’ gestation
Adjusted OR for spontaneous preterm 
delivery (95% CI): 
• Nonsmokers (reference)
• Quit smoking: 1.03 (0.49–2.18)
• Continued smoking: 3.21 (1.42–7.23)
Results adjusted for 
demographic factors 
(maternal age, ethnicity, 
marital status, employment 
status, and BMI) and clinical 
risk factors (bleeding during 
pregnancy; folic acid use; 
multivitamin use; alcohol 
use at 15 weeks’ gestation; 
and scores for depression, 
stress, or anxiety)
Did not account for 
substance use
Polakowski 
et al. (2009)
• Population-based 
retrospective 
cohort study
• Singleton deliveries, 
≥28 weeks’ gestation
• n = 915,441
• 2005
• United States (11 states)
• Nonsmoker: Smoked zero cigarettes in 
all trimesters of pregnancy
• Quit first trimester: Smoked during first 
trimester but not during second and 
third trimesters
• Quit second trimester: Smoked during 
second trimester but not during third 
trimester
• Continued smoking: Smoked during all 
three trimesters
• Excluded women who did not fit in any 
of these categories
• Smoking status based on certificates of 
live births
Preterm delivery 
28–≤37 weeks’ 
gestation based on 
last menstrual period, 
unless implausible 
(then based on 
clinical estimate)
Adjusted OR for preterm delivery (95% CI):
• Preterm, non-SGA:
 – Continued smoking (reference)
 – Nonsmokers: 0.72 (0.70–0.74)
 – Quit first trimester: 0.69 (0.65–0.74)
 – Quit second trimester 0.87 (0.79–0.96)
• Preterm, SGA:
 – Continued smoking (reference)
 – Nonsmokers: 0.45 (0.42–0.47)
 – Quit first trimester: 0.47 (0.40–0.55)
 – Quit second trimester: 0.88 (0.72–1.08)
Results adjusted for 
maternal age, race/
ethnicity, marital status, 
education, late entry into 
prenatal care, and history 
of preterm delivery
Did not account for 
alcohol or substance use
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Anderka et al. 
(2010)
• Population-based, case-
control study
• n = 4,667
• 1997–2003
• United States
• Nonsmoker: Did not smoke during 
3 months before conception or during 
any trimester of pregnancy
• Quit smoking: Smoked preconception 
but not during any trimester of 
pregnancy, smoked in first trimester 
but not in second or third trimesters, 
or smoked in second trimester but not 
in third trimester
• Continued smoking: Smoked during 
all three trimesters
• Smoking status based on maternal 
self-reports obtained during interviews 
conducted 6 weeks–24 months 
postpartum
<37 weeks’ gestation Percentage and adjusted OR for preterm 
delivery (95% CI):
• Nonsmoker 7.6% (reference)
• Quit smoking: 8.0%, adjusted OR 
not reported
• Continued smoking: 11.5%, 1.59 
(1.13–2.25)
Results adjusted for 
maternal age, race/
ethnicity, education, 
and birthplace
Did not account for 
alcohol or substance use
Vardavas 
et al. (2010)
• Population-based, 
prospective cohort study
• Singleton pregnancies
• 2007–2008
• n = 1,400
• Greece
• Nonsmokers: Did not smoke during 
3 months before pregnancy
• Quit smoking: Smoked within 3 months 
before pregnancy and/or during 
the first 12 weeks of pregnancy but 
quit by the time of study interview 
(~12 weeks’ gestation)
• Continued smoking: Smoked during 
3 months before pregnancy, during 
first 12 weeks of pregnancy, and 
at the time of the study interview 
(~12 weeks’ gestation)
• Smoking status based on self-
reports ascertained at approximately 
12 weeks’ gestation
<37 weeks’ gestation OR for preterm delivery (95% CI):
• Nonsmokers (reference)
• Quit smoking: 
 – Unadjusted: 0.86 (0.54–1.38)
 – Adjusted: 0.90 (0.56–1.46)
• Continued smoking:
 – Unadjusted: 1.22 (0.82–1.83)
 – Adjusted: 1.28 (0.84–1.94)
Results adjusted for 
origin, parity, maternal 
education and age, and 
sex of the infant
Did not account for 
alcohol or substance use
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Bakker et al. 
(2011)
• Population-based 
cohort study
• 2001–2005
• n = 5,389
• Netherlands
• Nonsmokers: Did not smoke during 
pregnancy
• Quit smoking, first trimester: Smoked 
only during first trimester (combined 
with “quit smoking, second and third 
trimesters” for analysis)
• Quit smoking, second trimester: Smoked 
during second trimester (combined with 
“quit smoking, first and third trimesters” 
for analysis)
• Continued smoking: Smoked during third 
trimester (combined with “quit smoking, 
first and second trimesters” for analysis)
• Smoking status based on self-reports 
obtained during each trimester
<37 weeks’ gestation Adjusted OR for preterm delivery (95% CI):
• Nonsmoker (reference)
• Quit smoking, first trimester: 
0.66 (0.37−1.17)
• Continued smoking: 1.25 (0.88–1.78)
Results adjusted for 
maternal age, BMI, 
height, education, 
ethnicity, parity, alcohol 
consumption, caffeine 
intake, folic acid intake, 
and stress; gestational 
age at birth; and sex of 
the fetus
Did not account for 
substance use
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Baba et al. 
(2012)
• Population-based 
retrospective cohort 
study using the Swedish 
Medical Birth Register
• n = 776,836
• 1999–2009 
• Sweden 
• Nonsmoker: Did not smoke during 
3 months before pregnancy or before 
registration for antenatal care
• Quit smoking: Smoked during 3 months 
before pregnancy but quit by registration 
for antenatal care
• Continued smoking: Smoking at 
registration for antenatal care
• Smoking status based on self-reports 
assessed at first antenatal visit (typically 
≤15 weeks’ gestation) 
• Overall preterm 
delivery: <37 weeks’ 
gestation
• Very preterm 
delivery: <32 weeks’ 
gestation
• Moderate preterm 
delivery: 32–36 
weeks’ gestation
• Spontaneous 
preterm delivery: 
Spontaneous onset 
of labor and preterm 
premature rupture 
of the membranes
• Induced preterm 
delivery: Vaginally 
induced onset of 
labor and cesarean 
delivery before the 
onset of labor
OR for preterm delivery (95% CI):
• Nonsmoker (reference)
• Quit smoking:
 – Unadjusted:
	| <37 weeks: 1.02 (0.99–1.06)
	| <32 weeks: 1.04 (0.94–1.15)
	|  32–36 weeks: 1.02 (0.98–1.06)
 – Adjusted:
	| <37 weeks: 0.90 (0.87–0.94)
	| <32 weeks: 0.91 (0.82–1.01)
	| 32–36 weeks: 0.90 (0.86–0.94)
 – Spontaneous preterm delivery: 0.92 
(0.88–0.96)
 – Induced preterm delivery: 0.86 (0.79–0.92)
• Continued smoking: 
 – Unadjusted:
	| <37 weeks: 1.43 (1.38–1.48)
	| <32 weeks: 1.84 (1.69–2.00)
	| 32–36 weeks: 1.37 (1.32–1.41)
 – Adjusted:
	| <37 weeks: 1.30 (1.25–1.36)
	| <32 weeks: 1.68 (1.52–1.84)
	| 32–36 weeks: 1.25 (1.20–1.30)
 – Spontaneous preterm delivery: 1.32 
(1.26–1.38)
 – Induced preterm delivery: 1.20 (1.12–1.29)
Results adjusted for BMI in 
early pregnancy, maternal 
age, parity, education, 
and cohabitation
Did not account for 
alcohol or substance use
Bickerstaff 
et al. (2012)
• Retrospective 
cohort study
• 1997–2006
• n = 30,524
• Australia
• Nonsmoker: Never smoked or quit 
>12 months before booking
• Quit smoking: Smoked during 12 months 
before booking but quit before booking
• Continued smoking: Currently smoking 
at booking
• Smoking status based on routinely 
collected clinical data
<37 weeks’ gestation Percentage with preterm delivery:
• Nonsmoker: 9.7%
• Quit smoking: 12.7%
• Continued smoking: 12.9%
Adjusted OR for preterm delivery (95% CI):
• Continued smoking vs. nonsmoker: 
1.42 (1.28–1.59)
• Quit smoking vs. continued smoking: 
0.92 (0.69–1.23)
Results adjusted for 
plurality, previous 
pregnancy complications, 
parity, and ethnicity
Did not account for 
alcohol or substance use
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Erickson 
and Arbour 
(2012)
• Population-based, 
retrospective cohort 
study using the 
British Columbia 
Perinatal Database 
Registry
• Singleton deliveries
• n = 233,891
• 2001–2006
• British Columbia, 
Canada
• Nonsmoker: Never smoked
• Quit smoking: Former smoker (time of 
cessation in former smokers with respect 
to pregnancy was not available)
• Continued smoking: Current smoker at 
time of smoking status assessment:
 – Light: 1–4 cigarettes/day
 – Moderate: 5–9 cigarettes/day
 – Heavy: ≥10 cigarettes/day
• Smoking history based on self-reports 
typically ascertained at first prenatal visit
20–36 completed 
weeks’ gestation
Adjusted OR for preterm delivery (95% CI):
• Nonsmoker (reference)
• Quit smoking: 1.18 (1.08–1.28)
• Continued smoking: 
 – 1–4 cigarettes/day: 1.25 (1.13–1.38)
 – 5–9 cigarettes/day: 1.24 (1.10–1.39)
 – ≥10 cigarettes/day: 1.39 (1.28–1.52)
Results adjusted for 
maternal age, parity, 
prenatal care visits, 
diabetes, hypertension, 
pre-pregnancy weight, 
presence of a partner, 
alcohol and drug use, 
and sex of the infant
Batech et al. 
(2013)
• Population-based, 
retrospective 
cohort study using 
certificates of live 
births in California
• n = 65,228
• 2007–2008
• California
• Nonsmoker: Did not smoke during 
3 months before pregnancy
• Quit smoking: Smoked during 3 months 
before pregnancy but not during any 
trimester of pregnancy
• Continued smoking: Smoked during 
any trimester of pregnancy
• Smoking history obtained from the 
state’s certificate of live births
<37 weeks’ gestation Adjusted OR for preterm delivery (95% CI):
• Continued smoking (reference)
• Nonsmokers:
 – 2007: 0.68 (0.58–0.79)
 – 2008: 0.68 (0.58–0.80)
• Quit smoking:
 – 2007: 0.69 (0.51–0.92)
 – 2008: 0.69 (0.51–0.93)
Results adjusted for age 
and various other factors 
in multiple models, 
including ethnicity; 
education; enrollment 
in the Women, Infants, 
and Children program; 
trimester of entry into 
prenatal care; and primary 
source of payment
Miyake et al. 
(2013)
• Retrospective 
cohort study
• n = 1,565
• 2007–2008
• Japan
• Nonsmoker: Did not smoke during 
pregnancy
• Quit smoking, first trimester: Smoked 
during first trimester only
• Quit smoking, second or third trimester: 
Smoked during second or third trimester 
but not throughout pregnancy
• Continued smoking: Smoked throughout 
pregnancy
• Smoking status for each trimester based 
on self-reports obtained after delivery
<37 weeks’ gestation Adjusted OR for preterm delivery (95% CI):
• Nonsmoker (reference)
• Quit smoking, first trimester: 
2.51 (0.90–5.98)
• Quit smoking, second or third trimester: 
3.14 (0.71–9.80)
• Continued smoking: 2.06 (0.47–6.34)
Results adjusted for 
maternal age, residence, 
education, employment, 
alcohol consumption, and 
BMI; family structure; 
gestational age at birth; 
and sex of the infant
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Murphy et al. 
(2013)
• Prospective cohort study
• Singleton pregnancies
• n = 1,216
• 2010–2011
• Dublin, Ireland
• Nonsmoker: Not defined
• Quit smoking: Smoked during 6 months 
before pregnancy but quit by first 
prenatal visit
• Continued smoking: Smoked during 
6 months before pregnancy, and 
smoking at first prenatal visit and 
during third trimester
• Smoking status based on self-reports 
obtained at enrollment and during 
third trimester
<37 weeks’ gestation Crude and adjusted OR for preterm delivery 
(95% CI):
• Nonsmokers (reference)
• Quit smoking:
 – Crude: 1.14 (0.51–2.56)
 – Adjusted: 1.68 (0.51–5.63)
• Continued smoking:
 – Crude: 1.25 (0.51–3.10)
 – Adjusted: 1.09 (0.86–1.75)
Birth weight adjusted 
for maternal age, BMI, 
nationality, unplanned 
pregnancy, private 
healthcare, alcohol use, 
and illicit drug use
Meghea et al. 
(2014)
• Prospective cohort study
• n = 474
• 2008–2009
• Romania
• Nonsmokers: Not smoking when 
learned of pregnancy
• Quit smoking: Quit upon learning 
of pregnancy
• Continued smoking: Smoking at time 
of study interview (gestational age 
not reported)
• Smoking history based on self-
reports obtained at study enrollment 
(gestational age not reported)
<37 weeks’ gestation Adjusted OR (95% CI):
• Nonsmokers (reference)
• Quit smoking: 1.41 (0.59–3.37)
• Continued smoking: 1.29 (0.46–3.67)
Results adjusted for 
stress, depressive 
symptoms, maternal age 
>35 years old, education, 
rural residence, marital 
status, and nulliparity
Did not account for 
alcohol or substance use
Räisänen 
et al. (2014)
• Population-based 
retrospective cohort 
using Finnish Medical 
Birth Register
• Singleton deliveries, 
live or stillborn after 
22 weeks’ gestation
• n = 1,164,953
• 1991–2010
• Finland
• Nonsmokers: Not further defined
• Quit smoking: Quit smoking during 
first trimester
• Continued smoking: Smoked after 
first trimester
• Smoking history based on self-reports 
ascertained from the Finnish Medical 
Birth Register
<37 weeks’ gestation Odds ratio for preterm delivery (95% CI):
• Nonsmokers (reference)
• Quit smoking:
 – Unadjusted: 1.04 (0.98–1.10)
 – Adjusted: 1.01 (0.95–1.07)
• Continuing smokers:
 – Unadjusted: 1.35 (1.31–1.38)
 – Adjusted: 1.39 (1.36–1.43)
Results adjusted for 
maternal age, parity, 
socioeconomic status, 
and sex of the infant
Did not account for 
alcohol or substance use
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Bailey (2015) • Randomized clinical 
trial of smoking 
cessation intervention
• 2008–2012
• n = 1,486
• Tennessee
• Quit smoking: Smoked at first prenatal 
visit but quit by third trimester
• Continued smoking: Smoked at first 
prenatal visit and still smoking during 
third trimester
• Smoking history based on self-reports 
obtained at first prenatal visit
• Quit status ascertained during third 
trimester by exhaled CO and urine 
cotinine and by self-report at delivery
Preterm delivery 
not defined
Percentage preterm delivery (95% CI):
• Quit smoking: 9.8%
• Continued smoking: 13.8%
• p = 0.089
Randomized cessation trial 
and thus no comparison 
group of never smokers
Results adjusted for 
maternal age, education, 
marital status, insurance 
status, and marijuana use
Examined maternal race, 
previous pregnancies, 
live deliveries, and alcohol 
use, but they were not 
significant in the model
Smith et al. 
(2015)
• Population-based case-
cohort study
• n = 1,887
• 2009–2010
• United Kingdom
• Nonsmoker: Did not smoke during 
preconception or early (1–13 weeks) or 
late (14–32 weeks) during pregnancy
• Quit smoking before pregnancy: Smoked 
preconception but not during early or 
late pregnancy
• Quit smoking, first trimester: Smoked 
during early pregnancy but not during 
late pregnancy
• Continued smoking: Smoked during 
late pregnancy
• Smoking status based on self-reports 
obtained from maternal interview 
conducted shortly after delivery
32–36 weeks’ gestation Adjusted RR for preterm delivery (95% CI):
• Nonsmokers (reference)
• Quit smoking before pregnancy: 
0.93 (0.72–1.20)
• Quit smoking, first trimester: 
1.12 (0.76–1.66)
• Continued smoking: 1.38 (1.04–1.84)
Results adjusted for 
maternal age, ethnicity, 
BMI, education level, 
and lifestyle factors 
(recreational drug and 
alcohol use, dietary 
practices, and folic 
acid supplements)
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Yan and 
Groothuis 
(2015)
• Population-based 
cohort study
• Singleton pregnancies
• Excluded women with 
chronic diseases
• n = 11,131
• 2000–2001
• United Kingdom
• Nonsmokers: Not defined
• Quit smoking before pregnancy: 
Timing of cessation not specified
• Quit smoking during pregnancy 
(month of cessation noted)
• Continued smoking: Quit during 
third trimester or did not quit
• Smoking history based on self-
reports ascertained when infants were 
9 months old
<37 weeks’ gestation, 
based on gestational 
age estimated by 
research team
• Difference in percentage of preterm 
delivery:
• Nonsmokers (reference)
• Quit smoking before pregnancy: +0.8%
• Quit smoking, first trimester: +0.1%, 
p = 0.8
• Quit smoking, second trimester: +2.8%, 
p = 0.08
• Continued smoking: +2.9%, p <0.01
Adjusted for birth year/
quarter of infant and 
maternal weight, height, 
income, initiation of 
prenatal care, alcohol 
use, employment status, 
home satisfaction, religion 
affiliation, and racist or 
religion-based insults in 
living area
Did not account for 
substance use
Dahlin et al. 
(2016)
• Population-based, 
retrospective cohort 
study using the Swedish 
Medical Birth Register
• n = 1,371,274
• 1999–2012
• Sweden
• Nonsmokers: No antenatal tobacco use 
• Quit smoking: Smoked during 3 months 
before pregnancy but quit by the first 
antenatal visit
• Continued smoking: Smoked ≥1 cigarette/
day at the time of the first antenatal visit
• Smoking status based on self-reports 
derived from the Swedish Medical 
Birth Register
• Extreme preterm 
delivery: <28 weeks’ 
gestation
• Very preterm 
delivery: 28–31 
weeks’ gestation
• Moderate preterm 
delivery: 32–36 
weeks’ gestation
OR for preterm delivery (95% CI):
• Nonsmokers (reference)
• Quit smoking:
 – Unadjusted preterm delivery:
	| Extreme: 1.12 (0.97–1.29)
	| Very: 1.03 (0.93–1.13)
	| Moderate: 1.05 (1.02–1.08)
 – Adjusted preterm delivery:
	| Extreme: 1.02 (0.88–1.18)
	| Very: 0.92 (0.83–1.02)
	| Moderate: 0.94 (0.91–1.01)
• Continued smoking:
 – Unadjusted preterm delivery:
	| Extreme: 1.87 (1.64–2.12)
	| Very: 1.68 (1.54–1.83)
	| Moderate: 1.39 (1.34–1.43)
 – Adjusted preterm delivery:
	| Extreme: 1.74 (1.51–1.99)
	| Very: 1.52 (1.38–1.67)
	| Moderate: 1.27 (1.23–1.31) 
Results adjusted for 
maternal age, parity, 
cohabitation with 
father, country of birth, 
education, and BMI
Did not account for 
alcohol or substance use
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Moore et al. 
(2016)
(continues on 
next page)
• Population-based, 
retrospective cohort 
using certificates of 
live births in Ohio
• Singleton births without 
congenital anomalies
• n = 913,757
• 2006–2012
• Ohio
• Nonsmoker: Did not smoke during 
3 months before pregnancy
• Quit smoking before pregnancy: Smoked 
during 3 months before pregnancy but 
not during first trimester
• Quit smoking, first trimester: Smoked 
during first trimester but not during 
second and third trimesters
• Quit smoking, second trimester: Smoked 
during second trimester but not during 
third trimester
• Continued smoking: Smoked during all 
three trimesters
• Smoking status obtained from Ohio 
certificates of live birth
• Overall preterm 
delivery: <37 weeks’ 
gestation based 
on clinician’s 
best estimate of 
gestational age
• Extreme preterm 
delivery: 20–27 weeks’ 
gestation
• Preterm delivery: 
28–36 weeks’ 
gestation
• Spontaneous 
preterm delivery: 
Not medically 
indicated
• Indicated preterm 
delivery: Births 
complicated by 
intrauterine 
growth restriction, 
preeclampsia, or 
eclampsia following 
induction of labor 
Adjusted OR for preterm delivery (95% CI):
• Overall:
 – Nonsmoker (reference)
 – Quit smoking before pregnancy: 
0.91 (0.88–0.94)
 – Quit smoking, first trimester: 
1.02 (0.98–1.07)
 – Quit smoking, second trimester: 
1.70 (1.60–1.80)
 – Continued smoking: 1.21 (1.19–1.24)
• Extreme preterm:
 – Nonsmoker (reference)
 – Quit smoking before pregnancy: 
0.87 (0.77–0.98)
 – Quit smoking, first trimester: 
1.20 (1.03–1.40)
 – Quit smoking, second trimester: 
Not applicable
 – Continued smoking: 0.90 (0.83–0.97)
• Preterm:
 – Nonsmoker (reference)
 – Quit smoking before pregnancy: 
0.91 (0.88–0.94)
 – Quit smoking, first trimester: 
1.01 (0.96–1.05)
 – Quit smoking, second trimester: 
1.46 (1.37−1.55)
 – Continued smoking: 1.24 (1.21–1.26)
Results adjusted for 
maternal race, education, 
age, Medicaid, marital 
status, and parity
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Moore et al. 
(2016)
(continues on 
next page)
— — — Indicated preterm delivery (95% CI):
• Overall:
 – Nonsmoker (reference)
 – Quit smoking before pregnancy: 
0.92 (0.87–0.97)
 – Quit smoking, first trimester: 
1.01 (0.94–1.09)
 – Quit smoking, second trimester: 
1.78 (1.62–1.96)
 – Continued smoking: 1.22 (1.18–1.26)
• Extreme preterm:
 – Nonsmoker (reference)
 – Quit smoking before pregnancy: 
0.85 (0.78–0.93)
 – Quit smoking, first trimester: 
0.93 (0.82–1.05)
 – Quit smoking, second trimester: 
Not applicable
 – Continued smoking: 0.73 (0.69–0.78)
• Preterm:
 – Nonsmoker (reference)
 – Quit smoking before pregnancy: 
0.91 (0.87–0.96)
 – Quit smoking, first trimester: 
0.99 (0.92–1.07)
 – Quit smoking, second trimester: 
1.66 (1.51–1.83)
 – Continued smoking: 1.18 (1.14–1.22)
—
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Moore et al. 
(2016)
— — — Spontaneous preterm delivery (95% CI):
• Overall:
 – Nonsmoker (reference)
 – Quit smoking before pregnancy: 
0.90 (0.87–0.93)
 – Quit smoking, first trimester: 
1.03 (0.97–1.08)
 – Quit smoking, second trimester: 
1.65 (1.54–1.77)
 – Continued smoking: 1.20 (1.17–1.22)
• Extreme preterm:
 – Nonsmoker (reference)
 – Quit smoking before pregnancy: 
0.88 (0.77–1.02)
 – Quit smoking, first trimester: 
1.20 (1.00–1.43)
 – Quit smoking, second trimester: 
Not applicable
 – Continued smoking: 0.93 (0.84–1.02)
• Preterm:
 – Nonsmoker (reference)
 – Quit smoking before pregnancy: 
0.90 (0.87–0.94)
 – Quit smoking, first trimester: 
1.02 (0.96–1.08)
 – Quit smoking, second trimester: 
1.37 (1.26–1.48)
 – Continued smoking: 1.25 (1.22–1.28)
—
Suzuki et al. 
(2016)
• Population-based, 
cohort study
• Singleton pregnancies
• n = 7734
• 2011–2014
• Japan
• Nonsmokers: Never smoked
• Quit smoking before pregnancy: 
Not further defined
• Quit smoking during early pregnancy: 
Not further defined
• Continued smoking: Currently 
smoking at time study questionnaire 
was administered
• Smoking status based on self-reports 
collected during second trimester
Preterm delivery 
not defined
Percentage preterm delivery:
• Nonsmoker: 5.0%
• Quit smoking before pregnancy: 5.8%
• Quit smoking during early pregnancy: 5.6%
• Continued smoking: 8.9%
• Chi-square test p = 0.008
Results not adjusted for 
potential confounders
Did not account for 
alcohol or substance use
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Wallace et al. 
(2017)
• Population-based, 
retrospective cohort 
study using certificates 
of live births in Ohio
• Singleton pregnancies
• Excluded congenital 
malformations
• All participants had 
at least one previous 
preterm delivery
• 2006–2012
• n = 36,432
• Ohio
• Nonsmoker: Did not smoke during 
3 months before pregnancy
• Quit smoking by first trimester: Smoked 
during 3 months before pregnancy but 
not during first trimester
• Quit by second trimester: Smoked 
during first trimester but not during 
second or third trimesters
• Quit by third trimester: Smoked 
during second trimester but not during 
third trimester
• Continued smoking: Smoked during 
all three trimesters
• Smoking status obtained from Ohio 
certificates of live birth
<37 weeks’ gestation Adjusted OR for preterm delivery (95% CI):
• Nonsmokers (reference)
• Quit smoking by first trimester: 
0.97 (0.86–1.09)
• Quit smoking by second trimester: 
1.10 (0.93–1.29)
• Quit smoking by third trimester: 
1.81 (1.48–2.21)
• Continued smoking: 1.14 (1.07–1.22)
Results adjusted for 
maternal race, marital 
status, and Medicaid 
enrollment
Did not account for 
alcohol or substance use
Tong et al. 
(2017)
• Population-based, 
retrospective 
cohort study
• n = 88,933
• 2009–2011
• United States
• Nonsmoker: Did not smoke during 
past 2 years and did not smoke during 
3 months before pregnancy
• Quit smoking: Smoked during 3 months 
before pregnancy but not during last 
3 months of pregnancy
• Continued smoking, nondaily: Smoked 
during 3 months before pregnancy and 
smoked <1 cigarette/day in last 3 months 
of pregnancy
• Continued smoking, daily: Smoked 
during 3 months before pregnancy and 
smoked ≥1 cigarette/day during last 
3 months of pregnancy
<37 weeks’ gestation 
based on clinical 
estimate of gestation 
from birth certificates
Crude and adjusted prevalence ratio for 
preterm delivery (95% CI):
• Nonsmoker (reference)
• Quit smoking:
 – Crude: 1.0 (0.9–1.1)
 – Adjusted: 1.0 (0.9–1.1)
• Continued smoking, nondaily:
 – Crude: 1.0 (0.8–1.3)
 – Adjusted: 1.0 (0.8–1.2)
• Continued smoking, daily:
 – Crude 1.3: (1.2–1.4)
 – Adjusted: 1.3 (1.2–1.4)
Prevalence ratios adjusted 
for maternal age, parity, 
education, marital status, 
BMI, trimester of entry into 
prenatal care, and alcohol 
use during pregnancy
Did not account for 
substance use
Notes: BMI = body mass index; CI = confidence interval; CO = carbon monoxide; OR = odds ratio; RR = risk ratio; SGA = small for gestational age.
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(Polakowski et al. 2009), and in a smaller study, no sig-
nificant difference was found between quitters and con-
tinuing smokers (Bailey 2015). Three studies were not 
sufficiently large to examine cessation during pregnancy, 
and the CIs were wide (McCowan et al. 2009; Miyake et al. 
2013; Meghea et al. 2014). 
In one of the 23  studies examining individual 
pregnancies, the timing of cessation was not described 
(Erickson and Arbour 2012); in that study, a modest but 
significant increase in risk was found among quitters com-
pared with nonsmokers (aOR = 1.18; 95% CI, 1.08–1.28). 
Only 1 of the 23 studies included biochemical validation of 
smoking status (Bailey 2015); that study was a randomized 
clinical trial of a smoking cessation intervention (n = 1,486 
who received the intervention vs. 461 who received usual 
care) in which no statistically significant difference was 
found in the risk of preterm delivery among women in 
the intervention group between women who quit smoking 
during pregnancy and continuing smokers (13.8% among 
continuing smokers and 9.8% among quitters [p = 0.09]).
Of the two studies that examined cessation across 
pregnancies, one found an increased risk of preterm 
delivery in the second pregnancy in women who quit 
between pregnancies versus those who did not smoke 
in either (aOR  =  1.41; 95%  CI, 1.29–1.55) (Mohsin and 
Jalaludin 2008), and the other found no difference in the 
risk of preterm delivery during the second pregnancy for 
women who quit between pregnancies compared with 
those who smoked during both pregnancies (Abrevaya 
2008). As was previously discussed, examining outcomes 
across pregnancies can be limited by an oversimplifica-
tion of exposure categories, but this design can reduce the 
contributions of confounding from environmental and 
genetic factors. If smoking cessation during pregnancy 
affects the risk of preterm delivery, then the effect could 
be missed using this method.
Summary of the Evidence. Since the 2004 Surgeon 
General’s report found a causal relationship between 
maternal smoking and preterm delivery (gestational age 
<37  weeks) and shorter gestational duration (USDHHS 
2004), numerous studies have assessed the relationships 
between smoking cessation before and/or during preg-
nancy and preterm delivery, and most have adjusted for 
multiple confounders. Most of these studies compared the 
risk of preterm delivery in quitters to that in nonsmokers, 
while fewer studies directly compared the risk in quitters 
to that in continuing smokers. The majority of studies 
that compared quitters and nonsmokers found no differ-
ence in risk of preterm delivery, and studies that compared 
quitters and continuing smokers reported mixed results 
(all  reported lower risk in quitters compared with con-
tinuing smokers overall, but not all findings were signifi-
cant). There were limited data with which to assess the role 
of timing of cessation for risk of preterm delivery, but the 
largest studies that examined trimester-specific cessation 
reported that earlier cessation produces greater benefits 
for risk of preterm delivery than later cessation. The evi-
dence is suggestive but not sufficient to infer that the risk 
of preterm delivery in women who quit smoking before or 
during early pregnancy does not differ from that of non-
smokers. The evidence is suggestive but not sufficient to 
infer that women who quit smoking before conception or 
during early pregnancy have a reduced risk of preterm 
delivery compared with women who continue to smoke.
Stillbirth, Perinatal Mortality, 
and Infant Mortality
Stillbirth (typically defined as a fetal death after 
28  weeks’ gestation), perinatal mortality (stillbirths and 
deaths in the first week of life), and infant mortality (neo-
natal [death in the first month of life] and postnatal [death 
from 1 month to 1 year of life]) have all been associated 
with prenatal exposure to tobacco in previous Surgeon 
General’s reports. The 1990 Surgeon General’s report on 
smoking cessation presented evidence that women who 
quit smoking are at lower risk of perinatal mortality rel-
ative to continuing smokers, although the studies were 
too few to be conclusive (USDHHS 1990). No conclusions 
were drawn about the relationship between smoking ces-
sation and infant mortality. The 2004 and 2014 Surgeon 
General’s reports concluded that infants of smokers are at 
higher risk of stillbirth, perinatal mortality, and neonatal 
mortality than infants of nonsmokers (USDHHS 2004, 
2014). Overall, these reports did not review the effects 
of cessation on these risks. The 2004 Surgeon General’s 
report also found that smoking during or after pregnancy 
increases the risk of sudden infant death syndrome, but 
this outcome was not reviewed in this report due to the 
lack of studies directly assessing the consequences of 
smoking cessation on sudden infant death syndrome 
(USDHHS 2004).
Stillbirth, perinatal, and infant mortality are mul-
tifactorial in etiology, and many of their causal factors 
are also causally associated with smoking. For example, 
smoking is causally associated with preterm delivery, 
PPROM, placenta previa, and placental abruption—all 
of which contribute to perinatal and neonatal mortality; 
and preterm delivery accounts for more than one-third of 
infant deaths (Matthews et al. 2015). Therefore, the effects 
of cessation on those pathways would likely translate 
into beneficial effects on more distal outcomes. In addi-
tion, approximately half of perinatal deaths in the United 
States are stillbirths, and half are deaths in the first week 
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of life. Therefore, effects of smoking cessation on stillbirth 
or deaths in the first week of life likely also affect rates 
of perinatal mortality. The relationship between smoking 
and fetal growth was explored in depth in the 2014 
Surgeon General’s report (USDHHS 2014). Briefly, when 
the distributions of birth weight for the infants of smokers 
and their corresponding mortality rates are examined, 
infants of smokers have higher mortality than those of 
nonsmokers at every birth weight when each population is 
adjusted to its own z-scale for birth weight (Wilcox 2001). 
Thus, maternal smoking affects infant mortality indepen-
dently of its effects on birth weight. Infants of nonsmokers 
are less likely to be born with low birth weight than those 
of smokers, but when they are, the underlying etiologies 
are associated with higher mortality (Wilcox 2001).
Stillbirth
Five studies published after 2000 were identified 
that examined smoking cessation and stillbirth; four 
examined cessation with respect to individual pregnancies 
(Wisborg et al. 2001; Erickson and Arbour 2012; Räisänen 
et al. 2014; Bjørnholt et al. 2016), and one examined ces-
sation across two consecutive pregnancies (Högberg and 
Cnattingius 2007) (Table  4.35). All four studies exam-
ining cessation with respect to individual pregnancies 
included adjustment for at least some confounders, and 
two included adjustment for alcohol use or for alcohol 
and other substance use (Wisborg et  al. 2001; Erickson 
and Arbour 2012). Three studies relied on data from reg-
istries (Erickson and Arbour 2012; Räisänen et al. 2014; 
Bjørnholt et al. 2016), and none included biochemical val-
idation of cessation status. Two studies examined women 
who quit smoking during early pregnancy (Räisänen 
et  al. 2014; Bjørnholt et  al. 2016), and one (Wisborg 
et  al. 2001) assessed smoking status in late pregnancy 
(30 weeks). No studies examined both the effects of quit-
ting early versus quitting late in pregnancy. Three studies 
found no increased risk of stillbirth among women who 
quit smoking during early pregnancy compared with 
nonsmokers (Wisborg et  al. 2001; Räisänen et  al. 2014; 
Bjørnholt et  al. 2016), and one found increased risk in 
quitters but not in continuing smokers (Erickson and 
Arbour 2012). This last study, however, did not address 
the timing of cessation in quitters with respect to preg-
nancy, and smoking status was ascertained only at the 
first prenatal visit, making it possible that some former 
smokers had relapsed by the end of pregnancy compared 
with women who smoked in neither pregnancy. However, 
the risk of stillbirth in the second pregnancy was sig-
nificantly elevated among women who smoked during 
both pregnancies. 
In the study that examined cessation across con-
secutive pregnancies (Högberg and Cnattingius 2007), 
a large, population-based study using data from the 
Swedish Medical Birth Register, women who smoked 
during the first pregnancy but not during the second 
pregnancy did not have an increased risk of stillbirth in 
the second pregnancy. 
Summary of the Evidence
Since the 2004 and 2014 Surgeon General’s reports 
found that infants of smokers are at higher risk of stillbirth 
than infants of nonsmokers (USDHHS 2004, 2014), sev-
eral studies have examined the effects of smoking cessa-
tion on the risk of stillbirth, and findings have been mixed. 
These studies were limited by a lack of biochemical vali-
dation and inconsistent assessment of the timing of ces-
sation during preconception and gestation. Consequently, 
the evidence is inadequate to infer that smoking cessation 
during pregnancy reduces the risk of stillbirth compared 
with continued smoking. 
Perinatal Mortality
Two studies published after 2000 were identified 
that examined smoking cessation and perinatal mor-
tality (Bickerstaff et  al. 2012; Bailey 2015) (Table  4.36). 
Bickerstaff and colleagues (2012) examined risk in a retro-
spective cohort study of Australian women who had quit 
smoking in the year before pregnancy or after becoming 
pregnant but before the first antenatal visit, while Bailey 
(2015) examined risk in women participating in a ran-
domized smoking cessation trial in the state of Tennessee 
who smoked during the first trimester of pregnancy but 
had quit by the third trimester. These two studies relied on 
self-reported tobacco use and adjusted for several potential 
confounders. Both studies found a reduction in the risk of 
perinatal mortality in quitters compared with continuing 
smokers, with findings from Bailey (2015) reaching statis-
tical significance. Neither study compared quitters with 
nonsmokers.
Summary of the Evidence
Since the 2004 and 2014 Surgeon General’s reports 
concluded that children of smokers are at higher risk of 
perinatal mortality than children of nonsmokers (USDHHS 
2004, 2014), few studies have addressed smoking cessa-
tion and perinatal mortality. The evidence is inadequate to 
determine whether cessation before or during pregnancy 
reduces the risk of perinatal mortality compared with 
continued smoking.
Infant Mortality
Three studies published later than 2000 were iden-
tified that examined smoking cessation and infant death 
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Table 4.35 Studies on smoking cessation and stillbirth
Study Design/population Exposure groups/how determined Outcome definition Findings Comments
Wisborg et al. 
(2001)
• Prospective cohort study
• Singleton pregnancies
• n = 25,102
• 1989–1996
• Denmark
• Nonsmokers: Not smoking at time of 
either antenatal interview
• Quit smoking: Stopped smoking by 
second antenatal interview
• Continued smoking: Smoking ≥1 
cigarette/day at both antenatal interviews
• Smoking status ascertained from 
maternal interviews conducted before 
first antenatal visit (typically 16 weeks’ 
gestation) and before the 30-week 
antenatal visit 
Death of a fetus at 
or after 28 weeks’ 
gestation
Crude and adjusted OR for stillbirth 
(95% CI):
• Nonsmokers (reference)
• Quit smoking: 
 – Unadjusted: 0.9 (0.5–1.9)
 – Adjusted: 0.9 (0.5–1.9)
• Continued smoking: 
 – Unadjusted: 2.0 (1.4–2.9)
 – Adjusted: 1.9 (1.3–2.9)
Results adjusted for parity; 
maternal age, education, 
employment, caffeine and 
alcohol intake, weight, 
and height; and sex of 
the infant
Did not account for 
substance use
Högberg and 
Cnattingius 
(2007)
• Population-based 
cohort study
• First and second 
singleton births
• n = 526,691
• 1983–2001
• Sweden
• Nonsmokers: Not smoking daily at 
time of first antenatal visit
• Moderate smoker: Smoking 
1–9 cigarettes/day at time of first 
antenatal visit
• Heavy smoker: Smoking ≥10 cigarettes/
day at time of first antenatal visit
• Quit smoking: Not smoking in 
second pregnancy
• Smoking history ascertained from 
medical birth registry, which included 
smoking status collected at first antenatal 
visit (typically <15 weeks’ gestation) 
Fetal death after at 
least 28 completed 
weeks’ gestation
Crude and adjusted OR for stillbirth in 
second pregnancy (95% CI):
• Nonsmoker both pregnancies (reference)
• Nonsmoker/moderate smoker: 
 – Unadjusted: 0.85 (0.54–1.32)
 – Adjusted: 0.82 (0.52–1.30)
• Nonsmoker/heavy smoker:
 – Unadjusted: 1.09 (0.49–2.45)
 – Adjusted: 0.92 (0.38–2.22)
• Moderate smoker/nonsmoker (quit smoking):
 – Unadjusted: 1.17 (0.91–1.50)
 – Adjusted: 1.11 (0.85–1.44)
• Moderate smoker/moderate smoker: 
 – Unadjusted: 1.15 (0.92–1.43)
 – Adjusted: 1.16 (0.92–1.46)
• Moderate smoker/heavy smoker: 
 – Unadjusted: 1.64 (1.21–2.23)
 – Adjusted: 1.56 (1.13–2.16)
• Heavy smoker/nonsmoker (quit smoking):
 – Unadjusted: 0.88 (0.51–1.51)
 – Adjusted: 0.67 (0.36–1.26)
• Heavy smoker/moderate smoker: 
 – Unadjusted: 1.50 (1.09–2.06)
 – Adjusted: 1.41 (1.01–1.96)
• Heavy smoker/heavy smoker:
 – Unadjusted: 1.70 (1.32–2.19)
 – Adjusted: 1.55 (1.17–2.04)
Results adjusted for 
maternal age, education, 
cohabitation with the 
father, mother’s country 
of birth, interpregnancy 
interval, stillbirth in first 
pregnancy, and year of 
second delivery
Did not account for 
alcohol or substance use
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Table 4.35 Continued
Study Design/population Exposure groups/how determined Outcome definition Findings Comments
Erickson 
and Arbour 
(2012)
• Population-based 
retrospective cohort 
study using the 
British Columbia 
Perinatal Database 
Registry
• Singleton deliveries
• n = 233,891
• 2001–2006
• British Columbia, 
Canada
• Nonsmoker: Never smoked
• Quit smoking: Former smoker (time of 
cessation in former smokers with respect 
to pregnancy was not available)
• Continued smoking: Current smoker 
at time of smoking status assessment
• Light: 1–4 cigarettes/day
• Moderate: 5–9 cigarettes/day
• Heavy: ≥10 cigarettes/day
• Smoking history based on self-reports 
typically ascertained at first prenatal visit
Fetal death ≥20 weeks’ 
gestation or >500 g
Adjusted OR for stillbirth (95% CI):
• Nonsmoker (reference)
• Quit smoking: 1.43 (1.03–2.00)
• Continued smoking
 – Light: 1.08 (0.67–1.72)
 – Moderate: 1.19 (0.71–1.97)
 – Heavy: 1.40 (0.97–2.03)
Results adjusted for 
parity; prenatal care 
visits; maternal age, 
diabetes, hypertension, 
pre-pregnancy weight, 
and alcohol and drug use; 
presence of a partner; 
and sex of the infant
Räisänen 
et al. (2014)
• Population-based 
retrospective cohort 
using Finnish Medical 
Birth Register
• Singleton deliveries, 
live or stillborn after 
22 weeks’ gestation
• 1991–2010
• n = 1,164,953
• Finland
• Nonsmokers: Not further defined
• Quit smoking: Quit smoking during 
first trimester
• Continued smoking: Smoked after 
first trimester
• Smoking history based on self-reports 
ascertained from the Finnish Medical 
Birth Register
• Details on when and how data were 
collected were not reported 
Stillbirth definition 
not provided
OR for stillbirth (95% CI):
• Reference (nonsmokers)
• Quit smoking:
 – Unadjusted: 0.70 (0.60–0.81)
 – Adjusted: 1.07 (0.92–1.26)
• Continued smoking: 
 – Unadjusted: 1.03 (0.97–1.10)
 – Adjusted: 1.13 (1.06–1.20)
Results adjusted for 
maternal age, parity, 
socioeconomic status, 
and sex of the infant
Did not account for 
alcohol or substance use
Bjørnholt 
et al. (2016)
• Population-based cohort 
study using the Danish 
Medical Birth Register
• Singleton births
• n = 841,228
• 1997–2010
• Denmark
• Nonsmoker: Did not smoke 
during pregnancy
• Quit smoking: Quit during first trimester 
or early in second trimester
• Continued smoking: Still smoking 
at time of first antenatal visit
• Smoking status ascertained from 
maternal interviews at first antenatal 
visit (13–15 weeks’ gestation)
• 1997–2004: 
Fetal death after 
28 completed 
weeks’ gestation
• 2004–2010: 
Fetal death after 
22 completed 
weeks’ gestation
• Stillbirth further 
categorized as 
antepartum 
(before delivery) 
or intrapartum 
(during delivery)
Adjusted OR for stillbirth (95% CI):
• All:
 – Nonsmoker (reference)
 – Quit smoking: 1.03 (0.80–1.32)
 – Continued smoking: 1.47 (1.35–1.62)
• Antepartum:
 – Nonsmoker (reference)
 – Quit smoking: 0.83 (0.61–1.13)
 – Continued smoking: 1.45 (1.31–1.61)
• Intrapartum:
 – Nonsmoker (reference)
 – Quit smoking: 1.94 (1.10–3.41)
 – Continued smoking: 1.47 (1.12–1.92)
Results adjusted for year of 
delivery, maternal age, and 
marital or partner status
Notes: CI = confidence interval; OR = odds ratio.
Smoking Cessation
The Health Benefits of Smoking Cessation  389
Table 4.36 Studies on smoking cessation and perinatal mortality
Study Design/population Exposure groups/how determined Outcome definition Findings Comments
Bickerstaff 
et al. (2012)
• Retrospective 
cohort study 
• 1997–2006
• n = 30,524
• Australia
• Nonsmoker: Never smoked or quit 
>12 months before booking
• Quit smoking: Smoked during 12 months 
before booking but quit before booking
• Continued smoking: Currently smoking 
at booking
• Smoking status based on routinely 
collected clinical data at antenatal booking
Stillbirths and neonatal 
deaths during delivery 
hospitalization
Adjusted OR for perinatal mortality (95% CI):
• Continued smoking vs. nonsmoker: 
1.36 (0.99–1.87)
• Quit smoking vs. continued smoking: 
0.78 (0.28–2.16)
Results adjusted for 
plurality, previous 
pregnancy complications, 
parity, and ethnicity
Did not account for 
alcohol or substance use
Bailey (2015) • Randomized clinical 
trial of smoking 
cessation intervention
• n = 1,486
• 2008–2012
• Tennessee
• Quit smoking: Smoked at first prenatal 
visit but quit by third trimester
• Continued smoking: Smoked at first 
prenatal visit and still smoking during 
third trimester
• Smoking history based on self-reports 
obtained at first prenatal visit
• Quit status ascertained during third 
trimester by exhaled CO and urine 
cotinine and by self-reports at delivery
Fetal or neonatal 
demise not defined
Percentage perinatal deaths: 
• Quit smoking: 0.2%
• Continued smoking: 1.0%
• p = 0.046
Randomized cessation trial 
and thus no comparison 
group of never smokers
Results adjusted for 
maternal age, education, 
marital status, insurance 
status, and marijuana use 
Examined alcohol use, 
but not significant in 
the model
Notes: CI = confidence interval; CO = carbon monoxide; OR = odds ratio.
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(Table 4.37). One study examined cessation with respect 
to individual pregnancies (Wisborg et al. 2001), and two 
examined cessation across two consecutive pregnancies 
(Abrevaya 2008; Johansson et al. 2009). All three studies 
relied on self-reported smoking status and adjusted for 
multiple potential confounders, with one also adjusting 
for alcohol use (Wisborg et al. 2001), but none adjusted 
for substance use. In a prospective cohort study of Danish 
women, Wisborg and colleagues (2001) found that, com-
pared with women who did not smoke at all during preg-
nancy, women who smoked during pregnancy but quit by 
the time of the first antenatal interview (around 16 weeks’ 
gestation) had no significant increase in the risk of infant 
death (aOR = 1.0; 95% CI, 0.5–1.9). Johansson and col-
leagues, who examined smoking status at the first ante-
natal visit in two consecutive pregnancies, found no 
increase in infant mortality for the second pregnancy 
among women who were light smokers in the first 
pregnancy but had quit by the second pregnancy com-
pared with women who did not smoke in either preg-
nancy (aOR = 1.0; 95% CI, 0.8–1.5). This study, however, 
found increased risk in women who were heavy smokers 
in the first pregnancy and quit by the second pregnancy 
(aOR  =  1.4; 95%  CI, 1.0–2.0). Similarly, heavy smokers 
who smoked only in the second pregnancy had a signifi-
cantly increased risk of infant mortality for that pregnancy 
(aOR = 1.8; 95% CI, 1.0–2.9). In the third study, Abrevaya 
and colleagues (2008) found no significant difference in 
the risk of infant mortality during the second pregnancy 
in women who smoked during the first but not the second 
pregnancy compared with women who smoked during 
both pregnancies. Comparisons between women who quit 
smoking by the second pregnancy and women who did not 
smoke in either pregnancy were not reported.
Summary of the Evidence
Since the 2004 Surgeon General’s report (USDHHS 
2004), few studies have addressed smoking cessation and 
infant mortality, and findings have been mixed. The evi-
dence is inadequate to infer that women who quit smoking 
before or during early pregnancy have reduced risk for 
infant mortality compared with continuing smokers.
Female Reproductive Health
Fertility
“Infertility” is defined as the inability to achieve preg-
nancy following 12 months of regular, unprotected sexual 
intercourse (Practice Committee of American Society for 
Reproductive Medicine [PCASRM] 2013), while “fecun-
dity” refers to the biologic ability to conceive. Subfertility 
is any form of reduced fertility in couples trying to con-
ceive. Up to 15% of couples have some form of infertility 
(Thoma et al. 2013), approximately half of which is related 
to female causes, 30% to male causes, and 20% to both 
male and female causes (Kovac et al. 2015). Women can 
have primary infertility (inability to conceive and no pre-
vious pregnancies), or secondary infertility (inability to 
conceive following a previous pregnancy). The PCASRM 
(2012) has estimated that 13% of infertility may be attrib-
utable to smoking.
Several pathways involved in reproduction could 
be targets of toxicants in cigarette smoke that adversely 
affect fertility (Dechanet et al. 2011; Marom-Haham and 
Shulman 2016). Cigarette smoking could affect folliculo-
genesis by inhibiting the growth of follicles or the matu-
ration of oocytes. Possible mechanisms include abnormal 
oxidative stress, increased apoptosis, abnormal cross 
talk between oocytes and granulosa cells by inhibition 
of gap-junction formation between cells, or impairment 
of oocyte nuclear function by damaging DNA or inter-
fering with meiosis. In addition, compounds in cigarette 
smoke could disrupt steroidogenesis, leading to altera-
tions of estrogens and/or androgens in the follicular envi-
ronment. Cigarette smoke, through its proangiogenic or 
antiangiogenic properties, could affect the early develop-
ment of the embryo. Additionally, cigarette smoke could 
target the oviduct (by acting on its adhesive properties, 
ciliary activity, or muscular contractions) or the endome-
trium (by impairing endometrial proliferation or matura-
tion, or by causing aberrant regulation of angiogenesis). 
Finally, tobacco smoke could cause vascular impairment 
in the uterine arteries or could affect myometrial contrac-
tility, which could adversely affect implantation (Dechanet 
et al. 2011; Marom-Haham and Shulman 2016).
The 1990 Surgeon General’s report found evidence 
that cessation before attempted conception restored 
the fertility of former smokers to that of never smokers 
(Baird and Wilcox 1985; Daling et  al. 1985; Howe et  al. 
1985; USDHHS 1990). The 2001 Surgeon General’s report 
reviewed conception delay and infertility and found that 
although active smoking was associated with conception 
delay, the effect appeared to be reversible, as several studies 
observed similar conception rates for former and never 
smokers (USDHHS 2001). The report noted that smoking 
was consistently associated with impaired fertility in both 
case-control and cohort studies, and some studies found 
evidence of a dose-response relationship. Former smokers 
appeared to have little excess risk of impaired fertility. The 
report also concluded that smokers are at increased risk of 
primary and secondary infertility, but it did not draw con-
clusions about smoking cessation (USDHHS 2001). 
The 2004 Surgeon General’s report reviewed studies 
of smoking and fertility in women and found consistent 
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Table 4.37 Studies on smoking cessation and infant mortality
Study Design/population Exposure groups/how determined Outcome definition Findings Comments
Wisborg et al. 
(2001)
• Prospective cohort study
• Singleton pregnancies
• n = 25,102
• 1989–1996
• Denmark
• Nonsmokers: Not smoking at time of 
either antenatal interview
• Quit smoking: Smoked during pregnancy 
but quit by first antenatal interview
• Continued smoking: Smoked ≥1 cigarette/
day at first antenatal interview
• Smoking status ascertained from 
maternal interviews conducted before 
first antenatal visit (typically 16 weeks’ 
gestation) and before the 30-week 
antenatal visit 
Death of a liveborn 
infant before 1 year 
of age
Crude and adjusted OR for infant mortality 
(95% CI):
• Nonsmokers (reference)
• Quit smoking: 
 – Unadjusted: 1.0 (0.5–1.9) 
 – Adjusted: 0.9 (0.5–1.9)
Results adjusted for parity; 
maternal age, education, 
employment, caffeine and 
alcohol intake, weight, 
and height; and sex of 
the infant
Did not account for 
substance use
Abrevaya 
et al. (2008)
• Population-based, 
retrospective cohort 
study using Michigan-
linked certificates of 
live births
• First and second 
pregnancies in which 
women smoked during 
the first pregnancy
• n = 14,731 (18–24 years 
of age)
• n = 8,044 (25–30 years 
of age)
• 1989–2004
• Michigan
• Quit smoking: Smoked during first 
pregnancy but not during second 
pregnancy
• Continued smoking during both 
pregnancies: Smoked during first and 
second pregnancies
• Smoking status based on smoking history 
collected from certificates of live birth, 
which used one question on tobacco use 
during pregnancy (yes/no)
Death of a liveborn 
infant within 1 year 
of birth
Adjusted OR for infant mortality (95% CI):
• Quit smoking (reference)
• Continued smoking during both pregnancies:
 – 18–24 years of age: 1.07 (0.71–1.61)
 – 25–30 years of age: 0.67 (0.28–1.62)
Results adjusted for 
maternal race, education, 
income, population, 
interpregnancy interval, 
year of birth, trimester 
of first prenatal visit, 
presence of father’s name 
on birth certificate, 
number of prenatal visits, 
and first-birth value of 
the outcome
Did not account for 
alcohol or substance use
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Table 4.37 Continued
Study Design/population Exposure groups/how determined Outcome definition Findings Comments
Johansson 
et al. (2009)
• Births from the Swedish 
Birth Register
• First and second 
singleton pregnancies
• n = 555,046
• Sweden
• Nonsmokers: Not smoking at first 
antenatal visit in either pregnancy
• Quit smoking: Smoked at first antenatal 
visit of first pregnancy but not at first 
antenatal visit of second pregnancy
• Relapsed: Did not smoke at first antenatal 
visit of first pregnancy but smoked at first 
antenatal visit of second pregnancy
• Continued smoking: Smoked at first 
antenatal visit of both pregnancies:
 – Light smoker: 1–9 cigarettes/day
 – Heavy smoker: ≥10 cigarettes/day
• Smoking status based on maternal self-
reports obtained at first antenatal visit 
and on Swedish Birth Register
Death during the 
first year of life in a 
liveborn infant from 
second pregnancy, born 
≥22 weeks’ gestation
Adjusted OR for infant mortality after second 
pregnancy (95% CI):
• Nonsmoker (reference)
• Quit smoking: 
 – Light smoker, first pregnancy: 
1.0 (0.8–1.5)
 – Heavy smoker, first pregnancy: 
1.4 (1.0–2.0)
• Relapsed: 
 – Light smoker, second pregnancy: 
1.1 (0.8–1.5)
 – Heavy smoker, second pregnancy: 
1.8 (1.0–2.9)
• Continued smoking (results attenuated 
when also adjusted for gestational age and 
placental abruption; remained significant 
for all but light/light smokers):
 – Light/light: 1.3 (1.1–1.6)
 – Heavy/light: 1.5 (1.1–1.9)
 – Light/heavy: 1.7 (1.3–2.2)
 – Heavy/heavy: 2.0 (1.7–2.4) 
Results adjusted for 
maternal age, education, 
country of birth, 
interpregnancy interval, 
and year of delivery
Did not account for 
alcohol or substance use
Notes: CI = confidence interval; OR = odds ratio.
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evidence that smoking reduces fecundity and increases 
the risk of primary infertility, with some evidence pre-
sented of a dose-response relationship with the number 
of cigarettes smoked. The report concluded that a causal 
relationship exists between smoking and reduced fertility 
in women, but it did not draw conclusions related to cessa-
tion (USDHHS 2004). The 2010 Surgeon General’s report 
provided an updated review of smoking and fertility in 
women, including a meta-analysis of 12 studies that calcu-
lated an overall OR of 1.6 (95% CI, 1.3–1.9) for infertility 
versus nonsmokers (Augood et al. 1998). Earlier, a meta-
analysis of data from seven studies of in vitro fertilization 
(IVF) patients indicated a significant reduction in concep-
tions per cycle in smokers compared with nonsmokers 
(OR  =  0.57; 95%  CI, 0.42–0.78) (Hughes and Brennan 
1996). A subsequent review of 22  studies reported that 
19 found evidence of adverse effects of smoking on female 
reproduction (Wilks and Hay 2004). 
Since 2000, two papers have examined smoking ces-
sation and fertility in women. In a study of 569 women who 
became pregnant without infertility treatment, Munafò 
and colleagues (2002) found that women who smoked in 
the year before conception took approximately 2 months 
longer to conceive than women who quit at least a year 
before conception. In multivariable models that adjusted 
for age, weight, lifetime use of oral contraceptives, alcohol 
consumption, and vigorous exercise, the number of pack-
years of smoking was not associated with time to concep-
tion among former smokers (p = 0.093), but the number 
of cigarettes smoked per day was associated with increased 
time to conception among women who smoked during 
the period in which they were trying to conceive.
Radin and colleagues (2014) examined the associa-
tion between fecundability (the probability of becoming 
pregnant in a single menstrual cycle), duration of active 
smoking, and smoking cessation in a prospective cohort 
of women in Denmark who were 18–40 years of age. The 
women were followed for up to 12 cycles after beginning to 
attempt conception. Overall, former smokers, occasional 
smokers, and regular smokers did not differ in fecund-
ability from never smokers in models that adjusted for 
age, partner smoking, passive smoking, and the number of 
cycles at risk (adjusted fecundability ratios [aFRs] = 0.99, 
1.11, and 0.89, respectively). Former smokers with at 
least 10 pack-years of smoking, however, had significantly 
reduced fecundability (aFR = 0.74). 
Summary of the Evidence
The current review confirms findings of previous 
Surgeon General’s reports that support a causal associa-
tion between smoking and reduced fertility (USDHHS 
2001, 2004). Although past reports of the Surgeon General 
found a causal association between smoking and reduced 
fertility and suggestive evidence of restored fertility after 
smoking cessation, studies published since 2000 do not 
provide sufficient evidence to build upon the findings of 
the previous reports. Recent evidence is inadequate to fur-
ther elucidate the association between smoking cessation 
or the timing of cessation and attempted conception and 
improved fecundability. The evidence is inadequate to elu-
cidate the association between smoking cessation or the 
timing of cessation and fertility or fecundity.
Age at Menopause
The age of natural menopause is defined as the age 
menses cease for 12 consecutive months with no obvious 
cause, such as pregnancy or lactation, and it may be an 
important predictor of subsequent morbidity and mor-
tality. The risks of cardiovascular disease and osteoporosis 
are higher for women with earlier menopause, but their 
risk of breast cancer is reduced (Gold 2011). Age at meno-
pause was found to be associated with increased all-cause 
mortality when women with natural menopause before 
40 years of age were compared with those who experienced 
menopause at 50 years of age or older (Gold 2011). Earlier, 
a large international study of women from 11 countries 
found the median age at menopause to be 50 years (range: 
49–52 years across the countries) (Morabia and Costanza 
1998). Factors associated with earlier menopause in epi-
demiologic studies include non-White race, low socioeco-
nomic status, nulliparity, never using oral contraceptives, 
and lower weight (Gold 2011). Mechanisms contributing 
to an effect of smoking on age at menopause could involve 
genetics, environmental exposures, hormonal pathways, 
and health status (Gold et al. 2001, 2011; He and Murabito 
2014; Sapre and Thakur 2014; Schoenaker et al. 2014). 
The 1990 Surgeon General’s report noted that ciga-
rette smoking has consistently been associated with ear-
lier menopause in epidemiologic studies (USDHHS 1990). 
The report found that smokers experience menopause 
1 to 2 years earlier than nonsmokers and that the consis-
tency of study findings and evidence for a dose-response 
relationship supported a causal association. The report 
also noted that the age of menopause in former smokers 
appeared to be closer to that in never smokers than in 
current smokers, suggesting that the effects of smoking 
on age at menopause may be at least partially reversible 
(USDHHS 1990). The data at that time were found to be 
limited, however, with few studies examining the duration 
of cessation or lifetime tobacco exposure.
The 2001 Surgeon General’s report found that 
smoking was consistently associated with a 1-  to 2-year 
decrease in age at natural menopause and concluded 
that smokers have a younger age at natural menopause 
than nonsmokers (USDHHS 2001). Possible mecha-
nisms addressed in that report included exposure of the 
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ovaries to toxic components in tobacco smoke (animal 
studies suggest that tobacco smoke may cause follicular 
atresia) and the effects of nicotine on the metabolism of 
sex hormones. Although the report did not draw conclu-
sions on smoking cessation, it did summarize studies that 
included former smokers (USDHHS 2001); those studies 
had mixed results. 
Just over a decade after the 2001 Surgeon General’s 
report, a meta-analysis of 11  papers published between 
1997 and 2009 (comprising about 50,000 women) found 
that smoking was significantly associated in all the studies 
with earlier age at natural menopause (Sun et al. 2012). 
After adjustment for heterogeneity, the OR for onset of 
earlier menopause was 0.67  (95%  CI, 0.61–0.73), and 
menopause was estimated to take place an average of 
approximately 1  year earlier in smokers compared with 
nonsmokers. Results from some of the studies supported 
the notion that the timing of menopause may be depen-
dent on the amount of cigarettes smoked and/or the dura-
tion of smoking. Kinney and colleagues (2006) analyzed 
longitudinal data from almost 500 women and found that 
a change in age of menopause was observed only among 
active smokers who smoked more than 14  cigarettes 
per day or who had accumulated at least 20 pack-years. 
Those authors found no association between menopause 
and previous smoking, even among women who had 
smoked more than 14  cigarettes per day, smoked more 
than 10 pack-years, or who had quit smoking within the 
past decade (Kinney et  al. 2006). Similarly, Blanck and 
colleagues (2004) found that in a study of 874  women, 
menopause came earliest among current smokers who 
started smoking in their teens, smoked at least 20 ciga-
rettes per day, smoked for 10 to 19 years, or had at least 
10 pack-years. Former smokers and never smokers did not 
differ in time to menopause, however, even after adjusting 
for number of term pregnancies and education (Blanck 
et al. 2004). 
In a study of more than 5,500 women, Van Asselt and 
colleagues (2004) found that although there was a signifi-
cant association between current smoking and earlier age 
of menopause (rate ratio = 1.41; 95% CI, 1.32–1.50), there 
was no association with former smoking (rate ratio = 0.95; 
95% CI, 0.89–1.02). The latter was true regardless of the 
number of years since cessation. In a more recent study 
of more than 2,000  women, Mikkelsen and colleagues 
(2007) found that—after adjusting for marital status, edu-
cation level, social participation, health status, and coffee 
consumption—women who stopped smoking more than 
10 years before menopause were significantly less likely to 
have an early menopause (<45 years of age) (aOR = 0.13; 
95%  CI, 0.05–0.36) than women who were current 
smokers (aOR = 1.59; 95% CI, 1.11–2.28). Finally, in one 
of the few longitudinal studies of smoking status and 
menopause, Hayatbakhsh and colleagues (2012) followed 
more than 3,500 Australian women and found that women 
smoking at the 21-year follow-up were 61% more likely to 
experience menopause before 45 years of age than women 
who had never smoked (adjusted hazard ratio [HR] = 1.61; 
95%  CI, 1.27–2.04), even after adjusting for education, 
ethnicity, BMI, use of oral contraceptives, and gravidity. 
Those who quit smoking before the 14-year follow-up 
assessment had a risk of early menopause that was the 
same as that of never smokers, while those who quit later 
(between 14 and 21 years of follow-up) may have been at 
increased risk (HR  =  1.36; 95%  CI, 0.89–2.07). Among 
those smoking at the 14-year follow-up, only smoking 
more than 20 cigarettes per day was significantly associ-
ated with early menopause. 
Menopause is associated with the exhaustion of the 
ovarian follicular pool (Vermeulen 1993; Hacker et  al. 
2015), and it has been hypothesized that smoking could 
alter the timing of menopause by hastening the decline of 
ovarian reserves. Evidence for this pathway (Richardson 
et al. 2014) includes studies demonstrating an increased 
concentration of follicular-stimulating hormone (FSH) 
in smokers compared with nonsmokers (Cooper et  al. 
1995) and a reduced number of oocytes retrieved in IVF 
cycles in smokers compared with nonsmokers (Zenzes 
et al. 1997; El-Nemr et al. 1998; Fuentes et al. 2010). The 
mechanisms underlying the potential effects of tobacco 
smoke on ovarian reserves are not well understood, but 
they could include direct effects on gametes or effects on 
ovarian vascularization (Richardson et al. 2014). A mecha-
nism involving depletion of ovarian reserves would likely 
result in an irreversible effect on age at menopause. 
It has also been hypothesized that antiestrogenic 
effects of environmental toxicants, such as those found 
in tobacco smoke, could contribute to earlier age at 
menopause (Gu et  al. 2013). Potential pathways include 
inhibition of estrogen biosynthesis, induction of the 
2-hydroxylation pathway, and competitive binding of 
estrogen receptors or sex hormone-binding globulin 
(Baron et al. 1990). Gu and colleagues (2013), who used 
luteal phase urine samples from 603  premenopausal 
women in the Nurses’ Health Study  II to study specific 
pathways, found lower total estrogen and estrogen metab-
olites and parent estrogens in current smokers compared 
with never smokers (with statistically significant differ-
ences for estradiol), suggesting that cigarette smoking 
reduces the biosynthesis of estrogen and induces estrogen 
metabolism. No differences were seen in levels of indi-
vidual estrogen metabolites, metabolic pathway groups, 
or  pathway ratios between never and former smokers 
(most of whom had quit more than 5 years earlier), sug-
gesting that the effects of smoking on estrogen biosyn-
thesis may be reversible. The authors were unable to 
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examine whether components of tobacco smoke bind 
estrogen receptors or sex hormone-binding globulin.
Summary of the Evidence
The 2001 Surgeon General’s report found that 
“[w]omen smokers have a younger age at natural meno-
pause than do nonsmokers and may experience more 
menopausal symptoms” (USDHHS 2001, p.  14). Several 
papers published since the 2001 report provide addi-
tional evidence that active smoking results in earlier age 
at menopause. Several of these recent papers also exam-
ined risk in former smokers and found no evidence of ear-
lier age at menopause, suggesting that the mechanisms 
through which smoking affects age at menopause are at 
least partially reversible. However, uncertainty remains 
regarding the role of the duration and amount of smoking 
in former smokers, and these variables were categorized 
differently across studies. Therefore, the evidence is sug-
gestive but not sufficient to conclude that cessation 
reduces the risk of earlier menopause compared with con-
tinued smoking, and uncertainty remains regarding the 
contributions to the risk of earlier menopause of age at 
cessation, the number of years smoked, the number of 
cigarettes smoked per day, and the number of pack-years 
smoked in former smokers. 
Male Reproductive Health
Fertility and Sperm Quality
The 1990 Surgeon General’s report found few 
studies about sperm quality after smoking cessation, and 
those studies had serious limitations (USDHHS 1990). 
The 2004 Surgeon General’s report concluded that the 
evidence was inadequate to infer the presence or absence 
of a causal relationship between active smoking and sperm 
quality, but the evidence did suggest that smokers have 
decreased semen volume and increased abnormal mor-
phologic forms (USDHHS 2004). The clinical relevance of 
these findings, however, was uncertain. The 2010 Surgeon 
General’s report, which also reviewed sperm quality and 
male fertility, noted that studies conducted after the 2004 
report strengthened the evidence that smoking affects 
semen quality and fertility (USDHHS 2010). The 2010 
report reviewed potential mechanisms, including altera-
tions in the hormonal milieu, effects on the sperm plasma 
membrane, and damage to DNA and/or chromosomes in 
sperm. The report also noted that (a) studies designed to 
address the timing of exposure in relation to the matura-
tion of sperm cells had not been conducted and (b)  the 
effects of tobacco smoke on spermatogonial stem cells 
could cause long-term effects that could persist after 
smoking cessation, while effects on both epididymal sperm 
and mature sperm could be reversible (USDHHS 2010). 
The report also noted that studies examining hormone 
levels in male smokers and nonsmokers found incon-
sistent results and variation in how obesity was consid-
ered (obesity is associated with the conversion of andro-
gens to estrogen) and in the type of circulating hormones 
studied (free or bioavailable levels). The report found con-
sistent evidence linking smoking in men to chromosomal 
changes and DNA damage in sperm, which affects male 
fertility, pregnancy viability, and anomalies in offspring. 
Among the studies published after the 2010 Surgeon 
General’s report was a meta-analysis of 20  studies com-
prising more than 5,800 men, with the authors’ finding 
that cigarette smoking was associated with reduced sperm 
count, lower motility, and changes in morphology (Sharma 
et al. 2016). Elsewhere, in a small study of 136 men that 
excluded those with known infertility, levels of testos-
terone, luteinizing hormone, and prolactin were higher in 
smokers (≥5 cigarettes/day) than never smokers, but there 
were no differences in these measures between former 
smokers and never smokers (Blanco-Munoz et al. 2012). 
In another study, Santos and colleagues (2011) evaluated 
sperm quality after participation in a 3-month smoking 
cessation program. A man in the study had smoked about 
30 cigarettes per day for about 13 years and had secondary 
infertility. The monitoring found an improvement in his 
sperm count (from 28.6  to 72.2  million/ejaculate) and 
motility (32.7% to 78.8%) but no changes in sperm DNA 
fragmentation, number of germinal cells, or morphology. 
In addition, the percentage of sperm tails increased with 
tyrosine-phosphorylated proteins and the number of rapid 
spermatozoa recuperated after an enrichment technique, 
suggesting that the transduction signals necessary for 
proper motility and capacitation were improved. Finally, 
a study of rats found that both the motility and amount 
of sperm decreased significantly with exposure to nico-
tine, and that this was accompanied by reduced fertility; 
declines were ameliorated by the cessation of nicotine 
exposure in the male rats (Oyeyipo et al. 2011). 
Summary of the Evidence
Little new evidence published since the 2010 
Surgeon General’s report has addressed whether the 
effects of smoking on male fertility and sperm quality are 
reversible with cessation. Therefore, the evidence is inad-
equate to determine whether smoking cessation reduces 
the effects of smoking on male fertility and sperm quality. 
Erectile Dysfunction
“Erectile dysfunction” (ED) is defined as the persis-
tent inability of a male to attain and maintain an erection 
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adequate for satisfactory sexual performance (National 
Institutes of Health Consensus Development Panel on 
Impotence 1993). Using data from the National Health 
and Nutrition Examination Survey of 2001–2002, Selvin 
and colleagues (2007) estimated that 18.4% of U.S. men 
20 years of age or older had ED, or 18 million nationwide. 
Globally, 322 million men may be affected by the year 2025. 
The 1990 Surgeon General’s report found that 
smoking may be associated with impaired male sexual per-
formance, but because the data were limited, no conclu-
sions could be drawn regarding the relationships between 
smoking cessation and sexual performance or the surrogate 
penile brachial index, which is calculated as the systolic 
blood pressure in the penis divided by the systolic blood 
pressure in the arm (USDHHS 1990). The 2014 Surgeon 
General’s report found the evidence sufficient to infer a 
causal relationship between smoking and ED. This conclu-
sion was on the basis of consistent findings of smoking as a 
risk factor for ED across both cross-sectional and prospec-
tive population-based cohort studies. These studies con-
firmed the appropriate temporality of the association and 
evidence of a dose-response relationship between the mag-
nitude of the risk and the level of exposure. Potential mech-
anisms were also reviewed in the 2014 Surgeon General’s 
report and included the effects of nicotine on the dynamics 
of blood flow required for erection (nicotine induces vaso-
spasm in the penile arteries); formation of atheroscle-
rotic lesions in the penile arteries; degenerative changes 
in the penile tissue, such as decreases in smooth muscle, 
sinusoidal endothelium, nerve fibers and capillaries, and 
increased collagen density; reduced endothelium-derived 
production of nitric oxide in the vasculature of the penis; 
adverse effects on vascular medial elastic fibers; and oxida-
tive injury due to the production of superoxide radicals in 
the cavernosal smooth muscle cells (USDHHS 2014).
The 2014 Surgeon General’s report also addressed 
smoking cessation, although that report did not draw 
related conclusions. The report reviewed selected 
results from two population-based studies (the Vietnam 
Experience Study of 1985–1986 and the prospective 
Massachusetts Male Aging Study) against findings that 
smoking cessation leads to recovery of erectile func-
tion (Mannino et al. 1994; Feldman et al. 2000; USDHHS 
2014). However, the Massachusetts Male Aging Study, 
which followed quitters for nearly 9 years, did not show 
evidence that the incidence of ED was reduced after ces-
sation (Feldman et  al. 2000). In that study, however, 
participants had started smoking at an early age (mean 
age:  16.6  years) and had a substantial lifetime exposure 
(mean pack-years: 39.4), so that results could not be gen-
eralized to populations with lower levels of tobacco expo-
sure (Feldman et al. 2000). Notably, a separate analysis of 
the Massachusetts Male Aging Study found that cessation 
appeared to protect against the progression of ED but had 
little effect on remission (Travison et al. 2007). 
Experimental studies of the acute effects of short-
term smoking cessation reviewed in the 2014 Surgeon 
General’s report show that cessation may result in 
improvements in erectile function. For example, Glina 
and colleagues (1988), who monitored intracavernous 
pressure after pharmacologic stimulation in 12 smokers 
on a day of abstinence and after smoking two cigarettes, 
found that all participants obtained an erection on days 
of abstinence, but only four smokers did so on days of 
smoking cigarettes (Glina et  al. 1988). Later, Sighinolfi 
and colleagues (2007), who studied 20  chronic smokers 
with ED using penile color Doppler ultrasonography after 
pharmacostimulation at baseline and after 24 to 36 hours 
of abstinence from smoking, also achieved positive results. 
At baseline, 50% of these smokers had abnormal peak sys-
tolic velocity and 75% had abnormal end diastolic velocity, 
but at 24  to 36 hours, none had abnormal peak systolic 
velocity and just 15% had abnormal end diastolic velocity. 
Finally, in a sample of 10  current, long-term smokers, 
cessation for 24  hours significantly improved nocturnal 
penile tumescence and rigidity (Guay et al. 1998).
Table 4.38 presents seven cross-sectional studies of 
risk of ED in former smokers that were not reviewed in the 
2014 Surgeon General’s report. Six of the seven studies 
found a higher prevalence of ED among both former and 
continuing smokers (range in aOR for former smokers 
relative to never smokers: 1.3–2.15) (Bortolotti et al. 2001; 
Mirone et al. 2002; Safarinejad 2003; Austoni et al. 2005; 
Chew et al. 2009), but the associations for both former and 
current smokers did not reach significance in one study 
(Shiri et al. 2005). One study reported an aOR of less than 
1.0 for former smokers (Lam et al. 2006), but this result 
was not statistically significant. 
In a study of 1,580 men, Chew and colleagues (2009) 
found that both former and current smokers were at 
higher risk of ED compared with never smokers (overall 
aOR = 1.3 and 1.6, respectively, adjusted for age and symp-
tomatic cardiovascular disease, including hypertension, 
ischemic heart disease, peripheral arterial disease, and 
stroke), but by age group, associations between former 
or current smoking and ED were significant only among 
men 50  years of age and older. Similarly, in a study of 
2,010 men, Mirone and colleagues (2002) found that cur-
rent smokers and former smokers had similar aORs for ED 
(1.7 and 1.6, respectively, adjusted for age and education); 
those researchers also found that smoking for more than 
20 years increased the odds of ED compared with smoking 
for 20 years or less (aOR = 1.6 and 1.2, respectively). The 
increased risk was limited to current and former smokers 
without chronic medical conditions (aOR  =  1.7–2.4 for 
current smokers without medical conditions, 0.4–1.2 for 
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Table 4.38 Studies on smoking cessation and erectile dysfunction 
Studya Design/population Reference Results: Adjusted OR (95% CI) Comments
Bortolotti et al. 
(2001)
• Cross-sectional
• Men with diabetes
• n = 9,670
• 1996
• Italy
Never smokers • Former smokers: 1.5 (1.3–1.6)b
• Current smokers: 1.4 (1.3–1.6)b
Former smoker if quit more 
than 1 year before survey; 
adjusted for age
Mirone et al. 
(2002)
• Cross-sectional
• n = 2,010
• 1996–1997
• Italy
Never smokers • Former smokers: 1.6 (1.1–2.3)b
• Current smokers: 1.7 (1.2–2.4)b
Former smoker if quit 
more than 1 year before 
survey; adjusted for age 
and education
Safarinejad 
(2003)
• Population-based, cross-sectional 
• Men 20–70 years of age
• n = 2,444
• Year: Not reported
• Iran
Never smokers • Former smokers: 2.15 (1.38–3.1)b
• Current smokers: 2.41 (1.52–3.30)b
Adjusted for age
Austoni et al. 
(2005)
• Cross-sectional
• Men attending free andrologic 
consultations 
• n = 16,724
• 2001–2002
• Italy
Never smokers • Former smokers:
 – Overall: 1.3 (1.2–1.5)b
 – Smoked <10 years: 1.0 (0.6–1.7)
 – Smoked 10–20 years: 1.2 (0.8–1.8)
 – Smoked >20 years: 2.0 (1.3–2.0)b
• Current smokers:
 – <10 cigarettes/day: 1.0 (0.9–1.2)
 – ≥10 cigarettes/day: 1.4 (1.2–1.5)b
 – Smoked <10 years: 1.1 (0.7–1.6)
 – Smoked 10–20 years: 1.7 (1.2–2.3)b
 – Smoked >20 years: 1.6 (1.3–2.0)b
Former smoker if quit 
more than 1 year before 
survey; adjusted for age, 
marital status, education, 
BMI, physical activity, 
and chronic diseases
Shiri et al. 
(2005)
• Population-based, cross-sectional 
analysis within prospective cohort
• Men 50, 60, or 70 years of age in 1994
• n = 1,442
• 1994
• Finland
Never smokers • Former smokers: 1.3 (0.9–1.8)
• Current smokers: 1.4 (0.9–2.2)
Adjusted for age, education, 
marital status, and alcohol 
consumption
Lam et al. 
(2006)
• Population-based, cross-sectional
• Men 31–60 years of age
• n = 819 
• 2001
• Hong Kong
Never smokers • Former smokers: 0.93 (0.60–1.45)
• Current smokers: 
 – <20 cigarettes/day: 1.02 (0.69–1.51)
 – ≥20 cigarettes/day: 1.47 (1.00–2.16)b
Erectile dysfunction defined 
as sexual dissatisfaction 
and/or erectile difficulty; 
adjusted for age
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Table 4.38 Continued
Studya Design/population Reference Results: Adjusted OR (95% CI) Comments
Chew et al. 
(2009)
• Population-based, cross-sectional 
• n = 1,580
• 2001–2002
• Australia
Never smokers • Former smokers:
 – Overall: 1.33 (0.95–1.87)
 – Quit ≤5 years: 1.22 (0.67–2.22)
 – Quit 6–10 years: 2.26 (1.09–4.70)b
 – Quit >10 years: 1.32 (0.92–1.89)
 – <50 years of age: 1.18 (0.61–2.31)
 – ≥50 years of age: 2.56 (1.42–4.58)b
• Current smokers:
 – Overall: 1.57 (1.02–2.42)b
 – 1–10 cigarettes/day: 1.30 (0.69–2.44)
 – 11–20 cigarettes/day: 1.69 (0.79–3.64)
 – >20 cigarettes/day: 1.57 (0.74–3.34)
 – <50 years of age: 0.82 (0.40–1.69)
 – ≥50 years of age: 1.47 (0.99–2.18)
Adjusted for age and 
symptomatic cardiovascular 
disease, including 
hypertension, ischemic 
heart disease, peripheral 
arterial disease, and stroke
Notes: BMI = body mass index; CI = confidence interval; OR = odds ratio.
aMeasure of association adjusted for covariate(s).
bp <0.05.
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current smokers with medical conditions; and aOR = 1.4–
1.7 for former smokers without medical conditions, 0.4–
1.2 for former smokers with medical conditions). Among 
former smokers, the risk of ED was not clearly associated 
with the number of years since cessation. 
In a large study with more than 16,000 participants, 
Austoni and colleagues (2005) found associations between 
smoking and ED that were similar for current smokers 
smoking more than 10  cigarettes per day and former 
smokers compared with never smokers (aOR = 1.4; 95% CI, 
1.2–1.5, and aOR  =  1.3; 95%  CI, 1.2–1.5, respectively, 
adjusted for age, marital status, education, BMI, physical 
activity, and chronic diseases). There was no increased risk 
for men who smoked 10 or fewer cigarettes per day, but 
the risk of ED increased with duration of smoking for both 
current and former smokers. When stratified by the pres-
ence or absence of medical conditions (hypertension, car-
diovascular disease, diabetes, and hypercholesterolemia), 
aORs were similar for those with and without each condi-
tion in former smokers, and all associations were signifi-
cant except for former smokers with hypercholesterolemia 
(aOR = 1.2; 95% CI, 0.9–1.6). Earlier, in a sample of nearly 
10,000 men with diabetes, Bortolotti and colleagues (2001) 
found that both former smokers and current smokers had 
a higher risk of ED relative to never smokers (aOR = 1.5; 
95% CI, 1.3–1.6 and aOR = 1.4; 95% CI, 1.3–1.6, respec-
tively, results adjusted for age). Increased time since ces-
sation was not clearly associated with reduced risk of ED 
among former smokers. 
In a prospective study of more than 1,400  men 
50–75 years of age, Shiri and colleagues (2005) observed 
elevated but nonsignificant aORs for ED among former 
and current smokers at baseline (1.3; 95% CI, 0.9–1.8, and 
1.4; 95% CI, 0.9–2.2, respectively, adjusted for age, edu-
cation, marital status, and alcohol consumption) but did 
not find a dose-response relationship in current smokers 
with duration of smoking or in former smokers with the 
number of years of smoking (not shown in table). In a 
follow-up survey conducted 5  years later, spontaneous 
recovery was not significantly associated with being a 
former smoker (aOR = 0.7; 95% CI, 0.3–1.3). When the 
sample was limited to men without ED at baseline in 1994, 
smokers who developed vascular disease by 1999 had a 
3-fold greater risk of developing ED by 2004 (adjusted 
incidence density ratio = 3.1; 95% CI, 1.3–7.5; covariates 
included age, education, marital status, diabetes, depres-
sion, BMI, and alcohol consumption) compared with men 
who never smoked and did not develop vascular disease 
(men included in the final model were not specified) (Shiri 
et al. 2006). In contrast, smokers who did not develop vas-
cular disease did not have an increased risk of ED. Former 
smokers were not at increased risk for ED, independent of 
vascular disease. Finally, in a prospective study of almost 
300  smokers seeking smoking cessation services who 
reported having symptoms of ED with onset more than 
5 years after initiating smoking, Pourmand and colleagues 
(2004) found that at 1-year follow-up, ED status improved 
by at least one grade in 25% of former smokers but 
such improvement was not observed among continuing 
smokers (results of statistical testing not presented). 
Summary of the Evidence
Cross-sectional studies consistently found that 
former smokers had an increased prevalence of ED rela-
tive to never smokers, and in some instances, prevalence 
was similar to that of current smokers. In contrast, results 
of prospective studies were mixed, with some showing no 
increased risk of ED in former smokers compared with never 
smokers, and others showing increased risk. Experimental 
studies of short-term cessation suggest that such cessation 
is associated with acute improvements in erectile function. 
Limited data suggest that smoking contributes to ED at 
least in part through its effects on the risk of vascular dis-
ease. Smoking likely has both reversible (such as nicotine-
induced vasospasm of penile arteries) and irreversible (such 
as degenerative tissue changes) effects on erectile function, 
complicating interpretation of data across different study 
designs. Changes in risk of ED by duration or intensity of 
smoking could further complicate the interpretation of 
data. Therefore, the evidence is inadequate to determine 
whether smoking cessation reduces the risk of ED com-
pared with continued smoking. The evidence is suggestive 
but not sufficient to conclude that former smokers are at 
increased risk of ED compared with never smokers.
Synthesis of the Evidence
Smoking has diverse adverse effects on the repro-
ductive health of females and males. This review has 
found numerous health benefits of cessation for women 
and their fetuses and newborns. For males, evidence of 
the reproductive health benefits (e.g.,  enhancing sperm 
quality and functionality, avoiding erectile dysfunction) of 
cessation is more limited. 
Conclusions
1. The evidence is sufficient to infer that smoking ces-
sation by pregnant women benefits their health and 
that of their fetuses and newborns.
2. The evidence is inadequate to infer that smoking 
cessation before or during early pregnancy reduces 
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the risk of placental abruption compared with con-
tinued smoking. 
3. The evidence is inadequate to infer that smoking 
cessation before or during pregnancy reduces the 
risk of placenta previa compared with continued 
smoking.
4. The evidence is inadequate to infer that smoking 
cessation before or during pregnancy reduces the 
risk of premature rupture of the membranes com-
pared with continued smoking. 
5. The evidence is inadequate to infer that smoking 
during early or mid-pregnancy alone, and not during 
late pregnancy, is associated with a reduced risk of 
preeclampsia. 
6. The evidence is sufficient to infer that women who 
quit smoking before or during pregnancy gain more 
weight during gestation than those who continue 
to smoke. 
7. The evidence is suggestive but not sufficient to infer 
that women who quit smoking before or during 
pregnancy gain more weight during gestation than 
nonsmokers.
8. The evidence is inadequate to infer that smoking 
cessation during pregnancy increases the risk of 
gestational diabetes. 
9. The evidence is sufficient to infer that smoking 
cessation during pregnancy reduces the effects of 
smoking on fetal growth and that quitting smoking 
early in pregnancy eliminates the adverse effects of 
smoking on fetal growth. 
10. The evidence is inadequate to determine the gesta-
tional age before which smoking cessation should 
occur to eliminate the effects of smoking on fetal 
growth. 
11. The evidence is sufficient to infer that smoking ces-
sation before or during early pregnancy reduces the 
risk for a small-for-gestational-age birth compared 
with continued smoking. 
12. The evidence is suggestive but not sufficient to infer 
that women who quit smoking before conception or 
during early pregnancy have a reduced risk of pre-
term delivery compared with women who continue 
to smoke. 
13. The evidence is suggestive but not sufficient to infer 
that the risk of preterm delivery in women who quit 
smoking before or during early pregnancy does not 
differ from that of nonsmokers. 
14. The evidence is inadequate to infer that smoking ces-
sation during pregnancy reduces the risk of stillbirth. 
15. The evidence is inadequate to infer that smoking 
cessation during pregnancy reduces the risk of peri-
natal mortality among smokers. 
16. The evidence is inadequate to infer that women who 
quit smoking before or during early pregnancy have 
a reduced risk for infant mortality compared with 
continued smokers.
17. The evidence is inadequate to infer an association 
between smoking cessation, the timing of cessation, 
and female fertility or fecundity.
18. The evidence is suggestive but not sufficient to infer 
that smoking cessation reduces the risk of earlier age 
at menopause compared with continued smoking.
19. The evidence is inadequate to infer that smoking 
cessation reduces the effects of smoking on male 
fertility and sperm quality.
20. The evidence is suggestive but not sufficient to infer 
that former smokers are at increased risk of erectile 
dysfunction compared with never smokers. 
21. The evidence is inadequate to infer that smoking 
cessation reduces the risk of erectile dysfunction 
compared with continued smoking.
Implications
As with previous reports, the evidence presented in 
this section reaffirms that cigarette smoking cessation 
before and during pregnancy reduces the adverse effects 
of smoking on fetal growth, including risk for being small 
for gestational age and low birth weight. The timing of the 
cessation and its beneficial effects are consistent with fetal 
growth patterns, which accelerate during the third tri-
mester; thus, quitting early in pregnancy obviates the birth 
weight reduction that results from smoking throughout 
pregnancy. The evidence also suggests that smoking ces-
sation may reduce the risk of other adverse outcomes, 
including placental abruption, preterm delivery, stillbirth, 
and early menopause. If smoking cessation reduces the 
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risk of such pregnancy complications as placental abrup-
tion and preterm delivery, then reductions in such down-
stream outcomes as stillbirths and perinatal and neonatal 
mortality would also be expected. More research on the 
timing of cessation with respect to pregnancy onset is 
needed to determine how to maximize improvements in 
pregnancy outcomes for women and infants.
Prenatal smoking cessation has substantial health 
benefits for mothers and offspring, but the evidence sum-
marized in this section also provides some support that 
selected adverse outcomes might also be increased with 
smoking cessation. For example, increased gestational 
weight gain associated with cessation could potentially 
increase the percentage of women who exceed recom-
mended gestational weight gain and experience associ-
ated complications, while simultaneously reducing the 
percentage of women with inadequate weight gain. 
Potential unintended consequences, such as excess weight 
gain, should be considered when implementing smoking 
cessation interventions for pregnant women. Such inter-
ventions could, for example, incorporate weight manage-
ment programs for at-risk women. 
The evidence related to cessation and reduced fer-
tility in men and women remains mixed and inconclusive, 
and our understanding of the mechanism(s) underlying 
these effects is limited, especially for women. Further 
research is needed to determine whether and when in the 
life course cessation of smoking needs to occur to ben-
efit female and male fertility. Such evidence is needed so 
that the appropriate information can be communicated 
to patients and providers so that interventions can be 
tailored accordingly.
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Smoking Cessation
Introduction
Cigarette smoking causes multiple diseases and 
reduces the general level of health of smokers (U.S. 
Department of Health and Human Services [USDHHS] 
2004, 2014). These health consequences have been well 
documented in previous Surgeon General’s reports. The 
1964 report first summarized results on smoking and all-
cause mortality, finding that smoking causes a 70% increase 
in risk of adverse health consequences (U.S. Department 
of Health, Education, and Welfare [USDHEW] 1964). The 
2004 report found smoking generally diminishes health 
(USDHHS 2004). General measures of health can be infor-
mative because they provide an integrative indicator of the 
health burden placed on smokers and on society overall. 
In addition to the direct human costs that smoking places 
on persons and society, one general measure with acknowl-
edged implications for public health policy and practice is 
the economic cost of smoking.
This chapter considers broad indicators of burden 
in relation to smoking cessation, including morbidity, 
mortality, and economic costs. Initially, it considers how 
general indicators of health can change after smoking ces-
sation. This type of information is critical to informing 
smokers about the potential benefits of cessation and serves 
as a strong rationale to provide interventions that can 
help increase the success of quitting smoking. Such pro-
grams may be offered through healthcare organizations, 
communities, states, and other organizations. Smoking is 
known to generate healthcare and other economic costs 
and to affect the economics of the households of smokers 
(USDHHS 2014). Previous Surgeon General’s reports on 
tobacco have periodically reviewed the economic costs of 
smoking, as tracked by the Centers for Disease Control 
and Prevention’s (CDC’s) Smoking-Attributable Mortality, 
Morbidity, and Economic Costs (SAMMEC) model. This 
chapter expands on this work by focusing on the most 
recently available scientific literature on the economic ben-
efits of smoking cessation, while also complementing the 
kinds of cost estimates previously provided by SAMMEC.
Benefits of Smoking Cessation on Overall Morbidity
Chapter 4 of this report (The Health Benefits of 
Smoking Cessation) describes the associations between 
smoking cessation and changes in risk for specific dis-
ease outcomes. It also addresses how cessation affects the 
natural history of various disease outcomes, such as by 
slowing the progression of underlying pathophysiological 
processes. In addition to the beneficial impacts on spe-
cific disease outcomes, previous reviews of smoking ces-
sation and morbidity (Goldenberg et al. 2014) have con-
cluded that cessation is associated with improvement in 
health-related quality of life (HRQoL), a broad construct 
defined by Healthy People 2020 as “a multi-dimensional 
concept that includes domains related to physical, mental, 
emotional, and social functioning” (Office of Disease 
Prevention and Health Promotion 2018). In a complemen-
tary conclusion, after evaluating a broad range of general 
evidence, the 2004 Surgeon General’s report concluded 
that active smoking is causally associated with diminished 
health status (USDHHS 2004).
This chapter addresses the evidence on smoking 
cessation and its relationship to more general mea-
sures of health outcomes, particularly whether cessation 
improves general QoL compared with continued smoking. 
This review aligns with and complements the approach 
used in previous Surgeon General’s reports on smoking, 
including the 2014 Surgeon General’s report (USDHHS 
2014). However, to limit the scope of this review, some of 
the many correlates of well-being (e.g., absenteeism from 
work) are not specifically considered.
Conclusions from Previous Surgeon 
General’s Reports
Previous Surgeon General’s reports (USDHHS 1990, 
2004) have comprehensively covered the relationship 
between smoking and general morbidity. The 1990 Surgeon 
General’s report on the health benefits of smoking cessa-
tion synthesized scientific evidence about cessation and 
its effects on general morbidity, concluding that “former 
smokers have better health status than current smokers 
as measured in a variety of ways, including days of illness, 
number of health complaints, and self-reported health 
status” (USDHHS 1990, p. 9). However, that report also 
found that the reviewed studies were “extremely heteroge-
neous, with some methodologic shortcomings” (USDHHS 
1990, p. 89) and that the “variety of measures used makes 
direct comparison across studies problematic” (USDHHS 
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1990, p. 87). The 2004 Surgeon General’s report on the 
health consequences of active smoking subsequently 
reviewed studies that included various indicators of gen-
eral health, concluding that “the evidence is sufficient to 
infer a causal relationship between smoking and dimin-
ished health status that may be manifest as increased 
absenteeism from work and increased use of medical care 
services” (USDHHS 2004, p. 676). In addition, a major 
conclusion of the 2004 report was that “quitting smoking 
has immediate as well as long-term benefits, reducing 
risks for diseases caused by smoking and improving health 
in general” (USDHHS 2004, p. 25). The present chapter 
updates these findings on the basis of more recent studies 
of smoking cessation and indicators of general morbidity.
Description of the Literature Review
Scientific literature from 1990 to 2017 was system-
atically reviewed, and reference lists from the identified 
articles were searched for additional studies. Search terms 
included “smoking cessation,” “epidemiology,” “mor-
bidity,” “health status,” and “quality of life.” Studies were 
included if they measured the benefit of smoking cessa-
tion for general morbidity in former cigarette smokers; 
thus, the appropriate comparison group was continuing 
cigarette smokers but not never smokers. Accordingly, 
only studies that specifically and directly compared out-
comes between former cigarette smokers (defined in 
multiple ways) and current cigarette smokers were con-
sidered. Studies that included former cigarette smokers 
but used only never smokers as the reference group were 
not included because such studies were not informative 
for the purpose of this chapter. However, when informa-
tive comparisons were made in eligible studies that met 
the criterion of comparisons with current smokers, some 
findings for never smokers were included.
Following the systematic review of literature, 
24  studies published from 1995 to 2016 were identified 
that assessed smoking cessation and general morbidity, 
including 7 cross-sectional studies (Table 5.1) (Tillmann 
and Silcock 1997; Olufade et al. 1999; Mulder et al. 2001; 
Bolliger et  al. 2002; Mody and Smith 2006; Heikkinen 
et al. 2008; McClave et al. 2009) and 16 prospective cohort 
studies (Tables 5.2–5.4) (Stewart et  al. 1995; Taira et  al. 
2000; Bolliger et  al. 2002; Zillich et  al. 2002; Erickson 
et al. 2004; Mitra et al. 2004; Croghan et al. 2005; Wiggers 
et  al. 2006; Jensen et  al. 2007; Rungruanghiranya et  al. 
2008; Gutiérrez-Bedmar et al. 2009; Balduyck et al. 2011; 
Papadopoulos et  al. 2011; Hays et  al. 2012; Piper et  al. 
2012; Tian et al. 2016).
Assessment of Morbidity
The general measures of morbidity used in the 
24 identified studies varied but cover three main catego-
ries: general, smoking specific, or disease specific:
1. General. Many studies used general measures of 
HRQoL, most frequently the Short Form (SF)-36 
(SF-36) and SF-12 surveys, both the Medical 
Outcomes Study (Ware Jr and Sherbourne 1992) 
and RAND versions (Hays and Morales 2001). One 
study (Mitra et al. 2004) adapted the SF-36 for use 
in a population with mobility impairments. The 
other generic measures of HRQoL included the 15-D 
(dimensional) (Sintonen 1995), the EuroQoL (The 
EuroQol Group 1990), the QoL Inventory (Frisch 
et al. 1992), the World Health Organization’s QOL-
BREF (Skevington et al. 2004), CDC’s HRQOL-4 and 
its Healthy Days Symptoms Module (Moriarty et al. 
2003), and the Functional Status Questionnaire 
(Jette et al. 1986). The studies identified in the lit-
erature review also assessed dissatisfaction with life 
and general health status.
2. Smoking specific. One study (Olufade et al. 1999) 
used the Smoking Cessation Quality of Life (SCQoL) 
questionnaire.
3. Disease specific. Some studies used disease-specific 
measures of HRQoL. These measures assess the 
impact of specific diseases on relevant components 
of QoL. The European Organisation for Research and 
Treatment of Cancer (EORTC) QoL Questionnaire 
QLQ-C30 (Aaronson et al. 1993) was used, along with 
the LC13 module for lung cancer (Bergman et  al. 
1994) and the H&N35 module for head and neck 
cancer (Bjordal et  al. 1994). Other disease-specific 
instruments included the Aquarel questionnaire for 
patients with pacemakers (Stofmeel et al. 2001), the 
Clinical COPD Questionnaire (van der Molen et al. 
2003), and the VascuQoL questionnaire for patients 
with peripheral arterial disease (Morgan et al. 2001).
Assessment of Smoking Status
Most of the 24 identified studies assessed cigarette 
smoking status by self-report. Self-reported smoking 
status continues to be sufficiently valid and reliable for 
studying the general population but may be less accurate 
for assessing smoking in high-risk or medical patients 
(Velicer et al. 1992; USDHHS 2004, 2014).
Smoking Cessation
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Table 5.1 Cross-sectional studies about smoking status and quality of life
Study Design/population Smoking status Health status measure Outcomes/findings Comments
Tillmann and 
Silcock (1997)
• Cross-sectional 
study
• Current smokers 
and ex-smokers 
randomly selected 
from records of nine 
general practices
• n = 3,000
• 1995
• Scotland
• Current smokers 
(n = 1,500)
• Ex-smokers of 
5 years or more 
(n = 1,500)
• SF-36
• EuroQoL tariff 
scores
• HRQoL, as measured by SF-36 and EuroQoL 
tariff scores, was significantly higher for 
ex-smokers than for current smokers.
• Mean difference by measure and QoL 
dimension:
 – EuroQoL tariff: 0.03 (95% CI, 0.011–0.058), 
p = 0.004
 – Physical functioning: 3.93 (95% CI, 1.267–
6.585), p = 0.004
 – Role-physical: 4.52 (95% CI, 0.519–8.516), 
p = 0.027
 – Bodily pain: 3.10 (95% CI, 0.508–5.698), 
p = 0.019
 – General health: 5.32 (95% CI, 3.027–7.611), 
p = 0.000
 – Vitality: 5.41 (95% CI, 3.348–7.469), 
p = 0.000
 – Social functioning: 4.36 (95% CI, 1.015–
6.810), p = 0.000
 – Role-emotional: 4.77 (95% CI, 0.960–8.588), 
p = 0.014
 – Mental health: 5.13 (95% CI, 3.401–6.907), 
p = 0.000
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Study Design/population Smoking status Health status measure Outcomes/findings Comments
Olufade et al. 
(1999)
• Cross-sectional 
study conducted as 
a pilot test of SCQoL 
questionnaire
• Convenience sample 
of smokers and 
former smokers, 
18 years of age 
and older at 
health clinics
• n = 101
• 1997–1998
• United States
• Current smokers 
(n = 75)
• Former smokers, 
smokefree for 
≥2 weeks (n = 23) 
• SF-36
• SCQoL
• Compared with current smokers, former 
smokers had significantly higher scores on 
physical functioning, vitality, general health, 
and PCS-36, but they showed no significant 
differences on other SF-36 measures
• Compared with current smokers, former 
smokers had significantly higher scores on 
SCQoL measures of self-control, sleep, and 
anxiety, but they did not differ on social 
interactions or cognitive functioning
• SF-36, mean difference (former smoker vs. 
current smoker) by QoL dimension:
 – Physical functioning: 15.7, p <0.05
 – Role-physical: 13.5, p >0.05
 – Role-emotional: 11.3, p >0.05
 – Vitality: 15.1, p <0.05
 – Mental health: 7.4, p >0.05
 – Social functioning: 5.4, p >0.05
 – Bodily pain: 2.9, p >0.05
 – General health: 21.5, p <0.01
 – PCS-36: 6.1, p <0.05
 – MCS-36: 3.4, p >0.05
• SCQoL, mean difference (former smoker vs. 
current smoker) by QoL dimension:
 – Social interactions: 7.9, p >0.05
 – Self-control: 45.2, p <0.01
 – Sleep: 15.1, p <0.01
 – Cognitive functioning: 9.7, p >0.05
 – Anxiety: 15.2, p <0.05
—
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Mulder et al. 
(2001)
• Cross-sectional 
study
• Random sample 
of the general 
population, 20–59 
years of age without 
a history of smoking-
related chronic 
diseases
• n = 9,660
• 1995–1997
• The Netherlands
• Never smokers
• Ex-smokers
• Current smokers
• RAND-36 (adapted 
from SF-36)
• Ex-smokers reported significantly higher 
QoL scores than current smokers for all QoL 
dimensions (p <.05), except for bodily pain
• Adjusted mean scores on QoL measures did 
not differ significantly between never smokers 
and ex-smokers, except for bodily pain 
(p <0.0001)
• A higher number of years since quitting was 
associated with higher scores on general 
health, vitality, mental health, and the MCS
• Differences in QoL scores between ex-smokers 
and current smokers were more pronounced 
for QoL dimensions reflecting mental health 
than physical health
• No significant trend was observed for time 
since quitting
—
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Bellido-Casado 
et al. (2004)
• Cross-sectional 
study
• Representative 
sample of the general 
population older 
than 14 years of age
• n = 265
• 1997–2000
• Spain
• Smokers
• Nonsmokers
• Former smokers
• SF-36 • No statistically significant differences by 
smoking status in measures of physical health 
(p = 0.682) or emotional health (p = 0.430)
• Physical QoL dimensions—mean scores 
(95% CI):
 – Physical function:
	| Smokers: 86.92 (83.14–90.71)
	| Former smokers: 89.09 (84.74–93.44)
 – Role-emotional:
	| Smokers: 86.81 (78.79–94.83)
	| Former smokers: 89.57 (80.35–98.79)
 – Bodily pain:
	| Smokers: 68.24 (62.36–74.13)
	| Former smokers: 67.22 (60.46–73.99)
 – General health:
	| Smokers: 59.54 (54.72–64.36)
	| Former smokers: 61.24 (55.71–66.78)
• Emotional QoL dimensions—mean scores 
(95% CI):
 – Vitality:
	| Smokers: 59.07 (53.32–64.83)
	| Former smokers: 63.55 (56.94–70.17)
 – Social function:
	| Smokers: 83.66 (78.10–89.22)
	| Former smokers: 88.00 (81.60–94.39)
 – Role-emotional:
	| Smokers: 79.44 (69.01–89.87)
	| Former smokers: 84.67 (72.68–96.66)
 – Mental health:
	| Smokers: 71.99 (66.90–77.08)
	| Former smokers: 74.33 (68.48–80.18)
Adjusted for age, 
sex, social class, 
alcohol consumption, 
accumulated 
exposure to tobacco, 
diurnal sleepiness, 
number of known 
risk factors, and BMI
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Mody and Smith 
(2006)
• Cross-sectional 
study
• Representative 
sample of 
noninstitutionalized 
adults from the 2001 
Behavioral Risk 
Factor Surveillance 
System
• n = 209,031
• 2001
• United States
• Nonsmokers 
(n = 108,072)
• Current smokers 
(n = 48,096)
• Ex-smokers 
(n = 52,863)
• HRQoL measured 
by self-rated health 
status, number of 
days of poor physical 
health, number of 
days of poor mental 
health, and number 
of days of activity 
limitations
• Compared with ex-smokers, current smokers 
were (reported as ORs):
 – 1.48 (95% CI, 1.32–1.65) times as likely to 
experience ≥14 days of activity limitations 
in the past 30 days
 – 1.29 (no CI provided) times as likely to 
report poor general health
 – 1.30 (95% CI, 1.19–1.42) times as likely to 
report ≥14 days of poor physical health
 – 1.65 (95% CI, 1.50–1.81) times as likely to 
report ≥14 days of poor mental health
Adjusted for age, 
sex, race, education 
level, marital status, 
annual household 
income, BMI, and 
presence of at least 
one comorbid disease
Heikkinen et al. 
(2008)
• Cross-sectional 
study
• Nationally 
representative 
sample of adults, 
30 years of age 
and older
• n = 8,028
• 2000–2001
• Finland
• Never smokers
• Daily smokers
• Occasional smokers
• Ex-smokers 
(reported not 
smoking for at 
least the past 
month)
• 15-D
• Overall QoL was 
assessed by a single- 
question measure 
that captured 
the respondent’s 
perception and 
estimation of his 
or her QoL
• Ex-smokers reported higher scores than daily 
smokers on most dimensions of QoL
• Compared with men who smoked daily, men 
who were ex-smokers scored significantly 
higher in mobility, seeing, breathing, 
usual activities, discomfort and symptoms, 
depression, distress, and vitality (p <.05) and 
significantly lower in excreting (p <0.05)
• Compared with women who smoked daily, 
women who were ex-smokers scored 
significantly higher on breathing, eating, 
depression, distress, and vitality (p <0.05)
Adjusted for age
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McClave et al. 
(2009)
(continues on 
next page)
• Cross-sectional 
study
• Representative 
sample of 
noninstitutionalized 
adults from the 2006 
Behavioral Risk 
Factor Surveillance 
System surveys in 
Delaware, Hawaii, 
Rhode Island, and 
New York
• n = 17,800
• United States
• Never smokers 
(n = 9,149)
• Former smokers 
(n = 5,522)
• Nonquitters 
(n = 1,363)
• Unsuccessful 
quitters (n = 1,766)
• CDC HRQoL-14 
Healthy Days 
Symptoms Module
• Self-rated general 
health status
• Life dissatisfaction
• Former smokers were less likely than 
nonquitters to report life dissatisfaction 
and frequent depressive symptoms 
• No significant differences were found in 
general health status, frequent anxiety 
symptoms, frequent mental distress, 
frequent physical distress, frequent activity 
limitations, frequent pain, infrequent 
vitality, and frequent sleep impairment
• Among men, no significant differences 
in HRQoL were found between former 
smokers and nonquitters
• Among women, unsuccessful quitters were 
more likely than current smokers to report 
the frequent occurrence of mental distress, 
physical distress, and pain (p <.05)
• OR (95% CI) by QoL dimension and 
smoking status:
 – Fair/poor general health:
	| Former smoker: 1.1 (0.7–1.7)
	| Never smoker: 1.1 (0.7–1.7)
 – Life dissatisfaction:
	| Former smoker: 0.5 (0.3–0.9)
	| Never smoker: 0.4 (0.2–0.7)
 – Frequent anxiety symptoms:
	| Former smoker: 0.7 (0.5–1.1)
	| Never smoker: 0.5 (0.4–0.7)
 – Frequent depressive symptoms:
	| Former smoker: 0.7 (0.4–1.0)
	| Never smoker: 0.6 (0.4–1.0)
 – Frequent mental distress:
	| Former smoker: 1.3 (0.8–2.0)
	| Never smoker: 0.8 (0.5–1.3)
 – Frequent physical distress:
	| Former smoker: 1.3 (0.8–2.0)
	| Never smoker: 1.0 (0.6–1.5)
Adjusted for age, 
race/ethnicity, 
sex, education, 
marital status, 
employment status, 
chronic disease, and 
healthcare coverage; 
unsuccessful quitters 
were respondents 
who had smoked at 
least 100 cigarettes 
in their lifetime, 
currently smoked 
every day or some 
days, and had 
abstained from 
smoking for 1 day 
or longer during the 
previous year in an 
unsuccessful attempt 
to quit smoking; and 
nonquitters were 
current smokers who 
made no attempt 
to quit
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(continued from 
previous page)
McClave et al. 
(2009)
— — —  – Frequent activity limitations:
	| Former smoker: 1.2 (0.7–2.1)
	| Never smoker: 0.8 (0.5–1.4)
 – Frequent pain:
	| Former smoker: 1.3 (0.8–1.9)
	| Never smoker: 1.0 (0.7–1.4)
 – Infrequent vitality:
	| Former smoker: 1.1 (0.8–1.5)
	| Never smoker: 1.1 (0.8–1.4)
 – Frequent sleep impairment:
	| Former smoker: 0.8 (0.6–1.1)
	| Never smoker: 0.6 (0.4–0.8)
—
Notes: 15-D = 15 dimensions (generic, self-administered measure of HRQoL); BMI = body mass index; CDC = Centers for Disease Control and Prevention; CI = confidence 
interval; EuroQoL = European quality of life; HRQoL = health-related quality of life; MCS = Mental Component Summary; OR = odds ratio; PCS = Physical Component 
Summary; QoL = quality of life; SCQoL = Smoking Cessation Quality of Life; SF = Short Form (survey).
Table 5.1 Continued
A Report of the Surgeon General
448  Chapter 5
Table 5.2 Prospective studies about smoking status and quality of life
Study Design/population Smoking status Health status measure Outcomes/findings Comments
Stewart et al. 
(1995)
• Cohort study from 
RCT of smoking 
cessation
• Current smokers, 
18–65 years of 
age at the time of 
enrollment into 
RCT, randomly 
selected in California 
and abstinent for 
24 hours at baseline
• n = 323
• United States
• HRQoL follow-up at 
6 months; smoking 
status assessed at 
3 and 6 months
• Smokers: Had 
smoked within the 
last 7 days (n = 220)
• Nonsmokers: 
Had not smoked 
within the past 
7 days; confirmed 
with cotinine test 
(n = 103)
• Mental health:
 – Psychological well-
being/distress
 – Depression/ 
behavioral–
emotional control
 – Anxiety
 – Positive affect
 – Cognitive 
functioning
 – Energy/fatigue
 – Sleep adequacy
 – Self-esteem
 – Sense of mastery
• Physical health:
 – Physical 
functioning
 – Role functioning
 – Social functioning
 – Pain
 – Current health 
perceptions
• Compared with smokers at 6 months, 
nonsmokers had:
• Significantly higher scores on mental health 
dimensions
• Significantly lower scores on physical and 
role functioning
• No difference in scores on physical 
functioning, social functioning, pain, and 
current health perceptions
• Mean difference (smokers vs. nonsmokers) at 
6 months by QoL component and dimension:
 – Mental health:
	| Psychological well-being/distress: 4.4, 
p <.05
	| Depression/behavioral–emotional control: 
4.9, p <.01
	| Anxiety: 7.7, p <.001
	| Positive affect: 4.2, p <.05
	| Cognitive functioning: 3.4, p <.05
	| Energy/fatigue: 6.6, p <.01
	| Sleep adequacy: 6.5, p <.05
	| Self-esteem: 3.6, p <.05
	| Sense of mastery: 9.3, p <.001
 – Physical health:
	| Physical functioning: 0.8, p >.05
	| Role functioning: -6.0, p <.05
	| Social functioning: -0.7, p >.05
	| Pain: 3.4, p >.05
	| Current health perceptions: 3.2, p >.05
For all QoL 
dimensions, except 
sleep adequacy, 
self-esteem, and 
sense of mastery, 
adjusted for age, sex, 
ethnicity, education, 
employment status, 
marital status, 
number of chronic 
conditions, number of 
cigarettes smoked at 
enrollment, nicotine 
dependence at 
enrollment, nicotine 
gum intervention, 
and initial assessment 
of HRQoL; and for 
sleep adequacy, self-
esteem, and sense of 
mastery dimensions, 
adjusted for all except 
initial assessment 
of HRQoL; excluded 
those who had 
relapsed at 3 months 
but quit again 
by 6 months and 
those who were not 
smoking at 3 months 
but were smoking at 
6 months
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Erickson et al. 
(2004)
• Short-term 
longitudinal 
cohort study
• Adults actively 
attempting to 
quit smoking
• n = 34
• 1999–2002
• United States
• Follow-up at 1 week 
after quitting
• Low addiction: 
FTND ≤6 (n = 22)
• High addiction: 
FTND >6 (n = 12)
• SCQoL questionnaire:
 – HRQoL
 – SF-36
• WPS
• Anxiety and cognitive functioning dimensions 
were significantly worse 1 week after quitting
• Self-control dimension improved significantly 
1 week after quitting
• SF-36 measure of general health showed a 
significant improvement 1 week after quitting.
• WPS score was lower 1 week after quitting 
but was not significant
• Low-addiction group had higher HRQoL 
at baseline
• Compared with the high-addiction group, 
the low-addiction group showed a significant 
improvement in more HRQoL domain scores 
after quitting 
• SCQoL results by domain:
 – Anxiety: p = 0.04
 – Cognitive function: p = 0.02
 – Self-control: p = 0.001
 – Sleep: p = 0.15
 – Social interaction: p = 0.34
• SF-36 results by domain:
 – Bodily pain: p = 0.12
 – General health: p = 0.01
 – Mental health: p = 0.14
 – Physical function: p = 0.27
 – Role-emotional: p = 0.65
 – Role-physical: p = 0.25
 – Social function: p = 0.26
 – Vitality: p = 0.53
• WPS: p = 0.17
—
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Gutiérrez-Bedmar 
et al. (2009)
• Cohort study
• University graduates
• n = 5,234
• 1999–2006
• Spain
• Follow-up at 4 years
• Baseline:
 – Nonsmokers 
(n = 2,639)
 – Ex-smokers 
(n = 1,419)
 – Smokers 
(n = 1,048)
• Follow-up:
 – Nonsmokers 
(n = 3,594)
 – Smokers (n = 818)
 – Recent quitters 
(n = 435)
 – Starters (n = 205)
• SF-36 (validated 
Spanish version)
• Ex-smokers had significantly lower mean 
scores on the SF-36 than nonsmokers in two 
QoL dimensions: role-physical and bodily pain
• Ex-smokers had significantly higher scores 
than smokers of 15–24 cigarettes per day in 
two QoL dimensions: general health and 
role-emotional
• Ex-smokers had significantly higher scores 
than smokers of ≥25 cigarettes per day in 
four QoL dimensions: general health, social 
functioning, role-emotional, and mental health
• At follow-up, the recent quitters group had 
significantly better mean scores than smokers 
in two QoL dimensions: general health and 
role-emotional
Adjusted for age 
and sex
Tian et al. (2016) • Cohort study
• 25-year follow-up 
of participants in 
a previous cohort, 
23–34 years of age 
at enrollment
• n = 2,080
• 2001–2011
• Australia
• Follow-up at 2 and 
5 years
• Baseline smoking 
status:
 – Never smoker
 – Former smoker
 – Current smoker
• Change in smoking 
status:
 – Stable, never 
smokers
 – Stable, former 
smokers
 – Resumed
 – Continuing
 – Quitter
• SF-12 PCS and MCS • No significant differences in HRQoL 
dimensions at baseline between never and 
former smokers.
• Continuing smokers had larger reductions 
than quitters
• The risk of clinically significant improvement 
in physical HRQoL was higher for quitters 
than for continuing smokers
• Clinically meaningful improvement in PCS 
(quitters vs. continuing): RR = 1.43 (95% CI, 
1.03–1.98)
• Mean difference, baseline PCS (former smokers 
vs. never smokers): -0.49 (95% CI, -1.32–0.34)
• Mean difference, baseline MCS (former smokers 
vs. never smokers): -0.36 (95% CI, -1.31–0.60)
Adjusted for age, sex, 
marital status, follow-
up duration, baseline 
PCS, residing in a 
major city, education 
level, BMI, IPAQ level, 
total alcoholic drinks 
per day, and diagnosis 
of current severe 
psychological distress
Notes: BMI = body mass index; CI = confidence interval; FTND = Fagerström Test for Nicotine Dependence; HRQoL = health-related quality of life; IPAQ = International 
Physical Activity Questionnaire; MCS = Mental Component Summary; PCS = Physical Component Summary; QoL = quality of life; RCT = randomized controlled trial; 
RR = relative risk; SCQoL = Smoking Cessation Quality of Life; SF = Short Form (survey); WPS = Work Performance Scale.
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Study Design/population Smoking status Health status measure Outcomes/findings Comments
Bolliger et al. 
(2002)
• Cohort study from 
RCT of oral nicotine 
inhaler for smoking 
reduction
• Healthy adult 
volunteers, unable 
or unwilling to 
stop smoking 
immediately, 
randomized to 
active or placebo 
inhalers for 
18 months and 
encouraged to 
reduce smoking as 
much as possible
• n = 400
• Switzerland
• Follow-up for 
24 months
• Successful reducers: 
Reduction of daily 
cigarettes of at least 
50% from week 6 to 
month 24 (n = 25)
• Control group: 
Failed to reduce 
smoking or carbon 
monoxide output, 
or failed to attend 
one or more of seven 
follow-up visits 
(n = 285)
• SF-36: General 
health, physical 
functioning, energy, 
and emotional 
well-being
• Significantly greater improvement in general 
health was seen in successful reducers 
compared with those in the control group
• Among successful reducers, physical 
functioning showed nonsignificant t trend 
toward greater improvement
• Emotional well-being and energy improved 
more in the successful reducers than among 
those in the control group, but the difference 
was not significant
• Mean change from baseline by QoL dimension 
and smoking status:
 – General health:
	| Successful reducer: 9.4
	| Control group: 2.3
	| p = 0.049
 – Physical functioning:
	| Successful reducer: 7.4
	| Control group: 4.9
	| p = 0.073
 – Energy:
	| Successful reducer: 6.8
	| Control group: 5.3
	| p = 0.23
 – Emotional well-being:
	| Successful reducer: 6.2
	| Control group: 4.2
	| p = 0.50
—
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Zillich et al. 
(2002)
• Cohort study
• Adult smokers 
interested in quitting 
and enrolled in a 
pharmacist-based 
smoking cessation 
program
• n = 31
• 2000–2001
• United States
• Follow-up at 
6 months
• Smoker
• Abstinent: Self-
reported abstinence 
during the previous 
7 days confirmed 
with exhaled carbon 
monoxide test
• SCQoL questionnaire • Among those who reported abstinence, there 
were statistically significant improvements 
for vitality, mental health, and self-control 
at 3 months (p <.05)
SCQoL missing for 
those who did not 
report abstinence
Croghan et al. 
(2005)
• Cohort study 
• Patients undergoing 
treatment 
for nicotine 
independence
• n = 206
• 1998
• United States
• Follow-up for 1 year
• Abstinent ≤6 days 
(n = 60)
• Continuously 
abstinent for entire 
year (n = 146)
• SF-36 • Compared with those who were not 
continuously abstinent for a year, those 
who were continuously abstinent for a year 
reported significantly improved MCS, role 
limitations-emotional, role limitations- 
physical, and general health
Controlled for scores 
at baseline; mean 
scores not reported
Rungruanghiranya 
et al. (2008)
• Placebo-controlled 
RCT for effectiveness 
of nicotine gum
• n = 43
• Thailand
• Follow-up at 
3 months
• Abstinence failure 
(n = 31)
• Abstinence 
successful: Complete 
and continuous 
abstinence for 
3 months (n = 12)
• WHOQoL-BREF • No significant differences in QoL scores were 
observed between those who successfully quit 
and those who failed
—
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Hays et al. (2012) • Placebo-controlled 
RCT of varenicline 
and bupropion 
sustained release
• Adults who 
had smoked 
≥10 cigarettes per 
day for the past year
• n = 2,052
• 2003–2005
• United States
• Follow-up for 1 year
• Adults who 
had smoked 
≥10 cigarettes per 
day for the past year
• SCQoL • Both treatment groups showed clinically 
relevant differences in health transition and 
self-control at 1 year
• Those with longer periods of abstinence 
reported better health transition, self-control, 
vitality, smoking-related anxiety, and MCS 
than those with shorter periods of abstinence
—
Piper et al. (2012) • Cohort study from 
RCT of smoking 
cessation treatments
• n = 1,504
• 2005–2007
• United States
• Follow-up for 3 years
• Non-quitter
• Quitter: 7-day 
point prevalence 
confirmed with 
carbon monoxide 
test
• QoL Inventory • Compared with nonquitters, quitters reported 
significantly lower QoL scores at years 1 and 3
• Compared with continuing smokers, quitters 
showed improved global QoL, HRQoL, and 
affect at years 1 and 3 and fewer stressors 
by year 3
—
Notes: MCS = Mental Component Summary; QoL = quality of life; RCT = randomized controlled trial; SCQoL = Smoking Cessation Quality of Life; SF = Short Form (survey); 
WHOQoL-BREF = World Health Organization Quality of Life-BREF.
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Table 5.4 Prospective studies of special populations
Study Design/population Smoking status Health status measure Outcomes/findings Comments
Taira et al. (2000) • Cohort study of 
RCT of atherectomy 
techniques
• Patients who 
underwent 
percutaneous 
coronary 
revascularization 
for coronary 
artery disease
• n = 1,432
• United States
• Follow-up for 1 year
• Nonsmokers
• Persistent smokers
• Quitters
• SF-36 • All groups showed improvement on 
dimensions of the SF-36, but persistent 
smokers showed a smaller improvement 
than nonsmokers across all dimensions
• Quitters showed improvement equal to or 
better than nonsmokers across all dimensions
• Persistent smokers showed significantly less 
improvement than quitters in three QoL 
dimensions: physical functioning, social 
functioning, and mental health
• Mean difference by QoL dimension and 
follow-up period:
 – Physical functioning:
	| 6 months: 8.4 (p <0.001)
	| 1 year: 5.8 (p = 0.01)
 – Role-physical:
	| 6 months: 10.3 (p <0.001)
	| 1 year: 6.2 (p = 0.14)
 – Bodily pain:
	| 6 months: 4.2 (p <0.001)
	| 1 year: 2.9 (p = 0.25)
 – General health:
	| 6 months: 5.5 (p = 0.001)
	| 1 year: 4.0 (p = 0.07)
 – Vitality:
	| 6 months: 5.2 (p <0.001)
	| 1 year: 2.7 (p = 0.25)
 – Social functioning:
	| 6 months: 7.5 (p <0.001)
	| 1 year: 6.0 (p = 0.01)
 – Role-emotional:
	| 6 months: 3.7 (p = 0.039)
	| 1 year: 0.1 (p = 0.92)
 – Mental health:
	| 6 months: 3.7 (p <0.001)
	| 1 year: 3.8 (p = 0.05)
Adjusted for 
demographic 
and clinical 
characteristics, 
comorbid conditions, 
and baseline 
health status
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Mitra et al. (2004) • Longitudinal 
survey of adults 
with disabilities 
(Massachusetts 
Survey of Secondary 
Conditions)
• n = 355
• 1996–2000
• Massachusetts
• Nonsmokers
• Smokers
• Quitters
• Starters
• SF-36 (enabled 
version)
• Compared with smokers, quitters experienced 
significantly more improvement in mental 
health, energy and vitality, and general 
health perception
Adjusted for sex, 
race/ethnicity, years 
of education, age at 
baseline, number of 
QoL dimensions on 
which respondents 
were dependent 
on activities of 
daily living
Wiggers et al. 
(2006)
• RCT of nicotine 
replacement therapy 
and behavioral 
intervention
• Patients with 
symptomatic 
atherosclerotic 
disease
• n = 344
• The Netherlands
• Follow-up for 1 year
• Smokers with a 
failed quit attempt
• Smokers without a 
failed quit attempt
• Quitters
• SF-36
• Aquarel
• VascuQoL
• Study found no effects of smoking status 
on QoL
—
Jensen et al. 
(2007)
• Longitudinal 
cohort study
• Patients after radical 
radiotherapy or 
surgery for head 
and neck cancer
• n = 114
• Denmark
• Never smokers
• Smokers
• Quitters
• EORTC-C30
• EORTC-H&N35
• Compared with smokers, those who had quit 
smoking at follow-up showed higher physical 
and mental functioning
• The QoL scores of quitters fell between those 
of never smokers and smokers
—
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Balduyck et al. 
(2011)
• Cohort study
• Patients undergoing 
non-small-cell lung 
cancer surgery
• n = 70
• Belgium
• Follow-up for 
12 months
• Nonsmokers
• Former smokers 
(stopped smoking 
before diagnosis 
of lung cancer)
• Recent quitters 
(patients who 
stopped smoking 
between diagnosis 
and surgery)
• EORTC-C30
• EORTC-LC13
• All groups had a reduction in QoL after surgery, 
but those who were former smokers at baseline 
and those who quit smoking after diagnosis 
showed improved QoL scores at follow-up 
compared with those who continued smoking
—
Papadopoulos 
et al. (2011)
• Longitudinal 
cohort study
• Patients with COPD 
who smoked and 
were recommended 
to quit smoking
• Greece
• n = 26
• Follow-up for 
2 months
• Smokers
• Quitters
• SF-12
• CCQ
• Those who successfully quit smoking for 
2 months showed significant differences in 
all domains of the SF-12 and in total CCQ 
score from baseline
• CCQ total score:
 – Before: 1.08 ± 0.82
 – Follow-up: 0.72 ± 0.69
 – p <0.001
—
Notes: CCQ = Clinical COPD Questionnaire; COPD = chronic obstructive pulmonary disease; EORTC-C30 = European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire, Core Module; EORTC-H&N35 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Head and 
Neck Module; EORTC-LC13 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Lung Cancer Module; QoL = quality of life; 
RCT = randomized controlled trial; SF = Short Form (survey); VascuQoL = Vascular Quality of Life (questionnaire).
Table 5.4 Continued
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All of the studies determined whether participants 
were former smokers, but the period of abstinence from 
smoking required for classification as a former smoker was 
not uniform across studies, and some studies did not specify 
a minimum time period of abstinence (McClave et al. 2009; 
Tian et al. 2016). Some studies confirmed smoking status by 
a biomarker, such as cotinine (Stewart et al. 1995) or carbon 
monoxide (Zillich et al. 2002; Rungruanghiranya et al. 2008; 
Hays et al. 2012; Piper et al. 2012). Several studies (Stewart 
et al. 1995; Croghan et al. 2005; Wiggers et al. 2006; Piper 
et al. 2012) defined abstinence as a period of 7 days without 
smoking, but others used different standards, including 
2 weeks (Olufade et al. 1999), 1 month (Mitra et al. 2004; 
Heikkinen et al. 2008), 3 months (Rungruanghiranya et al. 
2008), and 5 years (Tillmann and Silcock 1997). One study, 
Erickson and colleagues (2004), considered level of addic-
tion and divided former smokers into subgroups of low 
and high addiction, as assessed by the Fagerström Test for 
Nicotine Dependence (FTND) (Heatherton et al. 1991).
Some variation was also observed with regard to 
comparison groups used across studies. For example, as 
the reference group for comparing outcomes among those 
who had quit successfully, McClave and colleagues (2009) 
used unsuccessful quitters, defined as those who had 
attempted to quit at least once in the past year but were 
currently smoking. In a clinical trial of nicotine replace-
ment therapy (NRT), Bolliger and colleagues (2002) com-
pared successful reducers, who were ongoing smokers 
who had achieved at least a 50% reduction in the number 
of cigarettes smoked daily from week 6 to month 24 of the 
trial, with unsuccessful reducers.
Epidemiologic Evidence
Cross-Sectional Studies
Table 5.1 summarizes cross-sectional studies of 
smoking cessation and morbidity. Seven cross-sectional 
studies assessed smoking cessation and morbidity by 
asking participants to self-report smoking status and a 
measure of morbidity at the time of survey. Several studies 
that used the SF-36 to assess HRQoL observed that having 
quit smoking was associated with higher scores on some 
measures. Tillmann and Silcock (1997), in a study of 
3,000 participants, reported significantly higher HRQoL, 
as measured by SF-36 and EuroQoL tariff scores, among 
former smokers who had smoked 5 years or more com-
pared with current smokers in Scotland. Olufade and col-
leagues (1999), in a sample of 101 adults, reported that 
former smokers (smokefree for 2 or more weeks) had sig-
nificantly higher scores on physical functioning, vitality, 
general health, and the Physical Component Summary 
compared with current smokers; however, they found no 
significant differences for other measures on the SF-36. In 
the Netherlands, Mulder and colleagues (2001) reported 
significantly higher HRQoL scores for former smokers on 
all measures of the SF-36, except bodily pain compared 
with current smokers. In their sample, the HRQoL of 
former smokers approached that of never smokers, and 
adjusted mean scores on measures of the SF-36 did not 
differ significantly between never smokers and former 
smokers, except for bodily pain. Mulder and colleagues 
(2001) also found that increasing years since quitting was 
associated with higher scores on general health, vitality, 
mental health, and the Mental Component Summary. 
These researchers noted that overall differences in QoL 
between former smokers and current smokers were more 
pronounced for measures of mental health than for phys-
ical health. Although the first three studies found various 
differences by smoking status using the SF-36, in a rep-
resentative sample of adults older than 14 years of age 
in Spain, Bellido-Casado and colleagues (2004) found no 
differences by smoking status in measures of physical, 
emotional, or mental health in the SF-36.
Two studies used data from the Behavioral Risk 
Factor Surveillance System (BRFSS), a telephone-based 
survey of U.S. adults 18 years of age and older. In an anal-
ysis of data from 2001 from a representative sample of 
209,031 adults, Mody and Smith (2006) found that, com-
pared with nonsmokers and former smokers, current 
cigarette smokers were more likely to experience (in the 
past 30 days) 14 or more days of activity limitation, 14 or 
more days of poor physical health, and 14 or more days of 
poor mental health. In addition, in their comparisons with 
former smokers, they found that current smokers were 
more likely to report poor general health. McClave and 
colleagues (2009), who used BRFSS data from 2006 in four 
states, found that former smokers and nonsmokers were 
less likely than current smokers (nonquitters) to report 
life dissatisfaction and frequent depressive symptoms; 
however, there were no significant differences between 
current and former smokers in reported general health 
status, frequent anxiety symptoms, frequent mental dis-
tress, frequent physical distress, frequent activity limita-
tions, frequent pain, infrequent vitality, or frequent sleep 
impairment. Among men, there were no significant dif-
ferences in HRQoL between former and current smokers. 
Among women, reported frequent mental and physical 
distress did not differ significantly between former and 
never smokers and current smokers, but among current 
smokers, women who tried to quit smoking and failed 
were more likely to report frequent mental stress and 
physical distress than were women who did not try to quit.
Heikkinen and colleagues (2008) used the 15-D instru-
ment to assess HRQoL in a nationally representative sample 
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of about 8,000 adults 30 years of age and older in Finland. 
Compared with daily smokers, former smokers (defined 
as those who had not smoked for at least the past month) 
reported higher scores on most measures of the instrument.
Longitudinal Studies
Tables 5.2–5.4 summarize findings from 16 longitu-
dinal studies of smoking cessation and general morbidity. 
These studies fall into three categories: (1)  prospective 
cohort studies, (2)  randomized controlled trials (RCTs), 
and (3)  observational studies embedded within RCTs in 
which the data from the RCTs were analyzed as though 
the studies were observational without preservation of the 
randomization. With these types of longitudinal designs, 
smoking status is assessed before the outcome occurs. In 
contrast, cross-sectional studies assess smoking status 
and the outcome at the same point in time. Prospective 
studies were considered for quality of life (Table 5.2), pop-
ulations receiving cessation treatment (Table  5.3), and 
populations with specific medical conditions (Table 5.4). 
Studies included in Table  5.2 were all designed as pro-
spective cohorts (Stewart et al. 1995; Erickson et al. 2004; 
Gutiérrez-Bedmar et al. 2009; Tian et al. 2016). Table 5.3 
includes studies with different longitudinal designs: pro-
spective cohort (Zillich et al. 2002; Croghan et al. 2005), 
RCT (Rungruanghiranya et  al. 2008; Hays et  al. 2012), 
and observational study within an RCT (Bolliger et  al. 
2002; Piper et  al. 2012). Table  5.4 includes longitudinal 
studies designed as prospective cohorts (Taira et al. 2000; 
Mitra et al. 2004; Jensen et al. 2007; Balduyck et al. 2011; 
Papadopoulos et al. 2011) or observational studies within 
an RCT (Wiggers et al. 2006).
Longitudinal Studies of General Populations
At the 4-year follow-up of 5,234 participants of a 
study based in Spain, Gutiérrez-Bedmar and colleagues 
(2009) found that compared with current smokers, mean 
scores for general, emotional, and mental health were sig-
nificantly better among recent former smokers who had 
quit after the baseline assessment and before the 4-year 
follow-up. Tian and colleagues (2016) assessed HRQoL, 
using the SF-12, in relation to smoking status at baseline 
(never, former, and current smokers) and after 5 years of 
follow-up in about 2,000 Australian adults 31–41 years of 
age at follow-up. There were no significant differences in 
measures comparing never and former smokers at base-
line, but at the 5-year follow-up, those who had continued 
to smoke had larger reductions in QoL scores than those 
who reported being former smokers at follow-up and were 
smokers at baseline. For these quitters, the estimated rel-
ative risk for a clinically significant improvement in phys-
ical HRQoL scores was higher compared with continuing 
smokers. Additionally, former smokers had a higher like-
lihood of a clinically significant improvement in emo-
tional and mental health HRQoL scores compared with 
continuing smokers.
Longitudinal Studies of Populations 
Undergoing Cessation Treatment
Eight trials considered participants engaged in ces-
sation treatment. In one, Stewart and colleagues (1995) 
assessed the smoking status of 323 adults enrolled in a 
community-based RCT of smoking cessation. At base-
line, all participants were smokers. At 6 months, quitters 
had a significantly higher score on all assessed measures 
of mental health compared with continuing smokers, 
including psychological well-being, anxiety, positive 
affect, cognitive functioning, energy, sleep adequacy, self-
esteem, and sense of mastery. In contrast, for the five mea-
sures of physical health, there were no statistically signif-
icant differences between the groups on four measures: 
physical functioning, social functioning, pain, and current 
health perceptions.
Zillich and colleagues (2002) used the SCQoL ques-
tionnaire to evaluate changes in HRQoL among 31 partic-
ipants in a nonrandomized, unblinded trial to evaluate the 
effectiveness of a pharmacist-based smoking cessation pro-
gram. Vitality, mental health, and self-control improved 
significantly among those who successfully quit over the 
6 months of follow-up compared with baseline. However, 
data were missing for participants who did not success-
fully quit and did not return for follow-up. In Switzerland, 
Bolliger and colleagues (2002) enrolled a cohort of 
400 participants from an earlier RCT of an oral nicotine 
inhaler for smoking reduction and examined QoL in rela-
tion to smoking reduction. Healthy adult volunteers were 
randomized to active or placebo inhalers and encouraged 
to reduce their smoking as much as possible; the cohort 
was followed for 24  months. The comparison group of 
nonreducers (less than a 50%  reduction in the number 
of cigarettes smoked daily from week 6 to month 24) was 
used for comparison with successful reducers (at least a 
50% reduction). Compared with the control group, suc-
cessful reducers had significantly greater improvement in 
general health, as measured by the SF-36.
Among those who quit in a study of 34 smokers, 
Erickson and colleagues (2004) considered whether low 
(FTND score ≤6) or high (FTND score >6) levels of addic-
tion affected QoL 1  week after the quit date. The lower 
addiction group showed a significant improvement in 
more of the HRQoL domain scores after the quit date 
compared with the higher addiction group.
Croghan and colleagues (2005) evaluated 206 patients 
treated for nicotine dependence for changes in their health 
status, as measured by the SF-36, 1 year after consultation 
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at the Mayo Clinic. Patients who stopped smoking for 1 year 
or more had significantly higher QoL measures at baseline 
compared with a demographically similar group who had 
not stopped smoking. After controlling for baseline scores, 
patients who stopped smoking for 1 year or more had sig-
nificantly improved scores on the Mental Component 
Summary and for role limitations, both emotional and 
physical, and significantly improved general health com-
pared with those who were not abstinent for a year.
Rungruanghiranya and colleagues (2008) performed 
a placebo-controlled RCT in Thailand that considered the 
effectiveness of nicotine gum for cessation and examined 
changes in QoL after 3 months. Forty-six subjects under-
went screening for the study; two were excluded because 
of NRT use, and one was excluded due to a recent diagnosis 
of diabetes. Among the 43 participants, the study revealed 
no significant differences in improved QoL between those 
who had successfully quit smoking and those who had not.
Piper and colleagues (2012) assessed QoL in 
1,504 participants making a quit attempt as part of an RCT 
of smoking cessation. Both former smokers (i.e., quitters) 
and current smokers (nonquitters) experienced a reduction 
in global QoL at the 1- and 3-year follow-ups, but former 
smokers had a significantly smaller decrease in global QoL. 
Former smokers showed slight improvement in HRQoL 
at years 1 and 3, an outcome significantly different from 
the decreases in HRQoL reported by continuing smokers. 
Former smokers also reported a decrease in negative 
affect at 1 year, which differed significantly from the slight 
increase in continuing smokers.
Hays and colleagues (2012) implemented a placebo-
controlled RCT in which 2,052 participants were treated 
with varenicline, bupropion SR (sustained release), or 
placebo and followed for 52  weeks. Participants in both 
treatment groups showed clinically relevant differences in 
health transition (perceived health compared with base-
line) and self-control at follow-up compared with partici-
pants in the placebo group at follow-up. In terms of absti-
nence, those who had a longer period of abstinence reported 
better health transition and self-control at follow-up com-
pared with those who were abstinent for a shorter period. 
Among those with a longer period of abstinence, findings 
were similar to those abstinent for a shorter period of time 
for vitality, smoking-related anxiety, and improvement in 
scores on the Mental Component Summary.
Longitudinal Studies of Special Populations
Table 5.4 summarizes six longitudinal studies that 
considered smoking cessation in special populations 
defined by disease status. Taira and colleagues (2000) 
assessed QoL after percutaneous coronary revasculariza-
tion in 1,432 patients with coronary artery disease within 
two RCTs (Baim et al. 1998, 2001). All groups (nonsmokers, 
former smokers [quitters], and persistent smokers) showed 
improvements on measures of the SF-3, but the extent of 
improvement differed by smoking status. At 6  months, 
after controlling for baseline scores on the SF-36, improve-
ment among former smokers was comparable to that of 
nonsmokers. At 1  year, persistent smokers continued to 
show significantly less improvement than former smokers 
in physical functioning, social functioning, and mental 
health. Compared with continuing smokers, former 
smokers made significantly greater gains in both Physical 
Component Summary and Mental Component Summary 
scores at 6 months and 1 year.
Using data from Wilber and colleagues (2002), Mitra 
and colleagues (2004) performed a longitudinal study of 
355  adults with disabilities and found that changes in 
smoking status were associated with future changes in 
QoL scores—with former smokers experiencing signifi-
cantly more improvement in mental health, energy and 
vitality, and perceived general health compared with cur-
rent smokers. In the Netherlands, Wiggers and colleagues 
(2006) studied 344 smokers with atherosclerotic vascular 
disease who were participating in an RCT of NRT com-
bined with a behavioral intervention, and considered both 
general (SF-36) and disease-specific QoL (Aquarel and 
VascuQoL). Overall, participants showed improved phys-
ical and mental QoL, as measured by SF-36 at follow-up 
(2, 6,  and 12 months), but there were no differences by 
smoking status. In a study based in Denmark, Jensen and 
colleagues (2007) considered smoking status and QoL in 
114 patients surveyed after treatment for head and neck 
cancer. Those who had quit smoking at postsurgical 
follow-up showed higher physical and mental functioning 
compared with continuing smokers.
In Greece, Papadopoulos and colleagues (2011) 
investigated smoking cessation and QoL using a disease-
specific score (the Clinical COPD Questionnaire [CCQ]) 
in a cohort of 26  participants with chronic obstructive 
pulmonary disease who had successfully quit smoking 
for 2 months. QoL, as measured by both the CCQ and a 
generic scale (SF-12), improved after 2 months of cessa-
tion. Finally, Balduyck and colleagues (2011), in a study 
based in Belgium, considered 70 patients’ return-to-base-
line QoL after surgery for lung cancer using a disease-
specific score (EORTC-C30 and EORTC-LC13) that was 
administered after a reduction in smoking following sur-
gery in all three smoking status groups (current smoker, 
former smokers, and recent quitters). Those who were 
former smokers at baseline (i.e.,  before their diagnosis) 
and those who quit smoking after diagnosis both showed 
improved QoL at follow-up compared with those who 
continued to smoke, although those who were former 
smokers at baseline had a faster return to baseline QoL 
than recent quitters.
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Synthesis of the Evidence
Studies of morbidity and smoking cessation vary in 
their definitions of cessation, length of follow-up, and mor-
bidity measures, including QoL. Nonetheless, despite these 
variations, the overall findings indicate that smoking ces-
sation lessens general morbidity, specifically as measured 
by HRQoL and assessments of health status. Although the 
level of HRQoL for former cigarette smokers is between 
that of current smokers and never smokers, the HRQoL 
of former smokers approaches that of never smokers for 
many measures. This pattern is found in samples of the 
general population, in study participants undergoing ces-
sation treatment, and in persons with specific diseases. 
Moreover, greater benefits have been found for measures of 
mental health than for measures of physical health. Some 
evidence suggests that persons with lower levels of addic-
tion before cessation appear to experience greater gains in 
mental health, and those who are abstinent for a longer 
period show higher levels of improvement in mental health.
One critical factor to consider in interpreting the 
evidence on smoking cessation and health is the potential 
for reverse causation—that is, the presence of symptoms 
or a disease leading to a decision to quit. If that is the 
case, the rates of symptoms in cross-sectional data might 
be higher in former smokers than in current smokers. 
Even in prospective cohort studies, when changes in indi-
cators of health are tracked over time, the causal direction 
may be difficult to ascertain, particularly if participants 
quit as symptoms develop or as their well-being declines. 
Randomized trials of cessation interventions are not sub-
ject to such temporal limitations; however, generaliz-
ability may be limited because the populations in these 
studies may not reflect smokers in general.
Temporal ambiguity is a particular concern in cross-
sectional studies that assess smoking status and mor-
bidity at the same time. In these cases, a better HRQoL 
in former smokers than in current smokers may result 
from smoking cessation or be a contributing factor to 
successful smoking cessation. Additionally, lower HRQoL 
may reduce the ability to successfully quit smoking. One 
further complication in interpreting cross-sectional data 
is related to the motivation of smokers to quit because of 
the development of smoking-related symptoms of disease. 
This type of reverse causation generally tends to reduce 
associations of cessation with beneficial outcomes.
Longitudinal studies—including prospective cohort 
studies, RCTs, and observational studies within an RCT—
provide higher quality evidence with less opportunity for 
temporal ambiguity, and they can measure QoL at base-
line before differences across groups classified by smoking 
status are assessed. However, smokers who do not quit 
may be less likely to remain in longitudinal studies during 
follow-up (Zillich et al. 2002). Regardless, as with the evi-
dence considered in the 1990 Surgeon General’s report on 
the health benefits of smoking cessation (USDHHS 1990), 
the variety of measures used in studies of cessation can 
limit comparability and summarization across studies.
Summary of the Evidence
This section reviews evidence on smoking cessation 
and general morbidity using a variety of broad, nonspe-
cific but validated measures, such as QoL indicators and 
health status and disease-specific measures. For the mea-
sures that are broad and nonspecific, the determinants of 
responses are multifactorial. Thus, some studies reviewed 
in this chapter attempted to address potential con-
founding. Based on consistent evidence across the studies 
reviewed (Tables 5.1 and 5.2), former smokers have less 
general morbidity than current smokers, as reflected in 
higher QoL scores and in multiple measures of health 
status. Confounding may have affected the results of some 
of the studies reviewed; however, confounding alone does 
not adequately explain the consistent finding of lower 
morbidity and higher QoL among former smokers com-
pared with current smokers. Selection bias is also a poten-
tial concern if persistent smokers, particularly those who 
are ill, are less likely than quitters to remain in follow-up 
during longitudinal studies.
Despite such limitations, the evidence for lower 
morbidity and higher QoL among former smokers than 
among current smokers is strengthened by the higher 
levels of improvement in QoL seen among those who had 
abstained from smoking longer; such a finding supports 
a conclusion of causality. Former smokers tend to have 
higher morbidity than never smokers; and in some sub-
groups, the morbidity of former smokers can approach 
that of never smokers, such as among those with lower 
levels of addiction before cessation.
A causal link between smoking cessation and a 
decrease in general morbidity is supported by the biologic 
plausibility of the relationship. Active smoking drives var-
ious nonspecific processes of injury (e.g., inflammation), 
which lessen with the end of exposure to the toxins in 
tobacco smoke (USDHHS 2010). Because the morbidity 
measures addressed in the studies reviewed in this chapter 
are broad and nonspecific, a single mechanism cannot be 
invoked to explain the association between smoking ces-
sation and reduction of general morbidity. However, many 
well-supported mechanisms link smoking cessation to 
improvements in more specific measures of health, such 
as disease-specific outcomes, thus underscoring the like-
lihood that those who quit smoking will have lower rates 
of morbidity.
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Benefits of Smoking Cessation on All-Cause Mortality
Increased all-cause mortality is a well-established 
causal consequence of smoking (USDHHS 2004, 2014). 
Chapter 4 of this report (The Health Benefits of Smoking 
Cessation) summarizes disease risks from smoking and 
the changes in risk that follow smoking cessation for 
the major types of chronic diseases. This section briefly 
summarizes the well-documented and extensive sci-
entific evidence on the health benefits of smoking ces-
sation on all-cause mortality. The review is limited in 
scope because the topic has been extensively covered in 
prior reports.
Conclusions from Previous Surgeon 
General’s Reports
The 1964 Surgeon General’s report included a table 
on all-cause mortality with the findings of seven cohort 
studies. In a pioneering quantitative synthesis of the 
data from the seven studies, the ratio of deaths observed 
to deaths expected was 1.68:1 (USDHEW 1964). A con-
temporary analysis of the data from the 1964 Surgeon 
General’s report showed statistically significant increases 
in all-cause mortality in all of the studies (Figures 5.1a 
and 5.1b) (Schumacher et  al. 2014). The 1964 Surgeon 
General’s report concluded that, “Cigarette smoking is 
associated with a 70 percent increase in the age-specific 
death rates of males, and to a lesser extent with increased 
death rates of females. The total number of excess deaths 
causally related to cigarette smoking in the U.S. popu-
lation cannot be accurately estimated. In view of the 
continuing and mounting evidence from many sources, 
it is the judgment of the [Surgeon General’s Advisory 
Committee on Smoking and Health] that cigarette 
smoking contributes substantially to mortality from 
certain specific diseases and to the overall death rate” 
(USDHEW 1964, p. 31).
By the time of the 1964 report, evidence from five 
cohort studies showed lower risk for all-cause mortality in 
former smokers compared with current smokers, and data 
from several cohorts showed declining risk for death in 
former smokers, compared with current smokers, as the 
interval since cessation lengthened.
Subsequent Surgeon Generals’ reports (USDHEW 
1969, 1979; USDHHS 1989, 1990, 2004, 2014) have com-
prehensively covered this topic and published findings 
comparable to those in the 1964 Surgeon General’s report. 
In brief, using data from the American Cancer Society’s 
Cancer Prevention Study II, the 1990 Surgeon General’s 
report included lifetable analyses on the health benefits of 
smoking cessation, offering the following conclusions on 
all-cause mortality:
• “Former smokers live longer than continuing 
smokers, and the benefits of quitting extend to 
those who quit at older ages. For example, persons 
who quit smoking before age 50 have one-half the 
risk of dying in the next 15 years compared with 
continuing smokers.
• Smoking cessation at all ages reduces the risk of 
premature death.
• Among former smokers, the decline in risk of death 
compared with continuing smokers begins shortly 
after quitting and continues for at least 10  to 
15 years. After 10 to 15 years of abstinence, risk of 
all-cause mortality returns nearly to that of persons 
who never smoked” (USDHHS 1990, p. 92).
The 2004 Surgeon General’s report extended these 
findings by comprehensively documenting and updating 
the evidence on active smoking and disease, noting that 
“fortunately for former smokers, studies show that sub-
stantial risks of smoking can be reduced by successfully 
quitting at any age” (USDHHS 2004, p. 25). Furthermore, 
the report concluded that “quitting smoking has imme-
diate as well as long-term benefits, reducing risks for dis-
ease caused by smoking and improving health in general” 
(USDHHS 2004, p. 25).
The 2014 Surgeon General’s report provided the 
most recent extensive review of the consequences of 
smoking on health and confirmed findings from previous 
reports in the series:
• “The evidence is sufficient to infer that cigarette 
smoking increases risk for all-cause mortality in 
men and women.
• The evidence is sufficient to infer that the relative 
risk of dying from cigarette smoking has increased 
over the last 50 years in men and women in the 
United States” (USDHHS 2014, p. 641).
The 2014 Surgeon General’s report also compared 
the relative risks for all-cause mortality in the American 
Cancer Society’s Cancer Prevention Studies I (1959–1965) 
and II (1982–1988) with those in a pooled analysis of five 
contemporary cohorts with follow-up through 2010. The 
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Figure 5.1a Incidence rate ratios for death from any cause, by smoking status
Figure 5.1b Incidence rate ratios for death from lung cancer, by smoking status
Source: Schumacher and colleagues (2014). Copyright © 2014, Massachusetts Medical Society. Reprinted with permission from 
Massachusetts Medical Society.
Note: CI = confidence interval. “Panel A shows incidence-rate ratios for death from any cause, and Panel B shows incidence-rate ratios 
for death from lung cancer. The incidence rate is the number of events per 100 person-years. Person-years were attributed such that 
the incidence-rate ratios were equal to the reported mortality ratios implicitly, assuming that data were based on a homogeneous age 
group. Standard errors were not affected, since they depend only on the number of observed deaths. Since no study-specific detailed 
tables of data on persons who did not smoke were available, the group of nonsmokers in this forest plot is larger than the one used by 
Cochran and hence contains more observed deaths; to correct for this, standard errors were inflated accordingly. The horizontal lines 
represent confidence intervals, with arrows indicating extensions of the intervals. Boxes represent estimated incidence-rate ratios, 
with the sizes of the boxes indicating the inverse variance of the respective studies. Diamonds represent the pooled incidence-rate 
ratio. The width of the diamonds represents the width of the 95% confidence interval of the pooled incidence-rate ratio” (Schumacher 
et al. 2014, p. 187).
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comparison revealed rising relative risks for all-cause 
mortality among current smokers, both men and women, 
in the contemporary cohorts. Among former smokers, the 
relative risks were substantially lower in the contempo-
rary cohorts compared with those in the earlier American 
Cancer Society cohorts. However, compared with never 
smokers, the relative risks for former smokers were higher 
in the contemporary cohorts compared with the earlier 
cohorts (Tables 5.5a and 5.5b).
The 2014 Surgeon General’s report also found that 
despite advancement in disease prevention and treatment 
over the past 50 years, current cigarette smokers had not 
experienced as much improvement in life expectancy 
compared with former and never smokers. Former 
smokers had progressively lower relative risk of all-cause 
mortality the younger they quit smoking (USDHHS 
2014). For example, the Million Women Study found 
that women who quit smoking before 30 years of age and 
before 40 years of age avoided more than 97% and 90% of 
excess mortality risk, respectively, compared with those 
who continued smoking (Pirie et al. 2013). In an analysis 
of more than 216,000 adults from 1997 to 2004, Jha and 
colleagues (2013) found a similar relationship between 
smoking and survival: Smoking cessation before 40 years 
of age reduced the risk of death associated with continued 
smoking by approximately 90%. Additionally, adults who 
Table 5.5a Relative risks by smoking status and age group among adult men 35 years of age and older, United States
  Current smokers (years of age) Former smokers (years of age)
  35–54a 55–64b 65–74b ≥75b 35–54a 55–64b 65–74b ≥75b
Lung cancer 14.33 19.03 28.29 22.51 4.40 4.57 7.79 6.46
Other cancersc 1.74 1.86 2.35 2.18 1.36 1.31 1.49 1.46
Coronary heart disease 3.88 2.99 2.76 1.98 1.83 1.52 1.58 1.32
Other heart diseased — — 2.22 1.66 — — 1.32 1.15
Cerebrovascular disease — — 2.17 1.48 — — 1.23 1.12
Other vascular diseasese — — 7.25 4.93 — — 2.20 1.72
Diabetes mellitus — — 1.50 1.00 — — 1.53 1.06
Other cardiovascular diseasesf 2.40 2.51 — — 1.07 1.51 — —
Influenza, pneumonia, tuberculosis — — 2.58 1.62 — — 1.62 1.42
Chronic obstructive pulmonary diseaseg — — 29.69 23.01 — — 8.13 6.55
Influenza, pneumonia, tuberculosis, 
chronic obstructive pulmonary diseaseh
4.47 15.17 — — 2.22 3.98 — —
All causes 2.55 2.97 3.02 2.40 1.33 1.47 1.57 1.41
Source: Analyses of Cancer Prevention Study II and updated analyses of the pooled contemporary cohort population described in Thun 
and colleagues (2013) provided to the Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and 
Health Promotion, Office on Smoking and Health.
aRelative risks for 35–54 years of age were obtained from Cancer Prevention Study.
bRelative risks for 55–64 years of age, 65–74 years of age, and 75 years of age and older were obtained from merged contemporary cohorts 
(Thun et al. 2013).
cOther cancers consist of cancers of the lip, pharynx and oral cavity, esophagus, stomach, pancreas, larynx, cervix uteri (women), kidney 
and renal pelvis, bladder, liver, colon and rectum, and acute myeloid leukemia.
dOther heart disease is composed of rheumatic heart disease, pulmonary heart disease, and other forms of heart disease.
eOther vascular diseases are composed of atherosclerosis, aortic aneurysm, and other arterial diseases.
fFor 35–54 years of age and ages 55–64 years of age, other cardiovascular diseases are composed of other heart disease, cerebrovascular 
disease, other vascular diseases, and diabetes mellitus and were analyzed and reported as one category. A single relative risk based on 
combined conditions was used to compute smoking-attributable mortality. Relative risk based on combined conditions was used to 
compute smoking-attributable mortality in these age strata.
gChronic obstructive pulmonary disease is composed of bronchitis, emphysema, and chronic airways obstruction.
hFor 35–54 years of age and 55–64 years of age, influenza, pneumonia, tuberculosis, and chronic obstructive pulmonary disease 
were analyzed and reported as one category. A single relative risk based on combined conditions was used to compute smoking-
attributable mortality.
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had quit smoking at 25–34, 35–44, or 45–54 years of age 
gained about 10, 9, and 6 years of life, respectively, com-
pared with those who continued smoking. These find-
ings are consistent with those reported in the 2004 and 
2014 Surgeon General’s reports. Although smokers lose 
an estimated decade of life on average, smoking cessation 
by 40 years of age avoided more than 90% of the excess 
mortality caused by continued smoking (USDHHS 2004, 
2010; Pirie et al. 2013). Even quitting smoking by about 
60 years of age could reduce premature mortality by 40% 
(USDHHS 2004, 2010).
Summary of the Evidence
The health benefits of smoking cessation on all-
cause mortality have been systematically reviewed in pre-
vious Surgeon General’s reports (USDHHS 2004, 2014). 
The evidence published since the 1990 Surgeon General’s 
report continues to affirm that smoking cessation at any 
age reduces the risk of premature death (Jha et al. 2013; 
Pirie et al. 2013; USDHHS 2014). The relative risk for 
dying from smoking has increased over time, but the ben-
efit of quitting persists.
Table 5.5b Relative risks by smoking status and age group among adult women 35 years of age and older, United States
  Current smokers (years of age) Former smokers (years of age)
  35–54a 55–64b 65–74b ≥75b 35–54a 55–64b 65–74b ≥75b
Lung cancer 13.30 18.95 23.65 23.08 2.64 5.00 6.80 6.38
Other cancersc 1.28 2.08 2.06 1.93 1.24 1.28 1.26 1.27
Coronary heart disease 4.98 3.25 3.29 2.25 2.23 1.21 1.56 1.42
Other heart diseased — — 1.85 1.75 — — 1.29 1.32
Cerebrovascular disease — — 2.27 1.70 — — 1.24 1.10
Other vascular diseasese — — 6.81 5.77 — — 2.26 2.02
Diabetes mellitus — — 1.54 1.10 — — 1.29 1.06
Other cardiovascular diseasesf 2.44 1.98 — — 1.00 1.10 — —
Influenza, pneumonia, tuberculosis — — 1.75 2.06 — — 1.28 1.21
Chronic obstructive pulmonary diseaseg — — 38.89 20.96 — — 15.72 7.06
Influenza, pneumonia, tuberculosis, 
chronic obstructive pulmonary diseaseh
6.43 9.00 — — 1.85 4.84 — —
All causes 1.79 2.63 2.87 2.47 1.22 1.34 1.53 1.43
Source: Analyses of Cancer Prevention Study II and updated analyses of the pooled contemporary cohort population described in Thun 
and colleagues (2013) provided to the Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and 
Health Promotion, Office on Smoking and Health.
aRelative risks for 35–54 years of age were obtained from Cancer Prevention Study.
bRelative risks for 55–64 years of age, 65–74 years of age, and 75 years of age and older were obtained from merged contemporary cohorts 
(Thun et al. 2013). Relative risks for other vascular diseases among women 55 years of age and older do not include data from the 
Women’s Health Initiative of the National Heart, Lung, and Blood Institute.
cOther cancers consist of cancers of the lip, pharynx and oral cavity, esophagus, stomach, pancreas, larynx, cervix uteri (women), kidney 
and renal pelvis, bladder, liver, colon and rectum, and acute myeloid leukemia.
dOther heart disease is composed of rheumatic heart disease, pulmonary heart disease, and other forms of heart disease.
eOther vascular diseases are composed of atherosclerosis, aortic aneurysm, and other arterial diseases.
fFor 35–54 years of age and ages 55–64 years of age, other cardiovascular diseases are composed of other heart disease, cerebrovascular 
disease, other vascular diseases, and diabetes mellitus and were analyzed and reported as one category. A single relative risk based on 
combined conditions was used to compute smoking-attributable mortality. Relative risk based on combined conditions was used to 
compute smoking-attributable mortality in these age strata.
gChronic obstructive pulmonary disease is composed of bronchitis, emphysema, and chronic airways obstruction.
hFor 35–54 years of age and 55–64 years of age, influenza, pneumonia, tuberculosis, and chronic obstructive pulmonary disease 
were analyzed and reported as one category. A single relative risk based on combined conditions was used to compute smoking-
attributable mortality.
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Benefits of Smoking Cessation on Economic Costs
Cigarette smoking causes both substantial mor-
bidity and premature mortality, resulting in significant 
economic costs for smokers and their families and very 
large costs for society in general (USDHHS 2004). Because 
smoking cessation reduces these costs, the comparative 
costs and benefits of treatments for smoking cessation will 
help to inform tobacco control strategies for different set-
tings. In evaluating the economic dimensions of smoking 
cessation, consideration needs to be given to the specific 
costs and benefits generated by programs or policies that 
increase successful cessation. These costs and benefits, 
which extend into numerous sectors beyond healthcare, 
include the consequences for employment, such as lost 
productivity from active smoking, as well as for retire-
ment benefits and pensions that may be transferred to 
never smokers and former smokers from early tobacco-
related death among sustained smokers who do not quit 
(National Cancer Institute and World Health Organization 
2016). This section focuses on the economic dimensions 
of smoking cessation, including the critical comparator: 
the costs of smoking.
Economic Costs of Smoking
The economic costs of an intervention or man-
aging a health outcome represent the opportunity cost of 
resources used, which includes direct costs, productivity 
losses, and intangible costs. Direct costs include direct 
medical and nonmedical costs; productivity losses—often 
referred as indirect costs—include the costs associated 
with morbidity and premature mortality; and intangible 
costs include such difficult-to-monetize consequences as 
pain and suffering and emotional well-being (Haddix et al. 
2003). As with smoking-attributable increases in mor-
bidity and premature mortality, the economic costs of 
smoking have been estimated for decades. Since 1991, for 
example, CDC has used the SAMMEC model to estimate 
the economic costs associated with lost productivity due 
to premature death from tobacco use (Shultz et al. 1991; 
USDHHS 2014). These estimates are produced by first 
estimating the total number of years of productive life lost 
from early mortality attributable to smoking and then con-
verting that loss into financial terms to indicate monetary 
loss because of lost work productivity. Using the SAMMEC 
model, CDC estimated, for example, that the average 
annual smoking-attributable economic cost of lost pro-
ductivity for 2000−2004 was $96.8 billion when premature 
mortality alone was considered (CDC 2008). Combining the 
costs of lost productivity with the direct healthcare expen-
ditures attributable to smoking of $96 billion during the 
same period, the total annual smoking-attributable eco-
nomic cost was $193 billion (CDC 2008). Using data linked 
between the 2006–2010 Medical Expenditure Panel Survey 
and the 2004–2009 National Health Interview Survey, 
the estimated annual healthcare expenditure attribut-
able to smoking was as much as $170 billion in 2010 dol-
lars; public programs—including Medicare, Medicaid, and 
other federally sponsored programs—accounted for more 
than 60% of this estimate (Xu et al. 2015b). However, these 
estimates underestimate the economic impact of smoking, 
because they do not account for smoking-related dis-
ability, smoking-related absenteeism from work, smoking-
attributable loss of earnings, and morbidity and mortality 
attributable to exposure to secondhand smoke.
Regardless, national estimates that are similar to 
those presented above can be developed for states using 
the methodology underlying inclusive state-specific esti-
mates, such as those for the state of California made 
by Max and colleagues (2016). The authors estimated 
smoking-attributable healthcare costs in California in 
2009 using a series of econometric models, which esti-
mated expenditures for such healthcare categories as 
hospital care, ambulatory care, prescriptions, and home 
health and nursing home care. An econometric model was 
also used to predict lost productivity because of illness, 
particularly how smoking status influenced the number 
of days absent from work. Premature mortality because of 
smoking was estimated using an epidemiologic approach. 
Using these approaches, Max and colleagues (2016) cal-
culated $1.4 billion in lost productivity from illness and 
$6.8 million in lost productivity from premature mortality 
among smokers in California in 2009.
The 2014 Surgeon General’s report used three dif-
ferent approaches, all based on the SAMMEC method-
ology, to derive updated estimates of smoking-attributable 
direct healthcare expenditures (USDHHS 2014):
1. Using medical service costs from 2009, the esti-
mated aggregated annual healthcare expenditure 
attributable to cigarette smoking was $132.5 billion 
in 2009 dollars. Using the Medical Care part of 
the Consumer Price Index to account for inflation 
(available from the U.S. Bureau of Labor Statistics 
[2017]), the expenditure in 2017 dollars was 
$167.7 billion.
2. Using age- and sex-specific relative risks, the estimated 
smoking-attributable direct healthcare spending was 
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$175.9 billion (in 2013 dollars) and $196.7 billion in 
2017 dollars.
3. Using a two-part regression analysis of Medical 
Expenditure Panel Survey (MEPS) data, the esti-
mated smoking-attributable direct healthcare 
spending was $169.3  billion (in 2010 dollars) and 
$207.2 in 2017 dollars (Xu et al. 2015b).
4. The 2014 Surgeon General’s report also used 
updated lifetables and estimates of the present 
value of future earnings to estimate the smoking-
attributable economic cost of lost productivity; 
the estimate was $150.7  billion in 2009 dollars 
($190.7  billion in 2017 dollars) (USDHHS 2014). 
Moreover, the report estimated the economic cost 
of lost productivity because of exposure to sec-
ondhand smoke to be an additional $5.7 billion in 
2009 dollars ($7.2 billion in 2017 dollars), a figure 
that did not account for direct healthcare expendi-
tures attributable to exposure to secondhand smoke 
(USDHHS 2014). The value of lost productivity 
attributable to premature death from smoking was 
$172.2 billion in 2009 ($217.9 billion in 2017 dol-
lars), and the cost attributable to exposure to sec-
ondhand smoke was $6.5 billion in 2009 ($8.2 bil-
lion in 2017 dollars).
On the basis of these updated estimates, the 2014 
Surgeon General’s report concluded that the costs of cig-
arette smoking represented a significant portion (7.6–
8.7%) of healthcare expenditures in the United States 
(USDHHS 2014).
The SAMMEC model uses a cross-sectional approach 
to determine the economic expenditures of smoking; it 
estimates the burden of smoking-related disease and death 
of smokers compared with having a population of all non-
smokers and calculates the disease-attributable smoking 
expenditures within a specific period. Another method for 
evaluating the overall economic costs of smoking is the 
life-cycle approach, which estimates the present value of 
the cost of adding a smoker to society and also considers 
that benefits from longer lives because of smoking ces-
sation or prevention will be mitigated because of other 
costs later in life. The life-cycle approach has been imple-
mented using various datasets from national panels in the 
United States.
Sloan and colleagues (2004) used a life-cycle 
approach to estimate the overall cost of smoking. They 
incorporated private costs to smokers, including disability 
and absenteeism; external costs to society, including 
Social Security benefits, pensions, and life insurance; 
and quasi-external costs to family members because of 
their exposure to secondhand smoke. The authors esti-
mated that each new cohort of U.S. smokers, beginning at 
24 years of age, added $203.8 billion of new lifetime costs 
(in year 2000 dollars). Most of the lifetime costs to society 
were private ($168.5  billion), but external and quasi-
external costs (costs imposed by smoking on the spouse 
and children of a smoker) (total of $35.3 billion) were sub-
stantial, even after accounting for federal and state tobacco 
excise taxes at the time of estimation. These external and 
quasi-external costs are much higher than previous esti-
mates of externalities from cigarette smoking, primarily 
because of a better understanding of health effects from 
exposure to secondhand smoke (Chaloupka and Warner 
2000; Sloan et al. 2004). Although these estimates suggest 
that a rational decision maker would never choose to ini-
tiate tobacco use, individual decision making may highly 
discount future negative events for perceived current 
effects and may be further affected by the limited informa-
tion on risk considered by potential smokers (Gruber and 
Koszegi 2001; Gruber 2002).
Regardless of underlying methodology, these esti-
mates document the substantial costs associated with 
smoking. However, these macro-level costs hide the sig-
nificant costs incurred by the households of smokers, 
which include not only the costs of purchasing tobacco 
products but also economic losses because of absenteeism 
from work—because of smoking-related morbidity—and 
of the direct costs of healthcare. Such household costs are 
differentially distributed in the United States, given the 
strong gradient of less smoking with increasing income 
(CDC 2011). Furthermore, the estimated total costs 
include only direct costs and productivity losses; these 
estimates do not consider harder-to-quantify and intan-
gible costs, such as those from the grief and suffering of 
family members and friends of ill smokers. Those costs 
can be measured through surveys using a “willingness-to-
pay” approach, which asks how much a person would pay 
to avoid such a scenario. Costs estimated through willing-
ness-to-pay approaches are often much larger than costs 
that are measured directly (Gold et al. 1996).
Economics of Smoking Cessation
An economic analysis of smoking cessation must 
consider a variety of costs, including costs accrued by 
smokers before successful cessation. Although many per-
sons can quit smoking without any assistance, others need 
assistance from public health programs that encourage 
smoking cessation, or from healthcare services that pro-
vide psychological or pharmacologic assistance to help 
them stop smoking. These interventions, which increase 
smoking cessation, also have associated costs.
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Principles of Cost-Benefit and Cost-Effectiveness 
Analysis
Policies to encourage beneficial behaviors are often 
evaluated by cost-benefit analysis, which compares out-
comes in terms of dollar value and prioritizes different pol-
icies, particularly when resources are scarce or funds are 
limited (Russell 2015). The simplest method for comparison 
is to derive a single estimate for each policy by converting 
all costs and benefits into financial measures. In healthcare, 
however, the full benefits associated with improved health 
are not easily converted into financial benefits because of 
challenges in the financial valuations of extending life or 
avoiding morbidity (Gold et  al. 1996). As a result, cost-
effectiveness analysis is often used in healthcare, but the 
measurements of effect may not always be comparable across 
studies. One type of cost-effectiveness analysis is cost-utility 
analysis, in which health benefits are based on a common 
metric, such as quality-adjusted life-years (QALYs) gained 
(Gold et al. 1996). Recommendations on cost-effectiveness 
in health and medicine were published in 1996 (Gold et al. 
1996; Russell et al. 1996; Siegel et al. 1996; Weinstein et al. 
1996) and updated in 2016 (Sanders et al. 2016).
The particular analytic perspective to choose and 
the evaluation of ratios are two key considerations for 
both cost-benefit and cost-effectiveness analyses. The ana-
lytic perspective taken can change the costs and benefits 
of an evaluation, because evaluations using one perspec-
tive (e.g., that of a payer) may not include the same costs 
or benefits as those using another perspective (e.g.,  that 
of society in general). For example, if an insurance plan 
accrues the costs of paying for a smoking cessation pro-
gram but does not reap the benefits from cessation 
because persons frequently switch insurance plans, such 
switching may result in a less cost-effective scenario for 
the plan. From a societal perspective, however, benefits are 
accrued from all persons who quit successfully, regardless 
of switches in insurance plans. Gold and colleagues (1996) 
recommended the societal perspective as the appropriate 
analytic perspective to provide a full accounting of costs 
and benefits, but other perspectives, such as that of the 
payer when a program to promote smoking cessation is 
implemented, may be the focus of an analysis. Sanders and 
colleagues (2016) recommended considering components 
of cost from an analytical perspective (e.g.,  from health 
sector and societal perspectives).
To assess the cost-effectiveness of an intervention, the 
incremental cost-effectiveness ratio is calculated and evalu-
ated. The ratio estimates how much extra cost is needed 
for an intervention compared with alternatives (control 
or next best alternative in terms of effectiveness) to derive 
an extra unit of benefit (e.g., QALY). To compare the rela-
tive value of multiple policy interventions, both absolute 
cost-effectiveness ratio (the ratio of the cost of intervention 
minus costs averted by the intervention, divided by QALYs 
gained, where the comparison is between an interven-
tion and a “do nothing” or control) and incremental 
cost-effectiveness ratio (the ratio of costs of interventions 
minus costs averted by the intervention, divided by QALYs 
gained, where the comparison is between an intervention 
and the next best intervention) can be estimated (Cohen 
and Reynolds 2008). When evaluating one intervention 
versus a control, the absolute cost-effectiveness and incre-
mental cost-effectiveness are the same. However, an evalu-
ation of multiple interventions should be based on incre-
mental cost-effectiveness ratios. Relying only on absolute 
cost-effectiveness ratios can distort estimates and result in 
invalid conclusions. The absolute cost-effectiveness ratios 
of alternative interventions can be similar and cost-effective 
when compared with an acceptable threshold. However, 
when the incremental cost-effectiveness ratio for an alter-
native is evaluated and compared with the next best alterna-
tive, the alternative may not necessarily be cost-effective—
even if it is cost-effective when compared with the control.
An international consortium that evaluated the rela-
tive costs and benefits of a range of smoking cessation inter-
ventions found that in a high-income country, such as the 
United States, such interventions as automated text mes-
saging, self-help materials, and brief advice from a physician 
have a low cost but only small effects on smoking cessation. 
Conversely, pharmacological and psychological interven-
tions (either by telephone or provided in person) are higher 
in cost but have greater effects on increasing smoking ces-
sation (West et al. 2015). In another examination of relative 
costs and benefits that used a much different framework 
to gauge benefit, disability-adjusted life-years gained, Jha 
and colleagues (2006) found that NRT may be more cost-
effective than other interventions—its higher price not-
withstanding. A systematic review on the economic impact 
of a conservative 20% price increase of tobacco products 
through taxation found evidence of per capita cost savings 
over the short- and medium terms (Contreary et al. 2015).
Because of their relatively high cost, pharmaco-
logic and psychologic smoking cessation interventions 
have been more closely evaluated than inexpensive inter-
ventions. This report summarizes the cost-effectiveness 
ratios gleaned from the review of literature on the cost-
effectiveness of clinical cessation interventions and com-
pares the estimates to a threshold of cost-effectiveness for 
clinical interventions used in healthcare (Neumann et al. 
2014; Sanders et al. 2016).
Cost-Effectiveness of Clinical Smoking Cessation 
Interventions
In a systematic review of the literature, Ruger 
and Lazar (2012) summarized the evidence on the cost-
effectiveness of smoking cessation through 2009. This 
A Report of the Surgeon General
468  Chapter 5
review covered literature indexed in PubMed and the British 
National Health Service’s Economic Evaluation Database 
as containing an economic evaluation (cost-benefit, cost-
effectiveness, cost-utility, or cost-minimization analysis) 
of pharmacotherapy or counseling for smoking cessa-
tion. The review examined 36  economic evaluations in 
detail, including 14  studies of NRT, 12  studies of non-
nicotine-based pharmacotherapy, and 10  studies of brief 
counseling for smoking cessation. The review found that 
cost-effectiveness and other types of economic evaluation 
studies do not routinely use standard metrics to evaluate 
benefits and often use the payer’s perspective, not the 
societal perspective as recommended (Tables 5.6–5.8). 
To standardize dollar value of costs to the same base year, 
estimates in this section were converted to 2017 U.S. dol-
lars from the base case year (or publication year if the 
base case year was not known) using the Medical Care 
part of the Consumer Price Index (all urban consumers). 
When performing benefit-cost analyses, USDHHS typi-
cally values QALY gains at about $500,000  or $850,000, 
depending on the discount rate applied (USDHHS 2016). 
This is substantially larger than the recently recom-
mended values of $100,000 or $150,000 per QALY gained 
(Neumann et al. 2014).
Table 5.6 summarizes studies on nicotine-based 
pharmacotherapies. For NRT, RCTs in the United Kingdom 
estimated that when NRT was added to brief counseling in 
primary care settings, incremental cost per life-year saved 
ranged from $1,115 to $2,541 depending on the age groups 
from the national health system perspective (Stapleton 
et  al. 1999). According to two more recent studies, the 
cost of NRT per additional quitter was $171 compared with 
usual care from the health insurance perspective (Salize 
et  al. 2009) and was $3,781  compared with brief coun-
seling from the state program perspective (Hollis et  al. 
2007). In an examination of observational data, adding free 
NRT to quitline counseling in the United States resulted in 
incremental costs of $132 per life-year saved and $267 per 
quit attempt in Oregon from the program perspective 
(Fellows et  al. 2007) and of $808  per quit attempt in 
Minnesota from the funding agency perspective (An et al. 
2006). Three studies that used decision-analytic modeling 
found incremental cost-effectiveness ratios ranging from 
$9,463  to $23,589  per QALY gained for physician-based 
cessation counseling with nicotine patch compared with 
counseling alone from the payer perspective (Fiscella and 
Franks 1996), $2,388 to $9,791 per QALY gained from the 
societal perspective (Cromwell et al. 1997), and $2,511 to 
$6,020 per life-year saved for NRT compared with coun-
seling or advice alone from the national health services 
perspective (Song et al. 2002).
Five studies that modeled populations of smokers esti-
mated incremental cost-effectiveness ratios for counseling 
and NRT compared with brief physician counseling alone 
ranged from $1,267  to $42,160  per life-year saved from 
the payer perspective (Oster et al. 1986; Wasley et al. 1997; 
Gilbert et al. 2004; Cornuz et al. 2006) and from $2,021 to 
$9,002  per QALY gained from the societal perspective 
(Feenstra et al. 2005). Among two studies on pharmacist-
directed smoking cessation programs, one involving only 
the receipt of advice and motivation compared with usual 
advice from a pharmacist found cost-effectiveness ratios 
ranging from $628  to $2,678  per life-year saved from 
the payer perspective (Crealey et al. 1998), and the other 
incorporating four methods under pharmacist direction 
(quitting cold turkey, two kinds of NRT, and bupropion) 
compared with self-directed quit attempts found cost-
effectiveness ratios ranging from $478 to $2,496 per suc-
cessful quit from the payer perspective (Tran et al. 2002).
Table 5.7 summarizes cost-effectiveness studies of 
non-nicotine-based pharmacotherapies. Five studies eval-
uated varenicline and compared it with different compara-
tors (nortryptiline; bupropion, NRT, and unaided cessation; 
brief counseling alone and unaided cessation; counseling; 
or NRT). Incremental cost-effectiveness ratios ranged from 
$1,409  to $5,838  per quit attempt from the healthcare 
system perspective (Hoogendoorn et  al. 2008) and from 
dominates (i.e., less costly and more effective) to $4,981 per 
QALY gained from the healthcare payer/system perspective 
(Hoogendoorn et al. 2008; Howard et al. 2008; Annemans 
et al. 2009; Bolin et al. 2009b; Igarashi et al. 2009). In some 
trials, varenicline was more efficacious than the com-
parison strategy (whether unaided cessation or cessation 
with NRT or bupropion) and more cost-effective from var-
ious perspectives (healthcare payer/system) (Howard et al. 
2008; Annemans et  al. 2009; Bolin et  al. 2009b; Igarashi 
et al. 2009). Two other studies also showed that an extended 
period of varenicline treatment compared with placebo or 
12 weeks of varenicline, bupropion, or NRT was less costly 
and more effective per QALY gained from the healthcare 
perspective (Knight et  al. 2010) and was more effective 
than placebo, with incremental cost-effectiveness ratios as 
high as $41,053 per QALY gained from the societal perspec-
tive (Bolin et al. 2009a). Studies comparing bupropion with 
NRT found incremental cost-effectiveness ratios as high 
as $1,223  per QALY gained from the societal perspective 
(Bolin et  al. 2006). One study compared bupropion with 
counseling or advice alone and found that the incremental 
cost per life-year saved ranged from $1,603 to $3,746 from 
a national health system perspective (Song et al. 2002).
Table 5.8 summarizes 10  studies that evaluated 
brief counseling therapies conducted with a variety of 
methods, in diverse settings, and with diverse popula-
tions. Using data from RCTs, an evaluation of care that 
included 20  minutes of bedside counseling, 12  minutes 
of videos, self-help materials, and follow-up calls found 
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Table 5.6 Summary of economic evaluations of nicotine-based pharmacotherapies for smoking cessation
Study Design/population Effects Costs Outcomes/findings
Oster et al. 
(1986)
• Meta-analysis
• Cost-effectiveness analysis
• Hypothetical group of smokers seen in 
routine ofﬁce visits
• Intervention/comparison:
 – Physician advice and counseling alone
 – Nicotine gum and physician advice
• Perspective: Payer
• Lifetime
• Life-years saved • Physician time and gum
• Base year: 1984
• Source: Retail prices, 
salary rates
• Range of cost per life-year saved, by sex:
 – Men: $4,113–$6,465 ($18,305–$28,773 in 
2017 $)
 – Women: $6,880–$9,473 ($30,620–$42,160 
in 2017 $)
Fiscella and 
Franks (1996)
• Decision analytic model
• Cost-effectiveness and cost-utility analyses
• Male and female smokers, 25–69 years of 
age receiving primary care
• Intervention/comparison:
 – Physician-based smoking cessation 
counseling with nicotine patch
 – Physician-based smoking cessation 
counseling alone
• Perspective: Payer
• Lifetime
• QALYs saved • Physician time and retail 
price of nicotine patch
• Base year: 1995
• Source: Published average 
wholesale price
• The nicotine patch produced one additional 
lifetime quitter at a cost of $7,332 ($15,805 
in 2017 $)
• Range of incremental cost-effectiveness of 
the nicotine patch, by sex:
 – Men: $4,390–$10,943 per QALY 
($9,463–$23,589 per QALY in 2017 $)
 – Women: $4,955–$6,983 per QALY 
($10,681–$15,053 per QALY in 2017 $)
Cromwell et al. 
(1997)
• Decision probabilities model
• Cost-effectiveness analysis of clinical practice 
guidelines and cost-utility analysis
• Simulated model of U.S. smokers, 18 years 
of age or older who were willing to make a 
quit attempt within 1 year
• Intervention/comparison: Model of five 
counseling interventions for primary care 
physicians (minimal, brief, and full) and 
specialists (individual intensive and group 
intensive) with and without transdermal 
nicotine and nicotine gum
• Perspective: Societal
• 1 year
• QALYs and life- 
years saved
• Quit rates
• Implementation of 
guidelines (screening, 
advice, motivational 
sessions, and interventions)
• Base year: 1995
• Source: Published literature, 
guideline reports, and 
Medicare charges
• Implementing the guidelines cost $3,779 
($8,146 in 2017 $) per quitter, $2,587 ($5,577 
in 2017 $) per life-year saved, and $1,915 
($4,128 in 2017 $) per QALY saved
• Costs per QALY ranged from $1,108 to $4,542 
($2,388 to $9,791 in 2017 $)
• More intensive interventions were more cost-
effective than those with less intensity
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Wasley et al. 
(1997)
• Meta-analysis
• Cost-effectiveness analysis
• Hypothetical samples of 400 smokers 
who smoke ≥20 cigarettes per day
• Intervention/comparison:
 – Nicotine patch with brief counseling
 – Brief physician counseling alone
• Perspective: Payer
• Lifetime
• Life-years saved
• Quit rates
• Physician time and 
nicotine patch
• Base year: 1995
• Source: Average retail 
cost and physicians’ 
medical fee schedules
• Range of average cost per life-year saved, 
by sex:
 – Men: $965–$1,585 ($2,080–$3,417 in 
2017 $)
 – Women: $1,634–$2,360 ($3,522–$5,087 
in 2017 $)
• Range of incremental cost per life-year saved, 
by sex:
 – Men: $1,796–$2,949 ($3,872–$6,357 in 
2017 $)
 – Women: $3,040–$4,391 ($5,553–$9,379 
in 2017 $)
Crealey et al. 
(1998)
• Case control
• Cost-effectiveness analysis
• Matched cases (52) and controls (60) in 
PAS model program in Northern Ireland
• Intervention/comparison:
 – Cases received advice and motivation 
to quit from pharmacist
 – Matched controls received usual advice 
from pharmacists
• Perspective: Payer
• Lifetime
• Life-years saved • Direct intervention 
(PAS materials, training 
for pharmacists, and 
time spent counseling)
• Base year: 1997
• Source: Estimates of 
program costs and 
salary rates
• Range of cost for PAS program per life-year 
saved, by sex:
 – Men: $337–$603 ($683–$1,222 in 2017 $)
 – Women: $310–$1,322 ($628–$2,678 in 
2017 $)
Stapleton et al. 
(1999)
• Randomized controlled trial and survey
• Cost-effectiveness analysis
• 1,200 patients who smoked ≥15 cigarettes 
per day in 15 English counties
• Intervention/comparison:
 – Brief counseling with general practitioner 
plus 16-hour nicotine patch treatment 
and booklet
 – Brief counseling with general practitioner 
plus placebo and booklet
• Perspective: National Health Service
• 12 weeks
• Life-years saved • Treatment (counseling 
time, nicotine patches, 
patient booklets, and 
biochemical validation 
of abstinence)
• Base year: 1998
• Source: National survey 
data and resource 
use survey
• Incremental cost per life-year saved among 
patients if practitioners could prescribe 
nicotine patch, by age group:
 – <35 years: $656 ($1,288 in 2017 $)
 – 35–44 years: $568 ($1,115 in 2017 $)
 – 45–54 years: $712 ($1,398 in 2017 $)
 – 55–65 years: $1,294 ($2,541 in 2017 $)
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Tran et al. 
(2002)
• Observations
• Cost-effectiveness and cost-utility analyses
• 48 patients 21–70 years of age who had tried 
at least once to quit smoking
• Intervention/comparison:
 – Pharmacist-directed smoking cessation 
program using four methods (cold turkey, 
nicotine patch, nicotine gum, bupropion)
 – Self-directed quit attempt
• Perspective: Payer and societal
• 1 year, lifetime
• Quit rate
• Life-years saved
• QALYs saved
• Materials and 
pharmacist time
• Selected cessation 
methods (retail cost)
• Base year: 1997
• Source: Salary data 
and retail costs
• Incremental costs (in 2017 $) using 
pharmacist-directed program, by method 
of smoking cessation per successful quit 
from the payer perspective:
 – $236 ($478 in 2017 $) for cold turkey
 – $936 ($1,896 in 2017 $) for nicotine patch 
 – $1,232 ($2,496 in 2017 $) for nicotine gum
 – $1,150 ($2,370 in 2017 $) for bupropion
Gilbert et al. 
(2004)
• Markov chain cohort simulation
• Cost-effectiveness analysis
• Two simulated cohorts of smokers in 
Seychelles (Africa)
• Intervention/comparison:
 – Physician counseling alone
 – Counseling plus one of five cessation 
therapies (nicotine gum, patch, spray, 
inhaler, or bupropion)
• Perspective: Third-party payer
• Lifetime
• Life-years saved • Additional physician 
time required
• Treatment (retail prices 
for generic treatment 
medications)
• Base year: 2002–2003
• Source: Retail prices 
and wage data
• Incremental cost per life-year saved, by type 
of therapy (U.S. prices):
 – $3,712 ($5,939 in 2017 $) for nicotine gum
 – $1,982 ($3,171 in 2017 $) for nicotine patch
 – $4,597 ($7,355 in 2017 $) for nicotine spray
 – $4,291 ($6,865 in 2017 $) for nicotine 
inhaler
 – $1,324 ($2,118 in 2017 $) for bupropion
Feenstra et al. 
(2005)
• RIVM chronic disease
• Cost-effectiveness and cost-utility analyses
• Smokers in the Netherlands
• Intervention/comparison:
 – Minimal counseling by a general 
practitioner with or without NRT
 – Intensive counseling by a general 
practitioner with NRT or bupropion
 – Telephone counseling
• Perspective: Societal
• 1, 10, or 75 years
• Quit rate
• Life-years gained
• QALYs gained
• Intervention 
• Healthcare for 11 smoking-
related diseases (direct 
costs only)
• Base year: 2000
• Source: Estimated retail 
costs, standard costing 
manual, and salary data
• Cost per QALY gained ranged from $1,109 
($2,021 in 2017 $) for telephone counseling 
to $4,939 ($9,002 in 2017 $) for intensive 
counseling with nicotine patches or gum
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An et al. (2006) • Before and after initiative
• Cost-effectiveness analysis
• 373 callers to the Minnesota QUITPLAN 
helpline
• Intervention/comparison:
 – Quitline callers before initiative
 – Quitline callers enrolled in multisession 
counseling received NRT (patch or gum) 
by mail
• Perspective: Funding agency
• 6 months
• Quit rate • Counseling and provision 
of free NRT
• Base year: Not available
• Source: Estimated 
program costs
• Average number of ex-smokers per month 
increased from 16 to 124
• Average cost per quit increased from $1,362 
($1,926 in 2017 $) to $1,934 ($2,734 in 2017 $)
Cornuz et al. 
(2006)
• Markov-chain cohort simulation
• Cost-effectiveness analysis
• Simulated cohorts of smokers in six countries 
(Canada, France, Spain, Switzerland, United 
States, and United Kingdom)
• Intervention/comparison:
 – Brief cessation counseling by 
general practitioner
 – Counseling plus NRT
• Perspective: Third-party payer
• Lifetime
• Life-years saved • Additional physician time 
required plus medications 
(retail price)
• Base year: 2002–2003
• Source: Pharmacy prices 
and published price data 
from each country
• Range of cost per life-year saved, by type of 
therapy and sex:
 – Gum:
	| $2,230 for men ($3,568 in 2017 $)
	| $7,643 for women ($12,228 in 2017 $)
 – Patch:
	| $1,758 for men ($2,813 in 2017 $)
	| $5,131 for women ($8,209 in 2017 $)
 – Spray:
	| $1,935 for men ($3,096 in 2017 $)
	| $7,969 for women ($12,749 in 2017 $)
 – Inhaler:
	| $3,480 for men ($5,568 in 2017 $)
	| $8,700 for women ($13,919 in 2017 $)
 – Bupropion:
	| $792 for men ($1,267 in 2017 $)
	| $2,922 for women ($4,675 in 2017 $)
Fellows et al. 
(2007)
• Before and after free-patch initiative
• Cost-effectiveness analysis
• 959 smokers who registered for quitline 
service in Oregon
• Intervention/comparison:
 – Pre-initiative program
 – Free-patch initiative from the Oregon 
tobacco quitline
• Perspective: Program
• 1 year
• Quit rate
• Life-years saved
• Media and intervention 
(before and after the 
initiative)
• Base year: 2004
• Source: Quitline utilization 
and cost data from state, 
intervention providers, 
and patients
• Compared with the program before the free-
patch initiative, the new initiative increased 
quitting fourfold and reduced total costs per 
quit by $2,688 ($4,120 in 2017 $)
• Free-patch initiative cost $86 ($22–$353) 
($132 [$34–$541] in 2017 $) per life-year 
saved and $174 ($267 in 2017 $) per 
additional quit attempt
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Hollis et al. 
(2007)
• Randomized trial
• Cost-effectiveness analysis
• 4,614 callers to the Oregon tobacco quitline 
who smoked ≥5 cigarettes per day
• Intervention/comparison: Brief, moderate, 
and intensive telephone counseling with 
or without offers of free nicotine patches
• Perspective: State program
• 1 year
• Abstinence rate • Interventions
• Base year: 2004
• Source: Program records 
of resources consumed
• Compared with brief counseling with no 
NRT, the added costs for each additional 
quit were:
 – $2,467 ($3,781 in 2017 $) for brief 
counseling plus NRT
 – $1,912 ($2,931 in 2017 $) for moderate 
counseling and no NRT
 – $2,109 ($3,233 in 2017 $) for moderate 
counseling plus NRT
 – $2,640 ($4,047 in 2017 $) for intensive 
counseling and no NRT
 – $2,112 ($3,237 in 2017 $) for intensive 
counseling plus NRT
Salize et al. 
(2009)
• Cluster randomized trial
• Cost-effectiveness analysis
• 577 patients who smoked ≥10 cigarettes per 
day in Germany
• Intervention/comparison:
 – Training of general practitioners plus 
remuneration for each abstinent patient
 – Training of general practitioners plus cost-
free NRT and/or bupropion hydrochloride
 – A combination of both strategies
• Perspective: Health insurance
• 1 year
• Abstinence rate • Interventions
• Base year: 2003
• Source: Unit costs per each 
element of treatment in 
the trial
• Compared with usual care, both training of 
general practitioners plus drugs and training 
of general practitioners plus drugs and 
remuneration were cost-effective
• The cost per additional quitter was $107 
($171 in 2017 $) per patient for training of 
general practitioners plus drugs and $97 
($155 in 2017 $) per patient for training 
of general practitioners plus drugs and 
remuneration
Source: Table 4 in Ruger and Lazar (2012).
Notes: NRT = nicotine replacement therapy; PAS = pharmacists action on smoking; QALYs = quality-adjusted life-years; RIVM = chronic disease model developed at the 
National Institute of Public Health and the Environment in The Netherlands. Estimates converted to 2017 U.S. dollars from the base case year (or publication year if no 
base case year) using the Medical Care part of the Consumer Price Index (all urban consumers).
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Study Design/population Effects Costs Outcomes/findings
Song et al. 
(2002)
• Decision analytic model
• Cost-effectiveness analysis
• Simulation based on results from 
published studies
• Intervention/comparison:
 – Advice or counseling alone
 – Advice or counseling plus NRT or 
bupropion sustained release
 – Advice or counseling plus NRT and 
bupropion sustained release
• Perspective: United Kingdom National 
Health Services
• 1 year
• Quit rates
• Life-years saved
• Intervention
• Base year: 2001
• Source: Published studies
• Range of incremental cost per life-year saved 
compared with counseling or advice alone, 
by type of intervention:
 – $1,441–$3,455 ($2,511–$6,020 in 2017 $) 
for NRT
 – $920–$2,150 ($1,603–$3,746 in 2017 $) 
for bupropion sustained release
 – $1,282–$2,836 ($2,234–$4,941 in 2017 $) 
for NRT plus bupropion sustained release
Antoñanzas and 
Portillo (2003)
• Adaptation of health and economic 
consequences of smoking interactive 
simulation
• Cost-effectiveness analysis
• Smokers in Spain
• Intervention/comparison:
 – Bupropion
 – NRT (nicotine patch or gum)
• Perspective: National health system
• 20 years
• Deaths prevented
• Life-years saved
• Intervention
• Healthcare costs for 
tobacco-related diseases 
or conditions (cancers, 
CHD, stroke, COPD, and 
low birth weight)
• Base year: 1999
• Source: National Health 
Survey and National 
Institute of Statistics
• At 20 years, for bupropion and the nicotine 
patch, respectively, there was a net savings 
of $32,920 ($62,441 in 2017 $) and $15,993 
($30,334 in 2017 $) per death prevented 
and a net savings of $3,852 ($7,306 in 
2017 $) and $1,867 ($3,541 in 2017 $) 
per life-year saved
• At 20 years, nicotine gum had a cost-
effectiveness ratio of $41,325 ($78,402 in 
2017 $) per death prevented and $4,786 
($9,078 in 2017 $) per life-year saved
Bolin et al. 
(2006)
• Global health outcomes simulation model
• Cost-effectiveness analysis
• Model cohort of male and female smokers 
in Sweden
• Intervention/comparison:
 – Bupropion
 – NRT (nicotine patches and gum)
• Perspective: Societal
• 20 years
• QALYs gained • Intervention
• Direct costs of smoking 
(COPD, asthma, CHD, 
stroke, and lung cancer)
• Reduced production and 
consumption (indirect 
costs of smoking)
• Base year: 2001
• Source: Swedish unit 
costs, hospital records, 
and physician records
• When direct and indirect costs on production 
and consumption were included, bupropion 
was cost-saving compared with both types 
of NRT
• When only direct costs were included, 
incremental cost per QALY gained for 
bupropion compared with nicotine patches 
was $702 ($1,223 in 2017 $) for men and 
$521 ($908 in 2017 $) for women
Smoking Cessation
The Benefits of Smoking Cessation on Overall Morbidity, Mortality, and Economic Costs  475
Table 5.7 Continued
Study Design/population Effects Costs Outcomes/findings
Halpern et al. 
(2007)
• Decision analytic model
• Cost-effectiveness analysis
• Simulation in cohort of 1,000 smokers 
in the United States
• Intervention/comparison:
 – Varenicline (12 weeks)
 – Nicotine patch (9 weeks)
 – Bupropion (12 weeks)
 – No intervention
• Perspective: Private health plans, state 
Medicaid program, and employer
• 10 years
• Abstinence rates • Intervention
• Medical care for 
smoking-related diseases 
(CHD, COPD, and lung 
cancer) and pregnancy 
complications
• Productivity losses and 
absenteeism
• Base year: 2005
• Source: Literature
• Compared with unaided cessation, cost-
effectiveness of varenicline per additional 
cessation at 2 years ranged from $648 
($953 in 2017 $) in the private health plan 
model to $1,229 ($1,049 in 2017 $) in the 
Medicaid model
Hoogendoorn 
et al. (2008)
• BENESCO model
• Cost-effectiveness and cost-utility analyses
• Hypothetical cohort of Dutch smokers 
making a one-time quit attempt
• Intervention/comparison:
 – Varenicline
 – Untreated or treated with bupropion, 
nortriptyline, or NRT
• Perspective: Dutch healthcare system
• Lifetime
• Quit rate
• QALYs gained
• Intervention
• Direct medical costs of 
smoking-related diseases 
(COPD, lung cancer, CHD, 
and stroke)
• Base year: 2004
• Source: Estimates from 
Dutch source data
• Varenicline estimated to cost $1,472 ($2,256 
in 2017 $) per QALY gained compared with 
nortriptyline and $285 ($437 in 2017 $) 
per QALY gained compared with unaided 
cessation
• Cost of varenicline per additional quitter 
ranged from $919 ($1,409 in 2017 $) 
compared with NRT to $3,809 ($5,838 in 
2017 $) compared with nortriptyline
Jackson et al. 
(2007)
• Decision tree model
• Cost-beneﬁt analysis
• Simulation based on published results 
of clinical trial
• Intervention/comparison:
 – Varenicline
 – Bupropion (brand and generic)
 – Placebo
• Perspective: Employer
• 1 year
• Quit rates • Intervention
• Cost of smoking for 
employer (absenteeism, 
medical care, time lost, 
and insurance)
• Base year: 2006
• Source: Study detailing 
direct and indirect costs of 
smoker to an employer, and 
pricing related to wholesale 
acquisition costs
• Cost savings per nonsmoking employee at 
1 year, by type of intervention:
 – $541 ($765 in 2017 $) for varenicline
 – $270 ($382 in 2017 $) for bupropion 
sustained release (generic)
 – $151 ($213 in 2017 $) for bupropion 
sustained release (brand)
 – $82 ($116 in 2017 $) for placebo
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Howard et al. 
(2008)
• BENESCO Markov simulation
• Cost-utility analysis
• Hypothetical cohort of U.S. adult smokers 
who make a one-time quit attempt
• Intervention/comparison:
 – Varenicline
 – Bupropion
 – NRT
 – Unaided quitting
• Perspective: U.S. healthcare system
• 20 years and lifetime
• QALYs • Intervention
• Direct lifetime costs of 
smoking-related diseases 
(lung cancer, COPD, CHD, 
stroke, and asthma)
• Base year: 2005
• Varenicline was less costly and more effective 
(dominates) than other cessation strategies 
(bupropion, NRT, and unaided cessation) 
over either time period studied (20 years 
and lifetime)
Annemans et al. 
(2009)
• BENESCO Markov simulation
• Cost-effectiveness and cost-utility analyses
• Cohort of Belgian adult smokers making 
a one-time quit attempt
• Intervention/comparison:
 – Varenicline, bupropion, or NRT with 
brief counseling
 – Brief counseling alone
 – Unaided cessation
• Perspective: Healthcare payer (public 
and private)
• Lifetime
• Life-years gained
• QALYs gained
• Intervention
• Direct medical costs related 
to smoking comorbidities 
(COPD, lung cancer, CHD, 
stroke, and asthma)
• Base year: 2007
• Source: Literature and 
public health databases
• Compared with brief counseling alone and 
unaided cessation, varenicline cost $337 
($456 in 2017 $) per life-year gained and 
$2,325 ($3,148 in 2017 $) per QALY gained
• Varenicline is cost-saving compared with 
bupropion and NRT
Bolin et al. 
(2009a)
• BENESCO Markov simulation
• Cost-utility analysis
• Simulated cohort of adult smokers in Sweden 
who successfully abstained after an initial 
12-week treatment of varenicline
• Intervention/comparison:
 – Additional 12 weeks of varenicline
 – Placebo
• Perspective: Societal
• 50 years
• QALYs gained • Intervention
• Average direct medical 
costs from smoking-related 
diseases (COPD, CHD, 
stroke, and lung cancer)
• Average value of indirect 
effects (reduced consumption 
and production)
• Base year: 2003
• Source: Healthcare cost 
data from Skåne, Sweden; 
estimated prescription 
prices; and published 
literature
• Incremental costs per QALY for additional 
12 weeks of varenicline compared with 
placebo were $7,420 ($11,871 in 2017 $) 
for men and $7,464 ($11,941 in 2017 $) 
for women
• Incremental costs per QALY, including 
indirect effects, were $25,359 ($40,571 in 
2017 $) for men and $25,660 ($41,053 in 
2017 $) for women
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Bolin et al. 
(2009b)
• BENESCO Markov simulation
• Cost-effectiveness and cost-utility analyses
• Simulated model in four European 
countries (Belgium, France, Sweden, 
and United Kingdom)
• Intervention/comparison:
 – Varenicline
 – NRT
• Perspective: National healthcare system
• Lifetime
• Life-years gained
• QALYs gained
• Intervention 
• Morbidity-related 
healthcare costs from 
four smoking-related 
morbidities (lung cancer, 
COPD, CHD, and stroke)
• Base year: Not available
• Source: Country-speciﬁc 
databases
• In a typical smoking cessation intervention, 
using varenicline instead of NRT was cost-
saving in all countries except France, which 
had a cost-effectiveness ratio of $3,936 
($4,981 in 2017 $) per QALY gained
Igarashi et al. 
(2009)
• Markov model
• Cost-utility analysis
• Simulated cohort of smokers in Japan 
who started smoking at 20 years of age
• Intervention/comparison:
 – Counseling on smoking cessation by 
a physician
 – Counseling plus varenicline therapy
• Perspective: Healthcare payer
• Lifetime
• QALYs gained • Treatment
• Direct lifetime medical 
costs for tobacco-
associated disease
• Base year: 2007
• Source: Survey of public 
health insurance, National 
Health Insurance, and 
drug tariff
• Adding varenicline to counseling increased 
QALYs and saved medical costs among men
• Adding varenicline to counseling had an 
incremental cost-effectiveness ratio of 
$3,010 ($4,075 in 2017 $) per QALY gained 
in women
Knight et al. 
(2010)
• BENESCO Markov simulation
• Cost-effectiveness and cost-utility analyses
• Hypothetical population of adult American 
smokers who made a single quit attempt
• Intervention/comparison:
 – Initial 12 weeks plus additional 12 weeks 
of varenicline
 – 12 weeks of varenicline, bupropion, 
NRT, or unaided cessation
• Perspective: Healthcare system
• 5, 10, and 20 years and lifetime
• QALYs gained • Direct treatment 
• Morbidity-related 
healthcare costs of 
smoking-related diseases 
(lung cancer, stroke, CHD, 
COPD, and asthma)
• Base year: 2005
• Source: Literature, prices 
in 2005 U.S. Red Book
• An additional 12 weeks of varenicline 
increased 1-year abstinence rates from 23% 
to 28% (compared with initial 12 weeks 
of varenicline)
• During the lifetime of all participants, an 
additional 12 weeks of varenicline was cost-
effective compared with the initial 12 weeks 
of varenicline (an incremental cost per QALY 
gained of $972 ($1,429 in 2017 $)) and was 
less costly and more effective (dominates) 
than other alternatives (bupropion, NRT, 
and unaided cessation)
Source: Table 5 in Ruger and Lazar (2012).
Notes: BENESCO = beneﬁts of smoking cessation on outcomes; CHD = coronary heart disease; COPD = chronic obstructive pulmonary disease; NRT = nicotine replacement 
therapy; QALYs = quality-adjusted life-years. Estimates converted to 2017 dollars from the base case year (or publication year if no base case year) using the Medical Care part 
of the Consumer Price Index (all urban consumers).
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Cummings et al. 
(1989)
• Model: Not available
• Cost-effectiveness analysis
• Hypothetical group of patients who were 
smokers and were seen during a routine 
ofﬁce visit
• Intervention/comparison: Physician 
counseling patients for 4 minutes during 
a routine office visit to quit smoking
• Perspective: Societal
• Time: Not available
• Quit rates
• Life-years saved
• Physician time spent 
counseling 
• Self-help materials
• Base year: 1984
• Source: Average cost of 
physician visit ($30) and 
cost of materials ($2)
• Brief advice cost $705–$988 ($3,138–$4,397 
in 2017 $) per life-year saved for men and 
$1,204–$2,058 ($5,358–$9,159 in 2017 $) 
per life-year saved for women
Meenan et al. 
(1998)
• Randomized controlled trial
• Cost-effectiveness analysis
• Hospitalized adult smokers in two acute-
care hospitals in a large group model 
HMO in Oregon and Washington
• Intervention/comparison:
 – 20-minute bedside counseling session 
with health counselor, 12-minute video, 
self-help materials, and one or two 
follow-up phone calls
 – Usual care
• Perspective: Implementing hospital
• 1 year
• Quit rates
• Life-years saved
• Intervention (identify 
patients, deliver counseling, 
and follow-up)
• Base year: 1994
• Source: Project surveys, 
expense reports, 
retrospective labor 
estimates, ﬁnancial staff 
of HMO, and estimates 
from literature
• Cost of intervention was $159 ($358 in 2017 $) 
per smoker
• Incremental cost per incremental quit was 
$3,697 ($8,382 in 2017 $)
• Incremental cost per incremental discounted 
life-year saved was $1,691–$7,444 ($3,809–
$16,769 in 2017 $)
Haile et al. 
(2002)
• Cohort
• Cost-effectiveness analysis
• All smokers attending a noncardiac surgical 
preadmission clinic in Australia
• Intervention/comparison: Structured, 
interactive computerized smoking 
cessation program
• Perspective: Hospital/payer
• 2 months, 1 year
• Quit rates
• Acceptability of 
computerized 
smoking 
cessation 
intervention
• Intervention (developing 
program, computer 
hardware, and software)
• Base year: Not available 
(study conducted in 1999)
• Source: Invoice
• Costs of intervention at 1 year, by smoking 
status:
 – $5.80 ($11.0 in 2017 $) per patient
 – $24.19 ($45.9 in 2017 $) per smoker
 – $271.47 ($514.9 in 2017 $) per quitter
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Solberg et al. 
(2006)
• Model: Not available
• Cost-utility analysis
• Hypothetical group of patients in primary 
care clinics in the United States
• Intervention/comparison:
 – Model 1: One-time counseling
 – Model 2: Model 1 plus costs of smoking-
attributable illness
 – Model 3: Annual counseling
 – Model 4: Model 3 plus costs of smoking-
attributable illness
• Perspective: Societal
• Lifetime
• QALYs • Intervention (clinician 
time, medication, and 
patient time and travel)
• Preventable smoking-
attributed illness
• Base year: 2000
• Source: Medicare 
reimbursement rates, 
wholesale costs, and 
healthcare charges
• Cost-effectiveness per QALY saved was 
$1,100 ($2,005 in 2017 $) for Model 1 and 
2,266 ($4,130 in 2017 $) for Model 3 
• Models 2 and 4 were cost-saving, with net 
cost savings of $65 ($118 in 2017 $) and 
$542 ($988 in 2017 $), respectively, per 
smoker counseled
Akers et al. 
(2007)
• Randomized trial
• Cost-effectiveness analysis
• Persons in ﬁve northern states (Alaska, 
Idaho, Montana, Oregon, and Washington) 
who were interested in quitting 
smokeless tobacco
• Intervention/comparison:
 – Self-help manual only
 – Assisted self-help (manual plus videotape 
and two supportive phone calls from a 
tobacco cessation counselor)
• Perspective: Societal and provider/agency
• 18 months
• Quit rates • Program (materials, 
postage, phone services, 
and counselor and 
staff time)
• Participants’ and 
supporters’ time
• Base year: 2000
• Source: Cost of materials 
in bulk and minimum 
wage in Oregon
• Total cost per participant by perspective and 
type of treatment:
 – No treatment:
	| Societal: $0 ($0 in 2017 $)
	| Provider/agency: $0 ($0 in 2017 $) 
 – Manual only:
	| Societal: $20 ($36 in 2017 $)
	| Provider/agency: $8 ($15 in 2017 $) 
 – Assisted self-help:
	| Societal: $56 ($102 in 2017 $)
	| Provider/agency: $39 ($71 in 2017 $)
• Incremental cost per quit by perspective and 
type of treatment:
 – Manual only:
	| Societal: $691 ($1,259 in 2017 $)
	| Provider/agency: $481 ($376 in 2017 $)
 – Assisted self-help:
	| Societal: $1,131 ($2,061 in 2017 $)
	| Provider/agency: $973 ($1,773 in 2017 $)
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Barnett et al. 
(2008)
• Randomized trial
• Cost-effectiveness analysis
• Mental health outpatients who were smokers 
and being treated for depression
• Intervention/comparison:
 – Brief contact (stop-smoking guide and 
referral list)
 – Stepped smoking cessation program
• Perspective: Healthcare payer
• 18 months
• Abstinence rates
• Life-years gained
• All smoking cessation 
services used by 
participants, including 
intervention and referral
• Mental healthcare 
• Base year: 2003
• Source: Retail cost, 
Medicare reimbursement 
rates, hospital charge data, 
and Red Book prices
• Smoking cessation services cost $6,204 
($9,926 in 2017 $) per successful quit or 
$5,170 ($8,271 in 2017 $) per life-year gained
• Cessation services plus mental healthcare 
cost $11,496 ($18,392 in 2017 $) 
per successful quit or $9,580 ($15,327 
in 2017 $) per life-year gained
Dino et al. 
(2008)
• Markov transition model
• Cost-effectiveness analysis
• Students 17–25 years of age who smoked 
≥5 cigarettes per day and attended selected 
schools in Florida
• Intervention/comparison:
 – Not On Tobacco (or N-O-T) smoking 
cessation program
 – Brief, 20-minute intervention
• Perspective: School
• 25 years of age
• Quit rates
• Life-years saved
• Intervention (training, 
room and board for trainer, 
brochures, and gifts)
• Base year: 2000
• Source: Program and 
school records
• Incremental cost-effectiveness ratio for 
N-O-T program was $443 ($807 in 2017 $) 
per discounted life-year saved in base model:
 – $1,029 ($1,875 in 2017 $) in worst-case 
scenario
 – $274 ($499 in 2017 $) in best-case 
scenario
Ruger et al. 
(2008)
• Randomized controlled trial
• Cost-effectiveness and cost-utility analyses
• Low-income pregnant women in Boston, 
Massachusetts
• Intervention/comparison:
 – Motivational interviewing with nurse 
tailored to patient’s stage of readiness 
for cessation
 – Brief counseling
• Perspective: Societal
• Lifetime
• QALYs saved
• Life-years saved
• Program (intervention, 
travel, and training)
• Neonatal intensive care
• Maternal healthcare 
(cardiovascular and 
lung diseases)
• Base year: 1997
• Source: Program records 
and published estimates
• For smoking cessation, intervention was 
costlier and less effective than usual care
• For relapse prevention, cost-effectiveness of 
the intervention was $851 ($1,724 in 2017 $) 
per life-year saved and $628 ($1,272 in 
2017 $) per QALY saved
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Table 5.8 Continued
Study Design/population Effects Costs Outcomes/findings
Thavorn and 
Chaiyakunapruk 
et al. (2008)
• Markov model
• Cost-effectiveness analysis
• Two simulated cohorts of Thai smokers— 
40, 50, and 60 years of age—who regularly 
smoked 10–20 cigarettes per day
• Intervention/comparison:
 – Structured community pharmacist-based 
smoking cessation program (personalized 
and supportive advice, assessment, therapy, 
self-help material, and follow-up visits)
 – Usual care (assessment, brief advice 
and support, and therapy without 
follow-up care)
• Perspective: Healthcare system
• Lifetime
• Life-years gained • Intervention (pharmacist 
training, fees, and 
medications)
• Direct medical costs of 
smoking-related diseases 
(COPD, lung cancer, stroke, 
and cardiovascular disease)
• Base year: 2005
• Source: Published studies, 
information centers, and 
price index
• In the cohort of those 40 years of age, 
program resulted in cost savings to the 
health system of $500 ($735 in 2017 $) for 
men and $614 ($903 in 2017 $) for women, 
and 0.18 life-years gained for men and 
0.24 life-years gained for women
Boyd and Briggs 
(2009)
• Observational study
• Cost-effectiveness and cost-utility analyses
• Smokers who accessed either of two 
cessation services between March and 
May 2007 in Glasgow, Scotland
• Intervention/comparison:
 – One-to-one cessation support in 
pharmacies
 – Group counseling in the community
 – Self-quit attempt
• Perspective: National health system
• 4 weeks and 1 year
• Quit rates
• QALYs
• Intervention costs incurred 
by National Health 
Service (NRT, professional 
time, overhead, and 
materials used)
• Base year: 2007
• Source: Resource use 
and records from the 
National Health Service
• Incremental cost per additional 4-week 
quitter was $1,512 ($2,047 in 2017 $) for 
pharmacy support and $2,158 ($2,922 
in 2017 $) for group counseling in the 
community compared with self-quit 
cessation attempts
• Incremental cost per QALY gained was 
$8,620 ($11,671 in 2017 $) for pharmacy 
services and $10,579 ($14,324 in 2017 $) 
for group counseling in the community 
compared with self-quit cessation attempts
Source: Table 6 in Ruger and Lazar (2012).
Notes: COPD = chronic obstructive pulmonary disease; HMO = health maintenance organization; NRT = nicotine replacement therapy; QALYs = quality-adjusted life-
years. Estimates converted to 2017 dollars from the base case year (or publication year if no base case year) using the Medical Care part of the Consumer Price Index 
(all urban consumers).
A Report of the Surgeon General
482  Chapter 5
that incremental cost-effectiveness ratios ranged from 
$3,809 to $16,769 per life-year saved compared with usual 
care from the implementing hospital perspective (Meenan 
et al. 1998), and another evaluation of stepped cessation 
services found that ratios per life-year gained ranged from 
$8,271 to $15,327 compared with brief contact from the 
healthcare perspective (Barnett et al. 2008). Three evalua-
tions of counseling therapies per additional quit found that 
the incremental cost-effectiveness ratio was $8,382 from 
the implementing hospital perspective (Meenan et  al. 
1998) and that cost-effectiveness ratios ranged from 
$9,926 to $18,392 from the healthcare perspective (Barnett 
et al. 2008) and from $1,259 to $2,061 from the societal 
perspective (Akers et  al. 2007). Using an observational 
design, Boyd and Briggs (2009) found incremental cost-
effectiveness ratios per QALY gained of $11,671 for one-to-
one support (by a pharmacist) and $14,324 for group coun-
seling, and found incremental cost-effectiveness ratios per 
quit of $2,047 and $2,922 for one-to-one support and for 
group counseling, respectively, compared with self-quit 
cessation attempts from the national health system per-
spective. In other studies that compared brief counseling 
or smoking cessation programs with usual care, estimated 
incremental cost-effectiveness ratios ranged from $499 to 
$1,875  per life-year saved from the school perspective 
(Dino et  al. 2008), from $735  to $903  from the health-
care perspective (Thavorn and Chaiyakunapruk 2008), and 
from $3,138  to $9,159 per life-year saved from the soci-
etal perspective (Cummings et al. 1989). Additionally, the 
incremental cost-effectiveness ratio was $4,130 per QALY 
gained from the societal perspective (Solberg et al. 2006).
Cost-Effectiveness of Nonclinical Smoking 
Cessation Interventions
Table 5.9 summarizes studies on the cost-effectiveness 
of various policy interventions that promote smoking ces-
sation. To standardize the dollar value of costs to the same 
base year, estimates in this section were converted to 2017 
U.S. dollars from the base case year (or publication year 
if no base case year) using the Medical Care part of the 
Consumer Price Index (all urban consumers). Although 
these studies share this focus, the evaluations were highly 
heterogeneous (Ekpu and Brown 2015). Regardless, some 
of these evaluations estimated cost-effectiveness ratios 
similar to or greater than those for clinical smoking ces-
sation interventions. The estimated incremental cost-
effectiveness ratios for an NRT program and for a smoke-
free workplace policy compared with the clinical standard 
were $7,736 and $882 per QALY gained, respectively (Ong 
and Glantz 2005). Villanti and colleagues (2012) evalu-
ated the American Legacy Foundation’s national EX cam-
paign, which was a radio and television campaign from 
2008 designed to promote smoking cessation among adult 
smokers. The estimated incremental cost-effectiveness 
ratios ranged from $47,271 to $102,883 per QALY gained 
from the societal perspective when compared with a hypo-
thetical status quo of no program or change in cessation 
behavior. School-based antitobacco education programs 
compared with status quo have a much wider range of 
estimated incremental cost-effectiveness ratios per QALY 
gained over 50  years, ranging from $9,294  when consid-
ering a 56% reduction in smoking that dissipates in 4 years 
to $644,890 when considering a 5% reduction in smoking 
that dissipates in 1 year from the societal perspective. For 
the most plausible scenario of 30%  effectiveness in pre-
venting smoking, which dissipates in 4 years, the estimated 
cost-effectiveness ratio was $37,935 per QALY gained (Tengs 
et al. 2001). In a study evaluating CDC’s Tips From Former 
Smokers (Tips) Campaign among adults, Xu and colleagues 
(2015a) estimated an incremental cost-effectiveness ratio 
of $450 per life-year saved and $307 per QALY gained in the 
short run from the funding agency’s perspective compared 
with not having the campaign.
Cost-Effectiveness of Tobacco Price Increases 
Through Taxation
Contreary and colleagues (2015) conducted a sys-
tematic review of the cost-effectiveness of a tobacco price 
increase through taxation and found only one study that 
evaluated the cost-effectiveness per QALY gained. The study 
found that the cost-effectiveness ratio for a 10% increase in 
per unit price of tobacco through a 15% increase in excise 
tax was $3,839 (2017 dollars) per QALY gained over 100 
years from the healthcare perspective (van Baal et al. 2007).
Synthesis of the Evidence
The evidence on cost-effectiveness of smoking ces-
sation and the resulting reduction in healthcare expen-
ditures as a result of cessation strongly indicate that 
smoking cessation interventions should be implemented 
throughout the healthcare system and supported more 
broadly by population-level tobacco control measures 
(e.g., quitlines). The selection of the intervention depends 
on the feasibility of the intervention and on the context of 
an organization and its ability to fund the intervention.
Current estimates of the cost-effectiveness of 
smoking cessation are limited by the variation in meth-
odologies, including heterogeneity in comparators and 
perspectives. Despite specific recommendations made 
two decades ago to enhance the comparability of eco-
nomic evaluations (Gold et al. 1996), compliance with 
the full set of recommendations on a standard approach 
to conducting cost-effective analysis remains incomplete 
(Ronckers et al. 2005; Ruger and Lazar 2012; Ekpu and 
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Table 5.9 Summary of economic evaluations of nonclinical interventions for smoking cessation
Study Design/population Effects Costs Outcomes/findings
Tengs et al. 
(2001)
• Tobacco Policy Model (a dynamic simulation 
model)
• Intervention/comparison:
 – School-based antitobacco education 
to seventh- and eighth-grade students, 
with 5–56% smoking reductions that 
dissipate in 1–4 years
 – Status quo
• Students 8 years of age and older
• Perspective: Societal
• 25–50 years
• QALYs • Costs of school-based 
antitobacco education 
program and annual 
medical costs
• Base year: 1999
• Source: Salaries of 
educators for public 
middle school teachers, 
average class size, and 
census data
• Cost-effectiveness ratios per QALY gained 
over the 50 years ranged from $4,900 
($9,294 in 2017 $), when considering a 56% 
reduction in smoking that dissipates in 
4 years, to $340,000 ($644,890 in 2017 $), 
when considering a 5% reduction in 
smoking that dissipates in 1 year
• For most plausible scenario of 30% reduction 
in smoking that dissipates in 4 years, the 
cost-effectiveness ratio per QALY gained over 
the 50 years was $20,000 ($37,935 in 2017 $)
Ong and Glantz 
(2005)
• Monte Carlo simulation model
• Cost-effectiveness and cost-utility analyses
• 18 years of age and older
• Interventions/comparison:
 – A free NRT program and statewide 
smokefree workplace campaign
 – Common clinical standard 
• Perspective: Not stated
• 1 year
• Quit rates
• QALYs
• Free NRT program: Average 
wholesale price for NRT, 
cost of quit attempt, cost 
of therapy, and cost of total 
medication; did not include 
cost of administration
• Source: Wholesale prices 
for the most inexpensive 
NRTs
• Smokefree workplace 
policy: Costs for enactment 
and reinforcement
• Source: Occupational 
Employment Statistics 
Survey and published 
studies
• Base year: 2001
• Free NRT program: Generated 18,500 
quitters, and the cost-effectiveness ratios were 
$7,020 ($12,223 in 2017 $) per quitter and 
$4,440 ($7,736 in 2017 $) per QALY gained
• Smokefree workplace policy: Generated 
10,400 quitters, and the cost-effectiveness 
ratios were $799 ($1,392 in 2017 $) per 
quitter and $506 ($882 in 2017 $) per 
QALY gained
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Table 5.9 Continued
Study Design/population Effects Costs Outcomes/findings
Villanti et al. 
(2012)
• Cost-utility analysis
• 18- to 49-year-olds in eight designated 
markets
• Interventions/comparison:
 – National EX campaign to promote 
smoking cessation
 – Status quo
• Perspective: Societal
• 6 months
• QALYs • EX campaign costs (media, 
public relations, salaries, 
and recruitment) and other 
societal costs (consumer 
time and treatment costs)
• Base year: 2009
• Source: Consumer time 
lost during exposure to 
intervention and costs 
of treatment
• The EX campaign achieved 52,979 additional 
quit attempts and 4,238 additional quits, 
and saved 4,450 QALYs
• Incremental cost-utility ratios per QALY 
gained ranged from $37,355 ($47,271 in 
2017 $) to $81,301 ($102,883 in 2017 $)
Xu et al. (2015a) • Monte Carlo simulation model
• Cost-effectiveness and cost-utility analyses
• Quitters, 18 years of age and older
• Interventions/comparisons:
 – Tips Campaign
 – Without Tips Campaign
• Perspective: CDC (funding agency)
• 6 months
• Quit rates, 
premature death, 
life-years, and 
QALYs
• Cost of Tips Campaign 
(development, media 
placement, and evaluation) 
• Base year: 2012
• Source: CDC Office on 
Smoking and Health’s 
budget for Tips Campaign
• Prevented 17,109 premature deaths, and 
saved approximately 179,099 QALYs 
• Cost-effectiveness ratio was $480 ($550 in 
2017 $) per quitter, $2,819 ($3,229 in 2017 $) 
per premature death averted; $393 ($450 in 
2017 $) per life-year saved, and $268 ($307 in 
2007 $) per QALY gained
Notes: NRT = nicotine replacement therapy; QALYs = quality-adjusted life-years; Tips = Tips From Former Smokers Campaign. Estimates converted to 2017 dollars from 
the base case year (or publication year if no base case year) using the Medical Care part of the Consumer Price Index (all urban consumers).
The Benefits of Smoking Cessation on Overall Morbidity, Mortality, and Economic Costs  485
Smoking Cessation
Brown 2015). The new recommendations from the second 
Panel on Cost-Effectiveness in Health and Medicine, which 
were published after the publication of many of the studies 
reviewed in this chapter, emphasize the need for compli-
ance with the recommendations for consistency and com-
parability of studies (Sanders et al. 2016). Additionally, 
current trends in cigarette smoking and other forms of 
tobacco product use affect estimates of economic expendi-
tures from smoking and smoking cessation.
Nonetheless, the scientific evidence clearly doc-
uments that smoking cessation interventions reduce 
smoking-attributable expenditures. Evidence on the cost-
effectiveness of smoking cessation interventions is con-
sistent across numerous studies—even when considering 
different methodologies and outcomes.
The evidence from studies of economic burden 
has shown that cigarette smoking generates substantial 
smoking-attributable healthcare expenditures and lost 
productivity, a conclusion reached in previous reports 
of the Surgeon General (USDHHS 2014). These expen-
ditures affect the smoker specifically and society gen-
erally. Using the values per QALY discussed previously 
(USDHHS 2016), the evidence from economic evalua-
tions that focus on the cost-effectiveness of smoking ces-
sation interventions demonstrates that such interven-
tions are cost-effective from various perspectives and that 
the cost-effectiveness ratio from the societal perspective 
will always be higher than from other perspectives. Taken 
together, the scientific evidence on the health and cost 
benefits of smoking cessation interventions indicates that 
these interventions should be implemented as widely 
as possible throughout the healthcare system and sup-
ported more broadly by population-level tobacco control 
measures.
Summary of the Evidence
This chapter examines morbidity, mortality, and eco-
nomic costs in relation to smoking cessation. For general 
measures of health outcomes, particularly general QoL, 
there is evidence of higher levels of improvement in QoL 
among former smokers than among those who continue 
to smoke. Morbidity is higher in former smokers than in 
never smokers, but in some subgroups, morbidity among 
former smokers can approach that of never smokers, such 
as among those with lower levels of addiction at the time 
of cessation.
A causal link between smoking cessation and a 
decrease in general morbidity is supported by the bio-
logic plausibility of the relationship. Many well-supported 
mechanisms link smoking cessation to improvements in 
more specific measures of health, such as disease-specific 
outcomes, thus underscoring the certainty that those 
who quit smoking will have lower rates of morbidity.
The health benefits of smoking cessation on all-
cause mortality have been covered extensively in previous 
Surgeon General’s reports. The evidence that has accumu-
lated since the 1990 Surgeon General’s report affirms that 
smoking cessation at any age reduces the risk of prema-
ture death from a smoking-caused illness.
Cigarette smoking generates substantial smoking-
attributable healthcare expenditures and lost productivity. 
These expenditures affect the smoker specifically and 
society generally. The evidence from economic evaluations 
that focus on the cost-effectiveness of smoking cessation 
interventions demonstrates that such interventions are 
cost-effective from various perspectives. Taken together, 
the scientific evidence on the health and cost benefits 
of smoking cessation interventions indicates that these 
interventions should be implemented as widely as possible 
throughout the healthcare system and supported more 
broadly by population-level tobacco control measures.
Conclusions
1. The evidence is sufficient to infer that smoking ces-
sation improves well-being, including higher quality 
of life and improved health status.
2. The evidence is sufficient to infer that smoking ces-
sation reduces mortality and increases the lifespan.
3. The evidence is sufficient to infer that smoking 
exacts a high cost for smokers, healthcare systems, 
and society.
4. The evidence is sufficient to infer that smoking ces-
sation interventions are cost-effective.
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Introduction
There are now more former cigarette smokers than 
current smokers in the United States (U.S. Department of 
Health and Human Services [USDHHS] 2014). For more 
than a decade, national surveillance data on smoking 
cessation have revealed a similar pattern, with modest 
improvement—two-thirds of adult cigarette smokers indi-
cate a desire to quit, and just over half try to quit each year; 
however, less than 10% of smokers who try to quit suc-
ceed in quitting for 6 months or longer (Babb et al. 2017). 
A large body of evidence highlights the efficacy of mul-
tiple treatments that can double or triple the rate of suc-
cess in quitting smoking (Fiore et al. 2008; Prochaska and 
Benowitz 2016). This chapter reviews both evidence-based 
and emerging potential treatments for smoking cessation.
Current evidence-based treatment approaches 
to smoking cessation include several behavioral treat-
ments—such as individual, group, and telephone coun-
seling—and seven pharmacotherapies approved by the 
U.S. Food and Drug Administration (FDA). These treat-
ments have been shown to be effective when delivered 
across a wide variety of settings, via several platforms, and 
to a diversity of populations—including groups that have 
been disproportionately impacted by tobacco use, such 
as low-income populations, and populations with other 
comorbid medical conditions, including behavioral health 
conditions (U.S. Preventive Services Task Force [USPSTF] 
2015). Evidence indicates that the combined use of both 
behavioral interventions and pharmacotherapies pro-
duces the largest cessation effects (Fiore et al. 2008; Stead 
and Lancaster 2012a; Stead et al. 2015), but the evidence 
also indicates that several of these treatments are effec-
tive when used alone (Fiore et al. 2008; Cahill et al. 2013; 
USPSTF 2015; Lancaster and Stead 2017). 
The cost-effectiveness of smoking cessation has 
been documented extensively (Jha et  al. 2015) (see 
Chapter 5. The Benefits of Smoking Cessation on Overall 
Morbidity and Economic Costs). For example, Maciosek 
and colleagues (2017a,b) assessed the potential impact of 
28 evidence-based clinical preventive services in terms of 
their cost-effectiveness and clinically preventable burden 
(measured by quality-adjusted life-years [QALYs] saved). 
The assessment, which included clinical preventive ser-
vices for a variety of different risk factors, found that two 
of the three highest ranking preventive services were 
related to tobacco, including (a)  tobacco use screening 
and a brief counseling intervention to encourage cessa-
tion among adults and (b) counseling to prevent initiation 
of tobacco use among youth.
Data indicate that despite the availability of evidence-
based treatments to achieve smoking cessation, less than 
one-third of adult cigarette smokers who attempt to quit 
use any type of cessation counseling and/or FDA-approved 
cessation medication (Babb et  al. 2017). Furthermore, 
undertreatment is common among smokers who use ces-
sation treatments; rates of relapse are high (above 50%) 
(García-Rodríguez et al. 2013); and most smokers attempt 
to quit without using treatment (i.e., they try to quit unas-
sisted or “cold turkey”), with success rates of approximately 
7–8% (Fiore and Jaen 2008; Prochaska and Benowitz 
2016; Babb et  al. 2017; Caraballo et  al. 2017). Unaided 
quitting likely remains common for a number of reasons, 
including the frequent lack of health insurance among 
tobacco users (nearly 30% of adult cigarette smokers are 
uninsured [Jamal et al. 2018]); inadequate public and pri-
vate insurance coverage of cessation treatments (DiGiulio 
et al. 2018); inadequate and cumbersome reimbursement 
for cessation treatments offered by clinicians and hospi-
tals (Fiore et al. 2008); inadequate promotion of cessation 
treatments to smokers and healthcare providers, which 
can contribute to low use of these treatments (Fiore et al. 
2008); the widespread perception that quitting cold turkey 
is at least as effective as quitting with the help of coun-
seling and/or medication (Fiore et al. 2008); underfunding 
of state tobacco quitlines and other cessation services 
(USDHHS 2014; Campaign for Tobacco-Free Kids 2018); 
and inadequate integration of tobacco use screening and 
cessation interventions into routine clinical care (Babb 
et al. 2017). In addition, because of a lack of specialized 
training about nicotine dependence and treatment, many 
clinicians report being hesitant to engage patients in con-
versations about cessation because they feel they lack the 
requisite knowledge to do so effectively (Zapka et al. 1999; 
Simoyan et al. 2002; Blumenthal 2007). 
In the past, the tobacco industry has spread the mis-
conceptions that smoking is a personal choice or simply a 
bad habit, that quitting is a matter of willpower, and that 
addiction to nicotine is akin to being addicted to caffeine 
(Henningfield et al. 2006). These messages have contrib-
uted to most smokers trying to quit through sheer deter-
mination instead of combining a strong motivation to 
quit with the use of evidence-based cessation treatments. 
The reality is that nicotine is addictive, and smoking is 
not merely a habit (USDHHS 1988). Although habitual 
components of smoking reinforce use, nicotine is a highly 
addictive drug, like heroin and cocaine (USDHHS 1988, 
2014), and nicotine addiction is a chronic, relapsing 
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condition. Although a majority of smokers in the United 
States who quit successfully do so without assistance, 
smokers who use medication and/or behavioral support as 
part of a quit attempt substantially increase their chances 
of quitting (Fiore et al. 2008). The conceptualization of 
nicotine dependence as a chronic, relapsing condition is 
not new (Fiore et al. 2008), but it has led to reframing the 
delivery of smoking cessation treatment as “chronic dis-
ease management,” which in turn has given rise to more 
systematic approaches to delivering nicotine dependence 
treatment in healthcare settings (Steinberg et al. 2008; 
Foulds et al. 2010). 
Behavioral and Psychological Treatments
Notable discoveries in the behavioral and social sci-
ences have broadened and deepened understanding of psy-
chosocial influences on the nature and treatment of nico-
tine dependence, which has given rise to new approaches 
to behavioral treatment. It has become clear that, as acute 
nicotine withdrawal dissipates as the length of the quit 
attempt increases, several factors—including intermit-
tent negative emotional states, repeated urges to smoke, 
diminished motivation, and decreased self-efficacy about 
quitting—can persist throughout the cessation process 
Literature Review Methods
This chapter reviews the evidence base for current 
and potential emerging treatments for smoking cessation, 
adding to research from the U.S. Public Health Service’s 
Clinical Practice Guideline on Treating Tobacco Use and 
Dependence: 2008 Update (hereafter referred to as the 
Clinical Practice Guideline) (Fiore et al. 2008). It also 
explores approaches to increase the impact of smoking ces-
sation treatments through improved efficacy and increased 
reach. The impact of a smoking cessation intervention is a 
function of effectiveness (i.e., success as measured in sus-
tained quit rates of, for example, greater than 6 months) 
multiplied by reach (i.e., the proportion of the population 
of smokers engaged in treatment). Importantly, interven-
tions that increase reach (i.e., those that are more broadly 
available and accessible to people, have greater appeal, 
and are therefore more widely used) may sacrifice efficacy 
or intensity, while interventions that are more intensive 
and more effective may have limited reach (Glasgow et al. 
2011; Zhu et al. 2012). Given the reality of funding con-
straints, most states, healthcare systems, and other stake-
holders do not have the option of maximizing both the 
effectiveness and reach of cessation treatments; in prac-
tice, they have to balance these approaches.
For this chapter, 38 Cochrane reviews were examined 
in early 2017. Additional literature searches of English-
language articles in PubMed were used to identify new 
literature published since the original Cochrane reviews. 
Searches were primarily restricted to randomized con-
trolled trials (RCTs) of smoking cessation interventions 
using the terms smoking cessation and randomized con-
trolled trial. In areas where RCTs were not available, the 
chapter discusses the available science and identifies areas 
that lacked depth of evidence from RCTs. Consistent with 
previous Surgeon General’s reports on tobacco, the content 
in this report was revised throughout the review process to 
include studies and information not available at the time 
the chapters were initially drafted, most notably for topics in 
which the available science is rapidly emerging (e.g., elec-
tronic cigarettes [e-cigarettes]) (King et al. 2018a).
Data reviewed in this chapter are overwhelmingly 
drawn from studies of adult cigarette smoking cessation, 
as opposed to cessation of other forms of tobacco products 
(e.g., cigars, cigarillos, smokeless tobacco, hookah, and 
e-cigarettes). The paucity of research on cessation treat-
ments for noncigarette tobacco products does not allow 
for a separate and comprehensive scientific evaluation of 
such treatments. 
This chapter is divided into seven sections: behav-
ioral and psychological treatments, pharmacologic treat-
ments, teachable moments, considerations for subpopula-
tions, emerging intervention approaches, summary of the 
evidence, and conclusions. 
and undermine quitting (Liu et al. 2013; Ussher et al. 
2013). Furthermore, encountering environments and 
situations previously associated with smoking, such as 
going to establishments that serve alcohol or interacting 
with friends who smoke, has been shown to increase risk 
of relapse (Conklin et al. 2013). Intensive behavioral ces-
sation treatment models for smokers with mental health 
conditions and substance use disorders that have been 
adapted to address these factors have been shown to 
improve quit rates (Das and Prochaska 2017). 
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Behavioral and psychological strategies that have 
been shown to be effective in treating tobacco use and 
nicotine dependence include behavioral therapy and cog-
nitive behavioral therapy (CBT) (Sykes and Marks 2001; 
Fiore et al. 2008; Perkins et al. 2008), motivational inter-
viewing (Lindson-Hawley et  al. 2015), acceptance and 
commitment therapy (Bricker et  al. 2013), and contin-
gency management or incentive-based interventions 
(which have been found to be effective while incentives 
are in place) (Cahill et  al. 2015). These strategies can 
be individual- or group-based and can vary in intensity 
(from brief to more intensive) and in the mode of delivery 
(e.g., delivery by a clinician, counselor, telephone, or com-
puter). Most research on behavioral treatments has con-
sidered packages of multiple treatment elements instead 
of comparing one element with another (e.g.,  studies of 
treatment optimization), making a review of each treat-
ment approach challenging (Piper et  al. 2016). In gen-
eral, the data show a robust dose-response curve, with 
more intensive behavioral and psychological treatments 
(e.g.,  higher amounts of contact time, more sessions) 
yielding greater odds of sustained cessation (Fiore et al. 
2008; USPSTF 2015). 
Treatment Strategies
Behavioral Therapy
A large body of scientific literature supports the use 
of behavioral therapy to help people quit smoking (Fiore 
et al. 2008; Stead et al. 2016; Lancaster and Stead 2017). 
Such approaches can be delivered by various types of 
healthcare providers or counselors to individual persons 
or groups. Behavioral therapy, which is commonly used 
with smokers who are contemplating quitting or preparing 
to quit, seeks to address the historical learning processes 
directly relevant to smoking and the current contextual 
factors that make it difficult to quit (e.g., social, behav-
ioral, and environmental factors) (Webb et al. 2010b). 
Available evidence supports the effectiveness of both 
brief cessation interventions and longer, more intensive 
interventions. USPSTF (2015) and the Clinical Practice 
Guideline (Fiore et al. 2008) each concluded that both 
minimal (<20 minutes in a single visit) and intensive 
(≥20 minutes plus one or more follow-up visits) interven-
tions delivered by clinicians are effective in increasing the 
proportion of adults who successfully quit smoking and 
remain abstinent for at least 6 months, which is com-
monly referred to as recent successful cessation. USPSTF 
(2015) and the Clinical Practice Guideline (Fiore et al. 
2008) each also concluded that there is a dose-response 
relationship between the intensity of counseling and 
quitting success—that is, the greater the intensity of 
counseling, the higher the likelihood an individual will 
quit. Accordingly, behavioral therapy approaches for 
smoking cessation are delivered over several weeks and 
focus on the physiological, psychological, social, and envi-
ronmental aspects of smoking and nicotine dependence 
(Fiore et al. 2008; USDHHS 2010, 2014). Group treat-
ment typically occurs weekly for several weeks in a series 
of 60- to 90-minute sessions (Foulds et al. 2006; Kotsen 
et al. 2017). For example, Public Health England (2017) 
recommended weekly visits for 6–12 weeks for individ-
uals (30–45  minutes per visit) and groups (60 minutes 
per visit). 
Behavioral treatment approaches equip smokers 
with practical strategies to avoid and/or cope with trig-
gers, manage cravings, and reduce withdrawal symp-
toms (Center for Substance Abuse Treatment 2006). 
These interventions often cover a wide variety of topics—
including advice on quitting smoking; assessment of prior 
quit attempts and lessons that can be drawn from them; 
assessment of current motivation to quit; identification 
of cues and triggers for smoking and ways to avoid or 
manage them; tips on ways to manage mood; and promo-
tion of adherence to treatment engagement (such as using 
medications correctly) and continued treatment engage-
ment. Adherence to treatment engagement and continued 
treatment engagement can be promoted by addressing 
skill building; self-managing withdrawal symptoms; 
accepting social support; and managing such associated 
health issues as stress, moodiness, and other substance 
use (Fiore et al. 2008). 
Cognitive Therapy
Cognitive therapy, which includes CBT, is a psy-
chotherapeutic approach rooted in the idea that behav-
ioral problems can be maintained by cognitive factors, 
including beliefs that lead to automatic thoughts about 
particular situations. The model uses specific thera-
peutic strategies to target maladaptive cognitions and 
help change problematic behaviors (Ellis 1962; Beck 
1970; Butler et al. 2006). Contemporary applications 
of CBT typically emphasize cognitive factors and emo-
tional, physiological, and behavioral components that 
can reinforce behavior (Butler et al. 2006; Hofmann et al. 
2013). CBT is among the most researched psychothera-
peutic approaches (Hofmann et al. 2012), with studies 
addressing a wide variety of behavioral and cognitive dis-
orders, including smoking cessation.
Treatments based on CBT techniques have been 
found to be highly effective in smoking cessation (Sykes 
and Marks 2001; Fiore et al. 2008; Perkins et al. 2008). In 
a systematic review of cognitive therapies from 21 RCTs 
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that were conducted with 4,946 participants since 2009, 
the Norwegian Institute of Public Health concluded that: 
• Cognitive therapies have similar effects to usual care 
or minimal interventions in terms of rates of smoking 
abstinence (up to 6–12 months; n = 3 studies);
• Cognitive therapies combined with nicotine replace-
ment therapy (NRT) result in higher abstinence 
rates (up to 12 months) compared with other inter-
ventions that are combined with NRT (n = 8 studies); 
• Cognitive therapies result in a higher smoking absti-
nence rate (up to 12 months) compared with other 
interventions (e.g., advice to quit, exercise, health 
education) (n = 6 studies); and
• Cognitive therapies plus medications improve 
smoking abstinence rates (up to 12 months) com-
pared with medication only (n = 5 studies) (Denison 
et al. 2017). 
CBT has also been studied in relation to other ces-
sation treatments and was found in a meta-analysis by 
Garcia-Vera and Sanz (2006) to be superior, both alone 
and in combination with NRT, compared with NRT alone. 
Studies have also shown CBT to be effective for 
smoking cessation in specific populations. For example, 
in a sample of African Americans, Webb and colleagues 
(2010a) found that CBT at least doubled the likelihood 
of cessation through the 6-month follow-up compared 
with a control group that received only health education. 
In a separate study, Webb Hooper and colleagues (2017) 
found that culturally specific CBT resulted in double the 
7-day point-prevalence cessation rate compared with 
nonculturally specific CBT and was significantly more 
effective at 3-month follow up. CBT has been shown to 
increase cessation when combined with NRT or other ces-
sation medication in populations who use tobacco and 
have comorbid substance use or mental health condi-
tions (Haas et  al. 2004; Ziedonis et  al. 2008; Magill and 
Ray 2009). However, studies assessing the use of CBT in 
smokers with schizophrenia, either with or without other 
intervention components, have yielded more mixed find-
ings (Gelkopf et  al. 2012; Tsoi et  al. 2013; Rüther et  al. 
2014; Brody et al. 2017). 
Recent research has focused on improving smoking 
cessation outcomes from previous CBT trials. For example, 
in a 2017 two-arm, parallel group RCT of a community-
based adult sample (n  =  219), extended CBT treatment 
of 48 weeks did not yield better cessation outcomes com-
pared with 26  weeks of treatment (Laude et  al. 2017). 
Research has also focused on adapting CBT interventions 
to mobile health (mHealth) and web-based platforms and 
adding technology-based components to further enhance 
CBT, including testing the effectiveness of CBT in an app-
based format (vs. a non-CBT app) (Tudor-Sfetea et al. 2018) 
and adding virtual reality to CBT to create an immersive 
and interactive cue exposure paradigm (e.g., exposure to 
smoking cues without reinforcement, with the goal of dis-
associating those cues) to standard treatment (Culbertson 
et al. 2012).
Motivational Interviewing
Both motivational interviewing and adaptations 
of this approach make use of a distinct style of coun-
seling that is directive, patient-centered, nonconfronta-
tional, nonjudgmental, and highly collaborative (Miller 
and Rollnick 2002). Motivational interviewing—which 
can be delivered by healthcare providers, counselors, or 
quitline coaches—aims to help people explore and resolve 
any ambivalence about making a behavior change, such 
as quitting smoking (Miller and Rollnick 2002; Lindson-
Hawley et al. 2015). This technique is typically used with 
persons who are not yet ready to quit tobacco (Miller and 
Rollnick 2002; Fiore et al. 2008). Counseling techniques—
such as expressing empathy, actively listening, reflecting 
back on what one heard, and building self-efficacy—
are at the core of motivational interviewing (Miller and 
Rollnick 2002).
Motivational interviewing was initially developed to 
treat alcohol addiction (Miller 1983) and was subsequently 
adapted for use in tobacco cessation. Lindson-Hawley and 
colleagues (2015) reviewed 28 studies that compared moti-
vational interviewing to brief advice or usual care for the 
treatment of tobacco use. Motivational interviewing was 
used in one to six sessions lasting from 10 to 60 minutes and 
was delivered by clinicians in primary care settings, emer-
gency departments, or hospitals; in the community; via 
telephone quitlines; and in military settings. Motivational 
interviewing was found to significantly increase successful 
quitting compared to those not receiving the intervention 
(relative risk [RR]  =  1.26; 95% confidence interval [CI], 
1.16–1.36; 28  studies; N  =  16,803). Short motivational 
interviewing interventions (<20 minutes per session) had 
an RR of 1.69 (95% CI, 1.34–2.12; 9 trials; N = 3,651). Both 
single-session (RR  =  1.26; 95%  CI, 1.15–1.40; 16  trials; 
N = 12,103) and multiple-session (RR = 1.20; 95% CI, 1.02–
1.42; 11 trials; N = 3,928) treatments increased the like-
lihood of quitting compared with controls. In summary, 
motivational interviewing is an evidence-based approach 
that has been shown, when delivered by clinicians or 
trained counselors, to be more effective in increasing read-
iness to quit and in helping people quit smoking than brief 
advice or usual care (e.g.,  self-help materials) (Lindson-
Hawley et al. 2015). 
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Acceptance and Commitment Therapy
Acceptance-based therapies (ACTs) draw on cogni-
tive therapies but focus on changing psychological events 
directly. Specifically, ACTs seek to change the function 
of those events and the relationship an individual has 
to them (Hayes 2004; Hayes et  al. 2006). ACTs focus on 
the context and functions of psychological phenomena, 
emphasizing contextual and experiential change strate-
gies to help individuals become more willing to experience 
their physical sensations, emotions, and thoughts (Hayes 
et  al. 1999; Hayes et  al. 2006). In ACTs, “acceptance” is 
rooted in accepting intense physical sensations (e.g., nico-
tine withdrawal or urges to smoke) and the emotions and 
thoughts that accompany those sensations (e.g., anger or 
sadness, thoughts about wanting a cigarette, etc.). In con-
trast, “commitment” focuses on articulating what is par-
ticularly important to or valued by an individual and lever-
aging those values to motivate and guide specific actions, 
like quitting smoking (Hayes et  al. 2001, 2006, 2013; 
Bricker et al. 2010). Clinical treatment research supports 
ACTs for general behavior change and condition manage-
ment, including in populations diagnosed with such dis-
orders as major depression, anxiety disorders, borderline 
personality disorder, chronic pain, and substance abuse 
(including tobacco use) (Khoury et  al. 2013; Kelly et  al. 
2015; Linehan et  al. 2015; Cristea et  al. 2017; Meyers 
et  al. 2017). With regard to smoking cessation, a quasi-
experimental study (n = 81 adult smokers) by Hernández-
López and colleagues (2009) compared ACT with CBT 
using seven weekly 90-minute sessions in a group format. 
The 30-day point-prevalence quit rate at 12-month follow-
up was 30.2% in the ACT condition and 13.2% in the CBT 
condition (odds ratio [OR] = 5.13, p <.02). A randomized 
trial of 302 adult smokers compared individual and group 
ACT therapy with bupropion to bupropion only (Bricker 
et  al. 2014a). In this study, intent-to-treat quit rates at 
12-month follow-up were 32% in the ACT arm versus 
18% in the bupropion-only arm (p  <.05). ACT has also 
been studied as part of a telephone-based intervention. 
For example, in a pilot randomized trial on telephone-
delivered ACT versus telephone-delivered CBT in 121 unin-
sured callers to the South Carolina state quitline, Bricker 
and colleagues (2014a) found no significant difference in 
30-day point-prevalence quit rates at 6- month follow-up. 
In recent years, ACT has also been adapted and 
pilot tested as (a)  a smartphone application to reduce 
smoking (Singh et  al. 2017) and to motivate smoking 
cessation (Bricker et  al. 2014b; Bricker et  al. 2017) and 
(b) a web-based intervention (Bricker et al. 2013; Bricker 
et al. 2018). For example, in a single-arm pilot trial of a 
smartphone application of ACT (SmartQuit® 2.0) among 
smokers, Bricker and colleagues (2017) found that at 
2-month follow-up, quit rates were 21% for 7-day point 
prevalence (vs. 23% for SmartQuit®) and 11% for 30-day 
point prevalence (vs. 13% for SmartQuit®), and 75% of 
participants reduced their smoking frequency (vs. 57% for 
SmartQuit®). Among program completers (24%  of the 
total sample), quit rates were 33% for 7-day point preva-
lence and 28% for 30-day point prevalence, and 88% of 
participants reduced their smoking frequency. ACT has 
also been explored in specific populations, including 
smokers with depressive symptoms (Jones et  al. 2015), 
smokers with bipolar disorder (Heffner et al. 2015, 2018), 
veterans with posttraumatic stress disorder (Kelly et  al. 
2015), and female smokers with cessation-related weight 
concerns (Bloom et al. 2017). More research is needed to 
better understand populations and delivery modalities for 
which ACT is particularly promising as a smoking cessa-
tion approach compared with existing cognitive therapies.
Contingency Management and Monetary 
Incentives
A large body of evidence (Ainscough et al. 2017) sup-
ports contingency management, which involves the use of 
incentives (including money, gift cards, or other tangible 
goods) to motivate people to change health behaviors, 
including motivating them to maintain abstinence from 
substance use over an extended period of time (Lussier 
et al. 2006). Monetary incentives for quitting or not initi-
ating smoking or tobacco use, such as paying persons for 
engaging in cessation services and for achieving cessation-
related outcomes (e.g.,  abstinence or participation in 
treatment), have been tested alone and in combination 
with cessation medication or counseling as an approach to 
increase compliance with nicotine dependence treatment 
and sustained abstinence from tobacco use. In a meta-
analysis of the use of incentives for smoking cessation, 
Cahill and colleagues (2015) analyzed 21 trials of incentive 
programs that were implemented in a variety of settings 
for mixed populations and special groups (e.g., pregnant 
women). The OR for quitting with incentives (compared 
with controls) at the longest period of follow-up (at least 
6  months) was 1.42 (95%  CI, 1.19–1.69). Additionally, 
incentive-based programs increased rates of smoking ces-
sation among pregnant women at both end-of-pregnancy 
and postpartum assessments. In an analysis by Cahill and 
Perera (2011), the primary benefit of incentive-based inter-
ventions was often seen only while the incentive was still in 
place. Only one of the reviewed studies (Volpp et al. 2009) 
in the analysis showed a statistically significant effect of the 
incentive program after the active incentive phase ended.
A key factor in the success of incentives in moti-
vating smokers to quit may be the behavior that is being 
incentivized (quitting vs. engaging in treatment) and 
how the incentive is framed (reward vs. punishment). 
For example, in the study by Cahill and Perera (2011), 
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the participating employer opted to charge employees 
who smoked more for their insurance, rather than paying 
them for quitting, because nonsmoking employees viewed 
the latter approach as unacceptable. However, charging 
employees who smoke higher insurance premiums could 
have potential unintended consequences, such as leading 
them to forgo health insurance because it is too expensive 
or to conceal their smoking status to avoid the surcharges, 
making it harder to provide these employees with quit-
ting support (Friedman et al. 2016; also see Chapter 7). As 
this example shows, contingency management could have 
unintended effects if improperly designed. 
In 2011, the Centers for Medicare & Medicaid 
Services (CMS) launched the Medicaid Incentives for 
Prevention of Chronic Disease program in 10 states to 
assess the effectiveness of incentives in increasing certain 
preventive health behaviors, such as weight management 
and smoking cessation, among Medicaid beneficiaries as 
a strategy to improve the management of noncommuni-
cable disease (CMS 2011, 2018). The results described in 
the final report on the project generally support the incen-
tive approach (Hoerger et al. 2017). Five states (California, 
Connecticut, New Hampshire, New York, and Wisconsin) 
implemented incentive programs for smoking cessation. In 
the three states that tested impacts on program utilization 
(Connecticut, New Hampshire, and Wisconsin), incentives 
significantly increased the use of program services. Four 
of the states (California, Connecticut, New Hampshire, 
and Wisconsin) assessed the impact of incentives on rates 
of smoking cessation (which were biochemically verified 
in Connecticut, New Hampshire, and Wisconsin and self-
reported in California); in all four states, rates of smoking 
cessation increased among those in the incentive group 
relative to those in the control group (Witman et al. 2018). 
In general, motivation to quit and rates of cessa-
tion may increase while monetary incentives are in place, 
but these outcomes are rarely sustained after such incen-
tives are removed. It is unclear whether a monetary incen-
tive-based strategy is practical outside a research set-
ting, given the reluctance of employers and insurers to 
pay smokers to quit and the potential unintended con-
sequences of charging smokers more for health insur-
ance. More research is needed to (a) explore whether any 
approaches to incentivizing smoking cessation sustain 
their effects over time and do not lead to counterproduc-
tive outcomes and (b) identify what types of approaches 
meet these criteria.
Relapse Prevention and Recovery
Most smokers make multiple quit attempts before 
finally succeeding in quitting for good. Indeed, one study 
estimated that smokers may make an average of 30  or 
more quit attempts (i.e., serious attempts to quit smoking) 
before eventually succeeding (Chaiton et  al. 2016). This 
means that most quit attempts end in relapse. Most 
relapses occur during the first few hours, days, or weeks 
of a quit attempt (Fiore et al. 2008). Although the risk of 
relapse declines over time, even former smokers who have 
quit for months or years can relapse (Hawkins et al. 2010).
Several treatment strategies include compo-
nents designed to prevent relapse or to help smokers 
recover from relapses. Examples include relapse pre-
vention therapy, which equips smokers with skills for 
avoiding or coping with high-risk environments and situ-
ations (Collins et al. 2010); acceptance and commitment 
therapy, which teaches smokers coping strategies to help 
them avoid lapsing into states of distress or giving in to 
strong urges to smoke (Bricker et al. 2014b); and moti-
vation-enhancing interventions, which have been used to 
encourage smokers to make a quit attempt even if they are 
not ready to quit (Fiore et al. 2008; Lindson-Hawley et al. 
2015). Each of these treatment models has demonstrated 
efficacy that is greater than brief advice (Lindson-Hawley 
et al. 2015) but not substantially greater than an equal-
intensity intervention based on the Clinical Practice 
Guideline that addresses relevant risks of smoking, 
rewards of quitting, roadblocks to cessation, and repeti-
tion at each visit (Catley et al. 2016).
Despite the availability of relapse prevention and 
recovery interventions, scientific literature reviews on the 
topic highlight the difficulty of preventing and addressing 
relapse (Agboola et  al. 2010; Hajek et  al. 2013c). For 
example, in a Cochrane Review meta-analysis of relapse 
prevention interventions among smokers during the first 
6 months of a quit attempt, Hajek and colleagues (2013c) 
found no evidence of benefit for additional post-cessation 
behavioral interventions or combined behavioral and 
pharmacologic interventions, either overall or for any 
subgroup. Many of the studies included in the Cochrane 
Review used small sample sizes and had limited statistical 
power to detect modest but potentially clinically signifi-
cant effects, and the interventions may have been insuf-
ficient to achieve the desired effect. In addition, some 
studies focused on long-term abstinence. Therefore, these 
studies may have overlooked potentially beneficial recy-
cling or recovery effects that result in increased frequency 
of secondary quit attempts. In a more recent review, 
Livingstone-Banks and colleagues (2019) found that the 
evidence does not support the use of behavioral treat-
ments to help prevent relapse following smoking cessation 
among assisted abstainers. Instead, the most promising 
treatments involved extending treatment with certain 
pharmacotherapy, namely varenicline; extending treat-
ment with bupropion was not shown to prevent relapse. 
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Furthermore, the review found insufficient evidence on 
extending treatment with NRT in preventing relapse in 
assisted abstainers. However, evidence for extending NRT 
in unassisted abstainers suggested a benefit. At present, 
more research is needed on specific behavioral interven-
tions that can be delivered during the early stages of ces-
sation to help smokers avoid short-term relapse. 
Intervention Delivery Modalities
Research demonstrates that behavioral therapy 
approaches for smoking cessation can be delivered effec-
tively through face-to-face counseling (individually or in 
groups) and brief clinical interventions (Fiore et al. 2008); 
and technology-mediated approaches, including tele-
phone-based tobacco quitlines, mHealth, short message 
service (SMS) texts, web-based interventions, and smart-
phone applications; and, under certain circumstances, tai-
lored self-help materials (The Community Guide 2011b, 
2012b; Whittaker et al. 2012; Stead et al. 2013b, 2017; 
Lancaster and Stead 2017). 
Self-Help Materials
In general, self-help materials for smoking cessa-
tion that are not tailored to a particular person or group 
have limited effectiveness when they are not coupled with 
in-person or technology-based interventions (Fiore et al. 
2008). In a review of behavioral counseling interventions 
for tobacco cessation among adults, Patnode and col-
leagues (2015) did not find evidence of increased cessation 
in a comparison between nontailored self-help materials 
and no self-help materials. However, tailored self-help 
materials that are based on specific characteristics or con-
cerns of smokers have been shown to be effective (Fiore 
et al. 2008; Patnode et al. 2013). Additionally, a Cochrane 
Review found some efficacy for tailored self-help mate-
rials in print, audio, and video forms compared with non-
tailored materials, but the absolute size of the effect was 
small (RR = 1.28; 95% CI, 1.18–1.37), and the review did 
not examine Internet-based materials (Hartmann-Boyce et 
al. 2014). Still, an effect size of 1.28 can be consequential 
given how inexpensive tailored self-help materials are rel-
ative to cessation medications or multisession counseling. 
The Cochrane Review also concluded that, although tai-
lored self-help materials may offer some benefit, smokers 
trying to quit should also seek out more intensive cessa-
tion treatments.
Face-to-Face Counseling
Face-to-face counseling—whether delivered in 
traditional healthcare settings, behavioral healthcare 
settings, or community settings—has traditionally been 
the gold standard for behavioral treatment of nicotine 
dependence, and its effectiveness is well-established in the 
scientific literature (Fiore et al. 2008). Noting substantial 
variability in the specific content of counseling delivered 
and in the skills of those delivering the counseling, the 
Clinical Practice Guideline concluded that individual in-
person counseling achieved an average abstinence rate for 
cigarette smoking of 16.8%, compared with 10.8% for the 
control conditions (OR = 1.7; 95% CI, 1.4–2.0) (Fiore et al. 
2008). In contrast, in-person group counseling achieved a 
13.9% abstinence rate (OR = 1.3; 95% CI, 1.1–1.6). 
In a Cochrane Review, Lancaster and Stead (2017) 
assessed the effectiveness of intensive counseling delivered 
by a cessation counselor on a one-on-one basis. All 49 RCTs 
they reviewed, which included approximately 19,000 par-
ticipants combined, contained a face-to-face intervention 
component; however, some trials also included the use 
of other behavioral intervention modalities. The review 
concluded that individual counseling was more effective 
than minimal contact (brief advice, usual care, or self-help 
materials) when pharmacotherapy was not systematically 
offered to any participants (RR = 1.57; 95% CI, 1.40–1.77). 
Additionally, there was moderate evidence of a benefit for 
(a)  the addition of intensive counseling (vs.  usual care) 
when cessation pharmacotherapy was offered to all partic-
ipants (RR = 1.24; 95% CI, 1.01–1.51) and (b) more inten-
sive counseling compared with brief counseling (with 
or without the addition of cessation pharmacotherapy) 
(RR = 1.29; 95% CI, 1.09–1.53). 
Brief Clinician-Delivered Advice
Clinical and other healthcare settings are a nat-
ural channel for delivering brief cessation interventions 
because at least 70% of tobacco users visit a physician 
each year (Fiore et al. 2008), almost one-third visit a den-
tist (Fiore et  al. 2008; Carson et  al. 2012), and millions 
see a specialist or are hospitalized (National Center for 
Health Statistics 2018). Encounters with clinicians rep-
resent a key opportunity to engage smokers in cessation 
treatments because clinical visits can provide teachable 
moments for patients who are experiencing or at risk for 
tobacco-related diseases (Fiore et  al. 2008). Clinicians 
can take advantage of this opportunity and enhance the 
impact of their advice to quit by delivering this advice in 
a personalized manner that places it in the context of the 
patient’s specific diagnosis and health history (Fiore et al. 
2008). Furthermore, smokers respect and trust physi-
cians and expect them to address their tobacco use (Quinn 
et  al. 2005) and are more satisfied with healthcare pro-
viders when the providers discuss cessation with them 
(Bernstein and Boudreaux 2010; Winpenny et  al. 2017; 
Holla et al. 2018). 
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Evidence increasingly suggests that healthcare 
providers other than physicians can also be effective in 
advising smokers to quit. For example, in a Cochrane 
Review of 11 studies, Rice and colleagues (2017) found 
moderate evidence that behavioral support provided 
by nurses can motivate and sustain smoking cessa-
tion. In another Cochrane Review of 14 studies totaling 
more than 10,500 participants, Carr and Ebbert (2012) 
found evidence suggesting that behavioral interven-
tions conducted by oral health professionals (e.g., den-
tists and dental hygienists) as part of an oral examina-
tion in a dental office or other community setting could 
increase cessation rates in cigarette smokers and users 
of smokeless tobacco (pooled OR = 1.71; 95% CI, 1.44–
2.03). Research is also emerging about the role that phar-
macists and community pharmacies can play in helping 
to promote tobacco cessation (Augustine et al. 2016; 
Greenhalgh et al. 2016).
Based on the strong evidence base for brief tobacco 
cessation interventions, USPSTF (2015) recommends, as 
a “Grade A” recommendation, that clinicians deliver such 
interventions to all adult smokers. Even brief (<3 min-
utes) advice from a physician improves cessation rates 
(OR = 1.66; 95% CI, 1.42–1.94) (Stead et al. 2013a) and is 
highly cost-effective (Maciosek et al. 2017a). 
As a framework, the 5 A’s method is considered the 
gold standard for delivering a brief tobacco cessation inter-
vention. The 5 A’s method consists of the following steps: 
1. Ask all patients about tobacco use; 
2. Advise tobacco users to quit (e.g., “quitting is the 
best thing you can do for your health”);
3. Assess the patient’s willingness to make a quit 
attempt (e.g., “have you thought about quitting or 
are you interested in trying?”); 
4. Assist in the quit attempt with medications, coun-
seling, and referrals to behavioral treatment pro-
grams; and 
5. Arrange follow-up (Table 6.1) (Fiore et al. 2008, p. 39). 
Implementation of the 5 A’s by physicians is effec-
tive in increasing tobacco cessation and quit attempts 
among patients and in increasing engagement among 
patients in other empirically validated cessation treat-
ments (Quinn et al. 2009). Compared with patients who 
received only one or none of the 5 A’s, delivering all of the 
5 A’s increased patients’ receipt of counseling (OR = 11.2; 
95% CI, 7.1–17.5), use of FDA-approved cessation medi-
cations (OR = 6.2; 95% CI, 4.3–9.0), and combined use of 
counseling and medication (OR = 14.6; 95% CI, 9.3–23.0) 
(Kruger et al. 2016).
In practice, however, despite the robust evidence for 
the effectiveness of brief tobacco interventions, many cli-
nicians do not consistently address tobacco use and nico-
tine dependence. For example, in nationally representa-
tive data from 2000 to 2015, Babb and colleagues (2017) 
found that 57% of smokers who had seen a health profes-
sional in the past year reported receiving advice to quit. 
In an earlier study, King and colleagues (2013) found 
that patient reports of their physicians providing each of 
the 5 A’s typically decreased as the steps progressed, with 
“Asking” about tobacco use (87.9%) being more prevalent 
than “Assisting” with a quit attempt (78.2% of those who 
wanted to quit) and the prevalence of “Assisting” being 
far more prevalent than “Arranging for follow-up” (17.5% 
overall). Thus, in practice, clinicians are rarely performing 
all five actions in the 5 A’s approach. One way to address 
this problem is by delegating some of the steps of the 5 A’s 
(e.g., Ask, Assist, Arrange) in whole or in part to other 
members of the healthcare team (e.g., nurses, physician 
assistants, roomers, etc.) (Fiore et al. 2008). This approach 
Table 6.1 The 5 A’s model for treating tobacco use and dependence
Ask about tobacco use • Identify and document tobacco use status for every patient at every visit.
Advise to quit • In a clear, strong, and personalized manner, urge every tobacco user to quit.
Assess readiness to make a quit attempt • Is the tobacco user willing to make a quit attempt at this time?
Assist in quit attempts • For the patient willing to make a quit attempt, offer medication and provide or refer 
for counseling or additional treatment to help the patient quit.
• For patients unwilling to quit at the time, provide interventions designed to increase 
future quit attempts.
Arrange follow-up • For the patient willing to make a quit attempt, arrange for follow-up contacts, 
beginning within the first week after the quit date.
• For patients unwilling to make a quit attempt at the time, address tobacco 
dependence and willingness to quit at next clinic visit.
Source: Fiore and colleagues (2008, p. 39).
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lessens the burden on physicians and emphasizes the 
importance of quitting to patients (Fiore et al. 2008).
A diagnosis of a tobacco-related disease has been 
associated with an increase in quit attempts, use of ces-
sation resources (Patel et al. 2009; Schauer et al. 2014b; 
Gallaway et al. 2019), and cessation and can provide a teach-
able moment for patients, especially because quitting can 
often improve a patient’s prognosis or symptoms. Studies 
indicate that healthcare providers may be leveraging this 
opportunity. For example, in a study of patient-reported 
receipt of the 5 A’s in a nationally representative population 
of past-year cigarette smokers with and without chronic 
obstructive pulmonary disease (COPD), Schauer and col-
leagues (2016c) found that patients with COPD were more 
likely than those without COPD to receive each step in the 
5  A’s approach: Ask  =  95.4% vs. 85.8%; Advise  =  87.5% 
vs. 59.4%; Assess = 63.8% vs. 37.9%; Assist = 58.6% vs. 
34.0%; and Arrange = 14.9% vs. 5.2%. 
Barriers that can prevent clinicians from consis-
tently conducting brief cessation interventions include 
time constraints; a lack of knowledge, training, and con-
fidence; inadequate clinical and/or institutional support; 
a lack of adequate reimbursement for delivering tobacco 
treatment; and inadequate or confusing insurance ces-
sation coverage (Fiore et al. 2008; Sheffer et al. 2012). 
Concerns about the lack of adequate training to effectively 
deliver cessation interventions are also reported by other 
healthcare providers, such as nurses, psychologists, and 
social workers (Steinberg et al. 2006a,b; Applegate et al. 
2008; Sheffer et al. 2012).
Alternative Approaches to the 5 A’s
Research supports the value of alternative treat-
ment approaches that do not deliver all steps of the 5 A’s 
approach in the clinical setting. One such alternative that 
is widely used is the Ask-Advise-Refer (AAR) approach, 
which involves a provider in a clinical setting Asking 
about tobacco use; Advising patients to quit; and Referring 
interested patients to another cessation resource, such 
as a quitline (see Chapter 7), to complete the remaining 
“Assess,” “Assist,” and “Arrange” steps (Schroeder 2005; 
Gordon et al. 2010). Gordon and colleagues (2010) com-
pared the use of the 5 A’s with the use of the AAR approach 
in 68 dental clinics. At 12 months, participants receiving 
either the 5 A’s or the AAR were more likely to report 
tobacco cessation than those who received only usual care. 
Additionally, there was no significant difference (using a 
threshold of p <0.05) in rates of 9-month prolonged cessa-
tion between participants receiving the 5 A’s method and 
the AAR approach (3% vs. 2%, p <.10 for 9 months of pro-
longed abstinence) (Gordon et al. 2010).
Limited research supports a third approach, Ask-
Advise-Connect (AAC). Compared with AAR, AAC provides 
a more active and direct connection to an outside cessation 
resource (Vidrine et al. 2013a,b). One example of providing 
such a direct connection is referring smokers to tobacco 
quitlines via an electronic referral or “eReferral” that 
securely transfers patient registration information from 
electronic health records to the quitlines (Boyle et al. 2011, 
2014; Sheffer et al. 2012; Adsit et al. 2014; Tindle et al. 2016) 
(see Chapter 7 for more details on electronic health records 
and eReferrals). Some research suggests that AAC may be 
more effective than AAR in reaching smokers and engaging 
them in treatment. Specifically, in a pair-matched, two-
treatment-arm, group-randomized study conducted in 
10  family practice clinics in one metropolitan area, 7.8% 
of all identified smokers enrolled in treatment in the AAC 
arm compared with just 0.6% who enrolled in the AAR arm 
(OR = 11.6; 95% CI, 5.5–24.3) (Vidrine et al. 2013a).
Finally, because many smokers are ambivalent 
about quitting or have transient motivation to quit, a 
fourth hypothetical version of the 5 A’s might build on 
such approaches as the 5 R’s (Relevance, Risks, Rewards, 
Roadblocks, and Repetition) (Agency for Healthcare 
Research and Quality 2012), which is used for smokers 
who are not yet ready to quit and focuses on providing 
interventions and supports to all smokers, even those who 
are initially assessed as not ready to quit. This approach is 
appealing from a theoretical standpoint because of the lack 
of clear evidence demonstrating that a very brief assess-
ment of readiness to quit is sufficient to withhold an offer 
of more robust cessation support to these individuals. One 
potential downside of this approach could be that pro-
viding support to smokers who are not ready to quit could 
turn out to be time-consuming and inefficient. To date, 
randomized trials have not assessed this approach. 
As tobacco cessation interventions are increasingly 
integrated into inpatient care and into care in other set-
tings, such as pharmacies and behavioral health treat-
ment facilities, updates to the 5 A’s model may emerge 
that more explicitly coordinate and distribute cessation 
interventions across an integrated care team and across 
different clinical environments.
Intensive Face-To-Face Counseling
Intensive in-person behavioral treatment, which is 
sometimes combined with pharmacologic interventions, 
typically consists of multiple face-to-face counseling ses-
sions that last long periods of time (e.g., ≥10 minutes) by 
clinicians who have been trained in specialized smoking 
cessation interventions (Fiore et  al. 2008). Although 
intensive interventions are intended primarily for mod-
erately to heavily addicted smokers, the effectiveness and 
cost-effectiveness of such interventions are not limited 
to heavy or highly dependent smokers (Fiore et al. 2008; 
USPSTF 2015). A range of intensive treatment programs 
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are available at the individual and group levels in some 
communities, worksites, and healthcare systems (Institute 
of Medicine 2007). However, availability varies widely 
from community to community, and geographic loca-
tion and temporal availability are major barriers to uti-
lization. In practice, such intensive cessation approaches 
are generally the exception rather than the rule in the 
United States. Compared with the United States, some 
countries have invested more heavily to ensure that most 
smokers have access to intensive face-to-face counseling. 
For example, in addition to making brief cessation inter-
ventions delivered by primary care physicians and some 
pharmacists widely available, the United Kingdom has 
established Stop Smoking Services, which mainly target 
highly addicted smokers and are staffed by counselors 
who are trained in behavioral approaches to smoking ces-
sation (Dobbie et al. 2015; Public Health England 2017). 
Both intensive individual and group cessation treatments 
have been shown to be effective when delivered outside of 
healthcare clinics, particularly in workplace settings. For 
example, Cahill and Lancaster (2014) reported on rates of 
tobacco cessation in eight trials in workplace settings that 
involved intensive group treatments (N = 1,309) and indi-
vidual treatments (N = 3,516). Relative to controls, the OR 
for successful quitting among those in the intensive group 
treatments (OR = 1.71; 95% CI, 1.05–2.80) was generally 
comparable in magnitude to that for those receiving indi-
vidual treatments (OR  =  1.96; 95%  CI, 1.51–2.54), sug-
gesting that well-designed group counseling can be effec-
tive in workplace settings.
Although a strong evidence base exists for in-person 
behavioral approaches to treating tobacco use and nicotine 
dependence, few U.S. smokers use face-to-face individual 
and group counseling when trying to quit, possibly because 
of a lack of investment in these approaches and practical 
barriers to use (e.g., time, transportation, schedule, etc.) 
(Dobbie et al. 2015; Public Health England 2017). For 
example, in a U.S. study, Babb and colleagues (2017) found 
that in 2015 31.2% of U.S. adult cigarette smokers reported 
using cessation counseling and/or medication when trying 
to quit, 6.8% reported using counseling, 29.0% reported 
using medication, and 4.7% reported using both counseling 
and medication. In terms of specific types of counseling, 
4.1% of smokers reported using a telephone quitline; 2.8% 
one-on-one counseling; and 2.4% a stop-smoking clinic, 
class, or support group (Babb et al. 2017). 
Technology-Mediated Delivery Approaches
Evidence supports the effectiveness of certain non-
face-to-face delivery approaches for tobacco cessation, 
including telephone-based quitlines (The Community Guide 
2012a) and mHealth-based interventions (The Community 
Guide 2011b). These approaches have characteristics that 
can remove or reduce time, transportation, and child care 
issues that may hinder face-to-face service delivery, thereby 
potentially leading to more widespread use. The following 
section reviews technology-mediated tobacco cessation 
intervention delivery approaches, including quitlines, SMS 
texting, web-based interventions, and smartphone appli-
cations. Telehealth approaches, which are discussed later 
in the “Emerging Behavioral Treatments” section of this 
chapter, are another emerging technology that can be used 
to deliver tobacco cessation interventions. 
Tobacco Quitlines
Staffed by trained counselors or coaches, tobacco 
quitlines typically deliver a variety of services, including 
individual counseling, practical information on how to quit, 
referrals to other cessation or health-related resources, 
mailed self-help materials, information on FDA-approved 
cessation medications, and, in some cases, provision of lim-
ited quantities of free or discounted cessation medications 
(Keller et al. 2010; Anderson 2016). Publicly funded quit-
lines are available at no cost to U.S. residents in every state, 
the District of Columbia, Guam, and Puerto Rico (North 
American Quitline Consortium n.d.b). However, specific 
services vary across states, largely as a result of funding con-
straints that vary across states and jurisdictions and over 
time (Centers for Disease Control and Prevention [CDC] 
2014; Anderson 2016). In addition to publicly funded state 
quitlines, some public and private health insurance plans 
and employers also offer quitline services (CDC 2014). 
Since the 1990s, a large body of clinical literature 
has consistently demonstrated the effectiveness of tobacco 
quitlines (Zhu et  al. 1996; Fiore et  al. 2008). Although 
research on single- and multi-call quitline protocols has 
demonstrated that both are effective, better outcomes have 
been reported for multi-call approaches. Better outcomes 
have also been documented for proactive quitline ser-
vices, which make multiple outbound calls to engage the 
tobacco user in ongoing treatment, compared with reac-
tive quitline services, which simply respond to incoming 
calls from tobacco users. For example, in a meta-analysis of 
49 studies that compared proactive quitlines with reactive 
quitlines, The Community Guide (2012b) estimated that 
proactive quitlines yielded a median 3.1-percentage-point 
increase (0.5–3.3  percentage points, 12  studies) in quit-
ting and a 4.2 percentage-point increase when promoted 
through mass-reach health communication interventions. 
Similarly, in a Cochrane Review of 77  trials that 
assessed counseling provided through quitlines, Stead and 
colleagues (2013b) concluded that multiple sessions of 
proactive telephone counseling significantly boosted rates 
of smoking cessation (nine studies; >24,000 participants; 
RR for cessation at longest follow-up  =  1.37; 95%  CI, 
1.26–1.50). There was some evidence of a dose-response 
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effect—that is, more completed quitline counseling calls 
yielded higher rates of cessation. Even reactive calls to 
quitlines were effective in increasing cessation (51 studies, 
>30,000  participants, RR for cessation  =  1.27; 95%  CI, 
1.20–1.36). 
A toll-free national portal (1-800-QUIT-NOW) oper-
ated by the National Cancer Institute (NCI) links callers to 
their state quitline based on their area code. An electronic 
telecommunications device for the deaf (TDD) is also 
available to serve persons who are deaf or hard of hearing. 
From 2010 to 2015, state quitlines received an estimated 
1.1–1.3 million calls annually and provided cessation 
counseling and/or cessation medications to an estimated 
342,000–475,000 tobacco users each year (CDC, National 
Quitline Warehouse Database, unpublished data).
NCI also operates 1-855-DÉJELO-YA (1-855-335-
3569), a national portal that routes Spanish-speaking 
callers to Spanish-language services available through their 
state quitlines. From February 2013 (the portal’s inception) 
through December 2018, 1-855-DÉJELO-YA received more 
than 40,000 calls (CDC, NCI, unpublished data).
In addition, the Moores Cancer Center at the 
University of California–San Diego operates a nation-
wide Asian Smokers’ Quitline, which offers direct coun-
seling services in Chinese, Korean, and Vietnamese (Asian 
Smokers’ Quitline n.d.). Nearly 5,800 callers from 48 states 
enrolled in the Asian Quitline between 2012 and 2014; 
31% spoke Chinese (Cantonese or Mandarin), 38% spoke 
Korean, and 31% spoke Vietnamese (Kuiper et al. 2015). 
Nearly all eligible callers to the Asian Quitline (99%) 
received nicotine patches. Approximately 85% of smokers 
who called the Asian Quitline enrolled in counseling, com-
pleting an average of four sessions (Kuiper et al. 2015). 
Quitline counseling is readily accessible because 
it is free, convenient, and confidential, and it removes 
or reduces barriers related to time, transportation, child 
care, and other factors (World Health Organization [WHO] 
2011). As a result, quitline counseling has the potential for 
broad reach. Quitline counseling has also been found to 
be effective with an array of subpopulations (Baezconde-
Garbanati et  al. 2011). Tobacco users can be connected 
with a quitline in several ways: by calling directly; by 
having a healthcare provider’s office fax, send an online 
referral, or submit an eReferral through the patient’s elec-
tronic health record; by sending an e-mail; or by enrolling 
online. Most state quitlines provide at least one counseling 
session to any adult tobacco user who calls, and many state 
quitlines provide a multi-call program that includes both 
reactive and proactive calls. Some state quitlines prioritize 
multi-call services for subpopulations with a higher preva-
lence of tobacco use and/or limited access to other tobacco 
cessation services (e.g., persons who lack health insurance 
or are unemployed) (Anderson 2016). A study of quitline 
eReferrals in Wisconsin randomized 23  primary care 
clinics from two healthcare systems to one of two methods 
for referring adult patients who smoked to the Wisconsin 
quitline: a paper-based, fax-to-quit referral process or an 
eReferral process (Fiore et al. 2019). The eReferral process 
involved sending referrals to the quitline from patients’ 
electronic health records and receiving outcome reports 
from the quitline back into the electronic health records. 
The fax referral process transmitted the same informa-
tion in both directions via fax. A total of 14,636 smokers 
were seen in the two systems. Compared with clinics that 
were randomized to the fax referral process, clinics that 
were randomized to the eReferral process generated quit-
line referral rates that were 3- to 4-times higher and also 
generated higher rates of connecting patients with quit-
lines (i.e., having patients accept a quitline call and at least 
begin the process of registering for quitline services). The 
eReferral method generated especially high rates of refer-
rals among Medicaid recipients. The study, which was 
the first randomized study of this topic, concluded that 
eReferrals provide an effective means of referring patients 
who smoke to quitline services.
A major innovation in quitline services that occurred 
over the past decade was the integration of NRT and, in 
some cases, other FDA-approved cessation medications 
into state quitline services, along with counseling. A series 
of randomized and quasi-randomized trials (Cummings 
et al. 2006; Hollis et al. 2007; Tinkelman et al. 2007) dem-
onstrated that quitlines can feasibly and safely provide NRT 
to callers, either directly via mail order or by pharmacy 
voucher. This involved having quitlines screen callers for 
the medical appropriateness of NRT use, educate callers 
on how to properly use the NRT, and continue to provide 
callers with behavioral counseling. Making cessation med-
ication available to callers and promoting its availability 
results in more smokers calling quitlines and has the poten-
tial to increase quit rates among callers by providing them 
with the optimal combination of cessation counseling plus 
medications (An et  al. 2006). Even 2-week NRT “starter 
kits” have demonstrable benefits, including increased call 
volume to quitlines, higher quit rates, and increased caller 
satisfaction with the quitline (Bush et al. 2008; Deprey et al. 
2009; Kerr et  al. 2018). Distributing NRT through quit-
lines can be cost-effective (Fellows et al. 2007; Cummings 
et  al. 2011). For example, Fellows and colleagues (2007) 
estimated that the total cost per quit was $2,688 lower for 
callers who received free NRT ($1,050) compared with per-
sons who called the Oregon quitline before it began offering 
the nicotine patch to callers ($3,738).
The reach of state quitlines varies across states, over 
time, and by demographic factors, such as race/ethnicity 
(North American Quitline Consortium n.d.a). Despite 
reaching thousands of smokers each year in most states, 
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state quitlines reach an average of 1% of smokers annually 
(CDC 2014). Data suggest that even among smokers who 
tried to quit in the previous year and were aware of quit-
lines, quitline reach was around 8% (Schauer et al. 2014a). 
This limited awareness and reach, along with the variation 
in quitline services and eligibility for these services across 
states and over time, are largely the result of limited state 
funding for operating and promoting quitlines (e.g., state 
quitline expenditures) (CDC 2004; Schauer et al. 2014a). 
States have developed the capacity to carefully titrate their 
activities to promote quitlines and the level of quitline ser-
vices they provide to match available funding. Some states 
have been able to temporarily attain higher levels of reach, 
in some cases higher than 6%, during periods when they 
can fund quitlines at higher levels, often while also con-
ducting specific policy and promotional efforts that drive 
increased calls to the quitline (Woods and Haskins 2007; 
Mann et al. 2018).
Call volume to quitlines is highly sensitive to pro-
motional activities (Anderson 2016). For example, Tips 
From Former Smokers (Tips), a national tobacco educa-
tion campaign conducted annually by CDC for varying 
periods of time from 2012 to 2019, includes a message 
on the majority of its television ads directing smokers to 
call 1-800-QUIT-NOW for free help quitting. From 2012 
to 2018, this campaign generated more than 1.3 million 
additional calls to 1-800-QUIT-NOW (Nathan Mann, RTI 
International, personal communication, May 6, 2019). 
Call volume to 1-800-QUIT-NOW consistently increases 
when the campaign airs and decreases when it goes off the 
air (Zhang et al. 2016; McAfee et al. 2017; Murphy-Hoefer 
et al. 2018). 
In part, to maintain or improve their reach, state 
quitlines increasingly offer ancillary cessation services, 
such as Internet interventions, e-mail, chat, texting, and 
the dispensing of NRT both alone and in combination with 
counseling (Anderson 2016; Keller et al. 2016). This shift 
in quitline practice stems in part from the recognition that 
many younger adults prefer to access cessation assistance 
through these alternative channels rather than over the 
telephone (Dreher et al. 2015). For example, to increase 
both reach and quitting behavior, Minnesota implemented 
a model for state quitline services in 2014 that expanded 
tobacco users’ options for accessing cessation services, 
allowing tobacco users to enroll via telephone or online 
and to choose one or more cessation services from a menu 
of options that includes quitline counseling, a medica-
tion starter kit, text messaging, an e-mail program, and 
a quit guide (Keller et  al. 2016). Between March 2014 
and February 2015, 15,861  unique tobacco users regis-
tered for cessation services in the state—a 169% increase 
over calendar year 2013. More than four in five (83.7%) 
of the participants made a quit attempt, and the 30-day 
point-prevalence abstinence rate (among responders) 
was 26.1% for the overall program (regardless of services 
used); 29.6% for quitline services; and 25.5% for indi-
vidual non-quitline services. Thus, the reach of quitlines 
can be expanded, and new populations can be engaged in 
cessation services when quitlines (a) broaden their cessa-
tion service offerings beyond traditional telephone-based 
quitline services and (b) allow tobacco users to choose the 
service that best meets their needs and suits their prefer-
ences (Keller et al. 2016). 
Mobile Health Intervention Strategies
Desktop or laptop computer-based interactive pro-
gram modalities for delivering smoking cessation support 
have been developed and tested (USPSTF 2015), first via 
programs operated from a CD-ROM or hard drive, later via 
Internet downloads, and more recently from “the cloud” 
(Strecher et al. 2005; Haskins et al. 2017). The current 
state of science and technology also allows the leveraging 
of mobile phone and tablet applications (e.g., mHealth 
interventions) to deliver treatment for nicotine depen-
dence (Whittaker et al. 2016). mHealth strategies can 
be broadly defined as the use of technology to remotely 
monitor, track, respond to, and/or deliver an intervention 
for health-related events. mHealth treatment platforms 
have expanded greatly during the past 20 years and espe-
cially in the past decade, with the development of elec-
tronic and mHealth technologies. These platforms include 
applications offered by for-profit and not-for-profit orga-
nizations and academic institutions and by federal agen-
cies involving standardized text messages that enhance 
motivation to quit smoking or inform persons about quit-
ting strategies, some of which offer real-time, live peer or 
professional advising or counseling (Smokefree.gov n.d.). 
Preliminary evaluations suggest that these applications 
benefit users (Cole-Lewis et al. 2016; Squiers et al. 2016, 
2017; Taber et al. 2016) and that the cost of delivery is low.
Uptake of mobile technologies has been seen across 
almost all segments of the U.S. population (Pew Research 
Center 2017b). In 2016, cell phone ownership and usage 
were widespread: 95% of American adults owned a cell 
phone; 77% had a smartphone; and ownership levels were 
generally similar across all categories of race/ethnicity, age, 
education level, income level, and rural versus urban status 
(Pew Research Center 2017b). Texting is common among 
cell phone users, and many smartphone users report using 
their phones for texting, accessing the Internet, watching 
videos, and using apps (applications). Importantly, despite 
the widespread adoption of mobile technology, some popu-
lations—including some low-income and rural individuals 
and veterans—do not have equal access to mobile tech-
nology (Koutroumpisa and Leiponenb 2016; Markham 
et al. 2016). 
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Despite some remaining gaps in the availability and 
coverage of mobile technology, these technologies offer 
considerable potential to serve as platforms for delivering 
smoking cessation interventions. In 2011, the Community 
Preventive Services Task Force recommended mobile 
phone-based interventions, specifically automated tex-
ting programs, for tobacco cessation on the basis of suffi-
cient evidence of their effectiveness in increasing tobacco 
use cessation among persons interested in quitting (The 
Community Guide 2011b).
Potential advantages of mHealth interventions 
include greater reach to some disproportionately impacted 
populations (Markham et al. 2016; Anguiano et al. 2017) 
and reduced costs because mHealth interventions can be 
less costly to provide than other behavioral interventions. 
In terms of reach, the Smokefree.gov initiative—a large 
federal mHealth behavioral intervention program that 
focuses primarily on smokers—reaches 5–6.5 million per-
sons each year, including more than 3.6 million visitors 
to the Smokefree.gov website in 2018 (Yvonne Prutzman, 
NCI, personal communication, January  23, 2019). In 
addition, mHealth interventions may improve engage-
ment through increased access to intervention services, 
decreased barriers to participation (e.g., by removing bar-
riers related to scheduling, transportation, or child care), 
seamless integration of users’ interactions with treatment 
into their daily lives, and the ability to personalize treat-
ment based on passively (e.g.,  GPS [global positioning 
system] location) or actively (e.g., self-report of craving) 
gathered information (Atienza and Patrick 2011; Nilsen 
et al. 2012; Free et al. 2013; Borrelli et al. 2015; Marzano 
et al. 2015). 
The potential benefits from mHealth interventions 
are tempered by several challenges, including (1)  incon-
sistent access to cell phones among low-income popu-
lations (despite the increasing adoption of cell phones, 
low-income populations may still struggle to maintain 
cell phone contracts, have regular access to minutes, and 
have data plans that allow for repeated use of interven-
tions), (2)  different types of devices (e.g.,  cell phone vs. 
smartphone), (3) possible sharing of devices among mul-
tiple users, (4) differences in fee structures and costs for 
using cell phones, (5) the challenges of delivering content 
to populations with low literacy, and (6)  lack of broad-
band coverage (Atienza and Patrick 2011; Katz et al. 2012; 
Free et al. 2013; Marzano et al. 2015; McClure et al. 2016; 
Federal Communications Commission n.d.). 
At this time, optimal methods are not in place to 
fully assess the expanding array of available mHealth ces-
sation interventions. Future research should address 
the components of the Reach, Effectiveness, Adoption, 
Implementation, and Maintenance (RE-AIM) impact 
model (addressed later in this chapter) to determine the 
effectiveness of mobile cessation interventions under 
ideal conditions and their impact when used in real-world 
settings (Stearns et al. 2014). Research should include both 
process measures, such as engagement and reengagement, 
and measures of the interventions’ impact on quit attempts 
and successful quitting. In addition, assessing the com-
parative effectiveness and cost-effectiveness of mHealth 
cessation interventions relative to other modalities, such 
as in-person and quitline interventions, will be impor-
tant. Because of the rapid cycle of technological develop-
ment, the use of adaptive and iterative research methods 
in assessing development and performing evaluations may 
be necessary. Although opportunities are available for con-
ducting large cohort studies at a relatively low cost, the 
potential for selection bias and other types of bias in such 
studies underscores a need for RCTs in clinical settings.
Short Message Service Texting Interventions. 
Interventions based on SMS texting—which involve 
sending automated, one-way messages—offer a low-cost, 
convenient method of delivering smoking cessation inter-
ventions. Text messaging is a basic feature of almost all cell 
phones, making the delivery of cessation interventions via 
SMS texts an accessible and promising mHealth platform. 
A series of three studies from New Zealand and the United 
Kingdom provided the initial evidence supporting the use 
of this platform for delivering smoking cessation interven-
tions (Rodgers et al. 2005; Free et al. 2009, 2011). Notably, 
a large-scale RCT in the United Kingdom that compared 
smokers receiving a text-based intervention with controls 
who received SMS texts related to the importance of trial 
participation, found a significant difference in biochem-
ically verified abstinence at 6-month follow-up: 9.2% of 
smokers in the texting intervention achieved abstinence 
versus 4.3% of smokers in the control group (RR = 2.14; 
95% CI, 1.74–2.63) (Free et al. 2011). A subsequent meta-
analysis of a limited number of text-based cessation inter-
ventions found that, compared with control conditions, 
such interventions improved the 7-day point-prevalence 
of abstinence (OR = 1.38; 95% CI, 1.22–1.55) and contin-
uous abstinence (OR = 1.63; 95% CI, 1.19–2.24) (Scott-
Sheldon et al. 2016). 
Although the findings from studies of cessation tex-
ting interventions are generally encouraging, a review of 
these interventions found that, while smoking cessation 
outcomes measured at less than 6  months were better 
than those for controls, outcomes measured at 6 months 
or longer often failed to show differences between treat-
ment and control groups (Scott-Sheldon et  al. 2016). In 
addition, the review found that the studies’ findings were 
mixed and the analyses were based on a small number of 
RCTs. One reason for these mixed findings may be the 
substantial variation in key features of the interventions, 
including frequency of messages per day and per week; 
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length of programs; use of unidirectional versus bidirec-
tional messages; and, to a lesser extent, message content. 
Another reason may be variation in study design, such as 
the endpoint used for measuring abstinence (Free et  al. 
2013; Kong et  al. 2014; Scott-Sheldon et  al. 2016). This 
variability has presented a challenge when interpreting 
findings from specific studies. Nevertheless, the overall evi-
dence supports the efficacy of text-based smoking cessation 
treatment programs. However, to inform the optimization 
of treatment, more research is needed to better understand 
the contributions of various treatment elements. 
Web-Based Interventions. Web-based cessation 
interventions (i.e., cessation interventions delivered via the 
Internet) have the potential to achieve broad reach, as 88% 
of American adults report regularly accessing the Internet, 
including a majority of low-income Americans and mem-
bers of various racial/ethnic groups (Pew Research Center 
2017a). However, evidence on the effectiveness of web-
based smoking cessation interventions is mixed. Such 
interventions date back to the early 2000s, with studies 
exploring several approaches for delivering treatment 
and examining user behavior (Etter 2005; Stoddard et al. 
2005; Strecher et al. 2005; Cobb and Graham 2006). Initial 
research findings were inconsistent, and several reports 
found that websites frequently failed to deliver recom-
mended elements of behavioral treatment for smoking 
cessation (Bock et al. 2004, 2008; Fiore et al. 2008). 
In its 2011 review, the Community Preventive 
Services Task Force found insufficient evidence to deter-
mine the effectiveness of Internet-based interventions 
in increasing tobacco cessation (The Community Guide 
2011a). Later, a study on web-based tobacco cessation 
interventions by Civljak and colleagues (2013) concluded 
that some Internet-based interventions, particularly inter-
ventions that are interactive and tailored to individuals, 
can assist in achieving longer term smoking cessation. 
However, trials that compared Internet interventions with 
usual care or self-help did not show consistent effects. As 
web-based interventions have grown more sophisticated, 
incorporating better website design and improved func-
tionality, the efficacy of such interventions for smoking 
cessation has improved significantly (Graham et al. 2016). 
A meta-analysis of web-based cessation interventions 
found that, although sites with largely static content did 
not perform significantly better than printed materials 
in increasing abstinence (RR = 0.83; 95% CI, 0.63–1.10), 
sites that incorporated interactive elements significantly 
increased abstinence (RR = 2.10; 95% CI, 1.25–3.52) 
(Graham et al. 2016). Comparisons of web-based cessa-
tion interventions with face-to-face counseling and quit-
line counseling suggest that these different modalities 
have the potential to produce similar cessation outcomes 
(Graham et al. 2016; McCrabb et al. 2019).
In a meta-analysis, McCrabb and colleagues (2019) 
assessed the effectiveness of 45  RCTs of adult-focused 
Internet cessation programs, as well as the number and 
type of behavior change techniques employed in the inter-
vention (Michie et al. 2013), to determine how behavior 
change techniques impact program effectiveness. The 
study found short-term effectiveness for all measured ces-
sation outcomes (e.g.,  prolonged abstinence and 30-day 
point-prevalence abstinence) (OR = 1.29; 95% CI, 1.12–
1.50) and for long-term outcomes (OR  =  1.19; 95%  CI, 
1.06–1.35). Interventions used more behavior change 
techniques than comparison groups (6.6 vs. 3.1, p <.0002). 
Interventions that included goals and planning, social 
support, natural consequences, comparison of outcomes, 
reward and threat, or regulation were significantly associ-
ated with increased intervention effectiveness in the short 
and long terms, when compared with study arms that did 
not include the domain(s).
The fact that web technologies and web-based ces-
sation interventions continue to evolve, along with the 
potential reach and customizability of web-based tech-
nologies, suggests that future interventions could fur-
ther improve on current ones. For example, advances in 
web technologies could improve user experience, enhance 
content management, better incorporate interactive ele-
ments, and better integrate various types of media (e.g., 
videos and audio). The increasing penetration of smart-
phones and the broad availability of free Wi-Fi may also 
allow for access to the web in many nontraditional set-
tings. In response to this changing landscape, many web-
sites are using adaptive design (i.e., changing the format 
to match the type of device used) and are optimized for 
use on mobile devices (i.e., are designed to offer easy nav-
igation and high-quality user experience when accessed 
via such devices). Such sites have the potential to achieve 
broad population-level reach and widespread engagement 
with target audiences. Taken as a whole, the available evi-
dence suggests that web interventions with interactive 
components can increase abstinence to tobacco. As with 
text-based cessation programs, more research is needed to 
better understand the specific components that can fur-
ther enhance the effectiveness of web-based interventions 
for smoking cessation.
Smartphone Applications. Although most mobile 
phone interventions have traditionally relied on text mes-
saging platforms (Whittaker et  al. 2016), the increasing 
use of smartphones offers a platform to combine elements 
of texting and the web to create more interactive and 
visual interventions (Abroms et  al. 2011). In their 2013 
review of smartphone apps for smoking cessation, Abroms 
and colleagues (2013) identified 252 such apps for Apple’s 
iOS and 148 apps for Google’s Android operating systems. 
The review then analyzed nearly 100 of the most popular 
Interventions for Smoking Cessation and Treatments for Nicotine Dependence  509
Smoking Cessation
cessation apps and their adherence to an index criteria 
based on the Clinical Practice Guideline (Fiore et al. 2008). 
The average score suggested that overall levels of the apps’ 
adherence to evidence-based cessation approaches were 
low (Abroms et al. 2011). However, smartphone apps for 
smoking cessation continue to evolve, both as standalone 
interventions and in combination with other approaches 
to cessation interventions. For example, in 2017 FDA 
granted marketing authorization for a carbon monoxide 
breath sensor system that can be paired with a smart-
phone via Bluetooth technology to measure carbon mon-
oxide in exhaled breath and show smokers in real time how 
their cigarette smoking is impacting their levels of carbon 
monoxide (FDAnews 2017). The Smokefree.gov initiative 
now includes two free smoking cessation apps: QuitGuide, 
which helps smokers understand their smoking pat-
terns and build skills to quit, and quitSTART, which gives 
smokers tailored tips and motivation to quit. These feder-
ally funded apps provide opportunities to learn more about 
the components that make a smoking cessation smart-
phone application effective. In particular, more research 
is needed to assess the efficacy of smartphone applications 
that combine texting and web-based features.
As reviewed, a variety of technology-mediated 
approaches exist to deliver behavioral interventions for 
smoking cessation, and these interventions stand to 
further increase the reach of cessation interventions. 
However, technologies are evolving, as are the ways in 
which people interact with and use technology. Therefore, 
ongoing research is warranted to ensure that technology-
based approaches to cessation remain relevant and meet 
current user preferences. The elements that make a par-
ticular technology effective for cessation may shift as tech-
nologies evolve. For example, preferences for texting may 
shift as that technology becomes integrated into smart-
phone applications and user interfaces.
In summary, a variety of behavioral and counseling 
approaches are available through various delivery modal-
ities to motivate and aid successful smoking cessation. 
However, most smokers still try to quit on their own without 
using behavioral or counseling interventions. Therefore, 
innovative, technology-based delivery modalities have the 
potential to help increase the reach and use of these inter-
ventions, but more research is needed to better understand 
the impact that different delivery modalities have on moti-
vating and sustaining cessation in different subpopulations.
Pharmacologic Treatments
Nicotine is the drug in tobacco that leads to addic-
tion (USDHHS 1988). Epidemiologic and laboratory 
evidence indicates that nicotine delivered in tobacco 
products is substantially more addictive than nicotine 
delivered through current medications (USDHHS 2010). 
In addition to behavioral and environmental components, 
constituents other than nicotine in tobacco products and 
product delivery methods play critical supporting roles in 
promoting nicotine addiction. A major conclusion from 
the 2010 Surgeon General’s report is, “Sustained use and 
long-term exposures to tobacco smoke are due to the pow-
erfully addicting effects of tobacco products, which are 
mediated by diverse actions of nicotine and perhaps other 
compounds, at multiple types of nicotinic receptors in the 
brain” (USDHHS 2010, p.  9). The general rationale for 
having smokers use smoking cessation medications as part 
of a quit attempt is to reduce physical symptoms resulting 
from nicotine withdrawal, thus allowing smokers to focus 
on the behavioral and psychological aspects of quitting 
smoking (Prochaska and Benowitz 2016). Cessation med-
ications also have the additional benefit of eliminating 
or greatly reducing the immediate reinforcing effects of 
nicotine absorbed from tobacco smoke by desensitizing 
the nicotinic receptors (Prochaska and Benowitz 2016). 
Although not FDA-approved for smoking cessation, 
the prescription medications clonidine hydrochloride 
and nortriptyline hydrochloride are recommended as 
second-line agents in the U.S. Public Health Service’s 
Clinical Practice Guideline (Fiore et al. 2008). Lack of an 
FDA-approved indication for smoking cessation, as well as 
some side effects, currently preclude these medications 
from being classified as first-line agents; therefore, they 
are not reviewed in this report. 
To date, seven FDA-approved, first-line medications 
have been found to be safe and effective for treating nico-
tine dependence—although there are some contraindica-
tions for use (e.g., recent myocardial infarction for most 
NRT formulations, seizure disorder for bupropion), as well 
as insufficient evidence of effectiveness and, in some cases, 
safety in certain populations (e.g., pregnant women, light 
smokers, adolescents, and smokeless tobacco users) (Fiore 
et al. 2008). The seven medications include five nicotine-
based medications (the nicotine patch, gum, lozenge, nasal 
spray, and oral inhaler) and two non-nicotine oral medica-
tions, bupropion and varenicline. Table 6.2 offers in-depth 
information on these seven medications. The nicotine 
patch, gum, and lozenges are available over the counter; 
however, a prescription may still be required for insur-
ance coverage of over-the-counter products. The nicotine 
nasal spray and oral inhaler, bupropion, and varenicline 
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Table 6.2 Pharmacologic product guide: FDA-approved medications for smoking cessation
  NRT formulations    
  Gum Lozenge Transdermal patch Nasal spray Oral inhaler Bupropion SR Varenicline
Product Nicorette,a ZONNIC,b 
Generic
OTC
2 mg, 4 mg
original, cinnamon, 
fruit, mint
Nicorette Lozenge,a 
Nicorette Mini 
Lozenge,a Generic
OTC
2 mg, 4 mg
cherry, mint
NicoDerm CQ,a 
Generic
OTC (NicoDerm CQ, 
generic)
Rx (generic)
7 mg, 14 mg, 21 mg 
(24-hour release)
Nicotrol NSc
Rx
Metered spray
10 mg/ml aqueous 
solution 
Nicotrol Inhalerc
Rx
10-mg cartridge
delivers 4-mg 
inhaled vapor
Zyban,a Generic
Rx
150-mg sustained-
release tablet
Chantixc
Rx
0.5-mg, 1-mg tablet
FDA approval Nicorette:
• 2 mg (Rx) 1984
• 4 mg (Rx) 1991
ZONNIC:
• 2 mg (OTC) 1996
• 4 mg (OTC) 1996
Lozenge:
• 2 mg (OTC) 2002
• 4 mg (OTC) 2002
Mini-lozenge:
• 2 mg (OTC) 2009
• 4 mg (OTC) 2009
• Rx: 1991–1992
• OTC: 1996–2002
Rx: 1996 Rx: 1997 Rx: 1997 Rx: 2006
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  NRT formulations    
  Gum Lozenge Transdermal patch Nasal spray Oral inhaler Bupropion SR Varenicline
Precautions • Recent (≤2 weeks) 
myocardial infarction
• Serious underlying 
arrhythmias
• Serious or worsening 
angina pectoris
• Temporomandibular 
joint disease
• Pregnancyd and 
breastfeeding
• Adolescents 
(<18 years of age)
• Recent (≤2 weeks) 
myocardial infarction
• Serious underlying 
arrhythmias
• Serious or worsening 
angina pectoris
• Pregnancyd and 
breastfeeding
• Adolescents 
(<18 years of age)
• Recent (≤2 weeks) 
myocardial infarction
• Serious underlying 
arrhythmias
• Serious or worsening 
angina pectoris
• Pregnancyd 
(Rx formulations, 
category D) and 
breastfeeding
• Adolescents 
(<18 years of age)
• Recent (≤2 weeks) 
myocardial infarction
• Serious underlying 
arrhythmias
• Serious or worsening 
angina pectoris
• Underlying chronic 
nasal disorders 
(rhinitis, nasal 
polyps, sinusitis)
• Severe reactive 
airway disease
• Pregnancyd 
(category D) and 
breastfeeding
• Adolescents 
(<18 years of age)
• Recent (≤2 weeks) 
myocardial infarction
• Serious underlying 
arrhythmias
• Serious or worsening 
angina pectoris
• Bronchospastic 
disease
• Pregnancyd 
(category D) and 
breastfeeding
• Adolescents 
(<18 years of age)
• Concomitant therapy 
with medications/ 
conditions known 
to lower the seizure 
threshold
• Hepatic impairment
• Pregnancyd 
(category C) and 
breastfeeding
• Adolescents 
(<18 years of age)
• Treatment-emergent 
neuropsychiatric 
symptomse: Boxed 
warning removed 
December 2016
Contraindications:
• Seizure disorder
• Concomitant 
bupropion (e.g., 
Wellbutrin) therapy
• Current or prior 
diagnosis of bulimia 
or anorexia nervosa
• Simultaneous abrupt 
discontinuation of 
alcohol or sedatives/ 
benzodiazepines
• MAO inhibitors 
during preceding 
14 days; concurrent 
use of reversible 
MAO inhibitors
• Severe renal 
impairment (dosage 
adjustment is 
necessary)
• Pregnancyd 
(category C) and 
breastfeeding
• Adolescents 
(<18 years of age)
• Treatment-emergent 
neuropsychiatric 
symptomse: Boxed 
warning removed 
December 2016
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  NRT formulations    
  Gum Lozenge Transdermal patch Nasal spray Oral inhaler Bupropion SR Varenicline
Dosing • 1st cigarette 
≤30 minutes after 
waking: 4 mg
• 1st cigarette 
>30 minutes after 
waking: 2 mg
• Weeks 1–6: 1 piece 
every 1–2 hours
• Weeks 7–9: 1 piece 
every 2–4 hours
• Weeks 10–12: 1 piece 
every 4–8 hours
• Maximum 
24 pieces/day
• Chew each piece 
slowly
• Park between cheek 
and gum when 
peppery or tingling 
sensation appears 
(~15–30 chews)
• Resume chewing 
when tingle fades
• Repeat chew/park 
steps until most of 
the nicotine is gone 
(tingle does not 
return; generally 
30 min)
• Park in different 
areas of mouth
• No food or beverages 
15 minutes before 
or during use
• Duration: up to 
12 weeks
• 1st cigarette 
≤30 minutes after 
waking: 4 mg
• 1st cigarette 
>30 minutes after 
waking: 2 mg
• Weeks 1–6: 1 lozenge 
every 1–2 hours
• Weeks 7–9: 1 lozenge 
every 2–4 hours
• Weeks 10–12: 
1 lozenge every 
4–8 hours
• Maximum 
20 lozenges/day
• Allow to dissolve 
slowly (20–30 min-
utes for standard; 
10 minutes for mini)
• Nicotine release 
may cause a warm, 
tingling sensation
• Do not chew or 
swallow
• Occasionally 
rotate to different 
areas of the mouth
• No food or beverages 
15 minutes before 
or during use
• Duration: up to 
12 weeks
• >10 cigarettes/day:
 – 21 mg/day for 
4–6 weeks
 – 14 mg/day for 
2 weeks
 – 7 mg/day for 
2 weeks
• ≤10 cigarettes/day:
 – 14 mg/day for 
6 weeks
 – 7 mg/day for 
2 weeks
• Rotate patch 
application site daily; 
do not apply a new 
patch to the same 
skin site for at least 
1 week
• May wear patch 
for 16 hours if 
patient experiences 
sleep disturbances 
(remove at bedtime)
• Duration: 
8–10 weeks
• 1–2 doses/hour 
(8–40 doses/day)
• One dose = 2 sprays 
(1 in each nostril); 
each spray delivers 
0.5 mg of nicotine to 
the nasal mucosa
• Maximum: 5 doses/
hour or 40 doses/day
• For best results, 
initially use at least 
8 doses/day
• Do not sniff, swallow, 
or inhale through 
the nose as the spray 
is being administered
• Duration: 
3–6 months
• 6–16 cartridges/day
• Individualize 
dosing; initially use 
1 cartridge every 
1–2 hours
• Best effects with 
continuous puffing 
for 20 minutes
• Initially use at least 
6 cartridges/day
• Nicotine in cartridge 
is depleted after 
20 minutes of 
active puffing
• Inhale into back 
of throat or puff 
in short breaths
• Do NOT inhale into 
the lungs (like a 
cigarette) but “puff” 
as if lighting a pipe
• Open cartridge 
retains potency 
for 24 hours
• No food or beverages 
15 minutes before 
or during use
• Duration: 
3–6 months
• 150 mg po every 
morning for 3 days, 
then 150 mg po bid
• Do not exceed 
300 mg/day
• Begin therapy 
1–2 weeks prior 
to quit date
• Allow at least 8 hours 
between doses
• Avoid bedtime 
dosing to minimize 
insomnia
• Dose tapering is 
not necessary
• Duration: 
7–12 weeks, with 
maintenance up 
to 6 months in 
selected patients
• Days 1–3: 0.5 mg 
po every morning
• Days 4–7: 0.5 mg 
po bid
• Weeks 2–12: 1 mg 
po bid
• Begin therapy 1 week 
prior to quit date
• Take dose after 
eating and with a 
full glass of water
• Dose tapering is 
not necessary
• Dosing adjustment 
is necessary for 
patients with severe 
renal impairment
• Duration: 12 weeks; 
an additional 
12-week course 
may be used in 
selected patients
• May initiate up 
to 35 days before 
target quit date
• May reduce smoking 
over a 12-week 
period of treatment 
prior to quitting and 
continue treatment 
for an additional 
12 weeks
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  NRT formulations    
  Gum Lozenge Transdermal patch Nasal spray Oral inhaler Bupropion SR Varenicline
Adverse effects • Mouth/jaw soreness
• Hiccups
• Dyspepsia
• Hypersalivation
• Effects associated 
with incorrect 
chewing technique:
 – Lightheadedness
 – Nausea/vomiting
 – Throat and mouth 
irritation
• Nausea
• Hiccups
• Cough
• Heartburn
• Headache
• Flatulence
• Insomnia
• Local skin reactions 
(erythema, pruritus, 
burning)
• Headache
• Sleep disturbances 
(insomnia, abnormal/
vivid dreams); 
associated with 
nocturnal nicotine 
absorption
• Nasal and/or 
throat irritation 
(hot, peppery, or 
burning sensation)
• Rhinitis
• Tearing
• Sneezing
• Cough
• Headache
• Mouth and/or 
throat irritation
• Cough
• Headache
• Rhinitis
• Dyspepsia
• Hiccups
• Insomnia
• Dry mouth
• Nervousness/ 
difficulty 
concentrating
• Nausea
• Dizziness
• Constipation
• Rash
• Seizures 
(risk is 0.1%)
• Neuropsychiatric 
symptoms (rare; 
see PRECAUTIONS)
• Nausea
• Sleep disturbances 
(insomnia, abnormal/
vivid dreams)
• Constipation
• Flatulence
• Vomiting
• Neuropsychiatric 
symptoms (rare; 
see PRECAUTIONS)
Advantages • Might serve as 
an oral substitute 
for tobacco
• Might delay 
weight gain
• Can be titrated to 
manage withdrawal 
symptoms
• Can be used in 
combination with 
other agents to 
manage situational 
urges
• Might serve as 
an oral substitute 
for tobacco
• Might delay 
weight gain
• Can be titrated to 
manage withdrawal 
symptoms
• Can be used in 
combination with 
other agents to 
manage situational 
urges
• Once-daily dosing 
associated with fewer 
adherence problems
• Of all NRT products, 
its use is least 
obvious to others
• Can be used in 
combination with 
other agents; 
delivers consistent 
nicotine levels over 
24 hours
• Can be titrated to 
rapidly manage 
withdrawal 
symptoms
• Can be used in 
combination with 
other agents to 
manage situational 
urges
• Might serve as 
an oral substitute 
for tobacco
• Can be titrated to 
manage withdrawal 
symptoms
• Mimics hand-to-
mouth ritual of 
smoking
• Can be used in 
combination with 
other agents to 
manage situational 
urges
• Twice-daily oral 
dosing is simple 
and associated with 
fewer adherence 
problems
• Might delay 
weight gain
• Might be beneficial 
in patients with 
depression
• Can be used in 
combination with 
NRT agents
• Twice-daily oral 
dosing is simple 
and associated with 
fewer adherence 
problems
• Offers a different 
mechanism of 
action for patients 
who have failed 
other agents
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  NRT formulations    
  Gum Lozenge Transdermal patch Nasal spray Oral inhaler Bupropion SR Varenicline
Disadvantages • Need for frequent 
dosing can 
compromise 
adherence
• Might be problematic 
for patients with 
significant dental 
work
• Proper chewing 
technique is 
necessary for 
effectiveness 
and to minimize 
adverse effects
• Gum chewing might 
not be acceptable 
or desirable for 
some patients
• Need for frequent 
dosing can 
compromise 
adherence
• Gastrointestinal 
side effects 
(nausea, hiccups, 
heartburn) might 
be bothersome
• When used as 
monotherapy, cannot 
be titrated to acutely 
manage withdrawal 
symptoms
• Not recommended 
for use by patients 
with dermatologic 
conditions (e.g., 
psoriasis, eczema, 
atopic dermatitis)
• Need for frequent 
dosing can 
compromise 
adherence
• Nasal administration 
might not be 
acceptable or 
desirable for some 
patients; nasal 
irritation often 
problematic
• Not recommended 
for use by patients 
with chronic nasal 
disorders or severe 
reactive airway 
disease
• Need for frequent 
dosing can 
compromise 
adherence
• Cartridges might 
be less effective in 
cold environments 
(≤60°F)
• Seizure risk is 
increased
• Several 
contraindications 
and precautions 
preclude use in 
some patients 
(see PRECAUTIONS)
• Patients should 
be monitored 
for potential 
neuropsychiatric 
symptomse 
(see PRECAUTIONS)
• Should be taken 
with food or a full 
glass of water to 
reduce the incidence 
of nausea
• Patients should 
be monitored 
for potential 
neuropsychiatric 
symptomse 
(see PRECAUTIONS)
Cost/dayf 2 mg or 4 mg: $1.90–
$3.70 (9 pieces)
2 mg or 4 mg: $3.36–
$3.78 (9 pieces)
$1.52–$3.48
(1 patch)
$6.67
(8 doses)
$11.35
(6 cartridges)
$2.58–$7.87
(2 tablets)
$11.86
(2 tablets)
Source: Reproduced with permission from Rx for Change: Clinician-Assisted Tobacco Cessation program. The Regents of the University of California. Copyright © 1999–2017.
Notes: For complete prescribing information and a comprehensive listing of warnings and precautions, please refer to the manufacturers’ package inserts. bid = twice a day; FDA = U.S. Food and 
Drug Administration; MAO = monoamine oxidase; mg = milligram; ml = milliliter; NRT = nicotine replacement therapy; OTC = over the counter (nonprescription product); po = by mouth; 
Rx = prescription product; SR = sustained release.
aMarketed by GlaxoSmithKline.
bMarketed by Niconovum USA (a subsidiary of Reynolds American, Inc.).
cMarketed by Pfizer.
dThe Clinical Practice Guideline (Fiore et al. 2008) states that pregnant smokers should be encouraged to quit without medication based on insufficient evidence of effectiveness and theoretical 
concerns with safety. Pregnant smokers should be offered behavioral counseling interventions that exceed minimal advice to quit.
eIn July 2009, FDA mandated that the prescribing information for all bupropion- and varenicline-containing products include a black-boxed warning highlighting the risk of serious neuropsychiatric 
symptoms, including changes in behavior, hostility, agitation, depressed mood, suicidal thoughts and behavior, and attempted suicide. Clinicians should advise patients to stop taking varenicline or 
bupropion SR and contact a healthcare provider immediately if they experience agitation, depressed mood, or any changes in behavior that are not typical of nicotine withdrawal, or if they experience 
suicidal thoughts or behavior. If treatment is stopped due to neuropsychiatric symptoms, patients should be monitored until the symptoms resolve. Based on results of a mandated clinical trial, 
FDA removed this boxed warning in December 2016.
fWholesale acquisition cost from Red Book Online. Thomson Reuters, December 2016.
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are available by prescription only (FDA 2017). The use of 
FDA-approved cessation medications generally doubles 
quit rates relative to placebo, but results vary somewhat 
across products (ORs range from 1.82 for bupropion and 
1.84 for NRTs to 2.88 for varenicline) (Cahill et al. 2013). 
Certain combinations of NRTs have been shown to further 
increase quit rates, including using the transdermal patch 
with any of the other forms of NRT (nicotine gum, loz-
enges, nasal spray, or inhalers).
The seven cessation medications vary in their mecha-
nisms of action and modes of delivery. Each of the seven 
FDA-approved, first-line cessation medications is described 
below. In addition to a review of these medications and 
combination pharmacotherapy, this section also reviews 
evidence around longer term and pre-quit use of NRT. 
Nicotine Replacement Therapy
NRT delivers nicotine to address physical nicotine 
dependence without exposing the person who is trying to 
quit to the toxic constituents generated by combustion or 
other additives. NRT delivers plasma nicotine concentra-
tions that are lower than those in conventional cigarettes 
and that rise more slowly, thereby reducing the behav-
iorally reinforcing effect of smoking. Five forms of NRT 
are available in the United States: the transdermal nico-
tine patch, nicotine gum, nicotine lozenge, nicotine nasal 
spray, and nicotine inhaler; the latter two products are 
available only by prescription (Table 6.2). 
The five forms of NRT are similar in efficacy. Lindson 
and colleagues (2019) observed similar quit rates among 
persons who used a fast-acting form of NRT, such as gum 
or lozenge. Similarly, a meta-analysis of 117 clinical trials 
found that the RR for 6 or more months of abstinence for 
any form of NRT versus controls was 1.60 (95% CI, 1.53–
1.68), with an RR of 1.49 (95% CI, 1.40–1.60) for nicotine 
gum, 1.64 (95% CI, 1.52–1.78) for the nicotine patch, 1.95 
(95% CI, 1.61–2.36) for nicotine lozenges, 2.48 (95% CI, 
1.24–4.94) for the nasal spray, and 1.90 (95% CI, 1.36–
2.67) for the inhaler (Stead et al. 2012). An older random-
ized study found that medication adherence was lowest for 
the nasal spray and inhaler, moderate for the gum, and 
greatest for the patch; the study did not include the loz-
enge (Hajek et al. 1999). 
NRT is sold in different dosages (Table  6.2). Some 
healthcare providers recommend higher dosages of NRT 
or combinations of two forms of NRT for more dependent 
smokers, with dependence being defined by the number of 
cigarettes smoked per day or the time to first cigarette after 
awakening (Shiffman et al. 2013). Lindson and colleagues 
(2019) found that, compared with a 2-milligram (mg) dose 
of nicotine gum, using a 4-mg dose increases smokers’ 
chances of successfully stopping smoking. The review also 
found that higher dose nicotine patches appeared to be 
associated with higher rates of abstinence than lower dose 
patches, but this finding was less certain due to the quality 
of the evidence. Nicotine patches, which are applied in 
the morning, deliver nicotine slowly over 16–24  hours 
to achieve a continuous level of nicotine in the blood 
(Wadgave and Nagesh 2016). Several nicotine patches are 
marketed, some of which have tapering dosages (i.e., grad-
ually lowering the dosage over time). The 24-hour patch 
can be removed at bedtime if it causes side effects, such as 
insomnia or bothersome dreams. Oral NRT formulations 
include the nicotine gum, lozenge, and inhaler (Table 6.2). 
The nicotine inhaler is a cigarette-like plastic device that 
delivers nicotine to the throat and upper airway. Nicotine 
in gum and lozenges is primarily absorbed in oral mucosa, 
with a rapid absorption of the nicotine when used prop-
erly (Wadgave and Nagesh 2016). However, these oral 
medications are “short acting” and result in relatively low 
levels of nicotine in the blood, initially requiring use every 
1–2 hours to suppress withdrawal symptoms. 
The nicotine nasal spray is administered with one 
spray per nostril; each spray contains 0.5 mg of nicotine 
(Wadgave and Nagesh 2016). The medication can be used 
every 20–60 minutes, with a maximum of 5 doses per hour 
or 40  doses per day. Dosage is based on the number of 
cigarettes smoked per day before starting the medication 
(Pfizer 2010). Of all NRT products, the nasal spray delivers 
nicotine most rapidly, but inhaling cigarette smoke still 
delivers nicotine faster (Wadgave and Nagesh 2016). 
During initial treatment, irritation of the nose commonly 
produces burning, sneezing, and watery eyes; users gener-
ally develop tolerance to these effects in 1–2 days (Pfizer 
2010). Other side effects are minor and may include cough 
or headache (Table 6.2); however, NRT use, including long-
term use, has been generally found to be safe for most adults 
(Fiore et al. 2008). Some users may opt to start the nasal 
spray a few days before their quit date to work through the 
initial nasal irritation (Wadgave and Nagesh 2016).
Persons with higher levels of nicotine dependence 
are at increased risk for difficulty quitting, abstinence dis-
tress, and relapse (Piper et al. 2008). NRT has been shown 
to be particularly effective in highly nicotine-dependent 
smokers (e.g., Stead et al. 2012) relative to smokers with 
lower levels of nicotine dependence and in trials of smoking 
cessation pharmacotherapy in which the majority of par-
ticipants are at least moderately dependent on nicotine. 
The evidence regarding the efficacy and effectiveness of 
smoking cessation pharmacotherapies focuses mostly on 
highly dependent daily smokers (e.g., Stead et al. 2012). 
Lindson and colleagues (2019) note that there is little 
evidence on the role of NRT for persons smoking fewer 
than 15  cigarettes a day. Evidence supports the efficacy 
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of tailoring the dose of NRT to markers of dependence 
(e.g.,  time to first cigarette after waking) (e.g.,  Baker 
et  al. 2007), given that more highly nicotine-dependent 
smokers benefit more from higher doses of NRT than less 
nicotine-dependent smokers (e.g., Stead et al. 2012). 
Bupropion
Bupropion is a prescription medication that blocks 
reuptake of dopamine and, to a lesser extent, norepineph-
rine. It also has some nicotine receptor-blocking activity 
(Slemmer et  al. 2000). Thus, bupropion increases levels 
of dopamine and norepinephrine in the brain, simulating 
nicotine’s effects on these neurotransmitters. In studies 
with rats, bupropion in low doses was found to block nico-
tine’s rewarding effects, as assessed by the intracranial self-
stimulation threshold, and to reverse the negative affec-
tive actions of nicotine withdrawal (Cryan et al. 2003). For 
humans, bupropion’s blocking of nicotine receptors could 
contribute to lessened reinforcement from cigarettes in the 
event of a lapse or relapse during a quit attempt (Prochaska 
and Benowitz 2016). Bupropion was originally marketed 
and is still widely used as an antidepressant. However, the 
sustained-release formulation of bupropion was found to 
help smokers quit independent of whether smokers had a 
history of depression (Hurt et al. 1997). Bupropion is ini-
tiated 1 week before the scheduled quit date to allow time 
for the smoker to reach steady state therapeutic levels 
(Corelli and Hudmon 2002). In the sustained release for-
mulation, bupropion is started at 150 mg/day. If the ini-
tial dose is adequately tolerated, it is increased on day 4 
to 300 mg/day (the recommended maximum daily dose), 
given as two 150-mg doses taken at least 8 hours apart. If 
the 300-mg dose is not well tolerated, the dose is reduced 
to 150 mg/day, which is still efficacious (Swan et al. 2003). 
In a meta-analysis of 65 RCTs of bupropion for 
smoking cessation, Hughes and colleagues (2014) con-
cluded that bupropion alone significantly increased long-
term cessation of 6 months or greater (RR = 1.62; 95% CI, 
1.49–1.76) relative to placebo; this level of efficacy was 
comparable to NRT (RR = 0.96; 95% CI, 0.85–1.09) and 
lower than varenicline (RR = 0.68; 95% CI, 0.56–0.83). In 
an RCT conducted in 2001, participants who had quit suc-
cessfully by week 7 of the trial were randomized to receive 
bupropion or placebo for 1 year to prevent relapse (Hays 
et al. 2001). Bupropion was found to be safe and effective 
and significantly better than placebo at delaying relapse 
(median time to relapse 156 days vs. 65 days, p = 0.021). 
Bupropion also resulted in less weight gain among par-
ticipants. However, 1 year after treatment, quit rates did 
not differ between the bupropion and placebo groups 
(41.6% vs. 40.0%) (Hays et al. 2001). 
FDA continues to evaluate the safety and effective-
ness of cessation medications after they enter the market-
place. Following the introduction of bupropion, the agency 
received and assessed case reports of serious changes in 
mood and behaviors in patients taking bupropion. As a 
result, in 2009 the agency required new boxed warnings 
for bupropion’s product labeling (FDA 2018a). At the time, 
FDA also required the manufacturer to conduct a large 
clinical trial to evaluate the side effects. Based on FDA 
review of the findings from that clinical trial (Anthenelli 
et al. 2016), which is discussed further in the section on 
varenicline, the agency determined the risk of serious side 
effects on mood, behavior, or thinking was lower than pre-
viously suspected and determined the product labeling 
should be revised accordingly. FDA noted that while these 
mental health side effects were present, especially in those 
with current or mental illness, they were rare (Anthenelli 
et al. 2016). Additionally, side effects were rarely serious 
enough to result in hospitalization, and the occurrence 
of side effects was no greater for persons randomized to 
bupropion compared with those randomized to nicotine 
patch or placebo.
Varenicline
Varenicline is a prescription medicine marketed spe-
cifically for smoking cessation. The drug is a partial ago-
nist of the α4β2 nicotinic acetylcholine receptor subtype, 
which mediates dopamine release and is thought to be the 
major receptor involved in nicotine addiction. Varenicline 
activates the α4β2 nicotinic cholinergic receptor, with a 
maximal effect about 50% that of nicotine, relieving the 
symptoms of nicotine withdrawal, including craving, and 
at the same time blocking the effects of nicotine on the 
receptor, thereby diminishing the rewarding effects of 
cigarettes (Aubin et al. 2014). Thus, the desire to smoke 
and, in the event of a lapse or relapse, the likelihood of 
continued smoking are reduced. As with bupropion, var-
enicline is initiated 1 week before the quit date (Pfizer 
2018). The dose of varenicline starts at 0.5 mg/day and 
then increases on day 4 to 0.5 mg twice per day and on 
day 7 to 1 mg twice per day (the recommended maximum 
daily dose). This dosing regimen allows for gradual titra-
tion of the dose to minimize treatment-related nausea and 
insomnia (Pfizer 2018). The dosage can be lowered tem-
porarily or permanently for patients experiencing intol-
erable, treatment-associated adverse effects (Pfizer 2018). 
Notably, smokers taking varenicline often reduce their 
smoking even before their target quit day (Ashare et al. 
2012; Ebbert et al. 2015; Nakamura et al. 2017).
The largest clinical trial to date of approved tobacco 
cessation medications, the Evaluating Adverse Events 
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in a Global Smoking Cessation Study (EAGLES), which 
was primarily conducted to examine adverse effects, 
found that (a) varenicline was more effective for quitting 
smoking than placebo, the nicotine patch, or bupropion 
and (b) bupropion and the nicotine patch were more effec-
tive than placebo and were comparable to each other in 
efficacy (Anthenelli et al. 2016). This triple-blinded ran-
domized trial enrolled 8,144 daily smokers, about half of 
whom had a stably treated but active psychotic disorder or 
a history of a psychiatric disorder. In the nonpsychiatric 
cohort, continuous abstinence rates (for weeks 9–24) at 
the 6-month follow-up were 25.5% for varenicline, 18.8% 
for bupropion, 18.5% for nicotine patch, and 10.5% for 
placebo. In the psychiatric cohort, continuous abstinence 
rates at the 6-month follow-up were 18.3% for vareni-
cline, 13.7% for bupropion, 13.0% for nicotine patch, and 
8.3% for placebo (Anthenelli et al. 2016). 
Taking varenicline for 6  months has been shown 
to be effective in preventing relapse, including among 
smokers with schizophrenia (Evins et al. 2014). Varenicline 
is FDA-approved for extended (up to 6  months) treat-
ment (Tonstad et al. 2006). Common side effects include 
nausea, vomiting, and insomnia (Cahill et  al. 2013). 
Neuropsychiatric side effects—including depression, psy-
chosis, aggression, and suicidality—have been reported to 
FDA, and the agency required that boxed warning labels 
for both varenicline and bupropion note those possible side 
effects (FDA 2018a). In the EAGLES trial, the primary end-
point was neuropsychiatric safety; the frequency of mod-
erate to severe neuropsychiatric events was less than 3% in 
the nonpsychiatric cohort and less than 7% in the psychi-
atric cohort, with no significant difference by medication 
condition (Anthenelli et al. 2016). Notably, the findings in 
EAGLES were generally consistent with prior clinical trials 
and observational data. In previous clinical trials of var-
enicline conducted among smokers with depression and 
schizophrenia, neuropsychiatric side effects had not been 
observed at higher levels relative to those observed in con-
trol groups (Williams et  al. 2012; Anthenelli et  al. 2013; 
Cinciripini et al. 2013); this was also the case in large clin-
ical cohort studies (Thomas et al. 2013; Kotz et al. 2015). 
Importantly, smoking itself has been found to be associated 
with mood disturbance, including suicidality (Oquendo 
et al. 2004; Li et al. 2012). Nicotine withdrawal experienced 
during quitting attempts is also characterized by distur-
bances in mood—including agitation, depressive symp-
toms, and anxiety—and can cause sleep disturbance with 
associated mood effects (Prochaska and Benowitz 2019).
With regard to the cardiovascular safety of vareni-
cline, an initial meta-analysis raised concerns, showing 
a small but significant RR for serious adverse cardiovas-
cular events compared with placebo (Singh et al. 2011). 
However, a second, larger meta-analysis found the absolute 
risk to be small and statistically nonsignificant (Prochaska 
and Hilton 2012). In addition, a 52-week RCT that exam-
ined cardiovascular safety in the EAGLES cohort found no 
significant difference relative to placebo for varenicline, 
bupropion, or nicotine patch on the time to occurrence 
of a major adverse cardiovascular event (Benowitz et  al. 
2018). The three time points of interest were during the 
medication treatment period, 30  days post-medication 
use, and at 52 weeks (which marked the end of the study). 
At all three time points, the hazard ratio for major cardio-
vascular events associated with varenicline was less than 
0.50, which was statistically nonsignificant and suggests 
a reduced risk compared with placebo (Benowitz et  al. 
2018). A biological mechanism by which varenicline could 
produce cardiovascular toxicity has not been identified. 
Additional Approaches to 
Medication Therapy
The seven FDA-approved cessation medications have 
been evaluated in multiple research protocols, with many 
of the study variations aimed at improving our under-
standing of the reach and short- and long-term efficacy of 
treatment under conditions other than the labeled FDA-
approved use. These approaches have included combina-
tion pharmacotherapy (i.e., using more than one form of 
medication at a time), pre-loading (starting the medica-
tion before the quit date), gradual reduction (using medi-
cation as part of an attempt to gradually reduce consump-
tion of tobacco products as a prelude to quitting, instead 
of quitting abruptly), extended treatment (longer use of 
the medication aimed at preventing relapse), and preci-
sion medicine (tailoring the medication to differences in 
drug metabolism). The following sections discuss each of 
these approaches in detail.
Combination Pharmacotherapy
Combination pharmacotherapy combines the use 
of cessation drugs that have different mechanisms and/or 
different pharmacokinetic profiles. Dual regimens of NRT 
have generally demonstrated superior efficacy compared 
with a single form of NRT (Ebbert et al. 2010; Tulloch et al. 
2016; Windle et al. 2016). Dual NRT regimens combine the 
use of a transdermal patch, which acts slow and provides a 
base level of nicotine, with any of the other forms of NRT 
(nicotine gum, lozenges, nasal spray, or inhalers)—all of 
which act faster and can be used to offset acute episodes 
of craving or other relapse triggers. Based on evidence 
in their review of 11,356 participants across 14  studies, 
Lindson and colleagues (2019) concluded that combining 
fast-acting forms of NRT with the nicotine patch results in 
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long-term quit rates that are higher than those observed 
among persons who use a single form of NRT (RR = 1.25; 
95% CI, 1.15–1.36,). Similarly, in a meta-analysis of nine 
trials, combining the nicotine patch with nicotine gum, 
lozenges, inhalers, or nasal spray was shown to be more 
effective than using individual NRT products (RR = 1.34; 
95% CI, 1.18–1.51) (Stead et al. 2012). A different meta-
analysis found that combination NRT had an effect com-
parable to that of varenicline (OR = 1.06; 95% CI, 0.75–
1.48) (Cahill et al. 2013). 
Emerging evidence also suggests that combining 
varenicline with bupropion or NRT may be more effective 
than taking varenicline alone, particularly among heavier 
smokers (Koegelenberg et  al. 2014; Chang et  al. 2015). 
Two trials examined the combined use of varenicline and 
the nicotine patch. One trial (N  =  435) compared the 
nicotine patch with a placebo patch, both administered 
2 weeks before the target quit date, followed by the addi-
tion of varenicline for 1 week before the target quit date; 
the nicotine patch and varenicline were continued for 
12 additional weeks. Use of the nicotine patch plus vareni-
cline resulted in significantly greater quit rates than use of 
the placebo patch plus varenicline at 12 weeks (55.4% vs. 
40.9%, p = 0.007) and 24 weeks (49% vs. 36.2%, p = 0.004) 
(Koegelenberg et  al. 2014). The other trial, which was 
smaller and likely underpowered (N = 117), tested vareni-
cline alone 1  week before the target quit date and then 
with the nicotine patch added at the quit date. The trial 
found statistically nonsignificant differences at 12 weeks 
(38%  vs. 29% quit, p  =  0.14) (Hajek et  al. 2013b). The 
mechanism of benefit from combining varenicline and 
NRT is unclear: varenicline may not fully block α4β2 
receptors or, compared with varenicline alone, the nico-
tine from NRT may affect additional nicotinic receptors 
that contribute to the addictive effects of nicotine. The 
combination was well tolerated by users in both studies, 
with vivid dreams being the most common side effect 
(Hajek et al. 2013b; Koegelenberg et al. 2014).
In addition, combination therapy with bupropion 
and NRT has been shown to produce better outcomes than 
either medication used by itself (Ebbert et al. 2010). In a 
meta-analysis of eight trials, use of bupropion plus the 
nicotine patch was more effective than use of bupropion 
alone (RR = 1.24; 95% CI, 1.06–1.45) (Stead et al. 2012), 
but a different meta-analysis that reviewed 12  studies in 
which bupropion was added to NRT reported insufficient 
evidence of long-term benefit (at least 6  months) over 
NRT alone (RR = 1.19; 95% CI, 0.94–1.51) (Hughes et al. 
2014). One randomized trial compared the use of bupro-
pion plus varenicline versus the use of varenicline alone 
for 12 weeks (Ebbert et al. 2014); the combination signifi-
cantly increased continuous abstinence through 12 weeks 
(53.0% vs. 43.2%) and through 26 weeks (36.6% vs. 27.6%) 
but not through 52 weeks (30.9% vs. 24.5%). In a different 
randomized trial, use of bupropion plus varenicline was 
associated with greater depressive symptoms over the first 
2 weeks, but no differences in depressive symptoms were 
observed by week 4 (Hong et al. 2015). 
Pre-Loading Medication
Pre-loading with NRT, or providing NRT in advance 
of a quit attempt, has been tested to see whether it 
increases abstinence rates. The underlying mechanism 
would be to saturate and/or desensitize nicotinic cho-
linergic receptors to decrease the reward from nicotine 
delivered by smoking. Lindson and colleagues (2019) 
found with a moderate level of certainty that using NRT 
before quitting, instead of using it from the quit date, may 
improve quit rates, but noted that more research is needed 
to confirm this finding. In a meta-analysis of four studies, 
pre-loading with the nicotine patch doubled the odds of 
quitting at 6 weeks (OR = 1.96; 95% CI, 1.31–2.93) and at 
6 months (OR = 2.17; 95% CI, 1.46–3.22) (Shiffman and 
Ferguson 2008). In contrast, a large pragmatic random-
ized trial in New Zealand in which smokers called a quit-
line found no boost in abstinence rates when NRT was pre-
loaded, but such pre-loading was determined to be safe, 
acceptable, and easy to implement (Bullen et al. 2010). 
A meta-analysis of eight trials by Stead and colleagues 
(2012) found a moderate but statistically nonsignificant 
effect of pre-loading NRT on abstinence, but effects were 
significant when restricted to the six trials that tested pre-
loading with a nicotine patch. These findings suggest that 
pre-loading in advance of a quit attempt, especially with 
the nicotine patch, can increase abstinence rates. 
Gradual Reduction
Gradually reducing the number of cigarettes smoked 
per day leading up to a quit attempt, rather than quitting all 
at once, may be preferred by smokers who are unwilling to 
quit abruptly (Prochaska and Benowitz 2016). Nationally 
representative data from the 2010–2011 Tobacco Use 
Supplement to the Current Population Survey suggest 
that more than 40% of adult smokers in the United States 
who had tried to quit smoking in the past year reported 
gradually cutting down on their cigarette use as a cessa-
tion strategy (Schauer et  al. 2015b). A meta-analysis of 
10 trials evaluating gradual smoking reduction relative to 
quitting abruptly found comparable efficacy, with no dif-
ference by treatment approach (e.g., self-help, behavioral, 
pharmacologic) (Lindson-Hawley et al. 2012).
In a different placebo-controlled randomized trial of 
varenicline, Ebbert and colleagues (2015) studied smokers 
who were unwilling to quit in the next month but who were 
willing to reduce smoking immediately and to make a quit 
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attempt within 3 months. Participants received medication 
or placebo for 12 weeks before the quit attempt and were 
advised to reduce the number of cigarettes they smoked 
daily by 50% at 4 weeks, by 75% or more at 8 weeks, and 
then to quit completely at 12 weeks. Varenicline or pla-
cebo was continued for an additional 12 weeks after the 
quit date. Quit rates increased approximately threefold in 
the varenicline versus placebo-treated group from week 21 
to 24 (37.8% vs. 12.5%) and from week 21 to 52 (27.0% vs. 
9.9%). Pretreatment with varenicline may reduce craving 
for cigarettes and extinguish the rewarding effects of ciga-
rettes, thus making it easier to quit. Importantly, gradual 
reduction of cigarette consumption should be used only 
as an interim strategy on the path to completely quitting 
smoking, since in the absence of quitting, reduction of 
cigarette consumption alone does not substantially reduce 
health risks (Stead and Lancaster 2007; USDHHS 2014, 
2016; Lindson-Hawley et al. 2016).
Extended Treatment
Currently, NRT package inserts indicate that these 
products should be used for up to 8–12 weeks, depending 
on the type of product. However, studies have explored 
using cessation medications for much longer periods 
(up to 1 year) in an attempt to prevent relapse (Prochaska 
and Benowitz 2016). Similar to chronic disease manage-
ment approaches, this approach underscores the idea 
that smoking is a chronic, relapsing disease that warrants 
ongoing treatment.
The literature is insufficient, however, to determine 
whether extended NRT is more efficacious than standard-
duration NRT (Carpenter et  al. 2013). For example, an 
RCT with older smokers found that extended cessation 
treatment—consisting of NRT gum and bupropion for 
12 weeks combined with counseling (group and then indi-
vidual) extending to 1 year—resulted in abstinence rates 
exceeding 50% at the 2-year follow-up (Hall et al. 2009). 
Notably, the study showed that extending NRT to 52 weeks 
(with no bupropion) did not increase abstinence beyond 
what was achieved with 12 weeks of NRT gum combined 
with bupropion. A trial that assessed point-prevalence 
abstinence in smokers randomized to receive 12 weeks of 
behavioral counseling plus 8, 24, or 52 weeks of nicotine 
patches found that, after 24  weeks of treatment, 21.7% 
of participants in the 8-week arm were abstinent com-
pared with 27.2% (p = 0.17) in the 24- and 52-week arms 
(Schnoll et  al. 2015). Participants in the 52-week arm 
did not report greater abstinence rates than those in the 
24-week arm (20.3% vs. 23.8%, p = 0.57), suggesting that 
using NRT beyond 24 weeks may not confer added benefit.
In contrast, varenicline dosed over 6  months has 
been shown to be effective in preventing relapse (Tonstad 
et  al. 2006; Evins et  al. 2014). Currently, FDA labeling 
recommends 12 weeks of therapy, but treatment can be 
extended another 12 weeks if needed. However, patients are 
encouraged to stop sooner if they feel ready. Livingstone-
Banks and colleagues (2019) found that with a moderate 
level of certainty, because of unexplained statistical het-
erogeneity, extended treatment with varenicline helped 
to prevent relapse. In an RCT, Joseph and colleagues 
(2011) tested a chronic care model for smoking cessation. 
Participants in the extended care arm received counseling 
by telephone and NRT for 1 year, and participants in the 
usual care arm received counseling and NRT for 8 weeks. 
At 18 months, the proportion of subjects who were absti-
nent for 6 months or longer did not differ significantly by 
condition: 30% for extended treatment and 24% (p = 0.13) 
for usual care. Finally, in a meta-analysis of extended 
interventions for preventing relapse, Hajek and colleagues 
(2013c) reported insufficient evidence to support either 
extended cessation counseling or extended pharmaco-
therapies (NRT, varenicline, or bupropion). More research 
is warranted to continue to assess extended behavioral 
and/or pharmacological treatments for smoking cessation.
Precision Medicine
Precision medicine is an emerging approach to 
smoking cessation treatment (Prochaska and Benowitz 
2016). The goal of precision medicine is to enable clini-
cians to quickly, efficiently, and accurately predict the 
most appropriate course of action for a patient based on 
genetic and lifestyle factors (Aronson and Rehm 2015). 
Cessation medications are effective in increasing absti-
nence, but with long-term quit rates rarely surpassing 
30%  (Perkins and Scott 2008), there is great interest 
in identifying differences in response to medications 
to inform personalized treatment, which could poten-
tially increase quit rates. Smokers differ from each other 
in many ways. One is the rate at which they metabolize 
nicotine, which has been studied as a possible basis for 
selecting medications (Prochaska and Benowitz 2016). 
On average, a person who metabolizes nicotine rapidly 
smokes more heavily and appears to be more dependent 
on nicotine than a person who does not metabolize nic-
otine rapidly (Malaiyandi  et  al. 2005). CYP2A6, a liver 
enzyme, is the chief metabolizer of nicotine; CYP2A6 also 
metabolizes cotinine, the primary metabolite of nicotine, 
which is reduced to 3’-hydroxycotinine (USDHHS 2010). 
The cotinine/3’-hydroxycotinine ratio, also termed 
the nicotine metabolite ratio, can be measured in urine, 
blood, or plasma as a biomarker for the rate at which a 
smoker metabolizes nicotine (USDHHS 2010). In ret-
rospective studies, slow metabolizers received no incre-
mental benefit from bupropion, but they responded well to 
the nicotine patch, while normal metabolizers responded 
better to bupropion than to the patch (Prochaska and 
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Benowitz 2016). In a clinical trial that stratified partici-
pants by slow or normal nicotine metabolite ratio and 
compared treatment with placebo, the nicotine patch, or 
varenicline (Lerman et al. 2015), slow metabolizers expe-
rienced more side effects from varenicline and evidenced 
no benefit in quitting when taking varenicline relative to 
using the nicotine patch (OR = 1.13, p = 0.56), but normal 
metabolizers had greater success with varenicline relative 
to the patch (OR = 2.17, p = 0.001). Thus, use of the nic-
otine metabolite ratio shows promise in aiding in treat-
ment selection, given that the nicotine patch may be as 
effective as varenicline for slow metabolizers of nicotine, 
while costing less and exposing them to fewer side effects. 
However, use of the nicotine metabolite ratio in clinical 
practice is not yet possible because there is no widely 
available clinical test for this measure. 
Other precision medicine approaches are under 
investigation, including pharmacogenomic variation and 
variance in both behavioral and pharmacologic responses 
between men and women and among persons with cer-
tain mental health conditions. For example, pharmacoge-
nomic evidence suggests that variants in gene regions 
that impact dopaminergic neurotransmission, nicotine 
receptor expression, and nicotine and other drug metabo-
lism may predict response to various cessation pharmaco-
therapies (Chenoweth and Tyndale 2017). Some evidence 
suggests that (a) the superior efficacy of varenicline rela-
tive to bupropion and NRT may be greater among women 
than among men and (b) certain mental health conditions 
may also alter responses to behavioral and pharmacolog-
ical treatments (Luo et al. 2015; McKee et al. 2016; Piper 
et al. 2017; Smith et al. 2017).
Real-World Effectiveness of 
Cessation Medications
In RCTs, the provision of cessation medications 
has consistently increased successful quitting, particu-
larly among heavy cigarette smokers. Several studies 
have reported similar findings in real-world settings 
(West and Zhou 2007; Kasza et al. 2013). For example, the 
International Tobacco Control Four Country Survey found 
increased 6-month continuous abstinence from smoking 
among smokers who reported using varenicline, bupro-
pion, and the nicotine patch but not among those who 
reported using oral NRTs (Kasza et al. 2013). However, some 
population-based studies have found that smokers who used 
NRT (Pierce and Gilpin 2002), and in some cases bupropion 
and varenicline (Leas et al. 2018), reported similar or lower 
rates of quit success compared with those not using these 
medications. These studies have raised questions about the 
real-world effectiveness of these medications, and reviews 
have highlighted conflicting results in the scientific litera-
ture (Hughes et al. 2011; Pierce et al. 2012).
Leas and colleagues (2018), using nationally repre-
sentative data from the 2002–2003 and 2010–2011 waves 
of the Tobacco Use Supplement to the Current Population 
Survey, assessed the effectiveness of cessation medica-
tions among adults who smoked at baseline and attempted 
to quit prior to 1 year of follow-up. The study’s authors 
used propensity score matching to control for 12 poten-
tial confounders, including smoking intensity, nicotine 
dependence, previous quit history, and self-efficacy to 
quit. The study did not find evidence that the use of var-
enicline, bupropion, or NRT increases the likelihood of 
smokers being quit for 30 or more days at 1-year follow-
up. Similarly, a study by Kotz and colleagues (2014) con-
ducted in the United Kingdom using cross-sectional data 
from aggregated monthly waves of the Smoking Toolkit 
Study, a household survey, found that smokers who pur-
chased NRT over the counter with no behavioral support 
had similar odds of quitting as smokers who tried to quit 
with no quitting aids.
Several other studies have also found no effects of 
NRT on cessation. For example, a randomized study con-
ducted in New Zealand among 1,410 adult smokers who 
called the national quitline, found that subjects who were 
randomized to receive a free 1-week supply of their choice 
of NRT, followed by a voucher for a free 8-week supply of 
that product, did not have higher rates of abstinence at 
7 days or 6 months compared with those receiving usual 
care from the quitline (Walker et al. 2011). Similarly, a pro-
spective cohort study of a probability sample of 787 adult 
smokers from Massachusetts who had quit smoking found 
that those who quit using NRT were just as likely to 
relapse over the following year as were those who had quit 
without using medications (Alpert et  al. 2013). Finally, 
in a parallel group, factorial design RCT of 2,591 smokers 
16 years of age and older in England, Ferguson and col-
leagues (2012) found, contrary to findings from multiple 
U.S. randomized trials in quitline settings (An et al. 2006; 
Hollis et al. 2007; Smith et al. 2013), that adding NRT to 
proactive counseling offered through a quitline had no 
additional effect on abstinence. 
Several possible explanations exist for these con-
tradictory findings. Some of the studies that have found 
limited impact of the real-world effectiveness of cessa-
tion medications have specific limitations. For example, 
Alpert and colleagues (2013) measured whether prior use 
of NRT had a residual benefit of preventing relapse, which 
differs from assessing whether use of NRT increases ces-
sation success. McAfee (2012) noted several potential 
issues that could have impacted the findings of Ferguson 
and colleagues (2012), including (a) many differences and 
limitations in how NRT was provided in the Ferguson 
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trial compared with U.S. trials that found a positive effect 
(e.g., medications were provided through a voucher that 
had to be redeemed by telephone, adding an extra step for 
participants) and (b) caveats for interpreting the results. 
For example, in a large randomized trial with methods 
similar to those used for the Ferguson trial, which 
involved more than 4,600 U.S. adults who called a quitline, 
overall receipt of study medications was low (43%) com-
pared with the 90% rate at initial intake and the 80% rate 
of medication receipt at 5 weeks. The trial also included 
youth smokers (16–18 years of age), for whom NRT has 
not been found to be effective (Hollis et al. 2007). 
More broadly, most real-world studies have been 
nonrandomized cohort studies that have examined the 
association between self-selected use of cessation med-
ications and quitting success. Without randomiza-
tion, the study design cannot exclude the potential for 
residual confounding, even with multivariable adjustment. 
Researchers have suggested that conclusions about the 
real-world effectiveness of cessation medications may be 
the result of systematic biases that affect the outcomes of 
cross-sectional surveys (Borland et al. 2012). For example, 
participants may be more likely to recall failed medication-
assisted quit attempts than failed unassisted quit attempts. 
Furthermore, smokers who choose to use medications as 
part of a quit attempt may smoke more heavily and be more 
addicted, and therefore may be less likely to succeed, than 
smokers who try to quit without medications. Either of 
these factors could lead to an overrepresentation of failed 
quit attempts among smokers using medications, even if 
these medications actually conferred benefits (Borland 
et  al. 2012). However, Leas and colleagues (2018) used 
propensity score matching on 12 potential confounders, 
including nicotine dependence and smoking intensity, 
and concluded that confounding cannot explain the lack 
of effectiveness of cessation medications in increasing 
long-term cessation in real-world settings.
Another potential factor that could contribute to the 
findings of studies suggesting a lack of real-world effec-
tiveness for cessation medications is the important role 
that behavioral support can play in complementing med-
ication use to maximize cessation, in part by ensuring 
that smokers use cessation medications appropriately and 
effectively (Fiore et al. 2008; USPSTF 2015). While cessa-
tion medication and counseling are each effective alone, 
they are more effective when combined (Fiore et al. 2008; 
USPSTF 2015). In particular, providing counseling or deci-
sion support to help ensure that consumers use the appro-
priate medication correctly at the correct dose and for a 
recommended duration, could increase the effectiveness of 
over-the-counter (nonprescription) cessation medications 
in the general population. This type of support is typically 
present in RCTs but is often absent in real-world settings, 
which could explain why many therapies, including cessa-
tion medications, might perform more poorly in the real 
world than in clinical trials. The study by Leas and col-
leagues (2018) supports this hypothesis. Using data from 
the Tobacco Use Supplement to the Current Population 
Survey, they found that only 32 of 186 adult smokers who 
used bupropion and only 9 of 118 smokers who used var-
enicline as part of a quit attempt, reported receiving any 
form of behavioral counseling. Similarly, Kotz and col-
leagues (2014) found that smokers who purchased NRT 
over the counter with no behavioral support had similar 
odds of quitting as smokers who tried to quit with no 
quitting aids—also highlighting the important role that 
behavioral support can play in enhancing the effectiveness 
of cessation medications. Further support for this explana-
tion includes the markedly shorter duration of use of med-
ications in real-world settings compared with study set-
tings, averaging 1–2 weeks rather than the recommended 
8–12 weeks (Pierce and Gilpin 2002; Zhang et al. 2015). 
In the absence of behavioral support, tobacco users in 
the general population may not receive adequate informa-
tion or education about how to use cessation medications 
and what to expect from them (as described previously), or 
they may face barriers to accessing information, including 
such financial barriers as lack of insurance, copays, and 
cost-prohibitive prices (Pacek et al. 2018). Smokers may 
also have misconceptions about the safety of using a medica-
tion that contains nicotine (Pierce and Gilpin 2002; Zhang 
et al. 2015). Furthermore, many tobacco users may not be 
aware of changes to the labeling of over-the-counter NRT 
products introduced in 2013, indicating that it is safe to 
use NRT (a) longer than the recommended period, in con-
sultation with a physician if necessary to avoid relapsing, 
and (b) concurrently with smoking (e.g., following a lapse) 
or with another NRT product (Federal Register 2013; FDA 
2013). These and other misconceptions about smoking 
cessation medications could lead people to use them inef-
fectively, for example, by stopping use prematurely or by 
not using enough of the medication.
Some researchers who have questioned the real-
world effectiveness of cessation medications have sug-
gested that an excessive emphasis on the role of medi-
cations in helping smokers quit may overmedicalize and 
mystify smoking cessation. They also suggest that such an 
approach may discourage smokers from quitting without 
help (i.e., quitting “cold turkey”), which remains the pre-
dominant way that smokers try to quit—and, as a result, 
the predominant way that smokers succeed in quitting—
in the United States (Pierce et al. 2012). In addition, some 
evidence suggests that direct-to-consumer advertisements 
for smoking cessation medications may give smokers a 
false sense of security, suggesting that using these medica-
tions will make quitting easy (Frosch et al. 2007). 
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Combination Treatment—Behavioral 
Therapy and Pharmacotherapy
Although behavioral therapy and pharmacotherapy 
are each effective interventions for increasing quit rates 
when used alone, combining them is more effective (Fiore 
et al. 2008) and represents the “gold standard” in smoking 
cessation treatment. Use of cessation medications is more 
effective when accompanied by counseling, and use of ces-
sation counseling is more effective when accompanied by 
medications (Fiore et al. 2008). USPSTF (2015) recom-
mends combining medications with multisession, inten-
sive group or individual counseling to achieve the highest 
quit rates; using medication to target physical addic-
tion; and employing behavioral therapy and counseling 
to target psychological and behavioral addiction. A meta-
analysis by Stead and colleagues (2016) found that behav-
ioral therapy increased the efficacy of pharmacotherapy 
(RR = 1.27; 95% CI, 1.02–1.58), probably in part because 
it allows healthcare professionals who are delivering the 
behavioral therapy to instruct smokers on using cessa-
tion medications properly, managing side effects from the 
medications, understanding and managing cravings and 
withdrawal symptoms, and simultaneously addressing the 
behavioral aspects of tobacco dependence. Similarly, in the 
Smoking Toolkit study from the United Kingdom, Kotz 
and colleagues (2014) found that, compared with smokers 
who used neither cessation medications nor behavioral 
support, those who used prescription cessation medica-
tions combined with behavioral support from specialists 
had 3.25 times the adjusted odds (95% CI, 2.05–5.15) of 
remaining abstinent up to the time of the survey; those 
who used prescription cessation medications combined 
with brief advice to quit had 1.61 times the adjusted odds 
(95% CI, 1.33–1.94) of remaining abstinent; and those 
who used NRT purchased over the counter had 0.96 times 
the odds (95% CI, 0.81–1.13) of remaining abstinent. The 
authors concluded that smokers who use a combination of 
behavioral support and cessation medications in their quit 
attempts have almost three times the odds of successfully 
quitting than smokers who use neither. 
Notably, evidence from 40 studies with more 
than 15,000 participants found a significant increase in 
smoking abstinence at 6 months or longer compared with 
controls when pharmacotherapy was added to behavioral 
treatment (RR = 1.82; 95% CI, 1.66–2.00) (Stead and 
Lancaster 2012b; Stead et al. 2016). Earlier, Mottillo and 
colleagues (2009) conducted a meta-analysis of individual, 
group, and telephone counseling in clinical settings from 
50 RCTs (N = 26,927) and found that medications (the 
nicotine patch, bupropion, or nortriptyline) combined 
with counseling led to higher quit rates compared with 
controls. The ORs were similar for individual counseling 
(1.49; 95% CI, 1.08–2.07), group counseling (1.76; 95% CI, 
1.11–2.93), and telephone counseling (1.58; 95% CI, 1.15–
2.29). These results suggest that the highest quit rates are 
achieved through intensive individual or group coun-
seling combined with pharmacotherapy.
Modified and Alternative Tobacco 
Products
Very-Low-Nicotine-Content Cigarettes
Experimental very-low-nicotine-content (VLNC) 
cigarettes (also see Chapter  7) are engineered to have 
reduced content of nicotine in the tobacco used in the cig-
arette compared with conventionally manufactured ciga-
rettes. The smoke of VLNC cigarettes delivers lower levels 
of nicotine compared with cigarettes that were marketed 
by the tobacco industry in the past as “light” or “ultra-
light,” which did not have lower levels of nicotine in the 
tobacco itself (Benowitz and Henningfield 2013). Instead, 
light and ultra-light cigarettes relied on design features, 
such as ventilation holes in the filter, to allow these prod-
ucts to be rated as low nicotine (and low tar) when sub-
jected to machine smoking employing a standardized 
method. However, through compensatory behaviors, such 
as blocking ventilation holes with lips and/or fingers, 
drawing larger puffs, and inhaling more deeply, smokers 
were able to obtain levels of nicotine (and tar) that were as 
high as those delivered by conventional (regular strength) 
cigarettes (Benowitz and Henningfield 1994). Scientists 
have suggested that reducing the nicotine content of ciga-
rettes to approximately 0.5  mg per cigarette (compared 
with 10–15 mg per cigarette in most currently marketed 
cigarettes) would render cigarettes nonaddictive. This 
would potentially prevent adolescents from developing 
nicotine addiction and make it easier for adult smokers 
to quit, because cigarettes would be less reinforcing 
(Benowitz and Henningfield 1994). 
Several clinical trials have compared the effects of 
experimental VLNC cigarettes and conventional cigarettes 
on smoking and cessation behaviors. These trials suggest 
that VLNC cigarettes may reduce smoking, reduce nico-
tine dependence, increase cessation rates, and reduce 
exposure to toxicants (Benowitz et al. 2007, 2012; Donny 
et al. 2007, 2014, 2015; Donny and Jones 2009; Hatsukami 
et al. 2010, 2013, 2018; Dermody et al. 2018). For example, 
Donny and colleagues (2015) and Fiore and Baker (2015) 
conducted a large, multisite clinical trial that randomized 
840 daily smokers to their own cigarettes or to one of six 
variants of study-specific cigarettes with levels of nicotine 
ranging from 0.4 mg of nicotine per gram of tobacco to 
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15.8 mg of nicotine per gram of tobacco (levels typical of 
commercial brands). At 6 weeks, persons assigned to cig-
arettes with the lowest level of nicotine content smoked 
fewer cigarettes per day and reported less dependence and 
craving than those who smoked regular strength cigarettes 
(i.e., 15.8 mg of nicotine per gram of tobacco). In a random-
ized, parallel arm, semi-blind study in which 165 smokers 
were randomly assigned to either 0.3  mg nicotine yield 
cigarettes, 0.5 mg nicotine yield cigarettes, or 4 mg nic-
otine lozenges, Hatsukami and colleagues (2010) found 
that use of 0.5 mg nicotine yield cigarettes was associated 
with reduced carcinogen exposure and reduced nicotine 
dependence and product withdrawal scores, and led to a 
similar rate of cessation to the nicotine lozenge. 
More recently, Hatsukami and colleagues (2018) 
published findings from another large, multisite clinical 
trial that assessed the effects of immediate versus gradual 
reductions in the levels of nicotine content in ciga-
rettes. The authors randomized 1,250 smokers who were 
not interested in quitting into three groups: those who 
(a) continued to smoke conventional cigarettes containing 
15.5 mg of nicotine per gram of tobacco; (b) smoked ciga-
rettes in which the level of nicotine content was gradually 
reduced over 6 months from 15.5 mg to 0.4 mg of nico-
tine per gram of tobacco; or (c) switched immediately from 
conventional cigarettes to cigarettes with 0.4 mg of nico-
tine per gram of tobacco and continued to smoke those 
cigarettes for 6 months. The study found that smokers who 
switched immediately to cigarettes with low levels of nico-
tine tended to show greater benefits than smokers in the 
other two conditions. For instance, compared with gradual 
reduction of nicotine, immediate reduction yielded sig-
nificantly lower levels of biomarkers of exposure to toxic 
smoke constituents, a greater reduction in the number of 
cigarettes smoked per day, a greater reduction in nicotine 
dependence, and more days entirely free of cigarettes. Those 
in the immediate reduction group had significantly lower 
levels of breath carbon monoxide compared with those in 
the gradual reduction group (difference  =  4.1  parts per 
million; 95% CI, -4.89 to -3.23; P <.0055) and with those 
in the control group (difference  =  3.4 parts per million; 
95% CI, -4.40 to -2.36; P <.0055). Significantly lower levels 
in the immediate versus gradual and control groups were 
also observed for acrolein (difference  =  17% and 19%, 
respectively) and phenanthrene tetraol (difference = 12% 
and 14%, respectively). However, for carbon monoxide, 
acrolein, and phenanthrene tetraol, there were no signifi-
cant differences between the gradual reduction and control 
groups. Lower dependence scores (scale ranges from 0 to 
10, with higher scores associated with greater dependence) 
were observed in (a) the immediate reduction group versus 
the gradual reduction group (mean  =  4.27 [low depen-
dence]  vs. 5.13 [moderate dependence]; adjusted mean 
difference  =  -0.99 [95%  CI, -1.27  to -0.71]; p  <.00057) 
and (b) the immediate reduction group versus the control 
group (mean = 4.27 [low dependence] vs. 5.48 [moderate 
dependence]; adjusted mean difference  =  -1.44 [95%  CI, 
-1.75 to -1.12]; p <.00057). No differences were found in 
the gradual reduction group versus the control group 
(mean = 5.13 [moderate dependence] vs. 5.48 [moderate 
dependence]; adjusted mean difference  =  -0.45 [95%  CI, 
-0.76 to -0.13]; p = .006) (Hatsukami et al. 2018). 
However, a study with longer term follow-up reported 
that reducing the nicotine content in cigarettes over 
12 months did not result in sustained reductions in nico-
tine intake or increases in smoking cessation over the sub-
sequent 12 months (Benowitz et al. 2015). Experimental 
cigarettes were likely less acceptable because conventional 
cigarettes were readily available to the participants in the 
study. The lack of effect of nicotine intake on smoking 
cessation may be the result of compensatory behaviors, 
including consumption of regular-nicotine-content cig-
arettes. Compensatory smoking (i.e.,  altering smoking 
behaviors to continue to obtain enough nicotine to satisfy 
addiction) has been posited as a possible countervailing 
effect of setting a nicotine product standard (Gottlieb and 
Zeller 2017). However, in its advisory report on a global 
nicotine reduction strategy, which summarized the litera-
ture available at that time, WHO (2015) concluded that 
the use of cigarettes with a nicotine content of 0.4 mg/g 
(or less) of cigarette tobacco filler does not significantly 
increase craving or withdrawal and does not result in 
compensatory smoking behaviors. Studies have found 
this to be consistent in populations highly vulnerable to 
nicotine addiction, including individuals with serious 
mental illness (Denlinger-Apte et  al. 2018). However, 
among participants in clinical trials, levels of acceptability 
have been lower for experimental VLNC cigarettes than 
for commercially available cigarettes; and nonadherence 
has been prevalent, with one trial reporting greater than 
70% of participants having substituted traditional ciga-
rette brands for VLNC cigarettes (Nardone et  al. 2016). 
Additionally, 25–45% of participants dropped out of these 
studies (Nardone et al. 2016; Mercincavage et al. 2017).
Combining VLNC cigarettes with nicotine patches 
was hypothesized to perhaps aid with the transition to 
VLNC cigarettes and increase compliance. However, 
Hatsukami and colleagues (2013) did not find that such 
a combination improved long-term quit rates of conven-
tional cigarettes. Furthermore, in a two-by-two factorial 
RCT, Smith and colleagues (2019) found that assignment 
to the patch, along with VLNC cigarettes, did not signif-
icantly reduce cigarette smoking compared with assign-
ment to VLNC cigarettes alone (Smith et al. 2019).
If, as outlined by Benowitz and Henningfield (1994, 
2013) and summarized by USDHHS (2014), potential 
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“end-game” options to complement existing, proven 
tobacco control interventions include reducing the nic-
otine content of all cigarettes to make them less addic-
tive, then problems with adherence and attrition would 
not be an issue, unless there was widespread contraband, 
and long-term cessation rates would likely be higher 
than observed in the trials. Because a product standard 
reducing the nicotine content of cigarettes has not yet 
been implemented, studies have not examined the impact 
of a product standard that would reduce the level of nico-
tine in all cigarettes or other tobacco products would have 
on cessation.
Importantly, the advisory report from WHO (2015) 
noted that the ultimate health benefits of a nicotine 
reduction strategy aimed at individual smokers would 
require that the standard include all combustible tobacco 
products. The WHO report also noted that such a strategy 
needs to be accompanied by the provision of cessation 
treatments to help people quit, including behavioral sup-
port and NRT or other medications. In a randomized trial 
comparing the use of experimental VLNC cigarettes with 
the use of cigarettes with conventional levels of nicotine 
over an 8-week period, Hatsukami and colleagues (2017) 
found that smokers in the VLNC cigarette arm (a)  had 
consumed fewer combustible products at almost all 
visits compared with those in the conventional nicotine 
arm (p  <.02); (b)  had higher rates of abstinence (VLNC 
cigarette arm vs. conventional nicotine arm: RR = 9.96; 
95% CI, 5.01–19.81); and (c) used significantly more alter-
native tobacco products, including nonstudy cigarettes, 
noncigarette combustible products, and noncombustible 
products (RR  =  2.18; 95%  CI, 1.94–2.46 for the VLNC 
cigarette arm  vs. RR  =  1.64; 95%  CI, 1.46–1.85 for the 
conventional nicotine arm). As outlined by WHO (2015), 
for persons who switched from cigarettes to noncombus-
tible forms of tobacco to sustain their nicotine intake, the 
health benefits of not smoking conventional cigarettes 
depended on the level of tobacco-related toxicants deliv-
ered by the noncombustible products and the patterns and 
duration of use of such products.
Although evidence to date is suggestive but not suf-
ficient to infer that VLNC cigarettes could reduce smoking 
and nicotine dependence and increase smoking cessation, 
further research could help better understand the impact 
that a nicotine product standard could have on increasing 
cessation from conventional cigarettes. Several issues war-
rant continued consideration regarding the impacts of a 
nicotine product standard on cigarette cessation, including 
whether compensatory behaviors would occur in the given 
policy framework (Gottlieb and Zeller 2017), whether 
there would be illicit trade for products with higher nico-
tine yield and how to minimize such effects (Ribisl et al. 
2019), and how populations that are more vulnerable to 
nicotine may be impacted, including those with mental ill-
ness and substance use disorders (USDHHS 2016). 
Product standards to decrease nicotine in all 
cigarettes will likely have a greater impact on smoking 
cessation if they are accompanied by a comprehensive ces-
sation strategy that promotes available cessation treat-
ments, including FDA-approved medications and behav-
ioral support.
E-Cigarettes
E-cigarettes (also called electronic nicotine delivery 
systems [ENDS], vapes, vape pens, tanks, mods, and pod-
mods) are battery-powered devices designed to convert a 
liquid (often called e-liquid) into an aerosol for inhala-
tion by the user (Figure 6.1). E-liquid contains solvents 
(propylene glycol and vegetable glycerin) to produce the 
aerosol and typically contains nicotine, flavorings, and 
other compounds. E-cigarettes, which have been available 
in the United States since at least 2007 (USDHHS 2016), 
have been discussed as a potential harm-reduction tool for 
current smokers (Fagerstrom et al. 2015). For this reason, 
smokers, scientists, clinicians, and policymakers have an 
interest in understanding how e-cigarettes will impact the 
smoking cessation landscape.
As e-cigarettes are products designed to deliver nic-
otine to the body through the pulmonary route, which 
results in more rapid absorption and delivery of nico-
tine to the brain than through other modes of adminis-
tration (i.e., mouth, transdermal), it is useful to consider 
their ability to deliver nicotine in the context of a smoker 
attempting to use e-cigarettes to quit cigarette smoking. 
The design and components of many e-cigarettes are 
intended to generate aerosols that can rapidly deliver 
boluses of nicotine to the brain, similar to nicotine 
delivery by conventional cigarettes (Farsalinos et al. 2016). 
E-cigarettes vary in their ability to deliver nicotine to the 
body (Vansickel and Eissenberg 2013). However, the phar-
macokinetics of nicotine delivery of certain e-cigarette 
products, such as more recent generation e-cigarettes, 
resemble those of conventional cigarettes, and thus have 
the potential to mirror the pharmacologic effects of con-
ventional cigarettes (National Academies of Sciences, 
Engineering, and Medicine 2018). Therefore, for smokers 
of conventional cigarettes who seek a product with a 
rapid onset of the dose of nicotine similar to cigarettes, 
e-cigarettes that deliver nicotine in a similar way to con-
ventional cigarettes could have greater appeal than cur-
rent FDA-approved NRTs. However, although rapid boluses 
of nicotine could increase the appeal of these products rel-
ative to NRTs, whether this pharmacokinetic profile sup-
ports an effective method of cessation has not been exten-
sively studied (Shihadeh and Eissenberg 2015). However, 
when considering e-cigarettes as a potential cessation aid 
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for adult smokers, it is also important to take into account 
factors related to both safety and efficacy. NRT has been 
proven safe and effective, whereas the same has not 
been proven for any e-cigarette. There is no safe tobacco 
product. Although e-cigarette aerosol generally contains 
fewer toxic chemicals than conventional cigarette smoke, 
all tobacco products, including e-cigarettes, carry risks.
Other features of e-cigarettes that may enhance their 
appeal to conventional cigarette smokers are the ways in 
which e-cigarettes mirror some of the sensorimotor fea-
tures of conventional cigarette smoking, including stimu-
lation of the airways, the sensation and taste of e-cigarette 
aerosol in the mouth and lungs, the hand-to-mouth move-
ments and puffing in which e-cigarette users engage, and 
the exhalation of aerosol that may visually resemble cig-
arette smoking. Given the potentially important role of 
such sensorimotor factors in the reinforcing and addictive 
qualities of conventional cigarettes (Chaudhri et al. 2006), 
these attributes could make e-cigarettes more appealing to 
smokers than FDA-approved NRTs. However, the sensiro-
motor aspects of e-cigarettes could (a) facilitate uptake for 
use as a cessation aid, with the goal of attaining complete 
nicotine abstinence, similar to how NRTs are intended to 
be used or (b)  facilitate the use of e-cigarettes as a long-
term substitute for conventional cigarettes to sustain 
nicotine use. The potential abuse liability of e-cigarettes 
that deliver nicotine in a manner comparable, or higher 
than, conventional cigarettes should also be considered, 
including long-term dual use and decreased likelihood of 
cessation through maintenance of addiction. When consid-
ering the potential role of e-cigarettes used in smoking ces-
sation, it is important to consider the intent of therapeutic 
FDA-approved NRT (i.e., that they are intended to act as a 
support for attaining complete abstinence from smoking).
Two previous Surgeon General’s reports have 
addressed e-cigarettes. However, to date, no Surgeon 
General’s report has reviewed the available science related 
to e-cigarettes and cessation. E-cigarettes were first dis-
cussed in the 2014 Surgeon General’s report (USDHHS 
2014), which noted that the use of e-cigarettes could 
have positive and negative public health impacts at the 
individual and population levels. Additionally, the 2016 
Surgeon General’s report (USDHHS 2016), E-Cigarette 
Use Among Youth and Young Adults, examined many 
topics related to e-cigarettes, including patterns of use and 
health risks of e-cigarettes among young people, as well 
as the importance of population-based strategies to pre-
vent and reduce the use of e-cigarettes among this popula-
tion. USDHHS (2016) underscored the need to understand 
any effects of e-cigarettes on adult smoking cessation, 
as well as the risks that the products pose to youth and 
young adults. This is especially important in light of 
alarming increases in e-cigarette use among adolescents, 
which threaten decades of progress in tobacco control 
Figure 6.1 The evolution of e-cigarettes, by product generation and characteristics
Source: Photos by James Gathany and Lauren Bishop, CDC.
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(USDHHS 2016; Miech et al. 2018; Gentzke et al. 2019). 
Additionally, e-cigarette, or vaping, product use may be 
associated with other health risks beyond youth initiation 
and use. For example, CDC, FDA, state and local health 
departments, and public health and clinical partners have 
been investigating a multistate outbreak of e-cigarette, 
or  vaping, product use associated lung injury (EVALI) 
(Siegel et al. 2019). The latest national and state findings 
show e-cigarette, or vaping, products containing THC—
particularly those from informal sources, such as friends, 
family, or in-person or online dealers—are linked to most 
of the cases of lung injury and play a major role in the out-
break (Moritz et al. 2019; Navon et al. 2019). In particular, 
vitamin E acetate is closely associated with EVALI (Blount 
et al. 2019). Vitamin E acetate has been identified in sev-
eral tested products used by EVALI patients, and has been 
identified in bronchoalveolar lavage (BAL) fluid samples 
from 48 of 51 assessed EVALI patients, but not in the BAL 
fluid from a control group. However, as of January 2020, 
evidence is not yet sufficient to rule out the contribution of 
other chemicals of concern among some EVALI patients.
Current use of e-cigarettes among adults rose 
through 2014 (Adkison et al. 2013; Dockrell et al. 2013; 
Goniewicz et  al. 2013; Agaku et  al. 2014; Kasza et  al. 
2017), but has since declined gradually through 2017 
(Wang et al. 2018). In 2017, 2.8% of adults were current 
users of e-cigarettes (Wang et  al. 2018). More than half 
of current adult e-cigarette users also currently smoke 
cigarettes, which is commonly known as “dual use” (CDC 
2016; Mirbolouk et al. 2018). Among current e-cigarette 
users in 2016, 15.0% were never cigarette smokers, 30.4% 
were former smokers, and 54.6% were current smokers 
(Mirbolouk et  al. 2018). Data from the National Youth 
Tobacco Survey showed that among high school students, 
current (past 30-day) e-cigarette use rose from 1.5% in 
2011 to 20.8% in 2018 (Cullen et al. 2018), including a 78% 
increase from 2017 to 2018 (USDHHS 2018a). E-cigarette 
use among middle school students has also risen dramati-
cally in the same time period, with a 49% increase from 
2017 to 2018 (3.3% to 4.9%) (USDHHS 2018a). Dual use 
is also common among youth. In 2018, approximately half 
of youth who used tobacco products reported using two or 
more products; among high school students who reported 
currently using two or more tobacco products, the most 
common combinations reported were e-cigarettes and 
cigarettes (14.8%) (Gentzke et al. 2019).
Since its introduction into the U.S. marketplace 
in 2015, the JUUL brand e-cigarette has been increas-
ingly popular among U.S. youth (USDHHS 2018a), and 
increases in sales in recent years have corresponded with 
the previously described increases in current e-cigarette 
use among U.S. youth in recent years. For example, sales 
of JUUL increased 600% during 2016–2017, largely driven 
by uptake among youth and young adults, giving it the 
greatest market share of any e-cigarette in the United 
States by the end of 2017 (King et al. 2018b). Sales have 
continued to increase since that time; in the assessed 
channels by the end of 2018, JUUL held approximately 75% 
of the market share of total U.S. e-cigarette sales (Truth 
Initiative 2018). JUUL’s popularity with youth appears to 
stem from several factors:
• Appearance of a flash drive,
• Ease of concealment (small and does not emit as much 
aerosol or odor as some other types of e-cigarettes),
• Availability in a variety of flavors, 
• Widespread promotion through a variety of media, 
including social media, and 
• High nicotine content delivered in a form (e.g., nico-
tine salt) that may facilitate easier initiation (Cullen 
et  al. 2018; Goniewicz et  al. 2018a; Spindle and 
Eissenberg 2018).
E-cigarettes may appeal to adult smokers of con-
ventional cigarettes because they mimic cigarettes in sev-
eral ways: size, appearance (at least in the case of first-
generation e-cigarettes), method of inhalation, production 
of a smoke-like aerosol, and the taste and ritual behaviors 
associated with smoking (Prochaska and Benowitz 2016). 
In terms of exposure risks, as part of a comprehensive 
review on the public health consequences of e-cigarette 
use, the National Academies of Sciences, Engineering, 
and Medicine (2018) concluded that for current cigarette 
smokers, completely substituting e-cigarettes for combus-
tible tobacco products would reduce exposure to several 
toxicants and carcinogens present in tobacco cigarettes. 
For example, an analysis of 12 first-generation brands of 
e-cigarettes found that toxicants (including carcinogenic 
compounds) were present in the e-cigarettes’ aerosol 
across brands at varying levels, ranging from about 9- to 
450-times lower than cigarette smoke to levels in some 
brands that were comparable to levels in the NRT inhaler 
(Goniewicz et  al. 2014). In a separate analysis of urine 
samples from 5,105 adult participants in the 2013–2014 
wave of the Population Assessment of Tobacco and Health 
(PATH) Study, Goniewicz and colleagues (2018b) con-
cluded that the exclusive use of e-cigarettes was associ-
ated with exposure to known tobacco-related toxicants 
(e.g.,  tobacco-specific nitrosamines, such metals as cad-
mium and lead, and some volatile organic compounds), 
but that this exposure was markedly lower than that 
associated with both cigarette smoking and dual use of 
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cigarettes and e-cigarettes. However, depending on the 
toxicant analyzed, dual users (n  =  792) had similar or 
higher exposures to toxicants compared with users of only 
conventional cigarettes (n  =  2,411). Among dual users, 
the frequency of cigarette use was positively correlated 
with exposure to both nicotine and toxicants. These find-
ings suggest that exclusive use of e-cigarettes can result 
in markedly lower exposure to tobacco-related toxicants 
compared with exclusive use of conventional cigarettes, 
but that using e-cigarettes concurrently with conven-
tional cigarettes does not meaningfully reduce exposure to 
potentially harmful toxicants. Of note, ingredients unique 
to e-cigarettes (i.e., not found in conventional cigarettes) 
pose potential harms (Erythropel et al. 2019). It is impor-
tant to note that the findings from the PATH Study anal-
ysis pertain to e-cigarette products used in 2013–2014, and 
because the landscape of e-cigarette products continues 
to diversify and evolve rapidly, the findings may or may 
not be generalizable to behaviors surrounding the use of 
these products years later (e.g.,  in 2019). Moreover, the 
National Academies of Science Engineering and Medicine 
(2018) concluded that exposure to nicotine and exposure 
to potentially toxic substances in aerosol from e-cigarettes 
are highly variable and depend on product characteristics 
(e.g., e-liquid constituents and device characteristics and 
settings), how the device is operated, and user behavior.
Although the available scientific evidence indi-
cates that e-cigarettes generally have a markedly lower 
number and level of harmful toxicants than conventional 
cigarettes, use of the products is not without potential 
health risks; the long-term health effects of using these 
products remain unknown, and short-term risks are only 
slowly coming into focus (National Academies of Sciences, 
Engineering, and Medicine 2018). However, the National 
Academies of Sciences, Engineering, and Medicine (2018) 
concluded that there is substantial evidence that e-cigarette 
use is associated with several adverse health outcomes that 
are precursors to disease, including acute endothelial cell 
dysfunction, formation of reactive oxygen species/oxida-
tive stress, and increased heart rate (National Academies 
of Sciences, Engineering, and Medicine 2018). The report 
also concluded that there is substantial evidence that some 
chemicals present in e-cigarette aerosols are capable of 
causing DNA damage and mutagenesis, which supports the 
biologic plausibility that long-term exposure to e-cigarette 
aerosols could increase risk of cancer and adverse repro-
ductive outcomes; however, whether the levels of exposure 
are high enough to contribute to human carcinogenesis 
remains uncertain. The report further noted that there 
is no available evidence whether e-cigarette use is associ-
ated with certain longer term health outcomes, including 
clinical cardiovascular outcomes and subclinical ath-
erosclerosis, intermediate cancer endpoints in humans, 
respiratory diseases, and pregnancy outcomes (National 
Academies of Sciences, Engineering, and Medicine 2018). 
Additionally, Gotts and colleagues (2019) reviewed the 
available science to date on risks to the respiratory system 
from using e-cigarettes or being exposed to aerosol from 
e-cigarettes. The study found negative impacts on cel-
lular and organ physiology and immune function (Gotts 
et  al. 2019). Accordingly, more research is warranted to 
assess the extent to which e-cigarette use may impact the 
likelihood of these and other health outcomes. Of note, 
some studies have found that after accounting for con-
ventional cigarette smoking, e-cigarette use is associated 
with increased risk of having had a myocardial infarction 
(Alzahrani et  al. 2018; Alzahrani and Glantz 2019; Osei 
et al. 2019). However, the cross-sectional nature of these 
studies limits the ability to ascertain causality (Farsalinos 
and Niaura 2019a). A longitudinal study using data from 
the PATH Study found that having had a myocardial infarc-
tion at Wave 1 of the study did not predict e-cigarette use at 
Wave 2 (Bhatta and Glantz 2019). This finding, according 
to the study’s authors, suggests that reverse causality 
cannot explain the cross-sectional association between 
e-cigarette use and myocardial infarction observed at 
Wave  1. However, further longitudinal research is war-
ranted to fully account for the time period when myocar-
dial infarction has occurred relative to e-cigarette use. 
Research on the impact of e-cigarettes on smoking 
cessation is limited but growing. In addition to the review 
of this topic by the National Academies of Sciences, 
Engineering, and Medicine (2018), multiple systematic 
reviews have assessed the literature on e-cigarette use and 
smoking cessation, some of which conducted meta-analyses 
of RCT data and observational studies (Franck et al. 2014; 
Grana et al. 2014; Harrell et al. 2014; McRobbie et al. 2014; 
Lam and West 2015; Rahman et al. 2015; Hartmann-Boyce 
et al. 2016; Kalkhoran and Glantz 2016; Khoudigian et al. 
2016; Malas et al. 2016; El Dib et al. 2017).
Few RCTs have been conducted that directly inves-
tigate the utility of e-cigarettes for smoking cessation, 
and no RCTs on this topic have been conducted in the 
United States. Only four RCTs—a clinical trial of smokers 
in Italy who were not motivated to quit (Caponnetto et al. 
2013), a clinical trial of smokers in New Zealand who were 
motivated to quit (Bullen et  al. 2013), another clinical 
trial of smokers in New Zealand who were motivated to 
quit (Walker et al. 2019), and an RCT of adults using the 
stop-smoking service of the UK National Health Service 
(Hajek et  al. 2019)—have directly tested the efficacy of 
using e-cigarettes for smoking cessation with a follow-
up timepoint of at least 6 months; none were funded by 
the tobacco or e-cigarette industries. In a randomized 
clinical trial of smokers who were not motivated to quit, 
Caponnetto and colleagues (2013) found that the use of 
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first-generation e-cigarettes resulted in a nonsignificant 
(p = 0.24) increase in the likelihood of smoking abstinence 
at 52-weeks follow-up compared with those who used first-
generation e-cigarettes that did not contain nicotine (pla-
cebo e-cigarette). Abstinence rates were 13% in Group A 
(12-weeks supply of 7.2  mg nicotine cartridges), 9% in 
Group B (one 6-week supply of 7.2-mg nicotine cartridges 
and one 6-week supply of 5.4-mg nicotine cartridges), and 
4% in Group  C (cartridges without nicotine). However, 
in an intention-to-treat analysis, a statistically significant 
increase in the abstinence rate was observed at 52-weeks 
follow-up: 11.0% when Groups  A and  B were combined 
compared with 4.0% in Group C (p = 0.04). The RCT by 
Bullen and colleagues (2013) also showed (a) a nonsignifi-
cant elevated RR of 6-month continuous abstinence rates 
for smokers who were assigned to use first generation 
e-cigarettes that contained nicotine compared with those 
who were assigned to use first generation e-cigarettes that 
did not contain nicotine (7.3% vs 4.1%, RR 1.77, p = 0.44) 
and (b)  a nonsignificantly elevated RR for 6-month con-
tinuous abstinence (RR = 1.26; p = 0.46) between smokers 
who were assigned to use e-cigarettes that contained nic-
otine (7.3%) and those who were assigned to use nico-
tine patches (5.8%). As reviewed in National Academies of 
Sciences, Engineering, and Medicine (2018), the results 
of these two RCTs were pooled in two different, rigorous 
meta-analyses. A 2016 Cochrane review that pooled data 
from these two RCTs showed (a) no significant statistical 
heterogeneity between the two studies and (b) that use of 
nicotine-containing e-cigarettes was associated with statis-
tically significant higher abstinence rates than use of pla-
cebo e-cigarettes (RR = 2.29; 95% CI, 1.05–4.96; 9% for nic-
otine e-cigarette group vs. 4% in placebo e-cigarette group, 
among 662  participants) (Hartmann-Boyce et  al. 2016). 
El Dib and colleagues (2017) pooled the same two RCTs 
into a meta-analysis and found a nonsignificant increase 
in smoking cessation for nicotine e-cigarettes compared 
with placebo e-cigarettes (RR = 2.03; 95% CI, 0.94–4.38; 
p = 0.07). A notable difference in the methodology between 
these two reviews was that Hartmann-Boyce and col-
leagues (2016) considered participants with missing data 
as smokers and retained them in the analysis, increasing 
their sample size to 662 compared with the 481 cases ana-
lyzed by El Dib and colleagues (2017) (National Academies 
of Sciences, Engineering, and Medicine 2018).
A few notable limitations to two RCTs (Bullen et al. 
2013; Caponnetto et al. 2013) should be noted: They both 
produced fairly low quit rates in all conditions (range: 
4–13%) and used first generation e-cigarettes that do 
not have comparable nicotine pharmacokinetics as ciga-
rettes. Furthermore, Bullen and colleagues (2013) found 
that rates of compliance were substantially lower among 
smokers in the nicotine patch condition than among 
those in either of the e-cigarette conditions, suggesting 
that the similar efficacy among users of e-cigarettes with 
nicotine and of the nicotine patches might be mediated 
by different mechanisms of action. The greater adherence 
to e-cigarettes could be driven, in part, by past experience 
of failed quit attempts with patches and/or greater appeal 
of e-cigarettes.
The third RCT (Hajek et al. 2019) randomly assigned 
886 adults attending stop-smoking services from the UK 
National Health Service. Participants received either an 
NRT medication of their choice or an e-cigarette starter 
pack, which included a newer generation refillable 
e-cigarette with one bottle of nicotine e-liquid (18  mg 
per milliliter [ml]). Both conditions received face-to-
face smoking cessation counseling from a trained coun-
selor for at least 4  weeks. At 1  year, the biochemically 
verified cigarette smoking abstinence rate was 18.0% in 
the e-cigarette group compared with 9.9% in the NRT 
group. Of note, participants in both the e-cigarette and 
NRT groups rated their assigned products as less satis-
fying than cigarettes. However, participants who were 
assigned to use e-cigarettes reported that e-cigarettes pro-
vided them with greater satisfaction and rated e-cigarettes 
as more helpful to refrain from smoking than partici-
pants in the NRT group rated NRT medications (Hajek 
et al. 2019). The study concluded that use of e-cigarettes 
was more effective than use of NRT for smoking cessa-
tion in the trial when both were accompanied by behav-
ioral support. Of  note, among participants with 1-year 
abstinence, 80% of participants in the e-cigarette group 
were using e-cigarettes at 52  weeks follow-up and 9% 
of participants in the NRT group were using NRT, sug-
gesting greater likelihood of complete abstinence from all 
products in the long term from NRT use compared with 
e-cigarette use. This also suggests that, among those who 
use e-cigarettes for smoking cessation, cigarette absti-
nence may be predicated on long-term use of e-cigarettes, 
which may pose unknown long-term health risks, in addi-
tion to short-term risks that are only slowly coming into 
focus. Limitations of the study should also be considered. 
First, participants were enrolled through the UK National 
Health Service’s stop-smoking service, so they were moti-
vated to quit. Participants also received evidence-based 
cessation counseling in addition to e-cigarettes or NRT. 
Furthermore, the policy and regulatory environment 
regarding both e-cigarettes and tobacco products in the 
United Kingdom differs greatly from that of the United 
States. For example, compared with the United States, the 
United Kingdom limits the amount of nicotine permitted 
in e-cigarettes (maximum concentration 20 mg/ml) and 
has more restrictions on the advertising and marketing 
of e-cigarettes, which aligns with its advertising restric-
tions on tobacco products more generally. Further 
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well-designed RCTs will ultimately be important before 
any substantive conclusions can be made about the com-
parative efficacy of e-cigarettes relative to NRT, other ces-
sation pharmacotherapies, or not using a cessation aid. 
A fourth RCT conducted in 2016–2017 in New 
Zealand explored e-cigarettes, with and without nico-
tine, as an adjunct to the nicotine patch (Walker et  al. 
2019). The study randomized smokers motivated to quit 
(n = 1,124) to receive either nicotine patch, nicotine patch 
plus nicotine-containing e-cigarettes, or nicotine patch 
plus nicotine-free e-cigarettes. Participants randomized to 
the e-cigarette conditions received a tank-style device and 
tobacco-flavored e-liquid in either 0 mg/ml or 18 mg/ml 
concentration, depending on assigned group; and all par-
ticipants received 21 mg nicotine patches. Smokers using 
nicotine-containing e-cigarettes were more likely to have 
biochemically verified, continuous cigarette abstinence 
at 6-month follow-up than those randomized to patch 
plus nicotine-free e-cigarettes or to nicotine patch alone 
(7%, 4%, and 2%, respectively). However, the study had 
higher than expected rates of attrition: 50% in the patch-
only group, 32% in the patch plus nicotine-containing 
e-cigarettes group, and 33% in the patch plus nicotine-
free e-cigarettes group. Moreover, quit rates were much 
lower than expected among all three randomized groups. 
In addition to the aforementioned RCTs, an addi-
tional RCT assigned smokers employed by 54 companies 
to one of four workplace smoking-cessation interven-
tions or to usual care (Halpern et  al. 2018). Usual care 
consisted of access to information about the benefits of 
smoking cessation and to a motivational text-messaging 
service. The four interventions consisted of usual care and 
one of the following interventions: free access to cessation 
aids (NRT or pharmacotherapy, with e-cigarettes if stan-
dard therapies failed); free access to e-cigarettes, without 
a requirement that standard therapies had been tried; free 
access to cessation aids and $600 in rewards for sustained 
abstinence; or free access to cessation aids plus $600  in 
redeemable funds, with money removed from the account 
if cessation milestones were not met. The study found that 
rates of sustained abstinence through 6 months were 0.1% 
in the usual care group, 0.5% in the free cessation aids 
group, 1.0% in the free e-cigarettes group, 2.0% in the 
rewards group, and 2.9% in the redeemable funds group. 
Of note, the free e-cigarettes intervention was not superior 
to usual care (p = 0.20) or to the free cessation aids inter-
vention (p = 0.43), and among smokers who received usual 
care, the addition of free cessation aids or e-cigarettes did 
not significantly enhance cessation efficacy. However, 
the study did not assess actual use of e-cigarettes, only 
access to the products, nor did it compare free access to 
e-cigarettes with free access to conventional cessation aids 
without any option for e-cigarettes (Halpern et al. 2018).
In addition to the data from the previously summa-
rized RCTs, multiple observational studies have explored 
the effectiveness of using e-cigarettes for smoking ces-
sation. Several systematic reviews have synthesized the 
observational literature on the impact of e-cigarette use 
on smoking cessation (Franck et  al. 2014; Grana et  al. 
2014; Harrell et al. 2014; McRobbie et al. 2014; Lam and 
West 2015; Rahman et  al. 2015; Hartmann-Boyce et  al. 
2016; Kalkhoran and Glantz 2016; Khoudigian et al. 2016; 
Malas et al. 2016; El Dib et al. 2017). The review by El Dib 
and colleagues (2017), which used a methodology known 
as GRADE (Grading of Recommendations Assessment, 
Development, and Evaluation) to formally assess the cer-
tainty of evidence by outcome, concluded that the find-
ings on this topic from two RCTs (Bullen et  al. 2013; 
Caponnetto et  al. 2013) and eight observational studies 
(Vickerman et al. 2013; Borderud et al. 2014; Prochaska and 
Grana 2014; Al-Delaimy et al. 2015; Biener and Hargraves 
2015; Brose et  al. 2015; Harrington et  al. 2015; Manzoli 
et al. 2015) were of very low quality. Several of the reviews 
noted that findings from the observational studies varied, 
and differences in study design and the selection of par-
ticipants made it difficult to make conclusive comparisons. 
Similarly, a review conducted by USPSTF (2015), which 
also considered the existing RCTs, concluded that the cur-
rent evidence was insufficient to recommend e-cigarettes 
for tobacco cessation in adults, including pregnant women.
In one of the prospective observational studies, 
Manzoli and colleagues (2015) reported that the rate of 
quitting smoking did not differ between smokers who 
had used e-cigarettes weekly for at least 6  months and 
smokers who did not use e-cigarettes. However, in a lon-
gitudinal study of a nationally representative population 
of adults surveyed in 2012 and 2014, Zhuang and col-
leagues (2016) found that long-term e-cigarette users 
appeared to have (a)  higher rates of quit attempts than 
short-term e-cigarette users or nonusers of e-cigarettes 
(72.6% vs. 53.8% and 45.5%, respectively) and (b) higher 
rates of cigarette cessation (42.4% vs. 14.2% and 15.6%, 
respectively). Adjusting for smoking characteristics and 
demographics, long-term e-cigarette users were signifi-
cantly more likely than nonusers of e-cigarettes to try to 
quit smoking (OR = 2.94; 95% CI, 1.34–6.44) and to do so 
successfully (OR  =  4.14; 95%  CI, 1.50–11.42); cessation 
outcomes for short-term e-cigarette users were similar to 
those for nonusers. The study also found that 43.7% of 
adults who were dual users of cigarettes and e-cigarettes 
at baseline were still using e-cigarettes at follow-up. 
In a study of multiple years of nationally representative 
data from the U.S. Current Population Survey Tobacco 
Use Supplement, Zhu and colleagues (2017) found that 
the smoking cessation rate for the overall population 
increased from 4.5% in 2010–2011 to 5.6% in 2014–2015, 
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and in 2014–2015, e-cigarette users were more likely than 
nonusers to attempt to quit smoking (65.1% vs. 40.1%; 
percentage point change  =  25%; 95%  CI, 23.2–26.9%) 
and to succeed in quitting (8.2%  vs. 4.8%, p  <0.001). 
The study also examined the potential impact on cessa-
tion of other tobacco control efforts that were underway 
during the study period (e.g., mass media campaigns and 
increased taxation of cigarettes) and concluded that their 
effects could not fully account for the observed increase 
in the quit rate, leaving the use of e-cigarettes as a poten-
tial explanation. Finally, in a cross-sectional household 
survey of smokers 16 years of age and older in England, 
Beard and colleagues (2016) found that the success rate of 
attempts to quit cigarettes increased by 0.098% (p <.001) 
for every 1% increase in the prevalence of e-cigarette use 
among smokers, and by 0.058% for every 1% increase 
in the prevalence of e-cigarette use during a recent quit 
attempt. The study concluded that increases in e-cigarette 
use in England have been associated with increased suc-
cess in quitting cigarette smoking. 
As noted previously, some of the literature sug-
gests potential utility of e-cigarettes for smoking cessa-
tion. However, the current literature is limited by small 
numbers of trials, low event rates, and wide confidence 
intervals. Moreover, interpretation of results is further 
complicated by the wide variation in e-cigarette products 
(i.e., types of devices and components and levels of nico-
tine content in e-liquids) and the contexts in which they 
are used, including the motivation of smokers to quit and 
whether the products are used with behavioral support. 
Accordingly, more well-designed RCTs and prospective 
observational studies are needed to determine whether 
and how e-cigarettes influence smoking cessation, 
including whether the type of e-cigarette and the setting 
in which it is used impacts the potential for e-cigarette use 
to help smokers quit. 
Existing research suggests that the frequency of 
e-cigarette use and the type of product are important 
factors that influence the extent to which the products 
increase the likelihood of smoking cessation. As part of a 
comprehensive report on the public health consequences 
of e-cigarettes, the National Academies of Sciences, 
Engineering, and Medicine (2018) reviewed three RCTs 
(Bullen et al. 2013; Caponnetto et al. 2013; Adriaens et al. 
2014)—one of which assessed smoking reduction and 
not actual cessation (Adriaens et  al. 2014)—and results 
from several prospective cohort studies or repeated cross-
sectional design studies (Biener and Hargraves 2015; Brose 
et  al. 2015; Hitchman et  al. 2015; Delnevo et  al. 2016; 
Malas et  al. 2016; Zhuang et  al. 2016; Levy et  al. 2018) 
on the effectiveness of e-cigarettes for smoking cessation. 
The review concluded that while the overall evidence from 
observational trials is mixed, there is moderate evidence 
from observational studies that more frequent use of 
e-cigarettes is associated with an increased likelihood of 
cessation. For example, in a cross-sectional study using 
data from the 2016 and 2017 National Health Interview 
Survey, Farsalinos and Niaura (2019b) found that daily 
e-cigarette use was not associated with being a former 
smoker when quit duration was ignored, but was posi-
tively associated with being a former smoker of less than 
1  year (adjusted prevalence ratio [aPR]  =  3.44; 95%  CI, 
2.63–4.49), 1–3  years (aPR  =  2.51; 95%  CI, 2.13–2.95), 
and 4–6 years (aPR = 1.84; 95% CI, 1.49–2.26). Moreover, 
using data from waves 1 (2013–2014) and 2 (2014–2015) of 
the Population Assessment of Tobacco and Health Study, 
Berry and colleagues (2019) found that after adjusting for 
covariates, (a) cigarette smokers who initiated e-cigarette 
use between waves and reported that they used e-cigarettes 
daily at wave 2, had 7.88 (95% CI, 4.45–13.95) times the 
odds of 30-day cigarette cessation compared with nonusers 
of e-cigarettes at wave 2, and (b) nondaily e-cigarette users 
had significantly lower odds of cessation compared with 
nonusers. Similarly, in a longitudinal sample from two 
U.S. municipalities, Biener and Hargraves (2015) found 
that after accounting for demographic characteristics and 
tobacco dependence, intensive users of e-cigarettes (used 
e-cigarettes daily for at least 1 month) were six times more 
likely than nonusers to quit smoking (OR = 6.07; 95% CI, 
1.11–33.2); a comparable relationship was not observed 
between intermittent users (used e-cigarettes regularly 
but not daily for more than 1 month) and nonusers/triers 
(used e-cigarettes only once or twice). Furthermore, 
among a longitudinal sample of smokers in Great Britain, 
Hitchman and colleagues (2015) found that compared with 
smokers who did not report using e-cigarettes at follow-
up, nondaily users of disposable e-cigarettes were less 
likely to have quit smoking since baseline (p = 0.0002); 
daily users of disposable e-cigarettes and nondaily users 
of tank-style e-cigarettes were no more or less likely to 
have quit (p = 0.36 and p = 0.42, respectively); and daily 
users of tank-style e-cigarettes were more likely to have 
quit (p ≤0.01). These findings are consistent with findings 
from the RCT by Hajek and colleagues (2019), which found 
greater efficacy for cessation from the use of more recent 
generations of e-cigarettes with higher nicotine yield, and 
from studies showing that open tank e-cigarettes, which 
allow the user to refill the nicotine liquid and to titrate 
the dose of nicotine, result in greater nicotine absorption 
(Farsalinos et al. 2013a,b; 2015). Most recently, Gomajee 
and colleagues (2019) assessed longitudinal data from 
the CONSTANCES (Consultants des Centres d’Examens 
de Santé) cohort and found that among the 5,400  daily 
smokers, daily e-cigarette use was associated with a sig-
nificantly higher decrease in the number of cigarettes 
smoked per day compared with daily smokers who did 
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not use e-cigarettes (-4.4  [95%  CI, -4.8  to -3.9]  vs. -2.7 
[95% CI, -3.1 to -2.4]), as well as a higher adjusted RR of 
smoking cessation (1.67; 95%  CI, 1.51–1.84]). However, 
among 2,025  former smokers, e-cigarette use was asso-
ciated with an increase in the rate of smoking relapse 
(adjusted hazard ratio  =  1.70; 95%  CI, 1.25–2.30) com-
pared with former smokers who did not use e-cigarettes. 
In addition to frequency of use and product type, some 
data suggest that the reason for using e-cigarettes (e.g., to 
quit or reduce smoking  vs. all other reasons) may be 
an important factor that influences the effectiveness of 
e-cigarettes for smoking cessation (Vickerman et al. 2017). 
Taken together, these findings suggest that the type and 
design of e-cigarettes (e.g., open tank systems vs. closed 
systems vs. disposable) and the way in which they are used 
(e.g., more frequent use vs. less frequent use) may affect 
their utility for cessation (Hitchman et al. 2015).
The landscape of e-cigarettes continues to evolve, 
with the arrival of a new generation of devices and e-liquids 
that can more efficiently deliver nicotine (Farsalinos et al. 
2014; USDHHS 2018b). For example, some e-cigarettes 
contain nicotine salt e-liquids (also called nic salts); nic-
otine salts are created by adding an acid to the nicotine 
to lower the overall pH (Goniewicz et al. 2018a; Spindle 
and Eissenberg 2018). Nicotine salt-based liquids allow 
users to inhale aerosols with high levels of nicotine more 
easily and with less irritation than the freebase nicotine 
e-liquids that have been used in e-cigarettes since they 
were first introduced into the marketplace (USDHHS 
2018b; O’Connell et  al. 2019). Nicotine salt e-liquids 
may also help deliver nicotine to the brain faster and in 
a way that is more comparable to the nicotine delivery 
achieved via conventional cigarettes (Goniewicz et  al. 
2018a). Although justifiable concerns exist that nicotine 
salts could promote initiation of e-cigarette use among 
youth, this new product formulation also has the poten-
tial to enhance the dose and efficiency with which nico-
tine is delivered to adult smokers who may be attempting 
to quit smoking, thus potentially increasing the likelihood 
that they are able to transition completely to e-cigarettes. 
However, this formulation could also make it more diffi-
cult for those who fully transition to e-cigarettes to even-
tually quit using these products completely.
The 2014 Surgeon General’s report noted that “the 
promotion of noncombustible products is much more 
likely to provide public health benefits only in an environ-
ment where the appeal, accessibility, promotion, and use 
of cigarettes and other combusted tobacco products are 
being rapidly reduced” (USDHHS 2014, p. 874). Therefore, 
it is particularly important to consider both the potential 
benefits of e-cigarettes for smoking cessation and the high 
level of e-cigarette use among youth, which increased to 
unprecedented levels between 2017 and 2018 primarily 
because of the introduction of JUUL and other e-cigarettes 
shaped like USB flash drives (Cullen et al. 2018). As noted 
by the National Academies of Sciences, Engineering, and 
Medicine (2018), the specific time frame and magnitude 
of population health effects of e-cigarettes will depend on 
their impact on the rates of initiation and net cessation of 
combustible tobacco cigarettes and their intrinsic harm, 
and the risks of the high level of e-cigarette use among 
youth. To date, a variety of modeling projections have esti-
mated the potential magnitude of these effects, but it is 
important to note that results can vary greatly depending 
on parameter inputs, underlying assumptions, and other 
factors. Using a Mendez-Warner modeling approach, the 
National Academies of Sciences, Engineering, and Medicine 
(2018) found that the use of e-cigarettes will generate a net 
public health benefit, at least in the short term. The model 
found that the harms from increased initiation by youth 
will take time to manifest, occurring decades after the 
benefits of increased cessation are observed. However, for 
long-term projections, the net public health benefit was 
projected to be substantially less and was negative under 
some scenarios in the model. Importantly, irrespective of 
the range of assumptions used, the model projected a net 
public health harm in the short and long terms if the prod-
ucts do not increase net combustible tobacco cessation in 
adults. Warner and Mendez (2019) used a similar approach, 
concluding that potential life-years gained as a result of 
e-cigarette-induced smoking cessation are projected to 
exceed potential life-years lost due to e-cigarette-induced 
smoking initiation, and that these results held over a wide 
range of assessed parameters. In contrast, Soneji and col-
leagues (2018), using a Monte Carlo stochastic simula-
tion model, found that 2,070 additional current cigarette 
smoking adults (25–69  years of age) (95%  CI, -42,900–
46,200) would, because of e-cigarette use in 2014, quit 
smoking in 2015 and remain continually abstinent from 
smoking for 7  or more years. The model also estimated 
168,000  additional never-cigarette smoking adolescents 
(12–17 years of age) and young adults (18–29 years of age) 
(95% CI, 114,000–229,000) would, because of e-cigarette 
use in 2014, initiate cigarette smoking in 2015 and become 
daily cigarette smokers at 35–39 years of age. Based on the 
existing scientific evidence related to e-cigarettes and opti-
mistic assumptions about the relative harm of e-cigarette 
use compared with cigarette smoking, the authors con-
cluded that e-cigarette use currently represents more 
population-level harm than benefit.
In summary, the evidence is inadequate to infer that 
e-cigarettes, in general, increase smoking cessation; fac-
tors contributing to the uncertainty include the changing 
characteristics of e-cigarettes, the many different contexts 
in which they are used, and the limited number of studies 
conducted to date. However, the evidence is suggestive 
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but not sufficient to infer that the use of e-cigarettes con-
taining nicotine is associated with increased smoking ces-
sation compared with the use of e-cigarettes not containing 
nicotine; of important note, the evidence to support this 
conclusion lacks comparison to standard evidence-based 
therapy, and more research on this topic is warranted. 
The evidence is also suggestive but not sufficient to infer 
that more frequent use of e-cigarettes is associated with 
increased smoking cessation compared with less frequent 
use of e-cigarettes; however, future research on this topic 
is also warranted because existing evidence is primarily 
from observational studies that did not control for con-
founding based on motivation to quit smoking or assess 
potential characteristics of e-cigarette use that may be 
correlated with frequency of use, such as duration of use 
and product nicotine levels. The effects of e-cigarette use 
on smoking cessation will likely be determined by a com-
bination of the physical characteristics of these products; 
how they are used; and how society, policymakers, man-
ufacturers, smokers, and clinicians approach such prod-
ucts. Well-controlled clinical trials and rigorous, large-
scale observational studies with long-term follow-up will 
be critical to better understand the impact of various 
e-cigarettes under various conditions. E-cigarettes could 
help adult smokers, by reducing the risk of smoking-
attributable disease, if they completely switch from con-
ventional cigarettes to e-cigarettes and do not partake in 
an extended period of dual use that delays quitting. It is also 
important to consider the extent of health risks posed by 
ingredients that are unique to e-cigarettes but not present 
in conventional cigarettes (Clapp and Jaspers 2017; Gotts 
et al. 2019; Madison et al. 2019). Among those who have 
transitioned completely, the ultimate goal should be to 
also quit the use of e-cigarettes completely in order to 
achieve the maximum individual and public health ben-
efit. However, at the population level, any potential bene-
fits these products confer in terms of increasing cessation 
among adult smokers would need to outweigh poten-
tial risks related to use among youth (USDHHS 2014), 
including the already unprecedented increase in the use 
of e-cigarettes among youth that has occurred in recent 
years (Cullen et al. 2018; Miech et al. 2019). It is partic-
ularly important to emphasize the current diversity of 
e-cigarette products: they do not comprise a homogenous 
product category, and they have changed rapidly in design 
and characteristics since first entering the U.S. market-
place in 2007. Consequently, much of the existing scien-
tific literature on cessation relates to past generations of 
e-cigarette products. Therefore, further research is needed 
on the effects that e-cigarettes have on smoking cessation, 
including research on:
• Differential effects based on the type of e-cigarette 
product (e.g., newer vs. older devices), 
• Comparison groups (e.g.,  e-cigarettes that do not 
contain nicotine, NRT, no cessation aid), 
• Components in e-cigarette devices and the settings 
at which they are used (e.g.,  temperature of the 
heating coils), 
• Frequency of use (e.g., daily vs. less frequent use), 
• Informational context (e.g., forms of marketing and 
promotion, communication about risk and harm, 
behavioral support for use as a cessation aid), 
• Potential variations in effects across geographies, and 
• Real-world use of e-cigarettes in different regulatory 
contexts.
Such research will shed light on whether and how it 
may be possible to leverage e-cigarettes (or certain types 
of e-cigarette products) to maximize positive smoking ces-
sation outcomes while minimizing adverse consequences 
related to youth initiation and use.
Teachable Moments
with cigarette smoking or when a dentist, periodontist, or 
dental hygienist is treating a smoker). 
Hospitalization
Hospitalization can present an opportunity to 
change behavior, especially if the patient has been hospi-
talized for a condition caused or exacerbated by tobacco 
Teachable moments—including life changes, dis-
ease diagnoses, medical procedures, and screening 
results—can motivate patients to make and sustain a quit 
attempt. Smokers often come into contact with health-
care professionals—including physicians, nurses, medical 
staff, dentists, and pharmacists—during such moments. 
In addition to the specific situations described below, sev-
eral other situations can also serve as teachable moments 
(e.g., when a pharmacist is dispensing a drug that interacts 
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use. In most cases, hospitalization involves a temporary 
stay in a smokefree (and sometimes tobacco-free) clin-
ical environment, with ready access to smoking cessation 
counseling and pharmacotherapy, at a time when health 
concerns are acutely relevant. Patients who use cessation 
medications for relief of withdrawal symptoms while hos-
pitalized also have the opportunity to familiarize them-
selves with these medications and their benefits while in a 
clinical setting, potentially leading to a greater likelihood 
that they will subsequently use them to quit smoking 
(Fiore et al. 2012). Research indicates that tobacco ces-
sation interventions delivered in the hospital can reduce 
tobacco use, improve postsurgical outcomes, reduce read-
missions, and improve overall patient survival (Cummings 
et al. 1989; Mullen et al. 2015; Mullen et al. 2017; Nolan 
and Warner 2017; Cartmell et al. 2018b). 
Research also indicates that post-hospital follow-up 
is key to achieving and sustaining smoking abstinence, 
as reported in a 2012 Cochrane meta-analysis of 50 ran-
domized or quasi-RCTs evaluating smoking cessation 
interventions initiated in hospital settings (Rigotti et al. 
2012). The meta-analysis found that intensive counseling 
interventions that were initiated in an acute care hospital 
and included at least 1  month of supportive care after 
discharge from the hospital were effective in increasing 
smoking cessation rates postdischarge (RR = 1.37; 95% CI, 
1.27–1.48); adding NRT further increased the treatment 
effect (RR  =  1.54; 95%  CI, 1.34–1.79). No benefit was 
found for less intensive programs, or for adding bupro-
pion. However, a multicenter, double-blind, randomized, 
placebo-controlled trial in which smokers with acute 
coronary syndrome were randomized to receive vareni-
cline initiated in hospital or placebo for 12 weeks, found 
that patients randomized to varenicline had significantly 
higher rates of smoking abstinence and reduction than 
patients randomized to placebo (47.3% 6-month point-
prevalence abstinence  vs. 32.5% in the placebo group, 
p <.05) (Eisenberg et  al. 2016). All patients in this trial 
also received low-intensity counseling. 
Rigotti and colleagues (2012) found a comparable 
effect for intensive counseling in rehabilitation hospi-
tals after acute care for stroke, coronary heart disease, or 
cancer or chronic disorders, such as diabetes or asthma 
(RR = 1.71; 95% CI, 1.37–2.14). Although not included in 
Rigotti and colleagues (2012), other research has found 
that treatment of tobacco use during a visit to a smokefree 
psychiatric emergency room or during psychiatric hos-
pitalization was associated with reductions in agitation, 
greater abstinence from smoking, and lower readmission 
rates (Allen et al. 2011; Prochaska et al. 2014). For example, 
Allen and colleagues (2011) found that at baseline, partici-
pants were at least moderately agitated, and 28% reported 
aggressive behavior during the previous week. The mean 
Agitated Behavior Scale scores for the nicotine replace-
ment group were 33% lower at 4 hours and 23% lower at 
24 hours than the respective scores for the placebo group. 
Trials designed to link hospitalized smokers with 
quitline services have shown mixed results relative to 
standard, brief stop-smoking interventions (Rigotti 
et  al. 2014, 2016; Cummins et  al. 2016; Warner et  al. 
2016). For example, in a 2014 RCT of 397 smokers who 
received a cessation intervention during hospitalization 
at Massachusetts General Hospital, those assigned to the 
treatment condition that included postdischarge follow-
up care were significantly more likely to achieve biochem-
ically validated abstinence 6 months after discharge than 
those assigned to usual care (a referral to the state tobacco 
quitline) (27%  vs. 16%; RR  =  1.70; 95%  CI, 1.15–2.51; 
p = 0.007) (Rigotti et al. 2014). However, in a 2016 RCT, 
patients were randomized to receive brief, in-hospital 
cessation advice or a brief, 5-minute quitline facilitation 
intervention that consisted of either a fax referral or a 
“warm handoff” (direct phone call to enroll the patient and 
arrange for an initial counseling call) to a tobacco quit-
line. Compared to those who received the brief, 5-minute 
cessation advice, less than 50% of the intervention group 
completed the first quitline intervention call, and results 
suggested no difference in rates of abstinence 6 months 
after discharge (Warner et al. 2016). 
Overall, studies suggest that hospital-based cessa-
tion programs can lower readmission rates and are cost-
effective for hospitals. For example, the Ottawa Model 
for Smoking Cessation—which identifies hospitalized 
smokers and provides in-hospital cessation counseling 
and medications and post-hospitalization follow-up—
demonstrated increased smoking abstinence; lower rates 
of all-cause readmissions, smoking-related readmissions, 
and all-cause emergency department visits; and reduced 
healthcare costs (Mullen et  al. 2017). The continuous 
6-month abstinence rate was 29.4% for the intervention 
group versus 18.3% for controls (Reid et  al. 2010). The 
largest absolute risk reductions (ARRs) were for all-cause 
readmissions at 30 days (13% vs. 7%; ARR = 6% [3–9%]; 
p  <0.001); 1  year (38%  vs. 27%; ARR  =  12% [7–17%]; 
p <0.001); and 2 years (45% vs. 34%; ARR = 12% [7–17%]; 
p <0.001) (Mullen et al. 2017). The greatest reduction in 
risk for all-cause visits to the emergency department was 
at 30 days (21% vs. 16%; ARR = 5% [0.4–9%]; p = 0.03). 
Reduction in mortality was significant by year 1 (11% vs. 
5%; ARR = 6% [3% to 9%]; p <0.001) and continued to 
be significant at year 2 (15% vs. 8%; ARR = 7% [4–11%]; 
p <0.001). From the hospital payer’s perspective, delivery 
of in-hospital cessation services was cost-effective, with 
1-year cost per QALY gained of $C1,386 (Canadian dol-
lars), and lifetime cost per QALY gained of $C68 (Mullen 
et al. 2015). 
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In a study of acute care patients who were current 
smokers and were admitted to and discharged from the 
Medical University of South Carolina between November 
2014 and June 2015, researchers compared unplanned 
readmissions at 30, 90, and 180  days postdischarge 
between (a) current smokers who were exposed to a nic-
otine dependence treatment service while hospitalized 
with unplanned readmissions and (b)  smokers who did 
not receive the service (Nahhas et al. 2017; Cartmell et al. 
2018b). The treatment service consisted of at least a bed-
side consult and/or one interactive voice response (IVR) 
follow-up call. At 30 days postdischarge, smokers exposed 
to the nicotine dependence treatment service were about 
half as likely to be smoking as those who did not receive 
the service (51% abstinence vs. 27%) and had significantly 
lower odds of readmission (OR = 0.77, p <.05) than those 
who did not receive the service (Nahhas et al. 2017). Odds 
of readmission remained lower among smokers exposed 
to the intervention at both 90 and 180 days postdischarge 
but were no longer statistically significant (Cartmell et al. 
2018b). In a separate follow-up study, Cartmell and col-
leagues (2018a) assessed cost savings to the hospital at 
12  months postdischarge, finding that overall adjusted 
mean healthcare charges for smokers exposed to the 
intervention were about $7,300 lower than charges for 
those who did not receive the intervention.
Based on evidence of the effectiveness and ben-
efits of interventions to help hospitalized smokers quit, 
The Joint Commission released an updated set of per-
formance measures on tobacco cessation for hospi-
tals (Fiore et al. 2012) (also see Chapter 7), but the final 
measures no longer contain the postdischarge follow-up 
component. Despite the growing body of evidence that 
hospital-initiated tobacco cessation interventions, espe-
cially programs that continue postdischarge, can increase 
abstinence, reduce readmission rates, and lead to cost sav-
ings, only about 5% of accredited acute care hospitals in 
the United States have selected and are reporting on the 
tobacco cessation measures from The Joint Commission, 
even without the follow-up component, and the number 
of hospitals reporting on these measures has decreased in 
recent years (The Joint Commission, personal communi-
cation, March 18, 2019). This is likely due to the volun-
tary nature of the measures (they are not currently tied to 
payment)—coupled with the fact that certain other mea-
sure sets from The Joint Commission are required or tied 
to payment, with the fact that performance measures are 
increasingly being reported electronically and the Joint 
Commission cessation measures have still not been fully 
converted electronically, and with the perception that 
other measure sets may be easier to implement and report 
on (Freund et al. 2008, 2009). If the cessation measures 
from The Joint Commission are not included in a CMS 
rule or otherwise tied to payment or required, then the 
number of acute care hospitals reporting on these mea-
sures is likely to continue to decline. In contrast, two of 
these measures (offering cessation counseling and medi-
cation during hospitalization and again at discharge) are 
embedded in the Inpatient Psychiatric Facility Quality 
Reporting Program, and inpatient psychiatric facilities are 
accordingly required to report on these measures.
Surgery
Like being hospitalized, undergoing surgery can be a 
source of motivation to quit smoking, especially if the sur-
gery is related to a health condition caused by smoking and 
presents an opportunity for patients to quit and stay quit. 
Smoking is a risk factor for perioperative and postoperative 
complications (e.g., wound infection, respiratory failure, 
lengthy hospital stays, admission to intensive care unit, in-
hospital mortality, and readmission) (Lavernia et al. 1999; 
Delgado-Rodriguez et al. 2003; Barrera et al. 2005; Warner 
2006) across a variety of surgical specialties (Brooks-Brunn 
1997; Glassman et al. 2000; Møller et al. 2002; Thomsen 
et al. 2010). Quitting smoking before surgery can improve 
outcomes and reduce healthcare costs (American College 
of Surgeons 2014). Surgery also presents an opportunity 
for patients to quit and stay quit. For example, a large 
cross-sectional study found that having a major surgery 
doubled the likelihood of quitting smoking—particularly 
for surgery related to conditions caused or exacerbated 
by smoking, such as cancer and heart disease (Shi and 
Warner 2010). Even having minor surgery increased quit 
rates by 28%—a finding that, because of the high occur-
rence of such surgeries, could have a substantial impact 
on population-level tobacco abstinence (Keenan 2009). 
Requiring tobacco cessation and offering cessation treat-
ments before elective surgery could further increase this 
effect. In one study, perioperative patients who were given 
a brief consultation by a nurse, smoking cessation bro-
chures, and access to 6 weeks of NRT and were referred 
to a quitline were 2.7 times more likely to achieve long-
term cessation than patients who received usual treat-
ment, which did not include such components (Lee et al. 
2015). Although little research has focused on surgeons 
as providers of tobacco treatment, even brief counseling 
on smoking cessation by a vascular surgeon was found 
to increase patients’ interest in cessation and awareness 
of the harms of smoking, and this effect was maintained 
3 months after the intervention (Newhall et al. 2017). 
The evidence suggests that cessation interven-
tions delivered before and in connection with surgery can 
increase smoking cessation among patients and improve 
surgical outcomes. Based on data from observational 
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studies and systematic reviews of RCTs by Nolan and Warner 
(2017), offering evidence-based tobacco treatments before 
and/or immediately around the time of surgery improves 
surgical, cardiovascular, pulmonary, and wound-healing 
outcomes in the short and long terms. Across more than 
400  studies, effect sizes for improvement of outcomes 
ranged from 1.56 to 2.73 in the treatment group compared 
with placebo, usual care, or brief advice. Thomsen and col-
leagues (2014) suggested that while the optimal intensity 
and timing of preoperative intervention remain unclear, 
based on indirect comparisons and evidence from two 
small trials, cessation interventions that begin 4–8 weeks 
before surgery, include weekly counseling, and use NRT 
are beneficial to reduce postoperative surgical complica-
tions and increase long-term smoking cessation.
Lung Cancer Screening
Lung cancer screening with low-dose computed 
tomography (LDCT) is associated with an estimated 20% 
lower mortality rate from lung cancer relative to chest 
x-ray because of earlier detection of the cancer (Aberle 
et al. 2011; Bach et al. 2012). Based on findings from large, 
well-controlled clinical trials, USPSTF (2015) recom-
mends that LDCT screening be offered to patients at high 
risk for lung cancer, defined as adults 55–80 years of age 
with a 30-pack-year smoking history who currently smoke 
or have quit smoking within the past 15 years. USPSTF 
recommends that screening continue annually until the 
patient has remained abstinent from smoking for 15 years 
or reaches 80 years of age (Moyer 2014). In February 2015, 
CMS issued a national coverage determination requiring 
Medicare to cover LDCT screening for lung cancer if cer-
tain eligibility requirements are met, including being 
aged 55–77 years of age, having no signs or symptoms of 
lung cancer, having a tobacco smoking history of at least 
30 pack-years, being a current smoker or one who has quit 
smoking within the past 15 years, and receiving a written 
order for LDCT that meets several criteria (CMS 2015). 
In 2015, an estimated 6.8 million current and former U.S. 
smokers met the criteria for LDCT lung cancer screening 
(Jemal and Fedewa 2017). Medicare reimbursement of 
lung cancer screening requires that smoking cessation 
be addressed (CMS 2015). The shared decision-making 
visit must include counseling on the importance of main-
taining cigarette smoking abstinence (if the patient is 
a former smoker) or counseling on the importance of 
smoking cessation (if the patient is a current smoker), and 
providers must offer information about tobacco cessation 
interventions. In addition, eligibility criteria for radiology 
imaging facilities must include making smoking cessation 
interventions available for current smokers.
Because of the criteria for lung cancer screening, 
the population receiving screening by definition includes 
a large number of current longtime smokers. Given the 
heightened awareness of smoking-related cancers among 
patients presenting for LDCT screening, these men and 
women could be especially receptive to smoking cessa-
tion advice and interventions delivered throughout the 
screening process (including before, during, and after the 
screening). Research on the perceptions and beliefs about 
smoking and negative health outcomes among high-risk 
older smokers found high levels of awareness of the dan-
gers of continued smoking and strong interest in quit-
ting, even if the screening results showed no signs of lung 
cancer (Cataldo 2016).
Several studies of smokers undergoing a lung 
cancer screening trial found that (a)  motivation to quit 
and quit rates were higher among study participants than 
among those in the general population and (b)  persons 
with abnormal LDCT scans were significantly more likely 
to quit smoking than those without abnormal results 
(Taylor et  al. 2007; Styn et  al. 2009; Slatore et  al. 2014; 
Tammemägi et  al. 2014). For example, in the National 
Lung Screening Trial (a study of 53,454 current or former 
heavy smokers, 55–75  years of age, with 30  or more 
pack-years of smoking), participants with suspicious 
results (a nodule ≥4  mm on the computed tomography 
scan) reported approximately 6% lower rates of smoking 
compared with those with normal results from the scan 
(Slatore et al. 2014; Tammemägi et al. 2014).
Despite these findings, some researchers have pos-
ited that, in the absence of a comprehensive cessation 
component, lung cancer screening could potentially have 
a negative impact on smoking cessation, with smokers 
believing that they have already taken sufficient action 
to protect their health simply by undergoing screening 
(Harris 2015; Zeliadt et al. 2015). Such an impact could 
be especially pronounced among smokers who receive 
negative screening results (i.e., no sign of cancer), since 
they might interpret the results to mean that they have a 
clean bill of health and a green light to continue smoking 
(Harris 2015; Zeliadt et al. 2015). In the clinical guideline 
on Pairing Smoking-Cessation Services with Lung Cancer 
Screening issued by the Association for the Treatment of 
Tobacco Use and Dependence and the Society for Research 
on Nicotine and Tobacco, Fucito and colleagues (2016) 
reported that a limited amount of data are available on the 
topic. The small number of studies conducted to date have 
yielded mixed findings.
Several studies seeking to add cessation interven-
tions to LDCT scans have not observed improved cessa-
tion outcomes (e.g., Clark et al. 2004; van der Aalst et al. 
2012; Marshall et al. 2016). Most of these trials used min-
imally intensive cessation interventions (e.g.,  self-help 
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materials, lists of resources, tailored computer informa-
tion), which may have contributed to the lack of signifi-
cant findings. Some evidence suggests that more inten-
sive cessation interventions delivered in this setting 
might be more effective, and that the timing of such 
interventions may matter. For example, in a pilot study 
in which 18 patients were offered one face-to-face coun-
seling session and follow-up telephone counseling with 
medications, Ferketich and colleagues (2012) found bio-
chemically confirmed quit rates of 33.3% when the ces-
sation intervention was delivered before the lung cancer 
screening (vs. 22.2% when it was delivered later). In addi-
tion, Park and colleagues (2015) reported increased quit 
rates when patients undergoing lung cancer screening 
received multisession, more intensive visits that included 
providing assistance (e.g., providing cessation counseling 
and/or prescription medication) and arranging follow-up. 
In summary, although studies of LDCT scans have 
had positive effects on cessation behaviors, the optimal 
smoking cessation strategy for smokers who undergo 
LDCT screening remains unclear (Marshall et  al. 2016), 
and research on the effectiveness of cessation interven-
tions among persons receiving LDCT is still limited 
(Piñeiro et al. 2016). More research is needed to identify 
the most effective types of messaging and other types of 
cessation interventions to increase motivation to quit, 
quit attempts, and successful cessation among smokers 
who undergo lung cancer screening. Eight large RCTs of 
smoking cessation interventions for patients undergoing 
lung cancer screening are underway (Joseph et al. 2018; 
Taylor et al. 2019). These studies, along with future surveil-
lance of populations undergoing lung cancer screening, 
will be critical to better understanding the impact of 
lung cancer screening on smoking and smoking cessa-
tion behaviors. In the interim, it is important for clini-
cians and lung cancer screening sites to deliver cessation 
interventions to this high-risk population and to evaluate 
and report the results to inform best practices in this area.
Readiness to Quit and Approaches 
for Quitting Ambivalence
The Clinical Practice Guideline recommends pro-
viding brief motivational counseling to smokers who are 
ambivalent about quitting (Fiore et  al. 2008). Although 
nearly 7 out of 10 adult cigarette smokers reported that 
they want to stop smoking completely (Babb et al. 2017), 
just over 5 out of 10 reported trying to quit in the past year 
(Babb et al. 2017), suggesting that a substantial number 
of smokers are not yet ready to quit or are ambivalent 
about quitting. The Stages of Change Model provides a 
framework for assessing readiness to quit and for tailoring 
interventions accordingly. Cessation strategies tailored 
to a smoker’s readiness to quit are less likely to be per-
ceived as overwhelming because the smoker is less likely 
to feel that these strategies are rushing them into action 
(Hall et al. 2006; Fiore et al. 2008; Prochaska et al. 2014). 
Readiness to quit can be conceptualized as a continuum of 
stages proceeding from precontemplation (no immediate 
intention to stop smoking) to contemplation (intending 
to quit in the next 6 months) to preparation (considering 
quitting in the next month, with at least one quit attempt 
in the past year) to action (has quit smoking for less than 
6 months) and finally to maintenance (has quit smoking 
for at least 6 months) (Prochaska and DiClemente 1983). 
It should be noted, however, that smokers’ progression 
through the stages of change is not necessarily sequential 
or orderly. Rather, smokers’ motivations and readiness to 
quit are transient and fluctuate over time, and smokers 
may make spontaneous, unplanned quit attempts without 
first passing through all the stages of change (West 2005).
Unlike clinically based models, tailoring treatments 
to a smoker’s stage of readiness to change recognizes that 
individual smokers may not always be receptive to certain 
types of cessation interventions. Part of the utility of this 
model is that it identifies a patient’s stage of readiness and 
suggests interventions that can help move the patient to a 
point where he or she is ready to take advantage of standard 
treatment models. Motivational interviewing and adapta-
tions of this approach (reviewed previously in this chapter) 
follow an intervention framework that is distinct from, but 
generally consistent with, stage-based approaches. 
Stage-based, computer-delivered interventions have 
demonstrated efficacy for supporting smokers through the 
process of quitting, including smokers with depression or 
serious mental illness (Prochaska et  al. 1993, 2001a,b, 
2014; Velicer et al. 1999; Hall et al. 2006). In their review 
of 22  stage-based cessation interventions, Riemsma and 
colleagues (2003) found stronger effects in higher quality 
studies and with interventions tailored to all constructs 
of the Transtheoretical Model (Prochaska and DiClemente 
1983), not just to the stage of change (Spencer et al. 2002). 
The review noted generally positive outcomes of the inter-
ventions and indicated a clear relationship between study 
quality and statistical significance: only 1 of 5 (20%) low-
quality studies, 8  of 14  (57%) moderate-quality studies, 
and 3  of 4  (75%) of the highest quality studies yielded 
a significant finding. However, 1  of the 4  studies in the 
highest quality group had a small sample and a short 
follow-up, and was group-matched on only one stage of 
the Transtheoretical Model. 
Some have argued that applying the Transtheoretical 
Model and Stages of Change Model to smoking cessation 
assigns smokers to stages based on arbitrary time periods 
that are not rooted in the science of smoking cessation 
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(e.g., a smoker ready to quit in 30 days is considered to be 
in the preparation stage, but one ready to quit in 31 days is 
in the contemplation stage [West 2005]). Another poten-
tial limitation of a stage-based approach is that it assumes 
that smokers make coherent and stable plans about quit-
ting, but other research suggests that intentions to quit 
may be unstable (Hughes et al. 2005) and that smokers 
may make spontaneous quit attempts with no planning 
or preparation (Larabie 2005; Cooper et al. 2010). Finally, 
because the Stages of Change Model prioritizes inter-
vening with smokers who are preparing to quit or actively 
engaged in quitting, some have argued that this approach 
may fail to offer effective interventions to smokers who 
might have been receptive to them (e.g., smokers who are 
contemplating a quit attempt or who may be ambivalent 
[West 2005]). Indeed, some evidence suggests that cessa-
tion assistance should be offered to as broad a spectrum of 
smokers as possible, because current motivation to quit 
does not necessarily predict future abstinence (Pisinger 
et al. 2005). 
Although the Transtheoretical Model and the Stages 
of Change Model have been widely applied to the field of 
smoking cessation and can be used to assess interest in and 
ambivalence about quitting and to tailor cessation interven-
tions accordingly, clinicians should also be advised that the 
manner in which smokers approach quitting at a popula-
tion level may not map onto these models. Offering support 
to as wide a range of smokers as possible is likely the best 
approach to increase quit attempts and successful quitting. 
However, more research is needed on such an approach, 
including unintended consequences. For example, offering 
widespread support could reduce cost-effectiveness, as 
interventions could be given to more numbers of smokers 
who are not ready and, as a result, would not quit.
Considerations for Subpopulations
As the prevalence of cigarette smoking in the general 
U.S. population has declined over time, increased atten-
tion has been devoted to tobacco cessation interventions 
focused on certain subgroups that may be more likely 
to smoke, be heavier smokers, bear a disproportionate 
burden of smoking-related morbidity and mortality, and 
face special challenges in quitting. In some cases, certain 
populations or conditions may warrant specific cessation 
interventions and/or lack an indication for or have cer-
tain considerations or contraindications related to cessa-
tion medication. This section outlines the evidence and 
considerations for cessation interventions across specific 
populations and/or conditions for which existing inter-
ventions are not indicated and/or are less effective. 
Pregnant Women
Pregnant women are a priority population for 
tobacco cessation because of the health risks that tobacco 
use during pregnancy poses to the mother and the fetus 
(USDHHS 2001, 2004, 2014). Furthermore, pregnancy 
can offer an opportunity to quit smoking because pregnant 
women are highly motivated to take actions to protect the 
health of their babies (DiClemente et al. 2000). The litera-
ture indicates that, among American women who smoked 
during the 3 months before they became pregnant, about 
50% quit during pregnancy (Tong et al. 2013; Curtin and 
Mathews 2016). However, rates of postpartum relapse 
among women who quit smoking during pregnancy may 
be as high as 50% (Tong et al. 2013). Large variations in 
rates of smoking during pregnancy are seen across sub-
populations and states (Curtin and Mathews 2016; Drake 
et  al. 2018). Rates of smoking during pregnancy are 
higher among younger women, women with lower levels 
of education, economically disadvantaged women, and 
women who have not planned their pregnancy (Mosher 
et al. 2012; Curtin and Mathews 2016; Drake et al. 2018). 
Pregnant women and women of reproductive age who 
smoke are also more likely to live in low-resource envi-
ronments that potentially subject them to high levels of 
stress (Coleman-Cowger et al. 2016; Mazurek and England 
2016), and being pregnant may represent an additional 
stressor for these women. This context provides impor-
tant insights into the potential challenges of providing 
smoking cessation treatment during pregnancy. 
The Clinical Practice Guideline concluded that 
there was insufficient evidence for the effectiveness of 
smoking cessation medications in pregnant women (Fiore 
et al. 2008). Similarly, USPSTF (2015) concluded that evi-
dence is not sufficient to assess the balance of benefits and 
harms of pharmacotherapy interventions for tobacco ces-
sation in pregnant women. More research is needed before 
definitive guidance can be provided on this topic (Fiore 
et al. 2008; Coleman et al. 2012a, 2015; Myung et al. 2012). 
Results have been mixed in reviews of the use of cessation 
pharmacotherapies (with most of the studies focusing on 
NRT) in women who smoke during pregnancy. These find-
ings suggest that adding NRT to behavioral interventions 
may not increase quitting in this population (Coleman 
et al. 2012a, 2015; Myung et al. 2012). This may be due 
in part to a low medication adherence rate in trials to 
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date (Wisborg et  al. 2000; Pollak et  al. 2007; Coleman 
et al. 2012b). 
Pregnant smokers should be encouraged to attempt 
cessation using educational and behavioral interventions 
before using pharmacologic approaches. In individual 
cases, however, women and their physicians may opt to 
use cessation medications, including such alternatives to 
NRT as bupropion or varenicline. However, these deci-
sions should be made in consultation with a physician 
after carefully considering the specific circumstances and 
weighing the risks of using medication against the risks of 
continued smoking (Fiore et al. 2008).
With regard to behavioral cessation interventions 
for pregnant women, USPSTF (2015) recommends that, as 
a Grade A intervention, clinicians ask all pregnant women 
about tobacco use, advise pregnant women who use tobacco 
to stop, and provide behavioral cessation interventions to 
pregnant women who use tobacco. Recent studies have 
suggested that social support is highly predictive of suc-
cessful smoking cessation during pregnancy (Smedberg 
et al. 2014; Boucher and Konkle 2016). In addition, inter-
vention approaches that address the health of the mother 
and the health of the fetus may increase long-term absti-
nence (Flemming et al. 2015; Bauld et al. 2017). Cessation 
interventions that are more intensive, are tailored, and go 
beyond advice to quit are more effective in this popula-
tion (Fiore et al. 2008; Lumley et al. 2009). WHO (2013) 
recommends behavioral cessation interventions—such as 
health education, counseling, social support, and incen-
tives for abstinence—as effective approaches to increasing 
cessation during pregnancy and to improving health out-
comes for both the baby and the mother. Quitline coun-
seling may be a useful cessation intervention for preg-
nant smokers, but more research is needed on the specific 
features that make this intervention optimally effective 
(e.g., the timing and frequency of calls during pregnancy 
and/or postpartum for relapse prevention and tailoring 
approaches) (Bombard et al. 2013; Cummins et al. 2016). 
A growing body of evidence suggests that incentives 
and contingency management techniques (reviewed in 
detail elsewhere in this chapter) are effective cessation inter-
ventions for pregnant women (Higgins et al. 2004, 2010b, 
2014; Heil et al. 2008; Cahill et al. 2015). For example, Cahill 
and colleagues (2015) found that incentive-based smoking 
cessation programs produced better outcomes for preg-
nant women than among controls (OR = 3.6; 95% CI, 2.39–
5.43), with assessments out to 3 months postpartum. The 
same review concluded that such programs improve absti-
nence while the incentives remain in place. Despite these 
promising results, more evidence is needed to fully under-
stand the effectiveness of incentive interventions in pro-
ducing sustained cessation outcomes in pregnant women 
who smoke. Although it may be challenging to convince 
payers to implement incentive interventions on a popula-
tion scale, they may be more willing to consider doing so in 
this case, given the high costs of smoking-related adverse 
birth outcomes and the short-term cost savings associated 
with preventing these outcomes. 
Lesbian, Gay, Bisexual, and 
Transgender Populations
In part because the tobacco industry has directly tar-
geted the lesbian, gay, bisexual, and transgender (LGBT) 
population with marketing and outreach (Washington 
2002; Stevens et al. 2004; Dilley et al. 2008), the prevalence 
of cigarette smoking and other tobacco use is substantially 
higher in these groups than in non-LGBT populations (Hu 
et al. 2016). For example, in a large national health survey 
(Jamal et al. 2016), the prevalence of smoking was higher 
among adults who were lesbian, gay, or bisexual (20.6%) 
than among heterosexual adults (14.9%). In 2015, gay, les-
bian, and bisexual adult smokers, as a group, reported a 
lower prevalence of cessation counseling and/or medication 
use (14.5%) when trying to quit than did straight smokers 
(31.7%) (Babb et al. 2017). In addition, transgender adults 
report higher use of cigarettes and other tobacco prod-
ucts than cisgender persons (people whose gender iden-
tity matches the sex they were assigned at birth). Data 
from a 2013 nationally representative survey found that 
35.5% of transgender adults reported past-month cigarette 
use compared with 20.7% of cisgender adults (Buchting 
et al. 2017). Although data are not available on the use of 
tobacco cessation treatments by transgender adults, as a 
group they are more likely to postpone general medical 
care and to report barriers in accessing care, primarily 
because they encounter discrimination when seeking care 
and cannot afford care (Grant et al. 2010). 
Reviews of cessation treatments in LGBT populations 
have found that such treatments can be effective, but data 
are limited (Lee et al. 2014; Berger and Mooney-Somers 
2016). In addition to the inclusion of elements of standard 
behavioral cessation treatment, most studies of this topic 
have investigated the effect of cessation interventions 
that have been modified to address LGBT-specific issues, 
including providing information about the tobacco indus-
try’s targeting of LGBT communities, the role of tobacco 
use in LGBT social activities, LGBT-specific smoking trig-
gers, and social justice considerations (Berger and Mooney-
Somers 2016). Notably, a systematic review of 19 LGBT-
focused cessation interventions reported cessation rates of 
30–40% out to 3–6 months (Berger and Mooney-Somers 
2016). Although these results appear promising, none of 
the studies used adequate control groups, so a rigorous 
evaluation of efficacy was not possible.
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To more actively engage LGBT communities in 
smoking prevention and cessation, some national smoking 
cessation campaigns (e.g.,  Tips From Former Smokers 
[CDC]) have included multimedia promotional mate-
rials designed specifically for LGBT populations. In May 
2016, FDA launched This Free Life, a tobacco public edu-
cation campaign that aims to prevent the escalation to 
daily tobacco use among lesbian, gay, bisexual, and trans-
gender (LGBT) young adults, 18- to 24 years of age, who 
are nondaily or occasional smokers (FDA 2019b). This 
Free Life uses a range of primarily digital marketing tac-
tics, including social media and online advertisements, to 
deliver messages to diverse subpopulations of the LGBT 
community. Evaluations of the effect of these large-scale 
promotions are ongoing, but the data are not yet available. 
Populations with Mental Health 
Conditions and Co-Occurring 
Substance Use Disorders
Mental health conditions and substance use dis-
orders commonly co-occur with smoking. Adults with 
mental health or substance use disorders account for 40% 
of all cigarettes smoked (Substance Abuse and Mental 
Health Services Administration 2013). In 2012–2014, the 
prevalence of cigarette smoking was higher among adults 
with any mental illness than among adults with no mental 
illness (33.3% vs. 20.7%, respectively, p <.05) (Lipari and 
Van Horn 2017). Nationally representative data from 2017 
suggest that tobacco is used by 40.8% of individuals with 
serious psychological distress and 18.5 % of those without 
serious psychological distress (Wang et al. 2018). In 2013, 
65.2% of adult cigarette smokers also reported using 
alcohol (vs.  48.7% of nonsmoking adults), and 18.9% 
reported past-month use of other drugs (vs. 4.2% of non-
smoking adults) (Substance Abuse and Mental Health 
Services Administration n.d.). Behavioral health condi-
tions also affect smoking patterns in ways that can make 
quitting more difficult. For example, the average number 
of cigarettes smoked in the past month was higher among 
adult smokers with any mental illness (326) than among 
adult smokers with no mental illness (284) (Lipari and 
Van Horn 2017). 
The high prevalence of smoking among persons with 
mental illness is due in part to their lower rates of quit-
ting smoking over time (Prochaska et al. 2017). In addi-
tion, mental illness is associated with heavier smoking, 
greater nicotine dependence, more pronounced with-
drawal symptoms when quitting, and lower quit rates (Hall 
and Prochaska 2009). Although research on smoking and 
mental illness has increased markedly in recent years, 
cessation intervention studies on this population are still 
limited. A statistical analysis of the literature on tobacco and 
mental illness documented a steady increase in research 
publications in this area for three 2-year periods: 1993–1995 
(n = 65), 2003–2005 (n = 153), and 2013–2015 (n = 329) 
(Metse et al. 2017). However, the study designs remained 
predominantly descriptive in form (>80%), and few experi-
mental studies tested cessation interventions (<13%).
A meta-analysis of 26  tobacco intervention studies 
found that smoking cessation was significantly associated 
with decreases in anxiety, depression, and stress and with 
improvements in overall mood and quality of life (Taylor 
et al. 2014). Notably, the strength of these relationships did 
not vary based on the presence or absence of a psychiatric 
diagnosis. In trials of tobacco cessation interventions con-
ducted among smokers with psychiatric disorders, quitting 
smoking was associated with reductions in depression, anx-
iety, and symptoms of posttraumatic stress disorder and 
psychosis and with rapid changes in mood (Potkin et al. 
2003; McFall et al. 2010; Kahler et al. 2011; Krebs et al. 
2016). A meta-analysis that focused on smokers in treat-
ment for substance use disorders found that tobacco ces-
sation interventions were associated with a 25% increased 
likelihood of abstinence from alcohol and other drugs rel-
ative to usual care (Prochaska et al. 2004). A randomized 
trial of smokers recruited from inpatient psychiatric facili-
ties found that a tobacco cessation intervention was asso-
ciated with a significantly lower likelihood of readmission 
(Prochaska et al. 2004). In the past, many behavioral health 
clinicians believed that treating nicotine dependence and 
tobacco cessation jeopardize sobriety or mental health 
recovery (Baca and Yahne 2009), a misconception that has 
been actively fostered by the tobacco industry (Prochaska 
et al. 2008; Hall and Prochaska 2009). However, smoking 
cessation and the delivery of tobacco cessation treatments 
are associated with enhanced clinical outcomes, including 
improved sobriety, fewer symptoms of posttraumatic stress 
disorder, and lower rates of hospitalization.
Another RCT was conducted in 10 community 
mental health centers to determine whether smokers 
with schizophrenia or bipolar disease have higher rates of 
tobacco abstinence with pharmocotherapy than with stan-
dard treatment (Evins et al. 2014). There were 87 smokers 
with schizophrenia or bipolar disease who received 
12 weeks of varenicline and achieved 2 weeks or more of 
continuous abstinence by week  12 who were randomly 
assigned to receive cognitive behavioral therapy and vare-
nicline or placebo. At week 52, biochemically verified 7-day 
point-prevalence abstinence rates were 60% in the vareni-
cline group (24 of 40) versus 19% (9 of 47) in the placebo 
group (OR = 6.2; 95% CI, 2.2–19.2; P < .001). The authors 
concluded that among smokers with serious mental illness 
who attained initial abstinence with standard treatment, 
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maintenance pharmacotherapy with varenicline and cog-
nitive behavioral therapy improved prolonged tobacco 
abstinence rates compared with cognitive behavioral 
therapy alone after 1 year of treatment and at 6 months 
after treatment discontinuation (Evins et al. 2014).
Approaches to smoking cessation with demonstrated 
efficacy among smokers with mental illness or addictive 
disorders include motivational and stage-based treat-
ments and behavioral therapy that is offered outside of or 
integrated within mental health or addictions treatment, 
delivered in person or via a quitline, and combined with 
cessation pharmacotherapy (Hall and Prochaska 2009). 
The California Smokers’ Helpline reported that nearly 
1  in 4  of 844  smokers who called the helpline in 2007 
and were screened for depression, met criteria for a cur-
rent major depressive disorder and that quit rates at the 
2-month follow-up were lower in this group (19%) than 
among callers without depression (28%) (Hebert et  al. 
2011). More generally, the convenience and accessibility 
of quitlines make them an important option for clinician 
referrals among this population. Supplementary cessation 
services and treatments that can complement clinician 
and quitline interventions, such as in-person counseling 
and cessation medication, may further increase quit rates. 
A randomized trial of 577 mental health patients in the 
Veterans Health Administration found that a specialized 
quitline for smokers referred by a mental health provider 
outperformed standard state quitlines, with significantly 
greater 30-day abstinence at 6 months (26% vs. 18%) and 
greater patient satisfaction (Rogers et al. 2016).
A Cochrane Review of trials testing smoking cessa-
tion interventions that included specific mood manage-
ment components for depression versus a standard inter-
vention showed a significant positive effect for smokers 
with current depression (11 trials; N = 1,844; RR = 1.47; 
95% CI, 1.13–1.92) or past depression (13 trials; N = 1,496; 
RR = 1.41; 95% CI, 1.13–1.77) (van der Meer et al. 2013). 
The interventions largely followed a behavioral therapy 
approach, offering group or individual counseling ses-
sions. For example, the treatments encouraged partici-
pants to monitor their mood with a daily rating scale and 
to learn and apply skills to decrease negative moods and 
increase pleasant ones—such as by recognizing maladap-
tive thoughts, disputing negative thinking, engaging in 
pleasant activities, increasing positive social contacts, and 
setting realistic goals (Hall et al. 1994, 1996). 
Researchers have also tested the use of medications 
for mood management when quitting smoking. In  one 
systematic review, use of bupropion and nortriptyline, 
which are both antidepressants, resulted in a statistically 
significant increase in tobacco abstinence, irrespective of 
depression history, but selective serotonin reuptake inhib-
itors (e.g., fluoxetine, sertraline) and monoamine oxidase 
inhibitors (MAOIs) were not found to increase smoking 
cessation (Hughes et al. 2014). 
Postmarketing reports, which are mandated by 
FDA, have raised concerns that persons taking varenicline 
may experience increased intoxicating effects when con-
suming alcoholic beverages. However, these effects have 
not been observed in clinical trials. Instead, evidence sug-
gests that varenicline may aid in quitting smoking while 
also reducing drinking in men who drink excessively. 
A  double-blind RCT of 131  smokers (30% women) with 
alcohol use disorders found that varenicline with medical 
management resulted in an increased rate of smoking 
abstinence overall and in decreased heavy drinking among 
men (O’Malley et al. 2018). These findings are important 
in light of the high rate of comorbid smoking and heavy 
drinking, but more research is needed. 
In conclusion, individuals with behavioral health 
conditions smoke at a significantly higher rate than the 
general population and generally have a more difficult 
time quitting, despite being equally interested in quitting. 
However, evidence increasingly suggests that quitting 
smoking does not jeopardize the success of treatment for 
mental health conditions or substance abuse and may actu-
ally enhance recovery outcomes (McKelvey et  al. 2017). 
Additional research is needed on which tailored tobacco 
cessation interventions are most effective in helping per-
sons with behavioral health conditions quit smoking. 
Adolescents
Nearly 9  out of 10  smokers first try smoking by 
18 years of age, with 99% of smokers doing so by age 26 
(USDHHS 2012, 2014). Accordingly, tobacco use can be 
considered a pediatric disorder (USDHHS 2012). Other 
data suggest that initiating tobacco use at 13 years of age 
or younger is associated with continuous daily and non-
daily use during adolescence and with the development 
of nicotine dependence, compared with initiating tobacco 
use at 14 years of age and older (Sharapova et al. 2018). 
Once adolescents progress to established smoking, few of 
them attempt to quit, few quit successfully when trying on 
their own (7%), very few seek help quitting, and success 
rates are low—even among those who obtain help (12%) 
(Sussman et  al. 1999; USPSTF 2016). Estimates suggest 
that quitting smoking before 35 years of age prevents much 
of the harm from smoking (Doll et al. 2004; Jha et al. 2013; 
Pirie et al. 2013). However, the average age of quitting in 
the United States is approximately 40  years of age, and 
this age did not change significantly between 1997–98 and 
2011–12 (Schauer et  al. 2015a). Because most smokers 
start young and because quitting is difficult once smoking 
becomes established, efforts to prevent adolescents from 
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ever starting to smoke and to help adolescents who start 
smoking to quit as soon as possible are critical. 
The evidence for the effectiveness of cessation inter-
ventions targeting youth is mixed. A 2013 systematic review 
by USPSTF found stronger evidence for interventions by 
primary care providers to prevent youth smoking initia-
tion than for provider actions to help youth who already 
smoke quit. The review concluded that, while primary 
care-based behavioral interventions may prevent smoking 
initiation among youth, these interventions, alone or in 
combination with cessation medications (bupropion or 
bupropion plus NRT), have not been shown to increase 
rates of smoking cessation among youth (Patnode et  al. 
2013). The review included studies of smokeless tobacco 
cessation interventions and very brief advice, as well as 
limited print-based interventions. In a Cochrane Review 
of primary care- and school-based tobacco cessation inter-
ventions for young people, which had broader criteria for 
including trials, included smokers younger than 20 years 
of age, and pooled data from 28 controlled trials, Stanton 
and Grimshaw (2013) identified as “promising” those 
approaches that were based on the Stages of Change Model 
(pooled RR = 1.56 at 1 year; 95% CI, 1.21–2.01) or included 
motivational enhancement therapy (RR = 1.60; 95% CI, 
1.28–2.01). Only 3 of the 28  trials tested pharmacologic 
approaches, and those trials reported limited efficacy. 
Cessation medications are not approved by FDA 
for use with children or adolescents, and NRT cannot 
be purchased over-the-counter by persons younger than 
18 years of age (Johnson et al. 2004; Karpinski et al. 2010). 
However, cessation medications can be prescribed for and 
used by youth under the supervision of a physician. The 
Clinical Practice Guideline found insufficient evidence for 
the effectiveness of cessation medications in adolescents 
(Fiore et al. 2008). A study of 120 smokers 13–17 years of 
age found that the nicotine patch, but not nicotine gum, 
had a statistically significant effect on prolonging absti-
nence relative to placebo (Moolchan et  al. 2005). More 
explicit evidence-based recommendations are needed to 
guide clinicians and parents in weighing the potential 
benefits and risks of specific smoking cessation medica-
tions in adolescent patients (Federal Register 2018).
With regard to behavioral smoking cessation inter-
ventions for children and adolescents, a 2016 meta-
analysis of such interventions in primary care settings 
found a 34% increase in quit rates relative to control con-
ditions (RR = 1.34; 95% CI, 1.05–1.69), with an absolute 
effect of 7.98% for cessation and a number needed to treat 
of 13  (95%  CI, 6–77) (Peirson et  al. 2016). The review 
excluded studies of smokeless tobacco, brief counseling, 
print materials, and NRT. Of the four studies reviewed, the 
intervention with the strongest effect (a 24% reduction in 
smoking) was based on the Stages of Change Model and 
was personalized, computer assisted, and motivationally 
tailored (Hollis et al. 2005). Adolescents were recruited in 
a clinic setting, and the intervention lasted 12 months. The 
intervention focused solely on tobacco use (rather than 
addressing tobacco use in conjunction with additional risk 
behaviors) and included educational components (Hollis 
et  al. 2005). Further research is needed to identify and 
replicate best practices for tobacco cessation interven-
tions with adolescent smokers. However, recruitment is 
a major challenge to research on cessation among youth, 
in part because of parental consent and youth emancipa-
tion laws that are in place in most states. At this juncture, 
focusing on prevention efforts in youth (USDHHS 2012) is 
likely to yield the greatest impact in terms of reducing the 
prevalence of tobacco use in future generations. However, 
continued efforts are warranted to develop effective cessa-
tion treatments and interventions for young people who 
are already established cigarette smokers or established 
users of e-cigarettes or other tobacco products and who 
may already be addicted to nicotine. 
Dual Tobacco Product Users
Dual tobacco use, which is commonly defined as the 
use of cigarettes concurrently with other tobacco prod-
ucts (including e-cigarettes), has become increasingly 
common. Among current adult e-cigarette users in the 
2017 National Health Interview (NHIS) Survey, 49.6% 
were current smokers of conventional cigarettes (NHIS 
public use data 2017). Per data from NHIS, nearly 60% 
of adult e-cigarette users in 2015 were also current cig-
arette smokers, suggesting that dual use of e-cigarettes 
and cigarettes is a common pattern (CDC 2016). In fact, 
this was the most common product combination among 
adults who reported using two or more tobacco prod-
ucts. A study using data from the PATH Study found that 
more than one-third (37.8%) of adult tobacco users in 
2013–2014 were multiple-product (or polytobacco) users, 
with the most common combination being cigarettes 
plus e-cigarettes (Kasza et  al. 2017). Among the sample 
of youth (12–17 years of age) in the PATH Study, 43% of 
those using tobacco in the previous 30 days were multiple-
product users; again, cigarettes plus e-cigarettes was the 
most common combination, followed by cigarettes plus 
cigarillos. In the 2018 National Youth Tobacco Survey, 
the prevalence of multiple product use among current 
tobacco users of high school age was 37% for girls and 
45% for boys (Gentzke et  al. 2019). A  probability-based 
survey of 1,836  cigarette smokers found that concur-
rent use of cigarettes and alternative tobacco products 
(loose leaf chewing tobacco, moist snuff, snus, dissolv-
able tobacco, or e-cigarettes) was positively associated 
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with making cessation attempts and having intentions to 
quit but was not associated with quit success (Popova and 
Ling 2013). A larger study of quit attempts and interest in 
quitting among 26,000 smokers found no clear differences 
between cigarette-only use versus dual use of cigarettes 
and cigars or smokeless tobacco (Schauer et al. 2016b).
A few studies have compared quitting behaviors 
between adult cigarette-only users and dual users. In the 
2010–2011 Tobacco Use Supplement to the Current 
Population Survey, cigarette-only and dual users (defined 
as users of cigarettes plus cigars or smokeless tobacco) 
reported a comparable prevalence of attempts to quit 
cigarettes, with both groups making suboptimal use 
of evidence-based cessation treatments (Schauer et al. 
2016b). Other studies have suggested that many cigarette 
smokers who are trying to quit are using e-cigarettes as 
one method of quitting, as discussed previously in this 
chapter (Caraballo et al. 2017; Zhu et al. 2017). An online 
survey of 1,324 adults found that dual use of cigarettes 
with smokeless tobacco was associated with past attempts 
to quit smoking by switching to smokeless products, while 
dual use of cigarettes with e-cigarettes was associated with 
prior use of cessation medications and strong sentiment 
against the tobacco industry (Kalkhoran et al. 2015). 
Although at least one-third of tobacco users are dual 
users, most trials of tobacco treatments focus exclusively 
on cigarette smoking cessation and do not address ces-
sation interventions for other types of tobacco products. 
While noting that all tobacco products deliver toxicants 
and pose health risks, the 2014 Surgeon General’s report 
concluded that the overwhelming burden of death and dis-
ease from tobacco use in the United States is caused by cig-
arettes and other combustible tobacco products (USDHHS 
2014). The report also acknowledged that the recent shift 
in patterns of tobacco use could have several potential 
impacts, ranging from the positive effect of accelerating 
the rate at which smokers completely quit smoking ciga-
rettes to the negative effect of delaying complete cessation 
of all tobacco products, especially cigarettes. Despite the 
general acceptance of a continuum of risk across tobacco 
products (USDHHS 2014), the specific risk posed by each 
class of tobacco products has not been established and is 
difficult to estimate with precision because of the wide 
spectrum of products within each product class and the 
differences in how they are used. 
Although the use of noncombustible tobacco prod-
ucts does not expose users to the same mix of toxicants 
via the same mode of administration as cigarette smoking, 
all tobacco products carry inherent risks. Risks for dual 
users may be particularly harmful if they delay cessation 
from combustible tobacco (USDHHS 2014, 2016). For 
example, smokeless tobacco has been shown to cause can-
cers of the mouth, esophagus, and pancreas; diseases of 
the mouth; and adverse reproductive outcomes (WHO 
and International Agency for Research on Cancer 2007; 
USDHHS 2014; NCI and CDC 2014). E-cigarettes emit 
fewer and lower levels of certain harmful substances than 
conventional cigarettes, but the long-term health risks 
of using these products remain unknown, and short-
term risks are only slowly coming into focus. Several 
studies demonstrate e-cigarette aerosol contains fine and 
ultrafine particles, such that use of the products could 
potentially increase cardiovascular and respiratory risks 
(USDHHS 2016; Alzahrani et al. 2018; Nabavizadeh et al. 
2018; National Academies of Sciences, Engineering, and 
Medicine 2018; Gotts et  al. 2019). Therefore, only com-
plete cessation of all tobacco products fully eliminates all 
tobacco-related health risks. Nevertheless, based on cur-
rently available evidence, nonpregnant adults would be 
expected to reduce their risk of smoking-attributable dis-
ease and death if they completely substituted all combus-
tible tobacco products with noncombustible tobacco prod-
ucts. Whether these products will realize the potential of 
harm reduction depends in part on how their use affects 
smokers’ attempts to quit cigarettes—either by switching 
completely to a noncombustible tobacco product or by dis-
continuing all tobacco use—combined with their impact 
on youth uptake of e-cigarettes and other tobacco products.
The Clinical Practice Guideline called for more 
research on effective cessation medications and counseling 
interventions for persons who are dual users of cigarettes 
and smokeless tobacco (Fiore et  al. 2008), but research 
in this area remains sparse more than 10 years after the 
Guideline was released. In one study, an interactive, tai-
lored, web-based intervention for smokeless tobacco use 
was found to significantly increase (nearly double) the like-
lihood of participants abstaining from all tobacco products 
(Severson et al. 2008). Another study examined the impact 
of a 40-minute, single contact, tobacco cessation interven-
tion among 1,055 airmen enrolled in technical training in 
the U.S. Air Force (USAF) (Little et al. 2016). The USAF 
intervention addressed cigarettes, smokeless tobacco, 
snus, cigars, cigarillos, pipes, e-cigarettes, “roll your own” 
cigarettes, and hookah. From before the training to imme-
diately after the training, perceptions of harm increased 
for all nine tobacco products among both tobacco users 
and nonusers, but intention to consume tobacco prod-
ucts was reduced mainly among existing tobacco users. 
Behavioral outcomes were not assessed, given the short 
assessment window (Little et al. 2016).
Much remains to be learned about best practices 
for achieving and sustaining abstinence from all tobacco 
products among dual users. Although few interventions 
have been studied for cessation from all tobacco prod-
ucts, some cessation medications (bupropion, vareni-
cline, NRT) have been found to be effective for cessation 
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from cigarettes and smokeless products (independently) 
(Ebbert et  al. 2007; Fagerström et al. 2010; Cahill et  al. 
2016; Schwartz et al. 2016; Hartmann-Boyce et al. 2018). 
Such medications could be candidates for tobacco ces-
sation efforts among dual users of those two products. 
More also needs to be learned about (a)  the degree to 
which e-cigarettes may promote or impede efforts to quit 
smoking and (b)  the relative health benefits or harms 
from cessation of one tobacco product, but not all tobacco 
products, among dual or multiple tobacco product users.
Light and Nondaily Tobacco Users
The prevalence of daily smoking has decreased over 
the past two decades, but the proportion of light cigarette 
smoking (usually defined as 10 or fewer cigarettes smoked 
per day) has generally increased (Pierce et al. 2009; Jamal 
et al. 2018) and the prevalence of nondaily smoking has 
been generally stable (Schauer et al. 2016a). For example, 
among current U.S. smokers, the proportion of daily 
smokers was 76.1% in 2016, which declined from 80.8% 
in 2005 (p trend <0.05) (Jamal et al. 2018). During 2005–
2016, increases occurred in the proportion of daily smokers 
who smoked 1–9 cigarettes per day (16.4% to 25.0%) or 
10–19 (36.0% to 39.0%) cigarettes per day, and decreases 
occurred in the proportion of daily smokers who smoked 
20–29 (34.9% to 28.4%) or ≥30 (12.7% to 7.5%) cigarettes 
per day (p trend <0.05) (Jamal et al. 2018). Nationally repre-
sentative data from 2015 indicate that 24.3% of all smokers 
were nondaily smokers, and 25.1% of current daily smokers 
were light smokers (defined in this study as smoking 
1–9 cigarettes per day) (Jamal et al. 2016). Nondaily smokers 
often do not consider themselves to be smokers; up to 42% 
classify themselves as nonsmokers when asked (Fergusson 
and Horwood 1995). Consequently, nondaily smoking is 
under-recognized by clinicians (Schane et al. 2009), which 
might result in their being less likely to deliver cessation 
interventions to this group of smokers. Studies have also 
pointed to potential challenges in motivating light and 
nondaily smokers to quit, given they are more likely to 
concurrently use other tobacco products than are heavier 
smokers (Reyes-Guzman et al. 2016). On the other hand, 
some studies have found that nondaily smokers report 
greater intention to quit and are more likely to succeed 
in quitting than daily smokers (Hennrikus et  al. 1996; 
Sargent et al. 1998). Whereas daily smokers’ intentions to 
quit may be driven in part by their level of nicotine depen-
dence, nondaily smokers’ intentions to quit may be more 
related to situational cues and sociodemographic charac-
teristics (Fagan et al. 2007; Shiffman et al. 2014).
Most tobacco cessation interventions target daily 
heavy smokers (Fiore et  al. 2008). However, cessation 
interventions are also critically important for nondaily 
and light smokers, but cessation approaches for these 
populations may require a new treatment paradigm 
(Hassmiller et al. 2003; Wortley et al. 2003). The Clinical 
Practice Guideline concluded that there was insufficient 
evidence for the effectiveness of using cessation medica-
tions in persons who smoke fewer than 5–10 cigarettes per 
day (Fiore et al. 2008). A review by Lindson and colleagues 
(2019) identified few studies on the role of NRT for per-
sons smoking fewer than 15 cigarettes per day.
Furthermore, preliminary data suggest that stan-
dard cessation counseling that focuses on calling atten-
tion to personal health risks may not motivate nondaily 
or light smokers to quit, in part because they may believe 
that they have already minimized their health risks by 
using tobacco less intensively (Hyland et  al. 2005; Tong 
et  al. 2006). Despite these beliefs, studies indicate that 
light and nondaily smoking significantly increases risk 
for tobacco-related disease, especially cardiovascular and 
respiratory harms (Luoto et  al. 2000; Hackshaw et  al. 
2018; Kameyama et  al. 2018) and all-cause mortality 
(Inoue-Choi et al. 2017; Løchen et al. 2017). Moreover, the 
dose-response relationship between cigarette consump-
tion and cardiovascular risk is not linear (USDHHS 2010).
Studies testing the impact of messages about the 
health harms associated with cigarette smoking gener-
ally have not focused on specific tobacco-related harms 
that are relevant to light and nondaily smoking. Messages 
about these effects could be more impactful for these 
groups of smokers, both clinically and at a population 
level, and should continue to be studied.
Data from observational and pilot studies of treat-
ments suggest that counseling nondaily smokers on the 
dangers that their secondhand smoke poses to others could 
also be an effective approach for motivating them to quit 
(Tong et al. 2006; Schane and Glantz 2008; Schane et al. 
2013). In the 1970s, research conducted by the tobacco 
industry concluded that social, infrequent, or nondaily 
smokers felt immune to the personal health effects of 
tobacco use but were concerned about the effects that 
their secondhand smoke might have on others (Schane 
et al. 2009).
Although further research on cessation interven-
tions for nondaily smokers is needed, emerging evidence 
suggests that educating nondaily smokers about the dan-
gers that secondhand smoke poses to nonsmokers is a pow-
erful cessation message and may be more effective than 
traditional smoking cessation counseling that emphasizes 
the health consequences for the smoker (Schane et  al. 
2013). In addition, improved clinical identification of light 
and nondaily smokers is needed to help clinicians target 
these groups with strong messages emphasizing that no 
level of smoking is safe. 
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Emerging Behavioral Treatments
In considering potential future directions for behav-
ioral smoking cessation treatments, a wide variety of pos-
sible strategies exist to increase their reach while main-
taining or improving their efficacy, thus increasing their 
impact. Two innovative approaches are (1) the expansion 
of treatment targets and (2) the use of emerging technolo-
gies to better time and personalize the delivery of behav-
ioral cessation interventions.
Expanding Behavioral Treatment Targets
Although behavioral therapy is well established as 
the mainstay of most empirically based behavioral cessa-
tion interventions, applying constructs from other psy-
chological theories could potentially enhance the efficacy 
of these interventions. Two examples are (1)  treatments 
drawn from self-determination theory (SDT) (Ryan and 
Deci 2000; Ng et al. 2012) and (2) comprehensive, inten-
sive group treatment for nicotine dependence (Hajek et al. 
1999; Foulds et al. 2006; Hall and Prochaska 2009; Hall 
et al. 2011; Kotsen et al. 2017). 
SDT postulates that a necessary condition for sus-
tained change in health behavior is satisfaction of the basic 
psychological needs that a person has for autonomy, com-
petence, and relatedness (Williams et  al. 2016). Persons 
will be more motivated to change their behaviors and per-
ceive themselves as more capable of successfully changing 
their behaviors in social contexts that support these needs 
(Ng et al. 2012). SDT-based interventions target adaptive 
and maladaptive behaviors and motivations for behav-
ioral change. SDT-based treatments focus on shifting a 
patient’s motivation for behavior change from the external 
(e.g.,  because others want the patient to change) to the 
internal (e.g.,  the patient wants to change because it is 
consistent with his or her personal values). SDT involves 
working with clients to better align their motivations and 
behaviors to enhance motivation that supports sustained 
behavioral change (Ryan et al. 2008). SDT-based interven-
tions have demonstrated efficacy in a variety of contexts 
and populations, including among persons attempting 
to achieve long-term changes in health behavior, such as 
quitting smoking, losing weight, and engaging in physical 
activity (Williams et al. 2002, 2006a,b, 2009, 2011, 2016; 
Pesis-Katz et al. 2011; Teixeira et al. 2015). 
Although not a new concept, intensive comprehen-
sive tobacco use treatment at the group level likely brings to 
bear unique cessation mechanisms that have consistently 
led to high quit rates. Such treatment is professionally led 
and addresses key mechanisms of behavior change, such 
as group interactions, intergroup discussions between 
smokers, development of cohesion among group mem-
bers, and support for interventions that are unique to 
this cessation format (Hajek et  al. 1985, 1989; Yalom 
and Leszcz 2005; Kotsen et  al. 2017). Professionally led, 
group-based treatment has been a standard of care in all 
programs designed to treat other types of addictions, and 
has been shown to yield high rates of satisfaction and posi-
tive experiences for smokers (Dobbie et al. 2015). For more 
than two decades, these group smoking cessation interven-
tions have shown robust feasibility, acceptability, and effi-
cacy in a range of research and practice settings (Connett 
et  al. 1993; Foulds et  al. 2006; Hall et  al. 2009; Dobbie 
et  al. 2015; Kotsen et  al. 2017; Public Health England 
September 2017), to the point that they can be applied in 
all healthcare settings (including primary and specialty 
care) and behavioral healthcare settings. However, group 
interventions have traditionally been limited by their 
reach, because having to travel to an in-person meeting 
at a set meeting time can be a barrier for many smokers, 
particularly those with lower incomes. Future research 
could explore whether combining medication with inten-
sive group smoking cessation treatment led by a tobacco 
treatment specialist is feasible in a virtual telemedicine, 
telehealth, or other technology-based format, which could 
broaden the reach and availability of this approach.
Use of Emerging Technology
Given the dynamic, quickly evolving nature of the 
personal technology modalities used in mHealth, it is 
challenging to predict future developments in this area. 
More sophisticated applications are being developed 
that involve context-dependent, adaptive interventions 
and that are tailored to the needs of each individual. For 
example, just-in-time interventions are designed to pre-
vent relapse when a smoker is at greatest risk, including 
using sensors (e.g., through GPS monitoring) that track 
a person’s location and trigger support when the person 
enters a high-risk environment (e.g., when the person 
approaches a tobacco retailer) (Naughton 2016). Such 
innovations may lead to interventions that improve cessa-
tion outcomes in ways that could not have been achieved 
without such technology. Furthermore, the commercial-
ization of smoking cessation interventions delivered by a 
variety of mobile applications may lead to some promising 
approaches. However, the proliferation of these applica-
tions has far surpassed the capacity for the scientific eval-
uation of their content and effectiveness—thus, raising 
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concerns about their effectiveness and about how these 
interventions adhere to evidence-based recommendations 
for cessation (Abroms et al. 2013).
Ongoing smoking cessation research is exploring 
the utility of two specific approaches that do not rely 
on a particular technology platform. The first approach 
involves improving both the personalization of mHealth 
platforms and engagement with these platforms via 
the use of human-technology interactions that mimic 
human–human interactions. Basic versions, which are 
already widely used in commercial settings for other pur-
poses, include voice phone trees and web pop-ups that 
are designed to help triage the caller or website user to 
the appropriate customer service representative or sales-
person. More complex versions help consumers make deci-
sions about which product to buy in a manner that struc-
tures the interaction as a conversation (commonly called 
“chatbots”). Future mHealth cessation interventions may 
leverage these structured human-technology interactions 
to deliver highly personalized, real-time cessation support. 
A second strategy involves integrating treatment 
data from multiple sources so that the person delivering 
the cessation intervention and the smoker have access 
to a broader array of information and treatment options 
across multiple contexts. One example is integrating data 
from a quitline’s database with a cessation application on 
a caller’s smartphone. Although many cessation treatment 
approaches, such as quitlines, employ mHealth resources, 
integration across multiple platforms is rare. As with inte-
gration across treatment resources, the wide availability 
of electronic health records has created the possibility 
for increased connectivity between healthcare providers 
engaged in cessation treatment (see Chapter 7).
A large number (>500) of smartphone apps for quit-
ting smoking have been developed, and these apps have 
generated great interest (>20 million downloads glob-
ally) (Bricker et al. 2014b). These apps include interactive 
features, present content in various formats, and collect 
information that the smartphone then exchanges with 
external databases. Apps have many characteristics that 
can be leveraged to deliver behavioral treatment and to 
improve adherence to medication. Although reviews have 
identified some high-quality cessation apps, many ces-
sation apps lack appropriate, empirically based clinical 
approaches that are consistent with cessation guidelines 
(Abroms et al. 2011, 2013; Choi et al. 2014; Hoeppner et al. 
2016; Ubhi et al. 2016). As with SMS text programs, there 
is wide variability in content, functionality, and user expe-
rience across even those apps that use empirically based 
cessation treatment approaches, which makes evaluating 
their utility difficult.
Social media sites are visited by 80% of U.S. adults 
who have access to the Internet, and most of these adults 
visit such sites daily (Greenwood et al. 2016). Research into 
the potential utility of social media platforms for deliv-
ering and supporting cessation treatment is in its early 
stages. One logical and promising strategy is to leverage 
social media’s potential for facilitating self-help groups. 
This potential has not been fully realized to date because, 
as with such previous technologies as online bulletin 
boards and listservs, prolonged engagement is often poor, 
with initially high levels of interest often waning over time 
(Danaher et al. 2006; An et al. 2008; Stoddard et al. 2008; 
Prochaska et al. 2012). In one example of an emerging ces-
sation intervention, Twitter is being used to create small, 
private groups of 20 smokers who interact for 100 days, 
with twice-daily automessages sent to encourage group 
engagement among members (Lakon et  al. 2016). The 
intervention builds on successful past work with “buddy 
interventions” in which smokers were assigned physically 
proximal “buddies” who were also trying to quit (West et al. 
1998; May and West 2000; May et al. 2006). Preliminary 
results for the Twitter intervention indicate that partici-
pants in quit-smoking groups often form mutually recip-
rocated, strong, and enduring social bonds that support 
smoking cessation (Lakon et al. 2016).
In another intervention, which was assessed in an RCT 
pilot, all 160 participants were linked to Smokefree.gov and 
provided with nicotine patches. A subgroup of these par-
ticipants was randomized to participate in a quit-smoking 
group on Twitter; the study found that they were twice as 
likely to report sustained abstinence as those who used the 
website and patch alone (40% vs. 20%, OR = 2.67; 95% CI, 
1.19–5.99) (Pechmann et  al. 2017). Similar efforts are 
underway to leverage Facebook and WhatsApp to engage 
young adults in cessation treatment. Cessation interven-
tions leveraging these social media platforms have shown 
encouraging short-term effects (Cobb et al. 2014; Cheung 
et  al. 2015; Haines-Saah et  al. 2015; Ramo et  al. 2015; 
Baskerville et al. 2016).
Emerging Pharmacologic 
Approaches
Cytisine, which is not currently approved for use 
in the United States, was first used for quitting smoking 
more than 50 years ago in Eastern and Central Europe, 
well before the approval of any smoking cessation aids in 
the United States. A plant alkaloid with high affinity for 
the α4β2 nicotinic acetylcholine receptor subtype, cytisine 
is derived from the plant Cytisus laburnum. The course of 
treatment starts at one tablet every 2  hours (maximum 
of six tablets total per day) for days  1–3, with a sched-
uled quit date at day 5, tapered to one or two tablets daily 
by days 21–25 (Jeong et al. 2015). In meta-analyses, the 
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treatment effect of cytisine was comparable to published 
effects for NRT, bupropion, nortriptyline, and clonidine 
(Hajek et al. 2013a). Two randomized placebo-controlled 
trials also found that cytisine was effective for smoking 
cessation (pooled effect: RR  =  3.98; 95%  CI, 2.01–7.87) 
(Vinnikov et  al. 2008; West et  al. 2011), as reviewed by 
Cahill and colleagues (2016), but the quality of evidence 
from the reviewed trials was low, in part because of small 
sample sizes and loss to follow-up. Furthermore, the abso-
lute sustained long-term quit rates were modest (8.5% for 
cytisine vs. 2.1% for placebo at 1 year), which is generally 
consistent with cessation rates in the United States (Babb 
et al. 2017; Wang et al. 2019). The modest sustained quit 
rates were attributed to the minimal behavioral support 
provided and to the study locations, which included coun-
tries with more limited tobacco control policies than the 
United States. In an open-label, randomized comparative 
effectiveness trial conducted in New Zealand, Walker and 
colleagues (2014) reported 22% sustained abstinence for 
cytisine at the 6-month follow-up compared with 15% for 
the nicotine patch (RR = 1.4; 95% CI, 1.1–1.8).
The reported side effects of cytisine are primarily gas-
trointestinal, including abdominal discomfort, dry mouth, 
dyspepsia, and nausea. Notably, the cost of cytisine in places 
where it is available has increased, but it is still one-half to 
one-twentieth the cost of other cessation medications. 
In February 2019, the FDA Center for Drug 
Evaluation and Research (2019) issued a draft version of 
guidance intended to assist sponsors in the clinical devel-
opment of NRT drug products, including but not limited to 
products intended to help cigarette smokers stop smoking. 
This guidance incorporates feedback received from an 
FDA public hearing in January 2018 and from a notice in 
the Federal Register in November 2017 requesting com-
ments on the FDA’s approach to evaluating the safety and 
effectiveness of NRT products, including how these prod-
ucts should be used and labeled (Federal Register 2017; 
FDA 2019a). 
Summary of the Evidence
The prevalence of cigarette smoking in the gen-
eral U.S. population has declined steadily since the 1960s 
(USDHHS 2014), due in part to the development and con-
certed implementation of evidence-based tobacco control 
interventions, including cessation interventions. Since 
2002 the number of former smokers has been greater than 
the number of current smokers (CDC 2005). However, as 
of 2017, there were still 34  million adult current ciga-
rette smokers in the United States (Wang et al. 2018). This 
chapter highlighted key topics and developments associ-
ated with the content and delivery of smoking cessation 
interventions, with a focus on emerging evidence that can 
inform future smoking cessation efforts. 
The evidence indicates that nicotine addiction is a 
chronic, relapsing disorder and that the chances of suc-
cessfully sustaining a quit attempt and avoiding relapse 
increase with the use of evidence-based cessation treat-
ments, with those chances generally increasing with 
higher dose, duration, and intensity of treatment. A large 
number of high-quality studies continues to support 
the use of behavioral counseling, pharmacologic inter-
ventions, and combined counseling and pharmacologic 
interventions for smoking cessation, with the latter com-
bination being the most effective approach. Effective coun-
seling interventions include diverse behavioral treatments 
that can be delivered effectively in a variety of formats, 
including individual, group, and telephone counseling. 
There are currently seven FDA-approved medications for 
use as first-line tobacco cessation treatments. Although 
the products are not approved for combination use, there 
is clear scientific evidence that combinations of short- 
and long-acting forms of NRT are more effective in pro-
moting cessation than individual forms of NRT (Lindson 
et al. 2019). Both behavioral and pharmacologic tobacco 
cessation treatments have been shown to be highly cost-
effective (see Chapter 5).
Nationally representative data indicate that about 
three in five U.S. adults who ever smoked have quit suc-
cessfully and that just over half of current smokers try to 
quit each year, but the success of any given quit attempt 
remains low (Babb et al. 2017). Despite progress over the 
past 30 years, the reach and use of smoking cessation inter-
ventions remain low, with less than one-third of smokers 
using any proven cessation treatments (counseling 
and/or medication) from 2000 to 2015 (Babb et al. 2017). 
Regardless of the generally wide availability of proven cessa-
tion treatments, about two-thirds of smokers still attempt 
to quit without using these treatments, contributing to 
low rates of success (Hughes et al. 2004; Fiore et al. 2008).
Increasing smoking cessation will require several 
strategies, including (1) increasing the appeal, reach, and 
use of existing evidence-based cessation interventions; 
(2) further increasing the effectiveness of those interven-
tions; and (3)  developing additional cessation interven-
tions that have greater reach and/or effectiveness than 
existing interventions or that appeal to and are used by 
different populations of smokers. Increasing cessation 
at the population level will also require increasing quit 
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attempts (including the number of smokers making quit 
attempts and the number of quit attempts that individual 
smokers make) and quit success, with quit attempts being 
driven primarily by the reach of cessation interventions 
and quit success being driven primarily by the intensity of 
these interventions (Zhu et al. 2012).
Additional research is needed to better under-
stand (a)  how e-cigarette use impacts smoking cessa-
tion, including determining which types of e-cigarettes 
and which patterns and contexts of e-cigarette use may 
facilitate or hinder smoking cessation among adults, and 
(b) the negative impacts of e-cigarette use (e.g., increases 
in youth initiation of e-cigarettes, conventional cigarettes, 
and other tobacco products; dual use of e-cigarettes and 
other combusted tobacco products; decreased use of 
evidence-based cessation treatments; and decreased or 
delayed complete cessation of conventional cigarettes and 
other combustible tobacco products). The research will 
need to track the changes in products over time.
Promising directions include leveraging emerging 
technologies to enhance the sustained engagement of 
smokers in cessation treatment, accelerating the integra-
tion of cessation services across multiple platforms and 
within healthcare systems, and developing new tobacco 
cessation medications and new indications for existing ces-
sation medications. Although this chapter focuses on ces-
sation interventions at the individual level, several popula-
tion- and policy-based approaches (discussed in Chapter 7) 
have also been found to be effective in increasing tobacco 
cessation. Many of these broader approaches can be lever-
aged to complement and further increase the use of the 
cessation treatments described in this chapter.
Conclusions
1. The evidence is sufficient to infer that behavioral 
counseling and cessation medication interventions 
increase smoking cessation compared with self-help 
materials or no treatment. 
2. The evidence is sufficient to infer that behavioral 
counseling and cessation medications are indepen-
dently effective in increasing smoking cessation, 
and even more effective when used in combination.
3. The evidence is sufficient to infer that proactive quit-
line counseling, when provided alone or in combina-
tion with cessation medications, increases smoking 
cessation.
4. The evidence is sufficient to infer that short text 
message services about cessation are independently 
effective in increasing smoking cessation, particu-
larly if they are interactive or tailored to individual 
text responses.
5. The evidence is sufficient to infer that web or Internet-
based interventions increase smoking cessation and 
can be more effective when they contain behavior 
change techniques and interactive components.
6. The evidence is inadequate to infer that smartphone 
apps for smoking cessation are independently effec-
tive in increasing smoking cessation.
7. The evidence is sufficient to infer that combining 
short- and long-acting forms of nicotine replacement 
therapy increases smoking cessation compared with 
using single forms of nicotine replacement therapy.
8. The evidence is suggestive but not sufficient to infer 
that pre-loading (e.g.,  initiating cessation medica-
tion in advance of a quit attempt), especially with 
the nicotine patch, can increase smoking cessation.
9. The evidence is suggestive but not sufficient to infer 
that very-low-nicotine-content cigarettes can reduce 
smoking and nicotine dependence and increase 
smoking cessation when full-nicotine cigarettes are 
readily available; the effects on cessation may be fur-
ther strengthened in an environment in which con-
ventional cigarettes and other combustible tobacco 
products are not readily available.
10. The evidence is inadequate to infer that e-cigarettes, 
in general, increase smoking cessation. However, 
the evidence is suggestive but not sufficient to infer 
that the use of e-cigarettes containing nicotine is 
associated with increased smoking cessation com-
pared with the use of e-cigarettes not containing 
nicotine, and the evidence is suggestive but not suf-
ficient to infer that more frequent use of e-cigarettes 
is associated with increased smoking cessation com-
pared with less frequent use of e-cigarettes.
11. The evidence is sufficient to infer that certain life 
events—including hospitalization, surgery, and 
lung cancer screening—can trigger attempts to quit 
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smoking, uptake of smoking cessation treatment, 
and smoking cessation.
12. The evidence is suggestive but not sufficient to infer 
that fully and consistently integrating standardized, 
evidence-based smoking cessation interventions 
into lung cancer screening increases smoking ces-
sation while avoiding potential adverse effects of this 
screening on cessation outcomes.
13. The evidence is suggestive but not sufficient to infer 
that cytisine increases smoking cessation.
Interventions for Smoking Cessation and Treatments for Nicotine Dependence  549
Smoking Cessation
Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, 
Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, 
Sicks JD. Reduced lung-cancer mortality with low-
dose computed tomographic screening. New England 
Journal of Medicine 2011;365(5):395–409.
Abroms LC, Lee Westmaas J, Bontemps-Jones J, Ramani 
R, Mellerson J. A content analysis of popular smart-
phone apps for smoking cessation. American Journal 
of Preventive Medicine 2013;45(6):732–6.
Abroms LC, Padmanabhan N, Thaweethai L, Phillips T. 
iPhone apps for smoking cessation: a content anal-
ysis. American Journal of Preventive Medicine 
2011;40(3):279–85.
Adkison SE, O’Connor RJ, Bansal-Travers M, Hyland 
A, Borland R, Yong HH, Cummings KM, McNeill A, 
Thrasher JF, Hammond D, et al. Electronic nico-
tine delivery systems: international tobacco control 
four-country survey. American Journal of Preventive 
Medicine 2013;44(3):207–15.
Adriaens K, Van Gucht D, Declerck P, Baeyens F. 
Effectiveness of the electronic cigarette: An eight-week 
Flemish study with six-month follow-up on smoking 
reduction, craving and experienced benefits and com-
plaints. International Journal of Environmental 
Research and Public Health 2014;11(11):11220–48.
Adsit RT, Fox BM, Tsiolis T, Ogland C, Simerson M, Vind 
LM, Bell SM, Skora AD, Baker TB, Fiore MC. Using 
the electronic health record to connect primary care 
patients to evidence-based telephonic tobacco quit-
line services: a closed-loop demonstration project. 
Translational Behavioral Medicine 2014;4(3):324–32.
Agaku IT, King BA, Husten CG, Bunnell R, Ambrose BK, 
Hu SS, Holder-Hayes E, Day HR. Tobacco product use 
among adults—United States, 2012–2013. Morbidity 
and Mortality Weekly Report 2014;63(25):542–7.
Agboola S, McNeill A, Coleman T, Leonardi Bee J. A system-
atic review of the effectiveness of smoking relapse pre-
vention interventions for abstinent smokers. Addiction 
2010;105(8):1362–80.
Agency for Healthcare Research and Quality. Patients 
not ready to make a quit attempt now (The “5 R’s”). 
Rockville (MD): Agency for Healthcare Research and 
Quality, 2012; <http://www.ahrq.gov/professionals/
clinicians-providers/guidelines-recommendations/
tobacco/5rs.html. >; accessed: January 14, 2019.
Ainscough TS, Brose LS, Strang J, McNeill A. Contingency 
management for tobacco smoking during opioid 
addiction treatment: a randomised pilot study. BMJ 
Open 2017;7(9):e017467.
Al-Delaimy WK, Myers MG, Leas EC, Strong DR, Hofstetter 
CR. E-cigarette use in the past and quitting behavior in 
the future: a population-based study. American Journal 
of Public Health 2015;105(6):1213–9.
Allen MH, Debanné M, Lazignac C, Adam E, Dickinson 
LM, Damsa C. Effect of nicotine replacement therapy 
on agitation in smokers with schizophrenia: a double-
blind, randomized, placebo-controlled study. American 
Journal of Psychiatry 2011;168(4):395–9.
Alpert HR, Connolly GN, Biener L. A prospective cohort 
study challenging the effectiveness of population-based 
medical intervention for smoking cessation. Tobacco 
Control 2013;22(1):32–7.
Alzahrani T, Glantz SA. The association between e-cigarette 
use and myocardial infarction is what one would expect 
based on the biological and clinical evidence. American 
Journal of Preventive Medicine 2019;56(4):627.
Alzahrani T, Pena I, Temesgen N, Glantz SA. Association 
between electronic cigarette use and myocardial 
infarction. American Journal of Preventive Medicine 
2018;55(4):455–61.
American College of Surgeons. Statement on the effects of 
tobacco use on surgical complications and the utility of 
smoking cessation counseling, August 1, 2014; <https://
www.facs.org/about-acs/statements/71-tobacco-use>; 
accessed: February 13, 2018.
An LC, Bluhm JH, Foldes SS, Alesci NL, Klatt CM, Center 
BA, Nersesian WS, Larson ME, Ahluwalia JS, Manley MW. 
A randomized trial of a pay-for-performance program 
targeting clinician referral to a state tobacco quitline. 
Archives of Internal Medicine 2008;168(18):1993–9.
An LC, Schillo BA, Kavanaugh AM, Lachter RB, Luxenberg 
MG, Wendling AH, Joseph AM. Increased reach and 
effectiveness of a statewide tobacco quitline after the 
addition of access to free nicotine replacement therapy. 
Tobacco Control 2006;15(4):286–93.
Anderson CM. Quitline Services: Current Practice and 
Evidence Base. Phoenix (AZ): North American Quitline 
Consortium, 2016; <http://c.ymcdn.com/sites/www.
naquitline.org/resource/resmgr/issue_papers/Quitline_
Services_issue_pape.pdf>; accessed: May 24, 2017.
Anguiano B, Brown-Johnson C, Rosas LG, Pechmann C, 
Prochaska JJ. Latino adults’ perspectives on treating 
tobacco use via social media. JMIR Mhealth and Uhealth 
2017;5(2):e12.
References1
1For reference entries that contain URLs, those URLs were active on the access date presented in the respective reference entry.
A Report of the Surgeon General
550  Chapter 6
Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae 
T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE. 
Neuropsychiatric safety and efficacy of varenicline, 
bupropion, and nicotine patch in smokers with and 
without psychiatric disorders (EAGLES): a double-
blind, randomised, placebo-controlled clinical trial. 
Lancet 2016;387(10037):2507–20.
Anthenelli RM, Morris C, Ramey TS, Dubrava SJ, Tsilkos 
K, Russ C, Yunis C. Effects of varenicline on smoking 
cessation in adults with stably treated current or 
past major depression: a randomized trial. Annals of 
Internal Medicine 2013;159(6):390–400.
Applegate BW, Sheffer CE, Crews KM, Payne TJ, Smith 
PO. A survey of tobacco-related knowledge, atti-
tudes and behaviours of primary care providers in 
Mississippi. Journal of Evaluation in Clinical Practice 
2008;14(4):537–44.
Aronson SJ, Rehm HL. Building the foundation for genomics 
in precision medicine. Nature 2015;526(7573):336–42.
Ashare RL, Tang KZ, Mesaros AC, Blair IA, Leone F, Strasser 
AA. Effects of 21 days of varenicline versus placebo on 
smoking behaviors and urges among non-treatment 
seeking smokers. Journal of Psychopharmacology 
2012;26(10):1383–90.
Asian Smokers’ Quitline. Home page, n.d.; <http://www.
asiansmokersquitline.org>; accessed: August 17, 2017.
Atienza AA, Patrick K. Mobile health: the killer app for cyber-
infrastructure and consumer health. American Journal 
of Preventive Medicine 2011;40(5 Suppl 2):S151–S153.
Aubin HJ, Luquiens A, Berlin I. Pharmacotherapy 
for smoking cessation: pharmacological princi-
ples and clinical practice. British Journal of Clinical 
Pharmacology 2014;77(2):324–36.
Augustine JM, Taylor AM, Pelger M, Schiefer D, Warholak 
TL. Smoking quit rates among patients receiving phar-
macist-provided pharmacotherapy and telephonic 
smoking cessation counseling. Journal of the American 
Pharmacists Association 2016;56(2):129–36.
Babb S, Malarcher A, Schauer G, Asman K, Jamal A. 
Quitting smoking among adults—United States, 
2000–2015. Morbidity and Mortality Weekly Report 
2017;65(52):1457–64.
Baca CT, Yahne CE. Smoking cessation during substance 
abuse treatment: what you need to know. Journal of 
Substance Abuse Treatment 2009;36(2):205–19.
Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, 
Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, et 
al. Benefits and harms of CT screening for lung cancer: 
a systematic review. JAMA: the Journal of the American 
Medical Association 2012;307(22):2418–29.
Baezconde-Garbanati L, Guy M, Soto C. The Use of 
Quitlines Among Priority Populations in the U.S.: 
Lessons from the Scientific Evidence. Oakland (CA): 
North American Quitline Consortium, 2011; <https://
cdn.ymaws.com/www.naquitline.org/resource/resmgr/
Issue_Papers/IssuePaperTheUseofQuitlinesA.pdf>; 
accessed: May 2, 2019.
Baker TB, Piper ME, McCarthy DE, Bolt DM, Smith SS, 
Kim SY, Colby S, Conti D, Giovino GA, Hatsukami 
D, et al. Time to first cigarette in the morning as an 
index of ability to quit smoking: implications for nic-
otine dependence. Nicotine and Tobacco Research 
2007;9(Suppl 4):S555–S570.
Barrera R, Shi W, Amar D, Thaler HT, Gabovich N, Bains 
MS, White DA. Smoking and timing of cessation: impact 
on pulmonary complications after thoracotomy. Chest 
2005;127(6):1977–83.
Baskerville NB, Azagba S, Norman C, McKeown K, Brown 
KS. Effect of a digital social media campaign on 
young adult smoking cessation. Nicotine and Tobacco 
Research 2016;18(3):351–60.
Bauld L, Graham H, Sinclair L, Flemming K, Naughton 
F, Ford A, McKell J, McCaughan D, Hopewell S, Angus 
K, et al. Barriers to and facilitators of smoking ces-
sation in pregnancy and following childbirth: litera-
ture review and qualitative study. Health Technology 
Assessment 2017;21(36):1–158.
Beard E, West R, Michie S, Brown J. Association between 
electronic cigarette use and changes in quit attempts, 
success of quit attempts, use of smoking cessation 
pharmacotherapy, and use of stop smoking services in 
England: time series analysis of population trends. BMJ 
2016;354:i4645.
Beck AT. Cognitive therapy: nature and relation to behavior 
therapy. Behavior Therapy 1970;1(2):184–200.
Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, 
Dempsey D, Jacob P 3rd. Smoking behavior and expo-
sure to tobacco toxicants during 6 months of smoking 
progressively reduced nicotine content cigarettes. 
Cancer Epidemiology, Biomarkers and Prevention 
2012;21(5):761–9.
Benowitz NL, Hall SM, Stewart S, Wilson M, Dempsey 
D, Jacob P 3rd. Nicotine and carcinogen exposure 
with smoking of progressively reduced nicotine con-
tent cigarette. Cancer Epidemiology, Biomarkers and 
Prevention 2007;16(11):2479–85.
Benowitz NL, Henningfield JE. Establishing a nico-
tine threshold for addiction. The implications for 
tobacco regulation. New England Journal of Medicine 
1994;331(2):123–5.
Benowitz NL, Henningfield JE. Reducing the nicotine con-
tent to make cigarettes less addictive. Tobacco Control 
2013;22(Suppl 1)i14–i17.
Benowitz NL, Nardone N, Dains KM, Hall SM, Stewart S, 
Dempsey D, Jacob P 3rd. Effect of reducing the nicotine 
content of cigarettes on cigarette smoking behavior 
Interventions for Smoking Cessation and Treatments for Nicotine Dependence  551
Smoking Cessation
and tobacco smoke toxicant exposure: 2-year follow up. 
Addiction 2015;110(10):1667–75.
Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, 
Lawrence D, St Aubin L, Anthenelli RM. Cardiovascular 
safety of varenicline, bupropion, and nicotine patch in 
smokers: a randomized clinical trial. JAMA Internal 
Medicine 2018;178(5):622–31.
Berger I, Mooney-Somers J. Smoking cessation programs 
for lesbian, gay, bisexual, transgender, and intersex 
people: a content-based systematic review. Nicotine 
and Tobacco Research 2016.
Bernstein SL, Boudreaux ED. Emergency department-
based tobacco interventions improve patient satisfaction. 
Journal of Emergency Medicine 2010;38(4):e35–e40.
Berry KM, Reynolds LM, Collins JM, Siegel MB, Fetterman 
JL, Hamburg NM, Bhatnagar A, Benjamin EJ, Stokes 
A. E-cigarette initiation and associated changes in 
smoking cessation and reduction: the Population 
Assessment of Tobacco and Health Study, 2013–2015. 
Tobacco Control 2019;28(1):42–9.
Bhatta DN, Glantz SA. Electronic cigarette use and myo-
cardial infarction among adults in the U.S. Population 
Assessment of Tobacco and Health. Journal of the 
American Heart Association 2019;8(12):e012317.
Biener L, Hargraves JL. A longitudinal study of elec-
tronic cigarette use among a population-based sample 
of adult smokers: association with smoking cessation 
and motivation to quit. Nicotine and Tobacco Research 
2015;17(2):127–33.
Bloom EL, Wing RR, Kahler CW, Thompson JK, Meltzer 
S, Hecht J, Minami H, Price LH, Brown RA. Distress 
tolerance treatment for weight concern in smoking 
cessation among women: the WE QUIT Pilot Study. 
Behavior Modification 2017;41(4):468–98.
Blount BC, Karwowski MP, Shields PG, Morel-Espinosa 
M, Valentin-Blasini L, Gardner M, Braselton M, Brosius 
CR, Caron KT, Chambers D, et al. Vitamin E acetate 
in bronchoalveolar-lavage fluid associated with EVALI. 
New England Journal of Medicine 2019.
Blumenthal DS. Barriers to the provision of smoking ces-
sation services reported by clinicians in underserved 
communities. Journal of the American Board of Family 
Medicine 2007;20(3):272–9.
Bock B, Graham A, Sciamanna C, Krishnamoorthy J, 
Whiteley J, Carmona-Barros R, Niaura R, Abrams D. 
Smoking cessation treatment on the Internet: content, 
quality, and usability. Nicotine and Tobacco Research 
2004;6(2):207–19.
Bock BC, Graham AL, Whiteley JA, Stoddard JL. A review 
of web-assisted tobacco interventions (WATIs). Journal 
of Medical Internet Research 2008;10(5):e39.
Bombard JM, Farr SL, Dietz PM, Tong VT, Zhang L, Rabius 
V. Telephone smoking cessation quitline use among 
pregnant and non-pregnant women. Maternal and 
Child Health Journal 2013;17(6):989–95.
Borderud SP, Li Y, Burkhalter JE, Sheffer CE, Ostroff 
JS. Electronic cigarette use among patients with 
cancer: characteristics of electronic cigarette users 
and their smoking cessation outcomes. Cancer 
2014;120(22):3527–35.
Borland R, Partos TR, Cummings KM. Systematic biases 
in cross-sectional community studies may underesti-
mate the effectiveness of stop-smoking medications. 
Nicotine and Tobacco Research 2012;14(12):1483–7.
Borrelli B, Bartlett YK, Tooley E, Armitage CJ, Wearden A. 
Prevalence and frequency of mHealth and eHealth use 
among U.S. and UK smokers and differences by moti-
vation to quit. Journal of Medical Internet Research 
2015;17(7):e164.
Boucher J, Konkle AT. Understanding inequalities of maternal 
smoking—bridging the gap with adapted intervention 
strategies. International Journal of Environmental 
Research and Public Health 2016;13(3):pii: E282.
Boyle R, Solberg L, Fiore M. Use of electronic health records 
to support smoking cessation. Cochrane Database of 
Systematic Reviews 2011, Issue 12. Art. No.: CD008743. 
DOI: 10.1002/14651858.CD008743.pub2.
Boyle R, Solberg L, Fiore M. Use of electronic health records 
to support smoking cessation. Cochrane Database of 
Systematic Reviews 2014, Issue 12. Art. No.: CD008743. 
DOI: 10.1002/14651858.CD008743.pub3.
Bricker J, Wyszynski C, Comstock B, Heffner JL. Pilot ran-
domized controlled trial of web-based acceptance and 
commitment therapy for smoking cessation. Nicotine 
and Tobacco Research 2013;15(10):1756–64.
Bricker JB, Bush T, Zbikowski SM, Mercer LD, Heffner JL. 
Randomized trial of telephone-delivered acceptance 
and commitment therapy versus cognitive behavioral 
therapy for smoking cessation: a pilot study. Nicotine 
and Tobacco Research 2014a;16(11):1446–54.
Bricker JB, Copeland W, Mull KE, Zeng EY, Watson NL, 
Akioka KJ, Heffner JL. Single-arm trial of the second 
version of an acceptance & commitment therapy 
smartphone application for smoking cessation. Drug 
and Alcohol Dependence 2017;170:37–42.
Bricker JB, Mann SL, Marek PM, Liu J, Peterson AV. 
Telephone-delivered acceptance and commitment 
therapy for adult smoking cessation: a feasibility study. 
Nicotine and Tobacco Research 2010;12(4):454–8.
Bricker JB, Mull KE, Kientz JA, Vilardaga R, Mercer 
LD, Akioka KJ, Heffner JL. Randomized, controlled 
pilot trial of a smartphone app for smoking cessation 
using acceptance and commitment therapy. Drug and 
Alcohol Dependence 2014b;143:87–94.
Bricker JB, Sridharan V, Zhu Y, Mull KE, Heffner JL, 
Watson NL, McClure JB, Di C. Trajectories of 12-month 
A Report of the Surgeon General
552  Chapter 6
usage patterns for two smoking cessation websites: 
exploring how users engage over time. Journal of 
Medical Internet Research 2018;20(4):e10143.
Brody AL, Zorick T, Hubert R, Hellemann GS, Balali S, 
Kawasaki SS, Garcia LY, Enoki R, Abraham P, Young P, 
et al. Combination extended smoking cessation treat-
ment plus home visits for smokers with schizophrenia: 
a randomized controlled trial. Nicotine and Tobacco 
Research 2017;19(1):68–76.
Brooks-Brunn JA. Predictors of postoperative pulmonary 
complications following abdominal surgery. Chest 
1997;111(3):564–71.
Brose LS, Hitchman SC, Brown J, West R, McNeill A. Is 
the use of electronic cigarettes while smoking associ-
ated with smoking cessation attempts, cessation and 
reduced cigarette consumption? A survey with a 1-year 
follow-up. Addiction 2015;110(7):1160–8.
Buchting FO, Emory KT, Scout NFN, Kim Y, Fagan P, Vera 
LE, Emery S. Transgender use of cigarettes, cigars, and 
e-cigarettes in a national study. American Journal of 
Preventive Medicine 2017;53(1):e1–e7.
Bullen C, Howe C, Laugesen M, McRobbie H, Parag 
V, Williman J, Walker N. Electronic cigarettes for 
smoking cessation: a randomised controlled trial. 
Lancet 2013;382(9905):1629–37.
Bullen C, Howe C, Lin RB, Grigg M, Laugesen M, 
McRobbie H, Glover M, Walker N, Wallace-Bell M, 
Whittaker R, et al. Pre-cessation nicotine replace-
ment therapy: pragmatic randomized trial. Addiction 
2010;105(8):1474–83.
Bush TM, McAfee T, Deprey M, Mahoney L, Fellows JL, 
McClure J, Cushing C. The impact of a free nicotine 
patch starter kit on quit rates in a state quit line. 
Nicotine and Tobacco Research 2008;10(9):1511–6.
Butler AC, Chapman JE, Forman EM, Beck AT. The 
empirical status of cognitive-behavioral therapy: a 
review of meta-analyses. Clinical Psychology Review 
2006;26(1):17–31.
Cahill K, Hartmann-Boyce J, Perera R. Incentives for 
smoking cessation. Cochrane Database of Systematic 
Reviews 2015, Issue 5. Art. No.: CD004307. DOI: 
10.1002/14651858.CD004307.pub5.
Cahill K, Lancaster T. Workplace interventions for 
smoking cessation. Cochrane Database of Systematic 
Reviews 2014, Issue 2. Art. No.: CD003440. DOI: 
10.1002/14651858.CD003440.pub4.
Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, 
Lancaster T. Nicotine receptor partial agonists for 
smoking cessation. Cochrane Database of Systematic 
Reviews 2016, Issue 5. Art. No.: CD006103. DOI: 
10.1002/14651858.CD006103.pub7.
Cahill K, Perera R. Competitions and incentives for 
smoking cessation. Cochrane Database of Systematic 
Reviews 2011, Issue 4. Art. No.: CD004307. DOI: 
10.1002/14651858.CD004307.pub4.
Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological 
interventions for smoking cessation: an overview 
and network meta-analysis. Cochrane Database of 
Systematic Reviews 2013, Issue 5. Art. No.: CD009329. 
DOI: 10.1002/14651858.CD009329.pub2.
Campaign for Tobacco-Free Kids. Broken Promises to Our 
Children: A State-by-State Look at the 1998 Tobacco 
Settlement 20 Years Later, 2018; <https://www.tobac-
cofreekids.org/what-we-do/us/statereport>; accessed: 
January 15, 2019.
Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso 
M, Russo C, Polosa R. EffiCiency and Safety of an eLec-
tronic cigAreTte (ECLAT) as tobacco cigarettes sub-
stitute: a prospective 12-month randomized control 
design study. PLoS One 2013;8(6):e66317.
Caraballo RS, Shafer PR, Patel D, Davis KC, McAfee TA. Quit 
methods used by U.S. adult cigarette smokers, 2014–
2016. Preventing Chronic Disease 2017;14:160600.
Carpenter MJ, Jardin BF, Burris JL, Mathew AR, Schnoll 
RA, Rigotti NA, Cummings KM. Clinical strategies to 
enhance the efficacy of nicotine replacement therapy 
for smoking cessation: a review of the literature. Drugs 
2013;73(5):407–26.
Carr AB, Ebbert J. Interventions for tobacco cessation in 
the dental setting. Cochrane Database of Systematic 
Reviews 2012, Issue 6. Art. No.: CD005084. DOI: 
10.1002/14651858.CD005084.pub3.
Carson KV, Verbiest MEA, Crone MR, Brinn MP, Esterman 
AJ, Assendelft WJJ, Smith BJ. Training health profes-
sionals in smoking cessation. Cochrane Database of 
Systematic Reviews 2012, Issue 5. Art. No.: CD000214. 
DOI: 10.1002/14651858.CD000214.pub2.
Cartmell KB, Dismuke CE, Dooley M, Mueller M, Nahhas 
GJ, Warren GW, Fallis P, Cummings KM. Effect of an 
inpatient tobacco dependence treatment service on 
1-year postdischarge health care costs. Medical Care 
2018a;56(10):883–9.
Cartmell KB, Dooley M, Mueller M, Nahhas GJ, Dismuke 
CE, Warren GW, Talbot V, Cummings KM. Effect of an 
evidence-based inpatient tobacco dependence treat-
ment service on 30-, 90-, and 180-day hospital read-
mission rates. Medical Care 2018b;56(4):358–63.
Cataldo JK. High-risk older smokers’ perceptions, atti-
tudes, and beliefs about lung cancer screening. Cancer 
Medicine 2016;5(4):753–9.
Catley D, Goggin K, Harris KJ, Richter KP, Williams K, 
Patten C, Resnicow K, Ellerbeck EF, Bradley-Ewing A, 
Lee HS, et al. A randomized trial of motivational inter-
viewing: cessation induction among smokers with low 
desire to quit. American Journal of Preventive Medicine 
2016;50(5):573–83.
Interventions for Smoking Cessation and Treatments for Nicotine Dependence  553
Smoking Cessation
Center for Drug Evaluation and Research. Smoking 
Cessation and Related Indications: Developing Nicotine 
Replacement Therapy Drug Products, February 2019; 
<https://www.regulations.gov/document?D=FDA-
2019-D-0297-0002>; accessed: May 9, 2019.
Center for Substance Abuse Treatment. Chapter 8. Intensive 
outpatient treatment approaches. In: Substance Abuse: 
Clinical Issues in Intensive Outpatient Treatment. 
Treatment Improvement Protocol (TIP) Series, No. 47. 
Rockville (MD): Substance Abuse and Mental Health 
Services Administration, 2006. DHHS Publication No. 
(SMA) 06-4182.
Centers for Disease Control and Prevention. 
Telephone Quitlines: A Resource for Development, 
Implementation, and Evaluation. Atlanta (GA): U.S. 
Department of Health and Human Services, Centers 
for Disease Control and Prevention, National Center 
for Chronic Disease Prevention and Health Promotion, 
Office on Smoking and Health, September 2004. 
Centers for Disease Control and Prevention. State-specific 
prevalence of cigarette smoking and quitting among 
adults—United States, 2004. Morbidity and Mortality 
Weekly Report 2005;54(44):1124–7.
Centers for Disease Control and Prevention. Best Practices 
for Comprehensive Tobacco Control Programs—2014. 
Atlanta (GA): U.S. Department of Health and Human 
Services, Centers for Disease Control and Prevention, 
National Center for Chronic Disease Prevention and 
Health Promotion, Office on Smoking and Health, 
2014; <https://www.cdc.gov/tobacco/stateandcommu-
nity/best_practices/pdfs/2014/comprehensive.pdf>; 
accessed: July 26, 2017.
Centers for Disease Control and Prevention. QuickStats: 
cigarette smoking status among current adult e-ciga-
rette users, by age group—National Health Interview 
Survey, United States, 2015. Morbidity and Mortality 
Weekly Report 2016;65(42):1177.
Centers for Medicaid and Medicare Services. Medicaid 
Incentives for Prevention of Chronic Diseases grants 
[press release], September 13, 2011; <https://www.
cms.gov/Newsroom/MediaReleaseDatabase/Fact-
sheets/2011-Fact-sheets-items/2011-09-13.html>; 
accessed: February 23, 2018.
Centers for Medicaid and Medicare Services. Medicaid 
Incentives for the Prevention of Chronic Diseases 
Model, January 8 2018; <https://innovation.cms.gov/
initiatives/MIPCD/>; accessed: February 9, 2018.
Centers for Medicare and Medicaid Services. Decision 
memo for screening for lung cancer with low dose 
computed tomography (LDCT) (CAG-00439N), 2015; 
<https://www.cms.gov/medicare-coverage-data-
base/details/nca-decision-memo.aspx?NCAId=274>; 
accessed: July 18, 2019.
Chaiton M, Diemert L, Cohen JE, Bondy SJ, Selby P, 
Philipneri A, Schwartz R. Estimating the number of quit 
attempts it takes to quit smoking successfully in a longi-
tudinal cohort of smokers. BMJ Open 2016;6(6):e011045.
Chang PH, Chiang CH, Ho WC, Wu PZ, Tsai JS, Guo FR. 
Combination therapy of varenicline with nicotine 
replacement therapy is better than varenicline alone: 
a systematic review and meta-analysis of randomized 
controlled trials. BMC Public Health 2015;15:689.
Chaudhri N, Caggiula AR, Donny EC, Palmatier MI, Liu 
X, Sved AF. Complex interactions between nicotine 
and nonpharmacological stimuli reveal multiple roles 
for nicotine in reinforcement. Psychopharmacology 
2006;184(3-4):353–66.
Chenoweth MJ, Tyndale RF. Pharmacogenetic optimi-
zation of smoking cessation treatment. Trends in 
Pharmacological Sciences 2017;38(1):55–66.
Cheung YT, Chan CH, Lai CK, Chan WF, Wang MP, Li 
HC, Chan SS, Lam TH. Using WhatsApp and Facebook 
online social groups for smoking relapse prevention for 
recent quitters: a pilot pragmatic cluster randomized 
controlled trial. Journal of Medical Internet Research 
2015;17(10):e238.
Choi J, Noh GY, Park DJ. Smoking cessation apps for 
smartphones: content analysis with the self-determi-
nation theory. Journal of Medical Internet Research 
2014;16(2):e44.
Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, 
Lam C, Versace F, Brown VL, Engelmann JM, Wetter 
DW. Effects of varenicline and bupropion sustained-
release use plus intensive smoking cessation coun-
seling on prolonged abstinence from smoking and on 
depression, negative affect, and other symptoms of nic-
otine withdrawal. JAMA Psychiatry 2013;70(5):522–33.
Civljak M, Stead LF, Hartmann-Boyce J, Sheikh A, Car 
J. Internet-based interventions for smoking cessa-
tion. Cochrane Database of Systematic Reviews 2013, 
Issue 7. Art. No.: CD007078. DOI: 10.1002/14651858.
CD007078.pub4.
Clapp PW, Jaspers I. Electronic cigarettes: their constitu-
ents and potential links to asthma. Current Allergy and 
Asthma Reports 2017;17(11):79.
Clark MM, Cox LS, Jett JR, Patten CA, Schroeder DR, Nirelli 
LM, Vickers K, Hurt RD, Swensen SJ. Effectiveness of 
smoking cessation self-help materials in a lung cancer 
screening population. Lung Cancer 2004;44(1):13–21.
Cobb NK, Graham AL. Characterizing Internet searchers 
of smoking cessation information. Journal of Medical 
Internet Research 2006;8(3):e17.
Cobb NK, Jacobs MA, Saul J, Wileyto EP, Graham AL. 
Diffusion of an evidence-based smoking cessation inter-
vention through Facebook: a randomised controlled 
trial study protocol. BMJ Open 2014;4(1):e004089.
A Report of the Surgeon General
554  Chapter 6
Cole-Lewis H, Augustson E, Sanders A, Schwarz M, Geng 
Y, Coa K, Hunt Y. Analysing user-reported data for 
enhancement of SmokefreeTXT: a national text message 
smoking cessation intervention. Tobacco Control 2016.
Coleman-Cowger VH, Koszowski B, Rosenberry ZR, 
Terplan M. Factors associated with early pregnancy 
smoking status among low-income smokers. Maternal 
and Child Health Journal 2016;20(5):1054–60.
Coleman T, Chamberlain C, Davey MA, Cooper SE, 
Leonardi-Bee J. Pharmacological interventions for pro-
moting smoking cessation during pregnancy. Cochrane 
Database of Systematic Reviews 2012a, Issue 9. Art. 
No.: CD010078. DOI: 10.1002/14651858.CD010078.
Coleman T, Chamberlain C, Davey MA, Cooper SE, 
Leonardi-Bee J. Pharmacological interventions for pro-
moting smoking cessation during pregnancy. Cochrane 
Database of Systematic Reviews 2015, Issue 12. Art. No.: 
CD010078. DOI: 10.1002/14651858.CD010078.pub2.
Coleman T, Cooper S, Thornton JG, Grainge MJ, Watts 
K, Britton J, Lewis S. A randomized trial of nicotine-
replacement therapy patches in pregnancy. New England 
Journal of Medicine 2012b;366(9):808–18.
Collins SE, Witkiewitz K, Kirouac M, Marlatt GA. 
Preventing relapse following smoking cessation. 
Current Cardiovascular Risk Reports 2010;4(6):421–8.
Conklin CA, Salkeld RP, Perkins KA, Robin N. Do people 
serve as cues to smoke? Nicotine and Tobacco Research 
2013;15(12):2081–7.
Connett JE, Kusek JW, Bailey WC, O’Hara P, Wu M. Design 
of the Lung Health Study: a randomized clinical trial of 
early intervention for chronic obstructive pulmonary dis-
ease. Controlled Clinical Trials 1993;14(2 Suppl)3S–19S.
Cooper J, Borland R, Yong HH, McNeill A, Murray RL, 
O’Connor RJ, Cummings KM. To what extent do 
smokers make spontaneous quit attempts and what are 
the implications for smoking cessation maintenance? 
Findings from the International Tobacco Control 
Four country survey. Nicotine and Tobacco Research 
2010;12(Suppl):S51–S57.
Corelli RL, Hudmon KS. Medications for smoking cessa-
tion. Western Journal of Medicine 2002;176(2):131–5.
Corey CG, Chang JT, Rostron BL. Electronic nicotine 
delivery system (ENDS) battery-related burns pre-
senting to US emergency departments, 2016. Injury 
Epidemiology 2018;5(1):4.
Cristea IA, Gentili C, Cotet CD, Palomba D, Barbui C, 
Cuijpers P. Efficacy of psychotherapies for borderline 
personality disorder: a systematic review and meta-
analysis. JAMA Psychiatry 2017;74(4):319–28.
Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. Bupropion 
enhances brain reward function and reverses the affec-
tive and somatic aspects of nicotine withdrawal in the 
rat. Psychopharmacology 2003;168(3):347–58.
Culbertson CS, Shulenberger S, De La Garza R, Newton 
TF, Brody AL. Virtual reality cue exposure therapy for 
the treatment of tobacco dependence. Journal of Cyber 
Therapy and Rehabilitation 2012;5(1):57–64.
Cullen KA, Ambrose BK, Gentzke AS, Apelberg BJ, Jamal 
A, King BA. Notes from the field: use of electronic ciga-
rettes and any tobacco product among middle and high 
school students—United States, 2011–2018. Morbidity 
and Mortality Weekly Report 2018;67(45):1276–7.
Cummings KM, Fix B, Celestino P, Carlin-Menter S, 
O’Connor R, Hyland A. Reach, efficacy, and cost-effec-
tiveness of free nicotine medication giveaway pro-
grams. Journal of Public Health Management and 
Practice 2006;12(1):37–43.
Cummings KM, Hyland A, Carlin-Menter S, Mahoney MC, 
Willett J, Juster HR. Costs of giving out free nicotine 
patches through a telephone quit line. Journal of Public 
Health Management and Practice 2011;17(3):E16–E23.
Cummings SR, Stein MJ, Hansen B, Richard RJ, Gerbert 
B, Coates TJ. Smoking counseling and preventive med-
icine. A survey of internists in private practices and a 
health maintenance organization. Archives of Internal 
Medicine 1989;149(2):345–9.
Cummins SE, Tedeschi GJ, Anderson CM, Zhu SH. 
Telephone Intervention for pregnant smokers: a 
randomized controlled trial. American Journal of 
Preventive Medicine 2016;51(3):318–26.
Curtin SC, Mathews TJ. Smoking prevalence and cessa-
tion before and during pregnancy: data from the birth 
certificate, 2014. National Vital Statistics Reports 
2016;65(1):1–14.
Danaher BG, Boles SM, Akers L, Gordon JS, Severson HH. 
Defining participant exposure measures in Web-based 
health behavior change programs. Journal of Medical 
Internet Research 2006;8(3):e15.
Das S, Prochaska JJ. Innovative approaches to support 
smoking cessation for individuals with mental ill-
ness and co-occurring substance use disorders. Expert 
Review of Respiratory Medicine 2017;11(10):841–50.
Delgado-Rodriguez M, Medina-Cuadros M, Martinez-
Gallego G, Gómez-Ortega A, Mariscal-Ortiz M, Palma-
Pérez S, Sillero-Arenas M. A prospective study of tobacco 
smoking as a predictor of complications in general sur-
gery. Infection Control and Hospital Epidemiology 
2003;24(1):37–43.
Delnevo CD, Giovenco DP, Steinberg MB, Villanti AC, 
Pearson JL, Niaura RS, Abrams DB. Patterns of Electronic 
Cigarette Use Among Adults in the United States. 
Nicotine and Tobacco Research 2016;18(5):715–9.
Denison E, Underland V, Mosdøl A, Vist GE. Cognitive 
Therapies for Smoking Cessation: A Systematic Review. 
Oslo (Norway): The Norwegian Institute of Public 
Health, 2017. 
Interventions for Smoking Cessation and Treatments for Nicotine Dependence  555
Smoking Cessation
Denlinger-Apte RL, Donny EC, Lindgren BR, Rubin N, 
Goodwin C, DeAtley T, Colby SM, Cioe PA, Hatsukami 
DK, Tidey JW. Smoking topography characteristics 
during a six-week trial of very low nicotine content cig-
arettes in smokers with serious mental illness. Nicotine 
and Tobacco Research 2019:ntz198.
Deprey M, McAfee T, Bush T, McClure JB, Zbikowski S, 
Mahoney L. Using free patches to improve reach of the 
Oregon Quit Line. Journal of Public Health Management 
and Practice 2009;15(5):401–8.
Dermody SS, McClernon FJ, Benowitz N, Luo X, Tidey JW, 
Smith TT, Vandrey R, Hatsukami D, Donny EC. Effects 
of reduced nicotine content cigarettes on individual 
withdrawal symptoms over time and during abstinence. 
Experimental and Clinical Psychopharmacology 
2018;26(3):223–32.
DiClemente CC, Dolan-Mullen P, Windsor RA. The process 
of pregnancy smoking cessation: implications for inter-
ventions. Tobacco Control 2000;9(Suppl 3):iii16–iii21.
DiGiulio A, Jump Z, Yu A, Babb S, Schecter A, Williams 
KS, Yembra D, Armour BS. State Medicaid coverage for 
tobacco cessation treatments and barriers to accessing 
treatments—United States, 2015–2017. Morbidity and 
Mortality Weekly Report 2018;67(13):390–5.
Dilley JA, Spigner C, Boysun MJ, Dent CW, Pizacani BA. 
Does tobacco industry marketing excessively impact 
lesbian, gay and bisexual communities? Tobacco 
Control 2008;17(6):385–90.
Dobbie F, Hiscock R, Leonardi-Bee J, Murray S, Shahab L, 
Aveyard P, Coleman T, McEwen A, McRobbie H, Purves 
R, et al. Evaluating Long-term Outcomes of NHS Stop 
Smoking Services (ELONS): a prospective cohort study. 
Health Technology Assessment 2015;19(95):1–156.
Dockrell M, Morrison R, Bauld L, McNeill A. E-cigarettes: 
prevalence and attitudes in Great Britain. Nicotine and 
Tobacco Research 2013;15(10):1737–44.
Doll R, Peto R, Boreham J, Sutherland I. Mortality in rela-
tion to smoking: 50 years’ observations on male British 
doctors. BMJ 2004;328(7455):1519.
Donny EC, Denlinger RL, Tidey JW, Koopmeiners JS, 
Benowitz NL, Vandrey RG, al’Absi M, Carmella SG, 
Cinciripini PM, Dermody SS, et al. Randomized trial 
of reduced-nicotine standards for cigarettes. New 
England Journal of Medicine 2015;373(14):1340–9.
Donny EC, Hatsukami DK, Benowitz NL, Sved AF, Tidey 
JW, Cassidy RN. Reduced nicotine product stan-
dards for combustible tobacco: building an empirical 
basis for effective regulation. Preventive Medicine 
2014;68:17–22.
Donny EC, Houtsmuller E, Stitzer ML. Smoking in 
the absence of nicotine: behavioral, subjective 
and physiological effects over 11 days. Addiction 
2007;102(2):324–34.
Donny EC, Jones M. Prolonged exposure to denicotinized 
cigarettes with or without transdermal nicotine. Drug 
and Alcohol Dependence 2009;104(1–2):23–33.
Drake P, Driscoll AK, Mathews TJ. Cigarette Smoking 
During Pregnancy: United States, 2016. NCHS Data 
Brief, Number 305. Hyattsville (MD): National Center 
for Health Statistics, 2018. 
Dreher M, Schillo BA, Hull M, Esqueda V, Mowery A. A case 
study for redesigning tobacco cessation services gaining 
critical insights from current and former smokers. 
Social Marketing Quarterly 2015;21(4):200–13.
Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, 
Allen SS, Hays JT, Hurt RD. Combination vareni-
cline and bupropion SR for tobacco-dependence treat-
ment in cigarette smokers: a randomized trial. JAMA: 
the Journal of the American Medical Association 
2014;311(2):155–63.
Ebbert JO, Hays JT, Hurt RD. Combination pharmaco-
therapy for stopping smoking: what advantages does it 
offer? Drugs 2010;70(6):643–50.
Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C, McRae 
TD, Treadow J, Yu CR, Dutro MP, Park PW. Effect of var-
enicline on smoking cessation through smoking reduc-
tion: a randomized clinical trial. JAMA: the Journal of 
the American Medical Association 2015;313(7):687–94.
Ebbert JO, Post JA, Moyer TP, Dale LC, Schroeder DR, 
Hurt RD. Nicotine percentage replacement among 
smokeless tobacco users with nicotine patch. Drug and 
Alcohol Dependence 2007;89(2–3):223–6.
Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, 
Bata I, Iskander A, Lauzon C, Srivastava N, Clarke A, 
et al. Varenicline for smoking cessation in hospitalized 
patients with acute coronary syndrome. Circulation 
2016;133(1):21–30.
El Dib R, Suzumura EA, Akl EA, Gomaa H, Agarwal A, 
Chang Y, Prasad M, Ashoorion V, Heels-Ansdell D, 
Maziak W, et al. Electronic nicotine delivery systems 
and/or electronic non-nicotine delivery systems for 
tobacco smoking cessation or reduction: a systematic 
review and meta-analysis. BMJ Open 2017;7(2):e012680.
Ellis A. Reason and Emotion in Psychotherapy. New York 
(NY): Lyle Stuart, 1962.
Erythropel HC, Jabba SV, DeWinter TM, Mendizabal M, 
Anastas PT, Jordt SE, Zimmerman JB. Formation of fla-
vorant-propylene glycol adducts with novel toxicological 
properties in chemically unstable e-cigarette liquids. 
Nicotine and Tobacco Research 2019;21(9):1248–58.
Etter JF. Comparing the efficacy of two Internet-based, 
computer-tailored smoking cessation programs: a ran-
domized trial. Journal of Medical Internet Research 
2005;7(1):e2.
Evins AE, Cather C, Pratt SA, Pachas GN, Hoeppner SS, Goff 
DC, Achtyes ED, Ayer D, Schoenfeld DA. Maintenance 
A Report of the Surgeon General
556  Chapter 6
treatment with varenicline for smoking cessation in 
patients with schizophrenia and bipolar disorder: a 
randomized clinical trial. JAMA: the Journal of the 
American Medical Association 2014;311(2):145–54.
Fagan P, Augustson E, Backinger CL, O’Connell ME, 
Vollinger RE Jr, Kaufman A, Gibson JT. Quit attempts 
and intention to quit cigarette smoking among young 
adults in the United States. American Journal of Public 
Health 2007;97(8):1412–20.
Fagerström K, Etter JF, Unger JB. E-cigarettes: a disrup-
tive technology that revolutionizes our field? Nicotine 
and Tobacco Research 2015;17(2):125–6.
Fagerström K, Gilljam H, Metcalfe M, Tonstad S, Messig 
M. Stopping smokeless tobacco with varenicline: ran-
domised double blind placebo controlled trial. BMJ 
2010;341:c6549.
Farsalinos K, Niaura R. E-cigarette use and myocardial 
infarction: association versus causal inference. American 
Journal of Preventive Medicine 2019a;56(4):626–7.
Farsalinos K, Niaura R. E-cigarettes and smoking ces-
sation in the United States according to frequency of 
e-cigarette use and quitting duration: analysis of the 
2016 and 2017 National Health Interview Surveys. 
Nicotine and Tobacco Research 2019b.
Farsalinos KE, Romagna G, Tsiapras D, Kyrzopoulos S, 
Voudris V. Evaluating nicotine levels selection and pat-
terns of electronic cigarette use in a group of “vapers” 
who had achieved complete substitution of smoking. 
Substance Abuse 2013a;7:139–46.
Farsalinos KE, Romagna G, Tsiapras D, Kyrzopoulos 
S, Voudris V. Evaluation of electronic cigarette use 
(vaping) topography and estimation of liquid consump-
tion: implications for research protocol standards def-
inition and for public health authorities’ regulation. 
International Journal of Environmental Research and 
Public Health 2013b;10(6):2500–14.
Farsalinos KE, Spyrou A, Stefopoulos C, Tsimopoulou 
K, Kourkoveli P, Tsiapras D, Kyrzopoulos S, Poulas 
K, Voudris V. Corrigendum: Nicotine absorption from 
electronic cigarette use: comparison between experi-
enced consumers (vapers) and naive users (smokers). 
Scientific Reports 2015;5:13506.
Farsalinos KE, Spyrou A, Tsimopoulou K, Stefopoulos C, 
Romagna G, Voudris V. Nicotine absorption from elec-
tronic cigarette use: comparison between first and new-
generation devices. Scientific Reports 2014;4:4133.
Farsalinos KE, Yannovits N, Sarri T, Voudris V, Poulas K. 
Protocol proposal for, and evaluation of, consistency in 
nicotine delivery from the liquid to the aerosol of elec-
tronic cigarettes atomizers: regulatory implications. 
Addiction 2016;111(6):1069–76.
FDAnews. Carrot lands FDA approval for smoking cessation 
mobile device, October 11, 2017; <https://www.fdanews.
com/articles/183905-carrot-lands-fda-approval-for-
smoking-cessation-mobile-device>; accessed: January 8, 
2019.
Federal Communications Commission. Mapping broad-
band health in America, n.d.; <https://www.fcc.gov/
health/maps>; accessed: March 20, 2019.
Federal Register. U.S. Food and Drug Administration. The 
Food and Drug Administration’s Approach To Evaluating 
Nicotine Replacement Therapies; Public Hearing; Request 
for Comments. 82 Fed. Reg. 56759 (2017); <https://www.
federalregister.gov/d/2017-25671>; accessed: May 9, 2019.
Federal Register. U.S. Food and Drug Administration. 
Eliminating Youth Electronic Cigarette and Other 
Tobacco Product Use: The Role for Drug Therapies; 
Public Hearing; Request for Comments. 83 Fed. Reg. 
55318 (2018); <https://www.federalregister.gov/d/2018-
24126>; accessed: January 9, 2019.
Federal Register. U.S. Department of Health and Human 
Services, Food and Drug Administration. Modifications 
to labeling of nicotine replacement therapy products 
for over-the-counter human use. 78 Fed. Reg. 19718 
(2013).
Fellows JL, Bush T, McAfee T, Dickerson J. Cost effec-
tiveness of the Oregon quitline “free patch initiative”. 
Tobacco Control 2007;16(Suppl 1):i47–i52.
Ferguson J, Docherty G, Bauld L, Lewis S, Lorgelly P, Boyd 
KA, McEwen A, Coleman T. Effect of offering different 
levels of support and free nicotine replacement therapy 
via an English national telephone quitline: randomised 
controlled trial. BMJ 2012;344:e1696.
Fergusson DM, Horwood LJ. Transitions to cigarette 
smoking during adolescence. Addictive Behaviors 
1995;20(5):627–42.
Ferketich AK, Otterson GA, King M, Hall N, Browning KK, 
Wewers ME. A pilot test of a combined tobacco depen-
dence treatment and lung cancer screening program. 
Lung Cancer 2012;76(2):211–5.
Fiore M, Adsit R, Zehner M, McCarthy D, Lundsten S, 
Hartlaub P, Mahr T, Gorrilla A, Skora A, Baker T. An 
electronic health record-based interoperable eReferral 
system to enhance smoking quitline treatment in pri-
mary care. Journal of the American Medical Informatics 
Association 2019.
Fiore M, Baker T. Reduced-nicotine cigarettes—a prom-
ising regulatory pathway. New England Journal of 
Medicine 2015;373(14):1289–91.
Fiore MC, Goplerud E, Schroeder SA. The Joint 
Commission’s new tobacco-cessation measures—will 
hospitals do the right thing? New England Journal of 
Medicine 2012;366(13):1172–4.
Fiore MC, Jaen CR. A clinical blueprint to accelerate the 
elimination of tobacco use. JAMA: the Journal of the 
American Medical Association 2008;299(17):2083–5.
Interventions for Smoking Cessation and Treatments for Nicotine Dependence  557
Smoking Cessation
Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz NL, Curry 
SJ, Dorfman SF, Froelicher ES, Goldstein MG, Healton 
CG, et al. Treating Tobacco Use and Dependence: 2008 
Update. U.S. Public Health Service Clinical Practice 
Guideline. Rockville (MD): U.S. Department of Health 
and Human Services, 2008. 
Flemming K, McCaughan D, Angus K, Graham H. 
Qualitative systematic review: barriers and facilitators 
to smoking cessation experienced by women in preg-
nancy and following childbirth. Journal of Advanced 
Nursing 2015;71(6):1210–26.
Foulds J, Gandhi KK, Steinberg MB, Richardson DL, 
Williams JM, Burke MV, Rhoads GG. Factors associ-
ated with quitting smoking at a tobacco dependence 
treatment clinic. American Journal of Health Behavior 
2006;30(4):400–12.
Foulds J, Schmelzer AC, Steinberg MB. Treating tobacco 
dependence as a chronic illness and a key modifiable 
predictor of disease. International Journal of Clinical 
Practice 2010;64(2):142–6.
Franck C, Budlovsky T, Windle SB, Filion KB, Eisenberg 
MJ. Electronic cigarettes in North America: history, use, 
and implications for smoking cessation. Circulation 
2014;129(19):1945–52.
Free C, Knight R, Robertson S, Whittaker R, Edwards P, 
Zhou W, Rodgers A, Cairns J, Kenward MG, Roberts I. 
Smoking cessation support delivered via mobile phone 
text messaging (txt2stop): a single-blind, randomised 
trial. Lancet 2011;378(9785):49–55.
Free C, Phillips G, Galli L, Watson L, Felix L, Edwards P, 
Patel V, Haines A. The effectiveness of mobile-health 
technology-based health behaviour change or disease 
management interventions for health care consumers: a 
systematic review. PLoS Medicine 2013;10(1):e1001362.
Free C, Whittaker R, Knight R, Abramsky T, Rodgers A, 
Roberts IG. Txt2stop: a pilot randomised controlled 
trial of mobile phone-based smoking cessation support. 
Tobacco Control 2009;18(2):88–91.
Freund M, Campbell E, Paul C, McElduff P, Walsh RA, 
Sakrouge R, Wiggers J, Knight J. Smoking care provi-
sion in hospitals: a review of prevalence. Nicotine and 
Tobacco Research 2008;10(5):757–74.
Freund M, Campbell E, Paul C, Sakrouge R, McElduff P, 
Walsh RA, Wiggers J, Knight J, Girgis A. Increasing 
smoking cessation care provision in hospitals: a 
meta-analysis of intervention effect. Nicotine and 
Tobacco Research 2009;11(6):650–62.
Friedman AS, Schpero WL, Busch SH. Evidence suggests 
that the ACA’s tobacco surcharges reduced insurance 
take-up and did not increase smoking cessation. Health 
Affairs 2016;35(7):1176–83.
Frosch DL, Krueger PM, Hornik RC, Cronholm PF, Barg 
FK. Creating demand for prescription drugs: a content 
analysis of television direct-to-consumer advertising. 
Annals of Family Medicine 2007;5(1):6–13.
Fucito LM, Czabafy S, Hendricks PS, Kotsen C, Richardson 
D, Toll BA. Pairing smoking-cessation services with 
lung cancer screening: A clinical guideline from the 
Association for the Treatment of Tobacco Use and 
Dependence and the Society for Research on Nicotine 
and Tobacco. Cancer 2016;122(8):1150–9.
Gallaway MS, Huang B, Chen Q, Tucker TC, McDowell JK, 
Durbin E, Stewart SL, Tai E. Smoking and smoking ces-
sation among persons with tobacco- and non-tobacco-
associated cancers. Journal of Community Health 2019.
García-Rodríguez O, Secades-Villa R, Flórez-Salamanca 
L, Okuda M, Liu SM, Blanco C. Probability and pre-
dictors of relapse to smoking: results of the National 
Epidemiologic Survey on Alcohol and Related 
Conditions (NESARC). Drug and Alcohol Dependence 
2013;132(3):479–85.
García-Vera MP, Sanz J. Análisis de la situación de los trat-
amientos para dejar de fumar basados en terapia cogni-
tivo-conductual y en parches de Nicotina [Analysis of 
the situation of treatments for smoking cessation based 
on cognitive-behavioral therapy and nicotine patches]. 
Psicooncología 2006;3(2–3):269–89.
Gelkopf M, Noam S, Rudinski D, Lerner A, Behrbalk P, 
Bleich A, Melamed Y. Nonmedication smoking reduc-
tion program for inpatients with chronic schizo-
phrenia: a randomized control design study. Journal of 
Nervous and Mental Disease 2012;200(2):142–6.
Gentzke AS, Creamer M, Cullen KA, Ambrose BK, Willis 
G, Jamal A, King BA. Vital signs: tobacco product use 
among middle and high school students, United States, 
2011–2018. Morbidity and Mortality Weekly Report 
2019;68(6):157–64.
Glasgow RE, Dickinson P, Fisher L, Christiansen S, 
Toobert DJ, Bender BG, Dickinson LM, Jortberg B, 
Estabrooks PA. Use of RE-AIM to develop a multi-media 
facilitation tool for the patient-centered medical home. 
Implementation Science 2011;6:118.
Glassman SD, Anagnost SC, Parker A, Burke D, Johnson JR, 
Dimar JR. The effect of cigarette smoking and smoking 
cessation on spinal fusion. Spine 2000;25(20):2608–15.
Gomajee R, El-Khoury F, Goldberg M, Zins M, Lemogne C, 
Wiernik E, Lequy-Flahault E, Romanello L, Kousignian 
I, Melchior M. Association between electronic cigarette 
use and smoking reduction in France. JAMA Internal 
Medicine 2019.
Goniewicz ML, Boykan R, Messina CR, Eliscu A, Tolentino 
J. High exposure to nicotine among adolescents who 
use JUUL and other vape pod systems (“pods”). Tobacco 
Control 2018a.
Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak 
A, Kurek J, Prokopowicz A, Jablonska-Czapla M, 
A Report of the Surgeon General
558  Chapter 6
Rosik-Dulewska C, Havel C, et al. Levels of selected car-
cinogens and toxicants in vapour from electronic ciga-
rettes. Tobacco Control 2014;23(2):133–9.
Goniewicz ML, Lingas EO, Hajek P. Patterns of electronic 
cigarette use and user beliefs about their safety and 
benefits: an internet survey. Drug and Alcohol Review 
2013;32(2):133–40.
Goniewicz ML, Smith DM, Edwards KC, Blount BC, Caldwell 
KL, Feng J, Wang L, Christensen C, Ambrose B, Borek 
N, et al. Comparison of nicotine and toxicant exposure 
in users of electronic cigarettes and combustible ciga-
rettes. JAMA Network Open 2018b;1(8):e185937.
Gordon JS, Andrews JA, Crews KM, Payne TJ, Severson 
HH, Lichtenstein E. Do faxed quitline referrals add 
value to dental office-based tobacco-use cessation inter-
ventions? Journal of the American Dental Association 
2010;141(8):1000–7.
Gottlieb S, Zeller M. A nicotine-focused framework for 
public health. New England Journal of Medicine 
2017;377(12):1111–4.
Gotts JE, Jordt S-E, McConnell R, Tarran R. What are the 
respiratory effects of e-cigarettes? BMJ 2019;366:l5275.
Graham AL, Carpenter KM, Cha S, Cole S, Jacobs MA, 
Raskob M, Cole-Lewis H. Systematic review and meta-
analysis of Internet interventions for smoking cessation 
among adults. Substance Abuse and Rehabilitation 
2016;7:55–69.
Grana R, Benowitz N, Glantz SA. E-cigarettes: a scientific 
review. Circulation 2014;129(19):1972–86.
Grant JM, Mottet LA, Tanis J, Herman JL, Harrison J, 
Keisling M. National Transgender Discrimination 
Survey Report on Health and Health Care: Findings 
of a Study by the National Center for Transgender 
Equality and the National Gay and Lesbian Task Force. 
Washington (DC): National Center for Transgender 
Equality and the National Gay and Lesbian Task Force, 
October 2010. 
Greenhalgh T, Macfarlane F, Steed L, Walton R. What 
works for whom in pharmacist-led smoking cessation 
support: realist review. BMC Medicine 2016;14(1):209.
Greenwood S, Perrin A, Duggan M. Social media update 
2016: Facebook usage and engagement is on the rise, 
while adoption of other platforms holds steady, November 
11, 2016; <http://www.pewinternet.org/2016/11/11/
social-media-update-2016/>; accessed: June 5, 2017.
Haas AL, Munoz RF, Humfleet GL, Reus VI, Hall SM. 
Influences of mood, depression history, and treatment 
modality on outcomes in smoking cessation. Journal of 
Consulting and Clinical Psychology 2004;72(4):563–70.
Hackshaw A, Morris JK, Boniface S, Tang JL, Milenkovic 
D. Low cigarette consumption and risk of coronary 
heart disease and stroke: meta-analysis of 141 cohort 
studies in 55 study reports. BMJ 2018;360:j5855.
Haines-Saah RJ, Kelly MT, Oliffe JL, Bottorff JL. Picture 
Me Smokefree: a qualitative study using social media 
and digital photography to engage young adults in 
tobacco reduction and cessation. Journal of Medical 
Internet Research 2015;17(1):e27.
Hajek P. Withdrawal-oriented therapy for smokers. British 
Journal of Addiction 1989;84(6):591–8.
Hajek P, Belcher M, Stapleton J. Enhancing the impact 
of groups: an evaluation of two group formats for 
smokers. British Journal of Clinical Psychology 
1985;24(Pt 4):289–94.
Hajek P, McRobbie H, Myers K. Efficacy of cytisine in 
helping smokers quit: systematic review and meta-
analysis. Thorax 2013a;68(11):1037–42.
Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers 
Smith K, Bisal N, Li J, Parrott S, Sasieni P, Dawkins 
L, et al. A randomized trial of e-cigarettes versus nic-
otine-replacement therapy. New England Journal of 
Medicine 2019;380(7):629–37.
Hajek P, Smith KM, Dhanji AR, McRobbie H. Is a combi-
nation of varenicline and nicotine patch more effective 
in helping smokers quit than varenicline alone? A ran-
domised controlled trial. BMC Medicine 2013b;11:140.
Hajek P, Stead LF, West R, Jarvis M, Hartmann-Boyce 
J, Lancaster T. Relapse prevention interventions for 
smoking cessation. Cochrane Database of Systematic 
Reviews 2013c, Issue 8. Art. No.: CD003999. DOI: 
10.1002/14651858.CD003999.pub4.
Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow 
A. Randomized comparative trial of nicotine polac-
rilex, a transdermal patch, nasal spray, and an inhaler. 
Archives of Internal Medicine 1999;159(17):2033–8.
Hall SM, Humfleet GL, Munoz RF, Reus VI, Prochaska 
JJ, Robbins JA. Using extended cognitive behav-
ioral treatment and medication to treat depen-
dent smokers. American Journal of Public Health 
2011;101(12):2349–56.
Hall SM, Humfleet GL, Munoz RF, Reus VI, Robbins JA, 
Prochaska JJ. Extended treatment of older cigarette 
smokers. Addiction 2009;104(6):1043–52.
Hall SM, Munoz RF, Reus VI. Cognitive-behavioral inter-
vention increases abstinence rates for depressive-
history smokers. Journal of Consulting and Clinical 
Psychology 1994;62(1):141–6.
Hall SM, Munoz RF, Reus VI, Sees KL, Duncan C, Humfleet 
GL, Hartz DT. Mood management and nicotine gum in 
smoking treatment: a therapeutic contact and placebo-
controlled study. Journal of Consulting and Clinical 
Psychology 1996;64(5):1003–9.
Hall SM, Prochaska JJ. Treatment of smokers with co-
occurring disorders: emphasis on integration in mental 
health and addiction treatment settings. Annual Review 
of Clinical Psychology 2009;5:409–31.
Interventions for Smoking Cessation and Treatments for Nicotine Dependence  559
Smoking Cessation
Hall SM, Tsoh JY, Prochaska JJ, Eisendrath S, Rossi JS, 
Redding CA, Rosen AB, Meisner M, Humfleet GL, Gorecki 
JA. Treatment for cigarette smoking among depressed 
mental health outpatients: a randomized clinical trial. 
American Journal of Public Health 2006;96(10):1808–14.
Halpern SD, Harhay MO, Saulsgiver K, Brophy C, Troxel 
AB, Volpp KG. A pragmatic trial of e-cigarettes, incen-
tives, and drugs for smoking cessation. New England 
Journal of Medicine 2018;378(24):2302–10.
Harrell PT, Simmons VN, Correa JB, Padhya TA, Brandon 
TH. Electronic nicotine delivery systems (“e-ciga-
rettes”): review of safety and smoking cessation effi-
cacy. Otolaryngology—Head and Neck Surgery 
2014;151(3):381–93.
Harrington KF, Cheong J, Hendricks S, Kohler C, Bailey 
WC. E-cigarette and traditional cigarette use among 
smokers during hospitalization and 6 months later. 
Cancer Epidemiology, Biomarkers, and Prevention 
2015;24(4):762.
Harris RP. The psychological effects of lung cancer 
screening on heavy smokers: another reason for con-
cern. JAMA Internal Medicine 2015;175(9):1537–8.
Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster 
T. Nicotine replacement therapy versus control for 
smoking cessation. Cochrane Database of Systematic 
Reviews 2018, Issue 5. Art. No.: CD000146. DOI: 
10.1002/14651858.CD000146.pub5.
Hartmann-Boyce J, Lancaster T, Stead LF. Print-based self-
help interventions for smoking cessation. Cochrane 
Database of Systematic Reviews 2014, Issue 6. Art. No.: 
CD001118. DOI: 10.1002/14651858.CD001118.pub3.
Hartmann-Boyce J, McRobbie H, Bullen C, Begh R, Stead 
LF, Hajek P. Electronic cigarettes for smoking cessa-
tion. Cochrane Database of Systematic Reviews 2016, 
Issue 9. Art. No.: CD010216. DOI: 10.1002/14651858.
CD010216.pub3.
Haskins BL, Lesperance D, Gibbons P, Boudreaux ED. 
A systematic review of smartphone applications for 
smoking cessation. Translational Behavioral Medicine 
2017;7(2):292–9.
Hassmiller KM, Warner KE, Mendez D, Levy DT, Romano 
E. Nondaily smokers: who are they? American Journal 
of Public Health 2003;93(8):1321–7.
Hatsukami DK, Hertsgaard LA, Vogel RI, Jensen JA, 
Murphy SE, Hecht SS, Carmella SG, al’Absi M, Joseph 
AM, Allen SS. Reduced nicotine content cigarettes and 
nicotine patch. Cancer Epidemiology, Biomarkers and 
Prevention 2013;22(6):1015–24.
Hatsukami DK, Kotlyar M, Hertsgaard LA, Zhang Y, 
Carmella SG, Jensen JA, Allen SS, Shields PG, Murphy 
SE, Stepanov I, et al. Reduced nicotine content ciga-
rettes: effects on toxicant exposure, dependence and 
cessation. Addiction 2010;105(2):343–55.
Hatsukami DK, Luo X, Dick L, Kangkum M, Allen SS, Murphy 
SE, Hecht SS, Shields PG, al’Absi M. Reduced nicotine 
content cigarettes and use of alternative nicotine prod-
ucts: exploratory trial. Addiction 2017;112(1):156–67.
Hatsukami DK, Luo X, Jensen JA, al’Absi M, Allen SS, 
Carmella SG, Chen M, Cinciripini PM, Denlinger-Apte 
R, Drobes DJ, et al. Effect of immediate vs gradual 
reduction in nicotine content of cigarettes on bio-
markers of smoke exposure: a randomized clinical trial. 
JAMA: the Journal of the American Medical Association 
2018;320(9):880–91.
Hawkins J, Hollingworth W, Campbell R. Long-term 
smoking relapse: a study using the British Household 
Panel Survey. Nicotine and Tobacco Research 
2010;12(12):1228–35.
Hayes SC. Acceptance and commitment therapy, rela-
tional frame theory, and the third wave of behavior 
therapy. Behavior Therapy 2004;35:639–65.
Hayes SC, Barnes-Holmes D, Roche B, editors. Relational 
Frame Theory: A Post-Skinnerian Account of Human 
Language and Cognition. New York (NY): Plenum 
Press, 2001.
Hayes SC, Levin ME, Plumb-Vilardaga J, Villatte JL, 
Pistorello J. Acceptance and commitment therapy and 
contextual behavioral science: examining the prog-
ress of a distinctive model of behavioral and cognitive 
therapy. Behavior Therapy 2013;44(2):180–98.
Hayes SC, Luoma JB, Bond FW, Masuda A, Lillis J. 
Acceptance and commitment therapy: model, pro-
cesses and outcomes. Behaviour Research and Therapy 
2006;44(1):1–25.
Hayes SC, Strosahl K, Wilson KG. Acceptance and 
Commitment Therapy: An Experiential Approach to 
Behavior Change. 1st ed. New York: The Guilford Press, 
1999.
Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, 
Durcan MJ, Sachs DP, Wolter TD, Buist AS, Johnston 
JA, et al. Sustained-release bupropion for pharmaco-
logic relapse prevention after smoking cessation. a ran-
domized, controlled trial. Annals of Internal Medicine 
2001;135(6):423–33.
Hebert KK, Cummins SE, Hernandez S, Tedeschi GJ, 
Zhu SH. Current major depression among smokers 
using a state quitline. American Journal of Preventive 
Medicine 2011;40(1):47–53.
Heffner JL, McClure JB, Mull KE, Anthenelli RM, Bricker 
JB. Acceptance and commitment therapy and nicotine 
patch for smokers with bipolar disorder: preliminary 
evaluation of in-person and telephone-delivered treat-
ment. Bipolar Disorders 2015;17(5):560–6.
Heffner JL, Watson NL, McClure JB, Anthenelli RM, Hohl 
S, Bricker JB. “I smoke like this to suppress these 
issues that are flaws of my character”: challenges and 
A Report of the Surgeon General
560  Chapter 6
facilitators of cessation among smokers with bipolar 
disorder. Journal of Dual Diagnosis 2018;14(1):32–9.
Heil SH, Higgins ST, Bernstein IM, Solomon LJ, Rogers 
RE, Thomas CS, Badger GJ, Lynch ME. Effects of 
voucher-based incentives on abstinence from cigarette 
smoking and fetal growth among pregnant women. 
Addiction 2008;103(6):1009–18.
Henningfield JE, Rose CA, Zeller M. Tobacco industry liti-
gation position on addiction: continued dependence on 
past views. Tobacco Control 2006;15(Suppl 4)iv27–iv36.
Hennrikus DJ, Jeffery RW, Lando HA. Occasional smoking 
in a Minnesota working population. American Journal 
of Public Health 1996;86(9):1260–6.
Hernández-López M, Luciano MC, Bricker JB, Roales-
Nieto JG, Montesinos F. Acceptance and commitment 
therapy for smoking cessation: a preliminary study of 
its effectiveness in comparison with cognitive behav-
ioral therapy. Psychology of Addictive Behaviors 
2009;23(4):723–30.
Higgins ST, Heil SH, Solomon LJ, Bernstein IM, Lussier 
JP, Abel RL, Lynch ME, Badger GJ. A pilot study on 
voucher-based incentives to promote abstinence from 
cigarette smoking during pregnancy and postpartum. 
Nicotine and Tobacco Research 2004;6(6):1015–20.
Higgins ST, Washio Y, Lopez AA, Heil SH, Solomon LJ, 
Lynch ME, Hanson JD, Higgins TM, Skelly JM, Redner 
R, et al. Examining two different schedules of finan-
cial incentives for smoking cessation among pregnant 
women. Preventive Medicine 2014;68:51–7.
Higgins TM, Higgins ST, Heil SH, Badger GJ, Skelly JM, 
Bernstein IM, Solomon LJ, Washio Y, Preston AM. Effects 
of cigarette smoking cessation on breastfeeding dura-
tion. Nicotine and Tobacco Research 2010;12(5):483–8.
Hitchman SC, Brose LS, Brown J, Robson D, McNeill A. 
Associations between e-cigarette type, frequency of 
use, and quitting smoking: findings from a longitu-
dinal online panel survey in Great Britain. Nicotine and 
Tobacco Research 2015;17(10):1187–94.
Hoeppner BB, Hoeppner SS, Seaboyer L, Schick MR, 
Wu GW, Bergman BG, Kelly JF. How smart are smart-
phone apps for smoking cessation? A content analysis. 
Nicotine and Tobacco Research 2016;18(5):1025–31.
Hoerger T, Boland E, Acquah JK, Alva M, Kish Doto J, 
Farrell K, Gard Read J, Goodrich C, Perry R, Romaire 
M, et al. Medicaid Incentives for Prevention of Chronic 
Diseases Model: Final Evaluation Report. Research 
Triangle Park (NC): RTI International, April 2017. 
Hofmann SG, Asmundson GJ, Beck AT. The science of cog-
nitive therapy. Behavior Therapy 2013;44(2):199–212.
Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A. 
The efficacy of cognitive behavioral therapy: a review 
of meta-analyses. Cognitive Therapy and Research 
2012;36(5):427–40.
Holla N, Brantley E, Ku L. Physicians’ recommendations 
to Medicaid patients about tobacco cessation. American 
Journal of Preventive Medicine 2018;55(6):762–9.
Hollis JF, McAfee TA, Fellows JL, Zbikowski SM, Stark M, 
Riedlinger K. The effectiveness and cost effectiveness 
of telephone counselling and the nicotine patch in a 
state tobacco quitline. Tobacco Control 2007;16(Suppl 
1):i53–i59.
Hollis JF, Polen MR, Whitlock EP, Lichtenstein E, Mullooly 
JP, Velicer WF, Redding CA. Teen reach: outcomes from 
a randomized, controlled trial of a tobacco reduc-
tion program for teens seen in primary medical care. 
Pediatrics 2005;115(4):981–9.
Hong AS, Elrashidi MY, Schroeder DR, Ebbert JO. 
Depressive symptoms among patients receiving vareni-
cline and bupropion for smoking cessation. Journal of 
Substance Abuse Treatment 2015;52:78–81.
Hu SS, Neff L, Agaku IT, Cox S, Day HR, Holder-Hayes E, 
King BA. Tobacco product use among adults—United 
States, 2013–2014. Morbidity and Mortality Weekly 
Report 2016;65(27):685–91.
Hughes JR, Keely J, Naud S. Shape of the relapse curve 
and long-term abstinence among untreated smokers. 
Addiction 2004;99(1):29–38.
Hughes JR, Keely JP, Fagerstrom KO, Callas PW. Intentions 
to quit smoking change over short periods of time. 
Addictive Behaviors 2005;30(4):653–62.
Hughes JR, Peters EN, Naud S. Effectiveness of over-the-
counter nicotine replacement therapy: a qualitative 
review of nonrandomized trials. Nicotine and Tobacco 
Research 2011;13(7):512–22.
Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, 
Lancaster T. Antidepressants for smoking cessation. 
Cochrane Database of Systematic Reviews 2014, 
Issue 1. Art. No.: CD000031. DOI: 10.1002/14651858.
CD000031.pub4.
Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, 
Dale LC, Khayrallah MA, Schroeder DR, Glover PN, 
Sullivan CR, et al. A comparison of sustained-release 
bupropion and placebo for smoking cessation. New 
England Journal of Medicine 1997;337(17):1195–202.
Hyland A, Rezaishiraz H, Bauer J, Giovino GA, Cummings 
KM. Characteristics of low-level smokers. Nicotine and 
Tobacco Research 2005;7(3):461–8.
Inoue-Choi M, Liao LM, Reyes-Guzman C, Hartge P, 
Caporaso N, Freedman ND. Association of long-term, 
low-intensity smoking with all-cause and cause-spe-
cific mortality in the National Institutes of Health-
AARP Diet and Health Study. JAMA Internal Medicine 
2017;177(1):87–95.
Institute of Medicine. Ending the Tobacco Problem: 
A Blueprint for the Nation. Washington (DC): National 
Academies Press, 2007.
Interventions for Smoking Cessation and Treatments for Nicotine Dependence  561
Smoking Cessation
Jamal A, Gentzke A, Hu SS, Cullen KA, Apelberg BJ, Homa 
DM, King BA. Tobacco use among middle and high 
school students—United States, 2011–2016. Morbidity 
and Mortality Weekly Report 2017;66(23):597–603.
Jamal A, King BA, Neff LJ, Whitmill J, Babb SD, Graffunder 
CM. Current cigarette smoking among adults—United 
States, 2005–2015. Morbidity and Mortality Weekly 
Report 2016;65(44):1205–11.
Jamal A, Phillips E, Gentzke AS, Homa DM, Babb SD, King 
BA, Neff LJ. Current cigarette smoking among adults—
United States, 2016. Morbidity and Mortality Weekly 
Report 2018;67(2):53–9.
Jemal A, Fedewa SA. Lung cancer screening with low-dose 
computed tomography in the United States—2010 to 
2015. JAMA Oncology 2017.
Jeong SH, Newcombe D, Sheridan J, Tingle M. 
Pharmacokinetics of cytisine, an alpha4 beta2 nicotinic 
receptor partial agonist, in healthy smokers following a 
single dose. Drug Testing and Analysis 2015;7(6):475–82.
Jha P, MacLennan M, Chaloupka FJ, Yurekli A, 
Ramasundarahettige C, Palipudi K, Zatonksi W, Asma 
S, Gupta PC. Chapter 10. Global hazards of tobacco and 
the benefits of smoking cessation and tobacco taxes. In: 
Gelband H, Jha P, Sankaranarayanan R, Horton S, edi-
tors. Cancer: Disease Control Priorities. 3rd ed., Vol. 3. 
Washington (DC):2015:175–94. 
Jha P, Ramasundarahettige C, Landsman V, Rostron B, 
Thun M, Anderson RN, McAfee T, Peto R. 21st-cen-
tury hazards of smoking and benefits of cessation in 
the United States. New England Journal of Medicine 
2013;368(4):341–50.
Johnson KC, Klesges LM, Somes GW, Coday MC, DeBon 
M. Access of over-the-counter nicotine replacement 
therapy products to minors. Archives of Pediatrics and 
Adolescent Medicine 2004;158(3):212–6.
Jones HA, Heffner JL, Mercer L, Wyszynski CM, Vilardaga 
R, Bricker JB. Web-based acceptance and commitment 
therapy smoking cessation treatment for smokers 
with depressive symptoms. Journal of Dual Diagnosis 
2015;11(1):56–62.
Joseph AM, Fu SS, Lindgren B, Rothman AJ, Kodl M, Lando 
H, Doyle B, Hatsukami D. Chronic disease management 
for tobacco dependence: a randomized, controlled trial. 
Archives of Internal Medicine 2011;171(21):1894–900.
Joseph AM, Rothman AJ, Almirall D, Begnaud A, Chiles 
C, Cinciripini PM, Fu SS, Graham AL, Lindgren BR, 
Melzer AC, et al. Lung cancer screening and smoking 
cessation clinical trials. SCALE (Smoking Cessation 
within the Context of Lung Cancer Screening) collabo-
ration. American Journal of Respiratory Care Medicine 
2018;197(2):172–82.
Kahler CW, Spillane NS, Busch AM, Leventhal AM. Time-
varying smoking abstinence predicts lower depressive 
symptoms following smoking cessation treatment. 
Nicotine and Tobacco Research 2011;13(2):146–50.
Kalkhoran S, Glantz SA. E-cigarettes and smoking ces-
sation in real-world and clinical settings: a systematic 
review and meta-analysis. Lancet Respiratory Medicine 
2016;4(2):116–28.
Kalkhoran S, Grana RA, Neilands TB, Ling PM. Dual use 
of smokeless tobacco or e-cigarettes with cigarettes 
and cessation. American Journal of Health Behavior 
2015;39(2):277–84.
Kameyama N, Chubachi S, Hegab AE, Yasuda H, Kagawa 
S, Tsutsumi A, Fukunaga K, Shimoda M, Kanai Y, 
Soejima K, et al. Intermittent exposure to cigarette 
smoke increases lung tumors and the severity of 
emphysema more than continuous exposure. American 
Journal of Respiratory Cell and Molecular Biology 
2018;59(2):179–88.
Karpinski JP, Timpe EM, Lubsch L. Smoking cessation 
treatment for adolescents. Journal of Pediatric and 
Pharmacology and Therapeutics 2010;15(4):249–63.
Kasza KA, Ambrose BK, Conway KP, Borek N, Taylor K, 
Goniewicz ML, Cummings KM, Sharma E, Pearson 
JL, Green VR, et al. Tobacco-product use by adults and 
youths in the United States in 2013 and 2014. New 
England Journal of Medicine 2017;376(4):342–53.
Kasza KA, Hyland AJ, Borland R, McNeill AD, Bansal-
Travers M, Fix BV, Hammond D, Fong GT, Cummings 
KM. Effectiveness of stop-smoking medications: find-
ings from the International Tobacco Control (ITC) 
Four Country Survey. Addiction 2013;108(1):193–202.
Katz R, Mesfin T, Barr K. Lessons from a community-
based mHealth diabetes self-management program: 
“it’s not just about the cell phone”. Journal of Health 
Communication 2012;17(Suppl 1)67–72.
Keenan PS. Smoking and weight change after new health 
diagnoses in older adults. Archives of Internal Medicine 
2009;169(3):237–42.
Keller PA, Feltracco A, Bailey LA, Li Z, Niederdeppe J, 
Baker TB, Fiore MC. Changes in tobacco quitlines in 
the United States, 2005–2006. Preventing Chronic 
Disease 2010;7(2):A36.
Keller PA, Schillo BA, Kerr AN, Lien RK, Saul J, Dreher 
M, Lachter RB. Increasing reach by offering choices: 
results from an innovative model for statewide ser-
vices for smoking cessation. Preventive Medicine 
2016;91:96–102.
Kelly MM, Sido H, Forsyth JP, Ziedonis DM, Kalman D, 
Cooney JL. Acceptance and commitment therapy 
smoking cessation treatment for veterans with post-
traumatic stress disorder: a pilot study. Journal of Dual 
Diagnosis 2015;11(1):50–5.
Kerr AN, Schillo BA, Keller PA, Lachter RB, Lien RK, Zook 
HG. Impact and effectiveness of a stand-alone NRT 
A Report of the Surgeon General
562  Chapter 6
starter kit in a statewide tobacco cessation program. 
American Journal of Health Promotion 2018.
Khoudigian S, Devji T, Lytvyn L, Campbell K, Hopkins R, 
O’Reilly D. The efficacy and short-term effects of elec-
tronic cigarettes as a method for smoking cessation: a 
systematic review and a meta-analysis. International 
Journal of Public Health 2016;61(2):257–67.
Khoury B, Lecomte T, Fortin G, Masse M, Therien P, 
Bouchard V, Chapleau MA, Paquin K, Hofmann SG. 
Mindfulness-based therapy: a comprehensive meta-anal-
ysis. Clinical Psychology Review 2013;33(6):763–71.
King BA, Creamer MR, Harrell M, Kelder S, Norman L, 
Perry CL. Surgeon General’s reports on tobacco: a con-
tinued legacy of unbiased and rigorous synthesis of the 
scientific evidence. Nicotine and Tobacco Research 
2018a;20(8):1033–6.
King BA, Dube SR, Babb SD, McAfee TA. Patient-reported 
recall of smoking cessation interventions from a health 
professional. Preventive Medicine 2013;57(5):715–7.
King BA, Gammon DG, Marynak KL, Rogers T. Electronic 
cigarette sales in the United States, 2013–2017. JAMA: 
the Journal of the American Medical Association 
2018b;320(13):1379–80.
Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, 
Bruning A, O’Brien JA, Smith C, Abdool-Gaffar MS, 
Emanuel S, Esterhuizen TM, et al. Efficacy of vareni-
cline combined with nicotine replacement therapy vs. 
varenicline alone for smoking cessation: a random-
ized clinical trial. JAMA: the Journal of the American 
Medical Association 2014;312(2):155–61.
Kong G, Ells DM, Camenga DR, Krishnan-Sarin S. Text 
messaging-based smoking cessation intervention: a nar-
rative review. Addictive Behaviors 2014;39(5):907–17.
Kotsen C, Santorelli ML, Bloom EL, Goldstein AO, Ripley-
Moffitt C, Steinberg MB, Burke MV, Foulds J. A nar-
rative review of intensive group tobacco treatment: 
clinical, research, and U.S. policy recommendations. 
Nicotine & Tobacco Research 2017:1–10.
Kotz D, Brown J, West R. “Real-world” effectiveness of 
smoking cessation treatments: a population study. 
Addiction 2014;109(3):491–9.
Kotz D, Viechtbauer W, Simpson C, van Schayck OC, West 
R, Sheikh A. Cardiovascular and neuropsychiatric risks 
of varenicline: a retrospective cohort study. Lancet 
Respiratory Medicine 2015;3(10):761–8.
Koutroumpisa P, Leiponenb A. Crowdsourcing mobile cov-
erage. Telecommunications Policy 2016;40(6):532–44.
Krebs P, Rogers E, Smelson D, Fu S, Wang B, Sherman 
S. Relationship between tobacco cessation and mental 
health outcomes in a tobacco cessation trial. Journal of 
Health Psychology 2016.
Kruger J, O’Halloran A, Rosenthal AC, Babb SD, Fiore MC. 
Receipt of evidence-based brief cessation interventions 
by health professionals and use of cessation assisted 
treatments among current adult cigarette-only 
smokers: National Adult Tobacco Survey, 2009–2010. 
BMC Public Health 2016;16:141.
Kuiper N, Zhang L, Lee J, Babb SD, Anderson CM, 
Shannon C, Welton M, Lew R, Zhu SH. A national 
Asian-language smokers’ quitline—United States, 
2012–2014. Preventing Chronic Disease 2015;12:E99.
Lakon CM, Pechmann C, Wang C, Pan L, Delucchi K, 
Prochaska JJ. Mapping engagement in Twitter-based 
support networks for adult smoking cessation. American 
Journal of Public Health 2016;106(8):1374–80.
Lam C, West A. Are electronic nicotine delivery systems an 
effective smoking cessation tool? Canadian Journal of 
Respiratory Therapy 2015;51(4):93–8.
Lancaster T, Stead LF. Individual behavioural counsel-
ling for smoking cessation. Cochrane Database of 
Systematic Reviews 2017, Issue 3. Art. No.: CD001292. 
DOI: 10.1002/14651858.CD001292.pub3.
Larabie LC. To what extent do smokers plan quit attempts? 
Tobacco Control 2005;14(6):425–8.
Laude JR, Bailey SR, Crew E, Varady A, Lembke A, McFall 
D, Jeon A, Killen D, Killen JD, David SP. Extended 
treatment for cigarette smoking cessation: a random-
ized control trial. Addiction 2017;112(8):1451–9.
Lavernia CJ, Sierra RJ, Gomez-Marin O. Smoking and 
joint replacement: resource consumption and short-
term outcome. Clinical Orthopaedics and Related 
Research 1999;(367):172–80.
Leas EC, Pierce JP, Benmarhnia T, White MM, Noble ML, 
Trinidad DR, Strong DR. Effectiveness of pharmaceu-
tical smoking cessation aids in a nationally represen-
tative cohort of American smokers. Journal of the 
National Cancer Institute 2018;110(6):581–7.
Lee JG, Matthews AK, McCullen CA, Melvin CL. Promotion 
of tobacco use cessation for lesbian, gay, bisexual, and 
transgender people: a systematic review. American 
Journal of Preventive Medicine 2014;47(6):823–31.
Lee SM, Landry J, Jones PM, Buhrmann O, Morley-Forster 
P. Long-term quit rates after a perioperative smoking 
cessation randomized controlled trial. Anesthesia and 
Analgesia 2015;120(3):582–7.
Lerman C, Schnoll RA, Hawk LW Jr, Cinciripini P, George 
TP, Wileyto EP, Swan GE, Benowitz NL, Heitjan DF, 
Tyndale RF, et al. Use of the nicotine metabolite ratio as 
a genetically informed biomarker of response to nico-
tine patch or varenicline for smoking cessation: a ran-
domised, double-blind placebo-controlled trial. Lancet 
Respiratory Medicine 2015;3(2):131–8.
Levy DT, Yuan Z, Luo Y, Abrams DB. The Relationship of 
E-Cigarette Use to Cigarette Quit Attempts and Cessation: 
Insights From a Large, Nationally Representative U.S. 
Survey. Nicotine and Tobacco Research 2018;20(8):931–9.
Interventions for Smoking Cessation and Treatments for Nicotine Dependence  563
Smoking Cessation
Li S, Li Z, Pei L, Le AD, Liu F. The alpha7nACh-NMDA 
receptor complex is involved in cue-induced reinstate-
ment of nicotine seeking. Journal of Experimental 
Medicine 2012;209(12):2141–7.
Lindson-Hawley N, Aveyard P, Hughes JR. Reduction 
versus abrupt cessation in smokers who want to quit. 
Cochrane Database of Systematic Reviews 2012, 
Issue 11. Art. No.: CD008033. DOI: 10.1002/14651858.
CD008033.pub3.
Lindson-Hawley N, Hartmann-Boyce J, Fanshawe TR, 
Begh R, Farley A, Lancaster T. Interventions to reduce 
harm from continued tobacco use. Cochrane Database 
of Systematic Reviews 2016, Issue 10. Art. No.: 
CD005231. DOI: 10.1002/14651858.CD005231.pub3.
Lindson-Hawley N, Thompson TP, Begh R. Motivational 
interviewing for smoking cessation. Cochrane 
Database of Systematic Reviews 2015, Issue 3. Art. No.: 
CD006936. DOI: 10.1002/14651858.CD006936.pub3.
Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, 
Hartmann-Boyce J. Different doses, durations and 
modes of delivery of nicotine replacement therapy for 
smoking cessation. Cochrane Database of Systematic 
Reviews 2019, Issue 4. Art. No.: CD013308. DOI: 
10.1002/14651858.CD013308.
Linehan MM, Korslund KE, Harned MS, Gallop RJ, Lungu 
A, Neacsiu AD, McDavid J, Comtois KA, Murray-Gregory 
AM. Dialectical behavior therapy for high suicide risk in 
individuals with borderline personality disorder: a ran-
domized clinical trial and component analysis. JAMA 
Psychiatry 2015;72(5):475–82.
Lipari RN, Van Horn SL. Smoking and mental ill-
ness among adults in the United States. Rockville 
(MD): Center for Behavioral Health Statistics and 
Quality, Substance Abuse and Mental Health Services 
Administration, March 30, 2017. 
Little MA, Talcott GW, Bursac Z, Linde BD, Pagano LA, 
Messler EC, Ebbert JO, Klesges RC. Efficacy of a brief 
tobacco intervention for tobacco and nicotine con-
taining product use in the U.S. Air Force. Nicotine and 
Tobacco Research 2016;18(5):1142–9.
Liu X, Li R, Lanza ST, Vasilenko SA, Piper M. Understanding 
the role of cessation fatigue in the smoking cessation pro-
cess. Drug and Alcohol Dependence 2013;133(2):548–55.
Livingstone-Banks J, Norris E, Hartmann-Boyce J, West 
R, Jarvis M, Hajek P. Relapse prevention interven-
tions for smoking cessation. Cochrane Database of 
Systematic Reviews 2019, Issue 2. Art. No.: CD003999. 
DOI: 10.1002/14651858.CD003999.pub5.
Løchen ML, Gram IT, Mannsverk J, Mathiesen EB, Njølstad 
I, Schirmer H, Wilsgaard T, Jacobsen BK. Association 
of occasional smoking with total mortality in the pop-
ulation-based Tromsø study, 2001–2015. BMJ Open 
2017;7(12):e019107.
Lumley J, Chamberlain C, Dowswell T, Oliver S, Oakley 
L, Watson L. Interventions for promoting smoking 
cessation during pregnancy. Cochrane Database of 
Systematic Reviews 2009, Issue 3. Art. No.: CD001055. 
DOI: 10.1002/14651858.CD001055.pub3.
Luo SX, Covey LS, Hu MC, Levin FR, Nunes EV, Winhusen 
TM. Toward personalized smoking-cessation treatment: 
Using a predictive modeling approach to guide decisions 
regarding stimulant medication treatment of atten-
tion-deficit/hyperactivity disorder (ADHD) in smokers. 
American Journal on Addictions 2015;24(4):348–56.
Luoto R, Uutela A, Puska P. Occasional smoking increases 
total and cardiovascular mortality among men. Nicotine 
and Tobacco Research 2000;2(2):133–9.
Lussier JP, Heil SH, Mongeon JA, Badger GJ, Higgins 
ST. A meta-analysis of voucher-based reinforce-
ment therapy for substance use disorders. Addiction 
2006;101(2):192–203.
Maciosek MV, LaFrance AB, Dehmer SP, McGree DA, 
Flottemesch TJ, Xu Z, Solberg LI. Updated priorities 
among effective clinical preventive services. Annals of 
Family Medicine 2017a;15(1):14–22.
Maciosek MV, LaFrance AB, Dehmer SP, McGree DA, Xu 
Z, Flottemesch TJ, Solberg LI. Health benefits and 
cost-effectiveness of brief clinician tobacco coun-
seling for youth and adults. Annals of Family Medicine 
2017b;15(1):37–47.
Madison MC, Landers CT, Gu BH, Chang CY, Tung HY, 
You R, Hong MJ, Baghaei N, Song LZ, Porter P, et al. 
Electronic cigarettes disrupt lung lipid homeostasis 
and innate immunity independent of nicotine. Journal 
of Clinical Investigation 2019;129(10):4290–430.
Magill M, Ray LA. Cognitive-behavioral treatment with 
adult alcohol and illicit drug users: a meta-analysis 
of randomized controlled trials. Journal of Studies on 
Alcohol and Drugs 2009;70(4):516–27.
Malaiyandi V, Sellers EM, Tyndale RF. Implications of 
CYP2A6 genetic variation for smoking behaviors and 
nicotine dependence. Clinical Pharmacology and 
Therapeutics 2005;77(3):145–58.
Malas M, van der Tempel J, Schwartz R, Minichiello A, 
Lightfoot C, Noormohamed A, Andrews J, Zawertailo 
L, Ferrence R. Electronic Cigarettes for Smoking 
Cessation: A Systematic Review. Nicotine and Tobacco 
Research 2016;18(10):1926–36.
Mann N, Nonnemaker J, Chapman L, Shaikh A, Thompson 
J, Juster H. Comparing the New York State Smokers’ 
Quitline reach, services offered, and quit outcomes 
to 44 other state quitlines, 2010 to 2015. American 
Journal of Health Promotion 2018;32(5):1264–72.
Manzoli L, Flacco ME, Fiore M, La Vecchia C, Marzuillo 
C, Gualano MR, Liguori G, Cicolini G, Capasso L, 
D’Amario C, et al. Electronic cigarettes efficacy 
A Report of the Surgeon General
564  Chapter 6
and safety at 12  months: cohort study. PLoS One 
2015;10(6):e0129443.
Markham CM, Craig Rushing S, Jessen C, Gorman G, 
Torres J, Lambert WE, Prokhorov AV, Miller L, Allums-
Featherston K, Addy RC, et al. Internet-based delivery 
of evidence-based health promotion programs among 
American Indian and Alaska Native Youth: a case study. 
JMIR Research Protocols 2016;5(4):e225.
Marshall HM, Courtney DA, Passmore LH, McCaul EM, 
Yang IA, Bowman RV, Fong KM. Brief tailored smoking 
cessation counseling in a lung cancer screening popu-
lation is feasible: a pilot randomized controlled trial. 
Nicotine and Tobacco Research 2016;18(7):1665–9.
Marzano L, Bardill A, Fields B, Herd K, Veale D, Grey N, 
Moran P. The application of mHealth to mental health: 
opportunities and challenges. Lancet Psychiatry 
2015;2(10):942–8.
May S, West R. Do social support interventions (“buddy 
systems”) aid smoking cessation? A review. Tobacco 
Control 2000;9(4):415–22.
May S, West R, Hajek P, McEwen A, McRobbie H. 
Randomized controlled trial of a social support 
(‘buddy’) intervention for smoking cessation. Patient 
Education and Counseling 2006;64(1–3):235–41.
Mazurek JM, England LJ. Cigarette smoking among 
working women of reproductive age—United 
States, 2009–2013. Nicotine and Tobacco Research 
2016;18(5):894–9.
McAfee T. Re: effect of offering different levels of support 
and free nicotine replacement therapy via an English 
national telephone quitline: randomised controlled 
trial [letter to the editor]. BMJ 2012;344:e1696.
McAfee T, Davis KC, Shafer P, Patel D, Alexander R, 
Bunnell R. Increasing the dose of television adver-
tising in a national antismoking media campaign: 
results from a randomised field trial. Tobacco Control 
2017;26(1):19–28.
McClure JB, Hartzler AL, Catz SL. Design considerations 
for smoking cessation apps: feedback from nicotine 
dependence treatment providers and smokers. JMIR 
mHhealth uHhealth 2016;4(1):e17.
McCrabb S, Baker AL, Attia J, Skelton E, Twyman L, Palazzi 
K, McCarter K, Ku D, Bonevski B. Internet-based pro-
grams incorporating behavior change techniques are 
associated with increased smoking cessation in the gen-
eral population: a systematic review and meta-analysis. 
Annals of Behavioral Medicine 2019;53(2):180–95.
McFall M, Saxon AJ, Malte CA, Chow B, Bailey S, Baker 
DG, Beckham JC, Boardman KD, Carmody TP, Joseph 
AM, et al. Integrating tobacco cessation into mental 
health care for posttraumatic stress disorder: a ran-
domized controlled trial. JAMA: the Journal of the 
American Medical Association 2010;304(22):2485–93.
McKee SA, Smith PH, Kaufman M, Mazure CM, 
Weinberger AH. Sex differences in varenicline efficacy 
for smoking cessation: a meta-analysis. Nicotine and 
Tobacco Research 2016;18(5):1002–11.
McKelvey K, Thrul J, Ramo D. Impact of quitting smoking 
and smoking cessation treatment on substance use 
outcomes: an updated and narrative review. Addictive 
Behaviors 2017;65:161–70.
McRobbie H, Bullen C, Hartmann-Boyce J, Hajek P. 
Electronic cigarettes for smoking cessation and reduc-
tion. Cochrane Database of Systematic Reviews 2014, 
Issue 12. Art. No.: CD010216. DOI: 10.1002/14651858.
CD010216.pub2.
Mercincavage M, Wileyto EP, Saddleson ML, Lochbuehler 
K, Donny EC, Strasser AA. Attrition during a ran-
domized controlled trial of reduced nicotine con-
tent cigarettes as a proxy for understanding accept-
ability of nicotine product standards. Addiction 
2017;112(6):1095–103.
Metse AP, Wiggers JH, Wye PM, Wolfenden L, Prochaska 
JJ, Stockings EA, Williams JM, Ansell K, Fehily C, 
Bowman JA. Smoking and mental illness: a biblio-
metric analysis of research output over time. Nicotine 
and Tobacco Research 2017;19(1):24–31.
Meyers L, Voller EK, McCallum EB, Thuras P, Shallcross S, 
Velasquez T, Meis L. Treating veterans with PTSD and 
borderline personality symptoms in a 12-week inten-
sive outpatient setting: findings from a pilot program. 
Journal of Traumatic Stress 2017;30(2):178–81.
Michie S, Richardson M, Johnston M, Abraham C, Francis 
J, Hardeman W, Eccles MP, Cane J, Wood CE. The 
behavior change technique taxonomy (v1) of 93 hier-
archically clustered techniques: building an interna-
tional consensus for the reporting of behavior. Annals 
of Behavioral Medicine 2013;46(1):81–95. 
Miech R, Johnston L, O’Malley PM, Bachman JG, Patrick 
ME. Adolescent vaping and nicotine use in 2017–
2018—U.S. national estimates. New England Journal 
of Medicine 2019;380(2):192–3.
Miech RA, Schulenberg JE, Johnston LD, Bachman JG, 
O’Malley PM, Patrick ME. National adolescent drug trends 
in 2018 [press release], December 17, 2018; <http://
monitoringthefuture.org/pressreleases/18drugpr.pdf>; 
accessed: March 14, 2019.
Miller WR. Motivational interviewing with drinkers. 
Behavioural Psychotherapy 1983;11:147–72.
Miller WR, Rollnick S. Motivational Interviewing: 
Preparing People for Change. 2nd ed. New York: The 
Guilford Press, 2002.
Mirbolouk M, Charkhchi P, Kianoush S, Uddin SMI, 
Orimoloye OA, Jaber R, Bhatnagar A, Benjamin EJ, Hall 
ME, DeFilippis AP, et al. Prevalence and distribution 
of e-cigarette use among U.S. adults: Behavioral Risk 
Interventions for Smoking Cessation and Treatments for Nicotine Dependence  565
Smoking Cessation
Factor Surveillance System, 2016. Annals of Internal 
Medicine 2018;169(7):429–38.
Møller AM, Villebro N, Pedersen T, Tønnesen H. Effect 
of preoperative smoking intervention on postopera-
tive complications: a randomised clinical trial. Lancet 
2002;359(9301):114–7.
Moolchan ET, Robinson ML, Ernst M, Cadet JL, Pickworth 
WB, Heishman SJ, Schroeder JR. Safety and effi-
cacy of the nicotine patch and gum for the treat-
ment of adolescent tobacco addiction. Pediatrics 
2005;115(4):e407–14.
Moritz ED, Zapata LB, Lekiachvili A, Glidden E, Annor 
FB, Werner AK, Ussery EN, Hughes MM, Kimball A, 
DeSisto CL, et al. Update: characteristics of patients 
in a national outbreak of e-cigarette, or vaping, 
product use-associated lung injuries—United States, 
October 2019. Morbidity and Mortality Weekly Report 
2019;68(43):985–9.
Mosher WD, Jones J, Abma JC. Intended and unintended 
births in the United States: 1982–2010. National Health 
Statistics Reports No. 55. Hyattsville (MD): National 
Center for Health Statistics, 2012. 
Mottillo S, Filion KB, Belisle P, Joseph L, Gervais A, 
O’Loughlin J, Paradis G, Pihl R, Pilote L, Rinfret S, 
et al. Behavioural interventions for smoking cessa-
tion: a meta-analysis of randomized controlled trials. 
European Heart Journal 2009;30(6):718–30.
Moyer VA. Screening for lung cancer: U.S. Preventive 
Services Task Force recommendation statement. 
Annals of Internal Medicine 2014;160(5):330–8.
Mullen KA, Coyle D, Manuel D, Nguyen HV, Pham B, Pipe 
AL, Reid RD. Economic evaluation of a hospital-initiated 
intervention for smokers with chronic disease, in 
Ontario, Canada. Tobacco Control 2015;24(5):489–96.
Mullen KA, Manuel DG, Hawken SJ, Pipe AL, Coyle D, 
Hobler LA, Younger J, Wells GA, Reid RD. Effectiveness 
of a hospital-initiated smoking cessation programme: 
2-year health and healthcare outcomes. Tobacco 
Control 2017;26(3):293–9.
Murphy-Hoefer R, Davis KC, Beistle D, King BA, Duke J, 
Rodes R, Graffunder C. Impact of the Tips From Former 
Smokers campaign on population-level smoking 
cessation, 2012–2015. Preventing Chronic Disease 
2018;15:E71.
Myung SK, Ju W, Jung HS, Park CH, Oh SW, Seo H, Kim 
H. Efficacy and safety of pharmacotherapy for smoking 
cessation among pregnant smokers: a meta-analysis. 
BJOG 2012;119(9):1029–39.
Nabavizadeh P, Liu J, Havel CM, Ibrahim S, Derakhshandeh 
R, Jacob P III, Springer ML. Vascular endothelial 
function is impaired by aerosol from a single IQOS 
HeatStick to the same extent as by cigarette smoke. 
Tobacco Control 2018;27(Suppl 1):S13–S19.
Nahhas GJ, Wilson D, Talbot V, Cartmell KB, Warren GW, 
Toll BA, Carpenter MJ, Cummings KM. Feasibility of 
implementing a hospital-based “opt-out” tobacco-
cessation service. Nicotine and Tobacco Research 
2017;19(8):937–43.
Nakamura M, Abe M, Ohkura M, Treadow J, Yu CR, 
Park PW. Efficacy of varenicline for cigarette reduc-
tion before quitting in Japanese smokers: a subpopu-
lation analysis of the Reduce to Quit Trial. Clinical 
Therapeutics 2017;39(4):863–72.
Nardone N, Donny EC, Hatsukami DK, Koopmeiners JS, 
Murphy SE, Strasser AA, Tidey JW, Vandrey R, Benowitz 
NL. Estimations and predictors of non-compliance 
in switchers to reduced nicotine content cigarettes. 
Addiction 2016;111(12):2208–16.
Nathan Mann, RTI International. personal communica-
tion, May 6, 2019. 
National Academies of Sciences, Engineering, and 
Medicine. Public Health Consequences of E-Cigarettes. 
Washington (DC): The National Academies Press, 2018. 
National Cancer Institute and Centers for Disease Control 
and Prevention. Smokeless Tobacco and Public Health: 
A Global Perspective. Bethesda (MD): U.S. Department 
of Health and Human Services, Centers for Disease 
Control and Prevention and National Institutes of 
Health, National Cancer Institute, 2014. NIH Publication 
No. 14-7983.
National Center for Health Statistics. Health, United States, 
2017: With Special Feature on Mortality. Hyattsville 
(MD): National Center for Health Statistics, 2018. 
Naughton F. Delivering “just-in-time” smoking cessa-
tion support via mobile phones: current knowledge 
and future directions. Nicotine and Tobacco Research 
2016.
Navon L, Jones CM, Ghinai I, King BA, Briss PA, Hacker 
KA, Layden JE. Risk factors for e-cigarette, or vaping, 
product use-associated lung injury (EVALI) among 
adults who use e-cigarette, or vaping, products—
Illinois, July–October 2019. Morbidity and Mortality 
Weekly Report 2019 Nov 15;68(45):1034–9.
Newhall K, Suckow B, Spangler E, Brooke BS, Schanzer 
A, Tan TW, Burnette M, Edelen MO, Farber A, Goodney 
P. Impact and duration of brief surgeon-delivered 
smoking cessation advice on attitudes regarding nico-
tine dependence and tobacco harms for patients with 
peripheral arterial disease. Annals of Vascular Surgery 
2017;38:113–21.
Ng JY, Ntoumanis N, Thogersen-Ntoumani C, Deci EL, Ryan 
RM, Duda JL, Williams GC. Self-determination theory 
applied to health contexts: a meta-analysis. Perspectives 
on Psychological Science 2012;7(4):325–40.
Nilsen W, Kumar S, Shar A, Varoquiers C, Wiley T, Riley WT, 
Pavel M, Atienza AA. Advancing the science of mHealth. 
A Report of the Surgeon General
566  Chapter 6
Journal of Health Communication 2012;17(Suppl 
1):5–10.
Nolan MB, Warner DO. Perioperative tobacco use treat-
ments: putting them into practice. BMJ 2017;358:j3340.
North American Quitline Consortium. 2015 survey, n.d.a; 
<http://www.naquitline.org/?page=2015Survey>; 
accessed: August 1, 2017.
North American Quitline Consortium. Map: looking for 
data about quitlines?, n.d.b; <http://map.naquitline.
org/>; accessed: August 1, 2017.
O’Connell G, Pritchard JD, Prue C, Thompson J, Verron T, 
Graff D, Walele T. A randomised, open-label, cross-over 
clinical study to evaluate the pharmacokinetic profiles 
of cigarettes and e-cigarettes with nicotine salt formu-
lations in U.S. adult smokers. Internal and Emergency 
Medicine 2019.
O’Malley SS, Zweben A, Fucito LM, Wu R, Piepmeier ME, 
Ockert DM, Bold KW, Petrakis I, Muvvala S, Jatlow 
P, et al. Effect of varenicline combined with medical 
management on alcohol use disorder with comorbid 
cigarette smoking: a randomized clinical trial. JAMA 
Psychiatry 2018;75(2):129–38.
Oquendo MA, Galfalvy H, Russo S, Ellis SP, Grunebaum 
MF, Burke A, Mann JJ. Prospective study of clinical 
predictors of suicidal acts after a major depressive 
episode in patients with major depressive disorder 
or bipolar disorder. American Journal of Psychiatry 
2004;161(8):1433–41.
Osei AD, Mirbolouk M, Orimoloye OA, Dzaye O, Uddin 
SMI, Benjamin EJ, Hall ME, DeFilippis AP, Stokes A, 
Bhatnagar A, et al. Association between e-cigarette use 
and cardiovascular disease among never and current 
combustible-cigarette smokers. American Journal of 
Medicine 2019.
Pacek LR, McClernon FJ, Bosworth HB. Adherence to 
pharmacological smoking cessation interventions: a lit-
erature review and synthesis of correlates and barriers. 
Nicotine and Tobacco Research 2018;20(10):1163–72.
Park ER, Gareen IF, Japuntich S, Lennes I, Hyland K, 
DeMello S, Sicks JD, Rigotti NA. Primary care pro-
vider-delivered smoking cessation interventions and 
smoking cessation among participants in the National 
Lung Screening Trial. JAMA Internal Medicine 
2015;175(9):1509–16.
Patel K, Schlundt D, Larson C, Wang H, Brown A, 
Hargreaves M. Chronic illness and smoking cessation. 
Nicotine and Tobacco Research 2009;11(8):933–9.
Patnode CD, Henderson JT, Thompson JH, Senger CA, 
Fortmann SP, Whitlock EP. Behavioral Counseling and 
Pharmacotherapy Interventions for Tobacco Cessation 
in Adults, Including Pregnant Women: A Review of 
Reviews for the U.S. Preventive Services Task Force. 
Evidence Syntheses No. 134. Rockville (MD): Agency 
for Healthcare Research and Quality, 2015. Report No. 
14-05200-EF-1. 
Patnode CD, O’Connor E, Whitlock EP, Perdue LA, Soh 
C, Hollis J. Primary care-relevant interventions for 
tobacco use prevention and cessation in children and 
adolescents: a systematic evidence review for the U.S. 
Preventive Services Task Force. Annals of Internal 
Medicine 2013;158(4):253–60.
Pechmann C, Delucchi K, Lakon CM, Prochaska JJ. 
Randomised controlled trial evaluation of Tweet2Quit: 
a social network quit-smoking intervention. Tobacco 
Control 2017;26(2):188–94.
Peirson L, Ali MU, Kenny M, Raina P, Sherifali D. 
Interventions for prevention and treatment of tobacco 
smoking in school-aged children and adolescents: a sys-
tematic review and meta-analysis. Preventive Medicine 
2016;85:20–31.
Perkins KA, Conklin CA, Levine MD. Cognitive-Behavioral 
Therapy for Smoking Cessation: A Practical Guidebook 
to the Most Effective Treatments. New York (NY): 
Routledge, 2008.
Perkins KA, Scott J. Sex differences in long-term smoking 
cessation rates due to nicotine patch. Nicotine and 
Tobacco Research 2008;10(7):1245–50.
Pesis-Katz I, Williams GC, Niemiec CP, Fiscella K. Cost-
effectiveness of intensive tobacco dependence inter-
vention based on self-determination theory. American 
Journal of Managed Care 2011;17(10):e393–e398.
Pew Research Center. Internet/broadband fact sheet, 2017a; 
<http://www.pewinternet.org/fact-sheet/internet-broad-
band/>; accessed: June 8, 2017.
Pew Research Center. Mobile fact sheet, January 12, 2017b; 
<http://www.pewinternet.org/fact-sheet/mobile/>; 
accessed: March 6, 2017.
Pfizer. Nicotrol® NS (nicotine nasal spray), June 2010; 
<https://www.accessdata.fda.gov/drugsatfda_docs/
label/2010/020385s010lbl.pdf>; accessed: November 
29, 2018.
Pfizer. Medication guide: Chantix (varenicline) tablets, 
June 2018; <http://labeling.pfizer.com/ShowLabeling.
aspx?id=557&section=MedGuide>; accessed: January 
8, 2019.
Pierce JP, Cummins SE, White MM, Humphrey A, Messer 
K. Quitlines and nicotine replacement for smoking ces-
sation: do we need to change policy? Annual Review of 
Public Health 2012;33:341–56.
Pierce JP, Gilpin EA. Impact of over-the-counter sales on 
effectiveness of pharmaceutical aids for smoking ces-
sation. JAMA: the Journal of the American Medical 
Association 2002;288(10):1260–4.
Pierce JP, White MM, Messer K. Changing age-spe-
cific patterns of cigarette consumption in the United 
States, 1992–2002: association with smoke-free homes 
Interventions for Smoking Cessation and Treatments for Nicotine Dependence  567
Smoking Cessation
and state-level tobacco control activity. Nicotine and 
Tobacco Research 2009;11(2):171–7.
Piñeiro B, Simmons VN, Palmer AM, Correa JB, Brandon 
TH. Smoking cessation interventions within the 
context of Low-Dose Computed Tomography lung 
cancer screening: a systematic review. Lung Cancer 
2016;98:91–8.
Piper ME, Fiore MC, Smith SS, Fraser D, Bolt DM, Collins 
LM, Mermelstein R, Schlam TR, Cook JW, Jorenby DE, 
et al. Identifying effective intervention components for 
smoking cessation: a factorial screening experiment. 
Addiction 2016;111(1):129–41.
Piper ME, McCarthy DE, Bolt DM, Smith SS, Lerman C, 
Benowitz N, Fiore MC, Baker TB. Assessing dimensions 
of nicotine dependence: an evaluation of the Nicotine 
Dependence Syndrome Scale (NDSS) and the Wisconsin 
Inventory of Smoking Dependence Motives (WISDM). 
Nicotine and Tobacco Research 2008;10(6):1009–20.
Piper ME, Schlam TR, Cook JW, Smith SS, Bolt DM, Loh 
WY, Mermelstein R, Collins LM, Fiore MC, Baker TB. 
Toward precision smoking cessation treatment I: mod-
erator results from a factorial experiment. Drug and 
Alcohol Dependence 2017;171:59–65.
Pirie K, Peto R, Reeves GK, Green J, Beral V. The 21st cen-
tury hazards of smoking and benefits of stopping: a pro-
spective study of one million women in the UK. Lancet 
2013;381(9861):133–41.
Pisinger C, Vestbo J, Borch-Johnsen K, Jorgensen T. 
It is possible to help smokers in early motivational 
stages to quit. The Inter99 Study. Preventive Medicine 
2005;40(3):278–84.
Pollak KI, Oncken CA, Lipkus IM, Lyna P, Swamy GK, 
Pletsch PK, Peterson BL, Heine RP, Brouwer RJ, Fish 
L, et al. Nicotine replacement and behavioral therapy 
for smoking cessation in pregnancy. American Journal 
of Preventive Medicine 2007;33(4):297–305.
Popova L, Ling PM. Alternative tobacco product use and 
smoking cessation: a national study. American Journal 
of Public Health 2013;103(5):923–30.
Potkin SG, Alphs L, Hsu C, Krishnan KR, Anand R, 
Young FK, Meltzer H, Green A. Predicting suicidal 
risk in schizophrenic and schizoaffective patients in 
a prospective two-year trial. Biological Psychiatry 
2003;54(4):444–52.
Prochaska JJ, Benowitz NL. The past, present, and future of 
nicotine addiction therapy. Annual Review of Medicine 
2016;67:467–86.
Prochaska JJ, Benowitz NL. Current advances in research 
in treatment and recovery: nicotine addiction. Science 
Advances 2019;5(10):eaay9763.
Prochaska JJ, Das S, Young-Wolff KC. Smoking, mental 
illness, and public health. Annual Review of Public 
Health 2017;38:165–85.
Prochaska JJ, Delucchi K, Hall SM. A meta-anal-
ysis of smoking cessation interventions with indi-
viduals in substance abuse treatment or recovery. 
Journal of Consulting and Clinical Psychology 
2004;72(6):1144–56.
Prochaska JJ, Grana RA. E-cigarette use among smokers with 
serious mental illness. PLoS One 2014;9(11):e113013.
Prochaska JJ, Hall SE, Delucchi K, Hall SM. Efficacy of 
initiating tobacco dependence treatment in inpatient 
psychiatry: a randomized controlled trial. American 
Journal of Public Health 2014;104(8):1557–65.
Prochaska JJ, Hall SM, Bero LA. Tobacco use among 
individuals with schizophrenia: what role has the 
tobacco industry played? Schizophrenia Bulletin 
2008;34(3):555–67.
Prochaska JJ, Hilton JF. Risk of cardiovascular serious 
adverse events associated with varenicline use for 
tobacco cessation: systematic review and meta-anal-
ysis. BMJ 2012;344:e2856.
Prochaska JJ, Pechmann C, Kim R, Leonhardt JM. 
Twitter=quitter? An analysis of Twitter quit smoking 
social networks. Tobacco Control 2012;21(4):447–9.
Prochaska JO, DiClemente CC. Stages and processes of 
self-change of smoking: toward an integrative model of 
change. Journal of Consulting and Clinical Psychology 
1983;51(3):390–5.
Prochaska JO, DiClemente CC, Velicer WF, Rossi JS. 
Standardized, individualized, interactive, and personal-
ized self-help programs for smoking cessation. Health 
Psychology 1993;12(5):399–405.
Prochaska JO, Velicer WF, Fava JL, Rossi JS, Tsoh JY. 
Evaluating a population-based recruitment approach 
and a stage-based expert system intervention for smoking 
cessation. Addictive Behaviors 2001a;26(4):583–602.
Prochaska JO, Velicer WF, Fava JL, Ruggiero L, Laforge 
RG, Rossi JS, Johnson SS, Lee PA. Counselor and stim-
ulus control enhancements of a stage-matched expert 
system intervention for smokers in a managed care set-
ting. Preventive Medicine 2001b;32(1):23–32.
Public Health England. Models of Delivery for Stop 
Smoking Services: Options and Evidence. London 
(UK): Public Health England, September 2017. 
Quinn VP, Hollis JF, Smith KS, Rigotti NA, Solberg LI, Hu 
W, Stevens VJ. Effectiveness of the 5-As tobacco ces-
sation treatments in nine HMOs. Journal of General 
Internal Medicine 2009;24(2):149–54.
Quinn VP, Stevens VJ, Hollis JF, Rigotti NA, Solberg LI, 
Gordon N, Ritzwoller D, Smith KS, Hu W, Zapka J. 
Tobacco-cessation services and patient satisfaction in 
nine nonprofit HMOs. American Journal of Preventive 
Medicine 2005;29(2):77–84.
Rahman MA, Hann N, Wilson A, Mnatzaganian G, Worrall-
Carter L. E-cigarettes and smoking cessation: evidence 
A Report of the Surgeon General
568  Chapter 6
from a systematic review and meta-analysis. PLoS One 
2015;10(3):e0122544.
Ramo DE, Liu H, Prochaska JJ. A mixed-methods study of 
young adults’ receptivity to using Facebook for smoking 
cessation: if you build it, will they come? American 
Journal of Health Promotion 2015;29(4):e126–35.
Reid RD, Mullen KA, Slovinec D’Angelo ME, Aitken DA, 
Papadakis S, Haley PM, McLaughlin CA, Pipe AL. 
Smoking cessation for hospitalized smokers: an eval-
uation of the “Ottawa Model”. Nicotine and Tobacco 
Research 2010;12(1):11–8.
Reyes-Guzman CM, Pfeiffer RM, Lubin J, Freedman ND, 
Cleary SD, Levine PH, Caporaso NE. Determinants of 
light and intermittent smoking in the United States: 
results from three pooled national health surveys. 
Cancer Epidemiology, Biomarkers, and Prevention 
2017;26(2):228–39. 
Ribisl KM, Hatsukami DK, Huang J, Williams RS, Donny 
EC. Strategies to reduce illicit trade of regular nicotine 
tobacco products after introduction of a low-nicotine 
tobacco product standard. American Journal of Public 
Health 2019;109(7):1007–14.
Rice VH, Heath L, Livingstone-Banks J, Hartmann-
Boyce J. Nursing interventions for smoking cessa-
tion. Cochrane Database of Systematic Reviews 2017, 
Issue 12. Art. No.: CD001188. DOI: 10.1002/14651858.
CD001188.pub5.
Riemsma RP, Pattenden J, Bridle C, Sowden AJ, Mather L, 
Watt IS, Walker A. Systematic review of the effective-
ness of stage based interventions to promote smoking 
cessation. BMJ 2003;326(7400):1175–7.
Rigotti NA, Clair C, Munafo MR, Stead LF. Interventions for 
smoking cessation in hospitalised patients. Cochrane 
Database of Systematic Reviews 2012, Issue 5. Art. No.: 
CD001837. DOI: 10.1002/14651858.CD001837.pub3.
Rigotti NA, Regan S, Levy DE, Japuntich S, Chang Y, Park 
ER, Viana JC, Kelley JH, Reyen M, Singer DE. Sustained 
care intervention and postdischarge smoking cessation 
among hospitalized adults: a randomized clinical trial. 
JAMA: the Journal of the American Medical Association 
2014;312(7):719–28.
Rigotti NA, Tindle HA, Regan S, Levy DE, Chang Y, 
Carpenter KM, Park ER, Kelley JH, Streck JM, Reid 
ZZ, et al. A post-discharge smoking-cessation interven-
tion for hospital patients: Helping Hand 2 Randomized 
Clinical Trial. American Journal of Preventive Medicine 
2016;51(4):597–608.
Rodgers A, Corbett T, Bramley D, Riddell T, Wills M, Lin 
RB, Jones M. Do u smoke after txt? Results of a ran-
domised trial of smoking cessation using mobile phone 
text messaging. Tobacco Control 2005;14(4):255–61.
Rogers ES, Smelson DA, Gillespie CC, Elbel B, Poole S, 
Hagedorn HJ, Kalman D, Krebs P, Fang Y, Wang B, et al. 
Telephone smoking-cessation counseling for smokers 
in mental health clinics: a patient-randomized con-
trolled trial. American Journal of Preventive Medicine 
2016;50(4):518–27.
Rüther T, Bobes J, De Hert M, Svensson TH, Mann K, Batra 
A, Gorwood P, Möller HJ. EPA guidance on tobacco 
dependence and strategies for smoking cessation 
in people with mental illness. European Psychiatry 
2014;29(2):65–82.
Ryan RM, Deci EL. Self-determination theory and the facil-
itation of intrinsic motivation, social development, and 
well-being. American Psychologist 2000;55(1):68–78.
Ryan RM, Patrick H, Deci EL, Williams GC. Facilitating 
health behaviour change and its maintenance: 
Interventions based on self-determination theory. The 
European Health Psychologist 2008;10:2–5.
Sargent JD, Mott LA, Stevens M. Predictors of smoking 
cessation in adolescents. Archives of Pediatrics and 
Adolescent Medicine 1998;152(4):388–93.
Schane RE, Glantz SA. Education on the dangers of pas-
sive smoking: a cessation strategy past due. Circulation 
2008;118(15):1521–3.
Schane RE, Glantz SA, Ling PM. Nondaily and social 
smoking: an increasingly prevalent pattern. Archives of 
Internal Medicine 2009;169(19):1742–4.
Schane RE, Prochaska JJ, Glantz SA. Counseling nondaily 
smokers about secondhand smoke as a cessation mes-
sage: a pilot randomized trial. Nicotine and Tobacco 
Research 2013;15(2):334–42.
Schauer GL, Malarcher AM, Asman KJ. Trends in the 
average age of quitting among U.S. adult cigarette 
smokers. American Journal of Preventive Medicine 
2015a;49(6):939–44.
Schauer GL, Malarcher AM, Babb SD. Gradual reduc-
tion of cigarette consumption as a cessation strategy: 
prevalence, correlates, and relationship with quitting. 
Nicotine and Tobacco Research 2015b;17(5):530–8.
Schauer GL, Malarcher AM, Mowery P. National trends in 
frequency and amount of nondaily smoking, and rela-
tion to quit attempts, 2000–2012. Nicotine and Tobacco 
Research 2016a;18(6):1539–44.
Schauer GL, Malarcher AM, Zhang L, Engstrom MC, Zhu 
SH. Prevalence and correlates of quitline awareness 
and utilization in the United States: an update from the 
2009–2010 National Adult Tobacco Survey. Nicotine 
and Tobacco Research 2014a;16(5):544–53.
Schauer GL, Pederson LL, Malarcher AM. Past year quit 
attempts and use of cessation resources among ciga-
rette-only smokers and cigarette smokers who use 
other tobacco products. Nicotine and Tobacco Research 
2016b;18(1):41–7.
Schauer GL, Wheaton AG, Malarcher AM, Croft JB. 
Smoking prevalence and cessation characteristics 
Interventions for Smoking Cessation and Treatments for Nicotine Dependence  569
Smoking Cessation
among U.S. adults with and without COPD: findings 
from the 2011 Behavioral Risk Factor Surveillance 
System. COPD 2014b;11(6):697–704.
Schauer GL, Wheaton AG, Malarcher AM, Croft JB. 
Health-care provider screening and advice for smoking 
cessation among smokers with and without COPD: 
2009–2010 National Adult Tobacco Survey. Chest 
2016c;149(3):676–84.
Schnoll RA, Goelz PM, Veluz-Wilkins A, Blazekovic S, Powers 
L, Leone FT, Gariti P, Wileyto EP, Hitsman B. Long-term 
nicotine replacement therapy: a randomized clinical 
trial. JAMA Internal Medicine 2015;175(4):504–11.
Schroeder SA. What to do with a patient who smokes. 
JAMA: the Journal of the American Medical Association 
2005;294(4):482–7.
Schwartz J, Fadahunsi O, Hingorani R, Mainali NR, 
Oluwasanjo A, Aryal MR, Donato A. Use of varenicline 
in smokeless tobacco cessation: a systematic review 
and meta-analysis. Nicotine and Tobacco Research 
2016;18(1):10–6.
Scott-Sheldon LA, Lantini R, Jennings EG, Thind H, 
Rosen RK, Salmoirago-Blotcher E, Bock BC. Text mes-
saging-based interventions for smoking cessation: a 
systematic review and meta-analysis. JMIR mHealth 
and uHhealth 2016;4(2):e49.
Severson HH, Gordon JS, Danaher BG, Akers L. ChewFree.
com: evaluation of a Web-based cessation program 
for smokeless tobacco users. Nicotine and Tobacco 
Research 2008;10(2):381–91.
Sharapova S, Reyes-Guzman C, Singh T, Phillips E, 
Marynak KL, Agaku I. Age of tobacco use initiation and 
association with current use and nicotine dependence 
among U.S. middle and high school students, 2014–
2016. Tobacco Control 2018.
Sheffer MA, Baker TB, Fraser DL, Adsit RT, McAfee TA, 
Fiore MC. Fax referrals, academic detailing, and tobacco 
quitline use: a randomized trial. American Journal of 
Preventive Medicine 2012;42(1):21–8.
Shi Y, Warner DO. Surgery as a teachable moment for 
smoking cessation. Anesthesiology 2010;112(1):102–7.
Shiffman S, Dunbar MS, Li X, Scholl SM, Tindle HA, 
Anderson SJ, Ferguson SG. Smoking patterns and 
stimulus control in intermittent and daily smokers. 
PLoS One 2014;9(3):e89911.
Shiffman S, Ferguson SG. Nicotine patch therapy prior 
to quitting smoking: a meta-analysis. Addiction 
2008;103(4):557–63.
Shiffman S, Sembower MA, Rohay JM, Gitchell JG, Garvey 
AJ. Assigning dose of nicotine gum by time to first ciga-
rette. Nicotine and Tobacco Research 2013;15(2):407–12.
Shihadeh A, Eissenberg T. Electronic cigarette effectiveness 
and abuse liability: predicting and regulating nicotine 
flux. Nicotine and Tobacco Research 2015;17(2):158–62.
Siegel DA, Jatlaoui TC, Koumans EH, Kiernan EA, Layer 
M, Cates JE, Kimball A, Weissman DN, Petersen 
EE, Reagan-Steiner S, et al. Update: Interim guid-
ance for health care providers evaluating and caring 
for patients with suspected e-cigarette, or vaping, 
product use associated lung injury—United States, 
October 2019. Morbidity and Mortality Weekly Report 
2019;68:919–27.
Simoyan OM, Badner VM, Freeman KD. Tobacco cessation 
services in dental offices. Are we doing all we can? New 
York State Dental Journal 2002;68(7):34–40.
Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious 
adverse cardiovascular events associated with vareni-
cline: a systematic review and meta-analysis. Canadian 
Medical Association Journal 2011;183(12):1359–66.
Singh S, Starkey NJ, Sargisson RJ. Using SmartQuit®, 
an acceptance and commitment therapy smartphone 
application, to reduce smoking intake. Digital Health 
2017;3.
Slatore CG, Baumann C, Pappas M, Humphrey LL. Smoking 
behaviors among patients receiving computed tomog-
raphy for lung cancer screening. Systematic review in 
support of the U.S. Preventive Services Task Force. Annals 
of the American Thoracic Society 2014;11(4):619–27.
Slemmer JE, Martin BR, Damaj MI. Bupropion is a nic-
otinic antagonist. Journal of Pharmacology and 
Experimental Therapeutics 2000;295(1):321–7.
Smedberg J, Lupattelli A, Mardby AC, Nordeng H. 
Characteristics of women who continue smoking 
during pregnancy: a cross-sectional study of pregnant 
women and new mothers in 15 European countries. 
BMC Pregnancy and Childbirth 2014;14:213.
Smith PH, Weinberger AH, Zhang J, Emme E, Mazure 
CM, McKee SA. Sex differences in smoking cessa-
tion pharmacotherapy comparative efficacy: a net-
work meta-analysis. Nicotine and Tobacco Research 
2017;19(3):273–81.
Smith SS, Keller PA, Kobinsky KH, Baker TB, Fraser DL, 
Bush T, Magnusson B, Zbikowski SM, McAfee TA, Fiore 
MC. Enhancing tobacco quitline effectiveness: identi-
fying a superior pharmacotherapy adjuvant. Nicotine 
and Tobacco Research 2013;15(3):718–28.
Smith TT, Koopmeiners JS, Tessier KM, Davis EM, Conklin 
CA, Denlinger-Apte RL, Lane T, Murphy SE, Tidey JW, 
Hatsukami DK, et al. Randomized trial of low-nicotine 
cigarettes and transdermal nicotine. American Journal 
of Preventive Medicine 2019;57(4):515–24.
Smokefree.gov. Sign up for SmokefreeTXT, n.d.; <https://
smokefree.gov/smokefreetxt>; accessed: August 17, 2017.
Soneji SS, Sung HY, Primack BA, Pierce JP, Sargent JD. 
Quantifying population-level health benefits and harms 
of e-cigarette use in the United States. PLoS One 
2018;13(3):e0193328.
A Report of the Surgeon General
570  Chapter 6
Spencer L, Pagell F, Hallion ME, Adams TB. Applying the 
transtheoretical model to tobacco cessation and pre-
vention: a review of literature. American Journal of 
Health Promotion 2002;17(1):7–71.
Spindle TR, Eissenberg T. Pod mod electronic cigarettes—
an emerging threat to public health. JAMA Network 
Open 2018;1(6):e183518.
Squiers L, Brown D, Parvanta S, Dolina S, Kelly B, 
Dever J, Southwell BG, Sanders A, Augustson E. The 
SmokefreeTXT (SFTXT) study: web and mobile data 
collection to evaluate smoking cessation for young 
adults. JMIR Research Protocols 2016;5(2):e134.
Squiers LB, Augustson E, Brown D, Kelly B, Southwell B, 
Dever J, Dolina S, Tzeng J, Parvanta S, Holt S, et al. An 
experimental comparison of mobile texting programs 
to help young adults quit smoking. Health Systems 
2017;6(1):1–14.
Stanton A, Grimshaw G. Tobacco cessation interventions 
for young people. Cochrane Database of Systematic 
Reviews 2013, Issue 8. Art. No.: CD003289. DOI: 
10.1002/14651858.CD003289.pub5.
Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-
Boyce J, Lancaster T. Physician advice for smoking cessa-
tion. Cochrane Database of Systematic Reviews 2013a, 
Issue 5. Art. No.: CD000165. DOI: 10.1002/14651858.
CD000165.pub4.
Stead LF, Carroll AJ, Lancaster T. Group behaviour 
therapy programmes for smoking cessation. Cochrane 
Database of Systematic Reviews 2017, Issue 3. Art. No.: 
CD001007. DOI: 10.1002/14651858.CD001007.pub3.
Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. 
Telephone counselling for smoking cessation. Cochrane 
Database of Systematic Reviews 2013b, Issue 8. Art. No.: 
CD002850. DOI: 10.1002/14651858.CD002850.pub3.
Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. 
Combined pharmacotherapy and behavioural inter-
ventions for smoking cessation. Cochrane Database of 
Systematic Reviews 2016, Issue 3. Art. No.: CD008286. 
DOI: 10.1002/14651858.CD008286.pub3.
Stead LF, Koilpillai P, Lancaster T. Additional behav-
ioural support as an adjunct to pharmacotherapy for 
smoking cessation. Cochrane Database of Systematic 
Reviews 2015, Issue 10. Art. No.: CD009670. DOI: 
10.1002/14651858.CD009670.pub3.
Stead LF, Lancaster T. Interventions to reduce harm 
from continued tobacco use. Cochrane Database of 
Systematic Reviews 2007, Issue 3. Art. No.: CD005231. 
DOI: 10.1002/14651858.CD005231.pub2.
Stead LF, Lancaster T. Behavioural interventions as 
adjuncts to pharmacotherapy for smoking cessation. 
Cochrane Database of Systematic Reviews 2012a, 
Issue 10. Art. No.: CD009670. DOI: 10.1002/14651858.
CD009670.pub3.
Stead LF, Lancaster T. Combined pharmacotherapy and 
behavioural interventions for smoking cessation. 
Cochrane Database of Systematic Reviews 2012b, 
Issue 10. Art. No.: CD008286. DOI: 10.1002/14651858.
CD008286.pub2.
Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, 
Cahill K, Lancaster T. Nicotine replacement therapy for 
smoking cessation. Cochrane Database of Systematic 
Reviews 2012, Issue 11. Art. No.: CD000146. DOI: 
10.1002/14651858.CD000146.pub4.
Stearns M, Nambiar S, Nikolaev A, Semenov A, McIntosh 
S. Towards evaluating and enhancing the reach of 
online health forums for smoking cessation. Network 
Modeling and Analysis in Healthcare Informatics and 
Bioinformatics 2014;3.
Steinberg MB, Alvarez MS, Delnevo CD, Kaufman I, Cantor 
JC. Disparity of physicians’ utilization of tobacco treat-
ment services. American Journal of Health Behavior 
2006a;30(4):375–86.
Steinberg MB, Foulds J, Richardson DL, Burke MV, 
Shah P. Pharmacotherapy and smoking cessation at 
a tobacco dependence clinic. Preventive Medicine 
2006b;42(2):114–9.
Steinberg MB, Schmelzer AC, Richardson DL, Foulds J. 
The case for treating tobacco dependence as a chronic 
disease. Annals of Internal Medicine 2008;148(7):554–6.
Stevens P, Carlson LM, Hinman JM. An analysis of tobacco 
industry marketing to lesbian, gay, bisexual, and trans-
gender (LGBT) populations: strategies for mainstream 
tobacco control and prevention. Health Promotion 
Practice 2004;5(3 Suppl):129S–34S.
Stoddard J, Delucchi K, Munoz R, Collins N, Stable EP, 
Augustson E, Lenert L. Smoking cessation research 
via the internet: a feasibility study. Journal of Health 
Communication 2005;10(1):27–41.
Stoddard JL, Augustson EM, Moser RP. Effect of adding 
a virtual community (bulletin board) to smokefree.
gov: randomized controlled trial. Journal of Medical 
Internet Research 2008;10(5):e53.
Strecher VJ, Shiffman S, West R. Randomized controlled 
trial of a web-based computer-tailored smoking ces-
sation program as a supplement to nicotine patch 
therapy. Addiction 2005;100(5):682–8.
Styn MA, Land SR, Perkins KA, Wilson DO, Romkes M, 
Weissfeld JL. Smoking behavior 1 year after com-
puted tomography screening for lung cancer: effect 
of physician referral for abnormal CT findings. 
Cancer Epidemiology, Biomarkers, and Prevention 
2009;18(12):3484–9.
Substance Abuse and Mental Health Services Administration. 
Adults with mental illness or substance use disorder 
account for 40 percent of all cigarettes smoked, March 
20, 2013; <https://www.samhsa.gov/data/sites/default/
Interventions for Smoking Cessation and Treatments for Nicotine Dependence  571
Smoking Cessation
files/spot104-cigarettes-mental-illness-substance-use-
disorder/spot104-cigarettes-mental-illness-substance-
use-disorder.pdf>; accessed: November 4, 2019.
Substance Abuse and Mental Health Services Administration. 
Results from the 2013 National Survey on Drug Use 
and Health: detailed tables (tables 6.10B and 6.24B), 
n.d.; <https://www.samhsa.gov/data/sites/default/files/
NSDUH-DetTabs2013/NSDUH-DetTabs2013.htm>; 
accessed: February 13, 2018.
Sussman S, Lichtman K, Ritt A, Pallonen UE. Effects of 
thirty-four adolescent tobacco use cessation and pre-
vention trials on regular users of tobacco products. 
Substance Use and Misuse 1999;34(11):1469–503.
Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey 
S, Bergman K. Effectiveness of bupropion sustained 
release for smoking cessation in a health care set-
ting: a randomized trial. Archives of Internal Medicine 
2003;163(19):2337–44.
Sykes CM, Marks DF. Effectiveness of a cognitive behav-
iour therapy self-help programme for smokers 
in London, UK. Health Promotion International 
2001;16(3):255–60.
Taber JM, Klein WM, Ferrer RA, Augustson E, Patrick H. A 
pilot test of self-affirmations to promote smoking ces-
sation in a national smoking cessation text messaging 
program. JMIR mHealth uHealth 2016;4(2):e71.
Tammemägi MC, Berg CD, Riley TL, Cunningham CR, 
Taylor KL. Impact of lung cancer screening results on 
smoking cessation. Journal of the National Cancer 
Institute 2014;106(6):dju084.
Taylor KL, Deros DE, Fallon S, Stephens J, Kim E, Lobo 
T, Davis KM, Luta G, Jayasekera J, Meza R, et al. Study 
protocol for a telephone-based smoking cessation ran-
domized controlled trial in the lung cancer screening 
setting: The lung screening, tobacco, and health trial. 
Contemporary Clinical Trials 2019;82:25–35.
Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley 
N, Aveyard P. Change in mental health after smoking 
cessation: systematic review and meta-analysis. BMJ 
2014;348:g1151.
Taylor KL, Cox LS, Zincke N, Mehta L, McGuire C, Gelmann 
E. Lung cancer screening as a teachable moment for 
smoking cessation. Lung Cancer 2007;56(1):125–34.
Teixeira PJ, Carraca EV, Marques MM, Rutter H, Oppert 
JM, De Bourdeaudhuij I, Lakerveld J, Brug J. Successful 
behavior change in obesity interventions in adults: a 
systematic review of self-regulation mediators. BMC 
Medicine 2015;13:84.
The Community Guide. Tobacco use and secondhand 
smoke exposure: internet-based cessation interven-
tions, 2011a; <https://www.thecommunityguide.org/
topic/tobacco?field_recommendation_tid=All&items_
per_page=5>; accessed: May 24, 2017.
The Community Guide. Tobacco use and secondhand 
smoke exposure: mobile phone-based cessation inter-
ventions, 2011b; <https://www.thecommunityguide.
org/findings/tobacco-use-and-secondhand-smoke-
exposure-mobile-phone-based-cessation-interven-
tions>; accessed: May 24, 2017.
The Community Guide. Tobacco, 2012a; <https://www.
thecommunityguide.org/topic/tobacco?field_recom-
mendation_tid=All&items_per_page=5>; accessed: 
May 24, 2017.
The Community Guide. Tobacco use and secondhand 
smoke exposure: quitline interventions, 2012b; 
<https://www.thecommunityguide.org/findings/
tobacco-use-and-secondhand-smoke-exposure-quit-
line-interventions>; accessed: August 1, 2017.
The Joint Commission. personal communication, March 
18, 2019.
Thomas KH, Martin RM, Davies NM, Metcalfe C, 
Windmeijer F, Gunnell D. Smoking cessation treat-
ment and risk of depression, suicide, and self harm in 
the Clinical Practice Research Datalink: prospective 
cohort study. BMJ 2013;347:f5704.
Thomsen T, Villebro N, Møller AM. Interventions for pre-
operative smoking cessation. Cochrane Database of 
Systematic Reviews 2010, Issue 7. Art. No.: CD002294. 
DOI: 10.1002/14651858.CD002294.pub3.
Thomsen T, Villebro N, Møller AM. Interventions for pre-
operative smoking cessation. Cochrane Database of 
Systematic Reviews 2014, Issue 3. Art. No.: CD002294. 
DOI: 10.1002/14651858.CD002294.pub4.
Tindle HA, Daigh R, Reddy VK, Bailey LA, Ochs JA, Maness 
MH, Davis EM, Schulze AE, Powers KM, Ylioja TE, 
et al. eReferral between hospitals and quitlines: an 
emerging tobacco control strategy. American Journal 
of Preventive Medicine 2016;51(4):522–6.
Tinkelman D, Wilson SM, Willett J, Sweeney CT. Offering 
free NRT through a tobacco quitline: impact on utili-
sation and quit rates. Tobacco Control 2007;16(Suppl 
1):i42–i46.
Tong EK, Ong MK, Vittinghoff E, Perez-Stable EJ. Nondaily 
smokers should be asked and advised to quit. American 
Journal of Preventive Medicine 2006;30(1):23–30.
Tong VT, Dietz PM, Morrow B, D’Angelo DV, Farr SL, 
Rockhill KM, England LJ. Trends in smoking before, 
during, and after pregnancy—Pregnancy Risk 
Assessment Monitoring System, United States, 40 sites, 
2000–2010. Morbidity and Mortality Weekly Report: 
Surveillance Summaries 2013;62(6):1–19.
Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, 
Reeves KR. Effect of maintenance therapy with vareni-
cline on smoking cessation: a randomized controlled 
trial. JAMA: the Journal of the American Medical 
Association 2006;296(1):64–71.
A Report of the Surgeon General
572  Chapter 6
Truth Initiative. Behind the Explosive Growth of JUUL: 
Social Influences and Flavors Drive Rising Teen Use of 
the Top E-Cigarette, December 2018; <https://truthi-
nitiative.org/sites/default/files/media/files/2019/03/
Behind-the-explosive-growth-of-JUUL.pdf>; accessed: 
July 25, 2019.
Tsoi DT, Porwal M, Webster AC. Interventions for 
smoking cessation and reduction in individuals with 
schizophrenia. Cochrane Database of Systematic 
Reviews 2013, Issue 2. Art. No.: CD007253. DOI: 
10.1002/14651858.CD007253.pub3.
Tudor-Sfetea C, Rabee R, Najim M, Amin N, Chadha M, 
Jain M, Karia K, Kothari V, Patel T, Suseeharan M, et 
al. Evaluation of two mobile health apps in the con-
text of smoking cessation: qualitative study of cognitive 
behavioral therapy (CBT) versus non-CBT-based digital 
solutions. JMIR Mhealth and Uhealth 2018;6(4):e98.
Tulloch HE, Pipe AL, Els C, Clyde MJ, Reid RD. Flexible, 
dual-form nicotine replacement therapy or varenicline 
in comparison with nicotine patch for smoking ces-
sation: a randomized controlled trial. BMC Medicine 
2016;14:80.
U.S. Department of Health and Human Services. The 
Health Consequences of Smoking: Nicotine Addiction. 
A Report of the Surgeon General. Atlanta (GA): U.S. 
Department of Health and Human Services, Public 
Health Service, Centers for Disease Control, National 
Center for Chronic Disease Prevention and Health 
Promotion, Office on Smoking and Health, 1988. 
DHHS Publication No. (CDC) 88-8406. 
U.S. Department of Health and Human Services. Women 
and Smoking. A Report of the Surgeon General. 
Rockville (MD): U.S. Department of Health and Human 
Services, Public Health Service, Office of the Surgeon 
General, 2001. 
U.S. Department of Health and Human Services. The 
Health Consequences of Smoking: A Report of the 
Surgeon General. Atlanta (GA): U.S. Department 
of Health and Human Services, Centers for Disease 
Control and Prevention, National Center for Chronic 
Disease Prevention and Health Promotion, Office on 
Smoking and Health, 2004. 
U.S. Department of Health and Human Services. How 
Tobacco Smoke Causes Disease—The Biology and 
Behavioral Basis for Smoking-Attributable Disease: 
A Report of the Surgeon General. Atlanta (GA): U.S. 
Department of Health and Human Services, Centers 
for Disease Control and Prevention, National Center 
for Chronic Disease Prevention and Health Promotion, 
Office on Smoking and Health, 2010. 
U.S. Department of Health and Human Services. 
Preventing Tobacco Use Among Youth and Young 
Adults: A Report of the Surgeon General. Atlanta 
(GA): U.S. Department of Health and Human Services, 
Centers for Disease Control and Prevention, National 
Center for Chronic Disease Prevention and Health 
Promotion, Office on Smoking and Health, 2012. 
U.S. Department of Health and Human Services. The 
Health Consequences of Smoking—50 Years of 
Progress: A Report of the Surgeon General. Atlanta 
(GA): U.S. Department of Health and Human Services, 
Centers for Disease Control and Prevention, National 
Center for Chronic Disease Prevention and Health 
Promotion, Office on Smoking and Health, 2014. 
U.S. Department of Health and Human Services. 
E-Cigarette Use Among Youth and Young Adults. A 
Report of the Surgeon General. Atlanta (GA): U.S. 
Department of Health and Human Services, Centers 
for Disease Control and Prevention, National Center 
for Chronic Disease Prevention and Health Promotion, 
Office on Smoking and Health 2016. 
U.S. Department of Health and Human Services. Surgeon 
General releases advisory on e-cigarette epidemic 
among youth [press release], December 18, 2018a; 
<https://www.hhs.gov/about/news/2018/12/18/sur-
geon-general-releases-advisory-e-cigarette-epidemic-
among-youth.html>.
U.S. Department of Health and Human Services. Surgeon 
General’s Advisory on E-cigarette Use Among Youth, 
2018b; <https://e-cigarettes.surgeongeneral.gov/docu-
ments/surgeon-generals-advisory-on-e-cigarette-use-
among-youth-2018.pdf>; accessed: January 9, 2019.
U.S. Food and Drug Administration. Nicotine replace-
ment therapy labels may change, 2013; <https://www.
integration.samhsa.gov/health-wellness/NRT_Label_
Change_0413.pdf>; accessed: August 7, 2018.
U.S. Food and Drug Administration. Want to Quit 
Smoking? FDA-Approved Products Can Help [consumer 
update], 2017; <https://www.fda.gov/ForConsumers/
ConsumerUpdates/ucm198176.htm>; accessed: August 
1, 2018.
U.S. Food and Drug Administration. FDA drug safety com-
munication: FDA revises description of mental health 
side effects of the stop-smoking medicines Chantix 
(varenicline) and Zyban (bupropion) to reflect clin-
ical trial findings, 2018a; <https://www.fda.gov/Drugs/
DrugSafety/ucm532221.htm>; accessed: March 13, 
2019.
U.S. Food and Drug Administration. Statement from FDA 
Commissioner Scott Gottlieb, M.D., on pivotal public 
health step to dramatically reduce smoking rates by 
lowering nicotine in combustible cigarettes to mini-
mally or non-addictive levels [press release], March 15, 
2018b; <https://www.fda.gov/NewsEvents/Newsroom/
PressAnnouncements/ucm601039.htm>; accessed: 
November 14, 2018.
Interventions for Smoking Cessation and Treatments for Nicotine Dependence  573
Smoking Cessation
U.S. Food and Drug Administration. Smoking Cessation and 
Related Indications: Developing Nicotine Replacement 
Therapy Drug Products; Draft Guidance for Industry; 
Availability, February 2019a; <https://www.regulations.
gov/document?D=FDA-2019-D-0297-0001>; accessed: 
May 9, 2019.
U.S. Food and Drug Administration. This Free Life campaign, 
September 23, 2019b; < https://www.fda.gov/tobacco-
products/free-life-campaign?utm_campaign=ctp-
healthobservance&utm_medium=social&utm_
source=CTPTwitter>; accessed: November 4, 2019.
U.S. Preventive Services Task Force. Final Update 
Summary: Tobacco Smoking Cessation in Adults, 
Including Pregnant Women: Behavioral and 
Pharmacotherapy Interventions, September 2015; 
<https://www.uspreventiveservicestaskforce.org/Page/
Document/UpdateSummaryFinal/tobacco-use-in-
adults-and-pregnant-women-counseling-and-interven-
tions1>; accessed: May 24, 2017.
U.S. Preventive Services Task Force. Final Recommendation 
Statement—Tobacco Use in Children and Adolescents: 
Primary Care Interventions, December 2016; <https://
www.uspreventiveservicestaskforce.org/Page/
Document/RecommendationStatementFinal/tobacco-
use-in-children-and-adolescents-primary-care-inter-
ventions>; accessed: November 29, 2018.
Ubhi HK, Kotz D, Michie S, van Schayck OC, Sheard D, 
Selladurai A, West R. Comparative analysis of smoking 
cessation smartphone applications available in 2012 
versus 2014. Addictive Behaviors 2016;58:175–81.
Ussher M, Beard E, Abikoye G, Hajek P, West R. Urge to smoke 
over 52 weeks of abstinence. Psychopharmacology 
2013;226(1):83–9.
van der Aalst CM, de Koning HJ, van den Bergh KA, 
Willemsen MC, van Klaveren RJ. The effectiveness of a 
computer-tailored smoking cessation intervention for 
participants in lung cancer screening: a randomised 
controlled trial. Lung Cancer 2012;76(2):204–10.
van der Meer RM, Willemsen MC, Smit F, Cuijpers P. 
Smoking cessation interventions for smokers with 
current or past depression. Cochrane Database of 
Systematic Reviews 2013, 2013, Issue 8. Art. No.: 
CD006102. DOI: 10.1002/14651858.CD006102.pub2.
Vansickel AR, Eissenberg T. Electronic cigarettes: effective 
nicotine delivery after acute administration. Nicotine 
and Tobacco Research 2013;15(1):267–70.
Velicer WF, Prochaska JO, Fava JL, Laforge RG, Rossi 
JS. Interactive versus noninteractive interventions 
and dose-response relationships for stage-matched 
smoking cessation programs in a managed care setting. 
Health Psychology 1999;18(1):21–8.
Vickerman KA, Carpenter KM, Altman T, Nash CM, 
Zbikowski SM. Use of electronic cigarettes among 
state tobacco cessation quitline callers. Nicotine and 
Tobacco Research 2013;15(10):1787–91.
Vickerman KA, Schauer GL, Malarcher AM, Zhang L, 
Mowery P, Nash CM. Reasons for electronic nico-
tine delivery system use and smoking abstinence at 
6 months: a descriptive study of callers to employer 
and health plan-sponsored quitlines. Tobacco Control 
2017;26(2):126–34.
Vidrine JI, Shete S, Cao Y, Greisinger A, Harmonson 
P, Sharp B, Miles L, Zbikowski SM, Wetter DW. Ask-
Advise-Connect: a new approach to smoking treat-
ment delivery in health care settings. JAMA Internal 
Medicine 2013a;173(6):458–64.
Vidrine JI, Shete S, Li Y, Cao Y, Alford MH, Galindo-Talton 
M, Rabius V, Sharp B, Harmonson P, Zbikowski SM, 
et al. The Ask-Advise-Connect approach for smokers 
in a safety net healthcare system: a group-random-
ized trial. American Journal of Preventive Medicine 
2013b;45(6):737–41.
Vinnikov D, Brimkulov N, Burjubaeva A. A double-blind, 
randomised, placebo-controlled trial of cytisine for 
smoking cessation in medium-dependent workers. 
Journal of Smoking Cessation 2008;3(1):57–62.
Volpp KG, Troxel AB, Pauly MV, Glick HA, Puig A, Asch 
DA, Galvin R, Zhu J, Wan F, DeGuzman J, et al. A ran-
domized, controlled trial of financial incentives for 
smoking cessation. New England Journal of Medicine 
2009;360(7):699–709.
Wadgave U, Nagesh L. Nicotine replacement therapy: an 
overview. International Journal of Health Sciences 
2016;10(3):425–35.
Walker N, Howe C, Bullen C, Grigg M, Glover M, McRobbie 
H, Laugesen M, Jiang J, Chen MH, Whittaker R, et al. 
Does improved access and greater choice of nicotine 
replacement therapy affect smoking cessation success? 
Findings from a randomized controlled trial. Addiction 
2011;106(6):1176–85.
Walker N, Howe C, Glover M, McRobbie H, Barnes J, Nosa 
V, Parag V, Bassett B, Bullen C. Cytisine versus nico-
tine for smoking cessation. New England Journal of 
Medicine 2014;371(25):2353–62.
Walker N, Parag V, Verbiest M, Laking G, Laugesen M, 
Bullen C. Nicotine patches used in combination with 
e-cigarettes (with and without nicotine) for smoking 
cessation: a pragmatic, randomised trial. Lancet 
Respiratory Medicine 2019
Wang TW, Asman K, Gentzke AS, Cullen KA, Holder-
Hayes E, Reyes-Guzman C, Jamal A, Neff L, King 
BA. Tobacco product use among adults—United 
States, 2017. Morbidity and Mortality Weekly Report 
2018;67(44):1225–32.
Wang TW, Walton K, Jamal A, Babb SD, Schecter A, Prutzman 
YM, King BA. State-specific cessation behaviors among 
A Report of the Surgeon General
574  Chapter 6
adult cigarette smokers—United States, 2014–2015. 
Preventing Chronic Disease 2019;16:E26.
Warner DO. Perioperative abstinence from cigarettes: 
physiologic and clinical consequences. Anesthesiology 
2006;104(2):356–67.
Warner DO, Nolan MB, Kadimpati S, Burke MV, Hanson 
AC, Schroeder DR. Quitline Tobacco interventions in 
hospitalized patients: a randomized trial. American 
Journal of Preventive Medicine 2016;51(4):473–84.
Warner KE, Mendez D. E-cigarettes: comparing the pos-
sible risks of increasing smoking initiation with the 
potential benefits of increasing smoking cessation. 
Nicotine and Tobacco Research 2019;21(1):41–7.
Washington HA. Burning love: big tobacco takes aim at 
LGBT youths. American Journal of Public Health 
2002;92(7):1086–95.
Webb Hooper M, Antoni MH, Okuyemi K, Dietz NA, 
Resnicow K. Randomized controlled trial of group-
based culturally specific cognitive behavioral therapy 
among African American smokers. Nicotine and 
Tobacco Research 2017;19(3):333–41.
Webb MS, de Ybarra DR, Baker EA, Reis IM, Carey MP. 
Cognitive-behavioral therapy to promote smoking ces-
sation among African American smokers: a random-
ized clinical trial. Journal of Consulting and Clinical 
Psychology 2010a;78(1):24–33.
Webb TL, Sniehotta FF, Michie S. Using theories of behav-
iour change to inform interventions for addictive 
behaviours. Addiction 2010b;105(11):1879–92.
West R. Time for a change: putting the Transtheoretical 
(Stages of Change) Model to rest. Addiction 
2005;100(8):1036–9.
West R, Edwards M, Hajek P. A randomized controlled trial of 
a “buddy” system to improve success at giving up smoking 
in general practice. Addiction 1998;93(7):1007–11.
West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik 
J, Aveyard P, Stapleton J. Placebo-controlled trial of cyt-
isine for smoking cessation. New England Journal of 
Medicine 2011;365(13):1193–200.
West R, Zhou X. Is nicotine replacement therapy for 
smoking cessation effective in the “real world”? Findings 
from a prospective multinational cohort study. Thorax 
2007;62(11):998–1002.
Whittaker R, McRobbie H, Bullen C, Rodgers A, Gu Y. 
Mobile phone-based interventions for smoking cessa-
tion. Cochrane Database of Systematic Reviews 2016, 
Issue 4. Art. No.: CD006611. DOI: 10.1002/14651858.
CD006611.pub4.
Whittaker R, McRobbie H, Bullen C, Borland R, Rodgers A, 
Gu Y. Mobile phone-based interventions for smoking ces-
sation. Cochrane Database of Systematic Reviews 2012, 
Issue 11. Art. No.: CD006611. DOI: 10.1002/14651858.
CD006611.pub3.
Williams GC, McGregor H, Sharp D, Kouldes RW, Levesque 
CS, Ryan RM, Deci EL. A self-determination multiple risk 
intervention trial to improve smokers’ health. Journal 
of General Internal Medicine 2006a;21(12):1288–94.
Williams GC, McGregor HA, Sharp D, Levesque C, Kouides 
RW, Ryan RM, Deci EL. Testing a self-determination 
theory intervention for motivating tobacco cessation: 
supporting autonomy and competence in a clinical 
trial. Health Psychology 2006b;25(1):91–101.
Williams GC, Minicucci DS, Kouides RW, Levesque CS, 
Chirkov VI, Ryan RM, Deci EL. Self-determination, 
smoking, diet and health. Health Education Research 
2002;17(5):512–21.
Williams GC, Niemiec CP, Patrick H, Ryan RM, Deci EL. The 
importance of supporting autonomy and perceived com-
petence in facilitating long-term tobacco abstinence. 
Annals of Behavioral Medicine 2009;37(3):315–24.
Williams GC, Niemiec CP, Patrick H, Ryan RM, Deci EL. 
Outcomes of the Smoker’s Health Project: a pragmatic 
comparative effectiveness trial of tobacco-dependence 
interventions based on self-determination theory. 
Health Education Research 2016;31(6):749–59.
Williams GC, Patrick H, Niemiec CP, Ryan RM, Deci EL, 
Lavigne HM. The smoker’s health project: a self-deter-
mination theory intervention to facilitate maintenance 
of tobacco abstinence. Contemporary Clinical Trials 
2011;32(4):535–43.
Williams JM, Anthenelli RM, Morris CD, Treadow J, 
Thompson JR, Yunis C, George TP. A randomized, 
double-blind, placebo-controlled study evaluating the 
safety and efficacy of varenicline for smoking cessation 
in patients with schizophrenia or schizoaffective dis-
order. Journal of Clinical Psychiatry 2012;73(5):654–60.
Windle SB, Filion KB, Mancini JG, Adye-White L, Joseph 
L, Gore GC, Habib B, Grad R, Pilote L, Eisenberg MJ. 
Combination therapies for smoking cessation: a hier-
archical Bayesian meta-analysis. American Journal of 
Preventive Medicine 2016;51(6):1060–71.
Winpenny E, Elliott MN, Haas A, Haviland AM, Orr N, 
Shadel WG, Ma S, Friedberg MW, Cleary PD. Advice 
to quit smoking and ratings of health care among 
Medicaid beneficiaries aged 65+. Health Services 
Research 2017;52(1):207–19.
Wisborg K, Henriksen TB, Jespersen LB, Secher NJ. Nicotine 
patches for pregnant smokers: a randomized controlled 
study. Obstetrics and Gynecology 2000;96(6):967–71.
Witman A, Acquah J, Alva M, Hoerger T, Romaire M. 
Medicaid incentives for preventing chronic disease: 
effects of financial incentives for smoking cessation. 
Health Services Research 2018;53(6):5016–34.
Woods SS, Haskins AE. Increasing reach of quitline ser-
vices in a U.S. state with comprehensive tobacco treat-
ment. Tobacco Control 2007;16(Suppl 1):i33–i36.
Interventions for Smoking Cessation and Treatments for Nicotine Dependence  575
Smoking Cessation
World Health Organization. 1. Benefits and rationale 
for establishing quit-line services. In: Developing 
and Improving National Toll-Free Tobacco Quit Line 
Services: A World Health Organization Manual. Geneva 
(Switzerland): World Health Organization, 2011:7–11. 
World Health Organization. Recommendations. In: 
WHO Recommendations for the Prevention and 
Management of Tobacco Use and Second-Hand Smoke 
Exposure in Pregnancy. Geneva (Switzerland): World 
Health Organization, 2013:44–9. 
World Health Organization. Advisory Note: Global 
Nicotine Reduction Strategy. Geneva (Switzerland): 
World Health Organization, 2015. 
World Health Organization and International Agency 
for Research on Cancer. IARC Monographs on the 
Evaluation of Carcinogenic Risks to Humans. Volume 
89: Smokeless Tobacco and some Tobacco-Specific 
N-Nitrosamines Lyon (France): International Agency 
for Research on Cancer, 2007. 
Wortley PM, Husten CG, Trosclair A, Chrismon J, Pederson 
LL. Nondaily smokers: a descriptive analysis. Nicotine 
and Tobacco Research 2003;5(5):755–9.
Yalom ID, Leszcz M. Theory and Practice of Group 
Psychotherapy. 5th ed. New York (NY): Basic Books, 2005.
Yvonne Prutzman, NCI. personal communication, January 
23, 2019.
Zapka JG, Fletcher K, Pbert L, Druker SK, Ockene JK, 
Chen L. The perceptions and practices of pediatricians: 
tobacco intervention. Pediatrics 1999;103(5):e65.
Zeliadt SB, Heffner JL, Sayre G, Klein DE, Simons C, 
Williams J, Reinke LF, Au DH. Attitudes and perceptions 
about smoking cessation in the context of lung cancer 
screening. JAMA Internal Medicine 2015;175(9):1530–7.
Zhang B, Cohen JE, Bondy SJ, Selby P. Duration of nico-
tine replacement therapy use and smoking cessation: a 
population-based longitudinal study. American Journal 
of Epidemiology 2015;181(7):513–20.
Zhang L, Malarcher A, Mann N, Campbell K, Davis K, 
Anderson C, Alexander R, Rodes R. The influence of 
state-specific quitline numbers on call volume during 
a national tobacco education campaign promoting 
1-800-QUIT-NOW. Nicotine and Tobacco Research 
2016;18(8):1780–5.
Zhu SH, Lee M, Zhuang YL, Gamst A, Wolfson T. 
Interventions to increase smoking cessation at the pop-
ulation level: how much progress has been made in the 
last two decades? Tobacco Control 2012;21(2):110–8.
Zhu SH, Stretch V, Balabanis M, Rosbrook B, Sadler G, 
Pierce JP. Telephone counseling for smoking cessation: 
effects of single-session and multiple-session interven-
tions. Journal of Consulting and Clinical Psychology 
1996;64(1):202–11.
Zhu SH, Zhuang YL, Wong S, Cummins SE, Tedeschi GJ. 
E-cigarette use and associated changes in population 
smoking cessation: evidence from U.S. current popula-
tion surveys. BMJ 2017;358:j3262.
Zhuang YL, Cummins SE, J YS, Zhu SH. Long-term 
e-cigarette use and smoking cessation: a longitu-
dinal study with U.S. population. Tobacco Control 
2016;25(Suppl 1)i90–i95.
Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, 
Adler LE, Audrain-McGovern J, Breslau N, Brown 
RA, George TP, Williams J, et al. Tobacco use and ces-
sation in psychiatric disorders: National Institute of 
Mental Health report. Nicotine and Tobacco Research 
2008;10(12):1691–715.

577
Chapter 7 
Clinical-, System-, and Population-Level Strategies 
that Promote Smoking Cessation
Introduction     579
Literature Review Methods     579
Clinical- and Health System-Based Strategies on Smoking Cessation     581
Clinical Practice Guidelines     583
Clinical Practice Guideline from the U.S. Public Health Service     583
Recommendations from the U.S. Preventive Services Task Force     586
Improving and Promoting Coverage of Treatment for Tobacco Use and Dependence     587
Health Insurance Coverage     588
Removing Barriers to Access     592
Promoting Coverage for Utilization of Smoking Cessation Treatments and Benefits     594
Quality and Performance Measures and Payment Reforms     594
Linking Quality Measures to Payment     595
Health Plan-Based Quality Measures     595
Hospital-Based Performance Measures     595
Realigning Payment Incentives     596
Enhancing the Technology of Electronic Health Records     597
Population-Based Strategies on Smoking Cessation     598
Quitlines     598
Increasing the Price of Tobacco Products     599
Smokefree Policies     601
Mass Media Campaigns     603
Examples of Campaigns     603
Features of Antismoking Campaigns that Support the Use of Cessation Resources     604
Effectiveness of Campaigns     605
State Tobacco Control Programs     605
Pictorial Health Warnings     607
Plain Packaging     608
Reduced Retail Point-of-Sale Advertising and Retail Density     609
Restricting the Sale of Certain Types of Tobacco Products     610
Very-Low-Nicotine-Content Cigarettes     612
E-Cigarettes     612
Modeling to Assess the Impact of Policy and Regulatory Changes on Cessation     613
Limitations and Methodologic Gaps     617
Summary of the Evidence     618
Conclusions     619
References     620

Clinical-, System-, and Population-Level Strategies that Promote Smoking Cessation  579
Smoking Cessation
Introduction
Clinical-, system-, and population-level strategies 
can broadly influence the behavior of smokers as they try to 
quit or think about quitting smoking. This chapter focuses 
on these broad strategies that can facilitate the integra-
tion of individual components of treatment for smoking 
cessation, as discussed in Chapter  6, into routine clin-
ical care—making cessation interventions available and 
accessible to individual smokers and creating conditions 
whereby smokers become aware of these interventions and 
are motivated to use them. This chapter does not attempt 
to provide a review of all tobacco control policy actions 
that may result in smokers attempting to quit or that 
may increase quit success outside the context of cessation 
treatment interventions; these have been covered compre-
hensively in previous Surgeon General’s reports, including 
the 50th  anniversary report, The Health Consequences 
of Smoking—50  Years of Progress (U.S. Department of 
Health and Human Services [USDHHS] 2014), as well as 
in other documents (National Cancer Institute [NCI] and 
World Health Organization [WHO] 2017; WHO 2019). 
Table  7.1 describes key findings from the 2014 Surgeon 
General’s report that are relevant to smoking cessation.
Strategies that encourage smoking cessation beyond 
the individual smoker generally involve actions at one of 
three levels: (1) the clinical setting, (2) the health system, 
or (3)  the population. Actions taken at the clinical and 
health system levels typically target quitting behavior 
directly and generally focus on the use or effectiveness 
of treatments for smoking cessation (Fiore et  al. 2008; 
Centers for Disease Control and Prevention [CDC] 2014b; 
U.S. Preventive Services Task Force [USPSTF] 2015). 
These actions include implementing policies that trans-
form systems of care to better address tobacco use and 
dependence; promoting evidence-based treatments for 
tobacco cessation; and implementing policies that are 
clinically focused, address health insurance coverage, 
and promote cessation. These actions can reach a large 
proportion of Americans who smoke, considering nearly 
70% of U.S. adults who smoke cigarettes visit a primary 
care clinician each year (CDC 2012c) and millions of U.S. 
adults see specialty clinicians and are hospitalized annu-
ally (National Center for Health Statistics 2018).
In contrast, population-based strategies are aimed 
at influencing tobacco cessation at a macro level by moti-
vating smokers to quit and by providing an environment 
that supports or simplifies efforts to quit or lowers bar-
riers that smokers might encounter. These strategies 
are broader than those at the clinical or health system 
levels, affecting the larger community or population, 
not just individuals engaged with the healthcare system. 
Population-based strategies include increasing the price 
of and/or the tax on cigarettes and other tobacco prod-
ucts; restricting where tobacco can be used by imple-
menting smokefree and tobacco-free policies; adequately 
funding tobacco control programs at the state level; car-
rying out mass media campaigns (e.g., CDC’s Tips From 
Former Smokers campaign [Tips] [CDC 2018b] and the 
U.S. Food and Drug Administration’s [FDA’s] Real Cost 
Campaign [FDA 2018b]); making changes to the tobacco 
retail density and point-of-sale environments; and devel-
oping product regulations, including regulating nico-
tine content and requiring pictorial health warnings. 
Importantly, combining clinical and health system-based 
and macro-level strategies can have a synergistic effect 
on improving cessation outcomes. For example, in addi-
tion to motivating smokers to make a quit attempt, a 
mass media campaign (a macro-level strategy), such as 
the Tips campaign, can motivate smokers to use cessa-
tion resources, including state quitlines, web-based cessa-
tion support, and cessation interventions from healthcare 
providers.
This classification of strategies to promote smoking 
cessation is similar to CDC’s “three buckets framework,” 
in which prevention approaches include (1)  traditional 
patient-level clinical interventions; (2)  innovative clin-
ical prevention provided outside of the clinical or health 
system setting; and (3)  population- or community-wide 
interventions that reach a broader population, often 
defined geographically (Auerbach 2016) (Figure 7.1). With 
this framework in mind, a combination of strategies across 
the three buckets could potentially provide optimal cessa-
tion motivation and support for smokers by helping them 
quit and creating a broad environment that is conducive 
to and supportive of quitting.
Literature Review Methods
For the evidence presented in this chapter, PubMed/
Medline, Scopus, and Google Scholar were searched for 
studies that focused on smoking cessation policies as 
they are impacted by various strategies, technologies, and 
inducements at both the health system and population 
levels, with a specific focus on well-designed review articles 
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and meta-analysis, when available. Articles were published 
between January  1, 2002, and December  31, 2016, and 
included references to other sources (e.g., those in Clinical 
Practice Guideline [Fiore et al. 2008]) that predated 2002. 
Consistent with the longstanding process adhered to for 
the development of Surgeon General’s reports on tobacco 
(see Chapter 1), several additional studies published after 
2016 were added during the review and clearance process 
to ensure that the volume includes the most updated sci-
entific literature available. A combination of keywords 
and phrases were used in conjunction with “cessation” or 
“quit” to investigate the following topics as they relate to 
smoking cessation: (1) clinic and health system strategies, 
including guidelines, insurance coverage, provider pay-
ments/incentives, performance measures, and electronic 
health records (EHRs); and (2)  population-based poli-
cies, including tobacco taxes/price, quitlines, mass media 
campaigns, smokefree strategies, tobacco control pro-
grams, pictorial health warnings, plain packaging, retail 
density, low-nicotine-content cigarettes, and menthol or 
flavors. Chapter conclusions reflect evidence cited in pre-
vious Surgeon General’s reports and newly available evi-
dence. Search results were limited to studies published in 
English and to original research.
Table 7.1 Summary of policies from the 2014 Surgeon General’s report that encourage smoking cessation
Policy area Results for smoking cessation
Tax or price • A 10% increase in cigarette price is associated with a 3–5% decrease in cigarette consumption.
• Increasing the price of tobacco products reduces initiation, prevalence, and intensity of smoking in 
youth and adults.
Smokefree policies In addition to protecting nonsmokers from exposure to secondhand smoke, strong evidence suggests 
that smokefree laws and policies:
• Reduce the prevalence of tobacco use,
• Increase the number of tobacco users who quit, and
• Reduce the initiation of smoking among youth and young adults.
Specifically, smokefree laws and policies are associated with a:
• 3.4% reduction in the prevalence of tobacco use, and
• 6.4% increase in tobacco cessation.
Healthcare policies Federal regulations and legislation have included components to increase the delivery of evidence-based 
treatments for nicotine dependence in healthcare systems:
• The HITECH Act requires the identification and documentation of tobacco use in the EHRs of all patients 
13 years of age and older who use tobacco. This has made the identification and documentation of tobacco 
use in EHRs nearly universal in the U.S. healthcare system.
• The ACA contains several tobacco cessation elements:
 – Mandatory coverage for tobacco cessation medications in state Medicaid programs;
 – Coverage, without cost sharing, of treatment for nicotine dependence for pregnant smokers in state 
Medicaid programs; and
 – The elimination of copayments for preventive services rated A or B by USPSTF, including nicotine 
dependence treatment for all adults.
• In 2010, Medicare expanded coverage of tobacco cessation to all beneficiaries who use tobacco, replacing 
previous coverage limited to beneficiaries with signs or symptoms of a tobacco-related disease.
Comprehensive 
statewide tobacco 
control programs
States that have invested more funds in tobacco control have seen larger and faster declines in the 
prevalence of smoking. Several elements have been shown to be effective at promoting and facilitating 
tobacco cessation:
• Mass media health communications designed to discourage initiation and encourage cessation among 
youth. For example, CDC’s Tips campaign motivated an estimated 1.6 million additional smokers to 
make a quit attempt.
• Healthcare system- and population-based interventions encouraged by state programs can promote 
tobacco cessation via increased delivery of evidence-based tobacco use treatments, such as:
 – Tobacco cessation quitlines and
 – Evidence-based tobacco cessation programs housed in healthcare delivery systems.
Source: USDHHS (2014).
Notes: ACA = Patient Protection and Affordable Care Act; CDC = Centers for Disease Control and Prevention; EHRs = electronic health 
records; HITECH Act = Health Information Technology Economic and Clinical Health Act; USPSTF = U.S. Preventive Services Task Force.
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One hundred sixty-five articles were initially iden-
tified for review for this chapter, with additional litera-
ture added that was published following completion 
of the initial literature review. For the first section on 
clinical and health system-based strategies, 75  articles 
were initially reviewed. These articles fell into the fol-
lowing categories: clinical guideline training and com-
pliance (15  articles), provider and health system pay-
ments/incentives (22  articles), performance measures 
(4 articles), health information technology (12 articles), 
insurance coverage and benefits (13 articles), and health 
system enhancements (9 articles). For the second section 
on population-based strategies, 90 articles were initially 
reviewed. These articles fell into the following categories: 
tobacco taxes/price (19  articles), quitlines (16  articles), 
EHR enhancement (3  articles), mass media campaigns 
(16 articles), smokefree policies (17 articles), and picto-
rial health warnings (5 articles). Subsequent to the initial 
review, additional reviews were performed that identified 
articles on the following categories: tobacco control pro-
grams, plain packaging, retail density and point-of-sale 
advertising, and flavor and product restrictions. Each 
article was screened for level of relevance to the topic, 
its recency, whether it provided novel or complementary 
information (relative to other articles), and the quality 
and soundness of its experimental methods given the 
goals of the research. Articles that did not meet these cri-
teria were excluded. 
Figure 7.1 CDC’s conceptual population health and prevention framework
Source: Auerbach (2016), with permission.
Clinical- and Health System-Based Strategies on Smoking Cessation
Although significant progress has been made to 
integrate tobacco use and dependence treatment into 
clinical health systems, substantial opportunities remain 
for improvement. For example, in 2000, 52.4% of ciga-
rette smokers who had seen a health professional during 
the previous year reported that they had received advice 
to quit. In 2015, that figure rose to 57.2% (Babb et al. 
2017). This suggests that progress on this indicator has 
been slow, with more than 40% of smokers in healthcare 
settings not receiving basic tobacco cessation counseling 
from clinicians. Moreover, the rates at which physicians 
deliver more intensive interventions, such as cessation 
assistance and follow-up to help persons plan for and carry 
out quit attempts, are typically lower than the prevalence 
of screening for tobacco use and delivering advice to quit 
(King et al. 2013b; Bartsch et al. 2016); these more inten-
sive steps can play an important role in helping smokers 
carry out quit attempts (Fiore et al. 2008).
One way to increase smoking cessation interven-
tions from clinicians is through health systems policies 
and protocols that make smoking cessation a standard 
of care (Fiore et al. 2008). Systemwide strategies and 
changes can increase the delivery of clinical cessation 
interventions by routinizing the approach to smoking ces-
sation, making it easier for clinicians and their teams to 
consistently provide evidence-based cessation treatments 
(Fiore et al. 2007; Rigotti 2011; CDC 2014a). In particular, 
data and experiences from the field suggest that health 
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systems initiatives are most likely to increase the preva-
lence of clinical cessation interventions if these initiatives 
(a) embed policies and protocols for tobacco use screening 
and intervention into the clinical workflow, including pro-
vider reminder systems and support for clinical decisions; 
(b) embed decision support tools into health records, 
including EHRs1; and (c) delegate specific components of 
the intervention to the broader healthcare team to reduce 
the burden on time-constrained physicians (Fiore et al. 
2008; Lindholm et al. 2010; Land et al. 2012; Jansen et al. 
2014; Moody-Thomas et al. 2015; Smith et al. 2015).
However, evidence is mixed on the impact of health 
systems change on overall cessation. For example, a 2017 
Cochrane Review assessed the effectiveness of systems 
change interventions in healthcare settings for increasing 
smoking cessation and/or the provision of cessation care 
(Thomas et al. 2017). Evidence from the review indicated 
that systems change interventions improve performance 
on process outcomes, such as documenting smoking 
status and providing cessation counseling and treatment, 
but these interventions do not yet clearly demonstrate 
that they increase cessation rates. Conversely, a 2012 study 
of data from more than 100,000 patients in the Harvard 
Vanguard Medical system during 2005–2010 found that 
patients in clinics that implemented a systems change 
approach (defined as using a tobacco use identification 
system and screening at least half of all patients) had sig-
nificant reductions in the prevalence of smoking and in the 
rate of office visits for smoking-related disease (Land et al. 
2012).
Chapter 6 details the specific barriers that clinicians 
may face when delivering smoking cessation interventions 
to patients, along with approaches to overcoming these 
barriers. Barriers include time constraints, insufficient 
training on tobacco dependence and treatment, lack of 
confidence among clinicians on their ability to effectively 
deliver cessation interventions, a perception on the part 
of some clinicians that tobacco dependence treatment 
is not effective, limited clinician time and reimburse-
ment to provide treatment to patients, and failure to fully 
engage other clinical staff in providing cessation support 
to patients (Rojewski et al. 2019). Many of these individual 
barriers can be overcome by implementing the system-
wide policies discussed in this chapter.
In addition to strategies that seek to make the 
delivery of smoking cessation interventions in health sys-
tems more routine, those that remove cost and other bar-
riers (which impede smokers’ access to proven cessation 
treatments) have been shown to increase the delivery and 
utilization of tobacco dependence treatment, especially 
when the covered treatments are proactively promoted 
to health plan beneficiaries. For example, standardized 
comprehensive, barrier-free cessation coverage by private 
and public insurers expedites smokers’ access to evidence-
based cessation treatments and removes confusion about 
which treatments are covered and related barriers for both 
smokers and providers, thereby increasing the chances 
that smokers and providers will make use of these treat-
ments (Fiore et al. 2008; Kofman et al. 2012; CDC 2014b). 
Clinical guidelines and clinical quality measures also play 
an important role in ensuring that clinicians and health 
systems consistently intervene with tobacco users (Ward 
et al. 2003; Katz et al. 2004, 2014; Lesho et al. 2005; Smith 
et al. 2005, 2008; Caplan et al. 2011; Moody-Thomas et al. 
2011; Shelley et al. 2011; Fiore et al. 2012; Kruger et al. 
2015; Siu 2015).
During the past decade, numerous policy and regula-
tory efforts at the national, state, and local levels have been 
undertaken in the United States to encourage clinicians 
and health systems to identify, document, and treat per-
sons who use tobacco (USDHHS 2014; McAfee et al. 2015; 
Fiore 2016; Thomas et al. 2017) and to encourage health 
insurers to cover smoking cessation and to promote the 
covered treatments. Generally, these efforts have focused 
on achieving several goals, including (1)  increasing 
rates of cessation; (2)  improving smokers’ awareness of 
and access to evidence-based treatments; (3)  improving 
patient health and healthcare quality; (4) reducing health-
care costs associated with tobacco use; (5)  identifying 
and promoting evidence-based cessation treatments and 
programs; (6) establishing clinical standards for tobacco 
use and dependence treatment and making clinicians and 
health systems aware of such standards; (7) improving ces-
sation insurance coverage and promoting it to smokers; 
(8) enhancing compensation for providers or health sys-
tems through pay-for-performance quality measures, pay-
ment reforms, and improved, simpler reimbursement pro-
cedures; and (9) leveraging health information technology 
to improve and routinize treatment for tobacco use and 
dependence (CDC 2014b; USDHHS 2014; McAfee et  al. 
2015; Fiore 2016).
Achieving these goals involves taking action at mul-
tiple levels and may involve government (at the local, 
state, and/or national levels) and nongovernmental enti-
ties (e.g.,  accreditation and nonprofit organizations, 
health system administrators, and insurers). This section 
1An EHR is a collection of health-related information for a patient that is generated by one or more visits in any healthcare setting. The 
EHR typically includes demographic information about the patient, progress notes, problems, medications, vital signs, past medical his-
tory, immunizations, laboratory data, and radiology reports. EHRs focus on the total health of the patient and thus go beyond the stan-
dard clinical data that are collected in a healthcare provider’s office, offering a broader view of the patient’s care.
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describes the major types of strategies at the clinical and 
health system levels and the evidence regarding their 
effects on cessation interventions. Because some of the spe-
cific strategies were developed relatively recently (McAfee 
et  al. 2015; Fiore 2016), their effects on key endpoints, 
including increased access to clinical services for cessation 
and higher rates of cessation, are not yet fully known.
Clinical Practice Guidelines
Clinical practice guidelines from a variety of enti-
ties, including governmental, professional, and accred-
iting agencies, are relevant to clinical and health system 
policies in two ways. First, they contain best-practice rec-
ommendations for clinical treatment that are based on sci-
entific evidence. As such, clinical practice guidelines can 
increase the likelihood that clinicians will use evidence-
based approaches to help their patients quit using tobacco. 
Second, such guidelines seek to integrate evidence-based 
cessation interventions into routine clinical practice, 
serving as standards and laying the groundwork for the 
effective implementation of other policy levers, including 
insurance coverage policies and performance quality mea-
sures. Two examples of clinical practice guidelines will be 
described in this report—Clinical Practice Guidelines from 
the U.S. Public Health Service (Fiore et al. 2008) and the 
recommendations from the U.S. Preventive Services Task 
Force (USPSTF 2015). However, there are other guide-
lines, position statements, and consensus statements from 
a variety of organizations regarding the clinical treat-
ment of tobacco use disorder (e.g., American Psychiatric 
Association 2010; Larzelere and Williams 2012; American 
Academy of Family Physicians 2014; Farber et  al. 2015; 
Barua et al. 2018).
Clinical Practice Guideline from the U.S. Public 
Health Service
The U.S. Public Health Service first published in 
1996 its Clinical Practice Guideline Treating Tobacco 
Use and Dependence (Fiore et al. 1996) and updated it in 
2000 (Fiore et al. 2000) and 2008 (Fiore et al. 2008) (also 
discussed in Chapter 1). The Clinical Practice Guideline 
reviews extensive evidence indicating that health system 
changes can improve the delivery of treatment for smoking 
cessation in healthcare settings and can lead to improved 
downstream quitting behavior and quitting outcomes. 
Importantly, the findings and recommendations of the 
Clinical Practice Guideline are broadly applicable across 
most clinical settings, including primary care, specialty, 
and inpatient settings; dental care settings; and behavioral 
health settings (Hall et al. 1998; Hayford et al. 1999; Smith 
et al. 2003; Wagena et al. 2005; Gordon et al. 2006, 2007, 
2010). Moreover, the Clinical Practice Guideline recom-
mends specific changes in healthcare systems and poli-
cies to enhance the delivery of cessation interventions in 
clinical settings (Fiore et al. 2008). Table 7.2 describes the 
systems and policy findings of the 2008 Clinical Practice 
Guideline and the evidence base supporting them.
The Clinical Practice Guideline (Fiore et al. 2008) 
identified (a)  specific health system strategies and poli-
cies that can facilitate or complement clinical treatments 
for smokers who visit healthcare settings and (b) strate-
gies that can enhance the likelihood that smokers receive 
evidence-based treatments for tobacco use and depen-
dence and/or subsequently quit tobacco use. For example, 
the Clinical Practice Guideline found meta-analytic evi-
dence that training clinicians increases the likelihood 
that they will provide cessation treatment (odds ratio 
[OR] = 3.2; 95% confidence interval [CI], 2.0–5.2) and that 
such training is associated with subsequent increases in 
cessation among their patients (OR = 2.0; 95% CI, 1.2–
3.4). Similarly, in a Cochrane Review of training health 
professionals to conduct interventions in smoking ces-
sation, Carson and colleagues (2012) concluded that cli-
nicians who received training were more likely than 
untrained clinicians (control group) to ask patients to set 
a quit date, make follow-up appointments, and counsel 
smokers. However, in general, clinicians’ follow-up with 
patients who are trying to quit remains suboptimal (King 
et al. 2013b; Bartsch et al. 2016).
Additionally, as outlined in Table 7.2, meta-analytic 
evidence from the Clinical Practice Guideline found that 
implementing systems to identify the smoking status of 
patients further increases clinicians’ rates of intervention 
with patients (nine studies: OR  =  3.1; 95% CI, 2.2–4.2) 
(Fiore et  al. 2008). Because the prevalence of cigarette 
smoking remains high in certain subpopulations in the 
United States, such as persons of lower socioeconomic 
status (Wang et al. 2018) and those with comorbid mental 
health and other substance use diagnoses (Substance 
Abuse and Mental Health Services Administration 2013), 
specific types of healthcare providers or clinical environ-
ments that serve these subpopulations (e.g., psychiatrists, 
psychologists, social workers, federally qualified health 
centers) will likely play an increasingly important role in 
tobacco cessation.
Systems-level recommendations contained in the 
2000 and 2008 Clinical Practice Guidelines have influ-
enced numerous public and private sector policies and rec-
ommendations for treating tobacco use and dependence 
and have also served as the evidentiary basis for health-
care legislation (Torrijos and Glantz 2006). For example, 
evidence from the Clinical Practice Guidelines helped to 
inform cessation provisions in the 2010 Patient Protection 
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Table 7.2 Systems-level changes reviewed in the 2008 Clinical Practice Guideline to encourage smoking cessation
Strategy Action Strategies for implementation
Meta-analytic findings from the 
2008 Clinical Practice Guideline
1. Implement a 
tobacco user 
identification 
system in 
every clinic
Implement an 
officewide system to 
ensure that tobacco use 
status is queried and 
documented for every 
patient at every visit 
to the clinic
• Office system change: Expand 
the review of vital signs to 
include tobacco use or implement 
an alternative universal 
identification system
• Responsible staff (nurse, medical 
assistant, receptionist, or other 
person already responsible for 
recording the vital signs): Must 
be instructed on the importance 
of this activity and serve as 
nonsmoking role models
• Frequency of utilization: Every 
visit for every patient, regardless 
of the reason for the visit
• System-implementation steps: 
Routine smoker identification 
can be achieved by modifying data 
collection and documentation 
in EHRs to include tobacco use 
status as one of the vital signs
• Impact of having a tobacco use 
status identification system in place 
on rates of clinician intervention 
with their patients who smoke 
(n = 9 studies): OR = 3.1; 95% CI, 
2.2–4.2
• Impact of having a tobacco use 
status identification system in place 
on abstinence rates among patients 
who smoke (n = 3 studies): OR = 2.0; 
95% CI, 0.8–4.8
2. Provide education, 
resources, and 
feedback to promote 
interventions 
by healthcare 
providers
Healthcare systems 
should ensure that 
clinicians have 
sufficient training 
to treat nicotine 
dependence; that 
clinicians and patients 
have resources; 
and that clinicians 
are given feedback 
about their nicotine 
dependence treatment 
practices
• Educate all staff on a regular basis 
by offering training (e.g., lectures, 
workshops, in-services) on nicotine 
dependence treatments and 
providing continuing education 
credits and/or other incentives 
for participation
• Provide resources—such as 
having ready access to tobacco 
quitlines (800-QUIT-NOW 
and www.smokefree.gov) and 
establishing a tobacco quitline 
referral system—and other 
community resources, self-help 
materials, and information about 
effective tobacco use medications
• Report the provision of nicotine 
dependence interventions on 
performance measures, report 
cards, and evaluative standards for 
healthcare organizations, insurers, 
accreditation organizations, and 
physician group practices
• Provide feedback to clinicians about 
their performance, drawing on data 
from EHRs and quality reporting 
programs, and evaluate the degree 
to which clinicians are identifying, 
documenting, and treating patients 
who use tobacco
• Effectiveness of clinician training 
on asking about smoking status 
(“Ask”) (n = 3 studies): OR = 2.1; 
95% CI, 1.9–2.4
• Effectiveness of training on setting 
a quit date (“Assist”) (n = 2 studies): 
OR = 5.5; 95% CI, 4.1–7.4
• Effectiveness of training on rates 
of providing treatment (“Assist”) 
(n = 2 studies): OR = 3.2; 95% CI, 
2.0–5.2
• Effectiveness of training on 
providing materials (“Assist”) 
(n = 2 studies): OR = 4.2; 95% CI, 
3.4–5.3
• Effectiveness of training on 
arranging for follow-up (“Arrange”) 
(n = 2 studies): OR = 2.7; 95% CI, 
1.9–3.9
• Effectiveness of training on 
abstinence rates (vs. no training) 
(n = 2 studies): OR = 2.0; 95% CI, 
1.2–3.4
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Strategy Action Strategies for implementation
Meta-analytic findings from the 
2008 Clinical Practice Guideline
3. Dedicate staff to 
provide nicotine 
dependence 
treatment and 
assess the delivery 
of this treatment 
in the performance 
evaluations of staff
Clinical sites should 
communicate to all 
staff the importance 
of intervening with 
tobacco users and 
should designate a staff 
person (e.g., nurse, 
medical assistant, or 
other clinician) to 
coordinate nicotine 
dependence treatments. 
Nonphysician 
personnel may serve as 
effective providers of 
nicotine dependence 
interventions
• Designate a nicotine dependence 
treatment coordinator for every 
clinical site
• Delineate the responsibilities of 
the nicotine dependence treatment 
coordinator (e.g., ensuring the 
systematic identification of smokers, 
ready access to evidence-based 
cessation treatments [e.g., quitlines], 
and scheduling follow-up visits)
• Communicate to each staff member 
(e.g., nurse, physician, medical 
assistant, pharmacist, or other 
clinician) his or her role and 
responsibility in the workflow and 
delivery of nicotine dependence 
services. Discuss these staff 
responsibilities during training 
of new staff
No PHS Guideline meta-analysis.
4. Promote hospital 
policies that 
support and provide 
inpatient nicotine 
dependence services
Provide nicotine 
dependence treatment 
to all tobacco users 
who are admitted to 
a hospital
• Implement a system to identify 
and document the tobacco use 
status of all hospital patients
• Identify a clinician(s) to deliver 
nicotine dependence services to 
inpatients at every hospital and 
reimburse hospitals for delivering 
such services
• Offer nicotine dependence 
treatment to all hospital patients 
who use tobacco
• Expand hospital formularies to 
include FDA-approved nicotine 
dependence medications
• Ensure compliance with The 
Joint Commission’s regulations 
mandating that all sections of the 
hospital be entirely smokefree 
and that patients receive cessation 
treatments
• Educate hospital staff about 
medications that may be used 
to reduce nicotine withdrawal 
symptoms, even if the patient is 
not intending to quit at that time
• No PHS Guideline meta-analysis 
• Rigotti and colleagues (2012), in 
a Cochrane review of in-hospital 
tobacco dependence treatment 
programs, concluded that intensive 
counseling interventions that 
began during the hospital stay and 
continued with supportive contacts 
for at least 1 month after discharge 
increased smoking cessation rates 
after discharge (n = 25 studies): 
OR = 1.37; 95% CI, 1.27–1.48
• Rigotti and colleagues (2012) also 
concluded that adding nicotine 
replacement therapy to an intensive 
counseling intervention increased 
rates of smoking cessation compared 
with intensive counseling alone 
(n = 6 studies): OR = 1.54; 95% CI, 
1.34–1.79
Table 7.2 Continued
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and Affordable Care Act (ACA) and the approach for docu-
menting tobacco use in EHRs in the Health Information 
Technology for Economic and Clinical Health Act 
(HITECH) (Table 7.2).
As noted previously in this chapter, the Clinical 
Practice Guidelines were intended to help shape clinical 
practice, and thereby increase cessation—not just to serve 
as a repository of evidence on clinical policies. Numerous 
studies have addressed the impact of the Clinical Practice 
Guidelines on clinical performance and outcomes (Katz 
et  al. 2004, 2014; Lesho et  al. 2005; Smith et  al. 2005; 
Caplan et  al. 2011; Institute of Medicine, Committee on 
Standards for Developing Trustworthy Clinical Practice 
Guidelines 2011; Moody-Thomas et al. 2011; Shelley et al. 
2011; Kruger et al. 2015). These studies have generally dem-
onstrated that the implementation of guidelines (e.g., the 
Clinical Practice Guidelines or the “5  A’s” [Ask, Advise, 
Assess, Assist, Arrange] clinical intervention or its abbrevi-
ated version, the “AAR” [Ask, Advise, Refer])—via training, 
systems-level changes, or other actions—is associated 
with higher rates of delivery of guideline-recommended 
interventions for smoking cessation (see Chapter 6). Some 
studies have also demonstrated an association with higher 
rates of cessation and/or lower smoking prevalence. For 
example, Caplan and colleagues (2011) noted that training 
primary care physicians to deliver the 5 A’s was associated 
with significantly greater compliance with the interven-
tions recommended in the Clinical Practice Guideline. 
Data following the release of the guideline also revealed 
(a) a significant increase in the percentage of patients at 
U.S. Department of Veterans Affairs (VA) healthcare facili-
ties who were counseled about smoking cigarettes and 
(b) a significant decrease in the percentage of VA patients 
who smoked cigarettes (Ward et al. 2003; Katz et al. 2004). 
Thus, the practices recommended in the Clinical Practice 
Guideline can enhance the provision of treatment for 
smoking and cessation-related outcomes.
Recommendations from the U.S. Preventive 
Services Task Force
Created in 1984, USPSTF is an independent, volun-
teer panel of national, nonfederal experts in prevention 
and evidence-based medicine who review relevant scien-
tific evidence and make evidence-based recommendations 
about clinical preventive services, such as screenings, 
counseling services, and medications (USPSTF 2017).
In 2015, USPSTF conducted an evidence review and 
updated its recommendations regarding the clinical treat-
ment of tobacco use in primary care practices (USPSTF 
2015). The USPSTF recommended that clinicians (a) ask 
Table 7.2 Continued
Strategy Action Strategies for implementation
Meta-analytic findings from the 
2008 Clinical Practice Guideline
5. Include nicotine 
dependence 
treatments (both 
counseling and 
medication), 
identified as 
effective in the 
Clinical Practice 
Guideline, as paid 
or covered services 
for all subscribers 
or members of 
health insurance 
packages
Provide all insurance 
subscribers—
including those 
covered by managed 
care organizations, 
workplace health plans, 
Medicaid, Medicare, 
and other government 
insurance programs—
with comprehensive 
coverage for effective 
nicotine dependence 
treatments, including 
counseling and FDA-
approved medications
• Cover evidence-based nicotine 
dependence treatments (counseling 
and medications) as part of the 
basic benefits package for all 
health insurance packages
• Remove barriers to tobacco 
treatment benefits (e.g., copays, 
prior authorization)
• Educate all subscribers and 
clinicians about the availability 
of covered nicotine dependence 
treatments (both counseling 
and medications) and encourage 
patients to use these services
• Rates of intervention for persons 
who received tobacco use 
interventions as a covered health 
insurance benefit (vs. persons 
with no tobacco cessation health 
insurance benefit) (n = 3 studies): 
OR = 2.3; 95% CI, 1.8–2.9 
• Rates of quit attempts for persons 
who received tobacco use 
interventions as a covered health 
insurance benefit (vs. persons 
with no tobacco cessation health 
insurance benefit) (n = 3 studies): 
OR = 1.3; 95% CI, 1.0–1.5 
• Estimated abstinence rates for 
persons who received tobacco use 
interventions as a covered health 
insurance benefit (vs. persons 
with no tobacco cessation health 
insurance benefit) (n = 3 studies): 
OR = 1.6; 95% CI, 1.2–2.2
Source: Fiore and colleagues (2008).
Notes: CI = confidence interval; EHR = electronic health record; FDA = U.S. Food and Drug Administration; OR = odds ratio; 
PHS = U.S. Public Health Service.
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all nonpregnant adults about their tobacco use, advise 
them to stop using tobacco, and provide both behavioral 
interventions and FDA-approved pharmacotherapy for ces-
sation to nonpregnant adults who use tobacco; and (b) ask 
all pregnant women about their tobacco use, advise them 
to stop using tobacco, and provide behavioral interven-
tions for cessation to pregnant women who use tobacco. 
These recommendations are in the process of being 
updated. A draft research plan was posted on USPSTF’s 
website for public comment in early 2018 (USPSTF 2018).
Although the 2015 USPSTF recommendations focus 
primarily on clinical cessation interventions, they are 
included in this chapter because the USPSTF guidelines 
increasingly serve as the basis for making decisions about 
insurance coverage and assessing performance and quality 
measures. The USPSTF “A” rankings have federal regu-
latory and reimbursement implications (USPSTF 2015). 
For example, the 2010 ACA used USPSTF’s ratings as cri-
teria for coverage requirements, requiring all non-grand-
fathered, private insurance plans to cover—without cost 
to the patient—preventive services that received “A” or 
“B” ratings (Patient Protection and Affordable Care Act 
of 2010), which included provision of tobacco cessation 
interventions to those who use tobacco (USPSTF 2009). 
As a result, a growing number of private insurers have 
included USPSTF “A” recommended preventive services 
as part of their basic package of covered health benefits; 
however, the administration and implementation of cov-
erage for smoking cessation still varies widely across the 
insurance market, including among private insurers, state 
Medicaid programs, and Medicaid managed care plans 
(Kofman et al. 2012; American Lung Association 2015).
Overall, the evidence is sufficient to infer that the 
development and dissemination of evidence-based clinical 
practice guidelines increases the delivery of clinical inter-
ventions for smoking cessation.
Improving and Promoting Coverage 
of Treatment for Tobacco Use and 
Dependence
Treatments for tobacco use and dependence can be 
covered through (1) health insurance, which includes 
coverage through private insurance (both the individual 
market and the employer markets), Medicaid, or Medicare, 
or coverage provided to active-duty military and vet-
erans; and/or (2) employer-based wellness programs that 
may be offered in conjunction with health insurance. 
Comprehensive coverage of tobacco cessation treatments 
includes coverage of evidence-based cessation treat-
ments (individual, group, and telephone counseling) and 
FDA-approved cessation medications (Fiore et al. 2008). 
Comprehensive coverage removes or minimizes barriers, 
such as cost-sharing and prior authorization, that can 
impede access to cessation treatments (CDC 2014a, 2015; 
McAfee et al. 2015; Singleterry et al. 2015). As an example, 
effective 2011, the U.S. Office of Personnel Management 
(OPM) implemented model comprehensive insurance cov-
erage of evidence-based cessation interventions for fed-
eral employees (OPM 2010a,b,n.d.). The insurance covers 
individual, group, and telephone counseling and all seven 
FDA-approved cessation medications for at least two quit 
attempts per year with no copays, coinsurance, or deduct-
ibles and no annual or lifetime limits (OPM 2010a,b,n.d.; 
CDC 2014b). Despite the model coverage approach, one 
potential limitation of this benefit is that some federal pre-
scription plans require a health risk assessment as a pre-
condition to getting medications covered at 100%; other-
wise, there are copays for medications. Additionally, these 
assessments are primarily completed online, which could 
diminish utilization, particularly by persons with limited 
or no access to the Internet (CDC 2014a). Another bar-
rier is that many plans require a prescription for cessa-
tion medications, even if they can be purchased over the 
counter, so persons can be reimbursed.
In spring 2019, OPM included language in its annual 
call letter and technical guidance for Federal Employees 
Health Benefits (FEHB) program carriers that reaffirmed 
and updated the comprehensive tobacco cessation cov-
erage benefit, which was originally introduced in 2011, 
for federal employees (OPM 2019b). This new language 
highlights
• The effectiveness of combination nicotine replace-
ment therapy (NRT),
• The fact that the combination of counseling and med-
ication gives smokers the best chance of quitting,
• The importance of making cessation coverage barrier 
free and of promoting this coverage so that members 
and providers are aware of it and use it, and 
• Opportunities to partner with pharmacists to pro-
vide education and decision support on cessation 
medications.
The call letter (OPM 2019b) and technical guidance 
(OPM 2019a) also call for FEHB plans to educate parents and 
healthcare providers on approaches to help prevent youth 
from using all tobacco products, including e-cigarettes, and 
on approaches to help youth who already use tobacco prod-
ucts to quit. Beyond its direct impact on 8.2 million federal 
employees, family members, retirees, and annuitants, this 
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updated cessation coverage from OPM has the potential to 
provide a model for private health insurers and employers, 
and it creates an opportunity to promote the updated ces-
sation coverage to federal employees.
Health insurance coverage for evidence-based treat-
ment of tobacco use and dependence complements the 
efforts of health systems and healthcare providers by 
making it easier for them to connect patients with treat-
ment (Fiore et al. 2008; CDC 2014a; McAfee et al. 2015). 
Regardless of how well designed a coverage benefit may 
be, coverage alone, without promotion, is insufficient. It 
is critical that benefits for smoking cessation, whether 
offered through a health insurer or an employee wellness 
program, be promoted to increase awareness and use of 
covered treatments. The next section outlines the scien-
tific evidence base for the coverage and promotion of ben-
efits that address smoking cessation.
Health Insurance Coverage
The availability of comprehensive health insurance 
coverage for evidence-based treatment of tobacco use and 
dependence has been associated with higher utilization of 
cessation treatment and with successful cessation. In an 
examination of four insurance plans (N = 90,005 enrollees), 
Curry and colleagues (1998) showed that the highest 
rates of cessation were achieved for the group of smokers 
that had no barriers to benefits (i.e.,  no cost for behav-
ioral counseling and NRT). The study concluded that full 
insurance coverage, compared with coverage with copays, 
was associated with a doubling of the overall quit rate in 
this population. Later, the Clinical Practice Guideline 
(Fiore et al. 2008) reported that providing tobacco cessa-
tion treatments as a covered health insurance benefit was 
associated with a greater likelihood that smokers would 
make a quit attempt (OR = 1.3; 95% CI, 1.0–1.5); a greater 
likelihood that persons who smoke would receive treat-
ments for tobacco use and dependence during a healthcare 
visit (OR = 2.3; 95% CI, 1.8–2.9); and greater odds that 
they would quit successfully (OR = 1.6; 95% CI, 1.2–2.2) 
(Table 7.2) (Alesci et al. 2004; Holtrop et al. 2005; Murphy 
et al. 2005). Using nationally representative data, another 
study reported that Medicaid enrollees in states with 
more comprehensive coverage of cessation treatment had 
higher-than-predicted successful quit rates (8.3%) com-
pared with those living in states with more limited cov-
erage (ranging from 4.0% for pharmacotherapy without 
copayment to 5.6% for pharmacotherapy with copayment) 
(Greene et  al. 2014). In another study using nationally 
representative data, Kostova and colleagues (2018) found 
that state Medicaid coverage of both cessation counseling 
and cessation medication was associated with an estimated 
mean increase of 3.0 percentage points (p <.10) in past-year 
quitting among covered Medicaid beneficiaries compared 
with persons without coverage. In addition, Ku and col-
leagues (2016) found that among Medicaid enrollees, state 
Medicaid coverage of at least one form of NRT, bupropion, 
and varenicline was associated with a 24–34% increase in 
the use of cessation medications.
Uniform implementation of comprehensive, evidence-
based cessation coverage across health insurance products 
with minimal barriers (e.g., no prior authorizations) may 
also increase clinicians’ delivery of cessation interventions 
by making it easier for them to understand their patients’ 
coverage and increasing their confidence that their patients 
will be able to access the treatments they recommend 
(Kofman et al. 2012; McAfee et al. 2015; van den Brand 
et al. 2017).
Insurance coverage of tobacco cessation can also 
be a cost-effective benefit. For example, in 2006, the 
Massachusetts Medicaid program (MassHealth) began 
offering and intensely promoting comprehensive coverage 
for tobacco cessation with minimal barriers to all Medicaid 
enrollees. During the first 3 years of the program, more 
than 75,000 MassHealth members who smoked cigarettes 
(nearly 40% of MassHealth smokers) had used covered 
cessation treatments, with far more using cessation medi-
cations than counseling (Land et al. 2010a,b; CDC n.d.). 
Use of the benefit substantially influenced cessation, as 
the rate of cigarette smoking among MassHealth members 
decreased from 38.3% to 28.3% over 2-1/2 years (Land 
et al. 2010b). In another Massachusetts-based study, Land 
and colleagues (2010a) found that coverage for smoking 
cessation was associated with substantial decreases in hos-
pitalization rates for cardiovascular disease, with annu-
alized declines of 46% and 49% in admissions for acute 
myocardial infarction and other acute coronary heart dis-
ease diagnoses, respectively, among Medicaid smokers 
who used the benefit. An economic analysis focusing on 
the costs and savings from the perspective of the Medicaid 
program indicated that every $1.00 spent on medications, 
counseling, and promotional outreach was associated 
with a reduction of $3.12 in cardiovascular-related hospi-
talization expenditures, resulting in net savings between 
$2.00 and $2.25 (Richard et al. 2012).
Despite this evidence, numerous insurers have 
offered several reasons why they believe coverage should 
not be required, including
• Lack of evidence for effectiveness of interventions;
• Lack of evidence that coverage increases utilization;
• Coverage could decrease participant motivation 
by removing personal financial commitment to 
the cessation treatment program, thus potentially 
decreasing the odds of success;
Clinical-, System-, and Population-Level Strategies that Promote Smoking Cessation  589
Smoking Cessation
• Lack of interest from smokers and institutional 
purchasers;
• The perception that smoking is a societal problem, 
rather than a healthcare problem; 
• Concern that provision of coverage could make 
insurance unaffordable; and
• Concern that some of the health benefits of smoking 
cessation take years to be fully realized (e.g., reducing 
the risk of lung cancer or chronic obstructive pul-
monary disease), and therefore this benefit may 
not accrue to the insurer, since the smoker may no 
longer be in the health plan when the benefit is real-
ized (Gollust et al. 2008).
Over time, many of these rationales have been system-
atically refuted, often through large-scale research trials 
(Curry et al. 1998; Joyce et al. 2008; Hamlett-Berry et al. 
2009; Smith et al. 2010; Fu et al. 2014, 2016). Nonetheless, 
adoption of smoking cessation coverage remains limited 
and varies widely (Kofman et al. 2012). Coverage mandates 
at the state and national levels can provide an important 
lever to encourage the delivery and use of evidence-based 
treatments and clinical services for smoking cessation and 
to standardize a minimum level of coverage. Such man-
dates often have components that are designed to influ-
ence the behaviors of both the beneficiary and the clinician 
or health system.
Examples of current insurance coverage in the United 
States and considerations for coverage across the major 
health insurance categories are outlined below, including 
for private insurance, Medicaid, Medicare, and Military 
Health System and Veteran’s Health Administration. 
Specific epidemiologic data on the prevalence of quit 
attempts, use of cessation treatments, and recent cessation 
success is not covered in this chapter but can be found in 
Chapter 2.
Private Insurance
In 2017, 67% of insured U.S. adults were covered 
through the private market, 56% were insured through 
their employers, and 16% were insured through nongroup 
plans or health insurance exchanges; these figures do not 
total 100% because persons may have had more than one 
type of coverage during the calendar year (Berchick et al. 
2018). The 2010 ACA included components designed to 
increase rates of tobacco cessation among members of pri-
vate, non-grandfathered health plans via improved coverage 
for cessation treatments (Kofman et al. 2012; McAfee et al. 
2015). Further subregulatory guidance (U.S. Department 
of Labor 2014; McAfee et al. 2015) clarified that insurers 
should provide a minimum of two courses of evidence-
based treatment for tobacco cessation per year that include 
both cessation counseling and cessation medication with 
no cost sharing or prior authorization (Table 7.3).
The limited evidence available suggests that much 
private insurance coverage continues to fall short of this 
standard. Bloom and colleagues (2018) reported that some 
insurance plans may not recognize certain types of clini-
cians as providers of tobacco counseling for reimburse-
ment purposes. In addition, some plans may explicitly 
exclude intensive preventive counseling or may charge 
high copays for longer, more intensive counseling visits. 
This may be because of a reliance on the 2009 USPSTF 
tobacco cessation recommendations, which did not clearly 
define intensive treatment, instead of a reliance on the 
more detailed 2014 subregulatory guidance from the U.S. 
Department of Labor (2014). However, the 2015 tobacco 
cessation recommendations from USPSTF clarified that 
Table 7.3 Affordable Care Act guidance of coverage of tobacco cessation treatmenta
“A group health plan or health insurance issuer will be considered in compliance with the ACA’s requirement to cover tobacco-use 
counseling and interventions if, for example, it covers the following, without cost sharing or prior authorization:
• Screening of all patients for tobacco use; and
• For enrollees who use tobacco products, at least two tobacco cessation attempts per year, with coverage of each quit 
attempt including:
 – Four tobacco-cessation counseling sessions, each at least 10 minutes long (including telephone, group, and individual 
counseling); and
 – All FDA-approved tobacco-cessation medications (including prescription and over-the-counter) for a 90-day treatment 
regimen when prescribed by a health care provider”
Source: McAfee and colleagues (2015, p. 6) and U.S. Department of Labor (2014).
Notes: ACA = Patient Protection and Affordable Care Act; FDA = U.S. Food and Drug Administration.
aFDA has approved seven smoking cessation medications: five nicotine medications (patch, gum, lozenge, nasal spray, and inhaler) and 
two non-nicotine pills (bupropion and varenicline). Information is adapted from U.S. Department of Labor (2014); additional information 
is available at American Lung Association (n.d.a).
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intensive visits should last at least 20 minutes, multiple 
sessions should be provided (at least four in-person coun-
seling visits), and cessation rates may plateau after 90 min-
utes of total counseling contact time (USPSTF 2015).
Public Health England (2017) outlined an example 
of a model benefit that offers intensive counseling (i.e., 
individual and group counseling with more frequent and 
longer visits than outlined in the subregulatory guid-
ance in the United States) and robust medication benefits 
(e.g., combination short- and long-acting NRT) for every 
smoker in the country. Table 7.4 includes some examples 
of cessation benefit models. These models have strengths 
and weaknesses, with MassHealth and Public Health 
England having the most comprehensive and intensive 
models. As noted in Chapter 6, it is important for insurers 
to adequately and fairly reimburse or “incentivize” health-
care systems and clinicians at a macro level for the costs of 
providing cessation counseling (Nolan and Warner 2017). 
Increasing clinician reimbursement for cessation coun-
seling time (including high-intensity counseling) could 
help to increase reach and quit rates.
Medicaid
Medicaid is a joint federal and state program that 
provides health coverage for some individuals and fami-
lies with low-incomes, qualified pregnant women and 
children, senior citizens, and people with disabilities 
(Medicaid.gov n.d.). Given that Medicaid enrollees com-
prise a low-income, disadvantaged population with dispro-
portionately high rates of cigarette smoking (CDC 2014a, 
2015; Jamal et al. 2016), and that smoking-related disease 
is a major driver of Medicaid costs (Xu et al. 2015b), com-
prehensive Medicaid coverage for tobacco use and depen-
dence treatment is especially important. In 2016, almost 
20% of insured U.S. adults were covered through Medicaid 
(Kaiser Family Foundation n.d.b). Smokers who are 
enrolled in Medicaid are more likely than privately insured 
and uninsured smokers to have chronic diseases and to 
experience severe psychological distress (Zhu et al. 2017). 
In 2017, 24.5% of adult Medicaid enrollees were current 
cigarette smokers, compared with 10.5% of adults with 
private health insurance (Wang et  al. 2018) amounting 
to nearly 7.2  million Medicaid recipients, who make up 
about 21% of all U.S. adult smokers (NHIS, 2017 data). As 
discussed in Chapter 6, the smoking rate among Medicaid 
enrollees remained unchanged from 1998 to 2013 (Zhu 
et al. 2017). During 2006–2010, smoking-related diseases 
accounted for about 15% (or more than $39  billion) of 
annual Medicaid spending (Xu et al. 2015b).
National health objectives include a target for all 
state Medicaid programs to adopt comprehensive coverage 
of treatments for smoking cessation, including coverage of 
individual, group, and telephone cessation counseling and 
all seven FDA-approved cessation medications (DiGiulio 
et al. 2018). Although Medicaid cessation coverage varies 
by state, it has been gradually improving in recent years, 
especially with regard to cessation medications (DiGiulio 
et al. 2016, 2018). Changes in Medicaid policies have con-
tributed, in part, to improved cessation coverage. For 
example, the Section 4107 of the 2010 ACA requires tradi-
tional (non-expansion) state Medicaid programs to cover 
cessation counseling and FDA-approved cessation medi-
cations for pregnant women with no cost-sharing (effec-
tive October 2010), and Section  2502 of the 2010 ACA 
prohibits these programs from excluding cessation med-
ications from coverage for all traditional adult Medicaid 
enrollees (effective January 2014) (McAfee et al. 2015). In 
addition, in 2011, the Centers for Medicare & Medicaid 
Services (CMS) provided guidance that tobacco quitlines 
qualified as an allowable Medicaid administrative activity. 
As a result, state Medicaid programs became eligible to 
receive a 50% administrative match for quitline services 
provided to Medicaid beneficiaries (CMS 2011). While this 
policy does not impact state Medicaid cessation coverage 
per se, it provides Medicaid enrollees with increased access 
to evidence-based forms of cessation counseling.
Currently, all states (including the District of 
Columbia) cover at least some proven cessation treatments 
for all Medicaid enrollees; about three-fifths of states cover 
individual cessation counseling, and only about one-fifth 
of states cover group counseling; and about three-fifths of 
states cover all seven FDA-approved cessation medications 
(DiGiulio et al. 2018). Almost all states impose coverage 
barriers which restrict access to covered cessation treat-
ments, especially cessation medications; common barriers 
include prior authorization, limits on duration, annual 
limits on quit attempts, and copayments.
Medicare
Medicare is a health insurance program for people 
aged 65 or older, people under age 65 with certain disabili-
ties, and people of all ages with permanent kidney failure 
requiring dialysis or a kidney transplant (CMS 2019). 
In 2016, about 15% of insured U.S. adults received cov-
erage through Medicare (Kaiser Family Foundation n.d.b). 
Medicare coverage of tobacco cessation affects a smaller 
number of beneficiaries compared with Medicaid, but it is 
still important, particularly because tobacco-related dis-
eases often first become evident or worsen among older 
smokers, and cessation at any age is beneficial to health 
(USDHHS 2010). In recent years, Medicare has taken steps 
to improve coverage for cessation. For example, Medicare 
now covers—without cost sharing—multisession, indi-
vidual counseling for two quit attempts per year (eight 
total visits). However, Medicare does not cover group 
or telephone counseling (Medicare Interactive n.d.). 
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Table 7.4 Models of comprehensive tobacco cessation coverage and health insurance benefits
Benefit plan Counseling visits Counseling format Counseling dose/time Setting Clinician type Medications
Mass Medicaid 
(Massachusetts 
Department of Public 
Health 2014)
Up to 16 face-to-face 
visits per year; more 
visits with prior 
authorizationa
At least two 45-minute 
intake visits; 14 individual 
or group visits
Individual >30 minutes; 
group >60 minutes
Massachusetts Physicians or nurses, 
certified tobacco 
treatment specialists, etc.
Seven FDA-approved 
medications, 180 days 
each, combinations
U.S. Office of Personnel 
Management (n.d.)
At least 8 visits per year Individual, group, 
and telephone
>30 minutes for 
individual visits
Federal employee 
health benefit
Not specified Seven FDA-approved 
medications,b 180 days 
each, combinations
Patient Protection and 
Affordable Care Act, 
U.S. Department of 
Labor (2014)
At least 8 visits per year Individual, group, 
and telephone
>10 minutes for 
each visit
Applicable to group 
health plans and U.S. 
private health insurance 
Not specified Seven FDA-approved 
medications, 180 days 
each, combinations
Grade A Recommendation 
(U.S. Preventive Services 
Task Force 2015)
Multiple sessions, dose 
response, more or 
longer sessions improve 
cessation rates; >4 in-
person visits per year; 
>8 visits largest effect 
(quit rate)
Individual, group, 
and telephone
Intensive in-person 
counseling for 
>20 minutes per visitc; 
minimal or brief visits 
also covered
Applicable to U.S. 
health insurance plans; 
best and most effective 
combinations are those 
that are acceptable and 
feasible to the patient
Specialized cessation 
counselors, psychologists, 
social workers, physicians, 
nurses, etc.
Seven FDA-approved 
medications, 
combinations
Public Health England 
(2017)
6–12 groupd visits, 
6–12 individuald visits, 
and 6–12 telephone visits
Group, individual, 
telephone with 
pharmacotherapy, brief 
physician or pharmacist 
with pharmacotherapy
Approximately 
60 minutes per 
group, 30–45 minutes 
per person, and 
15–30 minutes 
for telephone
England National Health 
Service primary care, 
and Stop Smoking 
Specialist clinics
Tobacco treatment 
specialists,d primary 
care physicians, and 
pharmacists
Seven medications and 
combination medications
Veterans and Military, 
U.S. Department 
of Defense (Huang 
et al. 2018)
Not specified Individual, group, 
telephone, and brief 
primary care
Brief primary care; 
intensive counseling 
time not specified 
U.S. Department of 
Defense; Veterans 
Affairs health system
Not specified Seven FDA-approved 
medications, 
combinations
Notes: FDA = U.S. Food and Drug Administration.
aIn Massachusetts, the telephone quitline is independent of face-to-face treatment, and Mass Medicaid patients can access unlimited phone counseling via the quitline.
bFor smokers to receive quitting medications covered at 100%, some federal plans require them to complete an online health risk assessment as a precondition. Otherwise, smokers have copayments.
cSixteen of 38 studies reported more than 300 total minutes of counseling. For studies examining combinations of behavioral and pharmacotherapy interventions, the intensity of behavioral 
counseling was more than 300 minutes in 60% of the studies.
dBreath carbon monoxide testing—a validated biomedical outcome measure—occurs at each intensive individual or group visit with a tobacco treatment specialist, which assists with treatment 
planning and motivation. Clinicians are trained to the standards of the National Centre for Smoking Cessation and Training and receive continued supervision.
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Medicare Part D covers prescription cessation medications 
but not over-the-counter cessation medications (Medicare 
Interactive n.d.); the covered prescription medications are 
subject to copays.
Military Health Systems and Veteran’s 
Health Administration
Veterans and active-duty military personnel smoke 
cigarettes at higher rates than the general U.S. adult pop-
ulation (Bray et al. 2009), making coverage of smoking 
cessation through health plans from VA and the U.S. 
Department of Defense (DoD) important. Tobacco use 
can affect military readiness and is costly to the health-
care systems of the DoD and VA. A DoD (2013) survey 
estimated that nearly half of all military service members 
(49.2%) had used a tobacco product (cigarettes, smokeless 
tobacco, cigars, pipes, or e-cigarettes) during the previous 
12 months. Moreover, an estimated 171,000 persons who 
were active-duty service members in 2014 are projected 
to die in the coming decades because of tobacco-related 
disease (Roulo 2014). DoD spends more than $1.6 billion 
annually on tobacco-related health expenses (Institute 
of Medicine 2009). Tobacco cessation coverage through 
DoD’s Military Health System or Defense Health Agency 
is complicated due to varying health policies across the 
services. Coverage across all services generally includes 
cessation counseling, a dedicated telephone quitline that 
serves the military, online support, and access to over-the-
counter and prescription cessation medications.
In 2016, VA provided healthcare for approximately 
1.3  million enrollees (14.9% of its total enrollment) 
who currently smoked cigarettes (Huang et  al. 2017). 
Enrollees have access to several evidence-based benefits, 
including screening for tobacco use, brief counseling 
in primary care settings and more intensive counseling 
through clinics that specialize in treating tobacco use, all 
FDA-approved cessation medications, a dedicated national 
quitline (1-855-QUIT-VET) that serves veterans who are 
enrolled in the VA Health Care system, and a mobile tex-
ting program (SmokeFreeVET) (Huang et al. 2017). Once 
found eligible, veterans can receive all their health ser-
vices from a VA facility or a VA networked facility, which 
can further help to enhance the provision of and conti-
nuity in care to this population.
Removing Barriers to Access
Insurance coverage and benefits can be designed in 
ways that encourage persons to seek out specific types of 
care or specific types of clinicians to provide such care. For 
example, removing barriers to access (e.g.,  copays, cov-
erage limits, prior authorization) encourages individuals to 
use covered cessation treatments (Curry et al. 1998; Fiore 
et al. 2008; Land et al. 2010b; Greene et al. 2014; Friedman 
et  al. 2016; van den Brand et  al. 2017). The manner in 
which care is structured and reimbursed in clinical settings 
can also improve access to tobacco use and dependence 
treatment. Several incentive programs and quality mea-
sures have been put in place at the federal level to remove 
barriers and improve access to care. However, because 
many of these initiatives have been implemented in only 
the past 5–10 years, limited evidence exists on the effects 
they can have on cessation, particularly at a national level. 
Furthermore, evidence is unclear on the extent to which 
recent policy changes have been successful at removing 
these barriers. Table 7.5 lists each of these policy initiatives, 
their enactment date, and the specific provisions designed 
to encourage cessation through increased access to care 
or removal of barriers. Although specific studies on these 
recent policy initiatives have not been conducted, studies 
generally suggest that removing barriers to access increases 
the use of evidence-based cessation treatments and rates of 
quitting (Curry et  al. 1998; Fiore et  al. 2008; Land et  al. 
2010b; Greene et al. 2014; van den Brand et al. 2017).
Health insurance premium differentials, which 
allow insurers to charge higher premiums for tobacco 
users, could be another barrier to accessing cessation 
coverage and treatment. Tobacco use is one of only four 
factors that can be considered in setting health insur-
ance premiums under the ACA (Patient Protection and 
Affordable Care Act of 2010); the other factors are indi-
vidual (vs. family) coverage, rating area, and age (Curtis 
and Neuschler 2012; American Lung Association n.d.b). 
Although charging persons who use tobacco more for 
health insurance could motivate them to quit, such 
charges could also cause persons to avoid obtaining health 
insurance or to conceal their smoking status to avoid the 
additional charges, which would make it harder to iden-
tify smokers and engage them in cessation treatment 
(Kaplan et al. 2014). Based in part on these potential con-
cerns, as of October 16, 2019, four states and the District 
of Columbia have barred insurers in both the individual 
and small group markets from charging smokers more for 
insurance premiums (Kaiser Family Foundation n.d.a). 
Because premium differentials based on tobacco use status 
are a recent phenomenon, only limited data are available 
on their effect on tobacco use and cessation and on ways 
to design differentials that can minimize their potential 
negative impacts and promote tobacco cessation.
Friedman and colleagues (2016) used data from the 
2011–2014 Behavioral Risk Factor Surveillance System 
to examine the effects of surcharges for tobacco use on 
insurance status and smoking cessation among adults who 
were the most likely to purchase insurance from health 
insurance exchanges. The study found that, compared 
with smokers who faced no surcharges, smokers facing 
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Table 7.5 Healthcare system approaches designed to encourage smoking cessation
Organization Date enacted Provision
Quality Payment Program (n.d.b), part of the Medicare 
Access and Children’s Health Insurance Program 
Reauthorization Act, provides incentives to providers 
and health systems to deliver quality, evidence-based 
clinical care to treat Medicare patients.
2017 Requires the screening of all patients, 18 years of age 
and older, for tobacco use at least once within 24 months 
AND the provision of a tobacco cessation intervention 
if the patient is identified as a tobacco user
Comprehensive Primary Care is a collaboration between 
CMS and private and public payers that aims to improve 
the delivery of primary care and achieve better care, 
smarter spending, and healthier people (CMS 2017c).
2012 Requires the screening of all patients, 18 years of age 
and older, for tobacco use at least once within 24 months 
AND the provision of a tobacco cessation intervention 
if the patient is identified as a tobacco user
Accountable Care Organizations are groups of doctors, 
hospitals, and other healthcare providers that come 
together to give coordinated, high-quality care to 
patients. The goal of coordinated care is to ensure that 
patients, especially the chronically ill, get the right care 
at the right time, while avoiding unnecessary duplication 
of services and preventing medical errors (CMS 2017a).
2010 Identifies and treats all patients who use tobacco
National Quality Forum (n.d.b) is a nonprofit, 
nonpartisan, public service organization that reviews, 
endorses, and recommends the use of standardized 
healthcare performance measures that are frequently 
used to assess performance in outpatient settings.
2009 Endorses a measure that screens all patients 18 years 
of age and older for tobacco use at least once within 
24 months AND the provision of a tobacco cessation 
intervention if the patient is identified as a tobacco 
user. This performance measure is used in numerous 
programs that measure the quality of performance, 
including Meaningful Use, Medicare Shared Savings 
Program, CMS’s Accountable Care Organization 
Program, and Physician Quality Reporting System.
Patient-Centered Medical Home is a care delivery model 
in which primary care physicians are responsible for 
coordinating necessary care for their patients (CMS n.d.).
2006 Recommends the use of registries, including a tobacco 
registry, to drive patient care, including the tracking 
of patient tobacco use and quit attempts
National Committee for Quality Assurance (n.d.a,b) 
is a private, not-for-profit organization dedicated to 
improving healthcare quality and developing quality 
standards and performance measures for a broad range 
of healthcare entities.
2000 Measures performance on medical assistance with 
smoking and tobacco use cessation, including advising 
smokers and tobacco users to quit, discussing cessation 
medications, and discussing cessation strategies
Inpatient Prospective Payment System is the Medicare 
payment program for hospitals tied to performance 
measurement of:
• Acute care hospitals PPS (CMS 2017b) and
• Inpatient psychiatric facilities (CMS 2017d).
1983 Uses The Joint Commission’s Tobacco Inpatient 
Measures 1 (in 2015) and 2 and 3 (in 2016) for 
the prospective payment system for inpatient 
psychiatric facilities
Notes: CMS = Centers for Medicare & Medicaid Services.
medium or high surcharges had significantly reduced 
insurance coverage (reductions of 4.3 percentage points 
and 11.6 percentage points, respectively) and no signifi-
cant change in smoking cessation. However, compared 
with smokers with no surcharges, smokers facing low 
(but non-zero) surcharges were significantly less likely 
to quit smoking, and smokers in groups with high sur-
charges were more likely to quit smoking. In addition to 
these data suggesting reduced insurance among smokers 
who are charged surcharges, premium differentials could 
also cause financial hardship for tobacco users by substan-
tially increasing the cost of health insurance coverage (see 
Chapter 6). To decrease the potential negative impact of 
this barrier on smokers, insurers could offer policyholders 
access to a comprehensive smoking cessation benefit pro-
gram, promote the program to increase awareness and 
use, and waive the differential for those who are making 
an assisted quit attempt. As of 2017, insurers in the 
small-group market were required to waive the differen-
tial for tobacco users who are participating in a cessation 
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program, but this requirement does not apply to the indi-
vidual market (CMS 2013).
Another approach to decreasing barriers is wide-
spread implementation of cessation programs at worksites 
(Cahill and Lancaster 2014), which can increase employees’ 
access to high-quality treatment, boost employee morale, 
and give tools to smokers that help them successfully quit 
(Castellan et al. 2015). Employers and governments are two 
major purchasers of health insurance, so employers are 
also a key driver of health insurance coverage. Employers 
have an even greater economic incentive than insurers 
to help smokers quit because they stand to benefit from 
increased worker productivity and reduced healthcare 
costs; in particular, large self-insured employers have an 
especially strong incentive to reduce employee smoking 
rates because they often bear the risk for smoking-related 
disease costs (Bunn et al. 2006; Gollust et al. 2008; Berman 
et al. 2014; Xu et al. 2015b). Large employers are also well-
positioned to insist that insurers include cessation cov-
erage in standard insurance policies, rather than limiting 
this coverage to riders.
Promoting Coverage for Utilization of Smoking 
Cessation Treatments and Benefits
Coverage of proven cessation treatments by insurers 
and employers is a necessary but not sufficient condition 
for increasing smokers’ use of these treatments and their 
cessation rates. For such coverage to have an impact, it 
must be systematically promoted to smokers and health-
care providers to ensure that both groups are aware of 
the coverage and use the covered treatments (Land et al. 
2010b; CDC 2014a, 2015; McAfee et al. 2015). Promotion 
of coverage benefits is vital to increase use of these 
interventions, which in turn helps more smokers quit 
(McMenamin et  al. 2004, 2006; Keller et al. 2011). For 
example, in the MassHealth example discussed previously, 
widespread promotion of the benefit to members and 
providers was viewed as central to the program’s success 
(Land et al. 2010b). Similarly, the state Medicaid program 
in Wisconsin conducted a promotional campaign that 
targeted both Medicaid-certified providers and Medicaid 
enrollees. That campaign led to increases in the use of 
cessation medications and in the number of Medicaid 
members enrolling in the Wisconsin Tobacco Quit Line 
(Keller et  al. 2011). Finally, following an increase in 
Minnesota’s tobacco tax, ClearWay Minnesota conducted 
a 6-week media campaign to promote its quitline services 
(QUITPLAN). This campaign resulted in a 160% increase 
in calls and web visits combined and an 81% increase in 
enrollment for QUITPLAN services (Keller et al. 2015). For 
greatest impact, promotions should target both tobacco 
users and their healthcare providers, as was done in 
Massachusetts and Wisconsin. Ideally, states should track 
utilization of the covered treatments to gauge the effec-
tiveness of the coverage and to encourage improvements 
in the promotional efforts (Land et al. 2010b; CDC 2014a; 
McAfee et al. 2015; Singleterry et al. 2015).
Taken together, the evidence is sufficient to infer that 
with adequate promotion, comprehensive, barrier-free, 
evidence-based cessation insurance coverage increases 
the availability and utilization of treatment services for 
smoking cessation.
Quality and Performance Measures 
and Payment Reforms
In general, performance measures can motivate 
quality improvements and create accountability for deci-
sions and behaviors (Smith et al. 2008). Tobacco-related 
quality measures are tools that can be used to evaluate how 
well healthcare providers, practices, and systems are doing 
on the delivery of tobacco use and dependence treatment. 
Quality measures also exist for health plans. The most widely 
used tobacco-related quality measures are endorsed by the 
National Quality Forum (NQF)—a nonprofit, nonpartisan, 
public service organization that reviews, endorses, and 
recommends the use of standardized measures of health-
care performance (Kizer 2000). For example, NQF Number 
0028 is one of the most widely used measures for tobacco 
use screening and cessation (NQF n.d.a). It measures the 
percentage of patients 18 years of age and older who are 
screened for tobacco use at least once during a 2-year 
measurement period and, among those who are tobacco 
users, the percentage who have received an intervention 
(brief counseling [3  minutes or less]) and/or pharmaco-
therapy). Currently, this measure is used in several per-
formance and quality measurement programs, including 
Medicare and Medicaid Electronic Health Record Incentive 
Programs (commonly referred to as “Meaningful Use”2); 
the Medicare Shared Savings Program; CMS’ Accountable 
Care Organization Program; CMS’ Merit-based Incentive 
Payment System and Medicare Access and Children’s 
Health Insurance Program (or CHIP) Reauthorization 
Act of 2015; and the Physician Quality Reporting System. 
Although NQF Number 0028 includes both screening for 
2Meaningful Use is defined as the use of certified EHR technology to improve the quality, safety, and efficiency of healthcare and reduce 
health disparities; engage patients and families; improve the coordination of care for both population and public health; and maintain 
the privacy and security of patient health information.
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tobacco use and receipt of a counseling intervention, it 
does not include or require referral to other, more inten-
sive interventions with follow-up (e.g., quitlines, specific 
behavioral counseling, or coaching).
Linking Quality Measures to Payment
Quality measures can influence the frequency and 
consistency with which specific interventions are deliv-
ered. This effect may be strengthened when quality mea-
surement is linked to payment. Payment-based strate-
gies include (a) performance-based measures that provide 
financial incentives (or penalties) if a clinician or health 
system provides (or neglects to provide) the targeted clin-
ical intervention and (b) innovative payment and delivery 
models that link payment to the outcomes of care rather 
than the quantity of care provided (i.e.,  value-based as 
opposed to volume-based healthcare payment models). 
The Quality Payment Program (n.d.a) provides a tangible 
example of this. Substantial scientific evidence shows that 
“pay-for-performance” programs that target clinicians, 
clinics, and health systems are associated with higher 
rates of delivery of clinical interventions for tobacco use 
and dependence than programs that do not offer an incen-
tive (Kruse et al. 2013). However, the evidence is mixed as 
to whether such programs are associated with increases in 
quit rates (Roski et al. 2003; Millett et al. 2007; Twardella 
and Brenner 2007; An et al. 2008; Hung and Green 2012; 
Hamilton et al. 2013; Kruse et al. 2013; McLeod et al. 2015). 
For example, in a systematic review, Hamilton and col-
leagues (2013) identified 18 studies (including 3 random-
ized studies and 15 observational studies) that explored the 
effects of pay-for-performance programs on smoking ces-
sation. The review found that financial incentives appeared 
to increase the recording of smoking status and the provi-
sion of advice to quit and referral to cessation services, but 
results for quit rates and long-term abstinence were mixed 
in the five studies that reported these outcomes.
Overall, the evidence is sufficient to infer that strat-
egies that link smoking cessation-related quality mea-
sures to payments to clinicians, clinics, or health systems 
increase the rate of delivery of clinical treatments for 
smoking cessation.
Health Plan-Based Quality Measures
The National Committee for Quality Assurance 
(NCQA) works with health plans and others to improve 
the quality of healthcare. To be accredited by NCQA, 
health plans must report data for more than 40 perfor-
mance standards. Health plans in every state, the District 
of Columbia, and Puerto Rico are NCQA accredited, and 
recent data indicate that those plans cover 109  mil-
lion Americans, or 70.5% of all Americans enrolled in 
health plans (NCQA n.d.a). The Healthcare Effectiveness 
Data and Information Set (HEDIS) is an NCQA program 
that measures health plan performance and patient sat-
isfaction; more than 90% of America’s health plans use 
HEDIS. With regard to performance on tobacco use and 
dependence treatment, HEDIS measures the provision of 
tobacco cessation advice offered to tobacco users and dis-
cussions about cessation medications and other tobacco 
use and dependence treatment strategies (NCQA n.d.c). 
Because so many plans collect HEDIS data and the mea-
sures are so specifically defined and collected over time, 
the use of HEDIS makes it possible to compare perfor-
mance across health plans.
Hospital-Based Performance Measures
The Joint Commission is an independent, nonprofit 
organization that accredits more than 21,000 healthcare 
organizations and programs in the United States (The 
Joint Commission n.d.). Typically, payment by insurers, 
including CMS and other federal payers, is contingent 
upon successful accreditation by a certifying organiza-
tion, such as The Joint Commission. One criterion in 
the accreditation process for hospitals is to successfully 
meet selected performance measures. For certification by 
The Joint Commission, hospitals must select and report 
on 6  of 14  performance domains; 1  of these domains is 
tobacco cessation.
In 2012, The Joint Commission released an updated 
set of performance measures on tobacco cessation for 
hospitals (Fiore et al. 2012). To meet these performance 
measures, hospitals must (1)  identify and document 
tobacco use status for all hospital patients 18 years of age 
and older, (2) demonstrate that evidence-based cessation 
counseling and medication are provided or offered to iden-
tified tobacco users during hospitalization, and (3) dem-
onstrate that evidence-based cessation counseling and 
medication are provided or offered to identified tobacco 
users at discharge. Within certain constraints, hospitals 
may choose which performance measures they report. 
As of September 2018, only about 5% of accredited acute 
care hospitals in the United States (170 of 3,328 reporting 
hospitals, including 13  VA and 11  DoD hospitals) had 
selected the tobacco use identification and treatment 
delivery measures and were reporting relevant data to The 
Joint Commission (personal correspondence with The 
Joint Commission, March 18, 2019). This is likely because 
these performance measures (a) are voluntary and certain 
other measures are required or tied to payment; (b)  are 
increasingly being reported electronically, and the cessa-
tion measures from The Joint Commission have not been 
fully converted electronically; and (c)  may be more dif-
ficult to implement and report on than other measure 
sets (Freund et al. 2008, 2009). If the Joint Commission 
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cessation measures are not included in a CMS rule, oth-
erwise tied to payment, or required, the number of acute 
care hospitals reporting on these measures will likely 
continue to decline. In contrast, two of these measures 
(offering cessation counseling and medication during hos-
pitalization and again at discharge) are embedded in the 
Inpatient Psychiatric Facility Quality Reporting Program, 
and inpatient psychiatric facilities are required to report 
on these measures (CMS 2006).
Effective October 1, 2016, as part of its fiscal year 
2017 payment determination, CMS required inpatient 
psychiatric facilities to begin reporting on the first two 
tobacco cessation performance measures from The Joint 
Commission. CMS extended this requirement to the third 
Joint Commission cessation measure effective October 1, 
2017, as part of its fiscal year 2018 payment determina-
tion, and then discontinued the first measure for fiscal 
year 2019. These requirements, which embedded The 
Joint Commission’s measures in the Inpatient Psychiatric 
Facility Quality Reporting Program, are associated with an 
increase in the delivery of tobacco cessation treatments in 
psychiatric facilities. Specifically, Carrillo and colleagues 
(2017) documented a 10-fold increase in the number of 
smokers who received inpatient tobacco cessation treat-
ment after CMS implemented the requirement.
To realize the full potential of The Joint Commission’s 
tobacco measures, reporting on those measures must be 
tied to payment. Currently, for acute care general hospi-
tals, these measures are available for selection on a vol-
untary basis. As described previously, hospitals have sev-
eral other sets of measures to pick from, and there is no 
incentive for them to select the tobacco cessation mea-
sures. Nonetheless, voluntary implementation of The 
Joint Commission’s cessation measures in acute care gen-
eral hospitals has been associated with increased interven-
tion rates. For example, between 2014 and 2015, among 
365 hospitals reporting data on The Joint Commission’s 
tobacco measures in place at that time, the rate of 
screening for tobacco use increased from 94.1% to 97.8%; 
the rate at which treatment (brief counseling or NRT) 
was provided or offered during hospitalization increased 
from 51.2% to 60.5%; and the rate at which treatment was 
provided or offered at discharge increased from 36.4% to 
40.6% (The Joint Commission 2016). A 2017 study found 
that EHRs can be leveraged to facilitate integration of The 
Joint Commission’s tobacco measures into routine inpa-
tient care; the study reported a modest increase in orders 
for cessation medications (OR  =  1.35; 95% CI, 1.07–
1.70) and a 10-fold increase in rates of cessation coun-
seling (OR = 10.54; 95% CI, 7.87–14.12) (Shelley et al. 
2017). Although only limited data are available to assess 
the impact that The Joint Commission’s tobacco mea-
sures have had on increasing quit attempts and successful 
cessation, brief interventions that include screening for 
tobacco use and provision of brief counseling and/or med-
ication have been shown to double the likelihood of suc-
cessful quitting (Fiore et al. 2008).
Chapter 6 discusses the benefits of intensive bedside 
treatment (Rigotti et al. 2014; Mullen et al. 2015; Nahhas 
et al. 2017; Cartmell et al. 2018). Requiring hospitals to 
provide bedside counseling to patients who use tobacco 
and to provide these patients with cessation prescriptions 
and follow-up appointments for cessation counseling at 
discharge could facilitate the adoption of tobacco treat-
ment across the continuum of acute care, rehabilitation 
treatment, and outpatient treatment (Fiore et al. 2012). 
This approach would make the treatment of tobacco 
dependence consistent with the treatment of other chronic 
conditions and could also generate increased patient refer-
rals to face-to-face outpatient programs in hospitals and to 
state quitlines.
Realigning Payment Incentives
Another approach that has the potential to increase 
the availability, delivery, and efficacy of treatment for 
tobacco use and dependence in healthcare settings is the 
implementation of policies that align clinician and facility 
payment with the quality of care provided. Although 
tobacco-specific data are not yet available, broad-based 
payment reforms, such as value-based purchasing and 
bundled payments (i.e., payment for what a defined episode 
of care is predicted to cost), seek to reimburse clinicians or 
hospitals for the outcomes of care, rather than for sepa-
rate services provided (as is the case with fee-for-service 
approaches). Although not designed expressly for tobacco 
dependence treatment, new payment models could make 
such treatment more of a focus for clinicians and hos-
pitals because tobacco use causes and exacerbates many 
common and costly diseases, may lead to hospital readmis-
sions, and delays and complicates healing—all of which 
increase costs for the healthcare system (USDHHS 2014). 
Two other approaches of reimbursement for hospitals and 
physicians also have the potential to increase the delivery 
of evidence-based cessation interventions: (a)  allowing a 
wider variety of clinicians to bill for brief tobacco interven-
tions and (b) expanding scope of practice to allow pharma-
cists to write prescriptions for cessation medications.
Alternative quality contracts (AQCs) are another 
policy mechanism that could enhance and improve the 
provision of tobacco use and dependence treatment. Such 
contracts, which are initiated by insurers, combine incen-
tives to reduce healthcare spending with incentives to 
improve the quality of healthcare. Clinician groups share 
(a) the benefits of reducing costs (savings) and the finan-
cial risks of increased expenditures and (b) the opportunity 
to earn bonuses for improved quality of care. National data 
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are not yet available on AQCs, but early regional findings 
suggest that such strategies may increase rates of deliv-
ering tobacco cessation treatments. For example, in 2009, 
Blue Cross Blue Shield of Massachusetts established an 
AQC that was designed to pay healthcare service delivery 
systems a global fixed payment for all the services used 
by a covered population. Because they face a fixed budget 
for care delivered, health systems participating in AQCs 
have an incentive to emphasize preventive interventions, 
including those for tobacco use and dependence, that 
have been shown to reduce downstream healthcare costs. 
Huskamp and colleagues (2016) assessed the impact of the 
Massachusetts AQC on rates of the use of clinical smoking 
cessation services. The study found that rates of tobacco 
cessation treatment use were modestly higher among per-
sons in AQC provider organizations than among those in 
non-AQC provider organizations: 2.02% vs. 1.87%, overall; 
4.97% vs. 4.66 %, among enrollees at risk for tobacco-
related complications; and 3.67% vs. 3.25%, among users 
of behavioral health services.
Enhancing the Technology of 
Electronic Health Records
EHRs are an important tool to improve the fre-
quency, quality, and consistency of screening for tobacco 
use and dependence treatment, thereby increasing adher-
ence to the Clinical Practice Guideline (Linder et  al. 
2009; Boyle et al. 2014). EHRs can also be used to con-
nect persons who use tobacco with tobacco quitlines, text 
message-based support for cessation, and other clinical 
or community-based treatment resources by electroni-
cally referring patients to those services (i.e.,  through 
electronic referrals or eReferrals) (Greenwood et al. 2012; 
Kruse et  al. 2012). Federal and state programs to pro-
mote the adoption and use of EHRs and health informa-
tion technology have provided incentives to clinicians 
and healthcare systems to transition from paper records 
to EHRs and to use EHRs in ways that are intended to 
improve the quality, safety, efficiency, and coordina-
tion of healthcare while reducing health disparities (The 
Commonwealth Fund n.d.). For example, the HITECH 
Act of 2009 was designed, in part, to promote the adop-
tion and use of health information technology, including 
EHRs. Early on, HITECH provided financial incentives to 
Medicare- and Medicaid-eligible professionals and hospi-
tals that adopted and demonstrated “Meaningful Use” of 
EHRs through the Medicare and Medicaid EHR Incentive 
Programs (Berwick et  al. 2008; Institute for Healthcare 
Improvement 2009), and Medicaid continues to provide 
those incentives. Meaningful Use criteria have included 
requirements regarding the documentation of patients’ 
tobacco use and, for outpatient tobacco clinical quality 
measures, the delivery of cessation treatments for patients 
who use tobacco.
By 2017, 86% of office-based physicians had adopted 
EHRs, up from 42% in 2008 (Office of the National 
Coordinator for Health Information Technology 2019). In 
addition, 56% of eligible professionals and 97% of eligible 
hospitals and critical access hospitals (a designation given 
to eligible rural hospitals designed to improve access to 
healthcare in these communities) have participated in the 
Medicare and Medicaid EHR Incentive Programs. Through 
October  2018, eligible professionals and hospitals had 
received more than $38 billion from the program as part 
of incentive payments through Medicare and Medicaid 
reimbursement for adopting certified EHR technology and 
for using EHRs to achieve specified performance and tech-
nology objectives (i.e.,  demonstrating meaningful use) 
(CMS 2018).
As part of the EHR Incentive Programs, eligible pro-
fessionals and hospitals are evaluated on their rates of asking 
about and documenting (in their EHRs) cigarette smoking 
status for patients 13  years of age and older. Meeting 
this measure has been a requirement for receiving pay-
ments through the Medicare and Medicaid EHR Incentive 
Programs, which is important because the assessment of 
smoking status is a critical first step for engaging patients 
in cessation treatment (see Chapter  6). For established 
users of EHR technology (Stage 2 of Meaningful Use), eli-
gible professionals and hospitals must demonstrate that 
they use their EHRs to document the smoking status of 
at least 80% of their patients, 13 years of age and older, 
to receive performance payments through the program. 
By 2016, more than 97% of hospitals and eligible profes-
sionals that were reporting to the EHR Incentive Programs 
had met the requirement of documenting smoking status 
for patients visiting their healthcare facilities (CMS 2016).
In addition to encouraging the identification of 
patients who use tobacco, the EHR Incentive Programs 
include an electronic clinical quality measure to assess 
whether eligible professionals and hospitals provide cessa-
tion counseling services to patients identified as smokers 
and whether that counseling is documented in patients’ 
EHRs. Although not required, this clinical quality mea-
sure encourages eligible professionals and hospitals to 
move beyond documenting tobacco use status to deliv-
ering evidence-based cessation counseling. In the United 
States, clinical quality measures and related financial 
incentives have been major influences on clinician per-
formance for more than a decade (Papadakis et al. 2010; 
Thomas et al. 2017). Clinical quality measures help to 
drive accountability for eligible professionals and hospi-
tals, and the resulting feedback helps to improve medical 
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care. Accordingly, the EHR Incentive Programs and other 
incentive-based efforts to increase and improve the use 
of EHRs have the potential to increase the rates at which 
tobacco use is identified, documented, and treated when 
these initiatives are structured to integrate proven clinical 
tobacco cessation interventions into EHRs (Boyle et  al. 
2014; Schindler-Ruwisch et al. 2017).
Fiore and colleagues (2019) studied eReferrals to the 
Wisconsin quitline in which 23 primary care clinics from 
two healthcare systems were randomized to one of two 
methods for referring to the quitline adult patients who 
smoke: a paper-based fax-to-quit referral process or an 
eReferral process. The eReferral process involved sending 
referrals from patients’ EHRs to the quitline and receiving 
back into these EHRs outcome reports from the quitline. 
The fax referral process involved transmitting the same 
information in both directions via fax. The two systems 
saw a combined 14,636 smokers. Compared with clinics 
that were randomized to the fax referral process, clinics 
that were randomized to the eReferral process generated 
quitline referral rates 3–4 times higher and also connected 
patients with quitlines at higher rates (i.e., having patients 
accept a quitline call and at least begin the process or reg-
istering for quitline services). The eReferral method gen-
erated especially high rates of referrals among Medicaid 
recipients. The study, which was the first randomized 
study on this topic, concluded that eReferrals provide an 
effective way to refer patients who smoke to quitline ser-
vices (Fiore et al. 2019).
Overall, the evidence is suggestive, but not suffi-
cient, to infer that EHR technology increases the rate of 
delivery of smoking cessation treatments.
Population-Based Strategies on Smoking Cessation
In addition to strategies that can be implemented 
to increase the provision of clinical interventions to help 
smokers quit, broader population-level tobacco control 
strategies can also have important effects on tobacco ces-
sation. This section reviews (1)  strategies and programs 
that increase access to and use of evidence-based cessation 
treatments at the population level (e.g.,  funding tobacco 
quitlines) and (2) strategies that affect quit attempt rates, 
quit success rates, and smoking prevalence at the popula-
tion level, without necessarily directly influencing cessa-
tion support or treatment at the individual level (e.g., price 
or smokefree laws). Several interventions can fit into both 
of these categories (e.g.,  mass media campaigns, state 
tobacco control programs, pictorial health warnings, very-
low-nicotine-content cigarettes). Policy and regulatory 
details related to very-low-nicotine-content cigarettes and 
e-cigarettes are also described in this chapter. (Chapter 6 
presents details about very-low-nicotine-content cigarettes 
and e-cigarettes as they relate to cessation outcomes.) The 
population-based strategies discussed in this chapter are 
reviewed in the context of their effects on smoking ces-
sation. However, many of these strategies have broader 
effects. A review of these broader effects is beyond the 
scope of this report. The 2014 Surgeon General’s report 
includes additional information on the broader effects of 
many of these strategies (USDHHS 2014).
Quitlines
Although telephone quitlines are a cessation treat-
ment, they are included in this section on macro-level 
policy actions because they are designed to be accessed on 
a population-wide basis and are supported through broad 
policies, including funding at the state and federal levels. 
This chapter focuses on quitlines as an evidence-based, 
population-level strategy and on their relationships with 
cessation insurance coverage requirements and measures 
of treatment quality. Chapter 6 also addresses quitline ser-
vices but focuses on their role as cessation treatments and 
discusses their effectiveness and reach.
Tobacco quitlines have typically been funded at the 
state level (Beyer et al. 2010), but they can also be used and 
funded by employers, health plans, and health systems. 
Quitlines offer a convenient solution to helping health 
insurers partially meet the ACA requirements for tobacco 
cessation coverage (Lemaire et al. 2015); they can be used 
by employers as an employee benefit to promote quitting, 
help increase employee productivity, and reduce health 
expenditures related to tobacco use (Hughes et al. 2011). 
Similarly, health systems can use quitlines as an adjunct to 
clinical care and to provide ongoing follow-up support to 
patients who are engaged in a quit attempt (Warner et al. 
2012). Finally, health systems can leverage quitlines as a 
means to reduce hospital readmission rates and to meet 
tobacco use and dependence treatment quality measures.
A variety of models exist for employers, health plans, 
and health systems to establish and leverage quitline ser-
vices, including (1) contracting directly with quitline ven-
dors and other entities for their services; (2) providing 
funds to the state quitline to cover the costs incurred 
from directing employees, members, and patients to the 
state quitline; or (3) having their employees, members, or 
patients use state-funded quitline services without cost 
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sharing. The third model is less than ideal for the financial 
sustainability of state quitlines. Although this has been 
the default approach in many states, several states have 
sought to bring health plans and employers to the table 
to share costs and help sustain quitline services, espe-
cially in times of funding reductions for state quitlines. 
Funding for both service provision and promotion is a pri-
mary factor that can limit the reach of quitlines (North 
American Quitline Consortium 2016).
As briefly described in Chapter 6, quitlines are 
increasingly serving as “extended treatment” for busy cli-
nicians. The first method that healthcare providers used 
to refer patients to quitlines is the passive approach of 
simply giving patients information on how to contact 
the quitline (e.g.,  a card or brochure with the quitline’s 
number). In practice, few patients follow through and 
call the quitline. This method gradually gave way to a 
second approach: having healthcare personnel fax contact 
information for patients to the quitline (the “fax-to-quit” 
method). Quitlines then proactively call patients to deliver 
treatment. By 2009, all 50 states, the District of Columbia, 
Puerto Rico, and Guam reported offering fax referral ser-
vices, although fax referral programs and implementation 
varied widely across locations. Despite including a proac-
tive step to connect patients with the quitline, fax referrals 
can be cumbersome and time-consuming (Cantrell and 
Shelley 2009). For example, staff at quitlines sometimes 
had trouble reading clinicians’ handwriting. In addition, 
clinic staff often used fax referrals inconsistently (Sheffer 
et al. 2012), or required an intensive program to promote 
and routinize the use of fax referrals (Redmond et al. 2010; 
Schauer et al. 2012; Warner et al. 2012).
Recent efforts have focused on using EHR tech-
nology to “eRefer” patients who smoke to the state’s quit-
line (Boyle et  al. 2011; Vidrine et  al. 2013; Sharifi et  al. 
2014). This involves having clinicians make a HIPAA 
(Health Insurance Portability and Accountability Act of 
1996)-compliant eReferral to a quitline, which may be 
operated by a vendor contracting with the state tobacco 
control program, health plan, employer, wellness vendor, 
or other entity. The healthcare provider sends an eReferral 
to the quitline with key information that identifies the 
patient (e.g., name, telephone number, best time to call). 
This prompts staff at the quitline to attempt to call the 
patient to deliver cessation services. Finally, the quit-
line closes the loop by sending an eReferral back to the 
patient’s EHR with information about the outcome of the 
referral (e.g., was the patient successfully contacted, did 
the patient set a quit date, did the patient receive coun-
seling or medication, did the patient make a quit attempt 
and successfully quit). This type of bidirectional, closed-
loop approach is the most effective approach to imple-
menting eReferrals (North American Quitline Consortium 
2015), in part because hearing back from the quitline 
enables the provider to follow up with the patient and sup-
port any tobacco cessation attempt.
Data suggest that direct eReferrals to a quitline are 
more effective in connecting patients with that quitline 
than either traditional fax referral or passive referral, in 
which a tobacco user receives a business card or other mate-
rials featuring the phone number of the quitline; and both 
eReferral and fax referral offer benefits over passive referral 
because they proactively contact the patient to begin ser-
vices. In a pilot study of eReferrals, Adsit and colleagues 
(2014) found that 14% of adult smokers who had visited an 
outpatient clinic were referred to the quitline via eReferral, 
while only 0.3% were referred using the traditional fax 
method. Elsewhere, Vidrine and colleagues (2013) con-
ducted a two-arm, group-randomized study of 10 matched 
family practice clinics that compared eReferral to a quitline 
that used the passive referral approach of handing patients 
business cards for the quitline. Of all identified smokers in 
treatment, 7.8% were referred using eReferral, and 0.6% 
were referred through a passive referral (OR = 11.6; 95% 
CI, 5.5–24.3). EReferral serves as a good example of the 
complementary effects that can occur when healthcare 
systems respond to policy initiatives. The Meaningful Use 
program was effective in accelerating healthcare systems’ 
adoption of EHR systems. In turn, eReferrals leverage these 
EHR systems to link healthcare systems with quitline ser-
vices in a more seamless, consistent, and effective way.
Overall, the evidence is sufficient to infer that tobacco 
quitlines are an effective population-based approach to 
motivate quit attempts and to increase smoking cessation. 
Quitlines can be connected to health systems with EHRs 
to further facilitate and routinize the use and utility of 
quitlines.
Increasing the Price of Tobacco 
Products
Increasing the price of cigarettes, such as through 
taxation, is one of the most effective strategies for reducing 
cigarette consumption (USDHHS 2014). Cigarette price 
increases reduce cigarette consumption and smoking prev-
alence by leading some smokers to quit and some smokers 
to smoke fewer cigarettes per day and also reduce the 
number of young persons who initiate smoking (DeCicca 
and McLeod 2008; Reed et  al. 2008; Bader et  al. 2011; 
Chaloupka et  al. 2011; Ross et  al. 2011; Vijayaraghavan 
et  al. 2013; Ross et  al. 2014; USDHHS 2014; NCI and 
WHO 2016; Stevens et al. 2017). A comprehensive review 
by Chaloupka and colleagues (2011), which was summa-
rized in the 2014 Surgeon General’s report (USDHHS 
2014), concluded that a 10% increase in cigarette price 
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would result in a 3–5% reduction in overall cigarette con-
sumption. That review also concluded that increases in 
cigarette prices would result in decreases in the preva-
lence of smoking and in the average number of cigarettes 
smoked. In its report on the global tobacco epidemic, 
WHO (2017) concluded that raising taxes to increase the 
price of tobacco products is the most effective and cost-
effective means to reduce tobacco use and encourage ces-
sation. Moreover, reports from WHO (2017) and the U.S. 
Surgeon General (USDHHS 2012b, 2014) have concluded 
that youth and lower income populations are especially 
sensitive to price increases. 
Research has demonstrated that price increases 
can also influence tobacco cessation at the national and 
state levels. Specifically, data indicate that price increases 
are associated with increases in motivation to quit, quit 
attempts, and rates of cessation at the population level 
(Chaloupka et al. 2002; Ross et al. 2011; Bush et al. 2012; 
Chaloupka et al. 2012; Choi and Boyle 2013; Scollo et al. 
2013). For example, Stevens and colleagues (2017) found 
that each $1.00 increase in the average price of cigarettes 
was associated with a 6% increase in the quit rate of U.S. 
smokers 50 years of age and older.
The U.S. Community Preventive Services Task Force 
recommended increasing the unit price of tobacco prod-
ucts based on strong evidence that such a price increase is 
effective at reducing tobacco use (The Community Guide 
2012a). The Task Force reported that this effect is driven, 
in part, by an increase in the number of persons who quit. 
The Task Force reported that for every 10% increase in 
price, there is a 3.8-percentage-point increase in cessation 
(The Community Guide 2013). More recently, NCI and 
WHO (2016) noted that only a few studies have used lon-
gitudinal data to examine the specific relationship between 
taxes or prices and cessation. Those studies generally found 
that higher prices increase the likelihood of smoking ces-
sation (Tauras and Chaloupka 1999; Tauras 2004; Hyland 
et al. 2006; DeCicca et al. 2008; Ross et al. 2014). In partic-
ular, longitudinal data from the United States and Canada 
found evidence that (a) smokers living in areas with higher 
cigarette prices are significantly more motivated to quit, 
(b)  price increases for cigarettes over time appear to 
increase motivation to quit, and (c) higher cigarette prices 
increase the likelihood of actual quitting (Ross et al. 2011).
In addition to national examples, robust findings 
for price-related outcomes at the state level indicate that 
price increases have both short- and long-term effects. 
For example, Reed and colleagues (2008) assessed rates 
of smoking cessation in California after an increase in the 
state’s cigarette excise tax and a subsequent increase in 
retail prices by a cigarette manufacturer. For the months 
immediately following cigarette price increases, data from 
the 1996 and 1999 California Tobacco Surveys showed a 
significant increase in the proportion of smokers reporting 
quit attempts (a 45% year-over-year increase from 1995 
to 1996 and a 140% increase after the excise tax went 
into effect in December 1998, p <0.05), and a significant 
increase in abstinence rates (a 94% year-over-year increase 
from 1995 to 1996 and a 120% increase after the excise tax 
went into effect in December 1998, p <0.05). In addition, 
Tseng and colleagues (2014) used a health informatics 
system to assess the impact of an increase in the federal cig-
arette tax on readiness to quit among low-income smokers 
in Louisiana. In the month following the increase, readi-
ness to quit rose from 22% before the increase to 33%.
Increasing the price of cigarettes would also be 
expected to lead to smoking fewer cigarettes per day; how-
ever, the design of cigarettes has also changed over time 
in ways that allow smokers to more easily modify their 
nicotine intake (USDHHS 2010; Land et al. 2014). Jarvis 
and colleagues (2014) reported that today’s smokers may 
smoke fewer cigarettes, but the nicotine yield per cigarette 
(based on cotinine levels) has increased 42% from 1988 to 
2012. Thus, future research should address (a) how much 
smokers are compensating for reduced cigarette con-
sumption by smoking more efficiently, (b)  the effects of 
contemporary cigarettes, and (c) how these factors affect 
overall population health.
Although price increases have a strong impact on 
cessation at the population level, some recent data suggest 
that impacts may differ across subpopulations. For example, 
an analysis of data from the Tobacco Use Supplement to 
the Current Population Survey in the United States found 
that price is positively associated with (a)  intention to 
quit among non-Hispanic White smokers (p  <.001) and 
non-Hispanic African American smokers (p  <.001) and 
(b)  quit attempts among non-Hispanic White smokers 
(p <.001) but not among non-Hispanic African American 
smokers (Keeler et al. 2018). As another example, quali-
tative studies conducted in New York suggest that some 
low-income smokers may circumvent price increases by 
purchasing untaxed cigarettes from Native American res-
ervations, bootlegged cigarettes, and/or single cigarettes 
or by taking advantage of discounts and coupons from the 
tobacco industry (Shelley et al. 2007; Curry et al. 2018). 
However, it is important to note that increasing the price 
of tobacco products does not automatically result in the 
creation of substantial black markets (National Research 
Council 2015). Although taxes and price differentials on 
tobacco products can create incentives for tax evasion, 
several environmental and administrative factors play an 
equal or greater role, including high levels of corruption, 
lack of commitment to addressing illicit trade, and inef-
fective administration of customs charges and taxes (NCI 
and WHO 2016). Substantial evidence from many coun-
tries shows that illicit trade can be prevented as the price 
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of tobacco rises, resulting in increased tax revenues and 
reduced tobacco use (NCI and WHO 2016).
U.S. tobacco price increases in the form of excise 
taxes have become an important source of state govern-
ment revenues (Boonn 2017, 2018), contributing $13–
$15 billion annually to state and federal government rev-
enues (Orzechowski and Walker 2017), but little of that tax 
revenue is invested in tobacco control and cessation efforts 
(CDC 2012b). Because state tobacco control expenditures 
are correlated with decreased prevalence of tobacco use 
and increased use of evidence-based cessation treatments, 
funding of public education and treatment support related 
to tobacco cessation through excise taxes, along with funds 
from the Master Settlement Agreement (MSA) and other 
funds, could have a large impact on cessation (Ossip-Klein 
and McIntosh 2003; Farrelly et al. 2008; USDHHS 2014).
In summary, policies increasing the price of tobacco 
products have two important outcomes for tobacco cessa-
tion: (1)  they provide incentives that can increase moti-
vation to quit, decrease cigarette consumption, and drive 
smokers to make quit attempts; and (2) they provide a pos-
sible revenue stream to support evidence-based tobacco 
control strategies, including tobacco cessation activities. 
As policy makers consider increases in the price of tobacco 
products, they may consider ensuring that cessation ser-
vices are funded and available to meet the increased 
demand. Large increases in price can be particularly effec-
tive in reducing smoking among vulnerable populations, 
including young people and individuals with lower socio-
economic status. Overall, the evidence is sufficient to infer 
that increasing the price of cigarettes reduces the preva-
lence of smoking, reduces cigarette consumption, reduces 
the average number of cigarettes smoked, and increases 
smoking cessation.
Smokefree Policies
The number of state and local laws that pro-
hibit smoking in indoor public places and workplaces—
including restaurants and bars—has increased rapidly in 
the past two decades (USDHHS 2014). As of June 30, 2018, 
27 states and the District of Columbia had implemented 
comprehensive smokefree laws that prohibit smoking in all 
indoor areas of private sector worksites, restaurants, and 
bars (Centers for Disease Control and Prevention 2018a). 
In many states without comprehensive smokefree laws, 
local smokefree ordinances have protected substantial pro-
portions of the state population (Tynan et al. 2016). As of 
October 1, 2019, 61% of the U.S. population is protected by 
a comprehensive state or local smokefree law (American 
Nonsmokers’ Rights Foundation 2019b). Additionally, sev-
eral jurisdictions have removed exemptions and included 
such areas as casinos and other gaming facilities in these 
laws (American Nonsmokers’ Rights Foundation 2019a).
Although smokefree laws are primarily intended 
to eliminate involuntary exposure to secondhand smoke 
indoors, thereby protecting nonsmokers from the health 
risks of exposure to secondhand smoke, a substantial body 
of evidence has documented an association between the 
implementation of smokefree laws at the local, state, and 
national levels and decreased smoking among popula-
tions influenced by smokefree policies (USDHHS 2014). 
For example, USDHHS (2006) concluded that smoking 
restrictions in the workplace lead to less smoking among 
workers, and WHO (2009) concluded that smokefree work-
places reduce cigarette consumption among continuing 
smokers and lead to increased successful cessation. The 
impact of smokefree policies on cessation can be maxi-
mized when these policies are coupled with the promotion 
of free cessation resources (USDHHS 2006; International 
Agency for Research on Cancer [IARC] 2009).
The Community Guide (2012b) presented a system-
atic review on the effects of smokefree policies and con-
cluded that smokefree policies increase the number of 
tobacco users willing to quit (reported as a mean absolute 
increase of 3.8 percentage points). Hopkins and colleagues 
(2010) reviewed 57  studies published between 1976 and 
2005 and found that smokefree policies were associated 
with a median decrease of 3.4  percentage points (inter-
quartile interval: -6.3  to -1.4  percentage points) in the 
prevalence of cigarette use and an absolute increase of 
6.4 percentage points (interquartile interval: 1.3–7.9 per-
centage points) in cessation. The authors concluded that 
“the results of this review suggest that smokefree poli-
cies reduce consumption by continuing smokers, increase 
smoking cessation attempts, increase the number of 
smokers who successfully quit, and reduce the prevalence 
of tobacco use among workers” (p. S285).
Fichtenberg and Glantz (2002) reviewed 26 studies 
that evaluated the impact of smokefree ordinances at work-
sites and found that such ordinances were associated with 
a 3.8% (95% CI, 2.8–4.7%) reduction in the prevalence of 
smoking and 3.1% (95% CI, 2.4–3.8%) fewer cigarettes 
smoked among persons who continued to smoke. Other 
analyses found higher rates of smoking cessation at work-
sites that implemented smokefree policies (Longo et  al. 
2001); greater self-reported interest in quitting (Hammond 
et al. 2004); and a greater likelihood of smoking cessation 
the longer the smokefree policy was in effect (comparing 
rates of quitting at 18 and 36 months after implementation 
of a smokefree ordinance) (Hahn et al. 2009).
With the increasing adoption of smokefree policies 
in indoor public places and workplaces, private settings are 
becoming the major remaining source of exposure to sec-
ondhand smoke for many individuals. Residents of multiunit 
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housing are particularly likely to be exposed to secondhand 
smoke in their homes. An estimated 80 million people in 
the United States, or 25% of the U.S. population, reside in 
multiunit housing (King et al. 2013a). A subset of those 
individuals resides in government-subsidized housing, 
including public housing. Recent data indicate increases 
in the implementation of smokefree policies for subsidized, 
multiunit housing sites (Pizacani et  al. 2012). Notably, 
the U.S. Department of Housing and Urban Development 
(2016) finalized a rule requiring public housing authori-
ties to prohibit smoking in their buildings, including 
inside residents’ units. The policy was coupled with pro-
motion of tobacco cessation and cessation resources. This 
policy could help motivate many smokers to quit and may 
also encourage more private multiunit housing facilities to 
adopt similar policies (Levy et al. 2017a).
Promoting cessation resources in conjunction with 
the implementation of smokefree multiunit housing poli-
cies can help to facilitate the successful implementation 
of such policies and maximizes their impact on cessation. 
Increasing the adoption of smokefree policies in public 
and private multiunit housing and the availability of free 
cessation services to residents of multiunit housing is also 
important from a health equity standpoint because many 
residents of multiunit housing are from disadvantaged 
populations, including low-income persons, persons with 
behavioral health conditions, persons of minority racial/
ethnic groups, persons with disabilities, elderly persons, 
and children. These populations are more likely to smoke 
cigarettes and/or to be exposed to secondhand smoke 
due to a variety of factors, and they often have less access 
to healthcare, including smoking cessation treatments 
(USDHHS 2006; CDC 2014a; Jamal et al. 2018).
In addition to federal progress making government 
subsidized housing smokefree, as of October  1, 2019, 
more than 56 cities and counties have local laws requiring 
smokefree policies in all multiunit housing, including both 
government or subsidized and private-market rate housing 
(American Nonsmokers’ Rights Foundation 2019c). Data 
have shown that the adoption and maintenance of house-
hold smokefree rules in private single-family homes 
and smokefree policies in subsidized and public multi-
unit housing are associated with decreased consumption 
of cigarettes, increased confidence in achieving cessa-
tion, increased potentially considerable cost savings, and 
greater prevalence of successful cessation (Messer et  al. 
2008; Hyland et  al. 2009; Kegler et  al. 2012, 2015; King 
et al. 2014).
Smokefree restrictions can also be established in 
single-family homes to protect household members and to 
create an environment that can promote and support ces-
sation (USDHHS 2006; IARC 2009). Household rules are 
voluntarily made by the occupants of the home (USDHHS 
2006). Several studies have found that having rules in 
place for a smokefree home helps to prevent smoking 
relapse and increases other cessation behaviors, including 
quit attempts and successful cessation (Farkas et al. 1999, 
2000; Gilpin et  al. 1999; Borland et al. 2006; USDHHS 
2006; Hyland et al. 2009; IARC 2009). Rules for a smoke-
free home can also support smoking cessation by making 
smoking more inconvenient, delaying smoking initia-
tion, disrupting smoking rituals, and causing smokers to 
reduce their daily cigarette consumption (USDHHS 2006; 
IARC 2009). Coaching interventions can be (a) an effective 
way to motivate persons to establish rules for a smokefree 
home (Kegler et al. 2012; Escoffery et al. 2017; Bundy et al. 
2018) and (b)  delivered in a brief format through 2-1-1 
telephone helplines that are set up with the primary goal of 
providing low-income populations with support and link-
ages to essential health and human services (Kegler et al. 
2015; Mullen et al. 2016; Williams et al. 2016; Bundy et al. 
2018; Thompson et al. 2019). Although beyond the scope 
of this report, a smaller body of research suggests that 
rules for a smokefree home can also prevent youth from 
starting to smoke and perhaps help youth quit smoking, in 
part by functioning as an expression of antismoking norms 
(Farkas et  al. 2000). IARC (2009) concluded that poli-
cies for a smokefree home reduce adult smoking, youth 
smoking, and children’s exposure to secondhand smoke.
Healthcare facilities are another important setting 
in which to implement smokefree or tobacco-free policies 
(Sheffer et al. 2009). Behavioral health treatment facilities, 
including mental health and substance use treatment facil-
ities, are important because of the disproportional impact 
of tobacco use on populations with behavioral health 
comorbidities (Marynak et al. 2018). Despite attempts in 
the 1990s to explore the feasibility and acceptability of 
implementing smokefree policies in mental health and 
substance use treatment settings and taking other steps 
to address the high rates of smoking among persons with 
behavioral health conditions (Patten et  al. 1996), many 
mental health and substance use providers and treatment 
facilities have been reluctant to implement tobacco-free 
facility policies and to integrate tobacco use and depen-
dence treatment into routine clinical care (Schroeder 
et al. 2017). This may be due, in part, to some misconcep-
tions implying that persons with behavioral health condi-
tions do not want to quit and/or are not able to quit, and 
that helping smokers quit might undermine recovery from 
mental health problems and substance use (Schroeder 
and Morris 2010; American Legacy Foundation 2011; 
Prochaska 2011; CDC 2013b; USDHHS 2014). In addition, 
the tobacco industry has opposed smokefree polices in 
psychiatric hospitals, donated cigarettes to mental health 
facilities, and funded research suggesting that patients 
with psychiatric illnesses need tobacco for self-medication 
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(CDC 2013b; Prochaska et al. 2017; Marynak et al. 2018). 
However, attitudes toward such polices are changing, 
and mental health and substance use treatment facilities 
have increasingly begun to incorporate tobacco cessa-
tion into their missions, driven by greater efforts to inte-
grate behavioral healthcare with primary healthcare, an 
increasing emphasis by behavioral health providers on a 
holistic approach that addresses patients’ overall health 
and well-being, and the recognition that persons with 
behavioral health conditions are disproportionately likely 
to die prematurely of a smoking-related disease (USDHHS 
2014; Schroeder et al. 2017). These efforts have coincided 
with increased adoption of smokefree and tobacco-free 
policies, including campuswide policies, by state behav-
ioral health facilities (Marynak et al. 2018).
Overall, the evidence is sufficient to infer that smoke-
free policies reduce the prevalence of smoking, reduce 
cigarette consumption, and increase smoking cessation. 
Coupled with the aforementioned evidence, data also indi-
cate that smokefree policies are particularly effective when 
coupled with the promotion of resources for cessation. 
Specifically, the Community Guide (2012b) notes that 
to maximize cessation outcomes, the implementation of 
smokefree policies should include the provision and pro-
motion, including through quitlines, of proven cessation 
resources, such as counseling and medication.
Mass Media Campaigns
Scientific evidence shows that mass media edu-
cational campaigns can effectively motivate tobacco 
users to make quit attempts and promote tobacco cessa-
tion at the population level (NCI 2008; USDHHS 2014). 
Some hard-hitting advertisements (ads) seek to motivate 
smokers to quit by depicting the health consequences 
of continued smoking in emotionally compelling ways 
through graphic pictorial images and/or personal testi-
monials (Durkin et al. 2012). Other ads take a gain-frame 
approach by emphasizing the benefits of quitting rather 
than the losses associated with smoking (Toll et al. 2007). 
The latter type of ads is generally not as effective in moti-
vating quit attempts as the type of ads that focuses on the 
health consequences of smoking and evokes fear or nega-
tive emotions (Durkin et al. 2012, 2018). Very few ads and 
no ad campaigns have attempted to systematically provide 
smokers with evidence-based recommendations on how to 
quit smoking, as recommended in the Clinical Practice 
Guideline (i.e., set a quit date in the near future; abstain 
from all cigarettes; remove all smoking-related parapher-
nalia; consider use of counseling and medications; and 
avoid high-risk social situations, especially use of alcohol, 
during the first weeks of a quit attempt [Fiore et al. 2008]).
Examples of Campaigns
The Fairness Doctrine campaign of 1967–1970 
required stations broadcasting cigarette commercials 
to donate air time for antismoking messages that would 
provide the public, for the first time on television, with 
advertisements that countered messages from the tobacco 
industry (USDHHS 2014). In 2008, following a number 
of media campaigns in individual states, the Legacy 
Foundation (now known as Truth Initiative) launched 
EX, the first national adult cessation campaign since the 
Fairness Doctrine (Vallone et al. 2011). EX ran on televi-
sion and radio from March 31 to September 28, 2008, and 
was targeted to adult smokers 25–49 years of age (Villanti 
et al. 2012).
In 2012, CDC launched Tips From Former Smokers, 
the first federally funded, national tobacco education 
campaign. This campaign provides a particularly strong 
example of the impact that mass media campaigns can have 
on adult smoking cessation at the national level. The Tips 
campaign has been on air from 2012 to 2019 for varying 
durations, ranging from 12 weeks in 2012 to 29 weeks in 
2017. The hard-hitting, graphic testimonial campaign 
profiles real people who are living with serious long-term 
health effects from smoking and exposure to secondhand 
smoke (McAfee et al. 2017). Media placements vary from 
year to year, and the national ad buy has included place-
ments on national broadcast, cable television, and digital 
properties. The national media campaign has been supple-
mented with additional ad placements in local media mar-
kets that have the highest rates of smoking. The media 
placements are designed to reach low-income and other 
groups that have the highest rates of smoking.
In addition to motivating smokers to quit, the Tips 
campaign also directs smokers to services that can provide 
them help with quitting. All ads in the Tips campaign pro-
mote a free source of cessation assistance: either the national 
quitline portal, 1-800-QUIT-NOW, which routes callers, 
based on their area code, to the quitline in their state, or 
a website that contains information to help smokers quit.
In January 2018, FDA launched Every Try Counts, 
the agency’s first smoking cessation campaign. Every 
Try Counts builds on research that shows it takes many 
smokers multiple attempts to achieve long-term cessation 
(USDHHS 2014). The campaign aims to increase motiva-
tion to quit among adult smokers, 25–54 years of age, who 
have tried to quit smoking in the past but were unsuc-
cessful. Complementary to Tips From Former Smokers, 
Every Try Counts uses positive messaging to reframe 
past quit attempts as important steps toward future suc-
cess and to underscore that quitting is a process. The 
campaign is active in media markets with a high preva-
lence of smoking among adults, and messages are deliv-
ered through geotargeted digital, radio, and outdoor print 
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advertisements. Each ad includes a call to action to drive 
smokers to the campaign’s website, which was developed 
in partnership with NCI, and features quitting tips, text 
message programs to help smokers “practice the quit,” 
and online cessation counseling.
Features of Antismoking Campaigns that Support 
the Use of Cessation Resources
Mass media antismoking campaigns are frequently 
tagged with phone numbers for quitlines, an approach 
that serves several purposes. From a marketing and psy-
chological perspective, inclusion of the quitline number 
extends a helping hand to smokers and serves to soften the 
message of hard-hitting campaigns that feature emotional 
ads with graphic images or personal testimonials about 
the consequences of smoking. Studies of antismoking 
media campaigns have found this approach to advertising 
to be most effective (Wakefield et al. 2008). Marketing 
research suggests that when ads offer cessation help, 
smokers are more likely to consider and accept messages 
about negative smoking-related health consequences. 
From the quitline perspective, tagging mass media anti-
smoking ads with quitline numbers is a cost-effective 
means of increasing calls to quitlines (CDC 2006; Sheffer 
et al. 2010). The effectiveness of tagging ads with a quit-
line number is illustrated in Figure 7.2.
In addition to quitline numbers, mass media anti-
smoking ads have been tagged with website addresses 
that provide cessation support, including information 
about referral centers that can direct interested persons 
to a range of cessation resources, including in-person ser-
vices (ClearWay Minnesota n.d.). Other means of adver-
tising quitline services that have been shown to be effec-
tive include systematic encouragement of referrals from 
healthcare providers (Curry et al. 1998; Redmond et al. 
2010), which may also result in an improved capacity of 
healthcare systems to identify and engage with smokers 
because the quitline assists in follow-up. In addition, pro-
motion of services emphasizing the availability of cessation 
Figure 7.2 Intensity of ad placement for Tips From Former Smokers (Tips) campaign and call volume to 
1-800-QUIT-NOW, 2013
Source: National Cancer Institute (unpublished data); The Nielsen Company (unpublished data).
Notes: Call volume for 1-800 QUIT-NOW and 2013 Tips campaign gross ratings points (GRPs) are measures of the intensity of ad 
media placement.
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medications has been shown to increase quit success and 
increase calls (An et al. 2006; CDC 2006; Hollis et al. 2007; 
USPSTF 2015).
Effectiveness of Campaigns
The Fairness Doctrine campaign was associated with 
significant declines in cigarette smoking rates among 
both adults and youth (Hamilton 1972). An evaluation 
of the EX campaign that focused on adult smokers who 
were aware of the campaign in eight media market areas 
at baseline and approximately 6 months later found that 
EX had significantly increased quit attempts (OR = 1.24; 
p = .048) (Vallone et al. 2011).
In several studies, the Tips campaign was found to be 
associated with rapid and substantial increases in calls to 
states’ quitlines, which persisted for the duration of each 
Tips campaign cycle (CDC 2012a, 2013a; Davis et al. 2015). 
The Tips campaign has also been associated with increases 
in visitors to the websites featured in Tips ads (CDC 2012a, 
2013a; Shafer et al. 2016). Although call volumes to quit-
lines provide a tangible early indicator of the Tips cam-
paign’s impact, the campaign has a much broader impact on 
cessation, with many smokers indicating that they intend 
to quit smoking, that they tried to quit, or finally suc-
ceeded in quitting without ever calling a quitline. An anal-
ysis of nationally representative cohorts of 3,051 smokers 
who completed baseline and follow-up assessments during 
the first 3 months of the 2012 Tips campaign, found that 
quit attempts among smokers increased significantly from 
31.1% (95% CI, 30.3–31.9) to 34.8% (95% CI, 34.0–35.7). 
Moreover, 13.4% of smokers who reported making a quit 
attempt reported abstinence at follow-up. Although the 
3.2% absolute increase in quit attempts observed may 
seem small, this translates into an estimated 1.6 million 
additional smokers making a quit attempt, and an esti-
mated 220,000  of these smokers remained abstinent at 
3-month follow-up (McAfee et  al. 2013; USDHHS 2014). 
Analyses from the first year of the Tips campaign suggest 
that the campaign saved an estimated 179,099  quality-
adjusted life-years (QALYs) and prevented 17,109 prema-
ture deaths. The campaign was also cost-effective, costing 
an estimated $480 per quitter, $2,819 per premature death 
averted, $393  per life-year saved, and $268  per QALY 
gained (Grosse 2008; Xu et al. 2015a). In the United States, 
a commonly used threshold to consider an intervention 
cost-effective from a societal perspective is $50,000  per 
QALY gained (Xu et al. 2015a). In their evaluation of Tips, 
Neff and colleagues (2016) found that (a) exposure to the 
campaign was associated with increased odds of making a 
quit attempt in the previous 3 months (OR = 1.17; 95% CI, 
1.02–1.36, p <0.05) compared with baseline and (b) Tips 
was associated with an estimated 1.8  million additional 
quit attempts, suggesting that the effectiveness of the 
campaign was not diminishing over time. Murphy-Hoefer 
and colleagues (2018) found that during 2012–2015, the 
Tips campaign was associated with approximately 9.15 mil-
lion total additional persons who made a quit attempt and 
approximately 522,000 persons who quit smoking.
In 1997, Australia began a national tobacco ces-
sation campaign with an intense and long-running 
mass media component that targeted adults (Hill and 
Carroll 2003). An analysis of quit attempts in a cohort of 
3,047 Australian smokers exposed to the national tobacco 
cessation television ad campaign between 2002 and 2008 
found that exposure to tobacco control advertising in the 
previous 3  months was associated with a greater likeli-
hood of making a quit attempt, with each 1,000 increase in 
gross ratings points per quarter corresponding to an 11% 
increase in making a quit attempt (Wakefield et al. 2011).
In a detailed review of 70  studies (from January 
2000 to July 2012) about mass-reach health communica-
tions campaigns for tobacco cessation, The Community 
Preventive Services Task Force identified 64  studies that 
assessed intervention campaigns in which television was 
the primary medium. Overall, the mass-reach campaigns 
were associated with decreased prevalence of tobacco use, 
increased cessation, and increased use of available cessation 
services and decreased tobacco use initiation among young 
persons. The campaigns were associated with an average 
3.5-percentage-point absolute increase in cessation rates 
(2.0–5.0 in 12 studies); this translates to an approximate 
14% relative increase (The Community Guide 2013).
Studies also showed that a dose-response relationship 
between quitting rates and greater exposure to mass media 
campaigns was associated with increased calls to a quitline 
and increased quit rates (The Community Guide 2013). 
Since that review, Davis and colleagues (2012) reported a 
13% relative reduction in the prevalence of smoking and 
a 35% increase in quit attempts after a smoking cessa-
tion campaign in New York. Minnesota has also conducted 
extensive media campaigns to promote cessation, noting “a 
positive relation between weekly broadcast targeted rating 
points and the number of weekly calls to a cessation quit-
line and the number of weekly registrations to a web-based 
cessation program” (Schillo et al. 2011, p. 1).
Overall, the evidence is sufficient to infer that mass 
media campaigns increase the number of calls to quitlines 
and increase smoking cessation.
State Tobacco Control Programs
CDC’s Office on Smoking and Health created the 
National Tobacco Control Program (NTCP) in 1999 to pro-
vide funding and technical support to U.S. state and ter-
ritorial health departments, with the goal of encouraging 
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coordinated, national efforts to reduce tobacco use and 
tobacco-related disease and death. In particular, NTCP-
funded state programs seek to achieve the four core goals 
of a comprehensive tobacco control program outlined 
in Best Practices for Comprehensive Tobacco Control 
Programs (or Best Practices): 
• Prevent initiation among youth and young adults,
• Promote quitting among adults and youth,
• Eliminate exposure to secondhand smoke, and 
• Identify and eliminate tobacco-related disparities 
among population groups (CDC 2014a).
To achieve the goal of promoting quitting among 
adults and youth, as well as the other three goals, com-
prehensive state tobacco control programs should include 
the following components: state and community interven-
tions; mass-reach health communication interventions; 
cessation interventions; surveillance and evaluation; and 
infrastructure, administration, and management (CDC 
2014a). As recommended in CDC’s Best Practices, sup-
port for both direct provision of treatment and support 
for health systems and population-based tobacco control 
policies is what contributes to a comprehensive program 
(CDC 2014a), which has the greatest impact on increasing 
quit success.
The Community Preventive Services Task Force 
concluded that, based on the evidence, comprehensive 
tobacco control programs are effective in reducing tobacco 
use and exposure to secondhand smoke (The Community 
Guide 2014). Evidence indicates that such programs 
reduce the prevalence of tobacco use among adults and 
young people, increase the rate of quitting, and contribute 
to reductions in tobacco-related diseases and deaths. The 
Task Force concluded that comprehensive tobacco con-
trol programs are cost-effective, with savings from averted 
healthcare costs exceeding the costs of cessation interven-
tions (The Community Guide 2014).
The Task Force reviewed 61 studies (through August 
2014) on the impact of comprehensive tobacco control 
programs (The Community Guide 2014). Fifty-six of the 
studies evaluated the effects of such programs on cigarette 
use. Comprehensive tobacco control programs imple-
mented over a median of 9 years were associated with an 
overall median decrease of 3.9 percentage points (-5.6 to 
-2.6 percentage points in 16 studies) in the prevalence of 
smoking among adults. More specifically, national studies 
showed a median decrease of 2.8 percentage points (-3.5 to 
-2.4 percentage points in 12 studies) in the prevalence of 
smoking among adults.
One of the studies reviewed by the Task Force com-
pared California, a state with a comprehensive tobacco con-
trol program, with two states (New Jersey and New York) 
with similar policy climates but without comprehensive 
tobacco control programs from 1992 to 2002. The study 
found that long-term smoking cessation rates among adults 
were significantly higher in California compared with the 
other two states (Messer et  al. 2007). In another study, 
Farrelly and colleagues (2008) examined the association 
between cumulative expenditures for state-specific antito-
bacco programs and changes in the prevalence of smoking 
among adults from 1985 to 2003. The authors concluded 
that expenditures on state tobacco control programs were 
associated with overall reductions in adult smoking. Rhoads 
(2012) used data from 1991 to 2006 in the Behavioral Risk 
Factor Surveillance System to examine the effects of com-
prehensive state tobacco control programs on cigarette 
smoking among adults. This study found that state pro-
grams had a significant impact on reducing the prevalence 
of cigarette smoking among adults, and that if all states 
had funded comprehensive tobacco control programs at 
the CDC-recommended level every year from 1991 to 2006, 
the prevalence of adult smoking in 2006 would have been 
between 18.5% and 19.8% instead of the observed preva-
lence of 20.07% (i.e., a 1.4–8.8% change), which translates 
into 635,000–3.7 million fewer cigarette smokers.
Despite the strong evidence base for many compo-
nents of comprehensive tobacco control programs, the spe-
cific effects of state-funded clinical treatment programs for 
smoking cessation are less clear, and these effects appear 
to depend, in part, on sustained funding, availability, and 
promotion of cessation services. For example, two states 
have demonstrated that clinical cessation programs can 
yield high quit rates. New Jersey, with minimal funding, 
demonstrated high quit rates among moderate-to-heavy 
tobacco users who were treated at 15 clinics, worksites, or 
state-funded community cessation centers (Foulds et  al. 
2006; University of Medicine & Dentistry of New Jersey 
and School of Public Health 2007). Similarly, Minnesota 
developed QUITPLAN cessation treatment centers that 
operated for approximately 6 years (An et al. 2010). In an 
observational study of cohorts of participants of the ser-
vice in 2004, 616 adults enrolled in the treatment centers, 
and 2,351 adults contacted the telephone-based helpline. 
Smokers at the treatment centers had a higher level of nic-
otine dependence than those who used a worksite, phone, 
or web-based treatment program. The 30-day quit rate 
was higher among smokers who contacted the telephone-
based helpline (29.3%) than among smokers who attended 
the treatment centers (25.8%) (An et al. 2010). In another 
example, England’s Stop Smoking Services have demon-
strated high long-term quit rates with sustained funding 
for clinical treatment (>16 years) (Public Health England 
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2017). Existing evidence suggests that states that sustain 
adequate funding for comprehensive tobacco control pro-
grams can achieve higher rates of cessation.
Overall, the evidence is sufficient to infer that com-
prehensive state tobacco control programs can reduce 
the prevalence of smoking among adults, increase quit 
attempts, and increase smoking cessation. Because state 
tobacco control programs typically involve multiple strat-
egies and components, it is difficult to attribute their 
effects to specific cessation strategies (such as support for 
clinical or onsite cessation services). The final section of 
this chapter describes how simulation studies can be used 
to evaluate the individual and synergistic effects of mul-
tiple tobacco control strategies.
Pictorial Health Warnings
Since 1965, Congress has enacted legislation 
requiring cigarette packages in the United States to carry 
small, text-based health warnings. Health warnings on 
cigarette packages can be an important means of con-
veying information to smokers about the health effects 
of smoking and available cessation resources. Nearly 
50 countries now require large pictorial health warnings 
(also called graphic warning labels), often covering 50% or 
more of the cigarette package, that feature graphic depic-
tions of smoking-related disease and a phone number for 
a tobacco cessation quitline (Hammond 2011; USDHHS 
2014). However, health warnings on cigarette packages 
in the United States are weaker and less prominent than 
health warnings used on packages in many other coun-
tries (USDHHS 2000, 2014).
Evidence suggests that large, pictorial health warn-
ings are a more effective means of reaching smokers 
than small, text-based messages (Hammond 2011). 
Furthermore, substantial evidence suggests that large pic-
torial health warnings that highlight the health risks of 
smoking are associated with increased knowledge of the 
harms of smoking, increased perceptions of risk associated 
with smoking, increased interest in quitting and motiva-
tion to quit, increased number of quit attempts, increased 
likelihood of remaining abstinent after a quit attempt, 
and reduced prevalence of smoking (Borland et al. 2009; 
Hammond 2011; USDHHS 2012; NCI and WHO 2016; 
Noar et al. 2016a,b; Reid et al. 2017). Given this evidence, 
the NCI-WHO Monograph 21 concluded that “Large picto-
rial health warning labels on tobacco packages are effec-
tive in increasing smokers’ knowledge, stimulating their 
interest in quitting, and reducing smoking prevalence” 
(NCI and WHO 2016, p. 13).
Noar and colleagues (2016b) conducted a meta-
analysis of 37  experimental studies about the effects of 
pictorial health warnings on tobacco packages in 16 coun-
tries. The study reported that “relative to text-only warn-
ings, pictorial warnings (1)  attracted and held attention 
better, (2) garnered stronger cognitive and emotional reac-
tions, (3) elicited more negative pack attitudes and nega-
tive smoking attitudes, and (4) more effectively increased 
intentions to not start smoking and to quit smoking” 
(p. 341). 
In a separate meta-analysis of longitudinal studies, 
Noar and colleagues (2016a) found that pictorial health 
warnings were associated with a 13% relative reduction 
in the prevalence of smoking among adults and with 
increased quit attempts. In another study with a nation-
ally representative sample of Canadians, Azagba and col-
leagues (2013) assessed the impact of pictorial health 
warnings on smoking and quitting and found that the 
implementation of such warnings nationwide in Canada 
was associated with decreased prevalence of smoking 
(OR  =  0.875; 95%  CI: 0.82–0.93) and increased odds of 
making a quit attempt (OR  =  1.33; 95%  CI: 1.19–1.49). 
In a study of 14 countries that implemented graphic pic-
torial warnings, CDC (2011) found that the percentage 
of smokers thinking about quitting increased by at least 
25% in 13 of the 14 countries. 
Studies have also found that pictorial health warn-
ings can lead to increased engagement in cessation treat-
ment (Willemsen et al. 2002; International Tobacco Control 
Policy Evaluation Project 2009; Wilson et al. 2010; Noar 
et al. 2016a; Guydish et al. 2018). For example, in an exper-
imental study, Guydish and colleagues (2018) found that 
smokers exposed to pictorial health warnings on their cig-
arette packages were significantly more likely to engage in 
a cessation group program compared with controls who 
did not receive pictorial warnings on their cigarette pack-
ages. Additionally, Australia, Brazil, the Netherlands, New 
Zealand, and the United Kingdom reported significant 
increases in calls to their national quitlines after the tele-
phone numbers for the quitlines were included on picto-
rial health warnings (Willemsen et al. 2002; Miller et al. 
2009; Hammond 2011, 2012; Noar et al. 2016a). 
In summary, the evidence is sufficient to infer that 
pictorial health warnings increase smokers’ knowledge of 
health harms from smoking, motivation and intention to 
quit, and quit attempts, and decrease the prevalence of 
smoking, particularly when the labels cover at least 50% 
of the cigarette package and identify specific resources 
and contact information for cessation support, such as a 
phone number for a tobacco quitline. 
Although pictorial health warnings have been imple-
mented in numerous countries worldwide as part of rec-
ommendations from the WHO Framework Convention on 
Tobacco Control (FCTC), the United States is not a party 
to the FCTC. In the United States, the Family Smoking 
A Report of the Surgeon General
608  Chapter 7
Prevention and Tobacco Control Act of 2009 (or Tobacco 
Control Act) (2009) requires FDA to implement picto-
rial health warnings on cigarette packages and adver-
tisements. On June 22, 2011, FDA published a final rule 
requiring color graphics depicting the negative health 
consequences of smoking to accompany the nine textual 
warning statements set out in the Tobacco Control Act. 
However, several tobacco companies challenged the final 
rule in court, and on August 24, 2012, the U.S. Court of 
Appeals for the District of Columbia Circuit vacated the 
rule on First Amendment grounds and remanded the 
matter to the agency (R.J. Reynolds Tobacco Co., et al. v. 
FDA et al. 2012).
FDA conducted further research on pictorial health 
warnings. A subsequent lawsuit by public health groups 
filed in 2016 resulted in a September 2018 decision by the 
U.S. District Court of Massachusetts that ordered FDA to 
expedite the issuance of a final rule for cigarette health 
warnings, after finding that FDA had unlawfully withheld 
and unreasonably delayed execution of the provision in 
the Tobacco Control Act that requires the implementation 
of such warnings (American Academy of Pediatrics v. FDA 
2018; FDA 2018a). In March 2019, the U.S. District Court 
of Massachusetts ordered FDA to submit the proposed 
rule for publication in the Federal Register by August 15, 
2019, and to submit the final rule for publication in the 
Federal Register by March 25, 2020 (American Academy 
of Pediatrics v. FDA 2019a). 
FDA issued new cigarette health warnings through a 
proposed rule on August 16, 2019 (Federal Register 2019). 
When finalized, the new health warnings on cigarette 
packages and in advertisements would promote greater 
public understanding of the negative health consequences 
of smoking. The 13 proposed warnings, which feature text 
statements and photo-realistic color images of the lesser-
known health risks of cigarette smoking, stand to repre-
sent the most significant change to cigarette labels in the 
United States in 35 years.
Plain Packaging
Plain packaging requirements standardize the 
appearance of cigarette packages by removing all brand 
imagery; using a standard background color and spe-
cific text size, font, and position; and including govern-
ment-mandated information, such as health warnings 
(Figure 7.3) (USDHHS 2012b). In 2011, Australia became 
the first country to enact plain packaging requirements. 
Since then, some countries have passed similar laws stan-
dardizing the packaging of tobacco and/or cigarette prod-
ucts—including France, Ireland, New Zealand, Norway, 
Saudi Arabia, and the United Kingdom—and other 
countries are in the process of implementing such laws 
(Campaign for Tobacco-Free Kids 2019a). These laws are 
often combined with laws about pictorial health warnings.
Plain packaging can have several possible effects, par-
ticularly with regard to reducing the appeal of tobacco prod-
ucts (USDHHS 2012b; WHO 2016b). Plain packaging can:
• Make smoking less appealing because plain pack-
ages are less attractive and engaging than packages 
with normal branding (USDHHS 2012b; Hughes 
et al. 2016; WHO 2016b);
Figure 7.3 Pictorial warning on cigarette packages in Australia 
Source: Tobacco Labelling Resource Centre (n.d.a,b), with permission.
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• Enhance the effectiveness of health warnings by 
increasing their noticeability (Hammond 2010; WHO 
2016b); and
• Reduce false beliefs about the absolute risks of dif-
ferent tobacco products (Hammond 2010; WHO 
2016b).
Taken together, the scientific literature indicates 
that removing the color and brand imagery from cigarette 
packages reduces the appeal of cigarettes, enhances the 
effectiveness of health warnings, and may reduce the con-
sumption of cigarettes (USDHHS 2012b; NCI and WHO 
2016; WHO 2016b). Evaluation studies indicate that these 
reductions may, in turn, result in increased quit attempts 
and decreased prevalence of smoking (Durkin et al. 2015; 
McNeill et al. 2017).
Plain packaging can further support and enhance 
cessation efforts by removing misleading packaging and 
labeling and reducing false beliefs about the relative 
risks of different brands of cigarettes. The 2012 Surgeon 
General’s report found that plain packaging has the 
potential to reduce false beliefs on the part of youth and 
adults that one cigarette brand is less harmful or easier 
to quit than another (USDHHS 2012b). In addition, plain 
packaging could counteract efforts by tobacco compa-
nies to color-code packages as a way to communicate a 
hierarchy of supposed relative harm within brand fami-
lies (Dewhirst 2018). This activity occurs in countries, 
including the United States, that prohibit the use of unau-
thorized modified risk descriptors, such as “light,” “mild,” 
or “low tar” (United States v. Philip Morris USA, Inc. 2015; 
Dewhirst 2018). Reducing false beliefs about differences 
in risks between brands and within brand families could 
increase the number of current smokers who quit entirely 
instead of switching to other perceived “less risky” brands 
of cigarettes.
The tobacco industry has filed lawsuits alleging vio-
lations of domestic laws and international laws and trea-
ties in response to regulatory proposals to remove brand 
imagery in the United States and in other countries 
(USDHHS 2012b; WHO 2016b). This speaks to the impor-
tance of brand imagery in sustaining purchases and, thus, 
tobacco use (Wakefield et al. 2002). Studies have concluded 
that plain packaging requirements can reduce cigarette 
consumption (WHO 2016b); and Australia’s plain pack-
aging requirements, which were implemented in conjunc-
tion with requirements around pictorial health warnings, 
have helped to reduce the national prevalence of smoking 
(Chipty 2016; Australian Department of Health n.d.).
The evidence is suggestive, but not sufficient, to 
infer that plain packaging increases smoking cessation 
(Moodie et al. 2011; Mannocci et al. 2013; USDHHS 2014; 
WHO 2014; McNeill et  al. 2017). Although the body of 
evidence on the efficacy of plain packaging continues to 
grow, further evaluation of these policies is required to 
better understand the specific impacts of plain packaging 
requirements on smoking cessation behavior.
Reduced Retail Point-of-Sale 
Advertising and Retail Density
Population-based policies linked to the sale and 
retailing of tobacco products have the potential to increase 
rates of smoking cessation, but the level of evidence is not 
yet sufficient to draw broad conclusions about their impacts 
on cessation behavior. These policies include decreasing 
point-of-sale tobacco marketing or exposure to advertising 
and decreasing the retail availability of tobacco products. 
The 1998 MSA between 46 U.S. states and the four 
largest tobacco companies in the United States requires 
those companies to make payments to the settling states 
in perpetuity to offset medical costs associated with 
smoking. The MSA also restricts the advertising, mar-
keting, and promotional activities of the four companies, 
including the use of cartoons, billboards, or merchandise 
branding to advertise cigarettes (National Association 
of Attorneys General n.d.). Although smoking rates in 
the United States have continued to decline since 1998 
(USDHHS 2014), evidence suggests that the tobacco 
industry has shifted its marketing strategy to focus on the 
retail environment in direct response to the MSA (Ruel 
et al. 2004). Retail stores are now the primary means by 
which the tobacco industry advertises and promotes its 
products. In 2017, the tobacco industry spent more than 
$1 million per hour marketing cigarettes and smokeless 
tobacco, a large majority of which was spent on discounts 
to help retailers reduce the price of tobacco products for 
consumers (Federal Trade Commission 2019a,b). In addi-
tion to offering price discounts, the tobacco industry 
advertises its products in the interior and on the exterior 
of retail stores (USDHHS 2012b; Center for Public Health 
Systems Science 2016). 
Several policies that regulate the advertising of 
tobacco products in retail spaces have the potential to 
reduce the affordability, availability, and attractiveness 
of tobacco products (Center for Public Health Systems 
Science 2016) and to help support persons who are trying 
to quit using tobacco (Clattenburg et al. 2013; Mantey et al. 
2017). For example, in addition to increasing smoking ini-
tiation among youth (USDHHS 2012b, 2014), the adver-
tising of tobacco products in retail stores may undermine 
cessation attempts among adult smokers by increasing 
their cravings or prompting them to make unplanned 
purchases (McCarville and Bee 1999). The number and 
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location of tobacco retail stores (retail density) also can 
influence cessation. Proximity to tobacco retail outlets 
and higher retailer density are associated with reduced 
quit attempts for adults and can foster disparities in 
tobacco use and cessation behaviors (Chuang et al. 2005; 
Henriksen et al. 2008; Center for Public Health Systems 
Science 2014, 2016; Lipperman-Kreda et al. 2014; Young-
Wolff et al. 2014). 
Regarding exposure to point-of-sale tobacco mar-
keting, in a study of 999  adult smokers in Nebraska, 
Siahpush and colleagues (2016) found that exposure 
to greater amounts of point-of-sale advertising in one’s 
neighborhoods was associated with a lower probability 
of quit success among smokers who reported making a 
quit attempt in the previous 6 months. In a study of adult 
smokers in Australia, Germain and colleagues (2010) 
found a negative association between sensitivity to point-
of-sale tobacco marketing and making a quit attempt. 
Some jurisdictions have also restricted the use of cou-
pons and discounts, because evidence clearly shows that 
increasing price is the single most effective policy strategy 
to reduce tobacco use (USDHHS 2000, 2012b). 
Reducing the number of retailers is another policy 
strategy that may reduce tobacco use, given the relation-
ship between tobacco retailer density and tobacco use 
(Institute of Medicine 2007; Luke et  al. 2017). Several 
studies have associated decreased long-term tobacco ces-
sation with the increased availability of tobacco in retail 
markets, after considering retail density (i.e., the number 
of retailers per area or population) and retail proximity 
(i.e., the distance to the nearest retailer from one’s home 
or school). For example, in a study of more than 400 adult 
smokers in Houston, Texas, Reitzel and colleagues (2011) 
found that even after adjusting for several sociodemo-
graphic variables, residential proximity to tobacco out-
lets provided unique information for predicting long-
term continuous abstinence from smoking during a 
specific quit attempt. Those living less than 250  meters 
or less than 500 meters from a tobacco outlet were less 
likely to sustain a quit attempt than those living farther 
than 250 or 500 meters (p = 0.01 and p = 0.04, respec-
tively). In the United Kingdom, Han and colleagues (2014) 
could not replicate Reitzel and colleagues’ (2011) find-
ings; however, the location and coding of retail outlets dif-
fered between the two studies. In a study of 8,751 adult 
smokers in Finland, Halonen and colleagues (2014) found 
that, among men who were moderate to heavy smokers at 
baseline, those living less than 0.5 kilometers (km) from 
the nearest tobacco store had a 27% lower likelihood of 
cessation at follow-up compared with those living 0.5 km 
or more from such a store, and that having a store within 
0.5  km of one’s home decreased cessation in men who 
were moderate or heavy smokers. 
In summary, the evidence is suggestive, but not suf-
ficient, to infer that decreasing the retail availability of 
tobacco products and exposure to point-of-sale tobacco 
marketing and advertising increases smoking cessation. 
Although causal conclusions cannot be drawn at this 
time, these findings should not prevent tobacco control 
practitioners from taking action to reduce the retail den-
sity of tobacco outlets and the impact of point-of-sale 
tobacco marketing and product offerings and to evaluate 
and report the results of such actions. A strong theoret-
ical basis exists for limiting tobacco retail density, in part, 
because of the causal relationship between tobacco mar-
keting and increased tobacco consumption (NCI 2008). 
Furthermore, evidence from alcohol control research 
indicates that limiting alcohol retail density can reduce 
excessive alcohol consumption (Campbell et al. 2009); this 
relationship may translate to tobacco.
Restricting the Sale of Certain 
Types of Tobacco Products
The 2014 Surgeon General’s report concluded 
that imposing greater restrictions on the sale of certain 
types of tobacco products may also help to accelerate 
the decline of tobacco use (USDHHS 2014), particu-
larly when coupled with other cessation strategies. This 
may include restricting the sale of certain tobacco prod-
ucts (e.g.,  menthol-flavored tobacco products, products 
with other flavors) or restricting the sale of all tobacco 
products in a setting (e.g.,  a pharmacy). The appeal of 
flavored tobacco products to youth and young adults is 
well-documented (USDHHS 2012b, 2016). Congress, 
concerned about tobacco use among youth, enacted the 
Tobacco Control Act of 2009, which banned cigarettes with 
characterizing flavors (e.g., cherry, chocolate, etc.) other 
than menthol (USDHHS 2012a). Menthol is a widely used 
flavor-characterizing additive in cigarettes among all age 
groups (Rose et al. 2019), with approximately 39% of all 
smokers reporting use of menthol cigarettes in 2012–2014 
(Villanti et  al. 2016). Use of menthol cigarettes is more 
prevalent among African Americans, Hispanics, smokers 
of lower socioeconomic status, and women (Delnevo et al. 
2011; Giovino et al. 2015; Rath et al. 2016). 
Menthol has been found to impede tobacco cessa-
tion (FDA n.d.; Villanti et al. 2017). In a rigorous review of 
the scientific evidence, FDA’s Tobacco Products Scientific 
Advisory Committee concluded that menthol in cigarettes 
is associated with increased dependence and reduced 
success in smoking cessation, especially among African 
American smokers (Stahre et al. 2010; Hoffman and Miceli 
2011; Levy et al. 2011a; FDA n.d.). Several reviews (Foulds 
et al. 2010; Villanti et al. 2017; FDA n.d.) and randomized 
Clinical-, System-, and Population-Level Strategies that Promote Smoking Cessation  611
Smoking Cessation
controlled trials (Faseru et al. 2013; Rojewski et al. 2014; 
Smith et  al. 2014) have reached the same conclusions. 
Specifically, smokers of menthol cigarettes make more 
quit attempts than smokers of nonmenthol cigarettes but 
have a more difficult time quitting successfully (Trinidad 
et al. 2010; Delnevo et al. 2011; Levy et al. 2011a; Villanti 
et al. 2017). Potential explanations for the negative impact 
of menthol on cessation is that menthol leads to greater 
nicotine exposure and dependence (Benowitz et al. 2004; 
Giovino et al. 2004) or enhances the rewarding effects of 
nicotine (Wickham et al. 2015; Henderson et al. 2017).
However, not all studies have found an association 
between menthol use and cessation (Hyland et  al. 2002; 
Fu et al. 2008; Steinberg et al. 2011). Differences in sam-
pled populations, settings, study designs, and control 
variables may account for inconsistencies (Smith et  al. 
2019). Although, a meta-analysis of 19  studies of nearly 
150,000 cigarette smokers did not find a significant asso-
ciation between menthol use and cessation (adjusted 
OR  =  0.95; 95%  CI, 0.89–1.03), it found that Black or 
African American menthol users were significantly less 
likely to quit than their nonmenthol-using counterparts 
(adjusted OR: 0.88, p  <.05) (Smith et  al. 2019). Many 
studies that have not found an association between men-
thol cigarette use and cessation in the general population 
have found an association by race/ethnicity, with African 
American menthol smokers having a lower likelihood of 
smoking cessation (Lewis et al. 2014; Smith et al. 2019; 
FDA n.d.). Use of menthol cigarettes has been shown to 
contribute to tobacco cessation-related disparities in the 
United States (Gardiner and Clark 2010; Garrett et  al. 
2016; FDA n.d.). Smith and colleagues (2019) concluded 
that menthol bans will have a favorable impact on smoking 
cessation rates among Black or African American smokers.
In 2016, WHO conducted a review of menthol 
in tobacco products and based on the evidence, recom-
mended a ban on menthol in cigarettes, including men-
thol analogues, precursors, and derivatives (WHO 2016a). 
WHO also recommended prohibiting menthol in products 
other than cigarettes. Several countries have since adopted 
these WHO recommendations (WHO 2016a; 2018). In the 
United States in 2013, the city of Chicago was the first 
U.S. jurisdiction to restrict the sale of menthol tobacco 
products. After local retailers sued the city to block the 
policy, the court found that local governments have the 
authority to restrict the sale of menthol tobacco products 
(Independents Gas & Service Stations Associations, Inc. v. 
City of Chicago 2015; Tobacco Control Legal Consortium 
2018). As of October 2019, more than 50 U.S. municipali-
ties have restricted the sale of menthol tobacco products 
(Campaign for Tobacco-Free Kids 2019b). 
In several studies, menthol smokers reported that 
they would quit smoking if the sale of menthol cigarettes 
was prohibited (Tobacco Products Scientific Advisory 
Committee 2011; Pearson et  al. 2012; Wackowski et  al. 
2014, 2018; Zatonski et al. 2018; Rose et al. 2019; FDA n.d.), 
but cessation and health impacts could be diminished if 
other types of menthol-flavored tobacco products were 
still available (Wackowski et  al. 2015; Pacek et  al. 2019; 
Rose et al. 2019). For example, initial evaluations of quit 
behaviors and restrictions on the sales of menthol tobacco 
products in Ontario, Canada, suggested that such restric-
tions may impact cessation (Chaiton et al. 2018a,b; 2019a). 
Another study that evaluated the long-term, population-
level impact of the menthol restriction in Ontario showed 
that during the first year of implementation, a significantly 
higher percentage of persons who smoked menthol ciga-
rettes quit smoking than those who smoked nonmenthol 
cigarettes and quit that same year (Chaiton et al. 2019b). 
Less is known about the potential impacts that 
broader flavor bans could have on cessation. However, the 
role of flavors in promoting initiation of tobacco product 
use among youth is well established. Youth are more likely 
than adults to initiate tobacco product use with flavored 
tobacco products (Villanti et al. 2017, 2019), and appealing 
flavor is cited by youth as one of the main reasons for using 
e-cigarettes (USDHHS 2016; Villanti et al. 2017). Moreover, 
longitudinal analyses of data from the PATH Study show 
that first use of a flavored tobacco product is associated 
with an increased likelihood of subsequently using tobacco 
products (flavored or unflavored) compared with those who 
initiate tobacco use with an unflavored tobacco product 
(Villanti et al. 2019). Given the role of flavors in promoting 
tobacco product initiation among youth, more than 
220 U.S. municipalities have restricted the sale of flavored 
tobacco products, including e-cigarettes, and several states 
have adopted partial restrictions on the sale of flavored 
tobacco products, including those that passed emergency 
rules in 2019 to restrict the sale of flavored e-cigarettes 
(Campaign for Tobacco Free Kids 2019b; Public Health 
Law Center 2019). Most studies to date about restrictions 
on the sale of flavored tobacco products have focused on 
the impact of restrictions on sales, product availability, and 
use by youth (Courtemanche et al. 2017 ; Farley and Johns 
2017; Rogers et al. 2017, 2019; Brock et al. 2019; Czaplicki 
et al. 2019; Kingsley et al. 2019). More research is needed 
to understand the impacts that these types of policies have 
on cessation behaviors, and the implementation of such 
policies should be accompanied by a comprehensive ces-
sation approach that seeks to make available and promote 
evidence-based cessation treatment.
Policies restricting the sale of certain tobacco prod-
ucts may extend beyond flavors and encompass restrictions 
on the sale of all tobacco products in certain retail settings. 
A limited amount of evidence exists on the impacts that 
these policies may have on cessation, and their impact 
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likely depends on the level of evidence-based cessation 
support made available to smokers in conjunction with 
enacting such policies. For example, in September 2014, 
CVS Health stopped selling tobacco products in its phar-
macies and launched a comprehensive program to support 
smokers in their efforts to quit, including smoking cessa-
tion counseling offered through healthcare providers and 
retail pharmacists, promotion of NRT products, a dedicated 
quitline, and other resources (Brennan et al. 2014). Nearly 
1  year after the policy change, an evaluation found that 
in states in which the intervention was implemented, the 
average smoker purchased five fewer packs of cigarettes 
each month compared with three control states with no 
CVS stores (Polinski et al. 2015). Moreover, smokers who 
had purchased cigarettes exclusively at CVS were 38% more 
likely to stop buying them (Polinski et al. 2017). Cessation 
and quitting outcomes were not directly assessed.
Overall, the evidence is suggestive, but not suffi-
cient, to infer that restricting the sale of certain types of 
tobacco products, such as menthol and flavored products, 
increases smoking cessation. Rigorous evaluation of poli-
cies addressing this topic in the United States and abroad 
would be useful to better understand the effects that such 
policies have on tobacco cessation.
Very-Low-Nicotine-Content 
Cigarettes
Benowitz and Henningfield (1994) first proposed 
the idea of systematically reducing the levels of nicotine 
content in cigarettes as a way to prevent the development 
of nicotine addiction in youth. However, the authors noted 
that this strategy might also increase the likelihood that 
addicted (adult) smokers would stop smoking, because 
as the nicotine in cigarettes was lowered to nonaddictive 
levels, they would become less reinforcing and less satis-
fying. The authors estimated that, to avert addiction, daily 
intake of nicotine should be limited to 5  milligrams or 
less. Assuming a 30-cigarette-per-day smoker, this trans-
lates to less than 0.5 milligrams of nicotine per cigarette. 
Thus, very-low-nicotine-content cigarettes could achieve 
the dual goals of promoting cessation and preventing 
smoking initiation.
Since that time, several studies have tested the effects 
of experimental very-low-nicotine-content cigarettes on 
key relevant outcomes, and have suggested that such 
products may reduce smoking and dependence, increase 
abstinence, and reduce exposure to toxicants (Benowitz 
et al. 2007, 2012; Donny et al. 2007, 2014, 2015; Donny 
and Jones 2009; Hatsukami et  al. 2013; Dermody et  al. 
2018). This approach was noted as one of several poten-
tial “end game” strategies in the 2014 Surgeon General’s 
report (USDHHS 2014). Furthermore, the growing body of 
evidence (see Chapter 6 for a full review) has led to recent 
regulatory actions. 
Although the Tobacco Control Act (2009) bars FDA 
from requiring nicotine yields of a tobacco product to be 
reduced to zero, it allows FDA to promulgate regulations 
regarding the construction; components; ingredients; 
additives; constituents, including smoke constituents; 
and properties of tobacco products if such regulations 
are appropriate for the protection of the public health. In 
July 2017, Dr. Scott Gottlieb, then Commissioner of FDA, 
announced “a new comprehensive plan for tobacco and 
nicotine regulation that will serve as a multi-year roadmap 
to better protect kids and significantly reduce tobacco-
related disease and death. The approach places nicotine, 
and the issue of addiction, at the center of the agency’s 
tobacco regulation efforts” (FDA 2017). With that policy 
proposal, FDA had planned to “begin a public dialogue 
about lowering nicotine levels in combustible cigarettes to 
nonaddictive levels through achievable product standards” 
(FDA 2017). In 2018, the agency issued an Advance Notice 
of Proposed Rulemaking to seek input on the potential 
public health benefits and any possible adverse effects of 
lowering the level of nicotine in cigarettes (FDA 2018c). As 
outlined in the evidence review in Chapter 6 of this report, 
such regulatory action could reduce nicotine dependence 
and increase tobacco abstinence. No country, to date, has 
implemented such a policy around cigarettes. 
E-Cigarettes
The scientific evidence surrounding e-cigarettes 
and cessation occurs within a broader environmental con-
text with important policy and regulatory considerations. 
E-cigarette use has increased considerably among U.S. 
youth since 2011, with the U.S. Surgeon General declaring 
it an epidemic in 2018 (Office of the U.S. Surgeon General 
n.d.). By contrast, based on currently available evidence, 
e-cigarettes could benefit adult smokers if the products are 
used as a complete substitute for conventional cigarettes 
(see Chapter 6). However, the health effects of e-cigarettes 
to date remain uncertain. Furthermore, CDC, FDA, state 
and local health departments, and public health and clin-
ical partners have been investigating a multistate out-
break of lung injury associated with the use of e-cigarette, 
or vaping, products since August 2019. The latest national 
and state findings suggest e-cigarette, or vaping, prod-
ucts containing tetrahydrocannabinol (or THC), particu-
larly those obtained off the street or from other informal 
sources (e.g.,  friends, family members, illicit dealers), 
are linked to most of the cases and play a major role in 
the outbreak (Siegel et al. 2019). Federal, state, and local 
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governments have implemented, or are considering, regu-
lations and other policy activities related to e-cigarettes in 
an effort to respond to this outbreak.
In the United States, e-cigarettes can be regulated 
as either tobacco products or, when marketed for thera-
peutic purposes, as medical products (Federal Register 
2016). The Tobacco Control Act defines the term “tobacco 
product,” in part, as any product, “made or derived from 
tobacco,” including component, parts or accessories of a 
tobacco product that is not a “drug,” “device,” or “combina-
tion product” as defined by the Food, Drug, and Cosmetic 
Act (21 U.S.C. 321 (rr)) (Family Smoking Prevention and 
Tobacco Control Act 2009, §101(a)). In 2010, the U.S. 
Court of Appeals for the D.C. Circuit held that FDA has the 
authority to regulate customarily marketed tobacco prod-
ucts under the Tobacco Control Act and products made or 
derived from tobacco that are marketed for a therapeutic 
purpose under the medical product provisions of the Food, 
Drug, and Cosmetic Act (Sottera, Inc.  v. Food & Drug 
Administration 2010). 
The Center for Tobacco Products (CTP) issued a 
final rule (the “deeming rule”) in May 2016 extending the 
FDA’s authority to regulate tobacco products to all prod-
ucts meeting the definition of a “tobacco product” under 
the Food, Drug, and Cosmetic Act, except accessories of 
tobacco products. Therefore, all newly deemed tobacco 
products, including e-cigarettes must undergo premarket 
review and authorization by FDA (FDA 2016). In July 2017, 
FDA extended the compliance period for premarket appli-
cations to August 2022 for electronic nicotine delivery sys-
tems (or ENDS) and removed the “sunset policy,” whereby 
FDA deferred enforcement for products on the market 
while their application is reviewed. A lawsuit filed by 
American Academy of Pediatrics (AAP) and other public 
health groups challenged this compliance period. On 
July 12, 2019, the court issued the final order in the AAP 
case as follows: Premarket applications must be submitted 
within 10 months of the order (May 12, 2020) for deemed 
products on the market as of the Deeming Rule (August 8, 
2016). Deemed products that submit an application by 
the deadline might remain on the market for up to 1 year 
while FDA reviews the application and then would be 
required to come off the market (sunset provision) if the 
products have not yet received a marketing authorization 
(American Academy of Pediatrics v. FDA 2019b).
The statutory standards for tobacco products differ 
from those applied to FDA-approved NRTs, which are 
approved by the Center for Drug Evaluation and Research 
(CDER). For example, CDER requires evidence for the 
safety and efficacy of drugs, including cessation medi-
cations, generally coming from randomized controlled 
trials. By contrast, CTP employs a public health standard, 
which considers risks and benefits to users and nonusers 
of tobacco products and the population effects, for evalu-
ating the evidence base to support commercial marketing 
of tobacco products. Regarding the potential for regula-
tion of an e-cigarette product as a tobacco product, on 
October  11, 2019, one tobacco company announced the 
submission of a Premarket Tobacco Product Application 
(PMTA) to the FDA seeking orders authorizing the mar-
keting of an ENDS product (Reynolds American 2019). 
E-cigarettes currently on the market that meet the defini-
tion of tobacco product under the federal Food, Drug, and 
Cosmetic Act are classified as tobacco products. 
Under the Tobacco Control Act, states, localities, 
territories, and tribes maintain broad authority to adopt 
additional or more stringent requirements regarding 
tobacco product use, sales, marketing, and other topics. 
Accordingly, several states have enacted laws related to 
e-cigarettes in recent years, primarily to reduce youth 
initiation and use (Marynak et al. 2017). State, local, and 
territorial strategies to reduce initiation of e-cigarettes 
among youth and population-level exposure to e-cigarette 
aerosol, including educational initiatives, coupled with 
federal regulations around tobacco product manufac-
turing, labeling, and marketing, could help to reduce the 
risks of e-cigarettes on population health, especially among 
young persons (USDHHS 2016; Office of the U.S. Surgeon 
General n.d.). However, the extent to which population-
based policies focused on e-cigarettes impact adult use of 
e-cigarettes or conventional cigarettes, including cessa-
tion behaviors, is unknown.
Modeling to Assess the Impact of Policy and Regulatory Changes 
on Cessation
As part of empirical policy evaluations, statistical 
analyses can generally identify the effects of a single 
strategy or group of strategies over a time period soon after 
the strategies are implemented. Simulation modeling, an 
alternative approach, generally synthesizes information 
from empirical strategy evaluations and other sources 
to predict the long-term effects of a policy or a combi-
nation of strategies. In the context of tobacco use and 
cessation, simulation modeling estimates the individual 
and combined effects of strategies on such outcomes as 
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quit attempts, smoking prevalence, smoking-attributable 
deaths, and other health variables.
Most policy-oriented simulation models used for the 
United States have focused on the effects of implementing 
stronger tobacco control strategies, either individually or 
in combination, on the prevalence of future smoking and 
cessation (NCI 2007; USDHHS 2014). This section focuses 
on simulation models that examine the effects of strate-
gies that are relevant to tobacco cessation in the United 
States. The Appendix to Chapter 15 of the 2014 Surgeon 
General’s report (USDHHS 2014) offers an in-depth sum-
mary of tobacco control simulation models.
The most widely modeled policies are tax- and price-
related strategies (USDHHS 2014). The SimSmoke model 
is a commonly used model. It utilizes a discrete Markov 
model that projects smoking prevalence and smoking-
attributable deaths in the absence of policy change, and 
then estimates the effect of tobacco control policies on 
those outcomes; the policy effects are based on published 
reviews of the literature and the advice of an expert panel. 
The model has been described extensively in the scientific 
literature, as well as in previous U.S. Surgeon General’s 
reports, and has been shown to predict well at the 
national and state levels (Levy et al. 2000; USDHHS 2014). 
The SimSmoke model (Levy et  al. 2000) predicts that a 
$1.00 tax increase applied to an initial price of $2.00 would 
yield a 13% reduction in the prevalence of cigarette 
smoking among adults after 5  years (short-term) and a 
30% reduction after 40 years. Other models have projected 
similar reductions in smoking prevalence associated with 
comparable tax increases (Emery et al. 2001; Kaplan et al. 
2001; Ahmad 2005; Ahmad and Franz 2008), and one study 
of Latino smokers in California predicted a larger effect 
(Emery et al. 2001). A review of tax simulations found a 
linear relationship between the dollar amount of the tax 
and the relative reduction in the prevalence of smoking 
through both a reduction in initiation and an increase in 
cessation (Feirman et al. 2017). The decrease in smoking 
prevalence attributable to a tax on cigarettes ranged from 
8% (from a $0.71 tax) to 46% (from a $4.63 tax).
In analyses that focused on the use of cessation treat-
ments rather than on taxes or price, Apelberg and col-
leagues (2010) estimated that there would be 40,000 fewer 
smoking-attributable deaths in the United States with 
a gradual increase in the proportion of NRT-aided quit 
attempts to 100% by 2025, and the BENESCO (Benefits 
of Smoking Cessation on Outcomes) model projected that 
the provision of bupropion and varenicline to a hypothet-
ical cohort of U.S. adult smokers, who made a one-time 
quit attempt, would increase the cessation rate from 5% 
(unaided) to about 15% and 22%, respectively, and the pro-
vision would be cost-effective (Howard et al. 2008; Knight 
et al. 2010). Importantly, some of the assumptions in both of 
these models, especially assumptions related to the utiliza-
tion of medications, were based on data from clinical trials 
and are unlikely to correspond to findings on the effective-
ness of medications outside of a clinical trial setting.
In contrast to these studies, which focused on poli-
cies involving specific cessation treatments, the SimSmoke 
model considers a set of more comprehensive government 
cessation policies, including expansion of cessation treat-
ment coverage and provider reimbursement; adequate 
funding for the use and promotion of evidence-based 
state quitlines; and support for health system changes to 
prompt, guide, and incentivize tobacco treatment (Abrams 
et al. 2010; Levy et al. 2010) (Figure 7.4). The SimSmoke 
model projected that, if these evidence-based policies for 
cessation were undertaken in 2008, the prevalence of ciga-
rette smoking would be reduced from 20.1% in 2008 to 
9.7% in 2020 (a 10.4-percentage-point change) (Levy et al. 
2010). Finally, Ong and Glantz (2005) estimated that a free 
NRT program could reduce the prevalence of smoking by 
20% among smokers in Minnesota.
Simulation models have also been used to consider 
the impact of smokefree air laws and mass media cam-
paigns on smoking and smoking cessation behaviors. The 
SimSmoke model projected that implementing compre-
hensive smokefree laws would reduce the prevalence of 
cigarette smoking by 10% in the short term and 13% in 
the long term (Levy and Friend 2001), and Ong and Glantz 
(2005) estimated that 14.7% of current smokers would 
quit smoking if all U.S. indoor workplaces went smoke-
free. The SimSmoke model has predicted that large-scale 
mass media campaigns can reduce the prevalence of 
smoking by 6% in the short term and 10% in the long 
term (Levy and Friend 2001). Elsewhere, Rivara and col-
leagues (2004) estimated that a hypothetical multimedia 
campaign implemented for a cohort of 18-year-olds in the 
year 2000 would produce a 9% decrease in the prevalence 
of smoking in this cohort by 2067.
In an assessment of the historical impacts of com-
bined strategies, a SimSmoke model for the United States 
attributed a 53% reduction in the prevalence of cigarette 
smoking by adults to strategies that were implemented 
between 1964 and 2012 (Levy et al. 2016). In terms of rela-
tive reductions in the prevalence of smoking for states with 
relatively comprehensive cessation strategies, SimSmoke 
models predicted a 25% reduction from strategies imple-
mented in California between 1988 and 2003 (Levy et al. 
2007a), a 20% reduction from strategies implemented in 
Arizona between 1993 and 2002 (Levy et al. 2007b), and a 
29% reduction from strategies implemented in Minnesota 
between 1993 and 2011 (Levy et al. 2012). All of these 
models were validated against actual rates of smoking by 
age and sex during the time periods considered and were 
found to have high predictability.
Clinical-, System-, and Population-Level Strategies that Promote Smoking Cessation  615
Smoking Cessation
The aforementioned simulation models focused on 
strategies that directly affect cigarette use by individual 
smokers, but other simulation models have examined the 
effects of strategies at the population level. For example, in 
a recent modeling study, Apelberg and colleagues (2018) 
assessed the impact that reducing the nicotine content 
in cigarettes to minimally addictive levels would have 
on smoking cessation. The study predicted that approxi-
mately 5 million additional smokers would quit smoking 
within 1 year after implementing such a strategy and that 
this number would increase to 13 million within 5 years. 
The model accounted for dual use and switching behaviors 
by assuming that certain other combustible and noncom-
bustible tobacco products (e.g., premium cigars, hookah, 
e-cigarettes), which might serve as substitutes for conven-
tional cigarettes, would be excluded from the hypothetical 
nicotine reduction strategy. An older model of the poten-
tial impact of reducing the nicotine content in cigarettes 
projected a 75% reduction in the prevalence of smoking 
among adults over the long term (Tengs et  al. 2005). 
Another model, which estimated the impact over time of 
a ban on menthol cigarettes, predicted a 4–8% reduction 
in the prevalence of smoking among adults in the short 
term and a 5–10% reduction in the long term; percentage 
reductions were larger among African Americans (Levy 
et al. 2011b).
The Tobacco Control Act (2009) provides a regula-
tory framework in which companies may introduce and 
market tobacco products with lower exposure or risk 
claims, but only after such products have been reviewed 
and their marketing authorized by FDA. These prod-
ucts are classified as modified risk tobacco products 
(MRTPs) (i.e.,  products “sold or distributed for use to 
reduce harm or the risk of tobacco-related disease asso-
ciated with commercially marketed tobacco products” 
[Family Smoking Prevention and Tobacco Control Act 
of 2009, p. 1812]). Products such as heated tobacco prod-
ucts, snus, and e-cigarettes may have the potential to 
reduce the individual- and population-level harms asso-
ciated with tobacco use, and several companies have 
submitted applications to FDA seeking authorization to 
market specific products as MRTPs (Murphy et al. 2017). 
On October 22, 2019, FDA (2019) granted the first-ever 
modified risk orders to Swedish Match USA, Inc., for eight 
snus smokeless tobacco products sold under the “General” 
brand name.
Several models have assessed the projected 
population-level impact of potential reduced-harm prod-
ucts relative to cigarettes (Bachand and Sulsky 2013; 
Vugrin et  al. 2015; Weitkunat et  al. 2015), including 
e-cigarettes (Cobb et  al. 2015; Kalkhoran and Glantz 
2015; Cherng et al. 2016; Levy et al. 2017b) and smokeless 
Figure 7.4 Effects of individual and combined policies on the prevalence of smoking among men and women 
18 years of age and older, using the SimSmoke Model 
Notes: Model is described in Levy and colleagues (2010). The authors examined three evidence-based treatment policies related to 
cessation: (1) expand cessation treatment coverage and provider reimbursement; (2) mandate adequate funding for the use and 
promotion of evidence-based, state-sponsored tobacco quitlines; and (3) support healthcare system changes to prompt, guide, and 
incentivize tobacco treatment.
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tobacco (Near et al. 2014). These models vary in structure, 
population focus, and modeling methods.
Three simulation models estimated the population 
health impact after introduction of a potentially reduced-
harm product that is associated with lower health risks 
than cigarettes. Bachand and Sulsky (2013) estimated 
changes in all-cause mortality when potential or actual 
cigarette smokers substitute some or all of their cigarettes 
with a potentially reduced-harm product. The study con-
cluded that partial or complete substitution of cigarettes 
with a lower risk product should provide some overall 
health benefit at the individual level. Vugrin and colleagues 
(2015) provided a range of scenarios using a multiple 
product model that included product switching and dual 
use. The authors found a potential population-level ben-
efit if cigarette smokers switched to a lower risk product, 
but the benefit could be offset over time through increased 
initiation of the new product. Another model, developed 
by researchers at Philip Morris International, estimated a 
hypothetical reduction in smoking-attributable deaths in 
a 20-year period following the introduction of a reduced-
harm product (Weitkunat et  al. 2015). This model sug-
gests a reduction of approximately 935,000  smoking-
attributable deaths if cigarette smoking were to completely 
disappear. If a reduced-harm product completely replaced 
cigarette smoking, there would be an expected decrease of 
516,944–780,433 deaths, provided a new, similarly harmful 
alternative was not introduced. Near and colleagues (2014) 
examined the effects of tobacco control strategies on the 
prevalence of cigarette smoking, use of smokeless tobacco 
(snus), and premature mortality in Sweden. The authors 
adapted the SimSmoke model with data from Sweden 
and found that significant reductions in the prevalence of 
smoking, use of snus, and premature mortality could be 
achieved through tax increases, especially when combined 
with other strategies. The prevalence of smoking could 
decrease by as much as 26% in the first few years, reaching 
a 37% reduction within 30 years. 
Several models have estimated the impact of 
e-cigarettes on population health. However, results can 
vary greatly depending on parameter inputs, underlying 
assumptions, and other factors. Cobb and colleagues 
(2015) demonstrated a limited impact on patterns of cur-
rent and former cigarette use. The model also projected 
that prevalence of e-cigarette use and dual use would be 
low (1% at Years 1 and 5 and 2% at Year 10). According 
to the authors, this limited transition between e-cigarette, 
dual, and former use suggests that this model may have 
been based on insufficient data or that it may have been 
too early to draw inferences regarding the public health 
impact of e-cigarettes. Kalkhoran and Glantz (2015) esti-
mated a wide range of population health effects from the 
increased promotion and use of e-cigarettes. Population 
health benefits are found in scenarios where (1)  the use 
of e-cigarettes increases only among smokers who are 
interested in quitting, (2) there is no increased initiation 
of e-cigarette use among nonsmokers, and (3) e-cigarettes 
are used only by youth who would otherwise have smoked 
conventional cigarettes. However, net population harms 
were predicted in scenarios where (1) e-cigarette promo-
tion leads to the renormalization of cigarette smoking and 
(2)  e-cigarettes are used primarily by youth who never 
would have smoked. Cherng and colleagues (2016) con-
cluded that e-cigarettes could have a greater effect on 
smoking cessation than on smoking initiation. However, 
the rapid increase in e-cigarette use among youth in recent 
years and the substantial proportion of youth and young 
adults who use e-cigarettes but never smoked conven-
tional cigarettes (Mirbolouk et al. 2018) suggest that this 
conclusion may need to be re-evaluated. The study also 
suggested that if the use of e-cigarettes led to smoking ini-
tiation in never smokers, even small increases in smoking 
cessation due to the use of e-cigarettes could counteract 
any potential impact on the prevalence of smoking. The 
study also found that if e-cigarettes decreased smoking 
cessation by allowing current dual users to continue to 
smoke cigarettes, then the prevalence of smoking at the 
population level could increase considerably. 
More recently, using a Mendez-Warner mod-
eling approach, the National Academies of Sciences, 
Engineering, and Medicine (2018) found that the use of 
e-cigarettes will generate a net public health benefit, at 
least in the short term. The model found that the harms 
from increased initiation by youth will take time to mani-
fest, occurring decades after the benefits of increased ces-
sation are observed. However, for long-term projections, 
the net public health benefit was projected to be substan-
tially less and was negative under some scenarios in the 
model. Importantly, irrespective of the range of assump-
tions used, the model projected a net public health harm 
in the short and long terms if the products do not increase 
net combustible tobacco cessation in adults. Warner 
and Mendez (2019) used a similar approach, concluding 
that potential life-years gained as a result of e-cigarette-
induced smoking cessation would exceed potential life-
years lost due to e-cigarette-induced smoking initiation, 
and that these results would hold over a wide range of 
assessed parameters. In contrast, Soneji and colleagues 
(2018), using a Monte Carlo simulation model, found 
that 2,070  additional current cigarette smoking adults 
(25–69  years of age) (95%  CI, -42,900–46,200) would, 
because of e-cigarette use in 2014, quit smoking in 2015 
and remain continually abstinent from smoking for 7 or 
more years. The model also estimated 168,000  addi-
tional never-cigarette smoking adolescents (12–17  years 
of age) and young adults (18–29  years of age) (95%  CI, 
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114,000–229,000) would, because of e-cigarette use in 
2014, initiate cigarette smoking in 2015 and become daily 
cigarette smokers at 35–39  years of age. Based on the 
existing scientific evidence related to e-cigarettes and opti-
mistic assumptions about the relative harm of e-cigarette 
use compared with cigarette smoking, the authors con-
cluded that e-cigarette use currently represents more 
population-level harm than benefit. 
Overall, simulation models generally indicate greater 
effects of individual strategies as the effects fully unfold 
over time. The models also indicate that comprehensive, 
multicomponent, evidence-based tobacco control strate-
gies have the potential to yield substantial reductions in 
the prevalence of smoking. Such reductions are driven 
more by increases in smoking cessation than by reduced 
smoking initiation, but models are subject to some limita-
tions (Levy et al. 2001). Simulation models are useful and 
can often be the most reliable sources for estimating long-
term effects of interventions, but the projections are only 
as valid as their underlying assumptions and their input 
and transitional probability parameters, which are gener-
ally based on available data and sensitivity analysis (see 
Appendix 15.1 in USDHHS 2014). More research is war-
ranted to assess the effects of strategies on specific cessa-
tion behaviors and to distinguish between their effects on 
quit attempts, successful quitting, and relapse.
Limitations and Methodologic Gaps
Despite considerable evidence about the effects of 
certain strategies (e.g., media campaigns, price increases, 
and smokefree policies) on the population-wide prevalence 
of cigarette smoking and cessation, the available evidence 
for some strategies is not adequate to reach conclusions 
about the extent to which they influence quit attempts and 
successful quitting. Some analyses can generate estimates 
of the effects of certain policies on these and other specific 
outcomes, but for many policies, this evidence is limited. 
For example, some healthcare strategies (e.g., modifying 
EHRs and adopting EHR-based referral systems) have 
been shown to improve the identification of smokers and 
the delivery of tobacco use and dependence treatment, but 
there is less evidence on the degree to which they directly 
influence quit attempts and successful quitting.
In theory, both healthcare- or clinically oriented 
tobacco use and dependence treatment strategies and 
population-based tobacco control strategies should influ-
ence successful cessation, and thus ultimately improve 
health and reduce healthcare costs. Although it is well 
documented that any strategy that reduces the preva-
lence of smoking by a meaningful amount will improve 
health and thus reduce cost, specific information on strat-
egies’ effects on those outcomes would be beneficial. For 
example, strategies may differ in their relative effects on 
increasing successful quitting versus reducing smoking 
initiation, and such differences would affect how soon 
effects on health outcomes and health-related costs would 
be expected to occur.
The effects of population-based strategies on rates of 
cessation reflect many factors, such as the types of effects 
the strategy produces (e.g.,  effects on initiation vs. ces-
sation), the time lag between the strategy’s implementa-
tion and its effects, and the maintenance or duration of its 
effects (e.g., the elasticity between the price of cigarettes 
and cigarette consumption appears to change over time 
[NCI and WHO 2016]). Thus, although some evidence 
is available on the effects of certain policies on certain 
health outcomes (e.g.,  the effects of smokefree policies 
on the occurrence of coronary events [Meyers et al. 2009; 
Hahn 2010; Institute of Medicine 2010; Mackay et al. 2010; 
USDHHS 2014]), the scarcity of data on some potential 
outcomes of specific policies has made comprehensive 
evaluation strategies challenging.
A further limitation to better understanding the 
effects of policies—particularly population-level strate-
gies—on tobacco cessation is the challenge of isolating 
the effects of a particular strategy from those of other past 
or current strategies. The attempt to identify the contri-
bution of a specific strategy to an outcome is complicated 
by the fact that these strategies are rarely implemented in 
isolation. Specifically, the joint effects of new strategies 
may involve additive or interactive effects among similar 
or apparently dissimilar strategies at the federal, state, 
and local levels. A similar complexity is often encoun-
tered in analyzing strategies surrounding healthcare 
policies because healthcare systems often adopt a suite 
of tobacco-related strategies at the same time (Papadakis 
et al. 2010).
Progress is being made in addressing these ana-
lytic challenges, in part by taking advantage of the greater 
availability of relevant data and methodologic advances. 
For example, in the area of econometrics, the availability 
of improved longitudinal data for such key variables as 
income, cigarette consumption, cessation, tax avoidance, 
and tobacco price makes some analytic approaches more 
feasible (e.g., advanced time series analyses). Progress is 
aided by the greater availability of higher quality data, lon-
gitudinal data, and more comprehensive data (e.g.,  data 
that include measures of key covariates). In addition, 
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uniform approaches to data collection are increasingly 
being used across different sampling units, such as 
states and nations (International Tobacco Control Policy 
Evaluation Project 2017; WHO n.d.). The greater avail-
ability of uniform data across states and countries permits 
more powerful pooled analyses, which have the potential 
to permit statistical control of unmeasured factors that 
might otherwise bias results.
The greater availability of data and methodological 
advances could enhance the ability to accurately estimate 
the effects of different policies on tobacco use and cessa-
tion. Still, heightened focus on the effects of certain poli-
cies is needed because of their potential impacts on public 
health. These include policies applying to the use of cig-
arettes and noncigarette tobacco products and strategies 
addressing populations that have limited access to cessa-
tion interventions (e.g., the rural poor, psychiatric popu-
lations, low-income and unemployed persons, homeless 
populations, and individuals who are incarcerated). More 
research is also needed on the effects of the mechanisms 
through which policies ultimately influence outcomes for 
smoking cessation; on the interactive effects of strategies 
used to implement various policies; and on how strategies 
that are carried out to implement certain policies affect 
the use of nontraditional resources for promoting cessa-
tion (e.g., cessation apps, social media).
Summary of the Evidence
Strategies at the clinical, system, and population 
levels can influence the behavior of smokers in ways that 
increase their likelihood of attempting to quit smoking 
and/or of successful smoking cessation.
At the clinical level, important milestones in the evo-
lution of a health systems approach to increasing tobacco 
cessation include the relevant recommendations and 
clinical guidelines issued by The Community Preventive 
Services Task Force, notably its recommendations on pro-
vider reminder systems (Hopkins et al. 2001), the recom-
mendations in the Clinical Practice Guideline (Fiore et al. 
2008), and the guidelines issued by USPSTF (2015).
At the systems level, a growing body of research has 
documented the effectiveness of a health systems approach 
in increasing tobacco screening and cessation interven-
tions and in increasing cessation and reducing smoking 
rates at the health system and/or population level. Several 
studies have taken this a step further, reporting reductions 
in primary care office visits for and healthcare-related 
costs from smoking-related diseases (Land et  al. 2012; 
Moody-Thomas et al. 2015).
At the population level, several evidence-based 
tobacco control strategies—including tobacco quitlines; 
policies that raise the price of tobacco; smokefree poli-
cies; government-funded mass media and public educa-
tion campaigns; pictorial health warnings; and adequately 
funded, sustained, comprehensive state tobacco control 
programs—have been shown to reduce the prevalence 
of smoking among adults by increasing quit attempts 
and successful quitting. Although additional strategies—
including those focused on retail density, point-of-sale 
tobacco advertising, and very-low-nicotine-content ciga-
rettes—have been associated with reductions in the preva-
lence of smoking, more research could further clarify the 
impact of these policies on cessation behavior.
Overall, a landscape that combines both clinical 
and treatment-oriented strategies, as well as systems- and 
population-level strategy changes, is likely to create the 
most supportive environment for quit attempts and suc-
cessful cessation. The clinical strategies and interventions 
described here and in Chapter 6 focus primarily on behav-
iors at the individual level, and such behaviors become 
more routine and consistent when strategies and systems 
are put in place that reinforce the delivery of clinical ces-
sation interventions. The systems- and population-level 
strategies described in this chapter have a broad impact, 
can change the context and environment to make it easier 
for individuals to quit, and are more likely to be effective 
in helping people quit and stay quit when coupled with 
individual-level clinical interventions. Accordingly, cli-
nicians and public health practitioners should seek to 
better bridge clinical work with population-based policy 
approaches to maximize tobacco cessation and reduce the 
overall prevalence of tobacco use.
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Conclusions
1. The evidence is sufficient to infer that the develop-
ment and dissemination of evidence-based clinical 
practice guidelines increase the delivery of clinical 
interventions for smoking cessation.
2. The evidence is sufficient to infer that with adequate 
promotion, comprehensive, barrier-free, evidence-
based cessation insurance coverage increases the 
availability and utilization of treatment services for 
smoking cessation.
3. The evidence is sufficient to infer that strategies that 
link smoking cessation-related quality measures 
with payments to clinicians, clinics, or health sys-
tems increase the rate of delivery of clinical treat-
ments for smoking cessation.
4. The evidence is sufficient to infer that tobacco quit-
lines are an effective population-based approach 
to motivate quit attempts and increase smoking 
cessation.
5. The evidence is suggestive but not sufficient to infer 
that electronic health record technology increases 
the rate of delivery of smoking cessation treatments.
6. The evidence is sufficient to infer that increasing 
the price of cigarettes reduces smoking preva-
lence, reduces cigarette consumption, and increases 
smoking cessation.
7. The evidence is sufficient to infer that smokefree 
policies reduce smoking prevalence, reduce cigarette 
consumption, and increase smoking cessation.
8. The evidence is sufficient to infer that mass media 
campaigns increase the number of calls to quitlines 
and increase smoking cessation.
9. The evidence is sufficient to infer that comprehen-
sive state tobacco control programs reduce smoking 
prevalence, increase quit attempts, and increase 
smoking cessation.
10. The evidence is sufficient to infer that large, pictorial 
health warnings increase smokers’ knowledge about 
the health harms of smoking, interest in quitting, 
and quit attempts and decrease smoking prevalence.
11. The evidence is suggestive but not sufficient to infer 
that plain packaging increases smoking cessation.
12. The evidence is suggestive but not sufficient to infer 
that decreasing the retail availability of tobacco 
products and exposure to point-of-sale tobacco mar-
keting and advertising increases smoking cessation.
13. The evidence is suggestive but not sufficient to infer 
that restricting the sale of certain types of tobacco 
products, such as menthol and other flavored prod-
ucts, increases smoking cessation, especially among 
certain populations.
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Introduction
The progress made in reducing cigarette smoking 
in the United States over the past five decades represents 
one of the most notable public health achievements of the 
past century (Ward and Warren 2007; U.S. Department 
of Health and Human Services [USDHHS] 2014). Since 
the first Surgeon General’s report on smoking and health 
was released in 1964, current cigarette smoking among 
U.S. adults 18 years of age and older has declined from 
42.6% in 1964 to a low of 14.0% in 2017 (Wang et  al. 
2018). This decline has brought within reach USDHHS’ 
national Healthy People 2020 goal of reducing adult cig-
arette smoking prevalence to 12.0% (Office of Disease 
Prevention and Health Promotion n.d.). Similarly, cur-
rent cigarette smoking among youth in grades 9–12 has 
declined from 36.4% in 1997 to 8.8% in 2017, a decline 
that has persisted in the two decades since the Master 
Settlement Agreement of 1998 and has surpassed the 
national Healthy People 2020 target of 16.0% (Centers 
for Disease Control and Prevention [CDC] n.d.). This com-
mendable progress has been accomplished through the 
implementation of evidence-based tobacco control pro-
grams and policies at the federal, state, and local levels 
that effectively combat the tobacco use epidemic in the 
United States (Figure 8.1 and Table 8.1) (USDHHS 2012, 
2014). However, it is important to acknowledge that the 
tobacco product landscape has diversified in recent years. 
Although cigarettes remain the most commonly used 
tobacco product among U.S. adults (Wang et al. 2018), 
e-cigarettes have been the most commonly used tobacco 
product among youth since 2014, and recent increases in 
e-cigarette use have offset declines in cigarette smoking 
and led to a net increase in overall tobacco product use 
among youth (Gentzke et al. 2019).
The decline in cigarette smoking among adults have 
been driven, in part, by reductions in initiation among 
youth in recent years, especially over the past two decades 
(USDHHS 2012, 2014). For example, since 2002, ciga-
rette smoking initiation and daily smoking initiation has 
decreased among youth 12–17 years of age of both sexes 
and among nearly all races/ethnicities (Cantrell et  al. 
2018). Preventing tobacco use among youth is there-
fore critical to reduce the overall prevalence of tobacco 
use because the vast majority of adult smokers initiate 
tobacco use as youth or young adults (USDHHS 2012). 
However, despite these notable accomplishments, moti-
vating and helping people to quit smoking remains essen-
tial to (a) protecting the nation’s approximately 34 million 
adult cigarette smokers from a lifetime of addiction and 
tobacco-related disease and death (Wang et  al. 2018) 
and (b)  curbing the substantial financial costs incurred 
by society because of smoking-attributable healthcare 
spending and lost productivity (USDHHS 2014; Xu et al. 
2015). Accordingly, sustained efforts to increase access 
to and use of evidence-based cessation treatments among 
adult smokers, in coordination with population-based 
interventions, are essential to effectively address the full 
continuum of tobacco use from initiation to intermittent 
or routine use (USDHHS 2012, 2014).
Three decades after the first Surgeon General’s 
report to focus specifically on the health benefits of ces-
sation, this report reviews and updates evidence on the 
importance of cessation in the context of a comprehen-
sive tobacco control strategy. The report discusses histor-
ical patterns of smoking cessation in the United States, 
as well as the immediate and long-term health and eco-
nomic benefits of smoking cessation at the individual and 
societal levels. The report also presents updated findings 
on biological insights into smoking cessation, including 
findings on nicotine addiction and genetic factors that 
may impact smoking behaviors. Finally, the report dis-
cusses the extensive array of clinical and population-based 
interventions that have been scientifically shown to effec-
tively increase smoking cessation. The following sections 
discuss the past, present, and future of tobacco cessation 
in the United States. Specifically, these sections provide a 
historical perspective, discuss the current tobacco control 
landscape, and provide a vision for enhancing tobacco ces-
sation in the United States.
Past: Historical Perspective
In 2010, USDHHS published the first tobacco con-
trol strategic action plan for the United States, Ending the 
Tobacco Epidemic: A Tobacco Control Strategic Action Plan 
for the U.S. Department of Health and Human Services 
(USDHHS 2010). The main intent of this action plan was 
to reinvigorate national momentum toward advancing 
tobacco prevention and control by applying proven methods 
to reduce the burden of tobacco use and dependence. The 
50th anniversary Surgeon General’s report provided further 
scientific evidence for the effectiveness of the interventions 
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Figure 8.1 Per capita annual cigarette consumption among adults, 18 years of age and older, and major smoking and health events in the United States, 
1900–2017
Source: Adapted from Warner (1985) with permission from Massachusetts Medical Society, © 1985; as cited in USDHHS (2014).
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Table 8.1 Summary of milestones aimed at increasing tobacco cessation in the United States
Year Event
1964 • The first Surgeon General’s report, Smoking and Health, is released.
1967–1970 • Regulation from the Federal Communications Commission requires broadcasters to apply the Fairness Doctrine 
to cigarette advertising to counter messages in advertising from the tobacco industry.
1971 • Broadcast advertising of cigarettes ends.
• Surgeon General Jesse Steinfeld called for a national “Bill of Rights for the Non-Smoker.”
1979 • The Surgeon General’s report, Smoking and Health, is released. This report offers detailed reviews of major 
diseases and concludes that compared with smokers, risks are lower among former smokers for all-cause mortality, 
atherosclerosis and coronary heart disease, lung cancer, larynx cancer, lung function, and respiratory symptoms.
1984 • Nicotine gum, available by prescription only, becomes the first FDA-approved cessation medication.
1986 • The Surgeon General’s report, The Health Consequences of Involuntary Smoking, is released.
1987 • The United States House of Representatives passed an amendment to the Federal Aviation Act, making domestic 
flights of 2 hours or less smokefree.
1988 • The Surgeon General’s report, The Health Consequences of Smoking—Nicotine Addiction, is released.
1990 • A congressionally mandated smoking ban takes effect on all domestic airline flights of 6 hours or less.
• The Surgeon General’s report, The Health Benefits of Smoking Cessation, is released.
• San Luis Obispo, California, becomes the first city in the world to eliminate smoking in all public buildings, including 
bars and restaurants.
1992 • California lanches the first state-sponsored smoking cessation quitline.
1996 • FDA approves the nicotine patch and gum for over-the-counter use and the nicotine nasal spray for prescription use.
• The U.S. Public Health Service issues the first clinical practice guideline on Treating Tobacco Use and Dependence.
1997 • FDA approves the nicotine inhaler and bupropion for prescription use for cessation. (Bupropion had previously 
been available as an antidepressant and continues to be available for this indication.)
1998 • Attorneys General of 46 states sign the Master Settlement Agreement with the four largest tobacco companies in 
the United States. Among its provisions, the agreement prohibits tobacco advertising that targets people younger 
than 18 years of age.
• California becomes the first state to pass a comprehensive statewide smokefree air law.
1999 • CDC releases Best Practices for Comprehensive Tobacco Control with recommendations for tobacco cessation 
activities at the state level.
2000 • The U.S. Public Health Service issues the second clinical practice guideline on Treating Tobacco Use and Dependence.
2002 • The Joint Commission (on Accreditation of Healthcare Organizations) adds quality measures for treating tobacco 
dependence to accreditation requirements for hospitals.
• FDA approves the nicotine lozenge for over-the-counter use.
2003 • NCI launches the smokefree.gov cessation website.
• University of California, San Francisco establishes the Smoking Cessation Leadership Center.
2004 • USDHHS announces National Network of Quitlines; NCI’s 1-800-QUIT-NOW portal becomes operational; and CDC 
begins to dedicate funding for state quitlines.
• The North American Quitline Consortium begins activities.
• The Surgeon General’s report, The Health Consequences of Smoking, is released.
2006 • The Surgeon General’s report, The Health Consequences of Involuntary Exposure to Tobacco Smoke, is released.
• All 50 states, the District of Columbia, and Puerto Rico have publicly funded quitlines in place.
• Massachusetts implements an evidence-based, heavily promoted Medicaid cessation benefit.
• FDA approves varenicline for prescription use, making it the seventh FDA-approved cessation medication.
2007 • The Multistate Collaborative for Health Systems Change is established.
2008 • The U.S. Public Health Service issues the third clinical practice guideline on Treating Tobacco Use and Dependence, 
2008 Update.
2009 • Federal tax increase of $0.62 per pack of cigarettes raises the federal tax to $1.01 per pack of cigarettes.
• The Family Smoking Prevention and Tobacco Control Act is enacted.
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Table 8.1 Continued
Year Event
2010 • President Obama signs the Patient Protection and Affordable Care Act into law. The law includes important provisions 
that expand tobacco cessation benefits and establishes the Prevention and Public Health Fund, which provides funds 
to prevent and reduce tobacco use.
• Recording the smoking status in the electronic health records of all patients 13 years of age and older becomes a 
required measure to track and report as part of the Patient Protection and Affordable Care Act.
• The first tobacco control strategic action plan for the United States, Ending the Tobacco Epidemic: A Tobacco Control 
Strategic Action Plan for the U.S. Department of Health and Human Services, is published.
2011 • OPM implements an evidence-based cessation benefit for federal employees.
• NCI launches SmokefreeTXT, a cessation program administered via mobile text messaging.
2012 • The Joint Commission’s set of tobacco cessation measures for hospitals is strengthened to define required components 
of evidence-based treatment for tobacco dependence and becomes available for voluntary adoption by hospitals. 
• CDC launches Tips From Former Smokers, the first federally funded, national tobacco education campaign.
• The University of California, San Diego, launches the Asian Smokers’ Quitline.
2013 • NCI and CDC launch 1-855-DEJELO-YA portal for Spanish speakers.
2014 • The Surgeon General’s report The Health Consequences of Smoking—50 Years of Progress is released.
• CDC publishes a new edition of Best Practices for Comprehensive Tobacco Control Programs that includes updated 
recommendations for tobacco cessation activities at the state level.
• The U.S. Departments of Labor, Health and Human Services, and the Treasury issue subregulatory guidance that 
clarifies the tobacco cessation coverage requirements in the Patient Protection and Affordable Care Act.
• Major components of the Patient Protection and Affordable Care Act are implemented, including new health 
insurance options and requirements that most private health plans must cover preventive services, including 
a comprehensive quit smoking benefit. As part of another key component, Medicaid is expanded to provide a 
comprehensive quit smoking benefit to millions of low-income Americans.
2015 • The U.S. Preventive Services Task Force issues updated recommendations for tobacco cessation.
• CDC launches the 6/18 initiative, partnering with healthcare purchasers, payers, and providers to improve health 
and control costs. The initiative focuses on the reduction of tobacco use, which is a costly health condition with 
proven interventions.
2017 • Inpatient psychiatric facilities are required, as part of the Inpatient Psychiatric Facility Quality Reporting program, 
to report on the Joint Commission’s set of tobacco cessation measures for hospitals.
2018 • FDA launches the Every Try Counts media campaign that encourages smokers to quit smoking.
Notes: CDC = Centers for Disease Control and Prevention; FDA = U.S. Food and Drug Administration; NCI = National Cancer Institute; 
OPM = Office of Personnel Management; USDHHS = U.S. Department of Health and Human Services.
the percentage who have tried to quit has increased 
slowly over the past two decades.
However, several key findings of this report high-
light the tragic public health history of tobacco use in 
this country, including the continued legacy of millions 
of lives prematurely lost from this deadly and completely 
preventable health risk factor:
• Each year, less than 1 in 10 U.S. adult cigarette 
smokers successfully quits smoking (defined as being 
quit for at least 6 months at the time of the survey 
interview);
• Disparities in cessation remain by age, race/
ethnicity, educational attainment, socioeconomic 
status, healthcare insurance coverage, geography, 
and other factors;
described in the national action plan (USDHHS 2014). 
The report concluded that, “Comprehensive tobacco con-
trol programs and policies have been proven effective 
for controlling tobacco use. Further gains can be made 
with the full, forceful, and sustained use of these mea-
sures” (USDHHS 2014, p. 7). The evidence outlined in this 
Surgeon General’s report reinforces that conclusion and 
provides compelling evidence related to the successes of 
these measures in the context of cessation:
• More than three out of every five U.S. adults who 
were ever cigarette smokers have quit smoking;
• More than two-thirds of U.S. adult cigarette smokers 
report interest in quitting cigarette smoking; and
• The majority of adult cigarette smokers in the United 
States have tried to quit during the past year, and 
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• Interest in quitting is declining among high school 
students who are smokers, and the proportion 
who made a quit attempt during the past year has 
decreased over the past two decades;
• Support to quit smoking, in the form of advice from 
health professionals and assistance from clinicians, 
remains inadequate; and
• More than two-thirds of adult cigarette smokers in 
the United States who tried to quit during the past 
year did not use evidence-based cessation counseling 
or medication.
Despite progress over the past half century, chal-
lenges persist with regard to ensuring that the risks of cig-
arette smoking and the benefits of cessation are addressed 
by implementing evidence-based strategies in a timely 
manner and by sustaining these strategies over time. 
In  2000, Surgeon General Dr. David Satcher acknowl-
edged a recurring theme that still plagues the tobacco 
control movement today: “Our lack of greater progress in 
tobacco control is more the result of failure to implement 
proven strategies than it is the lack of knowledge about 
what to do” (USDHHS 2000). To that end, several advances 
have been made to better understand the immediate and 
long-term benefits of smoking cessation and of effective 
cessation interventions. However, these strategies have 
not necessarily been implemented in a timely, equitable, 
and sustainable manner (USDHHS 2014). The compre-
hensive body of scientific evidence that has emerged since 
the first Surgeon General’s report on cessation nearly 
three decades ago (USDHHS 1990) makes it even more 
important that we act on this knowledge and immediately 
implement effective cessation strategies.
When first introduced in the U.S. marketplace in the 
mid-1980s and early 1990s, nicotine replacement therapy 
(NRT) was available only by prescription (USDHHS 1990; 
JAMA: the Journal of the American Medical Association 
2000). However, a growing body of scientific evi-
dence on the safety of NRT led the U.S. Food and Drug 
Administration (FDA) to make certain NRT products avail-
able over the counter. In 1996, FDA approved the tran-
sition of certain NRT products from being available by 
prescription only to being available over the counter to 
enhance their availability and use (JAMA: the Journal of 
the American Medical Association 2000). In the same year, 
the U.S. Agency for Health Care Policy and Research for-
mally recommended that NRT be part of standard care for 
every adult smoker (Fiore et al. 1996).
As evidence on the efficacy of tobacco cessation inter-
ventions continued to grow, the U.S. Public Health Service 
(JAMA: the Journal of the American Medical Association 
2000) released A Clinical Practice Guideline for Treating 
Tobacco Use and Dependence. As noted in the guideline, 
a considerable increase in research during the previous 
two decades had clarified the nature of tobacco depen-
dence as a chronic disease, the addictive nature of nico-
tine, and the availability of multiple effective behavioral 
counseling and pharmacological strategies for treating 
tobacco use and dependence (JAMA: the Journal of the 
American Medical Association 2000). Based on this evi-
dence, the guideline provided specific recommendations 
regarding brief and intensive tobacco cessation interven-
tions, as well as systems-level changes designed to pro-
mote the assessment and treatment of tobacco use. These 
recommendations were updated in Treating Tobacco Use 
and Dependence: 2008 Update (Fiore et al. 2008). The 2008 
guideline concluded that “tobacco dependence is a chronic 
disease that often requires repeated intervention and mul-
tiple attempts to quit” (Fiore et al. 2008, p. vi). It provided 
healthcare professionals with additional effective treat-
ment strategies that had not been identified in the 2000 
guideline, such as stronger evidence on the effectiveness of 
counseling, evidence that quitline counseling is effective, 
and recommendations related to the efficacy of all seven 
first-line pharmacotherapies that are approved by FDA for 
smoking cessation. These seven medications include five 
nicotine-based medications (the nicotine patch, gum, loz-
enge, nasal spray, and oral inhaler) and two non-nicotine 
oral medications (bupropion and varenicline). Of note, the 
2008 guideline also reinforced the increasing body of evi-
dence demonstrating that the successful implementation 
of nicotine dependence treatment strategies depends on 
support from the healthcare system in which the strate-
gies are embedded. To that end, the guideline presented 
new evidence about the critical role the healthcare system 
plays in increasing the likelihood that clinicians con-
sistently identify and intervene with smokers and that 
smokers receive and use effective nicotine dependence 
treatments and successfully quit. The 2008 guideline also 
underlines the failure to fully implement proven tobacco 
cessation interventions: “Indeed, it  is difficult to identify 
any other condition that presents such a mix of lethality, 
prevalence, and neglect, despite effective and readily avail-
able interventions” (Fiore et al. 2008, p. 12).
In 2009, following the release of the 2008 guide-
line, landmark advancements helped to shape the reg-
ulatory landscape for tobacco products in the United 
States. In June 2009, the Family Smoking Prevention and 
Tobacco Control Act (Tobacco Control Act) gave, for the 
first time in history, FDA the authority to regulate the 
manufacturing, marketing, and sale of tobacco products. 
The statute empowered FDA to regulate tobacco products 
in a manner that is “appropriate for the protection of public 
health” (Tobacco Control Act 2009, §907(a)(3)(A)), which 
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was an unprecedented and critical departure from the 
standard of safety and efficacy that had governed the regu-
lation of human drugs and medical devices. For example, 
the Tobacco Control Act gives FDA the authority to pro-
mulgate regulations respecting the construction; com-
ponents; ingredients; additives; constituents, including 
smoke constituents; and properties of cigarettes, but the 
Act prohibits the agency from reducing nicotine yields in 
these products to zero. The Act also requires FDA to con-
sider the individual- and population-level health effects 
of its regulatory actions, including their impact on cessa-
tion. Despite these provisions, FDA has faced some legal 
challenges (Public Health Law Center 2019). Nonetheless, 
FDA authority over tobacco products has been, and con-
tinues to be, an instrumental lever to reduce tobacco use 
and its harms using a population-based standard. Ongoing 
FDA actions related to this authority have the potential to 
advance population-based cessation efforts, including
• Regulating existing tobacco products and their 
constituents;
• Conducting a premarket review of new tobacco 
products before they can be introduced into the 
marketplace; 
• Evaluating modified risk claims and products and 
requiring premarket testing and postmarket sur-
veillance to evaluate the potential consequences of 
introducing these products into the marketplace;
• Educating the public about the harms of tobacco 
products (Zeller 2012; USDHHS 2014).
In March 2010, the Patient Protection and Affordable 
Care Act (Affordable Care Act) (2010) was signed into law. 
In the context of cessation, the law
• Requires most private insurance plans and all 
Medicaid expansion plans to cover in network tobacco 
cessation with no cost-sharing;
• Requires state Medicaid programs to cover all seven 
FDA-approved tobacco cessation medications;
• Requires states to provide a comprehensive cessa-
tion benefit, including coverage of cessation coun-
seling and medication, for pregnant women enrolled 
in Medicaid; and
• Provides Medicare beneficiaries with an annual well-
ness visit that includes referrals for tobacco cessa-
tion services.
By contributing to improved Medicaid and private 
cessation coverage and increasing the number of smokers 
who have insurance coverage, the Affordable Care Act has 
increased smokers’ access to proven cessation treatments, 
which will improve their chances of quitting (McAfee et al. 
2015). Specifically, the Act requires Grade A or B recom-
mendations from the U.S. Preventive Services Task Force 
to be covered without cost-sharing. Since the implementa-
tion of the Affordable Care Act, some progress has occurred 
in traditional state Medicaid coverage of proven tobacco 
cessation treatments: The number of states covering indi-
vidual and group counseling and all seven FDA-approved 
cessation medications increased from 7 states at the end 
of 2008 to 15 states at the end of 2018, and the number of 
states covering all seven FDA-approved cessation medica-
tions increased from 20 states at the end of 2008 to 36 states 
at the end of 2018. However, cessation coverage still falls 
short of a comprehensive benefit across all 50 states and 
the District of Columbia, and nearly all states retain bar-
riers—such as prior authorization, duration limits, and 
copayments—that make it difficult for Medicaid enrollees 
to access cessation treatments (DiGiulio et al. 2018).
Effective August 2016, FDA finalized a rule that 
extended its regulatory authority to all tobacco products, 
except for accessories of newly deemed products, including 
electronic cigarettes (e-cigarettes), cigars, hookah and 
pipe tobacco, and future tobacco products, as part of its 
goal to improve public health. Known as the “deeming 
rule,” the rule makes these products subject to regulatory 
requirements imposed by or authorized under the Tobacco 
Control Act, including federal prohibition on free sam-
pling for most tobacco products, federal requirements for 
health warnings, and the requirement that tobacco manu-
facturers register with FDA and seek the agency’s review 
of new tobacco products (FDA 2018a). Of important note, 
the deeming rule does not preempt states and localities 
from implementing laws related to tobacco product sales, 
use, distribution, and advertising, as long as the laws are 
in addition to, or more stringent than, the requirements of 
the Tobacco Control Act (FDA 2018a). Expanding the diver-
sity of tobacco products under the regulatory jurisdiction 
of FDA enhanced the agency’s ability to effectively regulate 
these products in a manner that is appropriate for the pro-
tection of public health, as directed by the U.S. Congress. As 
was concluded in the 50th anniversary Surgeon General’s 
report, “The burden of death and disease from tobacco use 
in the United States is overwhelmingly caused by ciga-
rettes and other combusted tobacco products” (USDHHS 
2014, p. 7), thus reinforcing the importance of regulatory 
actions to address the variety of combustible tobacco prod-
ucts being sold and used in the United States. The report 
further noted that “the cigarette is also a defective product, 
meaning not just dangerous but unreasonably dangerous, 
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killing half of its long-term users” (Proctor 2013, p.  i27, 
as cited in USDHHS 2014). The report also noted that a 
variety of noncombustible and electronic tobacco prod-
ucts with the potential for modified risk are being devel-
oped and aggressively marketed. Further, it noted that the 
shift in patterns of tobacco use could have several potential 
impacts, ranging from the positive effect of accelerating 
the rates of complete cessation among adult smokers to 
the negative effects of delaying cessation and diminishing 
progress in reducing the use of all forms of tobacco prod-
ucts, especially among youth and young adults. However, 
the impact of these products on population health is con-
siderably more likely to be beneficial in an environment 
where the appeal, accessibility, promotion, and use of ciga-
rettes and other combustible tobacco products are being 
rapidly reduced and effectively regulated, most notably 
among youth and young adults (USDHHS 2014).
These major developments in the federal regulatory 
landscape since the release of the last Surgeon General’s 
report on cessation in 1990, coupled with the extensive and 
growing body of science documenting evidence-based clin-
ical and population-based strategies for reducing tobacco 
use and motivating and helping tobacco users to quit, 
have created a strong foundation for achieving success in 
helping the nation’s 34  million adult cigarette smokers 
quit for good. Increased implementation of proven tobacco 
control strategies would accelerate progress; however, the 
present levels of implementation of these strategies are 
unacceptably low and fall well below optimally effective 
levels based on the existing body of scientific evidence. 
Of particular note, state funding for tobacco control pro-
grams has been declining for more than a decade (CDC 
2014; Campaign for Tobacco-Free Kids 2018); this funding 
includes support for state cessation interventions, which 
is one of CDC’s five recommended components of a com-
prehensive state tobacco control program (CDC 2014). For 
example, in fiscal year 2019, states will collect $27.3 billion 
from taxes and payments as a result of the tobacco Master 
Settlement Agreement of 1998. However, states will spend 
just 2.4% of this revenue—$655  million—on tobacco 
control programs, including efforts to help smokers quit 
(Campaign for Tobacco-Free Kids 2018). The enormous 
health and financial burden of smoking-attributable dis-
ease, disability, and death in the United States will con-
tinue for decades unless comprehensive, meaningful, suf-
ficiently funded, and evidence-based actions take hold at 
the national, state, and local levels. Although the nation 
is on the cusp of reaching the Healthy People 2020 objec-
tive of reducing the prevalence of smoking among adults 
18  years of age and older to 12.0% (Wang et  al. 2018), 
more can and should be done to help implement the 
proven interventions that are readily available.
Present: Health Benefits of Cessation
Even more than 50 years after the first Surgeon 
General’s report on smoking, the number of diseases and 
other adverse health effects caused by smoking continues 
to grow as the available scientific evidence has expanded 
with time (U.S. Department of Health, Education, and 
Welfare 1964; USDHHS 2004, 2010, 2014). The conclu-
sions in earlier Surgeon General’s reports on tobacco use 
have focused primarily on causal associations between 
smoking and increased risk of disease and other adverse 
health outcomes, largely because of the lack of a sufficient 
body of scientific evidence at the time on the link between 
smoking cessation and decreased risk of such outcomes. 
The 1990 report was the first Surgeon General’s report to 
comprehensively synthesize the available scientific evi-
dence on the health benefits of smoking cessation. That 
report concluded that smoking cessation has major and 
immediate health benefits for men and women of all 
ages (USDHHS 1990). Specifically, the report concluded 
that compared with continued smoking, smoking cessa-
tion reduces rates of respiratory symptoms and respira-
tory infections, such as bronchitis and pneumonia. The 
report also reached conclusions related to the short- and 
long-term benefits of cessation. For example, smoking 
cessation improves pulmonary function by about 5% in 
only a few months after quitting smoking. Moreover, with 
sustained abstinence from smoking, the rate of decline in 
pulmonary function among former smokers returns to 
that of never smokers, and mortality rates from chronic 
obstructive pulmonary disease decline among former 
smokers compared with rates among persons who con-
tinue to smoke (USDHHS 1990). This report expands on 
the findings of the 1990 report, reaching several impor-
tant new conclusions about the specific health benefits of 
smoking cessation, including
• Smoking cessation benefits persons at any age, but 
the benefits are greater at younger ages compared 
with older ages;
• Smoking cessation improves well-being, including 
higher quality of life and improved health status;
• Smoking cessation reduces the risk of the following 
cancers: lung, larynx, oral cavity and pharynx, 
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esophagus, pancreas, bladder, stomach, liver, cervix, 
kidney, colorectal, and acute myeloid leukemia;
• Smoking cessation substantially reduces the risk of 
coronary heart disease among men and women of 
all ages and reduces risk of morbidity and mortality 
from stroke and cardiovascular diseases; and
• Smoking cessation by pregnant women benefits their 
health and that of their fetuses and newborns.
In addition to significant health benefits to indi-
vidual smokers and society, smoking cessation also has 
considerable economic benefits. Smoking cessation can 
reduce the costs of smoking for individual smokers, health 
systems, and society. Moreover, the report finds that 
smoking cessation interventions are cost-effective. The 
report documents an array of effective clinical and health 
systems interventions for increasing smoking cessation 
and treating tobacco use and dependence:
• Behavioral counseling and cessation medication 
interventions increase smoking cessation compared 
with self-help materials or no treatment.
• Behavioral counseling and cessation medications 
are each effective alone in treating tobacco use and 
nicotine addiction but are most effective when used 
in combination.
• Combination pharmacotherapy, including com-
bining short- and long-acting forms of NRT, increases 
smoking cessation compared with the use of single 
forms of NRT.
• Tobacco quitline counseling increases smoking ces-
sation, when provided alone or in combination with 
medication.
• Insurance coverage of cessation interventions that 
are comprehensive, barrier-free, and evidence-based 
increases the availability and utilization of treat-
ment services for smoking cessation.
This report further reinforces the importance of 
interventions promoting cessation at the individual and 
population levels. Specifically, actions at the clinical and 
health system levels are typically designed to integrate 
tobacco cessation interventions into routine clinical care, 
increase the use and effectiveness of smoking cessation 
treatments, or directly help smokers quit. However, such 
interventions should not function in isolation. Instead, 
they should complement population-based interven-
tions that have already been shown in multiple previous 
Surgeon General’s reports (USDHHS 2004, 2014) and 
other major reports to reduce tobacco use and tobacco-
related morbidity and mortality. Given the critical impor-
tance and impact of population-based interventions in 
combating the tobacco use epidemic, King and Graffunder 
(2018) described the importance of such strategies in the 
context of a “tobacco control vaccine,” whose ultimate 
impact on public health is contingent on its combination 
of individual components (including a “cessation access” 
component), robust population-level protection, and the 
extent to which these components are supported and 
advanced by key stakeholders at an adequate dose. In addi-
tion to preventing initiation of tobacco product use, 
population-based interventions can also influence cessa-
tion at a macro level by motivating tobacco users to quit 
and by providing an environment that makes it easier for 
them to do so (CDC 2014). Although previous Surgeon 
General’s reports have documented the efficacy of these 
interventions for reducing tobacco use, this is the first 
Surgeon General’s report to document the impact of such 
interventions on smoking cessation:
• Increasing the price of cigarettes reduces cigarette 
consumption, reduces the prevalence of smoking, 
and increases smoking cessation;
• Mass media campaigns increase the number of calls 
to quitlines and increase smoking cessation;
• Smokefree policies lead to decreased prevalence 
of smoking, decreased cigarette consumption, and 
increased smoking cessation among adults; and
• Comprehensive state tobacco control programs 
reduce the prevalence of smoking and increase 
smoking cessation.
Predictive models described in this report show that 
evidence-based tobacco control policies can yield substan-
tial reductions in the prevalence of smoking. Moreover, 
cessation treatment policies and other policies—including 
tax increases, smokefree laws, and media campaigns—
have complementary effects by increasing quit attempts 
and improving quitting success. Taken together, the pre-
ponderance of available data on the benefits of cessation 
and the efficacy of available clinical and population-based 
interventions reinforces the importance of a compre-
hensive approach to promoting tobacco cessation in the 
United States. While acknowledging the importance of 
the individual components, it is critical to recognize that 
these individual components must work together syner-
gistically to most effectively prevent initiation of tobacco 
use and promote cessation (CDC 2014; USDHHS 2014).
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Future: Ending the Tobacco Use Epidemic
Progress and Challenges
Tobacco use could remain the leading cause of pre-
ventable disease, disability, and death in the United States 
unless the prevalence of tobacco use, especially use of com-
bustible products, is reduced more rapidly than the current 
trajectory (USDHHS 2014). Such reductions will require 
coordinated efforts to prevent initiation of tobacco use and 
nicotine addiction among young people and to create an 
environment that promotes and supports cessation among 
current tobacco users (USDHHS 2014). Considerable 
progress has been made but more can be done—and with 
enhanced expediency. To end the tobacco use epidemic, the 
evidence-based strategies articulated in this report must be 
implemented fully and sustained with sufficient intensity 
and duration. If this does not happen, nearly half a million 
Americans will continue to die each year from smoking-
related diseases and exposure to secondhand smoke, and 
millions of Americans will continue to live with serious 
smoking-related diseases, costing society hundreds of bil-
lions of dollars in smoking-attributable healthcare expen-
ditures and lost productivity (USDHHS 2014).
Challenges remain to accomplish the goal of a society 
free of tobacco-related death and disease. For example, 
marked disparities exist in the use of tobacco products, and 
some subpopulations face a considerably higher burden of 
tobacco use and tobacco-associated morbidity and mor-
tality. Use of tobacco products remains higher among 
males, middle-aged adults, American Indians/Alaska 
Natives, persons with lower levels of education, persons 
living below the poverty level, persons living in the Midwest 
and South, persons with no health insurance or who are 
insured through Medicaid, sexual and gender minori-
ties, persons with disabilities, and persons with behav-
ioral health conditions (Wang et al. 2018). Additionally, 
as noted in this report, marked disparities in cessation 
persist across population groups. Disparities also persist 
regarding access to and use of proven cessation treatments 
(National Cancer Institute [NCI] 2017). The prevalence of 
key indicators of cessation—quit attempts, advice to quit 
from a health professional, and access to cessation ther-
apies—varies across populations, with lower prevalence 
among some vulnerable subgroups. For example, unin-
sured smokers and Hispanic smokers are less likely than 
their respective counterparts to report receiving advice 
to quit from a health professional; uninsured smokers, 
Hispanic smokers, and gay/lesbian/bisexual smokers are 
less likely than their counterparts to report using cessa-
tion counseling and/or medication as part of a quit attempt 
(Babb et al. 2017). To eliminate tobacco-related disparities, 
tobacco control programs and policies, including barrier-
free access to cessation treatments, must be implemented 
in a way that achieves equitable benefits for all (CDC 
2014). Such efforts would ultimately enhance access to 
effective cessation treatments and accelerate the decline 
in the prevalence of smoking across all population groups, 
thus alleviating the disproportionate health and economic 
burden experienced by vulnerable population groups (CDC 
2014; NCI 2017).
Disparities in tobacco use and cessation are com-
pounded by the fact that the tobacco industry continues 
to aggressively market and promote addictive and lethal 
products with the goals of retaining current users of these 
products and of recruiting new consumers, including 
youth and young adults (USDHHS 2012). Such mar-
keting and promotional activities, including decades of 
coordinated efforts targeting various vulnerable popula-
tion groups, have contributed to the disparities in ciga-
rette smoking and cessation that exist in the United States 
(USDHHS 1998, 2014; NCI 2008, 2017). The 50th anni-
versary Surgeon General’s report further underscored the 
deceptive nature of the tobacco industry’s efforts, reaching 
the following major conclusion: “The tobacco epidemic 
was initiated and has been sustained by the aggressive 
strategies of the tobacco industry, which has deliberately 
misled the public on the risks of smoking cigarettes” 
(USDHHS 2014, p. 7).
The landscape of tobacco products continues to 
evolve to include an array of combustible, noncombus-
tible, and electronic products (Cullen et  al. 2018; Wang 
et al. 2018). For example, heated tobacco products have 
recently reentered the U.S. marketplace, with IQOS being 
authorized by FDA for sale in April  2019 (FDA  2019). 
More research is needed to better understand the long-
term health effects of heated tobacco products. Although 
preliminary data from the tobacco industry suggest cer-
tain heated tobacco products generally have lower levels 
of harmful ingredients than conventional cigarettes 
(St. Helen et al. 2018), concerns remain around sustained 
dual use of heated products and conventional cigarettes, 
youth initiation, and the limited number of independent 
studies assessing the constituents in these products and 
the potential population-level health risks (Leigh et  al. 
2018; Max et al. 2018; McKelvey et al. 2018; Nabavizadeh 
et al. 2018). At present, data are not available on the long-
term health effects of these products.
The continued diversification of the tobacco product 
landscape could have several different potential impacts, 
ranging from accelerating the rates of complete ces-
sation among adult smokers to delaying cessation and 
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diminishing progress in reducing the use of all forms 
of tobacco products among youth and young adults 
(USDHHS 2014). Moreover, as the landscape of tobacco 
products continues to evolve, so does the tobacco industry. 
For example, during the past decade, three categories 
of e-cigarette brands have emerged in the U.S. market: 
brands developed by cigarette manufacturers, brands that 
were ultimately acquired by cigarette manufacturers, and 
brands that have no affiliation with cigarette manufac-
turers (USDHHS 2016). In recent years, the majority of 
e-cigarettes sold in traditional retail stores are those man-
ufactured by major cigarette companies (King et al. 2018). 
More recently, the tobacco industry has also made more 
prominent efforts to acquire a stake in e-cigarette compa-
nies not previously affiliated with the traditional tobacco 
industry. For example, in December 2018, Altria Group, 
the parent company of Philip Morris USA, purchased a 
35% stake in JUUL Labs, the maker of the most commonly 
sold e-cigarette in the United States (Altria Group 2018).
The increasing availability and use of novel tobacco 
products, most notably e-cigarettes, raise questions about 
the potential impact that such products could have on 
efforts to eliminate the individual- and population-level 
disease and death caused by tobacco use. However, when 
considering the impact of e-cigarettes on public health, it’s 
critical to acknowledge their potential benefits and their 
potential risks, including the recognition that population-
level increases in youth using e-cigarettes and becoming 
addicted to nicotine could offset any potential benefits 
realized among adult smokers using these products to 
quit. Additionally, e-cigarette, or vaping, product use may 
be associated with other health risks beyond youth ini-
tiation and use. For example, CDC, FDA, state and local 
health departments, and public health and clinical part-
ners have been investigating a multistate outbreak of 
e-cigarette, or vaping, product use associated lung injury 
(EVALI) (Siegel et al. 2019). The latest national and state 
findings show e-cigarette, or vaping, products containing 
THC—particularly those from informal sources, such as 
friends, family, or in-person or online dealers—are linked 
to most of the cases of lung injury and play a major role in 
the outbreak (Moritz et al. 2019; Navon et al. 2019). In par-
ticular, vitamin E acetate is closely associated with EVALI 
(Blount et  al. 2019). Vitamin  E acetate has been identi-
fied in several tested products used by EVALI patients, 
and has been identified in bronchoalveolar lavage (BAL) 
fluid samples from 48 of 51 assessed EVALI patients, but 
not in the BAL fluid from a control group. However, as of 
January 2020, evidence is not yet sufficient to rule out the 
contribution of other chemicals of concern among some 
EVALI patients.
The Tobacco Control Act is governed by a require-
ment to protect the overall public health. Such a 
population-level public health standard is essential because 
exposure to harmful toxicants from e-cigarettes at the 
individual level could adversely affect public health at the 
population level by (a) increasing initiation of e-cigarette 
use and nicotine addiction among vulnerable populations, 
including young people, and (b)  increasing the number 
of adult users of both combustible tobacco products and 
e-cigarettes (i.e., dual users) without necessarily increasing 
the number of successful adult quitters. Weighing the 
relative benefits and risks to individuals and the popula-
tion as a whole is essential when considering the potential 
role that any noncombustible tobacco product may play 
in reducing the occurrence of smoking-attributable dis-
ease and death (USDHHS 2014). E-cigarettes could help 
individual adult smokers if they completely switch from 
conventional cigarettes to e-cigarettes. Among those who 
have transitioned completely, the ultimate goal should be 
to also quit the use of e-cigarettes completely to achieve 
the maximal individual and public health benefit. However, 
at the population level, any potential benefits these prod-
ucts confer in terms of increasing cessation among adult 
smokers would need to outweigh potential risks related to 
increased initiation of tobacco product use among youth 
(USDHHS 2014). E-cigarette use among U.S. high school 
students increased 78% during 2017–2018, as 1 in 4 high 
school students reported currently using e-cigarettes in 
2019 (Cullen et  al. 2019). This increase coincided with 
the growing popularity of e-cigarettes shaped like a USB 
flash drive, including JUUL (King et  al. 2018; Gentzke 
et  al. 2019). Many of these e-cigarettes deliver nicotine 
in the form of nicotine salts, which allow users to inhale 
particularly high levels of nicotine more easily and with 
less irritation than the freebase nicotine that is used tra-
ditionally in tobacco products, including older generation 
e-cigarettes (USDHHS 2018). These high levels of nicotine 
introduce additional population-level risks because nico-
tine is extremely addictive, can harm the developing brain 
in adolescents, and can prime the brain for addiction to 
other drugs (USDHHS 2016).
It is also critical to acknowledge that for e-cigarettes 
or other noncombustible tobacco products to be effective 
harm-reduction tools, they must help smokers completely 
quit conventional cigarettes. Specifically, users must tran-
sition completely from combustible tobacco products to 
lower risk alternatives in order to realize a reduction in 
risk at the individual level. As noted in the major conclu-
sions of this report, e-cigarettes, a continually changing 
and heterogeneous group of products, are used in a variety 
of ways; and there is presently inadequate evidence to con-
clude that e-cigarettes, in general, increase smoking ces-
sation. Moreover, the available evidence indicates that a 
majority of e-cigarette users also smoke conventional cig-
arettes—a pattern of use that does not confer a substantial 
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risk reduction benefit to the individual (USDHHS 2014; 
Goniewicz et  al. 2018). However, the number and sci-
entific rigor of studies on e-cigarettes and smoking ces-
sation among adults continue to increase (Hajek et  al. 
2019), and a growing body of scientific evidence suggests 
that multiple factors related to e-cigarettes—including 
product type, frequency of use, and efficiency of nico-
tine delivery—could affect the efficacy of these products 
for successful smoking cessation. Of note, the diversifica-
tion of the e-cigarette landscape is especially important 
to consider in the context of cessation efficacy, as various 
aspects of these products—including their ability to effi-
ciently deliver nicotine to the user—have evolved with 
each generation of e-cigarette product that has entered 
the marketplace. For example, although justifiable con-
cerns exist that nicotine salts could promote initiation of 
e-cigarette use among youth, this new product formula-
tion also has the potential to enhance the dose and effi-
ciency with which nicotine is delivered to adult smokers 
who may be attempting to quit smoking, thus potentially 
increasing the likelihood that they are able to transi-
tion completely to e-cigarettes. However, this formula-
tion could also make it more difficult for those who fully 
transition to e-cigarettes to eventually quit using these 
products completely.
Studies on the relationship between e-cigarettes and 
smoking cessation continue to emerge, including ran-
domized clinical trials that will be critical to providing a 
comprehensive and evidence-based understanding of this 
topic. When considering current and future studies on 
e-cigarettes, it is important to note that findings may not 
be generalizable to all settings, including smokers who 
have different levels of dependency than those included in 
the reported research; smokers who try or use e-cigarettes 
for reasons other than quitting smoking; and smokers 
who live in countries that have different policy and regu-
latory environments, including limitations on the amount 
of nicotine permitted in e-cigarettes and restrictions on 
e-cigarette advertising and marketing. Also, e-cigarettes 
are not a uniform product category; the generalizability 
of research on their efficacy for smoking cessation is com-
plicated by the diversity of products available, the vola-
tile nature of the marketplace, and the extent to which 
the products can be modified by the user—including 
modifications that affect the level of nicotine the prod-
ucts deliver. More longitudinal research is needed on 
the long-term health effects of using e-cigarettes and 
on the effects of e-cigarette use on cessation, including 
research addressing internal validity and generalizability 
to real-world usage. Additionally, given the volatility of the 
e-cigarette landscape, including the introduction of nico-
tine salts, research on different types of e-cigarette prod-
ucts and frequency of use is essential.
As studies on e-cigarettes and cessation continue to 
emerge, it is critical that public health recommendations 
be based on a robust and scientifically rigorous evidence 
base that takes into account the potential detrimental 
impacts that the widespread availability and promotion of 
e-cigarettes for cessation could have on youth initiation of 
e-cigarettes, as well as other tobacco products (USDHHS 
2016). When considering public health, in order for a net 
gain to occur, any benefit of e-cigarette use among adult 
smokers would have to outweigh the risks of increased ini-
tiation among young people at the population level.
End-Game Strategies
Faced with the challenge of realizing the vision of 
a society free of tobacco-related death and disease, and 
especially given the increasing variety of tobacco products 
in the marketplace, the patterns of use of these products 
among adults and youth, and the changing demographics 
of users of these products, the 50th anniversary Surgeon 
General’s report summarized several potential end-game 
strategies and emphasized those judged most relevant 
for the United States (Table 8.2) (USDHHS 2014). These 
proposed strategies, in conjunction with the accelerated 
implementation of proven tobacco control interventions, 
are intended to end the epidemic of disease and prema-
ture death caused by tobacco use. The development of var-
ious end-game strategies by scholars around the world has 
taken place in the absence of a broad consensus on how 
to define the end related to tobacco. For example, some 
end-game strategies have focused on the elimination of all 
tobacco use and the use of any nicotine-containing prod-
ucts, including e-cigarettes; others have focused on elimi-
nating the use of combustible tobacco products because 
to date, these products have been responsible for the over-
whelming burden of death and disease caused by tobacco 
use (USDHHS 2014). Nonetheless, there is generally broad 
recognition and consensus that the overriding objective is 
to maximize health (USDHHS 2014).
Benowitz and Henningfield (1994) made one of the 
first end-game proposals, describing a policy approach of 
gradually reducing the levels of nicotine content in ciga-
rettes to nonaddictive levels, so as to prevent the devel-
opment of nicotine addiction in youth. The authors also 
noted that this strategy could increase the likelihood that 
adult smokers would stop smoking—as cigarettes would 
become “less satisfying.” In the decades since that 1994 
publication, several studies have assessed the potential 
impact of experimental very-low-nicotine-content cig-
arettes on adult smokers. Based on these studies, this 
report finds that reducing the level of nicotine content 
in cigarettes could have the potential to reduce smoking: 
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The evidence is suggestive but not sufficient to infer that 
very-low-nicotine-content cigarettes can reduce smoking 
and nicotine dependence and increase smoking cessation 
when full-nicotine cigarettes are readily available; the 
effects on cessation may be further strengthened in an 
environment in which conventional cigarettes and other 
combustible tobacco products are not readily available.
Moreover, a simulation model by Apelberg and col-
leagues (2018) suggested that if conventional cigarettes 
were not available, lowering the level of nicotine con-
tent in cigarettes to minimally addictive levels in the 
United States would decrease the prevalence of cigarette 
smoking to 1.4% by 2060, prevent 16  million people 
from initiating smoking, and avert an estimated 2.8 mil-
lion tobacco-related deaths. Of all end-game strategies 
proposed to date, nicotine reduction has received the 
greatest interest and attention in the United States, in 
part because the regulatory structure required to imple-
ment it is already in place and is explicitly articulated in 
the Tobacco Control Act. In 2018, FDA issued an advance 
notice of proposed rulemaking that specifically requested 
data and other information to inform a potential tobacco 
product standard to reduce nicotine in cigarettes to mini-
mally addictive or nonaddictive levels for the protection 
of public health (Federal Register 2018; FDA 2018a). The 
Tobacco Control Act gives FDA several tools to regulate 
cigarettes, including the ability to establish product stan-
dards, which could include reducing nicotine content to 
levels so low that they would be insufficient to cause or 
sustain nicotine addiction, but the Act expressly prohibits 
FDA from requiring the reduction of nicotine yields of 
cigarettes to zero. However, questions of potential interest 
related to a standard could include whether such a nico-
tine standard would lead to smokers inhaling more deeply 
to compensate for the reduced nicotine yield; would lead 
to illicit trade in products with higher nicotine yield; and 
would impact vulnerable populations with higher rates of 
smoking, such as those with mental illness and substance 
use disorders (USDHHS 2014; Gottlieb and Zeller 2017).
In addition to a potential standard around the level 
of nicotine content, several other end-game proposals also 
have the potential to contribute to increases in smoking 
cessation and reductions in the disease and premature 
death caused by tobacco. For example, strict standards 
for ingredients in tobacco products could be established 
to make some or all tobacco products less toxic and 
less appealing, particularly to young people (Table  8.2). 
The Tobacco Control Act authorizes FDA to implement 
product standards to control levels of chemicals and other 
ingredients in tobacco products or their emissions for the 
protection of public health (USDHHS 2014). Other poten-
tial end-game strategies could aim to reduce the supply 
of tobacco products, which could also influence cessa-
tion among current users of such products, or to pro-
hibit the sale of cigarettes and/or other tobacco prod-
ucts. Although the Tobacco Control Act prohibits FDA 
from banning the sale of cigarettes, it does authorize the 
agency to set standards for tobacco products that could 
significantly impact the marketing of tobacco products. 
Specifically, the act allows FDA to issue a product standard 
to prohibit menthol in cigarettes, or any other tobacco 
product, to protect public health. Moreover, the Tobacco 
Table 8.2 Potential end-game strategies discussed in the 50th anniversary Surgeon General’s report, 2014
Potential end-game strategy Description
Reduce nicotine yield in cigarettes and other tobacco products Use government regulations to gradually reduce the level of 
nicotine in cigarettes, and possibly other tobacco products, 
to nonaddictive levels 
Reduce toxicity in tobacco products Implement regulatory standards that require manufacturers 
to create tobacco products with very low toxicity
Gradually reduce the supply of tobacco products Phase out over time the use of tobacco products via systematic 
reduction of supply to zero or to some other minimal level 
Prohibit the sale of tobacco products to future generations Prohibit the sale of tobacco products to persons born after a 
specific date, essentially creating tobacco-free cohorts that 
progressively increase in coverage and size over time
Prohibit cigarettes and/or cigarettes and other tobacco products Prohibit the production and sale of cigarettes and possibly 
other types of tobacco products
Sell tobacco products through a not-for-profit agency Transfer control of the supply and sales of tobacco products to a 
not-for-profit agency that has the goal of reducing consumption
Sources: Benowitz and Henningfield 1994, 2013; Borland 2003, 2013; Callard et al. 2005a,b; Daynard et al. 2010; Hatsukami et al. 2010, 
2012, 2013; Khoo et al. 2010; Thomson et al. 2010; Proctor 2011, 2013; Berrick 2013; Callard and Collishaw 2013; Wilson et al. 2013; 
USDHHS 2014.
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Control Act does not preempt states and localities from 
prohibiting the sale of cigarettes or other tobacco prod-
ucts. However, other factors may preclude such actions, 
including state constitutions or other state laws, which 
could prevent the implementation of such measures at 
the local level. Additionally, prohibiting specific types of 
tobacco products (e.g., flavored tobacco products) could 
also impact population-level cessation. In November 2018, 
FDA indicated its intent to prohibit menthol in combus-
tible tobacco products, prohibit flavored cigars, and pro-
hibit flavored e-cigarettes (excluding tobacco and men-
thol flavors), except those sold in age-restricted, in-person 
locations (FDA 2018b). Several jurisdictions in California, 
Illinois, Massachusetts, Minnesota, New York, and Rhode 
Island have restricted the sale of flavored tobacco products, 
with some of these policies not exempting menthol flavors 
(Campaign for Tobacco-Free Kids 2019). Prohibiting fla-
vors, including menthol, in tobacco products can benefit 
public health by reducing initiation among young people 
and promoting cessation among adults (USDHHS 2014). 
For example, studies show that a sizable portion of adults 
who smoke menthol cigarettes report that they would try 
to quit smoking if menthol cigarettes were prohibited 
(O’Connor et al. 2012; Pearson et al. 2012). In 2011, the 
Tobacco Product Scientific Advisory Committee (TPSAC) 
to the FDA conducted an extensive review of the state of 
the science on menthol, concluding that the “[r]emoval 
of menthol cigarettes from the marketplace would benefit 
public health in the United States” (TPSAC 2011, p. 225). 
Furthermore, FDA conducted a subsequent independent 
review of the science and concluded, “From the avail-
able studies, the weight of evidence supports the conclu-
sion that menthol in cigarettes is likely associated with 
reduced success in smoking cessation, especially among 
African American menthol smokers” (FDA n.d., p. 6).
But end-game strategies cannot function in isola-
tion and should not be seen as a panacea or as a substi-
tute for the accelerated implementation of established 
population-based strategies. To that end, an integrated 
national tobacco control strategy is essential—one that is 
based on a foundation of enhanced implementation of the 
traditional strategies that have been shown to be effective, 
including taxation, smokefree policies, barrier-free ces-
sation support, and hard-hitting mass media campaigns 
(USDHHS 2014; King and Graffunder 2018). The most 
feasible end-game strategies—such as reducing the nico-
tine content in cigarettes to make them less addictive and 
placing greater restrictions on sales of tobacco products, 
including prohibitions on entire categories of tobacco 
products—could then be integrated into this foundational 
platform (Van der Eijk 2015). Using this paradigm, a more 
aggressive implementation of the proven population-
based interventions outlined in Chapter 7 would reinforce 
cessation efforts nationally and enhance the feasibility and 
impact of end-game strategies.
The pursuit of an integrated strategy of acceler-
ated implementation of proven interventions coupled 
with the introduction of novel end-game interventions is 
likely to encounter unique challenges (Isett 2013; Rabe 
2013; Thomas and Gostin 2013). These challenges are 
likely to come from two key groups. The first group is 
those with a financial stake in the continued widespread 
use of cigarettes and other tobacco products, including 
the traditional tobacco industry and the emerging array of 
e-cigarette companies and related entities advocating for 
their interests (USDHHS 2014). The tobacco industry has 
an extensive history of attempting to influence decision 
makers to oppose evidence-based tobacco control strat-
egies, and because local control is so integral to galva-
nizing evidence-based policies and shifting social norms, 
the tobacco industry and its allies have used strategies to 
preempt local smokefree laws and other types of tobacco 
control policies (USDHHS 2014). The second group is 
users of tobacco products and others who would be ideo-
logically opposed to any policy or strategy that would 
jeopardize the availability and sale of cigarettes and other 
tobacco products and the ability of adults to obtain and 
consume these products (USDHHS 2014). However, inno-
vation spurred by the proliferation of subnational poli-
cies has been a hallmark of tobacco control for decades, 
at times giving rise to approaches that have been emu-
lated by practitioners in other disciplines. As noted in the 
50th anniversary Surgeon General’s report, “It is impor-
tant to remember that many policy innovations, once 
thought inconceivable, have now become the law of the 
land” (USDHHS 2014, p.  858). Just two decades ago, 
it  would have been difficult to envision that more than 
half of U.S. states and more than 1,000  communities 
would be covered by comprehensive smokefree laws, and 
even a decade ago, most public health experts would not 
have predicted that more than a dozen states and several 
hundred communities would increase the legal age of sale 
for tobacco to 21  years of age (CDC 2018). Indeed, the 
profound and dynamic history of tobacco control over 
more than 50  years suggests that continued innovation 
is a key tenet of success. Therefore, the public health 
community must remain nimble and capable of evolving 
as quickly as the rapidly changing landscape of tobacco 
products. New developments and innovations will con-
tinue to occur, as has been the case for decades, but the 
public health community need not reinvent the wheel. 
Proven interventions can continue to be modernized with 
time. Additionally, new end-game strategies offer unprec-
edented opportunities to complement these interven-
tions to end the epidemic of disease and premature death 
caused by tobacco use.
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Advancing Cessation
As documented in Chapter 6, a comprehensive body 
of scientific evidence, which has grown stronger over time, 
supports the use of behavioral counseling and pharmaco-
logic interventions for smoking cessation, with the combi-
nation of both being the most effective approach. Effective 
counseling interventions include an array of behavioral 
treatments that can be delivered effectively by a variety of 
qualified personnel in many formats, including individual, 
group, and telephone counseling. Additionally, emerging 
evidence suggests that text messaging and web interven-
tions are also effective modalities for delivering cessation 
behavioral interventions. As documented in Chapter  5, 
strong evidence exists for the cost-effectiveness of both 
behavioral and pharmacologic tobacco cessation treat-
ments. However, although more than half of current 
smokers try to quit each year, the success rate of these quit 
attempts remains low, and successful cessation is typically 
preceded by multiple prior attempts (Babb et  al. 2017). 
Moreover, despite gains over the past three decades, both 
the reach and use of existing smoking cessation interven-
tions also remain low, with less than one-third of smokers 
using behavioral and/or pharmacologic interventions when 
trying to quit. The current state of the cessation landscape 
in the United States underscores the fact that more can 
and should be done to help smokers quit for good.
Two factors drive the rate of cessation in the pop-
ulation: the rate of quit attempts and the rate of suc-
cessful cessation among smokers who try to quit. Thus, 
increases in quit attempts and quit success rates can each 
drive increases in population-level cessation. Moreover, 
increasing the reach and intensity of cessation interven-
tions can each increase the cessation rate in the popula-
tion (CDC 2014). Of note, some strategies address only 
one of these factors, and others address both. For example, 
a mass media campaign can motivate more smokers to 
try to quit, and the development of a new, more effective 
cessation medication can increase the success rate for 
smokers who try to quit. In contrast, a mass media cam-
paign that drives smokers to a quitline or a promotional 
campaign that drives smokers enrolled in Medicaid to 
take advantage of newly improved Medicaid cessation cov-
erage in their state can (a) motivate more smokers to try 
to quit and (b) by connecting these smokers with proven 
cessation treatments, increase their chances of quitting 
successfully. Therefore, strategies that increase the rate 
of quit attempts and the rate of successful cessation are 
especially important.
As noted in this report, increasing quit rates requires 
several strategies that include increasing the appeal and 
reach of existing evidence-based interventions to smokers. 
Promising directions to increase appeal and reach could 
include expanding treatment targets, leveraging emerging 
technologies to enhance the initial and sustained engage-
ment of smokers in treatment, and accelerating the inte-
gration of cessation services across multiple platforms and 
in healthcare systems. Given shifts in the manner in which 
people communicate and obtain information, possible 
emerging technologies that could be considered include 
(a) mobile health platforms with applications that involve 
adaptive interventions that are tailored to the needs of 
each person and (b)  social media and other applications 
that deliver behavioral treatment and improve adherence 
to medication.
In addition to enhancing the reach of behavioral 
support, the enhanced availability of generic versions of 
FDA-approved brand-name drugs could enhance access 
to and the reach of these medications, particularly with 
regard to increased affordability among persons in lower 
socioeconomic groups, who traditionally have high rates 
of smoking (Wang et al. 2018). It is anticipated that health 
insurers would be more likely to cover generic cessation 
medications with no or minimal barriers because generic 
medications are typically less expensive; this would 
increase the affordability of and access to these medica-
tions among smokers, especially low-income smokers. 
Additionally, Leischow (2019) proposed enhancing access 
to and the reach of proven pharmacotherapies by making 
varenicline and other prescription medications for 
smoking cessation available over the counter. The conver-
sion of pharmacotherapies to over-the-counter medicines 
requires careful weighing of risks and benefits at the indi-
vidual and population levels.
Increasing quit rates could also be achieved by 
increasing the effectiveness of existing interventions. 
Chapter 6 of this report concluded, “The evidence is suf-
ficient to infer that combining short- and long-acting 
forms of nicotine replacement therapy increases smoking 
cessation compared with using single forms of nicotine 
replacement therapy.” Emerging evidence also suggests 
that combining varenicline with bupropion or NRT may 
be more effective than taking varenicline alone, particu-
larly among heavy smokers. In addition, combination 
therapy involving bupropion and NRT has been shown to 
produce better outcomes than either medication used by 
itself. Reaching a better understanding of both behavioral 
and pharmacological interventions that can safely and 
effectively promote cessation among youth is becoming 
increasingly important because of the dearth of evidence 
on this issue and because of recent surges in e-cigarette 
use and frequency among youth, particularly products 
that utilize nicotine salts (USDHHS 2018).
Efforts can also be made to increase quit rates 
through the development of cessation interventions that 
have greater reach and/or effectiveness than existing 
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interventions or that appeal to and are used by dif-
ferent populations of smokers. For example, according 
to this report, evidence is suggestive but not sufficient 
to conclude that cytisine is effective for smoking cessa-
tion (Chapter 6). Cytisine is used for cessation in several 
Eastern European countries but is not yet approved by 
FDA for use as a cessation medication in the United States. 
More research is needed to further assess the safety and 
efficacy of cytisine for smoking cessation and its possible 
utility in the United States.
Similarly, more research is needed on the potential 
of using e-cigarettes as a smoking cessation aid, including 
determining what types of e-cigarettes and what aspects 
of use may maximize positive cessation outcomes and 
minimize adverse consequences, especially related to use 
among young people. Chapter 6 of this report concluded 
that the evidence is inadequate to infer that e-cigarettes, 
in general, increase smoking cessation. It also concluded 
that the evidence is suggestive but not sufficient to infer 
that the use of e-cigarettes containing nicotine is associ-
ated with increased smoking cessation compared with the 
use of e-cigarettes not containing nicotine, and the evi-
dence is suggestive but not sufficient to infer that more 
frequent use of e-cigarettes is associated with increased 
smoking cessation compared with less frequent use of 
e-cigarettes. It is also important to note that the e-cigarette 
landscape continues to evolve, and existing research has 
not assessed newer types of e-cigarettes, including those 
that use nicotine salts. Such products may deliver nico-
tine content more efficiently and, therefore, may be more 
effective for smoking cessation than earlier generations of 
e-cigarettes. However, this formulation could also make it 
more difficult for those who fully transition to e-cigarettes 
to eventually quit using these products completely.
The aforementioned individual treatments for 
smoking cessation are necessary but not sufficient to 
fully achieve meaningful population-based cessation out-
comes. As discussed in Chapter 7, these interventions are 
most effective when complemented by actions taken at the 
clinical and health systems levels to create environments 
that support the use of cessation treatments and suc-
cessful cessation by smokers—including policies to trans-
form systems of care to better address tobacco use and 
dependence, the promotion of evidence-based treatments 
for tobacco use and dependence, and the implementa-
tion of policies (e.g., covering all evidence-based cessa-
tion treatments; removing barriers to treatments, such as 
prior authorization; and promoting covered treatments to 
smokers and providers so that they are aware of and use 
these treatments) to increase smokers’ access to clinical 
interventions and cessation treatments that could help 
them quit. Although considerable progress has been made 
to integrate nicotine dependence treatment into clinical 
health systems over the past several decades, substantial 
opportunities for improvement remain, for example: 
• Embedding policies and protocols for tobacco 
use screening and interventions into the clinical 
workflow;
• Embedding prompts, decision support, and docu-
mentation tools into health records, including elec-
tronic health records; and 
• Distributing specific components of the interven-
tion across the broader healthcare team to reduce 
the burden on time-constrained physicians and to 
reinforce the importance of cessation to patients. 
Because cigarette smoking remains high and quit-
ting smoking may be more difficult among certain sub-
populations in the United States, including persons of 
lower socioeconomic status and those with comorbid 
mental health and other substance use disorders (Wang 
et al. 2018), specific types of healthcare providers or clin-
ical environments could become increasingly important 
in promoting cessation and delivering targeted cessa-
tion support. In addition to policies that seek to make the 
delivery of clinical cessation interventions in health sys-
tems more consistent and routine, policies that remove 
cost and other barriers to access for patients are also 
essential to increase the delivery and utilization of nico-
tine dependence treatment, especially when barrier-free 
coverage is well promoted to health plan beneficiaries. 
Timely and relevant clinical guidelines and clinical quality 
measures also play critical roles in ensuring that clinicians 
and staff from healthcare systems intervene consistently 
with tobacco users. Improving and promoting insur-
ance coverage of treatment for tobacco use and depen-
dence are also essential. Cessation benefits should cover 
all evidence-based cessation interventions, including brief 
and intensive counseling and all FDA-approved medica-
tions, including combination NRT therapy. This coverage 
should be provided with no or minimal barriers, such 
as prior authorization, duration limits, or cost-sharing. 
Regardless of how well designed a coverage benefit may 
be, coverage alone, without promotion, is not sufficient. 
Benefits for smoking cessation, whether offered through a 
health insurer or an employee wellness program, must be 
promoted to increase awareness.
In addition to the individual and clinical health sys-
tems interventions cited previously, population-based 
policy and program actions also serve critical roles in 
broadly influencing the behavior of smokers as they try 
to quit or think about quitting smoking. As noted in 
Chapter  7, population-level policy and program actions 
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can facilitate the integration of individual treatments into 
routine clinical care, thus making cessation interven-
tions available and accessible to individual smokers and 
motivating smokers to use them. Such actions can occur 
at multiple levels—national, state, and local—and may 
involve government and nongovernment entities. These 
policies and programs include quitlines, which are an 
evidence-based, population-level strategy to increase the 
accessibility and uptake of scientifically proven cessation 
support, including the optimal combination of cessation 
counseling and medication.
Tobacco quitlines have typically been funded at 
the state level, but they can also be used by and funded 
through employers, health plans, and health systems. 
Quitlines offer convenient mechanisms through which 
health insurers and employers can partially meet fed-
eral requirements for coverage of tobacco cessation and 
reduce tobacco-related health expenditures. Employers 
can offer a tobacco quitline as an employee benefit to pro-
mote tobacco cessation and to help increase the produc-
tivity of employees who use tobacco by helping them to 
quit. Health systems can use quitlines as a complement 
to clinical care and to provide more intensive follow-up 
to patients engaged in a quit attempt. Provider referrals 
offer a less expensive and potentially more sustainable 
approach to drive smokers to quitline services, although 
developing and maintaining relationships with health sys-
tems and putting referral systems in place can be time- 
and staff-intensive. As described in Chapter  6, quitlines 
are increasingly linked to the delivery of cessation treat-
ment by primary care providers, and enhanced use of 
electronic health records to electronically refer patients 
who smoke to quitlines is warranted. Beyond quitline 
e-referrals, electronic health records can be a critical tool 
for improving the frequency, quality, and consistency of 
screening and treatment for tobacco use and dependence, 
thereby increasing adherence to clinical practice guide-
lines. However, it is important that careful and inten-
tional efforts must be made to integrate appropriate, evi-
dence-based cessation content into the electronic health 
record system and to make parallel changes to the clinical 
work flow.
Although telephone quitlines are a clinical treat-
ment, they are supported through broad policies at 
the local, state, and national levels and are designed to 
be accessed on a population-wide basis to address quit 
attempts, successful quitting, and the prevalence of 
smoking. Supportive policies include price increases 
(e.g.,  increasing excise taxes); restrictions on where 
tobacco can be used (e.g.,  smokefree policies); ade-
quately funding state programs for tobacco control; car-
rying out mass media campaigns (e.g., CDC’s Tips From 
Former Smokers campaign [Tips], FDA’s Every Try Counts 
campaign); and developing product regulations, such as 
requiring pictorial health warnings. Additionally, prom-
ising policies discussed in Chapter 7 include those focused 
on limiting retail density and point-of-sale tobacco adver-
tising and on policies seeking to regulate the nicotine con-
tent in cigarettes to very low, nonaddictive levels.
Population-level policies have a broad impact, can 
change the context and environment to make it easier for 
persons to quit, and are more likely to help people quit 
and stay quit when coupled with clinical interventions at 
the individual level. Specifically, combining clinical and 
health system-based and population-level policy actions 
can improve cessation outcomes. For example, in addi-
tion to motivating smokers to make a quit attempt, a mass 
media campaign, such as the Tips campaign and the Every 
Try Counts campaign, can connect smokers to evidence-
based resources for cessation treatment, such as a quitline 
or, in some cases, a healthcare provider. Therefore, clini-
cians and public health practitioners should connect clin-
ical work with macro-level policy work to maximize the 
impact of tobacco-control interventions at the population 
level on tobacco cessation and to facilitate the implemen-
tation of these interventions.
Accelerating National Momentum 
to Promote Cessation
As noted in the 50th anniversary Surgeon General’s 
report, the scientific evidence is undeniable: inhaling the 
combusted compounds from tobacco smoke is deadly 
(USDHHS 2014). Although substantial progress has been 
made to reduce smoking in the United States over the past 
five decades, by increasing adult smoking cessation and by 
reducing youth smoking initiation, more can and should 
be done. The following major conclusions from this report 
provide evidence that points to an urgent need for inten-
sified and coordinated actions to reduce the consider-
able—and preventable—human and financial burden of 
smoking in the United States:
• More than three out of five U.S. adults who have ever 
smoked cigarettes have quit. Although a majority of 
cigarette smokers make a quit attempt each year, 
less than one-third use FDA-approved cessation 
medications or behavioral counseling to support 
these attempts.
• Smoking places a substantial financial burden on 
smokers, healthcare systems, and society. Smoking 
cessation reduces this burden, including smoking-
attributable healthcare expenditures.
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• Considerable disparities exist in the prevalence of 
smoking across the U.S. population; such preva-
lence is higher in some subgroups. Similarly, the 
prevalence of key indicators of smoking cessation—
quit attempts, receiving advice to quit from a health 
professional, and using cessation therapies—also 
varies across the population, with lower prevalence 
among some subgroups. 
To increase smoking cessation and reduce smoking 
in the United States, this report outlines a broad range 
of well-defined and effective population-based interven-
tions that are necessary, at present, to help the 34 million 
American adults who currently smoke cigarettes quit:
• Fully funded, comprehensive statewide tobacco con-
trol programs;
• Higher average retail prices of cigarettes—at least 
$10 a pack;
• Complete protection of the entire U.S. population 
from exposure to secondhand smoke through com-
prehensive indoor smokefree policies in workplaces, 
restaurants, and bars;
• High-impact media campaigns, such as CDC’s Tips 
From Former Smokers, that run with sufficient reach, 
frequency, and duration—ideally for 12  months a 
year; and
• Product regulations, such as requiring pictorial 
health warnings.
However, these population-based actions and the 
more aggressive use of the evidence-based policies and 
programs reviewed in Chapter 7 are not enough. An array 
of effective clinical and health system-based interven-
tions should also be implemented to increase smoking 
cessation and treat tobacco use and dependence in the 
United States:
• Increasing the appeal and reach of existing evidence-
based interventions to individuals, including lever-
aging emerging technologies and accelerating the 
integration of cessation services across multiple 
platforms and in healthcare systems;
• Increasing the effectiveness of existing interven-
tions, including recommending the combination of 
short- and long-acting forms of NRT, combined with 
behavioral support interventions, as first-line treat-
ment for tobacco use;
• Conducting research to develop and better under-
stand cessation interventions that have the potential 
for greater reach and/or effectiveness than existing 
interventions or that appeal to and are used by dif-
ferent populations of smokers;
• Conducting research to develop and better under-
stand cessation interventions that are safe and effec-
tive among both youth and adults, including those 
that address the diversity of tobacco products being 
used by these populations, including e-cigarettes;
• Embedding policies and protocols for tobacco use 
screening and intervention into the clinical work-
flow; embedding prompts, decision support, and 
documentation tools into health records, such as 
electronic health records; and distributing specific 
components of the intervention across the broader 
healthcare team to reduce the burden on time-
constrained physicians and to reinforce the impor-
tance of cessation to patients;
• Adopting policies to make the provision of cessa-
tion care in health systems more routine, as well as 
policies that remove cost and barriers to access for 
patients to increase the delivery and utilization of 
tobacco dependence treatment;
• Providing timely and relevant clinical guidelines 
and clinical quality measures to ensure that clini-
cians and health systems intervene consistently 
with tobacco users;
• Providing barrier-free cessation insurance cov-
erage—without prior authorization, duration limits, 
cost-sharing, or other barriers that impede smokers’ 
access to cessation treatments—to increase the 
availability and utilization of treatment services for 
smoking cessation;
• Ensuring comprehensive cessation insurance ben-
efits for all smokers that include coverage of all 
evidence-based cessation interventions, including 
brief and intensive counseling and all FDA-approved 
medications, including combination NRT therapy;
• Promoting cessation coverage and services, whether 
offered through a health insurer or an employee 
wellness program, to smokers and healthcare pro-
viders to increase awareness and use of the covered 
treatments; coverage alone, without promotion, is 
not sufficient; and
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• Adequately funding and promoting tobacco quit-
lines to enable their operations and services to func-
tion at  levels sufficient to maximize their reach 
and impact.
The implementation of scientifically proven inter-
ventions has been a hallmark of the successes made in 
combating the tobacco use epidemic in the United States 
for more than 50 years. However, the tobacco control com-
munity must remain nimble and vigilant in conducting 
and disseminating timely, high-quality scientific studies 
on best practices; in modernizing existing interventions 
to keep pace with the rapidly diversifying landscape of 
tobacco products; and in identifying emerging strategies to 
ensure more rapid elimination of the health and economic 
burden of tobacco use in the United States. To that end, 
several end-game strategies could help to increase cessa-
tion and reduce the disease and premature death caused by 
tobacco use. Strategies that have been proposed include:
• Implementing a tobacco product standard to lower 
the level of nicotine in cigarettes to minimally addic-
tive or nonaddictive levels, and
• Restricting the sale of tobacco products, such as 
prohibitions on entire categories of flavored tobacco 
products, including menthol.
Such actions have the potential to accelerate 
increases in smoking cessation and declines in the prev-
alence of smoking in the United States, thus hastening 
the end of the tobacco epidemic. However, these actions 
and the extensive body of evidence-based clinical, health 
system, and population-based tobacco prevention, control, 
and cessation strategies that are outlined in this report 
are a necessary but insufficient means to end the tobacco 
epidemic. Reaching the finish line will require coordina-
tion across federal government agencies and other stake-
holders at the national, state, and local levels. To achieve 
success, we must work together to maximize resources 
and coordinate efforts across a wide range of stakeholders. 
Stakeholders who have a role to play include federal, state, 
local, tribal, and territorial governments; voluntary health 
agencies; nongovernmental and community-based orga-
nizations; civic and community leaders; public health 
and healthcare professionals; researchers; and individuals 
(USDHHS 2016). Stakeholders must also continue to hold 
the tobacco industry accountable for its role in creating, 
obscuring, and perpetuating the tobacco use epidemic in 
the United States (USDHHS 2014). For example, begin-
ning in 2017, the major U.S. tobacco companies were 
required by the U.S. District Court for the District of 
Columbia to run “corrective statements” via television and 
newspaper ads and to publish statements on their websites 
and cigarette packs that tell the American public the truth 
about the dangers of smoking and secondhand smoke 
(U.S. Department of Justice 2017; Farber et al. 2018). The 
tobacco control movement has achieved remarkable prog-
ress over time through coordinated actions by diverse 
stakeholders. The most effective interventions frequently 
originate at the local level before percolating to higher 
levels and ultimately becoming recognized as evidence-
based practices (CDC 2014; USDHHS 2014). Action at 
the federal level is a key lever to success, but such action 
must be complemented by subnational and nongovern-
mental efforts to continue to denormalize tobacco use and 
advance the strategies that we know work to combat the 
devastating effects of tobacco use on society (USDHHS 
2014). Each stakeholder can make unique and critical 
contributions toward reducing tobacco-related disease 
and death in the United States. In particular, there are 
opportunities for practitioners, experts, and researchers 
who have traditionally focused primarily on population-
based tobacco control policy interventions, to collaborate 
more closely with their counterparts who have tradition-
ally focused on cessation interventions as part of a broader 
effort to build linkages.
We are at the precipice of a critical period in the 
more-than-half-century history of the tobacco control 
movement in the United States. The considerable reduc-
tion in the prevalence of smoking since the mid-1960s is 
an important public health achievement, which has been 
driven in part by increases in adult smoking cessation 
and the multiple advances in smoking cessation interven-
tions since the last Surgeon General’s report on this topic 
nearly three decades ago (USDHHS 1990). However, we 
cannot rest on our laurels. More work must be done, and 
we have the experience and wherewithal to do it. Equipped 
with both science and resolve, we will continue to move 
forward to end the tobacco epidemic in the United States. 
Working together, we can make tobacco-related disease 
and death a thing of the past.
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